<SEC-DOCUMENT>0001564590-21-009871.txt : 20210301
<SEC-HEADER>0001564590-21-009871.hdr.sgml : 20210301
<ACCEPTANCE-DATETIME>20210301161840
ACCESSION NUMBER:		0001564590-21-009871
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		138
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210301
DATE AS OF CHANGE:		20210301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		21698003

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>fgen-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-01T20:53:06.3627208+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : c4cc8ad73bdd4a268962242d24ba2619 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:fgen="http://www.fibrogen.com/20201231" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
fgen-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000921299_20200101_20201231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0000921299_20200101_20201231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0000921299_20200101_20201231">0000921299</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0000921299_20200101_20201231">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000632" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20200101_20201231">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000634" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20200101_20201231">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000636" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">P3Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000839" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20190101_20191231" decimals="-6">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000841" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenGrossAccountsReceivableMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20190101_20191231" decimals="-6">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000843" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20190101_20191231" decimals="-6">0</ix:nonFraction>
			<ix:nonNumeric id="F_000941" name="us-gaap:LesseeFinanceLeaseExistenceOfOptionToExtend" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20060101_20061231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000945" name="us-gaap:LesseeFinanceLeaseExistenceOfOptionToExtend" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20130101_20131231">false</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_001454_2" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" contextRef="C_0000921299_20201231" decimals="INF">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_001455" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" contextRef="C_0000921299_20181231" decimals="INF">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_001454" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" contextRef="C_0000921299_20201231" decimals="INF">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_001455_2" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" contextRef="C_0000921299_20181231" decimals="INF">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0000921299_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0000921299_20191231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000970" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0000921299_20201231">fgen:AccruedAndOtherCurrentLiabilitiesMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000971" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0000921299_20191231">fgen:AccruedAndOtherCurrentLiabilitiesMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000976" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0000921299_20201231">us-gaap:OtherNoncurrentLiabilitiesMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000977" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0000921299_20191231">us-gaap:OtherNoncurrentLiabilitiesMember</ix:nonNumeric>
			<ix:nonNumeric id="F_001000" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0000921299_20201231">P2Y10M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_001001" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0000921299_20191231">P3Y7M6D</ix:nonNumeric>
			<ix:nonNumeric id="F_001002" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0000921299_20201231">P1Y9M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_001003" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0000921299_20191231">P2Y1M6D</ix:nonNumeric>
			<ix:nonNumeric id="F_001234" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0000921299_20200101_20201231">P6Y7M6D</ix:nonNumeric>
			<ix:nonNumeric id="F_001235" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_0000921299_20200101_20201231">P6Y6M</ix:nonNumeric>
			<ix:nonNumeric id="F_001236" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0000921299_20200101_20201231">P5Y1M6D</ix:nonNumeric>
			<ix:nonNumeric id="F_001275" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P5Y8M12D</ix:nonNumeric>
			<ix:nonNumeric id="F_001276" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">P5Y3M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_001277" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">P5Y4M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_001290" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231">P6M</ix:nonNumeric>
			<ix:nonNumeric id="F_001291" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231">P6M</ix:nonNumeric>
			<ix:nonNumeric id="F_001292" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231">P6M</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001296" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231" decimals="INF">0.475</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001297" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231" decimals="INF">0.481</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001298" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231" decimals="INF">0.473</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001302" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231" decimals="INF">0.001</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001303" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231" decimals="INF">0.013</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001304" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231" decimals="INF">0.008</ix:nonFraction>
			<ix:nonNumeric id="F_001293" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231">P2Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001294" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231">P2Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001295" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231">P2Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001299" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231" decimals="INF">0.771</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001300" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231" decimals="INF">0.621</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001301" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231" decimals="INF">0.753</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001305" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231" decimals="INF">0.029</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001306" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231" decimals="INF">0.029</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_001307" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231" decimals="INF">0.029</ix:nonFraction>
			<ix:nonNumeric id="F_000145" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" contextRef="C_0000921299_20200101_20201231">us-gaap:ProductMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000146" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" contextRef="C_0000921299_20190101_20191231">us-gaap:ProductMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000147" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" contextRef="C_0000921299_20180101_20181231">us-gaap:ProductMember</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="fgen-20201231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000921299_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000921299_20210131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-01-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000921299_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_fgenSegment">
				<xbrli:measure>fgen:Segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000921299_20200401">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-04-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_fgenAccountsReceivableFromDistributorsMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">fgen:AccountsReceivableFromDistributorsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapGeographicDistributionAxis_us-gaapGeographicDistributionForeignMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapGeographicDistributionAxis_us-gaapGeographicDistributionForeignMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fgen:LaboratoryEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fgen:LaboratoryEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_fgenImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member_20190101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">fgen:ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20180101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fgen:BeijingKangdaYongfuPharmaceuticalCoLTDMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FibroGenBeijingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217CNY">
				<xbrli:measure>iso4217:CNY</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200701_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fgen:BeijingKangdaYongfuPharmaceuticalCoLTDMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FibroGenBeijingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAcquiredLicenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200701_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fgen:BeijingKangdaYongfuPharmaceuticalCoLTDMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FibroGenBeijingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">fgen:AcquiredLicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAstraZenecaABMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200915_20200915">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fgen:BeijingKangdaYongfuPharmaceuticalCoLTDMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FibroGenBeijingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">fgen:AstraZenecaABMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-09-15</xbrli:startDate>
					<xbrli:endDate>2020-09-15</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FibroGenBeijingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FibroGenBeijingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtCounterpartyNameAxis_us-gaapVariableInterestEntityNotPrimaryBeneficiaryMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20090228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2005-06-01</xbrli:startDate>
					<xbrli:endDate>2009-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2005-06-01</xbrli:startDate>
					<xbrli:endDate>2005-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2005-06-01</xbrli:startDate>
					<xbrli:endDate>2005-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:RegulatoryMilestonesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2005-06-01</xbrli:startDate>
					<xbrli:endDate>2005-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190901_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-09-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180401_20180630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-04-01</xbrli:startDate>
					<xbrli:endDate>2018-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20090228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2006-04-01</xbrli:startDate>
					<xbrli:endDate>2009-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2006-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2006-04-01</xbrli:startDate>
					<xbrli:endDate>2006-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:RegulatoryMilestonesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2006-04-01</xbrli:startDate>
					<xbrli:endDate>2006-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2006-04-01</xbrli:startDate>
					<xbrli:endDate>2006-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-07-29</xbrli:startDate>
					<xbrli:endDate>2013-07-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-07-29</xbrli:startDate>
					<xbrli:endDate>2013-07-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:RegulatoryMilestonesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-07-29</xbrli:startDate>
					<xbrli:endDate>2013-07-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenDeferredApprovalMilestoneMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:DeferredApprovalMilestoneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-07-29</xbrli:startDate>
					<xbrli:endDate>2013-07-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20150101_20151231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-01-01</xbrli:startDate>
					<xbrli:endDate>2015-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibroGenIncMember_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20150101_20151231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibroGenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-01-01</xbrli:startDate>
					<xbrli:endDate>2015-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-07-29</xbrli:startDate>
					<xbrli:endDate>2013-07-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-07-29</xbrli:startDate>
					<xbrli:endDate>2013-07-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:RegulatoryMilestonesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-07-29</xbrli:startDate>
					<xbrli:endDate>2013-07-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20181216_20181217">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-12-16</xbrli:startDate>
					<xbrli:endDate>2018-12-17</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20181228_20181229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-12-28</xbrli:startDate>
					<xbrli:endDate>2018-12-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201001_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapBalanceSheetLocationAxis_us-gaapAccountsPayableMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapBalanceSheetLocationAxis_us-gaapAccruedLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapBalanceSheetLocationAxis_fgenAccruedAndOtherCurrentLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueDiscountedCashFlowMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueDiscountedCashFlowMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueDiscountedCashFlowMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenCoDevelopmentInformationSharingAndCommitteeServicesMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:CoDevelopmentInformationSharingAndCommitteeServicesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenChinaPerformanceObligationMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:ChinaPerformanceObligationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenPriceAdjustmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:PriceAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenPriceAdjustmentMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:PriceAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNonKeyAccountHospitalListingAwardMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:NonKeyAccountHospitalListingAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNonKeyAccountHospitalListingAwardMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:NonKeyAccountHospitalListingAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenContractualSalesRebateMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ContractualSalesRebateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenContractualSalesRebateMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ContractualSalesRebateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenOtherDiscountsAndRebatesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:OtherDiscountsAndRebatesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenOtherDiscountsAndRebatesMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:OtherDiscountsAndRebatesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNonKeyAccountHospitalListingAwardMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:NonKeyAccountHospitalListingAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenContractualSalesRebateMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ContractualSalesRebateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenContractualSalesRebateMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ContractualSalesRebateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenPriceAdjustmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:PriceAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:RebatesAndDiscountsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenGrossAccountsReceivableMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:RebatesAndDiscountsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:GrossAccountsReceivableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenGrossAccountsReceivableMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:RebatesAndDiscountsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:GrossAccountsReceivableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:RebatesAndDiscountsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:ContractLiabilitiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:RebatesAndDiscountsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:ContractLiabilitiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fgen:APIShipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fgen:LeaseObligationsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fgen:LeaseObligationsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fgen:LeaseObligationsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fgen:LeaseObligationsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fgen:LeaseObligationsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fgen:LeaseObligationsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fgen:LeaseObligationsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fgen:LeaseObligationsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_fgenLease">
				<xbrli:measure>fgen:Lease</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20061231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:ShorensteinPropertiesLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2006-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20060101_20061231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:ShorensteinPropertiesLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2006-01-01</xbrli:startDate>
					<xbrli:endDate>2006-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:ShorensteinPropertiesLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20131231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:BeijingEconomicTechnologicalDevelopmentAreaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2013-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20130101_20131231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:BeijingEconomicTechnologicalDevelopmentAreaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-01-01</xbrli:startDate>
					<xbrli:endDate>2013-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenOfficeSpacesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fgen:OfficeSpacesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMinimumMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMaximumMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_20180101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_fgenMilestone">
				<xbrli:measure>fgen:Milestone</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fgen:LaboratoryEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fgen:LaboratoryEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200701_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_fgenDevelopmentObligation">
				<xbrli:measure>fgen:DevelopmentObligation</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000921299_us-gaapVariableRateAxis_fgenBankOfFinlandInterestRateMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">fgen:BankOfFinlandInterestRateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfRoxadustatMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fgen:ManufactureAndSupplyOfRoxadustatMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfPamrevlumabMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fgen:ManufactureAndSupplyOfPamrevlumabMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenOtherPurchasesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fgen:OtherPurchasesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenResearchAndPreClinicalStageDevelopmentProgramsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fgen:ResearchAndPreClinicalStageDevelopmentProgramsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesEPreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesEPreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibroGenCaymanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibroGenCaymanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibroGenCaymanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibroGenCaymanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibroGenCaymanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibroGenCaymanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_deiLegalEntityAxis_fgenFibroGenCaymanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibroGenCaymanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20141119">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2014-11-19</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFiveStockPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFiveStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_fgenTwoThousandAndFiveStockPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFiveStockPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20140901_20140930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2014-09-01</xbrli:startDate>
					<xbrli:endDate>2014-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20140901_20140930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2014-09-01</xbrli:startDate>
					<xbrli:endDate>2014-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20140930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2014-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_fgenStockOptionAwardsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fgen:StockOptionAwardsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAwardTypeAxis_fgenStockOptionAwardsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fgen:StockOptionAwardsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_stprCA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">fgen:FederalAndStateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">fgen:FederalAndStateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">fgen:FederalAndStateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">fgen:FederalAndStateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">fgen:FederalAndStateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">fgen:FederalAndStateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">fgen:FederalAndStateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTaxPeriodAxis_us-gaapEarliestTaxYearMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTaxPeriodAxis_us-gaapLatestTaxYearMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenLicenseAndDevelopmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:LicenseAndDevelopmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenLicenseAndDevelopmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:LicenseAndDevelopmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtProductOrServiceAxis_fgenLicenseAndDevelopmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:LicenseAndDevelopmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fgen:APIShipmentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fgen:APIShipmentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fgen:APIShipmentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fgen:APIShipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20200901_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FalikangMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-09-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FalikangMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryJP_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenAllOtherMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:AllOtherMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenAllOtherMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:AllOtherMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_fgenAllOtherMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:AllOtherMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryUS_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryUS_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_srtStatementGeographicalAxis_countryCN_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ValuationAllowanceForRebatesAndDiscountsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ValuationAllowanceForRebatesAndDiscountsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ValuationAllowanceForRebatesAndDiscountsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ValuationAllowanceForRebatesAndDiscountsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ValuationAllowanceForRebatesAndDiscountsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="text-align:center;margin-top:2pt;border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000921299_20200101_20201231">10-K</ix:nonNumeric>&#160;</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Mark One)</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:12pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000030" name="dei:DocumentAnnualReport" contextRef="C_0000921299_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000921299_20200101_20201231" format="ixt:datemonthdayyearen">December&#160;31, <ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0000921299_20200101_20201231">2020</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:12pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000031" name="dei:DocumentTransitionReport" contextRef="C_0000921299_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-weight:normal;"></span>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from <span style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> to <span style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>.</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission file number: <ix:nonNumeric id="F_000019" name="dei:EntityFileNumber" contextRef="C_0000921299_20200101_20201231">001-36740</ix:nonNumeric>&#160;</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityRegistrantName" contextRef="C_0000921299_20200101_20201231">FIBROGEN, INC.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)&#160;</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:11.15pt;">
<td valign="top" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000921299_20200101_20201231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000921299_20200101_20201231">77-0357827</ix:nonNumeric></p></td>
</tr>
<tr style="height:9.45pt;">
<td valign="top" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of incorporation or organization)</p></td>
<td valign="bottom" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer Identification No.)</p></td>
</tr>
<tr style="height:23.4pt;">
<td valign="top" style="width:49%;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:EntityAddressAddressLine1" contextRef="C_0000921299_20200101_20201231">409 Illinois Street</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:EntityAddressCityOrTown" contextRef="C_0000921299_20200101_20201231">San Francisco</ix:nonNumeric>, <ix:nonNumeric id="F_000024" name="dei:EntityAddressStateOrProvince" contextRef="C_0000921299_20200101_20201231">CA</ix:nonNumeric></p></td>
<td valign="bottom" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000025" name="dei:EntityAddressPostalZipCode" contextRef="C_0000921299_20200101_20201231">94158</ix:nonNumeric></p></td>
</tr>
<tr style="height:9.9pt;">
<td valign="top" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(zip code)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code:</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000026" name="dei:CityAreaCode" contextRef="C_0000921299_20200101_20201231">415</ix:nonNumeric>) <ix:nonNumeric id="F_000027" name="dei:LocalPhoneNumber" contextRef="C_0000921299_20200101_20201231">978-1200&#160;</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:4.86%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-weight:bold;;font-size:4pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:5.54%;width:94.37%;">
<tr>
<td style="width:29.97%;"></td>
<td style="width:30.52%;"></td>
<td style="width:33.88%;"></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:Security12bTitle" contextRef="C_0000921299_20200101_20201231">Common Stock, $0.01 par value</ix:nonNumeric></p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0000921299_20200101_20201231">FGEN</ix:nonNumeric></p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:SecurityExchangeName" contextRef="C_0000921299_20200101_20201231" format="ixt-sec:exchnameen">The NASDAQ Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities <span style="font-size:10pt;">registered pursuant to Section&#160;12(g) of the Act:</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">None</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000009" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0000921299_20200101_20201231">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9745;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> &#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000011" name="dei:EntityVoluntaryFilers" contextRef="C_0000921299_20200101_20201231">No</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9745;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000010" name="dei:EntityCurrentReportingStatus" contextRef="C_0000921299_20200101_20201231">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9745;</span> &#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000016" name="dei:EntityInteractiveDataCurrent" contextRef="C_0000921299_20200101_20201231">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9745;</span> &#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:99.98%;">
<tr style="height:11.15pt;">
<td valign="bottom" style="width:21.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityFilerCategory" contextRef="C_0000921299_20200101_20201231" format="ixt-sec:entityfilercategoryen">Large&#160;accelerated&#160;filer</ix:nonNumeric></p></td>
<td valign="bottom" style="width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:43.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9745;</p></td>
<td valign="bottom" style="width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:21.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="bottom" style="width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:11.15pt;">
<td valign="bottom" style="width:21.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="bottom" style="width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:43.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;<span style="color:#000000;font-family:Times New Roman;">&#160;&#160;</span></p></td>
<td valign="bottom" style="width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:21.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="bottom" style="width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000014" name="dei:EntitySmallBusiness" contextRef="C_0000921299_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
<tr style="height:11.15pt;">
<td valign="bottom" style="width:21.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="bottom" style="width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:43.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000921299_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:21.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160; <span style="font-family:Segoe UI Symbol;">&#9744;</span>&#160;&#160;&#160;&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;&#160;&#160; <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000032" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0000921299_20200101_20201231" format="ixt-sec:boolballotbox">&#9745;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000013" name="dei:EntityShellCompany" contextRef="C_0000921299_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9745;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter, June 30, 2020, was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000029" name="dei:EntityPublicFloat" contextRef="C_0000921299_20200630" decimals="-5" format="ixt:numdotdecimal" scale="6">2,127.6</ix:nonFraction> million. Shares of Common Stock held by each executive officer and director and stockholders known by the registrant to own 10% or more of the outstanding stock based on public filings and other information known to the registrant have been excluded since such persons may be deemed affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of common stock outstanding as of January 31, 2021 was <ix:nonFraction unitRef="U_xbrlishares" id="F_000028" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0000921299_20210131" decimals="INF" format="ixt:numdotdecimal">91,560,468</ix:nonFraction>.</p><ix:nonNumeric id="F_000523" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K incorporate information by reference from the definitive proxy statement for the registrant&#8217;s 2021 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than after 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.43%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:9.6pt;">
<td valign="bottom" style="width:8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:85%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I111"><span style="text-decoration:none;">PART I</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr style="height:6pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:none;">Business</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:none;">Risk Factors</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:none;">Unresolved Staff Comments</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><span style="text-decoration:none;">Properties</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEEDINGS"><span style="text-decoration:none;">Legal Proceedings</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:none;">Mine Safety Disclosures</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><span style="text-decoration:none;">PART II</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr style="height:6pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:10.8pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:none;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><span style="text-decoration:none;">Selected Financial Data</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:none;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of&#160;Operations</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><span style="text-decoration:none;">Quantitative and Qualitative Disclosure About Market Risk</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_CONSOLIDATED_FINANCIAL_STATEMENTS"><span style="text-decoration:none;">Consolidated Financial Statements and Supplementary Data</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:none;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosures</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:none;">Controls and Procedures</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><span style="text-decoration:none;">Other Information</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</p></td>
</tr>
<tr style="height:6.6pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><span style="text-decoration:none;">PART&#160;III</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:none;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:none;">Executive Compensation</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:none;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="text-decoration:none;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="text-decoration:none;">Principal Accounting Fees and Services</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><span style="text-decoration:none;">PART IV</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><span style="text-decoration:none;">Exhibits and Financial Statement Schedules</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="bottom" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:none;">Signatures</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FORWARD-LOOKING STATEMENTS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">This Annual Report filed on Form&#160;10-K and the information incorporated herein by reference, particularly in the sections captioned &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business,&#8221; contains forward-looking statements, which involve substantial risks and uncertainties. In this Annual Report, all statements other than statements of historical or present facts contained in this Annual Report, including statements regarding our future financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;contemplate,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;predict,&#8221; &#8220;could,&#8221; &#8220;potentially&#8221; or the negative of these terms or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements appear in a number of places throughout this Annual Report and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for roxadustat, pamrevlumab and our other product candidates, our intellectual property position, the potential safety, efficacy, reimbursement, convenience clinical and pharmaco-economic benefits of our product candidates, the potential markets for any of our product candidates, our ability to develop commercial functions, our ability to operate in China, expectations regarding clinical trial data, our results of operations, cash needs, spending of the proceeds from our initial public offering, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate and the trends that may affect the industry or us. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">These forward-looking statements are subject to a number of risks, uncertainties and assumptions described in the section of this Annual Report captioned &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. A summary of these risk factors can be found in the following section, however please refer to the full risk factors in Item 1A &#8220;Risk Factors&#8221;. These risks are not exhaustive. Other sections of this Annual Report may include additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The forward-looking statements made in this Annual Report are based on circumstances as of the date on which the statements are made. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report or to conform these statements to actual results or to changes in our expectations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">This Annual Report also contains market data, research, industry forecasts and other similar information obtained from or based on industry reports and publications, including information concerning our industry, our business, and the potential markets for our product candidates, including data regarding the estimated size and patient populations of those and related markets, their projected growth rates and the incidence of certain medical conditions, as well as physician and patient practices within the related markets. Such data and information involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should read this Annual Report with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SUMMARY RISK FACTOR</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of the Company will depend on a number of factors, many of which are beyond our control and involve risks, including but not limited to the following:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Development and Commercialization of Our Product Candidates</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">We are substantially dependent on the success of our lead product, roxadustat, and our second compound in development, pamrevlumab.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">As a company, we have limited commercialization experience, and the time and resources to develop such experience are significant. If we fail to achieve and sustain commercial success for roxadustat with our collaboration partners, our business would be harmed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Although regulatory approval has been obtained for roxadustat in China, Japan, and Chile, we may be unable to obtain regulatory approval for other countries, or such approval may be delayed or limited, due to a number of factors, many of which are beyond our control.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">The </span><span style="color:#000000;">results of the FDA Cardiovascular and Renal Drugs Advisory Committee meeting may affect roxadustat&#8217;s approvability or label in CKD anemia.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Preclinical, Phase 1 and Phase 2 clinical trial results may not be indicative of the results that may be obtained in larger clinical trials.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">We do not know whether our ongoing or planned clinical trials of roxadustat or pamrevlumab will need to be redesigned based on interim results or if we will be able to achieve sufficient patient enrollment or complete planned clinical trials on schedule.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Our product candidates may cause or have attributed to them undesirable side effects or have other properties that delay or prevent their regulatory approval or limit their commercial potential.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Clinical trials of our product candidates may not uncover all possible adverse effects that patients may experience.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">If we or our manufacturers cannot properly manufacture sufficient product, we may experience delays in development, regulatory approval, launch or successful commercialization.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Regulatory authorities will do their own benefit risk analysis and may reach a different conclusion than we or our partners have, and these regulatory authorities may base their approval decision on different analyses, data, and statistical methods than ours.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Even if we are able to obtain regulatory approval of our product candidates, the label we obtain may limit the indicated uses for which our product candidates may be marketed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">We face substantial competition in the discovery, development and commercialization of product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">No or limited reimbursement or insurance coverage of our approved products, if any, by third-party payors may render our products less attractive to patients and healthcare providers.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Severe Acute Respiratory Syndrome Coronavirus 2 and the Resulting Coronavirus Disease (&#8220;COVID-19&#8221;)</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Our business could continue to be adversely affected by the ongoing COVID-19 global pandemic.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Reliance on Third Parties</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">If our collaborations were terminated or if Astellas or AstraZeneca were to prioritize other initiatives over their collaborations with us, our ability to successfully develop and commercialize our product candidates would suffer.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">If our preclinical and clinical trial contractors do not properly perform their agreed upon obligations, we may not be able to obtain or may be delayed in receiving regulatory approvals for our product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">We currently rely, and expect to continue to rely, on third parties to conduct many aspects of our product manufacturing and distribution, and these third parties may terminate these agreements or not perform satisfactorily.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Certain components of our products are acquired from single-source suppliers or without long-term supply agreements. The loss of these suppliers, or their failure to supply, would materially and adversely affect our business.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">If our efforts to protect our proprietary technologies are not adequate, we may not be able to compete effectively in our market.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Intellectual property disputes may be costly, time consuming, and may negatively affect our competitive position.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Our reliance on third parties and agreements with collaboration partners requires us to share our trade secrets, which increases the possibility that a competitor may discover them or that our trade secrets will be misappropriated or disclosed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">The cost of maintaining our patent protection is high and requires continuous review and diligence. We may not be able to effectively maintain our intellectual property position throughout the major markets of the world.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">The laws of some foreign countries do not protect proprietary rights to the same extent as do the laws of the U.S., and we may encounter significant problems in securing and defending our intellectual property rights outside the U.S.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Intellectual property rights do not address all potential threats to any competitive advantage we may have.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">The existence of counterfeit pharmaceutical products in pharmaceutical markets may compromise our brand and reputation and have a material adverse effect on our business, operations and prospects.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Government Regulation</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">The regulatory approval process is highly uncertain and we may not obtain regulatory approval for our product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Our product candidates could fail to receive regulatory approval from the FDA or other regulatory authorities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Our current and future relationships with customers, physicians, and third-party payors are subject to healthcare fraud and abuse laws, false claims laws, transparency laws, privacy and security laws, and other regulations. If we are unable to comply with such laws, we could face substantial penalties.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">We are subject to laws and regulations governing corruption, which will require us to maintain costly compliance programs.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these, or if we otherwise fail to maintain an effective system of internal control, it may result in material misstatements in our financial statements.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">The impact of recent U.S. healthcare reform, its potential partial or full repeal, and other changes in the healthcare industry and in healthcare spending is currently unknown, and may adversely affect our business model.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Roxadustat is considered a Class 2 substance on the 2019 World Anti-Doping Agency Prohibited List that could limit sales and increase security and distribution costs for our partners and us.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Our employees may engage in misconduct or improper activities, which could result in significant liability or harm our reputation.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">If we fail to comply with environmental, health or safety laws and regulations, we could incur fines, penalties or other costs.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our International Operations</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">We have established operations in China and are seeking approval to commercialize our product candidates outside of the U.S., and a number of risks associated with international operations could materially and adversely affect our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">The pharmaceutical industry in China is highly regulated and such regulations are subject to change.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">We have limited experience distributing drugs in China.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">We use our own manufacturing facilities in China to produce roxadustat API and drug product. There are risks inherent to operating commercial manufacturing facilities, and with these being our single source suppliers, we may not be able to continually meet market demand.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">As a company, we have limited experience in pharmacovigilance, medical affairs, and management of the third-party distribution logistics, and cannot assure you we will be able to meet regulatory requirements or operate in these capacities successfully.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">We and our collaboration partner in China, AstraZeneca, may experience difficulties in successfully growing and sustaining sales of roxadustat in China.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">The retail prices of any product candidates that we develop may be subject to pricing control in China and elsewhere.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">FibroGen (China) Medical Technology Development Co., Ltd. (&#8220;FibroGen Beijing&#8221;) would be subject to restrictions on paying dividends or making other payments to us, which may restrict our ability to satisfy our liquidity requirements.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Any capital contributions from us to FibroGen Beijing must be approved by the Ministry of Commerce in China, and failure to obtain such approval may materially and adversely affect the liquidity position of FibroGen Beijing.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">We may be subject to currency exchange rate fluctuations and currency exchange restrictions with respect to our operations in China, which could adversely affect our financial performance.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Because FibroGen Beijing&#8217;s funds are held in banks that do not provide insurance, the failure of any bank in which FibroGen Beijing deposits its funds could adversely affect our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">We may be subject to tax inefficiencies associated with our offshore corporate structure.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Our foreign operations, particularly those in China, are subject to significant risks involving the protection of intellectual property.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Uncertainties with respect to the China legal system could have a material adverse effect on us.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Changes in China&#8217;s economic, governmental, or social conditions could have a material adverse effect on our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Our operations in China subject us to various Chinese labor and social insurance laws, and our failure to comply with such laws may materially and adversely affect our business, financial condition and results of operations.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Operation of Our Business</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Please see below for additional risk factors related to the operation of our Business.&#160;&#160;</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">There are also a variety of Risks Related to Our Common Stock<span style="margin-left:324pt;"></span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9.5pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:9pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9.5pt;color:#000000;">Please see below for additional risk factors to our Common Stock. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I111">PART I</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_BUSINESS">ITEM&#160;1. BUSINESS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OVERVIEW</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a leading biopharmaceutical company discovering, developing and commercializing a pipeline of first-in-class therapeutics. We apply our pioneering expertise in hypoxia-inducible factor (&#8220;HIF&#8221;) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (&#8220;CTGF&#8221;) biology to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat, our most advanced product, is an oral small molecule inhibitor of HIF-prolyl hydroxylase (&#8220;HIF-PH&#8221;) activity that acts by stimulating the body&#8217;s natural pathway of erythropoiesis, or red blood cell production. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our collaboration partner AstraZeneca AB (&#8220;AstraZeneca&#8221;) continue to expand the commercialization of roxadustat (tradename: &#29233;&#29790;&#21331;<span style="font-size:9pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>) in the People&#8217;s Republic of China (&#8220;China&#8221;) where it is approved for the treatment of anemia caused by chronic kidney disease (&#8220;CKD&#8221;) in non-dialysis and dialysis patients. Roxadustat was added to the National Reimbursement Drug List (&#8220;NRDL&#8221;), effective January 1, 2020. As of the end of 2020, roxadustat was listed at hospitals that represent approximately 70% of the CKD anemia market opportunity in China and we continue to focus on adding additional temporary and permanent hospital listings for roxadustat. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Japan, our partner Astellas Pharma Inc. (&#8220;Astellas&#8221;) continues the commercial launch of EVRENZO&#174; (roxadustat). Astellas received approval of the supplemental New Drug Application (&#8220;NDA&#8221;) for the use of EVRENZO in patients with anemia of CKD not on dialysis from the Pharmaceuticals and Medical Devices Agency in November 2020, and it is now approved for the treatment of anemia associated with CKD in both non-dialysis and dialysis patients. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to our United States (&#8220;U.S.&#8221;) NDA for roxadustat for the treatment of anemia due to CKD submitted for review in December 2019 to the U.S. Food and Drug Administration (&#8220;FDA&#8221;), in December 2020, the FDA extended the review period of the NDA by three months for FibroGen to submit additional analyses of existing roxadustat clinical data, and set a new Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) goal date of March 20, 2021. On March 1, 2021, the FDA informed us that the Cardiovascular and Renal Drugs Advisory Committee will hold an advisory committee meeting to review the NDA for roxadustat. The date of the advisory committee meeting has not been set. As a result of this communication, we will not receive an approval decision by the PDUFA goal date. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, the Marketing Authorization Application (&#8220;MAA&#8221;) for roxadustat for the treatment of anemia in patients with CKD, submitted by our partner Astellas, was accepted for regulatory review by the European Medicines Agency (&#8220;EMA&#8221;). Astellas expects an approval decision mid-2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EVRENZO&#174; (roxadustat) has also been approved for the treatment of anemia in CKD patients on dialysis and patients not on dialysis in Chile. In collaboration with AstraZeneca, applications for marketing approval of roxadustat in CKD anemia have been submitted in Canada, Australia, Mexico, Brazil, Taiwan, South Korea, Philippines, Singapore, India, Colombia, and Thailand. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beyond anemia in CKD, roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (&#8220;MDS&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have completed enrollment in our Phase 2 clinical trial of roxadustat in the U.S. in chemotherapy-induced anemia (&#8220;CIA&#8221;), and we expect topline data from this study in the second half of 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab is our first-in-class antibody developed to inhibit the activity of CTGF, a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Pamrevlumab is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (&#8220;IPF&#8221;), locally advanced unresectable pancreatic cancer (&#8220;LAPC&#8221;), and Duchenne muscular dystrophy (&#8220;DMD&#8221;). </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ROXADUSTAT FOR THE TREATMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In collaboration with our partners AstraZeneca and Astellas, we have completed 16 Phase 3 studies worldwide in over 11,000 patients to support our regulatory filings in the U.S., Europe, China, and Japan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After describing the mechanism of action of roxadustat, which is the first in a new class of potential anemia drugs, we provide some background on the CKD anemia market and a summary of our Phase 3 program along with some of the most important results.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat Mechanism of Action</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat is an orally administered reversible inhibitor of HIF-PH. Inhibition of prolyl hydroxylase stabilizes HIF, which stimulates a coordinated erythropoietic response that includes the increase of plasma endogenous erythropoietin (&#8220;EPO&#8221;) levels and reduction of hepcidin, a key regulator of iron homeostasis. In healthy individuals under normal oxygen conditions, HIF-PH tags HIF-alpha for degradation and the HIF pathway is not activated. However, under low oxygen conditions, the HIF-PH enzymes cannot function and HIF-alpha accumulates. HIF-alpha then combines with HIF-beta, and the newly formed HIF complex initiates transcription of a number of genes involved in the erythropoietic process, which ultimately leads to increased oxygen delivery to tissues. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In anemia of CKD, roxadustat temporarily inhibits HIF-PH, preventing degradation of HIF-alpha and activating the HIF pathway, which stimulates a coordinated erythropoietic response that includes EPO production and the reduction of hepcidin.</p>
<p style="text-align:center;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gapk0ju0ozex000001.jpg" title="" alt="" style="width:504px;height:280px;" /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The coordinated erythropoiesis activated by roxadustat includes both the stimulation of erythroid maturation, by increasing the body&#8217;s production of EPO, and an increase in iron availability for hemoglobin synthesis in part through a decrease in hepcidin levels, which is particularly important in patients with inflammation. Patients taking roxadustat typically have a transient increase in circulating endogenous EPO levels at peak concentration within or near the physiologic range naturally experienced by humans adapting to hypoxic conditions such as at high altitude, following blood donation, or impaired lung function, such as pulmonary edema. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gapk0ju0ozex000002.jpg" title="" alt="" style="width:438px;height:288px;" /><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By contrast, erythropoiesis stimulating agents (&#8220;ESAs&#8221;) act only to stimulate erythroid maturation without a corresponding increase in iron availability, and are typically dosed at well above the natural physiologic range of EPO. The sudden demand for iron stimulated by ESA-induced erythropoiesis can lead to functional or absolute iron deficiency. We believe these high doses of ESAs are a main cause of the significant safety issues that have been attributed to this class of drugs. In addition, the lack of a coordinated increase in iron availability with ESAs may explain the hyporesponsiveness of patients with inflammation to this class of drugs. It also explains why patients taking ESAs need more IV iron supplementation and red blood cell transfusions than patients taking roxadustat do. Not only are IV iron and blood transfusions more costly than oral iron, but both are also associated with increased risk of hospitalization and death.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The differentiated mechanism of action of roxadustat, which involves induction of the body&#8217;s own natural pathways to achieve a more complete erythropoiesis, has the potential to provide a safe and effective treatment for anemia, including in the presence of inflammation, which normally limits iron availability.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Background of Anemia in Chronic Kidney Disease</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chronic kidney disease is a progressive disease characterized by gradual loss of kidney function that may eventually lead to kidney failure or end-stage renal disease requiring dialysis or a kidney transplant to survive. CKD affects 12% to 14% of the global adult population. CKD is more prevalent in developed countries but is also growing rapidly in emerging markets such as China.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anemia is a complication of CKD and can be a serious medical condition in which patients have insufficient red blood cells and low levels of hemoglobin, a protein in red blood cells that carries oxygen to cells throughout the body. Anemia becomes increasingly common as kidney function declines and is associated with increased risk of hospitalization, cardiovascular complications and death, and frequently causes significant fatigue, cognitive dysfunction, and considerable reduction of quality of life.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are approximately 39 million<sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup> CKD patients in the U.S., an estimated 6 million of whom have anemia<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When ESAs were introduced in 1989, they dramatically reduced the need for blood transfusions in CKD patients, which was a material development since transfusions reduce the patient&#8217;s opportunity for a kidney transplant and increase the risk of infections and complications such as heart failure and allergic reactions. However, multiple randomized clinical trials with ESAs suggested safety risks of ESA therapies, and as a result, the anemia guidelines and approved labels have changed to more restrictive use of ESAs. </p>
<div style="align:left;"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top" style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup>&#160;</span></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Bikbov B et al. &#8220;Global regional and national burden of chronic kidney disease 1990-2017 - a systematic analysis for the Global Burden of Disease Study 2017.&#8221; The Lancet, 395 (2020): 709-33. Web. 13 Feb. 2020.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>&#160;</span></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Based on 15.4% of CKD patients having anemia, (where anemia is defined as hemoglobin levels of &#8804; 12 g/dL in women and &#8804; 13 g/dL in men.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In the dialysis-dependent population, most patients start receiving ESAs when the patient is transitioning to dialysis care. As of the end of 2018, there were over 550,000 CKD patients on dialysis in the U.S., a large majority of whom required anemia therapy. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were approximately 127,000 incident dialysis patients in 2018.&#160;&#160;Despite the higher risk of blood transfusions, cardiovascular events, and hospitalization in patients with anemia, only 14.6% of patients in 2018 were treated with ESAs prior to initiating dialysis notwithstanding a mean hemoglobin level of 9.3 g/dL at the time of dialysis initiation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These treatment figures at the time of dialysis initiation demonstrate how undertreated CKD anemia is currently in non-dialysis patients. However, we believe there will be approximately 2 million addressable non-dialysis CKD anemia patients in the U.S. annually, based on the hemoglobin entry criteria in our Phase 3 clinical trials recommending initiation of treatment when a patient&#8217;s hemoglobin level is less than 10 g/dL. In addition to the safety concerns raised for ESAs, which may have been a greater impediment to treatment in the non-dialysis setting, other factors which contribute to the recent historical under-treatment of anemia in non-dialysis patients are related to the form of administration and accessibility of ESA products. ESAs are typically administered by subcutaneous injections, which is more difficult outside of dialysis centers or nephrology practices where non-dialysis patients are typically treated.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat Phase 3 CKD Anemia Clinical Program</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of Patients</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Study Sponsor, Number</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Comparator</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">U.S.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NON-DIALYSIS</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen - FGCL-4592-060 (ANDES)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Placebo</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-------- 922 --------</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - 1517-CL-0608 (ALPS)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Placebo</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-------- 597 --------</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca - D5740C00001 (OLYMPUS)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Placebo</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-------- 2,781 --------</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - 1517-CL-0610</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Darbepoetin alfa</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">616</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen - FGCL-4592-808</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Placebo</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - 1517-CL-0310</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Darbepoetin alfa</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - 1517-CL-0314</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-Dialysis-Dependent CKD Subtotal by Region</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,300</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,916</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">433</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">STABLE DIALYSIS</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - 1517-CL-0613 (PYRENEES)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Epoetin alfa or Darbepoetin alfa</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">838</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen - FGCL-4592-806</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Epoetin alfa</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">304</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - 1517-CL-0302</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - 1517-CL-0307</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Darbepoetin alfa</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - 1517-CL-0308</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - 1517-CL-0312</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">STABLE AND INCIDENT DIALYSIS</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca - D5740C00002 (ROCKIES)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Epoetin alfa</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-------- 2,133 --------</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen - FGCL-4592-064 (SIERRAS)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Epoetin alfa</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-------- 741 --------</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INCIDENT DIALYSIS</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen - FGCL-4592-063 (HIMALAYAS)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Epoetin alfa</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-------- 1,043 --------</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dialysis-Dependent-CKD Subtotal by Region</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,917</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,755</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">304</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total by Regulatory Approval Region</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.58%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8,217</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9,671</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">455</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,031</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Combined Total to Support U.S. and Europe Approvals</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9,671</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary efficacy endpoint was met in each of the pivotal studies for the U.S. NDA and Europe MAA, as shown below: </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Summary of Results from Individual Phase 3 Studies of Roxadustat in CKD Anemia</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Summary of Roxadustat U.S. and Europe Phase 3 Primary Efficacy Results</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:93.14%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Study Sponsor, Number</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:2.45pt;;text-indent:-2.45pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">U.S. Primary Endpoint</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Endpoint</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Met</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:15.25pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Europe Primary Endpoint</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Endpoint</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Met</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NON-DIALYSIS</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.45pt;;text-indent:-2.45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:13.72%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen - FGCL-4592-060 (ANDES)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.45pt;;text-indent:-2.45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Superior to Placebo (p&#60;0.0001)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:16pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><span style="font-size:16pt;font-family:'Times New Roman'">&#10003;</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Superior to Placebo (p&#60;0.0001)</p></td>
<td valign="middle" style="background-color:#FFFFFF;width:13.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:16pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><span style="font-size:16pt;font-family:'Times New Roman'">&#10003;</span></p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - 1517-CL-0608 (ALPS)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.45pt;;text-indent:-2.45pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.45pt;;text-indent:-2.45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Superior to Placebo (p&#60;0.001)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:16pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><span style="font-size:16pt;font-family:'Times New Roman'">&#10003;</span></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Superior to Placebo (p&#60;0.001)</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:13.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:16pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><span style="font-size:16pt;font-family:'Times New Roman'">&#10003;</span></p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca - D5740C00001 (OLYMPUS)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.45pt;;text-indent:-2.45pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.45pt;;text-indent:-2.45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statistically-Significant Improvement in Hb Change Compared to Placebo</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:16pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><span style="font-size:16pt;font-family:'Times New Roman'">&#10003;</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statistically-Significant Improvement in Hb Change Compared to Placebo</p></td>
<td valign="middle" style="background-color:#FFFFFF;width:13.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:16pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><span style="font-size:16pt;font-family:'Times New Roman'">&#10003;</span></p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.45pt;;text-indent:-2.45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:13.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">STABLE DIALYSIS</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.45pt;;text-indent:-2.45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:13.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas - 1517-CL-0613 (PYRENEES)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.45pt;;text-indent:-2.45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-Inferior to ESAs</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:16pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><span style="font-size:16pt;font-family:'Times New Roman'">&#10003;</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-Inferior to ESAs</p></td>
<td valign="middle" style="background-color:#FFFFFF;width:13.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:16pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><span style="font-size:16pt;font-family:'Times New Roman'">&#10003;</span></p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.45pt;;text-indent:-2.45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;width:13.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">STABLE AND INCIDENT DIALYSIS</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.45pt;;text-indent:-2.45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:13.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca - D5740C00002 (ROCKIES)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.45pt;;text-indent:-2.45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statistically-Significant Larger Hb Increase Compared to Epoetin Alfa</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:16pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><span style="font-size:16pt;font-family:'Times New Roman'">&#10003;</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statistically-Significant Larger Hb Increase Compared to Epoetin Alfa</p></td>
<td valign="middle" style="background-color:#FFFFFF;width:13.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:16pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><span style="font-size:16pt;font-family:'Times New Roman'">&#10003;</span></p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen - FGCL-4592-064 (SIERRAS)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.45pt;;text-indent:-2.45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Superior to Epoetin Alfa (p&#60;0.0001)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:16pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><span style="font-size:16pt;font-family:'Times New Roman'">&#10003;</span></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Superior to Epoetin Alfa (p&#60;0.0001)</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:13.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:16pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><span style="font-size:16pt;font-family:'Times New Roman'">&#10003;</span></p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.45pt;;text-indent:-2.45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;width:13.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INCIDENT DIALYSIS</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.45pt;;text-indent:-2.45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;width:13.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen - FGCL-4592-063 (HIMALAYAS)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.45pt;;text-indent:-2.45pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Superior to Epoetin Alfa (p&#61;0.0005)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:16pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><span style="font-size:16pt;font-family:'Times New Roman'">&#10003;</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-Inferior to Epoetin Alfa</p></td>
<td valign="middle" style="background-color:#FFFFFF;width:13.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:16pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><span style="font-size:16pt;font-family:'Times New Roman'">&#10003;</span></p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Additional Highlights from Recent Publications and Presentations of Roxadustat in CKD Anemia</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pooled Cardiovascular Safety Results</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-right:0.4%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S., the primary safety endpoint is time to first major adverse cardiovascular event (&#8220;MACE&#8221;), a composite endpoint of all-cause mortality, stroke and myocardial infarction, with secondary safety endpoint of &#8220;MACE+&#8221;, a composite endpoint consisting of the three components in MACE plus heart failure or unstable angina requiring hospitalization.The below cardiovascular safety analyses reflect the pooling strategy and analytical approach that was agreed upon with the FDA and presented in scientific journals/professional meetings. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Non-Dialysis - Pooled Cardiovascular Safety Data</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The intent-to-treat analyses, inclusive of data during on-treatment and post treatment long term follow-up (until a common study end date), was used in our primary cardiovascular safety analysis method for non-dialysis in the U.S. This approach accounts for the higher drop-out rate in the placebo arm. The figure below shows that in the 4,270 pooled non-dialysis patients (OLYMPUS, ANDES, and ALPS), the risk of MACE, MACE+, and all-cause mortality in roxadustat patients were comparable to that in placebo patients based on a reference non-inferiority margin of 1.3.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gapk0ju0ozex000003.jpg" title="" alt="" style="width:557px;height:276px;" /></p>
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dialysis - Pooled Cardiovascular Safety Data </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the pooled on-treatment analysis of 3,880 dialysis patients (HIMALAYAS, SIERRAS, and ROCKIES), the risk of MACE and all-cause mortality in roxadustat patients were comparable to epoetin alfa, based on a reference non-inferiority margin of 1.3. Roxadustat lowered the risk of MACE+ by 14% compared to epoetin alfa based on a hazard ratio of 0.86 and an upper bound of 95% CI under 1.0. The hazard ratios represent a point estimate of relative risk.&#160;&#160;</p>
<p style="text-align:center;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><img src="gapk0ju0ozex000004.jpg" title="" alt="" style="width:422px;height:216px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Incident Dialysis Subgroup - Pooled Cardiovascular Safety Data</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Data from the pooled incident dialysis patients were recently published in Kidney International Reports. (Provenzano R et al. Pooled Analysis of Roxadustat for Anemia in Patients with Kidney Failure Incident to Dialysis. KI Reports 2021. Available at https://www.kireports.org/article/S2468-0249(20)31851-9/fulltext.&#160;&#160;Accessed on 11FEB2021.) </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This is a clinically important subgroup of dialysis patients who started participation in roxadustat Phase 3 studies within their first four months of dialysis initiation. In these 1,526 incident dialysis patients, roxadustat reduced the risk of MACE by 30% and MACE+ by 34%, with a trend towards lower all-cause mortality. The lower MACE and MACE+ risks (compared to epoetin alfa) are based on hazard ratios of 0.70 and 0.66, respectively, with the upper bound of 95% CI under 1.0 for both endpoints. We believe this incident dialysis subpopulation provides clinically and commercially relevant and generalizable results for comparison of roxadustat versus epoetin alfa because most incident dialysis patients (as opposed to stable dialysis patients) were ESA-na&#239;ve or had only limited exposure to ESAs prior to study entry. In addition, the initiation of anemia therapy in this incident dialysis subgroup resembles clinical practice as the vast majority of U.S. patients start anemia therapy early in dialysis treatment (during the first four months of treatment).&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gapk0ju0ozex000005.jpg" title="" alt="" style="width:414px;height:256px;" /></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Iron-Metabolism Data</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In non-dialysis patients, roxadustat was effective regardless of whether the &#8220;iron-repletion&#8221; criteria (ferritin &#62;&#61;100 ng/mL AND TSAT &#62;&#61;20%) were met, including the 40% of patients whose iron stores were below those required for ESA treatment. Roxadustat also increased both serum iron and transferrin, resulting in the long-term clinical stability of TSAT while increasing the absolute amount of iron available for erythropoiesis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In dialysis patients, roxadustat treated patients required less IV iron supplementation than patients treated with ESA. Roxadustat facilitated iron transport and utilization by increasing both serum iron and iron-carrying capacity (TIBC), whereas these parameters were decreased and unchanged, respectively, with epoetin alfa. We believe these changes were most likely driven by the downstream effects of reduced hepcidin in roxadustat treated patients.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Efficacy at Raising Hemoglobin Irrespective of Iron Replete Status</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the non-dialysis pool (4,277 patients from ANDES, OLYMPUS, and ALPS), roxadustat increased hemoglobin (by 1.94 g/dL) regardless of whether patients were iron-replete (patients shown to have sufficient baseline stores of iron in their body, TSAT &#8805;20% and Ferritin &#8805;100 ng/mL) or not iron-replete.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sierras &#8211; U.S. Only Dialysis Study</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S. dialysis study SIERRAS, roxadustat raised and maintained Hb levels with stable mean doses over time regardless of baseline inflammation status, as measured by CRP levels. The dose requirement of roxadustat was not impacted by inflammation.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Mean Hb and Mean Weekly Dose of roxadustat (Top Figure) and Epoetin Alfa (Bottom Figure) Over Time in Patients with hsCRP &#8804;ULN or &#62;ULN (SIERRAS)</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gapk0ju0ozex000006.jpg" title="" alt="" style="width:624px;height:316px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gapk0ju0ozex000007.jpg" title="" alt="" style="width:624px;height:316px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:21.43%;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hsCRP: high-sensitivity C-reactive protein&#59; SE: standard error&#59; ULN: upper limit of normal.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The proportion of patients who required at least one red blood cell transfusion in the first 52 weeks was 12.5% with roxadustat compared to 21.1% with epoetin alfa (p&#60;0.05) in SIERRAS. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="page33"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ROXADUSTAT FOR THE TREATMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE IN CHINA</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2019, roxadustat (China tradename: &#29233;&#29790;&#21331;<span style="font-size:9pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>) received marketing authorization in China for the treatment of anemia caused by CKD in non-dialysis-dependent patients. Treatment for anemia caused by CKD in dialysis-dependent patients was approved in December 2018. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, results from our two China Phase 3 clinical trials were published in the <span style="font-style:italic;">New England Journal of Medicine</span>.<sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup> <sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, roxadustat was included on the updated NRDL released by China&#8217;s National Healthcare Security Administration. Roxadustat is included on the NRDL for the treatment of anemia in CKD.&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Opportunity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The currently available forms of treatment in China for anemia in CKD include ESAs, oral iron, intravenous iron, traditional Chinese medicine, and combinations thereof. ESAs are the largest segment, which we estimate to be approximately $275 million in sales, or approximately 80% of the total ESA market based on data from IQVIA China Hospital Pharmaceutical Audit. With the unique benefits of roxadustat to treat previously unaddressable patient populations, we believe the overall CKD anemia market will increase.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China is experiencing epidemiological changes in metabolic diseases due to economic development, urbanization and an aging population. Diabetes and hypertension are the leading causes of CKD in China, and rates have been growing over past two decades. We believe the increase in diabetes and hypertension prevalence will result in an increase of CKD anemia patients.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dialysis-Dependent CKD</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the latest estimates and published data, we believe there are over 600,000 dialysis patients in China, making it the largest single-country dialysis population in the world. With the substantial growth rate of dialysis patients (over 10% per year from 2011 to 2017), the Ministry of Health and the Chinese Society of Nephrology have publicly recognized the need for further investment in dialysis infrastructure.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The prevalence of CKD dialysis patients that have anemia (defined as hemoglobin &#60; 10g/dL) is estimated to be over 90%. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dialysis treatment is delivered in the form of hemodialysis or peritoneal dialysis. In China, approximately 85% of dialysis patients with CKD are on hemodialysis. Hemodialysis is performed primarily in dialysis clinics within hospitals, most of which are publicly owned. This is in contrast to the U.S. where freestanding dialysis centers located outside of hospitals is common practice. With recent regulatory changes, the number of privately owned dialysis clinics is growing at a rapid pace, a trend that has provided additional capacity to meet the growing demand. The remaining 14-15% of CKD patients (approximately 100,000) are on peritoneal dialysis, which is self-administered at home by patients, a setting which roxadustat is particularly well-suited for due to its oral administration. Peritoneal dialysis patients typically visit their nephrologists on a monthly basis at the hospital for monitoring and follow-up.&#160;&#160;</p>
<div style="align:left;"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top" style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&#160;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup>&#160;</span></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> N. Chen, et al. &#8220;Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis&#8221; N Engl J Med 381 (2019): 1011-22. DOI: 10.1056/NEJMoa1901713</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup>&#160;</span></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> N. Chen, et al. &#8220;Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis&#8221; N Engl J Med 381 (2019): 1001-1010. DOI: 10.1056/NEJMoa1813599</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Non-Dialysis-Dependent CKD</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate that there are over 10 million Stage 3-5 non-dialysis CKD patients in China with anemia (defined as hemoglobin &#60; 10g/dL). We believe the addressable population of non-dialysis patients with anemia (anemic patients that have been diagnosed and treated for CKD) is approximately 2-3 million, with 1-2 million of these addressable patients in Stages 3 and 4 and 1 million in Stage 5 non-dialysis. This Stage 5 population that is dialysis-eligible but not receiving dialysis is characteristic of developing markets like China, and presents a particular opportunity for roxadustat, as many patients have severe anemia.&#160;&#160; </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unmet Medical Need and Roxadustat Differentiation in China</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe there is a particularly significant unmet medical need for the treatment of anemia in CKD in China. Anemia is considered a risk multiplier for CKD patients and is commonly associated with increased rates of cardiovascular events, hospitalizations, CKD progression, and death. Several of the advantages that roxadustat, as an oral therapeutic, potentially offers over ESAs are particularly suited to address the unmet medical need in each of the three categories of CKD patients in China.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe there is chronic under-treatment of anemia within the CKD patient population on dialysis in China due in part to under-prescription of IV iron (often necessary for ESA treatment), and lack of efficacy in patients with inflammation. The most recent treatment guidelines published by the Chinese Society of Nephrology in 2018 recommended treatment to hemoglobin 11.0 g/dL to 12.0 g/dL. Even though over 70% of hemodialysis CKD patients, and approximately 60% of peritoneal dialysis CKD patients are treated with ESAs, based on the Chinese Renal Data System in 2015, less than 60% of dialysis patients reached 10.2 g/dL.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the non-dialysis population and peritoneal dialysis population, only a small percentage of patients receive anemia treatment, and those who do, they receive only a minimal level of treatment, including patients who are eligible for dialysis and who have severe anemia. Roxadustat, as an oral medication, can be easily administered in any setting and stored at room temperature. Injectable drugs like ESAs present a challenge in China because even subcutaneous administration is performed at hospitals and not in the home, in part due to the difficulty in refrigeration and administration of injectable medicines. Frequent hospital visits, for the sole purpose of receiving injectable ESA treatment (as well as IV iron, which is often necessary with ESA treatment), can present a substantial logistical and financial burden to patients.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the context of the rapidly growing China pharmaceutical market, we believe that the demand for anemia therapy will continue to grow as a result of an expanding CKD population, as well as the central government&#8217;s mandate to make dialysis more available through government reimbursement and build-out of dialysis facilities. In addition, as the standard of living improves in China, the demand for access to innovative drugs increases. In this context, we believe that roxadustat is a particularly promising product for this market.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commercialization</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca is our commercialization partner for roxadustat in China. Under our collaboration agreement, AstraZeneca leads commercialization activities and has responsibility for sales and marketing, and market access. FibroGen has responsibility for medical affairs, manufacturing (as the Marketing Authorization Holder), and pharmacovigilance. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pricing and Reimbursement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, roxadustat was included for the treatment of anemia in CKD on the updated NRDL released by China&#8217;s National Healthcare Security Administration. The list is effective for a standard two-year period from January 1, 2020 to December 31, 2021. Roxadustat will be subject to price re-negotiation at the end of 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe reimbursement is one of the two most critical market access factors for commercialization success in China, with the other being hospital listings. China is mostly a single-payor market with near universal healthcare provided by the government. Over 95% of the population receives healthcare coverage under one government-funded medical reimbursement plan or another, each with different levels of reimbursement. Commercial health insurance is available but is minimally adopted, and is seen as a supplement above and beyond government reimbursement.&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement for roxadustat will differ based on multiple factors including the CKD patient population (dialysis vs. non-dialysis), location, patient employment status, and if roxadustat is qualified into the &#8220;Critical Disease&#8221; or &#8220;Chronic Disease&#8221; insurance programs for such locations. We expect roxadustat reimbursement rates will be largely consistent with those ESAs listed on the NRDL. We believe in the next few years and in many parts of the country, reimbursement will reach a level where patient out-of-pocket costs will be in the range of 10-20% for dialysis and 30-50% for non-dialysis.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Hospital Listing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before roxadustat can be prescribed at a government hospital, which is 90% of the market in China, it has to be carried in the hospital formulary. The process of entry into the formulary is commonly referred to as &#8220;hospital listing&#8221;. Decisions are made on a hospital-by-hospital basis, where hospital listing committees meet anywhere from every six months to every five years. Temporary listings can be used in the interim, where the head of the department could place an ad-hoc order with the formulary for a single or handful of patients for small quantities of roxadustat. These market access constraints impact all drugs, not just roxadustat. Consistent with the experience of other product launches in China, significant market uptake is usually seen a few years after launch, although in the case of roxadustat, it could be sooner given the inclusion in NRDL within 12 months of market approval.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Tendering</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tendering is a provincial level procedure. For drugs with multiple brands, it is a collective tender process for purchases by government hospitals of a medicine included in provincial or local medicine procurement catalogs. In the case of roxadustat, it is a more administrative process than for most drugs as roxadustat is currently the only drug of its class (HIF-PHI) available on the market. The tendering process of roxadustat is substantially complete in all 31 provinces in China.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ROXADUSTAT FOR THE TREATMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE IN JAPAN</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Japan, our partner Astellas continues the commercial launch of EVRENZO&#174; (roxadustat), targeting healthcare providers that care for approximately 330,000 dialysis patients across Japan. EVRENZO is now approved for the treatment of anemia associated with CKD in both non-dialysis and dialysis patients. The supplemental NDA for the use of roxadustat in patients with anemia of CKD not on dialysis was approved in November 2020 by the Pharmaceuticals and Medical Devices Agency. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the 14-day Prescription Rule that is typically in place for the first 12 months of a product&#8217;s availability in Japan was lifted in December of 2020, creating a potential catalyst for EVRENZO utilization given it is the first HIF-PH inhibitor to no longer have this limitation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ROXADUSTAT FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA AND ANEMIA ASSOCIATED WITH MYELODYSPLASTIC SYNDROMES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on roxadustat&#8217;s mechanism of action and safety and efficacy profile to date, we believe it has the potential to treat anemia associated with many other conditions, including CIA and MDS.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Background of Chemotherapy-Induced Anemia</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As blood cell production in bone marrow is highly prolific, it is particularly vulnerable to the cytotoxic effects of chemotherapy used to treat cancer patients. Many chemotherapy agents directly impair hematopoiesis in bone marrow, including disruption of red blood cell production. The nephrotoxic effects of some cytotoxic agents, such as platinum-containing agents, can also result in decreased production of erythropoietin by the kidneys, further contributing to reduced red blood cell production. Radiation therapy has also been associated with hematologic toxicity.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approximately 40% of total solid tumor cancer patients, or approximately 6.8 million people, undergo chemotherapy each year globally, including 1.7 million in the U.S. and 3.2 million in China. Between 60% and 80% of these patients develop anemia. The incidence and severity of CIA depend on a variety of factors, including the tumor type or the level of toxicity of the therapy, and further increases with each successive chemotherapy round. We believe the addressable population is approximately 600,000 in the U.S. and 500,000 in China. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESAs have been recommended for patients experiencing CIA with the desirable goals of improvement in anemia-related symptoms and the avoidance of blood transfusion, which increases risk of infections and the risk of complications such as heart failure and allergic reactions. However, not all CIA patients respond to ESA therapy, which may be due to the etiology of their CIA or inflammatory comorbidity. ESA use also has associated toxicities, including increased thrombotic events, possible decreased survival and accelerated tumor progression, as published from randomized clinical trials and meta-analyses, that led to label restrictions and boxed warnings for ESAs in cancer populations in 2007, followed by the ESA Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) program.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Opportunity for Roxadustat in Chemotherapy-Induced Anemia</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESA sales for CIA dropped significantly in the U.S. since the reported safety risks of ESA use in cancer patients in 2006, from estimated $2.5 billion in 2006 to less than $0.5 billion in 2019. During the same period, the prevalence of diagnosed CIA remained at similar levels, and is expected to grow slightly.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that if our clinical program shows an acceptable safety and efficacy profile, roxadustat would have the potential to address anemia in this population of patients undergoing chemotherapy.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical Development of Roxadustat in Chemotherapy-Induced Anemia</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have completed enrollment in WHITNEY, our Phase 2 clinical trial of roxadustat in the U.S. in CIA. This is a single-arm open label study investigating the efficacy and safety of roxadustat for the treatment of anemia in 92 patients receiving myelosuppressive chemotherapy treatment for non-myeloid malignancies, with a treatment duration of 16 weeks. We expect topline data from this study in the second half of 2021.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Background of Anemia in Myelodysplastic Syndromes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Myelodysplastic syndromes are a diverse group of bone marrow disorders characterized by ineffective production of healthy blood cells and premature destruction of blood cells in the bone marrow, leading to anemia. In most MDS patients, the cause of the disease is unknown.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The prevalence of MDS in the U.S. is estimated to be between 60,000 and 170,000, and continues to rise as more therapies become available and patients are living longer with MDS. Annual incidence rates are estimated to be 4.9/100,000 adults in the U.S., and 1.51/100,000 adults in China.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anemia is the most common clinical presentation in MDS, seen in approximately 80% of MDS patients, and producing symptoms, including fatigue, weakness, exercise intolerance, shortness of breath, dizziness, and cognitive impairment.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Limitations of the Current Standard of Care for Anemia in Myelodysplastic Syndromes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stem cell transplant is the only potentially curative therapy for MDS, but it is not feasible in most patients due to their advanced age and frailty. The high rate of severe anemia leaves recurring red blood cell transfusions as the mainstay of care in MDS patients. Transfusion can result in direct organ damage through transfusional iron overload. Transfusion dependent MDS patients suffer higher rates of cardiac events, infections and transformation to acute leukemia, and a decreased overall survival rate when compared with non-transfused patients with MDS, and decreased survival compared to an age-matched elderly population. Patients receiving red blood cell transfusions may require an iron chelator in order to address toxic elements of iron overload such as lipid peroxidation and cell membrane, protein, DNA, and organ damage.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lower-risk MDS patients represent approximately 77% of total diagnosed MDS population. Most national and international guidelines recommend use of ESAs for anemia only in lower-risk MDS patients presenting with symptomatic anemia with serum EPO levels at or below 500 mU/mL.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even among the eligible subpopulation, the effectiveness of ESAs in treating anemia in MDS remains limited, with the best clinical study results showing 40% to 60% erythroid response rates, in studies where significantly high doses of ESAs were used, enrolled patients had low serum EPO levels, and in lower-risk categories. New strategies to broaden the eligible population, improve anemia and maintain adequate iron balance, as well as avoidance of transfusions, are highly desired in managing patients with MDS.&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reblozyl&#174; (luspatercept)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> was approved by the FDA in April 2020 for the treatment of anemia in adults with MDS with ring sideroblasts or myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis who need regular red blood cell transfusions and have not responded well to or cannot receive an ESA. It is the first and only erythroid maturation agent approved in the U.S., Europe, and Canada and is part of a global collaboration between Acceleron Pharma, Inc. and Bristol Myers Squibb. In 2020, Reblozyl net revenue was $274 million, including $115 million in Q4 2020.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Opportunity for Roxadustat in Myelodysplastic Syndromes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe there is a significant need for a safer, more effective, and more convenient option to address anemia in patients with lower-risk MDS. Roxadustat, our orally administered small molecule HIF-PH inhibitor, stimulates the body&#8217;s natural mechanism of red blood cell production and iron hemostasis based on cellular-level oxygen-sensing and iron-regulation mechanisms. Unlike ESAs which are limited to providing exogenous EPO, roxadustat activates a coordinated erythropoietic response in the body that includes the stimulation of red blood cell progenitors, an increase in the body&#8217;s production of endogenous EPO, and an increase in iron availability for hemoglobin synthesis, which we believe is important in a broad range of MDS patients. Moreover, in anemia of CKD, roxadustat has demonstrated the ability in clinical trials to increase and maintain hemoglobin levels in the presence of inflammation as measured by CRP, where ESAs have shown limited effect. We believe that roxadustat has the potential to replicate this result in MDS anemia patients, where it is not uncommon for patients to present with autoimmune and inflammatory conditions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical Development of Roxadustat in Myelodysplastic Syndromes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are continuing to enroll MATTERHORN, our Phase 3 placebo controlled, double-blind clinical trial to evaluate the safety and efficacy of roxadustat for treatment of anemia in MDS in the U.S. and Europe. This 160-patient trial is studying roxadustat in transfusion-dependent, lower-risk MDS patients, in which subjects are randomized 3:2 to receive roxadustat or placebo three-times-weekly. The primary endpoint is the proportion of patients who achieve transfusion independence by 28 weeks with secondary endpoints and safety evaluated at 52 weeks. We expect topline data from this study in the first half of 2022.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the open-label dose-finding component of this study, 24 lower-risk, transfusion dependent MDS patients with anemia were enrolled in three sequential starting dose cohorts (1.5 mg/kg, 2.0 mg/kg, and 2.5 mg/kg), with roxadustat doses adjusted every eight weeks per a pre-defined algorithm based on hemoglobin response. Best supporting care including red blood cell transfusion was allowed, as needed, per investigator&#8217;s discretion. Patients treated with roxadustat achieved a greater than or equal to 8-week transfusion independence rate of 38% in the first 28 weeks and 54% of patients had greater than or equal to 50% reduction in red blood cell transfusion over any eight weeks, from baseline. Roxadustat was generally well tolerated in each dose cohort. The dose level of 2.5 mg/kg was selected as the starting dose for the double-blind component of the study. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In China, we are preparing to enroll the Phase 3 double-blind, placebo-controlled portion of our Phase 2/3 clinical trial to evaluate the safety and efficacy of roxadustat in non-transfusion dependent, lower-risk MDS patients with anemia. One hundred thirty-five subjects will be randomized 2:1 to receive roxadustat or placebo three-times weekly for 26 weeks. The primary endpoint for this study is percentage of patients achieving a hemoglobin response.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PAMREVLUMAB FOR THE TREATMENT OF FIBROSIS AND CANCER</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were founded to discover and develop therapeutics for fibrosis and began studying CTGF shortly after its discovery. Our accumulated discovery research efforts indicate that CTGF is a critical common element in the progression of serious diseases associated with fibrosis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From our library of human monoclonal antibodies that bind to different parts of the CTGF protein and block various aspects of CTGF biological activity, we selected pamrevlumab, for which we have exclusive worldwide rights. We believe that pamrevlumab blocks CTGF and inhibits its central role in causing diseases associated with fibrosis. Our data to date indicate that pamrevlumab is a promising and highly differentiated product candidate with broad potential to treat a number of fibrotic diseases and cancers. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently conducting Phase 3 studies in pancreatic cancer, IPF and DMD. In the U.S., the FDA has granted Orphan Drug Designation to pamrevlumab for the treatment of IPF, LAPC, and DMD. In addition, the EMA has granted Orphan Medicinal Product Designation to pamrevlumab for the treatment of DMD. Pamrevlumab has also received Fast Track designation from the FDA for the treatment of both IPF and LAPC.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview of Fibrosis</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fibrosis is an aberrant response of the body to tissue injury that may be caused by trauma, inflammation, infection, cell injury, or cancer. The normal response to injury involves the activation of cells that produce collagen and other components of the extracellular matrix (&#8220;ECM&#8221;) that are part of the healing process. This healing process helps to fill in tissue voids created by the injury or damage, segregate infections or cancer, and provide strength to the recovering tissue. Under normal circumstances, where the cause of the tissue injury is limited, the scarring process is self-limited and the scar resolves to approximate normal tissue architecture. However, in certain disease states, this process is prolonged and excessive and results in progressive tissue scarring, or fibrosis, which can cause organ dysfunction and failure as well as, in the case of certain cancers, promote cancer progression.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Excess CTGF levels are associated with fibrosis. CTGF increases the abundance of myofibroblasts, a cell type that drives wound healing, and stimulates them to deposit ECM proteins such as collagen at the site of tissue injury. In the case of normal healing of a limited tissue injury, myofibroblasts eventually die by programmed cell death, or apoptosis, and the fibrous scarring process recedes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Multiple biological agents and pathways have been implicated in the fibrotic process, many of which converge on CTGF, a central mediator of fibrosis. In the case of cancer, the sustained tumor-associated fibrotic tissue promotes tumor cell survival and metastasis. CTGF is a secreted glycoprotein produced by fibroblasts, endothelium, mesangial cells and other cell types, including cancers, and is induced by a variety of regulatory modulators, including TGF-&#223; and VEGF. CTGF expression has been demonstrated to be up-regulated in fibrotic tissues. Thus, we believe that targeting CTGF to block or inhibit its activity could mitigate, stop or reverse tissue fibrosis. In addition, since CTGF is implicated in nearly all forms of fibrosis, we believe pamrevlumab has the potential to provide clinical benefit in a wide range of clinical indications that are characterized by fibrosis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until recently, it was believed that fibrosis was an irreversible process. It is now generally understood that the process is dynamic and potentially amenable to reversal. Based on studies in animal models of fibrosis of the liver, kidney, muscle and cardiovascular system, it has been shown that fibrosis can be reversed. It has also been demonstrated in humans that fibrosis caused by hepatitis virus can be reversed (Chang et al. Hepatology (2010)). Additionally, we have generated data in human and animal studies that lung fibrosis progression can be slowed, arrested, or possibly reversed in some instances upon treatment with pamrevlumab. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Clinical Development of Pamrevlumab &#8212; Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have performed clinical trials of pamrevlumab in IPF, pancreatic cancer, liver fibrosis and diabetic kidney disease. In eleven Phase 1 and Phase 2 clinical studies involving pamrevlumab to date, including more than 600 patients who were treated with pamrevlumab (about half of patients dosed for more than six months), pamrevlumab has been well-tolerated across the range of doses studied, and there have been no dose-limiting toxicities seen thus far.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Idiopathic Pulmonary Fibrosis</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Understanding IPF and Current Therapies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IPF is a form of progressive pulmonary fibrosis, or abnormal scarring, which destroys the structure and function of the lungs. As tissue scarring progresses in the lungs, transfer of oxygen into the bloodstream is increasingly impaired. Average life expectancy at the time of confirmed diagnosis of IPF is estimated to be between three to five years, with approximately two-thirds of patients dying within five years of diagnosis. Thus, the survival rates are comparable to some of the most deadly cancers. The cause of IPF is unknown but is believed to be related to unregulated cycles of injury, inflammation and fibrosis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with IPF experience debilitating symptoms, including shortness of breath and difficulty performing routine functions, such as walking and talking. Other symptoms include chronic dry, hacking cough, fatigue, weakness, discomfort in the chest, loss of appetite, and weight loss. Over the last decade, refinements in diagnosis criteria and enhancements in high-resolution computed tomography imaging technology (&#8220;quantitative HRCT&#8221;) have enabled more reliable diagnosis of IPF without the need for a lung biopsy.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. prevalence and incidence of IPF are estimated to be 44,000 to 135,000 cases, and 21,000 new cases per year, respectively, based on Raghu et al. (Am J Respir Crit Care Med (2006)) and on data from the United Nations Population Division. We believe that with the availability of technology to enable more accurate diagnoses, the number of individuals diagnosed per year with IPF will continue to increase.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are currently two therapies approved to treat IPF in Europe and the U.S., pirfenidone and nintedanib. The approvals and subsequent launches of Esbriet (pirfenidone) and Ofev (nintedanib) have clearly shown the commercial potential in IPF. Hoffmann-La Roche (&#8220;Roche&#8221;) reported worldwide sales of approximately $1.1 billion for 2019 and $1.2 billion for 2020 for Esbriet&#174; (pirfenidone). Similarly, Boehringer Ingelheim Pharma GmbH &#38; Co. KG (&#8220;Boehringer Ingelheim&#8221;) reported total sales of approximately $1.3 billion for Ofev&#174; (nintedanib) in 2018, and approximately $1.7 billion in 2019.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Phase 3 Clinical Development &#8211; Randomized, Double-Blind, Placebo-Controlled Trials of Pamrevlumab in IPF</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are conducting ZEPHYRUS-1, our Phase 3 trial of pamrevlumab in IPF patients, as well as our newly initiated ZEPHYRUS-2, a second IPF Phase 3 study. Both studies are double-blind, placebo-controlled Phase 3 trials targeting approximately 340 patients, each with a primary U.S. efficacy endpoint of change from baseline in forced vital capacity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary efficacy endpoint in Europe for each study is disease progression (defined by a decline in forced vital capacity (&#8220;FVC&#8221;) percent predicted of greater than or equal to 10% or death). Secondary endpoints will include clinical outcomes of disease progression, patient reported outcomes, and quantitative changes in lung fibrosis volume from baseline.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has affected enrollment in these IPF trials, more so than our other studies due to the vulnerability of this patient population. In addition to efforts we are making in ensuring patient safety, we are also working to expand enrollment through a number of methods, including expanding the number of clinical sites in China.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PRAISE &#8211; Study 067 &#8211; Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pamrevlumab in IPF</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, positive results from PRAISE, our randomized, double-blind, placebo-controlled Phase 2 clinical trial (Study 067), were published in <span style="font-style:italic;">The</span> <span style="font-style:italic;">Lancet Respiratory Medicine. </span>PRAISE was designed to evaluate the safety and efficacy of pamrevlumab in patients with mild-to-moderate IPF (baseline FVC<span style="font-style:italic;"> </span>percentage predicted of 55%), as well as topline results from two sub-studies that were added to evaluate the safety of combining pamrevlumab with approved IPF therapies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the double-blind, placebo-controlled 48-week portion of this study, 103 patients were randomized (1:1) to receive either 30mg/kg of pamrevlumab or placebo intravenously every three weeks. Lung function assessments were conducted at baseline and at Weeks 12, 24, 36 and 48. Quantitative HRCT assessments were performed at baseline and at Weeks 24 and 48.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab met the primary efficacy endpoint of change of FVC percent predicted, a measure of a patient&#8217;s lung volume as a percentage of what would be expected for such patient&#8217;s age, race, sex and height. The average decline (least squares mean) in FVC percent predicted from baseline to Week 48 was 2.9 in the pamrevlumab arm (n&#61;50) as compared to an average decline of 7.2 in the placebo arm (n&#61;51), a statistically significant difference of 4.33 (p&#61;0.033).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FVC Change by Visit</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gapk0ju0ozex000008.jpg" title="" alt="" style="width:500px;height:244px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab-treated patients had an average decrease (least squares mean) in FVC of 129 ml at Week 48 compared to an average decrease of 308 ml in patients receiving placebo, a statistically significant difference of 178 ml (p&#61;0.0249, using a linear slope analysis in the intent-to-treat population). This represents a 57.9% relative difference. In addition, the pamrevlumab-treated arm had a lower proportion of patients (10%) who experienced disease progression (defined by a decline in FVC percent predicted of greater than or equal to 10% or death), than did the placebo arm (31.4%) at Week 48 (p&#61;0.0103).</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Proportion of Patients with Decline in Percentage of Predicted FVC of 10% or Greater, or Death, by Visit</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gapk0ju0ozex000009.jpg" title="" alt="" style="width:464px;height:232px;" /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this study, we measured change in quantitative lung fibrosis (&#8220;QLF&#8221;) from baseline to Week 24 and Week 48 using quantitative HRCT. The pamrevlumab arm achieved a statistically significant reduction in the rate of progression of lung fibrosis compared to placebo using HRCT to measure QLF. The change in QLF volume from baseline to Week 24 for pamrevlumab-treated patients was 24.8 ml vs. 86.4 ml for placebo, with a treatment difference of -61.6 ml, p&#61;0.009. The change in QLF volume from baseline to 48 weeks was 75.4 ml in pamrevlumab-treated patients vs. 151.5 ml in patients on placebo, with a treatment difference of -76.2 ml, p&#61;0.038. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change from Baseline in Volume of Quantitative Lung Fibrosis (mL) in the Intention-to-Treat Population</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gapk0ju0ozex000010.jpg" title="" alt="" style="width:486px;height:240px;" /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As in our previous open label Phase 2 study, a correlation between FVC percent predicted and QLF was confirmed at both Week 24 and 48 in this study.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not aware of any other IPF therapies that have shown a statistically significant effect on lung fibrosis as measured by quantitative HRCT analysis.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The treatment effects of pamrevlumab were demonstrated not only on change in FVC, a measure of pulmonary function and IPF disease progression, and change in fibrosis using quantitative HRCT, but pamrevlumab-treated patients also showed a trend of clinically meaningful improvement in a measure of health-related quality of life using the St. George&#8217;s Respiratory Questionnaire (SGRQ) vs. a reduction in quality of life seen in placebo patients over the 48 weeks of treatment. The SGRQ quality of life measurement has been validated in chronic obstructive pulmonary disease. In the patients that were evaluated by the UCSD Shortness of Breath Questionnaire, pamrevlumab-treated patients had a significant attenuation of their worsening dyspnea in comparison to placebo patients.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab was well-tolerated in the placebo-controlled study. The treatment-emergent adverse events were comparable between the pamrevlumab and placebo arms and the adverse events in the pamrevlumab arm were consistent with the known safety profile of pamrevlumab. In this study, as compared with the placebo group, fewer pamrevlumab patients were hospitalized, following an IPF-related or respiratory treatment-emergent adverse event, or died for any reason.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The double-blind, active-controlled combination sub-studies were designed to assess the safety of combining pamrevlumab with standard of care medication in IPF patients. Study subjects were on stable doses of pirfenidone or nintedanib for at least three months and were randomized 2:1 to receive 30 mg/kg of pamrevlumab or placebo every three weeks for 24 weeks. Thirty-six patients were enrolled in the pirfenidone sub-study and 21 patients were enrolled in the nintedanib sub-study. Pamrevlumab appeared to be well-tolerated when given in combination with either pirfenidone or nintedanib.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Study 049 &#8211; Open-Label Phase 2 Trial of Pamrevlumab in IPF</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our completed open-label extension of Study 049, a Phase 2 open-label, dose-escalation study to evaluate the safety, tolerability, and efficacy of pamrevlumab in 89 patients with IPF, was consistent with our results from our randomized, double-blind, placebo-controlled Phase 2 clinical trial PRAISE. We presented data from our open-label Phase 2 IPF extension study (049) at the International Colloquium on Lung and Airway Fibrosis in November 2016, reporting that no safety issues were observed during prolonged treatment with pamrevlumab. Some of the 37 patients who enrolled in the extension study were treated with pamrevlumab for up to five years. Trends regarding improved or stable pulmonary function and stable fibrosis observed during the initial one-year study were also observed in the extension study.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pancreatic Cancer</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Understanding Pancreatic Cancer and the Limitations of Current Therapies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain solid malignant tumors have a prominent fibrosis component consisting mostly of ECM that contributes to metastasis and progressive disease. ECM is the connective tissue framework of an organ or tissue. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pancreatic ductal adenocarcinoma, or pancreatic cancer, is the third leading cause of cancer deaths in the U.S. According to the European Commission&#8217;s European Cancer Information System, there were 100,005 new cases of pancreatic cancer and 95,373 deaths from pancreatic cancer in Europe projected for 2018. The National Cancer Center of Japan estimated that there were 36,239 new cases of pancreatic cancer in 2014, increased from 24,442 cases in 2004. In its report of December 2017, Decision Resources Group estimated that the major market sales (U.S., Europe and Japan) of pancreatic cancer drugs will grow from $1.3 billion in 2016 to approximately $3.7 billion in 2026. According to the U.S. National Cancer Institute, there were an estimated 57,000 new cases of pancreatic cancer in the U.S. in 2019. Fifty percent of new cases are metastatic. Another 15-20% have localized resectable tumors. The remaining 30-35% have localized but unresectable tumors. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For those with non-resectable tumors, median survival is eight to 12 months post-diagnosis, and about 8% realize five years of survival&#59; similar to metastatic cases. For those with resectable tumors, 50% survive 17 to 27 months post-diagnosis and ~20% report five-year survival.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pancreatic cancer is aggressive and typically not diagnosed until it is largely incurable. Most patients are diagnosed after the age of 45, and according to the American Cancer Society, 94% of patients die within five years from diagnosis. The majority of patients are treated with chemotherapy, but pancreatic cancer is highly resistant to chemotherapy. Approximately 15% to 20% of patients are treated with surgery&#59; however, even for those with successful surgical resection, the median survival is approximately two years, with a five-year survival rate of 15% to 20% (Neesse et al. Gut (2011)). Radiation treatment may be used for locally advanced diseases, but it is not curative.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The duration of effect of approved anti-cancer agents to treat pancreatic cancer is limited. Gemcitabine demonstrated improvement in median overall survival from approximately four to six months, and erlotinib in combination with gemcitabine demonstrated an additional ten days of survival. Nab-paclitaxel in combination with gemcitabine was approved by the FDA in 2013 for the treatment of pancreatic cancer, having demonstrated median survival of 8.5 months. The combination of folinic acid, 5-fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) was reported to increase survival to 11.1 months from 6.8 months with gemcitabine. These drugs illustrate that progress in treatment for pancreatic cancer has been modest, and there remains a need for substantial improvement in patient survival and quality of life.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The approved chemotherapeutic treatments for pancreatic cancer target the cancer cells themselves. Tumors are composed of cancer cells and associated non-cancer tissue, or stroma, of which ECM is a major component. In certain cancers such as pancreatic cancer, both the stroma and tumor cells produce CTGF which in turn promotes the proliferation and survival of stromal and tumor cells. CTGF also induces ECM deposition that provides advantageous conditions for tumor cell adherence and proliferation, promotes blood vessel formation, or angiogenesis, and promotes metastasis, or tumor cell migration, to other parts of the body.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pancreatic cancers are generally resistant to powerful chemotherapeutic agents, and there is now growing interest in the use of an anti-fibrotic agent to diminish the supportive role of stroma in tumor cell growth and metastasis. The anti-tumor effects observed with pamrevlumab in preclinical models indicate that it has the potential to inhibit tumor expansion through effects on tumor cell proliferation and apoptosis as well as reduce metastasis.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Phase 3 Clinical Development &#8211; Randomized, Double-Blind, Placebo-Controlled Trial of Pamrevlumab in Locally Advanced, Unresectable Pancreatic Cancer</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to enroll LAPIS, our double-blind placebo controlled Phase 3 clinical program for pamrevlumab as a neoadjuvant therapy for LAPC. We intend to enroll approximately 260 patients, randomized at a 1:1 ratio to receive either pamrevlumab or placebo, in each case in combination with gemcitabine and nab-paclitaxel. We expect topline resection data from this study in the second half of 2022.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Study 069 &#8211; Randomized, Open-Label, Active-Controlled Phase 1/2 Trial of Pamrevlumab in Locally Advanced Pancreatic Cancer</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to follow patients in our ongoing open-label, randomized (2:1) Phase 1/2 trial (FGC004C-3019-069) of pamrevlumab combined with gemcitabine plus nab-paclitaxel chemotherapy vs. the chemotherapy regimen alone in patients with inoperable locally advanced pancreatic cancer that has not been previously treated. We enrolled 37 patients in this study and completed the six-month treatment period and surgical assessment at the end of 2017. The overall goal of the trial is to determine whether the pamrevlumab combination can convert inoperable pancreatic cancer to operable, or resectable, cancer. Tumor removal is the only chance for cure of pancreatic cancer, but only approximately 15% to 20% of patients are eligible for surgery.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We reported updated results from this ongoing study at the American Society of Clinical Oncology Annual Meeting in June 2018. A higher proportion (70.8%) of pamrevlumab-treated patients whose tumors were previously considered unresectable became eligible for surgical exploration than patients who received chemotherapy alone (15.4%), based on pre-specified eligibility criteria at the end of 6 months of treatment. Furthermore, a higher proportion of pamrevlumab-treated patients (33.3%) achieved surgical resection than those who received chemotherapy alone (7.7%).&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, this data showed improved overall survival among patients whose tumors were resected vs. not resected (NE vs. 18.56 months, p-value&#61;0.0141) and a trend toward improved overall survival in patients eligible for surgery vs. patients who were not (27.73 vs. 18.40 months, p-value&#61;0.0766). All of the patients on study at the time of the results reported in June 2018 continue to remain on study. No increase in serious adverse events was observed in the pamrevlumab arm and no delay in wound healing was observed post-surgery.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with LAPC have median survival of less than 12 months, only slightly better than patients with metastatic pancreatic cancer, whereas patients with resectable pancreatic cancer have a much better prognosis with median survival of approximately 23 months and some patients being cured. If pamrevlumab in combination with chemotherapy continues to demonstrate an enhanced rate of conversion from unresectable cancer to resectable cancer, it may support the possibility that pamrevlumab could provide a substantial survival benefit for locally advanced pancreatic cancer patients.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Completed Clinical Trials of Pamrevlumab in Pancreatic Cancer</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We completed an open-label Phase 1/2 (FGCL-MC3019-028) dose finding trial of pamrevlumab combined with gemcitabine plus erlotinib in patients with previously untreated locally advanced (Stage 3) or metastatic (Stage 4) pancreatic cancer. These study results were published in the <span style="font-style:italic;">Journal of Cancer</span> <span style="font-style:italic;">Clinical Trials </span>(Picozzi et al., J Cancer Clin Trials 2017, 2:123). Treatment continued until progression of the cancer or the patient withdrew for other reasons.<span style="font-style:italic;"> </span>Patients were then followed until death. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seventy-five patients were enrolled in this study with 66 (88%) having Stage 4 metastatic cancer. The study demonstrated a dose-related increase in survival. At the lowest doses, no patients survived for even one year while at the highest doses up to 31% of patients survived one year.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A post-hoc analysis found that there was a significant relationship between survival and trough levels of plasma pamrevlumab measured immediately before the second dose (Cmin), as illustrated below. Cmin greater than or equal to 150 &#181;g/mL was associated with significantly improved progression-free survival (p&#61;0.01) and overall survival (p&#61;0.03) vs. those patients with Cmin less than 150 &#181;g/mL. For patients with Cmin &#62;150 &#181;g/mL median survival was 9.0 months compared to median survival of 4.4 months for patients with Cmin &#60;150 &#181;g/mL. Similarly, 34.2% of patients with Cmin &#62;150 &#181;g/mL survived for longer than one year compared to 10.8% for patients with Cmin &#60;150 &#181;g/mL. These data suggest that sufficient blockade of CTGF requires pamrevlumab threshold blood levels of approximately 150 &#181;g/mL in order to improve survival in patients with advanced pancreatic cancer.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Increased Pancreatic Cancer Survival Associated with Increased Plasma Levels of Pamrevlumab</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><img src="gapk0ju0ozex000011.jpg" title="" alt="" style="width:440px;height:310px;" /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Kaplan-Meier plot provides a representation of survival of all patients in the clinical trial. Each vertical drop in the curve represents a recorded event (death) of one or more patients. When a patient&#8217;s event cannot be determined either because he or she has withdrawn from the study or because the analysis is completed before the event has occurred, that patient is &#8220;censored&#8221; and denoted by a symbol (&#9679;) on the curve at the time of the last reliable assessment of that patient.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the study, the majority of adverse events were mild to moderate, and were consistent with those observed for erlotinib plus gemcitabine treatment without pamrevlumab. There were 99 treatment-emergent serious adverse events&#59; six of which were assessed as possibly related to the investigational drug by the principal investigator, and 93 as not related to study treatment. After investigation, it is our belief that there is no causal relationship between pamrevlumab and the treatment-emergent serious adverse events deemed possibly related by the principal investigator. We did not identify any evolving dose-dependent pattern, and higher doses of pamrevlumab were not associated with higher numbers of serious adverse events or greater severity of the serious adverse events observed.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab for Duchenne Muscular Dystrophy</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Understanding DMD and the Limitations of Current Therapies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S., approximately one in every 5,000 boys have DMD, and approximately 20,000 children are diagnosed with DMD globally each year. There are currently no approved disease-modifying treatments. Despite taking steroids to mitigate progressive muscle loss, a majority of children with DMD are non-ambulatory by adolescence and median survival is age 25. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DMD is an inherited disorder of one of the dystrophin genes resulting in absence of the dystrophin protein and abnormal muscle structure and function, leading to progressively diminished mobility as well as pulmonary function and cardiac function, which result in early death. Constant myofiber breakdown results in persistent activation of myofibroblasts and altered production of ECM resulting in extensive fibrosis in skeletal muscles of DMD patients. Desguerre et al. (2009) showed that muscle fibrosis was the only myo-pathologic parameter that significantly correlated with poor motor outcome as assessed by quadriceps muscle strength, manual muscle testing of upper and lower limbs, and age at ambulation loss. Numerous pre-clinical studies including those in the mdx model of DMD suggest that CTGF contributes to the process by which muscle is replaced by fibrosis and fat and that CTGF may also impair muscle cell differentiation during muscle repair after injury.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Phase 3 Clinical Development &#8211; LELANTOS, a double-blind, placebo-controlled trial in non-ambulatory DMD patients</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the third quarter of 2020, we initiated a Phase 3 clinical trial, LELANTOS 1, evaluating pamrevlumab as a treatment for DMD. LELANTOS 1 is a double-blind, placebo-controlled trial in approximately 90 non-ambulatory DMD patients. Patients will be randomized at a 1:1 ratio to pamrevlumab or placebo and have a treatment period of 52 weeks. The primary endpoint will assess change in upper limb strength and additional endpoints will include pulmonary, performance, cardiac, and fibrosis assessments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also plan to initiate a Phase 3 clinical trial, LELANTOS 2, evaluating pamrevlumab in 70 ambulatory DMD patients.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect topline data from these studies in the second half of 2022.&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Phase 2 Open-Label Trial of Pamrevlumab in DMD<span style="font-weight:normal;font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019 at the Parent Project Muscular Dystrophy meeting, we reported topline results from this 21 patient open-label single-arm trial in non-ambulatory DMD patients. This one-year administrative analysis compared our Phase 2 data to previously published natural disease history studies of DMD patients. While we cannot make direct comparisons between our trial and previously published data due to, among other things, differences in subject numbers, baseline characteristics, inclusion/exclusion criteria, treatment protocols, and analysis methods, we are encouraged by the data obtained so far. Pamrevlumab was well tolerated in this study. &#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In pulmonary function tests, the results from our study indicate a potential reduction in the 1-year decline in FVC percent predicted from baseline for pamrevlumab-treated patients when compared to FVC data of DMD patients (whether such patients were taking steroids or not) published in 2019 by Ricotti. In the 2019 Ricotti study, the DMD patients were treated with steroids only. Similarly, all of the patients in our Phase 2 pamrevlumab trial were on steroids. In addition, pamrevlumab showed less decline in both percent predicted forced expiratory volume as compared to previously published study results of Meier in 2016, and in percent predicted peak expiratory flow rate, compared to what was observed in the study by Ricotti in 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our data showed an increase in cardiac function, measured by mean change of left ventricular ejection fraction (&#8220;LVEF&#8221;), of 0.29% from baseline for pamrevlumab-treated patients. Whereas, data published in 2018 by McDonald of DMD patients only on steroids showed a mean LVEF decline of 0.82% from baseline in one year.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In muscle function tests, the majority of the results of this Phase 2 study showed the mean change from baseline in pamrevlumab-treated patients were more favorable than previously published data. Our results showed a positive increase in grip-strength score in both dominant and non-dominant hands at one year of treatment with pamrevlumab, while earlier results from a 2015 study by Seferian showed a decline at one year as expected. In the performance of the upper limb (&#8220;PUL&#8221;) test specifically developed for DMD patients, pamrevlumab-treated patients had a mean change from baseline of -1.53. In the 2019 study by Ricotti of DMD patients taking either nothing or only steroids, the annual mean change in the PUL test was -4.13. Furthermore, in our study a strong correlation between change in biceps brachii T2-mapping and change in PUL score was observed, demonstrating stabilization and even possible improvement in the muscle fibrosis burden.&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commercialization Strategy for Pamrevlumab</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="page26">Our goal, if pamrevlumab is successful, is to be a leader in the development and commercialization of novel approaches for inhibiting fibrosis and treating certain forms of cancer and muscular dystrophy diseases. To date, we have retained exclusive worldwide rights for pamrevlumab. We have commenced brand development activities for pamrevlumab and will be advancing these efforts in preparation for potential launches in IPF, LAPC and DMD, consistent with the approaches of companies with a product in late-stage clinical development.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research at FibroGen</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-right:1.59%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research programs at FibroGen are grounded in our three areas of expertise: HIF biology, 2-oxoglutarate enzymology, and CTGF biology.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-right:1.59%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have applied our expertise in the field of HIF-PH inhibition to develop an understanding of other areas of HIF biology with important therapeutic implications. This consistent progression of discovery has led to findings relating to HIF-mediated effects associated with inflammatory pathways, various aspects of iron metabolism, insulin sensitivity and glucose and fat metabolism, neurological disease, and ischemic injury. There are at least three different HIF-PH enzymes that are known to regulate the stability of HIF &#8212; these enzymes are commonly referred to in the scientific literature as PHD1, PHD2 and PHD3. Studies of genetically modified mice, in which the individual HIF-PH enzymes have been deleted, have revealed that PHD2 plays a major role in the regulation of erythropoiesis by HIF. In contrast, PHD1 and PHD3 appear to play less important roles in HIF-mediated erythropoiesis, but instead have been implicated in other important biological pathways. We believe that both pan-PHD and PHD-selective inhibitors could have important therapeutic applications beyond anemia.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-right:1.59%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The HIF-PH enzymes that are the targets of roxadustat belong to a broader family of enzymes known as 2-oxoglutarate (2OG)-dependent oxygenases. In humans, this family comprises more than 60 members that play important roles in a diverse range of biological processes including collagen biosynthesis, oxygen sensing, epigenetic regulation, nucleic acid modification/repair, and lipid metabolism. The first members of this enzyme family to be characterized were the collagen prolyl hydroxylases, which play a critical role in the biosynthesis of collagen and as a result, are potential targets for the treatment of fibrotic disease. Other members of the 2OG-dependent oxygenase family with relevance to human disease include the Jumonji domain-containing histone demethylases, which are emerging cancer targets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-right:0.2%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fact that all members of the 2OG-dependent oxygenase enzyme family use 2OG as a co-substrate makes them viable targets for small molecule inhibitors that compete with 2OG. FibroGen has been a leader in inhibition of enzymes belonging to this family, and our internal medicinal chemistry efforts have generated a library of novel compounds designed to target the 2OG-dependent oxygenase family.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, we have applied our knowledge of CTGF to investigate additional applications of agents that interfere with the role of this protein in disease. In some instances, we are exploring direct engagement of CTGF itself.&#160;&#160;In other instances, we are studying the regulation of CTGF.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">COLLABORATIONS </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenue to date has been generated primarily from our collaboration agreements with Astellas and AstraZeneca for the development and commercialization of roxadustat. In addition, we started roxadustat commercial sales in China in the third quarter of 2019. For fiscal year ended December 31, 2020, 58% of our revenue was related to our collaboration agreements, and 42% of our revenue was from roxadustat commercial sales in China. For the fiscal years ended December&#160;31, 2019 and 2018, substantially all of our revenue was related to our collaboration agreements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Astellas</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have two agreements with Astellas for the development and commercialization of roxadustat, one for Japan, and one for Europe, the Commonwealth of Independent States, the Middle East and South Africa. Under these agreements, we provided Astellas the right to develop and commercialize roxadustat for anemia in these territories.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We share responsibility with Astellas for clinical development activities required for U.S. and Europe regulatory approval of roxadustat, and share equally those development costs under the agreed development plan for such activities. Astellas will be responsible for clinical development activities and all associated costs required for regulatory approval in all other countries in the Astellas territories. Astellas will hold and have responsibility for regulatory filings in its territories. We are responsible, either directly or through our contract manufacturers, for the manufacture and supply of all quantities of roxadustat to be used in development and commercialization under the agreements, other than roxadustat drug product for Japan. Astellas is responsible for roxadustat commercialization activities in the Astellas territories.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">AstraZeneca</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have two agreements with AstraZeneca for the development and commercialization of roxadustat for anemia, one for China (the &#8220;China Agreement&#8221;), and one for the U.S. and all other countries not previously licensed to Astellas (the &#8220;U.S./RoW Agreement&#8221;). Under these agreements, we provided AstraZeneca the right to develop and commercialize roxadustat for anemia in these territories. We share responsibility with AstraZeneca for clinical development activities required for U.S. regulatory approval of roxadustat, and FibroGen will transfer the U.S. NDA to AstraZeneca upon approval. AstraZeneca will hold the equivalent regulatory filings in the other licensed countries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In China, our subsidiary FibroGen (China) Medical Technology Development Co., Ltd. (&#8220;FibroGen Beijing&#8221;) has conducted the development work for CKD anemia and will continue to hold all of the regulatory licenses issued by China regulatory authorities and be primarily responsible for regulatory, clinical and manufacturing. China development costs are shared 50/50. AstraZeneca is also responsible for 100% of development expenses in all other licensed territories outside of China. We are responsible, ourselves and through our contract manufacturers, for the manufacture and supply of all quantities of roxadustat to be used in development and commercialization under the AstraZeneca agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the China Agreement, which is conducted through FibroGen China Anemia Holdings, Ltd. (&#8220;FibroGen Cayman&#8221;), FibroGen Beijing, and FibroGen International (Hong Kong) Limited (collectively, &#8220;FibroGen China&#8221;), the commercial collaboration is structured as a 50/50 profit share, which was restructured in the third quarter of 2020. Pursuant to an Amendment to the China Agreement, <span style="font-size:8pt;">t</span>he parties agreed to establish a jointly owned entity to conduct distribution. FibroGen Beijing will manufacture and transfer commercial product to the distribution entity in exchange for a transfer price at a percentage of net sales. AstraZeneca will conduct sales and marketing activities in China for roxadustat, which will be billed to the distribution entity, subject to a cap of a percentage of roxadustat net sales until AstraZeneca has recouped its sales and marketing expenses, at which time it will bill actual expenses, subject to the cap. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Additional Information Related to Collaboration Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional information related to our collaboration agreements is set forth in Item 7 of this Annual Report on Form 10-K, and Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues,</span> to our consolidated financial statements under Item&#160;8 of this Annual Report. Information about collaboration partners that accounted for more than 10% of our total revenue or accounts receivable for the last three fiscal years is set forth in Note 15, <span style="font-style:italic;">Segment and Geographic Information</span>, to our consolidated financial statements under Item&#160;8 of this Annual Report.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">COMPETITION</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pharmaceutical and biotechnology industries are highly competitive, particularly in some of the indications we are developing drug candidates, including anemia in CKD, IPF, pancreatic cancer, and DMD. We face competition from multiple other pharmaceutical and biotechnology companies, many of which have significantly greater financial, technical and human resources and experience in product development, manufacturing and marketing. These potential advantages of our competitors are particularly a risk in IPF, pancreatic cancer, and DMD, where we do not currently have a development or commercialization partner.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect any products that we develop and commercialize to compete based on, among other things, efficacy, safety, convenience of administration and delivery, price, the level of generic competition, and the availability of reimbursement from government and other third-party payors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When any of our product candidates are approved, they will compete with currently marketed products, and product candidates that may be approved for marketing in the future, for treatment of the indications described below.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we will likely face competition from other companies developing treatments of other anemia indications that we may also seek to pursue in the future or that may be sold in indications we are pursuing but for which they are not yet approved. We may face competition for patient recruitment, enrollment for clinical trials, and potentially in commercial sales. There may also be new therapies for renal-related diseases that could limit the market or level of reimbursement available for roxadustat.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Approved Medicines </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drugs that will compete with roxadustat are expected to include ESAs, particularly in those patient segments where ESAs are used. Some of the available ESAs include epoetin alfa (EPOGEN<span style="font-size:9pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> marketed by Amgen Inc. in the U.S., Procrit<span style="font-size:9pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> and Erypo<span style="font-size:9pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>/Eprex<span style="font-size:9pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>, marketed by Johnson&#160;&#38; Johnson, Inc. and Espo<span style="font-size:9pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> marketed by Kyowa Hakko Kirin in Japan and China), darbepoetin (Amgen/Kyowa Hakko Kirin&#8217;s Aranesp<span style="font-size:9pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> and NESP<span style="font-size:9pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>) and Mircera<span style="font-size:9pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span> marketed by Roche outside the U.S. and by<span style="font-size:12pt;"> </span>Vifor Pharma, a Roche licensee, in the U.S. and Puerto Rico, as well as biosimilar versions of these currently marketed ESA products. ESAs have been used in the treatment of anemia in CKD for more than 30 years, serving a significant majority of dialysis patients. While non-dialysis CKD anemia patients who are not under the care of nephrologists, including those with diabetes and hypertension, do not typically receive ESAs and are often left untreated, some patients under nephrology or hematology care may be receiving ESA therapy. It may be difficult to encourage healthcare providers and patients to switch to roxadustat from products with which they have become familiar. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.14%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Biosimilars</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first biosimilar ESA, Pfizer&#8217;s Retacrit&#174; (epoetin zeta), entered the U.S. market in November 2018. Market penetration of Retacrit and the potential addition of other biosimilar ESAs currently under development may alter the competitive and pricing landscape of anemia therapy in CKD patients on dialysis under the end-stage renal disease bundle. The patents for Amgen&#8217;s EPOGEN<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (epoetin alfa) expired in 2004 in Europe, and the final material patents in the U.S. expired in May 2015. Several biosimilar versions of currently marketed ESAs are available for sale in Europe, China and other territories. In the U.S., a few ESA biosimilars are currently under development. Sandoz, a division of Novartis, markets Binocrit&#174; (epoetin alfa) in Europe and may file a biosimilar Biologics License Application in the U.S.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.14%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Product Candidates in Development</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also face competition from potential new anemia therapies currently in clinical development, including in those patient segments not adequately addressed by ESAs. Companies that are currently developing HIF-PH inhibitors for anemia in CKD indications include GlaxoSmithKline plc (&#8220;GSK&#8221;), Bayer Corporation (&#8220;Bayer&#8221;), Akebia Therapeutics, Inc. (&#8220;Akebia&#8221;), Otsuka Pharmaceutical (&#8220;Otsuka&#8221;), Akebia&#8217;s partner in the U.S. and Europe, Japan Tobacco, and Zydus Cadila (India) (&#8220;Zydus&#8221;). Akebia has completed Phase 3 studies in CKD patients on dialysis and not on dialysis in the U.S., as well as a Phase 3b, randomized, open-label, active-controlled trial evaluating the efficacy and safety of oral vadadustat once daily and three times weekly for the maintenance treatment of anemia in hemodialysis subjects converting from erythropoiesis stimulating agents. The study completion date is estimated to be May 2022. Akebia announced an additional Phase 3 study evaluating the efficacy and safety of dose conversion from a long-acting erythropoiesis stimulating agent (Mircera&#174;) to three times weekly oral vadadustat for the maintenance treatment of anemia in hemodialysis subjects. The estimated study start date is February 2021. Akebia has publicly stated their intent to file the vadadustat NDA in the U.S. in the second quarter of 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.14%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Japan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Japan, Mitsubishi Tanabe Pharmaceutical Corporation, Akebia&#8217;s collaboration partner, received approval for vadadustat on June 29, 2020 for the treatment of anemia of CKD patients on and not on dialysis. GSK received approval for daprodustat in Japan on June 29, 2020 for the treatment of anemia of CKD patients on and not on dialysis. Price listing for the launch in Japan of both vadadustat and daprodustat occurred in the third quarter of 2020, with pricing in line with roxadustat pricing. GSK is also conducting global Phase 3 studies in CKD patients on dialysis and not on dialysis, and expects to complete those studies by March 2022. GSK and Kyowa Hakko Kirin announced in November 2018 that the two companies signed a strategic commercialization deal in Japan for daprodustat. Bayer has completed global Phase 2 studies and its HIF-PH inhibitor is now in Phase 3 development in CKD populations on dialysis and not on dialysis in Japan. Japan Tobacco received approval in Japan for enarodustat for the treatment of anemia in CKD patients on dialysis and not on dialysis, to be sold by Torii Pharmaceuticals Ltd as ENAROY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>. Japan Tobacco and its partner JW Pharmaceuticals started a Phase 3 study in dialysis patients in Korea in 2019. Zydus started Phase 3 studies in dialysis and non-dialysis CKD patients in India in 2019. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.14%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">China</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In China, biosimilars of epoetin alfa are offered by Chinese pharmaceutical companies such as EPIAO marketed by 3SBio Inc. as well as more than 15 other local manufacturers. We may also face competition by HIF-PH inhibitors from other companies such as Akebia, Bayer, and GSK, which was authorized by the National Medical Products Administration (&#8220;NMPA&#8221;) to conduct trials in China to support its ex-China regulatory filings. Two domestic companies, Jiangsu Hengrui Medicine Co., Ltd. and Guandong Sunshine Health Investment Co., Ltd, have been permitted by the NMPA to conduct clinical trials for CKD anemia patients both on dialysis and not on dialysis, and 3SBio Inc. has submitted a clinical trial application to the NMPA to initiate trials for their HIF-PH inhibitor. Another domestic company, China Medical System Holdings Ltd., in-licensed desidustat, a compound that is currently in Phase 3 trials in India, from Zydus for greater China in January 2020. In January 2021, China Medical System Holdings Ltd. was granted approval by the NMPA in China to begin trials for desidustat in patients with anemia of CKD, including dialysis and non-dialysis patients. Shenzhen Salubris Pharmaceutical Co., Ltd., a domestic company in China, has in-licensed enarodustat from Japan Tobacco and received NMPA approval in the third quarter of 2020 to initiate Phase 3 studies. Akebia announced in April 2017 an expansion of their U.S. collaboration with Otsuka to add markets, including China. 3SBio Inc. announced in 2016 its plan to begin a Phase 1 clinical trial of a HIF-PH inhibitor for the China market.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.14%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">CIA and MDS </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, Zydus received approval from the FDA to begin a Phase 1 study of desidustat for the treatment of CIA, which could potentially be competitive with roxadustat within this indication.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reblozyl&#174; (luspatercept) was approved by the FDA in April 2020 for the treatment of anemia in adults with MDS with ring sideroblasts or myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis who need regular red blood cell transfusions and have not responded well to or cannot receive an ESA. It is the first and only erythroid maturation agent approved in the U.S., Europe, and Canada and is part of a global collaboration between Acceleron Pharma, Inc. and Bristol Myers Squibb. In 2020, Reblozyl net revenue was $274 million, including $115 million in Q4 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.14%;"><span style="font-style:italic;">Large Dialysis Organizations</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The majority of the current CKD anemia market focuses on dialysis patients, who visit dialysis centers on a regular basis, typically three times a week, and anemia therapies are administered as part of the visit. Two of the largest operators of dialysis clinics in the U.S., DaVita Healthcare Partners Inc. (&#8220;DaVita&#8221;), and Fresenius Medical Care AG&#160;&#38; Co. KGaA (&#8220;Fresenius&#8221;), collectively provide dialysis care to more than 80% of U.S. dialysis patients, and therefore have historically secured long-term contracts including rebate terms with Amgen. DaVita has a six-year sourcing and supply agreement with Amgen effective through 2022. Fresenius&#8217; contract with Amgen expired in 2015, following which Fresenius is providing Roche&#8217;s ESA Mircera&#174; to a significant portion of its U.S. dialysis patients. Successful penetration in this market may require our partner AstraZeneca to enter into an agreement with Fresenius, DaVita, or other dialysis organizations, on favorable pricing terms to each party. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently in Phase 3 development of pamrevlumab in IPF, locally advanced pancreatic cancer, and DMD. Most of our competitors have significantly more resources and expertise in development, commercialization and manufacturing, particularly due to the fact that we have not yet established a partnership for pamrevlumab. For example, both Roche and Boehringer Ingelheim, which market products for the treatment of IPF in the U.S., have successfully developed and commercialized drugs in various indications and have built sales organizations that we do not currently have&#59; both have more resources and more established relationships when competing with us for patient recruitment and enrollment for clinical trials or, if we are approved, in the market.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:7.14%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Idiopathic Pulmonary Fibrosis</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If approved and launched commercially to treat IPF, pamrevlumab is expected to compete with Roche&#8217;s Esbriet&#174; (pirfenidone), and Boehringer Ingelheim&#8217;s Ofev&#174; (nintedanib). We believe that if pamrevlumab can be shown to safely stabilize or reverse lung fibrosis, and thus stabilize or improve lung function in IPF patients, it can compete with pirfenidone and nintedanib for market share in IPF. However, it may be difficult to encourage treatment providers and patients to switch to pamrevlumab from a product with which they are already familiar. We may also face competition from potential new IPF therapies in recruitment and enrollment in our clinical trials and potentially in commercialization.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab is administered via infusion, which may be more expensive and less convenient than small molecules such as nintedanib and pirfenidone. Other potential competitive product candidates in various stages of development for IPF include Kadmon Holdings, Inc.&#8217;s KD025, Liminal BioSciences&#8217; PBI-4050, and Roche/Promedior, Inc.&#8217;s PRM-151. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:7.14%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pancreatic Cancer</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing pamrevlumab to be used in combination with Abraxane<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (nab-paclitaxel) and gemcitabine in pancreatic cancer. Celgene&#8217;s Abraxane was launched in the U.S. and Europe in 2013 and 2014, respectively, and was the first drug approved in this disease in nearly a decade. In 2015, Merrimack Pharmaceuticals Inc. (&#8220;Merrimack&#8221;) received FDA approval for the use of ONIVYDE (irinotecan liposome injection, now licensed to Ipsen) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy, and the combination therapy with Abraxane and gemcitabine became the first-line standard of care in these patients. As treatments for pancreatic cancer have shown limited success to date, combination therapies are expected, but the incremental cost may slow a new product adoption in the market, at least until the generic versions of Abraxane becomes available. In addition, we may also face competition from other products seeking approval in conjunction with gemcitabine and Abraxane including FOLFRINOX, a combination chemotherapy regimen of folic acid, 5-fluouracil, oxaliplatin and irinotecan, Rafael Pharma&#8217;s defactinib/CPI-613, and Merrimack&#8217;s istiratumab.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:7.14%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Duchenne Muscular Dystrophy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If approved and launched commercially to treat DMD, pamrevlumab is expected to face competition from drugs that have been approved in major markets such as the U.S., European Union, and Japan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 19, 2016, the FDA approved Sarepta Therapeutics Inc.&#8217;s (&#8220;Sarepta&#8221;) Exondys 51<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> (eteplirsen). Exondys 51 is approved to treat patients who have a mutation of the dystrophin gene amenable to exon 51 skipping, representing approximately 13% of patients with DMD. In Europe, Sarepta received a negative opinion for its marketing application for eteplirsen from the EMA in September 2018. Sarepta has reported a full year Exondys 51 revenue of $380 million in 2019. Sarepta&#8217;s Vyondys 53<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> (golodirsen) was approved by the FDA in December 2019 for patients with a confirmed genetic mutation that is amenable to exon 53 skipping, which accounts for approximately 8% of the DMD population. Sarepta&#8217;s Amondys 45&#8482; (casimersen) was approved by the FDA in February 2021 for patients with a confirmed genetic mutation that is amenable to exon 45 skipping, which accounts for approximately 8% of the DMD population.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PTC Therapeutics&#8217; product Translarna<sup style="font-size:85%;line-height:120%;vertical-align:top"> TM</sup> received a conditional approval in Europe in 2014, which was renewed in November 2016 with a request for a new randomized placebo-controlled 18-month study by the Committee for Medicinal Products for Human Use of the EMA&#59; however, the FDA informed the sponsor in a complete response letter in October 2017, as well as in its response to PTC Therapeutics&#8217; appeal, that the FDA is unable to approve the application in its current form. While Translarna<sup style="font-size:85%;line-height:120%;vertical-align:top"> TM</sup> targets a different set of DMD patients from those targeted by Sarepta&#8217;s Exondys 51&#174;, it is also limited to a subset of patients who carry a specific mutation. Conversely, pamrevlumab is intended to treat DMD patients without limitation to type of mutation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab may also face competition from other drugs currently in clinical development in patient recruiting and enrollment in clinical trials, and, if approved, in commercialization. Examples of those compounds currently under clinical development are the drug candidates from Catabasis Pharmaceuticals, Santhera Pharmaceuticals, and Sarepta. &#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">MANUFACTURE AND SUPPLY</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have historically and in the future plan to continue to enter into contractual arrangements with qualified third-party manufacturers to manufacture and package our products and product candidates. We believe that this manufacturing strategy enables us to more efficiently direct financial resources to the research, development and commercialization of product candidates rather than diverting resources to establishing a significant internal manufacturing infrastructure, unless there is additional strategic value for establishing manufacturing capabilities, such as in China. As our product candidates proceed through development, we explore or enter into longer term commercial supply agreements with key suppliers and manufacturers in order to meet the ongoing and planned clinical and commercial supply needs for ourselves and our partners. Our timing of entry into these agreements is based on the current development and commercialization plans.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat is a small-molecule drug manufactured from generally available commercial starting materials and chemical technologies and multi-purpose equipment available from many third party contract manufacturers. We have entered into commercial supply arrangements with Shanghai SynTheAll Pharmaceutical Co., Ltd. (&#8220;WuXi STA&#8221;) and Catalent, Inc. (&#8220;Catalent&#8221;) as our primary manufacturers of roxadustat drug substance (also known as active pharmaceutical ingredient or &#8220;API&#8221;) and roxadustat drug product, respectively. WuXi STA is located in China and currently supplies our API globally except for China, for which it manufactures an intermediate to be further manufactured by FibroGen Beijing. WuXi STA has passed inspections by several regulatory agencies, including the FDA and NMPA, and is Current Good Manufacturing Practice (&#8220;cGMP&#8221;) compliant. Catalent is located in the U.S. and supplies our drug product tablets globally except for Japan, where they are manufactured by Astellas, and China, where they are manufactured by FibroGen Beijing. Catalent has passed several regulatory inspections, including by the FDA, and manufactures commercial products for other clients.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In China, our Beijing facility received the Good Manufacturing Practice (&#8220;GMP&#8221;) license for API and drug product. We are manufacturing drug product at our FibroGen Beijing manufacturing facility for commercial supply, but we are not currently manufacturing API at this facility. We are manufacturing API at our Cangzhou manufacturing facility, which has been fully qualified and licensed. We may also qualify a third party manufacturer to produce commercial API under the Marketing Authorization Holder System program.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Irix Pharmaceuticals, Inc. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2002, we and IRIX Pharmaceuticals, Inc. (&#8220;IRIX&#8221;), a third party manufacturer, entered into a Letter of Agreement for IRIX Pharmaceuticals Single Source Manufacturing Agreement (the &#8220;Letter of Agreement&#8221;), in connection with a contract manufacturing arrangement for clinical supplies of HIF-PH inhibitors, including roxadustat. The Letter of Agreement contained a service agreement that included terms and schedule for the delivery of clinical materials and also included a term sheet for a single source agreement for the cGMP manufacture of HIF-PH inhibitors, including roxadustat. Specifically, pursuant to the Letter of Agreement, we and IRIX agreed to negotiate a single source manufacturing agreement that included a first right to negotiate a manufacturing contract for HIF-PH inhibitors, including roxadustat, provided that IRIX is able to match any third party bids within 5%, and the exclusive right to manufacture extends for five years after approval of an NDA. Any agreement would provide that no minimum amounts would be specified until appropriate by forecast, that we and our commercialization partner would have the rights to contract with independent third parties that exceed IRIX&#8217;s internal capabilities or in the event that we or our commercialization partner determines for reasons of continuity and security that such a need exists, provided that IRIX would supply a majority of the product if it is able to meet the requirements and the schedule required by us and our partner. Subsequent to the Letter of Agreement, IRIX and we have entered into several additional service agreements. IRIX has requested in writing that we honor the Letter of Agreement with respect to the single source manufacturing agreement. To date, we have offered to IRIX opportunities to bid for the manufacture of HIF-PH inhibitors, including roxadustat. In 2015, Patheon Pharmaceuticals Inc., a business unit of DPx Holdings B.V., acquired IRIX, and in 2017 ThermoFisher Scientific Inc. acquired Patheon Pharmaceuticals Inc.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, pamrevlumab has been manufactured using specialized biopharmaceutical process techniques under a clinical supply agreement with a qualified third party contract manufacturer, Boehringer Ingelheim. We have entered into a clinical and commercial supply agreement for the manufacture of pamrevlumab with Samsung Biologics Co., Ltd., which has passed several regulatory inspections, including by the FDA, and manufactures commercial products for other clients.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">GOVERNMENT REGULATION</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business activities and operations, including the clinical testing, manufacturing, labeling, storage, distribution, record keeping, advertising, promotion, import, export and marketing of our product candidates, among other things, are subject to extensive regulation by governmental authorities in the U.S., China, and other countries. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations, including in Europe and China, requires the expenditure of substantial time and financial resources. Compliance with environmental laws, rules, and regulations has not had, and is not expected to have, a material effect on our capital expenditures, results of operations, or competitive position, and we do not currently anticipate material capital expenditures for environmental control facilities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to comply with the applicable requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by the applicable regulatory authority to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by FDA and the Department of Justice, or other governmental entities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict with certainty whether future costs of compliance with government regulations, including any changes thereto or reinterpretations thereof, will have a material impact on capital expenditures, earnings or the company&#8217;s competitive position. Refer to the section of this Annual Report captioned &#8220;<span style="font-style:italic;">Item 1A. Risk Factors</span>&#8221; for a discussion of these potential impacts.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">U.S. Product Approval Process</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S., the FDA regulates drugs and biological products, or biologics, under the Public Health Service Act, as well as the FDCA, which is the primary law for regulation of drug products. Both drugs and biologics are subject to the regulations and guidance implementing these laws. Pharmaceutical products are also subject to regulation by other governmental agencies, such as the Federal Trade Commission, the Office of Inspector General of the U.S. Department of Health and Human Services, the Consumer Product Safety Commission and the Environmental Protection Agency. The clinical testing, manufacturing, labeling, storage, distribution, record keeping, advertising, promotion, import, export and marketing, among other things, of our product candidates are subject to extensive regulation by governmental authorities in the U.S. and other countries. The steps required before a drug or biologic may be approved for marketing in the U.S. generally include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Preclinical laboratory tests and animal tests conducted under Good Laboratory Practices.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The submission to the FDA of an IND for human clinical testing, which must become effective before each human clinical trial commence.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Adequate and well-controlled human clinical trials to establish the safety and efficacy of the product and conducted in accordance with good clinical practices (&#8220;GCP&#8221;).</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The submission to the FDA of an NDA, in the case of a small molecule drug product, or a BLA, in the case of a biologic product.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">FDA acceptance, review and approval of the NDA or BLA, as applicable.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Satisfactory completion of an FDA inspection of the manufacturing facilities at which the product is made to assess compliance with cGMPs.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The testing and approval process requires substantial time, effort and financial resources, and the receipt and timing of any approval is uncertain. The FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to a potentially unacceptable health risk.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies include laboratory evaluations of the product candidate, as well as animal studies to assess the potential safety and efficacy of the product candidate. Preclinical studies must be conducted in compliance with FDA regulations regarding GLPs. The results of the preclinical studies, together with manufacturing information and analytical data, are submitted to the FDA as part of the IND, which includes the results of preclinical testing and a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the first phase or phases of the clinical trial lends themselves to an efficacy determination. The IND will become effective automatically 30&#160;days after receipt by the FDA, unless the FDA raises concerns or questions about the conduct of the trials as outlined in the IND prior to that time. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can proceed. The IND must become effective before clinical trials may be commenced.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the product candidates to healthy volunteers, or subjects, or patients with the disease to be treated under the supervision of a qualified principal investigator. Clinical trials must be conducted under the supervision of one or more qualified principal investigators in accordance with GCPs and in accordance with protocols detailing the objectives of the applicable phase of the trial, dosing procedures, research subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Progress reports detailing the status of clinical trials must be submitted to the FDA annually. Sponsors must also timely report to the FDA serious and unexpected adverse events, any clinically important increase in the rate of a serious suspected adverse event over that listed in the protocol or investigator&#8217;s brochure, or any findings from other studies or tests that suggest a significant risk in humans exposed to the product candidate. Further, the protocol for each clinical trial must be reviewed and approved by an independent institutional review board (&#8220;IRB&#8221;), either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, ethical factors, and the safety of human subjects and the possible liability of the institution.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials are typically conducted in three sequential phases prior to approval, but the phases may overlap and different trials may be initiated with the same drug candidate within the same phase of development in similar or different patient populations. These phases generally include the following:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Phase 1.<span style="font-style:normal;">&#160;Phase 1 clinical trials represent the initial introduction of a product candidate into human subjects, frequently healthy volunteers. In Phase 1, the product candidate is usually tested for pharmacodynamic and pharmacokinetic properties such as safety, including adverse effects, dosage tolerance, absorption, distribution, metabolism and excretion.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Phase 2.<span style="font-style:normal;">&#160;Phase 2 clinical trials usually involve studies in a limited patient population to (1)&#160;evaluate the efficacy of the product candidate for specific indications, (2)&#160;determine dosage tolerance and optimal dosage and (3)&#160;identify possible adverse effects and safety risks.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Phase 3.<span style="font-style:normal;">&#160;If a product candidate is found to be potentially effective and to have an acceptable safety profile in Phase 2 studies, the clinical trial program will be expanded to Phase 3 clinical trials to further evaluate clinical efficacy, optimal dosage and safety within an expanded patient population at geographically dispersed clinical study sites.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Phase 4.<span style="font-style:normal;"> Phase 4 clinical trials are conducted after approval to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of drugs approved under accelerated approval regulations, or when otherwise requested by the FDA in the form of post-market requirements or commitments. Failure to promptly conduct any required Phase 4 clinical trials could result in withdrawal of approval.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of preclinical studies and clinical trials, together with detailed information on the manufacture, composition and quality of the product candidate, are submitted to the FDA in the form of an NDA (for a drug) or BLA (for a biologic), requesting approval to market the product. The application must be accompanied by a significant user fee payment. The FDA has substantial discretion in the approval process and may refuse to accept any application or decide that the data is insufficient for approval and require additional preclinical, clinical or other studies.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Review of Application</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the NDA or BLA submission has been accepted for filing, which occurs, if at all, 60 days after submission, the FDA informs the applicant of the specific date by which the FDA intends to complete its review. This is typically 12 months from the date of submission. The review process is often extended by FDA requests for additional information or clarification. The FDA reviews NDAs and BLAs to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, strength, quality and purity. Before approving an NDA or BLA, the FDA may inspect the facilities at which the product is manufactured and will not approve the product unless the manufacturing facility complies with cGMPs and will also inspect clinical trial sites for integrity of data supporting safety and efficacy. During the approval process, the FDA also will determine whether a REMS, is necessary to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the application must submit a proposed REMS&#59; the FDA will not approve the application without an approved REMS, if required. A REMS can substantially increase the costs of obtaining approval. The FDA may also convene an advisory committee of external experts to provide input on certain review issues relating to risk, benefit and interpretation of clinical trial data. The FDA may delay approval of an NDA if applicable regulatory criteria are not satisfied and/or the FDA requires additional testing or information. The FDA may require post-marketing testing and surveillance to monitor safety or efficacy of a product. FDA will issue either an approval of the NDA or BLA or a complete response letter detailing the deficiencies and information required in order for reconsideration of the application.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pediatric Exclusivity and Pediatric Use</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Best Pharmaceuticals for Children Act, certain drugs or biologics may obtain an additional six months of exclusivity in an indication, if the sponsor submits information requested in writing by the FDA (&#8220;Written Request&#8221;), relating to the use of the active moiety of the drug or biologic in children. The FDA may not issue a Written Request for studies on unapproved or approved indications or where it determines that information relating to the use of a drug or biologic in a pediatric population, or part of the pediatric population, may not produce health benefits in that population.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not received a Written Request for such pediatric studies with respect to our product candidates, although we may ask the FDA to issue a Written Request for studies in the future. To receive the six-month pediatric market exclusivity, we would have to receive a Written Request from the FDA, conduct the requested studies in accordance with a written agreement with the FDA or, if there is no written agreement, in accordance with commonly accepted scientific principles, and submit reports of the studies. A Written Request may include studies for indications that are not currently in the labeling if the FDA determines that such information will benefit the public health. The FDA will accept the reports upon its determination that the studies were conducted in accordance with and are responsive to the original Written Request, agreement, or commonly accepted scientific principles, as appropriate, and that the reports comply with the FDA&#8217;s filing requirements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Pediatric Research Equity Act (&#8220;PREA&#8221;) requires a sponsor to conduct pediatric studies for most drugs and biologicals, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs, BLAs and supplements thereto must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must include the evaluation of the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA, on its own initiative or at the request of the sponsor, may request a deferral of pediatric studies for some or all of the pediatric subpopulations. A deferral may be granted by FDA if they believe that additional safety or effectiveness data in the adult population needs to be collected before the pediatric studies begin. After April 2013, the FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Post-Approval Requirements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even after approval, drugs and biologics manufactured or distributed pursuant to FDA approvals are subject to continuous regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA or BLA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, entities involved in the manufacture and distribution of approved drugs and biologics are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may also result in revisions to the approved labeling to add new safety information&#59; imposition of post-market studies or clinical trials to assess new safety risks&#59; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Fines, warning letters or holds on post-approval clinical trials.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Refusal of the FDA to approve pending NDAs or BLAs or supplements to approved NDAs or BLAs, or suspension or revocation of product license approvals.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Product seizure or detention, or refusal to permit the import or export of products.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Injunctions or the imposition of civil or criminal penalties.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Prescription Drug Marketing Act</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The distribution of pharmaceutical products is subject to the Prescription Drug Marketing Act (&#8220;PDMA&#8221;), which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors at the state level. Under the PDMA and state law, states require the registration of manufacturers and distributors who provide pharmaceuticals in that state, including in certain states manufacturers and distributors who ship pharmaceuticals into the state even if such manufacturers or distributors have no place of business within the state. The PDMA and state laws impose requirements and limitations upon drug sampling to ensure accountability in the distribution of samples. The PDMA sets forth civil and criminal penalties for violations of these and other provisions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Federal and State Fraud and Abuse and Data Privacy and Security and Transparency Laws and Regulations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to FDA restrictions on marketing of pharmaceutical products, federal and state healthcare laws restrict certain business practices in the biopharmaceutical industry. These laws include, but are not limited to, anti-kickback, false claims, data privacy and security, and transparency statutes and regulations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any good, facility, item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payment, ownership interests and providing anything at less than its fair market value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and our practices may not in all cases meet all of the criteria for a statutory exception or safe harbor protection. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. The intent standard under the Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act of 2010 (collectively &#8220;PPACA&#8221;), to a stricter intent standard such that a person or entity no longer needs to have actual knowledge of this statute or the specific intent to violate it in order to have committed a violation. In addition, PPACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act (discussed below). Further, civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal false claims laws prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment or approval to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and thus non-reimbursable, uses. The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of, or payment for, healthcare benefits, items or services.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and its implementing regulations, imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to business associates &#8212; independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the federal Physician Payments Sunshine Act within the PPACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, many states have similar healthcare statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Some states require the posting of information relating to clinical studies. In addition, California requires pharmaceutical companies to implement a comprehensive compliance program that includes a limit on expenditures for, or payments to, individual medical or health professionals. If our operations are found to be in violation of any of the health regulatory laws described above or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil and/or administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion of products from reimbursement under government programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products will be sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pharmaceutical Coverage, Pricing and Reimbursement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In both domestic and foreign markets, our sales of any approved products will depend in part on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include government health administrative authorities, managed care providers, private health insurers and other organizations. Patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. Sales of our products will therefore depend substantially, both domestically and abroad, on the extent to which the costs of our products will be paid by third-party payors. These third-party payors are increasingly focused on containing healthcare costs by challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the coverage and reimbursement status of newly approved healthcare product candidates. The market for our products and product candidates for which we may receive regulatory approval will depend significantly on access to third-party payors&#8217; drug formularies, or lists of medications for which third-party payors provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded drug in their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because each third-party payor individually approves coverage and reimbursement levels, obtaining coverage and adequate reimbursement is a time-consuming, costly and sometimes unpredictable process. We may be required to provide scientific and clinical support for the use of any product to each third-party payor separately with no assurance that approval would be obtained, and we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. This process could delay the market acceptance of any product and could have a negative effect on our future revenues and operating results. We cannot be certain that our products and our product candidates will be considered cost-effective. Because coverage and reimbursement determinations are made on a payor-by-payor basis, obtaining acceptable coverage and reimbursement from one payor does not guarantee that we will obtain similar acceptable coverage or reimbursement from another payor. If we are unable to obtain coverage of, and adequate reimbursement and payment levels for, our product candidates from third-party payors, physicians may limit how much or under what circumstances they will prescribe or administer them and patients may decline to purchase them. This in turn could affect our ability to successfully commercialize our products and impact our profitability, results of operations, financial condition and future success.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in many foreign countries, particularly the countries of the European Union and China, the pricing of prescription drugs is subject to government control. In some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of a company placing the medicinal product on the market. We may face competition for our product candidates from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. In addition, there may be importation of foreign products that compete with our own products, which could negatively impact our profitability.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Healthcare Reform</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S. and foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations as we begin to directly commercialize our products. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state level that seek to reduce healthcare costs. If a drug product is reimbursed by Medicare or Medicaid, pricing and rebate programs must comply with, as applicable, the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990, as amended, and the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (&#8220;MMA&#8221;). The MMA imposed new requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Part A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for our products for which we receive marketing approval. However, any negotiated prices for our future products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain from non-governmental payors. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from Medicare Part D may result in a similar reduction in payments from non-governmental payors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, on November 27, 2013, the federal Drug Supply Chain Security Act was signed into law, which imposes new obligations on manufacturers of pharmaceutical products, among others, related to product tracking and tracing. Among the requirements of this new federal legislation, manufacturers will be required to provide certain information regarding the drug product to individuals and entities to which product ownership is transferred, label drug product with a product identifier, and keep certain records regarding the drug product. Further, under this new legislation, manufacturers will have drug product investigation, quarantine, disposition, and notification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, political, economic and regulatory influences are subjecting the healthcare industry in the U.S. to fundamental change. Initiatives to reduce the federal budget and debt and to reform healthcare coverage are increasing cost-containment efforts. We anticipate that Congress, state legislatures and the private sector will continue to review and assess alternative healthcare benefits, controls on healthcare spending through limitations on the growth of private health insurance premiums and Medicare and Medicaid spending, the creation of large insurance purchasing groups, price controls on pharmaceuticals and other fundamental changes to the healthcare delivery system. Any proposed or actual changes could limit or eliminate our spending on development projects and affect our ultimate profitability. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Medicare Improvements for Patients and Providers Act (&#8220;MIPPA&#8221;), a basic case-mix adjusted composite, or bundled, payment system commenced in January 2011 and transitioned fully by January 2014 to a single reimbursement rate for drugs and all services furnished by renal dialysis centers for Medicare beneficiaries with end-stage renal disease. Specifically, under MIPPA the End-Stage Renal Disease Prospective Payment System (the &#8220;ESRD PPS&#8221;) bundle now covers drugs, services, lab tests and supplies under a single treatment base rate for reimbursement by the CMS based on the average cost per treatment, including the cost of ESAs and IV iron doses, typically without adjustment for usage. It is unknown whether roxadustat, if approved in the U.S., will be included in the payment bundle or the timing of inclusion. Under MIPPA, agents that have no IV equivalent in the bundle are currently expected to be excluded from the bundle until 2025. If roxadustat were included in the bundle, it may reduce the price that could be charged for roxadustat, and therefore potentially limit our profitability. Based on roxadustat&#8217;s differentiated mechanism of action and therapeutic effects, and discussions with our collaboration partner, we currently believe that roxadustat might not initially be included in the bundle and would instead be eligible for a Transitional Drug Add-on Payment Adjustment (&#8220;TDAPA&#8221;) for a 24-month period. At the 24-month mark, CMS would determine if the TDAPA period should be extended for roxadustat or ended. When the TDAPA period ends, CMS will determine if roxadustat should be included in the bundle and, if so, what changes to the ESRD PPS reimbursement should be made. If roxadustat is included in the ESRD PPS bundle, it may have an impact on roxadustat pricing within Dialysis Organizations. If roxadustat is not included in the bundle after the TDAPA period, and would therefore be reimbursed outside of the bundle, it may potentially limit further market penetration of roxadustat.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2010, PPACA was signed into law. PPACA has the potential to substantially change the way healthcare is financed by both governmental and private insurers. Among other cost containment measures, PPACA established: an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents&#59; revised the methodology by which rebates owed by manufacturers to the state and federal government for covered outpatient drugs under the Medicaid Drug Rebate Program are calculated&#59; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program&#59; and extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals&#160;enrolled in Medicaid managed care organizations. There remain judicial and Congressional challenges to certain aspects of the PPACA. The U.S. Supreme Court is currently reviewing the constitutionality of the PPACA, but it is unknown when a decision will be reached. It is unclear how the U.S. Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the PPACA. In the future, there may continue to be additional proposals relating to the reform of the U.S. healthcare system, some of which could further limit the prices we are able to charge for our products, or the amounts of reimbursement available for our products. If future legislation were to impose direct governmental price controls and access restrictions, it could have a significant adverse impact on our business. Managed care organizations, as well as Medicaid and other government agencies, continue to seek price discounts. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, in the U.S. there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals. The FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until March 22, 2021. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. However, it is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some states have implemented, and other states are considering, price controls or patient access constraints under the Medicaid program, and some states are considering price-control regimes that would apply to broader segments of their populations that are not Medicaid-eligible. Due to the volatility in the current economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown legislative, regulatory, payor or policy actions, which may include cost containment and healthcare reform measures. Such policy actions could have a material adverse impact on our profitability.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Approval Process and Other Regulation in China</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pharmaceutical industry in China is highly regulated. The primary regulatory authority is the NMPA, including its provincial and local branches. As a developer, manufacturer and supplier of drugs, we are subject to regulation and oversight by the NMPA and its provincial and local branches. The Drug Administration Law of China provides the basic legal framework for the administration of the production and sale of pharmaceuticals in China and covers the manufacturing, distributing, packaging, pricing and advertising of pharmaceutical products. Its implementing regulations set forth detailed rules with respect to the administration of pharmaceuticals in China. In addition, we are, and we will be, subject to other Chinese laws and regulations that are applicable to business operators, manufacturers and distributors in general.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pharmaceutical Clinical Development</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A new drug must be approved by the NMPA before it can be manufactured and marketed for sale. To obtain NMPA approval, the applicant must conduct clinical trials, which must be approved by the NMPA and are subject to the NMPA&#8217;s supervision and inspection. There are four phases of clinical trials. Application for registration of new drugs requires completion of Phase 1, 2 and 3 of clinical trials, similar to the U.S. In addition, the NMPA may require the conduct of Phase 4 studies as a condition to approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 4 studies are post-marketing studies to assess the therapeutic effectiveness of and adverse reactions to the new drug, including an evaluation of the benefits and risks, when used among the general population or specific groups, with findings used to inform adjustments to dosage, among other things.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NDA and Approval to Market</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China requires approval of the NDA as well as the manufacturing facility before a drug can be marketed in China. Approval and oversight are performed at national and provincial levels of the NMPA, involve multiple agencies and consist of various stages of approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the applicable drug registration regulations, drug registration applications are divided into three different types, namely Domestic NDA, Domestic Generic Drug Application, and Imported Drug Application. Drugs fall into one of three categories, namely chemical medicine, biological product or traditional Chinese or natural medicine.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our roxadustat NDA for treatment of CKD anemia was submitted by FibroGen Beijing as a domestic entity under the Domestic Class&#160;1 designation, which refers to a new drug that has never been marketed in any country.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our NDA package in China contained information similar to what is necessary for a U.S. NDA, including preclinical data, clinical data, technical data on API and drug product, and related stability data. We are currently performing a safety study of 2,000 patients who will be treated for 52 weeks as part of our post-approval commitment to the NMPA. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shortly before NDA approval, FibroGen Beijing conducted a three-batch validation campaign, one of which was observed onsite by the NMPA. Following the successful completion of the validation campaign and associated inspection, FibroGen Beijing was granted a cGMP certification for the commercial production of roxadustat at our Beijing manufacturing facility. We are using our FibroGen Beijing manufacturing facility for commercial supply of drug product.&#160;&#160;Our Cangzhou manufacturing facility has been fully qualified and licensed for manufacture of roxadustat API for the China market, and we will continue to use this facility for commercial supply. We may also qualify a third party manufacturer to produce commercial API under the Marketing Authorization Holder System program.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pricing, Reimbursement, Hospital Listing, and Tendering </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please see the discussion above in the section<span style="font-style:italic;"> </span>&#8220;<span style="font-style:italic;">Roxadustat for the Treatment of Anemia in Chronic Kidney Disease in China.</span>&#8221; <span style="font-weight:bold;font-style:italic;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Foreign Regulation Outside of China</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market any product outside of the U.S., we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, manufacturing, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to the U.S. apply similarly in the context of other countries we are seeking approval in, including Europe and China, the approval process varies between countries and jurisdictions and can involve different amounts of product testing and additional administrative review periods. For example, in Europe and in China, a sponsor must submit a clinical trial application (&#8220;CTA&#8221;), much like an IND prior to the commencement of human clinical trials. A CTA must be submitted to each national health authority and an independent ethics committee.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For other countries outside of the European Union, such as China and the countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to country. The time required to obtain approval in other countries and jurisdictions might differ from or be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory approval process in other countries.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Regulatory Exclusivity for Approved Products</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S. Patent Term Restoration</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration, and specifics of the FDA approval of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. The patent term restoration period is generally one-half the time between the effective date of an initial IND and the submission date of an NDA or BLA, plus the time between the submission date of the NDA or BLA and the approval of that product candidate application. Patent term restoration cannot, however, extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. In addition, only one patent applicable to an approved product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves applications for any patent term extension or restoration. In the future, we expect to apply for restoration of patent term for patents relating to each of our product candidates in order to add patent life beyond the current expiration date of such patents, depending on the length of the clinical trials and other factors involved in the filing of the relevant NDA or BLA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain applications of companies seeking to reference another company&#8217;s NDA or BLA. The Hatch-Waxman Act provides a 5-year period of exclusivity to any approved NDA for a product containing a NCE never previously approved by FDA either alone or in combination with another active moiety. No application or abbreviated NDA directed to the same NCE may be submitted during the 5-year exclusivity period, except that such applications may be submitted after four years if they contain a certification of patent invalidity or non-infringement of the patents listed with the FDA by the innovator NDA.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Biologic Price Competition and Innovation Act</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), established an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The abbreviated regulatory approval pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on similarity to an existing branded product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator BLA holder. The BPCIA is complex and is only beginning to be interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and interpretation are subject to uncertainty.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Orphan Drug Act</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab has received orphan drug designation in IPF, LAPC, and DMD in the U.S. Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the U.S., or if it affects more than 200,000 individuals in the U.S. there is no reasonable expectation that the cost of developing and making a drug product available in the U.S. for this type of disease or condition will be recovered from sales of the product. Orphan product designation must be requested before submitting an NDA. After the FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity. The designation of such drug also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval of the same drug or biological product as defined by the FDA or if our drug candidate is determined to be contained within the competitor&#8217;s product for the same indication or disease. If a drug product designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan product exclusivity in any indication.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EMA has granted Orphan Medicinal Product Designation to pamrevlumab for the treatment of DMD. Orphan Medicinal Product Designation status in Europe has similar but not identical benefits in that jurisdiction.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Products receiving orphan designation in Europe can receive ten years of market exclusivity, during which time no similar medicinal product for the same indication may be placed on the market. The ten-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation&#59; for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior&#59; the initial applicant consents to a second orphan medicinal product application&#59; or the initial applicant cannot supply enough orphan medicinal product. An orphan product can also obtain an additional two years of market exclusivity in Europe for pediatric studies. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Foreign Country Data Exclusivity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe also provides opportunities for additional market exclusivity. For example, in Europe, upon receiving marketing authorization, an NCE generally receives eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents regulatory authorities in Europe from referencing the innovator&#8217;s data to assess a generic application. During the additional two-year period of market exclusivity, a generic marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but no generic product can be marketed until the expiration of the market exclusivity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In China, there is also an opportunity for data exclusivity for a period of six years for data included in an NDA applicable to a NCE. According to the Implementing Regulations of the PRC Drug Administration Law, the Chinese government protects undisclosed data from drug studies and prevents the approval of an application made by another company that uses the undisclosed data for the approved drug. In practice, the NMPA has not established an effective mechanism to enforce data exclusivity. The NMPA issued a draft regulation on regulatory data protection on April 25, 2018 for public comments but this draft regulation has yet to be finalized and implemented. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if an approved drug manufactured in China qualifies as an innovative drug or an improved new drug before December 1, 2019, such drugs will be eligible for a monitoring surveillance period for up to five years. During this post-marketing observation period, the NMPA will not accept marketing authorization applications filed by another company for the same product. Nor will the NMPA approve marketing authorization applications filed by another company to produce, change dosage form of or import the drug while the innovative or improved new drug is under observation for the purpose of protecting public health. The approved manufacturer is required to provide an annual report to the regulatory department of the province, autonomous region or municipality directly under the central government where it is located. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of the data exclusivity period and the observation period runs from the date of approval for production of the NCE or innovative or improved new drug, as the case may be.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INTELLECTUAL PROPERTY</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in part upon our ability to obtain and maintain patent and other intellectual property protection for our product candidates including compositions-of-matter, dosages, and formulations, manufacturing methods, and novel applications, uses and technological innovations related to our product candidates and core technologies. We also rely on trade secrets, know-how and continuing technological innovation to further develop and maintain our competitive position.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our policy is to seek to protect our proprietary position by, among other methods, filing U.S. and foreign patent applications related to our proprietary technologies, inventions and any improvements that we consider important to the development and implementation of our business and strategy. Our ability to maintain and solidify our proprietary position for our products and technologies will depend, in part, on our success in obtaining and enforcing valid patent claims. Additionally, we may benefit from a variety of regulatory frameworks in the U.S., Europe, China, and other territories that provide periods of non-patent-based exclusivity for qualifying drug products. <span style="font-style:italic;">Refer to &#8220;Government Regulation &#8212; Regulatory Exclusivity for Approved Products.&#8221;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot ensure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications that may be filed by us in the future, nor can we ensure that any of our existing or subsequently granted patents will be useful in protecting our drug candidates, technological innovations, and processes. Additionally, any existing or subsequently granted patents may be challenged, invalidated, circumvented or infringed. We cannot guarantee that our intellectual property rights or proprietary position will be sufficient to permit us to take advantage of current market trends or otherwise to provide or protect competitive advantages. Furthermore, our competitors may be able to independently develop and commercialize similar products, or may be able to duplicate our technologies, business model, or strategy, without infringing our patents or otherwise using our intellectual property.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our extensive worldwide patent portfolio includes multiple granted and pending patent applications relating to roxadustat and pamrevlumab. Currently granted patents relating to composition-of-matter for roxadustat and for pamrevlumab are expected, for each product candidate, to expire in 2024 or 2025, in each case exclusive of any patent term extension that may be available. U.S. and foreign patents relating to crystalline forms of roxadustat are expected to expire in 2033, exclusive of any extension. Additional patents and patent applications relating to manufacturing processes, formulations, and various therapeutic uses, including treatment of specific indications and improvement of clinical parameters, provide further protection for product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The protection afforded by any particular patent depends upon many factors, including the type of patent, scope of coverage encompassed by the granted claims, availability of extensions of patent term, availability of legal remedies in the particular territory in which the patent is granted, and validity and enforceability of the patent. Changes in either patent laws or in the interpretation of patent laws in the U.S. and other countries could diminish our ability to protect our inventions and to enforce our intellectual property rights. Accordingly, we cannot predict with certainty the enforceability of any granted patent claims or of any claims that may be granted from our patent applications.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. Our ability to maintain and solidify our proprietary position for our products and core technologies will depend on our success in obtaining effective claims and enforcing those claims once granted. We have been in the past and are currently involved in various legal proceedings with respect to our patents and patent applications and may, as a result of our extensive portfolio, be involved in such proceedings in the future. Additionally, we may claim that a third party infringes our intellectual property or a third party may claim that we infringe its intellectual property. Such legal proceedings may be associated with significant expenses, damages, attorneys&#8217; fees, costs of proceedings and experts&#8217; fees, and management and employees may be required to spend significant time in connection with these actions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that any patent related to our product candidates may expire before any of our product candidates can be commercialized, or may remain in force for only a short period of time following commercialization, thereby reducing the advantage afforded by any such patent.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions for our most advanced programs are summarized below.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat Patent Portfolio</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our roxadustat patent portfolio includes multiple granted U.S. patents offering protection for roxadustat, including protection for roxadustat composition-of-matter, for pharmaceutical compositions containing roxadustat, and for methods for treating anemia using roxadustat or its analogs. Exclusive of any patent term extension, the granted U.S. patents relating to the composition-of-matter of roxadustat are due to expire in 2024 or 2025, and granted foreign patents are due to expire in 2024. U.S. and foreign patents relating to crystalline forms of roxadustat are due to expire in 2033, and U.S. and foreign patents relating to photostable formulations of roxadustat are due to expire in 2034. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, oppositions were filed against our European Patent No. 2872488 (the &#8220;`488 Patent&#8221;), which claims a crystalline form of roxadustat, and our European Patent No. 3003284 (the &#8220;`284 Patent&#8221;), which claims photostable formulations of roxadustat. Final resolution of the opposition proceedings will take time and we cannot be assured that all or any claims will remain.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that, if roxadustat is approved, a full five-year patent term extension under the Hatch-Waxman act will be available for a granted U.S. patent relating to roxadustat, which extension would expire in 2029 or 2030, depending on the patent extended.<span style="font-style:italic;"> </span>Refer to<span style="font-style:italic;"> &#8220;Government Regulation &#8212; Regulatory Exclusivity for Approved Products &#8212; U.S. Patent Term Restoration.&#8221;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also hold various U.S. and foreign granted patents and pending patent applications directed to manufacturing processes, formulations, and methods for use of roxadustat. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat China Patent Portfolio</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our roxadustat China patent portfolio includes granted patents covering roxadustat composition-of-matter, pharmaceutical compositions, methods of use, and manufacturing processes for roxadustat, as well as medicaments containing roxadustat for treating anemia and other conditions. Patents relating to roxadustat composition-of-matter and crystalline forms are due to expire in 2024 and 2033, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">HIF Anemia-Related Technologies Patent Portfolio</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have an extensive worldwide patent portfolio providing broad protection for proprietary technologies relating to the treatment of anemia and associated conditions. This portfolio currently contains granted patents and pending patent applications providing exclusivity for use of compounds falling within various and overlapping classes of HIF-PH inhibitors to achieve various therapeutic effects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-right:0.4%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Various legal challenges have been initiated against this portfolio in several territories, including in Europe, the United Kingdom, Canada, and Japan. Regardless of the final outcome of any such actions, the potential narrowing or revocation of any of these patents does not affect our exclusivity for roxadustat or our freedom-to-operate with respect to use of roxadustat for the treatment of anemia in these or in other territories. A settlement has been reached in the litigation in Canada, resulting in the discontinuance of the action and leaving FibroGen&#8217;s Canadian patents valid and enforceable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-right:0.4%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2020, in response to an invalidation action brought against certain of our United Kingdom patents by Akebia, the United Kingdom court handed down a decision invalidating United Kingdom designations of European Patent Nos. 1463823, 1633333, 2298301, 2322153, and 2322155. The United Kingdom designation to European Patent No. 2289531 was held to be valid in amended form, but not infringed by Akebia. We and our partner Astellas have filed an appeal of the decision in the United Kingdom Court of Appeal.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab Patent Portfolio</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our pamrevlumab patent portfolio includes U.S. patents providing composition-of-matter protection for pamrevlumab and related antibodies, and for methods of using such in the treatment of fibroproliferative disorders, including IPF, liver fibrosis, and pancreatic cancer. Exclusive of any patent term extension, U.S. patents relating to pamrevlumab composition-of-matter are due to expire in 2024 or 2025. Corresponding foreign patents are due to expire, exclusive of any patent term extension, in 2024.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that, if pamrevlumab is approved, a full five-year patent term extension under the Hatch-Waxman act will be available for a granted patent relating to pamrevlumab, which extension would expire in 2029 or 2030, depending on the patent extended. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also hold additional granted U.S. and foreign patents and pending patent applications directed to the use of pamrevlumab to treat IPF, DMD, pancreatic cancer, liver fibrosis, and other disorders. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Trade Secrets and Know-How</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to patents, we rely upon proprietary trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality and other terms in agreements with our commercial partners, collaboration partners, consultants and employees. Such agreements are designed to protect our proprietary information, and may also grant us ownership of technologies that are developed through a relationship with a third party, such as through invention assignment provisions. Agreements may expire and we could lose the benefit of confidentiality, or our agreements may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that our commercial partners, collaboration partners, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In-Licenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dana-Farber Cancer Institute</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective March 2006, we entered into a license agreement with the Dana-Farber Cancer Institute (&#8220;DFCI&#8221;), under which we obtained an exclusive license to certain patent applications, patents and biological materials for all uses. The patent rights relate to inhibition of prolyl hydroxylation of the alpha subunit of hypoxia-inducible factor (HIF&#945;), and include granted U.S. and foreign patents due to expire in 2022, exclusive of possible patent term extension. The licensed patents relate to use of HIF-PH inhibitors such as roxadustat.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the DFCI agreement, we are obligated to pay DFCI for past and ongoing patent prosecution expenses for the licensed patents. We are also obligated to pay DFCI annual maintenance fees, development milestone payments of up to $425,000, sales milestone payments of up to $3 million, and a sub-single-digit royalty on net sales by us or our affiliates or sublicensees of products that are covered by the licensed patents or incorporate the licensed biological materials. In addition, each sublicense we grant is subject to a one-time fixed amount payment to DFCI.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement, along with any ongoing payment obligations, will continue in effect until the expiration of all licensed patents on a country-by-country basis, or, if there is no patent covering a licensed product incorporating the licensed biological materials, until 20 years after the effective date of the agreement. DFCI may terminate the agreement for our uncured material breach, if we cease to carry on our business and development activities with respect to all licensed products, if we fail to comply with our insurance obligations, or if we are convicted of a felony related to the manufacture, use, sale or importation of licensed products. We may terminate the agreement at any time on prior written notice to DFCI.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">University of Miami</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 1997, we entered into a license agreement with the University of Miami (the &#8220;University&#8221;), amended in July 1999, under which we obtained an exclusive, worldwide license to certain patent applications and patents for all uses. The current patent rights consist of a U.S. patent that relates to antibodies that specifically bind to biologically active fragments of CTGF, and is due to expire in 2022, exclusive of any patent term extension or adjustment that may be available. The licensed patent relates to pamrevlumab and related products.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the University agreement, we are obligated to pay for all ongoing patent expenses for the licensed patent. We were also obligated to pay an upfront licensing fee of $21,500, all of which has been paid, and development milestone payments of up to $450,000, of which $150,000 has been paid, as well as an additional milestone payment, in the low hundreds of thousands of dollars, for each new indication for which we obtain approval for a licensed product, and a single digit royalty, subject to certain reductions, on net sales of licensed products by us or our affiliates or sublicensees.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement, along with any ongoing payment obligations, will continue in effect until the expiration of all licensed patents, on a country-by-country basis. The University may terminate the agreement for our uncured material breach or bankruptcy. We may terminate the agreement for the University&#8217;s uncured material breach or at any time on prior written notice to the University.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Bristol-Myers Squibb Company (Medarex, Inc.)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective July&#160;9, 1998 and as amended on June&#160;30, 2001 and January&#160;28, 2002, we entered into a research and commercialization agreement with Medarex, Inc. and its wholly-owned subsidiary GenPharm International, Inc. (now, collectively, part of Bristol-Myers Squibb Company (&#8220;Medarex&#8221;)) to develop fully human monoclonal antibodies for potential anti-fibrotic therapies. Under the agreement, Medarex was responsible for using its proprietary immunizable transgenic mice (&#8220;HuMAb-Mouse technology&#8221;) during a specified research period (the &#8220;Research Period&#8221;), to produce fully human antibodies against our proprietary antigen targets, including CTGF, for our exclusive use.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement granted us an option to obtain an exclusive worldwide, royalty-bearing, commercial license to develop antibodies derived from Medarex&#8217;s HuMAb-Mouse technology, for use in the development and commercialization of diagnostic and therapeutic products. In December 2002, we exercised that option with respect to twelve antibodies inclusive of the antibody from which pamrevlumab is derived. We granted back to Medarex an exclusive, worldwide, royalty-free, perpetual, irrevocable license, with the right to sublicense, to certain inventions created during the parties&#8217; research collaboration, with such license limited to use by Medarex outside the scope of our licensed antibodies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-right:1.79%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the exercise of our option to obtain the commercial license, Medarex is precluded from: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.79%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.79%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) knowingly using any technology involving immunizable transgenic mice containing unrearranged human immunoglobulin genes with any of our antigen targets that were the subject of the agreement,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.79%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0.08%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="Background-color:#auto;text-decoration:none;">(ii)</span><span style="margin-left:18pt;color:#000000;"></span><span style="color:#000000;">granting to a third party a commercial license that covers such antigen targets or those antibodies derived by Medarex during the Research Period, and</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii) using any antibodies derived by Medarex during the Research Period, except as permitted under the agreement for our benefit or to prosecute patent applications in accordance with the agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medarex retained ownership of the patent rights relating to certain mice, mice materials, antibodies and hybridoma cell lines used by Medarex in connection with its activities under the agreement, and Medarex also owns certain claims in patents covering inventions that arise during the Research Period, which claims are directed to (i)&#160;compositions of matter (e.g., an antibody) except formulations of antibodies for therapeutic or diagnostic use, or (ii)&#160;methods of production. We own the patent rights to any inventions that arise during the Research Period that relate to antigens, as well as claims in patents covering inventions directed to (a)&#160;methods of use of an antibody, or (b)&#160;formulations of antibodies for therapeutic or diagnostic use. Upon exercise of our option to obtain the commercial license, we obtained the sole right but not obligation to control prosecution of patents relating solely to the licensed antibodies or products. Medarex has back-up patent prosecution rights in the event we decline to further prosecute or maintain such patents.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to research support payments by us to Medarex during the Research Period, and an upfront commercial license fee in the form of 181,819 shares of FibroGen Series D Convertible Preferred Stock paid upon exercise of our option, we committed development-related milestone payments of up to $11 million per therapeutic product containing a licensed antibody, and we have paid a $1&#160;million development-related milestone, in the form of 133,333 shares of FibroGen Series G Convertible Preferred Stock, and a cash payment of $2 million, for pamrevlumab to date. At our election, the remaining milestone payments may be paid in common stock of FibroGen, Inc., or cash.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to our sales and sales by our affiliates, the agreement also requires us to pay Medarex low single-digit royalties for licensed therapeutic products and low double-digit royalties plus certain capped sales-based bonus royalties for licensed diagnostic products. With respect to sales of licensed products by a sublicensee, we may elect to pay the foregoing royalties based on our sublicensee&#8217;s sales, or a percentage (in the high-teens) of all payments received by us from such sublicensee. We are also required to reimburse Medarex any pass-through royalties, if any, payable under Medarex&#8217;s upstream license agreements with Medical Research Council and DNX. Royalties payable by us under the agreement are on a licensed product-by-licensed product and country-by-country basis and subject to reductions in specified circumstances, and royalties are payable for a period until either expiration of patents covering the applicable licensed product or a specified number of years following the first commercial sale of such product in the applicable country.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the agreement will continue in effect for as long as there are royalty payment obligations by us or our sublicensees. Either party may terminate the agreement for certain material breaches by the other party, or for bankruptcy, insolvency or similar circumstances. In addition, we may also terminate the agreement for convenience upon written notice.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Third Party Filings</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing products. Because patent applications can take many years to issue, there may be currently pending applications, unknown to us, which may later result in granted patents that use of our product candidates or proprietary technologies may infringe.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a third party claims that we infringe its intellectual property rights, we may face a number of issues, including but not limited to, litigation expenses, substantial damages, attorney fees, injunction, royalty payments, cross-licensing of our patents, redesign of our products, or processes and related fees and costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our products, product candidates, and/or proprietary technologies infringe their intellectual property rights. If one of these patents were to be found to cover our products, product candidates, proprietary technologies, or their uses, we could be required to pay damages and could be restricted from commercializing our products, product candidates or using our proprietary technologies unless we obtain a license to the patent. A license may not be available to us on acceptable terms, if at all. In addition, during litigation, the patent holder might obtain a preliminary injunction or other equitable right, which could prohibit us from making, using or selling our products, technologies, or methods.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">HUMAN RESOURCES </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We had a total of 599 employees at FibroGen as of January 31, 2021. None of our U.S. employees are represented by a labor union. The employees of FibroGen Beijing are represented by a labor union under the China Labor Union Law. None of our employees have entered into a collective agreement with us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly committed to building a diverse, committed, and impassioned team to deliver innovative therapies to patients facing serious unmet medical needs. In 2020 we developed and approved a new Corporate Vision Statement and Values through the participation and input of many staff across the organization. One of these core values is &#8220;Respect for People&#8221; which includes a strong commitment to build a culture of inclusiveness and equality and foster a culture of individual growth and an environment of continued learning. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, we conducted a company-wide employee engagement survey. We had an overall participation rate by employees of 86% with over 90% of respondents reporting that they felt engaged around our core values of excellence, respect for people, integrity, and empowerment. Both of these scores significantly exceed normative industry participation and engagement benchmarks.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology industry is an extremely competitive labor market and recruiting and retaining employees is critical to the continued success of our business. We focus on recruiting, retaining, and developing employees from a diverse range of backgrounds to conduct our research, development, commercialization, and administrative activities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consistently review and evaluate our compensation and employee benefits practices to ensure that we recruit and retain a highly trained and diverse workforce. This includes comprehensive medical and income protection, such as life insurance and retirement savings programs. In addition to coaching and internal growth and promotion opportunities, we provide employees access to over 5,000 developmental classes and programs through a learning management system.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020 we deployed a state-of-art, human capital management system that will allow us to significantly expand our capabilities to develop and assess our employees. This system will also allow us to build comprehensive development and succession plans at all levels in the organization to ensure that we have a strong pipeline of highly trained employees. We also invested in health and safety measures for our employees who must work in the offices and labs during the COVID-19 pandemic.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are committed to diversity, equity and inclusion. On our Board of Directors: five of our twelve members are women and/or from minority racial and ethnic groups. As of January&#160;31, 2021, women represented 54% of our global workforce and 27% of our global leadership (VP and above). As of January&#160;31, 2021, 57% of our U.S. workforce, and 16% of our U.S. leadership (VP and above), were from minority racial and ethnic groups. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to furthering our investments in our human resources, we plan on continuing our efforts in 2021 in critical environmental, social, and governance areas.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FACILITIES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate and research and development operations are located in San Francisco, California, where we lease approximately 234,000 square feet of office and laboratory space with approximately 35,000 square feet subleased. The lease for our San Francisco headquarters expires in 2023. We also lease approximately 67,000 square feet of office and manufacturing space in Beijing, China, and multiple office spaces in Beijing and Shanghai, China. Our leases in China expire in 2023. We have constructed a commercial manufacturing facility of approximately 5,500 square meters in Cangzhou, China, on approximately 33,000 square meters of land. Our right to use such land expires in 2068. We believe our facilities are adequate for our current needs and that suitable additional or substitute space would be available if needed. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AVAILABLE INFORMATION</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our internet website address is www.fibrogen.com. In addition to the information about us and our subsidiaries contained in this Annual Report, information about us can be found on our website. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated into, this Annual Report.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge through our website as soon as reasonably practicable after they are electronically filed with or furnished to the Securities and Exchange Commission (&#8220;SEC&#8221;). Additionally the SEC maintains an internet site that contains reports, proxy and information statements and other information. The address of the SEC&#8217;s website is www.sec.gov.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CORPORATE INFORMATION</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our headquarters are located at 409 Illinois Street, San Francisco, California 94158 and our telephone number is (415)&#160;978-1200. Our website address is www.FibroGen.com. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our subsidiaries consist of the following: 1) FibroGen Europe Oy, a majority owned entity incorporated in Finland in 1996&#59; 2) Skin Sciences, Inc., a majority owned entity incorporated in the State of Delaware in 1995&#59; 3) FibroGen International (Cayman) Limited, a majority owned entity incorporated in the Cayman Islands in 2011&#59; 4) FibroGen China Anemia Holdings Ltd., a majority owned entity incorporated in the Cayman Islands in 2012&#59; 5) FibroGen International (Hong Kong) Limited, a majority owned entity incorporated in Hong Kong in 2011&#59; 6) FibroGen (China) Medical Technology Development Co., Ltd., a majority owned entity incorporated in China in 2011&#59; and 7) Beijing Falikang Pharmaceutical Co. Ltd., an unconsolidated variable interest entity incorporated in China in 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;FibroGen,&#8221; the FibroGen logo and other trademarks or service marks of FibroGen, Inc. appearing in this Annual Report are the property of FibroGen, Inc. This Annual Report contains additional trade names, trademarks and service marks of others, which are the property of their respective owners. We do not intend our use of display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">ITEM 1A. RISK FACTORS </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below in addition to the other information included or incorporated by reference in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Although we have discussed all known material risks, the risks described below are not the only ones that we may face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Development and Commercialization of Our Product Candidates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are substantially dependent on the success of our lead product, roxadustat, and our second compound in development, pamrevlumab. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have invested a substantial portion of our efforts and financial resources in the research and development of roxadustat and pamrevlumab. While we have received approval of our New Drug Applications (&#8220;NDA&#8221;) for roxadustat in the People&#8217;s Republic of China (&#8220;China&#8221;), Japan, and Chile for chronic kidney disease (&#8220;CKD&#8221;) anemia for patients on dialysis and not on dialysis, we and our partners will need to make substantial additional investments in the development and commercialization of roxadustat worldwide and in various indications. Our near-term prospects, including maintaining our existing collaborations with Astellas Pharma Inc. (&#8220;Astellas&#8221;) and AstraZeneca AB (&#8220;AstraZeneca&#8221;), will depend heavily on successful development and commercialization of roxadustat, including obtaining additional regulatory approvals for the commercialization of roxadustat for anemia associated with CKD.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our other lead product candidate, pamrevlumab, is currently in clinical development for idiopathic pulmonary fibrosis (&#8220;IPF&#8221;), pancreatic cancer, and Duchenne muscular dystrophy (&#8220;DMD&#8221;). Pamrevlumab requires substantial further development and investment and we do not have a collaboration partner for support of this compound. In addition, pamrevlumab is a monoclonal antibody, which may require greater financial resources than for our small molecule, roxadustat.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">As a company, we have limited commercialization experience, and the time and resources to develop such experience are significant. If we fail to achieve and sustain commercial success for roxadustat with our collaboration partners, our business would be harmed. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have a sales or marketing infrastructure and have limited experience in the sales, marketing or distribution of pharmaceutical products in any country. To achieve commercial success for any product for which we obtain marketing approval, we will need to establish sales and marketing capabilities or make and maintain our existing arrangements with third parties to perform these services at a level sufficient to support our commercialization efforts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we would undertake sales and marketing of any of our products directly, there are risks involved with establishing our own sales, marketing and distribution capabilities. Factors that may inhibit our efforts to commercialize our products on our own include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our inability to effectively manage geographically dispersed commercial teams&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unforeseen costs and expenses associated with creating an independent commercial organization.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to roxadustat, we are dependent on the commercialization capabilities of our collaboration partners, AstraZeneca and Astellas. If either such partner were to terminate its agreement with us, we would have to commercialize on our own or with another third party. We will have limited control over the commercialization efforts of such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products, if any, effectively. If they are not successful in commercializing our product candidates, our business and financial condition would suffer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercializing roxadustat requires us to establish commercialization systems, including but not limited to, medical affairs, pharmacovigilance, supply-chain, and distribution capabilities to perform our portion of the collaborative efforts. These efforts require resources and time. If we, along with Astellas and AstraZeneca, are not successful in our marketing, pricing and reimbursement strategies, facilitating adoption by dialysis organizations, health care professionals, recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty commercializing roxadustat, which would adversely affect our business and financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Although regulatory approval has been obtained for roxadustat in China, Japan, and Chile, we may be unable to obtain regulatory approval in other countries, or such approval may be delayed or limited, due to a number of factors, many of which are beyond our control. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical trials and the manufacturing of our product candidates are and will continue to be, and the marketing of our product candidates will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States (&#8220;U.S.&#8221;) and in other countries where we intend to develop and, if approved, market any product candidates. Before obtaining regulatory approval for the commercial sale of any product candidate, we must demonstrate through extensive preclinical trials and clinical trials that the product candidate is safe and effective for use in each indication for which approval is sought. The regulatory review and approval process is expensive and requires substantial resources and time, and in general, very few product candidates that enter development ultimately receive regulatory approval. In addition, our collaboration partners for roxadustat have final control over development decisions in their respective territories and they may make decisions with respect to development or regulatory authorities that delay or limit the potential approval of roxadustat, or increase the cost of development or commercialization. Accordingly, we may be unable to successfully develop or commercialize roxadustat, pamrevlumab, or any of our other product candidates in one or more indications and jurisdictions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, for any Phase 3 clinical trial to support an NDA/Biologics License Application submission for approval, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and foreign regulatory authorities require compliance with regulations and standards (including good clinical practices (&#8220;GCP&#8221;) requirements for designing, conducting, monitoring, recording, analyzing, and reporting the results of clinical trials) to ensure that (1) the data and results from trials are credible and accurate&#59; and (2) that the rights, integrity and confidentiality of trial participants are protected. Although we rely on third parties to conduct our clinical trials, we as the sponsor remain responsible for ensuring that each of these clinical trials is conducted in accordance with its general investigational plan and protocol under legal and regulatory requirements, including GCP. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our clinical research organizations (&#8220;CROs&#8221;), trial sites, principal investigators or other third parties fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable. Accordingly, the FDA or other regulatory authorities may require us to exclude the use of patient data from these unreliable clinical trials, or perform additional clinical trials before approving our marketing applications. The FDA or other regulatory authorities may even reject our application for approval or refuse to accept our future applications.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory authorities may take actions or impose requirements that delay, limit or deny approval of our product candidates for many reasons, including, among others:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our failure to adequately demonstrate to the satisfaction of regulatory authorities that roxadustat is safe and effective in treating anemia in CKD or that pamrevlumab is safe and effective in treating IPF, pancreatic cancer, or DMD&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our failure to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our failure of clinical trials to meet the level of statistical significance required for approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the determination by regulatory authorities that additional clinical trials are necessary to demonstrate the safety and efficacy of roxadustat or pamrevlumab, or that ongoing clinical trials need to be modified in design, size, conduct or implementation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our product candidates may exhibit an unacceptable safety signal as they advance through clinical trials, in particular controlled Phase 3 trials&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">the CROs that conduct clinical trials on our behalf may take actions outside of our control that materially adversely impact our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we or third-party contractors manufacturing our product candidates may not maintain current good manufacturing practices (&#8220;cGMP&#8221;), successfully pass inspection or meet other applicable manufacturing regulatory requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities may not agree with our interpretation of the data from our preclinical trials and clinical trials&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaboration partners may not perform or complete their clinical programs in a timely manner, or at all.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these factors, many of which are beyond our control, could jeopardize our or our collaboration partners&#8217; abilities to obtain regulatory approval for our product candidates in one or more indications. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or other regulatory authorities may require more information (including additional preclinical or clinical data to support approval), which may delay or prevent approval or cause us to abandon the development program altogether. In addition, if our product candidates produce undesirable side effects or safety issues, the FDA may require the establishment of Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) (or other regulatory authorities may require the establishment of a similar strategy), that may restrict distribution of our approved products, if any, and impose burdensome implementation requirements on us. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The results of the FDA Cardiovascular and Renal Drugs Advisory Committee meeting may affect roxadustat&#8217;s approvability or label in CKD anemia.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 1, 2021, the FDA informed us that the Cardiovascular and Renal Drugs Advisory Committee will hold an advisory committee meeting to review the NDA for roxadustat. The date of the advisory committee meeting has not been set. As a result of this communication, we will not receive an approval decision by the PDUFA goal date of March 20, 2021. The advisory committee is a committee of external experts which will provide input on issues relating to benefit, risk, and interpretation of our roxadustat clinical trial data. We do not know when the FDA will convene the advisory committee or how long it will take after the committee convenes for the FDA to make a decision on our NDA. The results of the advisory committee may affect roxadustat&#8217;s approvability or label. The FDA may further delay approval of our NDA if applicable regulatory criteria are not satisfied and/or the FDA requires additional testing or information. The full extent of the delay on an approval decision and impact of the advisory committee is unknown.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preclinical, Phase 1 and Phase 2 clinical trial results may not be indicative of the results that may be obtained in larger clinical trials.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Success in preclinical and early clinical trials, which are often highly variable and use small sample sizes, may not be predictive of similar results in humans or in larger, controlled clinical trials, and successful results from clinical trials in one indication may not be replicated in other indications.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we may face similar setbacks.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not know whether our ongoing or planned clinical trials of roxadustat or pamrevlumab will need to be redesigned based on interim results or if we will be able to achieve sufficient patient enrollment or complete planned clinical trials on schedule. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials can be delayed or terminated for a variety of reasons, including delay or failure to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">address any physician or patient safety concerns that arise during the course of the trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtain required regulatory or institutional review board approval or guidance&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reach timely agreement on acceptable terms with prospective CROs and clinical trial sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">recruit, enroll and retain patients through the completion of the trial, including for the duration of the </span><span style="font-size:9.5pt;color:#000000;">Severe Acute Respiratory Syndrome Coronavirus 2 and the resulting Coronavirus Disease</span><span style="color:#000000;"> (&#8220;COVID-19&#8221;) pandemic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">maintain clinical sites in compliance with clinical trial protocols&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">initiate or add a sufficient number of clinical trial sites&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">manufacture sufficient quantities of product candidate for use in clinical trials.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on the rate at which we can recruit and enroll patients in testing our product candidates. Patients may be unwilling to participate in clinical trials of our product candidates for a variety of reasons, some of which may be beyond our control, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">severity of the disease under investigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">availability of alternative treatments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">size and nature of the patient population&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">eligibility criteria for and design of the study in question&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">perceived risks and benefits of the product candidate under study&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">ability to enroll patients in clinical trials during the COVID-19 pandemic (particularly for IPF)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">ongoing clinical trials of competitive agents&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">physicians&#8217; and patients&#8217; perceptions of the potential advantages of our product candidates being studied in relation to available therapies or other products under development&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our CRO&#8217;s and our trial sites&#8217; efforts to facilitate timely enrollment in clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">patient referral practices of physicians&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">ability to monitor patients and collect patient data adequately during and after treatment.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate on-going or planned clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we could encounter delays if a clinical trial is suspended or terminated by us, by the relevant institutional review boards at the sites at which such trials are being conducted, or by the FDA or other regulatory authorities. A&#160;suspension or termination of clinical trials may result from any number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, changes in laws or regulations, or a principal investigator&#8217;s determination that a serious adverse event could be related to our product candidates. Any delays in completing our clinical trials will increase the costs of the trial, delay the product candidate development and approval process and jeopardize our ability to commence marketing and generate revenues. Any of these occurrences may materially and adversely harm our business, operations, and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates may cause or have attributed to them undesirable side effects or have other properties that delay or prevent their regulatory approval or limit their commercial potential.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Undesirable side effects caused by our product candidates or that may be identified as related to our product candidates by physician investigators conducting our clinical trials or even competing products in development that utilize a similar mechanism of action or act through a similar biological disease pathway could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in the delay or denial of regulatory approval by the FDA or other regulatory authorities and potential product liability claims. If we determine that there is a likely causal relationship between a serious adverse event and our product candidate, and such safety event is material or significant enough, it may result in:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our clinical trial development plan becoming longer and more extensive&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities increasing the data and information required to approve our product candidates and imposing other requirements&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our collaboration partners terminating our existing agreements.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The occurrence of any or all of these events may cause the development of our product candidates to be delayed or terminated, which could materially and adversely affect our business and prospects. Refer to &#8220;<span style="font-style:italic;">Business &#8212; Overview</span>&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 for a discussion of the adverse events and serious adverse events that have emerged in clinical trials of roxadustat and pamrevlumab.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical trials of our product candidates may not uncover all possible adverse effects that patients may experience.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials are conducted in representative samples of the potential patient population, which may have significant variability. Clinical trials are by design based on a limited number of subjects and of limited duration for exposure to the product used to determine whether, on a potentially statistically significant basis, the planned safety and efficacy of any product candidate can be achieved. As with the results of any statistical sampling, we cannot be sure that all side effects of our product candidates may be uncovered, and it may be the case that only with a significantly larger number of patients exposed to the product candidate for a longer duration, that a more complete safety profile is identified. Further, even larger clinical trials may not identify rare serious adverse effects or the duration of such studies may not be sufficient to identify when those events may occur. There have been other products, including erythropoiesis stimulating agents (&#8220;ESAs&#8221;), for which safety concerns have been uncovered following approval by regulatory authorities. Such safety concerns have led to labeling changes or withdrawal of ESAs products from the market. While our most advanced product candidate is chemically unique from ESAs, it or any of our product candidates may be subject to known or unknown risks. Patients treated with our products, if approved, may experience adverse reactions and it is possible that the FDA or other regulatory authorities may ask for additional safety data as a condition of, or in connection with, our efforts to obtain approval of our product candidates. If safety problems occur or are identified after our product candidates reach the market, we may, or regulatory authorities may require us to amend the labeling of our products, recall our products or even withdraw approval for our products.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we or our manufacturers cannot properly manufacture sufficient product, we may experience delays in development, regulatory approval, launch or successful commercialization. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Completion of our clinical trials and commercialization of our products require access to, or development of, facilities to manufacture and manage our product candidates at sufficient yields, quality and at commercial scale. Although we have entered into commercial supply agreements for roxadustat and pamrevlumab, we will need to enter into additional commercial supply agreements, including for backup or second source third-party manufacturers.&#160;We may not be able to enter into these agreements with satisfactory terms or on a timely manner. In addition, we may experience delays or technical problems associated with technology transfer of manufacturing processes to any new suppliers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited experience manufacturing or managing third parties in manufacturing any of our product candidates in the volumes that are expected to be necessary to support large-scale clinical trials and sales. In addition, we have limited experience forecasting supply requirements or coordinating supply chain (including export management) for launch or commercialization, which is a complex process involving our third-party manufacturers and logistics providers, and for roxadustat, our collaboration partners.&#160;We may not be able to accurately forecast supplies for commercial launch, or do so in a timely manner and our efforts to establish these manufacturing and supply chain management capabilities may not meet our requirements as to quantities, scale-up, yield, cost, potency or quality in compliance with cGMP, particularly if the marketing authorization or market uptake is more rapid than anticipated or we have an unanticipated surge in demand.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a limited amount of roxadustat and pamrevlumab in storage, limited capacity reserved at our third-party manufacturers, and, even if we have or are able to put supply agreements in place for our products, there are long lead times required to manufacture and scale-up the manufacture of additional supply, as required for both late-stage clinical trials, post-approval trials, and commercial supply. If we are unable to forecast, order or manufacture sufficient quantities of roxadustat or pamrevlumab on a timely basis, it may delay our development, launch or commercialization in some or all indications we are currently pursuing. Any delay or interruption in the supply of our product candidates or products could have a material adverse effect on our business and operations.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial drug product and the product we use for clinical trials must be produced under applicable cGMP regulations. Failure to comply with these regulations may require us to recall commercial product or repeat clinical trials, which would impact sales revenue or delay the regulatory approval process. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may add or change manufacturers for our products. We may also make changes to our manufacturing processes or to our product specifications, including in order to accommodate changes in regulations, manufacturing equipment or to account for different processes at new or second source suppliers. If we make any such changes with respect to roxadustat or pamrevlumab we will need to demonstrate comparability to the products and processes already approved or in approval by various regulatory authorities, including potentially through the conduct of additional clinical trials. Even if we do demonstrate comparability, a regulatory agency could challenge that result which could delay our development or commercialization progress. Any of these occurrences may materially impact our operations and potential profitability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, and even an experienced third-party manufacturer, may encounter difficulties in production. Difficulties may include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs and challenges associated with scale-up and attaining sufficient manufacturing yields, in particular for biologic products such as pamrevlumab, which is a monoclonal antibody&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">contracting with additional suppliers and validation/qualification of additional facilities to meet growing demand&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">supply chain issues, including coordination of multiple contractors in our supply chain and securing necessary licenses (such as export licenses)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timely availability and shelf life requirements of raw materials and supplies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">limited stability and product shelf life&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">equipment maintenance issues or failure&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">quality control and quality assurance issues&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">shortages of qualified personnel and capital required to manufacture large quantities of product&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">compliance with regulatory requirements that vary in each country where a product might be sold&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">capacity or forecasting limitations and scheduling availability in contracted facilities&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">natural disasters, such as pandemics, including the COVID-19 pandemic, floods, storms, earthquakes, tsunamis, and droughts, or accidents such as fire, that affect facilities, possibly limit or postpone production, and increase costs.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Regulatory authorities will do their own benefit risk analysis and may reach a different conclusion than we or our partners have, and these regulatory authorities may base their approval decision on different analyses, data, and statistical methods than ours.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we believe we have achieved positive clinical results, such as superiority or non-inferiority, in certain endpoints, populations or subpopulations, or using certain statistical methods of analysis, the FDA and European Medicines Agency (&#8220;EMA&#8221;) will each conduct their own benefit-risk analysis and may reach different conclusions, using different statistical methods, different endpoints or definitions thereof, or different patient populations or sub-populations, and regulatory authorities may change their approvability criteria based on their internal analyses and discussions with expert advisors. Regulatory authorities may approve roxadustat for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-approval clinical trials. While we will present to regulatory authorities certain pre-specified and not pre-specified sub-populations and sub-group analyses (for example, incident dialysis), multiple secondary endpoints, and multiple analytical methods (such as long-term follow up analyses), including adjusted and censored data, regulatory authorities may reject these analyses, methods, or even parts of our trial design or certain data from our studies, the rationale for our pre-specified non-inferiority margins or other portions of our statistical analysis plans. In addition, even if we are able to provide positive data with respect to certain analyses, such as incident dialysis, estimated glomerular filtration rate, hepcidin, or quality of life measures, regulatory authorities may not include such claims on any approved labeling for roxadustat, which may limit the commercialization or market opportunity for roxadustat. The failure to obtain regulatory approval, or any label, population or other approval limitations in any jurisdiction, may significantly limit our ability to generate revenues, and any failure to obtain such approval for all of the indications and labeling claims we deem desirable could reduce our potential revenue.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we are able to obtain regulatory approval of our product candidates, the label we obtain may limit the indicated uses for which our product candidates may be marketed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to roxadustat, regulatory approvals obtained, could limit the approved indicated uses for which roxadustat may be marketed. For example, our label approved in Japan, includes the following warning: &#8220;Serious thromboembolism such as cerebral infarction, myocardial infarction, and pulmonary embolism may occur, possibly resulting in death, during treatment with roxadustat.&#8221; Additionally, in the U.S., ESAs have been subject to significant safety warnings, including the boxed warnings on their labels. The safety concerns relating to ESAs may result in labeling for roxadustat containing similar warnings even if our Phase 3 clinical trials do not suggest that roxadustat has similar safety issues. Even if the label for roxadustat does not contain all of the warnings contained in the boxed warning for ESAs, the label for roxadustat may contain other warnings or limit the market opportunity or approved indications for roxadustat. These warnings could include warnings against exceeding specified hemoglobin targets and other warnings that derive from the lack of clarity regarding the safety issues associated with ESAs, even if our Phase 3 clinical trials do not themselves raise safety concerns.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face substantial competition in the discovery, development and commercialization of product candidates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development and commercialization of new pharmaceutical products is highly competitive. Our future success depends on our ability and/or the ability of our collaboration partners to achieve and maintain a competitive advantage with respect to the development and commercialization of our product candidates. Our objective is to discover, develop and commercialize new products with superior efficacy, convenience, tolerability, and safety. We expect that in many cases, the products that we commercialize will compete with existing, market-leading products of companies that have large, established commercial organizations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If roxadustat is approved and launched commercially, competing drugs are expected to include ESAs, particularly in those patient segments where ESAs are used. Currently available ESAs include epoetin alfa (EPOGEN<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, marketed by Amgen Inc. in the U.S., Procrit<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Erypo<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>/Eprex<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, marketed by Johnson&#160;&#38; Johnson Inc., and Espo<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> marketed by Kyowa Hakko Kirin in Japan and China), darbepoetin (Amgen/Kyowa Hakko Kirin&#8217;s Aranesp<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and NESP<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>) and Mircera<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> marketed by Hoffmann-La&#160;Roche (&#8220;Roche&#8221;) outside of the U.S. and by Vifor Pharma, a Roche licensee, in the U.S. and Puerto Rico, as well as biosimilar versions of these currently marketed ESA products. ESAs have been used in the treatment of anemia in CKD for more than 30 years, serving a significant majority of dialysis CKD patients. While non-dialysis CKD patients who are not under the care of nephrologists, including those with diabetes and hypertension, do not typically receive ESAs and are often left untreated, some non-dialysis patients under nephrology or hematology care may be receiving ESA therapy. It may be difficult to encourage healthcare providers and patients to switch to roxadustat from products with which they have become familiar. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also face competition from potential new anemia therapies currently in clinical development, including in those patient segments not adequately addressed by ESAs. Companies that are currently developing </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hypoxia-inducible factor (&#8220;HIF&#8221;) prolyl hydroxylase (together with HIF, &#8220;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIF-PH&#8221;) inhibitors for anemia in CKD indications include GlaxoSmithKline plc (&#8220;GSK&#8221;), Bayer Corporation (&#8220;Bayer&#8221;), Akebia Therapeutics, Inc. (&#8220;Akebia&#8221;), </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Otsuka Pharmaceutical (&#8220;Otsuka&#8221;), Akebia&#8217;s partner in the U.S. and Europe, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japan Tobacco, and Zydus Cadila (India) (&#8220;Zydus&#8221;). </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Akebia has completed&#160;&#160;Phase 3 studies in CKD </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients on dialysis and not on dialysis</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the U.S.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, as well as a Phase 3b, randomized, open-label, active-controlled trial evaluating the efficacy and safety of oral </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vadadustat</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> once daily and three times weekly for the maintenance treatment of anemia in hemodialysis subjects converting from erythropoiesis stimulating agents. The study completion date is estimated to be May 2022. Akebia announced an additional Phase 3 </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">study evaluating the efficacy and safety of dose conversion from a long-acting erythropoiesis stimulating agent (Mircera&#174;) to three times weekly oral vadadustat for the maintenance treatment of anemia in hemodialysis subjects. The estimated study start date is February 2021</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Akebia has publicly stated their intent to file the vadadustat NDA in the U.S. in the second quarter of 2021. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Japan, Mitsubishi Tanabe Pharmaceutical Corporation, Akebia&#8217;s collaboration partner, received approval for vadadustat on June 29, 2020 for the treatment of anemia of CKD patients on and not on dialysis. GSK received approval for daprodustat in Japan on June 29, 2020 for the treatment of anemia of CKD patients on and not on dialysis. Price listing for the launch in Japan of both vadadustat and daprodustat occurred in the third quarter of 2020, with pricing in line with roxadustat pricing. GSK is also conducting global Phase 3 studies in CKD patients on dialysis and not on dialysis, and expects to complete those studies by March 2022. GSK and Kyowa Hakko Kirin announced in November 2018 that the two companies signed a strategic commercialization deal in Japan for daprodustat. Bayer has completed global Phase 2 studies and its HIF-PH inhibitor is now in Phase 3 development in CKD populations on dialysis and not on dialysis in Japan. Japan Tobacco received approval in Japan for enarodustat for the treatment of anemia in CKD patients on dialysis and not on dialysis, to be sold by Torii Pharmaceuticals Ltd as ENAROY<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>. Japan Tobacco and its partner JW Pharmaceuticals started a Phase 3 study in dialysis patients in Korea in 2019. Zydus started Phase 3 studies in dialysis and non-dialysis CKD patients in India in 2019. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, Zydus received approval from the FDA to begin a Phase 1 study of desidustat for the treatment of chemotherapy-induced anemia, which could potentially be competitive with roxadustat within this indication.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reblozyl&#174; (luspatercept)<span style="color:#000000;"> was approved by the FDA in April 2020 for the treatment of anemia in adults with myelodysplastic syndromes with ring sideroblasts or myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis who need regular red blood cell transfusions and have not responded well to or cannot receive an ESA. It is the first and only erythroid maturation agent approved in the U.S., Europe, and Canada and is part of a global collaboration between Acceleron Pharma, Inc. and Bristol Myers Squibb. In 2020, Reblozyl net revenue was $274 million, including $115 million in Q4 2020.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, <span style="color:#000000;">we will likely face competition from other companies developing biologic therapies for the treatment of other anemia indications that we may also seek to pursue in the future</span>. We may face competition for patient recruitment, enrollment for clinical trials, and potentially in commercial sales. There may also be new therapies for renal-related diseases that could limit the market or level of reimbursement available for roxadustat.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In China, ESA is considered the standard of care for treatment of anemia of CKD, and locally manufactured epoetin alfa is offered by 15 local manufacturers including the market leader EPIAO that is marketed by 3SBio Inc. We may face potential competition from other HIF-PH inhibitors.&#160;&#160; Companies active in the US such as Akebia, Bayer, and GSK have been authorized by the National Medical Products Administration (&#8220;NMPA&#8221;) to conduct trials in China to support its ex-China regulatory filings. A number of domestic companies, including Jiangsu Hengrui Medicine Co., Ltd., Guandong Sunshine Health Investment Co., Ltd., 3SBio Inc., and Hangzhou Andao Pharmaceutical Co. have been permitted by the NMPA to conduct clinical trials in their locally-developed HIF-PH inhibitor investigational compounds for the treatment of anemia in CKD. Domestic companies are also in-licensing global compounds to be developed as domestic drugs, including China Medical System which in-licensed desidustat, a compound that is currently in Phase 3 trials in India, from Zydus for greater China in January 2020. In January 2021, China Medical System Holdings Ltd. was granted approval by the Chinese NMPA to begin trials for desidustat in patients with anemia of CKD, including dialysis and non-dialysis patients. Shenzhen Salubris Pharmaceutical Co., Ltd., a domestic company in China, has in-licensed enarodustat from Japan Tobacco and received NMPA approval in the third quarter of 2020 to initiate Phase 3 studies. We will also face competition from generics who could enter the market after expiry of our patents in China, and two potential market players have already started bioequivalence studies, including Chia Tai-Tiangqing Pharmaceutical Holdings and CSPA Pharmaceutical Group. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first biosimilar ESA, Pfizer&#8217;s Retacrit</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (epoetin zeta), entered the U.S. market in November 2018. Market penetration of Retacrit and the potential addition of other biosimilar ESAs currently under development may alter the competitive and pricing landscape of anemia therapy in CKD patients on dialysis under the end-stage renal disease bundle. The patents for Amgen&#8217;s EPOGEN</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (epoetin alfa) expired in 2004 in Europe, and the final material patents in the U.S. expired in May 2015. Several biosimilar versions of currently marketed ESAs are available for sale in Europe, China and other territories. In the U.S., a few ESA biosimilars are currently under development. Sandoz, a division of Novartis, markets Binocrit</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (epoetin alfa) in Europe and may file a biosimilar </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biologics License Application</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the U.S</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The majority of the current CKD anemia market focuses on dialysis patients, who visit dialysis centers on a regular basis, typically three times a week, and anemia therapies are administered as part of the visit. Two of the largest operators of dialysis clinics in the U.S., DaVita Healthcare Partners Inc. (&#8220;DaVita&#8221;), and Fresenius Medical Care AG&#160;&#38; Co. KGaA (&#8220;Fresenius&#8221;), collectively provide dialysis care to more than 80% of U.S. dialysis patients, and therefore have historically executed long-term contracts including rebate terms with Amgen. Successful penetration in this market will likely require our partner AstraZeneca to enter into a definitive agreement with Fresenius, DaVita, or other dialysis organizations, on favorable pricing terms and on a timely basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If approved and launched commercially to treat IPF, pamrevlumab is expected to compete with Roche&#8217;s Esbriet<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (pirfenidone), and Boehringer Ingelheim&#8217;s Ofev<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (nintedanib). We believe that if pamrevlumab can be shown to safely stabilize or reverse lung fibrosis, and thus stabilize or improve lung function in IPF patients, it can compete with pirfenidone and nintedanib for market share in IPF. However, it may be difficult to encourage treatment providers and patients to switch to pamrevlumab from an oral product with which they are already familiar to a product delivered via in-office infusion. Furthermore, pirfenidone and nintedanib may be produced as generics in the near future. We may also face competition from potential new IPF therapies in recruitment and enrollment in our clinical trials and potentially in commercialization.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab is a monoclonal antibody that may be more expensive and less convenient than oral small molecules such as nintedanib and pirfenidone. Other potential competitive product candidates in various stages of development for IPF include Kadmon Holdings, Inc.&#8217;s KD025, Liminal BioSciences&#8217; PBI-4050, and Roche/Promedior, Inc.&#8217;s PRM-151. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If pamrevlumab is approved and launched commercially to treat locally advanced pancreatic cancer patients who are not candidates for surgical resection, pamrevlumab may face competition from products currently used for pancreatic cancer. These include FOLFRINOX, a combination chemotherapy regimen of folic acid, 5-fluouracil, oxaliplatin and irinotecan, and agents seeking approval in combination with gemcitibine and nab-paclitaxel from companies such as Rafael Pharma&#8217;s defactinib/CPI-613 and Merrimack&#8217;s istiratumab. Gemcitabine and/or nab-paclitaxel are the current standard of care in the first-line treatment of metastatic pancreatic cancer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Celgene Corporation&#8217;s Abraxane<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (nab-paclitaxel) was launched in the U.S. and Europe in 2013 and 2014, and was the first drug approved in this disease in nearly a decade. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If approved and launched commercially to treat DMD, pamrevlumab is expected to face competition from drugs that have been approved in major markets such as the U.S., European Union, and Japan. On September 19, 2016, the FDA approved Sarepta Therapeutics Inc.&#8217;s (&#8220;Sarepta&#8221;) Exondys 51<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> (eteplirsen). Exondys 51 is approved to treat patients who have a mutation of the dystrophin gene amenable to exon 51 skipping, representing approximately 13% of patients with DMD. In Europe, Sarepta received a negative opinion for its marketing application for eteplirsen from the EMA in September 2018. Sarepta has reported a full year Exondys 51 revenue of $380 million in 2019. Sarepta&#8217;s Vyondys 53<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> (golodirsen) was approved by the FDA in December 2019 for patients with a confirmed genetic mutation that is amenable to exon 53 skipping, which accounts for approximately 8% of the DMD population. Sarepta&#8217;s Amondys 45&#8482; (casimersen) was approved by the FDA in February 2021 for patients with a confirmed genetic mutation that is amenable to exon 45 skipping, which accounts for approximately 8% of the DMD population.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PTC Therapeutics&#8217; product Translarna<sup style="font-size:85%;line-height:120%;vertical-align:top"> TM</sup> received a conditional approval in Europe in 2014, which was renewed in November 2016 with a request for a new randomized placebo-controlled 18-month study by the Committee for Medicinal Products for Human Use of the EMA&#59; however, the FDA informed the sponsor in a complete response letter in October 2017, as well as in its response to PTC Therapeutics&#8217; appeal, that the FDA is unable to approve the application in its current form. An additional Phase 3 study is currently ongoing. While Translarna<sup style="font-size:85%;line-height:120%;vertical-align:top"> TM</sup> targets a different set of DMD patients from those targeted by Sarepta&#8217;s Exondys 51<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, it is also limited to a subset of patients who carry a specific mutation. Conversely, pamrevlumab is intended to treat DMD patients without limitation to type of mutation. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab may also face competition from other drugs currently in clinical development in patient recruiting and enrollment in clinical trials, and, if approved, in commercialization. Examples of those compounds currently under clinical development are the drug candidates from Pfizer, Pliant, Galecto, and Sarepta. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer initiated a Phase 3 study with </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PF-06939926, its AAV9 mini-dystrophin gene therapy for DMD in February 2020. Pliant&#8217;s PLN-74809 and Galecto&#8217;s lead candidate GB0139, are in Phase 2 development for IPF. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of any or all of these potential competitive products may negatively impact the development and potential for success of pamrevlumab. In addition, any competitive products that are on the market or in development may compete with pamrevlumab for patient recruitment and enrollment for clinical trials or may force us to change our clinical trial design, including, in order to compare pamrevlumab against another drug, which may be the new standard of care.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, many of our competitors have significantly greater resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients, manufacturing pharmaceutical products, and commercialization. In the potential anemia market for roxadustat, for example, large and established companies such as Amgen and Roche, among others, compete aggressively to maintain their market shares. In particular, the currently marketed ESA products are supported by large pharmaceutical companies that have greater experience and expertise in commercialization in the anemia market, including in securing reimbursement, government contracts and relationships with key opinion leaders&#59; conducting testing and clinical trials&#59; obtaining and maintaining regulatory approvals and distribution relationships to market products&#59; and marketing approved products. These companies also have significantly greater scale, research and marketing capabilities than we do and may also have products that have been approved or are in later stages of development and have collaboration agreements in our target markets with leading dialysis companies and research institutions. If we and our collaboration partners are not able to compete effectively against existing and potential competitors, our business and financial condition may be materially and adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">No or limited reimbursement or insurance coverage of our approved products, if any, by third-party payors may render our products less attractive to patients and healthcare providers. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market acceptance and sales of any approved products will depend significantly on reimbursement or coverage of our products by government or third-party payors and may be affected by existing and future healthcare reform measures or prices of related products for which the government or third-party reimbursement applies. Coverage and reimbursement by the government or a third-party payor may depend upon a number of factors, including the payor&#8217;s determination that use of a product is:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a covered benefit under applicable health plan&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">safe, effective and medically necessary&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">appropriate for the specific patient&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">cost-effective&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">neither experimental nor investigational.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor, which we may not be able to provide. Furthermore, the reimbursement policies of governments and third-party payors may significantly change in a manner that renders our clinical data insufficient for adequate reimbursement or otherwise limits the successful marketing of our products. Even if we obtain coverage for our product candidates, the pricing may be subject to re-negotiations or third-party payors may not establish adequate reimbursement amounts, which may reduce the demand for, or the price of, our products. For example, our current National Reimbursement Drug List reimbursement pricing for China is effective for a standard two-year period (between January 1, 2020 to December 31, 2021), after which time we will have to renegotiate a new price for roxadustat, which we expect to be lower based upon historical precedents.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reference pricing is used by various Europe member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, our partner or we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available products in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unacceptable levels, we or our partner may elect not to commercialize our products in such countries, and our business and financial condition could be adversely affected.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Severe Acute Respiratory Syndrome Coronavirus 2 and the Resulting Coronavirus Disease (&#8220;COVID-19&#8221;)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business could continue to be adversely affected by the ongoing COVID-19 global pandemic. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effects of the COVID-19 pandemic, the associated government-mandated restrictions and the other effects on healthcare systems, the economy, and society as a whole, may negatively impact productivity, disrupt our business, and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the progression of the disease, the length and severity of the restrictions, and other impacts and limitations on our ability to conduct our business in the ordinary course. These disruptions in our operations could negatively impact our business, operating results, and financial condition. While certain COVID-19 vaccines have received regulatory approval, it is uncertain if and when sufficient vaccines will have been distributed to lessen the economic and other effects of COVID-19, and the efficacy of such vaccines in preventing the spread and effects of COVID-19 and other variants is unclear.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The extent of the impact on the COVID-19 pandemic on our business and financial results will continue to depend on numerous evolving factors that we are not able to accurately predict and which will vary by market, including the duration and scope of the pandemic, global economic conditions during and after the pandemic, the speed and efficacy of vaccinations around the world, and governmental actions that have been taken, or may be taken in the future, in response to the pandemic.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have taken measures to minimize the health risks of COVID-19 to our staff, patients, healthcare providers, and their communities, as their safety and well-being are our top priority. Despite these efforts, there is a risk that one or more of our employees, including members of senior management, could contract COVID-19. Our U.S. employees are working remotely when possible, and we may experience reduced productivity due to the remote work environment. In addition, there are other risks from remote work including but not limited to the potential for reduced oversight of third parties we work with, such as manufacturing and clinical sites. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China was able to minimize the impact of COVID-19 on the economy in 2020 relative to other major economies. However, if there are any further COVID-19 outbreaks, we or our partners may need to re-institute or tighten restrictions on our operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have seen impacts from COVID-19 on all of our clinical trials to varying degrees. There is a risk that any or all of our clinical trials will be further delayed, in particular our studies in IPF, due to a continued or further outbreak which can slow or pause enrollment or site initiation and other direct COVID-19 impacts to clinical sites and clinical service providers. In addition, while we are trying to mitigate the effect of COVID-19 on existing patients, it is possible that some patients may not be able to continue to comply with protocols, which could further delay our clinical trial progress.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe we have sufficient roxadustat and pamrevlumab supplies for our expected commercial and clinical requirements over the next year and we and our manufacturing partners are currently continuing manufacturing operations. However, we only have a limited stockpile of these drug supply products, and therefore, if there is a greater impact from the COVID-19 pandemic than we have expected, or if manufacturing operations are halted again, or if drug product expires due to slowed clinical trials, we could face shortages in our global supply chains. COVID-19 has created increased demand for the limited global biologics manufacturing capacity, and as a result, we have faced competition for manufacturing supplies due to prioritization of COVID-19 related manufacturing. We could face additional competition for such manufacturing supplies, including reagents, supplements and media, and may face competition to use available capacity at our manufacturing partners. Any such supply disruptions could adversely impact our clinical development and ability to generate revenues from our approved products and our business, financial condition, results of operations and growth prospects could be materially adversely affected. There may be unexpected regulatory delays due to the COVID-19 pandemic including due to travel restrictions impacting pre-approval inspections.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to these and potentially additional business disruptions, there may be delays to any of our business areas including our drug supply chains, problems with our distribution or warehousing vendors, or delays to our (and our partners&#8217;) clinical trials or other development efforts, or commercialization and launch activities. The full extent of these effects are unknown, but all of them could have a material impact on our operations and revenue</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, to the extent the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#8220;<span style="font-style:italic;">Risk Factors</span>&#8221; section.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Reliance on Third Parties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our collaborations were terminated or if Astellas or AstraZeneca were to prioritize other initiatives over their collaborations with us, our ability to successfully develop and commercialize our product candidates would suffer. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into collaboration agreements with respect to the development and commercialization of our lead product candidate, roxadustat, with Astellas and AstraZeneca. These agreements provide for reimbursement of our development costs by our collaboration partners and also provide for commercialization of roxadustat throughout the major territories of the world.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our agreements with Astellas and AstraZeneca provide each of them with the right to terminate their respective agreements with us, upon the occurrence of negative clinical results, delays in the development and commercialization of our product candidates or adverse regulatory requirements or guidance. In addition, each of those agreements provides our respective partners the right to terminate any of those agreements upon written notice for convenience. The termination of any of our collaboration agreements would require us to fund and perform the further development and commercialization of roxadustat in the affected territory, or pursue another collaboration, which we may be unable to do, either of which could have an adverse effect on our business and operations. Moreover, if Astellas or AstraZeneca, or any successor entity, were to determine that their collaborations with us are no longer a strategic priority, or if either of them or a successor were to reduce their level of commitment to their collaborations with us, our ability to develop and commercialize roxadustat could suffer. In addition, our collaborations are exclusive and preclude us from entering into additional collaboration agreements with other parties in the area or field of exclusivity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not establish and maintain strategic collaborations related to our product candidates, we will bear all of the risk and costs related to the development and commercialization of any such product candidate, and we may need to seek additional financing, hire additional employees and otherwise develop expertise at significant cost. This in turn may negatively affect the development of our other product candidates as we direct resources to our most advanced product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our collaboration partners also have certain rights to control decisions regarding the development and commercialization of our product candidates with respect to which they are providing funding. If we have a disagreement over strategy and activities with our collaboration partners, our plans for obtaining regulatory approval may be revised and negatively affect the anticipated timing and potential for success of our product candidates. Even if a product under a collaboration agreement receives regulatory approval, we will remain substantially dependent on the commercialization strategy and efforts of our collaboration partners, and, our collaboration partners have limited or no experience in commercialization of an anemia drug. If our collaboration partners are unsuccessful in their commercialization efforts, our results will be negatively affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to our collaboration agreements for roxadustat, there are additional complexities in that our collaboration partners, Astellas and AstraZeneca, and we must reach consensus on our development programs and regulatory activities, including for the NDA in the U.S. and the Marketing Authorization Application in Europe. In addition, there are aspects of commercial operations that require cooperation among the collaboration partners, including safety data reporting. Multi-party decision-making is complex and involves significant time and effort, and there can be no assurance that the parties will cooperate or reach consensus, or that one or both of our partners will not ask to proceed independently in some or all of their respective territories or functional areas of responsibility in which the applicable collaboration partner would otherwise be obligated to cooperate with us. Any disputes or lack of cooperation with us by either Astellas or AstraZeneca, or both, may negatively impact the timing or success of our regulatory approval applications.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to conduct proprietary research programs in specific disease areas that are not covered by our collaboration agreements. Our pursuit of such opportunities could, however, result in conflicts with our collaboration partners in the event that any of our collaboration partners takes the position that our internal activities overlap with those areas that are exclusive to our collaboration agreements. Moreover, disagreements with our collaboration partners could develop over rights to our intellectual property, including the enforcement of those rights. In addition, our collaboration agreements may have provisions that give rise to disputes regarding the rights and obligations of the parties. Any conflict with our collaboration partners could lead to the termination of our collaboration agreements, delay collaborative activities, reduce our ability to renew agreements or obtain future collaboration agreements or result in litigation or arbitration and would negatively impact our relationship with existing collaboration partners, and could impact our commercial results.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our collaboration partners could also become our competitors in the future. If our collaboration partners develop competing products, fail to obtain necessary regulatory approvals, terminate their agreements with us prematurely or fail to devote sufficient resources to the development and commercialization of our product candidates, the development and commercialization of our product candidates and products could be delayed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our preclinical and clinical trial contractors do not properly perform their agreed upon obligations, we may not be able to obtain or may be delayed in receiving regulatory approvals for our product candidates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely heavily on university, hospital, dialysis centers and other institutions and third parties, including the principal investigators and their staff, to carry out our clinical trials in accordance with our clinical protocols and designs. We also rely on a number of third-party CROs to assist in undertaking, managing, monitoring and executing our ongoing clinical trials, including those for roxadustat. We expect to continue to rely on CROs, clinical data management organizations, medical institutions and clinical investigators to conduct our development efforts in the future, including our continued development of roxadustat. We compete with many other companies for the resources of these third parties, and large pharmaceutical companies often have significantly more extensive agreements and relationships with such third-party providers, and such third-party providers may prioritize the requirements of such large pharmaceutical companies over ours. The third parties on whom we rely may terminate their engagements with us at any time, which may cause delay in the development and commercialization of our product candidates. If any such third party terminates its engagement with us or fails to perform as agreed, we may be required to enter into alternative arrangements, which would result in significant cost and delay to our product development program. Moreover, our agreements with such third parties generally do not provide assurances regarding employee turnover and availability, which may cause interruptions in the research on our product candidates by such third parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, while our reliance on these third parties for certain development and management activities will reduce our control over these activities, it will not relieve us of our responsibilities. For example, the FDA and foreign regulatory authorities require compliance with regulations and standards, including GCP requirements for designing, conducting, monitoring, recording, analyzing and reporting the results of clinical trials to ensure that the data and results from trials are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Although we rely on third parties to conduct our clinical trials, we, as the sponsor, remain responsible for ensuring that each of these clinical trials is conducted in accordance with its general investigational plan and protocol under legal and regulatory requirements, including GCP. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our CROs, trial sites, principal investigators or other third parties fail to comply with applicable GCP requirements, other regulations, trial protocol or other requirements under their agreements with us, the quality or accuracy of the data they obtain may be compromised or unreliable, and the trials of our product candidates may not meet regulatory requirements. If trials do not meet regulatory requirements or if these third parties need to be replaced, the development of our product candidates may be delayed, suspended or terminated, regulatory authorities may require us to exclude the use of patient data from our approval applications or perform additional clinical trials before approving our marketing applications. Regulatory authorities may even reject our application for approval or refuse to accept our future applications for an extended period of time. We cannot assure that upon inspection by a regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements or that our results may be used in support of our regulatory submissions. If any of these events occur, we may not be able to obtain regulatory approval for our product candidates on a timely basis, at a reasonable cost, or at all.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We currently rely, and expect to continue to rely, on third parties to conduct many aspects of our product manufacturing and distribution, and these third parties may terminate these agreements or not perform satisfactorily. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have operating manufacturing facilities at this time other than our roxadustat manufacturing facilities in China, and our current commercial manufacturing plans in China are not expected to satisfy the requirements necessary to support development and commercialization outside of China. Other than in and for China specifically, we do not expect to independently manufacture our products. We currently rely, and expect to continue to rely, on third parties to scale-up, manufacture and supply roxadustat and our other product candidates outside of China. We rely on third parties for distribution, including our collaboration partners and their vendors, except in China where we have established a jointly owned entity with AstraZeneca to manage most of the&#160;&#160;distribution in China. Risks arising from our reliance on third-party manufacturers include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reduced control and additional burdens of oversight as a result of using third-party manufacturers and distributors for all aspects of manufacturing activities, including regulatory compliance and quality control and quality assurance&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">termination of manufacturing agreements, termination fees associated with such termination, or nonrenewal of manufacturing agreements with third parties may negatively impact our planned development and commercialization activities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the possible misappropriation of our proprietary technology, including our trade secrets and know-how&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disruptions to the operations of our third-party manufacturers, distributors or suppliers unrelated to our product, including the merger, acquisition, or bankruptcy of a manufacturer or supplier or a catastrophic event, including disruption resulting from the COVID-19 pandemic, affecting our manufacturers, distributors or suppliers.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could lead to development delays or failure to obtain regulatory approval or affect our ability to successfully commercialize our product candidates. Some of these events could be the basis for action by the FDA or another regulatory authority, including injunction, recall, seizure or total or partial suspension of production.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The facilities used by our contract manufacturers to manufacture our product candidates must pass inspections by the FDA and other regulatory authorities. Although, except for China, we do not control the manufacturing operations of, and expect to remain completely dependent on, our contract manufacturers for manufacture of drug substance and finished drug product, we are ultimately responsible for ensuring that our product candidates are manufactured in compliance with cGMP requirements. If our contract manufacturers cannot successfully manufacture material that conforms to our or our collaboration partners&#8217; specifications, or the regulatory requirements of the FDA or other regulatory authorities, we may not be able to secure and/or maintain regulatory approval for our product candidates and our development or commercialization plans may be delayed. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. In addition, although our longer-term agreements are expected to provide for requirements to meet our quantity and quality requirements to manufacture our products candidates for clinical studies and commercial sale, we will have minimal direct control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel and we expect to rely on our audit rights to ensure that those qualifications are maintained to meet our requirements. If our contract manufacturers&#8217; facilities do not pass inspection by regulatory authorities, or if regulatory authorities do not approve these facilities for the manufacture of our products, or withdraw any such approval in the future, we would need to identify and qualify alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our products, if approved. Moreover, any failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us or adverse regulatory consequences, including clinical holds, warnings or untitled letters, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which would be expected to significantly and adversely affect supplies of our products to us and our collaboration partners.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">W</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e have entered into a commercial supply agreement for the manufacture of pamrevlumab with Samsung Biologics Co., Ltd. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, we may experience delays or technical problems associated with technology transfer of the manufacturing process to Samsung and the qualification and scale-up thereof. We have made certain manufacturing commitments to Samsung </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biologics Co., Ltd., and there is a risk we will not require the quantities of pamrevlumab we have committed to, particularly if we cease some of our pamrevlumab clinical trials. In addition, our product candidates and any products that we may develop may compete with other product candidates and products for access and prioritization to manufacture. Certain third-party manufacturers may be contractually prohibited from manufacturing our product due to non-compete agreements with our competitors or a commitment to grant another party priority relative to our products. There are a limited number of third-party manufacturers that operate under cGMP and that might be capable of manufacturing to meet our requirements. Due to the limited number of third-party manufacturers with the contractual freedom, expertise, required regulatory approvals and facilities to manufacture our products on a commercial scale, identifying and qualifying a replacement third-party manufacturer would be expensive and time-consuming and may cause delay or interruptions in the production of our product candidates or products, which in turn may delay, prevent or impair our development and commercialization efforts.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a letter agreement with IRIX Pharmaceuticals, Inc. (&#8220;IRIX&#8221;), a third-party manufacturer that we have used in the past, pursuant to which we agreed to negotiate a single source manufacturing agreement that included a right of first negotiation for the cGMP manufacture of HIF-PH inhibitors, including roxadustat, provided that IRIX is able to match any third-party bids within 5%. The exclusive right to manufacture extends for five years after approval of an NDA for those compounds, and any agreement would provide that no minimum amounts would be specified until appropriate by forecast and that we and a commercialization partner would have the rights to contract with independent third parties that exceed IRIX&#8217;s internal manufacturing capabilities or in the event that we or our commercialization partner determines for reasons of continuity of supply and security that such a need exists, provided that IRIX would supply no less than 65% of the product if it is able to provide this level of supply. Subsequent to the letter agreement, we and IRIX have entered into several additional service agreements. IRIX has requested in writing that we honor the letter agreement with respect to the single source manufacturing agreement, and if we were to enter into any such exclusive manufacturing agreement, there can be no assurance that IRIX will not assert a claim for right to manufacture roxadustat or that IRIX could manufacture roxadustat successfully and in accordance with applicable regulations for a commercial product and the specifications of our collaboration partners. In 2015, Patheon Pharmaceuticals Inc., a business unit of DPx Holdings B.V., acquired IRIX, and in 2017, ThermoFisher Scientific Inc. acquired Patheon Pharmaceuticals Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any third-party manufacturer terminates its engagement with us or fails to perform as agreed, we may be required to find replacement manufacturers, which would result in significant cost and delay to our development programs. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur significant delays and added costs in identifying, qualifying and contracting with any such third party or potential second source manufacturer. In any event, with any third-party manufacturer we expect to enter into technical transfer agreements and share our know-how with the third-party manufacturer, which can be time-consuming and may result in delays. These delays could result in a suspension or delay of marketing roxadustat.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Certain components of our products are acquired from single-source suppliers or without long-term supply agreements. The loss of these suppliers, or their failure to supply, would materially and adversely affect our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have an alternative supplier of certain components of our product candidates. We may be unable to enter into long-term commercial supply arrangements for some of our products, or do so on commercially reasonable terms, which could have a material adverse impact upon our business.&#160;In addition, we currently rely on our contract manufacturers to purchase from third-party suppliers some of the materials necessary to produce our product candidates. We do not have direct control over the acquisition of those materials by our contract manufacturers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The logistics of our supply chain, which include shipment of materials and intermediates from countries such as China and India add additional time and risk (including risk of loss) to the manufacture of our product candidates. While we have in the past maintained sufficient inventory of materials, active pharmaceutical ingredients (&#8220;API&#8221;), and drug product to meet our and our collaboration partners&#8217; needs for roxadustat to date, the lead-time and regulatory approvals required to source from and into countries outside of the U.S. increase the risk of delay and potential shortages of supply.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our efforts to protect our proprietary technologies are not adequate, we may not be able to compete effectively in our market.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely upon a combination of patents, trade secret protection, and contractual arrangements to protect the intellectual property related to our technologies. We will only be able to protect our products and proprietary information and technology by preventing unauthorized use by third parties to the extent that our patents, trade secrets, and contractual position allow us to do so. Any disclosure to or misappropriation by third parties of our trade secrets or confidential information could compromise our competitive position. Moreover, we are involved in, have in the past been involved in, and may in the future be involved in legal proceedings involving our intellectual property initiated by third parties, which proceedings can be associated with significant costs and commitment of management time and attention. As our product candidates continue in development, third parties have attempted and may again attempt to challenge the validity and enforceability of our patents and proprietary information and technologies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also are involved in, have in the past been involved in, and may in the future be involved in initiating legal or administrative proceedings involving the product candidates and intellectual property of our competitors. These proceedings can result in significant costs and commitment of management time and attention, and there can be no assurance that our efforts would be successful in preventing or limiting the ability of our competitors to market competing products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Composition-of-matter patents relating to the API are generally considered to be the strongest form of intellectual property protection for pharmaceutical products, as such patents provide protection not limited to any one method of use. Method-of-use patents protect the use of a product for the specified method(s), and do not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. We rely on a combination of these and other types of patents to protect our product candidates, and there can be no assurance that our intellectual property will create and sustain the competitive position of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biotechnology and pharmaceutical product patents involve highly complex legal and scientific questions and can be uncertain. Any patent applications that we own or license may fail to result in issued patents. Even if patents do successfully issue from our applications, third parties may challenge their validity or enforceability, which may result in such patents being narrowed, invalidated, or held unenforceable. Even if our patents and patent applications are not challenged by third parties, those patents and patent applications may not prevent others from designing around our claims and may not otherwise adequately protect our product candidates. If the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates is threatened, competitors with significantly greater resources could threaten our ability to commercialize our product candidates. Discoveries are generally published in the scientific literature well after their actual development, and patent applications in the U.S. and other countries are typically not published until 18 months after their filing, and in some cases are never published. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in our owned and licensed patents or patent applications, or that we or our licensors were the first to file for patent protection covering such inventions. Subject to meeting other requirements for patentability, for U.S. patent applications filed prior to March&#160;16, 2013, the first to invent the claimed invention is entitled to receive patent protection for that invention while, outside the U.S., the first to file a patent application encompassing the invention is entitled to patent protection for the invention. The U.S. moved to a &#8220;first to file&#8221; system under the Leahy-Smith America Invents Act, effective March&#160;16, 2013. This system also includes procedures for challenging issued patents and pending patent applications, which creates additional uncertainty. We have, are, and may again become involved in opposition or interference proceedings challenging our patents and patent applications or the patents and patent applications of others, and the outcome of any such proceedings are highly uncertain. An unfavorable outcome in any such proceedings could reduce the scope of or invalidate our patent rights, allow third parties to commercialize our technology and compete directly with us, or result in our inability to manufacture, develop or commercialize our product candidates without infringing the patent rights of others.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how, information, or technology that is not covered by our patents. Although our agreements require all of our employees to acknowledge ownership by us of inventions conceived as a result of employment from the point of conception and, to the extent necessary, perfect such ownership by assignment, and we require all of our employees, consultants, advisors and any third parties who have access to our trade secrets, proprietary know-how and other confidential information and technology to enter into appropriate confidentiality agreements, we cannot be certain that our trade secrets, proprietary know-how and other confidential information and technology will not be subject to unauthorized disclosure or that our competitors will not otherwise gain access to or independently develop substantially equivalent trade secrets, proprietary know-how and other information and technology. Furthermore, the laws of some foreign countries, in particular, China, where we have operations, do not protect proprietary rights to the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant problems in protecting and defending our intellectual property globally. If we are unable to prevent unauthorized disclosure of our intellectual property related to our product candidates and technology to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business and operations.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property disputes may be costly, time consuming, and may negatively affect our competitive position. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success may depend on our avoiding infringement of the patents and other proprietary rights of third parties as well as on enforcing our patents and other proprietary rights against third parties. Pharmaceutical and biotechnology intellectual property disputes are characterized by complex, lengthy and expensive litigation over patents and other intellectual property rights. We have initiated and may again initiate or become party to or be threatened with future litigation or other proceedings regarding intellectual property rights with respect to our product candidates and competing products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As our product candidates progress toward commercialization, our collaboration partners or we may be subject to patent infringement claims from third parties. We attempt to ensure that our product candidates do not infringe third-party patents and other proprietary rights. However, the patent landscape in competitive product areas is highly complex, and there may be patents of third parties of which we are unaware that may result in claims of infringement. Accordingly, there can be no assurance that our product candidates do not infringe proprietary rights of third parties, and parties making claims against us may seek and obtain injunctive or other equitable relief, which could potentially block further efforts to develop and commercialize our product candidates including roxadustat or pamrevlumab. Any litigation involving defense against claims of infringement, regardless of the merit of such claims, would involve substantial litigation expense and would be a substantial diversion of management time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may consider administrative proceedings and other means for challenging third-party patents and patent applications. An unfavorable outcome in any such challenge could require us to cease using the related technology and to attempt to license rights to it from the prevailing third party, which may not be available on commercially reasonable terms, if at all, in which case our business could be harmed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend, if necessary, to vigorously enforce our intellectual property in order to protect the proprietary position of our product candidates, including roxadustat and pamrevlumab. In addition, our collaboration partners who have been granted licenses to our patents may also have rights related to enforcement of those patents. Active efforts to enforce our patents by us or by our partners may include litigation, administrative proceedings, or both, depending on the potential benefits that might be available from those actions and the costs associated with undertaking those efforts against third parties. We carefully review and monitor publicly available information regarding products that may be competitive with our product candidates and assert our intellectual property rights where appropriate. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties have challenged and may again challenge our patents and patent applications, through interference, reexamination, <span style="font-style:italic;">inter partes</span> review, and post-grant review proceedings before the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) or through comparable proceedings in other territories. For example, various legal challenges against our HIF anemia-related technologies patent portfolio have been filed in several territories including in Europe, the United Kingdom, Canada, and Japan,.&#160;&#160;Regardless of the final outcome of these actions, the potential narrowing or revocation of any of the HIF anemia-related technology patents does not affect our exclusivity for roxadustat or our freedom-to-operate with respect to use of roxadustat for the treatment of anemia in these or other territories. A settlement has been reached in the litigation in Canada, resulting in the discontinuance of the action and leaving FibroGen&#8217;s Canadian patents valid and enforceable.&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2020, in response to an invalidation action brought against certain of our United Kingdom patents by Akebia, the United Kingdom court handed down a decision invalidating United Kingdom designations of European Patent Nos.&#160;1463823, 1633333, 2298301, 2322153, and 2322155. The United Kingdom designation to European Patent No. 2289531 was held to be valid in amended form, but not infringed by Akebia. We and our partner Astellas have filed an appeal of the decision in the United Kingdom Court of Appeal. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, oppositions were filed against our European Patent No. 2872488 (the &#8220;`488 Patent&#8221;), which claims a crystalline form of roxadustat, and against our European Patent No. 3003284 (the &#8220;`284 Patent&#8221;), which claims photostable formulations of roxadustat. Final resolution of the opposition proceedings will take time, and we cannot be assured of the breadth of the claims that will remain in the `488 Patent or `284 Patent, or that either or both of the patents will not be revoked in their entirety.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, there is a risk that any public announcements concerning the status or outcomes of intellectual property litigation or administrative proceedings may adversely affect the price of our stock. If securities analysts or our investors interpret such status or outcomes as negative or otherwise creating uncertainty, our common stock price may be adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our reliance on third parties and agreements with collaboration partners requires us to share our trade secrets, which increases the possibility that a competitor may discover them or that our trade secrets will be misappropriated or disclosed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our reliance on third-party contractors to develop and manufacture our product candidates is based upon agreements that limit the rights of the third parties to use or disclose our confidential information, including our trade secrets and know-how. Despite the contractual provisions, the need to share trade secrets and other confidential information increases the risk that such trade secrets and information are disclosed or used, even if unintentionally, in violation of these agreements. In the highly competitive markets in which our product candidates are expected to compete, protecting our trade secrets, including our strategies for addressing competing products, is imperative, and any unauthorized use or disclosure could impair our competitive position and may have a material adverse effect on our business and operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our collaboration partners are larger, more complex organizations than ours, and the risk of inadvertent disclosure of our proprietary information may be increased despite their internal procedures and contractual obligations that we have in place with them. Despite our efforts to protect our trade secrets and other confidential information, a competitor&#8217;s discovery of such trade secrets and information could impair our competitive position and have an adverse impact on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The cost of maintaining our patent protection is high and requires continuous review and diligence. We may not be able to effectively maintain our intellectual property position throughout the major markets of the world.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The USPTO and foreign patent authorities require maintenance fees and payments as well as continued compliance with a number of procedural and documentary requirements. Noncompliance may result in abandonment or lapse of the subject patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance may result in reduced royalty payments for lack of patent coverage in a particular jurisdiction from our collaboration partners or may result in competition, either of which could have a material adverse effect on our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have made, and will continue to make, certain strategic decisions in balancing costs and the potential protection afforded by the patent laws of certain countries. As a result, we may not be able to prevent third parties from practicing our inventions in all countries throughout the world, or from selling or importing products made using our inventions in and into the U.S. or other countries. Third parties may use our technologies in territories in which we have not obtained patent protection to develop their own products and, further, may infringe our patents in territories which provide inadequate enforcement mechanisms, even if we have patent protection. Such third-party products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The laws of some foreign countries do not protect proprietary rights to the same extent as do the laws of the U.S., and we may encounter significant problems in securing and defending our intellectual property rights outside the U.S. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain countries. The legal systems of certain countries do not always favor the enforcement of patents, trade secrets, and other intellectual property rights, particularly those relating to pharmaceutical and biotechnology products, which could make it difficult for us to stop infringement of our patents, misappropriation of our trade secrets, or marketing of competing products in violation of our proprietary rights. In China, our intended establishment of significant operations will depend in substantial part on our ability to effectively enforce our intellectual property rights in that country. Proceedings to enforce our intellectual property rights in foreign countries could result in substantial costs and divert our efforts and attention from other aspects of our business, and could put our patents in these territories at risk of being invalidated or interpreted narrowly, or our patent applications at risk of not being granted, and could provoke third parties to assert claims against us. We may not prevail in all legal or other proceedings that we may initiate and, if we were to prevail, the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property rights do not address all potential threats to any competitive advantage we may have.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and intellectual property rights may not adequately protect our business or permit us to maintain our competitive advantage. The following examples are illustrative:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Others may be able to make compounds that are the same as or similar to our current or future product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We or any of our licensors or strategic partners might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We or any of our licensors or strategic partners might not have been the first to file patent applications covering certain of our inventions.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The prosecution of our pending patent applications may not result in granted patents.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Granted patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Patent protection on our product candidates may expire before we are able to develop and commercialize the product, or before we are able to recover our investment in the product.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our competitors might conduct research and development activities in the U.S. and other countries that provide a safe harbor from patent infringement claims for such activities, as well as in countries in which we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in markets where we intend to market our product candidates.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The existence of counterfeit pharmaceutical products in pharmaceutical markets may compromise our brand and reputation and have a material adverse effect on our business, operations and prospects.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Counterfeit products, including counterfeit pharmaceutical products, are a significant problem, particularly in China. Counterfeit pharmaceuticals are products sold or used for research under the same or similar names, or similar mechanism of action or product class, but which are sold without proper licenses or approvals, and are often lower cost, lower quality, different potency, or have different ingredients or formulations, and have the potential to damage the reputation for quality and effectiveness of the genuine product. Such products may be used for indications or purposes that are not recommended or approved or for which there is no data or inadequate data with regard to safety or efficacy. Such products divert sales from genuine products. If counterfeit pharmaceuticals illegally sold or used for research result in adverse events or side effects to consumers, we may be associated with any negative publicity resulting from such incidents. Consumers may buy counterfeit pharmaceuticals that are in direct competition with our pharmaceuticals, which could have an adverse impact on our revenues, business and results of operations. In addition, the use of counterfeit products could be used in non-clinical or clinical studies, or could otherwise produce undesirable side effects or adverse events that may be attributed to our products as well, which could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in the delay or denial of regulatory approval by the FDA or other regulatory authorities and potential product liability claims. With respect to China, although the government has recently been increasingly active in policing counterfeit pharmaceuticals, there is not yet an effective counterfeit pharmaceutical regulation control and enforcement system in China. As a result, we may not be able to prevent third parties from selling or purporting to sell our products in China. The proliferation of counterfeit pharmaceuticals has grown in recent years and may continue to grow in the future. The existence of and any increase in the sales and production of counterfeit pharmaceuticals, or the technological capabilities of counterfeiters, could negatively impact our revenues, brand reputation, business and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Government Regulation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The regulatory approval process is highly uncertain and we may not obtain regulatory approval for our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable, but typically takes many years following the commencement of preclinical studies and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. Except for roxadustat in China, Japan, and Chile for patients on dialysis and not on dialysis, we have not obtained regulatory approval for any product candidate, and it is possible that neither roxadustat nor pamrevlumab, nor any future product candidates we may discover, in-license or acquire and seek to develop in the future, will obtain regulatory approval in additional countries.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates could fail to receive regulatory approval from the FDA or other regulatory authorities for many reasons, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disagreement over the design or implementation of our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to demonstrate that a product candidate is safe and effective for its proposed indication&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure of clinical trials to meet the level of statistical significance required for approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disagreement over our interpretation of data from preclinical studies or clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disagreement over whether to accept efficacy results from clinical trial sites outside the U.S. where the standard of care is potentially different from that in the U.S.&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the insufficiency of data collected from clinical trials of our present or future product candidates to support the submission and filing of an NDA or other submission or to obtain regulatory approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disapproval of the manufacturing processes or facilities of either our manufacturing plant or third party manufacturers with whom we contract for clinical and commercial supplies&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in the approval policies or regulations that render our preclinical and clinical data insufficient for approval.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or other regulatory authorities may require more information, including additional preclinical or clinical data to support approval, or different analyses, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the development program altogether. Even if we do obtain regulatory approval, our product candidates may be approved for fewer or more limited indications than we request, approval may be contingent on the performance of costly post-marketing clinical trials, or approval may require labeling that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. In addition, if our product candidates produce undesirable side effects or safety issues, the FDA may require the establishment of REMS or other regulatory authorities may require the establishment of a similar strategy, that may restrict distribution of our approved products, if any, and impose burdensome implementation requirements on us. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we believe our clinical trials are successful, regulatory authorities may not agree that our completed clinical trials provide adequate data on safety or efficacy. Approval by one regulatory authority does not ensure approval by any other regulatory authority. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. We may not be able to file for regulatory approvals and even if we file we may not receive the necessary approvals to commercialize our product candidates in any market.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our current and future relationships with customers, physicians, and third-party payors are subject to healthcare fraud and abuse laws, false claims laws, transparency laws, privacy and security laws, and other regulations. If we are unable to comply with such laws, we could face substantial penalties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and future relationships with customers, physicians, and third-party payors are subject to health care laws and regulations, which may constrain the business or financial arrangements and relationships through which we research, as well as, sell, market and distribute any products for which we obtain marketing approval. If we obtain approval in the U.S. for any of our product candidates, the regulatory requirements applicable to our operations, in particular our sales and marketing efforts, will increase significantly with respect to our operations and the potential for administrative, civil and criminal enforcement by the federal government and the states and foreign governments will increase with respect to the conduct of our business. The laws that may affect our operations in the U.S. include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">HIPAA, as amended by Health Information Technology and Clinical Health Act, and its implementing regulations, which imposes certain requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information as well as their covered subcontractors relating to the privacy, security, and transmission of individually identifiable health information&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal physician sunshine requirements under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;PPACA&#8221;), which requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to the Centers for Medicare &#38; Medicaid Services (&#8220;CMS&#8221;), information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">foreign and state law equivalents of each of the above federal laws, such as the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers&#59; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources&#59; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures&#59; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the Trade Agreements Act (&#8220;TAA&#8221;), which requires that drugs sold to the U.S. Government must be manufactured in the U.S. or in TAA approved and designated countries. Drugs manufactured in countries not approved under the TAA, may not be sold to the U.S. without specific regulatory approval. We have little experience with this regulation and there is a risk that drugs made from Chinese-made API may not be sold to an entity of the U.S. such as the Veterans Health Administration (&#8220;VA&#8221;) due to our inability to obtain regulatory approval. While there have been recent VA policy changes that appear to allow for sale of drugs from non-TAA approved countries, this policy may change or there may be additional policies or legislation that affect our ability to sell drug to the U.S. Government.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The scope of these laws and our lack of experience in establishing the compliance programs necessary to comply with this complex and evolving regulatory environment increases the risks that we may unknowingly violate the applicable laws and regulations. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs and imprisonment, any of which could materially adversely affect our ability to operate our business and our financial results. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to healthcare laws and regulations may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, manufacturing, sales, marketing or distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other proceedings relating to applicable healthcare laws and regulations could have a material adverse effect on our ability to compete in the marketplace.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to laws and regulations governing corruption, which will require us to maintain costly compliance programs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We must comply with a wide range of laws and regulations to prevent corruption, bribery, and other unethical business practices, including the FCPA, anti-bribery and anti-corruption laws in other countries, particularly China. The implementation and maintenance of compliance programs is costly and such programs may be difficult to enforce, particularly where reliance on third parties is required.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anti-bribery laws prohibit us, our employees, and some of our agents or representatives from offering or providing any personal benefit to covered government officials to influence their performance of their duties or induce them to serve interests other than the missions of the public organizations in which they serve. Certain commercial bribery rules also prohibit offering or providing any personal benefit to employees and representatives of commercial companies to influence their performance of their duties or induce them to serve interests other than their employers. The FCPA also obligates companies whose securities are listed in the U.S. to comply with certain accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The SEC is involved with enforcement of the books and records provisions of the FCPA.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with these anti-bribery laws is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the anti-bribery laws present particular challenges in the pharmaceutical industry because in many countries including China, hospitals are state-owned or operated by the government, and doctors and other hospital employees are considered foreign government officials. Furthermore, in certain countries (China in particular), hospitals and clinics are permitted to sell pharmaceuticals to their patients and are primary or significant distributors of pharmaceuticals. Certain payments to hospitals in connection with clinical studies, procurement of pharmaceuticals and other work have been deemed to be improper payments to government officials that have led to vigorous anti-bribery law enforcement actions and heavy fines in multiple jurisdictions, particularly in the U.S. and China.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is not always possible to identify and deter violations, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the pharmaceutical industry, corrupt practices include, among others, acceptance of kickbacks, bribes or other illegal gains or benefits by the hospitals and medical practitioners from pharmaceutical manufacturers, distributors or their third-party agents in connection with the prescription of certain pharmaceuticals. If our employees, affiliates, distributors or third-party marketing firms violate these laws or otherwise engage in illegal practices with respect to their sales or marketing of our products or other activities involving our products, we could be required to pay damages or heavy fines by multiple jurisdictions where we operate, which could materially and adversely affect our financial condition and results of operations. The Chinese government has also sponsored anti-corruption campaigns from time to time, which could have a chilling effect on any future marketing efforts by us to new hospital customers. There have been recent occurrences in which certain hospitals have denied access to sales representatives from pharmaceutical companies because the hospitals wanted to avoid the perception of corruption. If this attitude becomes widespread among our potential customers, our ability to promote our products to hospitals may be adversely affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we expand our operations in China and other jurisdictions internationally, we will need to increase the scope of our compliance programs to address the risks relating to the potential for violations of the FCPA and other anti-bribery and anti-corruption laws. Our compliance programs will need to include policies addressing not only the FCPA, but also the provisions of a variety of anti-bribery and anti-corruption laws in multiple foreign jurisdictions, including China, provisions relating to books and records that apply to us as a public company, and include effective training for our personnel throughout our organization. The creation and implementation of anti-corruption compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required. Violation of the FCPA and other anti-corruption laws can result in significant administrative and criminal penalties for us and our employees, including substantial fines, suspension or debarment from government contracting, prison sentences, or even the death penalty in extremely serious cases in certain countries. The SEC also may suspend or bar us from trading securities on U.S. exchanges for violation of the FCPA&#8217;s accounting provisions. Even if we are not ultimately punished by government authorities, the costs of investigation and review, distraction of our personnel, legal defense costs, and harm to our reputation could be substantial and could limit our profitability or our ability to develop or commercialize our product candidates. In addition, if any of our competitors are not subject to the FCPA, they may engage in practices that will lead to their receipt of preferential treatment from foreign hospitals and enable them to secure business from foreign hospitals in ways that are unavailable to us.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these, or if we otherwise fail to maintain an effective system of internal control, it may result in material misstatements in our financial statements. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting and for evaluating and reporting on the effectiveness of our system of internal control. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles. As a public company, we are required to comply with the Sarbanes-Oxley Act and other rules that govern public companies.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020, we have identified a material weakness in the risk assessment component of internal control as we did not appropriately design and maintain an effective risk assessment process at a precise enough level to identify new and evolving risks of material misstatement to the financial statements as a result of changes in our business operation. This material weakness gave rise to the following additional control deficiencies, which we also determined to be material weaknesses. We did not design and maintain effective controls related to the timely identification of shipments associated with drug product revenue and we did not design and maintain effective controls related to the timely identification of changes in estimated variable consideration related to drug product revenue. Each of these material weaknesses could result in material misstatements in the drug product revenue, contract asset, or contract liability account balances or disclosures in our annual or interim consolidated financial statements that would not be prevented or detected. The material weaknesses described above did not result in any material misstatements of our consolidated financial statements or disclosures, but did result in immaterial out-of-period adjustments to drug product revenue related to pre-commercial shipments of drug product, contract assets and contract liabilities, and related financial statement disclosures during the quarter ended September 30, 2020. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have developed a detailed remediation plan and are making progress to improve our related internal control over financial reporting. For further discussion of the material weaknesses identified and our remedial efforts, see Part II, Item 9A, &#8220;<span style="font-style:italic;">Controls and Procedures&#8221; </span>in this Annual Report on Form 10-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remediation efforts place a significant burden on management and add increased pressure on our financial resources and processes. If we are unable to successfully remediate our existing or any future material weaknesses or other deficiencies in our internal control over financial reporting, the accuracy and timing of our financial reporting may be adversely affected, our liquidity, our access to capital markets may be adversely affected, we may be unable to maintain or regain compliance with applicable securities laws, and the NASDAQ Stock Market LLC listing requirements, we may be subject to regulatory investigations and penalties, investors may lose confidence in our financial reporting, and our stock price may decline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The impact of recent U.S. healthcare reform, its potential partial or full repeal, and other changes in the healthcare industry and in healthcare spending is currently unknown, and may adversely affect our business model. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The commercial potential for our approved products could be affected by changes in healthcare spending and policy in the U.S. and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S., the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (&#8220;MMA&#8221;) altered Medicare coverage and payments for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. The MMA also provided authority for limiting the number of drugs that will be covered in any therapeutic class and as a result, we expect that there will be additional pressure to reduce costs. For example, the CMS in implementing the MMA has enacted regulations that reduced capitated payments to dialysis providers. These cost reduction initiatives and other provisions of the MMA could decrease the scope of coverage and the price that may be received for any approved dialysis products and could seriously harm our business and financial condition. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policies and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement that results from the MMA may cause a similar reduction in payments from private payors. Similar regulations or reimbursement policies have been enacted in many international markets that could similarly impact the commercial potential for our products.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Medicare Improvements for Patients and Providers Act (&#8220;MIPPA&#8221;), a basic case-mix adjusted composite, or bundled, payment system commenced in January 2011 and transitioned fully by January 2014 to a single reimbursement rate for drugs and all services furnished by renal dialysis centers for Medicare beneficiaries with end-stage renal disease. Specifically, under MIPPA the End-Stage Renal Disease Prospective Payment System (the &#8220;ESRD PPS&#8221;) bundle now covers drugs, services, lab tests and supplies under a single treatment base rate for reimbursement by the CMS based on the average cost per treatment, including the cost of ESAs and IV iron doses, typically without adjustment for usage. It is unknown whether roxadustat, if approved in the U.S., will be included in the payment bundle or the timing of inclusion. Under MIPPA, agents that have no IV equivalent in the bundle are currently expected to be excluded from the bundle until 2025. If roxadustat were included in the bundle, it may reduce the price that could be charged for roxadustat, and therefore potentially limit our profitability. Based on roxadustat&#8217;s differentiated mechanism of action and therapeutic effects, and discussions with our collaboration partner, we currently believe that roxadustat might not initially be included in the bundle and would instead be eligible for a Transitional Drug Add-on Payment Adjustment (&#8220;TDAPA&#8221;) for a 24-month period. At the 24-month mark, CMS would determine if the TDAPA period should be extended for roxadustat or ended. When the TDAPA period ends, CMS will determine if roxadustat should be included in the bundle and, if so, what changes to the ESRD PPS reimbursement should be made. If roxadustat is included in the ESRD PPS bundle, it may have an impact on roxadustat pricing within Dialysis Organizations. If roxadustat is not included in the bundle after the TDAPA period, and would therefore be reimbursed outside of the bundle, it may potentially limit further market penetration of roxadustat. We currently expect roxadustat to be granted TDAPA designation either July 1 or October 1 of 2021. However, there is a risk that we do not receive TDAPA designation, or when we expect it, in which case, there would be a significant impact on roxadustat revenue in 2021, or until TDAPA designation is granted.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2010, the PPACA was passed, which substantially changed the way healthcare is financed by both governmental and private payors in the U.S. There remain judicial and Congressional challenges to certain aspects of the PPACA. For example, the Tax Cuts and Jobs Act of 2017, (the &#8220;Tax Act&#8221;), was enacted, which includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221;&#160;&#160;In addition, the 2020 federal spending package permanently eliminates, effective January 1, 2020, the PPACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. Additionally, on December 14, 2018, a Texas U.S. District Court Judge ruled that the PPACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the PPACA are invalid as well. The U.S. Supreme Court is currently reviewing this case, but it is unknown when a decision will be reached. Although the U.S. Supreme Court has yet ruled on the constitutionality of the PPACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the PPACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the PPACA. It is unclear how the U.S. Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the PPACA and our business.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, in the U.S. there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals. The FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November&#160;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part&#160;D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until March 22, 2021. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the U.S. District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. However, it is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that additional U.S. healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for any future products or additional pricing pressures.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Roxadustat is considered a Class 2 substance on the 2019 World Anti-Doping Agency Prohibited List that could limit sales and increase security and distribution costs for our partners and us. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat is considered a Class 2 substance on the World Anti-Doping Agency Prohibited List. There are enhanced security and distribution procedures we and our collaboration partners and third-party contractors will have to take to limit the risk of loss of product in the supply chain. As a result, our distribution, manufacturing and sales costs for roxadustat, as well as for our partners, will be increased which will reduce profitability. In addition, there is a risk of reduced sales due to patient access to this drug. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees may engage in misconduct or improper activities, which could result in significant liability or harm our reputation.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of employee fraud or other misconduct, including intentional failure to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">comply with FDA regulations or similar regulations of comparable foreign regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">provide accurate information to the FDA or comparable foreign regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">comply with manufacturing standards we have established&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">comply with privacy laws protecting personal information&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">comply with the FCPA and other anti-bribery laws&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">report financial information or data accurately&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disclose unauthorized activities to us.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions, delays in clinical trials, or serious harm to our reputation. We have adopted a code of conduct for our directors, officers and employees, but it is not always possible to identify and deter employee misconduct. The precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could harm our business, results of operations, financial condition and cash flows, including through the imposition of significant fines or other sanctions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with environmental, health or safety laws and regulations, we could incur fines, penalties or other costs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations applicable to our operations in the U.S. and foreign countries. These current or future laws and regulations may impair our research, development or manufacturing efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our International Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have established operations in China and are seeking approval to commercialize our product candidates outside of the U.S., and a number of risks associated with international operations could materially and adversely affect our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to be subject to a number of risks related with our international operations, many of which may be beyond our control. These risks include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">different regulatory requirements for drug approvals in different countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">different standards of care in various countries that could complicate the evaluation of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">different U.S. and foreign drug import and export rules&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reduced protection for intellectual property rights in certain countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in tariffs, trade barriers and regulatory requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">different reimbursement systems and different competitive drugs indicated to treat the indications for which our product candidates are being developed&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">economic weakness, including inflation, or political instability in particular foreign economies and markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">compliance with the FCPA, and other anti-corruption and anti-bribery laws&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">U.S. and foreign taxes, including income, excise, customs, consumption, withholding, and payroll taxes&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">foreign currency fluctuations, which could result in increased operating costs and expenses and reduced revenues, and other obligations incident to doing business in another country&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">workforce uncertainty in countries where labor unrest is more common than in the U.S.&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a reliance on CROs, clinical trial sites, principal investigators and other third parties that may be less experienced with clinical trials or have different methods of performing such clinical trials than we are used to in the U.S.&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential liability resulting from development work conducted by foreign distributors&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">business interruptions resulting from geopolitical actions specific to an international region, including war and terrorism, or natural disasters, including the differing impact of the COVID-19 pandemic on each region.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The pharmaceutical industry in China is highly regulated and such regulations are subject to change. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pharmaceutical industry in China is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new drugs. In recent years, many aspects of pharmaceutical industry regulation have undergone significant reform, and reform may continue. For example, the Chinese government implemented regulations that impact distribution of pharmaceutical products in China, where at most two invoices may be issued throughout the distribution chain, a change that required us to change our distribution paradigm. Any regulatory changes or amendments may result in increased compliance costs to our business or cause delays in or prevent the successful development or commercialization of our product candidates in China. Any failure by us or our partners to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our business activities in China.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have limited experience distributing drugs in China.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have established a jointly owned entity with AstraZeneca in China, one that has a distribution license. It is subject to a new body of regulations pertaining to distribution with which we have limited experience. This new distribution structure may impose higher costs or limit or delay our ability to sell products to our principal customers, and may limit the near term sales of our products. There are operational risks associated with the jointly owned entity, such as working capital funding requirements and regulatory challenges, which could impact our ability to operate in China, including increasing sales of roxadustat. We have limited experience managing distribution of pharmaceutical products, and this new distribution structure may impose higher costs or limit or delay our ability to sell products to our principal customers, and may limit the near term sales of our products. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We use our own manufacturing facilities in China to produce roxadustat API and drug product. There are risks inherent to operating commercial manufacturing facilities, and with these being our single source suppliers, we may not be able to continually meet market demand. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have two manufacturing facilities in China, with one located in Beijing and the other in Cangzhou, Hebei. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will be obligated to comply with continuing cGMP requirements and there can be no assurance that we will maintain all of the appropriate licenses required to manufacture our product candidates for clinical and commercial use in China. In addition, we and our product suppliers must continually spend time, money and effort in production, record-keeping and quality assurance and appropriate controls in order to ensure that any products manufactured in our facilities meet applicable specifications and other requirements for product safety, efficacy and quality and there can be no assurance that our efforts will continue to be successful in meeting these requirements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing facilities in China are subject to periodic unannounced inspections by the NMPA and other regulatory authorities. We expect to depend on these facilities for our product candidates and business operations in China, and we do not yet have a secondary source supplier for either roxadustat API or drug product in China. Natural disasters or other unanticipated catastrophic events, including power interruptions, water shortages, storms, fires, pandemics (including the COVID-19 pandemic), earthquakes, terrorist attacks, government appropriation of our facilities, and wars, could significantly impair our ability to operate our manufacturing facilities. Certain equipment, records and other materials located in these facilities would be difficult to replace or would require substantial replacement lead-time that would impact our ability to successfully commercialize our product candidates in China. The occurrence of any such event could materially and adversely affect our business, financial condition, results of operations, cash flows and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">As a company, we have limited experience in pharmacovigilance, medical affairs, and management of the third-party distribution logistics, and cannot assure you we will be able to meet regulatory requirements or operate in these capacities successfully.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are responsible for commercial manufacturing, pharmacovigilance, medical affairs, and management of the third-party distribution logistics (with AstraZeneca through a jointly owned entity that will perform roxadustat distribution) for roxadustat commercial activities in China. While we have been increasing our staffing in these areas, as a company, we have no experience managing or operating these functions for a commercial product and there can be no guarantee that we will do so efficiently or effectively. Mistakes or delays in these areas could limit our ability to successfully commercialize roxadustat in China, could limit our eventual market penetration, sales and profitability, and could subject us to significant liability in China.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We and our collaboration partner in China, AstraZeneca, may experience difficulties in successfully growing and sustaining sales of roxadustat in China.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and AstraZeneca have a profit sharing arrangement with respect to roxadustat in China and any difficulties we may experience in growing and sustaining sales will affect our bottom line. Difficulties may be related to our ability to maintain reasonable pricing and reimbursement, obtain hospital listing, or other difficulties related to distribution, marketing, and sales efforts in China. For example, our current National Reimbursement Drug List reimbursement pricing is effective for a standard two-year period (between January 1, 2020 to December 31, 2021), after which time we will have to renegotiate a new price for roxadustat, which we expect to be lower based upon historical precedents. Sales of roxadustat in China may ultimately be limited due to the complex nature of the healthcare system, low average personal income, pricing controls, still developing infrastructure and potentially rapid competition from other products. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The retail prices of any product candidates that we develop may be subject to pricing control in China and elsewhere.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The price for pharmaceutical products is highly regulated in China, both at the national and provincial level. Price controls may reduce prices to levels significantly below those that would prevail in less regulated markets or limit the volume of products that may be sold, either of which may have a material and adverse effect on potential revenues from sales of roxadustat in China. Moreover, the process and timing for the implementation of price restrictions is unpredictable, which may cause potential revenues from the sales of roxadustat to fluctuate from period to period.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FibroGen (China) Medical Technology Development Co., Ltd. (&#8220;FibroGen Beijing&#8221;) would be subject to restrictions on paying dividends or making other payments to us, which may restrict our ability to satisfy our liquidity requirements. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to conduct all of our business in China through FibroGen China Anemia Holdings, Ltd. and FibroGen Beijing. We may rely on dividends and royalties paid by FibroGen Beijing for a portion of our cash needs, including the funds necessary to service any debt we may incur and to pay our operating costs and expenses. The payment of dividends by FibroGen Beijing is subject to limitations. Regulations in China currently permit payment of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China. FibroGen Beijing is not permitted to distribute any profits until losses from prior fiscal years have been recouped and in any event must maintain certain minimum capital requirements. FibroGen Beijing is also required to set aside at least 10.0% of its after-tax profit based on Chinese accounting standards each year to its statutory reserve fund until the cumulative amount of such reserves reaches 50.0% of its registered capital. Statutory reserves are not distributable as cash dividends. In addition, if FibroGen Beijing incurs debt on its own behalf in the future, the agreements governing such debt may restrict its ability to pay dividends or make other distributions to us. As of December 31, 2020, approximately $44.6 million of our cash and cash equivalents is held in China.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any capital contributions from us to FibroGen Beijing must be approved by the Ministry of Commerce in China, and failure to obtain such approval may materially and adversely affect the liquidity position of FibroGen Beijing.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Ministry of Commerce in China or its local counterpart must approve the amount and use of any capital contributions from us to FibroGen Beijing, and there can be no assurance that we will be able to complete the necessary government registrations and obtain the necessary government approvals on a timely basis, or at all. If we fail to do so, we may not be able to contribute additional capital to fund our Chinese operations, and the liquidity and financial position of FibroGen Beijing may be materially and adversely affected.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to currency exchange rate fluctuations and currency exchange restrictions with respect to our operations in China, which could adversely affect our financial performance.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of our product sales will occur in local Chinese currency and our operating results will be subject to volatility from currency exchange rate fluctuations. To date, we have not hedged against the risks associated with fluctuations in exchange rates and, therefore, exchange rate fluctuations could have an adverse impact on our future operating results. Changes in value of the Renminbi against the U.S. dollar, Euro and other currencies is affected by, among other things, changes in China&#8217;s political and economic conditions. Currently, the Renminbi is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. Any significant currency exchange rate fluctuations may have a material adverse effect on our business and financial condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Chinese government imposes controls on the convertibility of the Renminbi into foreign currencies and the remittance of foreign currency out of China for certain transactions. Shortages in the availability of foreign currency may restrict the ability of FibroGen Beijing to remit sufficient foreign currency to pay dividends or other payments to us, or otherwise satisfy their foreign currency-denominated obligations. Under existing Chinese foreign exchange regulations, payments of current account items, including profit distributions, interest payments and balance of trade, can be made in foreign currencies without prior approval from the State Administration of Foreign Exchange by complying with certain procedural requirements. However, approval from State Administration of Foreign Exchange or its local branch is required where Renminbi is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. The Chinese government may also at its discretion restrict access in the future to foreign currencies for current account transactions. If the foreign exchange control system prevents us from obtaining sufficient foreign currency to satisfy our operational requirements, our liquidity and financial position may be materially and adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because FibroGen Beijing&#8217;s funds are held in banks that do not provide insurance, the failure of any bank in which FibroGen Beijing deposits its funds could adversely affect our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Banks and other financial institutions in China do not provide insurance for funds held on deposit. As a result, in the event of a bank failure, FibroGen Beijing may not have access to funds on deposit. Depending upon the amount of money FibroGen Beijing maintains in a bank that fails, its inability to have access to cash could materially impair its operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to tax inefficiencies associated with our offshore corporate structure. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The tax regulations of the U.S. and other jurisdictions in which we operate are extremely complex and subject to change. New laws, new interpretations of existing laws, such as the Base Erosion Profit Shifting project initiated by the Organization for Economic Co-operation and Development, and any legislation proposed by the relevant taxing authorities, or limitations on our ability to structure our operations and intercompany transactions may lead to inefficient tax treatment of our revenue, profits, royalties, and distributions, if any are achieved.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our foreign subsidiaries and we have various intercompany transactions. We may not be able to obtain certain benefits under relevant tax treaties to avoid double taxation on certain transactions among our subsidiaries. If we are not able to avail ourselves to the tax treaties, we could be subject to additional taxes, which could adversely affect our financial condition and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 22, 2017, the Tax Cuts and Jobs Act (Tax Act) was enacted which instituted various changes to the taxation of multinational corporations. Since inception, various regulations and interpretations have been issued by governing authorities and we continue to examine the impacts to our business, which could potentially have a material adverse effect on our business, results of operations or financial conditions. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our foreign operations, particularly those in China, are subject to significant risks involving the protection of intellectual property.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We seek to protect the products and technology that we consider important to our business by pursuing patent applications in China and other countries, relying on trade secrets or pharmaceutical regulatory protection or employing a combination of these methods. We note that the filing of a patent application does not mean that we will be granted a patent, or that any patent eventually granted will be as broad as requested in the patent application or will be sufficient to protect our technology. There are a number of factors that could cause our patents, if granted, to become invalid or unenforceable or that could cause our patent applications not to be granted, including known or unknown prior art, deficiencies in the patent application, or lack of originality of the technology. Furthermore, the terms of our patents are limited. The patents we hold and the patents that may be granted from our currently pending patent applications have, absent any patent term adjustment or extension, a twenty-year protection period starting from the date of application.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intellectual property rights and confidentiality protections in China may not be as effective as those in the U.S. or other countries for many reasons, including lack of procedural rules for discovery and evidence, low damage awards, and lack of judicial independence. Implementation and enforcement of China intellectual property laws have historically been deficient and ineffective and may be hampered by corruption and local protectionism. Policing unauthorized use of proprietary technology is difficult and expensive, and we may need to resort to litigation to enforce or defend patents issued to us or to determine the enforceability and validity of our proprietary rights or those of others. The experience and capabilities of China courts in handling intellectual property litigation varies and outcomes are unpredictable. An adverse determination in any such litigation could materially impair our intellectual property rights and may harm our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Uncertainties with respect to the China legal system could have a material adverse effect on us.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The legal system of China is a civil law system primarily based on written statutes. Unlike in a common law system, prior court decisions may be cited for reference but are not binding. Because the China legal system continues to rapidly evolve, the interpretations of many laws, regulations and rules are not always uniform and enforcement of these laws, regulations and rules involve uncertainties, which may limit legal protections available to us. Moreover, decision makers in the China judicial system have significant discretion in interpreting and implementing statutory and contractual terms, which may render it difficult for FibroGen Beijing to enforce the contracts it has entered into with our business partners, customers and suppliers. Different government departments may have different interpretations of certain laws and regulations, and licenses and permits issued or granted by one government authority may be revoked by a higher government authority at a later time. Navigating the uncertainty and change in the China legal system will require the devotion of significant resources and time, and there can be no assurance that our contractual and other rights will ultimately be enforced.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in China&#8217;s economic, governmental, or social conditions could have a material adverse effect on our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chinese society and the Chinese economy continue to undergo significant change. Changes in the regulatory structure, regulations, and economic policies of the Chinese government could have a material adverse effect on the overall economic growth of China, which could adversely affect our ability to conduct business in China. The Chinese government continues to adjust economic policies to promote economic growth. Some of these measures benefit the overall Chinese economy, but may also have a negative effect on us. For example, our financial condition and results of operations in China may be adversely affected by government control over capital investments or changes in tax regulations. As the Chinese pharmaceutical industry grows and evolves, the Chinese government may also implement measures to change the regulatory structure and structure of foreign investment in this industry. We are unable to predict the frequency and scope of such policy changes and structural changes, any of which could materially and adversely affect FibroGen Beijing&#8217;s development and commercialization timelines, liquidity, access to capital, and its ability to conduct business in China. Any failure on our part to comply with changing government regulations and policies could result in the loss of our ability to develop and commercialize our product candidates in China. In addition, the changing government regulations and policies could result in delays and cost increases to our development, manufacturing, approval, and commercialization timelines in China.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our operations in China subject us to various Chinese labor and social insurance laws, and our failure to comply with such laws may materially and adversely affect our business, financial condition and results of operations.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to China Labor Contract Law, which provides strong protections for employees and imposes many obligations on employers. The Labor Contract Law places certain restrictions on the circumstances under which employers may terminate labor contracts and require economic compensation to employees upon termination of employment, among other things. In addition, companies operating in China are generally required to contribute to labor union funds and the mandatory social insurance and housing funds. Any failure by us to comply with Chinese labor and social insurance laws may subject us to late fees, fines and penalties, or cause the suspension or termination of our ability to conduct business in China, any of which could have a material and adverse effect on business, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Operation of Our Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future and may never achieve or sustain profitability. We may require additional financings in order to fund our operations. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a biopharmaceutical company with two lead product candidates in clinical development, roxadustat for anemia in CKD, myelodysplastic syndromes, and chemotherapy-induced anemia, and pamrevlumab for IPF, pancreatic cancer, and DMD. Most of our revenue generated to date has been based on our collaboration agreements and we have limited commercial drug product sales to date. We continue to incur significant research and development and other expenses related to our ongoing operations. Our net loss for the year ended December&#160;31, 2020, 2019 and 2018 were $189.3 million, $77.0 million and $86.4 million, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $974.0 million. As of December&#160;31, 2020, we had capital resources consisting of cash, cash equivalents and short-term investments of $686.5 million plus $0.2 million of long-term investments classified as available for sale securities. Despite contractual development and cost coverage commitments from our collaboration partners, AstraZeneca and Astellas, and the potential to receive milestone and other payments from these partners, and despite commercialization efforts in the China and Japan for roxadustat for the treatment of anemia caused by CKD, we anticipate we will continue to incur losses on an annual basis for the foreseeable future. If we do not successfully develop and continue to obtain regulatory approval for our existing or any future product candidates and effectively manufacture, market and sell the product candidates that are approved, we may never achieve or sustain profitability on a quarterly or annual basis. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. Our failure to become and remain profitable would depress the market price of our common stock and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that we will continue to expend substantial resources for the foreseeable future as we continue late-stage clinical development of roxadustat, grow our operations in China, expand our clinical development efforts on pamrevlumab, continue to seek regulatory approval, establish commercialization capabilities of our product candidates, and pursue additional indications. These expenditures will include costs associated with research and development, conducting preclinical trials and clinical trials, obtaining regulatory approvals in various jurisdictions, and manufacturing and supplying products and product candidates for ourselves and our partners. The outcome of any clinical trial and/or regulatory approval process is highly uncertain and we are unable to fully estimate the actual costs necessary to successfully complete the development and regulatory approval process for our compounds in development and any future product candidates. We believe that the net proceeds from our 2017 public offerings, our existing cash and cash equivalents, short-term and long-term investments and accounts receivable, and expected third-party collaboration revenues will allow us to fund our operating plans through at least the next 12 months. Our operating plans or third-party collaborations may change as a result of many factors, including the success of our development and commercialization efforts, operations costs (including manufacturing and regulatory), competition, and other factors that may not currently be known to us, and we therefore may need to seek additional funds sooner than planned, through offerings of public or private securities, debt financings or other sources, such as royalty monetization or other structured financings. Such financings may result in dilution to stockholders, imposition of debt covenants and repayment obligations, or other restrictions that may adversely affect our business. We may also seek additional capital due to favorable market conditions or strategic considerations even if we currently believe that we have sufficient funds for our current or future operating plans.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional funds may not be available when we require them, or on terms that are acceptable to us. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate our research and development efforts or other operations or activities that may be necessary to commercialize our product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Most of our recent revenue has been earned from collaboration partners for our product candidates under development.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If either or both of our Astellas and AstraZeneca collaborations were to be terminated, we could require significant additional capital in order to proceed with development and commercialization of our product candidates, including with respect to our commercialization of roxadustat for the treatment of anemia caused by CKD, or we may require additional partnering in order to help fund such development and commercialization. If adequate funds or partners are not available to us on a timely basis or on favorable terms, we may be required to delay, limit, reduce or terminate our development or commercialization efforts or other operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may encounter difficulties in managing our growth and expanding our operations successfully.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we seek to advance our product candidates through clinical trials and commercialization, we will need to expand our development, regulatory, manufacturing, commercialization and administration capabilities or contract with third parties to provide these capabilities for us. As our operations expand and we continue to undertake the efforts and expense to operate as a public reporting company, we expect that we will need to increase the responsibilities on members of management in order to manage any future growth effectively. Our failure to accomplish any of these steps could prevent us from successfully implementing our strategy and maintaining the confidence of investors in us. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Loss of senior management and key personnel could adversely affect our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on members of our senior management team, including Enrique Conterno, our Chief Executive Officer. The loss of the services of Mr.&#160;Conterno or any of our senior management could significantly impact the development and commercialization of our products and product candidates and our ability to successfully implement our business strategy.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recruiting and retaining qualified commercial, development, scientific, clinical, and manufacturing personnel are and will continue to be critical to our success, particularly as we expand our commercialization operations. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize product candidates. We may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the intense competition among numerous biopharmaceutical companies for similar personnel.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is also significant competition, in particular in the San Francisco Bay Area, for the hiring of experienced and qualified personnel, which increases the importance of retention of our existing personnel. If we are unable to continue to attract and retain personnel with the quality and experience applicable to our product candidates, our ability to pursue our strategy will be limited and our business and operations would be adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may have to limit commercial operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability as a result of the clinical testing, manufacturing and commercialization of our product candidates. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in a product, negligence, strict liability or breach of warranty. Claims could also be asserted under state consumer protection acts. If we are unable to obtain insurance coverage at levels that are appropriate to maintain our business and operations, or if we are unable to successfully defend ourselves against product liability claims, we may incur substantial liabilities or otherwise cease operations. Product liability claims may result in:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">termination of further development of unapproved product candidates or significantly reduced demand for any approved products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">material costs and expenses to defend the related litigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a diversion of time and resources across the entire organization, including our executive management&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product recalls, withdrawals or labeling restrictions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">termination of our collaboration relationships or disputes with our collaboration partners&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reputational damage negatively impacting our other product candidates in development.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims, we may not be able to continue to develop our product candidates. We maintain product liability insurance in a customary amount for the stage of development of our product candidates. Although we believe that we have sufficient coverage based on the advice of our third-party advisors, there can be no assurance that such levels will be sufficient for our needs. Moreover, our insurance policies have various exclusions, and we may be in a dispute with our carrier as to the extent and nature of our coverage, including whether we are covered under the applicable product liability policy. If we are not able to ensure coverage or are required to pay substantial amounts to settle or otherwise contest the claims for product liability, our business and operations would be negatively affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business and operations would suffer in the event of computer system failures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the implementation of security measures, our internal computer systems, and those of our CROs, collaboration partners, and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, fire, terrorism, war and telecommunication and electrical failures. We upgraded our disaster and data recovery capabilities in 2019, and have continued to upgrade these capabilities. However, to the extent that any disruption or security breach, in particular with our partners&#8217; operations, results in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and it could result in a material disruption and delay of our drug development programs. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We depend on sophisticated information technology systems and could face a cyber-attack or other breach of these systems. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on information technology systems to process, transmit and store electronic information in our day-to-day operations. The size and complexity of our information technology systems makes them vulnerable to a cyber-attack, malicious intrusion, breakdown, destruction, loss of data privacy or other significant disruption. While we upgraded our disaster data recovery program in March 2019, a successful attack could result in the theft or destruction of intellectual property, data, or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyber-attacks are becoming more sophisticated and frequent. We have invested in our systems and the protection and recoverability of our data to reduce the risk of an intrusion or interruption, and we monitor and test our systems on an ongoing basis for any current or potential threats. There can be no assurance that these measures and efforts will prevent future interruptions or breakdowns. If we fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to these systems, we could have difficulty preventing, detecting and controlling such cyber-attacks and any such attacks could result in losses described above as well as disputes with physicians, patients and our partners, regulatory sanctions or penalties, increases in operating costs and expenses, expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our headquarters are located near known earthquake fault zones.&#160;&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and some of the third-party service providers on which we depend for various support functions are vulnerable to damage from catastrophic events, such as power loss, natural disasters, terrorism and similar unforeseen events beyond our control. Our corporate headquarters and other facilities are located in the San Francisco Bay Area, which in the past has experienced severe earthquakes and fires, and has been affected by the COVID-19 pandemic, including economic disruption resulting from the related shelter-in-place and stay-at-home governmental orders.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After a comprehensive earthquake risk analysis conducted by Marsh Risk, we decided not to purchase earthquake or flood insurance. Based upon (among other factors) the Marsh Risk analysis, the design and construction of our building, the expected potential loss, and the costs and deductible associated with earthquake and flood insurance, we chose to self-insure. However, earthquakes or other natural disasters could severely disrupt our operations, or have a larger cost than expected, and have a material adverse effect on our business, results of operations, financial condition and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, damaged critical infrastructure, or otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place are unlikely to provide adequate protection in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events, such as the COVID-19 pandemic. If such an event were to affect our supply chain, it could have a material adverse effect on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market price of our common stock may be highly volatile, and you may not be able to resell your shares at or above your purchase price.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, pharmaceutical, biotechnology and other life sciences company stocks have been highly volatile in the current market. The volatility of pharmaceutical, biotechnology and other life sciences company stocks is sometimes unrelated to the operating performance of particular companies and biotechnology and life science companies stocks often respond to trends and perceptions rather than financial performance. In particular, the market price of shares of our common stock could be subject to wide fluctuations in response to the following factors:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">results of clinical trials of our product candidates, including roxadustat and pamrevlumab&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing of the release of results of and regulatory updates regarding our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the level of expenses related to any of our product candidates or clinical development programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">results of clinical trials of our competitors&#8217; products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">safety issues with respect to our product candidates or our competitors&#8217; products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory actions with respect to our product candidates and any approved products or our competitors&#8217; products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fluctuations in our financial condition and operating results, which will be significantly affected by the manner in which we recognize revenue from the achievement of milestones under our collaboration agreements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adverse developments concerning our collaborations and our manufacturers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the termination of a collaboration or the inability to establish additional collaborations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the inability to obtain adequate product supply for any approved drug product or inability to do so at acceptable prices&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in legislation or other regulatory developments affecting our product candidates or our industry&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fluctuations in the valuation of the biotechnology industry and particular companies perceived by investors to be comparable to us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">speculation in the press or investment community&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">activities of the government of China, including those related to the pharmaceutical industry as well as industrial policy generally&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">performance of other U.S. publicly traded companies with significant operations in China&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in market conditions for biopharmaceutical stocks&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the other factors described in this &#8220;</span><span style="font-style:italic;color:#000000;">Risk Factors</span><span style="color:#000000;">&#8221; section.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of fluctuations caused by these and other factors, comparisons of our operating results across different periods may not be accurate indicators of our future performance. Any fluctuations that we report in the future may differ from the expectations of market analysts and investors, which could cause the price of our common stock to fluctuate significantly. Moreover, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management&#8217;s attention and resources and could also require us to make substantial payments to satisfy judgments or to settle litigation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our principal stockholders own a significant percentage of our stock and will be able to exercise influence over stockholder approvals. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 31, 2021, our executive officers, directors and principal stockholders, together with their respective affiliates, owned approximately 41.43% of our common stock, including shares subject to outstanding options that are exercisable within 60&#160;days after such date and shares issuable upon settlement of restricted stock units that will vest within 60 days after such date. This percentage is based upon information supplied by officers, directors and principal stockholders and Schedules 13D and 13G, if any, filed with the SEC, which information may not be accurate as of January 31, 2020. Accordingly, these stockholders will be able to exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of our board of directors and approval of significant corporate transactions. The interests of this group may differ from those of other stockholders and they may vote their shares in a way that is contrary to the way other stockholders vote their shares. This concentration of ownership could have the effect of entrenching our management and/or the board of directors, delaying or preventing a change in our control or otherwise discouraging a potential acquirer from attempting to obtain control of us, which in turn could have a material and adverse effect on the fair market value of our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may engage in acquisitions that could dilute stockholders and harm our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may, in the future, make acquisitions of or investments in companies that we believe have products or capabilities that are a strategic or commercial fit with our present or future product candidates and business or otherwise offer opportunities for us. In connection with these acquisitions or investments, we may:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">issue stock that would dilute our existing stockholders&#8217; percentage of ownership&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">incur debt and assume liabilities&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">incur amortization expenses related to intangible assets or incur large and immediate write-offs.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to complete acquisitions on favorable terms, if at all. If we do complete an acquisition, we cannot assure you that it will ultimately strengthen our competitive position or that it will be viewed positively by customers, financial markets or investors. Furthermore, future acquisitions could pose numerous additional risks to our operations, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">problems integrating the purchased business, products or technologies, or employees or other assets of the acquisition target&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">increases to our expenses&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disclosed or undisclosed liabilities of the acquired asset or company&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">diversion of management&#8217;s attention from their day-to-day responsibilities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reprioritization of our development programs and even cessation of development and commercialization of our current product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">harm to our operating results or financial condition&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">entrance into markets in which we have limited or no prior experience&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential loss of key employees, particularly those of the acquired entity.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to complete any acquisitions or effectively integrate the operations, products or personnel gained through any such acquisition.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Provisions in our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, and may prevent attempts by our stockholders to replace or remove our current directors or management.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">create a classified board of directors whose members serve staggered three-year terms&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">specify that special meetings of our stockholders can be called only by our board of directors pursuant to a resolution adopted by a majority of the total number of directors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">prohibit stockholder action by written consent&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">provide that our directors may be removed prior to the end of their term only for cause&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">require a supermajority vote of the holders of our common stock or the majority vote of our board of directors to amend our bylaws&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">require a supermajority vote of the holders of our common stock to amend the classification of our board of directors into three classes and to amend certain other provisions of our certificate of incorporation.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, because we are incorporated in Delaware, we are governed by certain anti-takeover provisions under Delaware law which may discourage, delay or prevent someone from acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders. We are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any provision of our amended and restated certificate of incorporation, our amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in our tax provision or exposure to additional tax liabilities could adversely affect our earnings and financial condition. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a multinational corporation, we are subject to income taxes in the U.S. and various foreign jurisdictions. Significant judgment is required in determining our global provision for income taxes and other tax liabilities. In the ordinary course of a global business, there are intercompany transactions and calculations where the ultimate tax determination is uncertain. Our income tax returns are&#160;subject to audits by tax authorities. Although we regularly assess the likelihood of adverse outcomes resulting from these examinations to determine our tax estimates, a final determination of tax audits or tax disputes could have an adverse effect on our results of operations and financial condition.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to non-income taxes, such as payroll, excise, customs and duties, sales, use, value-added, net worth, property, gross receipts, and goods and services taxes in the U.S., state and local, and various foreign jurisdictions. We are subject to audit and assessments&#160;by tax authorities with respect to these non-income taxes and may have exposure to additional non-income tax liabilities, which could have an adverse effect on our results of operations and financial condition</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#8203;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and state tax laws impose substantial restrictions on the utilization of net operating loss and credit carryforwards in the event of an &#8220;ownership change&#8221; for tax purposes, as defined in IRC Section&#160;382. If additional ownership change occurs, the utilization of net operating loss and credit carryforwards could be significantly reduced.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our judgment in providing for the possible impact of the Tax Act remains subject to developing interpretations of the provisions of the Tax Act. As regulations and guidance evolve with respect to the Tax Act, we continue to examine the impact to our tax provision or exposure to additional tax liabilities, which could have a material adverse effect on our business, results of operations or financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Tariffs imposed by the U.S. and those imposed in response by other countries could have a material adverse effect on our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in U.S. and foreign governments&#8217; trade policies have resulted in, and may continue to result in, tariffs on imports into and exports from the U.S. Throughout 2018 and 2019, the U.S. imposed tariffs on imports from several countries, including China. In response, China has proposed and implemented their own tariffs on certain products, which may impact our supply chain and our costs of doing business. If we are impacted by the changing trade relations between the U.S. and China, our business and results of operations may be negatively impacted. Continued diminished trade relations between the U.S. and other countries, including potential reductions in trade with China and others, as well as the continued escalation of tariffs, could have a material adverse effect on our financial performance and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our certificate of incorporation designates courts located in Delaware as the sole forum for certain proceedings, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that, subject to limited exceptions, the state and federal courts located in the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (1)&#160;any derivative action or proceeding brought on our behalf, (2)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3)&#160;any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated by-laws, or (4)&#160;any other action asserting a claim against us that is governed by the internal affairs doctrine. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the U.S. federal district courts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. If a court were to find these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not plan to pay dividends. Capital appreciation will be your sole possible source of gain, which may never occur.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should not rely on an investment in our common stock to provide dividend income. We do not anticipate that we will pay any cash dividends to holders of our common stock in the foreseeable future and investors seeking cash dividends should not purchase our common stock. We plan to retain any earnings to invest in our product candidates and maintain and expand our operations. Therefore, capital appreciation, or an increase in your stock price, which may never occur, may be the only way to realize any return on your investment.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS">ITEM&#160;1B. UNRESOLVED STAFF COMMENTS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_PROPERTIES">ITEM&#160;2. PROPERTIES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate and research and development operations are located in San Francisco, California, where we lease approximately 234,000 square feet of office and laboratory space with approximately 35,000 square feet subleased. The lease for our San Francisco headquarters expires in 2023. We also lease approximately 67,000 square feet of office and manufacturing space in Beijing, China, and multiple office spaces in Beijing and Shanghai, China. Our leases in China expire in 2023. We have constructed a commercial manufacturing facility of approximately 5,500 square meters in Cangzhou, China, on approximately 33,000 square meters of land. Our right to use such land expires in 2068. We believe our facilities are adequate for our current needs and that suitable additional or substitute space would be available if needed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_LEGAL_PROCEEEDINGS">ITEM&#160;3. LEGAL PROCEEEDINGS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to various legal actions that arose in the ordinary course of our business. We recognize accruals for any legal action when we conclude that a loss is probable and reasonably estimable. We did not have any material accruals for any currently active legal action in our consolidated balance sheets as of December 31, 2020, as we could not predict the ultimate outcome of these matters, or reasonably estimate the potential exposure.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 20, 2020, in response to an invalidation action brought against certain FibroGen United Kingdom patents by Akebia, the United Kingdom court handed down a decision invalidating United Kingdom designations of European Patent Nos. 1463823, 1633333, 2298301, 2322153, and 2322155. The United Kingdom designation to European Patent No. 2289531 was held to be valid in amended form, but not infringed by Akebia. We and our partner Astellas have filed an appeal of the decision in the United Kingdom Court of Appeal. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">ITEM&#160;4. MINE SAFETY DISCLOSURES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II">PART II</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU">ITEM&#160;5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Information for Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock has been listed on the NASDAQ Global Select Market (&#8220;NASDAQ&#8221;) since November&#160;14, 2014, under the symbol &#8220;FGEN.&#8221; Prior to our initial public offering, there was no public market for our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock Price Performance Graph</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following graph illustrates a comparison of the total cumulative stockholder return for our common stock since December&#160;31, 2015 to two indices: the NASDAQ Composite Index and the NASDAQ Biotechnology Index. The graph assumes an initial investment of $100 on December 31, 2015, in our common stock, the stocks comprising the NASDAQ Composite Index, and the stocks comprising the NASDAQ Biotechnology Index. The stockholder return shown in the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gapk0ju0ozex000012.jpg" title="" alt="" style="width:596px;height:362px;" /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above Stock Price Performance Graph and related information shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the Securities and Exchange Commission, nor shall such information be incorporated by reference into any future filing under the Securities Act or Exchange Act, except to the extent that we specifically incorporate it by reference into such filing.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stockholders</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 31, 2021, there were 129 registered stockholders of record for our common stock. This number of registered stockholders does not include stockholders whose shares are held in street name by brokers and other nominees, or may be held in trust by other entities. Therefore, the actual number of stockholders is greater than this number of registered stockholders of record. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Proceeds from Initial Public Offering of Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November&#160;13, 2014, our Registration Statement on Form&#160;S-1, as amended (Reg. Nos.&#160;333-199069 and 333-200189) was declared effective in connection with the initial public offering of our common stock. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC pursuant to Rule&#160;424(b) under the Securities Act on November&#160;14, 2014.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_SELECTED_FINANCIAL_DATA">ITEM&#160;6. SELECTED FINANCIAL DATA</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted the amendment to eliminate Item 301 of Regulation S-K, and we are omitting this disclosure in reliance thereon. <span style="color:#000000;">&#160;</span></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes and other financial information included in Item&#160;8 of this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business, international operations and product candidates, includes forward-looking statements that involve risks and uncertainties. You should review the &#8220;Risk Factors&#8221; section of this Annual Report for a discussion of important factors that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BUSINESS OVERVIEW</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#8217;s Republic of China (&#8220;China&#8221;). We are a leading biopharmaceutical company developing and commercializing a pipeline of first-in-class therapeutics. We apply our pioneering expertise in hypoxia-inducible factor (&#8220;HIF&#8221;) biology, 2-oxoglutarate enzymology, connective tissue growth factor (&#8220;CTGF&#8221;) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat, our most advanced product, is an oral small molecule inhibitor of HIF prolyl hydroxylase (together with HIF, &#8220;HIF-PH&#8221;) activity that has received marketing authorization in China (tradename: &#29233;&#29790;&#21331;<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>) for the treatment of anemia caused by chronic kidney disease (&#8220;CKD&#8221;) in dialysis and non-dialysis patients. EVRENZO&#174; (roxadustat) is also approved in Japan and Chile for the treatment of anemia associated with CKD in dialysis and non-dialysis patients. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our New Drug Application (&#8220;NDA&#8221;) filing in the United States (&#8220;U.S.&#8221;) for roxadustat for the treatment of anemia in dialysis and non-dialysis CKD patients was submitted for review in December 2019 to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and in December 2020, the FDA extended the review period of the NDA by three months for FibroGen to submit additional analyses of existing roxadustat clinical data, and set a new Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) goal date of March 20, 2021. On March 1, 2021, the FDA informed us that the Cardiovascular and Renal Drugs Advisory Committee will hold an advisory committee meeting to review the NDA for roxadustat. The date of the advisory committee meeting has not been set. As a result of this communication, we will not receive an approval decision by the PDUFA goal date. In Europe, the Marketing Authorization Application (&#8220;MAA&#8221;) filing for roxadustat for the treatment of anemia in dialysis and non-dialysis CKD patients was accepted for regulatory review by the European Medicines Agency (&#8220;EMA&#8221;) in May 2020 and Astellas Pharma Inc. (&#8220;Astellas&#8221;) expects an approval decision mid-2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes. Roxadustat is in Phase 2 clinical development for chemotherapy-induced anemia. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab, an anti-CTGF human monoclonal antibody, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (&#8220;IPF&#8221;), pancreatic cancer and Duchenne muscular dystrophy. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Impact of COVID-19</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 11, 2020, COVID-19, a disease caused by a novel strain of the coronavirus, was characterized as a pandemic by the World Health Organization. The rapid spread has resulted in authorities implementing numerous measures to contain the virus, such as travel restrictions, social distancing requirements, quarantines, shelter-in-place orders or voluntarily adopted practices, and business shutdowns.&#160;&#160; </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have taken measures to minimize the health risks of COVID-19 to our staff, patients, healthcare providers and their communities, as their safety and well-being are our top priority. In the U.S., our employees are working remotely when possible, while in China they have returned to work in our offices, manufacturing plants, and are performing medical affairs out in the field. While we have seen some impacts from COVID-19, such as slower enrollment in our clinical trials, particularly our Phase 3 IPF program, we do not know if, or to what extent, these effects will continue in the future, as the impact of the COVID-19 pandemic continues to unfold. The effect on our operational and financial performance beyond those effects described above, including any impact on sales of roxadustat, will depend in large part on future developments with the pandemic, which cannot be predicted with confidence at this time. Future developments include the duration, scope, and severity of the COVID-19 pandemic, the actions taken to contain or mitigate its impact, the impact on governmental programs and budgets, the impact on healthcare systems and operating procedures, the development of treatments or vaccines, and the resumption of widespread economic activity. Due to the inherent uncertainty of the largely unprecedented and rapidly evolving situation, we are unable to predict with any confidence the likely impact of the COVID-19 pandemic on our future operations.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial results for the year ended December 31, 2020 were not significantly impacted by COVID-19 relative to prior years. However, we will continue to monitor, and to the extent possible, mitigate the impact of the COVID-19 pandemic on our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Highlights</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except for per share data)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Result of Operations</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,319</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256,577</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,958</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating costs and expenses</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">368,199</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345,891</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299,651</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(189,291</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76,970</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(86,420</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.11</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.89</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.03</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">678,393</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,266</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term and long-term investments</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,388</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">468,609</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,883</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,455</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenue for the year ended December&#160;31, 2020 included the revenues recognized related to the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$15.0 million regulatory milestone associated with the NDA approval in Japan&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$80.6 million development revenue recognized under collaboration agreements with our partners Astellas and AstraZeneca AB (&#8220;AstraZeneca&#8221;)&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$72.5 million of net product revenue from roxadustat commercial sales in China&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$8.9 million of drug product revenue related to roxadustat bulk drug or active pharmaceutical ingredient (&#8220;API&#8221;) deliveries to AstraZeneca and Astellas.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As comparison, our revenue for the year ended December 31, 2019 included the revenues recognized related to the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$130.0 million total of two regulatory milestones associated with the planned MAA submission to the EMA under the collaboration agreement with Astellas for roxadustat as a treatment for dialysis and non-dialysis CKD patients&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$50.0 million regulatory milestone associated with the NDA submission to the FDA under the collaboration agreement with AstraZeneca for roxadustat as a treatment for dialysis and non-dialysis CKD patients&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$22.0 million total of three regulatory milestones associated with roxadustat being included on the updated National Reimbursement Drug List (&#8220;NRDL&#8221;) released by China&#8217;s National Healthcare Security Administration (&#8220;NHSA&#8221;)&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$12.5 million regulatory milestone associated with the NDA approval in Japan&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">$36.3 million reduction in drug product revenue of a change in estimated variable consideration related to the API product revenue that was recognized in 2018, which reflected the total difference between estimated and actual listed price and yield from the manufacture of bulk product tablets. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating costs and expenses increased for the year ended </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> compared to the prior year primarily due to the following:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Higher clinical trial expenses associated with post-approval safety studies in China, and commencement of Phase 3 trials for pamrevlumab&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Higher drug development expenses associated with drug substance manufacturing activities related to pamrevlumab, partially offset by lower activities related to roxadustat and capitalization of inventory manufacturing costs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Higher employee-related expenses primarily resulting from higher average compensation level and headcount&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Higher stock-based compensation expense, primarily due to the cumulative impact of stock option grant activities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Higher legal expenses primarily associated with patent-related activities in the United Kingdom&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Lower sales and marketing expenses due to a reversal in co-promotion expenses with AstraZeneca as a result of the China Amendment between FibroGen China and AstraZeneca&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Lower outside services due to lower consulting expenses and scientific contract work related to roxadustat Phase 3 and submission activities.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development expenses were $252.9 million, $209.3 million and $235.8 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Since inception and through December&#160;31, 2020, we have incurred a total of approximately $2.2&#160;billion in research and development expenses, a majority of which relates to the development of roxadustat, pamrevlumab and other HIF-PH inhibitors. We expect to continue to incur significant expenses and operating losses over at least the next several years and we expect our research and development expenses to increase in the future as we advance our product candidates through clinical trials and expand our product candidate portfolio. In addition, we expect to incur significant expenses relating to seeking regulatory approval for our product candidates and commercializing those products in various markets, including China. We consider the active management and development of our clinical pipeline to be particularly crucial to our long-term success. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time consuming. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The actual probability of success for each of our product candidates and clinical programs, and our ability to generate product revenue and become profitable, depends upon a variety of factors, including the quality of the product candidate, clinical results, investment in the program, competition, manufacturing capability, commercial viability, and our and our partners&#8217; ability to successfully execute our development and commercialization plans. For a description of the numerous risks and uncertainties associated with product development, refer to &#8220;<span style="font-style:italic;">Risk Factors</span>.&#8221;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, we had a net loss of $189.3 million, or net loss per basic and diluted share of $2.11, as compared to a net loss of $77.0 million, or net loss per basic and diluted share of $0.89 for the prior year, primarily due to a decrease in revenue and an increase in operating expenses.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, investments and accounts receivable totaled $728.7 million at December&#160;31, 2020, an increase of $105.4&#160;million from December&#160;31, 2019, primarily due to cash provided by operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Collaboration Partnerships for Roxadustat </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and future research, development, manufacturing and commercialization efforts with respect to roxadustat and our other product candidates currently in development depend on funds from our collaboration agreements with Astellas and AstraZeneca as described below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Astellas</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2005, we entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (&#8220;Japan Agreement&#8221;). In April 2006, we entered into the Europe Agreement with Astellas for roxadustat for the treatment of anemia in Europe, the Commonwealth of Independent States, the Middle East, and South Africa. Under these agreements, we provide Astellas the right to develop and commercialize roxadustat for anemia indications in these territories.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We share responsibility with Astellas for clinical development activities required for the U.S. and the Europe regulatory approval of roxadustat, and share equally those development costs under the agreed development plan for such activities. Astellas will be responsible for clinical development activities and all associated costs required for regulatory approval in all other countries in the Astellas territories. Astellas will own and have responsibility for regulatory filings in its territories. We are responsible, either directly or through our contract manufacturers, for the manufacture and supply of all quantities of roxadustat to be used in development and commercialization under the agreements. Astellas is responsible for roxadustat commercialization activities in the Astellas territories.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Astellas agreements will continue in effect until terminated. Either party may terminate the agreements for certain material breaches by the other party. In addition, Astellas will have the right to terminate the agreements for certain specified technical product failures, upon generic sales reaching a particular threshold, upon certain regulatory actions, or upon our entering into a settlement admitting the invalidity or unenforceability of our licensed patents. Astellas may also terminate the agreements for convenience upon advance written notice to us. In the event of any termination of the agreements, Astellas will transfer and assign to us the regulatory filings for roxadustat and will assign or license to us the relevant trademarks used with the products in the Astellas territories. Under certain terminations, Astellas is also obligated to pay us a termination fee.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consideration under these agreements includes a total of $360.1 million in upfront and non-contingent payments, and milestone payments totaling $557.5 million, of which $542.5 million are development and regulatory milestones and $15.0 million are commercial-based milestones. Total consideration, excluding development cost reimbursement and product sales-related payments, could reach $917.6 million. The aggregate amount of such consideration received through December&#160;31, 2020 totals $645.1 million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, under these agreements, Astellas pays 100% of the commercialization costs in their territories. In Europe, Astellas will pay us a tiered transfer price for our manufacture and supply of roxadustat based on net sales of roxadustat in the low 20% range. In Japan, Astellas pays us a transfer price in the low 20% range of the list price published by the Japanese Ministry of Health, Labour and Welfare, adjusted for certain elements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fourth quarter of 2020, the Japanese Ministry of Health, Labour and Welfare approved EVRENZO&#174; (roxadustat) for the treatment of anemia of CKD in adult patients not on dialysis. Accordingly, the consideration of $15.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the Japan Agreement in the fourth quarter of 2020, substantially all of which was recognized as revenue during the year ended December 31, 2020 from performance obligations satisfied or partially satisfied.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, the Japanese Ministry of Health, Labour and Welfare approved roxadustat for the treatment of anemia associated with dialysis CKD patients. Accordingly, the consideration of $12.5 million associated with this milestone was included in the transaction price and allocated to performance obligations under the Japan Agreement in the third quarter of 2019. This milestone payment was received in October 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2019, we received positive topline results from analyses of pooled major adverse cardiovascular event (&#8220;MACE&#8221;) and MACE+ data from its Phase 3 trials evaluating roxadustat as a treatment for dialysis and non-dialysis CKD patients, enabling Astellas to prepare for an MAA submission to the EMA in the second quarter of 2020, following our NDA submission to the FDA in 2019 and acceptance for review in February 2020. These milestones became probable of being achieved in the second quarter of 2019, and substantially all of the total consideration of $130.0 million associated with these milestones was included in the transaction price and allocated to performance obligations under the Europe Agreement in the second quarter of 2019, of which $128.8 million was recognized as revenue during 2019, and $0.8 million was recognized as revenue during 2020, from performance obligations satisfied or partially satisfied. According to the Europe Agreement, these milestone payments were billed to Astellas upon the submission of an MAA in the second quarter of 2020 and the total $130.0 million was received during the same quarter. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, FibroGen and Astellas entered into an amendment to the Japan Agreement that will allow Astellas to manufacture roxadustat drug product for commercialization in Japan (the &#8220;Japan Amendment&#8221;). Under this amendment, FibroGen would continue to manufacture and supply roxadustat API to Astellas. The commercial terms of the Japan Agreement relating to the transfer price for roxadustat for commercial use remain substantially the same, reflecting an adjustment for the manufacture of drug product by Astellas rather than FibroGen. We fulfilled delivery of a total of $64.8 million API under this amendment in 2018. In 2019, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">change in estimated variable consideration </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resulted in a $36.3 million reduction to revenue</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> associated with these API shipments</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, at the time the listed price for roxadustat was issued by the Japanese Ministry of Health, Labour and Welfare, which reflected the total difference between estimated and actual listed price and yield from the manufacture of bulk product tablets.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In addition, in 2020, we recorded another $4.0 million reduction to revenue associated with these API shipments, related to a change in estimated variable consideration, based on the API held by Astellas at March 31, 2020 adjusted to reflect the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> updated listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and possible future changes to the listed price, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adjusted for the timing of and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk product tablets, and estimated yield from the manufacture of bulk product tablets, among others.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2020, we fulfilled delivery obligations under the term of the Japan Amendment, and recognized related drug product revenue of $8.2 million in the same period. The amount represents variable consideration and was estimated based on the quantity of product shipped, actual listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and possible future changes to the listed price, adjusted for the timing of and estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk product tablets, and estimated yield from the manufacture of bulk product tablets, among others.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fourth quarter of 2020, we shipped bulk drug product from process validation supplies for commercial sales under the term of the Europe Agreement. We constrained the estimated variable consideration due to a high degree of uncertainty associated to the final consideration because of an extended length of time over which the considerations may be adjusted. As a result, we constrained the consideration from this shipment, and recorded $1.4 million as current deferred revenue and $4.6 million as long-term deferred revenue as of December 31, 2020. The deferred revenue will be recognized over the duration of the contract and when uncertainty is resolved. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the fourth quarter of 2018, we were engaged in the final stages of review with our partners over the proposed development of roxadustat for the treatment of chemotherapy-induced anemia. AstraZeneca and Astellas approved the program in December 2018 and January 2019, respectively. Costs associated with the development of this indication are shared 50-50 between our two partners. For revenue recognition purposes, we concluded that this new indication represents a modification to the Europe agreements and will be accounted for separately, meaning the development costs associated with the new indications are distinct from the original development costs. The development service period for roxadustat for the treatment of CIA under the Europe Agreement is estimated to continue through the end of 2023&#160;to allow for development of this indication.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as of December&#160;31, 2020, Astellas had separate investments of $80.5 million in the equity of FibroGen, Inc.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">AstraZeneca</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, we entered into the U.S./RoW Agreement a collaboration agreement with AstraZeneca for roxadustat for the treatment of anemia in the U.S. and all territories not previously licensed to Astellas, except China. In July 2013, through our China subsidiary and related affiliates, we entered into the China Agreement a collaboration agreement with AstraZeneca for roxadustat for the treatment of anemia in China. Under these agreements, we provide AstraZeneca the right to develop and commercialize roxadustat for anemia in these territories. We share responsibility with AstraZeneca for clinical development activities required for U.S. regulatory approval of roxadustat, and FibroGen will transfer the U.S. NDA to AstraZeneca upon approval. AstraZeneca will hold the equivalent regulatory filings in the other licensed countries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2015, we reached the $116.5 million cap on our initial funding obligations (during which time we shared 50% of the joint initial development costs), therefore all development and commercialization costs for roxadustat for the treatment of anemia in CKD in the U.S., Europe, Japan and all other markets outside of China have been paid by Astellas and AstraZeneca since reaching the cap. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In China, FibroGen (China) Medical Technology Development Co., Ltd. (&#8220;FibroGen Beijing&#8221;) will conduct the development work for CKD anemia, will hold all of the regulatory licenses issued by China regulatory authorities, and will be primarily responsible for regulatory, clinical and manufacturing. China development costs are shared 50/50. AstraZeneca is also responsible for 100% of development expenses in all other licensed territories outside of China. Outside of China, we are responsible, through our contract manufacturers, for the manufacture and supply of all quantities of roxadustat to be used in development and commercialization under the AstraZeneca agreements.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the AstraZeneca agreements, we will receive upfront and subsequent non-contingent payments totaling $402.2&#160;million. Potential milestone payments under the agreements total $1.2&#160;billion, of which $571.0&#160;million are development and regulatory milestones and $652.5&#160;million are commercial-based milestones. Total consideration under the agreements, excluding development cost reimbursement, transfer price payments, royalties and profit share, could reach $1.6&#160;billion. The aggregate amount of such consideration received through December&#160;31, 2020 totals $516.2 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the U.S./RoW Agreement, AstraZeneca will pay for all commercialization costs in the U.S. and RoW and AstraZeneca will be responsible for the U.S. commercialization of roxadustat, with FibroGen undertaking specified commercial activities in the U.S. In addition, we will receive a transfer price for delivery of commercial product based on a percentage of net sales in the low- to mid-single digit range and AstraZeneca will pay us a tiered royalty on net sales of roxadustat in the low 20% range.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the China Agreement, which is conducted through FibroGen China Anemia Holdings, Ltd. (&#8220;FibroGen Cayman&#8221;), FibroGen Beijing, and FibroGen International (Hong Kong) Limited (collectively, (&#8220;FibroGen China, the commercial collaboration was structured as a 50/50 profit share, which was amended by the China Amendment&#160;&#160;in the third quarter of 2020, as discussed and defined below in <span style="font-style:italic;">China Amendment</span>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca may terminate the U.S./RoW Agreement upon specified events, including our bankruptcy or insolvency, our uncured material breach, technical product failure, or upon 180 days prior written notice at will. If AstraZeneca terminates the U.S./RoW Agreement at will, in addition to any unpaid non-contingent payments, it will be responsible for paying for a substantial portion of the post-termination development costs under the agreed development plan until regulatory approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca may terminate the China Agreement upon specified events, including our bankruptcy or insolvency, our uncured material breach, technical product failure, or upon advance prior written notice at will. If AstraZeneca terminates our China Agreement at will, it will be responsible for paying for transition costs as well as make a specified payment to FibroGen.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of any termination of the agreements, but subject to modification upon termination for technical product failure, AstraZeneca will transfer and assign to us any regulatory filings and approvals for roxadustat in the affected territories that they may hold under our agreements, grant us licenses and conduct certain transition activities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As mentioned above, during the second quarter of 2019, we received positive topline results from analyses of pooled MACE and MACE+ data from its Phase 3 trials for roxadustat, enabling our U.S. NDA submission to the FDA. The regulatory milestone payment associated with this NDA submission became probable of being achieved in the second quarter of 2019. Accordingly, the consideration of $50.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the combined arrangement in the second quarter of 2019, of which $42.4 million was recognized as revenue during 2019, and $0.6 million was recognized as revenue during 2020, from performance obligations satisfied or partially satisfied. We submitted such NDA to the FDA in December 2019, which was accepted for review in February 2020. According to the U.S/RoW Agreement, this milestone payment is billable to AstraZeneca when the NDA is accepted by the FDA. Therefore, this $50.0 million milestone was billed during the first quarter of 2020, the payment of which was fully received in April 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, roxadustat has been included on the updated NRDL released by China&#8217;s NHSA for the treatment of anemia in CKD, covering patients who are non-dialysis-dependent as well as those who are dialysis-dependent. Accordingly, the total consideration of $22.0 million associated with these milestones was included in the transaction price and allocated to performance obligations under the combined arrangement in the fourth quarter of 2019. This milestone payment was fully received during the first quarter of 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As mentioned above, in the fourth quarter of 2018, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we were engaged in the final stages of review with our partners over </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the proposed development of roxadustat for the treatment of CIA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. AstraZeneca and Astellas approved the program in December 2018 and January 2019, respectively.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Costs associated with the development of this indication are expected to be shared 50-50 between our two partners. In addition to CIA, in December 2018, anemia of chronic inflammation and multiple myeloma have been approved for development by AstraZeneca and is expected to be fully funded by them. For revenue recognition purposes, we concluded that </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the approval of additional research and development services for these new indications represent modifications to our collaboration agreements in the periods in which approval was received. The research and development services associated with the new indications are distinct from other promises in our collaboration agreements, and will be accounted for separately</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development service period for roxadustat for the treatment of CIA, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">anemia of chronic inflammation</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">multiple myeloma</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> under the AstraZeneca agreements is estimated to continue through the end of 2024, to allow for development of these additional indications</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">China Amendment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 8, 2020, FibroGen China and AstraZeneca (together with FibroGen China, the &#8220;Parties&#8221;) entered into an amendment, effective July 1, 2020, to the China Agreement, relating to the development and commercialization of roxadustat in China (the &#8220;China Amendment&#8221;). While the responsibilities of the Parties under the China Agreement remain largely the same, certain changes were made.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The China Amendment provides for the establishment of a jointly owned entity that will perform roxadustat distribution, as well as conduct sales and marketing through AstraZeneca. To prepare for the establishment of this jointly owned entity, in July 2020, FibroGen Beijing acquired Beijing Kangda Yongfu Pharmaceutical Co., LTD (&#8220;Kangda&#8221;). The purpose of the acquisition was to acquire a distribution license owned by Kangda for commercializing and distributing roxadustat in China. FibroGen Beijing continues to hold all of the regulatory licenses issued by China regulatory authorities and continues to be primarily responsible for regulatory, clinical, manufacturing, medical affairs and pharmacovigilance activities. In September 2020, FibroGen Beijing and AstraZeneca entered into an equity transfer agreement and shareholders agreement related to Kangda. Concurrently with the equity transfer, the two parties renamed Kangda to Beijing Falikang Pharmaceutical Co. Ltd. (&#8220;Falikang&#8221;). See Note 3,<span style="font-style:italic;"> Acquisition and Variable Interest Entity</span>, to the consolidated financial statements for details. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As Falikang is a distribution entity for roxadustat and AstraZeneca is the final decision maker for all the roxadustat commercialization activities, we lack the power criterion while AstraZeneca meets both the power and economic criteria under ASC 810, to direct the activities of Falikang that most significantly impact its performance. Therefore, we are not the primary beneficiary of Falikang. As a result, we accounted for our investment in Falikang under the equity method, and Falikang is not consolidated into our consolidated financial statements. In addition, we recognized our proportionate share of the reported profits or losses of Falikang, as other income (loss) in the consolidated statement of operations, and as an adjustment to its investment in unconsolidated subsidiary in the consolidated balance sheet. Falikang has not incurred material profit or loss to date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the China Amendment, we are currently in the interim period. The interim period is defined as the period from April 1, 2020 to the time when Falikang is fully operational, which commenced in January 2021. During the interim period, FibroGen continues to sell product directly to the distributors, who remain as our customers. The calculation for profit or loss share has changed related to sales of roxadustat in China for the period from April 1, 2020 onwards. With effect from April 1, 2020, the Parties have changed the method under which commercial expenses incurred by AstraZeneca are calculated and billed. AstraZeneca&#8217;s co-promotion expenses for their sales and marketing efforts are now subject to a cap of a percentage of net sales. Once AstraZeneca has been fully reimbursed for their sales and marketing costs under the cap, AstraZeneca will bill the co-promotion expenses based on actual costs on a prospective basis. In addition, the China Amendment has allowed for a higher cost of manufacturing incurred by FibroGen Beijing to be included in the profit or loss share calculation, subject to an annual cap, among other changes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once Falikang is fully operational, AstraZeneca will bill the co-promotion expenses to Falikang, rather than FibroGen Beijing. In addition, FibroGen Beijing will manufacture and supply commercial product to Falikang based on an agreed upon transfer price. Development costs will continue to be shared 50/50 between the Parties. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, the interim period </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">primarily includes the following activities</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Co-promotion expenses: The China Amendment revised the payment arrangements and calculation of the historical unpaid co-promotion expenses to AstraZeneca for its sales and marketing efforts associated with the commercial sales for roxadustat in China since the product launch. Under the previous China Agreement, payment of these historical co-promotion expenses was subject to certain profitability and cash flow thresholds. No amount of the historical co-promotion costs had been paid prior to the China Amendment as these thresholds had not yet been met. Under the China Amendment, a portion of the historical unpaid co-promotion expenses was adjusted to reduce the amount owed by FibroGen Beijing and the current period co-promotion expenses are capped at a percentage of net roxadustat sales in China. As a result, in the third quarter of 2020, we reversed approximately $84.4 million of previously accrued co-promotion expenses payable, which was recorded as a reduction to selling, general and administrative expenses, where these expenses were initially recorded during the periods from the initiation of commercial activities in the first quarter of 2019 to the second quarter of 2020. The co-promotion expenses for the year ended December 31, 2020, capped at a percentage of net roxadustat sales in China, were $27.2 million, included in the selling, general and administrative expenses. After this adjustment, as of December 31, 2020, $16.9 million and $11.5 million of the recalculated accrued co-promotion expenses were recorded in accounts payable and accrued liabilities, respectively, as they were anticipated to be paid within the next 12 months&#59; and $27.4 million of the recalculated accrued co-promotion expenses remained in the long-term liabilities, as it is not anticipated to be paid within the next 12 months.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Profit share: Profit/loss share between FibroGen Beijing and AstraZeneca is based on a calculation of the current period net roxadustat sales in China and deductible expenses pursuant to the China Agreement. Based on the calculation revised under the China Amendment, profit was achieved during the third and fourth quarter of 2020. As a result, we recorded a profit share liability of $7.0 million to AstraZeneca as of December 31, 2020 in the accrued and other current liabilities, which correspondingly reduced the deferred revenue related to the performance obligation in accordance with the China Agreement.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc. and AstraZeneca concurrently amended the U.S./RoW Agreement to reflect minor changes in the governance structure under the China Agreement.<span style="font-weight:bold;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Starting in the first quarter of 2021, our revenue will be made of 1) a transfer price from our sales to Falikang, and 2) sales made directly by FibroGen Beijing to distributors who have not transitioned to Falikang. The transfer price earned is expected to be in the range of 30-45% of Falikang&#8217;s net sales, which reflects the fact that Falikang will pay AstraZeneca the commercialization expenses and AstraZeneca&#8217;s profit share. For revenue recognition purposes, we estimate the total consideration on a per unit basis and recognize as we transfer control of the commercial drug product to Falikang.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Additional Information Related to Collaboration Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the $1.1 billion in development and regulatory milestones payable in the aggregate under our Astellas and AstraZeneca collaboration agreements, $425.0 million is payable upon achievement of milestones relating to the submission and approval of roxadustat in dialysis-dependent CKD and non-dialysis-dependent CKD in the U.S. and Europe.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For more detailed discussions on the accounting for these agreements, refer to Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues,</span> to the consolidated financial statements. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash consideration received through </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and potential cash consideration, other than development cost reimbursement, transfer price payments, royalties and profit share, pursuant to our existing collaboration agreements are as follows:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Received Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Potential</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash&#160;Payments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Potential</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash&#160;Payments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Astellas--related-party:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japan Agreement</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,093</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,500</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,593</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe Agreement</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">745,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Astellas</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">645,093</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">272,500</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917,593</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. / RoW Agreement</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">439,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">810,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,249,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China Agreement</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,200</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299,500</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">376,700</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total AstraZeneca</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">516,200</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,109,500</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,625,700</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,161,293</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,382,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,543,293</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These collaboration agreements also provide for reimbursement of certain fully burdened research and development costs as well as direct out of pocket expenses.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RESULTS OF OPERATIONS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change 2020 vs. 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="20" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(dollars in thousands)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,323</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">177,086</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,269</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(162,763</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development and other revenue</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,592</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,115</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,913</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,523</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue, net</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,498</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,700</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,798</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,165</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,906</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,324</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,776</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,230</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(125</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,319</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256,577</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,958</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(80,258</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenue to date has been generated substantially from our collaboration agreements with Astellas and AstraZeneca. In addition, we started roxadustat commercial sales in China in the third quarter of 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under our revenue recognition policy, license revenue includes amounts from upfront, non-refundable license payments and amounts allocated pursuant to the standalone selling price method from other consideration received during the periods. This revenue is generally recognized as deliverables are met and services are performed. License revenues represented 8%, 69% and 11% of total revenues for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue includes co-development and other development related services. Co-development services are recognized as revenue in the period in which they are billed to our partners, excluding China. For China co-development services, revenue is deferred until we begin to transfer control of the manufactured commercial drug product to AstraZeneca.. Other development related services are recognized as revenue over the non-contingent development period based on a proportional performance method. As of December 31, 2020, the estimated future non-contingent development periods range from 3 to 48 months. Other revenues consist of sales of research and development material and have not been material for any of the periods presented. Development and other revenues represented 46%, 44% and 59% of total revenues for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We started generating net product revenue from commercial sales of roxadustat drug product in China in the third quarter of 2019. Product revenue is recognized when our <span style="Background-color:#FFFFFF;">customer obtains control of promised goods or services in an amount that reflects the consideration we expect to receive in exchange for those goods or services.</span> Product revenue represented 41% and 1% of total revenue for the year ended December 31, 2020 and 2019, respectively.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Drug product revenue includes </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercial-grade API or bulk drug product sales to AstraZeneca and Astellas i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n support of pre-commercial preparation prior to the NDA or MAA approval, and to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas for ongoing commercial </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">launch in Japan. Drug product revenue is recognized when we fulfill the delivery obligations.</span><span style="Background-color:#FFFFFF;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of variable consideration that is included in the transaction price may be constrained, and is included in the drug product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received in the future may differ from our estimates, for which we will adjust these estimates and affect the drug product revenue in the period such variances become known. </span><span style="Background-color:#FFFFFF;">Drug product </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revenues represented 5%, (14)% and 30% of total revenues for the years ended </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020, 2019 and 2018</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, we will continue generating revenue from collaboration agreements in the form of license fees, milestone payments, reimbursements for collaboration services and royalties on product sales, and from product sales. We expect that any revenues we generate will fluctuate from quarter to quarter due to the uncertain timing and amount of such payments and sales.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue decreased $80.3 million, or 31% for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019 for the reasons discussed in the sections below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">License Revenue</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change 2020 vs. 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="20" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(dollars in thousands)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,323</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129,405</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,323</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(115,082</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,681</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,946</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,681</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license revenue</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,323</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">177,086</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,269</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(162,763</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue decreased $162.8 million, or 92% for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue recognized under our collaboration agreements with Astellas decreased $115.1 million, or 89% for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019. License revenue recognized under our collaboration agreements with Astellas for the year ended December 31, 2020 represented the allocated revenue of related to a regulatory milestone of $15.0 million associated with the NDA approval in Japan achieved during the fourth quarter of 2020. License revenue recognized under our collaboration agreements with Astellas for the year ended December 31, 2019 represented the allocated revenue of $117.5 million related to two regulatory milestones totaling $130.0 million associated with the planned MAA submission in Europe that were included in the transaction price during the second quarter of 2019 when these milestones became probable of being achieved&#59; and the allocated revenue of $11.9 million related to a regulatory milestone of $12.5 million associated with the NDA approval in Japan achieved during the third quarter of 2019. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have any license revenue under our collaboration agreements with AstraZeneca for the year ended December 31, 2020.&#160;License revenue recognized under our collaboration agreements with AstraZeneca for the year ended December 31, 2019 represented the revenue allocated to the U.S./RoW license of $33.1 million related to a regulatory milestone of $50.0 million associated with the NDA submission in the U.S. that was included in the transaction price during the second quarter of 2019 when this milestone became probable of being achieved&#59; and the revenue allocated to the U.S./RoW license of $14.6 million related to three regulatory milestones totaling $22.0 million associated with roxadustat being included on the updated NRDL released by China&#8217;s NHSA during the fourth quarter of 2019.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Development and Other Revenue</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change 2020 vs. 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="20" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(dollars in thousands)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,174</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,394</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,903</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,220</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,418</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,719</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,970</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,301</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total development revenue</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,592</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,113</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,873</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,521</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other revenue</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total development and other revenue</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,592</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,115</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,913</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,523</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development and other revenue decreased $33.5 million, or 29% for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue recognized under our collaboration agreements with Astellas decreased $10.2 million, or 35% for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019. Development revenue recognized under our collaboration agreements with Astellas for the year ended December 31, 2020 included the allocated revenue of $0.7 million related to the above-mentioned $15.0 million associated with the NDA approval in Japan achieved during the fourth quarter of 2020. Development revenue recognized under our collaboration agreements with Astellas for the year ended December&#160;31, 2019 included the allocated revenue of $11.4 million related to the above-mentioned $130.0 million associated with the regulatory milestones of the planned MAA submission in Europe, and the allocated revenue of $0.5 million related to the above-mentioned $12.5 million associated with the NDA approval in Japan. The decrease for the year ended December 31, 2020 was partially offset by an increase in co-development billings related to related to higher medical affairs activities under the Europe Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue recognized under our collaboration agreements with AstraZeneca decreased $23.3 million, or 28% for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019, primarily due to a decrease in co-development billings related to the development of roxadustat as a result of the substantial completion of Phase 3 trials for roxadustat. Development revenue recognized under our collaboration agreements with AstraZeneca for the year ended December&#160;31, 2019 also included the allocated revenue of $9.3 million related to the above-mentioned $50.0 million associated with the regulatory milestone of the NDA submission in the U.S., and the allocated revenue of $4.1 million related to the above-mentioned regulatory milestones totaling $22.0 million associated with roxadustat being included on the updated NRDL released by China&#8217;s NHSA.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Product Revenue, Net</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change 2020 vs. 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="16" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(dollars in thousands)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross revenue</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,027</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,803</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,224</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,076</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Price adjustment</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(936</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">936</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-key account hospital listing award</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,325</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,325</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual sales rebate</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,189</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(149</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,040</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,054</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other discounts and rebates</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(923</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(905</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,028</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales return</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.56%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue, net</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,498</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,700</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,798</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.56%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,165</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We started roxadustat commercial sales in China in the third quarter of 2019. Therefore, the year-over-year comparison would not be meaningful, as the prior year was at limited sales volume.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The gross product revenue for the year ended December 31, 2020 was $89.0 million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the second quarter of 2020, we amended the agreement with our pharmaceutical distributors, which triggered accounting modifications particularly related to non-key account hospital listing award. For the year ended December 31, 2020, the non-key account hospital listing award was $9.3 million, which was recorded as a reduction to the revenue and calculated based on eligible non-key account hospital listing to date achieved by each distributor with certain requirements met during the period. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020 and 2019, the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contractual sales rebate was $6.2 million and $0.1 million, respectively, which were </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other rebates and discounts, including </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sales return allowance were immaterial for the periods presented</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2019, a $0.9 million of price adjustment was recorded based on government-listed price guidance and estimated channel inventory levels.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Drug Product Revenue</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change 2020 vs. 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="20" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(dollars in thousands)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,281</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,324</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,776</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,605</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(112</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,625</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,625</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total drug product revenue:</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,906</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,324</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,776</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,230</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(125</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, FibroGen and Astellas entered into the Japan Amendment. Under this amendment, FibroGen would continue to manufacture and supply roxadustat API to Astellas for the roxadustat commercial launch in Japan. We fulfilled the shipment obligations under the term of the Japan Amendment during the year ended December 31, 2018, and recognized the related product revenue of $64.8 million based on a transaction price that was subject to potential future adjustments, which represented a form of variable consideration. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related to the above API shipments in 2018, a change in estimated variable consideration incurred in 2019 at the time the actual listed price for roxadustat was issued by the Japanese Ministry of Health, Labour and Welfare, which resulted in a total difference of $36.3 million between the estimated and the actual listed price and yield from the manufacture of bulk product tablets. In addition, during the year ended December 31, 2020, we recorded another $4.0 million reduction to drug product revenue, related to a change in estimated variable consideration, based on the API held by Astellas at March 31, 2020 adjusted to reflect the updated listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and changes in the estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk product tablets, and estimated yield from the manufacture of bulk product tablets, among others. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2020, we fulfilled shipment obligations under the term of the Japan Amendment, and recognized the related drug product revenue of $8.2 million in the same period. The amount represents variable consideration and was estimated based on the quantity of product shipped, actual listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and possible future changes to the listed price, adjusted for the timing of and estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk product tablets, and estimated yield from the manufacture of bulk product tablets, among others.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fourth quarter of 2020, we shipped bulk drug product from process validation supplies for commercial purposes under the term of the Europe Agreement. We constrained the consideration of this shipment due to a high degree of uncertainty associated to the final consideration. As a result, we recorded $1.4 million as current deferred revenue and $4.6 million as long-term deferred revenue as of December 31, 2020. The deferred revenue will be recognized as and when uncertainty is resolved.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the U.S./RoW Agreement, FibroGen would manufacture and supply roxadustat bulk drug product to AstraZeneca in support of commercial supplies. We shipped bulk drug product to AstraZeneca as pre-commercial supply for process validation purposes during the year ended December 31, 2020 and recognized drug product revenue of $4.6 million. The drug product revenue amount represents variable consideration and was estimated based on the quantity of product shipped and an estimated price.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Costs and Expenses</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change 2020 vs. 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="20" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(dollars in thousands)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating costs and expenses</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,869</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,147</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,722</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">673</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252,924</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209,265</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235,839</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,659</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,406</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135,479</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,812</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,073</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.4%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating costs and expenses</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">368,199</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345,891</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299,651</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,308</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.4%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have taken measures to minimize the health risks of COVID-19 to our staff, patients, healthcare providers and their communities, as their safety and well-being are our top priority. In the U.S., our employees are working remotely when possible, while in China they have returned to work in our offices, manufacturing plants, and are performing medical affairs out in the field. We have also seen some reduced enrollment in our clinical trials, particularly for our IPF pamrevlumab trial. However, the overall impact of COVID-19 on our expenses was not significant. In the year ended December 31, 2020, some reduction in expenses, such as due to reduced travel and paused or slowed enrollment for trials, were offset by some increased expenses, such as in patient care.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses increased $22.3 million, or 6%, for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019, for the reasons discussed in the sections below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Cost of goods sold</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold was $8.9 million and $1.1 million for the years ended December 31, 2020 and 2019, respectively, and primarily consisted of costs associated with the manufacturing of roxadustat product and storage and logistic costs. We started commercial sales of roxadustat drug product in China in the third quarter of 2019. Cost of goods sold, associated with the roxadustat commercial sales in China, consists of direct costs to manufacture commercial product, as well as indirect costs including factory overhead, storage, shipping, quality assurance, idle capacity charges, and inventory valuation adjustments. The year-over-year comparison would not be meaningful as the prior year was the first year for roxadustat commercial sales with limited sales volume. Cost of goods sold associated with the roxadustat <span style="Background-color:#FFFFFF;">drug product </span>revenue in the U.S. was not material for the year ended December 31, 2020 and 2019. W<span style="Background-color:#FFFFFF;">e expect costs of goods sold to increase in relation to drug product revenue as we deplete inventories that we had expensed prior to receiving regulatory approvals.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Research and Development Expenses</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of third-party research and development costs and the fully-burdened amount of costs associated with work performed under collaboration agreements. Research and development costs include employee-related expenses for research and development functions, expenses incurred under agreements with clinical research organizations (&#8220;CROs&#8221;), other clinical and preclinical costs and allocated direct and indirect overhead costs, such as facilities costs, information technology costs and other overhead. Research and development costs are expensed as incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our research and development expenses incurred during the years ended December&#160;31, 2020, 2019 and 2018:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Product Candidate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Phase&#160;of&#160;Development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 3</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122,962</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,429</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,876</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 2/3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,728</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,750</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,063</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FG-5200</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,132</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,323</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,122</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,102</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,763</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,778</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252,924</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209,265</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235,839</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The program-specific expenses summarized in the table above include costs we directly attribute to our product candidates. We allocate research and development salaries, benefits, stock-based compensation and other indirect costs to our product candidates on a program-specific basis, and we include these costs in the program-specific expenses. We expect our research and development expenses to increase in the future as we advance our product candidates through clinical trials and expand our product candidate portfolio.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses increased $43.7 million, or 21%, for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019 as a result of the net effect of the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $36.1 million in clinical trials costs, primarily due to commencement of Phase 3 trials for pamrevlumab and post-approval safety studies in China&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $10.3 million in drug development expenses, primarily due to higher drug substance manufacturing activities and supplies related to pamrevlumab, and higher supply chain expenses related to roxadustat, partially offset by lower drug substance manufacturing activities related to roxadustat and lower drug product manufacturing costs related to pamrevlumab&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $5.2 million in stock-based compensation expense, primarily due to the cumulative impact of stock option grant activities and accelerated recognition due to departure of certain executive employees&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $3.2 million in employee-related costs primarily due to higher headcount in the research and development functions in China and higher compensation levels, partially offset by decrease in events and travel costs due to the COVID-19 pandemic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $3.1 million in facility related expense, primarily due to higher allocated overhead costs, higher depreciation expenses related to China facilities and general maintenance expenses&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Decrease of $6.1 million due to capitalization of inventory manufacturing costs associated with roxadustat production&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Decrease of $5.3 million in outside services due to lower consulting expenses and scientific contract work related to roxadustat Phase 3 and submission activities.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Selling, General and Administrative Expenses </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We started to incur sales and marketing expenses in the first quarter of 2019 in China to prepare for commercial operations. Selling, general and administrative (&#8220;SG&#38;A&#8221;) expenses consist primarily of employee-related expenses for executive, operational, finance, legal, compliance, and human resource functions. SG&#38;A expenses also include facility-related costs, professional fees, accounting and legal services, other outside services including co-promotional expenses, recruiting fees and expenses associated with obtaining and maintaining patents.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that our SG&#38;A expenses will increase in the future as we anticipate an increase in payroll and related expenses associated with an increase in headcount to support the growth of the business in connection with potential commercialization of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SG&#38;A expenses decreased $29.1 million, or 21%, for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019, as a result of the net effect of the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Decrease of $44.9 million in outside service expenses, resulting from the above-mentioned reversal of previously accrued co-promotion expenses payable, which was recorded as a reduction to selling, general and administrative expenses. In addition, current year co-promotion expenses are capped at a percentage of net sales&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $6.8 million in employee-related costs primarily due to higher headcount in the sales and marketing functions in China and higher compensation levels&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Increase of $4.2 million in legal expenses primarily associated with patent-related activities in United Kingdom.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Interest and Other, Net</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change 2020 vs. 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="20" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(dollars in thousands)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest&#160;and&#160;other,&#160;net:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,402</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,876</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,991</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">474</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment loss in unconsolidated variable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; interest entity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(202</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(202</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income and other, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,553</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,548</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,568</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,995</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest and other, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,949</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,672</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">577</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,723</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(77</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Interest Expense</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense relates to our finance lease liabilities accretion primarily for our leased facilities in San Francisco and China. Interest expense also includes interest related to the Technology Development Center of the Republic of Finland product development obligations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense decreased $0.5 million, or 16%, for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019 due to lower interest rates related to our finance lease liabilities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Investment Loss in Unconsolidated Variable Interest Entity </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment loss in unconsolidated variable interest entity represented our proportionate share of the reported profits or losses of Falikang, an unconsolidated VIE accounted for under the equity method, and was immaterial for the year ended December 31, 2020. See Note 3,<span style="font-style:italic;"> Acquisition and Variable Interest Entity</span>, to the consolidated financial statements for details.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Interest Income and Other, Net</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income and other, net primarily include interest income earned on our cash, cash equivalents and investments, foreign currency transaction gains (losses), remeasurement of certain monetary assets and liabilities in non-functional currency of our subsidiaries into the functional currency, realized gains (losses) on sales of investments. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income and other, net decreased $10.0 million, or 64%, for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019, primarily due to lower interest earned on our cash, cash equivalents and investments of $9.4 million associated with the lower average balances. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 1, 2020, FibroGen Beijing adopted Renminbi Yuan (&#8220;CNY&#8221;) as its functional currency based on reassessment of the primary economic environment in which FibroGen Beijing operates, as such environment was mainly associated with its growing manufacturing and product sales activities conducted in CNY. Prior to April 1, 2020, FibroGen Beijing&#8217;s functional currency was the U.S. dollar. This change did not result in material impact to unrealized foreign currency gain or loss during the year ended December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Provision for Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(dollars in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(188,931</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76,642</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(86,116</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">304</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective tax rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provisions for income taxes for the years end December&#160;31, 2020 and 2019 were due to foreign taxes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;) was enacted and signed into law. The CARES Act includes changes to the tax provisions that benefits business entities, and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act. U.S. GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. We evaluated and determined that the impact is immaterial. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon the weight of available evidence, which includes our historical operating performance, reported cumulative net losses since inception and expected continuing net loss, we have established a full valuation allowance against our net deferred tax assets as we do not currently believe that realization of those assets is more likely than not. We will continue to maintain a full valuation allowance on our net deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of this allowance. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, we transferred certain intellectual property rights relating to our Chinese business between our wholly owned subsidiaries that are based in different tax jurisdictions. The transferor entity was not subject to income taxes in its local jurisdiction. The acquiring entity of the intellectual property is entitled to amortize the acquisition price of the intangible assets for tax purposes. In accordance with ASU 2016-16, <span style="font-style:italic;">Intra-Entity Transfers of Assets Other Than Inventory</span>, we recognized a deferred tax asset of $78.7 million for the temporary difference arising from the acquirer&#8217;s excess tax basis. Furthermore, based upon the weight of available evidence, we recognized a full valuation allowance against this deferred tax asset since it does not currently believe that realization of this gross deductible temporary difference is more likely than not. Accordingly, this inter-company transfer did not have a material impact to our consolidated financial statements. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LIQUIDITY AND CAPITAL RESOURCES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Conditions</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have historically funded our operations principally from the sale of common stock (including our public offering proceeds) and from the execution of collaboration agreements involving license payments, milestones and reimbursement for development services. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had cash and cash equivalents of $678.4 million. As of December&#160;31, 2020, we had short-term and long-term investments of $8.1 million and $0.2 million, respectively. Cash is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Investments, consisting of available-for-sale debt investments and marketable equity investments, and stated at fair value, are also available as a source of liquidity. &#160;As of December&#160;31, 2020, a total of $66.0 million of our cash and cash equivalents was held outside of the U.S. in our foreign subsidiaries to be used primarily for our China operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Capital Requirements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the third quarter of 2019, we started generating revenue from commercial sales of roxadustat product in China. Even with the expectation of increases in revenue from product sales, we anticipate that we will continue to generate losses for the foreseeable future. We expect increase in our operating expenses as we continue the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. To date, we have funded certain portions of our research and development and manufacturing efforts in China and Europe through outside parties. There is no guarantee that sufficient funds will be available to continue to fund these development efforts through commercialization or otherwise. Although our share of expenses for roxadustat will decrease as a result of AstraZeneca funding all non-China collaboration expenses not reimbursed by Astellas, we expect our research and development expenses to continue to increase as we invest in our other programs. We are subject to all the risks related to the development and commercialization of novel therapeutics, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business, such as from the COVID-19 pandemic or other factors outlined under Part I, Item 1A &#8220;<span style="font-style:italic;">Risk Factors</span>&#8221; in this Annual Report on Form 10-K. We anticipate that we will need substantial additional funding in connection with our continuing operations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our existing cash and cash equivalents, short-term and long-term investments and accounts receivable will be sufficient to meet our anticipated cash requirements for at least the next 12&#160;months from the date of this Annual Report on Form 10-K. However, our liquidity assumptions may change over time, and we could utilize our available financial resources sooner than we currently expect. In addition, we may elect to raise additional funds at any time through equity, equity-linked or debt financing arrangements. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements and the adequacy of available funds will depend on many factors, including those set forth under Part I, Item 1A &#8220;</span><span style="font-style:italic;">Risk Factors</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; in this Annual Report on Form 10-K. We may not be able to secure additional financing to meet our operating requirements on acceptable terms, or at all. If we raise additional funds by issuing equity or equity-linked securities, the ownership of our existing stockholders will be diluted. If we raise additional financing by the incurrence of indebtedness, we will be subject to increased fixed payment obligations and could also be subject to restrictive covenants, such as limitations on our ability to incur additional debt, and other operating restrictions that could adversely impact our ability to conduct our business. If we are unable to obtain needed additional funds, we will have to reduce our operating costs and expenses, which would impair our growth prospects and could otherwise negatively impact our business.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash Sources and Uses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the primary sources and uses of cash for the years ended December&#160;31, 2020, 2019 and 2018:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in):</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,602</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(78,705</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76,144</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">452,487</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(522,123</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,343</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,300</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,875</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect of exchange rate changes on cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,695</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">552,127</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,008</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(584,400</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities was $81.6 million for the year ended December&#160;31, 2020 and consisted primarily of net loss of $189.3 million adjusted for non-cash items of $96.3 million and a net increase in operating assets and liabilities of $174.6&#160;million. The significant non-cash items included stock-based compensation expense of $72.7 million, depreciation expense of $11.7 million, and amortization of finance lease ROU of $10.4 million. The significant items in the changes in operating assets and liabilities included the increases resulting from the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Prepaid expenses and other current assets of $123.5 million and Deferred revenue of $45.1 million, primarily related to the billing and receipt of $130.0 million in regulatory milestones under the Europe Agreement with Astellas associated with the MAA submission in Europe&#59; and the billing and receipt of $50.0 million regulatory milestone under the U.S./RoW Agreement with AstraZeneca associated with the NDA submission for review in the U.S. These milestones were not billable as of December 31, 2019, and was net of the associated deferred revenues of $4.8 million and $50.0 million, respectively. The change in deferred revenue was also driven by the recognition of revenues under our collaboration agreements with Astellas and AstraZeneca&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Accrued and other liabilities of $31.0 million, primarily driven by $11.5 million of the accrued co-promotion expenses at December 31, 2020 that is anticipated to be paid within the next 12 months resulting from the China Amendment in the third quarter of 2020, $7.0 million of profit share liability to AstraZeneca accrued at December 31, 2020, as well as driven by the timing of invoicing and payment&#59; offset by the payment of $36.3 million that was accrued at December 31, 2019, related to the change in estimated variable consideration associated with the API shipment&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Accounts payable of $17.7 million, primarily driven by $16.9 million of the co-promotion expenses at December 31, 2020 that is scheduled to be paid to AstraZeneca&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Other assets of $6.8 million, primarily related to the return and consumption of input value added tax by FibroGen Beijing.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increases were partially offset by the decreases resulting from the following:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Other long-term liabilities of $28.2 million, primarily due to the adjustment in long-term co-promotion expenses payable to AstraZeneca for its sales and marketing efforts related to the commercial sales of roxadustat in China resulting from the China Amendment in the third quarter of 2020&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Accounts receivable of $12.0 million, primarily driven by the increase in accounts receivable from customers in China for roxadustat sales, as well as the timing of the receipt of upfront payments and the recognition of revenues under our collaboration agreements with Astellas and AstraZeneca&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Inventories of $9.2 million, driven by the increased inventory level primarily related to FibroGen Beijing&#8217;s productions of roxadustat for commercial sales purposes and pre-launch inventory cost capitalized in the U.S.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities was $78.7 million for the year ended December&#160;31, 2019 and consisted primarily of net loss of $77.0 million adjusted for non-cash items of $83.9 million and a net decrease in operating assets and liabilities of $85.7&#160;million. The significant non-cash items included stock-based compensation expense of $66.3 million, depreciation expense of $11.1 million, amortization of finance lease ROU of $10.3 million, and net amortization of premium and discount on investments of $3.7 million. The significant items in the changes in operating assets and liabilities included the decreases resulting from the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Prepaid expenses and other current assets of $128.6 million and deferred revenue of $49.9 million, primarily driven by a $130.0 million unbilled contract asset related to regulatory milestones under the Europe Agreement with Astellas associated with the planned MAA submission in Europe and a $50.0 million contract asset related to a regulatory milestone under the U.S./RoW Agreement with AstraZeneca associated with the NDA submission in the U.S., which were not billable to Astellas or AstraZeneca as of December 31, 2019, net of the associated deferred revenues of $4.8 million and $50.0 million, respectively. The change in deferred revenue was also related to the recognition of revenues under our collaboration agreements with Astellas and AstraZeneca&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Inventories of $6.9 million, due to the capitalization of inventory costs starting in June 2019 when FibroGen Beijing began productions of roxadustat for commercial sales purposes.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Other assets of $3.3 million, primarily related to the net accumulation of input value added tax by FibroGen Beijing&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Accounts payable of $3.1 million, primarily driven by the timing of invoicing and payments.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The decreases were partially offset by the increases resulting from the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Other long-term liabilities of $52.4 million, primarily due to the accrual of co-promotional expenses with AstraZeneca for sales and marketing efforts related to the commercial launch of roxadustat in China that were not expected to be paid in the next year&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Accounts receivable of $35.2 million, primarily related to the collection of $43.9 million from Astellas for the API shipment in December 2018 under the Japan Amendment, as well as the timing of the receipt of upfront payments and recognition of revenues under our collaboration agreements with Astellas and AstraZeneca&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Accrued and other liabilities of $18.3 million, primarily driven by the accrued $36.3 million related to the change in estimated variable consideration associated with the roxadustat API, offset by the timing of invoicing and payments.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investing Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities primarily consist of purchases of property and equipment, purchases of investments, and proceeds from the maturity and sale of investments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities was $452.5 million for the year ended December&#160;31, 2020 and consisted of proceeds from maturities of investments of $456.9 million, proceeds from sales of available-for-sale securities of $10.6 million, partially offset by cash used in purchases of available-for-sale securities of $8.2 million, purchases of property and equipment of $4.0 million, and net payments of $2.8 million made for investment in Falikang. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities was $120.0 million for the year ended December&#160;31, 2019 and consisted of proceeds from maturities of investments of $537.1 million, partially offset by cash used in purchases of available-for-sale securities and term deposit of $411.3 million, and purchases of property and equipment of $5.8 million. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financing Activities</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities primarily reflect proceeds from the issuance of our common stock, cash paid for payroll taxes on restricted stock unit releases, repayments of our lease liabilities and obligations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities was $13.3 million for the year ended December&#160;31, 2020 and consisted primarily of $37.8 million of proceeds from the issuance of common stock upon exercise of stock options and purchases under ESPP, partially offset by $12.6 million of repayments of finance lease liabilities, $11.5 million of cash paid for payroll taxes on restricted stock unit releases, and $0.4 million of repayments on our lease obligations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in financing activities was $4.3 million for the year ended December&#160;31, 2019 and consisted primarily of $12.8 million of cash paid for payroll taxes on restricted stock unit releases, $11.9 million of repayments of finance lease liabilities, and $0.4 million of repayments on our lease obligations, partially offset by $20.8 million of proceeds from the issuance of common stock upon exercise of stock options and purchases under ESPP.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Indemnification Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We enter into standard indemnification arrangements in the ordinary course of business, including for example, service, manufacturing and collaboration agreements. Pursuant to these arrangements, we indemnify, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, including in connection with intellectual property infringement claims by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. We have entered into indemnification agreements with our directors and officers that may require us to indemnify our directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the extent permissible under applicable law. The maximum potential amount of future payments we could be required to make under these arrangements is not determinable. We have never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, we believe the estimated fair value of these arrangements is minimal.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contractual Obligations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020, our contractual obligations were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments Due In</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less Than 1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1 - 3 Years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3 - 5 Years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More Than 5 Years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,142</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">982</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,124</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,689</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,412</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,101</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase obligation - Manufacture and supply of roxadustat</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,114</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,951</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,065</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase obligation - Manufacture and supply of pamrevlumab</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,480</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,063</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,543</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase obligation - Other purchases</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,418</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,418</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total contractual obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,843</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,408</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,251</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contractual obligations table excludes uncertain tax benefits of approximately $48.6 million that are disclosed in Note 13,<span style="font-weight:bold;"> </span><span style="font-style:italic;">Income Taxes</span>, to the consolidated financial statements because these uncertain tax positions, if recognized, would be an adjustment to the gross deferred tax assets and the corresponding valuation allowance, if warranted.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our license agreements provide for periodic maintenance fees over specified time periods, as well as payments by us upon the achievement of development, regulatory and commercial milestones. Future milestone payments for research and pre-clinical stage development programs consisted of up to $10.9 million in total potential future milestone payments under our license agreements with Dana-Farber Cancer Institute, University of Miami and Medarex, Inc. These milestone payments generally become due and payable only upon the achievement of certain developmental, clinical, regulatory and/or commercial milestones. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The event triggering such payment or obligation has not yet occurred</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we have several on-going clinical studies in various stages. Under agreements with various CROs, and clinical study sites, we incur expenses related to clinical studies of our product candidates and potential other clinical candidates. The timing and amounts of these disbursements are contingent upon the achievement of certain milestones, patient enrollment and services rendered or as expenses are incurred by the CROs or clinical trial sites. Therefore, we cannot estimate the potential timing and amount of these payments and they have been excluded from the table above. Although our material contracts with CROs are cancellable, we have historically not cancelled such contracts.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product Development Obligations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, our FibroGen Europe Oy (&#8220;FibroGen Europe&#8221;) subsidiary had $11.6 million of principal outstanding and $7.1 million of interest accrued related to the TEKES loans, respectively, which have been included as product development obligations on our consolidated balance sheet.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no stated maturity date related to these loans and each loan may be forgiven if the research work funded by TEKES does not result in an economically profitable business or does not meet its technological objectives. In addition, we are not a guarantor of the TEKES loans, and these loans are not repayable by FibroGen Europe until it has distributable funds. We do not expect FibroGen Europe to have such funds for at least the next five years. For the foregoing reasons, we cannot estimate the potential timing and the amounts of repayments (if required) or forgiveness. As a result, the TEKES loans have been excluded from the table above.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Legal Proceedings</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to various legal actions that arose in the ordinary course of our business. We recognize accruals for any legal action when we conclude that a loss is probable and reasonably estimable. On April 20, 2020, in response to an invalidation action brought against certain FibroGen United Kingdom patents by Akebia, the United Kingdom court handed down a decision invalidating United Kingdom designations of European Patent Nos. 1463823, 1633333, 2298301, 2322153, and 2322155. The United Kingdom designation to European Patent No. 2289531 was held to be valid in amended form, but not infringed by Akebia. We and our partner Astellas have filed an appeal of the decision in the United Kingdom Court of Appeal. We did not have any material accruals for any currently active legal action in our consolidated balance sheets as of December 31, 2020, as we could not predict the ultimate outcome of these matters, or reasonably estimate the potential exposure. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued and Adopted Accounting Guidance</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-15, <span style="font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. </span>This guidance requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This guidance was effective for annual reporting periods beginning after December 15, 2019, including interim periods. We adopted this guidance on January 1, 2020 using the prospective method, and the adoption of this guidance did not have material impact to our consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(&#8220;ASU 2016-13&#8221;). This guidance is intended to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This guidance requires the measurement of financial assets with </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. This guidance requires an impairment model, known as the current expected credit loss model, which is based on expected losses rather than incurred losses. Entities are required to carry an allowance for expected credit losses for financial assets, including most debt instruments (except those carried at fair value) and trade receivables. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, the FASB issued ASU No. 2019-11, </span><span style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments-Credit Losses </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(&#8220;ASU 2019-11&#8221;)</span><span style="font-style:italic;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which has the same effective dates and transition requirements as ASU </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2016</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU 2016-13 and ASU 2019-11 were effective for annual reporting periods beginning after December 15, 2019 including interim periods. Our investment portfolio primarily consists of U.S. Treasury bills and notes carried at fair value, which is required to follow the impairment model under Topic 326. We adopted this guidance on January 1, 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Based on the composition of our trade receivables and investment portfolio, economic conditions and historical credit loss activity, the adoption of this guidance did not have material impact to our consolidated financial statements.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are described in more detail in the notes to our financial statements appearing elsewhere in this Annual Report, we believe the following accounting policies to be most critical to the judgments and estimates used in the preparation of our financial statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenues under collaboration agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our collaboration agreements include multiple performance obligations comprised of promised services, or bundles of services, that are distinct. Services that are not distinct are combined with other services in the agreement until they form a distinct bundle of services. Our process for identifying performance obligations and an enumeration of each obligation for each agreement is outlined in Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, to our consolidated financial statements. Determining the performance obligations within a collaboration agreement often involves significant judgment and is specific to the facts and circumstances contained in each agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have identified the following material promises under our collaboration agreements: (1) license of FibroGen technology, (2) the performance of co-development services, including manufacturing of clinical supplies and other services during the development period, and (3) manufacture of commercial supply. The evaluation as to whether these promises are distinct, and therefore represent separate performance obligations, is described in more details in Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, to our consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For revenue recognition purposes, we determine that the term of our collaboration agreements begin on the effective date and ends upon the completion of all performance obligations contained in the agreements. In each agreement, the contract term is defined as the period in which parties to the contract have present and enforceable rights and obligations. We believe that the existence of what it considers to be substantive termination penalties on the part of the counterparty create sufficient incentive for the counterparty to avoid exercising its right to terminate the agreement unless in exceptionally rare situations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price for each collaboration agreement is determined based on the amount of consideration we expect to be entitled for satisfying all performance obligations within the agreement. Our collaboration agreements include payments to us of one or more of the following: non-refundable upfront license fees&#59; co-development billings&#59; development, regulatory, and commercial milestone payments&#59; payments from sales of API&#59; payments from sales of bulk drug product and royalties on net sales of licensed products. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront license fees are non-contingent and non-refundable in nature and are included in the transaction price at the point when the license fees become due to us. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-development billings resulting from our research and development efforts, which are reimbursable under our collaboration agreements, are considered variable consideration. Determining the reimbursable amount of research and development efforts requires detailed analysis of the terms of the collaboration agreements and the nature of the research and development efforts incurred. Determining the amount of variable consideration from co-development billings requires us to make estimates of future research and development efforts, which involves significant judgment. Co-development billings are allocated entirely to the co-development services performance obligation when amounts are related specifically to research and development efforts necessary to satisfy the performance obligation, and such an allocation is consistent with the allocation objective.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone payments are also considered variable consideration, which requires us to make estimates of when achievement of a particular milestone becomes probable. Similar to other forms of variable consideration, milestone payments are included in the transaction price when it becomes probable that such inclusion would not result in a significant revenue reversal. Milestone payments are therefore included in the transaction price when achievement of the milestone becomes probable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For arrangements that include sales-based royalties and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from our collaboration arrangements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is allocated to performance obligations based on their relative standalone selling price (&#8220;SSP&#8221;), with the exception of co-development billings allocated entirely to co-development services performance obligations. The SSP is determined based on observable prices at which we separately sell the products and services. If an SSP is not directly observable, then we will estimate the SSP considering marketing conditions, entity-specific factors, and information about the customer or class of customer that is reasonably available. The process for determining SSP involves significant judgment and includes consideration of multiple factors, including assumptions related to the market opportunity and the time needed to commercialize a product candidate pursuant to the relevant license, estimated direct expenses and other costs, which include the rates normally charged by contract research and contract manufacturing organizations for development and manufacturing obligations, and rates that would be charged by qualified outsiders for committee services.&#160;&#160; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant judgment may be required in determining whether a performance obligation is distinct, determining the amount of variable consideration to be included in the transaction price, and estimating the SSP of each performance obligation. An enumeration of our significant judgments is outlined in Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, to our consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each performance obligation identified within an arrangement, we determine the period over which the promised services are transferred and the performance obligation is satisfied. Service revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. For each performance obligation satisfied over time, we assess the proper method to be used for revenue recognition, either an input method to measure progress toward the satisfaction of services or an output method of determining the progress of completion of performance obligation.<span style="font-weight:bold;font-style:italic;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Drug product revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue includes commercial-grade API or bulk drug product sales to AstraZeneca and Astellas, and is recognized when we fulfill the shipment obligations. The drug product revenue is accounted for as variable consideration, estimated at the time of sale using the expected value method. We apply significant judgment in estimating the variable consideration, which involves the use of significant assumptions such as the future list price adjustments set by the Japanese Ministry of Health, Labour and Welfare, product mix, and timing of processing of API into bulk drug product.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, FibroGen and Astellas entered into an amendment to the Japan Agreement that allows Astellas to manufacture roxadustat drug product for commercialization in Japan (the &#8220;Japan Amendment&#8221;). Under this amendment, FibroGen would continue to manufacture and supply roxadustat </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">API</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to Astellas for the roxadustat commercial launch in Japan. The drug product revenue represents variable consideration and is estimated </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">based on the quantity of product shipped, actual listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and possible future changes to the listed price</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, adjusted for the timing of and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk drug product tablets, and estimated yield from the manufacture of bulk product tablets, among others.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Europe Agreement with Astellas, Astellas has an option to purchase roxadustat bulk drug product in support of commercial supplies. The drug product revenue amount represents variable consideration and is estimated based on the quantity of product shipped and an estimated price. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price per strength, which is estimated to be realized by Astellas from the end sale of roxadustat in its approved territories.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, we entered into Commercial Supply Agreement under the U.S./RoW Agreement with AstraZeneca to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from us in support of commercial supplies. The drug product revenue amount represents variable consideration and was estimated based on the quantity of product shipped and an estimated price. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price per strength, which is estimated to be realized by AstraZeneca from the end sale of roxadustat in its approved territories.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of variable consideration that is included in the transaction price may be constrained, and is included in the drug product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. Estimating variable consideration and the related constraint requires the use of significant management judgment. We review new information that may affect its variable consideration estimate at every reporting period and record revenue adjustment, if certain and material. Actual amounts of consideration ultimately received in the future may differ from our estimates, for which we will adjust these estimates and affect the drug product revenue in the period such variances become known. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As each of our collaboration agreements provide for annual true up to the considerations paid for our commercial supplies, we will re-evaluate the transaction price in each reporting period and record an adjustment to revenue as uncertain events are resolved or other changes in circumstances occur.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product revenue, net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We sell roxadustat in China through a number of pharmaceutical distributors located in China. These pharmaceutical distributors are our customers. Hospitals order roxadustat through a distributor and we ship the product directly to the distributors. The delivery of roxadustat to a distributor represents a single performance obligation.&#160;Distributors are responsible for delivering product to end users, primarily hospitals. Distributors bear inventory risk once they receive and accept the product. Product revenue is recognized when control of the promised good is transferred to the customer in an amount that reflects the consideration to which we expect to be entitled to in exchange for the product. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The period between the transfer of control of the promised goods and when we receive payment is based on a general 60-day payment term. As such, product revenue is not adjusted for the effects of a significant financing component. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue is recorded at the net sales prices (transaction price) which includes the following estimates of variable consideration:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Price adjustment:</span><span style="color:#000000;"> In December 2019, China&#8217;s National Healthcare Security Administration released price guidance for roxadustat under the NRDL, effective January 1, 2020. Any channel inventories as of January 1, 2020 that had not been sold to hospitals by distributors, or to patients by hospitals, were eligible for a price adjustment under the price protection. The price adjustment is calculated based on estimated channel inventory levels at January 1, 2020. If price guidance changes in the future, the price adjustment will be calculated in the same manner&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Contractual sales rebate</span><span style="color:#000000;">: The contractual sales rebate is calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. The contractual sales rebate is recorded as a reduction to revenue at the point of sale to the distributor&#59;&#160;&#160;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Key account hospital sales rebate</span><span style="color:#000000;">: </span><span style="color:#000000;">An a</span><span style="color:#000000;">dditional sales rebate is provided to a distributor for product sold to key account hospitals</span><span style="color:#000000;"> as a percentage of gross </span><span style="color:#000000;">sales made by the distributor to eligible hospitals</span><span style="color:#000000;">. This additional rebate is recorded as a reduction to revenue at the point of sale to the distributor&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Transfer fee discount</span><span style="color:#000000;">: The transfer fee discount is offered to a distributor who has its downstream distributors supply to eligible hospitals. This discount is calculated based on a percentage of gross sales made to the downstream distributors, and recorded as a reduction to revenue as incurred&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Sales return</span><span style="color:#000000;">: Distributors can request to return product to us only due to quality issues or for product purchased within one year prior to the product&#8217;s expiration date&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Non-key account hospital listing award: </span><span style="color:#000000;">A one-time fixed-amount award is offered to a distributor who successfully lists the product with an eligible hospital, and who meets certain requirements. We consider this particular award to be an upfront payment to a customer within the definitions of ASC 606. The non-key account hospital listing award is capitalized when the distributor meets eligibility requirements, and amortized as reduction to product revenue over future sales orders made by the distributor until exhausted. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The calculation of the above variable consideration is based on gross sales to the distributor, or estimated utilizing best available information from the distributor, maximum known exposures and other available information including estimated channel inventory levels and estimated sales made by the distributor to hospitals, which involve a substantial degree of judgment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above rebates and discounts all together are eligible to be applied against the distributor&#8217;s future sales order, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible and in the same period that the related revenue is recorded. Due to the distributor&#8217;s legal right to offset, at each balance sheet date, the rebates and discounts are presented as reductions to gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when we expect to settle the discount in cash. The distributor&#8217;s legal right of offset is calculated at the individual distributor level.<span style="font-weight:bold;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Valuation of inter-company transfer of intellectual property</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASU 2016-16,&#160;<span style="font-style:italic;">Income Taxes (Topic 740), Intra-Entity Transfers of Assets Other Than Inventory,</span>&#160;issued by the FASB requires companies to recognize the income tax consequences of an inter-company transfer of assets when the transfer occurs. The guidance in ASU 2016-16 does not change accounting for the pre-tax effects of inter-company asset transfers under Accounting Standards Codification Topic 810,&#160;<span style="font-style:italic;">Consolidation.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described in Note 13, <span style="font-style:italic;">Income Taxes</span>, to our consolidated financial statements, during 2020, we transferred certain intellectual property rights relating to our Chinese business between our wholly owned subsidiaries that are based in different tax jurisdictions. The transferor entity was not subject to income taxes in its local jurisdiction. The acquiring entity of the intellectual property is entitled to amortize the acquisition price of the intangible assets for tax purposes. In accordance with ASU 2016-16, we recognized a deferred tax asset of $78.7 million for the temporary difference arising from the acquirer&#8217;s excess tax basis. Furthermore, based upon the weight of available evidence, we recognized a full valuation allowance against this deferred tax asset since we do not currently believe that realization of this gross deductible temporary difference is more likely than not. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated fair value for the transfer of these intellectual property rights was determined using the excess earning method, a variation of the income valuation approach. The excess earnings method estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to that intangible asset over its remaining economic life. Long-term cash flow projections for the asset require the use of significant estimates and judgements, including revenue volume and price. The fair value of the asset was determined using an estimated discount rate of 12.3%, which reflects the risks inherent in future cash flow projections and represents a rate of return that a market participant would expect for this asset. The transferred intangible asset is being amortized over an estimated useful life of approximately 8 years by the acquiring entity. We believe our assumptions are consistent with the plans and estimates that a market participant would use to acquire this intangible asset. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS">ITEM&#160;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in foreign currency exchange rates. Most of our revenue from collaboration agreements are denominated in U.S. dollars, and therefore our revenue is not currently subject to significant foreign currency risk. The functional currency of our FibroGen Europe Oy subsidiary is the local currency. On April 1, 2020, our subsidiary FibroGen Beijing changed its functional currency from U.S. dollars to its local currency. Our operating expenses are denominated in the currencies of the countries in which our operations are located, which are primarily in the United States, China, and Europe. Our consolidated results of operations and cash flows are, therefore, subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we did not have material financial assets and liabilities denominated in foreign currencies that are subject to fluctuation in the exchange rate with the U.S. dollar. Therefore, the effect of a hypothetical 10% change in foreign currency exchange rates would not have resulted in a material net gain or loss on foreign currency for the year ended December&#160;31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary objective of our investment activities is to preserve our capital to fund our operations. We also seek to maximize income from our cash and cash equivalents without assuming significant risk. To achieve our objectives, we invest our non-operating cash and cash equivalents primarily in U.S. treasuries and money market funds as of December 31, 2020.&#160;Given the nature of our investments as of December&#160;31, 2020, we believe that our exposure to interest rate risk is not significant. We actively monitor changes in interest rates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not entered into any hedging arrangements with respect to foreign currency risk or other derivative financial instruments.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_8_CONSOLIDATED_FINANCIAL_STATEMENTS">ITEM&#160;8. CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:9.9pt;">
<td valign="bottom" style="width:94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="font-weight:bold;">Page</span>&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:none;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Statements:</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:6.6pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:none;">Consolidated Balance Sheets</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr style="height:6.6pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><span style="text-decoration:none;">Consolidated Statements of Operations</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr style="height:4.35pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO"><span style="text-decoration:none;">Consolidated Statements of Comprehensive Loss</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
</tr>
<tr style="height:5.4pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_EQUITY"><span style="text-decoration:none;">Consolidated Statements of Changes in Stockholders' Equity</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:none;">Consolidated Statements of Cash Flows</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p></td>
</tr>
<tr style="height:7.8pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_THE_CONSOLIDATED_FS"><span style="text-decoration:none;">Notes to Consolidated Financial Statements</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Statement Schedule:</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4.35pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.8pt;;text-indent:-8.8pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SCHEDULE_II"><span style="text-decoration:none;">II Valuation and Qualifying Accounts for each of the three years ended December&#160;31, 2020</span></a></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC">Report of Independent Registered Public Accounting Firm</p>
<p style="margin-top:12pt;margin-bottom:10pt;text-indent:0%;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Board of Directors and Stockholders of FibroGen, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Opinions on the Financial Statements and Internal Control over Financial Reporting</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of FibroGen, Inc.<span style="font-weight:bold;"> </span>and its subsidiaries<span style="font-weight:bold;"> </span>(the &#8220;Company&#8221;) as of December 31, 2020 and 2019,<span style="font-weight:bold;"> </span>and the related consolidated statements of operations, of comprehensive loss, of changes in stockholders&#8217; equity and of cash flows<span style="font-weight:bold;"> </span>for each of the three years in the period ended December 31, 2020, including the related notes and financial statement schedule listed in the accompanying index (collectively referred to as the &#8220;consolidated<span style="font-weight:bold;"> </span>financial statements&#8221;).<span style="font-weight:bold;"> </span>We also have audited the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in <span style="font-style:italic;">Internal Control - Integrated Framework</span> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020<span style="font-weight:bold;"> </span>in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company did not maintain, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in <span style="font-style:italic;">Internal Control - Integrated Framework</span> (2013) issued by the COSO because material weaknesses in internal control over financial reporting existed as of that date related to the risk assessment component of internal control, as the Company did not design and maintain an effective risk assessment process at a precise enough level to identify new and evolving risks of material misstatement to the financial statements as a result of changes in the Company&#8217;s business operation, which gave rise to additional material weaknesses as the Company did not design and maintain effective controls related to the timely identification of shipments associated with drug product revenue, or changes in estimated variable consideration related to drug product revenue.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses referred to above are described in Management&#8217;s Annual Report on Internal Control over Financial Reporting appearing under Item 9A. We considered these material weaknesses in determining the nature, timing, and extent of audit tests applied in our audit of the 2020 consolidated<span style="font-weight:bold;"> </span>financial statements, and our opinion regarding the effectiveness of the Company&#8217;s internal control over financial reporting does not affect our opinion on those consolidated<span style="font-weight:bold;"> </span>financial statements.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Change in Accounting Principle</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis for Opinions </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's management is responsible for these consolidated<span style="font-weight:bold;"> </span>financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in management's report referred to above. Our responsibility is to express opinions on the Company&#8217;s consolidated<span style="font-weight:bold;"> </span>financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Definition and Limitations of Internal Control over Financial Reporting</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company&#59; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company&#59; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.<span style="font-weight:bold;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Critical Audit Matters</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Deferred Tax Asset &#8211; Valuation of Intellectual Property Rights</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described in Notes 2 and 13 to the consolidated financial statements, in 2020, the Company transferred certain intellectual property rights relating to its Chinese business. Management estimated the fair value of the intellectual property rights using the excess earning method. The transaction resulted in the recognition of a deferred tax asset in the amount of $78.7 million. The establishment of a deferred tax asset from the intra-entity transfer of intangible assets required management to make significant estimates and assumptions to determine the fair value of intellectual property rights transferred which include, but are not limited to, management&#8217;s expectations of discount rate, revenue volume and price.<span style="font-style:italic;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The principal considerations for our determination that performing procedures relating to the valuation of intellectual property rights is a critical audit matter are the significant judgment by management when estimating the fair value of the intellectual property rights, which in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management&#8217;s significant assumptions related to discount rate, revenue volume and price.<span style="font-style:italic;"> </span>Also, the audit effort involved the use of professionals with specialized skill and knowledge.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls over management&#8217;s valuation of intellectual property rights<span style="font-style:italic;">.</span> These procedures also included, among others (i) reading the intellectual property license agreement and (ii) testing management&#8217;s process for estimating the fair value of intellectual property rights, which included (a) evaluating the appropriateness of the valuation method used, (b) testing the completeness, accuracy, and relevance of the data used in the method, and (c) evaluating the reasonableness of management&#8217;s significant assumptions relating to discount rate, revenue volume and price. Evaluating the reasonableness of the revenue volume and price assumptions involved considering the current performance of the business and evaluating management&#8217;s forecasts. Professionals with specialized skill and knowledge were used to assist in the evaluation of valuation method and discount rate used to value the intellectual property rights.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Revenue Recognition &#8211; Estimates in Variable Consideration for Active Pharmaceutical Ingredients Sales<span style="font-style:normal;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described in Notes 2 and 4 to the consolidated financial statements, the Company recognizes revenue from sales to its collaboration partners for the shipment of bulk drug product. The revenue from customers under these arrangements are accounted for as variable consideration, estimated at the time of sale using the expected value method. Revenue recognized under these arrangements was $8.9 million for the year ended December 31, 2020. Management applied significant judgment in estimating the variable consideration, which involved the use of significant assumptions such as (i) the future list price adjustments set by the Japanese Ministry of Health, Labour and Welfare, (ii) product mix, and (iii) timing of processing of active pharmaceutical ingredient (API) into bulk drug product.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The principal considerations for our determination that performing procedures relating to estimates in variable consideration for active pharmaceutical ingredients sales is a critical audit matter are the significant judgment by management in estimating the variable consideration, which in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management&#8217;s significant assumptions related to the future list price adjustments, product mix and timing of processing of API into bulk drug product. As described in the &#8220;Opinions on the Financial Statements and Internal Control over Financial Reporting&#8221; section, a material weakness was identified related to this matter.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, testing management&#8217;s process for estimating the variable consideration, which included (a) evaluating the appropriateness of the expected value method, (b) evaluating the reasonableness of management&#8217;s significant assumptions related to future list price adjustments, product mix, and timing of processing of API into bulk drug product, and (c) testing the completeness, accuracy, and relevance of underlying data. Evaluating management&#8217;s assumption related to future list price adjustments involved evaluating whether the assumption was reasonable considering historical price list changes and industry data. Evaluating management&#8217;s assumptions related to product mix and timing of processing of API into bulk drug product involved evaluating whether the assumptions were reasonable considering current and historical manufacturing levels and mix and other external data.</p>
<p style="margin-top:24pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ PricewaterhouseCoopers LLP </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Jose, California</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2000.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FIBROGEN, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_BALANCE_SHEETS">CONSOLIDATED BALANCE SHEETS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000033" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">678,393</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">126,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:ShortTermInvestments" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:ShortTermInvestments" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">407,491</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, net ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,127</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,845</ix:nonFraction> from a related party)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,883</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,455</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:InventoryNet" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,530</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:InventoryNet" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,887</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0000921299_20201231" decimals="-3" scale="3">889</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">125,210</ix:nonFraction> from</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,160</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">133,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:AssetsCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">755,110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:AssetsCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">702,490</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted time deposits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="fgen:RestrictedTimeDepositsNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,072</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="fgen:RestrictedTimeDepositsNoncurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,072</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:LongTermInvestments" contextRef="C_0000921299_20201231" decimals="-3" scale="3">244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:LongTermInvestments" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">61,118</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">33,647</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity method investment in unconsolidated variable interest entity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="fgen:EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,728</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="fgen:EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,433</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:Assets" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">826,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:Assets" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">857,397</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, stockholders&#8217; equity and non-controlling interests</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,118</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="C_0000921299_20191231" decimals="-3" scale="3">0</ix:nonFraction> to a related party)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:AccountsPayableCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,789</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:AccountsPayableCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,088</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0000921299_20201231" decimals="-3" scale="3">24</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,883</ix:nonFraction> to a related party)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">119,521</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">83,816</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="fgen:DueToRelatedPartiesDeferredRevenueCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,907</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="fgen:DueToRelatedPartiesDeferredRevenueCurrent" contextRef="C_0000921299_20191231" decimals="-3" scale="3">249</ix:nonFraction> to a related party)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,547</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000921299_20191231" decimals="-3" scale="3">490</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,330</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,351</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:LiabilitiesCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">163,187</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:LiabilitiesCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">102,745</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product development obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="fgen:AccruedProductDevelopmentCosts" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,697</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="fgen:AccruedProductDevelopmentCosts" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,780</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="fgen:DueToRelatedPartiesDeferredRevenueNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,636</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="fgen:DueToRelatedPartiesDeferredRevenueNoncurrent" contextRef="C_0000921299_20191231" decimals="-3" scale="3">125</ix:nonFraction> to a related party)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">138,474</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">99,449</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, non-current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,610</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,642</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">65,407</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:Liabilities" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">385,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:Liabilities" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">321,991</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and Contingencies (Note 9)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000079">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000080">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000111" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0000921299_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000112" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0000921299_20191231" decimals="INF">0.01</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000113" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0000921299_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000114" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0000921299_20191231" decimals="INF" format="ixt:numdotdecimal" scale="3">125,000</ix:nonFraction></ix:nonFraction> shares authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000115" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0000921299_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000116" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0000921299_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000117" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000118" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and outstanding at December 31, 2020 and 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:PreferredStockValue" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:PreferredStockValue" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000119" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0000921299_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000120" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0000921299_20191231" decimals="INF">0.01</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000121" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0000921299_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000122" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0000921299_20191231" decimals="INF" format="ixt:numdotdecimal" scale="3">225,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2020 and 2019&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000123" name="us-gaap:CommonStockSharesIssued" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000125" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">91,441</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000124" name="us-gaap:CommonStockSharesIssued" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000126" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">87,657</ix:nonFraction></ix:nonFraction> shares issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2020 and 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:CommonStockValue" contextRef="C_0000921299_20201231" decimals="-3" scale="3">914</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:CommonStockValue" contextRef="C_0000921299_20191231" decimals="-3" scale="3">877</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,399,774</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,300,725</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0000921299_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,499</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0000921299_20191231" decimals="-3" sign="-" scale="3">747</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0000921299_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">974,011</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0000921299_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">784,720</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:StockholdersEquity" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">422,178</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:StockholdersEquity" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">516,135</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling interests</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:MinorityInterest" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:MinorityInterest" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">441,449</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">535,406</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities, stockholders&#8217; equity and non-controlling interests</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000097" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">826,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000098" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">857,397</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these Consolidated Financial Statements.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FIBROGEN, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_OPERATIONS">CONSOLIDATED STATEMENTS OF OPERATIONS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue (includes $<ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="fgen:LicenseFeesAndMilestonesRevenue" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,323</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="fgen:LicenseFeesAndMilestonesRevenue" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">129,405</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="fgen:LicenseFeesAndMilestonesRevenue" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,323</ix:nonFraction></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; from a related party)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">177,086</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,269</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development and other revenue (includes $<ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="fgen:CollaborationServicesAndOtherRevenue" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,174</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="fgen:CollaborationServicesAndOtherRevenue" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,393</ix:nonFraction></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="fgen:CollaborationServicesAndOtherRevenue" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,903</ix:nonFraction> from a related party)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">80,592</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">114,115</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">125,913</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">72,498</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue (includes $<ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="fgen:ProductRevenue" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,281</ix:nonFraction>, $(<ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="fgen:ProductRevenue" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">36,324</ix:nonFraction>)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="fgen:ProductRevenue" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">64,776</ix:nonFraction> from a related party)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,906</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">36,324</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">64,776</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">176,319</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">256,577</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">212,958</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating costs and expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="fgen:CostOfGoodsAndServicesSoldOperatingExpense" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,869</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="fgen:CostOfGoodsAndServicesSoldOperatingExpense" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,147</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="fgen:CostOfGoodsAndServicesSoldOperatingExpense" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">252,924</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">209,265</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">235,839</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">106,406</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">135,479</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">63,812</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating costs and expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:OperatingExpenses" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">368,199</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:OperatingExpenses" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">345,891</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:OperatingExpenses" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">299,651</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">191,880</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000921299_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">89,314</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">86,693</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Interest and other, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:InterestExpense" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,402</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:InterestExpense" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:InterestExpense" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,991</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment loss in unconsolidated variable interest entity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="fgen:UnconsolidatedVariableInterestEntityInvestmentLoss" contextRef="C_0000921299_20200101_20201231" decimals="-3" scale="3">202</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="fgen:UnconsolidatedVariableInterestEntityInvestmentLoss" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="fgen:UnconsolidatedVariableInterestEntityInvestmentLoss" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income and other, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:InterestAndOtherIncome" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,553</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:InterestAndOtherIncome" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,548</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:InterestAndOtherIncome" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,568</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest and other, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,949</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,672</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">577</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">188,931</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0000921299_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">76,642</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">86,116</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000921299_20200101_20201231" decimals="-3" scale="3">360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">328</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">304</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">189,291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">76,970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">86,420</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000181" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0000921299_20200101_20201231" decimals="2" sign="-">2.11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000182" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0000921299_20190101_20191231" decimals="2" sign="-">0.89</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000183" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0000921299_20180101_20181231" decimals="2" sign="-">1.03</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Weighted average number of common shares used to calculate</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net loss per share - basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000184" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">89,854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000185" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">86,633</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000186" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">84,062</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these Consolidated Financial Statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FIBROGEN, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">189,291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">76,970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">86,420</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income (loss):</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation adjustments <span style="font-weight:bold;">(Note 2)</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,207</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">331</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">771</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale investments:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain (loss) on investments, net of tax effect</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" scale="3">545</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">592</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" scale="3">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income (loss), net of taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,752</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">923</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">764</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive income (loss)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">193,043</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0000921299_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">76,047</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,656</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these Consolidated Financial Statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FIBROGEN, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_EQUITY">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share data)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common&#160;Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Controlling</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.06%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interests</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Note 2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2017</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000211" name="us-gaap:SharesOutstanding" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="INF" format="ixt:numdotdecimal">82,498,128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="-3" scale="3">825</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,160,094</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,795</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">630,657</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">547,738</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of change in</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; accounting principle</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; upon adoption of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; ASU 2016-01 <span style="font-weight:bold;">(Note 2)</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20171231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_20171231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">86,420</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">86,420</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in unrealized gain</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; or loss on investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" sign="-" scale="3">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" scale="3">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; translation adjustments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000239" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000241" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" scale="3">771</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">771</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment to issuance</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; costs for Follow-on</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Offerings</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issued from stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; plans, net of payroll</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; taxes paid</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000253" name="fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">2,933,974</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" scale="3">29</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,206</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,235</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,142</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,142</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000267" name="us-gaap:SharesOutstanding" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" format="ixt:numdotdecimal">85,432,102</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" scale="3">854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,226,453</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,281</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">715,827</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">528,470</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of adoption of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; ASC 842 <span style="font-weight:bold;">(Note 2)</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,688</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,688</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of change in</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; accounting principle</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; upon adoption of ASU</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2018-02 <span style="font-weight:bold;">(Note 2)</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="-3" scale="3">611</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" sign="-" scale="3">611</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">76,970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">76,970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in unrealized gain</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; or loss on investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" scale="3">592</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">592</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; translation adjustments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" scale="3">331</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">331</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issued from stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; plans, net of payroll</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; taxes paid</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000309" name="fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">2,220,957</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" scale="3">23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,939</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000313" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,962</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants exercised</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000316" name="fgen:WarrantExercisedDuringPeriodShares" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">4,430</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="fgen:WarrantsExercisedDuringPeriodValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="fgen:WarrantsExercisedDuringPeriodValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">66</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="fgen:WarrantsExercisedDuringPeriodValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="fgen:WarrantsExercisedDuringPeriodValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="fgen:WarrantsExercisedDuringPeriodValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="fgen:WarrantsExercisedDuringPeriodValue" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">66</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">66,267</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">66,267</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000330" name="us-gaap:SharesOutstanding" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">87,657,489</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">877</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,300,725</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" sign="-" scale="3">747</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">784,720</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">535,406</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000339" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">189,291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000342" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="us-gaap:NetIncomeLoss" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">189,291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in unrealized gain</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; or loss on investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000345" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" sign="-" scale="3">545</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" scale="3">545</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; translation adjustments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000351" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000353" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,207</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000355" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000356" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000357" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,207</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issued from stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; plans, net of payroll</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; taxes paid</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000358" name="fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">3,783,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000359" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,329</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000361" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000363" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000364" name="fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,366</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000365" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000366" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">72,720</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000368" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000369" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000370" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000371" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">72,720</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000372" name="us-gaap:SharesOutstanding" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">91,440,633</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000373" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">914</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000374" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,399,774</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000375" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,499</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000376" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">974,011</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000377" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000378" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">441,449</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these Consolidated Financial Statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FIBROGEN, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CASH_FLOWS">CONSOLIDATED STATEMENTS OF CASH FLOWS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000379" name="us-gaap:ProfitLoss" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">189,291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000380" name="us-gaap:ProfitLoss" contextRef="C_0000921299_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">76,970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000381" name="us-gaap:ProfitLoss" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">86,420</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000382" name="us-gaap:Depreciation" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,678</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000383" name="us-gaap:Depreciation" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,147</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000384" name="us-gaap:Depreciation" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,562</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of finance lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000385" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,369</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000386" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,307</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000387" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net accretion of discount on investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000388" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,667</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000390" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">42</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss (gain) on equity investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="fgen:UnrealizedLossGainOnEquityInvestments" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="fgen:UnrealizedLossGainOnEquityInvestments" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">88</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000393" name="fgen:UnrealizedLossGainOnEquityInvestments" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,120</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment loss in unconsolidated variable interest entity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000394" name="fgen:InvestmentLossInUnconsolidatedVariableInterestEntity" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">202</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000395" name="fgen:InvestmentLossInUnconsolidatedVariableInterestEntity" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000396" name="fgen:InvestmentLossInUnconsolidatedVariableInterestEntity" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss (gain) on disposal of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000397" name="us-gaap:GainLossOnDispositionOfAssets" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">933</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000398" name="us-gaap:GainLossOnDispositionOfAssets" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">42</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000399" name="us-gaap:GainLossOnDispositionOfAssets" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">53</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000400" name="us-gaap:ShareBasedCompensation" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">72,720</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000401" name="us-gaap:ShareBasedCompensation" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">66,267</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000402" name="us-gaap:ShareBasedCompensation" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,142</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized foreign currency gain</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000403" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000404" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000405" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,074</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realized loss (gain) on sales of available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000406" name="us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">258</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000407" name="us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000408" name="us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">87</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, net ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" contextRef="C_0000921299_20200101_20201231" decimals="-3" scale="3">718</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,365</ix:nonFraction> and $(<ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">43,486</ix:nonFraction>) from a related party)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000409" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,973</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000410" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0000921299_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">35,229</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000411" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,232</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000412" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,175</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000413" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,887</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000414" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="fgen:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">124,321</ix:nonFraction>, $(<ix:nonFraction unitRef="U_iso4217USD" id="F_000512" name="fgen:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties" contextRef="C_0000921299_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">125,210</ix:nonFraction>)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="fgen:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">0</ix:nonFraction> from a related party)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">123,492</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000416" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">128,598</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000417" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">6,843</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000419" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,253</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000420" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,090</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000514" name="fgen:IncreaseDecreaseInAccountsPayableFromRelatedParty" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,118</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000515" name="fgen:IncreaseDecreaseInAccountsPayableFromRelatedParty" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">0</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000516" name="fgen:IncreaseDecreaseInAccountsPayableFromRelatedParty" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">0</ix:nonFraction> from a related party)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000421" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,731</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0000921299_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,630</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other liabilities ($(<ix:nonFraction unitRef="U_iso4217USD" id="F_000517" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">36,859</ix:nonFraction>), $<ix:nonFraction unitRef="U_iso4217USD" id="F_000518" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,439</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000519" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">172</ix:nonFraction> from a related party)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000424" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,048</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000425" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000426" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,169</ix:nonFraction>, $(<ix:nonFraction unitRef="U_iso4217USD" id="F_000521" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_0000921299_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,137</ix:nonFraction>) and $(<ix:nonFraction unitRef="U_iso4217USD" id="F_000522" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,908</ix:nonFraction>) from a related party)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">45,077</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0000921299_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">49,941</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">5,031</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease obligations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000430" name="fgen:IncreaseDecreaseInLeaseObligations" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000431" name="fgen:IncreaseDecreaseInLeaseObligations" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000432" name="fgen:IncreaseDecreaseInLeaseObligations" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">32</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest for finance lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="fgen:IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" scale="3">177</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000434" name="fgen:IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000435" name="fgen:IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000436" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">28,236</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000437" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,636</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">81,602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000440" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0000921299_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">78,705</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000441" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">76,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000442" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,994</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000443" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,762</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000444" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,020</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment made for investment in unconsolidated variable interest entity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000445" name="fgen:PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,896</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000446" name="fgen:PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000447" name="fgen:PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from equity transfer of unconsolidated variable interest entity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000448" name="fgen:ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,063</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000449" name="fgen:ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000450" name="fgen:ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sale of property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000451" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">184</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of available-for-sale securities and term deposit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="fgen:PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,192</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000455" name="fgen:PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">411,299</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000456" name="fgen:PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">576,880</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sales of available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000459" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,167</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities of investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">456,900</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000461" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">537,072</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,426</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">452,487</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">120,018</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">522,123</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrowings under capital lease obligations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000466" name="us-gaap:ProceedsFromLongTermCapitalLeaseObligations" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="us-gaap:ProceedsFromLongTermCapitalLeaseObligations" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="us-gaap:ProceedsFromLongTermCapitalLeaseObligations" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">49</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repayments of capital lease obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000469" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repayments of finance lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="fgen:RepaymentsOfFinanceLeaseLiabilities" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,620</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="fgen:RepaymentsOfFinanceLeaseLiabilities" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,925</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="fgen:RepaymentsOfFinanceLeaseLiabilities" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repayments of lease obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" contextRef="C_0000921299_20200101_20201231" decimals="-3" scale="3">403</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">403</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">403</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for payroll taxes on restricted stock unit releases</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,463</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,750</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,612</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,829</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000482" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,778</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,847</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,343</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0000921299_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,875</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect of exchange rate change on cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,695</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000921299_20190101_20191231" decimals="-3" sign="-" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">552,127</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,008</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">584,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents at beginning of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">126,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000921299_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">89,258</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000921299_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">673,658</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents at end of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">678,393</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">126,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000921299_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">89,258</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest payments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:InterestPaidNet" contextRef="C_0000921299_20200101_20201231" decimals="-3" scale="3">135</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="us-gaap:InterestPaidNet" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">174</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="us-gaap:InterestPaidNet" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">218</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance in accounts payable and accrued liabilities related to purchases of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; property and equipment</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0000921299_20200101_20201231" decimals="-3" scale="3">884</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">460</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">276</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred offering costs recorded in accounts payable and accrued liabilities</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:LiabilitiesAssumed1" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="us-gaap:LiabilitiesAssumed1" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="us-gaap:LiabilitiesAssumed1" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">24</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these Consolidated Financial Statements.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FIBROGEN, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_THE_CONSOLIDATED_FS">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000524" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;" id="NOTE_1_COMPANY"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-weight:normal;color:#000000;"></span><span style="color:#000000;">The Company</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc. (&#8220;FibroGen&#8221; or the &#8220;Company&#8221;) is headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#8217;s Republic of China (&#8220;China&#8221;). FibroGen is a leading biopharmaceutical company developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (&#8220;HIF&#8221;) biology, 2-oxoglutarate enzymology, connective tissue growth factor (&#8220;CTGF&#8221;) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat, FibroGen&#8217;s most advanced product, is an oral small molecule inhibitor of HIF prolyl hydroxylase&#160;&#160;activity that has received marketing authorization in China (tradename: &#29233;&#29790;&#21331;<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>) for the treatment of anemia caused by chronic kidney disease (&#8220;CKD&#8221;) in dialysis and non-dialysis patients. EVRENZO&#174; (roxadustat) is also approved in Japan and Chile for the treatment of anemia associated with CKD in dialysis and non-dialysis patients. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s New Drug Application (&#8220;NDA&#8221;) filing in the United States (&#8220;U.S.&#8221;) for roxadustat for the treatment of anemia in dialysis and non-dialysis CKD patients was submitted in December 2019 to the U.S. Food and Drug Administration (&#8220;FDA&#8221;). In December 2020, the FDA extended the review period of the NDA by three months for FibroGen to submit additional analyses of existing roxadustat clinical data, and set a new Prescription Drug User Fee Act goal date of March 20, 2021. On March 1, 2021, the FDA informed us that the Cardiovascular and Renal Drugs Advisory Committee will hold an advisory committee meeting to review the NDA for roxadustat. The date of the advisory committee meeting has not been set. As a result of this communication, we will not receive an approval decision by the PDUFA goal date. In Europe, the Marketing Authorization Application (&#8220;MAA&#8221;) filing for roxadustat for the treatment of anemia in dialysis and non-dialysis CKD patients was accepted for regulatory review by the European Medicines Agency (&#8220;EMA&#8221;) in May 2020 and Astellas expects an approval decision by the EMA mid-2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 3 development in China for anemia associated with myelodysplastic syndromes. Roxadustat is in Phase 2 clinical development for chemotherapy-induced anemia. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab, an anti-CTGF human monoclonal antibody, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis, locally advanced unresectable pancreatic cancer and Duchenne muscular dystrophy.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000525" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000525_dcnt_160d1e44-7916-4e12-9b26-4906259524db">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Summary of Significant Accounting Policies</p></td></tr></table></div><ix:nonNumeric id="F_000540" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;). <span style="color:#000000;">The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and its majority-owned subsidiaries, FibroGen Europe and FibroGen China Anemia Holdings, Ltd. (&#8220;FibroGen Cayman&#8221;). All inter-company transactions and balances have been eliminated in consolidation. For any variable interest entity for which FibroGen is not the primary beneficiary, the Company uses the equity method of accounting.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in <ix:nonFraction unitRef="U_fgenSegment" id="F_000616" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0000921299_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> segment &#8212; the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. </p></ix:nonNumeric><ix:nonNumeric id="F_000541" name="us-gaap:ConsolidationVariableInterestEntityPolicy" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000541_dcnt_e1c2d0b3-92b1-47da-8849-2a391643eecd">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Variable Interest Entity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Accounting Standards Codification (&#8220;ASC&#8221;) 810, <span style="font-style:italic;">Consolidation </span>(&#8220;ASC 810&#8221;), when the Company obtains an economic interest in an entity, it evaluates the entity to determine if it should be deemed a variable interest entity (&#8220;VIE&#8221;), and, if so, whether the Company is the primary beneficiary and is therefore required to consolidate the VIE, based on significant judgment whether the Company (i) has the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) has the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. </p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000525_dcnt_160d1e44-7916-4e12-9b26-4906259524db" continuedAt="F_000525_dcnt_b7f07bd9-1182-4710-804b-c639b9e8faf2"><ix:continuation id="F_000541_dcnt_e1c2d0b3-92b1-47da-8849-2a391643eecd">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an ongoing basis, the Company re-evaluates </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the VIE assessment based on potential changes in facts and circumstances, including but not limited to, the shareholder loans to the entity and the execution of any future significant agreements between the entity and its shareholders and/or other third parties.</span></p></ix:continuation><ix:nonNumeric id="F_000542" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency Translation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reporting currency of the Company and its subsidiaries is the U.S. dollar. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of FibroGen Europe is the Euro. The assets and liabilities of FibroGen Europe are translated to U.S. dollars at exchange rates in effect at the balance sheet date. All income statement accounts are translated at monthly average exchange rates. Resulting foreign currency translation adjustments are recorded directly in accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to April 1, 2020, the functional currency of the Company&#8217;s subsidiary, FibroGen (China) Medical Technology Development Co., Ltd. (&#8220;FibroGen Beijing&#8221;), was the U.S. dollar. Accordingly, monetary assets and liabilities of FibroGen Beijing in the currencies other than U.S. dollar were remeasured using exchange rates in effect at the end of the period. Revenues and costs in its local currency, Renminbi Yuan (&#8220;CNY&#8221;), were remeasured using average exchange rates for the period, except for costs related to those balance sheet items that were remeasured using historical exchange rates. The resulting remeasurement gains and losses were included within interest income and other, net in the consolidated statements of operations as incurred. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 1, 2020, FibroGen Beijing adopted CNY as its functional currency based on reassessment of the primary economic operational environment of FibroGen Beijing that is mainly associated with its growing manufacturing and product sales activities conducted in CNY. As such, monetary assets and liabilities of FibroGen Beijing in currencies other than CNY are remeasured using exchange rates in effect at the end of the period. The assets and liabilities of FibroGen Beijing are translated to U.S. dollars at exchange rates in effect at the balance sheet date. All income statement accounts are translated at monthly average exchange rates. Resulting foreign currency translation adjustments are recorded directly in accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity. This change in FibroGen Beijing&#8217;s functional currency was accounted for prospectively from April 1, 2020, and the prior consolidated financial statements were not restated. The related currency translation adjustment was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000617" name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax" contextRef="C_0000921299_20200401" decimals="-5" scale="6">1.3</ix:nonFraction> million at April 1, 2020 upon adoption.<span style="font-size:12pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of FibroGen, Inc. and all other subsidiaries is the U.S. dollar. Accordingly, monetary assets and liabilities in the non-functional currency of these subsidiaries are remeasured using exchange rates in effect at the end of the period. Revenues and costs in local currency are remeasured using average exchange rates for the period, except for costs related to those balance sheet items that are remeasured using historical exchange rates. The resulting remeasurement gains and losses are included within interest income and other, net in the consolidated statements of operations as incurred and have not been material for all periods presented.</p></ix:nonNumeric><ix:nonNumeric id="F_000543" name="us-gaap:UseOfEstimates" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000543_dcnt_3433e243-f644-4f53-9dea-d2eaaab81126">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000525_dcnt_b7f07bd9-1182-4710-804b-c639b9e8faf2" continuedAt="F_000525_dcnt_66ef5765-fa95-4ec8-9560-c2b6d43535f3"><ix:continuation id="F_000543_dcnt_3433e243-f644-4f53-9dea-d2eaaab81126">
</ix:continuation><ix:nonNumeric id="F_000544" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks associated with concentration of credit for cash and cash equivalents. Outside of short-term operating needs, the majority of cash on hand is invested in U.S. treasuries and money market funds. Any remaining cash is deposited with major financial institutions in the U.S., Finland, China and the Cayman Islands. At times, such deposits may be in excess of insured limits. <ix:nonNumeric id="F_000572" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000572_cnt_1">The Company has not experienced any loss on its deposits of cash and cash equivalents. Included in current assets are significant balances of accounts receivable as follows:</ix:nonNumeric></p><ix:continuation id="F_000572_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas Pharma Inc. (&#8220;Astellas&#8221;)&#8212;Related party</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000618" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="2" scale="-2">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000619" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231" decimals="2" scale="-2">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca AB (&#8220;AstraZeneca&#8221;)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000620" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231" decimals="2" scale="-2">26</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000621" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231" decimals="2" scale="-2">81</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company started selling roxadustat in China since late 2019 through a growing number of pharmaceutical distributors located in China. As of December 31, 2019, the aggregate accounts receivable from distributors was immaterial. As of December 31, 2020, along with the growing roxadustat sales in China, the aggregate accounts receivable from distributors represented <ix:nonFraction unitRef="U_xbrlipure" id="F_000622" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_fgenAccountsReceivableFromDistributorsMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_20200101_20201231" decimals="2" scale="-2">64</ix:nonFraction>% of the consolidated accounts receivable, with no material balance from any individual distributor.</p></ix:nonNumeric><ix:nonNumeric id="F_000545" name="fgen:OtherRisksAndUncertaintiesPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s business is subject to risks and uncertainties, including those related to COVID-19 and the related shelter-in-place, stay-at-home and other similar governmental orders issued in response to the COVID-19 pandemic.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, obtaining second source suppliers, <span style="font-size:9.5pt;">regulatory approval from the FDA or other regulatory authorities, </span>the results of clinical trials and the achievement of milestones, market acceptance of the Company&#8217;s product candidates, competition from other products and larger companies, protection of proprietary technology, strategic relationships and dependence on key individuals.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Starting in the first quarter of 2020, the Company experienced slower enrollment in its clinical trials due to the interruption caused by COVID-19 in the worldwide healthcare system. The future impact of the COVID-19 pandemic on the Company&#8217;s business is highly uncertain and difficult to predict. The COVID-19 pandemic may continue to affect enrollment in and initiation of the Company&#8217;s clinical trials, and could affect the Company&#8217;s supply chain if further social distancing and other business restrictions are put in place by various government entities, particularly in China and the U.S. COVID-19 may affect the health of the Company&#8217;s employees limiting the Company&#8217;s productivity. The COVID-19 pandemic may also impact the market for the Company&#8217;s products and product candidates in the future, affecting sales of the Company&#8217;s products. Such possible risks and uncertain impacts from the COVID-19 pandemic could have a material adverse effect on the Company&#8217;s drug development, commercialization revenues, and other portions of its business, and in particular, could impact the Company&#8217;s assumptions of accounts receivable collectability, fair value measurements of investments, liquidity, and development costs. The extent of the pandemic&#8217;s effect on the Company&#8217;s operational and financial performance will depend in large part on future developments, particularly with respect to the scope and severity of the pandemic, governmental restrictions put in place to fight the pandemic, and the development of vaccines and treatments for COVID-19. Due to the inherent uncertainty of the unprecedented and rapidly evolving situation, the Company is unable to estimate the likely impact of the COVID-19 pandemic on its future operations.</p></ix:nonNumeric><ix:nonNumeric id="F_000546" name="fgen:CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000546_dcnt_428f0a0c-ca4e-4d89-8cdd-8601105b0621">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Restricted Time Deposits</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with maturities of <ix:nonNumeric id="F_000623" name="fgen:HighlyLiquidInvestmentMaturityPeriod" contextRef="C_0000921299_20200101_20201231">three months or less</ix:nonNumeric> and that are used in the Company&#8217;s cash management activities at the date of purchase to be cash equivalents. Cash and cash equivalents also include money market accounts and various deposit accounts. Restricted time deposits include an irrevocable standby letter of credit as security deposit for a long-term property lease with the Company&#8217;s landlord. Restricted time deposits as of December&#160;31, 2020 and 2019 totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000624" name="fgen:RestrictedTimeDepositsNoncurrent" contextRef="C_0000921299_20201231" decimals="-5" scale="6">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000625" name="fgen:RestrictedTimeDepositsNoncurrent" contextRef="C_0000921299_20191231" decimals="-5" scale="6">2.1</ix:nonFraction>&#160;million, respectively. As of December&#160;31, 2020 and 2019, a total of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000626" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0000921299_us-gaapGeographicDistributionAxis_us-gaapGeographicDistributionForeignMember_20201231" decimals="-5" scale="6">66.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000627" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0000921299_us-gaapGeographicDistributionAxis_us-gaapGeographicDistributionForeignMember_20191231" decimals="-5" scale="6">11.9</ix:nonFraction> million, respectively, of the Company&#8217;s cash and cash equivalents was held outside of the U.S. in the Company&#8217;s foreign subsidiaries to be used primarily for the Company&#8217;s China operations.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000525_dcnt_66ef5765-fa95-4ec8-9560-c2b6d43535f3" continuedAt="F_000525_dcnt_8237d8ef-6acc-4e89-a55b-f704ed019cb3"><ix:continuation id="F_000546_dcnt_428f0a0c-ca4e-4d89-8cdd-8601105b0621">
</ix:continuation><ix:nonNumeric id="F_000547" name="us-gaap:InvestmentPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company&#8217;s investments consist of diversified bond funds and marketable equity investments. Those investments with original maturities of greater than three months and remaining maturities of less than <ix:nonNumeric id="F_000628" name="fgen:ShortTermInvestmentsMaximumMaturityPeriod" contextRef="C_0000921299_20200101_20201231" format="ixt-sec:durmonth">12</ix:nonNumeric>&#160;months (365 days) are considered short-term investments. Those investments with maturities greater than <ix:nonNumeric id="F_000629" name="fgen:LongTermInvestmentsMinimumMaturityPeriod" contextRef="C_0000921299_20200101_20201231" format="ixt-sec:durmonth">12</ix:nonNumeric> months (365 days) from the balance sheet date are considered long-term investments. When such investments are held, the Company&#8217;s investments classified as available-for-sale are recorded at fair value based upon quoted market prices at period end. Unrealized gains and losses for available-for-sale debt investments that are deemed temporary in nature are recorded in accumulated other comprehensive income (loss) as a separate component of stockholder&#8217; equity. Marketable equity securities are equity securities with readily determinable fair value, and are measured and recorded at fair value. Realized and unrealized gains or losses resulting from changes in value and sale of the Company&#8217;s marketable equity investments are recorded in other income (expenses) in the consolidated statement of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Premiums and discounts are amortized (accreted) over the life of the related security as an adjustment to its yield. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of investments sold.</p></ix:nonNumeric><ix:nonNumeric id="F_000548" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying amounts of certain of the Company&#8217;s financial instruments including cash equivalents, investments, receivables, accounts payable and accrued liabilities approximate fair value (refer to Note 5, <span style="font-style:italic;">Fair Value Measurements</span>).</p></ix:nonNumeric><ix:nonNumeric id="F_000549" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Trade accounts receivable</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The allowance for doubtful accounts is based on the Company&#8217;s assessment of the collectability of customer accounts. The Company makes estimates of expected credit losses for the allowance for doubtful accounts by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, current economic and regulatory conditions that may affect a customer&#8217;s ability to pay, and estimates of expected future losses. The Company&#8217;s bad debt expense for the years ended December&#160;31, 2020, 2019 and 2018 and the allowance for doubtful accounts as of December&#160;31, 2020 and 2019 were immaterial.</p></ix:nonNumeric><ix:nonNumeric id="F_000550" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000550_dcnt_d84580cb-6476-48de-83a4-9dd2b6c3ca58">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Credit losses &#8211; Available-for-sale debt securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company periodically assesses its available-for-sale investments for other-than-temporary impairment. For debt securities in an unrealized loss position, the Company first considers its intent to sell, or whether it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis. If either of these criteria are met, the amortized cost basis of such debt securities is written down to fair value through interest and other, net. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in the fair value of such debt securities has resulted from credit losses or other factors. The Company considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the securities, among other factors. If this assessment indicates that a credit loss may exist, the Company then compares the present value of cash flows expected to be collected from such securities to their amortized cost basis. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded through interest and other, net, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive income.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in the allowance for credit losses are recorded as provision for, or reversal of, credit loss expense. Losses are charged against the allowance when the Company believes that an available-for-sale security is confirmed uncollectable or when either of the criteria regarding intent or requirement to sell is met.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000525_dcnt_8237d8ef-6acc-4e89-a55b-f704ed019cb3" continuedAt="F_000525_dcnt_b895d815-f809-49d4-a25e-ba04d7e737fe"><ix:continuation id="F_000550_dcnt_d84580cb-6476-48de-83a4-9dd2b6c3ca58">
</ix:continuation><ix:nonNumeric id="F_000551" name="us-gaap:InventoryPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories are stated at the lower of cost or net realizable value, on a first-in, first-out, or FIFO, basis. The cost of the Company&#8217;s inventories in China is determined using full absorption and standard costing method. The Company reviews the standard cost of raw materials, work-in-process and finished goods annually and more often as appropriate to ensure that its inventories approximate current actual cost. The cost of the Company&#8217;s inventories in the U.S. uses actual costs to determine its cost basis. The cost of inventories includes direct material cost, direct labor and manufacturing overhead.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When the technical feasibility of the Company&#8217;s future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, the Company capitalizes pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the status in the validation process in significant jurisdictions, regulatory application and approval process, and terms and condition for future sale of such inventory or future alternative use. The pre-launch inventory cost includes purchase cost of raw materials, <span style="color:#000000;">cost paid to contract manufacturers for inventory manufacturing, freight and custom charges, and certain direct internal labor and overhead expenses.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company <span style="color:#auto;">periodically</span> reviews its inventories to identify obsolete, slow-moving, excess or otherwise unsaleable items. If obsolete, excess or unsaleable items are observed and there are no alternate uses for the <span style="color:#auto;">inventory</span>, an inventory valuation adjustment is recorded through a charge to cost of goods sold on the Company&#8217;s consolidated statements of operations. The establishment of inventory valuation reserves, together with the calculation of the amount of such reserves, requires judgment including consideration of many factors, such as estimates of future product demand and product expiration period, among others.</p></ix:nonNumeric><ix:nonNumeric id="F_000552" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Computer equipment, laboratory equipment, machinery and furniture and fixtures are depreciated over three to <ix:nonNumeric id="F_000631" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_000633" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20200101_20201231" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_000635" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20200101_20201231" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_000637" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231" format="ixt-sec:durwordsen">five years</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>. Leasehold improvements are recorded at cost and amortized over the term of the lease or their useful life, whichever is shorter.</p></ix:nonNumeric><ix:nonNumeric id="F_000553" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000553_dcnt_3b89c36f-a466-49d3-8e1a-eac00d4cd41d">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is or contains a lease at inception date when it is given control of the underlying assets. The Company elected the practical expedient not to apply the lease recognition and measurement requirements to short-term leases, which is any lease with a term of <ix:nonNumeric id="F_000638" name="fgen:ShortTermInvestmentsMaximumMaturityPeriod" contextRef="C_0000921299_20200101_20201231" format="ixt-sec:durmonth">12</ix:nonNumeric> months or less as of the commencement date that does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s building leases previously accounted for as build-to-suit arrangements prior to the adoption of Accounting Standards Codification (&#8220;ASC&#8221;) 842 - <span style="font-style:italic;">Leases</span> (&#8220;ASC 842&#8221;) are accounted for as finance leases under the requirements of ASC 842.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease right-of-use (&#8220;ROU&#8221;) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As its leases do not typically provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company reassesses the incremental borrowing rate periodically for application to any new leases or lease modifications, which approximates the rate at which the Company would borrow, on a secured basis, in the country where the lease was executed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease ROU assets include any lease payments made and initial direct costs incurred. The Company has lease agreements with lease and non-lease components. The Company generally accounts for each lease component separately from the non-lease components, and excludes all non-lease components from the calculation of minimum lease payments in measuring the ROU asset and lease liability. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease terms. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regarding leases denominated in a foreign currency, the related ROU assets and the corresponding ROU asset amortization costs are remeasured using the exchange rate in effect at the date of initial recognition&#59; the related lease liabilities are remeasured using the exchange rate in effect at the end of the reporting period&#59; the lease costs and interest expenses related to lease liability accretion are remeasured using average exchange rates for the reporting period.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000525_dcnt_b895d815-f809-49d4-a25e-ba04d7e737fe" continuedAt="F_000525_dcnt_b457da09-d8a8-45c5-a543-630223554f02"><ix:continuation id="F_000553_dcnt_3b89c36f-a466-49d3-8e1a-eac00d4cd41d">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases are included in finance lease ROU assets, finance lease liabilities, current and non-current on the Company&#8217;s consolidated balance sheets. Operating leases are included in other assets, accrued and other current liabilities, and other long-term liabilities on the Company&#8217;s consolidated balance sheets.</span></p></ix:continuation><ix:nonNumeric id="F_000554" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. If the Company determines that an impairment trigger has been met, the Company evaluates the realizability of its long-lived assets based on a comparison of projected undiscounted cash flows from use and eventual disposition with the carrying value of the related asset. Any write-downs (which are measured based on the difference between the fair value and the carrying value of the asset) are treated as permanent reductions in the carrying amount of the assets (asset group). Based on this evaluation, the Company believes that, as of each of the balance sheet dates presented, <ix:nonFraction unitRef="U_iso4217USD" id="F_000639" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="C_0000921299_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>ne of the Company&#8217;s long-lived assets were impaired. The Company&#8217;s impairment of long-lived assets for the years ended December&#160;31, 2020, 2019 and 2018 were immaterial.</p></ix:nonNumeric><ix:nonNumeric id="F_000555" name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000555_dcnt_1ad40589-5c6c-49fb-9cb8-37405d8d17c5">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenues under collaboration agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s collaboration agreements include multiple performance obligations comprised of promised services, or bundles of services, that are distinct. Services that are not distinct are combined with other services in the agreement until they form a distinct bundle of services. The Company&#8217;s process for identifying performance obligations and an enumeration of each obligation for each agreement is outlined in Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>. Determining the performance obligations within a collaboration agreement often involves significant judgment and is specific to the facts and circumstances contained in each agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified the following material promises under its collaboration agreements: (1) license of FibroGen technology, (2) the performance of co-development services, including manufacturing of clinical supplies and other services during the development period, and (3) manufacture of commercial supply. The evaluation as to whether these promises are distinct, and therefore represent separate performance obligations, is described in more details in Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For revenue recognition purposes, the Company determines that the term of its collaboration agreements begin on the effective date and ends upon the completion of all performance obligations contained in the agreements. In each agreement, the contract term is defined as the period in which parties to the contract have present and enforceable rights and obligations. The Company believes that the existence of what it considers to be substantive termination penalties on the part of the counterparty create sufficient incentive for the counterparty to avoid exercising its right to terminate the agreement unless in exceptionally rare situations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price for each collaboration agreement is determined based on the amount of consideration the Company expects to be entitled for satisfying all performance obligations within the agreement. The Company&#8217;s collaboration agreements include payments to the Company of one or more of the following: non-refundable upfront license fees&#59; co-development billings&#59; development, regulatory, and commercial milestone payments&#59; payments from sales of active pharmaceutical ingredient (&#8220;API&#8221;)&#59; payments from sales of bulk drug product and royalties on net sales of licensed products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront license fees are non-contingent and non-refundable in nature and are included in the transaction price at the point when the license fees become due to the Company. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-development billings resulting from the Company&#8217;s research and development efforts, which are reimbursable under its collaboration agreements, are considered variable consideration. Determining the reimbursable amount of research and development efforts requires detailed analysis of the terms of the collaboration agreements and the nature of the research and development efforts incurred. Determining the amount of variable consideration from co-development billings requires the Company to make estimates of future research and development efforts, which involves significant judgment. Co-development billings are allocated entirely to the co-development services performance obligation when amounts are related specifically to research and development efforts necessary to satisfy the performance obligation, and such an allocation is consistent with the allocation objective.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000525_dcnt_b457da09-d8a8-45c5-a543-630223554f02" continuedAt="F_000525_dcnt_cd22a94c-8e94-4b40-a105-7746f41a29ec"><ix:continuation id="F_000555_dcnt_1ad40589-5c6c-49fb-9cb8-37405d8d17c5" continuedAt="F_000555_dcnt_cdfe602d-48da-411f-af5c-4a8a83bf8870">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone payments are also considered variable consideration, which requires the Company to make estimates of when achievement of a particular milestone becomes probable. Similar to other forms of variable consideration, milestone payments are included in the transaction price when it becomes probable that such inclusion would not result in a significant revenue reversal. Milestone payments are therefore included in the transaction price when achievement of the milestone becomes probable.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For arrangements that include sales-based royalties and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from its collaboration arrangements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is allocated to performance obligations based on their relative standalone selling price (&#8220;SSP&#8221;), with the exception of co-development billings allocated entirely to co-development services performance obligations. The SSP is determined based on observable prices at which the Company separately sells the products and services. If an SSP is not directly observable, then the Company will estimate the SSP considering marketing conditions, entity-specific factors, and information about the customer or class of customer that is reasonably available. The process for determining SSP involves significant judgment and includes consideration of multiple factors, including assumptions related to the market opportunity and the time needed to commercialize a product candidate pursuant to the relevant license, estimated direct expenses and other costs, which include the rates normally charged by contract research and contract manufacturing organizations for development and manufacturing obligations, and rates that would be charged by qualified outsiders for committee services.&#160;&#160; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant judgment may be required in determining whether a performance obligation is distinct, determining the amount of variable consideration to be included in the transaction price, and estimating the SSP of each performance obligation. An enumeration of the Company&#8217;s significant judgments is outlined in Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each performance obligation identified within an arrangement, the Company determines the period over which the promised services are transferred and the performance obligation is satisfied. Service revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. For each performance obligation satisfied over time, the Company assesses the proper method to be used for revenue recognition, either an input method to measure progress toward the satisfaction of services or an output method of determining the progress of completion of performance obligation.<span style="font-weight:bold;font-style:italic;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Drug product revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue includes commercial-grade API or bulk drug product sales to AstraZeneca and Astellas, and is recognized when the Company fulfills the shipment obligations. The drug product revenue is accounted for as variable consideration, estimated at the time of sale using the expected value method. The Company applies significant judgment in estimating the variable consideration, which involves the use of significant assumptions such as the future list price adjustments set by the Japanese Ministry of Health, Labour and Welfare, product mix, and timing of processing of API into bulk drug product.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, FibroGen and Astellas entered into an amendment to the Japan Agreement that allows Astellas to manufacture roxadustat drug product for commercialization in Japan (the &#8220;Japan Amendment&#8221;). Under this amendment, FibroGen would continue to manufacture and supply roxadustat API to Astellas for the roxadustat commercial launch in Japan. The drug product revenue represents variable consideration and is estimated based on the quantity of product shipped, actual listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and possible future changes to the listed price, adjusted for the timing of and estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk drug product tablets, and estimated yield from the manufacture of bulk product tablets, among others.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Europe Agreement with Astellas, Astellas has an option to purchase roxadustat bulk drug product in support of commercial supplies. The drug product revenue amount represents variable consideration and was estimated based on the quantity of product shipped and an estimated price. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price per strength, which is estimated to be realized by Astellas from the end sale of roxadustat in its approved territories.</p></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000525_dcnt_cd22a94c-8e94-4b40-a105-7746f41a29ec" continuedAt="F_000525_dcnt_a691ea6f-a908-4a53-bb56-9a4f5264b718"><ix:continuation id="F_000555_dcnt_cdfe602d-48da-411f-af5c-4a8a83bf8870" continuedAt="F_000555_dcnt_9bf866d1-edbd-415d-9d76-08939874469c">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, the Company entered into Commercial Supply Agreement under the U.S./RoW Agreement with AstraZeneca to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The drug product revenue amount represents variable consideration and was estimated based on the quantity of product shipped and an estimated price. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price per strength, which is estimated to be realized by AstraZeneca from the end sale of roxadustat in its approved territories.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of variable consideration that is included in the transaction price may be constrained, and is included in the drug product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. Estimating variable consideration and the related constraint requires the use of significant management judgment. The Company reviews new information that may affect its variable consideration estimate at every reporting period and record revenue adjustment, if certain and material. Actual amounts of consideration ultimately received in the future may differ from the Company&#8217;s estimates, for which the Company will adjust these estimates and affect the drug product revenue in the period such variances become known. The amount constrained as of December 31, 2020 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000640" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="-5" scale="6">6.0</ix:nonFraction> million related to the drug product shipment to Astellas under the Europe Agreement in the fourth quarter of 2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As each of the Company&#8217;s collaboration agreements provide for annual true up to the considerations paid for its commercial supplies, the Company will re-evaluate the transaction price in each reporting period and record adjustment to revenue as uncertain events are resolved or other changes in circumstances occur.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product revenue, net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sells roxadustat in China through a number of pharmaceutical distributors located in China. These pharmaceutical distributors are the Company&#8217;s customers. Hospitals order roxadustat through a distributor and the Company ships the product directly to the distributors. The delivery of roxadustat to a distributor represents a single performance obligation.&#160;Distributors are responsible for delivering product to end users, primarily hospitals. Distributors bear inventory risk once they receive and accept the product. Product revenue is recognized when control of the promised good is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for the product. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000641" name="us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms" contextRef="C_0000921299_20200101_20201231">The period between the transfer of control of the promised goods and when the Company receives payment is based on a general 60-day payment term.</ix:nonNumeric> As such, product revenue is not adjusted for the effects of a significant financing component. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue is recorded at the net sales prices (transaction price) which includes the following estimates of variable consideration:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Price adjustment:</span><span style="color:#000000;"> In December 2019, China&#8217;s National Healthcare Security Administration released price guidance for roxadustat under the National Reimbursement Drug List (&#8220;NRDL&#8221;), effective January 1, 2020. Any channel inventories as of January 1, 2020 that had not been sold to hospitals by distributors, or to patients by hospitals, were eligible for a price adjustment under the price protection. The price adjustment is calculated based on estimated channel inventory levels at January 1, 2020. If price guidance changes in the future, the price adjustment will be calculated in the same manner&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Contractual sales rebate</span><span style="color:#000000;">: The contractual sales rebate is calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. The contractual sales rebate is recorded as a reduction to revenue at the point of sale to the distributor&#59;&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Key account hospital sales rebate</span><span style="color:#000000;">: An additional sales rebate is provided to a distributor for product sold to key account hospitals as a percentage of gross sales made by the distributor to eligible hospitals. This additional rebate is recorded as a reduction to revenue at the point of sale to the distributor&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Transfer fee discount</span><span style="color:#000000;">: The transfer fee discount is offered to a distributor who has its downstream distributors supply to eligible hospitals. This discount is calculated based on a percentage of gross sales made to the downstream distributors, and recorded as a reduction to revenue as incurred&#59; </span></p></td></tr></table></div></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000525_dcnt_a691ea6f-a908-4a53-bb56-9a4f5264b718" continuedAt="F_000525_dcnt_cf968815-556a-4a23-9d36-5fc2566a18f1"><ix:continuation id="F_000555_dcnt_9bf866d1-edbd-415d-9d76-08939874469c">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Sales return</span><span style="color:#000000;">: <ix:nonNumeric id="F_000642" name="fgen:DescriptionOfSalesReturn" contextRef="C_0000921299_20200101_20201231">Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product&#8217;s expiration date</ix:nonNumeric>&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Non-key account hospital listing award: </span><span style="color:#000000;">A one-time fixed-amount award is offered to a distributor who successfully lists the product with an eligible hospital, and who meets certain requirements. The Company considers this particular award to be an upfront payment to a customer within the definitions of ASC 606. The non-key account hospital listing award is capitalized when the distributor meets eligibility requirements, and amortized as reduction to product revenue over future sales orders made by the distributor until exhausted. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The calculation of the above variable consideration is based on gross sales to the distributor, or estimated utilizing best available information from the distributor, maximum known exposures and other available information including estimated channel inventory levels and estimated sales made by the distributor to hospitals, which involve a substantial degree of judgment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above rebates and discounts all together are eligible to be applied against the distributor&#8217;s future sales order, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible and in the same period that the related revenue is recorded. Due to the distributor&#8217;s legal right to offset, at each balance sheet date, the liability for rebates and discounts are presented as reductions of gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The distributor&#8217;s legal right of offset is calculated at the individual distributor level.<span style="font-weight:bold;color:#FF0000;"> </span></p></ix:continuation><ix:nonNumeric id="F_000556" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of independent research and development costs and the gross amount of costs associated with work performed under collaboration agreements. Research and development costs include employee-related expenses, expenses incurred under agreements with clinical research organizations, other clinical and preclinical costs and allocated direct and indirect overhead costs, such as facilities costs, information technology costs and other overhead. All research and development costs are expensed as incurred.</p></ix:nonNumeric><ix:nonNumeric id="F_000557" name="fgen:ClinicalTrialAccrualPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trial Accruals</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with clinical research organizations and clinical sites. The Company determines the costs to be recorded based upon validation with the external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.</p></ix:nonNumeric><ix:nonNumeric id="F_000558" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Selling, General and Administrative Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (&#8220;SG&#38;A&#8221;) expenses consist primarily of employee-related expenses for executive, operational, finance, legal, compliance and human resource functions. SG&#38;A expenses also include facility-related costs, professional fees, accounting and legal services, other outside services including co-promotional expenses, recruiting fees and expenses associated with obtaining and maintaining patents.</p></ix:nonNumeric><ix:nonNumeric id="F_000559" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000559_dcnt_46ec4ae2-e3b4-4761-b56a-1b2f669726bd">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes the asset and liability method of accounting for income taxes, which requires the recognition of deferred tax assets and liabilities for expected future consequences of temporary differences between the financial reporting and income tax bases of assets and liabilities using enacted tax rates. Management makes estimates, assumptions and judgments to determine the Company&#8217;s provision for income taxes and for deferred tax assets and liabilities, and any valuation allowances recorded against the Company&#8217;s deferred tax assets. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000525_dcnt_cf968815-556a-4a23-9d36-5fc2566a18f1" continuedAt="F_000525_dcnt_aec69cd0-97a3-4fb5-82c6-3d6d87a41957"><ix:continuation id="F_000559_dcnt_46ec4ae2-e3b4-4761-b56a-1b2f669726bd">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The calculation of the Company&#8217;s current provision for income taxes involves the use of estimates, assumptions and judgments while taking into account current tax laws, interpretation of current tax laws and possible outcomes of future tax audits. The Company has established reserves to address potential exposures related to tax positions that could be challenged by tax authorities. Although the Company believes its estimates, assumptions and judgments to be reasonable, any changes in tax law or its interpretation of tax laws and the resolutions of potential tax audits could significantly impact the amounts provided for income taxes in the Company&#8217;s consolidated financial statements.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The calculation of the Company&#8217;s deferred tax asset balance involves the use of estimates, assumptions and judgments while taking into account estimates of the amounts and type of future taxable income. Actual future operating results and the underlying amount and type of income could differ materially from the Company&#8217;s estimates, assumptions and judgments thereby impacting the Company&#8217;s financial position and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, the Company transferred certain intellectual property rights relating to its Chinese business between its wholly owned subsidiaries that are based in different tax jurisdictions. Refer to Note 13, <span style="font-style:italic;">Income Taxes</span>, for more information. The establishment of a deferred tax asset from the intra-entity transfer of intangible assets required the Company to make significant estimates and assumptions to determine the fair value of intellectual property rights transferred, which include but are not limited to, its expectations of discount rate, revenue volume and price.<span style="Background-color:#F8F9FA;color:#202124;"> The accuracy of these estimates could be affected by unforeseen events or actual results, and the sustainability of the Company&#8217;s future tax benefits is dependent upon the acceptance of these valuation estimates and assumptions by the taxing authorities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has adopted ASC 740-10, <span style="font-style:italic;">Accounting for Uncertainty in Income Taxes</span>, that prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company&#8217;s income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company includes interest and penalties related to unrecognized tax benefits within income tax expense in the Consolidated Statements of Operations. </p></ix:continuation><ix:nonNumeric id="F_000560" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000560_cnt_1">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains equity incentive plans under which incentive and nonqualified stock options are granted to employees and non-employee consultants. Compensation expense relating to non-employee stock options has not been material for all the periods presented.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures and recognizes compensation expense for all stock options and restricted stock units (&#8220;RSUs&#8221;) granted to its employees and directors based on the estimated fair value of the award on the grant date. The Company uses the Black-Scholes valuation model to estimate the fair value of stock option awards. The fair value is recognized as expense, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis. The Company believes that the fair value of stock options granted to non-employees is more reliably measured than the fair value of the services received. The determination of the grant date fair value of options using an option pricing model is affected by the Company&#8217;s estimated Common Stock fair value and requires management to make a number of assumptions including the expected life of the option, the volatility of the underlying stock, the risk-free interest rate and expected dividends.</p></ix:nonNumeric><ix:nonNumeric id="F_000561" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000561_dcnt_9615825e-8f70-47f5-81ec-b9042deacd11">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Income (Loss)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to report all components of comprehensive income (loss), including net loss, in the consolidated financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation adjustments. Comprehensive gains (losses) have been reflected in the consolidated statements of comprehensive income (loss) for all periods presented.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000525_dcnt_aec69cd0-97a3-4fb5-82c6-3d6d87a41957" continuedAt="F_000525_dcnt_a52fecfb-b2b3-4cbe-b953-8ed6f9bf4155"><ix:continuation id="F_000561_dcnt_9615825e-8f70-47f5-81ec-b9042deacd11">
</ix:continuation><ix:nonNumeric id="F_000562" name="fgen:RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000562_dcnt_75f44f1c-16f4-4009-912d-3d2d1b8066e3">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued and Adopted Accounting Guidance</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-15, <span style="font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. </span>This guidance requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This guidance was effective for annual reporting periods beginning after December 15, 2019, including interim periods. The Company adopted this guidance on January 1, 2020 using the prospective method, and the adoption of this guidance did not have material impact to the Company&#8217;s consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span>(&#8220;ASU 2016-13&#8221;). This guidance is intended to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. This guidance requires the measurement of financial assets with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. This guidance requires an impairment model, known as the current expected credit loss model, which is based on expected losses rather than incurred losses. Entities are required to carry an allowance for expected credit losses for financial assets, including most debt instruments (except those carried at fair value) and trade receivables. In November 2019, the FASB issued ASU No. 2019-11, <span style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments-Credit Losses </span>(&#8220;ASU 2019-11&#8221;)<span style="font-style:italic;">, </span>which has the same effective dates and transition requirements as ASU 2016-13. ASU 2016-13 and ASU 2019-11 were effective for annual reporting periods beginning after December 15, 2019 including interim periods. The Company&#8217;s investment portfolio primarily consists of U.S. Treasury bills and notes carried at fair value, which is required to follow the impairment model under Topic 326. The Company adopted this guidance on January 1, 2020. Based on the composition of the Company&#8217;s trade receivables and investment portfolio, economic conditions and historical credit loss activity, the adoption of this guidance did not have material impact to the Company&#8217;s consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02, <span style="font-style:italic;">Leases (Topic 842). </span>The Company adopted the lease guidance under ASC 842 as of January 1, 2019, using the modified retrospective transition method, through a cumulative-effect adjustment. The adoption of this guidance resulted in a reduction of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000643" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101" decimals="-5" sign="-" scale="6">8.7</ix:nonFraction> million to the Company&#8217;s accumulated deficit and also impacted various balance sheet line items in its consolidated balance sheet as of January 1, 2019 upon adoption. The adoption of this guidance did not have a material impact to the Company&#8217;s consolidated statement of operations or consolidated statement of cash flows for the year ended December 31, 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, the FASB issued ASU 2018-02, <span style="font-style:italic;">Income Statement - Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</span>. The Company adopted this guidance on January 1, 2019 using the modified retrospective approach, with a reduction of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000644" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_fgenImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member_20190101" decimals="-5" sign="-" scale="6">0.6</ix:nonFraction> million to its accumulated other comprehensive loss and an increase of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000645" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_fgenImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member_20190101" decimals="-5" scale="6">0.6</ix:nonFraction> million to its accumulated deficit as of January 1, 2019 upon adoption. The adoption of this guidance had no impact to the Company&#8217;s consolidated statement of operations or consolidated statement of cash flows for the year ended December 31, 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2016, the FASB issued ASU 2016-01, <span style="font-style:italic;">Financial Instruments-Overall (Subtopic 825-10)</span>. The Company adopted this guidance as of January 1, 2018 using the modified retrospective approach, with an increase of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000646" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20180101" decimals="-5" scale="6">1.3</ix:nonFraction> million to its accumulated other comprehensive loss and a reduction of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000647" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20180101" decimals="-5" sign="-" scale="6">1.3</ix:nonFraction> million to its accumulated deficit as of January 1, 2018 upon adoption. The adoption of this guidance had no impact to the Company&#8217;s consolidated statement of cash flows for the year ended December 31, 2018. </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000525_dcnt_a52fecfb-b2b3-4cbe-b953-8ed6f9bf4155"><ix:continuation id="F_000562_dcnt_75f44f1c-16f4-4009-912d-3d2d1b8066e3">
</ix:continuation><ix:nonNumeric id="F_000563" name="fgen:RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Guidance Not Yet Adopted</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the FASB issued ASU 2020-04, <span style="font-style:italic;">Reference Rate Reform (Topic 848): </span><span style="font-style:italic;color:#000000;">Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span> (&#8220;ASU<span style="font-style:italic;"> </span>2020<span style="font-style:italic;">-</span>04<span style="font-style:italic;">&#8221;</span>)<span style="font-style:italic;">,</span> which provides companies with optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform. This guidance is effective as of March 12, 2020 through December 31, 2022. Subsequently in January 2021, the FASB issued ASU 2021-01, <span style="font-style:italic;">Reference Rate Reform (Topic 848): Scope</span>, which clarifies ASU 2020-04 and provides certain optional expedients that allow derivative instruments impacted by changes in the interest rate used for margining, discounting or contract price alignment to qualify for certain optional relief. ASU 2021-01 is effective in the same timeframe as ASU 2020-04. The relief offered by this guidance, if adopted, is available to companies for the period March 12, 2020 through December 31, 2022. <span style="Background-color:#FFFFFF;">The Company has certain lease arrangements that are linked to LIBOR. The Company is in the process of evaluating options for transitioning away from LIBOR and expects to complete by the time LIBOR is phased out. The Company did not elect to apply any of the expedients or exceptions as of and for the year ended December 31, 2020 and is currently evaluating the impact on its consolidated financial statements and related disclosures upon adoption of this guidance.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span>. This guidance simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step up in the tax basis of goodwill, and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. This guidance is effective for annual reporting periods beginning after December 15, 2020 including interim periods, with early adoption permitted. The Company does not plan to early adopt this guidance and does not anticipate a material impact to its consolidated financial statements upon adoption of this guidance.</p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000526" name="fgen:AcquisitionAndVariableInterestEntityTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000526_dcnt_01b25f3d-2b79-4c37-b508-a071630babf0">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Acquisition and Variable Interest Entity</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 8, 2020, FibroGen Cayman, FibroGen Beijing, and FibroGen International (Hong Kong) Limited (collectively, &#8220;FibroGen China&#8221;) and AstraZeneca entered into an amendment, effective July 1, 2020, to the collaboration agreement for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in China (&#8220;China Agreement&#8221;), relating to the development and commercialization of roxadustat in China (the &#8220;China Amendment&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The China Amendment provides for the establishment of a jointly owned entity that will perform roxadustat distribution, as well as conduct sales and marketing through AstraZeneca. To prepare for the establishment of this jointly owned entity, in July 2020, FibroGen Beijing acquired <ix:nonFraction unitRef="U_xbrlipure" id="F_000648" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200731" decimals="INF" scale="-2">100</ix:nonFraction>% of the outstanding shares of Beijing Kangda Yongfu Pharmaceutical Co., LTD (&#8220;Kangda&#8221;) in exchange for cash consideration of CNY<ix:nonFraction unitRef="U_iso4217CNY" id="F_000649" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200701_20200731" decimals="-5" scale="6">15.0</ix:nonFraction> million (approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000650" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200701_20200731" decimals="-5" scale="6">2.1</ix:nonFraction> million). The purpose of the acquisition was to acquire a distribution license owned by Kangda for commercializing and distributing roxadustat in China. FibroGen Beijing continues to hold all of the regulatory licenses issued by China regulatory authorities and continues to be primarily responsible for regulatory, clinical, manufacturing, medical affairs and pharmacovigilance. The transaction costs related to the execution of the acquisition, primarily legal expenses, totaled CNY<ix:nonFraction unitRef="U_iso4217CNY" id="F_000651" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200731" decimals="-5" scale="6">5.0</ix:nonFraction> million and were shared equally with AstraZeneca. Therefore, the acquisition costs for FibroGen Beijing were CNY<ix:nonFraction unitRef="U_iso4217CNY" id="F_000652" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200701_20200731" decimals="-5" scale="6">2.5</ix:nonFraction> million (approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000653" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200701_20200731" decimals="-5" scale="6">0.4</ix:nonFraction> million).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the ASU No. 2017-01, <span style="font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</span>, the Company determined that the all of the value of Kangda was attributable to the acquired license, and therefore the transaction was accounted for as an asset acquisition. The Company allocated the entire purchase price of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000654" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAcquiredLicenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200701_20200731" decimals="-5" scale="6">2.5</ix:nonFraction> million to the acquired license that was recorded as an intangible asset, to be amortized over the duration of expected sales of roxadustat. There was no excess consideration over the estimated fair value. Through September 15, 2020, Kangda was consolidated as a wholly owned subsidiary of the Company. The amortization of the license was immaterial during the short period of time before Kangda was deconsolidated upon the establishment of the jointly owned entity described below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 15, 2020, FibroGen Beijing and AstraZeneca entered into an equity transfer agreement and shareholders agreement, under which FibroGen Beijing sold <ix:nonFraction unitRef="U_xbrlipure" id="F_000655" name="fgen:PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer" contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAstraZenecaABMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200915_20200915" decimals="3" scale="-2">48.9</ix:nonFraction>% of the outstanding shares of Kangda to AstraZeneca in exchange for cash consideration of CNY<ix:nonFraction unitRef="U_iso4217CNY" id="F_000656" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAstraZenecaABMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200915_20200915" decimals="-5" scale="6">7.3</ix:nonFraction> million (approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000657" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAstraZenecaABMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200915_20200915" decimals="-5" scale="6">1.0</ix:nonFraction> million). Concurrently with the equity transfer, the two parties renamed Kangda to Beijing Falikang Pharmaceutical Co. Ltd. (&#8220;Falikang&#8221;). Following the sale, FibroGen Beijing owns <ix:nonFraction unitRef="U_xbrlipure" id="F_000658" name="us-gaap:VariableInterestEntityOwnershipPercentage" contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAstraZenecaABMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200915_20200915" decimals="3" scale="-2">51.1</ix:nonFraction>% of the outstanding shares of Falikang. The gain (loss) resulting from the equity transfer was immaterial.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, based on the shareholders&#8217; resolutions of Falikang, in December 2020, FibroGen Beijing made cash contribution of CNY<ix:nonFraction unitRef="U_iso4217CNY" id="F_000659" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200101_20201231" decimals="-5" scale="6">8.9</ix:nonFraction> million (approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000660" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200101_20201231" decimals="-5" scale="6">1.4</ix:nonFraction> million) to Falikang, representing <ix:nonFraction unitRef="U_xbrlipure" id="F_000661" name="us-gaap:VariableInterestEntityOwnershipPercentage" contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200101_20201231" decimals="3" scale="-2">51.1</ix:nonFraction>% of Falikang&#8217;s registered capital of CNY<ix:nonFraction unitRef="U_iso4217CNY" id="F_000662" name="us-gaap:Capital" contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20201231" decimals="-5" scale="6">17.5</ix:nonFraction> million. AstraZeneca completed its cash contribution of <ix:nonFraction unitRef="U_xbrlipure" id="F_000663" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20201231" decimals="3" scale="-2">48.9</ix:nonFraction>% of Falikang&#8217;s registered capital in December 2020 as well.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000526_dcnt_01b25f3d-2b79-4c37-b508-a071630babf0">

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the guidance under ASC 810, the Company concluded that Falikang qualifies as a VIE. As Falikang is a distribution entity for roxadustat and AstraZeneca is the final decision maker for all the roxadustat commercialization activities, the Company lacks the power criterion while AstraZeneca meets both the power and economic criteria under ASC 810, to direct the activities of Falikang that most significantly impact its performance. Therefore, the Company is not the primary beneficiary of this VIE. As a result, the Company accounted for its investment in Falikang under the equity method, and Falikang is not consolidated into the Company&#8217;s consolidated financial statements. Accordingly, The Company recorded its total investments in Falikang of CNY<ix:nonFraction unitRef="U_iso4217CNY" id="F_000664" name="fgen:EquityMethodInvestmentAdditions" contextRef="C_0000921299_srtCounterpartyNameAxis_us-gaapVariableInterestEntityNotPrimaryBeneficiaryMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20200101_20201231" decimals="-5" scale="6">19.2</ix:nonFraction> million (approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000665" name="fgen:EquityMethodInvestmentAdditions" contextRef="C_0000921299_srtCounterpartyNameAxis_us-gaapVariableInterestEntityNotPrimaryBeneficiaryMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20200101_20201231" decimals="-5" scale="6">2.8</ix:nonFraction> million), which is the total of the <ix:nonFraction unitRef="U_xbrlipure" id="F_000666" name="us-gaap:VariableInterestEntityOwnershipPercentage" contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20200101_20201231" decimals="3" scale="-2">51.1</ix:nonFraction>% of Falikang&#8217;s equity and the acquisition costs, as an investment in unconsolidated subsidiary in other assets in the consolidated balance sheet. In addition, the Company recognized its proportionate share of the reported profits or losses of Falikang, beginning September 15, 2020, as other income (loss) in the consolidated statement of operations, and as an adjustment to its investment in unconsolidated subsidiary in the consolidated balance sheet. Falikang has not incurred material profit or loss to date. The Company may be required to provide shareholder loans to Falikang to meet necessary financial obligations as part of its operations. To date, these loans have been immaterial. </p><ix:nonNumeric id="F_000573" name="us-gaap:EquityMethodInvestmentsTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s&#160;equity&#160;method&#160;investment&#160;in Falikang was as follows for the year ended December 31, 2020 (in thousands):</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Entity</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership Percentage</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share of Net Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Currency</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Translation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000667" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20201231" decimals="3" scale="-2">51.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000668" name="us-gaap:EquityMethodInvestments" contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000669" name="fgen:EquityMethodInvestmentAdditions" contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,825</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000670" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20200101_20201231" decimals="-3" scale="3">202</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000671" name="fgen:EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20200101_20201231" decimals="-3" scale="3">105</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000672" name="us-gaap:EquityMethodInvestments" contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,728</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang is considered as a related party to the Company. See Note 14, <span style="font-style:italic;">Related Party Transactions</span>, for related disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an ongoing basis, the Company will re-evaluate the VIE assessment based on changes in facts and circumstances, including but not limited to, the shareholder loans received by Falikang and the execution of any future significant agreements between Falikang and its shareholders and/or other third parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will assess the impairment of its equity method&#160;investment whenever events or changes in circumstances indicate that a decrease in value of the investment has occurred that is other than temporary.</p></ix:continuation><ix:nonNumeric id="F_000527" name="fgen:CollaborativeArrangementAndRevenuesDisclosureTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000527_dcnt_4e0d1a82-8662-462b-9a0a-5d053451d249">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaboration Agreements and Revenues</p></td></tr></table></div><ix:nonNumeric id="F_000564" name="fgen:CollaborativeArrangementAndRevenuesPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000564_dcnt_f2ffc228-9fcc-4d4b-9843-c04cb1346aaa">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Astellas Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Japan Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2005, the Company entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (&#8220;Japan Agreement&#8221;). Under this agreement, Astellas paid license fees and other consideration totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000673" name="fgen:ProceedsFromUpfrontNonContingentAndTimeBasedPayments" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20090228" decimals="-5" scale="6">40.1</ix:nonFraction>&#160;million (such amounts were fully received as of February 2009). Under the Japan Agreement, the Company is also eligible to receive from Astellas an aggregate of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000674" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630" decimals="-5" scale="6">132.5</ix:nonFraction>&#160;million in potential milestone payments, comprised of (i)&#160;up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000675" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630" decimals="-5" scale="6">22.5</ix:nonFraction>&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of July 2016), (ii)&#160;up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000676" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630" decimals="-5" scale="6">95.0</ix:nonFraction>&#160;million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000677" name="fgen:CommercialSalesMilestone" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630" decimals="-5" scale="6">15.0</ix:nonFraction>&#160;million in milestone payments upon the achievement of specified commercial sales milestone. The Japan Agreement also provides for tiered payments based on net sales of product (as defined) in <ix:nonNumeric id="F_000678" name="fgen:AdditionalConsiderationBasedOnNetSales" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">the low 20% range of the list price</ix:nonNumeric> published by the Japanese Ministry of Health, Labour and Welfare, adjusted for certain elements, after commercial launch. The aggregate amount of the considerations received under the Japan Agreement, through December&#160;31, 2020 totals $<ix:nonFraction unitRef="U_iso4217USD" id="F_000679" name="fgen:CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-5" scale="6">105.1</ix:nonFraction> million, excluding drug product revenue that is discussed separately below.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fourth quarter of 2020, the Japanese Ministry of Health, Labour and Welfare approved EVRENZO&#174; (roxadustat) for the treatment of anemia of CKD in adult patients not on dialysis. This approval triggered a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000680" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201201_20201231" decimals="-5" scale="6">15.0</ix:nonFraction> million milestone payable to the Company by Astellas under the Japan Agreement. Accordingly, the consideration of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000681" name="fgen:TransactionPriceAllocatedToPerformanceObligations" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-5" scale="6">15.0</ix:nonFraction> million associated with this milestone was included in the transaction price and allocated to performance obligations under the Japan Agreement in the fourth quarter of 2020, substantially all of which was recognized as revenue during the year ended December 31, 2020 from performance obligations satisfied or partially satisfied.</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000527_dcnt_4e0d1a82-8662-462b-9a0a-5d053451d249" continuedAt="F_000527_dcnt_7a7f7806-4b00-42e7-804d-a978b2f52a4d"><ix:continuation id="F_000564_dcnt_f2ffc228-9fcc-4d4b-9843-c04cb1346aaa" continuedAt="F_000564_dcnt_f38b469f-19bc-4649-ad1a-863393159f19">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Septembe</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r 2019, the Japanese Ministry of Health, Labour and Welfare approved EVRENZO&#174; (generic name: roxadustat&#59; tradename EVRENZO&#174; in Japan) for the treatment of anemia associated with CKD in dialysis patients. This approval triggered a $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000682" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190901_20190930" decimals="-5" scale="6">12.5</ix:nonFraction> million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> milestone </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payable to the Company by Astellas under the Japan Agreement. Accordingly, the consideration of $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000683" name="fgen:TransactionPriceAllocatedToPerformanceObligations" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190930" decimals="-5" scale="6">12.5</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million associated with this milestone was included in the transaction price and allocated to performance obligations under the Japan Agreement in the t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hird quarter of 2019, substantially all of which was recognized as revenue during the year ended December 31, 2019 from performance obligations satisfied or partially satisfied.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2018, Astellas reported positive results from the final phase 3 CKD-dialysis trial of roxadustat in Japan, indicating that Astellas was ready to make an NDA submission for the treatment of anemia with roxadustat in CKD-dialysis patients in 2018. The Company evaluated the regulatory milestone payment associated with NDA submission in Japan based on variable consideration requirements under the current revenue standards and concluded that this milestone became probable of being achieved in the second quarter of 2018. Accordingly, the consideration of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000684" name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180401_20180630" decimals="-5" scale="6">15.0</ix:nonFraction> million associated with this milestone was included in the transaction price and allocated to performance obligations under the Japan Agreement in the second quarter of 2018, substantially all of which was recognized as revenue during the year ended December 31, 2018 from performance obligations satisfied or partially satisfied. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, FibroGen and Astellas entered into an amendment to the Japan Agreement that allows Astellas to manufacture roxadustat drug product for commercialization in Japan (the &#8220;Japan Amendment&#8221;). Under this amendment, FibroGen would continue to manufacture and supply roxadustat API<span style="font-weight:bold;"> </span>to Astellas for the roxadustat commercial launch in Japan. The commercial terms of the Japan Agreement relating to the transfer price for roxadustat for commercial use remain substantially the same, reflecting an adjustment for the manufacture of drug product by Astellas rather than FibroGen. The Company fulfilled shipment obligations under the term of the Japan Amendment in the second quarter of 2020 and in 2018. The related drug product revenue, as described in details under <span style="font-style:italic;">Drug Product Revenue</span> section below, were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000685" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231" decimals="-5" scale="6">4.3</ix:nonFraction> million, $(<ix:nonFraction unitRef="U_iso4217USD" id="F_000686" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20190101_20191231" decimals="-5" sign="-" scale="6">36.3</ix:nonFraction>) million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000687" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231" decimals="-5" scale="6">64.8</ix:nonFraction> million in the years ended December 31, 2020, 2019 and 2018, respectively. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Europe Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2006, the Company entered into a separate collaboration agreement with Astellas for the development and commercialization of roxadustat for the treatment of anemia in Europe, the Middle East, the Commonwealth of Independent States and South Africa (&#8220;Europe Agreement&#8221;). Under the terms of the Europe Agreement, Astellas paid license fees and other upfront consideration totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000688" name="fgen:ProceedsFromUpfrontNonContingentAndTimeBasedPayments" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20090228" decimals="-5" scale="6">320.0</ix:nonFraction> million (such amounts were fully received as of February 2009). The Europe Agreement also provides for additional development and regulatory approval milestone payments up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000689" name="fgen:DevelopmentAndRegulatoryApprovalMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060430" decimals="-5" scale="6">425.0</ix:nonFraction> million, comprised of (i)&#160;up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000690" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430" decimals="-5" scale="6">90.0</ix:nonFraction>&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of 2012), (ii)&#160;up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000691" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430" decimals="-5" scale="6">335.0</ix:nonFraction>&#160;million in milestone payments upon achievement of specified regulatory milestone events. Under the Europe Agreement, Astellas committed to fund <ix:nonFraction unitRef="U_xbrlipure" id="F_000692" name="fgen:PercentageOfFundingForCosts" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430" decimals="2" scale="-2">50</ix:nonFraction>% of joint development costs for Europe and North America, and all territory-specific costs. The Europe Agreement also provides for tiered payments based on net sales of product (as defined) in the <ix:nonNumeric id="F_000693" name="fgen:AdditionalConsiderationBasedOnNetSales" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">low 20% range</ix:nonNumeric>. The aggregate amount of the considerations received under the Europe Agreement through December&#160;31, 2020 totals $<ix:nonFraction unitRef="U_iso4217USD" id="F_000694" name="fgen:CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-5" scale="6">540.0</ix:nonFraction> million, excluding drug product revenue that is discussed separately below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2019, the Company received positive topline results from analyses of pooled major adverse cardiovascular event (&#8220;MACE&#8221;) and MACE+ data from its Phase 3 trials evaluating roxadustat as a treatment for dialysis and non-dialysis CKD patients, enabling Astellas to prepare for an MAA submission to the EMA in the second quarter of 2020, following the Company&#8217;s NDA submission to the FDA that was accepted for review in February 2020. The Company evaluated the two regulatory milestone payments associated with the planned MAA submission and concluded that these milestones became probable of being achieved in the second quarter of 2019. Accordingly, the total consideration of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000695" name="fgen:TransactionPriceAllocatedToPerformanceObligations" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190630" decimals="-5" scale="6">130.0</ix:nonFraction> million associated with these milestones was included in the transaction price and allocated to performance obligations under the Europe Agreement in the second quarter of 2019, of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_000696" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20191231" decimals="-5" scale="6">128.8</ix:nonFraction> million was recognized as revenue during the year ended December 31, 2019 and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000697" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-5" scale="6">0.8</ix:nonFraction> million was recognized as revenue during the year ended December 31, 2020, from performance obligations satisfied or partially satisfied. According to the Europe Agreement, these milestone payments are billable to Astellas upon the submission of an MAA, therefore this $<ix:nonFraction unitRef="U_iso4217USD" id="F_000698" name="us-gaap:Supplies" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20191231" decimals="-5" scale="6">130.0</ix:nonFraction> million was an unbilled contract asset as of December 31, 2019, and billed to Astellas upon the submission of an MAA in the second quarter of 2020 with the total $<ix:nonFraction unitRef="U_iso4217USD" id="F_000699" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630" decimals="-5" scale="6">130.0</ix:nonFraction> million received during the same quarter. </p></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000527_dcnt_7a7f7806-4b00-42e7-804d-a978b2f52a4d" continuedAt="F_000527_dcnt_9336a60c-a7f6-46f4-a2f0-552b5198f793"><ix:continuation id="F_000564_dcnt_f38b469f-19bc-4649-ad1a-863393159f19" continuedAt="F_000564_dcnt_e581a0cb-663f-4834-9cac-ec47e1412af9">

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the fourth quarter of 2018, the Company was engaged in the final stages of review with its partners over the proposed development of roxadustat for the treatment of chemotherapy-induced anemia (&#8220;CIA&#8221;).&#160;AstraZeneca and Astellas approved the program in December 2018 and January 2019, respectively. Costs associated with the development of this indication are expected to be shared 50-50 between the Company&#8217;s two partners.&#160;For revenue recognition purposes, the Company concluded that this new indication represents a modification to the Europe agreements and will be accounted for separately, meaning the development costs associated with the new indications are distinct from the original development costs. The development service period for roxadustat for the treatment of CIA under the Europe Agreement is estimated to continue through the second quarter of <ix:nonNumeric id="F_000700" name="fgen:EstimatedJointDevelopmentExtendedServicePeriod" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">2024</ix:nonNumeric> to allow for development of this indication.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Europe Agreement, Astellas has an option to purchase roxadustat bulk drug product in support of commercial supplies. The Company fulfilled a shipment obligation under the term of the Europe Amendment in the fourth quarter of 2020, as described in details under <span style="font-style:italic;">Drug Product Revenue</span> section below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">U.S./Rest of World (&#8220;RoW&#8221;) Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective July&#160;30, 2013, the Company entered into a collaboration agreement with AstraZeneca for the development and commercialization of roxadustat for the treatment of anemia in the U.S. and all other countries in the world, other than China, not previously licensed under the Astellas Europe and Astellas Japan Agreements (&#8220;U.S./RoW Agreement&#8221;). It also excludes China, which is covered by a separate agreement with AstraZeneca described below. Under the terms of the U.S./RoW Agreement, AstraZeneca paid upfront, non-contingent, non-refundable and time-based payments totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000701" name="fgen:ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">374.0</ix:nonFraction> million (such amounts were fully received as of June 2016). Under the U.S./RoW Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000702" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">875.0</ix:nonFraction> million in potential milestone payments, comprised of (i)&#160;up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000703" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">65.0</ix:nonFraction> million in milestone payments upon achievement of specified clinical and development milestone events, (ii)&#160;up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000704" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">325.0</ix:nonFraction> million in milestone payments upon achievement of specified regulatory milestone events, (iii)&#160;up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000705" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenDeferredApprovalMilestoneMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">160.0</ix:nonFraction>&#160;million in milestone payments related to activity by potential competitors and (iv)&#160;up to approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000706" name="fgen:CommercialSalesMilestone" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">325.0</ix:nonFraction> million in milestone payments upon the achievement of specified commercial sales events. The aggregate amount of the considerations received under the U.S./RoW Agreement through December&#160;31, 2020 totals $<ix:nonFraction unitRef="U_iso4217USD" id="F_000707" name="fgen:CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-5" scale="6">439.0</ix:nonFraction> million, excluding drug product revenue that is discussed separately below.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the U.S./RoW Agreement, the Company and AstraZeneca will share equally in the development costs of roxadustat not already paid for by Astellas, up to a total of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000708" name="fgen:SharedDevelopmentCosts" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20150101_20151231" decimals="-5" scale="6">233.0</ix:nonFraction> million (i.e. the Company&#8217;s share of development costs is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000709" name="fgen:SharedDevelopmentCosts" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibroGenIncMember_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20150101_20151231" decimals="-5" scale="6">116.5</ix:nonFraction> million, which was reached in 2015). Development costs incurred by FibroGen during the development period in excess of the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000710" name="fgen:SharedDevelopmentCosts" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20150101_20151231" decimals="-5" scale="6">233.0</ix:nonFraction> million (aggregated spend) are fully reimbursed by AstraZeneca. AstraZeneca will pay the Company tiered royalty payments on AstraZeneca&#8217;s future net sales (as defined in the agreement) of roxadustat in the <ix:nonNumeric id="F_000711" name="fgen:AdditionalConsiderationBasedOnNetSales" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">low 20% range</ix:nonNumeric>. In addition, the Company will receive a transfer price for shipment of commercial product based on a percentage of AstraZeneca&#8217;s net sales (as defined in the agreement) in the low- to mid-single digit range.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As mentioned above, during the second quarter of 2019, the Company received positive topline results from analyses of pooled MACE and MACE+ data from its Phase 3 trials for roxadustat, enabling the Company&#8217;s NDA submission to the FDA. The Company evaluated the regulatory milestone payment associated with this planned NDA submission and concluded that this milestone became probable of being achieved in the second quarter of 2019. Accordingly, the consideration of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000712" name="fgen:TransactionPriceAllocatedToPerformanceObligations" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190630" decimals="-5" scale="6">50.0</ix:nonFraction> million associated with this milestone was included in the transaction price and allocated to performance obligations under the combined arrangement in the second quarter of 2019, of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_000713" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20191231" decimals="-5" scale="6">42.4</ix:nonFraction> million was recognized as revenue during the year ended December 31, 2019 and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000714" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-5" scale="6">0.6</ix:nonFraction> million was recognized as revenue during the year ended December 31, 2020, from performance obligations satisfied or partially satisfied. The Company submitted such NDA in December 2019, which was accepted by FDA in February 2020. According to the U.S/RoW Agreement, this milestone payment is billable to AstraZeneca when the NDA is accepted by the FDA, therefore this $<ix:nonFraction unitRef="U_iso4217USD" id="F_000715" name="us-gaap:Supplies" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20191231" decimals="-5" scale="6">50.0</ix:nonFraction> million was an unbilled contract asset as of December 31, 2019, and was billed during the first quarter of 2020, the payment of which was fully received in April 2020.</p></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000527_dcnt_9336a60c-a7f6-46f4-a2f0-552b5198f793" continuedAt="F_000527_dcnt_1d891f3c-b554-4e60-a221-32bd79d0cd0d"><ix:continuation id="F_000564_dcnt_e581a0cb-663f-4834-9cac-ec47e1412af9" continuedAt="F_000564_dcnt_9175d4d0-e116-4e39-a9a6-8858e73909c1">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As mentioned above, AstraZeneca and Astellas approved the development of roxadustat for the treatment of CIA in December 2018 and January 2019, respectively. Costs associated with the development of this indication are expected to be shared 50/50 between AstraZeneca and Astellas.&#160;In addition, in December 2018, anemia of chronic inflammation and multiple myeloma was approved for development by AstraZeneca and is expected to be fully funded by them.&#160;For revenue recognition purposes, the Company concluded that the addition of these new indications represents a modification to the collaboration agreements and will be accounted for separately, meaning the development costs associated with the new indications are distinct from the original development costs. The development service period for roxadustat for the treatment of CIA, anemia of chronic inflammation and multiple myeloma under the AstraZeneca agreements is estimated to continue through the end of <ix:nonNumeric id="F_000716" name="fgen:EstimatedJointDevelopmentExtendedServicePeriod" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">2024</ix:nonNumeric>, to allow for development of these additional indications.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, the Company entered into Commercial Supply Agreement under the U.S./RoW Agreement with AstraZeneca to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. The Company shipped bulk drug product to AstraZeneca as pre-commercial supply for process validation purposes during the year ended December 31, 2020 and recognized related drug product revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000717" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231" decimals="-5" scale="6">4.6</ix:nonFraction> million, as described in details under <span style="font-style:italic;">Drug Product Revenue</span> section below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">China Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective July&#160;30, 2013, the Company (through its subsidiaries affiliated with China) entered into a collaboration agreement with AstraZeneca for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in China (&#8220;China Agreement&#8221;). Under the terms of the China Agreement, AstraZeneca agreed to pay upfront consideration totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000718" name="fgen:ProceedsFromUpfrontNonContingentAndNonRefundablePayments" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">28.2</ix:nonFraction>&#160;million (such amounts were fully received in 2014). Under the China Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000719" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">348.5</ix:nonFraction> million in potential milestone payments, comprised of (i)&#160;up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000720" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">15.0</ix:nonFraction> million in milestone payments upon achievement of specified clinical and development milestone events, (ii)&#160;up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000721" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">146.0</ix:nonFraction> million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000722" name="fgen:CommercialSalesAndOtherEventsMilestone" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730" decimals="-5" scale="6">187.5</ix:nonFraction> million in milestone payments upon the achievement of specified commercial sales and other events. The China Agreement is structured as a 50/50 profit or loss share (as defined), which was amended under the China Amendment discussed below in the third quarter of 2020, and provides for joint development costs (including capital and equipment costs for construction of the manufacturing plant in China), to be shared equally during the development. The aggregate amount of the considerations received under the China Agreement through December&#160;31, 2020 totals $<ix:nonFraction unitRef="U_iso4217USD" id="F_000723" name="fgen:CollaborativeArrangementAggregateConsideration" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-5" scale="6">77.2</ix:nonFraction> million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="C2">In December 2019, roxadustat has been included on the updated NRDL released by China&#8217;s National Healthcare Security Administration for the treatment of anemia in CKD, covering patients who are non-dialysis dependent as well as those who are dialysis-dependent. The inclusion on the NRDL triggered a total of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000724" name="fgen:PotentialMilestones" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231" decimals="-5" scale="6">22.0</ix:nonFraction> million milestones payable to the Company by AstraZeneca. Accordingly, the total consideration of $22.0 million associated with these milestones was included in the transaction price and allocated to performance obligations under the combined arrangement, of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_000725" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231" decimals="-5" scale="6">18.7</ix:nonFraction> million was recognized as revenue during the year ended December 31, 2019. The Company continued to recognize related revenue during the year ended December 31, 2020, from performance obligations satisfied or partially satisfied, and the amount was not material. This milestone payment was received during the first quarter of 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 17, 2018, FibroGen Beijing, received marketing authorization from the NMPA for roxadustat, a first-in-class HIF prolyl hydroxylase inhibitor, for the treatment of anemia caused by CKD in patients on dialysis. This approval triggered a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000726" name="fgen:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20181216_20181217" decimals="-5" scale="6">6.0</ix:nonFraction> million milestone payable to the Company by AstraZeneca. On December 29, 2018, FibroGen Beijing received First Manufacturing Approval for a Product in the Field in the Territory, which allows production for Phase 4 clinical studies, patients&#8217; early experience programs, donation programs, as well as to supply products for testing and assessments required prior to launch. This approval triggered a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000727" name="fgen:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20181228_20181229" decimals="-5" scale="6">6.0</ix:nonFraction> million milestone payable to the Company by AstraZeneca. Approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000728" name="fgen:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20180101_20181231" decimals="-5" scale="6">9.9</ix:nonFraction> million of the total $<ix:nonFraction unitRef="U_iso4217USD" id="F_000729" name="fgen:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231" decimals="-5" scale="6">12.0</ix:nonFraction> million milestone payables was recognized as revenue during the year ended December 31, 2018. The Company continued to recognize related revenues during the years ended December 31, 2019 and 2020, from performance obligations satisfied or partially satisfied, and the amounts were not material.</p></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000527_dcnt_1d891f3c-b554-4e60-a221-32bd79d0cd0d" continuedAt="F_000527_dcnt_2b2d0d8b-70a3-42ae-938f-d94e036809b4"><ix:continuation id="F_000564_dcnt_9175d4d0-e116-4e39-a9a6-8858e73909c1" continuedAt="F_000564_dcnt_ed39d9dc-fdec-4476-a7b5-1406abde85db">

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">China Amendment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 8, 2020, FibroGen China and AstraZeneca (together with FibroGen China, the &#8220;Parties&#8221;) entered into the China Amendment, effective July 1, 2020, relating to the development and commercialization of roxadustat in China. While the responsibilities of the Parties under the China Agreement remain largely the same, certain changes were made. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the China Amendment, in September 2020, FibroGen Beijing and AstraZeneca completed the establishment of a jointly owned entity, Falikang, which will perform roxadustat distribution, as well as conduct sales and marketing through AstraZeneca. See Note 3,<span style="font-style:italic;"> Acquisition and Variable Interest Entity</span>, for details. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the China Amendment, the Company is currently in the interim period. Under the China Amendment, the interim period is defined as the period from April 1, 2020 to the time when Falikang is fully operational, which commenced in January 2021. During the interim period, FibroGen continues to sell product directly to the distributors, who remain as the Company&#8217;s customers. Under the China Amendment, the calculation for profit or loss share has changed related to sales of roxadustat in China for the period from April 1, 2020 onwards. With effect from April 1, 2020, the Parties have changed the method under which commercial expenses incurred by AstraZeneca are calculated and billed. AstraZeneca&#8217;s co-promotion expenses for their sales and marketing efforts are now subject to a cap of a percentage of net sales. Once AstraZeneca has been fully reimbursed for their sales and marketing costs under the cap, AstraZeneca will bill the co-promotion expenses based on actual costs on a prospective basis. In addition, the China Amendment has allowed for a higher cost of manufacturing incurred by FibroGen Beijing to be included in the profit or loss share calculation, subject to an annual cap, among other changes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once Falikang is fully operational, substantially all direct product sales will be made by Falikang while the Company continues to sell product directly in few provinces in China. AstraZeneca will bill the co-promotion expenses to Falikang and to FibroGen Beijing, respectively, for its services provided to the respective entity. In addition, FibroGen Beijing will sell commercial product to Falikang based on an agreed upon transfer price. Development costs will continue to be shared 50/50 between the Parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, the interim period primarily includes the following activities:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.36%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Co-promotion expenses: The China Amendment revised the payment arrangements and calculation of the historical unpaid co-promotion expenses to AstraZeneca for its sales and marketing efforts associated with the commercial sales for roxadustat in China since the product launch. Under the previous China Agreement, payment of these historical co-promotion expenses was subject to certain profitability and cash flow thresholds. <ix:nonFraction unitRef="U_iso4217USD" id="F_000730" name="fgen:HistoricalCoPromotionCosts" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction> amount of the historical co-promotion costs had been paid prior to the China Amendment as these thresholds had not yet been met. Under the China Amendment, a portion of the historical unpaid co-promotion expenses was adjusted to reduce the amount owed by FibroGen Beijing and the current period co-promotion expenses are capped at a percentage of net roxadustat sales in China. As a result, in the third quarter of 2020, the Company reversed approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000731" name="fgen:ReversalOfAccruedCoPromotionExpenses" contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201001_20201231" decimals="-5" scale="6">84.4</ix:nonFraction> million of previously accrued co-promotion expenses payable, which was recorded as a reduction to selling, general and administrative expenses, where these expenses were initially recorded during the periods from the initiation of commercial activities in the first quarter of 2019 to the second quarter of 2020. The co-promotion expenses for the year ended December 31, 2020, capped at a percentage of net roxadustat sales in China, were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000732" name="fgen:CoPromotionExpenses" contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231" decimals="-5" scale="6">27.2</ix:nonFraction> million, included in the selling, general and administrative expenses. After this adjustment, as of December 31, 2020, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000734" name="fgen:AccruedLongTermCoPromotionLiabilityCurrent" contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_us-gaapAccountsPayableMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-5" scale="6">16.9</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000735" name="fgen:AccruedLongTermCoPromotionLiabilityCurrent" contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_us-gaapAccruedLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-2" scale="3">11.5</ix:nonFraction> million of the recalculated accrued co-promotion expenses were recorded in accounts payable and accrued liabilities, respectively, as they were anticipated to be paid within the next 12 months&#59; and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000733" name="fgen:AccruedLongTermCoPromotionLiabilityNonCurrent" contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-5" scale="6">27.4</ix:nonFraction> million of the recalculated accrued co-promotion expenses adjusted under the China Amendment remained in the long-term liabilities, as it is not anticipated to be paid within the next 12 months.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.36%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Profit share: Profit/loss share between FibroGen Beijing and AstraZeneca is based on a calculation of the current period net roxadustat sales in China and deductible expenses pursuant to the China Agreement. Based on the calculation revised under the China Amendment, profit was achieved during the third and fourth quarter of 2020. As a result, the Company recorded a profit share liability of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000736" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapBalanceSheetLocationAxis_fgenAccruedAndOtherCurrentLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-5" scale="6">7.0</ix:nonFraction> million to AstraZeneca as of December 31, 2020 in the accrued and other current liabilities, which correspondingly reduced the deferred revenue related to the performance obligation in accordance with the China Agreement.</span></p></td></tr></table></div></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000527_dcnt_2b2d0d8b-70a3-42ae-938f-d94e036809b4" continuedAt="F_000527_dcnt_d1c4b1f0-f845-44fa-90d5-a453e2359ab2"><ix:continuation id="F_000564_dcnt_ed39d9dc-fdec-4476-a7b5-1406abde85db" continuedAt="F_000564_dcnt_c67486e9-65b9-4ef7-8b93-8e6c4d335793">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.36%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accounting for the Astellas Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each of the Astellas agreements, the Company has evaluated the promised services within the respective arrangements and has identified performance obligations representing those services and bundles of services that are distinct.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Promised services that were not distinct have been combined with other promised services to form a distinct bundle of promised services, with revenue being recognized on the bundle of services rather than the individual services. There are no right-of-return provisions for the delivered items in the Astellas agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the transaction price for the Japan Agreement, excluding manufacturing services that is discussed separately below, included $<ix:nonFraction unitRef="U_iso4217USD" id="F_000737" name="fgen:ProceedsFromNonContingentUpfrontPayments" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="-5" scale="6">40.1</ix:nonFraction> million of non-contingent upfront payments, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000738" name="fgen:VariableConsiderationPaymentReceivedUponAchievementOfMilestone" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="-5" scale="6">65.0</ix:nonFraction> million of variable consideration related to payments for milestones considered probable of being achieved, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000739" name="fgen:VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="-5" scale="6">11.7</ix:nonFraction> million of variable consideration related to co-development billings. The transaction price for the Europe Agreement, excluding manufacturing services that is discussed separately below, included $<ix:nonFraction unitRef="U_iso4217USD" id="F_000740" name="fgen:ProceedsFromNonContingentUpfrontPayments" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="-5" scale="6">320.0</ix:nonFraction> million of non-contingent upfront payments, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000741" name="fgen:VariableConsiderationPaymentReceivedUponAchievementOfMilestone" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="-5" scale="6">220.0</ix:nonFraction> million of variable consideration related to payments for milestones considered probable of being achieved, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000742" name="fgen:VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="-5" scale="6">225.9</ix:nonFraction> million of variable consideration related to co-development billings. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For revenue recognition purposes, the Company determined that the term of each collaboration agreement with Astellas begins on the effective date and ends upon the completion of all performance obligations contained in the agreement. The contract term is defined as the period in which parties to the contract have present and enforceable rights and obligations. The Company believes that the requirement to continue funding development for a substantive period of time and loss of product rights, along with non-refundable upfront payments already remitted by Astellas, create significant disincentive for Astellas to exercise its right to terminate the agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the Astellas agreements, the Company allocated the transaction price to the various performance obligations based on the relative SSP of each performance obligation, with the exception of co-development billings allocated entirely to co-development services performance obligations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the technology license under the Japan Agreement and the Europe Agreement, SSP was determined primarily by using the discounted cash flow (&#8220;DCF&#8221;) method, which aggregates the present value of future cash flows to determine the valuation as of the effective date of each of the agreements. The DCF method involves the following key steps: 1) the determination of cash flow forecasts and 2) the selection of a range of comparative risk-adjusted discount rates to apply against the cash flow forecasts. The discount rates selected were based on expectations of the total rate of return, the rate at which capital would be attracted to the Company and the level of risk inherent within the Company. The discounts applied in the DCF analysis ranged from <ix:nonFraction unitRef="U_xbrlipure" id="F_000743" name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueDiscountedCashFlowMember_20201231" decimals="INF">17.5</ix:nonFraction>% to <ix:nonFraction unitRef="U_xbrlipure" id="F_000744" name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueDiscountedCashFlowMember_20201231" decimals="INF">20.0</ix:nonFraction>%. The Company&#8217;s cash flow forecasts were derived from probability-adjusted revenue and expense projections by territory. Such projections included consideration of taxes and cash flow adjustments. The probability adjustments were made after considering the likelihood of technical success at various stages of clinical trials and regulatory approval phases. SSP also considered certain future royalty payments associated with commercial performance of the Company&#8217;s compounds, transfer prices and expected gross margins.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promised services that were analyzed, along with their general timing of satisfaction and recognition as revenue, are as follows:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-style:normal;color:#000000;"></span><span style="color:#000000;">License to the Company&#8217;s technology existing at the effective date of the agreements.</span><span style="font-style:normal;color:#000000;"> For both of the Astellas agreements, the license was delivered at the beginning of the agreement term. In both cases, the Company concluded at the time of the agreement that its collaboration partner, Astellas, would have the knowledge and capabilities to fully exploit the licenses without the Company&#8217;s further involvement. However, the Japan Agreement has contractual limitations that might affect Astellas&#8217; ability to fully exploit the license and therefore, potentially, the conclusion as to whether the license is capable of being distinct. In the Japan Agreement, Astellas does not have the right to manufacture commercial supplies of the drug. In order to determine whether this characteristic of the agreement should lead to a conclusion that the license was not distinct in the context of the agreement, the Company considered the ability of Astellas to benefit from the license together with other resources readily available to Astellas. Finally, the Company considered the fact that at the time of delivery of the license, the development services were beyond the preclinical development phase and any remaining development work in either agreement would not be expected to result in any significant modification or customization to the licensed technology. As such, the development services are separately identifiable from the licensed technology, indicating that the license is a distinct performance obligation.</span></p></td></tr></table></div></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000527_dcnt_d1c4b1f0-f845-44fa-90d5-a453e2359ab2" continuedAt="F_000527_dcnt_799e6089-89a2-47fd-a22f-82daea74fe9b"><ix:continuation id="F_000564_dcnt_c67486e9-65b9-4ef7-8b93-8e6c4d335793" continuedAt="F_000564_dcnt_9b35570e-2f64-460e-a05a-9a1ee1842ed5">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Manufacturing rights.</span><span style="font-style:normal;"> In the case of the Japan Agreement, the Company retained manufacturing rights largel</span><span style="font-style:normal;">y because of the way the parties chose for FibroGen to be compensated under the agreement. At the time the agreement was signed, the Company believed that it was more advantageous upon commercialization to have a transfer price revenue model in place as op</span><span style="font-style:normal;">posed to a traditional sales-based model. The manufacturing process does not require specialized knowledge or expertise uniquely held by FibroGen, and notwithstanding contractual restrictions, Astellas could employ manufacturing services from readily avail</span><span style="font-style:normal;">able third parties in order to benefit from the license. Therefore, along with the foregoing paragraph, the Company determined that the license in Japan is a distinct performance obligation despite the retention of manufacturing rights by the Company.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In summary, the Company concludes that item (1) represents a performance obligation. The portion of the transaction price allocated to this performance obligation based on a relative SSP basis is recognized as revenue in its entirety at the point in time the license transfers to Astellas.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.42%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-style:normal;color:#000000;"></span><span style="color:#000000;">Co-development services (Europe Agreement). </span><span style="font-style:normal;color:#000000;">This promise relates to co-development services that were reasonably expected to be performed by the Company at the time the collaboration agreement was signed and is considered distinct. Co-development billings are allocated entirely to the co-development services performance obligation as amounts are related specifically to research and development efforts necessary to satisfy the performance obligation, and such an allocation is consistent with the allocation objective. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours and out-of-pocket expenses incurred relative to total expected costs to be incurred. The measure of progress is updated each reporting period. Co-development services are expected to continue over the development period that is currently estimated to continue through the end of 2021. In addition, the Company concluded that the new indication related to CIA approved in January 2019 represents a modification to the Europe agreements at that time and will be accounted for separately, for which the development service period is estimated to continue through the second quarter of <ix:nonNumeric id="F_000745" name="fgen:CoDevelopmentServicesEstimatedContinuationYear" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">2024</ix:nonNumeric>. There was <ix:nonFraction unitRef="U_iso4217USD" id="F_000746" name="fgen:ProvisionForCoDevelopmentServices" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> provision for co-development services in the Japan Agreement. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-style:normal;color:#000000;"></span><span style="color:#000000;">License to the Company&#8217;s technology developed during the term of the agreement and development (referred to as &#8220;when and if available&#8221;) and information sharing services. </span><span style="font-style:normal;color:#000000;">These promises are generally satisfied throughout the term of the agreements.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-style:normal;color:#000000;"></span><span style="color:#000000;">Manufacturing of clinical supplies of products.</span><span style="font-style:normal;color:#000000;"> This promise is satisfied as supplies for clinical product are delivered for use in the Company&#8217;s clinical trial programs during the development period, or pre-commercialization period.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(5)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-style:normal;color:#000000;"></span><span style="color:#000000;">Committee service</span><span style="font-style:normal;color:#000000;">. This promise is satisfied throughout the course of the agreements as meetings are attended.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0.04%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Items (2)-(5) are bundled into a single performance obligation that is distinct given the fact that all are highly interrelated during the development period (pre-commercial phase of development) such that satisfying them independently is not practicable. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours or full time equivalents and out-of-pocket expenses incurred relative to total expected costs to be incurred. The measure of progress is updated each reporting period.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(6)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-style:normal;color:#000000;"></span><span style="color:#000000;">Manufacturing commercial supplies of products.</span><span style="font-style:normal;color:#000000;"> This promised service is distinct as services are not interrelated with any of the other performance obligations. Payments received for commercial supplies of products represent sales-based payments related predominately to the license of intellectual property under both Astellas agreements. Revenue is recognized as supplies are shipped for commercial use during the commercialization period. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Japan Amendment the drug product revenue represents variable consideration and is estimated based on the quantity of product shipped, actual listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and possible future changes to the listed price, adjusted for estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk drug product tablets, and estimated yield from the manufacture of bulk product tablets, among others.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Europe Agreement, the drug product revenue amount represents variable consideration and is estimated based on the quantity of product shipped and an estimated price. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price per strength, which is estimated to be realized by Astellas from the end sale of roxadustat in its approved territories.</p></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000527_dcnt_799e6089-89a2-47fd-a22f-82daea74fe9b" continuedAt="F_000527_dcnt_d4def8ce-7528-499e-8b47-ffe815d9822d"><ix:continuation id="F_000564_dcnt_9b35570e-2f64-460e-a05a-9a1ee1842ed5" continuedAt="F_000564_dcnt_398b0dd1-03db-40fc-8241-0e9eca5f2d5b">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of variable consideration that is included in the transaction price may be constrained, and is included in the drug product revenue only to the extent that </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it is probable that a significant re</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">versal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. Estimating variable consideration and the related constraint requires the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use of significant management judgment. The Company reviews new information that may affect its variable consideration estimate at every reporting period and records an adjustment to revenue, if certain and material</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Actual amounts of consideration </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ultimately received in the future may differ from the Company&#8217;s estimates, for which the Company will adjust these estimates and affect the drug product revenue in the period such variances become known.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As each of the agreements provides for annual true up to the considerations paid for its commercial supplies, the Company will re-evaluate the transaction price in each reporting period and record adjustment to revenue as uncertain events are resolved or other changes in circumstances occur. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accounting for the AstraZeneca Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluated whether the U.S./RoW Agreement and the China Agreement should be accounted for as a single or separate arrangements and concluded that the agreements should be accounted for as a single arrangement with the presumption that two or more agreements executed with a single customer at or around the same time should be presumed to be a single arrangement. The key points the Company considered in reaching this conclusion are as follows: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">While the two agreements were largely negotiated separately, those negotiations proceeded concurrently, and were intended to be completed contemporaneously, presuming AstraZeneca</span><span style="font-weight:bold;color:#000000;"> </span><span style="color:#000000;">decided to proceed with licenses in all regions available. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Throughout negotiations for both agreements, the Company and the counterparties understood and considered the possibility that one arrangement may be executed without the execution of the other arrangement. However, the preference for the Company and the counterparties during the negotiations was to execute both arrangements concurrently.&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The two agreements were executed as separate agreements because different development, regulatory and commercial approaches required certain terms of the agreements to be structured differently, rather than because the Company or the counterparties considered the agreements to be fundamentally separate negotiations.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, as the agreements are being accounted for as a single arrangement, upfront and other non-contingent consideration received and to be received has been and will be pooled together and allocated to each of the performance obligations in both the U.S./RoW Agreement and the China Agreement based on their relative SSPs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each of the AstraZeneca agreements, the Company has evaluated the promised services within the respective arrangements and has identified performance obligations representing those services and bundled services that are distinct.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Promised services that were not distinct have been combined with other promised services to form a distinct bundle of promised services, with revenue being recognized on the bundle of services rather than the individual promised services. There are no right-of-return provisions for the delivered items in the AstraZeneca agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the transaction price for the U.S./RoW Agreement and the China Agreement, excluding manufacturing services that is discussed separately below, included $<ix:nonFraction unitRef="U_iso4217USD" id="F_000747" name="fgen:ProceedsFromNonContingentUpfrontPayments" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231" decimals="-5" scale="6">402.2</ix:nonFraction> million of non-contingent upfront payments, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000748" name="fgen:VariableConsiderationPaymentReceivedUponAchievementOfMilestone" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231" decimals="-5" scale="6">114.0</ix:nonFraction> million of variable consideration related to payments for milestones considered probable of being achieved, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000749" name="fgen:VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231" decimals="-5" scale="6">564.9</ix:nonFraction> million of variable consideration related to co-development billings, offset by $<ix:nonFraction unitRef="U_iso4217USD" id="F_000750" name="fgen:VariableConsiderationRelatedToProfitShare" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231" decimals="-5" scale="6">7.0</ix:nonFraction> million of variable consideration related to profit share under the China Amendment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the AstraZeneca agreements, the Company allocated the transaction price to the various performance obligations based on the relative SSP of each performance obligation, with the exception of co-development billings and commercial sale of product. Co-development billings under the U.S./RoW Agreement were allocated entirely to the U.S./RoW co-development services performance obligation, and co-development billings under the China Agreement were allocated entirely to the combined performance obligation under the China Agreement. Commercial sale of product under the U.S./ROW Agreement is entirely allocated to the manufacturing commercial supply of products performance obligation, and commercial sale of product under the China Agreement is allocated entirely to the combined China performance obligation.</p></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000527_dcnt_d4def8ce-7528-499e-8b47-ffe815d9822d" continuedAt="F_000527_dcnt_6ca7642e-9692-437b-9d18-36e4882b3071"><ix:continuation id="F_000564_dcnt_398b0dd1-03db-40fc-8241-0e9eca5f2d5b" continuedAt="F_000564_dcnt_8e2d21c3-090c-4a7c-8b16-5c4addd3c653">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For revenue recognition purposes, the Company determined that the term of its collaboration agreements with AstraZeneca begin on the effective date and ends upon the completion of all performance obligations c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ontained in the agreements. T</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he contract term is defined as the period in which parties to the contract have present and enforceable rights and obligations. The Company believes that the requirement to continue funding development for a substantive period </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of time and the loss of product rights, along with non-refundable upfront payments already remitted by AstraZeneca, represent substantive termination penalties that create significant disincentive for AstraZeneca to exercise its right to terminate the agre</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ement.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the technology license under the AstraZeneca U.S./RoW Agreement, SSP was determined based on a two-step process. The first step involved determining an implied royalty rate that would result in the net present value of future cash flows to equal to zero (i.e. where the implied royalty rate on the transaction would equal the target return for the investment). This results in an upper bound estimation of the magnitude of royalties that a hypothetical acquirer would reasonably pay for the forecasted cash flow stream. The Company&#8217;s cash flow forecasts were derived from probability-adjusted revenue and expense projections. Such projections included consideration of taxes and cash flow adjustments. The probability adjustments were made after considering the likelihood of technical success at various stages of clinical trials and regulatory approval phases. The second step involved applying the implied royalty rate, which was determined to be <ix:nonFraction unitRef="U_xbrlipure" id="F_000751" name="fgen:RoyaltyRateOnNetRevenue" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="2" scale="-2">40</ix:nonFraction>%, against the probability-adjusted projected net revenues by territory and determining the value of the license as the net present value of future cash flows after adjusting for taxes. The discount rate utilized was <ix:nonFraction unitRef="U_xbrlipure" id="F_000752" name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="C_0000921299_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueDiscountedCashFlowMember_20201231" decimals="1">17.5</ix:nonFraction>%.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">U.S./RoW Agreement:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promised services that were analyzed, along with their general timing of satisfaction and recognition as revenue, are as follows:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-style:normal;color:#000000;"></span><span style="color:#000000;">License to the Company&#8217;s technology existing at the effective date of the agreements.</span><span style="font-style:normal;color:#000000;"> For the U.S./RoW Agreement, the license was delivered at the beginning of the agreement term. The Company concluded that AstraZeneca has the knowledge and capabilities to fully exploit the license under the U.S./RoW Agreement without the Company&#8217;s further involvement. Finally, the Company considered the fact that at the time of delivery of the license, the development services were beyond the preclinical development phase and any remaining development work would not be expected to result in any significant modification or customization to the licensed technology. As such, the development services are separately identifiable from the licensed technology, indicating that the license is a distinct performance obligation. Therefore, the Company has concluded that the license is distinct and represents a performance obligation. The portion of the transaction price allocated to this performance obligation based on a relative SSP basis is recognized as revenue in its entirety at the point in time the license transfers to AstraZeneca.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-style:normal;color:#000000;"></span><span style="color:#000000;">Co-development services. </span><span style="font-style:normal;color:#000000;">This promise relates to co-development services that were reasonably expected to be performed by the Company at the time the collaboration agreement was signed and is distinct. Co-development billings are allocated entirely to the co-development services performance obligation as amounts are related specifically to research and development efforts necessary to satisfy the performance obligation, and such an allocation is consistent with the allocation objective. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours or full time equivalents and out-of-pocket expenses incurred relative to total expected costs to be incurred. Co-development services are expected to continue over the development period that is currently estimated to continue through the end of the first quarter of 2021. In addition, the Company concluded that the addition of the new indications related to CIA, anemia of chronic inflammation and multiple myeloma approved during the fourth quarter of 2018 represents a modification to the collaboration agreements and will be accounted for separately, for which the joint development service period is estimated to continue through the end of <ix:nonNumeric id="F_000753" name="fgen:CoDevelopmentServicesEstimatedContinuationYear" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">2024</ix:nonNumeric>. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-style:normal;color:#000000;"></span><span style="color:#000000;">Manufacturing of clinical supplies of products.</span><span style="font-style:normal;color:#000000;"> This promise is satisfied as supplies for clinical product are delivered for use in the Company&#8217;s clinical trial programs during the development period, or pre-commercialization period.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-style:normal;color:#000000;"></span><span style="color:#000000;">Information sharing and committee service.</span><span style="font-style:normal;color:#000000;"> These promises are satisfied throughout the course of the agreement as services are provided.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Items (2)-(4) are bundled into a single performance obligation that is distinct given the fact that all are highly interrelated during the development period (pre-commercial phase of development) such that delivering them independently is not practicable. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours or full time equivalents and out-of-pocket expenses incurred relative to total expected costs to be incurred. The measure of progress is updated each reporting period.</p></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000527_dcnt_6ca7642e-9692-437b-9d18-36e4882b3071" continuedAt="F_000527_dcnt_f8ecd33f-6913-46cf-afd2-111f012458b2"><ix:continuation id="F_000564_dcnt_8e2d21c3-090c-4a7c-8b16-5c4addd3c653" continuedAt="F_000564_dcnt_acd5cfd8-a455-493a-ab96-288f4949d310">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(5)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;"></span><span style="font-style:normal;color:#000000;"></span><span style="color:#000000;">Manufacturing commercial supplies of products. </span><span style="font-style:normal;color:#000000;">This promise is distinct as services are not interrelated with any of the other</span><span style="font-style:normal;color:#000000;"> performance obligations. Revenue is recognized as supplies are shipped for commercial use during the commercialization period. </span><span style="font-style:normal;color:#000000;">The drug product revenue amount represents variable consideration and is estimated based on the quantity of product shipped and </span><span style="font-style:normal;color:#000000;">an estimated price for each individual purchase order. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price, which is estimated to be realized by AstraZeneca from the end sale o</span><span style="font-style:normal;color:#000000;">f roxadustat in its approved territories.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of variable consideration that is included in the transaction price may be constrained, and is included in the drug product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. Estimating variable consideration and the related constraint requires the use of significant management judgment. The Company reviews new information that may affect its variable consideration estimate at every reporting period and records an adjustment to revenue, if certain and material. Actual amounts of consideration ultimately received in the future may differ from the Company&#8217;s estimates, for which the Company will adjust these estimates and affect the drug product revenue in the period such variances become known.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the agreement provides for an annual true up to the considerations paid for its commercial supplies, the Company will re-evaluate the transaction price in each reporting period and record an adjustment to revenue as uncertain events are resolved or other changes in circumstances occur. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">China Agreement:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promised services that were analyzed are consistent with the U.S./RoW Agreement, except for license to the Company&#8217;s technology existing at the effective date of the agreement, described as follows:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">License to the Company&#8217;s technology existing at the effective date of the agreement.</span><span style="color:#000000;"> The license was delivered at the beginning of the agreement term. However, the China Agreement with AstraZeneca has contractual limitations that might affect AstraZeneca&#8217;s ability to fully exploit the license and therefore, potentially, the conclusion as to whether the license is distinct in the context of the agreement. In the China Agreement, AstraZeneca does not have the right to manufacture commercial supplies of the drug. In order to determine whether this characteristic of the arrangement should lead to a conclusion that the license was not distinct in the context of the agreement, the Company considered the ability of AstraZeneca to benefit from the license on its own or together with other resources readily available to AstraZeneca.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the China Agreement, the Company retained manufacturing rights as an essential part of a strategy to pursue domestic regulatory pathway for product approval which requires the regulatory licensure of the manufacturing facility in order to commence commercial shipment. The prospects for the collaboration as a whole would have been substantially different had manufacturing rights been provided to AstraZeneca. We hold the rights to manufacture commercial drug product in China. Therefore, AstraZeneca cannot benefit from the license on its own or together with other readily available resources. Accordingly, all the promises identified, including the license, co-development services and manufacturing of commercial supplies,, under the China Agreement have been bundled into a single performance obligation and amounts of the transaction price allocable to this performance obligation are deferred until control of the manufactured commercial drug product has begun to transfer to AstraZeneca. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the China Amendment, once Falikang is fully operational, which commenced in January 2021, substantially all product sales will be made by Falikang directly to the distributors in China, while the Company continues to sell directly in few provinces in China. Revenue will be recognized upon the transfer of control of commercial drug product to Falikang. For the Company&#8217;s direct sales of commercial drug product, revenue will be recognized when control of the promised good is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for the product.</p></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000527_dcnt_f8ecd33f-6913-46cf-afd2-111f012458b2" continuedAt="F_000527_dcnt_b4b10d2d-a2aa-4659-84c3-a5e6c62e4909"><ix:continuation id="F_000564_dcnt_acd5cfd8-a455-493a-ab96-288f4949d310">
</ix:continuation>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Summary of revenue recognized under the collaboration agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes the accounting treatment for the various performance obligations pursuant to each of the Astellas and AstraZeneca agreements. License amounts identified below are included in the &#8220;License revenue&#8221; line item in the consolidated statements of operations. All other elements identified</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> below are included in the &#8220;Development and other revenue&#8221; line item in the consolidated statements of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000574" name="fgen:ContractWithCustomerMilestoneMethodTableTextBlock" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_20200101_20201231" escape="true" continuedAt="F_000574_cnt_1">Amounts recognized as license revenue and development revenue under the Japan Agreement with Astellas were as follows (in thousands):</ix:nonNumeric></p><ix:continuation id="F_000574_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Obligation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000754" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000755" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,935</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000756" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000757" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,220</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000758" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,222</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000759" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000575" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_20200101_20201231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Japan Agreement</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#160;at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000760" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">100,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000763" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000766" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">100,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000761" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,350</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000764" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" scale="3">130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000767" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000762" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">116,697</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000765" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" scale="3">130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000768" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">116,827</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue recognized under the Japan Agreement for the year ended December 31, 2020 included an increase of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000769" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="-5" scale="6">15.1</ix:nonFraction> million resulting from changes to estimated variable consideration in the current year relating to performance obligations satisfied or partially satisfied in previous periods. The Company does <ix:nonFraction unitRef="U_iso4217USD" id="F_000770" name="fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction>t expect material variable consideration from estimated future co-development billing beyond development period in the transaction price related to the Japan Agreement.</p><ix:nonNumeric id="F_000576" name="fgen:ContractWithCustomerMilestoneMethodTableTextBlock" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts recognized as license revenue and development revenue under the Europe Agreement with Astellas were as follows (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Obligation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000771" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000772" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">117,470</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000773" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000774" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,954</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000775" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,172</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000776" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,503</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000577" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20200101_20201231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Europe Agreement</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#160;at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000777" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">487,951</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000780" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000783" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">487,951</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000778" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">248,962</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000781" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,429</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000784" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">250,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000779" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">736,913</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000782" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,429</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000785" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">738,342</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:2.68%;text-indent:-2.68%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue recognized under the Europe Agreement for the year ended December 31, 2020 included an increase in revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000786" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="-5" scale="6">1.5</ix:nonFraction> million resulting from changes to estimated variable consideration in the current year relating to performance obligations satisfied or partially satisfied in previous periods. The remainder of the transaction price related to the Europe Agreement includes $<ix:nonFraction unitRef="U_iso4217USD" id="F_000787" name="fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20200101_20201231" decimals="-5" scale="6">27.6</ix:nonFraction> million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000527_dcnt_b4b10d2d-a2aa-4659-84c3-a5e6c62e4909" continuedAt="F_000527_dcnt_f0e27359-298a-4017-9ae8-8d7a4838a65b">
<ix:nonNumeric id="F_000578" name="fgen:ContractWithCustomerMilestoneMethodTableTextBlock" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts recognized as license revenue and development revenue under the U.S./RoW and China Agreements with AstraZeneca were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Obligation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.&#160;/&#160;RoW</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and China</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000788" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000789" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">47,681</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000790" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,946</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000791" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">61,508</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000792" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">84,629</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000793" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">104,970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China performance obligation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000794" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231" decimals="-3" sign="-" scale="3">90</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000795" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231" decimals="-3" scale="3">90</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000796" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000579" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_20200101_20201231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement, along with any associated deferred revenue as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U.S.&#160;/&#160;RoW and China Agreements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#160;at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000797" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">341,844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000801" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000805" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">341,844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-development, information sharing &#38;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;committee services</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000798" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtProductOrServiceAxis_fgenCoDevelopmentInformationSharingAndCommitteeServicesMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">554,775</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000802" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_fgenCoDevelopmentInformationSharingAndCommitteeServicesMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,276</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000806" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtProductOrServiceAxis_fgenCoDevelopmentInformationSharingAndCommitteeServicesMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">557,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China performance obligation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000799" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtProductOrServiceAxis_fgenChinaPerformanceObligationMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000803" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_fgenChinaPerformanceObligationMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">137,338</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000807" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtProductOrServiceAxis_fgenChinaPerformanceObligationMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">137,338</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000800" name="fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">896,619</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000804" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">139,614</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000808" name="fgen:CashConsiderationReceivedUnderCollaborationAgreement" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,036,233</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:92.86%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* </span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the consolidated balance sheets. As of December 31, 2020, deferred revenue included $<ix:nonFraction unitRef="U_iso4217USD" id="F_000809" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-5" scale="6">137.5</ix:nonFraction> million related to the U.S./RoW and China Agreement, which represents the net of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000810" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-5" scale="6">139.6</ix:nonFraction> million of deferred revenue presented above and a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000811" name="fgen:SuppliesNet" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-5" scale="6">2.1</ix:nonFraction> million unbilled co-development revenue under the China Amendment with AstraZeneca.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue recognized under the U.S./RoW Agreement and China Agreement for the year ended December 31, 2020 included a reduction in revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000813" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="-5" sign="-" scale="6">2.9</ix:nonFraction> million resulting from changes to estimated variable consideration in the current year relating to performance obligations satisfied or partially satisfied in previous periods. The remainder of the transaction price related to the U.S./RoW Agreement and China Agreement includes $<ix:nonFraction unitRef="U_iso4217USD" id="F_000812" name="fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_20200101_20201231" decimals="-5" scale="6">37.9</ix:nonFraction> million of variable consideration from estimated future co-development billing. The amount allocated to the U.S./RoW Agreement is expected to be recognized over the remaining development service period. The amount allocated to the China performance obligation is expected to be recognized as the Company transfers control of the commercial drug product to Falikang.</p><ix:nonNumeric id="F_000565" name="fgen:ProductRevenuePolicyPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000565_dcnt_fade0b5e-8754-44e1-bf0f-b978578deb61">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Product Revenue, Net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue from roxadustat commercial sales in China is recognized in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products, net of various sales rebates and discounts. <ix:nonNumeric id="F_000580" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000580_cnt_1">Product revenue, net was as follows (in thousands):</ix:nonNumeric></p><ix:continuation id="F_000580_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross revenue</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000814" name="fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">89,027</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000815" name="fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,803</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Price adjustment</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000816" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenPriceAdjustmentMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000817" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenPriceAdjustmentMember_20190101_20191231" decimals="-3" sign="-" scale="3">936</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-key account hospital listing award</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000818" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNonKeyAccountHospitalListingAwardMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">9,325</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000819" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNonKeyAccountHospitalListingAwardMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual sales rebate</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000820" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenContractualSalesRebateMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">6,189</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000821" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenContractualSalesRebateMember_20190101_20191231" decimals="-3" sign="-" scale="3">149</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other discounts and rebates</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000822" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenOtherDiscountsAndRebatesMember_20200101_20201231" decimals="-3" sign="-" scale="3">923</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000823" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenOtherDiscountsAndRebatesMember_20190101_20191231" decimals="-3" sign="-" scale="3">18</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales return</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000824" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20200101_20201231" decimals="-3" sign="-" scale="3">92</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000825" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue, net</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000826" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">72,498</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000827" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000527_dcnt_f0e27359-298a-4017-9ae8-8d7a4838a65b" continuedAt="F_000527_dcnt_9bc5e535-07d9-46a5-99f4-1d8e6e39057c"><ix:continuation id="F_000565_dcnt_fade0b5e-8754-44e1-bf0f-b978578deb61">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the second quarter of 2020, the Company amended the agreement with its pharmaceutical distributors, which triggered accounting modifications particularly related to the non-key account hospital listing award. For the year ended December 31, 2020, the non-key account hospital listing award was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000828" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNonKeyAccountHospitalListingAwardMember_20200101_20201231" decimals="-5" scale="6">9.3</ix:nonFraction> million, which was recorded as a reduction to the revenue and calculated based on eligible non-key account hospital listings to date achieved by each distributor with certain requirements met during the period. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020 and 2019, the contractual sales rebate was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000829" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenContractualSalesRebateMember_20200101_20201231" decimals="-5" scale="6">6.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000830" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenContractualSalesRebateMember_20190101_20191231" decimals="-5" scale="6">0.1</ix:nonFraction> million, respectively, which were calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. All other rebates and discounts, including sales return allowance were immaterial for the periods presented. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2019, a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000831" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenPriceAdjustmentMember_20200101_20201231" decimals="-5" scale="6">0.9</ix:nonFraction> million of price adjustment was recorded based on government-listed price guidance and estimated channel inventory levels.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rebates and discounts that the Company&#8217;s pharmaceutical distributors have earned are eligible to be applied against future sales orders, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible in the same period that the related revenue is recorded. Due to the distributor&#8217;s legal right to offset, at each balance sheet date, the rebates and discounts are presented as reductions to gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The distributor&#8217;s legal right of offset is calculated at the individual distributor level<ix:nonNumeric id="F_000581" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000581_cnt_1">. The following table includes a roll-forward of the related contract liabilities (in thousands):</ix:nonNumeric></p><ix:continuation id="F_000581_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deduction</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Currency</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Translation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contract</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Presented Net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Against</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Receivable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue - Contract liabilities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000832" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,102</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000833" name="fgen:ContractWithCustomerLiabilityAdditions" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,497</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000834" name="fgen:ContractWithCustomerLiabilityDeduction" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,184</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000835" name="fgen:ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231" decimals="-3" sign="-" scale="3">270</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000836" name="fgen:ContractWithCustomerLiabilityGross" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">15,685</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000837" name="fgen:ContractWithCustomerLiabilityNetOfAccountsReceivable" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20201231" decimals="-3" scale="3">548</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000838" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,137</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the total rebates and discounts as reductions to gross accounts receivable was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000840" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenGrossAccountsReceivableMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20200101_20201231" decimals="-5" scale="6">0.5</ix:nonFraction> million, and the total contract liabilities was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000842" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20200101_20201231" decimals="-5" scale="6">15.1</ix:nonFraction> million, which was included in accrued and other current liabilities in the consolidated balance sheet. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reductions to gross accounts receivable, including the above-mentioned contra-accounts receivable items related to product revenue, totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000844" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20201231" decimals="-5" scale="6">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000845" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20191231" decimals="-5" scale="6">1.1</ix:nonFraction> million as of December 31, 2020 and 2019, respectively.</p></ix:continuation><ix:nonNumeric id="F_000566" name="fgen:DrugProductRevenuePolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000566_dcnt_f2730d72-2785-4fc5-802f-710d476cb751">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Drug Product Revenue<span style="font-weight:normal;"> </span></p><ix:nonNumeric id="F_000582" name="fgen:ScheduleOfDrugProductRevenueTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue was as follows (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000846" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,281</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000847" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">36,324</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000848" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">64,776</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000849" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,625</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000850" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000851" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000852" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,906</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000853" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">36,324</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000854" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">64,776</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company fulfilled all the shipment obligations under the term of the Japan Amendment during the year ended December 31, 2018, and recognized the related product revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000855" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231" decimals="-5" scale="6">64.8</ix:nonFraction> million in the same period<span style="font-weight:bold;"> </span>based on a transaction price that was subject to potential future adjustments, which represented a form of variable consideration. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in estimated variable consideration incurred in 2019 related to the above API shipments in 2018, at the time the actual listed price for roxadustat was issued by the Japanese Ministry of Health, Labour and Welfare, which resulted in a total difference of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000856" name="fgen:EstimatedVariableConsiderationTransactionPrice" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20191231" decimals="-5" scale="6">36.3</ix:nonFraction> million between the estimated and the actual listed price and yield from the manufacture of bulk product tablets. </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000527_dcnt_9bc5e535-07d9-46a5-99f4-1d8e6e39057c"><ix:continuation id="F_000566_dcnt_f2730d72-2785-4fc5-802f-710d476cb751">

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, during the year ended December 31, 2020, the Company recorded another $<ix:nonFraction unitRef="U_iso4217USD" id="F_000857" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231" decimals="-5" scale="6">4.0</ix:nonFraction> million reduction to drug product revenue related to the above API shipments, due to a change in estimated variable consideration. Specifically, the change in estimated variable consideration was based on the API held by Astellas at March 31, 2020 adjusted to reflect the updated listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and changes in the estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk product tablets, and estimated yield from the manufacture of bulk product tablets, among others. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2020, the Company fulfilled shipment obligations under the term of Japan Amendment with Astellas, and recognized related drug product revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000858" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200401_20200630" decimals="-5" scale="6">8.2</ix:nonFraction> million in the same period. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fourth quarter of 2020, the Company shipped bulk drug product from process validation supplies for commercial purposes under the term of the Europe Agreement with Astellas. The Company constrained the consideration from this shipment due to a high degree of uncertainty associated to the final consideration. As a result, the Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000859" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20201231" decimals="-5" scale="6">1.4</ix:nonFraction> million as current deferred revenue and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000860" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20201231" decimals="-5" scale="6">4.6</ix:nonFraction> million as long-term deferred revenue as of December 31, 2020. The deferred revenue will be recognized as and when uncertainty is resolved. <ix:nonNumeric id="F_000583" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20200101_20201231" escape="true" continuedAt="F_000583_cnt_1">The following table includes a roll-forward of the related contract liabilities (in thousands):</ix:nonNumeric></p><ix:continuation id="F_000583_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue - Astellas - contract liabilities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000861" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000862" name="fgen:ContractWithCustomerLiabilityAdditions" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,984</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000863" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,984</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the Company shipped bulk drug product to AstraZeneca as pre-commercial supply for process validation purposes, under the term of Commercial Supply Agreement under the U.S./RoW Agreement with AstraZeneca, and recognized drug product revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000864" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231" decimals="-2" scale="3">4.6</ix:nonFraction> million.</p></ix:continuation><ix:nonNumeric id="F_000567" name="fgen:OtherRevenuesPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Revenues</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other revenues consist primarily of collagen material sold for research purposes. Other revenues were immaterial for each of the three years ended December&#160;31, 2020.</p></ix:nonNumeric><ix:nonNumeric id="F_000568" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue represents amounts billed, or in certain cases, yet to be billed to the Company&#8217;s collaboration partners for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying performance obligations. The long-term portion of deferred revenue represents amounts to be recognized after one year through the end of the non-contingent performance period of the underlying performance obligations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue includes amounts allocated to the China performance obligation under the AstraZeneca arrangement as revenue recognition associated with this unit of accounting is tied to the commercial launch of the products within China and to when the control of the manufactured commercial drug product is transferred to AstraZeneca. As of December 31, 2020, approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000865" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-5" scale="6">3.5</ix:nonFraction> million of the deferred revenue related to the China unit of accounting was included in short-term deferred revenue, which represents the amount of deferred revenue associated with the China unit of accounting that is expected to be recognized within the next 12 months, associated with the commercial sales in China.</p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000528" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000528_dcnt_69b2d095-717d-4cfe-89b2-01e2733e1d03">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><ix:nonNumeric id="F_000569" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000569_cnt_1">Fair Value Measurements</ix:nonNumeric></p></td></tr></table></div><ix:continuation id="F_000569_cnt_1" continuedAt="F_000569_dcnt_4e9257f8-1a2f-42b7-94cf-2ee33e5f2546">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the authoritative guidance on fair value measurements and disclosures under U.S. GAAP, the Company presents all financial assets and liabilities and any other assets and liabilities that are recognized or disclosed at fair value on a nonrecurring basis. The guidance defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair-value measurements. The guidance also requires fair value measurements be classified and disclosed in one of the following three categories:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 1<span style="font-style:normal;">: Quoted prices in active markets for identical assets or liabilities.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 2<span style="font-style:normal;">: Observable inputs other than quoted prices in active markets for identical assets or liabilities.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 3<span style="font-style:normal;">: Unobservable inputs.</span></p></ix:continuation></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000528_dcnt_69b2d095-717d-4cfe-89b2-01e2733e1d03" continuedAt="F_000528_dcnt_6c720901-8a53-48c1-837f-e691a288089e"><ix:continuation id="F_000569_dcnt_4e9257f8-1a2f-42b7-94cf-2ee33e5f2546">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="T0"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company values certain assets and liabilities, focusing on the inputs used to measure fair value, particularly in instances where the measurement uses significant unobservable (Level 3) inputs. The Company&#8217;s financial instruments are valued using quoted prices in active markets (Level 1) or based upon other observable inputs (Level 2). The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability. In addition, the categories presented do not suggest how prices may be affected by the size of the purchases or sales, particularly with the largest highly liquid financial issuers who are in markets continuously with non-equity instruments, or how any such financial assets may be impacted by other factors such as U.S. government guarantees. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. </span><span style="color:#000000;">The availability of observable data is monitored to assess </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">appropriate</span><span style="color:#000000;"> classification of financial instruments within the fair value hierarchy. Depending upon the availability of such inputs, specific securities may </span><span style="color:#000000;">transfer between levels. In such instances, the transfer is reported at the end of the reporting period.</span></p></ix:continuation><ix:nonNumeric id="F_000584" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of the Company&#8217;s financial assets that are measured on a recurring basis are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000866" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000867" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000868" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000869" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000870" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" scale="3">244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000871" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000872" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000873" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" scale="3">244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000874" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">590,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000875" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000876" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000877" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">590,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000878" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">590,591</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000879" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000880" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000881" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">598,735</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury notes and bills</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000882" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">347,383</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000883" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">80,123</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000884" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000885" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">427,506</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000886" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,816</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000887" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000888" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000889" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,816</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000890" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231" decimals="-3" scale="3">255</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000891" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000892" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000893" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231" decimals="-3" scale="3">255</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000894" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">85,551</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000895" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000896" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000897" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">85,551</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificate of deposit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000898" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000899" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,032</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000900" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000901" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,032</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000902" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">444,005</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000903" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">110,155</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000904" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000905" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">554,160</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Level 2 investments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar investments, issuer credit spreads, benchmark investments, prepayment/default projections based on historical data and other observable inputs. There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000907" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" contextRef="C_0000921299_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000908" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" contextRef="C_0000921299_20181231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000909" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" contextRef="C_0000921299_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000910" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" contextRef="C_0000921299_20181231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000911" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" contextRef="C_0000921299_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000913" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" contextRef="C_0000921299_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000912" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" contextRef="C_0000921299_20180101_20181231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000914" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" contextRef="C_0000921299_20180101_20181231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> transfers of assets between levels for the years ended December&#160;31, 2020 and 2018. During the fourth quarter of 2019, there was a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000906" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" contextRef="C_0000921299_20191231" decimals="-5" scale="6">29.8</ix:nonFraction> million transfer of assets from Level 1 to Level 2 as such US treasury notes and bills were changed to off-the-run when they were issued before the most recent issue and were still outstanding at measurement day.</p><ix:nonNumeric id="F_000585" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of the Company&#8217;s financial liabilities that are carried at historical cost are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease obligations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000915" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000916" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000917" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,141</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000918" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,141</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease obligations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000919" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000920" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000921" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,544</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000922" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0000921299_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,544</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the Company&#8217;s financial liabilities were derived by using an income approach, which required Level 3 inputs such as discounted estimated future cash flows. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000923" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" contextRef="C_0000921299_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000924" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" contextRef="C_0000921299_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000925" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" contextRef="C_0000921299_20181231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000926" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" contextRef="C_0000921299_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000927" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" contextRef="C_0000921299_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000928" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" contextRef="C_0000921299_20181231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000929" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" contextRef="C_0000921299_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000930" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" contextRef="C_0000921299_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000931" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" contextRef="C_0000921299_20180101_20181231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000932" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" contextRef="C_0000921299_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000933" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" contextRef="C_0000921299_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000934" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" contextRef="C_0000921299_20180101_20181231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> transfers of liabilities between levels for the years ended December&#160;31, 2020, 2019 and 2018.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000528_dcnt_6c720901-8a53-48c1-837f-e691a288089e">
</ix:continuation><ix:nonNumeric id="F_000529" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000529_dcnt_d6c062d9-9730-42e7-a8a4-2bb0e2e596f9">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Leases</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently has <ix:nonFraction unitRef="U_fgenLease" id="F_000935" name="fgen:NumberOfFinanceLeases" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> building leases treated as finance leases. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2006, the Company entered into a long-term property lease with Alexandria for its corporate headquarters in San Francisco, California, with an initial term of <ix:nonNumeric id="F_000936" name="us-gaap:LesseeFinanceLeaseTermOfContract1" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20061231" format="ixt-sec:duryear">15</ix:nonNumeric>&#160;years, scheduled to expire in <ix:nonNumeric id="F_000937" name="fgen:LesseeFinanceLeaseExpirationPeriod" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20060101_20061231">2023</ix:nonNumeric>. <ix:nonNumeric id="F_000942" name="us-gaap:LesseeFinanceLeaseOptionToExtend" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20200101_20201231">The Company has an option to extend the lease for an additional <ix:nonNumeric id="F_000938" name="fgen:LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20060101_20061231" format="ixt-sec:duryear">10</ix:nonNumeric> years through <ix:nonNumeric id="F_000939" name="fgen:LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20060101_20061231">2033</ix:nonNumeric>.</ix:nonNumeric> The lease contract provides for a fixed annual rent, with scheduled increases of <ix:nonFraction unitRef="U_xbrlipure" id="F_000940" name="fgen:PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20060101_20061231" decimals="2" format="ixt-sec:numwordsen" scale="-2">two</ix:nonFraction> percent that occur on each anniversary of the rent commencement date. This lease requires the Company to pay all costs of ownership, operation, and maintenance of the premises, including without limitation all operating costs, insurance costs, and taxes.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2013, the Company entered into a long-term property lease with Beijing Economic-Technological Development Area (&#8220;BDA&#8221;) Management Committee for a pilot plant located in Beijing Yizhuang Biomedical Park of BDA. The building is leased for an initial lease term of <ix:nonNumeric id="F_000943" name="us-gaap:LesseeFinanceLeaseTermOfContract1" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20131231" format="ixt-sec:durwordsen">eight years</ix:nonNumeric>, scheduled to expire in <ix:nonNumeric id="F_000944" name="fgen:LesseeFinanceLeaseExpirationPeriod" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20130101_20131231">2021</ix:nonNumeric>. Renewal options are not specified within the lease contract. The lease contract provides for fixed quarterly rent payments, with scheduled increases that occur as detailed in the lease contract. This lease requires the Company to pay all operating and maintenance costs, and a fixed amount for property management fees.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently has <ix:nonFraction unitRef="U_fgenLease" id="F_000946" name="fgen:NumberOfOperatingLeases" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenOfficeSpacesMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">six</ix:nonFraction> additional real estate leases for office spaces in Shanghai and Beijing, China, which are treated as operating leases. These leases have lease terms ranging from <ix:nonNumeric id="F_000947" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_20201231" format="ixt-sec:durwordsen" continuedAt="C_17db6c68-592a-4be2-b999-64a4c3c233eb">two</ix:nonNumeric> to <ix:nonNumeric id="F_000948" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_20201231" format="ixt-sec:durwordsen">three<ix:continuation id="C_17db6c68-592a-4be2-b999-64a4c3c233eb"> years</ix:continuation></ix:nonNumeric>, expiring in <ix:nonNumeric id="F_000949" name="fgen:LesseeOperatingLeaseExpirationPeriod" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenOfficeSpacesMember_20200101_20201231">2023</ix:nonNumeric>. These lease contracts provide for fixed quarterly rent payments, and require the Company to pay operating and maintenance costs, and a fixed amount for property management fees.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company has several immaterial lease arrangements in China and U.S. for office equipment, scientific devices and automobile leases, with contracted lease terms ranging from <ix:nonNumeric id="F_000950" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231" format="ixt-sec:durwordsen" continuedAt="C_ce855a72-983d-4a9b-a44e-2c2abd329425">two</ix:nonNumeric> to <ix:nonNumeric id="F_000951" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231" format="ixt-sec:durwordsen">four<ix:continuation id="C_ce855a72-983d-4a9b-a44e-2c2abd329425"> years</ix:continuation></ix:nonNumeric>, treated as finance leases or operating leases, respectively.&#160;&#160; </p><ix:nonNumeric id="F_000586" name="fgen:ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s lease assets and related lease liabilities were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Line Item</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets - cost</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000952" name="fgen:FinanceLeaseRightOfUseAssetsCost" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">50,477</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000953" name="fgen:FinanceLeaseRightOfUseAssetsCost" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,909</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000954" name="fgen:FinanceLeaseAccumulatedAmortization" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,871</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000955" name="fgen:FinanceLeaseAccumulatedAmortization" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,307</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets, net</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000956" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000957" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating:</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets - cost</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000958" name="fgen:OperatingLeaseRightOfUseAssetsCost" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,934</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000959" name="fgen:OperatingLeaseRightOfUseAssetsCost" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,736</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000960" name="fgen:OperatingLeaseAccumulatedAmortization" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,891</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000961" name="fgen:OperatingLeaseAccumulatedAmortization" contextRef="C_0000921299_20191231" decimals="-3" scale="3">805</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets, net</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000962" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,043</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000963" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,931</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease assets</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000964" name="fgen:FinanceLeaseAndOperatingLeaseAssets" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,649</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000965" name="fgen:FinanceLeaseAndOperatingLeaseAssets" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,533</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, current</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000966" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,330</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000967" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,351</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000968" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000969" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0000921299_20191231" decimals="-3" scale="3">983</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, non-current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000972" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000973" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,610</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000974" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" scale="3">853</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000975" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0000921299_20191231" decimals="-3" scale="3">942</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liabilities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000978" name="fgen:FinanceLeaseAndOperatingLeaseLiability" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,762</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000979" name="fgen:FinanceLeaseAndOperatingLeaseLiability" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,886</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000529_dcnt_d6c062d9-9730-42e7-a8a4-2bb0e2e596f9" continuedAt="F_000529_dcnt_b49fe1e8-f2e8-4c44-9a21-ea3c20b18774">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000587" name="us-gaap:LeaseCostTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease expense were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of Operations Line Item</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease cost:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; right-of-use assets</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold&#59;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development&#59;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000980" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,369</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000981" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,307</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000982" name="us-gaap:FinanceLeaseInterestExpense" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,932</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000983" name="us-gaap:FinanceLeaseInterestExpense" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,373</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold&#59;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development&#59;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000984" name="us-gaap:OperatingLeaseCost" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000985" name="us-gaap:OperatingLeaseCost" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">891</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000986" name="us-gaap:SubleaseIncome" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,201</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000987" name="us-gaap:SubleaseIncome" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,385</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000988" name="us-gaap:LeaseCost" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,251</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000989" name="us-gaap:LeaseCost" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000588" name="fgen:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to leases were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000990" name="us-gaap:OperatingLeasePayments" contextRef="C_0000921299_20200101_20201231" decimals="-3" scale="3">951</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000991" name="us-gaap:OperatingLeasePayments" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">914</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from finance leases</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000992" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,896</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000993" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,196</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flows from finance leases</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000994" name="fgen:RepaymentsOfFinanceLeaseLiabilities" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,620</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000995" name="fgen:RepaymentsOfFinanceLeaseLiabilities" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,925</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for new lease liabilities:</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000996" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" contextRef="C_0000921299_20200101_20201231" decimals="-3" scale="3">662</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000997" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,909</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000998" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,072</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000999" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,736</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000589" name="fgen:ScheduleOfLeaseTermAndDiscountRateTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease term and discount rate were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (years):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001000">2.9</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001001">3.6</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001002">1.8</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001003">2.1</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate:</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001004" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="C_0000921299_20201231" decimals="4" scale="-2">4.39</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001005" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="C_0000921299_20191231" decimals="4" scale="-2">4.42</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001006" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0000921299_20201231" decimals="4" scale="-2">4.74</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001007" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0000921299_20191231" decimals="4" scale="-2">4.75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000590" name="fgen:ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of lease liabilities as of December&#160;31, 2020 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance&#160;Leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating&#160;Leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001008" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,689</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001014" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,142</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001009" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,886</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001015" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0000921299_20201231" decimals="-3" scale="3">839</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001010" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,526</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001016" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0000921299_20201231" decimals="-3" scale="3">143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future lease payments</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001011" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,101</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001017" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,124</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Interest</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001012" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,380</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001018" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0000921299_20201231" decimals="-3" scale="3">83</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001013" name="us-gaap:FinanceLeaseLiability" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,721</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001019" name="us-gaap:OperatingLeaseLiability" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,041</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000529_dcnt_b49fe1e8-f2e8-4c44-9a21-ea3c20b18774">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000530" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000530_dcnt_dd5c5967-5d53-481d-936e-0c38fa3b40a7">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Balance Sheet Components</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p><ix:nonNumeric id="F_000591" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001020" name="us-gaap:Cash" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">88,046</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001021" name="us-gaap:Cash" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,715</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001022" name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">590,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001023" name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">85,551</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001024" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">678,393</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001025" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">126,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investments</p><ix:nonNumeric id="F_000592" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s investments consist of available-for-sale debt investments, marketable equity investments, term deposit and certificate of deposit. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#8217;s investments by major investments type are summarized in the tables below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001026" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,147</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001034" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001042" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001050" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001027" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" scale="3">125</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001035" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" scale="3">119</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001043" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001051" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" scale="3">244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001028" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,272</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001036" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_20201231" decimals="-3" scale="3">119</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001044" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_20201231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001052" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,388</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury notes and bills</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001029" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">426,995</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001037" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" scale="3">536</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001045" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" scale="3">25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001053" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">427,506</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001030" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001038" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231" decimals="-3" scale="3">32</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001046" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001054" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,032</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001031" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,730</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001039" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231" decimals="-3" scale="3">86</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001047" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001055" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,816</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001032" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231" decimals="-3" scale="3">125</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001040" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231" decimals="-3" scale="3">130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001048" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001056" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231" decimals="-3" scale="3">255</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001033" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">467,850</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001041" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0000921299_20191231" decimals="-3" scale="3">784</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001049" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000921299_20191231" decimals="-3" scale="3">25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001057" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">468,609</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000593" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contractual maturities of the available-for-sale investments were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within one year - Bond and mutual funds</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001058" name="fgen:AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001059" name="us-gaap:AvailableForSaleSecuritiesEquitySecurities" contextRef="C_0000921299_20201231" decimals="-3" scale="3">244</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001060" name="us-gaap:AvailableForSaleSecurities" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,388</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company periodically reviews its available-for-sale investments and term deposit for other-than-temporary impairment. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period and its intent to sell. For debt securities, the Company also considers whether (i)&#160;it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. During the three years ended December 31, 2020, the Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_001061" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" contextRef="C_0000921299_20180101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t recognize any other-than-temporary impairment loss.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000530_dcnt_dd5c5967-5d53-481d-936e-0c38fa3b40a7" continuedAt="F_000530_dcnt_50c60f32-9ed0-45d5-b7e7-ce819dbb92db">

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p><ix:nonNumeric id="F_000594" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001062" name="us-gaap:InventoryRawMaterials" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001063" name="us-gaap:InventoryRawMaterials" contextRef="C_0000921299_20191231" decimals="-3" scale="3">325</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work-in-progress</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001064" name="us-gaap:InventoryWorkInProcess" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,114</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001065" name="us-gaap:InventoryWorkInProcess" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,264</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001066" name="us-gaap:InventoryFinishedGoods" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001067" name="us-gaap:InventoryFinishedGoods" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,298</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001068" name="us-gaap:InventoryNet" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,530</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001069" name="us-gaap:InventoryNet" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,887</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company started capitalizing inventory costs in June 2019 when FibroGen Beijing began productions of roxadustat for commercial sales purposes. The Company started capitalizing pre-launch inventory costs in the U.S. the second quarter of 2020 prior to regulatory approval. As of December 31, 2020, pre-launch inventory capitalized was <ix:nonFraction unitRef="U_xbrlipure" id="F_001070" name="fgen:PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" contextRef="C_0000921299_20201231" decimals="2" scale="-2">29</ix:nonFraction>% of the total inventory balance. The provision to write-down excess and obsolete inventory was nominal for the years ended December&#160;31, 2020 and 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p><ix:nonNumeric id="F_000595" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unbilled contract assets</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001071" name="us-gaap:Supplies" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,147</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001072" name="us-gaap:Supplies" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">180,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues from associated contracts</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001073" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,147</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001074" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,790</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net unbilled contract assets</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001075" name="fgen:SuppliesNet" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001076" name="fgen:SuppliesNet" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">125,210</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid assets</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001077" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,353</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001078" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,464</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001079" name="us-gaap:OtherAssetsCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,807</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001080" name="us-gaap:OtherAssetsCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,717</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001081" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,160</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001082" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">133,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unbilled contract assets as of December 31, 2020 were related to unbilled co-development revenue under the China Amendment with AstraZeneca. The unbilled contract assets as of December 31, 2019 were related to <ix:nonFraction unitRef="U_fgenMilestone" id="F_001083" name="fgen:NumberOfRegulatoryMilestones" contextRef="C_0000921299_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> regulatory milestones totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_001084" name="us-gaap:Supplies" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20191231" decimals="-5" scale="6">130.0</ix:nonFraction> million under the Europe Agreement with Astellas associated with the planned MAA submission in Europe, and a $<ix:nonFraction unitRef="U_iso4217USD" id="F_001085" name="us-gaap:Supplies" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20191231" decimals="-5" scale="6">50.0</ix:nonFraction> million regulatory milestone under the U.S./RoW Agreement with AstraZeneca associated with the NDA submission in the U.S., which was submitted in December 2019 and accepted for review in February 2020. See Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, for details.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment</p><ix:nonNumeric id="F_000596" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001086" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">102,006</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001087" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">101,548</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001088" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001089" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,329</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001090" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,312</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001091" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,217</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001092" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,545</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001093" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,399</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001094" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001095" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001096" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" scale="3">760</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001097" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001098" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">144,894</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001099" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">143,107</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001100" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">111,247</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001101" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">100,364</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001102" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">33,647</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001103" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense for the years ended December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001104" name="us-gaap:Depreciation" contextRef="C_0000921299_20200101_20201231" decimals="-5" scale="6">11.7</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_001105" name="us-gaap:Depreciation" contextRef="C_0000921299_20190101_20191231" decimals="-5" scale="6">11.1</ix:nonFraction> million, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001106" name="us-gaap:Depreciation" contextRef="C_0000921299_20180101_20181231" decimals="-5" scale="6">6.6</ix:nonFraction> million, respectively.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000530_dcnt_50c60f32-9ed0-45d5-b7e7-ce819dbb92db" continuedAt="F_000530_dcnt_b34b4bac-a0a2-4bcf-98af-92a55e015415">

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accrued and Other Current Liabilities</p><ix:nonNumeric id="F_000597" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and clinical trial accruals</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001107" name="fgen:AccruedPreclinicalAndClinicalTrialCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001108" name="fgen:AccruedPreclinicalAndClinicalTrialCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,279</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">API product price adjustment</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001109" name="fgen:AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001110" name="fgen:AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,324</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and related accruals</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001111" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001112" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,784</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities to pharmaceutical distributors</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001113" name="fgen:AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,137</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001114" name="fgen:AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued co-promotion expenses - current</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001115" name="fgen:AccruedCoPromotionExpensesCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,537</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001116" name="fgen:AccruedCoPromotionExpensesCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat profit share to AstraZeneca</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001117" name="fgen:AccruedProfitShareCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001118" name="fgen:AccruedProfitShareCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property taxes and other</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001119" name="fgen:PropertyTaxesAndOtherCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001120" name="fgen:PropertyTaxesAndOtherCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,044</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional services</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001121" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,869</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001122" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,842</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001123" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,088</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001124" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,543</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued and other current liabilities</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001125" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">119,521</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001126" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">83,816</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The API product price adjustment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001127" name="fgen:AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" contextRef="C_0000921299_20191231" decimals="-5" scale="6">36.3</ix:nonFraction> million accrued as of December 31, 2019 was related to the change in estimated variable consideration of API product at the time the roxadustat listed price was issued by the Japanese Ministry of Health, Labour and Welfare in the fourth quarter of 2019. This amount was fully paid during the first quarter of 2020. Refer to Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, for details.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 8, 2020, the Parties entered into an amendment to the China Agreement, relating to the development and commercialization of roxadustat in China, which revised, among other things, the arrangements and calculation of the estimated co-promotion expenses payable to AstraZeneca for its sales and marketing efforts associated with the commercial sales for roxadustat in China. As a result, the previously accrued long-term co-promotion expenses were significantly reduced during the third quarter of 2020. $<ix:nonFraction unitRef="U_iso4217USD" id="F_001128" name="fgen:AccruedLongTermCoPromotionLiabilityCurrent" contextRef="C_0000921299_20201231" decimals="-5" scale="6">11.5</ix:nonFraction> million of the recalculated accrued co-promotion expenses is anticipated to be paid within the next 12 months, therefore was recorded as a current liability as of December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The profit share liability of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001129" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-5" scale="6">7.0</ix:nonFraction> million to AstraZeneca as of December 31, 2020 represented the profit/loss share between FibroGen Beijing and AstraZeneca that is calculated pursuant to the China Agreement. This liability correspondingly reduced the deferred revenue related to the performance obligation in accordance with the China Agreement.<span style="font-weight:bold;color:#FF0000;"> </span>Refer to Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, for details.<span style="font-weight:bold;color:#FF0000;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Long-term Liabilities</p><ix:nonNumeric id="F_000598" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities consisted of the following (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued long-term co-promotion expenses</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001130" name="fgen:AccruedLongTermCoPromotionLiabilityNonCurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,424</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001131" name="fgen:AccruedLongTermCoPromotionLiabilityNonCurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,071</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term tax liabilities</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001132" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,675</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001133" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,913</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, non-current</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001134" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" scale="3">853</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001135" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0000921299_20191231" decimals="-3" scale="3">942</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001136" name="us-gaap:OtherSundryLiabilitiesNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,690</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001137" name="us-gaap:OtherSundryLiabilitiesNoncurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,481</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other long-term liabilities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001138" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,642</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001139" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">65,407</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The a<span style="color:#000000;">ccrued long-term co-promotional expenses </span>of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001140" name="fgen:AccruedLongTermCoPromotionalLiabilityNonCurrent" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20191231" decimals="-5" scale="6">53.1</ix:nonFraction> million <span style="color:#000000;">as of December 31, 2019 was related to the estimated amount payable to AstraZeneca for its sales and marketing efforts related to the commercial launch for roxadustat in China. </span>As mentioned above, the China Amendment revised the arrangements and calculation of the estimated co-promotion expenses payable to AstraZeneca. As a result, we reversed approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001142" name="fgen:ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses" contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200701_20200930" decimals="-5" scale="6">84.4</ix:nonFraction> million of previously accrued long-term co-promotion expenses during the third quarter of 2020. $<ix:nonFraction unitRef="U_iso4217USD" id="F_001141" name="fgen:AccruedLongTermCoPromotionalLiabilityNonCurrent" contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231" decimals="-5" scale="6">27.4</ix:nonFraction> million of the recalculated accrued co-promotion expenses remained in the long-term liabilities as of December 31, 2020, as it is not anticipated to be paid within the next 12 months.<span style="color:#000000;"> </span> </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000530_dcnt_b34b4bac-a0a2-4bcf-98af-92a55e015415">
</ix:continuation><ix:nonNumeric id="F_000531" name="fgen:ProductDevelopmentObligationsDisclosureTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Product Development Obligations</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Technology Development Center of the Republic of Finland (&#8220;TEKES&#8221;) product development obligations consist of <ix:nonFraction unitRef="U_fgenDevelopmentObligation" id="F_001143" name="fgen:NumberOfProductDevelopmentObligations" contextRef="C_0000921299_20200101_20201231" decimals="INF">11</ix:nonFraction> separate advances (each in the form of a note agreement) received by FibroGen Europe between 1996 and 2008 from TEKES. These advances are granted on a project-by-project basis to fund various product development efforts undertaken by FibroGen Europe only. Each separate note is denominated in EUR and bears interest (not compounded) calculated as <ix:nonFraction unitRef="U_xbrlipure" id="F_001144" name="us-gaap:LoansReceivableBasisSpreadOnVariableRate" contextRef="C_0000921299_us-gaapVariableRateAxis_fgenBankOfFinlandInterestRateMember_20201231" decimals="2" format="ixt-sec:numwordsen" scale="-2">one</ix:nonFraction> percentage point less than the Bank of Finland rate in effect at the time of the note, but no less than <ix:nonFraction unitRef="U_xbrlipure" id="F_001145" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_20201231" decimals="INF" scale="-2">3.0</ix:nonFraction>%.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the research work funded by TEKES does not result in an economically profitable business or does not meet its technological objectives, TEKES may, on application from FibroGen Europe, forgive each of these loans, including accrued interest, either in full or in part. As of December&#160;31, 2020 and 2019, the Company had U.S. Dollar equivalent of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001146" name="fgen:AccruedProductDevelopmentCostsExcludingInterest" contextRef="C_0000921299_20201231" decimals="-5" scale="6">11.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001147" name="fgen:AccruedProductDevelopmentCostsExcludingInterest" contextRef="C_0000921299_20191231" decimals="-5" scale="6">10.6</ix:nonFraction> million of principal outstanding, respectively, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001148" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0000921299_20201231" decimals="-5" scale="6">7.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001149" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0000921299_20191231" decimals="-5" scale="6">6.2</ix:nonFraction> million of interest accrued, respectively, which were presented in the product development obligations line on the consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not a guarantor of these loans, and these loans are not repayable by FibroGen Europe until it has distributable funds.</p></ix:nonNumeric><ix:nonNumeric id="F_000532" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000532_dcnt_5dc08afe-f162-470f-859f-2cc534bca5bc">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract Obligations </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had outstanding total non-cancelable purchase obligations of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001150" name="us-gaap:ContractualObligation" contextRef="C_0000921299_20201231" decimals="-5" scale="6">86.0</ix:nonFraction> million. The Company expects to fulfill our commitments under these agreements in the normal course of business, and as such, no liability has been recorded. <ix:nonNumeric id="F_000599" name="us-gaap:RecordedUnconditionalPurchaseObligationsTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000599_cnt_1">The unconditional purchase obligations consisted of the following (in thousands):</ix:nonNumeric> </p><ix:continuation id="F_000599_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchase Obligations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Due In The Year Ending December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacture and supply of roxadustat</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001151" name="us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear" contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfRoxadustatMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,114</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001155" name="us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear" contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfRoxadustatMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,951</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001159" name="us-gaap:RecordedUnconditionalPurchaseObligation" contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfRoxadustatMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,065</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacture and supply of pamrevlumab</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001152" name="us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear" contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfPamrevlumabMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001156" name="us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear" contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfPamrevlumabMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">33,063</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001160" name="us-gaap:RecordedUnconditionalPurchaseObligation" contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfPamrevlumabMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">57,543</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other purchases</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001153" name="us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear" contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenOtherPurchasesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,418</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001157" name="us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear" contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenOtherPurchasesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001161" name="us-gaap:RecordedUnconditionalPurchaseObligation" contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenOtherPurchasesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,418</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total purchase obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001154" name="us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,012</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001158" name="us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,014</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001162" name="us-gaap:RecordedUnconditionalPurchaseObligation" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">86,026</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the Company&#8217;s license agreements provide for periodic maintenance fees over specified time periods, as well as payments by the Company upon the achievement of development, regulatory and commercial milestones. Future milestone payments for research and pre-clinical stage development programs consisted of up to approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001163" name="fgen:MaximumFutureMilestonePayments" contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenResearchAndPreClinicalStageDevelopmentProgramsMember_20200101_20201231" decimals="-5" scale="6">10.9</ix:nonFraction> million in total potential future milestone payments under the Company&#8217;s license agreements with Dana-Farber Cancer Institute, University of Miami and Medarex, Inc. These milestone payments generally become due and payable only upon the achievement of certain developmental, clinical, regulatory and/or commercial milestones. The event triggering such payment or obligation has not yet occurred.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Legal Proceedings</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company is a party to various legal actions, both inside and outside the U.S., arising in the ordinary course of its business or otherwise. The Company accrues amounts, to the extent they can be reasonably estimated, that the Company believes will result in a probable loss (including, among other things, probable settlement value), to adequately address any liabilities related to legal proceedings and other loss contingencies. A loss or a range of loss is disclosed when it is reasonably possible that a material loss will incur and can be estimated, or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 20, 2020, in response to an invalidation action brought against certain FibroGen United Kingdom patents by Akebia, the United Kingdom court handed down a decision invalidating United Kingdom designations of European Patent Nos. 1463823, 1633333, 2298301, 2322153, and 2322155. The United Kingdom designation to European Patent No. 2289531 was held to be valid in amended form, but not infringed by Akebia. The Company and its partner Astellas have filed an appeal of the decision in the United Kingdom Court of Appeal. The Company did not have material accruals for any currently active legal action in its consolidated balance sheets as of December&#160;31, 2020, as it could not predict the ultimate outcome of these matters, or reasonably estimate the potential exposure.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000532_dcnt_5dc08afe-f162-470f-859f-2cc534bca5bc">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Indemnification Agreements</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into standard indemnification arrangements in the ordinary course of business, including for example, service, manufacturing and collaboration agreements. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, including in connection with intellectual property infringement claims by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the extent permissible under applicable law. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these arrangements is minimal.</p></ix:continuation><ix:nonNumeric id="F_000533" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000533_dcnt_cff32437-b2ef-498f-8a66-9f1d45505d85">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Equity and Stock-based Compensation</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Subsidiary Stock and Non-Controlling Interests</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">FibroGen Europe</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, respectively, FibroGen Europe had a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_001164" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_001165" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_20191231" decimals="INF" format="ixt:numdotdecimal">42,619,022</ix:nonFraction></ix:nonFraction>&#160;shares of Preferred Stock outstanding, of which there were <ix:nonFraction unitRef="U_xbrlishares" id="F_001166" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_001167" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">1,700,845</ix:nonFraction></ix:nonFraction> shares of Series&#160;A Preferred Stock, <ix:nonFraction unitRef="U_xbrlishares" id="F_001168" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_001169" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">1,875,000</ix:nonFraction></ix:nonFraction>&#160;shares of Series&#160;B Preferred Stock, <ix:nonFraction unitRef="U_xbrlishares" id="F_001170" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_001171" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">1,599,503</ix:nonFraction></ix:nonFraction>&#160;shares of Series&#160;C Preferred Stock, <ix:nonFraction unitRef="U_xbrlishares" id="F_001172" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_001173" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">1,520,141</ix:nonFraction></ix:nonFraction>&#160;shares of Series&#160;D Preferred Stock, <ix:nonFraction unitRef="U_xbrlishares" id="F_001174" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesEPreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_001175" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesEPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">459,565</ix:nonFraction></ix:nonFraction>&#160;shares of Series&#160;E Preferred Stock, <ix:nonFraction unitRef="U_xbrlishares" id="F_001176" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_001177" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">5,714,332</ix:nonFraction></ix:nonFraction>&#160;shares of Series&#160;F Preferred Stock, <ix:nonFraction unitRef="U_xbrlishares" id="F_001178" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_001179" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">9,927,500</ix:nonFraction></ix:nonFraction>&#160;shares of Series&#160;G Preferred Stock and <ix:nonFraction unitRef="U_xbrlishares" id="F_001180" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_001181" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">19,822,136</ix:nonFraction></ix:nonFraction>&#160;shares of Series&#160;H Preferred Stock, all of which shares no longer have any right to be exchanged for FibroGen, Inc. Common Stock. The holders of FibroGen Europe&#8217;s shares of Preferred Stock (&#8220;Preferred Shares&#8221;) have the following rights, preferences and privileges:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.36%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dividend Rights <span style="font-style:normal;">&#8212; When the assets of FibroGen Europe are distributed (except for distribution in a liquidation), Preferred Shares shall have the same rights to dividend or other forms of distribution as shares of Common Stock of FibroGen Europe. In the event of a merger, holders of Preferred Shares do not have the right to demand FibroGen Europe to redeem all or part of their Preferred Shares. FibroGen Europe may repurchase shares of Common Stock or Preferred Shares for consideration.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.36%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pre-emptive Right <span style="font-style:normal;">&#8212; Preferred Shares shall have pre-emptive subscription right in accordance with the Finnish Limited Liability Companies Act if additional shares are issued, option rights are given, or convertible loan is taken, </span>provided<span style="font-style:normal;">, </span>however<span style="font-style:normal;">, that the foregoing pre-emptive right does not apply to a directed share issue, for which two thirds (2/3)&#160;of the voting shares represented at a general meeting of shareholders approve for an important legitimate cause.</span></p><ix:nonNumeric id="F_001182" name="us-gaap:PreferredStockRedemptionTerms" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_20200101_20201231"><p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.36%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Redemption Right <span style="font-style:normal;">&#8212; If a Preferred Share can be redeemed by a majority shareholder owning more than ninety percent (<ix:nonFraction unitRef="U_xbrlipure" id="F_001183" name="fgen:RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_20200101_20201231" decimals="INF" scale="-2">90</ix:nonFraction>%)&#160;of the shares of FibroGen Europe in accordance with the provisions of the Finnish Limited Liability Companies Act, the minority holders of Preferred Shares have the right to request redemption of their shares.</span></p></ix:nonNumeric>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.36%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Voting Right <span style="font-style:normal;">&#8212; Each share has <ix:nonNumeric id="F_001184" name="us-gaap:PreferredStockVotingRights" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_20200101_20201231">one vote</ix:nonNumeric>. Preferred Shares have voting rights only in situations that are specifically provided in the Articles of Association, which include a merger transaction and directed share issue. In addition, Preferred Shares have right to vote in a general shareholder meeting for amending the Articles of Association if the amendment will affect the rights of Preferred Shares.</span></p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000533_dcnt_cff32437-b2ef-498f-8a66-9f1d45505d85" continuedAt="F_000533_dcnt_c18c2561-1719-45fb-8d94-c10d71099d9e">

<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.36%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Conversion Right<span style="font-style:normal;"> (1-for-<ix:nonFraction unitRef="U_xbrlishares" id="F_001185" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_20201231" decimals="INF">1</ix:nonFraction> basis into Common Stock of FibroGen Europe):</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.42%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Voluntary conversion right: Preferred Shares can be converted into common shares upon the written request of a shareholder provided that the conversion is feasible within the maximum and minimum amounts of shares of classes of FibroGen Europe as set forth in its Articles of Association. Such request can be withdrawn before the notification of conversion is filed with the Finnish Trade Register.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.36%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Compulsory conversion right: Preferred Shares will be converted into common shares if (i)&#160;FibroGen Europe&#8217;s shares are listed in a stock exchange or other trading system in the European Economic Area, or (ii)&#160;FibroGen Europe&#8217;s recombinant collagen and gelatin production technology is being put into commercial use in the area of Europe and certain other European states. Commercial use means there is income generated from the first commercial sale of the products incorporating the above mentioned technology and does not include license fees, development financing, milestone payments or income from test products or equipment used in research. The board of directors of FibroGen Europe shall notify the shareholders of the compulsory conversion in writing, and the shareholders shall request to convert their shares within the timeframe provided in the notification. Should the shareholders fail to make the conversion request within the time limit, FibroGen Europe may redeem the shares of such shareholders.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Liquidation Right <span style="font-style:normal;">&#8212; In the event of a dissolution of FibroGen Europe, holders of Preferred Shares are entitled to be paid in an amount equal to the subscription price of the shares before any distribution is made to holders of common shares. Among holders of Preferred Shares, holders of shares of Series F Preferred Stock are entitled to be paid in an amount equal to the subscription price of Series F Preferred Stock before any distribution is made to holders of other Preferred Shares.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">FibroGen Cayman</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen Cayman had <ix:nonFraction unitRef="U_xbrlishares" id="F_001186" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibroGenCaymanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_001187" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibroGenCaymanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">6,758,000</ix:nonFraction></ix:nonFraction> Series A Preference Shares outstanding as of December&#160;31, 2020 and 2019, respectively. The holders of the FibroGen Cayman Series A Preference Shares have the following rights, preferences and privileges:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Liquidation <span style="font-style:normal;">&#8212; In the event of liquidation, dissolution, or winding up of the Company, either voluntary or involuntary, including by means of a merger, the holders of FibroGen Cayman Series A Preference Shares are entitled to be paid an amount equal to the product of the number of shares held by a holder of shares of FibroGen Cayman Series A Preference Shares and the original issue price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001188" name="fgen:PreferredSharesIssuedPricePerShare" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibroGenCaymanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20201231" decimals="INF">1.00</ix:nonFraction> (subject to equitable adjustment for any stock dividend, combination, split, reclassification, recapitalization) plus all declared and unpaid dividends thereon.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Conversion <span style="font-style:normal;">&#8212; Each share of FibroGen Cayman Series A Preference Shares is convertible into the number of fully paid and non-assessable shares of Common Stock of FibroGen Cayman that results from dividing the original issue price by the conversion price in effect at the time of the conversion, subject to adjustments for stock splits, stock dividends, reclassifications and like events. The FibroGen Cayman Series A Preference Shares have a conversion price that is equal to the original issuance price such that the conversion ratio to FibroGen Cayman Common Stock is 1:<ix:nonFraction unitRef="U_xbrlishares" id="F_001189" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibroGenCaymanMember_20201231" decimals="INF">1</ix:nonFraction> as of all periods presented.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Voting <span style="font-style:normal;">&#8212; The holders of FibroGen Cayman Series A Preference Shares are entitled to vote together with the FibroGen Cayman Common Stock holders on all matters submitted for a vote of the stockholders. The holder of each share of FibroGen Cayman Series A Preference Shares has the number of votes equal to the number of shares of FibroGen Cayman Common Stock into which it is convertible.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dividends <span style="font-style:normal;">&#8212; The holders of FibroGen Cayman Series A Preference Shares are entitled to receive cash dividends when and if declared, at a rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_001190" name="us-gaap:PreferredStockDividendRatePercentage" contextRef="C_0000921299_deiLegalEntityAxis_fgenFibroGenCaymanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20200101_20201231" decimals="INF" scale="-2">6</ix:nonFraction>%.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Non-Controlling Interests</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling interest positions related to the issuance of subsidiary stock as described above are reported as a separate component of consolidated equity from the equity attributable to the Company&#8217;s stockholders at December&#160;31, 2020 and 2019. In addition, the Company does not allocate losses to the non-controlling interests as the outstanding shares representing the non-controlling interest do not represent a residual equity interest in the subsidiary. Upon the initial public offering and as described above, all eligible FibroGen Europe preferred shares were exchanged for <ix:nonFraction unitRef="U_xbrlishares" id="F_001191" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="C_0000921299_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20141119" decimals="INF" format="ixt:numdotdecimal">958,996</ix:nonFraction> shares of FibroGen Common Stock. No other FibroGen Europe shares have the right to be exchanged for FibroGen, Inc. Common Stock.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000533_dcnt_c18c2561-1719-45fb-8d94-c10d71099d9e" continuedAt="F_000533_dcnt_47159627-8e91-48c6-85f2-23479bd5072e">

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each share of Common Stock is entitled to <ix:nonNumeric id="F_001192" name="us-gaap:CommonStockVotingRights" contextRef="C_0000921299_20200101_20201231">one vote</ix:nonNumeric>. The holders of Common Stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding.</p><ix:nonNumeric id="F_000600" name="fgen:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares of Common Stock outstanding, shares of stock plans outstanding and shares reserved for future issuance related to stock options and RSU grants and the Company&#8217;s Employee Stock Purchase Plan (&#8220;ESPP&#8221;) purchases are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock outstanding</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001193" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">91,441</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001194" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">87,657</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options outstanding</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001195" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,290</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001196" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,018</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs outstanding</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001197" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,893</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001198" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,483</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for future stock options and RSUs grant</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001199" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,910</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001200" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,725</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for future ESPP offering</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001201" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0000921299_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,070</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001202" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0000921299_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares of common stock reserved</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001203" name="fgen:CommonStockSharesReserved" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">114,604</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001204" name="fgen:CommonStockSharesReserved" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">110,220</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock Plans</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Option and RSU Plans</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Company&#8217;s Amended and Restated 2005 Stock Plan (&#8220;2005 Stock Plan&#8221;), the Company may issue shares of Common Stock and options to purchase Common Stock and other forms of equity incentives to employees, directors and consultants. Options granted under the 2005 Stock Plan may be incentive stock options or nonqualified stock options. Incentive stock options (&#8220;ISO&#8221;) may be granted only to employees and officers of the Company. Nonqualified stock options (&#8220;NSO&#8221;) and stock purchase rights may be granted to employees, directors and consultants. The board of directors has the authority to determine to whom options will be granted, the number of options, the term and the exercise price. Options are to be granted at an exercise price not less than fair market value for an ISO or an NSO. Options generally vest over <ix:nonNumeric id="F_001205" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFiveStockPlanMember_20200101_20201231" format="ixt-sec:durwordsen">four years</ix:nonNumeric>. Options expire no more than <ix:nonNumeric id="F_001206" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_fgenTwoThousandAndFiveStockPlanMember_20200101_20201231" format="ixt-sec:duryear">10</ix:nonNumeric> years after the date of grant. Upon the effective date of the registration statement related to the Company&#8217;s initial public offering, the 2005 Plan was amended to cease the grant of any additional awards thereunder, although the Company will continue to issue common stock upon the exercise of previously granted stock options under the 2005 Plan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2014, the Company adopted a 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) which became effective on November&#160;13, 2014. The 2014 Plan is the successor equity compensation plan to the 2005 Plan. The 2014 Plan will terminate on <ix:nonNumeric id="F_001207" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20200101_20201231" format="ixt:datemonthdayyearen">November&#160;12, 2024</ix:nonNumeric>. The 2014 Plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock awards, stock appreciation rights, performance stock awards, performance cash awards, restricted stock units and other stock awards to employees, directors and consultants. Stock options granted must be at prices not less than <ix:nonFraction unitRef="U_xbrlipure" id="F_001209" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20200101_20201231" decimals="INF" scale="-2">100</ix:nonFraction>% of the fair market value at date of grant. <ix:nonNumeric id="F_001208" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20200101_20201231">Option vesting schedules are determined by the Company at the time of issuance and generally have a four year vesting schedule (<ix:nonFraction unitRef="U_xbrlipure" id="F_001210" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231" decimals="2" scale="-2">25</ix:nonFraction>% vesting on the first anniversary of the vesting base date and quarterly thereafter over the next 3 years).</ix:nonNumeric> Options generally expire <ix:nonNumeric id="F_001215" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20200101_20201231" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the date of grant unless the optionee is a 10% stockholder, in which case the term will be <ix:nonNumeric id="F_001214" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20200101_20201231" format="ixt-sec:durwordsen">five years</ix:nonNumeric> from the date of grant. Unvested options exercised are subject to the Company&#8217;s repurchase right. <ix:nonNumeric id="F_001212" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20200101_20201231">Shares reserved for issuance increases on January&#160;1 of each year commencing on January&#160;1, 2016 and ending on January&#160;1, 2024 by the lesser of (i)&#160;the amount equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_001213" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20140901_20140930" decimals="INF" scale="-2">4</ix:nonFraction>% of the number of shares issued and outstanding on December&#160;31 immediately prior to the date of increase or (ii)&#160;such lower number of shares as may be determined by the board of directors. As of December&#160;31, 2020, the Company has reserved <ix:nonFraction unitRef="U_xbrlishares" id="F_001211" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">7,909,854</ix:nonFraction> shares of its common stock that remains unissued for issuance under the 2014 Plan.</ix:nonNumeric></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of shares upon share option exercise or share unit conversion is made through issuance of new shares authorized under the plan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain Common Stock option holders have the right to exercise unvested options, subject to a right held by the Company to repurchase the stock, at the original exercise price, in the event of voluntary or involuntary termination of employment of the stockholder. The shares are generally released from repurchase provisions ratably over four years. The Company accounts for the cash received in consideration for the early exercised options as a liability. At December&#160;31, 2020 and 2019, <ix:nonFraction unitRef="U_xbrlishares" id="F_001216" name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_001217" name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> shares of Common Stock were subject to repurchase by the Company.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000533_dcnt_47159627-8e91-48c6-85f2-23479bd5072e" continuedAt="F_000533_dcnt_bd35e49e-6fef-429e-8d1e-b4acb20abc1b">
<ix:nonNumeric id="F_000601" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option transactions, including forfeited options granted under the 2014 Plan as well as prior plans, are summarized below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In Years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic&#160;Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001218" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,018</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001226" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0000921299_20191231" decimals="2">26.63</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001219" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,692</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001227" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0000921299_20200101_20201231" decimals="2">31.55</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_001220" name="fgen:StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001228" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0000921299_20200101_20201231" decimals="2">10.73</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_001221" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_0000921299_20200101_20201231" decimals="-3" scale="3">73</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001229" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0000921299_20200101_20201231" decimals="2">39.92</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_001222" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0000921299_20200101_20201231" decimals="-3" scale="3">234</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001230" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0000921299_20200101_20201231" decimals="2">40.11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001223" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,290</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0000921299_20201231" decimals="2">32.94</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001234">6.60</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001237" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">86,013</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest, December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001224" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,929</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001232" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_0000921299_20201231" decimals="2">32.76</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001235">6.50</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001238" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">84,125</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001225" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,576</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001233" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0000921299_20201231" decimals="2">29.50</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001236">5.10</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001239" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">66,943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total intrinsic value of options exercised during the years ended December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001240" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20201231" decimals="-5" scale="6">89.6</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_001241" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20191231" decimals="-5" scale="6">59.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001242" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20181231" decimals="-5" scale="6">97.5</ix:nonFraction> million, respectively.</p><ix:nonNumeric id="F_000602" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes RSU activity:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value&#160;at&#160;Grant</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2019</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001243" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,483</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001248" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231" decimals="2">49.05</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001244" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,354</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001249" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="2">29.99</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_001245" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="-3" scale="3">813</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001250" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="2">45.55</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_001246" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="-3" scale="3">131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.14%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001251" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="2">39.25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,893</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.14%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001252" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="2">37.60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among the vested RSUs during the year ended December&#160;31, 2020, <ix:nonFraction unitRef="U_xbrlishares" id="F_001253" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" contextRef="C_0000921299_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">526,055</ix:nonFraction> shares were released and issued, while the remaining was withheld for the related payroll taxes. The estimated weighted-average fair value of the awards granted during the years ended December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001254" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_20200101_20201231" decimals="2">29.99</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001255" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_20190101_20191231" decimals="2">54.74</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001256" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_20180101_20181231" decimals="2">53.69</ix:nonFraction>, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ESPP</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2014, the Company adopted a 2014 ESPP that became effective on November&#160;13, 2014. The 2014 ESPP is designed to enable eligible employees to periodically purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="U_xbrlipure" id="F_001257" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20140901_20140930" decimals="2" scale="-2">15</ix:nonFraction>% of their eligible compensation, subject to any plan or IRS limitations. At the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="U_xbrlipure" id="F_001258" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20140901_20140930" decimals="2" scale="-2">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last day of the offering period. Purchases are accomplished through participation in discrete offering periods. The 2014 ESPP is intended to qualify as an ESPP under Section&#160;423 of the Internal Revenue Code. <ix:nonNumeric id="F_001260" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20200101_20201231">The Company has reserved <ix:nonFraction unitRef="U_xbrlishares" id="F_001259" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20140930" decimals="INF" format="ixt:numdotdecimal">1,600,000</ix:nonFraction> shares of its common stock for issuance under the 2014 ESPP and shares reserved for issuance increases January&#160;1 of each year commencing January&#160;1, 2016 by the lesser of (i)&#160;a number of shares equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_001261" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20140901_20140930" decimals="INF" scale="-2">1</ix:nonFraction>% of the total number of outstanding shares of common stock on December&#160;31 immediately prior to the date of increase&#59; (ii)&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_001262" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20140901_20140930" decimals="INF" format="ixt:numdotdecimal">1,200,000</ix:nonFraction> shares or (iii)&#160;such number of shares as may be determined by the board of directors.</ix:nonNumeric> There were <ix:nonFraction unitRef="U_xbrlishares" id="F_001263" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">143,876</ix:nonFraction> shares, <ix:nonFraction unitRef="U_xbrlishares" id="F_001264" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">135,115</ix:nonFraction> shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_001265" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">230,317</ix:nonFraction> shares purchased by employees under the 2014 Purchased Plan for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expected term of 2014 ESPP shares is the average of the remaining purchase periods under each offering period.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000533_dcnt_bd35e49e-6fef-429e-8d1e-b4acb20abc1b" continuedAt="F_000533_dcnt_c8201a19-6d9c-4ab8-9407-903e5c91bfeb">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation</span></p><ix:nonNumeric id="F_000603" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was recorded directly to research and development and selling, general and administrative expense for the years ended December&#160;31, 2020, 2019 and 2018 was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001266" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,229</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001267" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,015</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001268" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,491</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001269" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,491</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001270" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001271" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,651</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001272" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">72,720</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001273" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">66,267</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001274" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,142</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:continuation id="F_000560_cnt_1">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the fair value of stock options using the Black-Scholes option valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair market value of common stock is based on the closing price of the Company&#8217;s common stock as reported on the NASDAQ Global Select Market on the date of the grant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of employee stock-based compensation is estimated using the following assumptions:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Expected Term.</span><span style="color:#000000;"> Expressed as a weighted-average, the expected life of the options is based on the average period the stock options are expected to be outstanding and was based on the Company&#8217;s historical information of the option exercise patterns and post-vesting termination behavior as well as contractual terms of the instruments.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Expected Volatility.</span><span style="color:#000000;"> The Company considers its historical volatility data for volatility considerations for its ESPP. </span><span style="Background-color:#FFFFFF;">Historically, the expected volatility for all other stock-based compensation was based upon a blend of the Company&#8217;s and comparable public entities&#8217;&#160;historical volatility. Since the third quarter of 2020, the</span><span style="color:#000000;"> expected volatility for all other stock-based compensation is currently based upon the Company&#8217;s historical volatility data.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Risk-Free Interest Rate.</span><span style="color:#000000;"> Expressed as a weighted-average, the risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company&#8217;s stock options.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Expected Dividend Yield.</span><span style="color:#000000;"> The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future.</span></p></td></tr></table></div></ix:continuation><ix:nonNumeric id="F_000604" name="fgen:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to estimate the fair value of stock options granted and ESPPs using the Black-Scholes option valuation model were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001275">5.7</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001276">5.3</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001277">5.4</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001278" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="3" scale="-2">67.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001279" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="3" scale="-2">68.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001280" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="3" scale="-2">67.9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001281" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="3" scale="-2">0.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001282" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="3" scale="-2">2.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001283" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="3" scale="-2">2.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001284" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001285" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001286" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average estimated fair value</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001287" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="2">18.36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001288" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="2">31.98</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001289" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="2">32.12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ESPPs</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001290">0.5 - 2.0</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001291">0.5 - 2.0</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001292">0.5 - 2.0</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001296">47.5 - 77.1</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001297">48.1 - 62.1</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001298">47.3 - 75.3</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001302">0.1 - 2.9</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001303">1.3 - 2.9</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001304">0.8 - 2.9</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001308" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001309" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001310" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average estimated fair value</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001311" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231" decimals="2">17.53</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001312" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231" decimals="2">19.27</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001313" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231" decimals="2">16.27</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, there was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001314" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0000921299_us-gaapAwardTypeAxis_fgenStockOptionAwardsMember_20201231" decimals="-5" scale="6">63.9</ix:nonFraction> million of total unrecognized compensation costs, net of estimated forfeitures, related to non-vested stock option awards granted that will be recognized on a straight-line basis over the weighted-average period of <ix:nonNumeric id="F_001315" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0000921299_us-gaapAwardTypeAxis_fgenStockOptionAwardsMember_20200101_20201231" format="ixt-sec:duryear">2.59</ix:nonNumeric> years. As of December&#160;31, 2020, there was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001316" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="-5" scale="6">55.5</ix:nonFraction> million of total unrecognized compensation costs, net of estimated forfeitures, related to non-vested RSUs granted that will be recognized on a straight-line basis over the weighted-average period of <ix:nonNumeric id="F_001317" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" format="ixt-sec:duryear">2.73</ix:nonNumeric> years.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000533_dcnt_c8201a19-6d9c-4ab8-9407-903e5c91bfeb">

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2019, a warrant to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_001318" name="fgen:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod" contextRef="C_0000921299_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">4,430</ix:nonFraction> shares of our common stock was exercised and there was <ix:nonFraction unitRef="U_xbrlishares" id="F_001320" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0000921299_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_001319" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0000921299_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> warrant to purchase shares of Common Stock outstanding at December&#160;31, 2020 and 2019.</p></ix:continuation><ix:nonNumeric id="F_000534" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net Loss Per Share</p></td></tr></table></div><ix:nonNumeric id="F_000605" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following weighted impacts of outstanding securities were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the three years presented (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001321" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,694</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001322" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,602</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001323" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,815</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001324" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="-3" scale="3">564</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001325" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,187</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001326" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20180101_20181231" decimals="-3" scale="3">820</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001327" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20200101_20201231" decimals="-3" scale="3">306</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001328" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20190101_20191231" decimals="-3" scale="3">260</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001329" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20180101_20181231" decimals="-3" scale="3">195</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001330" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001331" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20190101_20191231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001332" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20180101_20181231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001333" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,564</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001334" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,050</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001335" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,834</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000535" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">FibroGen,&#160;Inc. 401(k) Plan</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company&#8217;s full-time U.S.-based employees are eligible to make contributions to the Company&#8217;s 401(k) Plan. Under this plan, participating employees may defer up to <ix:nonFraction unitRef="U_xbrlipure" id="F_001336" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" contextRef="C_0000921299_20200101_20201231" decimals="INF" scale="-2">60</ix:nonFraction>% of their pretax salary during the year, but not more than statutory limits. The Company may elect to match employee contributions. Matching contributions of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001337" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="C_0000921299_20200101_20201231" decimals="-5" scale="6">3.2</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_001338" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="C_0000921299_20190101_20191231" decimals="-5" scale="6">3.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001339" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="C_0000921299_20180101_20181231" decimals="-5" scale="6">2.9</ix:nonFraction> million were made during years ended December&#160;31, 2020, 2019 and 2018, respectively.</p></ix:nonNumeric><ix:nonNumeric id="F_000536" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000536_dcnt_3ca04126-9427-4215-b5d6-4faccd740483">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div><ix:nonNumeric id="F_000606" name="fgen:ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of loss before income taxes are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Domestic</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001340" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">195,617</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001341" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,538</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001342" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">38,472</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001343" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,686</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001344" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_0000921299_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">79,180</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001345" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">47,644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before provision for income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001346" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0000921299_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">188,931</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001347" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0000921299_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">76,642</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001348" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0000921299_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">86,116</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000607" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision for income taxes consists of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001349" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001350" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001351" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001352" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001353" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001354" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001355" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="C_0000921299_20200101_20201231" decimals="-3" scale="3">360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001356" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">328</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001357" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001358" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_0000921299_20200101_20201231" decimals="-3" scale="3">360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001359" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">328</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001360" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">304</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001361" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001362" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001363" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001364" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001365" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001366" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001367" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001368" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001369" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001370" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001371" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001372" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total provision for income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001373" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000921299_20200101_20201231" decimals="-3" scale="3">360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001374" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000921299_20190101_20191231" decimals="-3" scale="3">328</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001375" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000921299_20180101_20181231" decimals="-3" scale="3">304</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000536_dcnt_3ca04126-9427-4215-b5d6-4faccd740483" continuedAt="F_000536_dcnt_bf1ae849-fb76-4a8a-9935-4dd8f52c1ace">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000608" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is the reconciliation between the statutory federal income tax rate and the Company&#8217;s effective tax rate:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax at statutory federal rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001376" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0000921299_20200101_20201231" decimals="3" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001377" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0000921299_20190101_20191231" decimals="3" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001378" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0000921299_20180101_20181231" decimals="3" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001379" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0000921299_20200101_20201231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001380" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0000921299_20190101_20191231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001381" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0000921299_20180101_20181231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001382" name="fgen:EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost" contextRef="C_0000921299_20200101_20201231" decimals="3" scale="-2">2.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001383" name="fgen:EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost" contextRef="C_0000921299_20190101_20191231" decimals="3" scale="-2">6.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001384" name="fgen:EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost" contextRef="C_0000921299_20180101_20181231" decimals="3" scale="-2">14.5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefit due to intercompany transfer of assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001385" name="fgen:EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets" contextRef="C_0000921299_20200101_20201231" decimals="3" scale="-2">41.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001386" name="fgen:EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets" contextRef="C_0000921299_20190101_20191231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001387" name="fgen:EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets" contextRef="C_0000921299_20180101_20181231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance on intercompany transfer of assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001388" name="fgen:EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets" contextRef="C_0000921299_20200101_20201231" decimals="3" sign="-" scale="-2">41.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001389" name="fgen:EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets" contextRef="C_0000921299_20190101_20191231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001390" name="fgen:EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets" contextRef="C_0000921299_20180101_20181231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses not benefitted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001391" name="fgen:EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted" contextRef="C_0000921299_20200101_20201231" decimals="3" sign="-" scale="-2">23.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001392" name="fgen:EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted" contextRef="C_0000921299_20190101_20191231" decimals="3" sign="-" scale="-2">2.9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001393" name="fgen:EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted" contextRef="C_0000921299_20180101_20181231" decimals="3" sign="-" scale="-2">23.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign net operating losses not benefitted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001394" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="C_0000921299_20200101_20201231" decimals="3" scale="-2">0.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001395" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="C_0000921299_20190101_20191231" decimals="3" sign="-" scale="-2">21.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001396" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="C_0000921299_20180101_20181231" decimals="3" sign="-" scale="-2">11.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deduction limitation on executive compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001397" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" contextRef="C_0000921299_20200101_20201231" decimals="3" sign="-" scale="-2">0.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001398" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" contextRef="C_0000921299_20190101_20191231" decimals="3" sign="-" scale="-2">2.5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001399" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" contextRef="C_0000921299_20180101_20181231" decimals="3" sign="-" scale="-2">0.5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001400" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0000921299_20200101_20201231" decimals="3" sign="-" scale="-2">0.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001401" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0000921299_20190101_20191231" decimals="3" sign="-" scale="-2">0.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001402" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0000921299_20180101_20181231" decimals="3" sign="-" scale="-2">0.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001403" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0000921299_20200101_20201231" decimals="3" sign="-" scale="-2">0.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001404" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0000921299_20190101_20191231" decimals="3" sign="-" scale="-2">0.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001405" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0000921299_20180101_20181231" decimals="3" sign="-" scale="-2">0.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000609" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and state net operating loss carryforwards</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001406" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">134,033</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001407" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">91,267</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carryforwards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001408" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">62,465</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001409" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign net operating loss carryforwards</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001410" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,417</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001411" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,786</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001412" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,399</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001413" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease obligations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001414" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001415" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,698</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserves and accruals</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001416" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,875</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001417" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,353</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001418" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,550</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001419" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001420" name="fgen:DeferredTaxAssetsIntangibleAssets" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">75,915</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001421" name="fgen:DeferredTaxAssetsIntangibleAssets" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001422" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001423" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0000921299_20191231" decimals="-3" scale="3">284</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001424" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">342,897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001425" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">222,113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001426" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">337,824</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001427" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">213,847</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001428" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,073</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001429" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001430" name="fgen:DeferredTaxLiabilitiesFixedAssets" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,073</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001431" name="fgen:DeferredTaxLiabilitiesFixedAssets" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001432" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001433" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001434" name="us-gaap:DeferredTaxLiabilities" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,073</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001435" name="us-gaap:DeferredTaxLiabilities" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net deferred tax assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001436" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001437" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A valuation allowance has been provided to reduce the deferred tax assets to an amount management believes is more likely than not to be realized. Expected realization of the deferred tax assets for which a valuation allowance has not been recognized is based on upon the reversal of existing temporary differences and future taxable income.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The valuation allowance increased by $<ix:nonFraction unitRef="U_iso4217USD" id="F_001438" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0000921299_20200101_20201231" decimals="-5" scale="6">124.0</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_001439" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0000921299_20190101_20191231" decimals="-5" scale="6">19.9</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001440" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0000921299_20180101_20181231" decimals="-5" scale="6">34.4</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Due to uncertainty surrounding the realization of the favorable tax attributes in the future tax returns, the Company has established a valuation allowance against its otherwise recognizable net deferred tax assets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, the Company transferred certain intellectual property rights relating to its Chinese business between its wholly owned subsidiaries that are based in different tax jurisdictions. The transferor entity was not subject to income taxes in its local jurisdiction. The acquiring entity of the intellectual property is entitled to amortize the acquisition price of the intangible assets for tax purposes. In accordance with ASU 2016-16, <span style="font-style:italic;">Intra-Entity Transfers of Assets Other Than Inventory</span>, the Company recognized a deferred tax asset of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001441" name="us-gaap:DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory" contextRef="C_0000921299_20201231" decimals="-5" scale="6">78.7</ix:nonFraction> million for the temporary difference arising from the acquirer&#8217;s excess tax basis. Furthermore, based upon the weight of available evidence, the Company recognized a full valuation allowance against this deferred tax asset since it does not currently believe that realization of this gross deductible temporary difference is more likely than not. Accordingly, this inter-company transfer did not have a material impact to the Company&#8217;s consolidated financial statements.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000536_dcnt_bf1ae849-fb76-4a8a-9935-4dd8f52c1ace" continuedAt="F_000536_dcnt_27448a18-7259-4d29-9169-ef9a45c2054d">

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020, the Company had net operating loss carryforwards available to offset future taxable income of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001442" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">606.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001443" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-5" scale="6">133.6</ix:nonFraction> million for federal and state tax purposes, respectively. These carryforwards will begin to expire in <ix:nonNumeric id="F_001444" name="fgen:OperatingLossCarryforwardsExpirationYear" contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2026</ix:nonNumeric> for federal and <ix:nonNumeric id="F_001445" name="fgen:OperatingLossCarryforwardsExpirationYear" contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">2021</ix:nonNumeric> for state purposes, if not utilized before these dates. The Company also had foreign net operating loss carryforwards of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001446" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20201231" decimals="-5" scale="6">172.9</ix:nonFraction> million which expire between <ix:nonNumeric id="F_001447" name="fgen:OperatingLossCarryforwardsExpirationYear" contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20200101_20201231">2021</ix:nonNumeric> and <ix:nonNumeric id="F_001448" name="fgen:OperatingLossCarryforwardsExpirationYear" contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20200101_20201231">2030</ix:nonNumeric> if not utilized.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020, the Company had approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001449" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">66.9</ix:nonFraction>&#160;million of federal and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001450" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" contextRef="C_0000921299_srtStatementGeographicalAxis_stprCA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-5" scale="6">32.9</ix:nonFraction>&#160;million of California research and development tax credit and other tax credit carryforwards available to offset future taxable income. The federal credits begin to expire in <ix:nonNumeric id="F_001451" name="fgen:OtherTaxCreditCarryforwardsExpirationYear" contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2021</ix:nonNumeric> and the California research credits have no expiration dates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and state tax laws impose substantial restrictions on the utilization of net operating loss and credit carryforwards in the event of an &#8220;ownership change&#8221; for tax purposes, as defined in IRC Section&#160;382. The Company reviewed its stock ownership for year ended December&#160;31, 2020 and concluded <ix:nonFraction unitRef="U_xbrlipure" id="F_001452" name="fgen:ExperienceHistoricalOwnershipChanges" contextRef="C_0000921299_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="-2">no</ix:nonFraction> ownership changes occurred which would result in a reduction of its net operating loss or in its research and development credits expiring unused. If additional ownership change occurs, the utilization of net operating loss and credit carryforwards could be significantly reduced.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Uncertain Tax Positions</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had unrecognized tax benefits of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001453" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0000921299_20201231" decimals="-5" scale="6">48.6</ix:nonFraction> million as of December&#160;31, 2020. Approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001456" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="C_0000921299_20201231" decimals="-5" scale="6">0.5</ix:nonFraction> million of unrecognized tax benefits, if recognized, would affect the effective tax rate. The interest accrued as of December&#160;31, 2020 and 2019 was immaterial.</p><ix:nonNumeric id="F_000610" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending amounts of unrecognized income tax benefits during the three years ended December&#160;31, 2020 is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Federal&#160;and&#160;State</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2017</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001457" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,361</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase due to prior positions</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001458" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20180101_20181231" decimals="-3" scale="3">379</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase due to current year position</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001459" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,216</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001460" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,956</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease due to prior positions</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001461" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20190101_20191231" decimals="-3" scale="3">111</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase due to current year position</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001462" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,418</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001463" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,263</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease due to prior positions</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001464" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20200101_20201231" decimals="-3" scale="3">137</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase due to current year position</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001465" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,448</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001466" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">48,574</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. <ix:nonNumeric id="F_001467" name="us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible" contextRef="C_0000921299_20200101_20201231">The Company does not anticipate a material change to its unrecognized tax benefits over the next twelve months that would affect the Company&#8217;s effective tax rate.</ix:nonNumeric></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies interest and penalties as a component of tax expense, if any.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the U.S. federal jurisdiction, U.S. state and other foreign jurisdictions. The U.S. federal and U.S. state taxing authorities may choose to audit tax returns for tax years beyond the statute of limitation period due to significant tax attribute carryforwards from prior years, making adjustments only to carryforward attributes. The foreign statute of limitation generally remains open from <ix:nonNumeric id="F_001468" name="us-gaap:OpenTaxYear" contextRef="C_0000921299_us-gaapTaxPeriodAxis_us-gaapEarliestTaxYearMember_20200101_20201231">2011</ix:nonNumeric> to <ix:nonNumeric id="F_001469" name="us-gaap:OpenTaxYear" contextRef="C_0000921299_us-gaapTaxPeriodAxis_us-gaapLatestTaxYearMember_20200101_20201231">2020</ix:nonNumeric>. The Company is not currently under audit in any tax jurisdiction.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000536_dcnt_27448a18-7259-4d29-9169-ef9a45c2054d">
</ix:continuation><ix:nonNumeric id="F_000537" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000537_dcnt_197a77c5-fd5f-4a43-9eb1-d43c95f9959b">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Related Party Transactions</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas is an equity investor in the Company and considered a related party. During the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded license and development revenue related to collaboration agreements with Astellas of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001470" name="us-gaap:RevenueFromRelatedParties" contextRef="C_0000921299_srtProductOrServiceAxis_fgenLicenseAndDevelopmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231" decimals="-5" scale="6">33.5</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_001471" name="us-gaap:RevenueFromRelatedParties" contextRef="C_0000921299_srtProductOrServiceAxis_fgenLicenseAndDevelopmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231" decimals="-5" scale="6">158.8</ix:nonFraction> million, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001472" name="us-gaap:RevenueFromRelatedParties" contextRef="C_0000921299_srtProductOrServiceAxis_fgenLicenseAndDevelopmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231" decimals="-5" scale="6">35.2</ix:nonFraction> million, respectively. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2020, 2019 and 2018, the Company also recorded drug product revenue from Astellas of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001473" name="fgen:DrugProductRevenueFromRelatedParty" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20200101_20201231" decimals="-5" scale="6">4.3</ix:nonFraction> million, $(<ix:nonFraction unitRef="U_iso4217USD" id="F_001474" name="fgen:DrugProductRevenueFromRelatedParty" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20190101_20191231" decimals="-5" sign="-" scale="6">36.3</ix:nonFraction>) million, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001475" name="fgen:DrugProductRevenueFromRelatedParty" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20180101_20181231" decimals="-5" scale="6">64.8</ix:nonFraction> million, respectively. The drug product revenue from Astellas for the year ended December 31, 2020 included $<ix:nonFraction unitRef="U_iso4217USD" id="F_001476" name="fgen:DrugProductRevenueFromRelatedParty" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20200101_20201231" decimals="-5" scale="6">8.2</ix:nonFraction> million under the Japan Agreement, and a $<ix:nonFraction unitRef="U_iso4217USD" id="F_001477" name="us-gaap:RevenueFromRelatedParties" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_20200101_20201231" decimals="-5" sign="-" scale="6">4.0</ix:nonFraction> million reduction to revenue as a change in estimated variable consideration at the time an updated listed price for roxadustat was issued by the Japanese Ministry of Health, Labour and Welfare related to roxadustat API sales in 2018. The drug product revenue from Astellas for the year ended December 31, 2019 included a change in estimated variable consideration that resulted in a $<ix:nonFraction unitRef="U_iso4217USD" id="F_001478" name="us-gaap:RevenueFromRelatedParties" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_20190101_20191231" decimals="-5" sign="-" scale="6">36.3</ix:nonFraction> million reduction to revenue related to the product revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001479" name="us-gaap:RevenueFromRelatedParties" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_20180101_20181231" decimals="-5" scale="6">64.8</ix:nonFraction> million for API recorded in 2018. See Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, for details. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded expense related to collaboration agreements with Astellas of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001480" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231" decimals="-5" scale="6">0.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_001481" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231" decimals="-5" scale="6">2.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001482" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231" decimals="-5" scale="6">1.5</ix:nonFraction>&#160;million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, accounts receivable from Astellas were $<ix:nonFraction unitRef="U_iso4217USD" id="F_001483" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231" decimals="-5" scale="6">4.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001484" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231" decimals="-5" scale="6">4.8</ix:nonFraction>&#160;million, respectively. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, total deferred revenue from Astellas were $<ix:nonFraction unitRef="U_iso4217USD" id="F_001485" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231" decimals="-5" scale="6">7.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001486" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231" decimals="-5" scale="6">0.4</ix:nonFraction>&#160;million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019, prepaid expenses and other current assets from Astellas was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001489" name="fgen:SuppliesNet" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20191231" decimals="-5" scale="6">125.2</ix:nonFraction> million of net unbilled contract assets, representing a $<ix:nonFraction unitRef="U_iso4217USD" id="F_001487" name="us-gaap:Supplies" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20191231" decimals="-5" scale="6">130.0</ix:nonFraction> million unbilled contract asset related to two regulatory milestones under the Europe Agreement with Astellas associated with the planned MAA submission to the EMA, net of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001491" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20191231" decimals="-5" scale="6">4.8</ix:nonFraction> million of associated deferred revenue. According to the Europe Agreement, this $<ix:nonFraction unitRef="U_iso4217USD" id="F_001488" name="us-gaap:Supplies" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20191231" decimals="-5" scale="6">130.0</ix:nonFraction> million is not billable to Astellas until the submission of an MAA, therefore the net contract asset was included in the prepaid expenses and other current assets line on the Company&#8217;s consolidated balance sheet as of December 31, 2019. The $<ix:nonFraction unitRef="U_iso4217USD" id="F_001492" name="us-gaap:Supplies" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20200630" decimals="-5" scale="6">130.0</ix:nonFraction> million was billed to Astellas upon the submission of an MAA in the second quarter of 2020. There was <ix:nonFraction unitRef="U_iso4217USD" id="F_001490" name="fgen:SuppliesNet" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> such contract asset balance as of December 31, 2020. See Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, for details.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, amounts due to Astellas were $<ix:nonFraction unitRef="U_iso4217USD" id="F_001493" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20201231" decimals="-5" scale="6">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001494" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20191231" decimals="-5" scale="6">36.9</ix:nonFraction>&#160;million, respectively. The amounts due are included in accrued liabilities and accounts payable on the consolidated balance sheets. The amount as of December 31, 2019 included the above-mentioned $<ix:nonFraction unitRef="U_iso4217USD" id="F_001495" name="us-gaap:RevenueFromRelatedParties" contextRef="C_0000921299_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_20190101_20191231" decimals="-5" scale="6">36.3</ix:nonFraction> million of a change in estimated variable consideration related to the API product revenue recognized in 2018, which was fully paid during the first quarter of 2020.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000537_dcnt_197a77c5-fd5f-4a43-9eb1-d43c95f9959b">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, FibroGen Beijing and AstraZeneca completed the establishment of a jointly owned entity, Falikang, which was determined to be an unconsolidated VIE. As such, Falikang is accounted for as an equity method investment, and considered as a related party to the Company. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s total investments in Falikang was </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approximately $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001496" name="us-gaap:InvestmentIncomeNet" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20200901_20200930" decimals="-5" scale="6">2.8</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which is the total of the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001497" name="us-gaap:VariableInterestEntityOwnershipPercentage" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20200901_20200930" decimals="3" scale="-2">51.1</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of Falikang&#8217;s equity and the acquisition costs. In addition, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company recognized its proportionate share of the reported profits or losses of Falikang, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eginning September 15, 2020, as other income (loss) in the consolidated statement of operations, and as an adjustment to its investment in unconsolidated subsidiary in the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condensed </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated balance sheet. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang has not incurred material profit or loss to date. As of December 31, 2020, the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company&#8217;s </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">equity method </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investment in Falikang was $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001498" name="us-gaap:EquityMethodInvestments" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20201231" decimals="-5" scale="6">2.7</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> prepaid expenses and other current assets</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> included its miscellaneous receivables of $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001499" name="fgen:MiscellaneousReceivables" contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20201231" decimals="-5" scale="6">0.9</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million from Falikang. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 3, </span><span style="font-style:italic;">Acquisition and Variable Interest Entity</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for details</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></ix:continuation><ix:nonNumeric id="F_000538" name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true" continuedAt="F_000538_dcnt_103a86d2-a5cc-4bf8-ae37-d4c8c0c72275">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Segment and Geographic Information</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has determined that the chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). The CODM reviews financial information presented for the Company&#8217;s various clinical trial programs as well as results on a consolidated basis. License revenues and development revenues received are not allocated to various programs for purposes of determining a profit measure and resource allocation decisions are made by the CODM based primarily on consolidated results. As such, the Company has concluded that it operates as <ix:nonFraction unitRef="U_fgenSegment" id="F_001500" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0000921299_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> segment. Supplemental enterprise-wide information has been presented below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Geographic Revenues</p><ix:nonNumeric id="F_000611" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Geographic revenues, which are based on the bill-to region, are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001501" name="us-gaap:Revenues" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">67,161</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001502" name="us-gaap:Revenues" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">132,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001503" name="us-gaap:Revenues" contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">112,916</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japan</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001504" name="us-gaap:Revenues" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,660</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001505" name="us-gaap:Revenues" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">122,475</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001506" name="us-gaap:Revenues" contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">100,002</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001507" name="us-gaap:Revenues" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">72,498</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001508" name="us-gaap:Revenues" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001509" name="us-gaap:Revenues" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001510" name="us-gaap:Revenues" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenAllOtherMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001511" name="us-gaap:Revenues" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenAllOtherMember_20190101_20191231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001512" name="us-gaap:Revenues" contextRef="C_0000921299_srtStatementGeographicalAxis_fgenAllOtherMember_20180101_20181231" decimals="-3" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001513" name="us-gaap:Revenues" contextRef="C_0000921299_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">176,319</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001514" name="us-gaap:Revenues" contextRef="C_0000921299_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">256,577</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001515" name="us-gaap:Revenues" contextRef="C_0000921299_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">212,958</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Geographic Assets</p><ix:nonNumeric id="F_000612" name="fgen:InventoryByGeographicAreasTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory by geographic location are as follows (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001516" name="us-gaap:InventoryNet" contextRef="C_0000921299_srtStatementGeographicalAxis_countryUS_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,715</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001517" name="us-gaap:InventoryNet" contextRef="C_0000921299_srtStatementGeographicalAxis_countryUS_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001518" name="us-gaap:InventoryNet" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,815</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001519" name="us-gaap:InventoryNet" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,887</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventory</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001520" name="us-gaap:InventoryNet" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,530</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001521" name="us-gaap:InventoryNet" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,887</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000613" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net by geographic location are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001522" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000921299_srtStatementGeographicalAxis_countryUS_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,673</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001523" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000921299_srtStatementGeographicalAxis_countryUS_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,325</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001524" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,974</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001525" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,418</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001526" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">33,647</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001527" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000614" name="fgen:SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets and operating lease right-of-use assets, net by geographic location are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001528" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0000921299_srtStatementGeographicalAxis_countryUS_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,551</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001529" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0000921299_srtStatementGeographicalAxis_countryUS_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,237</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001530" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20201231" decimals="-3" scale="3">55</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001531" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20191231" decimals="-3" scale="3">365</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total finance lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001532" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001533" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001534" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000921299_srtStatementGeographicalAxis_countryUS_20201231" decimals="-3" scale="3">47</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001535" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000921299_srtStatementGeographicalAxis_countryUS_20191231" decimals="-3" scale="3">75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001536" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,996</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001537" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,856</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001538" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000921299_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,043</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001539" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000921299_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,931</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000538_dcnt_103a86d2-a5cc-4bf8-ae37-d4c8c0c72275">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Customer Concentration</p><ix:nonNumeric id="F_000615" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s revenues to date have been generated from the following collaboration partners that respectively accounted for 10% or more of the Company&#8217;s total revenue and accounts receivable:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage&#160;of&#160;Revenue</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage&#160;of&#160;Accounts&#160;Receivable</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas&#8212;Related party</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001540" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="2" scale="-2">21</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001541" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231" decimals="2" scale="-2">48</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001542" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231" decimals="2" scale="-2">47</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001543" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231" decimals="2" scale="-2">10</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001544" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231" decimals="2" scale="-2">17</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001545" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231" decimals="2" scale="-2">37</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001546" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231" decimals="2" scale="-2">52</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001547" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20180101_20181231" decimals="2" scale="-2">53</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001548" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231" decimals="2" scale="-2">26</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001549" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231" decimals="2" scale="-2">81</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company started selling roxadustat in China since late 2019 through a growing number of pharmaceutical distributors located in China. For the year ended December 31, 2020, the aggregate revenue from distributors represented <ix:nonFraction unitRef="U_xbrlipure" id="F_001550" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" scale="-2">42</ix:nonFraction>% of the consolidated revenue, with no individual distributor representing over 10% of the total revenue. As of December 31, 2020, the aggregate accounts receivable from distributors represented <ix:nonFraction unitRef="U_xbrlipure" id="F_001551" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" scale="-2">64</ix:nonFraction>% of the consolidated accounts receivable, with no material balance from any individual distributor. The aggregate revenue from distributors for the year ended December 31, 2019 and the aggregate accounts receivable from distributors as of December 31, 2019 were immaterial.</p></ix:continuation>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000539" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" contextRef="C_0000921299_20200101_20201231" escape="true">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SCHEDULE_II">Schedule II: Valuation and Qualifying Accounts</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Charged</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Charged</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">to Other</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance&#160;at</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Credited)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts -</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beginning&#160;of</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">to Statement</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deductions,</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance&#160;at</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Operation</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Equity</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End&#160;of&#160;Year</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowances for deferred tax assets</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year ended December&#160;31, 2020</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001552" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">213,847</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001557" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">123,977</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001562" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001567" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001572" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">337,824</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year ended December&#160;31, 2019</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001553" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">193,987</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001558" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,860</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001563" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001568" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001573" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">213,847</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year ended December&#160;31, 2018</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001554" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">159,540</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001559" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,447</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001564" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001569" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20180101_20181231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001574" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">193,987</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Allowances for rebates and discounts</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year ended December&#160;31, 2020</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001555" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,102</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001560" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,497</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001565" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">14,867</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001570" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,184</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001575" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20201231" decimals="-3" scale="3">548</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year ended December&#160;31, 2019</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001556" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20181231" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001561" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,102</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001566" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001571" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20190101_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001576" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,102</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC">ITEM&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9A_CONTROLS_PROCEDURES">ITEM&#160;9A. CONTROLS AND PROCEDURES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attached as exhibits 31.1 and 31.2 to this Annual Report on Form 10-K are certifications of our <span style="color:#000000;">Chief Executive Officer and our Chief Financial Officer</span> required by Rule 13a-14(a) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;Rule 13a-14(a) and 15d-15(e) Certifications&#8221;). This Controls and Procedures section of the Annual Report on Form 10-K includes the information concerning the controls evaluation referred to in the Rule 13a-14(a) and 15d-15(e) Certifications.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of <span style="color:#000000;">December 31, 2020, the end of the period covered by this Annual Report on Form 10-K.</span> Disclosure controls and procedures (as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the <span style="color:#000000;">Securities Exchange Act of 1934, as amended (the &#8220;</span>Exchange Act&#8221;)) are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules&#160;and forms and that such information is accumulated and communicated to the company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective as of December 31, 2020 because of the material weaknesses in our internal control over financial reporting described below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rule 13a-15(f) of the Exchange Act. Our internal control over financial reporting is a process established under the supervision of and with the participation of our management, including our <span style="color:#000000;">Chief Executive Officer and our Chief Financial Officer. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. </span>In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management, with the participation and under the supervision of our <span style="color:#000000;">Chief Executive Officer and our Chief Financial Officer</span>, evaluated our internal control over financial reporting as of December&#160;31, 2020, the end of our fiscal year, using the criteria established in<span style="font-style:italic;"> Internal Control - Integrated Framework (2013)</span> set forth by the Committee of Sponsoring Organizations of the Treadway Commission. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our evaluation, our management has concluded that our internal control over financial reporting was not effective as of December 31, 2020 because of the material weaknesses in our internal control over financial reporting described below. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020, we have identified a material weakness in the risk assessment component of internal control as we did not appropriately design and maintain an effective risk assessment process at a precise enough level to identify new and evolving risks of material misstatement to the financial statements as a result of changes in our business operation. This material weakness gave rise to the following additional control deficiencies, which we also determined to be material weaknesses. We did not design and maintain effective controls related to the timely identification of shipments associated with drug product revenue, and we did not design and maintain effective controls related to the timely identification of changes in estimated variable consideration related to drug product revenue. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of these material weaknesses could result in material misstatements in the drug product revenue, contract asset or contract liability account balances or disclosures in our annual or interim consolidated financial statements that would not be prevented or detected.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The material weaknesses described above did not result in any material misstatements of our consolidated financial statements or disclosures, but did result in immaterial out-of-period adjustments to drug product revenue related to pre-commercial shipments of drug product, contract assets and contract liabilities, and related financial statement disclosures during the quarter ended September 30, 2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2020 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report that appears herein.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Remediation Plan and Status</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Board of Directors and management are committed to maintaining a strong internal control environment. We have developed a detailed remediation plan and are making progress of what will be a multi-step remediation process to fully remediate the material weaknesses described above. Specifically, as of December 31, 2020, we have started, and will continue to the process of the steps including, but not limited to, the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have performed a comprehensive risk assessment process, and will continue to refine the risk assessment, to identify and design our control activities related to the above mentioned material weaknesses&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have identified and designed new controls and procedures associated with drug product revenue, and where applicable implemented new procedures and controls during the fourth quarter of 2020, and will continue to implement new procedures and controls in the future&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We started the process to hire additional resources to strengthen our accounting and internal audit functions.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we will continue to assess risks on a continuous basis to timely identify new exposures or risk categories as business practices change, and we plan to conduct a comprehensive review and, as applicable, update our existing internal control framework to ensure that it has identified, developed and deployed the appropriate business process controls to meet the objectives and address the risks identified. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The material weaknesses will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. We believe the measures described above will remediate these material weaknesses and strengthen our internal control over financial reporting. As we continue to evaluate and work to remediate these material weaknesses, we may determine to take additional measures to address these deficiencies or determine to modify certain of the remediation measures described above.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Limitations on the Effectiveness of Controls</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule&#160;13a-15(d)&#160;and 15d-15(d)&#160;of the Exchange Act that occurred during the most recent fiscal quarter ended December&#160;31, 2020 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9B_OR_INFORMATION">ITEM&#160;9B. OTHER INFORMATION</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_III">PART III</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">ITEM&#160;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference to our Proxy Statement for our 2021 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days after the end of the fiscal year ended December&#160;31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Code of Conduct</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a Code of Business Conduct that applies to all of our directors, officers and employees. A copy of our Code of Business Conduct can be found on our website (<span style="text-decoration:underline;">www.FibroGen.com</span>) under &#8220;Corporate Governance.&#8221; The contents of our website are not a part of this report.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we intend to promptly disclose the nature of any amendment to, or waiver from, our Code of Business Conduct that applies to our principal executive officer, principal financial officer, principal accounting officer or persons performing similar functions on our website in the future.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_11_EXECUTIVE_COMPENSATION">ITEM&#160;11. EXECUTIVE COMPENSATION</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference to our Proxy Statement for our 2021 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days after the end of the fiscal year ended December&#160;31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference to our Proxy Statement for our 2021 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days after the end of the fiscal year ended December&#160;31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference to our Proxy Statement for our 2021 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days after the end of the fiscal year ended December&#160;31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC">ITEM&#160;14. PRINCIPAL ACCOUNTING FEES AND SERVICES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference to our Proxy Statement for our 2021 Annual Meeting of Stockholders to be filed with the SEC within 120&#160;days after the end of the fiscal year ended December&#160;31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IV">PART IV</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH">ITEM&#160;15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(a)<span style="font-weight:normal;">&#160;We have filed the following documents as part of this Annual Report on Form 10-K:</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Consolidated Financial Statements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information in response to this Item is included in Part II, Item&#160;8 of this Annual Report on Form 10-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Financial Statement Schedules</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule II is included on page <a href="#SCHEDULE_II"><span style="text-decoration:none;">168</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. All other schedules are omitted because they are not required or the required information is included in the consolidated financial statements or notes thereto.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Exhibits</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Item&#160;15(b) below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;<span style="font-style:italic;">Exhibits</span><span style="font-weight:normal;">&#8212;We have filed, or incorporated into this Annual Report on Form 10-K by reference, the exhibits listed below. Where an exhibit is incorporated by reference, the number in parentheses indicates the document to which cross-reference is made. Refer to the end of this table for a listing of cross-reference documents.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="8" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporation By Reference</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Description</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SEC File No.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.1</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514420380/d824859dex31.htm"><span style="text-decoration:none;">Amended and Restated Certificate of Incorporation of FibroGen, Inc.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/21/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.2</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514380087/d720189dex34.htm"><span style="text-decoration:none;">Amended and Restated Bylaws of FibroGen, Inc.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/23/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.1</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514420380/d824859dex41.htm"><span style="text-decoration:none;">Form of Common Stock Certificate.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/21/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.2</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459017022738/fgen-ex46_97.htm"><span style="text-decoration:none;">Shareholders&#8217; Agreement by and among FibroGen International (Cayman) Limited and certain of its shareholders, dated as of September 8, 2017.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/8/2017</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.3</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514381669/d720189dex417.htm"><span style="text-decoration:none;">Common Stock Purchase Agreement by and between FibroGen, Inc. and AstraZeneca AB, dated as of October&#160;20, 2014.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/24/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.4</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020008161/fgen-ex44_244.htm"><span style="text-decoration:none;">Description of Capital Stock of FibroGen, Inc.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/2/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1(i)+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex103i.htm"><span style="text-decoration:none;">FibroGen, Inc. Amended and Restated 2005 Stock Plan.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3(i)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1(ii)+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex103ii.htm"><span style="text-decoration:none;">Forms of stock option agreement, restricted stock purchase agreement and stock appreciation right agreement under the FibroGen, Inc. Amended and Restated 2005 Stock Plan.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3(ii)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1(iii)+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex103iii.htm"><span style="text-decoration:none;">Form of stock option agreement under the FibroGen, Inc. Amended and Restated 2005 Stock Plan applicable to options exchanged pursuant to FibroGen, Inc.&#8217;s 2010 amendment and exchange offer.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3(iii)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1(iv)+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex103iv.htm"><span style="text-decoration:none;">Form of 2010 amendment to the form of stock option agreement under the FibroGen, Inc. Amended and Restated 2005 Stock Plan applicable to options amended pursuant to FibroGen, Inc.&#8217;s 2010 amendment and exchange offer.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3(iv)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1(v)+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex103v.htm"><span style="text-decoration:none;">Form of 2013 amendment to the form of stock option agreement under the FibroGen, Inc. Amended and Restated 2005 Stock Plan applicable to options amended or exchanged pursuant to FibroGen, Inc.&#8217;s 2010 amendment and exchange offer.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3(v)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514406755/d808943dex104.htm"><span style="text-decoration:none;">FibroGen, Inc. 2014 Equity Incentive Plan and forms of agreement thereunder.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/12/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514406755/d808943dex105.htm"><span style="text-decoration:none;">FibroGen, Inc. 2014 Employee Stock Purchase Plan.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/12/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020022855/fgen-ex101_190.htm"><span style="text-decoration:none;">FibroGen, Inc. Non-Employee Director Compensation Policy, as amended.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/7/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312518048551/d500266dex105.htm"><span style="text-decoration:none;">FibroGen, Inc. 2018 Bonus Plan.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/16/2018</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex108.htm"><span style="text-decoration:none;">Lease Agreement by and between FibroGen, Inc. and X-4 Dolphin LLC, dated as of September&#160;22, 2006&#59; as amended by First Amendment to Lease by and between FibroGen, Inc. and X-4 Dolphin LLC, dated as of October&#160;10, 2007&#59; as amended by Second Amendment to Lease by and between FibroGen, Inc. and X-4 Dolphin LLC, dated as of June&#160;29, 2009&#59; as amended by Third Amendment to Lease by and between FibroGen, Inc. and Are-San Francisco No. 43, LLC (as successor in interest to X-4 Dolphin LLC), dated as of May&#160;19, 2011&#59; as amended by Fourth Amendment to Lease by and between FibroGen, Inc. and Are-San Francisco No. 43, LLC, dated as of September&#160;8, 2011.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex109.htm"><span style="text-decoration:none;">Lease for Premises in Beijing BDA Biomedical Park by and among Beijing FibroGen Medical Technology Development Co., Ltd., Beijing Economic and Technology Investment Development Parent Company and Beijing BDA International Biological Pharmaceutical Investment Management Co., Ltd., effective as of February&#160;1, 2013, as supplemented by the Supplementary Agreement to Lease of Premises in Beijing BDA Biomedical Park by and among Beijing FibroGen Medical Technology Development Co., Ltd., Beijing Economic Technology Investment Development Parent Company and Beijing BDA International Biological Pharmaceutical Investment Management Co., Ltd., dated as of January&#160;30, 2013.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1010.htm"><span style="text-decoration:none;">Form of Employment Offer Letter.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020051315/fgen-ex101_102.htm"><span style="text-decoration:none;">Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., effective as of June&#160;1, 2005.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/5/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9(i)&#8224;</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459019004979/fgen-ex109i_141.htm"><span style="text-decoration:none;">Amendment No. 1 to Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., effective as of January&#160;1, 2013.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9(i)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/27/2019</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1012.htm"><span style="text-decoration:none;">Anemia License and Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., effective as of April&#160;28, 2006.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1013.htm"><span style="text-decoration:none;">Amendment to Anemia License and Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., effective as of August&#160;31, 2006.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1014.htm"><span style="text-decoration:none;">Amendment No. 2 to Anemia License and Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., effective as of December&#160;1, 2006.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1015.htm"><span style="text-decoration:none;">Supplement to Anemia License and Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., effective as of April&#160;28, 2006.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1016.htm"><span style="text-decoration:none;">Amendment No. 3 to Anemia License and Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., dated as of May&#160;10, 2012.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020051315/fgen-ex103_98.htm"><span style="text-decoration:none;">Amended and Restated License, Development and Commercialization Agreement (China) by and among FibroGen China Anemia Holdings, Ltd., Beijing FibroGen Medical Technology Development Co., Ltd., FibroGen International (Hong Kong) Limited and AstraZeneca AB, effective as of July&#160;30, 2013.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/5/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020051315/fgen-ex102_99.htm"><span style="text-decoration:none;">Amended and Restated License, Development and Commercialization Agreement (for the U.S. and Certain Other Territories) by and between FibroGen, Inc. and AstraZeneca AB, effective as of July&#160;30, 2013.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/5/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020051315/fgen-ex104_97.htm"><span style="text-decoration:none;">License Agreement by and between FibroGen, Inc. and the University of Miami and its School of Medicine, dated as of May&#160;23, 1997.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/5/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020051315/fgen-ex105_96.htm"><span style="text-decoration:none;">First Amendment to May&#160;23, 1997 License Agreement by and between FibroGen, Inc. and University of Miami, effective as of July&#160;29, 1999.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/5/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1021.htm"><span style="text-decoration:none;">Research and Commercialization Agreement by and among FibroGen, Inc., GenPharm International Inc., Medarex, Inc. and FibroPharma, Inc., effective as of July&#160;9, 1998.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1022.htm"><span style="text-decoration:none;">Amendment No. 1 to Research and Commercialization Agreement by and among FibroGen, Inc., GenPharm International Inc., Medarex, Inc. and FibroPharma, Inc., effective as of June&#160;30, 2001.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21&#8224;</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020051315/fgen-ex106_95.htm"><span style="text-decoration:none;">Amendment No. 2 to Research and Commercialization Agreement by and among FibroGen, Inc., GenPharm International Inc., Medarex, Inc. and FibroPharma, Inc., effective as of January&#160;28, 2002.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/5/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020051315/fgen-ex107_101.htm"><span style="text-decoration:none;">License Agreement by and between FibroGen, Inc. and the Dana-Farber Cancer Institute, Inc., effective as of March&#160;29, 2006.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/5/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1025.htm"><span style="text-decoration:none;">Amendment No. 1 to License agreement by and between FibroGen, Inc. and Dana-Farber Cancer Institute, Inc., effective as of February&#160;28, 2006.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.25</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.24</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1026.htm"><span style="text-decoration:none;">Amendment No. 2 to License Agreement by and between FibroGen, Inc. and Dana-Farber Cancer Institute, Inc., effective as of March&#160;14, 2006.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.25+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514380087/d720189dex1027.htm"><span style="text-decoration:none;">Form of Indemnity Agreement by and between FibroGen, Inc. and its directors and officers.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.27</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/23/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(i)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1028i.htm"><span style="text-decoration:none;">Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of November&#160;29, 2007.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(i)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(ii)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1028ii.htm"><span style="text-decoration:none;">Letter Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of June&#160;26, 2008.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(ii)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(iii)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1028iii.htm"><span style="text-decoration:none;">Letter Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of August&#160;18, 2008.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(iii)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(iv)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1028iv.htm"><span style="text-decoration:none;">Amendment No. 1 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of May&#160;28, 2009.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(iv)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(v)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1028v.htm"><span style="text-decoration:none;">Amendment No. 3 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of November&#160;5, 2010.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(v)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(vi)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1028vi.htm"><span style="text-decoration:none;">Amendment No. 4 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of January&#160;24, 2011.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(vi)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(vii)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1028vii.htm"><span style="text-decoration:none;">Amendment No. 5 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of April&#160;15, 2011.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(vii)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(viii)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1028viii.htm"><span style="text-decoration:none;">Amendment No. 6 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of May&#160;26, 2011.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(viii)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(ix)&#8224;</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1028ix.htm"><span style="text-decoration:none;">Amendment No. 7 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of January&#160;1, 2012.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(ix)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(x)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1028x.htm"><span style="text-decoration:none;">Amendment No. 8 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of July&#160;10, 2012.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(x)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xi)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1028xi.htm"><span style="text-decoration:none;">Amendment No. 9 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of November&#160;26, 2012.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(xi)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xii)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1028xii.htm"><span style="text-decoration:none;">Amendment No. 10 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of June&#160;21, 2013.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(xii)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xiii)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1028xiii.htm"><span style="text-decoration:none;">Amendment No. 11 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of July&#160;9, 2013.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(xiii)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xiv)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1028xiv.htm"><span style="text-decoration:none;">Amendment No. 12 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of August&#160;1, 2013.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(xiv)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xv)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1028xv.htm"><span style="text-decoration:none;">Amendment No. 13 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of March&#160;6, 2014.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(xv)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xvi)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1028xvi.htm"><span style="text-decoration:none;">Amendment No. 14 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of February&#160;5, 2014.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(xvi)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xvii)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459015010594/fgen-ex1028xvii_777.htm"><span style="text-decoration:none;">Amendment No. 15 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of October 20, 2014.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(xvii)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/12/2015</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xviii)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459015010594/fgen-ex1028xviii_778.htm"><span style="text-decoration:none;">Amendment No. 16 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of December 8, 2014.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(xviii)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/12/2015</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xix)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459015010594/fgen-ex1028xix_776.htm"><span style="text-decoration:none;">Amendment No. 17 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of December 8, 2014.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(xix)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/12/2015</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xx)&#8224;</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459015010594/fgen-ex1028xx_779.htm"><span style="text-decoration:none;">Amendment No. 18 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of February 15, 2015.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(xx)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/12/2015</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxi)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459015010594/fgen-ex1028xxi_780.htm"><span style="text-decoration:none;">Amendment No. 19 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of March 1, 2015.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(xxi)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/12/2015</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxii)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459015010594/fgen-ex1028xxii_775.htm"><span style="text-decoration:none;">Amendment No. 20 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of June 1, 2015.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(xxii)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/12/2015</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxiii)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459015010594/fgen-ex1028xxiii_781.htm"><span style="text-decoration:none;">Amendment No. 21 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of May 29, 2015.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(xxiii)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/12/2015</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxiv)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459015010594/fgen-ex1028xxiv_782.htm"><span style="text-decoration:none;">Amendment No. 23 to the Process Development and Clinical Supply Agreement by and between FibroGen, Inc. and Boehringer Ingelheim Pharma GmbH &#38; Co. KG, effective as of September 1, 2015.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28(xxiv)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/12/2015</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxv)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459016023280/fgen-ex1026xxv_114.htm"><span style="text-decoration:none;">Amendment No. 22 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, effective as of April 14, 2016.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxv)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/8/2016</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxvi)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459016023280/fgen-ex1026xxvi_113.htm"><span style="text-decoration:none;">Amendment No. 24 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, retroactively effective as of September 15, 2015.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxvi)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/8/2016</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxvii)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459016023280/fgen-ex1026xxvii_111.htm"><span style="text-decoration:none;">Amendment No. 25 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, retroactively effective as of October 15, 2015.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxvii)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/8/2016</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxviii)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459016023280/fgen-ex1026xxviii_112.htm"><span style="text-decoration:none;">Amendment No. 26 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, effective as of June 30, 2016.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxviii)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/8/2016</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxix)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459016028331/fgen-ex1026_175.htm"><span style="text-decoration:none;">Amendment No. 27 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, effective as of July 25, 2016.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxix)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/8/2016</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxx)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459016028331/fgen-ex1026_174.htm"><span style="text-decoration:none;">Amendment No. 28 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, effective as of September 22, 2016.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxx)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/8/2016</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">177</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxxi)&#8224;</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459017003095/fgen-ex1026_997.htm"><span style="text-decoration:none;">Amendment No. 29 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, effective as of December 20, 2016.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxxi)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/2017</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxxii)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459017003095/fgen-ex1026_996.htm"><span style="text-decoration:none;">Amendment No. 30 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, effective as of December 20, 2016.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxxii)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/1/2017</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxxiii)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459017009854/fgen-ex1026_231.htm"><span style="text-decoration:none;">Amendment No. 31 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, effective as of March 2, 2017</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxxiii)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/9/2017</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxxiv)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459018003508/fgen-ex1026xxxiv_389.htm"><span style="text-decoration:none;">Amendment No. 32 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, effective as of September 1, 2017</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxxiv)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/27/2018</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxxv)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459018003508/fgen-ex1026xxxv_390.htm"><span style="text-decoration:none;">Work Order No. 1 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, effective as of September 1, 2017</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxxv)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/27/2018</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxxvi)&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459019018022/fgen-ex1026xxxvi_150.htm"><span style="text-decoration:none;">Amendment No. 33 to the Process Development and Clinical Supply Agreement, by and between FibroGen, Inc. and Boehringer Ingelheim Biopharmaceuticals GmbH, effective as of January 4, 2019</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26(xxxvi)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/9/2019</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.27&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459017009854/fgen-ex1032_233.htm"><span style="text-decoration:none;">State-Owned Construction Land Use Right Granting Contract by and between FibroGen (China) Medical Technology Development Co., Ltd. and The Bureau of Land and Resources of Cangzhou, dated as of February 24, 2017</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/9/2017</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020008161/fgen-ex1028_711.htm"><span style="text-decoration:none;">Commercial Supply Agreement by and between FibroGen, Inc. and Catalent Pharma Solutions, LLC, effective as of January 1, 2020</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/2/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.29&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020012585/fgen-ex991_15.htm"><span style="text-decoration:none;">Master Supply Agreement by and among FibroGen, Inc., Shanghai SynTheAll Pharmaceutical Co., Ltd. and STA Pharmaceutical Hong Kong Limited, effective March 2, 2020</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/24/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.30&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020037760/fgen-ex102_89.htm"><span style="text-decoration:none;">Amendment No.1 to Master Supply Agreement by and among FibroGen, Inc., Shanghai SynTheAll Pharmaceutical Co., Ltd. and STA Pharmaceutical Hong Kong Limited, effective May 11, 2020</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/6/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.31&#8224;</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020037760/fgen-ex103_247.htm"><span style="text-decoration:none;">Second Amended and Restated License, Development and Commercialization Agreement by and among FibroGen China Anemia Holdings, Ltd., FibroGen China Medical Technology Development Co., Ltd., FibroGen International (Hong Kong) Limited, and AstraZeneca AB, effective July 1, 2020</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/6/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020037760/fgen-ex104_222.htm"><span style="text-decoration:none;">Amendment No. 1 to the Amended and Restated License, Development and Commercialization Agreement by and between FibroGen, Inc. and AstraZeneca AB, effective July 1, 2020</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/6/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.33&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020051315/fgen-ex108_100.htm"><span style="text-decoration:none;">Amendment No. 2 to Master Supply Agreement by and among FibroGen, Inc., Shanghai SynTheAll Pharmaceutical Co., Ltd. and STA Pharmaceutical Hong Kong Limited, effective July 24, 2020</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/5/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.34&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020051315/fgen-ex109_217.htm"><span style="text-decoration:none;">Master Supply Agreement by and between FibroGen, Inc. and AstraZeneca UK Limited, effective September 10, 2020</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/5/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.35*&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex1035_604.htm"><span style="text-decoration:none;">Master Services Agreement by and between FibroGen, Inc. and Samsung Biologics Co., Ltd., effective as of October 30, 2020</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.36*&#8224;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex1036_605.htm"><span style="text-decoration:none;">Product Specific Agreement by and between FibroGen, Inc. and Samsung Biologics Co., Ltd., effective as of October 30, 2020</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.37+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1031.htm"><span style="text-decoration:none;">Offer Letter, by and between FibroGen, Inc. and Pat Cotroneo, dated as of October&#160;23, 2000.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.31</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.38+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000119312514359619/d720189dex1030.htm"><span style="text-decoration:none;">Offer Letter, by and between FibroGen, Inc. and K. Peony Yu, dated as of November&#160;21, 2008.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-199069</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.30</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2014</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.39+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/921299/000156459019042615/fgen-ex107_130.htm"><span style="text-decoration:none;">Offer Letter, by and between FibroGen, Inc. and James Schoeneck, dated as of September 18, 2019.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/12/2019</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.40+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020008161/fgen-ex1032_243.htm"><span style="text-decoration:none;">Offer Letter, by and between FibroGen, Inc. and Christine Chung, dated as of June 17, 2008.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/2/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.41+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020008161/fgen-ex1033_241.htm"><span style="text-decoration:none;">Offer Letter, by and between FibroGen, Inc. and Elias Kouchakji, dated as of January 24, 2014.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.33</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/2/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.42+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020008161/fgen-ex1034_242.htm"><span style="text-decoration:none;">Offer Letter, by and between FibroGen, Inc. and Enrique Conterno, dated as of December 17, 2019.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.34</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/2/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.43+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020037760/fgen-ex101_12.htm"><span style="text-decoration:none;">Offer Letter, by and between FibroGen, Inc. and Thane Wettig, dated as of May 7, 2020.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/6/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.44*+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex1044_204.htm"><span style="text-decoration:none;">Offer Letter, by and between FibroGen, Inc. and Mark Eisner, dated as of October 22, 2020.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.45+</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0000921299/000156459020008161/fgen-ex1035_673.htm"><span style="text-decoration:none;">Form of Executive Officer Change in Control and Severance Agreement</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-36740</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.35</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/2/2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1*</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex211_241.htm"><span style="text-decoration:none;">Subsidiaries of FibroGen, Inc.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1*</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex231_10.htm"><span style="text-decoration:none;">Consent of PricewaterhouseCoopers LLP.</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1*</span></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#POWER_OF_ATTORNEY"><span style="text-decoration:none;">Power of Attorney (included in signature pages).</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1*</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex311_14.htm"><span style="text-decoration:none;">Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2*</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex312_9.htm"><span style="text-decoration:none;">Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1*</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex321_13.htm"><span style="text-decoration:none;">Certification of Principal Executive Officer and Principal Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350)(1).</span></a></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS*</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH*</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL&#160;Taxonomy Schema Linkbase Document</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL*</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Calculation Linkbase Document</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF*</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Definition Linkbase Document</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB*</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Labels Linkbase Document</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE*</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Presentation Linkbase Document</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the inline XBRL document)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:89.29%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">*</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Filed herewith.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Portions of this exhibit (indicated by asterisks) have been omitted as the Company has determined that (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm if publicly disclosed.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates a management contract or compensatory plan.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of FibroGen, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;<span style="font-style:italic;">Financial Statement Schedules</span><span style="font-weight:normal;">&#8212;See (a)&#160;2 above. All other financial statement schedules are omitted because they are not applicable because the requested information is included in the consolidated financial statements or notes thereto.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;16.&#160;&#160;FORM 10-K SUMMARY</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized,&#160;in the City of San Francisco, State of California.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:7.2pt;">
<td valign="top" style="width:45.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top" style="width:53.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FIBROGEN, INC.</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:45.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:45.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 1, 2021</p></td>
<td valign="bottom" style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" style="width:3.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:44.78%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Enrique Conterno</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:45.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:44.78%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enrique Conterno</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:45.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:45.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: <span style="color:#000000;">March 1, 2021</span></p></td>
<td valign="bottom" style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&#160;&#160;&#160;&#160;</p></td>
<td valign="bottom" style="width:3.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:44.78%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Pat Cotroneo</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:45.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:3.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:44.78%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pat Cotroneo</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President, Finance and Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="POWER_OF_ATTORNEY">POWER OF ATTORNEY</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Enrique Conterno and Pat Cotroneo, jointly and severally, his or her attorneys-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:7.2pt;">
<td valign="bottom" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Signature</span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Title</span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Date</span></p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Enrique Conterno</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Enrique Conterno</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Pat Cotroneo</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President, Finance and Chief Financial Officer <span style="font-style:italic;">(Principal Financial and Accounting Officer)</span></p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pat Cotroneo</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ James A. Schoeneck</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman of the Board and Director</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">James A. Schoeneck</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Suzanne Blaug</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Suzanne Blaug</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Aoife Brennan, M.B., B.Ch.</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Aoife Brennan, M.B., B.Ch.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Benjamin F. Cravatt, Ph.D.</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Benjamin F. Cravatt, Ph.D.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jeffrey L. Edwards</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Jeffrey L. Edwards</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jeffrey W. Henderson</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Jeffrey W. Henderson</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Maykin Ho, Ph.D.</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Maykin Ho, Ph.D.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Thomas F. Kearns Jr.</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Thomas F. Kearns Jr.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kalevi Kurkij&#228;rvi, Ph.D.</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Kalevi Kurkij&#228;rvi, Ph.D.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Gerald Lema</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Gerald Lema</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Rory B. Riggs</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Rory B. Riggs</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>2
<FILENAME>fgen-ex1035_604.htm
<DESCRIPTION>EX-10.35
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex1035_604.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.35</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MASTER SERVICES AGREEMENT</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">between</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SAMSUNG BIOLOGICS CO., LTD.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FIBROGEN, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211058746 v8</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;text-align:left;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:14.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 1</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.24%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEFINITIONS</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 2</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.24%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RELATED AGREEMENTS AND EXHIBITS</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 3</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.24%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MANAGEMENT OF SERVICE</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 4</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.24%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SERVICES</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 5</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.24%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SERVICE DESCRIPTIONS</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 6</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.24%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHANGES TO THE SPECIFICATIONS, ANALYTICAL METHODS, MANUFACTURING PROCESS, FACILITY OR EQUIPMENT</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 7</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.24%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REGULATORY APPROVALS AND INSPECTIONS.</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 8</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.24%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">QUALITY COMPLIANCE</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 9</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.24%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONSIDERATION AND PAYMENT TERMS</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 10</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.24%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIALITY</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 11</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.24%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OWNERSHIP OF MATERIALS AND INTELLECTUAL PROPERTY</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 12</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.24%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WARRANTIES.</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 13</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.24%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INDEMNIFICATION</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 14</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.24%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DISCLAIMER OF CONSEQUENTIAL DAMAGES; LIMITATION OF LIABILITY</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 15</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.24%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TERM AND TERMINATION OF AGREEMENT</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 16</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.24%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARBITRATION</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
</tr>
<tr>
<td valign="top"  style="width:14.12%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECTION 17</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.24%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MISCELLANEOUS</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:5.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MASTER SERVICES AGREEMENT</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Master Services Agreement<font style="font-weight:bold;"> </font>(this &#8220;<font style="font-weight:bold;">MSA</font>&#8221;) is <font style="letter-spacing:-0.15pt;">entered into as of the date of the last signature below, and is effective as of</font> October 30, 2020 <font style="letter-spacing:-0.15pt;">(the &#8220;</font><font style="font-weight:bold;letter-spacing:-0.15pt;">Effective Date</font><font style="letter-spacing:-0.15pt;">&#8221;) </font>by and between FibroGen, Inc., a Delaware corporation having its principal place of business at 409 Illinois Street, San Francisco, California, USA 94158 (<font style="font-weight:bold;">&#8220;Client&#8221;</font>), and Samsung Biologics Co., Ltd., a company with offices at [*] (<font style="font-weight:bold;">&#8220;SBL&#8221;</font>).&nbsp;&nbsp;Client and SBL are sometimes referred to herein individually as a <font style="font-weight:bold;">&#8220;Party&#8221;</font> and collectively as the <font style="font-weight:bold;">&#8220;Parties&#8221;</font>.</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;letter-spacing:-0.15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, Client and SBL entered into the binding Technology Transfer Agreement with effective date September 18, 2020 (&#8220;</font>TTA<font style="font-weight:normal;">&#8221;); and</font></p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;letter-spacing:-0.15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, Client and SBL wish to enter into a business relationship whereby SBL will provide Client with certain biologics manufacturing and/or development services, as contemplated by the TTA. </font></p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE,<font style="font-weight:normal;"> in consideration of the mutual promises, covenants and agreements hereinafter set forth and for other valuable consideration, the Parties agree as follows:</font></p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;text-transform:uppercase;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc457579730"></a><font style="text-decoration:underline;">SECTION 1</font><font style="text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="text-decoration:underline;text-transform:none;">DEFINITIONS</font></p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">Each of the following capitalized terms as used in this MSA, whether in the singular or plural, shall have the respective meanings set forth below.</font></p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.1</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Acceptance<font style="font-weight:normal;">&#8221; means the completion of the Acceptance Procedure by Client.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.2</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Acceptance Procedure<font style="font-weight:normal;">&#8221; means Client&#8217;s Quality Assurance review, if applicable, and approval of SBL&#8217;s Batch Related Documents, Certificate of Analysis, and Certificate of Compliance according to the applicable cGMP rules, regulations, standards, procedures, and QAA requirements, which typically commences following SBL&#8217;s Release of a Batch to the Client.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.3</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Affected Party<font style="font-weight:normal;">&#8221; is defined in Section 17.3.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.4</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Affiliate<font style="font-weight:normal;">&#8221; means any corporation, company, partnership or other entity which directly or indirectly, controls, is controlled by or is under common control with a Party hereto.&nbsp;&nbsp;For purposes of this definition, a corporation or other entity shall be regarded as controlling another corporation or other entity if it owns or directly or indirectly controls more than [*] of the voting stock or other ownership interest of the corporation or other entity, or if possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the corporation or other entity or the power to elect or appoint more than [*] of the members of the governing body of the corporation or other entity.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.5</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Applicable Laws<font style="font-weight:normal;">&#8221; means any and all applicable laws, rules, regulations, regulatory authority guidance standards  of any jurisdiction which are applicable to the Services in this MSA or any PSAs </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">3</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">that may be in effect from time to </font><font style="font-weight:normal;">time</font><font style="font-weight:normal;">, and shall include all statutes, enactments, acts of legislature, laws, ordinances, rules, regulations, notifications, guidelines, directions, directives and orders of any </font><font style="font-weight:normal;">Regulatory Authority, </font><font style="font-weight:normal;">statutory authority, </font><font style="font-weight:normal;">stock exchange, securities regulatory agency, </font><font style="font-weight:normal;">tribunal, board, or court or any central or state government or local authority or other governmental entity in such jurisdictions</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.6</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Background IP<font style="font-weight:normal;">&#8221; means any Intellectual Property related to a Product and/or its use, or the Manufacture of such Product, in each case, which is owned and/or controlled by a Party prior to the PSA Effective Date for such Product or developed or obtained by such Party outside of or not relating to the performance of this MSA and any PSA, and without use of any Confidential Information or Intellectual Property of the other Party.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.7</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Batch<font style="font-weight:normal;">&#8221; means the quantity of Product Manufactured by SBL which results from a single run of the applicable Manufacturing Process.</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.8</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Batch Record<font style="font-weight:normal;">&#8221; is defined in the applicable QAA.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:8.98%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.9</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Batch Related Documents<font style="font-weight:normal;">&#8221; means Manufacturing Documentation in support of the SBL&#8217;s Release of a Product.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.10</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Binding Year<font style="font-weight:normal;">&#8221; shall be defined in the applicable PSA.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.11</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">[*].&nbsp;&nbsp; </font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.12</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Cell Line<font style="font-weight:normal;">&#8221; means [*].</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.13</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Certificate of Analysis<font style="font-weight:normal;">&#8221; is defined in the applicable QAA.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.14</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Certificate of Compliance<font style="font-weight:normal;">&#8221; is defined in the applicable QAA.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.15</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Change<font style="font-weight:normal;">&#8221; is defined in Section 6.1.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.16</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Client<font style="font-weight:normal;">&#8221; is defined in the preamble.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.17</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Client Materials<font style="font-weight:normal;">&#8221; means Client reagents and other materials supplied by Client or its third party supplier to be used in the Service hereunder, as each is further defined in the PSA and/or applicable QAA.&nbsp;&nbsp;In the case of a Drug Product PSA, Client Materials shall also include Drug Substance and/or other active pharmaceutical ingredients, which may or may not be Manufactured by SBL.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.18</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Client Technology<font style="font-weight:normal;">&#8221; means know-how, technology, research and other information of Client relating to the Client Materials, Manufacturing Process, including analytical methods, quality control </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">4</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">analysis, specifications, transportation and storage requirements</font><font style="font-weight:normal;">,</font><font style="font-weight:normal;"> provided by </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> to SBL in connection with this MSA and applicable </font><font style="font-weight:normal;">PSA</font><font style="font-weight:normal;">. </font><font style="font-weight:normal;"> </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.19</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;[</font>*]<font style="font-weight:normal;">&#8221; has the meaning set forth in the PSA.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.20</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Clinical Product<font style="font-weight:normal;">&#8221; means a Drug Substance or Drug Product which is Manufactured by SBL pursuant to a PSA and which is to be used by Client in a research study or studies that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.21</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Commercial Product<font style="font-weight:normal;">&#8221; means a Drug Substance or Drug Product which is Manufactured by SBL which is intended for commercial sale and use by humans and for importation or exportation into countries or regions designated in each PSA.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.22</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Commercially Reasonable Efforts<font style="font-weight:normal;">&#8221; means with respect to an activity to be carried out by a Party pursuant to this MSA, the carrying out of such activity in a diligent manner, and using efforts and resources comparable to the efforts and resources commonly used in the contract manufacturing of biologics (in the case of SBL) or in the biopharmaceutical industry (in the case of Client) by companies with resources and expertise similar to those of such Party. &#8220;Commercially Reasonable Efforts&#8221; requires prompt assignment of responsibility for such task or activity to specific qualified employee(s) and allocation of resources designed to advance progress with respect to such task or activity but does not require the taking of actions (i) [*], (ii) [*], or (iii) [*].  </font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.23</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Critical<font style="font-weight:normal;"> </font>Raw Materials<font style="font-weight:normal;">&#8221;, &#8220;</font>Customized or Dedicated Raw Materials<font style="font-weight:normal;">&#8221; and &#8220;</font>Other Raw Materials<font style="font-weight:normal;">&#8221; shall be defined on a per-Product basis by the Core Team pursuant to 5.3.1.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.24</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Confidential Information<font style="font-weight:normal;">&#8221; means any confidential, trade secret or proprietary data, know-how and other information, whether technical or non-technical, of one Party that is disclosed by that Party (hereinafter the &#8220;</font>Disclosing Party<font style="font-weight:normal;">&#8221;) or otherwise becomes known to the other Party (hereinafter the &#8220;</font>Receiving Party<font style="font-weight:normal;">&#8221;) either under the Mutual Confidential Disclosure Agreement by and between the Parties, dated as of September 3, 2015 as amended, or hereunder in connection with this MSA or any PSA or QAA, regardless of form or manner of disclosure, i.e., whether disclosed in writing, in electric file or format or in other tangible manner, or orally, visually or in other intangible manner. Notwithstanding the foregoing, [*]. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.25</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Core Manufacturing Services<font style="font-weight:normal;">&#8221; shall mean the Services that range from storage of cell bank vials, manufacturing of Drug Substance and preparation of the final Drug Product, as well as storage of intermediates of Drug Substance and Drug Product. [*]. [*].</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.26</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Core Team<font style="font-weight:normal;">&#8221; is defined in Section 3.3.1.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">5</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.27</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Current Good Manufacturing Practices<font style="font-weight:normal;">&#8221; or &#8220;</font>cGMP<font style="font-weight:normal;">&#8221; means current good manufacturing practices and regulations applicable to the Manufacture of Product that are promulgated by any Regulatory Authority, including as promulgated under and in accordance with (i) the U.S. Federal Food, Drug and Cosmetic Act, Title 21 of the U.S. Code of Federal Regulations, Parts 210, 211, 600, 601 and 610, (ii) relevant EU legislation, including European Directive 2003/94/EC or national implementations of that Directive, (iii) relevant guidelines, including the EU Guidelines for Good Manufacturing Practices for Medicinal Products (Eudralex Vol. 4 and Annexes thereto), (iv) International Conference on Harmonization Good Manufacturing Practice Guide for Active Pharmaceuticals Ingredients and (v) and any analogous set of regulations, guidelines or standards as defined, from time to time, by any relevant Regulatory Authority having jurisdiction over the development, manufacture or commercialization of the Product, as applicable, in each case as in effect as of the date such manufacturing for the Product are or were conducted.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.28</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Damages<font style="font-weight:normal;">&#8221; means any damages, costs, expenses, fines, penalties (including reasonable attorneys&#8217; fees and costs), losses and liabilities.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.29</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Dispute<font style="font-weight:normal;">&#8221; is defined in Section 16.1.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.30</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Drug Product<font style="font-weight:normal;">&#8221; means a finished or intermediate dosage form that contains a Drug Substance, generally, but not necessarily, in association with one or more other ingredients.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.31</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Drug Substance<font style="font-weight:normal;">&#8221; means an active ingredient specified in the relevant PSA that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient.</font><font style="text-decoration:underline;font-weight:normal;"> </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.32</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Effective Date<font style="font-weight:normal;">&#8221; is defined in the preamble.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.33</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>EMA<font style="font-weight:normal;">&#8221; means the European Medicines Agency, or any successor agency.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.77%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.34</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="color:#000000;font-weight:normal;">&#8220;</font><font style="color:#000000;">Engineering Batch</font><font style="color:#000000;font-weight:normal;">&#8221; means a Batch that is intended to demonstrate the transfer of the Manufacturing Process to the Facility, and may be conducted under cGMP.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.35</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Facility<font style="font-weight:normal;">&#8221; means one or more of the manufacturing facilities of SBL where the Services shall be performed, located [*].</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.36</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>FDA<font style="font-weight:normal;">&#8221; means the United States Food and Drug Administration or any successor agency thereto.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.37</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Firm Period<font style="font-weight:normal;">&#8221; means the portion of a forecast that is binding on both Parties as defined pursuant to the applicable PSA.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.38</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Force Majeure Event<font style="font-weight:normal;">&#8221; is defined in Section 17.3.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">6</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.39</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Implementation Plan and Budget<font style="font-weight:normal;">&#8221; is defined in Section 6.2(b).</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.40</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Indemnified Party<font style="font-weight:normal;">&#8221; is defined in Section 13.3.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.41</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Indemnifying Party<font style="font-weight:normal;">&#8221; is defined in Section 13.3.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.42</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Intellectual Property<font style="font-weight:normal;">&#8221; means (i) patents, patent rights, provisional patent applications, patent applications, designs, registered designs, registered design applications, industrial designs, industrial design applications and industrial design registrations, including any and all divisions, continuations, continuations-in-part, extensions, restorations, substitutions, renewals, registrations, revalidations, reexaminations, reissues or additions, including supplementary certificates of protection, of or to any of the foregoing items; (ii) copyrights, copyright registrations, copyright applications, original works of authorship fixed in any tangible medium of expression, including literary works (including all forms and types of computer software, including all source code, object code, firmware, development tools, files, records and data, and all documentation related to any of the foregoing), pictorial and graphic works; (iii) trade secrets, technology, developments, discoveries and improvements, know-how, proprietary rights, formulae, confidential and proprietary information, technical information, techniques, inventions, designs, drawings, procedures, processes, models, formulations, manuals and systems, whether or not patentable or copyrightable, including all biological, chemical, biochemical, toxicological, pharmacological and metabolic material and information and data relating thereto and formulation, clinical, analytical and stability information and data which have actual or potential commercial value and are not available in the public domain; (iv) trademarks, trademark registrations, trademark applications, service marks, service mark registrations, service mark applications, business marks, brand names, trade names, trade dress, names, logos and slogans, Internet domain names, and all goodwill associated therewith; and (v) all other intellectual property or proprietary rights, in each case whether or not subject to statutory registration or protection.</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.43</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Invention<font style="font-weight:normal;">&#8221; is defined in Section 11.3.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.44</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Joint Steering Committee<font style="font-weight:normal;">&#8221; or &#8220;</font>JSC<font style="font-weight:normal;">&#8221; is defined in Section 3.2.1.</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.45</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Manufacturing<font style="font-weight:normal;">&#8221; or to &#8220;</font>Manufacture<font style="font-weight:normal;">&#8221; means the manufacturing of the Product, and any services relating to such manufacturing, including, but not limited to, testing, quality control, documentation, archiving, and packaging, and up to release of the Product, to be performed by SBL at the Facility under the MSA and any applicable PSA.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.46</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Manufacturing Documentation<font style="font-weight:normal;">&#8221; means with respect to a given Product, the data acquired and generated, documents and records describing or otherwise related to the Manufacturing Process including, without limitation: documents and records consisting of or containing process descriptions, requirements and specifications; Client Materials and Specifications; analytical methods, process trend and variability data; validations protocols and reports; process development reports; Master Batch Record, executed Batch Records; Batch Related Documents, Product specific SOPs, final </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">7</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Product and stability </font><font style="font-weight:normal;">quality</font><font style="font-weight:normal;"> control testing</font><font style="font-weight:normal;"> (including all raw data)</font><font style="font-weight:normal;">,</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">q</font><font style="font-weight:normal;">uality assurance, validation, </font><font style="font-weight:normal;">storage</font><font style="font-weight:normal;"> and shipping.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.47</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Manufacturing Process<font style="font-weight:normal;">&#8221; means, with respect to a given Product, the mutually agreed production process and analytical methods for the Manufacturing of the Product pursuant to the applicable PSA, as summarily described in the applicable QAA and as described in the Manufacturing Documentation, as such process may be changed from time to time in accordance with the MSA.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.48</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Master Batch Record<font style="font-weight:normal;">&#8221; means a document that is approved by Client and contains processing instructions (such as the detailed step, in-process controls, raw materials, ranges, etc.) for the Manufacture of the Product to ensure uniformity from batch to batch. A terminology of Manufacturing Batch Record can be used when Master Batch Record (MBR) is issued for the batch execution.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.49</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Non-Affected Party<font style="font-weight:normal;">&#8221; is defined in Section 17.3.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.50</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Non-Conforming Product<font style="font-weight:normal;">&#8221; means a Batch of Product that fails to conform to the Specifications, cGMP (if applicable), and/or other mutually agreed upon written express requirements for SBL to follow under the applicable PSA and the applicable QAA.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.51</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">[*]. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.52</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Party<font style="font-weight:normal;">&#8221; and &#8220;</font>Parties<font style="font-weight:normal;">&#8221; is defined in the preamble.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.53</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Pilot Batch<font style="font-weight:normal;">&#8221; means a Batch of Product designated as a pilot Batch which shall not comply with cGMP and is not required to meet the Specifications.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.54</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Pre-Approval Inspection<font style="font-weight:normal;">&#8221; or &#8220;</font>PAI<font style="font-weight:normal;">&#8221; means an on-site inspection of the Facility by the Regulatory Authority prior to granting the Regulatory Approval for a Commercial Product as required by various Regulatory Authorities to ensure that the Manufacturing Process and the Facility meet the appropriate requirements and comply with cGMP.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.55</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Process Validation Batch<font style="font-weight:normal;">&#8221; means a Batch of Commercial Product produced from a process validation (process performance qualification, or PPQ) run conducted by SBL hereunder to (i) demonstrate and document the consistency and reproducibility of the Manufacturing Process at the Facility, and (ii) support the Regulatory Approval of both the Product Manufactured and the Manufacturing Process at the Facility.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.56</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Product<font style="font-weight:normal;">&#8221; means Clinical Product or Commercial Product (whether bulk Drug Substance or Drug Product) to be Manufactured by SBL pursuant to this MSA and any applicable PSA.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.57</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Product Purchase Commitment<font style="font-weight:normal;">&#8221; is defined in Section 5.7.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">8</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.58</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Product Specific Agreement<font style="font-weight:normal;">&#8221; or &#8220;</font>PSA<font style="font-weight:normal;">&#8221; is defined in Section 2.1.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.59</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Project Management Team Leader<font style="font-weight:normal;">&#8221; is defined in Section 3.3.2.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.60</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>PSA Effective Date<font style="font-weight:normal;">&#8221; means the effective date of any PSA governed by this MSA.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.61</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Purchase Order<font style="font-weight:normal;">&#8221; is defined in Section 5.6.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.62</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Quality Agreement<font style="font-weight:normal;">&#8221; or &#8220;</font>QAA<font style="font-weight:normal;">&#8221; means that certain quality agreement that governs the responsibilities related to quality systems and quality requirements for the Product(s) Manufactured hereunder, including quality control, testing and release of such Product(s) at the Facility entered into by the Parties.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.63</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">[*].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.64</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Quarter<font style="font-weight:normal;">&#8221; means each period of three (3) consecutive calendar months beginning on January 1, April 1, July 1, or October 1.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.65</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Raw Materials<font style="font-weight:normal;">&#8221; means those materials that are used in the Services, including, but not limited to, chemicals, reagents, filters, excipients, disposable consumables, and secondary packaging materials. Raw Materials exclude the Client Materials. </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.66</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Reference Standards<font style="font-weight:normal;">&#8221; means standard materials prepared by Client and/or SBL in accordance with the applicable QAA. </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.67</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Regulatory Approval<font style="font-weight:normal;">&#8221; means all approvals, licenses, registrations or authorizations thereof of any national, regional, state or local regulatory agency, department, bureau or other governmental entity in any jurisdiction where the Product is marketed or intended to be marketed, necessary for the manufacture and sale of the Product, which manufacturing includes the Manufacturing of the Products at the Facility.</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.68</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Regulatory Authority<font style="font-weight:normal;">&#8221; means any national (e.g., the FDA), supra-national (e.g., the EMA), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, in any jurisdiction responsible for granting the Regulatory Approval.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.69</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>SBL Assignable Error<font style="font-weight:normal;">&#8221; means [*].</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.70</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>SBL&#8217;s Release<font style="font-weight:normal;">&#8221; means SBL&#8217;s release of Product to Client based on testing and manufacturing conformance with Applicable Laws and cGMPs (as per the Certificate of Compliance), the Process Description, the QAA, the Master Batch Record (MBR) and the Specifications (as documented on the Certificate of Analysis). </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">9</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.71</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Service<font style="font-weight:normal;">&#8221; or &#8220;</font>Services<font style="font-weight:normal;">&#8221; is defined in Section 2.1.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.72</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Service Fee<font style="font-weight:normal;">&#8221; is defined in Section 9.1.</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.73</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Specification(s)<font style="font-weight:normal;">&#8221; means the criteria for the Products, Client Materials, or Raw Materials, as the case may be, which details are provided in documentation as reviewed and approved in writing by the Parties.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.74</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Standard Operating Procedure(s)<font style="font-weight:normal;">&#8221; or &#8220;</font>SOP(s)<font style="font-weight:normal;">&#8221; means the standard operating procedures established by and mutually agreed upon by the Parties regarding the Manufacturing Process, and any other SBL standard operating procedures that are used in the performance of Services under the MSA or any PSA.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.75</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">[*]. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.76</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Technology Transfer<font style="font-weight:normal;">&#8221; means the activities by the Parties necessary to Manufacture the Product for Client at the Facility and may include: (i) transfer of the Client Technology and Client Material from Client to SBL; (ii) implementation of the Manufacturing Process at the Facility, including establishing a small scale Manufacturing Process model at SBL; (iii) Manufacturing Process fit activities, including required small- and large-scale process development and validation work as allocated between the Parties to SBL and process engineering required to modify / equip, qualify and validate the Facility for the Manufacturing of the Commercial Product; (iv) stability testing, if applicable, for the Product required for licensure; (v) comparability testing to the appropriate reference product, and (vi) regulatory support for Regulatory Approvals.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.77</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Term<font style="font-weight:normal;">&#8221; is defined in Section 15.1.</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.78</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">&#8220;</font>Warehouse<font style="font-weight:normal;">&#8221; means SBL&#8217;s warehouse for storage of the Product located at [*]</font><font style="color:#000000;font-weight:normal;">.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;text-transform:uppercase;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc457579731"></a><font style="text-decoration:underline;">SECTION 2</font><font style="text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="text-decoration:underline;text-transform:none;">RELATED AGREEMENTS AND EXHIBITS</font></p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.1</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Product Specific Agreements</font>.<font style="font-weight:normal;">&nbsp;&nbsp;Pursuant to one or more Product specific agreements entered into and mutually agreed from time to time by duly authorized representatives of the Parties (</font>&#8220;Product Specific Agreements&#8221; <font style="font-weight:normal;">or</font> &#8220;PSAs&#8221;<font style="font-weight:normal;">), SBL will perform Manufacturing Services for Client as specified in such PSAs and in accordance with the terms and conditions of this MSA (</font>&#8220;Services&#8221;<font style="font-weight:normal;">).&nbsp;&nbsp;Each PSA shall refer to this MSA and contain as applicable (i) a high level scope of work of the Services to be performed under such PSA which describes key activities, (ii) the Product for which SBL will perform such Services for Client, (iii) a description of the Cell Line; (iv) fees to be paid to SBL by Client for such Services with a general timing plan for invoicing and a more detailed plan to be provided where appropriate, (v) if such Services pertain to the Manufacture of the Product, the number of Batches of Product to be manufactured by SBL and delivered to Client and the </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">10</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Specifications, (vi) any other deliverables, (vii) the </font><font style="font-weight:normal;">F</font><font style="font-weight:normal;">acility where </font><font style="font-weight:normal;">such </font><font style="font-weight:normal;">Services are to be performed</font><font style="font-weight:normal;">, and (viii</font><font style="font-weight:normal;">) the Regulatory Approvals </font><font style="font-weight:normal;">to be obtained by the Parties</font><font style="font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;</font><font style="font-weight:normal;">[</font><font style="font-weight:normal;">*</font><font style="font-weight:normal;">]</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.2</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Quality Agreement (QAA).</font><font style="font-weight:normal;">&nbsp;&nbsp;The Parties shall agree upon and finalize a Quality Agreement within a reasonable period time after the execution of each PSA, and such PSA and Quality Agreement shall be incorporated into this MSA.&nbsp;&nbsp;The Quality Agreement may be amended from time to time, subject to the JSC&#8217;s approval followed by the Parties&#8217; written agreement pursuant to Section 17.10 (if applicable).</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.3</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Order of Precedence</font><font style="font-weight:normal;">. The Services shall be governed by the terms and conditions of this MSA, the applicable PSA, and any applicable Quality Agreement. In the event of a conflict between a Quality Agreement and either any provision of this MSA or any PSA, the MSA or PSA, respectively, shall control except with respect to Product quality terms, in which case, the Quality Agreement will control. In the event of a conflict between any provision of this MSA and the PSA, this MSA shall control, provided that the PSA shall control solely to the extent the PSA expressly states the Parties&#8217; intent to control as to a specific provision. </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;text-transform:uppercase;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc457579732"></a><font style="text-decoration:underline;">SECTION 3</font><font style="text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="text-decoration:underline;text-transform:none;">MANAGEMENT OF SERVICE</font></p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.1</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">General.</font><font style="font-weight:normal;">&nbsp;&nbsp;Each Party will be responsible for its internal decision-making process and for reasonably informing the other Party of its decisions affecting the Services in a regular and timely manner. Without limiting the foregoing, the Parties shall establish the joint committees or teams set forth herein to advise the Parties on certain matters including, without limitation, the Facility modification, the Technology Transfer, and optimization of the Manufacturing operations relating to the Product.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.2</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Joint Steering Committee.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.2.1</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Formation and Composition.</font><font style="font-weight:normal;">&nbsp;&nbsp;A joint steering committee will be formed for the Product (the &#8220;</font>Joint Steering Committee<font style="font-weight:normal;">&#8221; or &#8220;</font>JSC<font style="font-weight:normal;">&#8221;) if the Parties mutually agree that such JSC is necessary.&nbsp;&nbsp;The JSC will be a cross-functional committee composed of an equal number of representatives appointed by each of Client and SBL with each of Client and SBL having [*], and with [*] from each of Client and SBL having oversight for quality activities, and with [*] from each of Client and SBL having oversight for manufacturing and supply chain activities, including the transfer and implementation of the Manufacturing Process at the Facility. Either Party may replace any or all of its representatives at any time by providing notice, in writing, of such replacement to the other Party.  Each JSC representative (and any replacement therefor) shall have appropriate seniority, knowledge and experience to appropriately carry out its responsibilities on the JSC.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.2.2</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Responsibilities.</font>&nbsp;&nbsp;<font style="font-weight:normal;">The JSC shall (i) establish and oversee the governance structure for the Services, including the formation of the subcommittees herein; (ii) monitor any Facility modification and the Technology Transfer and Manufacturing strategy for the Product at the Facility, including strategies for the Regulatory Approval of the Facility to Manufacture the </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">11</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Product; (iii) provide strategic guidance to the </font><font style="font-weight:normal;">Core Team</font><font style="font-weight:normal;">; (iv) conduct</font><font style="font-weight:normal;"> high level</font><font style="font-weight:normal;"> project stage reviews with the </font><font style="font-weight:normal;">Core Team</font><font style="font-weight:normal;"> at appropriate milestones or completion of key deliverables or a </font><font style="font-weight:normal;">specified </font><font style="font-weight:normal;">sequence of event</font><font style="font-weight:normal;">s</font><font style="font-weight:normal;"> to review and approve key deliverables</font><font style="font-weight:normal;"> and </font><font style="font-weight:normal;">evaluate the </font><font style="font-weight:normal;">Core Team</font><font style="font-weight:normal;">&#8217;s progress and performance, all in order to ensure that the </font><font style="font-weight:normal;">Services are </font><font style="font-weight:normal;">being implemented appropriately; (v) advise on and/or resolve business, manufacturing, supply chain, quality, regulatory or other issues </font><font style="font-weight:normal;">unresolved at the </font><font style="font-weight:normal;">Core Team</font><font style="font-weight:normal;"> level</font><font style="font-weight:normal;">, including discussing any </font><font style="font-weight:normal;">[</font><font style="font-weight:normal;">*</font><font style="font-weight:normal;">]</font><font style="font-weight:normal;">; (vi) review and recommend for approval by the Parties any changes to the MSA</font><font style="font-weight:normal;"> or the applicable </font><font style="font-weight:normal;">PSA</font><font style="font-weight:normal;">; (vii) review and approve changes to the </font><font style="font-weight:normal;">Services, </font><font style="font-weight:normal;">Specifications, analytical methods, the Manufacturing Process, the Facility or equipment as </font><font style="font-weight:normal;">escalated to the JSC </font><font style="font-weight:normal;">by the </font><font style="font-weight:normal;">Core Team</font><font style="font-weight:normal;"> or by a Party pu</font><font style="font-weight:normal;">rsuant to Section 3.6</font><font style="font-weight:normal;"> below; (viii</font><font style="font-weight:normal;">) </font><font style="font-weight:normal;">review </font><font style="font-weight:normal;">completion of the Service</font><font style="font-weight:normal;">s</font><font style="font-weight:normal;">; (ix</font><font style="font-weight:normal;">) </font><font style="font-weight:normal;">seek to </font><font style="font-weight:normal;">settle </font><font style="font-weight:normal;">D</font><font style="font-weight:normal;">isputes unresolved by a subcommittee; and (x) perform such other functions as appropriate to further the purposes of the MSA as determined </font><font style="font-weight:normal;">in writing </font><font style="font-weight:normal;">by the Parties.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.3</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Core Team.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.3.1</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Formation and Composition.</font><font style="font-weight:normal;"> A core team for that Product (the &#8220;</font>Core Team<font style="font-weight:normal;">&#8221;) will be formed.&nbsp;&nbsp;The Core Team shall be composed of an equal number of representatives from each of SBL and Client, with [*] appointed by each of Client and SBL. Such representatives will include the Project Management Team Leaders of Client and SBL as well as their representatives from manufacturing, technical operations, supply chain, quality assurance, quality control, regulatory affairs or other individuals with expertise and responsibilities for those functions required to execute the Facility modification, the Technology Transfer and Manufacturing.&nbsp;&nbsp;Either Party may replace any or all of its representatives at any time by providing notice, in writing, of such replacement to the other Party.&nbsp;&nbsp;Each Core Team representative (and any replacement therefor) shall have appropriate seniority, knowledge and experience to appropriately carry out its responsibilities on the Core Team.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.3.2</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Appointment of Project Management Team Leader.</font><font style="font-weight:normal;">&nbsp;&nbsp;Each Party shall appoint a project management team leader (each, a &#8220;</font>Project Management Team Leader<font style="font-weight:normal;">&#8221;) to act as the primary contact for such Party in connection with matters related to the Service. The Project Management Team Leaders, unless otherwise mutually agreed by the Parties, shall serve as the leaders of the Core Team. A Party may replace its Project Management Team Leader at any time and from time to time for any reason by providing notice, in writing, of such replacement to the other Party.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.3.3</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Responsibilities.</font>&nbsp;&nbsp;<font style="font-weight:normal;">The Core Team shall (i) monitor, review and manage the Services according to the MSA and applicable PSA; (ii) conduct project stage reviews with the JSC at appropriate milestones or completion of key deliverables or a specified sequence of events to review key deliverables and its progress and performance against plans; (iii) develop a change management process to identify, review and recommend to the JSC any changes in the project scope, time, fee or risk that are likely to be material to the Services; (iv) investigate and resolve business, manufacturing, supply chain, quality, regulatory or other issues arising during the Service, including any [*]; (v) review and escalate to the JSC, as needed, changes to the </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">12</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">applicable </font><font style="font-weight:normal;">QAA</font><font style="font-weight:normal;">; (vi) review and recommend to the JSC changes to the </font><font style="font-weight:normal;">Services, </font><font style="font-weight:normal;">Specifications, analytical methods, the Manufacturing Process, the Facility or equipment; (vii) coordinate the activities of the Parties relating to the </font><font style="font-weight:normal;">Services </font><font style="font-weight:normal;">hereunder, including but not limited to: managing the technical operations and quality aspects of routine manufacturing, conducting Product testing technical operations and quality aspects of routine manufacturing, conducting Product testing and release, and managing supply chain activities including shipping and delivery logistics; (viii) report periodically on operation and quality progress and performance; and (ix) perform such other tasks and undertake such other responsibilities as may be specifically delegate</font><font style="font-weight:normal;">d</font><font style="font-weight:normal;"> to the </font><font style="font-weight:normal;">Core Team</font><font style="font-weight:normal;"> by mutual </font><font style="font-weight:normal;">written </font><font style="font-weight:normal;">agreement of the Parties.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.4</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Meetings.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.4.1</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">JSC.</font><font style="font-weight:normal;">The JSC shall meet by audio or video teleconference, or in person, as agreed by the JSC, on [*] as agreed by the Parties, or as necessary to make determinations as required of it. Any member of the JSC may designate a substitute to attend and perform the functions of that member at any meeting of the JSC and each Party may, in its reasonable discretion, invite non-member representatives of such Party to attend such meetings with advance written notice to the other Party.&nbsp;&nbsp;Either Party may request a meeting of the JSC, which shall occur as soon as reasonably necessary to address the stated purpose of the meeting. For clarity, the JSC will timely meet in a manner sufficient to address any urgent issues. </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.4.2</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Core Team.</font><font style="font-weight:normal;">The Core Team shall meet by audio or video teleconference, or in person, on a monthly basis, or as agreed by the Core Team. Any member of the Core Team may designate a substitute to attend and perform the functions of that member at any meeting of the Core Team and each Party may, in its reasonable discretion, invite non-member representatives of such Party to attend such meetings with advance written notice to the other Party. Either Party may request a meeting of the Core Team, which shall occur as soon as reasonably necessary, taking no longer than [*] to meet to address urgent issues, understanding that the issue may not be resolved within the [*], to address the stated purpose of the meeting.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.4.3</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Travel Expenses.</font><font style="font-weight:normal;">&nbsp;&nbsp;Each Party shall be responsible for all of its own expenses of traveling to and participating in any joint committee or team meeting, including the JSC and Core Team.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.5</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Decisions.</font><font style="font-weight:normal;">&nbsp;&nbsp;All decisions of the JSC, the Core Team and any other joint (sub)committee or team formed under the MSA or any applicable PSA, except as expressly set forth herein, shall be made by the unanimous agreement of all of its members or their designated representatives, and shall be reflected in written meeting reports which summarily address topics discussed, delegation of work, schedules and decision of such committee or team.&nbsp;&nbsp;Written reports of the JSC and Core Team shall be subject to approval by the authorized representatives of the Parties; </font><font style="text-decoration:underline;font-weight:normal;">provided, however, that</font><font style="font-weight:normal;"> no joint (sub)committee or team herein may amend or waive any provision of the MSA or applicable PSA, including without limitation, the financial terms set forth in Section 9.   The MSA and any PSA may be amended, and any provision of the MSA or any PSA may be waived, pursuant to Section 17.10 only.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">13</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.6</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Disputes.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.6.1</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">General.</font><font style="font-weight:normal;">&nbsp;&nbsp;In the event that the Core Team and any other joint (sub)committee or team formed under the MSA or any applicable PSA, is unable, despite the good faith efforts of all members, to resolve a disputed issue that is within the purview of such joint (sub)committee or team within [*] following a meeting request therefor by either Party, the disputed issue shall be referred immediately by such joint committee or team to the JSC.&nbsp;&nbsp;If the disputed issue still cannot be resolved within [*] following such referral to the JSC, the matter shall be handled in accordance with Section 16.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.6.2</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Project Management Team Leaders.</font><font style="font-weight:normal;">&nbsp;&nbsp;Subject to Section 3.6.1, the Project Management Team Leaders (or their respective designee) will in good faith attempt to mutually resolve in a timely fashion any disagreement with respect to the Services hereunder which could reasonably be expected to affect the quality of the Manufacturing of the Product, including without limitation, the related management processes and operations, control of production planning and scheduling, prioritization decisions, allocation of resources, timing of in-process and release testing, oversight of auxiliary facilities (e.g., in-process tests that need to be conducted at laboratories other than those at the Facility), Facility modification, the Technology Transfer, registration and troubleshooting decisions, and any other matters relating to implementation of the Manufacturing Process and the Manufacturing of the Product hereunder.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;text-transform:uppercase;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc457579733"></a><font style="text-decoration:underline;">SECTION 4</font><font style="text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="text-decoration:underline;text-transform:none;">SERVICES</font></p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.1</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Services.</font>&nbsp;&nbsp;<font style="font-weight:normal;">During the Term, in accordance with and subject to the terms and conditions set forth in this MSA, the applicable PSA, and the applicable QAA, SBL shall provide the Services to Client relating to the Product(s). SBL and Client shall at all times make Commercially Reasonable Efforts to complete the Services in accordance with the timelines set forth in the applicable PSA, except as otherwise expressly set forth in the MSA, applicable PSA, or the applicable QAA or as otherwise mutually agreed in writing by the Parties.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.2</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Compliance with Applicable Laws.</font><font style="font-weight:normal;">&nbsp;&nbsp;Subject to the provisions of Section 6 below, SBL shall maintain the Facility in accordance with cGMP and in such condition as will allow SBL to Manufacture the Products in accordance with the terms of the MSA and the applicable QAA.&nbsp;&nbsp;SBL shall perform the Services under the MSA in conformance of cGMP, if applicable, any requirements of the Regulatory Authorities that shall be mutually agreed upon by the Parties, and all Applicable Laws.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;font-weight:bold;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.3</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Project Personnel</font>.<font style="font-weight:normal;">&nbsp;&nbsp;SBL shall adequately staff the Facility with personnel necessary (including consultants and contractors), and with sufficient technical expertise to perform its obligations under the MSA, and who are up to date on all required trainings under SBL policy and Applicable Laws. Notwithstanding anything to the contrary herein, and in addition to the JSC and Core Team meetings </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">14</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">described in Section 3 above, </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> and SBL may </font><font style="font-weight:normal;">arrange for core project personnel to have regular meetings, which shall be </font><font style="font-weight:normal;">by audio or video teleconference</font><font style="font-weight:normal;">. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.4</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Subcontract.</font><font style="font-weight:normal;">&nbsp;&nbsp;SBL may not subcontract any portion of the Services without prior written approval from the Client, which may not be unreasonably withheld, [*].  In the event SBL subcontracts any portion of the Services, SBL shall be primarily obligated to Client for any subcontracted Services as if it were providing the Services itself.&nbsp;&nbsp;[*].</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.5</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Development and Manufacturing Site.</font><font style="font-weight:normal;">&nbsp;&nbsp;Unless otherwise agreed by Client in writing, all Services shall be performed by SBL at the Facility.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.6</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Manufacturing Documentation</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;SBL shall maintain the Manufacturing Documentation to be true and accurate, and shall keep the Manufacturing Documentation in strict confidence and shall not use the Manufacturing Documentation for any purposes other than providing or performing the Services or other obligations hereunder.&nbsp;&nbsp;SBL shall maintain all Manufacturing Documentation for at least that period specified in the applicable QAA. Upon written request of Client and at mutually agreeable times, Client shall have the right to review [*] Manufacturing Documentation, including the executed Batch Records [*] as further defined in the applicable QAA.&nbsp;&nbsp;Client may also [*] copies of such Manufacturing Documentation, [*]. SBL shall record and maintain such records, data, documentation and other information in the language required in the applicable QAA or as so required by a Regulatory Authority and in compliance with Applicable Laws. T</font><font style="color:#000000;font-weight:normal;">o the extent necessary, SBL may redact or withhold </font><font style="font-weight:normal;">Manufacturing Documentation provided pursuant this MSA or any applicable PSA</font><font style="color:#000000;font-weight:normal;"> solely to the extent necessary to protect the confidential information of its other clients</font><font style="font-weight:normal;"> or third parties. The form and style of Batch documents, including, but not limited to, Batch production records, lot packaging records, equipment set up control, operating parameters, and data printouts, raw material data, and laboratory notebooks are the exclusive property of SBL.&nbsp;&nbsp;Notwithstanding anything to the contrary, SBL SOPs not specific to the Client&#8217;s Products may be provided to Client for on-site review and/or through electronic data room if deemed reasonably necessary by both SBL and Client. Such SOPs cannot be removed from the SBL premises, copied, photographed or otherwise replicated.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.7</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Use of Proprietary or Confidential Information</font>. <font style="font-weight:normal;">SBL shall not use any SBL or third party (other than Client) proprietary or confidential information, or any proprietary process (whether that of SBL or any third party, but not including any proprietary or confidential information or process provided by Client for such use) in the manufacture of Product without the prior written consent of Client, which may be withheld in its sole discretion. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;text-transform:uppercase;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc457579734"></a><font style="text-decoration:underline;">SECTION 5</font><font style="text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="text-decoration:underline;text-transform:none;">-SERVICE DESCRIPTIONS </font></p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.1</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Technology Transfer.</font><font style="font-weight:normal;">The Parties shall make their personnel available at the Facility to the extent reasonably necessary to enable their transfer and implementation activities in accordance with the PSA. Client shall transfer to SBL the Reference Standards, Client Technology, Client Materials, and Cell Line to SBL in accordance with the plan, timelines and quantities set forth in the PSA, which </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">15</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">materials and technology</font><font style="font-weight:normal;"> shall be subject to the limited license set forth below in Section</font><font style="font-weight:normal;">s</font><font style="font-weight:normal;"> 11.2</font><font style="font-weight:normal;"> and 11.3</font><font style="font-weight:normal;">. </font><font style="font-weight:normal;">In the event that Client agrees to utilize </font><font style="font-weight:normal;">[</font><font style="font-weight:normal;">*</font><font style="font-weight:normal;">]</font><font style="font-weight:normal;"> for Technology Transfer, Client agrees that (a) in the event of any relevant change that affects a Client user&#8217;s authorization to use such portal, Client shall </font><font style="font-weight:normal;">promptly </font><font style="font-weight:normal;">notify SBL </font><font style="font-weight:normal;">thereof </font><font style="font-weight:normal;">so that SBL may disable </font><font style="font-weight:normal;">such Client user&#8217;s </font><font style="font-weight:normal;">usernames and</font><font style="font-weight:normal;">/or</font><font style="font-weight:normal;"> remove </font><font style="font-weight:normal;">or </font><font style="font-weight:normal;">change passwords in order to secure the </font><font style="font-weight:normal;">[</font><font style="font-weight:normal;">*</font><font style="font-weight:normal;">]</font><font style="font-weight:normal;"> and (b) Client shall ensure that all of Client&#8217;s users have up-to-date antivirus software installed on the computer devices used to access such portal.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.1.1</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">As part of the Technology Transfer, Client and SBL will define in the Drug Substance and Drug Product PSAs, the specific in process and release tests to be performed by SBL. Client and SBL will also provide the necessary resources to support the transfer of the specified test methods to SBL, in accordance with the timelines established in the applicable PSA.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.2</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Facility Modification and Equipment.</font><font style="font-weight:normal;">&nbsp;&nbsp;Except as otherwise specifically provided herein to the contrary, and upon mutual written agreement of the Parties, Client and SBL will agree on what equipment in the Facility is necessary to perform the Services, and, if the Parties deem it necessary, to procure additional equipment beyond that which is in the Facility as of the applicable PSA Effective Date. The Core Team shall determine [*]. Thereafter, if any additional equipment is necessary, such costs shall be dealt with by the Change provisions of this MSA.&nbsp;&nbsp;Except as provided in this MSA or any applicable PSA, the Facility, Warehouse and all the equipment shall be maintained, tested, validated, calibrated and qualified for their intended use by SBL [*]. </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.3</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Raw Materials.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.3.1</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Management</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;SBL shall procure and maintain a reasonable quantity of the Raw Materials required for the Services in accordance with the MSA and any applicable PSA.  [*], the Core Team shall finalize the categorization of the Raw Materials into (i) Critical Raw Materials, (ii) Customized or Dedicated Raw Materials, and (iii) Other Raw Materials, or such other categorizations as are appropriate, and send the categorization to Client for approval as soon as practicable after the Effective Date.&nbsp;&nbsp;The Parties shall discuss and approve the categorization in accordance with this MSA and any applicable PSA no later than [*] after the receipt of such categorization from SBL. [*]. The list of Raw Materials may be amended from time to time, subject to the Parties&#8217; mutual agreement; [*].&nbsp;&nbsp;During Technology Transfer, the Core Team shall agree on estimates for Raw Materials anticipated to be consumed in the Manufacture of each Batch.&nbsp;&nbsp;[*].&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.3.2</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Raw Material Strategy</font><font style="font-weight:normal;">. Client and SBL shall agree to strategies regarding Raw Material safety stock and sourcing from qualified vendors, provided that such strategies shall be reasonable under industry standard and given the nature of the particular Raw Material and its use in the Manufacture Process.&nbsp;&nbsp;Such strategies would be reviewed and agreed in the JSC.&nbsp;&nbsp;[*]. </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.3.3</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Raw Material Specifications</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;Client and SBL shall agree in writing on the Specifications for the Raw Materials, including without limitation analytical methods, supplier information including supplier site information, and other information concerning the stability, storage, and </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">16</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">safety thereof </font><font style="font-weight:normal;">that are required for the Manufacturing </font><font style="font-weight:normal;">of the applicable Product </font><font style="font-weight:normal;">hereunder, as further described in the </font><font style="font-weight:normal;">applicable </font><font style="font-weight:normal;">QAA</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.3.4</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Testing and Evaluation</font><font style="font-weight:normal;">.&nbsp;&nbsp;SBL or vendors qualified by SBL and approved by Client shall perform all testing and evaluation of the Raw Materials as required by the Specifications for the Raw Materials and the cGMPs, as further described in the applicable QAA, if applicable.</font><font style="text-decoration:underline;"> </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.3.5</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Storage.</font><font style="font-weight:normal;">&nbsp;&nbsp;SBL shall secure sufficient and suitable cGMP storage for the Raw Materials; provided that such storage requirements shall be consistent with customary standards within SBL&#8217;s industry.&nbsp;&nbsp;SBL shall exercise [*] to preserve and protect the Raw Materials [*], [*]. [*] (to the extent purchased in accordance with such PSA and this MSA, and in reliance on a Purchase Order, Firm Period, or Binding Year) [*].</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.3.6</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Service Fee Related to Raw Material.</font><font style="font-weight:normal;">&nbsp;&nbsp;Critical Raw Materials and Customized or Dedicated Raw Materials [*] as further detailed in the applicable PSA, and charged [*] in accordance with Sections 9.1(ii) and 9.2.2, subject to any Changes in the scope of work.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.4</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Client Materials.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.4.1</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Management.</font><font style="font-weight:normal;">&nbsp;&nbsp;Client shall provide, either by itself or through its third party supplier, to SBL free of charge, Client Materials in amounts reasonably necessary to carry out the Services as agreed by the Parties in the applicable PSA. SBL shall make [*] to import the Client Materials to the Republic of Korea in a timely manner, provided that Client provides reasonable assistance.  [*] Delivery conditions for the Client Materials shall be [*] (INCOTERMS 2010), provided further that the title to such Client Materials shall remain at all times with the Client.&nbsp;&nbsp;[*]. During Technology Transfer, the Core Team shall agree on estimates for Client Material anticipated to be consumed in the Manufacture of each Batch.&nbsp;&nbsp;[*].&nbsp;&nbsp;Both Parties shall agree to joint strategies regarding Client Material safety stock and sourcing from qualified vendors, provided that the strategies shall be reasonable under the industry standard and given the nature of the particular Client Material and its use in the Manufacture Process.&nbsp;&nbsp;[*].</font> [<font style="font-weight:normal;">*].  </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.4.2</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Client Materials Specifications.</font><font style="font-weight:normal;">&nbsp;&nbsp;Client shall provide SBL with the Specifications for the Client Materials, including without limitation analytical methods, supplier information, and other information concerning the stability, storage, and safety thereof that are required for the Manufacturing hereunder, as further described in the applicable QAA.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.4.3</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Testing and Evaluation.</font><font style="font-weight:normal;">&nbsp;&nbsp;SBL shall start to perform testing of the Client Materials in accordance with the applicable QAA and/or Client&#8217;s instructions prior to the performance of the Manufacturing hereunder, in order to determine whether such Client Materials meet the Specifications described in the applicable QAA (if applicable) within [*].&nbsp;&nbsp;SBL shall inform Client in writing of (a) [*] and (b) [*]: (i) within [*] after SBL&#8217;s receipt of the Client Materials or (ii) if release testing of Client Materials is not performed until it is needed for Manufacture, within [*] after such release testing is completed; or (iii) as otherwise agreed in writing between </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">17</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">the Parties</font><font style="font-weight:normal;">, provided that</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">SBL</font><font style="font-weight:normal;"> shall conduct any testing in a time sufficient to address </font><font style="font-weight:normal;">the</font><font style="font-weight:normal;"> procurement of replacement Client Materials</font><font style="font-weight:normal;">, in the event replacement Client Materials need to be delivered to SBL, Client shall timely deliver (or have delivered) the replacement Client Materials to SBL&#8217;s Facility</font><font style="font-weight:normal;">, and SBL shall use best efforts to </font><font style="font-weight:normal;">timely </font><font style="font-weight:normal;">test such Client Materials</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">so as to enable their use in the applicable manufacturing runs</font><font style="font-weight:normal;">. </font><font style="font-weight:normal;">If, prior to performing any Service</font><font style="font-weight:normal;">s</font><font style="font-weight:normal;"> on the </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> Material</font><font style="font-weight:normal;">s</font><font style="font-weight:normal;">, SBL determines that such </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> Material</font><font style="font-weight:normal;">s</font><font style="font-weight:normal;"> are defective or damaged, SBL shall not perform the</font><font style="font-weight:normal;"> affected</font><font style="font-weight:normal;"> Service on such </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> Material</font><font style="font-weight:normal;">s</font><font style="font-weight:normal;">; rather,</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">SBL</font><font style="font-weight:normal;"> shall consult with Client to determine whether the Client Materials are in fact defective, and if so</font><font style="font-weight:normal;">,</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">SBL </font><font style="font-weight:normal;">shall follow </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;">&#8217;s written instructions regarding disposal or return of such </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">M</font><font style="font-weight:normal;">aterials to </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;">, </font><font style="font-weight:normal;">[</font><font style="font-weight:normal;">*</font><font style="font-weight:normal;">]</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">[</font><font style="font-weight:normal;">*</font><font style="font-weight:normal;">]</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">SBL shall perform the Service </font><font style="font-weight:normal;">[</font><font style="font-weight:normal;">*</font><font style="font-weight:normal;">]</font><font style="font-weight:normal;"> after receiving replacement Client Materials</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.4.4</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Storage.</font><font style="font-weight:normal;">&nbsp;&nbsp;SBL shall secure sufficient and suitable cGMP storage for the Client Materials; provided that such storage requirements shall be consistent with customary standards within SBL&#8217;s industry.&nbsp;&nbsp;SBL shall exercise industry standard care and [*].</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.4.5</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Handling Fee Related to Client Material.</font><font style="font-weight:normal;">&nbsp;&nbsp;Handling fees relating to the Client Material will be charged to Client in accordance with Sections 9.1(iii) and 9.2.3.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.5</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Forecasts.</font><font style="font-weight:normal;">&nbsp;&nbsp;For each Commercial Product, the Parties shall determine a mutually agreeable mechanism for forecasting quantities to be ordered, which shall be detailed in writing and incorporated into the applicable PSA.&nbsp;&nbsp;For Clinical Product, the Parties shall agree upon the number and schedule of Batches to be Manufactured by SBL in the applicable PSA.  The Firm Period within each such forecast (which is binding on both Parties) will be set forth in the applicable PSA. In the event SBL is not able to utilize any capacity reserved to Manufacture Product [*].</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.5.1</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">Upon such notification, then the Parties will meet promptly at the JSC and to discuss in good faith potential options for resolution including, without limitation [*].</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.5.2</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">[*]:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">[*]. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">[*].&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">[*].</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">[*].&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">[*].&nbsp;&nbsp; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">[*].</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">[*].</p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.6</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Purchase Orders.</font><font style="font-weight:normal;">&nbsp;&nbsp;For each Clinical Product or Commercial Product, Client shall notify SBL in a binding purchase order specifying a specific amount of Product to be Manufactured (a &#8220;</font>Purchase Order<font style="font-weight:normal;">&#8221;) in accordance with a procedure to be agreed upon in the applicable PSA. The terms and conditions of this MSA shall control over any conflicting terms and conditions stated in any Purchase Order, acceptance or other communication or documents submitted or issued relating to this MSA.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">18</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Any other document that conflict</font><font style="font-weight:normal;">s</font><font style="font-weight:normal;"> with the terms and conditions of this </font><font style="font-weight:normal;">MSA </font><font style="font-weight:normal;">is hereby expressly rejected (unless the Parties </font><font style="font-weight:normal;">mutually agree</font><font style="font-weight:normal;"> to the contrary in writing </font><font style="font-weight:normal;">with respect to </font><font style="font-weight:normal;">a particular instance).&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.7</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Product Purchase Commitment.</font><font style="font-weight:normal;">&nbsp;&nbsp;As further set forth in the applicable PSA, during the Term the Parties may agree that Client will purchase a minimum quantity of Batches of a certain Product in a given year on a [*] basis (a &#8220;</font>Product Purchase Commitment<font style="font-weight:normal;">&#8221;).  </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.8</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Non-Conforming Product.  </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.8.1</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">If, (a) during Manufacture of a Batch and prior to Acceptance, the QA unit specified in the QAA determines that a Batch is Non-Conforming Product, or any Product is determined by either Party to be Non-Conforming Product, SBL shall propose the earliest possible date or dates for the replacement Manufacture of the Batch, [*], if the Parties agree in writing on a date, Manufacture a replacement Batch and deliver to Client the quantity of the Product equivalent to the quantity of Non-Conforming Product that was to be delivered in the original Batch. Before SBL schedules Manufacture of a replacement Batch, the Parties shall confirm that SBL has, or will have, adequate Client Materials to Manufacture such replacement Batch.  Except in the event of [*], the remedies contained in Section 5.8 of this MSA shall be [*] of Client regarding a Non-Conforming Product (provided that Client shall retain its rights to indemnification under Section 13) and any Non-Conforming Product from an individual Batch shall [*].</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.8.2</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">If the Product produced in a Batch is Non-Conforming, the Parties shall conduct a root cause analysis and impact assessment of the non-conformance under the terms of the QAA. If the Quality units of the Parties do not agree on the root cause or impact assessment, then the Heads of Quality from both Parties, in consultation with the JSC, shall discuss, and if the disagreement is not resolved, the Heads of Quality shall determine that the Parties shall retain a mutually agreed upon independent expert or laboratory to (a) conduct the necessary investigative testing in accordance with regulatory authority expectations and/or (b) perform a root cause analysis/product impact assessment prior to the final completion of the relevant non-conformance investigation report. The costs of the independent expert [*]. The Quality units from both Parties will be required to review and approve the final non-conformance investigation report. </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.8.3</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">This Section 5.8.3 sets forth responsibility between the Parties for the following costs in the event of a Non-Conforming Product: (1) the [*]; (2) SBL&#8217;s costs to [*] plus applicable SBL [*]; (3) the [*]; and (4) [*] which amount is to be calculated based on the [*] as supported by reasonable documentary evidence [*]. SBL shall be responsible for the foregoing costs to the extent the Non-Conforming Product [*]. In the event of Non-Conforming Product and the payment for the Batch has already been made, SBL shall, [*] (i) replace the batch as provided for in Section 5.8.1, or (ii) where SBL is [*].To the extent the Non-Conforming Product is caused by Client&#8217;s breach of its obligations under the MSA or applicable PSA, [*]. To the extent no root cause of the Non-Conforming Product is identified, [*]. [*]. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">19</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.8.4</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;"> In the event that any of the foregoing procedures results in a Batch being delivered in a different year than the year in which the original Batch was ordered for delivery by Client, the Service Fee for such replacement Batch shall be the Service Fee in effect in the Year in which such replacement Batch is actually delivered by SBL. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.8.5</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">If during Manufacture of a Batch and prior to SBL&#8217;s Release, the Core Team determines that all of a Batch is Non-Conforming Product (&#8220;</font>Batch Failure<font style="font-weight:normal;">&#8221;), all terms and conditions including remedies in Sections 5.8.1 to 5.8.3 shall apply to the Batch Failure </font><font style="font-style:italic;font-weight:normal;">mutatis mutandis</font><font style="font-weight:normal;">. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.8.6</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">In the case of an anticipated [*], SBL shall promptly inform Client in writing and provide Client with a reasonably detailed [*].&nbsp;&nbsp;&nbsp;&nbsp; </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.8.7</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">In any Commercial PSA, the Parties shall agree to a definition of [*]. In the case of an [*], SBL and Client shall meet and work together reasonably and in good faith to seek a prompt and commercially reasonable solution [*]. SBL shall use [*].&nbsp;&nbsp;[*]. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.9</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Storage, Packaging and Delivery</font>.</p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;font-weight:bold;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.9.1</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Service Deliverables other than Products.</font>&nbsp;&nbsp;<font style="font-weight:normal;">Storage, packaging and delivery of the Service deliverables other than Products Manufactured, and the Products Manufactured hereunder, shall be made in accordance with the terms of this MSA, applicable PSA, applicable QAA and the Applicable Laws.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.9.2</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Products.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.82%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;">Release by SBL and Acceptance by Client.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:21.21%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">SBL shall perform all testing in accordance with the Specifications for SBL&#8217;s Release of the Product, and will, upon completion of the Manufacturing Process for any Batch: (1) as soon as reasonably possible, and in any case [*] as defined in the QAA, timely prepare, in accordance with the shipping details received from Client, the samples to be delivered to Client or its designated contract service provider to conduct testing specified in the PSA, and (2) within [*], will conduct SBLs Release Testing, review the Batch Records, and otherwise complete SBL&#8217;s Release for the Product in accordance with the terms of the applicable QAA.&nbsp;&nbsp;For clarity, Client shall be responsible for the delivery and logistics of the samples of the Product and notify SBL in a timely manner of the shipping details.&nbsp;&nbsp;Concurrent with such SBL&#8217;s Release, SBL shall deliver to Client a copy of the Manufacturing Documentation supporting SBL&#8217;s Release of the Product for each Batch, [*] (&#8220;</font>Batch Related </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">20</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Documents</font><font style="font-weight:normal;">&#8221;), including a Certificate of Analysis, in accordance with the </font><font style="font-weight:normal;">applicable </font><font style="font-weight:normal;">requirements of the </font><font style="font-weight:normal;">QA</font><font style="font-weight:normal;">A</font><font style="font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;</font><font style="font-weight:normal;">[</font><font style="font-weight:normal;">*</font><font style="font-weight:normal;">]</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:27.27%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Acceptance of Product. <font style="font-weight:normal;">Subject to (a) [*] and (b) [*], as set forth herein or in the PSA and/or the QAA, Client will complete the Acceptance Procedure and determine the acceptability of such Product in accordance with the applicable QAA within [*] following SBL&#8217;s Release except [*], and for (3) as mutually agreed by the Parties. As part of the Acceptance Procedures, Client will notify SBL of any issues, including questions, clarifications or corrections needed to the Batch Related Documents, and SBL shall promptly provide responses, and will work with Client to ensure that Batches are released in a timely manner.  [*]. [*]. Upon completion of the Acceptance, Client will promptly notify SBL.&nbsp;&nbsp;Upon Client&#8217;s Acceptance, SBL will have [*].&nbsp;&nbsp;Subject to [*], if Client does not reject such Product within the periods described above, such Product will be deemed to have been Accepted by Client and SBL will have [*], and Client&#8217;s right to indemnification under Section 13. </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:21.17%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Latent Defect.<font style="font-weight:normal;">After Client&#8217;s Acceptance of the Product, if Client finds any defects of the Product which could not have been reasonably discovered [*] (</font>&#8220;Latent Defect&#8221;<font style="font-weight:normal;">), Client shall promptly give written notice of such claim to SBL within [*]. [*].&nbsp;&nbsp;Notwithstanding anything to the contrary, such claim for Latent Defect must be made within [*].</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:27.27%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Delivery. <font style="font-weight:normal;"> The Product Manufactured hereunder shall be delivered to Client or its designee [*] (INCOTERMS 2010), unless otherwise agreed to in the applicable PSA.&nbsp;&nbsp;The title to Product hereunder shall be transferred from SBL to Client when the Product is delivered consistent with [*]. The Parties further agree as follows:</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:27.27%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">After SBL&#8217;s Release of the Product and [*], SBL shall propose to Client a delivery schedule of the Product, in order for the Parties to agree on it in writing in advance [*].&nbsp;&nbsp;[*];</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:16.37%;text-indent:-6.1%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">SBL shall not deliver the Product until it has been instructed to do so by Client in accordance with the applicable QAA.&nbsp;&nbsp;Client shall confirm specific delivery instructions with SBL prior to SBL&#8217;s Release of such Product.&nbsp;&nbsp;Upon SBL&#8217;s Release of such Product, SBL shall store the Product as described in Section 5.9.2(c) and Client shall compensate SBL for storage costs for the Product as set forth in the applicable PSA;</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:27.27%;text-indent:-6.1%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">21</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">SBL shall provide Client with invoice, packing lists, and supporting export documents as specified by Client by separate delivery and shipment documentation instructions, together with each shipment of the Product (or such other deliverables); and</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:16.37%;text-indent:-6.1%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">In cooperation with Client and subject to the delivery schedule agreed by the Parties, SBL shall adhere to the first-expire-first-out (FEFO) principle in shipping all released Product, unless otherwise agreed upon by the Parties.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:27.27%;text-indent:-6.1%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Storage, Packaging and Shipping Container.</p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:27.27%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Pursuant to the terms of this MSA and any applicable PSA, SBL shall store the Products Manufactured hereunder under appropriate conditions as specified in the applicable PSA and QAA. </font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:27.27%;text-indent:-6.1%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">SBL shall store, package, label and prepare shipment of the Product according to the Specifications for such Product, the applicable QAA and the SOPs, and using storage and/or shipping containers determined in the applicable PSA. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:16.37%;text-indent:-6.1%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">[*], subject to the availability of space and storage conditions, SBL shall store the Product under the terms and storage conditions specified in the applicable PSA/QAA, and [*].  [*].</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;text-transform:uppercase;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc457579735"></a><font style="text-decoration:underline;">SECTION 6</font><font style="text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="text-decoration:underline;text-transform:none;">CHANGES TO THE SPECIFICATIONS, ANALYTICAL METHODS, MANUFACTURING PROCESS, FACILITY OR EQUIPMENT</font></p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.1</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Approval for Change.</font><font style="font-weight:normal;">&nbsp;&nbsp;SBL shall not make any change to the Manufacturing Process, the Services, or the Specifications (a &#8220;</font>Change<font style="font-weight:normal;">&#8221;), without the prior written consent of Client in accordance with the applicable QAA.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.2</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Changes Required by cGMP, Regulatory Authorities or Requested by Client.</font><font style="font-weight:normal;">  Except as otherwise expressly set forth to the contrary in the applicable QAA, in the event that cGMP, a Regulatory Authority, Applicable Laws, or any other regulatory or legal authority requires, or Client requests in writing, a Change, SBL shall accommodate such requirements or requests, subject to the following:</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Client shall promptly notify SBL in writing of the required and/or requested Change(s), and provide information necessary for SBL to evaluate the effect of such Change(s), and SBL shall promptly advise Client in writing as to any applicable (i) additional equipment required, modifications to the Facility or equipment, and/or additional equipment and the Facility qualification and validation requirements; (ii) Manufacturing Process development, transfer, scale-up, testing, qualification, or validation requirements; (iii) regulatory requirements pursuant to such Changes; (iv) </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">22</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">changes to the Manufacturing scheduling and/or Product delivery schedule; and (v) other impacts on the Facility or </font><font style="font-weight:normal;">SBL</font><font style="font-weight:normal;">&#8217;s ability to manufacture products (including the Products) in the Facility, if any, which may result from such Change(s). The notification and formal approval procedure </font><font style="font-weight:normal;">of such </font><font style="font-weight:normal;">C</font><font style="font-weight:normal;">hanges </font><font style="font-weight:normal;">shall be in accordance with </font><font style="font-weight:normal;">the </font><font style="font-weight:normal;">applicable </font><font style="font-weight:normal;">QAA</font><font style="font-weight:normal;"> (i.e., change control procedures) (if applicable).&nbsp;&nbsp;The Parties shall meet in a timely manner to identify and discuss such Changes as </font><font style="font-weight:normal;">appropriate;</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Prior to implementation of any such Change(s), SBL shall provide Client with an estimated plan and budget of the reasonable and necessary costs that would be incurred by SBL as a result of the implementation of any such Change(s), including, but not limited to for (i) process and analytical development; (ii) equipment and/or the Facility modifications, qualification, validation, maintenance, and decommissioning/disposal; (iii) process and analytical validation; (iv) document revisions or changes, and any Facility, equipment, and system modifications or changes; (v) additional stability testing; and (vi) preparing submissions to Regulatory Authorities (collectively, the &#8220;</font>Implementation Plan and Budget<font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;Following review and written approval by Client of such Implementation Plan and Budget, and subject to the Core Team&#8217;s approval and agreement followed by the Parties&#8217; written agreement, SBL shall commence implementation of such Change(s);&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">During any such implementation, SBL shall provide Client with regular updates on the progress of implementation. Subject to any timeframe imposed by Applicable Law, SBL shall exercise [*] to implement the Change according to the Implementation Plan and Budget&#8217;s target completion date.&nbsp;&nbsp;SBL shall provide written notice to Client if SBL becomes aware of any cause which may create delay with the implementation of such Change(s).&nbsp;&nbsp;Following any such notice, both Parties shall discuss an amendment of Implementation Plan and Budget; and</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Upon the approval of the Implementation Plan and Budget for particular Change(s), both Parties shall negotiate in good faith to determine the reasonable allocation between the Parties of the costs incurred by SBL for the implementation of any such Change(s), in accordance with the Implementation Plan and Budget and the following principles:</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">[*];</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:21.21%;text-indent:-6.1%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">[*]; and</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:16.37%;text-indent:-6.1%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">[*].</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">23</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;text-transform:uppercase;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc457579736"></a><font style="text-decoration:underline;">SECTION 7</font><font style="text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="text-decoration:underline;text-transform:none;">REGULATORY APPROVALS AND INSPECTIONS.</font></p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.1</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Regulatory Approvals.</font> <font style="font-weight:normal;">SBL shall provide reasonable assistance and cooperation in order for Client to obtain and maintain the Regulatory Approvals. The costs and fees associated with such assistance and cooperation, to the extent not detailed in the MSA or applicable PSA shall be mutually agreed in writing between the Parties.&nbsp;&nbsp;As specified in the applicable PSA, the Parties shall agree on which Regulatory Approvals are to be obtained.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.2</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Regulatory Approvals for the Facility</font>.&nbsp;&nbsp;<font style="font-weight:normal;">SBL shall obtain and maintain all Regulatory Approvals that are required to Manufacture and ship the Product at the Facility and perform the Services.  For clarity, as between the Parties, Client shall obtain and hold all clinical trial applications and marketing approvals (and applications therefor) for the Product.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.3</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Regulatory Inspections.</font>&nbsp;&nbsp;<font style="font-weight:normal;">SBL shall facilitate on-site inspections of the Facility conducted by Regulatory Authorities.&nbsp;&nbsp;SBL shall notify Client according to the applicable QAA provisions of any contacts or inquiries by the Regulatory Authorities, including inspections, Pre-Approval Inspections, sample requests, and written correspondence and its result, related to the Product, as further defined in the applicable QAA.  [*].</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;text-transform:uppercase;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc457579737"></a><font style="text-decoration:underline;">SECTION 8</font><font style="text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="text-decoration:underline;text-transform:none;">QUALITY COMPLIANCE</font></p>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.1</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref536497994"></a><a name="_Ref536444852"></a><a name="_Ref536609135"></a><font style="text-decoration:underline;">Quality Agreement</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;Both Parties shall adhere to the provisions of the applicable QAA and the Parties agree that all elements of quality assurance, quality control and the like shall be governed by the terms and conditions of the applicable QAA.&nbsp;&nbsp;In the event of a conflict between the MSA and the applicable QAA, the MSA shall prevail over those of the applicable QAA with the exception of Product <a name="_Ref536609135"></a>quality-related matters, cGMP and related regulatory requirements in which case, the terms of the applicable QAA shall prevail.&nbsp;&nbsp;The QAA for any Product is incorporated herein, and any material breach of the QAA may constitute a breach of this MSA</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.2</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref427918709"></a><font style="text-decoration:underline;">A<a name="_Ref427918709"></a>udit.</font>&nbsp;&nbsp;<font style="font-weight:normal;">Upon Client&#8217;s request, [*], SBL shall accept an audit of the Facility and, if necessary, the Warehouse, by Client or its designee and shall allow Client or its designee to inspect the Manufacture of the Product during provision of the Services and related records and documentation, and provide Client or its designee access to relevant personnel, solely to ascertain compliance by SBL with the terms of this MSA or any applicable PSA or QAA, provided, however, that in the event Client uses a designee, SBL shall not unreasonably withhold consent, provided, that SBL may reasonably withhold consent for a designee [*], and execute a separate confidentiality agreement with such designee and SBL as may be appropriate in the circumstances. [*]. [*].&nbsp;&nbsp;Client will provide SBL with written notice [*] prior to any audit, and the Parties shall decide on a mutually agreeable date, duration, visitor list, and agenda prior to the audit. Notwithstanding the foregoing, if the audit is required for cause [*], the foregoing sentence shall not apply [*]. While at the Facility, all such Client personnel shall have reasonable access to all areas as are relevant to SBL&#8217;s performance of the Services hereunder, provided that SBL may reasonably restrict Client personnel&#8217;s access to the Facility as it deems necessary and visitors pursuant to this Section shall comply with all applicable </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">24</font><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">SBL</font><font style="font-weight:normal;"> policies and procedures including but not limited to safety and </font><font style="font-weight:normal;">cGMP, and shall be bound by confidentiality obligations consistent with Section 10</font><font style="font-weight:normal;">. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.3</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">[*]</font><font style="font-weight:normal;">.&nbsp;&nbsp;For a Commercial Product or a [*], either Party shall notify the other Party as soon as practicably possible if any Commercial Product or a [*] is the subject of a potential, threatened or actual recall or withdrawal (a &#8220;</font>Recall<font style="font-weight:normal;">&#8221; or &#8220;</font>Withdrawal<font style="font-weight:normal;">&#8221;) which may be attributable to any Service or Manufacture by or on behalf of SBL hereunder.&nbsp;&nbsp;Client shall be responsible for conducting all Recalls/Withdrawals and shall make all decisions regarding, and in all events shall have sole authority for, conducting any Recalls, Withdrawals or corrections with respect to the Product and SBL shall at all times exercise [*] to provide its assistance and cooperation to Client in conducting such Recalls/Withdrawals to the extent the Recall/Withdrawal arises out of SBL&#8217;s Manufacture of Product. Details regarding the roles and responsibilities of the Parties in regard to Recalls/Withdrawals are set forth in the applicable QAA. If such Recall/Withdrawal results solely from SBL Assignable Error, SBL shall be responsible for [*]. [*]. &nbsp;&nbsp; </font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.4</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">For the purpose of this Section, Recall/Withdrawal expenses shall not include [*] (which shall be addressed pursuant to the provisions regarding replacement or refunding of costs in Section 8.3) [*].&nbsp;&nbsp;If SBL and Client cannot agree which Party is at fault or whether a Recall/Withdrawal was reasonably beyond the control of the Parties, then an independent third party technical expert of international repute, acceptable to both Parties, shall be designated to make such determination.&nbsp;&nbsp;[*]. </font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.5</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Person-in Plant</font><font style="font-weight:normal;">.&nbsp;&nbsp;During the term of this MSA, for any PSA, Client shall have the right to have experienced (i) technical, and (ii) quality personnel of Client, who may be employees, contractors, or agents (each, a &#8220;</font>PIP<font style="font-weight:normal;">&#8221;) as the Parties may reasonably determine necessary to be present at the Facility during any Manufacture and SBL&#8217;s Release under this MSA, to the extent set forth below, for the purpose of observing Manufacturing and SBL&#8217;s Release of the Product, participating in reviews, acting as liaison between Client and SBL with respect to Manufacturing Process related issues and performing such other actions set forth in the QAA. Client understands only [*] PIPs at any one time are allowed entry [*].&nbsp;&nbsp;During Technology Transfer, Client shall have a right to have up to [*] people present at the Facility to facilitate the Technology Transfer process. Such PIPs shall be entitled to make decisions on quality and/or technical matters related to the Product. Client shall provide SBL reasonable notice of the timing and scope of the visits which shall, except in exceptional circumstances, be provided at least [*] prior to each visit in order to provide adequate time to schedule the required activities and resources, provided, that Client shall have the right to have such PIP present during any and all Manufacturing and/or release Services provided hereunder by SBL. SBL shall ensure that the PIP at the Facility is kept informed of the relevant issues which may affect the Product quality and will use the PIP to coordinate the performance of activities with respect thereto that are the responsibility of Client.&nbsp;&nbsp;[*]. Client shall bear its own costs with respect to the PIP&#8217;s presence at the Facility, flight expenses, transportations, hotel accommodations, meals etc. While at the Facility, all such Client personnel shall have reasonable access to all areas as are relevant to SBL&#8217;s performance of the Services hereunder, provided that SBL may reasonably restrict Client personnel&#8217;s access to the Facility as it deems necessary to safeguard the information of third parties, and all such Client personnel shall agree to and comply with confidentiality obligations to third </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">25</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">parties, SBL policies and procedures related to safety, confidentiality, and cGMP, and all instructions of SBL employees at the Facility. Client </font><font style="font-weight:normal;">shall remain responsible at all times</font><font style="font-weight:normal;"> for the compliance with the terms of this MSA and PSA by its employees and personnel. </font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.6</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">[*</font><font style="font-weight:normal;">].  </font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;text-transform:uppercase;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc457579738"></a><font style="text-decoration:underline;">SECTION 9</font><font style="text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="text-decoration:underline;text-transform:none;">CONSIDERATION AND PAYMENT TERMS</font></p>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.1</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Consideration</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">In consideration for SBL&#8217;s performing the Services and other obligations undertaken by SBL pursuant to this MSA or a PSA, Client shall pay SBL (i) amounts as set forth in the applicable PSA (the &#8220;</font>Service Fee<font style="font-weight:normal;">&#8221;); [*].&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.2</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Invoices.</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.05%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.18%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.2.1</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Service Fee of the Project Stages and Batches.</font>&nbsp;&nbsp;<font style="font-weight:normal;">Batches of Product shall be invoiced upon SBL&#8217;s Release of a Batch of Product. Otherwise, Service Fees shall be invoiced according to the invoicing plan set forth in the applicable PSA. SBL&#8217;s invoices pursuant to this MSA shall be electronic, unless otherwise agreed by the Parties in writing.</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.2.2</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Raw Materials.</font>&nbsp;&nbsp;<font style="font-weight:normal;">With respect to the Raw Materials, [*].&nbsp;&nbsp;The Parties shall collaborate in the selection of the vendors of the Raw Materials. All such vendors shall be approved in writing by Client before supplying SBL with Raw Materials for Product.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.2.3</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Client Materials</font>.&nbsp;&nbsp;<font style="font-weight:normal;">With respect to the Client Materials, which shall be supplied by Client to SBL [*] during SBL&#8217;s performance the Services [*], SBL shall submit an invoice to Client in an amount as set forth in Section 9.1 upon SBL&#8217;s completion of such the applicable stage of the Services or upon SBL&#8217;s Release of a Batch of Product, as applicable.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.3</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Payment</font><font style="text-decoration:underline;font-weight:normal;">.</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.3.1</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Mode of Payment; Foreign Exchange</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;All payments to SBL due under the MSA or any applicable PSA shall be made in USD $ within [*] from the receipt of SBL&#8217;s [*] invoice in USD $ by means of telegraphic transfer to the account with the bank designated by SBL in the foregoing invoice, provided however that payment for Manufactured Batches shall be made in accordance with Section 5.9.2(a)(i) and 5.9.2(ii). For the purpose of computing payment amounts incurred by SBL in a currency other than USD $, such currency shall be converted into USD $ using the basic exchange rate published by Bank of Korea (or its successor institution) on its website &#8220;</font>http://ecos.bok.or.kr/<font style="font-weight:normal;">&#8221; (or any other website that may be used by the Bank of Korea or its successor institution for publication of currency exchange rates) at the opening of business on such invoice date.&nbsp;&nbsp;[*].</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.3.2</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc144700779"></a><font style="text-decoration:underline;">Taxes</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;"><a name="_Toc144700779"></a> All prices and charges are exclusive of any applicable taxes, levies, imposts, duties and fees of whatever nature imposed by any law or regulations in any country in respect of the </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">26</font><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Services, importation or exportation of Raw Materials, </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> Materials, Batches, and Product, which shall be paid by </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;">For the avoidance of doubt, the</font><font style="font-weight:normal;"> foregoing shall</font><font style="font-weight:normal;"> not include any taxes imposed on the income or profit of SBL and any withholding tax lawfully levied on any payment to be made by </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> to SBL, each of which shall be solely borne by SBL.&nbsp;&nbsp;</font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> shall pay or reimburse </font><font style="font-weight:normal;">SBL (to the extent actually incurred and paid by SBL)</font><font style="font-weight:normal;"> for all customs duties and taxes in connection with the purchase, sale, importation or exportation of any Raw Materials, </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> Materials, Batches, or Product or the provision of Services, except to the extent such</font><font style="font-weight:normal;"> customs</font><font style="font-weight:normal;"> duties and taxes are recoverable by or refundable to SBL. SBL agrees to assist </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> in claiming exemption under double taxation or similar agreement or treaty from time to time in force to obtain a refund of any customs duties, value added taxes, and other taxes payable by SBL</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:-4.54%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.3.3</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Price Adjustments</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;The Service Fees as set forth in the applicable PSA shall be adjusted annually on January 1 of each year during the Term, effective immediately, by [*</font>]. <font style="font-weight:normal;">The relevant date for price adjustment under this Section shall be the issue date of SBL&#8217;s invoice. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.3.4</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Default Interest.</font><font style="font-weight:normal;">  [*].&nbsp;&nbsp;In the event there is an undisputed amount which is invoiced by SBL but not paid by Client for [*], such event shall be considered a material breach of the relevant PSA, subject to Section 15.2.1.</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;text-transform:uppercase;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc457579739"></a><font style="text-decoration:underline;">SECTION 10</font><font style="text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="text-decoration:underline;text-transform:none;">CONFIDENTIALITY</font></p>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.1</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Confidential Information.</font><font style="font-weight:normal;">  </font><font style="color:#000000;font-weight:normal;">The Disclosing Party shall use reasonable efforts to indicate Confidential Information it discloses in writing, in electric file or format or in other tangible manner is confidential and, with respect to its Confidential Information disclosed orally, visually or in other intangible manner, to reduce it in writing or in electric file or format, identified as confidential and delivered to another Party within [*] after such oral or visual disclosure: provided, however, that, in each case of the foregoing, a failure to do so shall not constitute a breach of this MSA nor shall deny, negate or destroy the confidential nature thereof, and no such failure shall relieve the Receiving Party of its obligations hereunder with respect to such Confidential Information. For clarity, information that Receiving Party knows or has reason to know is confidential, trade secret or proprietary information of the Disclosing Party at the time of disclosure shall be deemed to be the Confidential Information of the Disclosing Party.&nbsp;&nbsp;Furthermore, the existence and terms of the MSA shall be deemed to be the Confidential Information of both Parties.</font><font style="font-weight:normal;"> </font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing, Confidential Information shall not include the information, which the Receiving Party can evidence by written records:</p>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">was at the time of disclosure by the Disclosing Party or generation hereunder publicly known or available;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">after disclosure by the Disclosing Party or generation hereunder, became publicly known or available by publication or otherwise, other than by an authorized act or omission by the Receiving Party;</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">27</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was in the possession of the Receiving Party without confidentiality restriction at the time of the disclosure by the Disclosing Party</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or generation</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hereunder</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">;</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">was lawfully received from any third party having the lawful right to make such disclosure, without obligation of confidentiality; or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">was independently developed by or on behalf of the Receiving Party without reference to or use of the Disclosing Party&#8217;s Confidential Information, as demonstrated by records contemporaneous with such development.</p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.18%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.2</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Confidentiality.</font><font style="font-weight:normal;">The </font><font style="color:#000000;font-weight:normal;">Receiving Party recognizes the proprietary and confidential nature of the</font><font style="font-weight:normal;"> Disclosing Party&#8217;s Confidential</font><font style="color:#000000;font-weight:normal;"> Information and agrees that no right, title, ownership, license, or interest of any character in the Disclosing Party&#8217;s Confidential Information other than as specifically granted herein, is conveyed or transferred to the Receiving Party.&nbsp;&nbsp;Each Receiving Party further agrees to maintain the Disclosing Party&#8217;s Confidential Information in confidence, not to disclose or divulge the Disclosing Party&#8217;s Confidential Information, in whole or in part, to any third party, and not to use the Disclosing Party&#8217;s Confidential Information for any purpose other than performance of its obligations and exercise of its rights under this MSA and applicable PSA or QAA. Each Receiving Party shall guard such Confidential Information using the same degree of care as it normally uses to guard its own confidential or proprietary information of like importance, but in any event no less than reasonable care.&nbsp;&nbsp;The Receiving Party shall limit disclosure of the Disclosing Party&#8217;s Confidential Information to its and those of its Affiliates&#8217; directors, officers, employees, consultants and agents (&#8220;</font><font style="color:#000000;">Representatives</font><font style="color:#000000;font-weight:normal;">&#8221;) who have a need to know the Disclosing Party&#8217;s Confidential Information for performance of the </font><font style="font-weight:normal;">Services</font><font style="color:#000000;font-weight:normal;"> and implementation of this MSA and applicable PSA or QAA, </font><font style="text-decoration:underline;color:#000000;font-weight:normal;">provided that</font><font style="color:#000000;font-weight:normal;">, the Receiving Party shall undertake procedures to ensure that each of its Representatives to whom the Disclosing Party&#8217;s Confidential Information is disclosed (i) understands the confidential nature of the Disclosing Party&#8217;s Confidential Information and (ii) that he or she is bound by obligations at least as restrictive as those contained herein with respect to the Disclosing Party&#8217;s Confidential Information.&nbsp;&nbsp;The Receiving Party shall remain directly responsible for any failure by any of its Representatives to comply with this Section 10. SBL agrees not to reverse engineer any Confidential Information or Product of Client. </font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.3</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Authorized Disclosures.</font>&nbsp;&nbsp;<font style="font-weight:normal;">The Receiving Party may disclose the Disclosing Party&#8217;s Confidential Information in the event that (a) the Disclosing Party&#8217;s Confidential Information is reasonably required to obtain or maintain any Regulatory Approvals for the Products in any or all jurisdictions or (b) the Disclosing Party needs to disclose such Confidential Information to comply with Applicable Laws; provided that such Receiving Party shall give the Disclosing Party prior written notice of such requirement (to the extent permitted by Applicable Laws), shall exercise its Commercially Reasonable Efforts to limit disclosure of the Disclosing Party&#8217;s Confidential Information to that which is necessary for compliance and shall otherwise maintain the confidentiality of the Confidential Information.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.4</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Survival of Confidentiality Obligations</font>. <font style="font-weight:normal;">The obligations of the Receiving Party under this Section 10 shall survive for a period of [*] of this MSA, except that such obligations with respect to any </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">28</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Confidential Information that is a trade secret will survive for so long as such information remains a trade secret</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.5</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="text-decoration:underline;color:#000000;">Return of the Confidential Information.</font><font style="color:#000000;"> </font><font style="color:#000000;font-weight:normal;">All written, printed or other tangible Confidential Information of the Disclosing Party, and all copies thereof shall be returned to the Disclosing Party by the Receiving Party (or destroyed at the Receiving Party&#8217;s election, with such destruction certified in writing by an officer of the Disclosing Party) within [*] from the written request by the Disclosing Party.&nbsp;&nbsp;All Confidential Information disclosed electronically shall be completely deleted and destroyed by the Receiving Party within [*] from the receipt of the Disclosing Party&#8217;s written request. Notwithstanding the foregoing,</font><font style="font-weight:normal;"> (i) digital backup files automatically generated by the Receiving Party&#8217;s customary electronic data processing system may be retained and properly stored as confidential files for the sole purpose of backup and will be deleted in accordance with the Receiving Party&#8217;s retention policy, and</font><font style="color:#000000;font-weight:normal;"> (ii) a single copy of the Confidential Information may be retained in the secured files of the Receiving Party for the sole purpose of determining the scope of obligations incurred by it under this MSA provided that the Receiving Party shall keep such Confidential Information in confidence, which Confidential Information shall remain subject to this Section 10</font><font style="font-weight:normal;">.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;text-transform:uppercase;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc457579740"></a><font style="text-decoration:underline;">SECTION 11</font><font style="text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="text-decoration:underline;text-transform:none;">OWNERSHIP OF MATERIALS AND INTELLECTUAL PROPERTY; [*]</font></p>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.1</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Reference Standard, Client Technology, Client Materials, Cell Line, and Product.</font><font style="font-weight:normal;"> SBL hereby understands and agrees that all rights to, titles of and interests in the Reference Standards, Client Technology, Client Materials, Product that has been Accepted, and Cell Line belong exclusively to Client, unless otherwise provided herein.</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.2</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Background Intellectual Property.</font><font style="font-weight:normal;">&nbsp;&nbsp;It is acknowledged that each Party owns or controls Background IP.&nbsp;&nbsp;Any Intellectual Property relating to the Reference Standards, Client Technology, Client Materials, Cell Line, and Product owned and/or controlled by Client as of the date of provision of such Reference Standards, Client Technology, Client Materials, Cell Line and Product by Client to SBL pursuant to Section 5.1, shall be deemed to be included in the Background IP of Client. Client hereby grants SBL a royalty-free, non-transferable, revocable, non-sublicensable, fully-paid-up right and license to use such Intellectual Property relating to such Reference Standards and Client Background IP during the Term for the sole purposes of Manufacturing of the Product or Services in accordance with this MSA and the applicable PSA. SBL shall not use any of the foregoing outside the scope of such limited license granted by Client to SBL.  </font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.3</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref54893483"></a><font style="text-decoration:underline;">Inventions.</font>&nbsp;&nbsp;<font style="font-weight:normal;">Any Intellectual Property arising out of or resulting from the Services performed under this MSA and any PSA, including but not limited to those contained in the Manufacturing Documentation, shall be hereinafter collectively called an &#8220;</font>Invention<font style="font-weight:normal;">&#8221;.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.3.1</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Client Invention.</font><font style="font-weight:normal;"> Any Invention that [*] shall be a &#8220;</font>Client Invention<font style="font-weight:normal;">&#8221;. SBL hereby assigns, and shall cause to be assigned, to Client all right, title and interest in and to all Client Inventions.&nbsp;&nbsp;SBL shall notify Client of such Client Invention(s) in writing immediately after SBL, the Project Management Team Leader, respective project personnel, SBL&#8217;s or its </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">29</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">Affiliate&#8217;s </font><font style="font-weight:normal;">or its Affiliate&#8217;s</font><font style="font-weight:normal;"> employees or officers or other applicable third parties working for SBL hereunder makes, conceives or reduces to practic</font><font style="font-weight:normal;">e such</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> Invention, and shall take all necessary measures so that </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> would </font><font style="font-weight:normal;">[</font><font style="font-weight:normal;">*</font><font style="font-weight:normal;">]</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> Invention.&nbsp;&nbsp;</font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> may use any </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> Invention for any purpose, including filing patent application and SBL shall provide reasonable cooperation to </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">[</font><font style="font-weight:normal;">*</font><font style="font-weight:normal;">]</font><font style="font-weight:normal;">.</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">Client hereby grants SBL a </font><font style="font-weight:normal;">royalty-free, non-transferable, revocable, non-sublicensable, fully-paid-up</font><font style="font-weight:normal;"> right and license to use any Client Inventions or other Intellectual Property generated under this </font><font style="font-weight:normal;">MSA</font><font style="font-weight:normal;"> for the sole purposes of Manufacturing of the Product or Services in accordance with this MSA and the applicable PSA.</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.92%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.3.2</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_cp_text_1_679"></a><font style="text-decoration:underline;">SBL Invention.</font><font style="font-weight:normal;">&nbsp;&nbsp;Any Invention that is [*] (an &#8220;</font>SBL Invention<font style="font-weight:normal;">&#8221;) shall be the sole property of SBL, and shall not be deemed to be Client Invention for the purposes of the <a name="_cp_text_1_679"></a>MSA; provided, however, that SBL hereby grants to Client a worldwide, irrevocable, [*], royalty-free and fully-paid-up right and license under such Background IP of SBL and the SBL Invention to make, use, sell, offer to sell, export and import and otherwise exploit the Product(s), to the extent such SBL Background IP or SBL Invention is incorporated into the Product(s) or its manufacture. </font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.92%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.4</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">[*</font><font style="font-weight:normal;">].&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;text-transform:uppercase;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc457579741"></a><font style="text-decoration:underline;">SECTION 12</font><font style="text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="text-decoration:underline;text-transform:none;">WARRANTIES.</font></p>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.1</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">The Parties&#8217; General Warranties.</font>&nbsp;&nbsp;<font style="font-weight:normal;">Each Party warrants and represents that: (i) it has the corporate power and authority to enter into this MSA and has taken all necessary action on its part required to authorize the execution, delivery and performance of this MSA; (ii) it is aware of no legal, contractual or other restriction, limitation or condition that might adversely affect its ability to enter into this MSA and perform its obligations hereunder; (iii) it is duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated; (iv) this MSA (a) has been duly executed and delivered by a duly authorized representative of it, and (b) is the legal, valid and binding obligation of it, enforceable against it in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws now or hereafter in effect relating to or affecting creditors&#8217; rights generally; and (v) the execution, delivery and performance of this MSA by it does not and will not (a) violate any Applicable Laws applicable to it, or (b) violate or conflict with any provision of its Articles of Incorporation or By-laws or other organizational documents. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.2</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Client&#8217;s Warranties</font><font style="font-weight:normal;">. Client represents and warrants to SBL that as of the Effective Date and during the Term: (a) Client will comply with all Applicable Laws in connection with its performance under this MSA and applicable PSA, and that it will keep SBL informed of any information known to Client which would affect SBL&#8217;s provision of the Services hereunder; (b) to the best of its knowledge, all Reference Standard, Client Technology, Client Materials, and Cell Line provided to SBL by or on behalf of Client will be suitable for the Manufacture of the Product; (c) to the best of its knowledge, as of the Effective Date of this MSA, SBL&#8217;s use of the Client Materials, Manufacturing Process, and Client Technology for the purpose of the Services and in accordance with this MSA and the applicable PSA will not infringe any third party&#8217;s Intellectual Property rights.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">30</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.3</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc58642482"></a><a name="_Ref536522390"></a><font style="text-decoration:underline;"></font><font style="text-decoration:underline;"></font><font style="text-decoration:underline;">SBL&#8217;s </font><font style="text-decoration:underline;">Warranties</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;SBL represents and warrants that:</font><font style="font-weight:normal;"><a name="_Toc58642482"></a><a name="_Ref536522390"></a> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.3.1</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">As of the Effective Date and during the Term, (i) SBL is the lawful owner, lessee, operator, or licensee of the Facility, and the equipment and machinery therein, (ii) SBL possesses all permissions and approvals required to enable SBL to perform its obligations under this MSA and the applicable PSA, and (ii) to the best of SBL&#8217;s knowledge, none of the SBL Inventions or SBL Background IP infringes any third party Intellectual Property Right.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.3.2</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">All Product Batches, at the time of delivery to Client&#8217;s designated carrier, shall (a) conform to the Specifications [*]</font><font style="color:#000000;font-weight:normal;">; (b)</font><font style="color:#000000;"> </font><font style="color:#000000;font-weight:normal;">be Manufactured, packaged, handled and stored in compliance with the requirements of cGMP [*] and all Applicable Laws; (c) comply with the Standard Operating Procedures; (d) be Manufactured in compliance with this MSA and the applicable PSA and QAA; and (e) be transferred free and clear of any liens</font><font style="font-weight:normal;">, claims or encumbrances of any kind.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.3.3</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">Neither SBL nor any SBL employee who performs the Manufacturing Services under the MSA or applicable PSA is listed on the FDA Debarment List (Drug Product Applications) (link: </font><font style="text-decoration:underline;color:#0000FF;font-weight:normal;">https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/fda-debarment-list-drug-product-applications</font><font style="font-weight:normal;">, which link may be updated from time to time) pursuant to 21 U.S.C. &#167; 335a (&#8220;</font>Debarred<font style="font-weight:normal;">&#8221;), and, to SBL&#8217;s knowledge, neither SBL nor any such SBL employee subject to any investigation that could result in SBL or such person becoming Debarred. SBL agrees to notify Client in writing immediately if (i) SBL or any employee, contractor or agent who is performing any work under this MSA or any PSA is Debarred, or (ii) SBL confirms that debarment investigations on SBL or any employee, contractor or agent performing any work under this MSA or PSA could reasonably result in such person becoming Debarred, and promptly remove such employee from performing the Services. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.4</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">No Other Warranties.</font><font style="font-weight:normal;">THE REPRESENTATIONS AND WARRANTIES CONTAINED IN THIS SECTION 12 ARE EXPRESSLY IN LIEU OF AND EXCLUDE, AND THE PARTIES HEREBY EXPRESSLY DISCLAIM AND NEGATE, TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAWS, ALL OTHER REPRESENTATIONS AND WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED (ARISING BY OPERATION OF LAW OR OTHERWISE), INCLUDING IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, EVEN IF THAT PURPOSE IS KNOWN.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;text-transform:uppercase;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc457579742"></a><font style="text-decoration:underline;">SECTION 13</font><font style="text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="text-decoration:underline;text-transform:none;">INDEMNIFICATION</font></p>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.1</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref37644011"></a><font style="text-decoration:underline;">Indemnification by SBL.</font>&nbsp;&nbsp;<font style="font-weight:normal;">SBL shall defend, indemnify and hold harmless Client, its Affiliates, and their officers, directors, employees or agents from and against any Damages arising or resulting from any third party (which shall exclude Client Affiliates) claims to the extent such Damages arise out of or in connection with any claims, demands, or actions based upon (i) [*] Services under this MSA or the applicable PSA; (ii) a breach of SBL&#8217;s warranties under Section 12; or (iii) any claims alleging that the Services (excluding use of Client&#8217;s Background IP) infringe any Intellectual Property rights of a third party; except in each case to the extent that such Damages are caused by the causes as set </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">31</font><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">forth in Section 13.2 for which </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> is obliged to indemnify</font><font style="font-weight:normal;"> (or would be obligated to indemnify SBL but for the limitations of liability set forth herein or in</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">any PSA</font><font style="font-weight:normal;">, in accordance with the limitations on liability set forth in the PSA)</font><font style="font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.2</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Indemnification by Client.</font>&nbsp;&nbsp;<font style="font-weight:normal;">Client shall defend, indemnify and hold harmless SBL, its Affiliates, and their officers, directors, employees or agents from and against any Damages arising or resulting from any third party (which shall exclude SBL Affiliates) claims to the extent such Damages arise out of or in connection with any claims, demands or actions based upon (i) [*] this MSA or the applicable PSA; (ii) a breach of Client&#8217;s warranties under Section 12; or (iii) any claim alleging that any specific Client instructions to SBL that constitute an additional manufacturing activity beyond what is provided for in the Master Batch Record or use of Client&#8217;s Background IP necessary for SBL&#8217;s performance of the Services  pursuant to the MSA or any PSA (including but not limited to use of the Client Materials and Client Technology in SBL&#8217;s performance of the Services) infringes any third party&#8217;s Intellectual Property rights; except in each case to the extent that such Damages are caused by the causes as set forth in Section 13.1 for which SBL is obliged to indemnify Client (or would be obligated to indemnify SBL but for the limitations of liability set forth herein or in any PSA, in accordance with the limitations on liability set forth in the PSA). </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.3</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Indemnification Procedure.</font><font style="font-weight:normal;">&nbsp;&nbsp;The foregoing indemnification by SBL or Client shall be conditioned upon the Party who intends to claim indemnification under Section 13.1 or 13.2 (the &#8220;</font>Indemnified Party<font style="font-weight:normal;">&#8221;) (i) providing written notice to the other Party (&#8220;</font>Indemnifying Party<font style="font-weight:normal;">&#8221;) within twenty (20) calendar days after the Indemnified Party has been given written notice of such third party claim, provided that absence or delay of such prior written notice will not relieve the Indemnifying Party of its obligation to indemnify except to the extent such absence or delay materially prejudices the Indemnifying Party&#8217;s ability to defend the third party claim; (ii) permitting the Indemnifying Party, upon timely notice by the Indemnified Party, the opportunity to assume full control and responsibility (at the Indemnifying Party&#8217;s cost and expense) for the investigation and defense of any such claim with counsel reasonably satisfactory to the Indemnified Party, </font><font style="text-decoration:underline;font-weight:normal;">provided, however</font><font style="font-weight:normal;">, that the Indemnifying Party shall keep the Indemnified Party informed as to the progress of the defense of any such claim and that the Indemnified Party shall cooperate in such defense and shall make available all records, materials and witness reasonably requested by the Indemnifying Party in connection therewith; and (iii) not settling or compromising any such claim without the Indemnifying Party&#8217;s prior written consent, with such consent not to be unreasonably denied, withheld or conditioned.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;text-transform:uppercase;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc457579743"></a><font style="text-decoration:underline;">SECTION 14</font><font style="text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="text-decoration:underline;text-transform:none;">DISCLAIMER OF CONSEQUENTIAL DAMAGES; LIMITATION OF LIABILITY</font></p>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.1</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Disclaimer of Consequential Damages.</font>&nbsp;&nbsp;<font style="font-weight:normal;">EXCEPT PURSUANT TO A PARTY&#8217;S INDEMNIFICATION OBLIGATIONS UNDER SECTION 13.1(iii) or 13.2(iii), OR IN [*], NEITHER PARTY WILL BE LIABLE UNDER THIS MSA FOR ANY SPECIAL, PUNITIVE, EXEMPLARY, MULTIPLIED, CONSEQUENTIAL, INCIDENTAL OR OTHER INDIRECT DAMAGES OF ANY TYPE OR NATURE, WHETHER BASED IN CONTRACT, TORT, STRICT </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">32</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">LIABILITY, NEGLIGENCE OR OTHERWISE, INCLUDING LOSS OF PROFITS OR REVENUES.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;font-weight:bold;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.2</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Limitation of Liability.</font> <font style="font-weight:normal;"> Specific caps on Damages shall be set forth in the applicable PSA. </font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;text-transform:uppercase;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc258845442"></a><a name="_Toc457579744"></a><font style="text-decoration:underline;">SECTION 15</font><font style="text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="text-decoration:underline;text-transform:none;">TERM AND TERMINATION OF AGREEMENT</font></p>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.1</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Term.</font> <font style="font-weight:normal;">This MSA will become effective as of the Effective Date and will be in effect for as long as a PSA is in effect, unless earlier terminated as set forth in Section 15.2 (the &#8220;</font>Term<font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;Each PSA will have its own initial term as stated therein and shall [*], unless either Party gives written notice to the other Party of its intention to terminate such PSA [*] prior to the end of the then current PSA term.</font></p></td></tr></table></div>
<p style="margin-top:11pt;line-height:15pt;text-align:justify;margin-bottom:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing, for the [*] Commercial Drug Substance PSA, the Initial Commercial Term shall be [*]. </p>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.2</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref119051812"></a><font style="text-decoration:underline;">Termination</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;This MSA or a PSA may be earlier terminated as set forth in this Section 15.2. </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.2.1</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref536600447"></a><a name="_Ref102960347"></a><a name="_Ref536600472"></a><font style="text-decoration:underline;">Material Breach</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">  A Party may terminate any MSA or any PSA for a material breach thereof by the other Party, as follows: The non-breaching Party shall give the breaching Party written notice specifying such breach.&nbsp;&nbsp;If the breaching Party: (a) fails to cure such breach within [*] after receipt of such written notice; or (b) cannot cure such material breach within the said [*] period, then fails to commence to cure such material breach within [*] of receiving such written notice and complete such cure within a mutually agreed upon timeline, then the non-breaching Party may terminate this MSA on ten [*]<a name="_Ref536600472"></a> written notice after expiration of such period stated above. This MSA shall terminate if all then-effective PSAs are terminated, and all then-effective PSAs shall terminate if this MSA is terminated.</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.2.2</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref102963654"></a><a name="_Ref536589307"></a><font style="text-decoration:underline;">Insolvency</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;This MSA may be terminated by either Party upon written notice at any time during the Term if the other Party: (a)&#160;files in any court pursuant to any statute a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of such Party, or of its assets; (b)&#160;proposes a written agreement of composition for extension of its debts; (c)&#160;is served with an involuntary petition against it, filed in any insolvency proceeding which is not dismissed within ninety (90) days<a name="_Ref536589307"></a>; or (d)&#160;makes an assignment for the benefit of its creditors.&nbsp;&nbsp;The Party affected shall immediately notify the other Party in writing of the occurrence of any of the foregoing events.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.01%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.62%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.2.3</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref153255933"></a><a name="_Ref536600226"></a><a name="_Ref536606853"></a><a name="_Ref176267"></a><font style="text-decoration:underline;">Force Majeure</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp; Either Party may terminate this MSA or a PSA if a Party is unable to perform its obligations pursuant to this MSA or such PSA in the event of a Force Majeure Event in accordance with Section 17.3.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.2.4</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Other Termination</font><font style="font-weight:normal;">.&nbsp;&nbsp;The Parties may terminate a PSA as set forth in such PSA.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.3</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref102964345"></a><font style="text-decoration:underline;">Effect of Expiration or Termination</font><font style="text-decoration:underline;font-weight:normal;">.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">33</font><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.3.1</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref102964266"></a><font style="text-decoration:underline;">Payment of Amounts Due</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;Expiration or termination of this MSA or any PSA for any reason shall not exempt a Party from paying to the other Party any amounts owing to such Party at the time of such expiration or termination.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.6%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.3.2</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Decommissioning</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">  Upon expiration or termination of a PSA for any reason, SBL shall cease and refrain from performing the Services described in such PSA (including Manufacturing and supplying the Product thereunder) for Client unless otherwise provided in the following Sections 15.3.2(a) to 15.3.2(d), and both Parties shall pursue decommissioning activities as set forth hereunder. [*]. </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Fully Manufactured Product. </p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:21.21%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">If Client terminates a PSA pursuant to Section 15.2.1 or 15.2.2, upon Client&#8217;s written election to SBL, SBL shall (i) deliver already fully Manufactured and Accepted Product to Client in accordance with the terms and conditions of the MSA and applicable PSA or (ii) destroy such Product.&nbsp;&nbsp;[*].</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:27.27%;text-indent:-6.1%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">If SBL terminates a PSA pursuant to Section 15.2.1, or 15.2.2, upon Client&#8217;s election, SBL shall (i) deliver any then-existing fully Manufactured and properly released Product to Client in accordance with the terms and conditions of the MSA and applicable PSA, or (ii) destroy such Product. [*]. </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:16.37%;text-indent:-6.1%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">If either Party terminates a PSA pursuant to Section 15.2.3, both Parties shall negotiate in good faith a reasonable manner for the handling of the fully Manufactured Product and the allocation of costs and expenses between the Parties.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">If a PSA expires or is terminated pursuant to Section 15.1, the provisions of (ii) above shall apply. </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;font-weight:bold;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Client Materials being used for the Services (Product in Process). </p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:21.21%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">If Client terminates a PSA pursuant to Section 15.2.1 or 15.2.2, upon Client&#8217;s written election to SBL, SBL shall (i) continue to use the Client Materials being used for the Manufacturing hereunder (for the Product in process) and deliver the fully Manufactured and Accepted Product therefrom to Client in accordance with the terms and conditions of the MSA and applicable PSA, or (ii) deliver to Client or destroy such Product in process.&nbsp;&nbsp;[*].</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:27.27%;text-indent:-6.1%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">If SBL terminates a PSA pursuant to Section 15.2.1 or 15.2.2, upon Client&#8217;s written election, SBL shall (i) continue to use the Client Materials being used for the Manufacturing hereunder (for the Product in process) and deliver the </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">34</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap"></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">fully </font><font style="font-weight:normal;">Manufactured </font><font style="font-weight:normal;">and Accepted</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">Product </font><font style="font-weight:normal;">therefrom </font><font style="font-weight:normal;">to </font><font style="font-weight:normal;">Client</font><font style="font-weight:normal;"> in accordance with the terms and conditions of the MSA</font><font style="font-weight:normal;"> and applicable </font><font style="font-weight:normal;">PSA</font><font style="font-weight:normal;">, or (ii) destroy </font><font style="font-weight:normal;">such</font><font style="font-weight:normal;"> Product in process.&nbsp;&nbsp;</font><font style="font-weight:normal;">[</font><font style="font-weight:normal;">*</font><font style="font-weight:normal;">]</font><font style="font-weight:normal;">. </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:16.37%;text-indent:-6.1%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">If either Party terminates a PSA pursuant to Section 15.2.3, both Parties shall negotiate in good faith a reasonable manner for the handling of Product in process the Client Materials being used for the Manufacturing hereunder (for the Product in process) and the allocation of costs and expenses between the Parties. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:16.37%;text-indent:-6.1%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">If a PSA expires or is terminated pursuant to Section 15.1, the provisions of (ii) above shall apply. </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:16.37%;text-indent:-6.1%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Client Materials, Cell Line, and Reference Standards.<font style="font-weight:normal;">Upon expiration or termination of a PSA, and upon Client&#8217;s written election to SBL, SBL shall deliver to Client and/or destroy all remaining Client Materials (subject to Sections 15.3.2(a) and 15.3.2(b)), all remaining Cell Line vials, Reference Standards and other materials required for Manufacturing.</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:21.21%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:21.21%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The costs and expenses for such activities shall be borne by the Parties as follows:</p>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:21.21%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">If Client terminates the PSA pursuant to Section 15.2.1 or 15.2.2, SBL shall deliver or dispose in accordance with Client&#8217;s written instructions, [*];</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:27.27%;text-indent:-6.1%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">[*];</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:27.27%;text-indent:-6.1%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">If either Party terminates the PSA pursuant to Section 15.2.3, both Parties shall negotiate in good faith a reasonable manner for all such costs and expenses for such activities; and</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:16.37%;text-indent:-6.1%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">If a PSA expires or is terminated pursuant to Section 15.1, the provisions of (ii) above shall apply. </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Raw Materials. </p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:21.21%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">If Client terminates a PSA pursuant to Section 15.2.1 or 15.2.2, upon Client&#8217;s written election to SBL, SBL shall, at Client&#8217;s election (with respect to any portion of the Raw Materials) deliver the remaining Raw Materials to Client [*], or dispose of them.&nbsp;&nbsp;[*].</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:27.27%;text-indent:-6.1%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">If SBL terminates a PSA pursuant to Section 15.2.1 or 15.2.2, SBL will deliver the remaining Raw Materials to Client or dispose of them at Client&#8217;s election.&nbsp;&nbsp;[*].&nbsp;&nbsp;[*].</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">35</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:16.37%;text-indent:-6.1%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">If either Party terminates a PSA pursuant to Section 15.2.3, both Parties shall negotiate in good faith a reasonable manner for the handling of the Raw Materials and the allocation of costs and expenses between the Parties.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:16.37%;text-indent:-6.1%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.1%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">If a PSA expires or is terminated pursuant to Section 15.1, the provisions of (ii) shall apply. </font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Outstanding Obligations Regarding Purchase of Product.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:21.21%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.08%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">If Client terminates a PSA pursuant to Section 15.2.1 or 15.2.2, Client shall [*].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.08%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">If SBL terminates a PSA pursuant to Section 15.2.1 or 15.2.2, [*].&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:21.17%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:6.08%;white-space:nowrap">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;line-height:15pt;text-align:justify;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">For all other cases of termination of a PSA, the Parties will discuss in good faith the extent to which Client and SBL will be released from such obligations. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Survival</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;Any termination or expiration of this MSA or any PSA shall not affect any outstanding obligations due hereunder prior to such termination or expiration, nor shall it prejudice any other remedies that the Parties may have under this MSA or such PSA. For greater certainty, except as otherwise expressly provided, termination or expiration of this MSA, irrespective of the cause, shall not affect any rights or obligations which, from the context thereof, are intended to survive termination or expiration of this MSA, including but not limited to Sections 8.3, 8.4, 8.6, 9, 10, 11 (excluding the license granted to SBL under Section 11.2), 12, 13, 14, 15, 16, and 17.2.  </font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;text-transform:uppercase;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc457579745"></a><font style="text-decoration:underline;">SECTION 16</font><font style="text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="text-decoration:underline;text-transform:none;">ARBITRATION</font></p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:11pt;font-weight:bold;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-weight:bold;text-decoration:underline;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16.1</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Informal Discussions.</font><font style="font-weight:normal;text-decoration:none;">&nbsp;&nbsp;Except as otherwise provided herein, in the event of any dispute, controversy or claim arising out of or relating to this MSA or any PSA, or the rights or obligations of the Parties hereunder (a &#8220;</font><font style="text-decoration:none;">Dispute</font><font style="font-weight:normal;text-decoration:none;">&#8221;), the Parties shall first try to settle their differences amicably between themselves through the Core Team and then, if necessary, through the JSC. Thereafter, if the JSC cannot resolve such Dispute, either Party may initiate informal dispute resolution on the executive level by sending written notice of the Dispute to the other Party, and within [*], appropriate executive officers of the Parties shall meet for attempted resolution by good faith negotiations.&nbsp;&nbsp;If such representatives are unable to resolve promptly such Dispute within [*], either Party may initiate arbitration proceedings to resolve such Dispute in accordance with the provisions of this Article 16.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;font-weight:bold;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="margin-bottom:12pt;text-align:justify;line-height:15pt;margin-top:0pt;font-size:11pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-weight:bold;text-decoration:underline;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16.2</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;text-align:justify;line-height:15pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Arbitration.</font><font style="font-weight:normal;text-decoration:none;">&nbsp;&nbsp;If the Parties do not fully settle a Dispute pursuant to Section 16.1, and a Party wishes to pursue the matter, each such Dispute shall be finally resolved by binding arbitration in accordance with the Commercial Arbitration Rules of the International Chamber of Commerce (&#8220;</font><font style="text-decoration:none;">ICC</font><font style="font-weight:normal;text-decoration:none;">&#8221;), and </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">36</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:12pt;text-align:justify;line-height:15pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;text-decoration:none;">judgment on the arbitration award may be entered in any court having jurisdiction thereof to enforce the arbitration award.&nbsp;&nbsp;The arbitration shall be conducted by a panel of three persons</font><font style="font-weight:normal;text-decoration:none;">, each of which shall be </font><font style="font-weight:normal;text-decoration:none;">experienced in the pharmaceutical</font><font style="font-weight:normal;text-decoration:none;"> biologics manufacturing</font><font style="font-weight:normal;text-decoration:none;">. W</font><font style="font-weight:normal;text-decoration:none;">ithin </font><font style="font-weight:normal;text-decoration:none;">[</font><font style="font-weight:normal;text-decoration:none;">*</font><font style="font-weight:normal;text-decoration:none;">]</font><font style="font-weight:normal;text-decoration:none;"> after initiation of arbitration, each Party shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator within </font><font style="font-weight:normal;text-decoration:none;">[</font><font style="font-weight:normal;text-decoration:none;">*</font><font style="font-weight:normal;text-decoration:none;">]</font><font style="font-weight:normal;text-decoration:none;"> of their appointment.&nbsp;&nbsp;If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator, the third arbitrator shall be appointed by the ICC. The place of arbitration shall be </font><font style="font-weight:normal;text-decoration:none;">New York, New York, United States</font><font style="font-weight:normal;text-decoration:none;"> and all proceedings and communications shall be in English.&nbsp;&nbsp;</font><font style="font-weight:normal;text-decoration:none;">The award rendered by the arbitrators shall be final, </font><font style="font-weight:normal;text-decoration:none;">binding</font><font style="font-weight:normal;text-decoration:none;"> and non-appealable, and judgment may be entered upon it in any court of competent jurisdiction.</font><font style="font-weight:normal;text-decoration:none;">&nbsp;&nbsp;</font><font style="font-weight:normal;text-decoration:none;">Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved.&nbsp;&nbsp;Either Party also may</font><font style="font-weight:normal;text-decoration:none;"> at any time</font><font style="font-weight:normal;text-decoration:none;">, without waiving any remedy under this </font><font style="font-weight:normal;text-decoration:none;">MSA</font><font style="font-weight:normal;text-decoration:none;">, seek from any court having jurisdiction any injunctive or provisional relief to protect the rights or property of that Party pending the arbitration award.&nbsp;&nbsp;</font><font style="font-weight:normal;text-decoration:none;">I</font><font style="font-weight:normal;text-decoration:none;">n all cases, any decision or determination by the arbitrators shall comply with Article&#160;14.&nbsp;&nbsp;The Parties further agree that any payments made pursuant to this </font><font style="font-weight:normal;text-decoration:none;">MSA or any PSA </font><font style="font-weight:normal;text-decoration:none;">pending resolution of the dispute shall be refunded if an arbitrator or court determines that such payments are not due.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-weight:bold;text-decoration:underline;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16.3</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Confidentiality</font><font style="text-decoration:none;">.&nbsp;&nbsp;</font><font style="font-weight:normal;text-decoration:none;">Except to the extent necessary to confirm or enforce an award or as may be required by law or regulation, neither Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of the other Party.&nbsp;&nbsp;In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable New York statute of limitations.</font><font style="font-weight:normal;text-decoration:underline;">&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;font-weight:bold;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-weight:bold;text-decoration:underline;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16.4</font></p></td>
<td valign="top">
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Costs and Fees.</font><font style="text-decoration:none;">&nbsp;&nbsp;</font><font style="font-weight:normal;text-decoration:none;">Each Party shall bear its own attorneys&#8217; fees, costs, and disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of the arbitrators.&nbsp;&nbsp;Absent the filing of an application to correct or vacate the arbitration award as permitted by Applicable Law, each Party shall fully perform and satisfy the arbitration award within [*].</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;text-transform:uppercase;font-weight:bold;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc457579746"></a><font style="text-decoration:underline;">SECTION 17</font><font style="text-decoration:none;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="text-decoration:underline;text-transform:none;">MISCELLANEOUS</font></p>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.1</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Notices.</font>&nbsp;&nbsp;<font style="font-weight:normal;">Any notice required or permitted under the MSA shall be in writing with duly authorized signature and made to the following addresses or facsimile numbers:</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">If to Client:</font></p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc.</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">409 Illinois St.</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Francisco, CA 94158 USA</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Vice President of Biologics Manufacturing</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With copy to: Chief Legal Officer</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">If to SBL</font>:</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Samsung Biologics Co., Ltd.</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">37</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Head of </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate Business </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Planning</font></p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facsimile: +82-32-455-3242</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With copy to: SBL Legal &amp; Compliance Team</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:7.7%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Either Party may change its designated address and facsimile number by notice to the other Party in the manner provided in this Section 17.1.</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc58642567"></a><a name="_Ref184692892"></a>Any notice shall be deemed to have been delivered on the date of delivery if delivered personally (of the first business day following such date, if such date is not a business day), or on the next business day of sending if sent by facsimile with receipt confirmed by the recipient, or on the fifth business <a name="_Toc58642567"></a><a name="_Ref184692892"></a>day of posting if sent by registered or certified mail with return receipt requested and postage prepaid.</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.13%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.2</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Governing Law.</font><font style="font-weight:normal;">&nbsp;&nbsp;This MSA shall be construed and interpreted in accordance with the laws of State of New York, United States and all rights and remedies shall be governed by such laws without regard to principles of conflicts of law.&nbsp;&nbsp;The United Nations Convention on Contracts for the International Sale of Goods shall not apply to the transactions contemplated by the MSA.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:11pt;font-weight:bold;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.3</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Effect of Force Majeure Event</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;Except as set forth in this Section 17.3, neither Party (the &#8220;</font>Affected Party<font style="font-weight:normal;">&#8221;) shall be liable to the other Party (the &#8220;</font>Non-Affected Party<font style="font-weight:normal;">&#8221;) for failure or delay to perform its obligation under the MSA or any applicable PSA when such failure or delay is due to riots, storms, fires, explosions, floods, earthquakes, war, embargoes, blockades, insurrections, an act of God or any other cause which is beyond the reasonable control of the Affected Party, including those affected upstream suppliers, that prevents the Affected Party from performing such obligations (&#8220;</font>Force Majeure Event<font style="font-weight:normal;">&#8221;).</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Party agrees to give the other Party prompt written notice of the occurrence of any Force Majeure Event, the nature thereof, and the extent to which the affected Party will be unable fully to perform its obligations under this MSA or any PSA.&nbsp;&nbsp;If a condition constituting Force Majeure Event [*], the Parties shall negotiate a mutually satisfactory solution to the problem, if practicable, including termination of this MSA and any then-effective PSAs upon [*], or the use of a third party to fulfill the obligations hereunder of the Party invoking Force Majeure Event, [*].</p>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.4</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref154307839"></a><a name="_Ref183152647"></a><font style="text-decoration:underline;">Assignment</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;Neither Party shall assign, in whole or in part, this MSA or any PSA without the prior written consent of the other Party, which may not be unreasonably withheld; provided, however, that without SBL&#8217;s prior written consent, Client may assign this MSA and any then-effective PSAs in their entirety to an Affiliate or to a third party in connection with the sale or transfer (by whatever method) of all or substantially all of the business or assets of Client&#8217;s business to which this MSA relates.&nbsp;&nbsp;In such case, such Affiliate or third party shall subscribe in writing to be bound to this MSA and applicable PSAs and Client shall remain liable to SBL, on a joint and several basis, for full performance of the assignee third party&#8217;s obligations and covenants under this MSA if such assignee is an Affiliate.&nbsp;&nbsp;Client shall notify SBL in writing of any such sale or transfer within [*] of such sale. For clarity, in the event that any Party assigns this MSA as permitted under this Section 17.4, it shall </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">38</font><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">be required to contemporaneously assign any and all PSAs which are then in effect together with this MSA. </font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.5</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">No Grant of License.</font><font style="font-weight:normal;">&nbsp;&nbsp;Nothing in this MSA shall affect, or grant any right to, patents, know-how or other Intellectual Property owned by either Party prior to the commencement of this MSA unless otherwise expressly provided in this MSA.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.6</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Ethical Practices.</font><font style="font-weight:normal;">&nbsp;&nbsp;SBL and its employees, subcontractors, agents and other representatives have not performed and shall not perform any of the following acts, either directly or through a third party, in connection with this MSA: </font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">give or offer to give, or authorize the giving of, any property, services, payment, money, or anything else of benefit or value to an official, public servant or employee (each, an &#8220;<font style="font-weight:bold;">Official</font>&#8221;) of any governmental authority, state functionary, or instrumentality, or of any public international organization, or of any agency or subdivision thereof, or to any political party or official thereof, or to any candidate for political office (&#8220;<font style="font-weight:bold;">Governmental, Public or Political Entity</font>&#8221;), or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">enter into any other transactions with any Official of a Governmental, Public or Political Entity, in each case, for the purpose of:  (i) influencing or inducing any act or decision of the Official of a Governmental, Public or Political Entity in his or her official capacity, including an act or decision to fail to perform such Official&#8217;s functions with such Governmental, Public or Political Entity, or use his or her influence with such Governmental, Public or Political Entity to affect or influence any act or decision thereof, or (ii) securing any improper advantage, pursuing any business opportunity or business interests, or obtaining unjust or preferential benefits. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">SBL shall: (i) conduct due diligence to ensure that SBL and its affiliates, employees, subcontractors, agents or other representatives who perform Services hereunder do not improperly give, or offer to give, any Official of a Governmental, Public or Political Entity any property, payment, money, or anything else of benefit or value and comply with the terms of this Section; and (ii) maintain accurate and honest record-keeping and effective internal controls, including records that would reveal, and controls that would prevent, unethical practices to confirm that SBL&#8217;s performance of Services conforms to all Applicable Laws.&nbsp;&nbsp; [*].&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.64%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.57%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">If SBL breaches any of the covenants set forth in this Section: (i) this MSA may be immediately terminated at Client&#8217;s sole discretion;  [*].</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.7</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">No Right to Use Names.</font>&nbsp;&nbsp;<font style="font-weight:normal;">Except as expressly provided herein, no right, expressed or implied, is granted by either Party to the other Party under this MSA to use in any manner the name of such Party or any other trade name, trade dress, symbol, logo or trademark of such Party in connection with the performance of this MSA, without the prior written consent of the other Party.&nbsp;&nbsp;For clarity, Client may identify SBL as providing Manufacturing services for the Products to applicable Regulatory Authorities as required, and to the extent required under U.S. securities or other </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">39</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">applicable</font><font style="font-weight:normal;"> laws</font><font style="font-weight:normal;"> and regulations</font><font style="font-weight:normal;">, and SBL may identify Client to the extent required in its filings with the Korea Stock Exchange</font><font style="font-weight:normal;">, both with prior written notice to the other Party. </font><font style="font-weight:normal;">Notwithstanding anything to the contrary, Client&#8217;s name and Product name shall not be included in SBL&#8217;s public disclosures required by the Korea Stock Exchange, unless otherwise agreed by the Parties.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.8</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Independent Contractors</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;The Parties hereto are independent contractors and nothing contained in the MSA shall be deemed or construed to create a partnership, joint venture, employment, franchise, agency or fiduciary relationship between the Parties.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.9</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Integration</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;This MSA constitutes the entire agreement between the Parties relating to the subject matter of the MSA and supersedes all previous oral and written communications between the Parties with respect to the subject matter of this MSA, including any conflicting provisions as set forth in the TTA.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.10</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref427917663"></a><font style="text-decoration:underline;">Amendment; Waiver</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;Except as otherwise expressly provided herein, no alteration of or modification to this MSA or any PSA shall be effective unless made in writing and executed by an authorized representative of each Party.&nbsp;&nbsp;No course of dealing or failing of either Party to strictly enforce any term, right or condition of this MSA in any instance shall be construed as a general waiver or relinquishment of such term, right or condition.&nbsp;&nbsp;The observance of any provision of this MSA may be waived (either generally or any given instance and either retroactively or prospectively) only with the written consent of the Party granting such waiver, which shall only be effective as to the specific instance set forth in such waiver.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.11</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Severability</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;The Parties do not intend to violate any applicable law.&nbsp;&nbsp;However, if any sentence, paragraph, clause or combination of this MSA is in violation of any law or is found to be otherwise unenforceable, such sentence, paragraph, clause or combination of the same shall be deleted and the remainder of this MSA shall remain binding, </font><font style="text-decoration:underline;font-weight:normal;">provided that</font><font style="font-weight:normal;"> such deletion does not alter the basic purpose and structure of this MSA.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.12</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Construction</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;The Parties mutually acknowledge that they have participated in the negotiation and preparation of this MSA.&nbsp;&nbsp;Ambiguities, if any, in this MSA shall not be construed against any Party, irrespective of which Party may be deemed to have drafted this MSA or authorized the ambiguous provision.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;margin-left:10.26%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.13</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Interpretation</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;The captions and headings to the MSA are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of the MSA.&nbsp;&nbsp;Unless context otherwise clearly requires, whenever used in the MSA: (a)&#160;the words &#8220;include&#8221; or &#8220;including&#8221; shall be construed as incorporating, also, &#8220;but not limited to&#8221; or &#8220;without limitation&#8221;; (b)&#160;the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby&#8221; and derivative or similar words refer to the MSA; (c)&#160;the word &#8220;law&#8221; or &#8220;laws&#8221; means any applicable, legally binding statute, ordinance, resolution, regulation, code, guideline, rule, order, decree, judgment, injunction, mandate or other legally binding requirement of a governmental authority (including a court, tribunal, agency, legislative body or other instrumentality of any (i)&#160;government or country or territory, (ii)&#160;any state, province, county, city or </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">40</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap"></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="font-weight:normal;">other political subdivision thereof, or (iii)&#160;any supranational body); and (d)&#160;all references to the word &#8220;will&#8221; are interchangeable with the word &#8220;shall&#8221; and shall be understood to be imperative or mandatory in nature.&nbsp;&nbsp;All references to days, months, </font><font style="font-weight:normal;">quarters</font><font style="font-weight:normal;"> or years are references to calendar days, calendar months, calendar quarters, or calendar years.&nbsp;&nbsp;Whenever any matter hereunder requires consent or approval, such consent or approval shall not be unreasonably withheld</font><font style="font-weight:normal;">, </font><font style="font-weight:normal;">conditioned</font><font style="font-weight:normal;"> or delayed.</font></p></td></tr></table></div>
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.06%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.06%;white-space:nowrap">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.14</font></p></td>
<td valign="top">
<p style="line-height:15pt;text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:underline;">Counterparts</font><font style="text-decoration:underline;font-weight:normal;">.</font><font style="font-weight:normal;">  This MSA may be executed in two&#160;or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. This MSA shall be effective upon full execution by portable document format (pdf), facsimile or original, and a pdf or facsimile signature shall be deemed to be and shall be as effective as an original signature.</font></p></td></tr></table></div>
<p style="text-align:justify;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[THE REMAINDER OF THIS PAGE LEFT BLANK INTENTIONALLY]</p>
<p style="line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">41</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;line-height:15pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the Parties have executed the MSA as of the last date of signature written below.</p>
<p style="line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FIBROGEN, INC. </p></td>
</tr>
<tr>
<td valign="top"  style="width:19.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.32%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.32%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature:</p></td>
<td valign="top"  style="width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Michael Martinelli</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:2.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.32%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Martinelli, Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: </p></td>
<td valign="top"  style="width:2.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.32%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SVP, Technical Dev, Drug Development</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top"  style="width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">05 November 2020</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.32%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.32%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.32%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SAMSUNG BIOLOGICS CO., LTD.</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.32%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.32%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature:</p></td>
<td valign="top"  style="width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Tae Han Kim</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:2.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.32%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Tae Han Kim</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:2.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.32%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Representative Director and President</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top"  style="width:2.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:78.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09 November 2020</p></td>
</tr>
</table></div>
<p style="line-height:15pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:14pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REF: 00038830.0</p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Century;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;">42</font></a><font style="font-family:Times New Roman;">.</font></p></td>
<td valign="top"  style="width:33.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/// Fibrogen - Samsung Master Services Agreement (38830.0) 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[* ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>3
<FILENAME>fgen-ex1036_605.htm
<DESCRIPTION>EX-10.36
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex1036_605.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;letter-spacing:0pt;font-family:Times New Roman;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;"> [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.36</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">SAMSUNG BIOLOGICS CO., LTD.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">PRODUCT SPECIFIC AGREEMENT &#8211; CLINICAL PRODUCT DRUG SUBSTANCE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, this Clinical Product Specific Agreement (this &#8220;<font style="font-weight:bold;">PSA</font>&#8221;) is entered into as of the date of the last signature below, and made effective October 30, 2020 (the &#8220;<font style="font-weight:bold;">PSA</font> <font style="font-weight:bold;">Effective Date</font>&#8221;) by and between FibroGen, Inc., a Delaware corporation having its principal place of business at 409 Illinois Street, San Francisco, California, USA 94158 (&#8220;<font style="font-weight:bold;">Client</font>&#8221;) and Samsung Biologics Co., Ltd., a company with offices at [*] (&#8220;<font style="font-weight:bold;">SBL</font>&#8221;).&nbsp;&nbsp;Client and SBL are sometimes referred to herein individually as a &#8220;<font style="font-weight:bold;">Party</font>&#8221; and collectively as the &#8220;<font style="font-weight:bold;">Parties</font>&#8221;.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Client and SBL entered into a Master Services Agreement effective October 30, 2020 (the &#8220;<font style="font-weight:bold;">MSA</font>&#8221;) and whereas pursuant to Section 2.1 of the MSA, the Parties wish to enter into this PSA whereby SBL will provide certain Services as detailed herein with respect to the Clinical Product specified below;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, understanding that Product manufactured under this PSA may be used for either clinical or commercial purposes, the rights and obligations of each Party related to ongoing commercial Manufacturing of the same Drug Substance will be specified in a Product Specific Agreement &#8211; Commercial Product Drug Substance (the &#8220;Commercial PSA&#8221;). Similar terms as those agreed upon in this PSA shall be incorporated into the Commercial PSA.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, the Parties agree as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">Relationship to the MSA</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;All capitalized terms not defined in this PSA will have the meanings given to them in the MSA.&nbsp;&nbsp;This PSA is hereby incorporated by reference into the MSA.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">Definitions</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;Campaign&#8221; shall mean a series of Batches of the Product that are produced in sequence using the same manufacturing equipment (including but not limited to the same bioreactor) followed by validated cleaning of such equipment and purification suite, and for the purposes of counting the number of Product Batches in a Campaign in a given period, the start date of such Campaign shall be the determining factor. A Campaign will be deemed to end upon the completion of such cleaning.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;"> &#8220;PSA Term&#8221; is defined in Section 9. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">[*].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">d.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">&#8220;Year&#8221; means each one (1) year period that begins on January 1 and ends on December 31.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">General Information</font><font style="font-family:Times New Roman;color:#000000;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;"> Product: [*].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;"> Product Specification: The Product Specification will be contained in mutually agreed upon cGMP documentation and/or the QAA.&nbsp;&nbsp;  </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Cell Line: [*]</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">d.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Manufacturing Facility: [*].</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fibrogen - Samsung Product Specific Agreement (Clinical DS)(38831) 2020 11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">e.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Shelf life of the Product for the purposes of Section 5.9.2(a)(iii) of the MSA is [*], which may be updated by Client and notified to SBL at the JSC. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">Raw Materials</font><font style="font-family:Times New Roman;color:#000000;">.</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">Client Materials</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Client Materials to be supplied by Client to SBL free of charge by itself or a third party designee.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.31%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">i.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">List: See Exhibit A: Client Materials</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.31%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">ii.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Timing of provision of Client Materials to SBL (target) : [*]</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">Raw Materials</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;The Parties shall finalize the categorization of Raw Materials to be used in performing the Services of this PSA into Critical Raw Materials, Customized or Dedicated Raw Materials, and Other Raw Materials, and shall attach such list to this PSA as Exhibit B. Raw Materials will be procured by SBL [*]. Handling Fees for all Raw Materials included (Critical Raw Materials, Customized or Dedicated Raw Materials, and Other Raw Materials) for the Product shall be [*]. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">Technology Transfer, Manufacturing, and Supply Services</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;SBL shall perform the Services as set forth in this Section 5.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">Services.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.31%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">i.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">SBL shall provide the Services as set forth in Exhibit D in accordance with this PSA and the MSA.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.31%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">ii.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Fees and invoicing.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:23.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">[*].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:23.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">[*].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">Service Fees</font><font style="font-family:Times New Roman;color:#000000;">. [*].  Additional Service Fees and costs may be detailed in an amendment to this PSA pursuant to Section 17.10 of the MSA or in an Implementation Plan and Budget pursuant to Section 6.2(b) of the MSA. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">Product Purchase Commitment</font><font style="font-family:Times New Roman;color:#000000;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.31%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">i.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Notwithstanding anything to the contrary, during [*](each a &#8220;Binding Year&#8221;), Client shall order from SBL on a [*], and SBL commits to manufacture, the number of Batches of Product set forth in the table below on the terms and conditions set forth herein and in the MSA (the &#8220;Product Purchase Commitment&#8221;). The Product Purchase Commitment [*].&nbsp;&nbsp;[*]. For clarity, the timeline below is an estimate only, and may be subject to change upon mutual agreement of the Parties.  </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:19.23%;width:55%;">
<tr>
<td style="width:27.5%;"></td>
<td style="width:27.5%;"></td>
</tr>
<tr style="height:16.1pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] </p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.31%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">ii.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Within [*], Client shall issue a binding Purchase Order for [*] for the [*]. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.31%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">iii.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">[*]. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:23.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Upon such notification, then the Parties will meet promptly at the JSC and to discuss in good faith potential options for resolution including, without limitation [*].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:23.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">[*]:</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fibrogen - Samsung Product Specific Agreement (Clinical DS)(38831) 2020 11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:23.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">[*]. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">[*].&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">[*].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">d.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">[*].&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">e.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">[*].&nbsp;&nbsp; </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*].</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.31%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">iv.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">[*]. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">d.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">Batch Failure</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Pursuant to Section 5.8.3 of the MSA, the Parties shall be responsible for costs related to Batch Failure as follows:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.31%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">i.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">To the extent the Batch Failure is caused by an SBL Assignable Error, SBL shall be responsible for (1) the [*] which amount is to be calculated based on the [*]; (2) SBL&#8217;s costs to [*] plus applicable SBL [*] as described in this PSA; (3) [*] as described in this PSA; and (4) [*] which amount is to be calculated based on the [*] as supported by reasonable documentary evidence [*].&nbsp;&nbsp;Any such cost responsibility shall be issued as a [*].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.31%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">ii.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">To the extent the Batch Failure is caused by Client&#8217;s breach of its obligations hereunder, [*].  If a Batch Failure is caused by [*].</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:17.31%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:1.92%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">iii.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">To the extent no root cause of the Batch Failure is identified, [*]. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">Regulatory Filings</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Client&#8217;s regulatory filings covered by this PSA are clinical trial applications (e.g., USA IND, EU CTA/IMPD, China CTA (which in the case of China, may require additional fees)) commercial marketing applications (e.g., US BLA, EU MAA), as well as other filings as required by local regulatory requirements (e.g., GMP applications, drug master files).&nbsp;&nbsp;SBL shall use Commercially Reasonable Efforts to support Client&#8217;s submissions or applications to any new Regulatory Authority, provided Client has provided SBL with reasonable notice and the Parties agree on an Implementation Plan and Budget, and [*].&nbsp;&nbsp;Details of the scope of SBL&#8217;s Services in regards to Regulatory Approvals shall be detailed in Exhibit D.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">Storage</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;Pursuant to Section 5.9 of the MSA, if Client does not direct SBL to prepare Manufactured Clinical Product to be picked up by Client or Client&#8217;s designated carrier with a pick-up date within [*], SBL shall store the Clinical Product at the Warehouse for up to [*] depending on the available storage capacity and [*].&nbsp;&nbsp;[*].&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">8.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">Limitation of Liability</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;In addition to the limitation of liability in Section 14.1 of the MSA for special, punitive, incidental, indirect or consequential damages, the Parties&#8217; liability under the PSA shall be as set forth in this Section 8.&nbsp;&nbsp;Except for (i) a Party&#8217;s indemnification obligations under Section 13.1(iii) and 13.2(iii) of the MSA; (ii) the Client&#8217;s payment obligations under Section 9.3 of the MSA; (iii) [*], or (iv) [*], a Party&#8217;s maximum aggregate liability to compensate the other Party for all Damages under this PSA will be [*] in which the cause of such liability lies or exists (whether in contract, tort, strict liability, statute or otherwise), and [*]. [*].    </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">9.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">Term</font><font style="font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;This PSA will commence as of the PSA Effective Date and will continue in full force and effect until all the Services stated under this PSA are completed (&#8220;PSA Term&#8221;), unless earlier terminated in accordance with the provisions of this PSA and/or Section 15 of the MSA.</font></p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fibrogen - Samsung Product Specific Agreement (Clinical DS)(38831) 2020 11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">10.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="text-decoration:none;Background-color:#auto;font-family:Times New Roman;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-family:Times New Roman;color:#000000;">Method Transfer</font><font style="font-family:Times New Roman;color:#000000;">. </font><font style="font-family:Times New Roman;color:#000000;">The Parties agree that, upon request by Client and with appropriate cooperation from Client, SBL will</font><font style="font-family:Times New Roman;color:#000000;"> complete the transfer, and </font><font style="font-family:Times New Roman;color:#000000;">validation</font><font style="font-family:Times New Roman;color:#000000;"> (if applicable)</font><font style="font-family:Times New Roman;color:#000000;">, and to pe</font><font style="font-family:Times New Roman;color:#000000;">rform all IPC </font><font style="font-family:Times New Roman;color:#000000;">and</font><font style="font-family:Times New Roman;color:#000000;"> release testing</font><font style="font-family:Times New Roman;color:#000000;"> for </font><font style="font-family:Times New Roman;color:#000000;">D</font><font style="font-family:Times New Roman;color:#000000;">rug </font><font style="font-family:Times New Roman;color:#000000;">S</font><font style="font-family:Times New Roman;color:#000000;">ubstance</font><font style="font-family:Times New Roman;color:#000000;">, </font><font style="font-family:Times New Roman;color:#000000;">[</font><font style="font-family:Times New Roman;color:#000000;">*</font><font style="font-family:Times New Roman;color:#000000;">]</font><font style="font-family:Times New Roman;color:#000000;">, and will use Commercially Reasonable Efforts to complete such activities as soon as reasonably possible, but in any event prior to the commencement of the PPQ batches</font><font style="font-family:Times New Roman;color:#000000;">.</font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[THE REMAINDER OF THIS PAGE LEFT BLANK INTENTIONALLY]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:3pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fibrogen - Samsung Product Specific Agreement (Clinical DS)(38831) 2020 11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Parties have entered into this PSA as of the date of the last signature below by their respective duly authorized representatives.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:48.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-variant: small-caps;font-size:11pt;font-style:normal;text-transform:none;">Samsung Biologics Co., Ltd.</p></td>
<td valign="top"  style="width:3.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:47.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-variant: small-caps;font-size:11pt;font-style:normal;text-transform:none;">FibroGen, Inc.</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:6.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:42.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:3.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:41.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:42.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Tae Han Kim</p></td>
<td valign="top"  style="width:3.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:41.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Michael Martinelli </p></td>
</tr>
<tr>
<td valign="bottom"  style="width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:42.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tae Han Kim</p></td>
<td valign="top"  style="width:3.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:41.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Martinelli</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp; </p></td>
<td valign="bottom"  style="width:42.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Representative Director &amp; President</p></td>
<td valign="top"  style="width:3.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: </p></td>
<td valign="top"  style="width:41.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SVP, Manufacturing </p></td>
</tr>
<tr>
<td valign="bottom"  style="width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: </p></td>
<td valign="bottom"  style="width:42.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09 November 2020</p></td>
<td valign="top"  style="width:3.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:6.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: </p></td>
<td valign="top"  style="width:41.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">05 November 2020</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fibrogen - Samsung Product Specific Agreement (Clinical DS)(38831) 2020 11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A: Client Materials</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fibrogen - Samsung Product Specific Agreement (Clinical DS)(38831) 2020 11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit B: Categorization of Raw Materials</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Categorization to be agreed by the Parties.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fibrogen - Samsung Product Specific Agreement (Clinical DS)(38831) 2020 11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C: Service Fees </p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fibrogen - Samsung Product Specific Agreement (Clinical DS)(38831) 2020 11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION COPY</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit D: Scope of Work</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fibrogen - Samsung Product Specific Agreement (Clinical DS)(38831) 2020 11 05 EXECUTION CLEAN FINAL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.44
<SEQUENCE>4
<FILENAME>fgen-ex1044_204.htm
<DESCRIPTION>EX-10.44
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex1044_204.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.44</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gs4n3b54niev000001.jpg" title="" alt="" style="width:310px;height:112px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October 22, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark Eisner, M.D., M.P.H.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[PRIVATE ADDRESS]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.7%;text-indent:-4.7%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear Mark,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.7%;text-indent:-4.7%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc. is pleased to offer you the position of Chief Medical Officer reporting to me.&nbsp;&nbsp;The<font style="letter-spacing:-0.9pt;"> </font>effective<font style="letter-spacing:-0.8pt;"> </font>date<font style="letter-spacing:-0.65pt;"> </font>of<font style="letter-spacing:-0.9pt;"> </font>your<font style="letter-spacing:-0.5pt;"> </font>employment<font style="letter-spacing:1.1pt;"> </font>("<font style="font-weight:bold;">Effective</font><font style="font-weight:bold;letter-spacing:-0.6pt;"> </font><font style="font-weight:bold;">Date</font>")<font style="letter-spacing:-0.75pt;"> </font>will<font style="letter-spacing:-0.2pt;"> </font>be<font style="letter-spacing:-0.5pt;"> </font>set,<font style="letter-spacing:-0.95pt;"> </font>as<font style="letter-spacing:-0.8pt;"> </font>mutually<font style="letter-spacing:-0.4pt;"> </font>agreed<font style="letter-spacing:-0.1pt;"> </font>upon in<font style="letter-spacing:-0.55pt;"> </font><font style="letter-spacing:0.1pt;">advance</font><font style="letter-spacing:-0.5pt;"> </font>with FibroGen, Inc. (&#8220;<font style="font-weight:bold;">FibroGen</font>&#8221;) and confirmed with Human Resources. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This offer of employment is made contingent upon successful completion of FibroGen&#8217;s background check or upon completion of all required documentation that will be made available to you on the Effective Date. This includes verification of the information provided online and your employment application. If necessary, you will be contacted to resolve any discrepancies in the verification of information. Your employment hire date will be determined after the completion of the background check process and your signed acceptance of this offer.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:-0.5pt;"> </font>terms<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.7pt;"> </font>this<font style="letter-spacing:-0.5pt;"> </font>offer<font style="letter-spacing:-0.75pt;"> </font>of<font style="letter-spacing:-0.8pt;"> </font>employment<font style="letter-spacing:0.2pt;"> </font>are<font style="letter-spacing:-0.85pt;"> </font>as<font style="letter-spacing:-0.45pt;"> </font>follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:10pt;font-weight:normal;font-style:normal;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;line-height:10pt;font-weight:normal;font-style:normal;color:#282828;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:9.5pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Compensation</font><font style="font-size:10pt;color:#000000;">.</font><font style="font-size:10pt;letter-spacing:0.6pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">FibroGen</font><font style="font-size:10pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">will</font><font style="font-size:10pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">pay</font><font style="font-size:10pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">you</font><font style="font-size:10pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">a</font><font style="font-size:10pt;letter-spacing:-0.85pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">starting</font><font style="font-size:10pt;letter-spacing:-1pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">annual salary</font><font style="font-size:10pt;letter-spacing:-0.8pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">of</font><font style="font-size:10pt;letter-spacing:-1.25pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">$600,000,</font><font style="font-size:10pt;letter-spacing:-0.95pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">payable</font><font style="font-size:10pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">in</font><font style="font-size:10pt;letter-spacing:-0.85pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">semi-monthly installments</font><font style="font-size:10pt;letter-spacing:-0.8pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">on</font><font style="font-size:10pt;letter-spacing:-1.05pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">our</font><font style="font-size:10pt;letter-spacing:-1.15pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">regular</font><font style="font-size:10pt;letter-spacing:-0.85pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">paydays</font><font style="font-size:10pt;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">in</font><font style="font-size:10pt;letter-spacing:-1pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">accordance</font><font style="font-size:10pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">with</font><font style="font-size:10pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">FibroGen's</font><font style="font-size:10pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">standard</font><font style="font-size:10pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">payroll</font><font style="font-size:10pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:10pt;letter-spacing:0.1pt;color:#000000;">policies</font><font style="font-size:10pt;letter-spacing:0.05pt;color:#000000;">.</font><font style="font-size:10pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">Your</font><font style="font-size:10pt;letter-spacing:-0.8pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">salary</font><font style="font-size:10pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">will</font><font style="font-size:10pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">begin</font><font style="font-size:10pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">as</font><font style="font-size:10pt;letter-spacing:-1.05pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">of</font><font style="font-size:10pt;letter-spacing:-0.95pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">the</font><font style="font-size:10pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">Effective</font><font style="font-size:10pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">Date.</font><font style="font-size:10pt;letter-spacing:0.6pt;color:#000000;">&nbsp;&nbsp;The position is classified as exempt and therefore not eligible for overtime pay.</font><font style="font-size:10pt;letter-spacing:0.4pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">The</font><font style="font-size:10pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">first</font><font style="font-size:10pt;letter-spacing:-0.8pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">and</font><font style="font-size:10pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">last</font><font style="font-size:10pt;letter-spacing:1.4pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">payment</font><font style="font-size:10pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">by</font><font style="font-size:10pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">FibroGen</font><font style="font-size:10pt;letter-spacing:-0.95pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">to</font><font style="font-size:10pt;letter-spacing:-1.3pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">you</font><font style="font-size:10pt;letter-spacing:-0.9pt;color:#000000;"> </font><font style="font-size:10pt;letter-spacing:0.05pt;color:#000000;">will</font><font style="font-size:10pt;letter-spacing:-1pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">be</font><font style="font-size:10pt;letter-spacing:-1.05pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">adjusted,</font><font style="font-size:10pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">if</font><font style="font-size:10pt;letter-spacing:-1.35pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">necessary,</font><font style="font-size:10pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">to</font><font style="font-size:10pt;letter-spacing:-1.3pt;color:#000000;"> </font><font style="font-size:10pt;letter-spacing:0.1pt;color:#000000;">reflect</font><font style="font-size:10pt;letter-spacing:-1.1pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">a</font><font style="font-size:10pt;letter-spacing:-1.1pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">commencement</font><font style="font-size:10pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">or</font><font style="font-size:10pt;letter-spacing:-1.45pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">termination</font><font style="font-size:10pt;letter-spacing:1.15pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">date</font><font style="font-size:10pt;letter-spacing:-0.9pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">other</font><font style="font-size:10pt;letter-spacing:-0.85pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">than</font><font style="font-size:10pt;letter-spacing:-0.05pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">the</font><font style="font-size:10pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">first</font><font style="font-size:10pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">or</font><font style="font-size:10pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">last</font><font style="font-size:10pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">working</font><font style="font-size:10pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">day</font><font style="font-size:10pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">of</font><font style="font-size:10pt;letter-spacing:-0.85pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">a</font><font style="font-size:10pt;letter-spacing:-0.3pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">pay</font><font style="font-size:10pt;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">period.</font></p></td></tr></table></div>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#282828;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;font-family:Times New Roman;letter-spacing:0.1pt;color:#000000;">Signing Bonus</font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;letter-spacing:0.1pt;color:#000000;">. </font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1.1pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">FibroGen</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1.25pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">will pay you</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1.05pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">a</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1.3pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">sign-on</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1.15pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">bonus</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1.05pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">in</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1.25pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1.2pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;color:#000000;">amount of</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1.2pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;color:#000000;">$1,500,000 </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">(subject</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1.05pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">to</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1.3pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.1pt;color:#000000;">app</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.15pt;color:#000000;">l</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.1pt;color:#000000;">icable</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:1.3pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">payroll</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.1pt;color:#000000;">taxes and withholdings)</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.95pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">to</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">be</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">payable, contingent up on your continued employment with the Company,</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1.05pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">in three installments as follows:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">$500,000</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.75pt;color:#000000;"> on </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">first</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">payroll</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">date</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">following</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.9pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1.1pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Effective</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Date</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1.25pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">of</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1.15pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">your</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">employment</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">$500,000 on March15, 2021</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">$500,000 on August 2, 2021</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#282828;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;font-family:Times New Roman;color:#000000;">Stock</font><font style="text-decoration:underline;font-size:10pt;font-family:Times New Roman;letter-spacing:-1.35pt;color:#000000;"> </font><font style="text-decoration:underline;font-size:10pt;font-family:Times New Roman;color:#000000;">Options and Restricted Stock Units</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">.</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;color:#000000;">&nbsp;&nbsp;</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">You will be granted the following equity incentive grant(s) pursuant to the terms and conditions of the Equity Plan effective on the date of acceptance of this letter (the &#8220;</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;color:#000000;">Equity Plan</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">&#8221;), as may be amended or modified from time to time:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">a stock option to purchase 80,000 shares of FibroGen's Common Stock with an exercise price set at the fair market value on the date of grant (&#8220;</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;color:#000000;">Stock Options</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">&#8221;); and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.41%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">a grant of 35,000 restricted stock units relating to shares of FibroGen&#8217;s Common Stock (&#8220;</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;color:#000000;">RSUs</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">&#8221;).</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:3.85%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The actual number of shares subject to the grant hereunder may be adjusted, if required, for events such as stock splits, stock dividends, etc. pursuant to the Equity Plan.&nbsp;&nbsp;The Stock Options and RSUs will vest according to the schedule set forth in the Equity Plan.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#282828;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:9.5pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Bonus</font><font style="text-decoration:underline;font-size:10pt;letter-spacing:0.6pt;color:#000000;"> </font><font style="text-decoration:underline;font-size:10pt;color:#000000;">Plan</font><font style="font-size:10pt;color:#000000;">. You&nbsp;&nbsp;will be eligible to participate in FibroGen&#8217;s Incentive Compensation Plan (the &#8220;</font><font style="font-weight:bold;font-size:10pt;color:#000000;">Bonus Plan</font><font style="font-size:10pt;color:#000000;">&#8221;)&nbsp;&nbsp;adopted</font><font style="font-size:10pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">by</font><font style="font-size:10pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:10pt;letter-spacing:0.2pt;color:#000000;">FibroGen</font><font style="font-size:10pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">for</font><font style="font-size:10pt;letter-spacing:-0.95pt;color:#000000;"> </font><font style="font-size:10pt;letter-spacing:0.35pt;color:#000000;">i</font><font style="font-size:10pt;letter-spacing:0.25pt;color:#000000;">ts</font><font style="font-size:10pt;letter-spacing:1.05pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">employees</font><font style="font-size:10pt;letter-spacing:-0.5pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">on</font><font style="font-size:10pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">such</font><font style="font-size:10pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">terms</font><font style="font-size:10pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">as</font><font style="font-size:10pt;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">FibroGen's</font><font style="font-size:10pt;letter-spacing:-0.25pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">Board</font><font style="font-size:10pt;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">of</font><font style="font-size:10pt;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">Directors</font><font style="font-size:10pt;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">(the</font><font style="font-size:10pt;letter-spacing:-1.3pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">"Board")</font><font style="font-size:10pt;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">may</font><font style="font-size:10pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">determine</font><font style="font-size:10pt;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">in</font><font style="font-size:10pt;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">its discretion.</font><font style="font-size:10pt;letter-spacing:0.8pt;color:#000000;"> </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gs4n3b54niev000002.jpg" title="" alt="" style="width:624px;height:44px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The target bonus for your level will be 50%.&nbsp;&nbsp;Under the terms of the Plan, both corporate and individual performance is assessed annually and subject to final approval by the Company&#8217;s Board of Directors.&nbsp;&nbsp;Employees hired during the course of a year will have a pro-rated bonus provided they commence their employment on or before September 30th of a calendar year. To remain eligible, employees must maintain satisfactory performance and be in an active status on the day of payment.&nbsp;&nbsp;Payments are expected to occur no later than the 15th of March in the year following the performance cycle.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#282828;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;font-family:Times New Roman;color:#000000;">Change in Control and Severance Agreement</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">.&nbsp;&nbsp;You will be eligible to enter into the form of Company&#8217;s Change in Control and Severance Agreement approved by the Board that provides for certain severance benefits upon a termination following a Change in Control (as defined therein) and upon certain other terminations.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#282828;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;font-family:Times New Roman;letter-spacing:0.1pt;color:#000000;">Benefits</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;color:#000000;">.</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.1pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">During</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.8pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">the</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">term</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.35pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">of</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1.3pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">your</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">employment,</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.8pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">you</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">will</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">be</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.95pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">eligible</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">to participate in FibroGen&#8217;s benefits program, which may include FibroGen's</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">standard</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.45pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">vacation benefits</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:1.35pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">and other employee</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.6pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">benefits such as medical, vision and dental health insurance, covering employees and officers. </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;">These benefits may be modified or subject to change from time to time.</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;"> A copy</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.8pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">of</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1.2pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">FibroGen's</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.75pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">current</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.7pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">benefits</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.55pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">summary</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">has</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.9pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">been</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.65pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">provided</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.4pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">to</font><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-1.1pt;color:#000000;"> </font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">you.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#282828;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;font-family:Times New Roman;color:#000000;">Employment Eligibility.</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;"> You will also be required to sign the Employment Eligibility Verification (Form I-9).&nbsp;&nbsp;(You will need to complete and return Section One of Form I-9 along with your signed offer letter). On your first day of employment, please bring the necessary original documents that establish your identity and employment eligibility to work in the United States. Acceptable documents are listed on the reverse side of Form I-9. Such documentation must be provided to us within three (3) business days of your date of hire, or our employment relationship with you may be terminated.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">8.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#282828;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;font-family:Times New Roman;color:#000000;">Proprietary Information</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">. You will abide by FibroGen&#8217;s strict company policy that prohibits any new employee from using or bringing with them from any prior employer any proprietary information, trade secrets, proprietary materials or processes of such former employers.&nbsp;&nbsp;Moreover, because FibroGen&#8217;s proprietary information is extremely important, this offer of employment is expressly subject to your execution of the enclosed Confidential Information, Secrecy and Invention Agreement for Employees. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">9.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#282828;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;font-family:Times New Roman;color:#000000;">At Will Employment.</font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">&nbsp;&nbsp;You should be aware that your employment with FibroGen is for no specified period and constitutes "at-will" employment.&nbsp;&nbsp;As a result, both FibroGen and you are free to terminate the employment relationship at any time, for any reason or for no reason, and with or without advance notice. The changing needs of FibroGen could also result in changes to certain aspects of your employment, such as compensation, responsibilities, location, etc. These provisions expressly supersede any previous representations, oral or written. Your at-will employment cannot be modified or amended except by written agreement signed by both you and the Chief Executive Officer of FibroGen.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#282828;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">10.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#282828;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-weight:normal;color:#000000;">Arbitration.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;color:#000000;">&nbsp;&nbsp;Any dispute or claim, including all contract, tort, discrimination, and statutory claims, arising under or relating to your employment or termination of your employment with FibroGen (&#8220;Arbitrable Claim(s)&#8221;) shall be resolved by arbitration.&nbsp;&nbsp;&#8220;Arbitrable Claims&#8221; shall not include: (1) claims under applicable workers&#8217; compensation law, (2) unemployment insurance claims, and (3) any disputes or claims relating to or arising out of the misuse or misappropriation of trade secrets.&nbsp;&nbsp;You and FibroGen hereby waive any rights each may have to a jury trial in regard to Arbitrable Claims.&nbsp;&nbsp;Arbitration for Arbitrable Claims will be conducted by the American Arbitration Association (&#8220;AAA&#8221;) in San Francisco (or other mutually agreed upon city) under the Employment Arbitration Rules and Mediation Procedures (&#8220;AAA Rules&#8221;). The AAA Rules are available at </font><font style="color:#auto;font-size:10pt;font-family:Times New Roman;text-decoration:underline;font-weight:normal;">https://www.adr.org/sites/default/files/EmploymentRules_Web_0.pdf</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;color:#000000;">, or can be obtained by contacting the FibroGen Human Resources department or by calling AAA at 800-778-7879.&nbsp;&nbsp;FibroGen will pay the fees and costs of the arbitrator.&nbsp;&nbsp;The arbitrator shall have the same authority as a court to award equitable relief, damages, costs, and fees (excluding the costs and fees for the arbitrator) as provided by law for the particular claims asserted.&nbsp;&nbsp;The arbitrator shall also have exclusive authority to rule on his or her own jurisdiction, </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#282828;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;color:#000000;">including any objections with respect to the existence, scope, enforceability or validity of the arbitration agreement. Such arbitration shall be final and binding on the parties and shall be the exclusive remedy for Arbitrable Claims.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise notified by FibroGen, this offer of employment is effective for five business days from the date of this letter.&nbsp;&nbsp;However, if you have any questions regarding the above provisions including the arbitration provision, please do not hesitate to contact us. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of conflict between the terms contained in this offer letter and any other document, the terms of this offer letter (including any amendment to this letter) shall control.&nbsp;&nbsp;FibroGen reserves the right to amend the terms contained in this offer letter from time to time.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We look forward to your joining our team at FibroGen. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sincerely,</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Enrique Conterno</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enrique Conterno</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td style="width:8.86%;"></td>
<td style="width:9.91%;"></td>
<td style="width:11.58%;"></td>
<td style="width:9.65%;"></td>
</tr>
<tr>
<td colspan="4" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACCEPTED AND AGREED TO this</p></td>
</tr>
<tr>
<td colspan="4" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td valign="middle"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Day of</p></td>
<td valign="middle"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October</p></td>
<td valign="middle"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2020</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td style="width:50%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Mark Eisner</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark Eisner, M.D., M.P.H.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 1, 2020</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:90pt;;text-indent:-90pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intended Start Date</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enclosures:<font style="margin-left:36pt;">Benefits Overview</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>fgen-ex211_241.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex211_241.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1</p>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">List of Subsidiaries of FibroGen, Inc.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:73.02%;"></td>
<td style="width:26.87%;"></td>
</tr>
<tr style="height:26.05pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Subsidiaries</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Incorporation</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beijing Falikang Pharmaceutical Co., Ltd.</p></td>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen (China) Medical Technology Development Co., Ltd.</p></td>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen China Anemia Holdings, Ltd.</p></td>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cayman Islands</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen Europe Oy</p></td>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finland</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen International (Cayman) Limited</p></td>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cayman Islands</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen International (Hong Kong) Limited</p></td>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hong Kong</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Skin Sciences, Inc.</p></td>
<td valign="top" >
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware, USA</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>fgen-ex231_10.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex231_10.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;23.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm</p>
<p style="margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-236844) and Form S-8 (No. 333-200348, No. 333-213816, No. 333-216369, and No. 333-233204) of FibroGen Inc. of our report dated March 1, 2021 relating to the financial statements and financial statement schedule and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</p>
<p style="margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ PricewaterhouseCoopers LLP</p>
<p style="margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Jose, California</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2021</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>fgen-ex311_14.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex311_14.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Enrique Conterno, certify that;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this annual report on Form 10-K of FibroGen, Inc.;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 1, 2021</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Enrique Conterno</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160; Enrique Conterno</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160; Chief Executive Officer </p></td>
</tr>
<tr>
<td valign="bottom"  style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45%;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160; (Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>fgen-ex312_9.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex312_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Pat Cotroneo, certify that;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this annual report on Form 10-K of FibroGen, Inc.;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 1, 2021</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Pat Cotroneo</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160; Pat Cotroneo</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160; Senior Vice President, Finance and Chief Financial</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.25pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Officer (Principal Financial Officer)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>fgen-ex321_13.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex321_13.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Enrique Conterno, Chief Executive Officer of FibroGen, Inc. (the &#8220;Company&#8221;), and Pat Cotroneo, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 (the &#8220;Annual Report&#8221;), to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Exchange Act, and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">In Witness Whereof<font style="font-weight:normal;">, the undersigned have set their hands hereto as of the 1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup> day of March, 2021.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Enrique Conterno</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Pat Cotroneo</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enrique Conterno</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pat Cotroneo</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President, Finance and Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of FibroGen, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gapk0ju0ozex000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gapk0ju0ozex000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *D!2<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M81W@8")XQ)GV(S7B/[1'ATRV%GKL2\PMY<I Y.< 5<T7Q\B_ N6]D?$\*&S
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M*@\V21"R;N^,&L#]H7_D=X_^N"?RKVCX=^&-,L?A_8PK:Q$7ELLDQQ][<O-
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M,9KP74_VA=7FU%TT32HWMU8@>8A9B/7@UO?'#4IH/ASIEHC,!.(F8@]<+_\
M7J3X >'+&/PQ)K#PI)=3R8#L.4 )&!0!EW_Q_N%\->=;644.K)(JM!<*<,IS
MD@5Z1\,_%E[XR\*)JE_%#',SLI6($#@D=Z\M_:%\.6-M]BU>VB6*9LI)M&-^
M3P379_ 3_DG<7_75_P#T(T >I5\^_M$>)+A9K/0H9"L)'F3+GJ>,?SKZ"KY8
M^/Z,/'VX@[6A7!]>!0!V'PJ^$.D76@PZQKUL+F6?)6"094+V-='XT^"WA[4]
M&F;1-/BLKU%+1B$8#D=OQKL? <L<W@K2VB8,H@49'J ,UO7-Q#:6TEQ.XCAC
M4L['H .IH \@^#O@'Q+X0OIIM1=(K2=?G@_BW#H?2NR\>?$33/ UD&N,S7<G
M^K@4\GWK>TOQ'H^M'&G7\-P>N$/-?+?CJ\D\5?%U;6X8B-KJ.V"GH!NVT =-
M+^T!XIDF,EMHT'V7/5HF)Q]0<5Z/\/\ XO:;XQG%A<1&TU #(5R,/ZXKM=-\
M.:9INC1Z7%9PBW6,(R[>&XP3^-?+GCK38_!'Q<$>G'RT22*=0G&-QW8H ]D^
M*?COQ5X'GBN+"SLY].E&-\B,2K>_-:?@[XG6>O\ @RXUF]:*&XM58S1@XZ#C
M'UQ6_JFD6WC+P8MM>QJ1=6ZNI;^%BN0?P-?'>KV]]X>U#4-$%PPB$NUU4\/M
M)P: /<?"_P 7O%GB_P 7#3-+L+'[*9"2[HQ*Q@]^>N*]U7.T;L9QSBO,_@QX
M.MO#_A6._)CDN[U0[2+V7J!^&:]-H IZM=/8Z-?7D8!D@MY)5!Z$JI(_E7@>
MA_M#Z@S3G6+"W8!?W26RD,S?B?I7NOB3_D5]7_Z\IO\ T U\J_!G0[77/B#:
MQ7L2RV\:-(48?Q 9'ZB@#KC^T)XA@U!3<Z1#'9EONF-@Y'U)Q74Z]\>+.'3+
M9M#M&N[Z5 SQ[21%QT.*B_:$TNT'A>RNEA5989-JD#L<"H?V>]#L7T&YU22!
M'N7D,>YAR /_ -= %7PG\?KN\UF*Q\06,4*RN$#PJ5VDG SDU[G=7UM9V+WD
M\JI B[RY/&*^4?BI:067Q:V6T2QJS1.0H[EN37J'QAU>>P^%NG6T3,/M:JK,
M#Z8- &5XB_:"N!?26WAS3EG5&P))5+!O< <U#H?[0=]'>)%XCTH1HS8W0J4V
M^YW&M']G[PM8/X>E\030I)<O,T*EARFW'3\ZTOCQX8T^?P;+K2P1I=VKK\X'
M+ D#% 'J.GZM9:GI<>I6LZO:NF\..F,9KQGQE\>I-/U:73_#MG'<M$VTRR L
MK'V .:Y_X>>*+NW^$^O6@9C]F7*G/0.=N*H? #0+/6?%-]<WD2RFRB61 PSR
M210!>U?XS7.O>$K[2=;TQK:XG4".1$*IG.>_-3?LU?\ (>UW_KUC_P#0C7HO
MQE\.:?J'@2[NVMXQ=6P!BDQRO(S^E>;?LY.8]5\1..JV:$?]]&@#TCXB_%NR
M\%S"PMHOM6HD9V \)]:\[M?V@O$<-P)-1T:$6A/5(F4X^I.*X#5M:M_^%G7>
MIZS ]Y;I=,SQ C)'8#/O7?\ B7XR^$_$/AV;26\-7:*R;8R63"'MWH ]O\(^
M+=/\8Z,FHV#8!X>,GYD/H:^9/B3_ ,EAN?\ K]7_ -#%=)^SOJDL'B.^L"V8
MIH1A3V.>M<W\2?\ DL-S_P!?J_\ H8H ^N1]T?2EI!]T?2EH **** "BBB@
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MR%?2?@_PC9>#-'_LVQFFEBSG=*1G]*YKQ9\&]$\7ZW)JM[>WL4SCE8BN/U%
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M&&4_SH \"^!_C30O#^FW-EJ=\EO/+(!&K _.2>@P*^B8W66-74Y5AD5Y3;_
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M7RY=HY5,'^IKT7P?\-- \&$R6,)EN2,&XE WX_"NMG@BN87AF0/&XPRD<$4
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MQ(ISOB90/U-6?%_Q_P#[9T>:PT?3IK4S+M:28@D#VP:ZS_AG+PS_ -!+4O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .!
M\:?"?2/&^MQ:I?7EW#-'&(PL)7& 2>X]Z['2--BT?2+73H79XK>,1JS=2!ZU
M=HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** *U_86NIV4MG>PK-;RC:Z,."*\QU+X >%;^X,L4MU: G[D.W
M _,5ZO10!YCH?P+\*Z-=I</YUZ4.0MQ@C/X5Z9'&D,2QQJ%1 %51V IU% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>.O^AEO?S7_"OH+X8_\ )'?^W63_ - KYH\(Z.NO>(H=/?I(DC?]\H3_ $H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;7%C;PW+(1'B8G&.!VJ3X8^-[SQSX??4;RU@MY%E9-L)../K0!W%>3?M ?\
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MS$8V.0KYQG^=?4%?,'P1\)ZAJ?BY=>N(W2VMV\SS"/OOG/\ C7I?Q7^*6I>
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MIB5FZ EL<U]"?"OXEZAX^DO5O;&VMOLY7;Y);G(/J:\-?_DMEO\ ]A1?_1E
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MOE?X3?\ )9[/_?E_]!- %GXK^%I_ _C:/6=/#1VMQ+YL97HK9R5^G2N>\?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%1SSQ6T#S3NL<2#+,W0"G@AE# Y!&0: %HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MJ*>YAM8P\\BQJ6"@L>I/ % $M%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 <I\2V*_#?72I((MN"#[BNBT__D&V
MO_7%/Y"N<^)O_)-M>_Z]C_,5T>G_ /(-M?\ KBG\A0!9HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_&VCWFMZ+;
M6UD0)8[ZWG;)Q\J2!F_05TE<QX[UB[T30[6YLGV22:A;0,?]EY #^AH Z>BB
MB@ HHHH **** "BBB@ HHHH ***\T^-'BG5O"WANUN-(NC;S2RE2X / QZT
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M<4_D* +-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %9/B'4=.TS3XIM33?"]S%$HQGYV8!3^=:U8GBC0!XCTR"S,QB
M\J[AN=P'7RW#8_'% &W1110 4444 %%%% !1110 4444 %>-?M%?\BII_P#U
MW;^0KV6O&OVBO^14T_\ Z[M_(4 <C\*OBSH'@KPBVEZE#>/.;EY<PH",$#W]
MJK_%?XIZ'XVT*ULM,BNTDBD+,9D &"![UN?!KX>>&/$_@AK_ %?3%N;D73Q[
MR[#Y0!@<'WJM\:/ /AKPMX=M+K1].6VFDE*LP=CD8'J: .O^$7_)'KK_ ')O
M_0*\)^&OBBQ\(^+(=4U!)6@0$$1+D]#7NWPB_P"2/77^Y-_Z!7B7PHT'3O$?
MC2"PU2W$]LX.4)(['TH ZGXE?$:T^(T-GI.A:;,\@D)!=,.<CMBO9?A1X>N_
M#G@:VM+Y"EPY\QD(Y7(''Z5X;\2?"3?#3Q;9ZIHQ:.TD?=%D9VMW7GVKZ*\%
M>(D\4>%;'5!@22Q@R*/X6[B@#=E;9"[_ -U2:^6]!#ZW^T*9G#,CWKNQQT&T
MU]17/-K,!_</\J^8/ LWV;X]&%U(:2Z=?I\I- 'I/[0,<K>"8#&K%4F)<CL,
M=ZR?@]XZ\*:1X-%EJ.HVME<HWSB9@I?@?G7KOB"PTS4M(FM-6"&TD&&WG KR
M6\_9_P##(9M0.N7$%I]_8$7:!]: /,-=U2QO_C =0TB13!)=[E=.A^E=U^T0
MY1M%?J5(/Z&N&LM'TV_^+%KIGAU3)9Q3[1*IR' R=U?4ES+H=QJ$5E>-:RWL
M:AEBD + =,X- '@6B?M"W^G6=K8RZ):F"%0A=9&W$?2O:/"OB[2_B#X>FDM#
MABI26)NJDBL'XN:=X:A\#WTEW;VT-R(_]'*J%8MD=,=>,UP'[-\=S_:^K29/
MV3R  /\ ;W#^E #]+T;Q]\.+S5-/TC07U2TO&.V90<+GOQ5:R:^^%OA2YMYC
MCQ#K#?N8%ZQ ]S^(->[^*/$5IX7T*XU*[<!8U.U>['T%>3> /#UYXOUNZ\=Z
M\A*Y+V43<@<=1[=: -7P#8Z!\.].%WXEU6UMM9OQOD^T/AESV'Y5ZG8:C9ZI
M:K<V-S'<0-T>,Y!KYX\ >'K'XA^)-?O?$"O.4+;(V<C81CD<UM?!"::P\8:]
MH"S/):0 NF3D Y H ]V)PI/H*^1_%SR^+/C)-9RR$Q278BC']U<#@5]<$94C
MU%?(OC6.?PC\7[B]>(K&ER)HB?XEP!G^= 'U?I=A;Z;IT%M;0I%&B  *,5,T
M$*[Y%B02%2"P49_.J'A_7=/U_28+RPN4F1T!.TYQ4@UK3)KV33X[V%KQ4+&$
M-\P'KB@#Y5\*?\ETTW_L)?XU[W\9K5+GX<:BS]8D+K]<5X)X4_Y+IIO_ &$O
M\:^@?B^0/AKJV?\ GB: .._9ROVF\-ZG:NV?*N%V#VVU[77A'[-L3'3-8EQ\
MHG5<^^T5[O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH Y/XF_P#)-M>_Z]C_ #%='I__ "#;7_KBG\A7.?$W_DFVO?\ 7L?YBNCT
M_P#Y!MK_ -<4_D* +-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %9'B*QTR_T^&+59%2!;F*1"S8_>*P*#\ZUZYGQS
MI%YK6B6UM8@>;'?V\S9./D20%OT% '34444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!R?Q-_Y)MKW_7L?YBNCT__
M )!MK_UQ3^0KG/B;_P DVU[_ *]C_,5T>G_\@VU_ZXI_(4 6:*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YGQSK5W
MH6B6UU9L%DDO[>!B1_"\@4_H:Z:LGQ#=:9:6$4FJJ# US$B9&?WA8!/UH UJ
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_ A:\I_X9ILO^ADN/_ 8?XT?\,TV7_0R7'_@,/\ &@#U;_A._"G_ $,.F_\
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MR%8>[8]^E97[/:-%\0K^-CEEM'4_4,*^C-2@AATJ\,42(60D[5 S7SQ\ _\
MDI>J?]>\G_H8H ]G^)'AW5O%'AAM,TF9(GD?]X6;&5P>*\IE^%WA+PIX09O%
MMY''K;Q,ZJDW/!Q\HR-U>^7NIV.FH'O;N&W4]#*X4&O.?B!\-8OB7+;:K;:R
M%2"%D@$:!E?G/7/K0!PO[/46H#Q#J#Q;SI(1ADYP7R,?I5GXY6DWA_Q7I/BC
M3_DE7EV!ZN#Q^@J+X/\ BJ_T'Q4_@V_2+RMY1&5 #NSQDXYKJ/VB(4/@2VF(
M_>+>(H/M@T >E^'-5CUOP_9:A$<K-$"3[]_UK4KSKX)3R2_#6P5VR$W!?^^C
M7HM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '$?%
MO_DFNL?]<&_E7FW[.D*7%AK4,B[D>10P]1MKWR>"&YB:*>*.6-AADD4,#^!J
M*UTZRL PL[.WM]WWO)B5,_D* /C2?P[(WQ&.A'.9KS8!_O'(KUKX_6ZVWAK1
MHMH!B14Z>E>W?V3IOVH77]GVGV@'<)?)7>#ZYQFI+JPL[Y0MW:07 '031A\?
MG0!\XW_B$Z7^SSI.GQ.!->,ZD>J;F!_I6G\*/A-H'B+PF-4URUEEDF?]UME9
M, 9!Z5[J^BZ5)$D3Z99-'']Q&@4A?H,<5:@MX;6%8K>&.*->B1J% _ 4 >6:
MW\"_"(T2\.FV,Z7HB/DL9V;#=N,UYQ\$M8_LKQ=>^'+P_P"CW6Y&#=W4[0/U
M-?3U4H]&TN*X\^/3;-)LY\Q8%#9]<XS0!\V>+/!?B#X<^,/[>T.*2:V+F171
M2=N3DAAZ5IO^T5K)MOLRZ'$MWC'F>8<Y_P!W%?14D4<R%)8U=#U5AD&J/]@:
M-OW_ -DV&[U^S)G^5 'AWPR?Q_KWBHZE>33P:<6WR^:IPP]%!_I6/\?I?(\<
M64H&=D><>O2OI>.*.% D4:HHZ*HP*KW6E:=>R![NPM;AQT:6%7/ZB@#Y]M/V
MCKJULH+<>'86$4:IG[0><#'I5^P_:,NKW4+>U/AZ%1+($W?:#QD_2O:_^$=T
M/_H#:?\ ^ J?X4Y?#^BHP9=(L%8'((MD!'Z4 7+>7S[6&8C'F(&QZ9&:EI
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M-^^6(]F( Q7ANF>+Q%XJDU[6;!=5F9MX220JH;]?RK[1N+6WNXO*N;>*:/\
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M$I<?0XS5FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *K)IUC%=-=1V=NEPW#2K$H<_CC-6:* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM80!M^PX/O\ +7)).I4:OL?04JD<'A*=113<WK?L<U\+O&TWB.TFL;YLW=N
M=V,;@>G\J]%KP'X7$VWQ&N+>,XC.Y2/IFO?JUH2<H:G#FU&%+$/D5DTF><?%
M/QI=^'K6&RT_Y;F?J^/NCVKS9K3QY!I"^(6N[G[*?F'^D,>/]WTKO/C%H N[
M&'5([B))8#RCN!N'MFN)F^*5U/X/30A9J) @C\_<,8'M7/5?OOF?H>OE\']6
M@Z$$VW[USTSX9>,I_$NDRQWV#<6HRS@8!6N.\8^.=:UOQ&^@Z [*J.4!3AF/
MU':MSX9Z$-)\'W^H?:8Y)KBW<[48': ,C..]>4>&O$5UH^MOJ%O;FXO'_P!6
M,9()]N].<Y*$5)[BP^%I2Q-:I2BGR[+I<W_[3\9^!-9MQJ-Q-)O()5Y#*I'?
M\:]_TJ_75-*M;]%*K/&'"GMFO#4^)6L+J</_  DVDP2Q;N!+:A&4>V17N.DW
M=K?:5;7-D%%M(@:,*, #Z5I0:NTF<6;1GRPE4@D^ZV9=KR#Q_P")+_4O%]EX
M<TJYDBV2#S&B8J2>XR/85ZS=R>59SR#^"-F_(5X-\.2==^),^I2?.58RY;WR
M*JLWI%=3'+*<4JE>2OR+\6>F^-O$A\&>%HS$Q>Y<>5$SG))]37D5O#X\UJQD
MUV"ZN3;K\QVS,N?HO<5TWQPE=KC3H"?W>[('OS7HGA&W2'X?Z?$HX^QX/OP:
MSDG4J.-]$==*I'"82%913E-ZW[',_"SQO<:_'-INHONNH%W*V,9'3\Z]+KY\
M^'Q:S^*#V\1PAD*D>W-?0=:4).4-3BS:C"EB+P5DTF>9_$/PSXNUG6X)] N7
MCMEA"L%NO+^;)[9K@=8\->/M"T][V_U.2.%.N+_)/T&>:^BJ\(^)FLS>)?%U
MOX>L6+1Q2;"JG[S]_P!*SKPBES:W9V97BJM22HVCRQ6KMT+7P?GUO4=:N+BY
MN[J>U2/&996*YSVS7L6I:A;Z7I\UY<N$BB7<2:H^&M"MO#FAP64"@;%^=N['
MU->8?$'Q!<>*O$$'A72<M&),3,O0GW/I5K]U3UW.>:688MN*M%;^B.0O/&NK
M:UXP6>.^N(;=YL)%'(5 7Z"OI2+F&,G^Z*^8]7TB+0O'$6G1'*PRA<^M?3D/
M^HC_ -T?RJ<,W>5S?.E34:3IJRM_D/HHHKJ/!/,?BGXWNM"\G2]-?;<SKN9@
M,X&<?G7GUS#X\T*SBURXNKD0-\PW3%@/JO:K?CDM>?%18)3E%E"@>W6O7O&D
M"3> -2B8<?9>#Z=*XVG4<G?8^EA.&$IT8**?/O?S(_ /BK_A*O#ZW$F!<Q'9
M-C^]U_E755XS\#I75M2@!_=[MV/? %>RD9!'M6]&3E!-GD9C1C1Q,H1V/%/'
MGCK5K_Q&?#^ALR;7\O*?>=O8U@W,WCKP--!?7UQ,T;G(WRF5?H:9JDDW@[XI
M&_NX2T4=P) <?>7':MKXC?$31_$N@16.G"1Y-X=RZ%=O!]:Y&[\SD[-'T-.F
MX>RITJ:E"2U9Z9I'B^#4?!IUTK_JXBTJ#L17CG]L^,/'NMS1:9<21[22%CD,
M:@>YKJOA)!_:_@C6M/FDV1M((]WH"M<?HOB*;X<>);R$)%>Q$D$1R#G\1FKG
M-RC%R>ASX;#QI5:T*44YK:_8T_#/C#Q#X8\51Z1K,DDL;2!)%D8L1GN":Z_X
MK/J5A:V&O:;=3Q"$@,BR$*<\\KWKA=$,OQ ^(2ZA<R0VR!PY0N 2!C@>M>O^
M/=/6Z\":C" "T5N2F?4"G!.5.6NG0C%2A2Q=)N*4G\2Z:E_PKK<?B#P_:WZ'
MEUPP]".*VJ\@^"&HN;6_T^1B=KAE'H .:]?KHI2YH)GC8Z@J&(E36P4445H<
M@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4A.!GTI:1_N-]* /-Y?CIX&
MAGDA>]N@Z,5;_17Z@XKT#3[^WU2PAO;1]\$R[D;'45\0_P!G2:GKU]!%S)YL
MA4>IW&OIGX':T=1\#+9.^Z73W\EL]><F@#>\3_$WPQX0OTLM7NIDG9=P$<+/
MQ^%6_"GCO0O&B3MHL\L@@(5_,B*8/7O7S#\1+BY\3^-=:U"$[K>VSSGA0  1
M7H_[-W_'MJ__ %U7_P!!H ]MUK6;+0-)GU/4)#';0*6<@9./8=ZY'1_C'X.U
MW58--LKR<W,[!(P]NR@D^YKC_P!H;Q&+71;30XWQ+<MYK8/\(R"#^=>0ZQX9
MU#P1!H&M#(EF7S]W96!X_2@#[+J&ZN[>RMVGNIHX8EZO(P4#\36=X8U>+7/#
MEC?Q,&62(9.>X&#^M?/_ ,7_ !7J7B7QFOA73I6%NKK&%4X\QCZ_K0!ZK?\
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M<@9X R: 2OH2T5S&B_$#PWKS2BTU!4\H M]H_=9SZ;NM:_\ ;ND?]!6Q_P#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/:I^WHU95<147)KI>YNV?QO2TLXK>XTB6::-=KR><!N/KTJ?_A?%M_T Y?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KYO_:!U\:AX@L=#@D!2 9E7/1\G^AKZ(OKJ.RL9KF5MJ1(6)KY%L]$
MO_BK\0]0\B=8'F<R-)("P4#"]J /6_%/AS26^"\.E0WEF]S8P^;&!,N2W/O[
MU1_9Y\1F6TO=!GDR\3>9$,]%& 1^9K&_X9KU;_H8;+_OPW^-<EX=^U?#/XK1
M6=W*"L,PBFD P'4X/% &]\8O^2J6?U'\Z]%^-G_)+X/JG_H-><?%R19OB=82
M*<JX##\<5Z/\;/\ DE\'U3_T&@";X#?\B"O^_P#XUZE7EOP&_P"1!7_?_P :
M]2H ^7OVA)Y)?&5K&^=L4)"?3(KZ&\(Q1P^%--2-0JB%< ?2O*?C_P"#KO4[
M>UUVRB:3[*A255'."<YI/AU\:-&M?#T.G>(9FMKBV&SS"I(8?0"@#W*L?Q1I
M][JGAZ\LK"]2RGFC*B=P2$]^*\L\6?'[3[4Q1>'$^V.7!>1E.-OH <'-3>-O
M&>M7OP<76(;6:QGN9!&P'4(<Y/MTH H:'X/\">"[.Z7Q7J.G:I=2-N,FS=M]
M<#FO/_ %S;6WQ@M_['E(LI9]JXXRI(XK=^%OA+P=K&B7&K^(;Q'N4?+1R2
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M=*\"P7_FNJK/'&H'/?!&>* /=[&?[5I]M<?\]8E?\P#5BHK=$CM8HXXQ$BH
ML8_A ' _"I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$$NA17H_M&+[T+*1^I^M &]1110 4444 %%%% !1110 4444 %%%% !1110
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MB">3?<PQ>2SD\E^!G]:\H^'G@:W^(-Q>ZQXCU%DAW$;O,"LS=^3]:M6"R?\
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M;1PWUW"OH>\TZSL=+OFM;:.)I$+.4&-QKY]^ ?\ R4O5/^O>3_T,4 >W^,O
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MN8HE!'1V8!3^=:]8GBC0X_$&F06DDPB6.[AN Q/4HX8#\<4 ;=%%% !1110
M4444 ?-7QBT'4M \>V_B:UB9[9BC J,X93DYJEXX^+]QXZ\.QZ%::7-%)*R^
M=WW$$$8 Z<U]-WEE;7]NUO=P)-"W5'&0:Q;'P+X6TV\^UV6A64%QG/F)'@T
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MH **** "LJX\,Z)=ZQ'J]QIMO)J$0PEPR_.H^OXUJT4 %%%% !1110 4444
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M/_?Z'_XJ@#MZ*XC_ (3;Q!_T3_6?^_T/_P 51_PFWB#_ *)_K/\ W^A_^*H
M[>BN(_X3;Q!_T3_6?^_T/_Q5'_";>(/^B?ZS_P!_H?\ XJ@#MMJ@Y"C/TH*J
M>H!^HKB?^$V\0?\ 1/\ 6?\ O]#_ /%4?\)MX@_Z)_K/_?Z'_P"*H [; QC
MQZ4!5'0 ?05Q/_";>(/^B?ZS_P!_H?\ XJC_ (3;Q!_T3_6?^_T/_P 50!VQ
M /4 T!5'10/H*XG_ (3;Q!_T3_6?^_T/_P 51_PFWB#_ *)_K/\ W^A_^*H
M[<C(P:0*HZ #Z"N)_P"$V\0?]$_UG_O]#_\ %4?\)MX@_P"B?ZS_ -_H?_BJ
M .WI-BYSM'Y5Q/\ PFWB#_HG^L_]_H?_ (JC_A-O$'_1/]9_[_0__%4 =L54
M]0#]11M7&-HQ]*XG_A-O$'_1/]9_[_0__%4?\)MX@_Z)_K/_ '^A_P#BJ .V
M"@#   ^E 51T 'T%<3_PFWB#_HG^L_\ ?Z'_ .*H_P"$V\0?]$_UG_O]#_\
M%4 =MM7.=HSZXI:XC_A-O$'_ $3_ %G_ +_0_P#Q5'_";>(/^B?ZS_W^A_\
MBJ .PNBT5I+) B^:JDKD=Z^7/%_BGQI\0;UO#\FGE8DN"%2*-E#$-@$YKW/_
M (3;Q!_T3_6?^_T/_P 53?\ A,]=!R/A[K&?^NL/_P 50!I> /#2^%/"-GIN
M/W@&^3_>/)%=/7$?\)MX@_Z)_K/_ '^A_P#BJ/\ A-O$'_1/]9_[_0__ !5
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M?ZS_ -_H?_BJ/^$V\0?]$_UG_O\ 0_\ Q5 ';T5Q'_";>(/^B?ZS_P!_H?\
MXJC_ (3;Q!_T3_6?^_T/_P 50!V]%<1_PFWB#_HG^L_]_H?_ (JC_A-O$'_1
M/]9_[_0__%4 =O63XAM-,O=/ACU5E6!;F)T)_P">@8%?UKGO^$V\0?\ 1/\
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M/^B?ZS_W^A_^*H_X3;Q!_P!$_P!9_P"_T/\ \50!V]%<1_PFWB#_ *)_K/\
MW^A_^*H_X3;Q!_T3_6?^_P!#_P#%4 =O17$?\)MX@_Z)_K/_ '^A_P#BJ/\
MA-O$'_1/]9_[_0__ !5 ';T5Q'_";>(/^B?ZS_W^A_\ BJ/^$V\0?]$_UG_O
M]#_\50!V]%<1_P )MX@_Z)_K/_?Z'_XJC_A-O$'_ $3_ %G_ +_0_P#Q5 ';
MT5Q'_";>(/\ HG^L_P#?Z'_XJC_A-O$'_1/]9_[_ $/_ ,50!V]%<1_PFWB#
M_HG^L_\ ?Z'_ .*H_P"$V\0?]$_UG_O]#_\ %4 =O17$?\)MX@_Z)_K/_?Z'
M_P"*H_X3;Q!_T3_6?^_T/_Q5 ';T5Q'_  FWB#_HG^L_]_H?_BJ/^$V\0?\
M1/\ 6?\ O]#_ /%4 =O17$?\)MX@_P"B?ZS_ -_H?_BJ/^$V\0?]$_UG_O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%0M=6ZL5:XB##J"XS4H((R""
M#W% "T45";RV!P;B$$=BXH FHID<L<HS'(C@?W6!I] !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !137=(UW.RJH[DXI58,H*
MD$'H0: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBLO6M?T[0+-[B^N%3"DJG=CZ"@#4HK'\,^(8/$^C)J5O#)#&SLFR
M3&>#[5L4 %%8NL>(1IES':V]A<7]TX)\F#&0/7G JC8>-8)]7&F:A87.F7+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ;145OYGV:/S?]9M&[ZU+0 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]J3FW=7MY&L,/&#IR4>9:>\WHO\ AC0^&+%OAK<9.<+(!_WS3?@G_P B;/\
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MHH"[$V+MV[1M],<5#]CM<Y^S0Y]?+%3T4!=H0  8 P!V%1M;6[OO:")F_O%
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G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gapk0ju0ozex000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gapk0ju0ozex000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +7!:H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8X-%UJ^@)/1=3N**R-$\06VK>';35W=((YXPQ\Q@ I[C)]ZM?VQIG_01M/\
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M=-ZY&?T%6/&A&CZ[HFOQ_*1/]EFQ_$C\\_BM-:V??\]OS!IJZ[:_J=Q1112
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5W=R_K:R.SB!$* ]0HS3Z**"4K*P4444#"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'BOB3_DXS1/^N<7_H+U[57BOB3_ ).,
MT3_KG%_Z"]>U4#"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'BOB3_ ).,T3_KG%_Z"]>U5XKXD_Y.,T3_ *YQ?^@O7M5
MPHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1137=8XVD=@JJ,L3T H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)_R<9HG_ %SB_P#07KVJO%?$G_)QFB?]<XO_ $%Z]JH&%%%% @HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!>O:J!A1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOB#Q/XIGT7PYJHTZ"Q0-<7(CW[G/.W]16_X,U._O;"YM=4=9+ZQG,$LBC ?
M!!Q^-6/"_A:T\+6,D$$DD\TSF2:>3[TC'N:C\+QV:R:M);2O)(]ZWG;U *MM
M7CZ4TDM/+\=!-WU.AHHHI %%%% !1110 4444 %%%% 'BOB3_DXS1/\ KG%_
MZ"]>U5XKXD_Y.,T3_KG%_P"@O7M5 PHHHH$%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M; ;<#/?ZUUE>-_M!?\@?1?\ KXD_]!% #O\ AH+2O^@'>?\ ?U:/^&@M*_Z
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M5Q'JA1110 4444 %%%% !1110 4444 %%%% !7!^/=9?0-4TK4+?2KZ]N$W
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M4 %%%% !1110 4444 %%%% !7C?[07_('T7_ *^)/_017LE>-_M!?\@?1?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7FOQ>_X]-(_Z[/\ R6O2J\U^+W_'II'_ %V?^2UG5^!F^&_BH]_@_P"/>/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *\;_:"_Y ^B_]?$G_ *"*]DKQO]H+_D#Z+_U\2?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\;
M_:"_Y ^B_P#7Q)_Z"*]DKQO]H+_D#Z+_ -?$G_H(H O>"_\ D3-)_P"O=:W:
MPO!?_(F:3_U[K6[7?'X4>-4^-A1115$!1110!S/Q"_Y$74_]U/\ T-:ZWX4_
M\DRT3_KF_P#Z,:N2^(7_ "(NI_[J?^AK76_"G_DF6B?]<W_]&-7+7^(]+!_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!'/<0VL#37$T<,2<L\C!5'U)JA_P )'H?_ $&M._\
M I/\:P?BI_R3/6_^N2?^C%KQ_P *_#G2M<\-VFHW-S=I+,&W+&RA1AB.X]JJ
M,7)V1$ZD8*\CW[_A(]#_ .@UIW_@4G^-'_"1Z'_T&M._\"D_QKQK_A4>A_\
M/W?_ /?:_P#Q-'_"H]#_ .?N_P#^^U_^)J_8S,OK5,]E_P"$CT/_ *#6G?\
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M84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH X[XJ?\ ),];_P"N2?\ HQ:X_P"'G_(B
MZ;]'_P#0VKL/BI_R3/6_^N2?^C%KC_AY_P B+IOT?_T-JVH?$<N,_AKU.HHH
MHKK/-"BBB@ J.?\ X]Y/]P_RJ2HY_P#CWD_W#_*@9R_[/O\ R"M<_P"N\?\
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M]EKSCVPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O&_P!H+_D#Z+_U\2?^@BO9*\;_ &@O^0/HO_7Q)_Z"* +W@O\ Y$S2
M?^O=:W:PO!?_ ")FD_\ 7NM;M=\?A1XU3XV%%%%40%%%% ',_$+_ )$74_\
M=3_T-:ZWX4_\DRT3_KF__HQJY+XA?\B+J?\ NI_Z&M=;\*?^29:)_P!<W_\
M1C5RU_B/2P?P/U.RHHHK Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /FBX_Y+U<_]A&3^1KUZO(;C_DO5S_V$9/Y&O7JZ
MJ'PGGXSXUZ!1116YQA1110 5YK\7O^/32/\ KL_\EKTJO-?B]_QZ:1_UV?\
MDM9U?@9OAOXJ/?X/^/>/_<'\JDJ.#_CWC_W!_*I*XCU0HHHH **** "BBB@
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M7FOQ>_X]-(_Z[/\ R6O2J\U^+W_'II'_ %V?^2UG5^!F^&_BH]_@_P"/>/\
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M<%X,_P"2^ZA_URD_] 6N]K@O!G_)?=0_ZY2?^@+6%?X3LP?QOT/=J***Y3T
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ..
M^*G_ "3/6_\ KDG_ *,6N/\ AY_R(NF_1_\ T-J[#XJ?\DSUO_KDG_HQ:X_X
M>?\ (BZ;]'_]#:MJ'Q'+C/X:]3J****ZSS0HHHH *CG_ ./>3_</\JDJ.?\
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M750^$\_&?&O0****W.,**** "O-?B]_QZ:1_UV?^2UZ57FOQ>_X]-(_Z[/\
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MZ=36Q110W< HHHI %%%% !1110 4444 >*^)/^3C-$_ZYQ?^@O7M5>*^)/\
MDXS1/^N<7_H+U[50,****!!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !3)?\ 4O\ [II],E_U+_[IH ^?_A%_J-9_Z[)_)J]*KS7X
M1?ZC6?\ KLG\FKTJNVE\"/*Q/\5A1116A@%%%% !7!>#/^2^ZA_URD_] 6N]
MK@O!G_)?=0_ZY2?^@+6%?X3LP?QOT/=J***Y3T HHHH **** "BBB@ HHHH
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MIV_*D]T-=1#XJ\=7#-9P^$#!<8P+F6;,0/KTKI_"VBSZ-I;+>3":^N)#-<2
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M_P#(*US_ *[Q_P#H)KV6O&OV??\ D%:Y_P!=X_\ T$U[+7G'MA1110 4444
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M_KF__HQJY:_Q'I8/X'ZG94445@=04444 %%%% !1110 4444 %%%% !1110
M4444 %>>WOQF\*6%_<64YOO.MY6B?;!D;E)!QSZBO0J^:="T^SU#X@^)DO+6
M*X5;F8J)$# 'S3ZT"E+E5STW_A>/@_\ O7__ (#_ /UZ/^%X^#_[U_\ ^ __
M ->L+_A&=#_Z!%E_WY6C_A&=#_Z!%E_WY6ES&/UB/8W?^%X^#_[U_P#^ _\
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M^/>/_<'\JDKB/5"BBB@ HHHH **** "BBB@ HHHH **** ,W7=9@T#1Y]1N
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MOT?_ -#:MJ'Q'+C/X:]3J****ZSS0HHHH *CG_X]Y/\ </\ *I*CG_X]Y/\
M</\ *@9R_P"S[_R"M<_Z[Q_^@FO9:\:_9]_Y!6N?]=X__037LM><>V%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!X+\0O\ DN&F_P#7"+_V:NIK
MEOB%_P EPTW_ *X1?^S5U-3(Y<1\2"BBBI.<**** "O/_BG_ ,>&G?\ 75_Y
M"O0*\_\ BG_QX:=_UU?^0IK<UH_&CN_!?_(F:3_U[K6[6%X+_P"1,TG_ *]U
MK=KTH_"CCJ?&PHHHJB HHHH YGXA?\B+J?\ NI_Z&M=;\*?^29:)_P!<W_\
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MUS_KO'_Z":]EKQK]GW_D%:Y_UWC_ /037LM><>V%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!X+\0O^2X:;_P!<(O\ V:NIKEOB%_R7#3?^N$7_
M +-74U,CEQ'Q(****DYPHHHH *\_^*?_ !X:=_UU?^0KT"O/_BG_ ,>&G?\
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M?\(%X<_Y\#_W^?\ QHY@]O Z'XA^/_"NK^ ]5L+#689[J:-1'&JL"Q#J>X]
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M6O\ QZ0_]<U_E4M16O\ QZ0_]<U_E4M9GG!1110(**** ,#QM_R)VH_[B_\
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M**H@**** .9^(7_(BZG_ +J?^AK76_"G_DF6B?\ 7-__ $8U<E\0O^1%U/\
MW4_]#6NM^%/_ "3+1/\ KF__ *,:N6O\1Z6#^!^IV5%%%8'4%%%% !1110 4
M444 %%%% !1110 4444 %%%% !7SEX6_Y*+XH_Z^)O\ T::^C:^<O"W_ "47
MQ1_U\3?^C32>Q%7X&=Y1114' %%%% !1110!Y7I__)85_P"OU_Y&O;*\3T__
M )+"O_7Z_P#(U[97=A_A#%;Q] HHHK<Y0HHHH *\U^+W_'II'_79_P"2UZ57
MFOQ>_P"/32/^NS_R6LZOP,WPW\5'O\'_ ![Q_P"X/Y5)4<'_ ![Q_P"X/Y5)
M7$>J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'BOB3_DXS1/^N<7_H+U[57BOB3_ ).,T3_KG%_Z"]>U4#"B
MBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!Y;\>?^1&M?\ K_3_ - >
MN;\ _P#(G67U?_T,UTGQY_Y$:U_Z_P!/_0'KF_ /_(G67U?_ -#-)F-?X#I:
M***@XPHHHH *:_\ JV^AIU-?_5M]#0!QWP@_X]M8_P"NL?\ )J]+KS3X0?\
M'MK'_76/^35Z77HTO@1&)_BL****T, HHHH *X+P9_R7W4/^N4G_ * M=[7!
M>#/^2^ZA_P!<I/\ T!:PK_"=F#^-^A[M1117*>@%%%% !1110 4444 %%%%
M!1110 4444 %%%% !7CO[07_ " ]&_Z^7_\ 0:]BKQW]H+_D!Z-_U\O_ .@T
M 7+7_CTA_P"N:_RJ6HK7_CTA_P"N:_RJ6LSS@HHHH$%%%% &!XV_Y$[4?]Q?
M_0A5_P"'G_(BZ;]'_P#0VJAXV_Y$[4?]Q?\ T(5?^'G_ "(NF_1__0VKIPWQ
M#J?POF=111178<@4444 %1S_ /'O)_N'^525'/\ \>\G^X?Y4#.7_9]_Y!6N
M?]=X_P#T$U[+7C7[/O\ R"M<_P"N\?\ Z":]EKSCVPHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /!?B%_R7#3?^N$7_ +-74URWQ"_Y+AIO_7"+
M_P!FKJ:F1RXCXD%%%%2<X4444 %>?_%/_CPT[_KJ_P#(5Z!7G_Q3_P"/#3O^
MNK_R%-;FM'XT=WX+_P"1,TG_ *]UK=K"\%_\B9I/_7NM;M>E'X4<=3XV%%%%
M40%%%% ',_$+_D1=3_W4_P#0UKK?A3_R3+1/^N;_ /HQJY+XA?\ (BZG_NI_
MZ&M=;\*?^29:)_US?_T8U<M?XCTL'\#]3LJ***P.H**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "OG+PM_P E%\4?]?$W_HTU]&U\Y>%O^2B^*/\ KXF_
M]&FD]B*OP,[RBBBH. **** "BBB@#RO3_P#DL*_]?K_R->V5XGI__)85_P"O
MU_Y&O;*[L/\ "&*WCZ!1116YRA1110 5YK\7O^/32/\ KL_\EKTJO-?B]_QZ
M:1_UV?\ DM9U?@9OAOXJ/?X/^/>/_<'\JDJ.#_CWC_W!_*I*XCU0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M \5\2?\ )QFB?]<XO_07KVJO%?$G_)QFB?\ 7.+_ -!>O:J!A1110(**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH \M^//_ "(UK_U_I_Z ]<WX!_Y$ZR^K
M_P#H9KI/CS_R(UK_ -?Z?^@/7-^ ?^1.LOJ__H9I,QK_  '2T445!QA1110
M4U_]6WT-.IK_ .K;Z&@#COA!_P >VL?]=8_Y-7I=>:?"#_CVUC_KK'_)J]+K
MT:7P(C$_Q6%%%%:& 4444 %<%X,_Y+[J'_7*3_T!:[VN"\&?\E]U#_KE)_Z
MM85_A.S!_&_0]VHHHKE/0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MQW]H+_D!Z-_U\O\ ^@U[%7CO[07_ " ]&_Z^7_\ 0: +EK_QZ0_]<U_E4M16
MO_'I#_US7^52UF><%%%% @HHHH P/&W_ ")VH_[B_P#H0J_\//\ D1=-^C_^
MAM5#QM_R)VH_[B_^A"K_ ,//^1%TWZ/_ .AM73AOB'4_A?,ZBBBBNPY HHHH
M *CG_P"/>3_</\JDJ.?_ (]Y/]P_RH&<O^S[_P @K7/^N\?_ *":]EKQK]GW
M_D%:Y_UWC_\ 037LM><>V%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!X+\0O^2X:;_UPB_]FKJ:Y;XA?\EPTW_KA%_[-74U,CEQ'Q(****DYPHH
MHH *\_\ BG_QX:=_UU?^0KT"O/\ XI_\>&G?]=7_ )"FMS6C\:.[\%_\B9I/
M_7NM;M87@O\ Y$S2?^O=:W:]*/PHXZGQL****H@**** .9^(7_(BZG_NI_Z&
MM=;\*?\ DF6B?]<W_P#1C5R7Q"_Y$74_]U/_ $-:ZWX4_P#),M$_ZYO_ .C&
MKEK_ !'I8/X'ZG94445@=04444 %%%% !1110 4444 %%%% !1110 4444 %
M?.7A;_DHOBC_ *^)O_1IKZ-KYR\+?\E%\4?]?$W_ *--)[$5?@9WE%%%0< 4
M444 %%%% 'E>G_\ )85_Z_7_ )&O;*\3T_\ Y+"O_7Z_\C7ME=V'^$,5O'T"
MBBBMSE"BBB@ KS7XO?\ 'II'_79_Y+7I5>:_%[_CTTC_ *[/_):SJ_ S?#?Q
M4>_P?\>\?^X/Y5)4<'_'O'_N#^525Q'JA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XKXD_Y.,T3_KG%_P"@
MO7M5>*^)/^3C-$_ZYQ?^@O7M5 PHHHH$%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 >6_'G_D1K7_K_3_T!ZYOP#_R)UE]7_\ 0S72?'G_ )$:U_Z_T_\
M0'KF_ /_ ")UE]7_ /0S29C7^ Z6BBBH.,**** "FO\ ZMOH:=37_P!6WT-
M''?"#_CVUC_KK'_)J]+KS3X0?\>VL?\ 76/^35Z77HTO@1&)_BL****T, HH
MHH *X+P9_P E]U#_ *Y2?^@+7>UP7@S_ )+[J'_7*3_T!:PK_"=F#^-^A[M1
M117*>@%%%% !1110 4444 %%%% !1110 4444 %%%% !7CO[07_(#T;_ *^7
M_P#0:]BKQW]H+_D!Z-_U\O\ ^@T 7+7_ (](?^N:_P JEJ*U_P"/2'_KFO\
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MX_\ <'\JDJ.#_CWC_P!P?RJ2N(]4**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /%?$G_)QFB?]<XO_07KVJO%
M?$G_ "<9HG_7.+_T%Z]JH&%%%% @HHHH *Y[QT[)X"UYT8JRV,I!!P1\IKH:
MYWQ[_P B!K__ %X2_P#H)H ^>O#GA?4/$&E"^&N3P9<IL^9NGON%:_\ PKS4
M/^ACG_[Y;_XJM'X;_P#(J#_KN_\ 2NNJ6V<LZLU)I,X#_A7FH?\ 0QS_ /?+
M?_%4?\*\U#_H8Y_^^6_^*KOZ*5V1[:?<X#_A7FH?]#'/_P!\M_\ %4?\*\U#
M_H8Y_P#OEO\ XJN_HHNP]M/N<!_PKS4/^ACG_P"^6_\ BJP_#'AZ_P#$>I:A
M:#6KB#[&<;LLV[DC^\,=*];KAOAA_P C)X@_WA_Z&U:4ES2LRO:SY).^Q-_P
MJ[4?^AGG_P"_;?\ Q='_  J[4?\ H9Y_^_;?_%UZ7179[*'8YOK-7N>:?\*N
MU'_H9Y_^_;?_ !='_"KM1_Z&>?\ []M_\77I=%'LH=@^LU>YYI_PJ[4?^AGG
M_P"_;?\ Q='_  J[4?\ H9Y_^_;?_%UZ711[*'8/K-7N>7>#;"[T+XRZ=I4N
MHS72J&8LQ(!S$QZ9-?15>#6/_)PME_US_P#:#5[S7))6DTCT:;;@FPHHHJ2P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \M^//\ R(UK_P!?Z?\ H#US
M?@'_ )$ZR^K_ /H9KI/CS_R(UK_U_I_Z ]<WX!_Y$ZR^K_\ H9I,QK_ =+11
M14'&%%%% !37_P!6WT-.IK_ZMOH: ..^$'_'MK'_ %UC_DU>EUYI\(/^/;6/
M^NL?\FKTNO1I? B,3_%84445H8!1110 5P7@S_DONH?]<I/_ $!:[VN"\&?\
ME]U#_KE)_P"@+6%?X3LP?QOT/=J***Y3T HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *\=_:"_Y >C?]?+_^@U[%7CO[07_(#T;_ *^7_P#0: +EK_QZ
M0_\ 7-?Y5+45K_QZ0_\ 7-?Y5+69YP4444""BBB@# \;?\B=J/\ N+_Z$*O_
M  \_Y$73?H__ *&U4/&W_(G:C_N+_P"A"K_P\_Y$73?H_P#Z&U=.&^(=3^%\
MSJ****[#D"BBB@ J.?\ X]Y/]P_RJ2HY_P#CWD_W#_*@9R_[/O\ R"M<_P"N
M\?\ Z":]EKQK]GW_ )!6N?\ 7>/_ -!->RUYQ[84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% '@OQ"_Y+AIO_7"+_P!FKJ:Y;XA?\EPTW_KA%_[-
M74U,CEQ'Q(****DYPHHHH *\_P#BG_QX:=_UU?\ D*] KS_XI_\ 'AIW_75_
MY"FMS6C\:.[\%_\ (F:3_P!>ZUNUA>"_^1,TG_KW6MVO2C\*..I\;"BBBJ("
MBBB@#F?B%_R(NI_[J?\ H:UUOPI_Y)EHG_7-_P#T8U<E\0O^1%U/_=3_ -#6
MNM^%/_),M$_ZYO\ ^C&KEK_$>E@_@?J=E1116!U!1110 4444 %%%% !1110
M 4444 %%%% !1110 5\Y>%O^2B^*/^OB;_T::^C:^<O"W_)1?%'_ %\3?^C3
M2>Q%7X&=Y1114' %%%% !1110!Y7I_\ R6%?^OU_Y&O;*\3T_P#Y+"O_ %^O
M_(U[97=A_A#%;Q] HHHK<Y0HHHH *\U^+W_'II'_ %V?^2UZ57FOQ>_X]-(_
MZ[/_ "6LZOP,WPW\5'O\'_'O'_N#^525'!_Q[Q_[@_E4E<1ZH4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >*
M^)/^3C-$_P"N<7_H+U[57BOB3_DXS1/^N<7_ *"]>U4#"BBB@04444 %<[X]
M_P"1 U__ *\)?_03715SOCW_ )$#7_\ KPE_]!- 'D7PW_Y%0?\ 7=_Z5UU<
MC\-_^14'_7=_Z5UU0]S@J?&PHHHI$!1110 5PWPP_P"1D\0?[P_]#:NYKAOA
MA_R,GB#_ 'A_Z&U;4?C1?_+N1ZC1117><04444 %%%% 'G]C_P G"V7_ %S_
M /:#5[S7@UC_ ,G"V7_7/_V@U>\UP3^)GL4OX<?0****DT"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#RWX\_P#(C6O_ %_I_P"@/7-^ ?\ D3K+ZO\
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M_'I#_P!<U_E4M9GG!1110(**** ,#QM_R)VH_P"XO_H0J_\ #S_D1=-^C_\
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M ]<TO3_#8@N[^"&7SG.QWP<<5TW_  E6@_\ 06M/^_@J'N<52+YWH;%%8_\
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MPH_X6%X0_P"ACT__ +_"@#I:*YK_ (6%X0_Z&/3_ /O\*/\ A87A#_H8]/\
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MN678V**Q_P#A*M!_Z"UI_P!_!1_PE6@_]!:T_P"_@H#EEV-BBL?_ (2K0?\
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M5[/10W?42T5D?+^J?#J#3_B98>$UU&1XKI5)N#$ 5R&/3/MZUW/_  SY9?\
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MQ_PSY9?]#!<?^ R__%4?\,^67_0P7'_@,O\ \57L]% 'C'_#/EE_T,%Q_P"
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M_%4?\,^67_0P7'_@,O\ \57L]% CQC_AGRR_Z&"X_P# 9?\ XJC_ (9\LO\
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M9\LO^A@N/_ 9?_BJ]GHH \8_X9\LO^A@N/\ P&7_ .*H_P"&?++_ *&"X_\
M 9?_ (JO9Z* /&/^&?++_H8+C_P&7_XJC_AGRR_Z&"X_\!E_^*KV>B@#QC_A
MGRR_Z&"X_P# 9?\ XJC_ (9\LO\ H8+C_P !E_\ BJ]GHH \8_X9\LO^A@N/
M_ 9?_BJ/^&?++_H8+C_P&7_XJO9Z* /&/^&?++_H8+C_ ,!E_P#BJX;P5\.H
M/%?B'6=+DU&2W73F(618@Q?#E>1GCI7U!7BOP=_Y'[Q=_P!=&_\ 1K4#'_\
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M (JC_AGRR_Z&"X_\!E_^*KV>B@#QC_AGRR_Z&"X_\!E_^*H_X9\LO^A@N/\
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M^67_ $,%Q_X#+_\ %4?\,^67_0P7'_@,O_Q5>ST4 >,?\,^67_0P7'_@,O\
M\51_PSY9?]#!<?\ @,O_ ,57L]% 'C'_  SY9?\ 0P7'_@,O_P 51_PSY9?]
M#!<?^ R__%5[/10!XQ_PSY9?]#!<?^ R_P#Q5'_#/EE_T,%Q_P" R_\ Q5>S
MT4 >,?\ #/EE_P!#!<?^ R__ !5'_#/EE_T,%Q_X#+_\57L]% 'C'_#/EE_T
M,%Q_X#+_ /%4?\,^67_0P7'_ (#+_P#%5[/10!XQ_P ,^67_ $,%Q_X#+_\
M%4?\,^67_0P7'_@,O_Q5>ST4 >,?\,^67_0P7'_@,O\ \51_PSY9?]#!<?\
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M:CX2TK5KR2YOTEN-X \MY"4'T7I7)0V9\(?$C3M.TN:7^SM0A8O:LY94(!Y
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M9;>9"DD;=&4]0:GHH R]&\.:/X>69=(T^&T68@R",'YL9QG\S6I110 4444
M%%%% !1110 4444 %%%% !1110 4C.J*6=@JCJ2<"EKRGXI:O<ZIIM_IFG2;
M;6RC\R]E!X+=H_\ 'ZTFQI7/5=PV[LC'7-<K<>.K4WDUKI>G7VJ/ VV5K6,%
M4/<9SUK7L8VF\-0Q(<,]MM!]"17&?#V^MO#>G76B:PZV5Y!<2.7G.T3*6)#!
MCP>#5-6DUV$G>"D=9H/BG3_$!FCM_,BN8#B:WF7:Z?45MUYYX>MY=6^)6H^(
M;6)X]-%NMNLC+M$S DD@=QR.:]#HZ)BZM!1112&%%%% !1110 4444 %%%%
M%34M,LM7L)+'4+=+BUDQOB?H<'(_44ZPT^TTNQBLK&!(+:$8CC3HHSG^M6:*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH SM?_ .1?U#_K@_\ *O,_ /@Z;5O ]I./$6JVRR!AY,+(
M$')_V<_K7J6J6SWFE75M$5$DL3(NX\9(KA_"VC^-O#VA0Z0(=)\N(';,+AF/
M)S]W8/YT*WO?+]0=]/G^A/X/OO['UZ^\*3P0J]N@GCGC!S*ISRV2>>*N0>++
M[6Y;A- TI9[2%FC:ZFD"HQ'7 [U/H/A%M/OKW5-1O#>:E>KLD<+M5%&<*HS[
MFLG0_"WB7PX)]+T^[LSI4DC.DKY\V/)Y&W&#^=#UT?;\?^&!65VN_P"'_#F5
M\-;(ZIH?BJPN3Y?GWTT;[#]W(P<5+9:CK_PXTZ.SU33TO=%A;:EY;G#1J3_$
M*V_#7A#4?"]SJ_V74$F@O"9HQ*O(E(Y)]J@U31_&'B*UETO47TVUL)2!)+"[
M.[+Z8*C'YTV]5;LOP'H[WVNS+U[4I+_XD>'FLX4NX3:M/ CN%5B1UY]C6CXD
MTKQ-X@ET]ET^VMGM+A9EE\\$C!&1^E:&L^"([JTTQM,N39WVEJ%M9MN1@#&U
MO8BI=/\ ^$U:X5+\:6D*D9EB=F9AW^4J,?G35M$NC_6Y+O:[ZK]+&#KN1\8/
M#8/7[-)G_P =JQ_S6L_]>']*T=4\-7UYX_TG7(VA^RVD3I(&8AR3C&!CV]:E
M_P"$=O?^%C?V_NA^Q_9?)QN._=],=/QJ8_9_[>_4'O+Y?H<^(XY/CJQ=%8KI
MH*Y&<'<U2?%@!;?0) ,.-3C ;N.#6NGAJ^7XF/XA+0_8C9B #<=^[)/3&,<^
MM+XZ\-7WB2WTQ+%H5-K>I/)YK$?*,YQ@'GFG':'D_P#VXI?%+T_0P;BZOG^+
M<BP6:W3V]DODK)(% SG)&?K5[5-&\1ZQXET?4FL;:U%C*2[K,&9E.,C]*T_$
M/A6XO=3M=:TF[6TU6V38&=<I(O\ =:IM+_X2][E/[4738H5/S&!V<N/Q48I1
MZ>7^8GU\_P#*QTE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 1S_P#'O)_N'^5<)\)/^1<O_P#L(2_TKH/$!\3>8J:'
M;Z?+"R$2&ZF9"#[84URW@[0?&OAJ,VDD&DO:RW+32NMR^X!NN!LY_.G#=^?^
M8I+1?UT._O[^WTRQEO+J01PQ+N9B:Y+PQ876LZ_-XLU"(Q*Z>58PL.5C_O'W
M/)_&J_BG1/%NJ^((9K6/39]+M_FCMYYV3<_JP"'I6GITGC?[9"E]9:/': @.
M8;EF8#V&P?SI1[CEM8ZNBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *Q_$6O0Z#IWG.#)<2'9!"OWI'/
M0 5KG.#CK7F_]A^.AXCGU:6WT>Z?.VV$MTX$*^PV'DTMW8:VN=#X,T*XTFSN
M;[4B#J=_)YUP1T4_W1[#-45;_A,O$^>NC:7)CVGF'\P#C\16KHQ\433RQZ];
M:=';-&0#;3L[$_0J.,9JFWPU\+,[N=.&YV+-ANI-5U3%T:,K3F4_&?4@O1;!
M!^IKT*O'-.\&:(_Q6U'36M,VL5JLB)NZ')KU^&%+>".&,82-0JCV%"^"/]=6
M3]N7]=$24444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHI&940NQPH&2: .9\17OBR&9H]$TRVE@('[^27YAZ
MX7-9OP]_LM6U)8IIGUAIMU\+A=L@; QQ_=QC%;[>+=!6(R'4X-H&>IS^76N5
M\)>9K/C[5O$-O \6FO&L,;NNWSB.IQ1'>WD$MBKX/TFPN/''BN/4+6.:=;E7
M02C(VG/.#Q2^/M.MO#^I:'K.DQ):7)O4AD6$;1(C'!! X[UT&M>%[W^WEU_0
M;F.#4-GERQ2C]W,O;)'0_@:KQ>&=8US5K/4/$\ML$LVWPVEJ2R;^S%B!_*G'
M[/E;\/\ ,;WEYG9H2T:L1@D TZBBD(**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** ,#Q7KC:38);VHWZC>-Y-M
M'WW'O] ,G\*Y3Q?I$6@?"J^@)WW$HWSRGJ\AZD_R_"NPUOPIH_B*6&34[43-
M""$)/2N ^(W@?0-)\&7=Y9V?ES(1M;<:E[%QUDCT2SN19^%XKDC(BMM^/H*X
M_P +Z/;^.;!O$'B&-;K[0SK;P$X6%,E>,<YQZUO^%_#&E:9HR_9;?9]JA EY
MSNX_^O639>&_$OA42VOAZ>RN=/>0ND-VQ0PY.2 0#D<^U:2MSNYE#X%8;H=[
M<>'O',GA-I3-8RV_VBU+?>B&2"OTXKOJY70?"MQ;:W/K^L72W.J3((QL7"1)
M_=7\ZZJET5]RM+NVP4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gapk0ju0ozex000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gapk0ju0ozex000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /<!YX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@%KO_@$U;W@3_D0M"_Z\H_\ T&NAH X#_A:UA_T M=_\ FH_X6M8?] +7?\
MP":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\
M FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_H
MH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^
M%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A
M:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +
M7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T
MM=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P"
M:N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=_P#
M)J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH
MX#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8
M?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:U
MA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"U
MW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=
M_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N
M_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_
MX6M8?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#
M_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'
M_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_
MT M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\
MP":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\
M FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_H
MH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^
M%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A
M:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +
M7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T
MM=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P"
M:N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=_P#
M)J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH
MX#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8
M?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:U
MA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"U
MW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=
M_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N
M_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_
MX6M8?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#
M_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'
M_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_
MT M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\
MP":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\
M FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_H
MH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^
M%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A
M:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +
M7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T
MM=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P"
M:N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=_P#
M)J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH
MX#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8
M?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:U
MA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"U
MW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=
M_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N
M_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#_A:UA_T M=_\ FH_
MX6M8?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'_0"UW_P":N_HH X#
M_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_T M=_P# )J/^%K6'
M_0"UW_P":N_HH X#_A:UA_T M=_\ FH_X6M8?] +7?\ P":N_HH X#_A:UA_
MT M=_P# )J#\5]/ S_86N_\ @$U=_3)?]4_^Z: ,3PAXKLO&6B?VK81310^:
MT168 ,"N,_SK>KS/X%_\B%/_ -A&?_V6O3* "BBN03Q??#XA0>&+G2E@CGMY
M+A)_.#$A?84 =?163K^LR:19H;6RDO;R9MD%O&<%SZD]@.YKEM*\?ZG'XJMO
M#_BC0?[+N;P$VDL<WFQR$<XSZT =_1110 4444 %%%% !1110 4444 %%%%
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M,HY]^<5Z#0!1U+5[+2EB^UR[7E;;'&HW,Y]@*IZ;XMT#5]1;3['4X)KQ4WF
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M9Z-I^L>&M(74+59UCM8BH8D8^0>E;Q 92K $$8(/>A55$"J %48 '84 8/\
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MLEP1EHT[E!_>],]*DT?2;/0M)M]-L(O+MK=-JCN?4D]R3R30!>HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ IDO^J?_=-/IDO^J?\ W30!YM\"_P#D0I_^
MPC/_ .RUZ97F?P+_ .1"G_[",_\ [+7IE !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %<E\4/^2::]_P!>W_LPKK:Y+XH?\DTU[_KV_P#9A0!<\"?\B%H7
M_7E'_P"@UT-<]X$_Y$+0O^O*/_T&NAH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ IDO\ JG_W33Z9+_JG_P!TT >;? O_ )$*
M?_L(S_\ LM>F5YG\"_\ D0I_^PC/_P"RUZ90 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7)?%#_DFFO?]>W_LPKK:Y+XH?\DTU[_KV_\ 9A0!<\"?\B%H
M7_7E'_Z#70USW@3_ )$+0O\ KRC_ /0:Z&@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !7)?%#_DFFO?\ 7M_[,*ZVN2^*'_)-->_Z]O\
MV84 7/ G_(A:%_UY1_\ H-=#7/>!/^1"T+_KRC_]!KH: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9+_ *I_]TT^F2_ZI_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7)?%#_DFFO?\ 7M_[,*ZVN2^*'_)-->_Z]O\ V84 7/ G_(A:
M%_UY1_\ H-=#7/>!/^1"T+_KRC_]!KH: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N2^*'_)-->_Z]O_9A76UR7Q0_Y)IKW_7M_P"S"@"YX$_Y$+0O
M^O*/_P!!KH:Y[P)_R(6A?]>4?_H-=#0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M70USW@3_ )$+0O\ KRC_ /0:Z&@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KDOBA_P DTU[_ *]O_9A76UR7Q0_Y)IKW
M_7M_[,* +G@3_D0M"_Z\H_\ T&NAKGO G_(A:%_UY1_^@UT- !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYSZ"O(=0^.7BFYO6ELQ:VMOGY8O+WX'N3UKG[OX9^+K&TENI]'F$42EW(P<
M=:Y*O4R[(\L@G*#53U:=ON,YU9]=#ZC^&OQ&3QM;S6]U"EOJ5N SJA^61?[P
M_'M7?U\;>&/$U_X3UE-3TXIYJ@JRN,JRGJ#7O_A/XRZ'KWEVVH_\2V];C$A_
M=L?9O\:^=SSA^K0JNKA87I]EK;Y;V-J55-6EN>E44U)$E0/&RNK#(93D&G5\
MJ;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7!VG/L>AKYW'9%C<'K*/-'NM?^"C:-6,CLJ*0$$9!R#T-+7C&@4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %,E_U3_[II],E_P!4_P#NF@#S
M;X%_\B%/_P!A&?\ ]EKTRO,_@7_R(4__ &$9_P#V6O3* "BJ>K:E!H^DW6HW
M)Q#;1-(_T KB9/$'BG_A$1XMB:U:#9]H.F^5SY7^_P!=V.?2@#T*BJ&BZM;Z
M[HMGJEH<P740D3\:OT %%%% !1110 445%=3?9K2:?&?*C9\>N!F@"6BO-O
MUQXHN_$UQ<Z_?AK?4=/^U6MI'P+=2X _'!%3Z!XIN[7XF:CX,N[AKR-(1<VT
M[??4=2C'OB@#T*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCGA4JR=HLKS:C=7'WYFQZ#@4R*SN;@_NXG;/?%=3!IEI;\K""1W;DU;  &
M/I7,\7&.D(FZPLI:S9SD'A^=^9I%0>@Y-:4&B6D7+*9#_M&M*BL)XBI+J;QH
M4X]!B1I&,(BJ/84U[:"1MSQ(6]2*EHK&[W-;(I:C8F\MA&C[-IR!V-<O-!/9
MS;7!1AT(KM:BN+:*YC*2H&'\JZ*.(=/1[&%:@IZK<Q=/UPC$5U^#_P"-;;+%
M<PE6"21..01D$5S5_H\MKEX\R1?J*@LM1GLF^4[D[H>E;SH1J+GI,RA7E3?+
M4,/Q9\&=$USS+G3/^)=>'GY!F-C[CM^%>'>)? VO^$YC]OM'\D'Y;F+E#^/;
M\:^L[._@O4S&V&[J>HJ'7-*AUS1+S3)^$N8BF?[I/0_@:]3+N(L7A)*G6?-#
MSW7HS:5.$U>)\=3ZQJ5RD:3W]S(L2[4#2D[171>'_B7XG\-VDEK9WV^%L;5G
M7S-GTSTK/U[P=KGA[49+2\T^?AB$D1"RN/4$5U_PW^%ESXAOOMFNVD\&DHA(
M#$HTS'H!WQWS]*^XQE?+UA?:5N5PWZ._IYG/%3YK+<YV_P#B7XOU#(EUJX13
MU6([1^E8376K:I(09KRZ8]1N9_TKZFL/AGX0T_!BT2W=AT:4;S^M=%#IVGV,
M?[FTMX47NL8&*^;?$^#HZ8:A^2_*YM[&3^)GR58>!/%.I8^S:)>,#W9-O\\5
MTMG\%/%4Z[[H6MG'W,LO(_ 5]"7FNPQ92W'F-Z]A6%<7EQ=OF5RWHHZ5#XDQ
MU7X8QBOFV83=.&BU9Y9:_!J!956]UHN#U,$> /SK4B^%&@VQ9)S<3,.,E\?R
MKTJST6XN,-(/*C]3U-;,FCVLL:*X8LHQOSR:X:V?XF]G4?RT_(4:52:OL>4Z
M)X#TK2;2ZMI8TNXYY-P\U02HQTJW8>&WT"[-UX>OYK$DY:!COA?ZJ>GX5Z9%
MH]G$A4Q;\]VYJK<>'X7R8)"A]#R*Y7F\ZDGSR;OO?9_(?U>K'5,9I6OFXC$>
MH1K!..K(<HWT]/I6VKJZY5@P]0:X'4Y%T>4)J'[A&.%E;_5G_@70?CBIK:\=
M LEO/\IZ%&R#7+4P:DN>&B?W%+$RCI-'<T5S=OX@G3 F02#U'!K5M]8LY\#S
M-C>C\5Q3P]2&Z.B%>$MF7Z*8TT2)O:10OKGBF1W4$H.R9#CKS67*]S6Z)J*S
M;K6K:WRJ'S7]%Z?G6)=:O=7.1N\M/[JUO3PU2?D8SQ$(>9T5SJ5K:CYY 6_N
MKR:Q;K7IY<K /+7U[U@WM]:Z?;FXOKF.WB'.^5L9^G<_A7GVN_%BTM]T.C6Y
MN'Z>?-PH^@ZFO7P645*[_=QYO/H<LJ]2>VB/1[BY5$:>YF"J/O/(V /Q->?Z
MW\5-.L9)(-.A:[D7@2YPF?YD5YAJGB#6/$-R/MEU+.S'"1+]T9[!16S;_#'Q
M=<Z2VHII$HC'(C8@2,/4+7U%')L+ADI8R:UZ7LO^"0J=_,ZCPY\4I+O4$M=7
MC@AB<G]^N1M],BO4[.^>+;/;2@JPR"IR&%>$Z/\ "OQ;K%P8QIS6JJ,F2Y.T
M5MVMAX\^'TNVXTZ:[T\'YA'^\3'J".1^58YA@,%6GRX:I%2_ENM?3S&Z4E[R
M/H"PUB&ZPDF(Y??H:TZ\IT#Q1IWB"'-K+LG7[\#\.I^E=9:ZW<VL>TKYRCHI
M.#^=?(XG+YTY.-K/LS:GB>DSJJ*Y>#Q]H+78L[VX.GW1Z1W0V!OHW0C\:Z6*
M6.>-9(9$DC;D,C9!_&N&K0JTOXD6CL4E+8?11160PHIDLL<$32RR+'&HRS.<
M #W->=^)OC+X=T/?#9,=2NEXVPG" ^[?X5TX;!U\5+DH1<F*4E'<]'Z#)KC_
M !+\3/#?AE62>\6XN1T@MSN.?<]!7@?B;XI^)?$A>)KK[':M_P L+?Y1CW/4
MUBZ-X4UKQ!(&M;5_+8\SR\+^9Z_A7U>%X5A3C[7'5++LO\_\CGGB/Y3L?$WQ
MJU[6-\&F :;;'C*',A'U[?A7!VUEJNOWA,,5Q>3N?F<Y;\R:]6T'X6Z;8;9M
M3<WLPYV8P@_#O7IEEIMNVD+#8VT43P'[D:@;A7=+-L%E\>3!T_GM_P %G-SN
M;\SP^U^$FJ36GF3WD$$QZ1X+?K5=_A)XI*NUK!#=*O:.3YC^!KV_[/,7V>4^
M[.,;:4&>UEXWQN/PKD7$&,3NFG\C-2:?O;'S??>$/$>EM_I>C7L>.XC+ ?B,
MU!:Z[K>E2_Z/J-Y;NO82,,?@:^KK77N/+NT#+_> _F*LSZ+H.M0YGT^SN4/7
M=$*O_6F2]W$T$UY/_,Z80C/X)'S?I_Q?\96& =2%RHZB= V?QKJM/_: U"/"
MZAI$$H'5HG*D_GQ7H.H?!_P=?Y(TXVS'H8)"H'X5RFH?L_6+Y.G:S/$3T$R!
M@/RQ2_M#(,5_%I\K]+?^DFG)5CLS2M?CSX;EA9KBTO() N0@4/D^F:X^\^/F
MM/>LUGI]M';9^5'R6Q[FL3Q1\(->\,Z9-J)FM[NUAY<QY# >N*\]KT\!DV45
M4ZM!<Z\W>Q$JE1:,^L? GQ L?&FGLX46UY$<2P,WZCU%=C7Q)";J)3- 9D4<
M%TR!^8K3L_%WB*PQ]EUF]BQTQ*:\[%\(*=1RP]2R[-;?,J.(TU1]D45\K6?Q
M>\9V>,:IYP'_ #VC#_SKH+/X^>((<"YL+*X'<X*G]#7E5.$\?'X>5_/_ #-%
M7@?1-%>*V?[0=L<"\T.1?5HIAC\B*W[3XY>$YQB87L#?[40(_,&N"ID.8T]Z
M3^6OY%*K!]3TNBO -;^/6I/?L-&LH8K120K3C<S^Y]*BO/CYK$NEI#;:=;PW
MA&'G)+#ZA:Z8\,9BTGRK7SV]1>V@>]WVH6>F6S7%]<Q6\*]7D8 5Y=XF^.>D
MZ?O@T2!KZ8<>:WRQC^IKP[4M;UOQ/?!KVZN;V=S\J9+?@%%=CX9^#/B+6]DU
M\HTVU/.91ER/9?\ &O9I</X' Q]KF%2_ELO\V9NK*6D$<[XB\?>(O$\A%]?R
M"$GB"([4'X#K5GPW\-?$OB9E>WLF@MCUGN!M7\.YKWWPU\+/#7AO9*MK]KNE
M_P"6]Q\QS[#H*[55"J%4  = !6>)XHI4(^RR^FDN[5OP_P P5!O6;/,/#/P2
MT+2=D^JLVI7 YVMQ&#]._P"->EVUK;V<"PVT,<,2\!(U  J6BOE<5CL1BY<U
M>;?Y?<;QBH[!1117(4%%%% !1110 53U'2K#5K9K?4+2&YB88*R*#5RBJC*4
M7S1=F!X_XF^!.G7F^?0;IK.4\^3+\R'Z'J*\@\0>"/$7A>4_VA82+&IXGB^9
M#[Y'3\:^OZ9)%'-&8Y45T;JK#(-?18'B?&8>T:OOQ\]_O_SN8RHQ>VA\I>&O
MB?XE\-%8XKPW-J/^6%P=PQ['J*]C\-?&O0-7V0ZF&TVY/&7YC)^O:K7B7X.^
M&]=WS6L1TZZ;G?!]TGW7I7CGB7X2>)O#Q>6.W^WVJ_\ +6V&2![KU_G7L\V2
MYO\ %^[J/Y/_ "?YF?[RGYH^H;>Y@NX%FMIHYHFZ/&P8'\14M?'.B>*M>\,7
M.[3KZ>W*GYHF/RGV*FO1!\?M6_LKRCIEL;[IYV3MQZ[?6O,Q7">+IR_<-33^
M7WEQKQ>Y]!45X5X8^.UW+J<=MKUI#]GE<+YT(P8\]R.XKW-'62-70AE89!'<
M5XF/RW$8"2C75K[=C6,U+8=1117 4%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1169K?B'2O#MG]JU6\CMX
MS]W<>6]@.IJH0E4DHP5VP;L:=%<IHOQ(\+:_>BSLM247#8")*-F\^@SU-=75
MUJ%6A+EJQ<7YJPDT]@HHHK(84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4R7_ %3_ .Z:?3)?]4_^Z: /"_A7IWC6
MY\*3R:#KVG65E]NF'E7%GYC;N,G.>G2O2M"TWQQ;:K'+K?B#3;RQ"MOA@LO+
M8G''S9]:P/@7_P B%/\ ]A&?_P!EKTR@#.UW28M=T&^TJ9BL=U"T3,.V:\UU
M2Y\0^"OA;=Z7J<%G,L,)M;:Y6;F8-PHV8SNY]:]7G$QMY!;LBS;?D,@)4'W
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M76Z5XXT#5P!#?)%*?^6<_P A_7C]:]%\0^%M'\461M=5LTF'\#XPZ'U!ZBO
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M:39SIHVG0R(;N9-OGR/@84>@Q0!Z)1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <
M_+XOTNS\3W6BZA>6EF\5M%/&T\ZIY@8L#C..FT?G5K_A*?#W_0>TO_P,C_QK
ME/$7PPT7Q;XRN-6UY6E@6TB@@C28IR"Y8G'/=<?C57_A1WP__P"?";_P,?\
MQH U_&7B309_#%Q!%K.GRS2O$L<<=RC,S>8O  .:[2O']:^$7@G3I+%=,#VN
MJRW"&TWW#,LC*0Q4YR.@->P4 %%%% !1110 4444 %%%% !7)?%#_DFFO?\
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M$W)JY17E5,14GNSKA0A#9!1116)J%%%% !1110 4444 %%%% !1110 4444
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M!_M'2+.X8_QO"-W_ 'UU%:V0.I%1M<P)]Z:,?5A6E.=2#YJ;:?D)VZGG&J?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.%>:]XYZNMBU".#3[:6Y<@N ,XK,M_#\ID'GNH0=0O4U8UC3[FX,7D*#%&N
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M ?J6KVJFO(D8R[!1[FN2?$F93VG;T2_R*]C!'EUM\!O"\6#/=:C,?^NBJ/\
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MM0MM)TZXO[R416]NA>1CV IQBY-16[ ^:/B]J-_J?C6^-PQ6TLY/LUO'GC@
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M?ZN%0?4C-6:*XI5IRW9UQI0CL@Z4445F:!1110 4444 %%%% !1110 4444
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M$_2@#T:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBB@ KDOBA_R337O^O;_V85UM<E\4/^2::]_U[?\ LPH N>!/^1"T+_KRC_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7[VS*G0C!W04445P&P4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDO^J?_=-/IDO^
MJ?\ W30!YM\"_P#D0I_^PC/_ .RUZ97F?P+_ .1"G_[",_\ [+7IE !1110
M4444 %%%% !1110 5!?1O-I]S%']]XF5?J0<5/4%Y.;:QN+A5W-%$S@>N!F@
M#R/2AH,^D+!:>&L:KH&V2]AFLP3..DF&(^8GJ*N>#O$VD:O\2YXO#&FB+37L
MLW4@M?*"R@\ <#''!KLO#?C#3-<\/+JTCQVCK&&NHY?E,1QWSV]#7+>'_']E
MK_Q'ATK0+,1Z7Y,SS72PA%N)!CH<<XH ].HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ///$?Q2;P_XGGT-?#.I7TT:+('MR"'0]_P \BLV7XMSSQF.;P#K4B'JK
MH"#^&*].^QVWV[[;Y*?:O+\KS<?-LSG'TR*X;Q%\4K#PMXGNM(O;6ZN66**2
M);2+>V&W;MWTP* .;NOBO<VUM';Z=X+O]+:>>./SY(@(T!8 D@#TKV2N$USQ
MYI-SX".M64"WT<T\=NEO.NW;*S  ..HP:U].US4(-7ATC78[9+JYB,MO+;Y"
M/C[RX/((H Z2BBB@ HHHH **X6^U_7K#XJ:'H<LUJVF:C'<2;4B^<>6A(R3^
M'2MOQCXFB\)^'9M3>/S9 RQPQ9^_(QPH_.@#?HKA-0U_6_"1TJ\UVYAN;*]E
M6"Y5(@GV5VZ$$=1GCFN[H *Y+XH?\DTU[_KV_P#9A76UR7Q0_P"2::]_U[?^
MS"@"YX$_Y$+0O^O*/_T&NAKGO G_ "(6A?\ 7E'_ .@UT- !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,E_U3_P"Z:?3)?]4_
M^Z: /-O@7_R(4_\ V$9__9:],KS/X%_\B%/_ -A&?_V6O3* "B@D 9/ %<.G
MBC5?%&L7-CX8\F&QLW\NXU*9=X+CJL:]\>IH [BBH+.*>&TCCN;C[1,HP\NP
M+N/K@<"IZ "BBB@ HHHH *K:C*T.EW<J8W)"[#(R,A35FF3>6()#-CRMIWYZ
M8QS0!X7I7A'Q+\4X8=:\0O%I=CY"K!! FTW&.A<?W:]!T/5;73=<T[PJ^ABR
MNT@D='C0>5M7'*-WSZ5S3>)?B#X@G)\&:/9V>BPGRX)KSCSE7C('8>E=9X9U
M75;J_2R\4Z3!:ZO%&6AGA;='*G1MIZ@^HH Z^BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *\QU/Q3IG@+Q-JTFN:3=N-0E$T%Y! ) R[0-A/8@@\>]>G5Y]XS\>
M7>GZL-"\/: ^MZLJAY5Q^[@!Z;CZGZB@#@_$6K3:IIDDR:#?VB:KJMI<6D8@
M)W)$?F8@=&/7'M76ZWX@LO$7Q,\(V6CW"W#VDDMQ<[,_NU*[<-Z'/:M#P]XT
MU]KR"S\7>%7TDS-L@N8W$D.[LIP3MSZYKLH-&TVUU&;4+>PMXKR88EG2,!W'
MN: +U%%% !1110!YUXC_ .2W>"O^O6]_]%U5^-:M_8^@2'_41ZO$9CV"X(Y_
M'%:^L>$->U'QSIWB2#6;"'^SED2WMWLF;*N,-N/F#)QZ8KI=>T*T\1Z)/I=^
MNZ*91EEX*L.0P]P>: .+^-OS> TB7F62^MQ&!USO%>@V:/'90))]]8U#?7'-
M<NO@^\O[G36U_5$OK?36#P1)!Y>]P,!I#D[B/; ]JZZ@#C-5T;Q[<:I<2Z;X
MML;2R9\PP/IJR,B^A;/-<GXYT;QW;^"=6FU3Q98WEBL!,L$>G+&SC(X#9XYQ
M7K]<E\4/^2::]_U[?^S"@"YX$_Y$+0O^O*/_ -!KH:Y[P)_R(6A?]>4?_H-=
M#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M, *!USGH17$Z'XS/C#XFPQ:)#,^@Z=;RK+=!2(Y)3C&/RXH ]-HHHH ****
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M_H-=#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2S:[8BWFB+NP(B8XQT]: /4**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RSQ9\/
M-3\5_$&YU"#5[G2K>*QAB$D/65MSDC\./SJ@WP2U%Y(Y&\;:F7C)*,>JY&#B
MO8J* /$M5^#^LVEO#=Q^)[_43;W$4AM9>0X#C/>O;:9++'!&9)9$C0=6=L ?
MC3Z "BBB@ HHHH **** "BBB@ KDOBA_R337O^O;_P!F%=;7)?%#_DFFO?\
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MY /<5Y/IWQ?NK;Q_>>()[!&M;N,0-;H<,L:_<P?[WKZ\]*]6CG%U$MPJE1*
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M^_7-5TOB'_CSC_WZYJO5PG\(\S%?Q#J- _Y!W_ S6I67H'_(._X&:U*\^O\
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M#TQSZT >N1?ZI/\ =%/JKIR74=A$M[<13S@?-)%$8U/_  $LV/SJU0 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOU.;$=#T;X/_ .MU+_=6O5:\J^#_ /K=2_W5KU6HSO\ WV?R_(\^>YUNC_\
M(,BJ_5#1_P#D&15?KX^K\;/6I_ @HHHK,L\V^*'C+0D\$ZE81W\4UU<CR$BB
M.XAL\Y] ,5:T[Q+I?B'PUIK:?<J\D42K)$?O(0,'(^HKYKUS_D/ZC_U]2?\
MH1KO/@__ ,A#4O\ KDO\Z^^Q&14<-@%*,FW%\WWV5C@JU7),];KK-%_Y!D?U
M-<G76:+_ ,@R/ZFOE,9_#)PGQFA1117F'HA7R?\ %3_DI&K_ /70?R%?6%?)
M_P 5/^2D:O\ ]=!_(5]9PA_OD_\ #^J,,1\(GPP_Y'2'_KD_\J]UKPKX8?\
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M_D)P_6LC3_\ D&VO_7%/Y"M?2/\ D)P_6OB\1M+YG+3^-'74445X1ZX5Y_\
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M_P"L7ZBNX3[B_2OSO&_9.G!]1U%%%<!VA1110 4444 >)?M!_P#'MHW^^_\
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MC3M9MO%%W>W-Q>1Q2::ZCR7#'D(HZ "@#U:BD4DJ"PP<<BEH **** "BBB@
MKD_"&JZ9;^'5BFO[2.07-SN1YE!'[^3J":ZRO)[3X':'>M=7NLM=->W-U-,P
MBG*JH:1BH&/;% '0Z/-X>M_&WB"Z2XTZ-G6WVR"1!GY6S@Y^E7;S4+"\\;Z
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MZYKY&^(__)1==_Z^C_(5]=P?_O53_#^J.?$?"C0^%7_(W'_K@]>VUXE\*O\
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M\C?$?_DHNN_]?1_D*^NX/_WJI_A_5'/B/A1H?"K_ )&X_P#7!Z]MKQ+X5?\
M(W'_ *X/7MM=G$'^^?)'GSW.E\/?\><G^_6O61X>_P"/.3_?K7KXO$?Q6>G0
M_AH****Q-0HHHH *X_XI?\DWUG_KC_45V%<?\4O^2;ZS_P!<?ZBNS+O][I?X
ME^9,_A9\FU[S\-_^1+M?]YOYUX-7O/PW_P"1+M?]YOYU^C\1?[JO7]&>7/8Z
M^/\ UB_45W"?<7Z5P\?^L7ZBNX3[B_2OSO&_9.G!]1U%%%<!VA1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?SK@/"__ "-&F_\ 7=:_2LK_ .13#_"_U,:OQ,^CZV?#O_'U+_N5C5L^'?\
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MX$GWU^M>^_M!_P#("T;_ *^7_P#0:\"3[Z_6OU'AG_D60]7^;.*M\9]-Z?\
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MC/+GL=?'_K%^HKN$^XOTKAX_]8OU%=PGW%^E?G>-^R=.#ZCJ***X#M"BBB@
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M_'O'_N#^5</7<0?\>\?^X/Y5^<XW9&^#W9)1117GG<%%%% !1110!Y'\?O\
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MS_0\RH:VC?\ (3C_ !KK*Y/1O^0G'^-=97P6,_B([<)\ 4445R'4>.?M!_\
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M'/5"O%?V@_\ CQT;_KJ_\J]JKQ7]H/\ X\=&_P"NK_RKV^'?^1E2^?Y,SK?
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MT=6#V84445PG887C3_D2]8_Z]7_E7QU7V+XT_P"1+UC_ *]7_E7QU7Z!P=_
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MX?M!_P#'MHW^^_\ *O#[;_C[A_WU_G7ZEPY_R+(?/\V<-;XV?3EK_P >D/\
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MJ'U]!CUYH ]9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[G1>'?\ CVF_WQ_*MJL7P[_Q[3?[X_E6U7Q>)_BL]*A_#04445@;'SE\>?\
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MX&:U*^-K_P 21ZE'^&@HHHK(T"BBB@ K \<?\B1K'_7JU;]8'CC_ )$C6/\
MKU:NC"?[Q3]5^8I;,^/*]M^%7_(I'_KNU>)5[;\*O^12/_7=J_3N(/\ <_FC
MRY['<UW$'_'O'_N#^5</7<0?\>\?^X/Y5^<XW9&^#W9)1117GG<%%%% !111
M0!Y'\?O^17TW_KY/_H-?/-?0WQ^_Y%?3?^OD_P#H-?/-?J'"_P#R+8^K_,XJ
M_P 9]-:3_P @>R_ZX)_Z"*V-*_Y"<'^]6/I/_('LO^N"?^@BMC2O^0G!_O5\
M;B/M_,Y(?&O4["BBBO!/8"BBB@ HHHH *^2OB=_R4?6_^N_]!7UK7R5\3O\
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M<G^_6O61X>_X\Y/]^M>OB\1_%9Z=#^&@HHHK$U"BBB@ KC_BE_R3?6?^N/\
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M *\ZU$#_ (7SHIQUTJ?^8KT6O*=3UW3E^.6ESF?]Q!8RV\DNT[5D8C"DXZT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOI'_ "$X?K7Q>(VE\SEI_&CKJ***\(]<*\_^,_\ R3B[_P"NL?\ .O0*\_\
MC/\ \DXN_P#KK'_.O0RG_?J/^)?F1/X6?+M?0O@;_D2M+_ZX_P!37SU7T+X&
M_P"1*TO_ *X_U-?H'$?^[Q]?T9YD]CIK?_CYB_WQ_.NWKB+?_CYB_P!\?SKM
MZ_/<;NCJP>S"BBBN$[#"\:?\B7K'_7J_\J^.J^Q?&G_(EZQ_UZO_ "KXZK]
MX._@5?5?D<F(W1[9\*?^14?_ *[M7=5POPI_Y%1_^N[5W5>9F?\ OE3U.&6Y
MV]M_Q[1?[@J6HK;_ (]HO]P5+7R<MSV([!4=Q_Q[2_[A_E4E1W'_ ![2_P"X
M?Y41W&?%>I?\A2\_Z[O_ .A&O2/@_P#>U+Z+7F^I?\A2\_Z[O_Z$:](^#_WM
M2^BU^LYM_P B^7R_-'ESV/5*Z[2/^09#]*Y&NNTC_D&0_2OSC&_ C3"?&R]1
M117F'H!7R-\1_P#DHNN_]?1_D*^N:^1OB/\ \E%UW_KZ/\A7UW!_^]5/\/ZH
MY\1\*-#X5?\ (W'_ *X/7MM>)?"K_D;C_P!<'KVVNSB#_?/DCSY[G2^'O^/.
M3_?K7K(\/?\ 'G)_OUKU\7B/XK/3H?PT%%%%8FH4444 %<?\4O\ DF^L_P#7
M'^HKL*X_XI?\DWUG_KC_ %%=F7?[W2_Q+\R9_"SY-KWGX;_\B7:_[S?SKP:O
M>?AO_P B7:_[S?SK]'XB_P!U7K^C/+GL=?'_ *Q?J*[A/N+]*X>/_6+]17<)
M]Q?I7YWC?LG3@^HZBBBN [0HHHH **** /$OV@_^/;1O]]_Y5X?;?\?</^^O
M\Z]P_:#_ ./;1O\ ??\ E7A]M_Q]P_[Z_P Z_4N'/^19#Y_FSAK?&SZ<M?\
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M67_?K9K&\._\>LO^_6S7Q>(_BL].A_#04445B:A1110 50US_D7]1_Z]9/\
MT$U?JAKG_(OZC_UZR?\ H)K2E_$CZH3V/BRO8?A#_P @.^_Z[C^5>/5[#\(?
M^0'??]=Q_*OU7/?]REZK\SRY['HM=I8?\>$'^X*XNNTL/^/"#_<%?F^-^%&V
M#^)EBBBBO..\**** "F2_P"J?_=-/IDO^J?_ '30!YM\"_\ D0I_^PC/_P"R
MUZ97F?P+_P"1"G_[",__ ++7IE !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117)?$NZ
MU.R\"WUQI0F\Y-AD,/WQ%N&\K[[<T =;17E$;Z'>S>'KKP"R_:Y9U:X,!/$/
M\?G_ /V7.>E>KT %<E\4/^2::]_U[?\ LPKK:Y+XH?\ )-->_P"O;_V84 7/
M G_(A:%_UY1_^@UT-<]X$_Y$+0O^O*/_ -!KH: "BBB@ HHHH **** "BBB@
M KQ[]H+_ )%_2/\ KZ;_ -!KV&O'OV@O^1?TC_KZ;_T&O8R#_D94O5_DS.K\
M#/G]?O#ZU].:=_R"[3_KBG_H(KYC7[P^M?3FG?\ (+M/^N*?^@BOLN)?AI_/
M]#S:AK:3_P A.'ZUU]<AI/\ R$X?K77U\#C?C7H=F$^!GSG\>O\ D<+3_KU'
M\ZX#PO\ \C1IO_7=:[_X]?\ (X6G_7J/YUP'A?\ Y&C3?^NZU^E97_R*8?X7
M^IC5^)GT?6SX=_X^I?\ <K&K9\._\?4O^Y7P.(_A,RH?Q$='1117CGJA1110
M 5B>,/\ D3M7_P"O5_Y5MUB>,/\ D3M7_P"O5_Y5OA?X\/5?F*6Q\<5[5\*/
M^16D_P"NYKQ6O:OA1_R*TG_7<U^H9_\ [F_5'ESV.\KM[;_CUB_W!7$5V]M_
MQZQ?[@K\XQNR-L'NR6BBBO/.\9+_ *F3_=-?%>J?\A>]_P"N[_\ H1K[4E_U
M,G^Z:^*]4_Y"][_UW?\ ]"-?;\&_%6^7ZG-B.AZ-\'_];J7^ZM>JUY5\'_\
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MR^//_(Y6O_7J/YUP7A7_ )&K3?\ KNM=[\>?^1RM?^O4?SK@O"O_ "-6F_\
M7=:_5LK_ .13#_"_U//J_$SZ.K9\._\ 'U+_ +E8U;/AW_CZE_W*^!Q'\)F5
M#^(CHZ***\<]4*\5_:#_ ./'1O\ KJ_\J]JKQ7]H/_CQT;_KJ_\ *O;X=_Y&
M5+Y_DS.M\#/"[?\ X^8O]\?SKZ<M/^/*#_KFO\J^8[?_ (^8O]\?SKZ<M/\
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MG4:!_P @[_@9K4K+T#_D'?\  S6I7QM?^)(]2C_#04445D:!1110 5@>./\
MD2-8_P"O5JWZP/''_(D:Q_UZM71A/]XI^J_,4MF?'E>V_"K_ )%(_P#7=J\2
MKVWX5?\ (I'_ *[M7Z=Q!_N?S1Y<]CN:[B#_ (]X_P#<'\JX>NX@_P"/>/\
MW!_*OSG&[(WP>[)****\\[@HHHH **** /(_C]_R*^F_]?)_]!KYYKZ&^/W_
M "*^F_\ 7R?_ $&OGFOU#A?_ )%L?5_F<5?XSZ:TG_D#V7_7!/\ T$5L:5_R
M$X/]ZL?2?^0/9?\ 7!/_ $$5L:5_R$X/]ZOC<1]OYG)#XUZG84445X)[ 444
M4 %%%% !7R5\3O\ DH^M_P#7?^@KZUKY*^)W_)1];_Z[_P!!7UO!_P#O<_\
M#^J,,1\*+'PL_P"1S3_KA)_*O<:\.^%G_(YI_P!<)/Y5[C7;Q!_O?R7ZGG3W
M.C\._P#'K+_OULUC>'?^/67_ 'ZV:^+Q'\5GIT/X:"BBBL34**** "J&N?\
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M  8R5WN]/[R_G1O3^\OYT <%_P *AT'_ *".N_\ @QDH_P"%0Z#_ -!'7?\
MP8R5WN]/[R_G1O3^\OYT <%_PJ'0?^@CKO\ X,9*BN/@UX=NH&AEO];9&&"&
MU!F'Y'(KT+>G]Y?SHWI_>7\Z:;3N@/*_^&??!W_/QJW_ ($K_P#$U;M_@AX9
MMH_+COM:"#HHO2 /R KTG>G]Y?SHWI_>7\ZN5:<E9L5D>>?\*8\.?\_VM_\
M@>U3?\*AT'_H(Z[_ .#%Z[W>G]Y?SHWI_>7\ZAML$DC@O^%0Z#_T$==_\&,E
M'_"H=!_Z".N_^#&2N]WI_>7\Z-Z?WE_.D,X+_A4.@_\ 01UW_P &,E'_  J'
M0?\ H(Z[_P"#&2N]WI_>7\Z-Z?WE_.@#@O\ A4.@_P#01UW_ ,&,E'_"H=!_
MZ".N_P#@QDKO=Z?WE_.C>G]Y?SH \WO?@AX8U *+B\UE]O3?>EO_ $(&J@_9
M^\'@Y%QJW'_3R/\ XFO4]Z?WE_.C>G]Y?SK2-:<59,5D>=K\%O#BJ!]OULX_
MZ?V_PIZ?!KPZC;EO];!_["#UZ#O3^\OYT;T_O+^=3S-ARHX+_A4.@_\ 01UW
M_P &,E'_  J'0?\ H(Z[_P"#&2N]WI_>7\Z-Z?WE_.I&<%_PJ'0?^@CKO_@Q
MDH_X5#H/_01UW_P8R5WN]/[R_G1O3^\OYT <%_PJ'0?^@CKO_@QDH_X5#H/_
M $$==_\ !C)7>[T_O+^=&]/[R_G0!P7_  J'0?\ H(Z[_P"#&2LN7X!>$9I6
MD>YU<LQR2;H']2M>H[T_O+^=&]/[R_G5PG*'PNP6/,;?X#^%+63?#>:PC'@[
M;O;G\EJW_P *8\.?\_VM_P#@>U>A[T_O+^=&]/[R_G1*I*3NV+E1P"?![P_&
MN%U#7 /;47%._P"%0Z#_ -!'7?\ P8R5WN]/[R_G1O3^\OYU S@O^%0Z#_T$
M==_\&,E'_"H=!_Z".N_^#&2N]WI_>7\Z-Z?WE_.@#@O^%0Z#_P!!'7?_  8R
M4?\ "H=!_P"@CKO_ (,9*[W>G]Y?SHWI_>7\Z ."_P"%0Z#_ -!'7?\ P8R4
MR;X.>'IX6B>_UPJPP0=0<_H:] WI_>7\Z-Z?WE_.A.P'E?\ PS[X._Y^-6_\
M"5_^)JU;? [PQ:ILBO=:5>NU;TJ/T KTK>G]Y?SHWI_>7\ZUE6J25FQ61YY_
MPICPY_S_ &M_^![5,/A#H &/[0UW_P &+UWN]/[R_G1O3^\OYUFVV"21P7_"
MH=!_Z".N_P#@QDH_X5#H/_01UW_P8R5WN]/[R_G1O3^\OYTAG!?\*AT'_H(Z
M[_X,9*/^%0Z#_P!!'7?_  8R5WN]/[R_G1O3^\OYT <%_P *AT'_ *".N_\
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M $$==_\ !C)1_P *AT'_ *".N_\ @QDKO=Z?WE_.C>G]Y?SH X+_ (5#H/\
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MA&6^U?37N+E;V6+S/M4J?*,8X5@.]>EZ%\,_"7AK58]3TG2V@O(U95D-U*^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVUFZCN;6V3354?9YDD)D<]]P[5B?%#_DFFO?]>W_ +,*ZVN2^*'_ "337O\
MKV_]F% %SP)_R(6A?]>4?_H-=#7/>!/^1"T+_KRC_P#0:Z&@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F2_ZI_\ =-/IDO\
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MY)Y=K=RQ;89V]%.<\X.,@9[5PGBOQGJ=SX'\::1?6\5OJ^EQHKO;9\N2*1@
MR@Y(R,\9J[\1XTL?@E"]M\LEFMK);E?X6#+@C\S0!ZE14<!9K>)F&&* G\JD
MH *P9/%VFQ>*K?PXR70OKA7:,F$B,A5R?F/7CTS6]7!>(_\ DKW@W_KA>?\
MH H [#5=3M]'TR>_NMYBA7)6-=S-[*.Y/I63X;\8P>)KB:*'1]9LO*4,7O[,
MPJWL,GDT[Q;X:F\3:?#;P:O=Z;)!*)DDM\<L.F<CH#]*Q/"6O:U8ZKJ?AWQ5
M/%//80BYCOU7:)H3QEAV(H Z3Q!XFTWPS!;2ZC(R_:9TMXD099F8X''ISS6Q
M7DGCZ&34-#LM>NT*M-JUHEI&W_+.'S.OU;J:];'2@ HHHH P;GQ=IMIXJLO#
MLJ70OKPN(6\DB,[4WM\QX.!Z9Y-:>I:C;Z3IMQ?W180P(78*,L?8#N3V%<;X
MM_Y*I\/O]^__ /1 K?\ %OAR3Q/I4=G%JMUIS1S+,LMMC)9>5SD=,X/X4 0>
M'/&EOXENY;>'1M;LO+3>9+^S,*'G& 2>34[^+M-3Q5!X<9+H7TZNR$PD1D*,
MG#'K^&:PO!^K>(++Q)>>$_$DR7L\%N+JUOT3;YT6[:0P_O FF^(/^2P^$?\
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M:]$Y^][D@?05A>+/AEI&JZ?9PZ/HVCVDT5[#-*QMU3=$IRZY53G([=#7?44
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MIP#ZUQ^G7FHZ;)H>F>*//G\*O<(VFWNP!F8']TLW/ Z$?AF@#V^B@8QQTHH
M**** "L7Q/XDMO"VD2:E=VUW/!&"7^S1%]H'<]@/K6U7*_$K_DF^O_\ 7HU
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M>G(/X&@#&LOB4;G6+#3KCPCXCL6O9A#%+=VJQIG!)R=W8 GCTKNZY5/^)O\
M$=WZV^B6NP?]=YN3^(C4?]_*ZJ@ HHHH Y[2_%]GJOB6^T*.TO8;JSB65S/%
ML#*3@8SS^E6?$7B"/P]8I.;*\OII'V16ME'OED/? ST%<UIO_);=<_[!5O\
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MK-,X V#)QMSGK6[7F7AN&QT[XOZC:V]Q&ZC1X1OW@F1RY)/N2>:]-H ****
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M=0&QNVM)4N4V-O4 GC/OWK=K@OAM_P A#QM_V,5Q_P"@I0!:\0_$C3O#][/
M=,U6^CM2!=W-G;[XK<XSAFR.<'MFMB;Q9I$?AB+Q MP9;"95,+1J2TA8X"@=
M=Q/&/6G:S-;Z/H=RL%LLDMP7$5L!DSS2$G'XDDGT&>U<EJ/A33]#^#]MH%_>
M20FT1#'/",L+@ON&T=_G. * .GL_%,<VK6^F7VG7FFW5RK/;K<A")0HR0"C$
M @=C@UOUY5X8U+4W\;6.G^.83'K$$#?V;(BCR9LCYVR/X\<8Z=:]5H ****
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MTR7_ %3_ .Z: /-O@7_R(4__ &$9_P#V6O3*\S^!?_(A3_\ 81G_ /9:],H
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M5B3DL?<DDGZUY?J7Q/\ &FD+:M?>!C"+JX2UAW3_ 'Y'^ZOU.*N_\)Q\0O\
MHG[_ /?^@#M_#NCRZ3;7C7,B2W=Y=RW4SIG!+'"@9]$"+^%;%>8?\)Q\0O\
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MZ=!J%CX$,UK.N^.19^&'K5K_ (3CXA?]$_?_ +_T >GT5YA_PG'Q"_Z)^_\
MW_H_X3CXA?\ 1/W_ ._] 'I]%>8?\)Q\0O\ HG[_ /?^C_A./B%_T3]_^_\
M0!Z?17F'_"<?$+_HG[_]_P"C_A./B%_T3]_^_P#0!Z3=?:/LLGV01&XV_NQ*
M2%S[XYQ7*^ O#FM>&+2\M-2FL9HIKF2Y1K<ON#.V2""!Q6!_PG'Q"_Z)^_\
MW_H_X3CXA?\ 1/W_ ._] '3OI_BJ]@O+&_O-,%I<;D$T".)%C/&-IXSCOFM-
M/#6C"PM;.73+2XBM8Q%%Y\*R%5'ID5YQ>?$_QII][8V=UX&,<]\YCMT,_,C
M9('X5=_X3CXA?]$_?_O_ $ ;^C>!;32?'&KZZEK8+;W4<"VL4< #0,BD,1Q@
M9SVKL*\P_P"$X^(7_1/W_P"_]'_"<?$+_HG[_P#?^@#T^BO,/^$X^(7_ $3]
M_P#O_1_PG'Q"_P"B?O\ ]_Z /3Z*\P_X3CXA?]$_?_O_ $?\)Q\0O^B?O_W_
M * /3ZYKQUHFI^(_"]UH^FR6D1NUV2R7!;Y5R#P #D\5RO\ PG'Q"_Z)^_\
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MQ!_U[?\ LRUV=5K_ $^TU6PFL;ZW2XM9EVR12#*L/0T ,TG_ ) UC_U[Q_\
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M-LD4@RK#.>: $TS_ )!-G_UP3_T$5:IJ(L<:QHH5% "@=@*=0 4444 %%%%
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M%J[^JE[IECJ,EJ]Y:QSM:3"> N,^7(.C#WYJW0 4444 %%%% !1110 4444
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M,PN1-N.P0CKC[H 7B@#VZBLSPX-2'AO3AJYSJ/V=/M!_V\<Y]_6M.@ HHHH
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MC<>0*W_"^C:!90F[T>XCOI'79)>_://>3UR^3W[4 =%1110 444V1!+$\9+
M,I4E3@C/H1TH =17FO@.W%E\3O'%G'+,\,0M"@EE9RN5<GDGU-3?$S5!IFI^
M&CJAF7PQ+<2+J3QYQNVCR@^.=FXDD=\4 >B45P&@10Q_$!AX89?^$?%CF[\E
MLV_GD@IL[;MN<X[8S7?T %%%% !15;4$NI+":.RD6.X9=L;MT4GO^%>3^.?
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MM8S"O"@8(&2<MSC[V*]/U#P^TNA6NB:;<26-DNV.1XG(D$0'16ZY/ )Z\DT
M;M%>1:CX:/@+QKX;G\-W=X(=2N_LUW9RSM*KK@DO\Q/I7KM !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M MEV+'EV^IS6M6#X:\%^'_""3KH6GBT$Y!D/FO(6QTY=B:WJ "BBB@ HHHH
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M)R,CV+UWB(L:*B#"J, #L* %HHHH *Q=8O+BY=M'TN0+>R)^]FQD6L9_B/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gapk0ju0ozex000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gapk0ju0ozex000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,B!1 # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH #Q43,J'IUJ1AD8J)]IPIH #O891L"C!49/+5BZCXHTS2)!'<2X.<=
M:H-X\T?.Y)NOJ10!U1;=\O>DY"D.<BN9'CC1CRTPW?45:?Q3IT,'GR2_)C/!
MH WXR", 8I]4=-U2VU.'S+8Y7&:O4 %%%% !1110 4444 %5Y@Q==O'-6*:3
MD$#K0!& ^3N88I=JD;&&:KS3Q6ZAIY%!/'6I898YDW1G- $X&!@4M':B@ HH
MHH **** "BBB@ HHHH **** "BBB@!#Z4S!!P*>?6C@B@!.%IK.%7=BFR8^\
M3P*K+J5K-<BU5P7/8&@"Z/FP::%PS9[TAR" M.)QC- #E&%Q2T@.1FEH ***
M* "BBB@"-D)?<".*0AL@YI67Y3CK3)I1!;M(YX44 2%MN..M/KG[7Q5IUS>&
MU63,@.,9KH* "BBB@ HHHH 0G IA##D' I[=*KW-S'!;M+(<*O6@!XDR<#K3
MT4!B>_>N?L/%NEWUXUK;N3*&VGZUT"=3GK0 ^BBB@!CYR,'%(R[EZ\BF3D(1
M(S *.O-06][;W$CK$X8KUP: )UW9PQR*F50HP*AD)"KCUJ8=* %HHHH ****
M "BBB@ H[44'I0!$/E/7BEY!SGBHV9(P03P.36+;^*M*N=0^PQR$S9VXS0!N
MCYFY/TJ6H5VR'_=Z5-0 4444 %%%% #)" .1FF_='MZ4]R O-,1L*2U  N #
MM&":C"X<ECDGI2K(78] HZYK*OO$.EZ9)B:8;L]F% &P XZGBD\Q<XVFL:U\
M7:5>OLCG7/NPK8602+NC*D&@"5#D4ZF(21S3Z "BBB@ HHHH **** "BBB@
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M/Z]=7.E-#=S-,8U9OF/H* /6;_5;/2HS-=S;$'.:YS4O&&C:EI=Q#:7FZ4C
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MW<_TH ]VT_Q;I&K@?8+D2DU+K4-O)IKI/,T:,,DBO /%GAK4OA[<+>6VHRO
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M$VI2H$NO$-L5/8FM3Q3\)[S^U6U#0-L3ELC<:HIX)\>:A.@N[J$HI'0^GXT
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MXU+2I;="-S*0,^XH \(^"ZC_ (2QW'!WO_,UO_'5CL3;Q^[J]\.?AWJGAOQ
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M*%7&/FS0 X!63!H5 BX4"@NJG%(RAF^]B@!>,X/>D**>@Y%+PO>F@8W$G&:
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MZ5"2C;SBOEVYTZ7P1XZ@96;8)"5SW%>I^/;#4/$GA;3K[3IY4D5-["-L9ZT
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1Q[SD[!3M5T#3]5(-Y9QSX.1N'2M4*#]T8-)\Y^4-R* *EAIEOIMDL%I$L2
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MN75M3AMH-.,DB3JS3 <D9%>IVL,-I;1V\*;(U&$'I4OV6(.97 \SN: ,W0[
MZ=I<4>.BC*_A6N2NW<%R?2DC._D\ =J53DD*,4 95WX>TO4YEEN[")V4Y!85
MH6]I!:0K%;(L:+T"U,=P/)R*, _=H S=2T'3-5&^[LHYF]6%2:5I%EI4#1VE
MND*DYPM7RP3M2%P3C')H 9D^8 4S[U8J+#;A\W'I4M !37.%Z9IU-<$KP<4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5Q7C3(\?:!NZ%^<?C7J>%* J,>E "0Y4>6>HJ:HXU/WF^]4E !1110 4444
M%%%% !1110 4444 %%%% !43@[P_85+46#G!Z&@"*5]Z[QT7K65I>H0W.LW$
M,:D,HY)K89 58#H>M8^FVD$&N7#QGYR.: -^BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \H\:<^
M/]!S_P ]/\:]43I7E?C/_D?]!_ZZ?XUZJG2@!:6CO10 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'E'C/_D?]!_ZZ?XUZJG2O*O&?_(_Z#_UT_QKU5.E #N]%'>B@ HHHH ****
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MG!CYSR['0=0#@<U[3JWV:WL9;N9$_<KNS@5Y'IL3^*/$6HZLRYM/(9HQC^(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH \H\9_\ (_Z#_P!=/\:]53I7E7C/
M_D?]!_ZZ?XUZJG2@!W>BCO10 4444 %%%% !1110 4444 %%%% !1110 5%S
MDDG@5+43YWA?X3UH :T@V,PZ+UK%TN_CN=<N8U3#*.36O,H4;1]UNM9FFVEK
M#J\\D(_>,.>: -VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI#10 M)
M12T )12T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !112'I0 9I:93J 89HW4W%&*9-V.W"C(IM HL/7J.S1FFYHS2
M"Z'9HS3<T9H"Z'9HS3<T9H"Z'9HS3<T9H"Z'9HS3<T9H"Z'9HS3<T9H"Z'9H
MS3<T9H"Z'9HS3<T9H"Z'9H!IM(3BF#DDA^:;O&::&HVY-%@A)2)-PHW"F'@4
M@HL2Y:V'[AFES30*,T%MI#LT9IN:,TA70[-&:;FC- 70[-&:;FC- 70[-&:;
MFC- 70[-&:;FC- 70[-&:;FC- 70[-&:;FC- 70[-&:;FC- 70[=1NIM% [H
M=FC--HH%S(=FC--I1UH"Z/*O&?\ R/\ H/\ UT_QKU5.E>5>,_\ D?\ 0?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#_O_ .->JITKRKQG_P C_H/_ %T_QKU5.E46.[T4=Z* "BBB@ HHHH ****
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M9'B(6,@YJGXSCN?%_P 06M8B?L^U>.U &OX-G\.1^ KNQO;^!;J63>-W7O\
MXU0^%>O)IOBNYTZ)P\<\^%;/:NJM_@O;M!',?+W;1D8]JX7Q1H$O@7Q)8W-G
M&0 =Q*"@#MOV@/,%AIA0$KN.['XUT_P>C@/@BTD0+N.>GT%0:UIG_":_#^WN
M6^:81%@#US7F'A;QGJ7@#_B7WEG<20(,* .,T ?1>H+8"W+:@$:'/)?I69<2
M:8VB7']FM'@==E>&^)OB3J?BJV^PZ9:W$>\C@#->B^#]%OM,\%W)OI"\TH##
M(Y% 'A<T^JP>+=0.EB5Y3+SLZ]JZ,:G\0?* :TO3[Y%9MGX@3PYXQO+B6T>5
M?.R<5Z$?COI8^7^QYJ .N^&LFMSZ0AU>.59,\^97HJ@ <5Y]X)^(4'BBZ$,%
MG)"I&?FKT%2".* %HHHH **** "BBB@ HHHH **** "BBB@ I#TI:0]* &BE
M- I:$$D-(!ZU7D+*C']*L$9%,.UQBE((-)GDWQ9EDCMK1HY3&Q!Z?C7&:1J/
MB?\ LR(6T=Q*G9@:]E\4>%H_$/DJVW]UZU<T/0X=,L4LU0?NQU%8ZW/0C6@H
MV9XY_:/C#_GUN?S%']H^,/\ GUN?S%>[_8H_2C[%'Z55B?;P/"/[1\8?\^MS
M^8H_M'QA_P ^MS^8KW?[%'Z4?8H_046#V\#PC^T?&'_/K<_F*/[1\8?\^MS^
M8KW?[%'Z"C[%'Z"BP>W@>$?VCXP_Y];G\Q1_:/C#_GUN?S%>[_8H_04?8H_0
M46#V\#PC^T?&'_/K<_F*/[1\8?\ /K<_F*]W^Q1^@H^Q1^@HL'MX'A']H^,/
M^?6Y_,4?VCXP_P"?6Y_,5[O]BC]!1]BC]!18/;P/"/[1\8?\^MS^8H_M'QA_
MSZW/YBO=_L4?H*/L4?H*+![>!X3_ &AXP_Y];G\Q1_:'C#_GUN?S%>[_ &./
MT%'V./T%%@]O#L>#_P!H^,/^?6Z_,4G]H^,?^?:Z_,5[S]BC]!1]AB_NBFDP
M^L4^QX-_:/C _P#+M=?F*/[0\7CEK:Z(^HKWC['$/X137M8BA^3-9R@Q+%4U
M+8^7-7EOIKDMJ#.&SPK]JSG!VJ0,#->Z^-_ T&J6C7%LBI-&,^Y->16GAW4)
MM06R>)\A@#\O2N>=.1])ALQHJE:Q+H-SJ\,H_LT2OQ]U*Z+^T?%__/K<_G7I
M7A#P;!HMHGF!6GQDM76?88_05M2BTCQ<5BZ<YW1X3_:/B_\ Y];G\Z/[1\7_
M //K<_F*]V^PQ^@I18Q^@K6QS>W@>$?VCXP_Y];G\Q1_:/C#_GUN?S%>[_8H
M_04?8H_046#V\#PC^T?&'_/K<_F*/[1\8?\ /K<_F*]W^Q1^@H^Q1^@HL'MX
M'A']H^,/^?6Y_,4?VCXP_P"?6Y_,5[O]BC]!1]BC]!18/;P/"/[1\8?\^MS^
M8H_M'QA_SZW/YBO=_L4?H*/L4?H*+![>!X1_:/C#_GUN?S%']H^,/^?6Y_,5
M[O\ 8H_04?8H_046#V\#PC^T?&'_ #ZW/YBE_M'QA_SZW/YBO=OL4?H*7[%'
MZ"BP>W@>$?VCXP_Y];G\Q1_:/C#_ )];G\Q7N_V./T%'V*/T%%@]O#L>#?VC
MXO\ ^?6Y_,4O]H>+_P#GUN?SKW<6,8["E^QQ?W14N,@>)@>#G4/%V.;:Y'OD
M5CZCJ&M-<0I>></G&=QKZ,DLH\'Y<BN<UCPG;:FR.(P"&SS0E(UC6IR6Q/X-
M8G0X_FR:Z=!CKUK-TK31IMFL2XX]*T5;+5NHGG5IKFT/+O&?_(_Z#_UT_P :
M]53I7E7C/_D?]!_W_P#&O54Z4$CN]%'>B@ HHHH **** "BBB@ HHHH ****
M "BBB@ J(#&<C\:EJ)R?, _A[T (Y"1LXYP*Q--OH[C6IXT@"L!RP[ULS$8P
M/NGK69IT5JFK3M%M\PCG!H VZ*** #M3<TX]*9BF@"F28VG-/IDO"'C-2QQ9
MYEXOD^T^);*+=A>A%3^*E9-&MHXS\NW!QVJOXKC%MXFLI60[>I-;VL6@O?#I
M>)-Q,?RXK%IG;&212T"&,>"QD _NVPWX5F_#S>+QUW$KN;^=9%EJ^H:?HR:<
MUK,YP5X'K77^"-.>QTMKN:,J^2<$<T<K:)K:P.M=VVLQ&".@]:\RG\)7-UJ=
MW<Q7+QL7R,=JZW3M=EU2>6(V\B;7*AB*Y.6_UG1=7N'E\R6%WRH4=!2Y&5AU
MR+0;HFJWFBZP;*[E>8DA<N:[34M#M;Q))Y@LA*$X(]JXG3K2?7-?^UO$RKN#
M?,*]/N4"VDB!.?+/\J:@PJS<9IH\V\&QI'XBVHH"AV&!]:]37YN6&,5Y=X2M
MKE=>=V1E_>-R1[UVNL^(ETAHXV@:0L.HK2$;&%9N]S<!"D^]<5\17_XE$ 4Y
M)E&?TKI[2[^W64=PJE-PS@UC>*=-;4]+"H/G0[JJ:T%!6U,K2;9&\,N#@#KF
MJ7P^<B>]0-N_?'%8L>M:A8Z>^FFTF9BW! KHO">G2Z1I]Q>2*0SMOQCFL$F=
ME_W>IUFJ027&FW,()#,N!7E^F3WWA[4KF-[1I%9=H)KO].UJ76ENHTA>%H1P
MS=ZXW4=4N;+4IDN[66?/"L!WIRBR:%K^\9>F7,TOBIYGB,0*'BFW$TY\30M#
MN:3!P!^%;?A;2[C4-:-]/&RVY4@(PIGB'3Y])\00W]O"[1HO.T?2L>69U*I"
M[1735;RQU6!+^!BLC?*7[5TOBE8[O189HV VC(Q7+7ES<^(]0L_]'D01G!+"
MNEU\+9>'XH"/F*D"M8IF%9.R:-+P+<-)H,63GDUU@&1C-<AX!MGBT"+>.<FN
MO7DU<6SBJ6'YP0,9IU,4[C]*?6Q@M0HHH[U+&+1113 **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/W37+ZQ
MX*TKQ#.+F^B+3 \'/I74TFT9S0!DWGA^RO\ 2?[-N4W6^T+CV%5='\)Z9X?B
MFBT^(HLWW\UT!7-)M&,4 <M_PB6E6]Y+=/"2\_#$467@C1K/43?PPGS",9)K
MJ?+7;M//UI$C"+M% $>TA L?&*Q=<\)Z?KVPWL>XJ,5T&*1E##% &9IFDVVF
M6BVD"XB08 K,U?P=I&K.6NX-P/3'K73*@48HV C% '*:/X"T71YQ<0P8D'3.
M*W[F"%K<HR_NL<@5<V#-(T88\T <//\ #'P]>223O;-NF.3S4'_"H?"R(H-J
MV?K7H. !CTHVC.: .:T/PCI'AR7=8PE6QBND08'UI=H)S2T %%%% !1110 4
M444 %%%% !1110 4444 %%%(>E !BEIN:4TD"=QDC%5R*:JJ!N'6GDU&D80D
MY)S56!Q C;R.II4YY[TK1JS DGBGXJ>4FSN&*,4446*L)BC%%&*+"Y0Q11BC
M%%@Y0Q11BC%%@Y0HQ1BC%%@Y0HHQ1BBP<H8HQ1BC%%@Y0Q1BBBBP^4*-PH(X
MI@2FK#44.QFD"8.33AQ0WS#%#,W&-RI+'O)P.E9\>E6D=XUR(OW[_>.*V-HQ
MB@*OI2LC=5DE82./!W'&:DIJJ!WIU%C/?4****+"Y0HQ1BC%%@Y0Q11BC%%@
MY0Q1BC%&*+!RABBC%&*+!RA1BC%&*+!RA1BC%%%@Y0Q1BB@T6'RB&F8.:=3N
MU63*F- XYIO!X':I*;@;LU&@X.PS)S@T]5&<TN!F@*,YJKE-)GEGC/\ Y'_0
M?^NG^->JITKRKQG_ ,C_ *#_ -=/\:]53I2$.[T4=Z* "BBB@ HHHH ****
M"BBB@ HHHH **** "HB=V5-2TP]<D<4 0M'B-T_O"L/1]/>VUZYE9@0P]:WG
MR$8_E6'IANO[=N#*N(B/E- '1T444 %)2TE,!*".**",B@2.0\6Z/+J-NTJ
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!Y1XS_P"1_P!!_P"NG^->JITKRKQG_P C_H/_ %T_QKU5.E #N]%'
M>B@ HHHH **** "BBB@ HHHH **** "BBB@ IAY.*?3&Z<=: &%CL<>E8>EW
MSS:_=0%%"J."!6X<;#^M9=B]LVK3+'M\T#YL=: -JBBB@ HHHH **** "BBB
M@!#12TE !1110"$H-+3<T U<0]:80<U)1BF*&@T"G=J#2]J+ FVQ": :0TJT
M$IOF$QS3@*6B@:6H44E+2*"BEHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1X5.%"^GYUWB;6Z#!JU*YG5ARD^:6H<E1\W-2]JLYTQU)112*%HHHI@%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%(6"C)Z4!@PR* %HI-P%(SA1DGB@!U%(&!'6C(H 6BBD
MR* %HI,B@D 9- "T4F1C-)O7.,T .HI,C%&X @9Y- "T4UI%0@,<$]*4,"<9
MY% "T4A8#J:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3-&X4 +
M12;A1D4 +1129&<4 +1110 4444 %%%% !1110 4444 %%%% !129HS0 M%-
M+JIY-&]?6@!U%)N&,]J0.K+N!XHN ZBF"16Z&EW T#LQU%)FEH$%%)2T %%%
M% !1110 4444 %%%)F@!:*3-&: %HI,BC(H 6BDR*0N ,FBX#J*0,&&12;UW
M;<\T .HHHH **** "BBB@#RCQG_R/^@_]=/\:]53I7E7C/\ Y'_0?^NG^->J
MITH =WHH[T4 %%%% !1110 4444 %%%% !1110 4444 %0D^6V!WJ:F%E!P>
MM $;_)$T@ZXS6'I5ZT^N7"D 8'I6ZS!5;S.%K'TY[<ZU<&,@G% &]1110 44
M44 %%&::7 ZF@!U%)N&1[T%@.IZT !IM!89QWH/ S2Z@MQ!2MGBD'6D?MSS5
M!+8:67Y@>M>6ZS,L'CAR_0J ,UZGLX)[XKA/%WAJ:^D^U6RDSYZ"LIW-\,TG
MJ9?C,YT?:<;V (Q]*[3PTI30[?/4QCK7G\'A_6M3O8TOH'2%1C.?2NVU-;_3
MM+BBL(?-94QBERG3C))P21F>/XV_L]&7L"37':/H\][HPNHG(V@MC=CI7H4V
MGSZOX>5;M"DY3E?>N(71]?TZ+[):VSM">,Y[&DX&N'G%4K7U)=+U.;4M$ELG
M W*Q&1[5D:!I-QJ+72(Y""0AL-BNW\-^&'L[!A,A$K$DY]ZP;CP_J^C7D@T^
M%Y$E8L3GI4<C*4X#_"6I7%MJUS92$%8FV@]?2O3XW$B97K7 ^&/#5S;7<EW=
MJRO*=V#7H$8$25I%-''B7%["J#CYJE[5&<;<D\4X$'C-;(X8Z/4<*6F @GCM
M2E@.M)HN1)13!(I.,\T[<#WH"XM%)FC<* %HI,T9H 6BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)U768-+B
M,ET52,<DM678>,](U6806U]#OSC"FN8^,<C)X=G&>J5X)X-GETGQ!87#Y*2R
M@G% 'V!-,EI SRN-JC))[5S(^(&@[O)%_!(^[&,FLSX@>(4MO":W,+<7&4X/
M7/\ ^NOF:QA9/$*;HV7=(&Y'O0!]KQR+/:K)'C#*""*QM5\3:;H147MW&A;H
M&-6=&D T>R).U1"N<_2OG3XAW$_C#Q2;"T)_<2E">H_SS0!]%Z5KMEK$7FVM
MPD@QG"FM!921C;7SY\*K^YT'Q-<Z/>S B,!1VKW75M1BT[3I+@]D)!_"@!-1
MUW3](A+75U&A'.&-8UM\0_#]S+Y1U"W4YQU->$WEQK/Q%\1M;03E8-S(=PXX
M.*VM1^"UWI^EFZA=&G"Y!4<YH ]\AOK>[17M9EE3U6LC5?&>CZ5=M;W-U"DJ
M]0QYKS?X7MK]A<RVM_YAA4 #*D"N'^*MJ+KXB31*P02.J\^Y- 'M_P#PLO0&
M/_'_   ?4U8T_P >:-J=_':P7<+2,<#!KRFW^#5J]O&QO+;YE#?>'<5O^%OA
M7;:3KD%W'/ YC/12* /6\$'?_K >GM3T!8[LX;N*HW=]#9V<@$Z(T:]S7EFC
M>/[VY\=7=C)=9@3&.>.] 'LO!7G@T]1@=<U5BNH+@*$D5VQG@U90\4 .HHHH
M **** "BBB@ HHHH **** "BBB@ I#2TAZ4 )2$9HHS3)O9B%,C@XI">WZTV
M:39&6STKG8?%UA-=-;;U#AL?>J;FL:4I['29X^]0@YW9SFL]+ZWP2TR8/3FI
M5O[<+Q.@'^]2Y@=*:+U%4O[0M_\ GXC_ .^J/[0M_P#GXC_[ZI\R%R/L7:*I
M?VA;_P#/Q'_WU1_:%O\ \_$?_?5%T'(^Q=HJE_:%O_S\1_\ ?5']H6__ #\1
M_P#?5',@Y'V+M%4O[0M_^?B/_OJC^T+?_GXC_P"^J.9!R/L7:*I?VA;_ //Q
M'_WU1_:%O_S\1_\ ?5%T'(^Q=I,>]4_[0M_^?B/_ +ZI?[0M>\R?]]4FT')+
MHBWCWI,<'YJK?VA:?\]4_.C^T+7_ )[)^=--#<9]B2'D$/USQFG9V$Y&?056
M:]M@V_[1'Q_M5!<:I:QKYK3IA?\ :I.:"%*;>Q8EN4MT>29PB 9YJM:WL%Z/
M,MYU9#V%>1^/_&\]RQMK"?"@X;!S7/>#_&5[I=RL%Q*QBZ5DZD;G?# 5''FL
M?18 ;[IQ4JXSUK%TG7K*^ME=)4!(Y^:M#[7;9R)T'_ JV]I&QQ5(3B[6+F:6
MJ?V^W_Y^(_\ OJD_M"W_ .>\?_?53S(S5.?8NTN:H_VA;_\ /PG_ 'U1_:%O
M_P _"?\ ?55=%<DNQ>S252_M"W_Y^$_[ZH_M"W_Y^(_^^J+H.278NT52_M"W
M_P"?B/\ [ZH_M"W_ .?B/_OJBZ%R/L7:*I?VA;_\_$?_ 'U1_:%O_P _$?\
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M."M:Q(5 E6IQ4,1R2#VJ>M4<BW"D%%%,L=1110(**** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP ]ZYCP=JDNI:<%FQE%QQ73&)7*@$_*:Z8R."NM2T.E%':BJ,PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RCQG_R
M/^@_]=/\:]53I7E7C/\ Y'_0?^NG^->JITH =WHH[T4 %%%% !1110 4444
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M R33%+;^O%3;!05S1<:2N-+8YHX/(IP0"E"@#BBXV-W"CK2[!FG8I"04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ%3YBXW8HWC.TF@":BHSTSGI3 [$YQQ0!/14'1MP;/M4RG(H 6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*/&?\ R/\ H/\
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M<<UFV.G6NE0".&-8T'3:,5H1,S+EACTH ?1110 4444 %%%% !1110 4444
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MH **** "BBB@ HHHH **** "N=\9DCP[= #.8F_E7156OK6&\MVAF3<C#!%
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M $$+W]/\*^FJ* /F7_A!_&O_ $$+W]/\*/\ A!_&O_00O?T_PKZ:HH ^9?\
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M_P"->JI]V@!1TI:04M !3';:1[T^FMG' H :5#'--)"G!Z4X1DC)ZT[!QTH
M9%MP=H/XT_-+CCI1B@!:**0=* %HHHH **** "F$%C@]*?4;%BV.U #'7*E1
M]T]:R-.M;>+6KAXOOD<\UJS$A&1.6-8>E6<]OKEQ(V<,.YH Z6BBB@ HHHH
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M % !.:?2 4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M''_01;_OD_XUZWL7^ZOY4;%_NK^5 'DGE^./^@BW_?)_QH\OQQ_T$6_[Y/\
MC7K>Q?[J_E1L7^ZOY4 >2>7XX_Z"+?\ ?)_QH\OQQ_T$6_[Y/^->M[%_NK^5
M&Q?[J_E0!Y)Y?CC_ *"+?]\G_&CR_''_ $$6_P"^3_C7K>Q?[J_E1L7^ZOY4
M >2>7XX_Z"+?]\G_ !H\OQQ_T$6_[Y/^->M[%_NK^5&Q?[J_E0!Y)Y?CC_H(
MM_WR?\:/+\<?]!%O^^3_ (UZWL7^ZOY4;%_NK^5 'D93QP/^8BW_ 'R?\::8
M?&[<-J+$?[I_QKUQD7^ZOY4S9_LK^5.ZL)1L^9,\4U#PMXFU52LUWG/J*H:?
M\-_$.EW N8;U0P.>!7OFQ>ZC\J:WEHX&W]*R=.+.GZU4M9,\B2P\:NP3^T2%
M7C[O_P!>GR6?C%2$6_/UQ7K+J3@J%Q]*3:I'*C/TJE"*,U4:W9Y0++QJO']I
M'\O_ *]+]D\;?]!(_E_]>O5U1<?,HS]*79'_ '1^5/EB'/<\G^R>-O\ H)'\
MO_KT?9/&W_02/Y?_ %Z]8V1_W1^5&R/^Z/RI<L0YSR?[)XV_Z"1_+_Z]'V3Q
MM_T$C^7_ ->O6-D?]T?E1LC_ +H_*CEB'.>3_9/&W_02/Y?_ %Z/LGC;_H)'
M\O\ Z]>L;(_[H_*C8G]T?E1RQ#G/)_LGC;_H)'\O_KT?9/&W_02/Y?\ UZ]8
MV)_='Y4;(_[H_*CEB'.>3_9/&W_02/Y?_7H^R>-O^@D?R_\ KUZQL3^Z/RHV
M1_W1^5'+$.<\G^R>-O\ H)'\O_KT?9/&W_02/Y?_ %Z]8V1_W1^5&Q/[H_*C
MEB'.>3&U\9JI+ZB2H&<8_P#KUS]EX@\6W6J&R6_;AMO0U[M-'&87&T?=/:O+
M]!L)H?%K.\1V&4G.WWHY8CYB)[7QBN"NH')]J3[+XU)_Y"1_(_XUZLT0+*0H
MQ]*=Y0#DE1CZ4<L0YSRC[)XV_P"@D?R_^O1]D\;?]!(_E_\ 7KUC8G]T?E1L
MC_NC\J.6(N<\G^R>-O\ H)'\O_KT?9/&W_02/Y?_ %Z]8V1_W1^5&R/^Z/RH
MY8ASGD_V3QM_T$C^7_UZ/LGC;_H)'\O_ *]>L;(_[H_*C8G]T?E1RQ#G/)_L
MGC;_ *"1_+_Z]'V3QM_T$C^7_P!>O6-D?]T?E1L3^Z/RHY8ASGD_V3QM_P!!
M(_E_]>C[)XV_Z"1_+_Z]>L;$_NC\J-D?]T?E1RQ#G/)_LGC;_H)'\O\ Z]'V
M3QM_T$C^7_UZ]8V)_='Y4;$_NC\J.6(<YY/]D\;?]!(_E_\ 7H^R>-O^@D?R
M_P#KUZQLC_NC\J-D?]T?E1RQ#G/)_LGC;_H)'\O_ *]'V3QM_P!!(_E_]>O6
M-D?]T?E1L3^Z/RHY8ASGD_V3QM_T$C^7_P!>C[)XV_Z"1_+_ .O7K&R/^Z/R
MHV1_W1^5'+$.<\G^R>-O^@D?R_\ KT?9/&W_ $$C^7_UZ]8V1_W1^5&Q/[H_
M*CEB'.>3_9/&W_02/Y?_ %Z/LGC;_H)'\O\ Z]>L;$_NC\J-D?\ ='Y4<L0Y
MSR?[)XV_Z"1_+_Z]'V3QM_T$C^7_ ->O6-D?]T?E1L3^Z/RHY8ASGD_V3QM_
MT$C^7_UZ/LGC;_H)'\O_ *]>L;$_NC\J-B?W1^5'+$.<\G^R>-O^@D?R_P#K
MT?9/&W_02/Y?_7KUC8G]T?E1LC_NC\J.6(<YY/\ 9/&W_02/Y?\ UZ/LGC;_
M *"1_+_Z]>L;(_[H_*C9'_='Y4<L0YSR?[)XV_Z"1_+_ .O1]D\;?]!(_E_]
M>O6-D?\ ='Y4;(_[H_*CEB'.>3_9/&W_ $$C^7_UZ/LGC;_H)'\O_KUZQLC_
M +H_*C8G]T?E1RQ#G/)_LGC;_H)'\O\ Z]'V3QM_T$C^7_UZ]8V)_='Y4;(_
M[H_*CEB'.>3_ &3QM_T$C^7_ ->C[)XV_P"@D?R_^O7K&Q/[H_*C9'_='Y4<
ML0YSR?[)XV_Z"1_+_P"O1]D\;?\ 02/Y?_7KUC9'_='Y4;$_NC\J.6(<YY/]
MD\;?]!(_E_\ 7H^R>-O^@D?R_P#KUZQLC_NC\J-D?]T?E1RQ#G/)_LGC;_H)
M'\O_ *]'V3QM_P!!(_E_]>O6-B?W1^5&Q/[H_*CEB'.>3_9/&W_02/Y?_7H^
MR^.!]W4R#]/_ *]>L;$_NC\J-BX^51GZ4^6(.1X3J>K^*;#4[:SFO':6<X!Q
M6\(_&WE*$U(J/3:?\:M^+;>>?QSHDD<>4C?YCM^M>E[$ W%1S[4S,\I">.-^
MW^T6_P"^3_C3O+\<?]!%O^^3_C7JL:LSYVKL[<5-L7^ZOY4 >2>7XX_Z"+?]
M\G_&CR_''_01;_OD_P"->M[%_NK^5&Q?[J_E0!Y)Y?CC_H(M_P!\G_&CR_''
M_01;_OD_XUZWL7^ZOY4;%_NK^5 'DGE^./\ H(M_WR?\:/+\<?\ 01;_ +Y/
M^->M[%_NK^5&Q?[J_E0!Y)Y?CC_H(M_WR?\ &CR_''_01;_OD_XUZWL7^ZOY
M4;%_NK^5 'DGE^./^@BW_?)_QH\OQQ_T$6_[Y/\ C7K>Q?[J_E1L7^ZOY4 >
M2>7XX_Z"+?\ ?)_QH\OQQ_T$6_[Y/^->M[%_NK^5&Q?[J_E0!Y)Y?CC_ *"+
M?]\G_&CR_'6/^0FW_?)_QKUK8/[J_E3 I#\JN/I0!Y.(O&SD!M2)QU^4_P"-
M22:7XLB07"7_ .\;J<5ZE'& SDJO/3BA<%L,HP.G% 'E7E^-_P#H(M_WR?\
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M "BBB@ HHHH **** "BBB@ HHHH 0C--\L9SDT^BE9 )MI-@IU%.P##&#W-
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MSCBO1=/CTM9-EOMW ?WA0!KABR D8J1<8X-19)^7-.B4J#DT 24444 %%%%
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MG%MJY-#-W]*S=7^UW%HT=DP20C&6H F;4;-9]AF3=]:L\,0P;*UY#JGA3Q9
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M=03^56D& :KQ+Y,2(@RJJ!5A.E #Z*** "BBB@ HHHH **** "BBB@ HHHH
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M .FT&\^VV">9]ZM<=-K51LK)+6V5(SR!5X$E.1S0 1,Q+ C@=*EID>>XQ3Z
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M;I.H1WT]XT;)"T[,!V()H ]BCWYP0,"IJBCP3UY[U+0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C' S6+X@UJ/2
MK!WR/-9?D'O6Q*S+&2HR?2O*[N/7+WQ%(US:$6L4F4R>"* -;PCIEQJ%\^NW
MB8:=?\_SKNXRJML!.:YNQU.]640Q62K".F.E=,F& ;'.* )**** "BBB@ HH
MHH *3 SG%+10 @4#H*:(D&<*.>M/HH 3:,8QTHP/2EHH C\B+.=@H6"-#E4
M-244 ,>))/O*#2JBJNT# IU% "!0!@"@ #I2T4 %%%% !1110 4444 %%%%
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MQ:DQQ05P*I$4[WU'KR*=34^[3JDT>X4444""BBB@ HHHH **** "@C(P:**
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M$]L4M,5MPS3ZSA>X6$I110*;>HK#J***H84444 %%%% !1110 4444 %%%%
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M>Z"S#CZ4VU\5Z;!;*C"+"#^Z*W-&UNTU4,UHD9(7(P!5RB81F[G2I*%@!E8
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M2WDD4)4@,1TISZ]XEVM@+C_=K&T?4VL)9)A$CC>3EA6Y_P )A<.RJEI 0>O
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M5IKET+A!W+W 0L*E3[N:CQ_ !4B@CK7+&5T=*0ZBBBF,**** "BBB@ HHHH
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M* "BBB@ HHHH **** $P*,4M% !BBBB@ HQ110 F*,"EHH **** $P*6BB@
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K HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gs4n3b54niev000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gs4n3b54niev000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "*!YX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)/M#C?-(7...,FGR-1YA<RO8[JBN"\8_\)=J>O6VD:(LUG8,H,M\HP,]3SU
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *KO864M['>R6D#W48VI.T8+J
M.> V,CJ?SJQ10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!72PLHKV2]CM($NI!M>=8P'8<<%L9/0?E5BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#C?$GP_AU[5?[5@U6]L+[:%\R)L@ >@R"
M/P-5M*^&5O;:K#J6L:O=ZO<0D&/[1G:".F<DD_G7=T5?M)6M<GDC>X4445!0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gapk0ju0ozex000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gapk0ju0ozex000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +\!AL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%07DSV]C<3
M1IODCC9U3^\0,@4 3T5X@_QC\7QHSOX.*JHRS&*8 #UZ5%:_&WQ/?(SVGA:.
MX13@M"LC@'TXH"Q[I17+^!/$>I>)]#EO=4TPZ?.DYC$15AE0 <_-SW/Y5U%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !2,RHI9B HZDFEKD_&]A8:LFG:??WEU;I<7 5?LYP7.#
MP3Z4:]!DVL>/?#>CY2XU&*67IY4!\QB?3"YKE+R:?QD&73?!D:(>!=WR^2?J
M -K5UNG^$O#7AJW:XBLH4V#+SS?,?J2:Z""2*:".6%E:)U#(5Z$'IBBRZBN^
MAS?@CPU?>&M-E@OK]KIY'WJNXE8Q_=&><5U%%%-NXDK!1112&%%%% !1110
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M<W_H!KS;X ?\BIJ?_7]_[(M>D^(O^19U;_KSF_\ 0#7FWP _Y%34_P#K^_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445ROCCQA%X5TT%
M)+V;B%/3W/M0W8F<XPBY2V1K>))$7PSJH9E!-G*!D_[!KSGX!?)X6U-6X8WN
M<'_<6O--5UW4]:G,M_=R3$G(!;@?05#I^IWNE7 GL;B2"0=T.,U'.>8\TCS6
MY=#ZKHK@_A]XZ/B2)K*^VK?1#((Z2#U^M=Y5)W/2IU(U(J4=@HHHIEA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&1LT)W-(58SVW+%%%%,T"BBB@ HHHH **\O\6/\ %,>);L>'50Z5\ODY$/\
M=&?O<]<UQ,/C+XIW'B:3P[%<QMJD6=\/E0\8&3SC'0^M 'T-17F_@IOB6?$*
MCQ2J#3?*;.!#]_C'W>:](H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?.8^.^,$9KF/^$>^$7II/_@<W_Q==SK/A;1/$)B.K:=%=F($)O)^7/T-9/\
MPK'P7_T+]K^;?XTD-LN>$[+PS8V,R>&/LWV8R9D\B8R#=CU)/:NAK-T;P_I7
MA^W>#2;*.UB=MS*F>3Z\UI53=V2@HHHI#"BBB@ HHHH **** "BBB@ HHHH
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M[R_$])HKDM \?Z7K$HM+C-E?@X:"8XY] >]=;33N;0G&:O%A11104%>):/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^()P:Z:BA:; ]=PHHHH \4^)7_)9O"7_ &P_]'&O:Z\4^)7_ "6;PE_VP_\
M1QKVN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#(UOP]9:Y#MG0+,OW)5'S*:YRWU;5?"<ZV>KJUS8DX2Y7DJ/>N
MZJ*XMX;J%H9XUDC88*L,UM"K9<LM5_6QRU<-S2]I3?++OW]>XVUN[>^MUGMI
M5DC89!4U/7#W6AZEX8N'O]#=IK7K):,<\>U;^A^)+/6XL(WEW"\/"_# T3I6
M7-#5?UN*EB;R]G57++\'Z&S1116)UA7DWQID?R]-CS\F2V/?FO6:X;XH>'Y=
M9\.B>V4M-:-YFT=67H?YY_"E+8Y\7%RHR2/ J*""#@C!%%9'S(5['X>U3QW>
MZ%9I8V,$5N(E$=S*0=X]<5Y5H^EW.LZI!8VJ%I)6 Z< >I]J^G].LX]/TZWL
MXAA(4"*/I511Z>74I2;E=I'$#P_XZO@?MOB"WA4]H%*G]!1'\-)I>=0\2:C<
MCNAD.#^M>@45=D>I]7AUN_5LXNU^%OAFWD$CV\LS^KRD@_A6W;>$]!M"#%I-
MIN'0M$I(_2MFBBR+C1IQVBB**WA@&(8DC'HJ@5+113- HHHH **** "BBB@
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M)]<=:\?O-&>R\2ZIHCS*9M/@DG=P.&")OP/J*^HZ^=-?_P"2M>+_ /L'W/\
MZ3BHY4<T\%0G+F:.[^"5O;7'A6?4S @NFNGB\SOM 4@?J:]0KS+X%?\ )/Y/
M^OZ3_P!!2O3:HZ(PC!<L5H%%%%!04444 %%%% !1110 4444 %%%% !1110
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MV?F>DT445P'MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<YJ7CWPOI&H2V%
M_K,$%U$0)(V#97(SV'H10!T=%<E_PL_P7_T,%M_WRW^%:VB>*-$\1F8:1J$5
MWY&/,V _+G..H]C0!KT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !535/^03>?\
M7!__ $$U;JIJG_()O/\ K@__ *": /*/V??^0)K/_7RG_H->Q5X[^S[_ ,@3
M6?\ KY3_ -!KV*@&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %-*(>JJ?PIU% $$EC:S#$EO$WU45GW'A;0KL8GTJVDSZI6O10)Q3W1R\
MOP]\,2=-,CC_ -SBL^?X5^'I6W(UY$?19N/Y5W%%*R,W0I/>*.!_X5FL"XL=
M<O;?&<<[L?K3/^$*\56QS;>+[AL=F3 /ZUZ#119$_5Z?16^;//7TWXBVW_'O
MJ5E< $_ZW(-"7WQ'MA^_L;&X Q_J\@UZ%118/8:W4G]YYZ?&/B^V;%QX0F<#
MNLF ?TJ3_A94D"YOM O8,#)P-U=]119A[.HMI_@CAH/BIH,A"R0WT1/=H>/Y
MU?C^(OAB0#.HK'GM(,5T<MG;3_ZV"-_]Y<UFW'A/P_=',VCV;MZF$9HU#EK)
M:-/Y?\$+?Q9H%UCR-5MGR<<-6A%J%G-_J[J)OHXKGYOAWX8FSG3(TS_<&VLV
M3X2^&V.8EN8SV_>DXHU#FKKHG\_^ =R)$/1U/T-<1\3/$\N@Z(L%HY6ZNB55
MQ_".YJ-OAJ8Q_H7B'4+;G(P<_P!:\X^(6CZAHNI6UO>ZG<:@C1;DDF/W>3P.
M?\YI-NQSXJM4A2?NV\[G',[.Y9R68G))[TE%%9G@'4>!_$]QX=UR'#L;29@D
ML>>#GH?K7T:K!U#*<J1D&ODR/=YB[/O9&/K7U+HAD.@Z<91B0VT>\>^T9JX,
M]G+*C<7!]"_1115GJA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.<?B5C>G7I5/@DF6****@U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M):#_ ,G(ZK_NR?\ HM:]MH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MJZG;S7>E7EM;R^5/- \<<F2-C%2 <CG@UXS-\)/'5Q"\,WC 21.I5T>YG(8'
MJ",<BO<** /"[/X-^,]/@\FR\516T6=VR&>9%SZX KU'P3HFJ>'_  \+'6-1
M^WW0E9_.WL_RG&!EN:Z.B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "H9K2WN!B>"*0'^^@-3447L)I/<P;SP=H=Z/GLE
M0^L9V_RK,D\!B)@VGZM>6V.BASBNQHK6->HMF<T\'0F[N*O]WY''#3O&&GD^
M1J,%U&.BNOS'\2*9_P )-XBL0?[0T)F4?Q0G<?R!KM**KVR?Q13_  )^J2C_
M  ZDE^/YG)V_C[36'^F0W-F>G[V,_P!*V;;Q#I-XH,-_"0>FYMO\ZMS6-I<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX^^(W_)1M?_ .OQ_P"=?8-?
M'WQ&_P"2C:__ -?C_P Z: [']G__ )'B]_Z\&_\ 0TKZ0KYO_9__ .1XO?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO3:**!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAO1-0L/&OB&_N;?9;7<@,+[@=PY[ Y%=E10M'<'JK!1110!XI\2O^2S>$O\
MMA_Z.->UUXI\2O\ DLWA+_MA_P"CC7M= !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XEH/_ "<C
MJO\ NR?^BUKVVO$M!_Y.1U7_ '9/_1:U[;0 4444 %%%% !1110!E:EX=TO5
M4(N;2,L?XU&UOS%8#>%-6TEO,T/57VC_ )8SG(QZ#M7:45K&M.*M?0YJF$I5
M'S-6?=:,XM/%^HZ;((M<TJ5,<&:(97ZFNBT_7M,U1 UK=QL3_"3@_D:OR11R
MH4D174]0PR*Y[4?!6EWK&6!7M)S_ ,M(6Q5<U*>ZMZ&?)B:7POF7GH_O_P"
M=)17$BS\5Z#S;SIJ5LO2.3[P'\S5FS\=V9D6#4K>:QG/&)$.#_A0Z$GK#7T&
ML;!.U5.+\_\ /8ZVBH;>[M[N,26\T<J'NC U-6#5CK335T%%%% PHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\4C_Y.:;_</_I/
M7M=>*1_\G--_N'_TGH ]KHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N)UB
MSU70?$MQK^E:<VI1W4(CFMT?:X*]"/7J:[:BCK=!TLSQF_\ '/B&7Q9IUR?!
MVJQR11.!;$',@)'(X[?UK=_X6-XE_P"B?:Q_WR?_ (FO07L;=[^.]:,&>-"B
MMZ D$_RJQ1TL-[F#X7UR_P!=LI9K_1+K2G1]JQW Y88ZC@5O444V(P_%.G:S
MJ>EB#1-5_LVZW@F;8&X],5P6I>'?B#I>GS7L_CS]W$N3_HZ\UZS63XFTI]:\
M/7EA$VV21/D/N.14/17*C9M)GGUAX7^)-Y807+^-6A:5 QC:W4E<]JMZ'HVO
MZ9XSM1XF\137VY#]EPH1';!R"/7&3^%/M_B4^A6D=GXDT>^M[N(",O%'O20C
MN/K4EGJ.H^-O%&G7D.FSV>E6#-)YLXPTK%2, ?C6BMSZ;$._+[VYZ+1114C"
MBBB@ HHHH **** "BBB@ HHHH \4^)7_ "6;PE_VP_\ 1QKVNO%/B5_R6;PE
M_P!L/_1QKVN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH \2T'_DY'5?]V3_ -%K7MM>):#_ ,G(
MZK_NR?\ HM:]MH **** "BBB@ HHHH **** "BBB@ JK>:;97\92ZMHY5/7<
M.?SJU133:U0G%25F<?=>!_(D\_1;^:SD'1"<I^51#6?$NA\:G8?;(!_RUAZX
M]37:TA (P1D5M[=O2:O_ %W.1X.,7>BW%^6WW;&#IOC#1]2(1;D12GC9+\IS
M6\"",@Y!K(U'PQI.IY,]L%D/_+2/AA6"WAO7M&.[1=2\V(=()^E'+2G\+MZ_
MYB]IB*7QQYEW6_W/_,[:BN-A\:7-A((-=TV6W;IYJ#*G\*Z2PUG3]33=:74<
MGJ >143I3AJUH:TL52JNT7KVV?W%ZBBBLSH"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *\4C_Y.:;_ '#_ .D]>UUXI'_R<TW^X?\ TGH ]KHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KROQ5X6^(^H>);RZT3Q +;3I&4PP_:W3:-H!X"
M\<YKU2B@#P"+X5?$6'6'U:+6+5-1DSON1=/O;(P>=OI7I'P_T3Q=HYO_ /A*
M=5%\)-GD8G:39C.[J!CJ*[>B@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** (Y88IXS'+&KH>H89KF[WP-ID\GG69>RG'1H>@_"NHHJX5)0^%F56
MA3JKWU<X@_\ "7:$>"FIVR^I^>K]CXXTZ9A%?+)939P1*O&?8UU%4;_2+#4T
MVW=K'+_M%1D?0UI[6$OCC\T<_P!7JT_X4_D]?QW+4-Q#<('AD5U/0J<U)7&R
M^"I[%S-H>I2VS#GRF8[#48\1Z_HIV:QIK3Q#CSX #G\*/8J7\-W_  8?6Y4_
MX\&O-:K^OD=M16-IOBC2=3 $5TJ2=XY/E(K8!!&001ZBLI1E%VDCJA4A45X.
MZ%HHHJ2PHHHH **** "BBB@ HHHH **** "O%(_^3FF_W#_Z3U[77BD?_)S3
M?[A_])Z /:Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XOQK/XA%_I
M]IX=U5+:YN"08GA5QM'\1)!/'3\:R&T;XJJC$>)].8@9 %JO/_CM:OC!=1TG
M7+#Q)96DE[%;QM#<01C+;&(.0/P%5#\8/#_,207[W8'_ ![BV?=GTZ4E:WF4
M]S*T<_$R]CDG77M.F:!RDEL]NJL&'8D+W_K7:>$?$4VO64Z7EO\ 9[^TD,-Q
M$.@; .1[<U1\"P:A-_:>L7]LUJ=1G$D<##!50H49'KQ4WARV=?%'B"Z\IXXI
M)E5=RX#D*.1_GM5];/M^.A'FNYU58_BI$?PQ?^9=26JB(GSHR0R>_'-;%0W;
MV\=I*]UL\A5)?>!MQ[YK.6Q4=T>;:%\7?"\.BVL&HZBYN8D".QB=MY'&[..]
M=%HWQ)\,:]J<6G:??-)<RYVJ8G&<#/4CVKF9_'OAUI2-*\'3:G"&VF:"Q&WZ
M_=YKI/"NO^&M<N72PL(;._A&7ADMA'(OZ UHGS.[):Y59'7T445(PHHHH **
M** "BBB@#B]2\3:^?%T^B:-8V,PA@65GN'8'G/''TJ[8W7C)[V);ZPTM+4G]
MXT4CE@/;-<Y_;NE:-\5-6FU&\CMP;6)5,C8SRV:[W3=8T[5X3+I]Y!<H.IB<
M-CZXIQ^%,)?$U_6Q=HKD=>^)7AGPWJTFF:G=RQW4:JS*L#,,$9'(%9O_  NC
MP3_S_P!Q_P" K_X4@.4^)7_)9O"7_;#_ -'&O:Z^>_$WBG2O%GQ9\+WFD3/+
M#%)!$Q>,IAO-)Z'V(KZ$H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0@,,$ @]C2T4 86I^$=(U
M/YGMQ%+VDB^4C\JQ_P"P_$FA MI>H?;(1_RQG.6/XFNUHK:->:5GJO,Y9X.E
M)\R]U]UH<=;^.#;2>1K6GS6CC@R!24KIK/4[+4$#VMS'*#V5N?RJ6XM;>Z0I
M/"DBGLRYKFKWP+9M(9M-GEL)LY_=L=I/OFG>E/\ NO[T1;$TMK37W/\ R_(Z
MNBN)%QXLT$?OXEU.V7^)1\^/H*T=/\;Z5=R>3<,UG/W2<;0/Q-)T)6O'5>14
M<93;Y9^Z^ST_X!TM%-CD25 \;JZGHRG(-.K$ZPHHHH **** "BBB@ KQ2/\
MY.:;_</_ *3U[77BD?\ R<TW^X?_ $GH ]KHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5G:AH6FZFA6ZM(W_V@,&M&
MBFI.+NB90C-6DKHXN7P?J&G2>=H6J21]_*E.0?;/:A?%.L:/\FNZ6VP=9X0=
MM=I36177:ZA@>Q%;>WYM*BO^9R?4^36C)Q_%?=_D9FF^)-*U4#[+=(7/\#'#
M?E6K7/:CX-TF_)D6(V\QYWQ''/O65_9OBK0CFQNUO[<'_5RCD#T%')3G\#MZ
M_P"8>VKT_P")"Z[Q_P M_P SMJ*Y&U\<PQR"#5[2:RF[DC*_G736M]:WT0DM
MITE0]"IJ)TIP^)&]+$4JOP/_ #^XL444A( R3@"LS86O%(_^3FF_W#_Z3UV'
MB+X@I93O:Z:BRR+PTK'Y0?ZUYXNIS+XL_P"$EVQG4N[[>/N[>GTKKA@JLU?8
M\NMG&&I3Y+W]#WZBN/\ #7CJ#5Y5M;Q!!<GA2#\K_P"%=A7/4IRIRY9([J&(
MIUX<]-W04445!L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '.^*XO"JVT=UXGAL7
MCCX1KI V,^E<;_:?P>_Y]]&_\!O_ *U;GB/2K75/'VCQ:G"L]F()"D<@RADR
M,9'0\9J@=(\)Z5XROK34M,TV&&YB62W,L"!!@ $#C /4TE^=RF;W@B]T"]L+
MA_#VF"RM!*02L(C60X^\,=:ZFN-\":A!/)JUC8LKZ?9W&RW=1Q@@$@?0DUV5
M7+H_0A=4%%%<]J8U[3[Q[ZP9+VU.-]FP =?=#W^A(J1FEJNLV&BVWVB_G$2$
MX'!))]@*IZ/XKTC7)3%97!,HY\N1"I/YUB7.K?VK=VNI:9 LU[;*R2:?<_)(
M,]2N>,@C&<X]ZEM(=9U_6;&^O]*_LN.S9G D=6D<E2N/E)&.<]::6NH/;0[&
MBBBD 4444 %%%% !1110 4444 %%%% 'BGQ*_P"2S>$O^V'_ *.->UUXI\2O
M^2S>$O\ MA_Z.->UT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 5[NQM;Z(Q74"2H>SC-<S<^!8(Y&N-(NYK&<_W#Q_\ 6KKJ*TA5G#X6
M8U</2J_&O\_O.)_M/Q5H1Q?6:W]N.LL1Y J'7/'-I<:!,EH9(KN3Y-CK@@=S
M7>5POQ&TR'^R$O(;=!*LH#NJ@'&#UKHHRIU*B4HZ^1P8NG7H4)RISNK;/5_)
MGEU%%%>X?%CD=HW5T8JRG((Z@U[IX;U!M4T"UNG_ -8RX;ZBO":]H\#0M#X5
MMMP(WY;FO/S%+D3\SWL@E+VTH]+'1T445XY]6%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%-,B*<%@#[F@#(\0:UHN@V\=[K$T42HW[MF7<V?8#FN%UOX@_#7Q% L.J
MRFX13E28) 1]"!FMWQ'IUI=>--'O-05)K%4>-5?E5D.""1] :Z7^RM%_Z!]A
M_P!^$_PI6NKL=[/0R?!&I>&[_1V7PRH6SA?8P$97G&>_)KIZ@M;>TMD*VD,,
M2DY(B0*"?PJ>J;NR4K!7+ZA/K.J:O<V&F:C#IZ6ZKN<H&D8G/0$$8XKH+ZZ%
ME92W)C>01KN*1KEC]!7./8>&_&\2WD<A>51@M#,T<B^S $?K4[LKH44TF74-
M6?3=6N(YKR.+S8;^V'ERK@@8;;CUZ=*V-.DUW3[Z.QOT6]M6X2\3 9<#^,?X
M"KNC^']/T*)DLHF#/]]W=G9OQ)-:;,%4LQ 4<DFJO8G<6BLBQ\1Z?J6JRV%E
M(;AH1F26,913Z;NF?:M>D,**** "BBB@ HHHH **** "BBB@#Q3XE?\ )9O"
M7_;#_P!'&O:Z\4^)7_)9O"7_ &P_]'&O:Z "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ JMJ%E%J-A-:3#*2+@^U6:*:;3NA-*2L
MSPO7?#UYH5VT4T;-%GY)0."*R*^AYH(;A-DT22*>S#->,1JO_#0ATK:OV$+D
M0;1MSY&?Y\UZ<,QLO?6I\Y6R"\[TI67F-T#PK?:[+\B&* =97&!^'K7:1W?B
M7PQ$L5S;+?V2<*\0^8#Z"NWCC2) D:*BCH%&!3B 1@C-<]3%NH_>6AWX?*HT
M(^Y)J7?_ (!@Z7XNTK4V\L3>1,.#'-\I!_&MT$$9!R#W%8^J>%]+U529;<1R
M]I8_E85@_P!B^)- ;?IE[]MME_Y83'G\ZRY*<_A=O7_,Z/:XBE_$CS+NO\O\
MCMZ*Y*S\<VXF6VU:VEL;CI\ZG:?_ *U=1;W,%U$);>5)4/1D;(K.=.</B1O2
MQ%.K\#N2T445!L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5R^N_$+PUX:U(Z?JM^T-R$#[!"[<'IR
M!BNHKGM8\#>&O$%_]NU72H[FY*A/,9W!P.@X(H Q?^%P^"/^@L__ (#2?_$U
M>T?XE>%==U2'3=.U%I;J;.Q# ZYP"3R1CH*\FU7PIH<'QSL-!BT]%TN0)OM]
MS8.8R3SG/7WKV'2_A_X5T748M0T[2(H+J+.R19')7(P>IQT- SI:***!!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %<=XA^&^D^)-5;4+N]U.*
M5E"E;>X"+Q[8-=C118=SRN?X5>$XM1@T^;5]8^TS O'&;L9('4_=]ZO?\*8T
M#_H)ZW_X%C_XFM7Q.@TGQ)I_B.6*22U@B>&;RUR4#$'=]./UHG^*'A*&!I%U
M1)' R(D&7/MBBZL%G<L>#-)TC0DO].TN[O+AH9AYWVJ3<RL5!XX'&,5U-<9X
M!2ZO!JFN74#0#4;CS(HVZA H4$_7%=G52OI?>R)TN[!7,ZOX&TK5+@W41FL;
MP_\ +>U?83]1R*Z:BIL.YYY/X'\7JX%CX[NHHA_#)"'/Y\59@^'DUR5.N^(=
M0U%1UCW!%;Z@#/ZUW5% %73]-L]+MEM[*W2&)>RBK5%% !1110 4444 %%%%
M !17#ZCJVI^(_$<V@Z+<&TMK7'VR\7E@3_"OOP:W=%\-Q:+,\JZA?W3N,-]I
MFWCZ@8H6JN#TT-NBBB@#Q3XE?\EF\)?]L/\ T<:]KKQ3XE?\EF\)?]L/_1QK
MVN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN<N/B#<74C)H'A^^U%1TF*B-#]-Q!JI'XM^("R%I_ X$/8I<H6_+=0NXST0
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M)KF? UQ:W>I>(KBSN([B"2]5EDC8$']VO<5V=.UDO-+\@>[79A1112 ****
M"BBB@ HHHH **** "BBB@#)U;PUI&N%6O[-7D48$BL4<?\"4@U)I.@:9HD;+
M86JQ%OO.269OJQY-:5%"TV!ZA1110!XI\2O^2S>$O^V'_HXU[77BGQ*_Y+-X
M2_[8?^CC7M= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>*1_\G--_N'_ -)Z]KKQ2/\ Y.:;_</_ *3T >UT444 %%%%
M !1110 4444 %%%% !1110 4C*KJ5=0RGJ",TM% '.:GX+TR^?SH%:TN.TD!
MV_ITK+V^*O#O(*ZG:+V_B _F37;T5M&O*UI:KS.2>#IM\T/=?E^JV9S6F^-=
M-O7$-QOL[CO',-OZUT:.LBAD8,IZ$'(-9^HZ#INJQE;JU1F[.!@C\JYMO#&M
M:*[2Z'J+R1YSY$YSG\:KEI3^%V?G_F3SXBE\:YEW6_W?Y';45QUOXV>SE%OK
MMA):29QY@4[3]*ZBSU"TU"+S+6>.5?56SBLYTIPW1M2Q-*KI%Z]NOW%FBBBL
MS<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q+6_P#DY/3/]V/_
M -%-7MM>):W_ ,G)Z9_NQ_\ HIJ]MH&%%%% @HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "L3Q'9:#J$5K::[;PW"2RA88Y.[^U;=<=XSG2QU?0
M+^X.+2*YVR,>BDC@G\C2ZI,-;.Q-_P *T\&?]"]9_D?\:Y#53\)='U$V-SI=
MJTRMM?RD+!#[G/%=;XT\66NDZ!(+2XCEOKH>5;1HV26/?BG>#_"%GHWA^.*Y
MMTEN[A?,NI'7)9FY(/YTU=W?8;LK>9H>&+#0+/2Q+X=@@BL[@[\PGACT_I6W
M7%^!X1I^J^(-,AXM;>[!B7LNY%8@?B37:4WK9DV:NF%%%%(84444 %%%% !1
M110 4444 %%%% !1110 4444 >*?$K_DLWA+_MA_Z.->UUXI\2O^2S>$O^V'
M_HXU[70 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7BD?_ "<TW^X?_2>O3M3\:>&]&OFLM2UBVMKE "T<A.0",BO'$\3:
M*/CZVMG48/[,V$?:<_)_J=O\^* /H"BL+2_&?AS6KY;+3=7MKFY8%ECC)R0.
M36[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $-Q:6]W&8[B%)
M%/4,*Y>]\#QI)]HT:[EL9QT .5_*NNHK2%6</A9C5P].K\:_S^\XE=<\1:"0
MFL6)NK<?\MX>WN:W]+\3:7JP M[E1(?^6;\-^5:Q 88(!'O6!J?@_2M1)D$7
MD3]1)%P<^]7STY_$K/R_R,/9XBE_#ES+L]_O_P SH**X@VOBKP\?]&E74K1?
MX'^_BM#3O&^GW#B"]5[*XS@K*.,^QH="5KQU7D5'&0ORU%ROS_SV.GHID<L<
MJ!XW5U/0@YI]8'6%%%% !1110 4444 %%%% !1110 4444 >):W_ ,G)Z9_N
MQ_\ HIJ]MKQ+6_\ DY/3/]V/_P!%-7MM PHHHH$%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5B^(+C1GC32]9"&&[! $B_*2.V>QYK:JKJ&G6F
MJ6CVM[ DT+]5<9I,:.7T/X9>%=$OUU"QM"\H.4:23>%^E=E7#MX&U/3F)\/^
M([NUC[0W!\Y%^F[)J!=#^)+2%9O%6G"'U2U&[_T"G>^@K=3J;>QT_06OKUIA
M']ID\V9Y&[@ ?R%6]-U*VU6T%U:L6A8D*Q4C.*Y>T\ B:X6YU_5;K574Y$3L
M5B!_W!P?Q%=C'&D,:QQHJ(HPJJ, "GT#J.HHHI %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'BGQ*_Y+-X2_[8?^CC7M=>*?$K_DLWA+_MA_Z.->UT %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %/-;-%%>'*3E)R?4^SIP5."A'9!1114EA1110 4444 %%%% !1110 4444
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MT'\Z( 8? .,T)7:7<=M&^QW5%%% @HJEJNIV^CZ9/?W3A8HEW'WJ/0[N\O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'B6M_\G)Z9_NQ_^BFKVVO$M;_Y
M.3TS_=C_ /135[;0,****!!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '#>/-;CT:_TV2SM9KK62Q\B"(<NO\ $#[=*S?^$^\9?]$^O_\
MOY_]C6EXOU72O#GBC2=7O[F.-BCPE6Z[#@EA]"!^=6O^%H>#/^@Y;_K_ (4E
ML-[FCX6UG5-:LIIM5T2;2I4?:L4K9+#'7H*WJS-%\0Z5XAMWGTJ[2YBC;:S)
MV-:=4]R4%%%%(84444 %%%% !1110 4444 %%%(QPI(H>@$-Q>6UHNZXGCB'
M^TV*?#/%<('AD5U/=3FO,O!VDV7C*YU34_$4"WEU'<M$D$_S+$HZ8%/CMD\*
M_%&PTW1<QV-]"S3VJ'Y$(QA@.W6FEJD^O^5PEI?R_P ['IU%%%(#Q3XE?\EF
M\)?]L/\ T<:]KKQ3XE?\EF\)?]L/_1QKVN@ HHHH 89H@<&1 1_M"CSHO^>J
M?]]"O-]1^$,6H:E=7AUN9#<2M+L$ .W<2<?>]ZK?\*6A_P"@]-_X#C_XJE=]
MCE=7$7TI_BCFOB/XPN=5UB73K:9DL;<[<*?OMZFN#R<YSSZU;U73Y=*U2YL9
ML[X7*D^OH?RJG63/ KU)3J-RW.Z^'GC&[TC6(;"XF+V,[;2K'[A]17O/G1?\
M]4_[Z%?*^F6,NIZE;V4.=\SA1@=*]7_X4M#_ -!Z;_P''_Q57%L]'!5JW):,
M>9+S/4?.B)P)$_[Z%/KS*S^#T5I?6]R-<F;R9%DVF #.#G'WJ]-JM3TZ4JDO
MCC;YW/,O -_:66N^*#<W$<0^V9^<X["G7ERGC+X@Z/+I(:2STIC)-= ?*2<?
M*#^%5O FB:9J7B;Q)/>V,$\L=WA'D3)48'2O4(H(K:+9#&J(!PJC IQT4)/H
ME^1J]Y)=6_S,'4M&UF_N9677GL[<_P"K2!,,/JV>?RK(\&:UJC>(-6\/ZI="
M\>RPT=P!@LI]?>J&ES3>+_$6LC4=4N+6TL)_*CM(9?+W#GEO7I53P1]AM?B=
MKUM:S9C,0V;FR6P1G![T0W2[JXIO3T:+T&L^(M2^(&L:+:7445K!&C"1UR8\
M@9P,\GFH+^_\2>$_%=C9'4CJ5MJ641;C@QO]?2I_#/\ R5OQ-_UQC_DM+X\_
MY';PG_U\&G!?P_.P3=N=]AGB\>)_#>DG7XM<:9H"&FM2F(F7V&:O^-?$]]IO
M@2WUC3F5)Y7C^\,C!SFIOBE_R3S5/^N=<[XZ_P"21Z=_OP_UJ5JK>:_$N*]^
M/HSI=-/B&&677-9OXDL5MR5LHUX7H02V>3^'>LS2U\0^+=.;6AK4FG1R$M:6
M\(XV]M_KGCTKI=9M9;WP7=6T.?,DML+CZ5Q_@#3=,U7PI:QRW]['<P+Y4T/V
MDKL(XZ53U;7;_@D)^ZGW$/B'6];\#ZI]GN6MM:TF4K*\/ D"G)X]U%=GH.N1
MZCX3M=6=\@P;Y"?5>OZ@TW1/#.D:.EVM@&;[4?WY:3<6..]>=2W5QHNF:YX1
M4D3370CM!ZQRX!(^A9ORI.[NEN[??L_\RK+1]$_P-G1;O5-5\#Z_JNHW4LD=
MP)?L\;'A$ P,?K3="N[BP^"1NK65HIXK9F1UZJ:Z;4-/CTOX?W-E$,+#9LN/
M?'-<SH=K)>?!%K>%=TCVK!1ZU,[+GMT2_4JGJX-]6_T.K\$7MSJ'@O2[N[F:
M:XEMU9Y&ZL<=:P_!.L:AJ&M>*(KN[DFCM;ID@5SP@YX%7?AU>VS?#_3/WR#R
M8 D@)P5('.:Q_ARAEOO%=^G-O/>OY;]F )Y%:U/XDK=G^:(A_#U[K]2+PCJ7
MB;Q4NJ1OJ*VUO;WDD0E5<N0"0 .>/KS1INI^*++Q;=^%I+^.[9HQ+!=S+\R+
MWR,\]/:I_A+_ ,>>N_\ 82E_F:5/^2W'_KP_^*J;>]%=U_[;<EOW9/L_UL,U
MFYU_PCKNE7,NL/?6-[.(9H95QLSCE?SKL=6L]3OA"MAJ*V46"92(]S'TP<C'
M>N5^*/\ JM"_Z_U_F*/$^JWMQXNTKPW%?26%K<1&26:,[6;&/E![=:2U5O-K
M\$RGH[^7ZM%>XU#6_"?C#2K*;5GU*PU%F0B;[\9Z\&JWCX73?$GPNMDR)<%9
M C.,@<'G%9_BNPTO1O&GAD07<LCB<^8\TN\CCC)K4\;3QP?$[PK/(VV)5?<W
M89!']:<-7'U?Y%/3F_PEKQ-;^*O#EB=<M=;:\$&&N+61,(RYYV\\<?6NVTC4
M$U72;6_C^[/&'Q7/_$#6+2S\&WR^:KR7,9AB1#DLS<#'YUI>#[&33?".F6DH
M(DCA&X'MGG^M*.S\K?\ !_0E[KY_H8?C:3[=KOA_0^L=Q<&68>JKCC]:Z37K
MB2P\/WD]N=LD4)*'T(KEM?!B^*7AZ5S\CQ2(OU^6NE\4_P#(K:E_UP:HDW[%
MOU_R*2_>)>AR7A<^)O%OA6VO;G5S8^8GRM N78^I/]*M^!]<U.34-6T36KA;
MBXTYLB<#&].Q/OS5KX8_\D^TK_KD*R?"N?\ A97BO"ACL3 /?A:UEI4<5V?Z
M&2=Z:?FCHW\>>%8Y&C?7;-74D,"_0BK.G>+- U:[%KI^JVUQ.02(XVR<"N9F
M?Q)Y\FSP5I3KN.&-V02,]?\ 5UH: VMG5%%]X8L+"':<SPW!=@?3&P?SI1U+
M>AFVUW:VWQ:U62XN$B LHE&\XYR]=[#/%<)OAD613W4YK)U#PCX?U:Z:ZO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR#BK0  P!@"A:7!ZV04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFG@O89;;F96!3CO7H']N>//^@2/^_!_QK.\%>%+FZOXM0NXS';1'<H8<N?\
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M*U/A4Z3:'?S$YN'O9#,3USG_  Q5O1O!MYHWBR?5DU(SQ7<>+I)%Y9O4>@J
M^$-6T'5[N_\ "]Y D5VWF2V=P"$W>H(SC\J(Z))]K?B#5V_6_P"!%\79I8O"
M42(,I)<QK("< C/0^U7;J'Q-J&B-9)I^GK#+%LYGSQC_ ':O7.@W?B/P[<:;
MXC\C=-T^SDD)Z$$@<UFV6G^.-*CCLH;K3KRUC^59IV9) OT"G/YT65G%]?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \2UO
M_DY/3/\ =C_]%-7MM>):W_R<GIG^['_Z*:O;:!A1110(**** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M #VO?_ 8_P"- 'HU%><_\+N\&_\ /:]_\!C_ (T?\+N\&_\ /:]_\!C_ (T
M>C45YS_PN[P;_P ]KW_P&/\ C1_PN[P;_P ]KW_P&/\ C0!Z-17G/_"[O!O_
M #VO?_ 8_P"-'_"[O!O_ #VO?_ 8_P"- 'HU%><_\+N\&_\ /:]_\!C_ (T?
M\+N\&_\ /:]_\!C_ (T >C45YS_PN[P;_P ]KW_P&/\ C1_PN[P;_P ]KW_P
M&/\ C0!Z-17G/_"[O!O_ #VO?_ 8_P"-'_"[O!O_ #VO?_ 8_P"- 'HU%><_
M\+N\&_\ /:]_\!C_ (T?\+N\&_\ /:]_\!C_ (T >C45YS_PN[P;_P ]KW_P
M&/\ C1_PN[P;_P ]KW_P&/\ C0!Z-17G/_"[O!O_ #VO?_ 8_P"-'_"[O!O_
M #VO?_ 8_P"- 'HU%><_\+N\&_\ /:]_\!C_ (T?\+N\&_\ /:]_\!C_ (T
M>C45YS_PN[P;_P ]KW_P&/\ C1_PN[P;_P ]KW_P&/\ C0!Z-17G/_"[O!O_
M #VO?_ 8_P"-'_"[O!O_ #VO?_ 8_P"- 'HU%><_\+N\&_\ /:]_\!C_ (T?
M\+N\&_\ /:]_\!C_ (T >C45YS_PN[P;_P ]KW_P&/\ C1_PN[P;_P ]KW_P
M&/\ C0!Z-17G/_"[O!O_ #VO?_ 8_P"-'_"[O!O_ #VO?_ 8_P"- 'HU%><_
M\+N\&_\ /:]_\!C_ (T?\+N\&_\ /:]_\!C_ (T >C45YS_PN[P;_P ]KW_P
M&/\ C1_PN[P;_P ]KW_P&/\ C0!Z-17G/_"[O!O_ #VO?_ 8_P"-'_"[O!O_
M #VO?_ 8_P"- 'HU%><_\+N\&_\ /:]_\!C_ (T?\+N\&_\ /:]_\!C_ (T
M>C45YS_PN[P;_P ]KW_P&/\ C1_PN[P;_P ]KW_P&/\ C0!Z-17G/_"[O!O_
M #VO?_ 8_P"-'_"[O!O_ #VO?_ 8_P"- 'HU%><_\+N\&_\ /:]_\!C_ (T?
M\+N\&_\ /:]_\!C_ (T >C45YS_PN[P;_P ]KW_P&/\ C1_PN[P;_P ]KW_P
M&/\ C0!Z-17G/_"[O!O_ #VO?_ 8_P"-'_"[O!O_ #VO?_ 8_P"- 'HU%><_
M\+N\&_\ /:]_\!C_ (T?\+N\&_\ /:]_\!C_ (T >C45YS_PN[P;_P ]KW_P
M&/\ C1_PN[P;_P ]KW_P&/\ C0!Z-17G/_"[O!O_ #VO?_ 8_P"-'_"[O!O_
M #VO?_ 8_P"- 'HU%><_\+N\&_\ /:]_\!C_ (T?\+N\&_\ /:]_\!C_ (T
M>C45YS_PN[P;_P ]KW_P&/\ C1_PN[P;_P ]KW_P&/\ C0!Z-17G/_"[O!O_
M #VO?_ 8_P"-'_"[O!O_ #VO?_ 8_P"- 'HU%><_\+N\&_\ /:]_\!C_ (T?
M\+N\&_\ /:]_\!C_ (T >C45YS_PN[P;_P ]KW_P&/\ C1_PN[P;_P ]KW_P
M&/\ C0!Z-17G/_"[O!O_ #VO?_ 8_P"-'_"[O!O_ #VO?_ 8_P"- 'HU%><_
M\+N\&_\ /:]_\!C_ (T?\+N\&_\ /:]_\!C_ (T >C45YS_PN[P;_P ]KW_P
M&/\ C1_PN[P;_P ]KW_P&/\ C0!Z-17G/_"[O!O_ #VO?_ 8_P"-'_"[O!O_
M #VO?_ 8_P"- 'HU%><_\+N\&_\ /:]_\!C_ (T?\+N\&_\ /:]_\!C_ (T
M>C45YS_PN[P;_P ]KW_P&/\ C1_PN[P;_P ]KW_P&/\ C0!Z-17G/_"[O!O_
M #VO?_ 8_P"-'_"[O!O_ #VO?_ 8_P"- 'HU%><_\+N\&_\ /:]_\!C_ (T?
M\+N\&_\ /:]_\!C_ (T >C45YS_PN[P;_P ]KW_P&/\ C1_PN[P;_P ]KW_P
M&/\ C0!Z-17G/_"[O!O_ #VO?_ 8_P"-'_"[O!O_ #VO?_ 8_P"- 'HU%><_
M\+N\&_\ /:]_\!C_ (T?\+N\&_\ /:]_\!C_ (T >C45YS_PN[P;_P ]KW_P
M&/\ C1_PN[P;_P ]KW_P&/\ C0!Z-17G/_"[O!O_ #VO?_ 8_P"-'_"[O!O_
M #VO?_ 8_P"- 'HU%><_\+N\&_\ /:]_\!C_ (T?\+N\&_\ /:]_\!C_ (T
M>C45YS_PN[P;_P ]KW_P&/\ C1_PN[P;_P ]KW_P&/\ C0!Z-17G/_"[O!O_
M #VO?_ 8_P"-'_"[O!O_ #VO?_ 8_P"- 'HU%><_\+N\&_\ /:]_\!C_ (T?
M\+N\&_\ /:]_\!C_ (T >C45YS_PN[P;_P ]KW_P&/\ C1_PN[P;_P ]KW_P
M&/\ C0!Z-17G/_"[O!O_ #VO?_ 8_P"-'_"[O!O_ #VO?_ 8_P"- 'HU%><_
M\+N\&_\ /:]_\!C_ (T?\+N\&_\ /:]_\!C_ (T >C45YS_PN[P;_P ]KW_P
M&/\ C1_PN[P;_P ]KW_P&/\ C0!Z-17G/_"[O!O_ #VO?_ 8_P"-'_"[O!O_
M #VO?_ 8_P"- 'HU%><_\+N\&_\ /:]_\!C_ (T?\+N\&_\ /:]_\!C_ (T
M>C45YS_PN[P;_P ]KW_P&/\ C1_PN[P;_P ]KW_P&/\ C0!Z-17G/_"[O!O_
M #VO?_ 8_P"-'_"[O!O_ #VO?_ 8_P"- 'HU%><_\+N\&_\ /:]_\!C_ (T?
M\+N\&_\ /:]_\!C_ (T >C45YS_PN[P;_P ]KW_P&/\ C1_PN[P;_P ]KW_P
M&/\ C0!Z-17G/_"[O!O_ #VO?_ 8_P"-'_"[O!O_ #VO?_ 8_P"- 'HU%><_
M\+N\&_\ /:]_\!C_ (T?\+N\&_\ /:]_\!C_ (T >C45YS_PN[P;_P ]KW_P
M&/\ C1_PN[P;_P ]KW_P&/\ C0!Z-17G/_"[O!O_ #VO?_ 8_P"-'_"[O!O_
M #VO?_ 8_P"- 'HU%><_\+N\&_\ /:]_\!C_ (T?\+N\&_\ /:]_\!C_ (T
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ME(.?PXKUC_A77@[_ *%VP_[]UYW\2O\ DLWA+_MA_P"CC7M= SF/^%=>#O\
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MPRY=0?T-2?#?P5X9U3P!I5[?:+:7%S*CEY9$RS8=AS^ K9^+W_),M6_[9?\
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M='_"NO!W_0NV'_?NNGHH YC_ (5UX._Z%VP_[]T?\*Z\'?\ 0NV'_?NNGHH
MYC_A77@[_H7;#_OW1_PKKP=_T+MA_P!^ZZ>B@#F/^%=>#O\ H7;#_OW1_P *
MZ\'?]"[8?]^ZZ>B@#F/^%=>#O^A=L/\ OW1_PKKP=_T+MA_W[KIZ* .8_P"%
M=>#O^A=L/^_=5M0^'OA&+3;J1/#]BKK"[*1'T(!KL*J:I_R";S_K@_\ Z":
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %-M)L&U1=3:TB-
M\J>6L^WY@OIFKE%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8]UX4T&]N?M%
MSI5M+-G.]DYS6A:65K8Q>5:P1PI_=1<58HH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** *FHZ78ZM;"WU"UBN80P;9(N1D=#5I5"J%48 & *6B@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gapk0ju0ozex000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gapk0ju0ozex000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -K!B@# 2(  A$! Q$!_\0
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MFC- #J*;FC- #J*;FC- #J*;FC- #J*;FC- #J*;FC- #J*;FC- #J*;FC-
M#J*;FC- #J*;FC- #J*;FC- #J*;FC- #J*;FC- #J*;FC- #J*;FC- #J*;
MFC- #J*;FC- #J*;FC- #J*;FC- #J*;FC- #J*;FC- #J*;FC- #J*;FC-
M#J*;FC- #J*;FC- #J*;FC- #J*;FES0 M%)FEH **** "BBB@ HHHH 2D)I
M":C9J '%J;NJ%I,5"TU %O?[TF^J1G]Z;]H]Z +^_P!Z-_O5#[1[T?:/>@"_
MO]Z-_O5#[1[T?:/>@"_O]Z-_O5#[1[T?:/>@"_O]Z-_O5#[1[T?:/>@"_O\
M>C?[U0^T>]'VCWH O[_>C?[U0^T>]'VCWH O[_>C?[U0^T>]'VCWH O[_>C?
M[U0^T>]'VCWH O[_ 'HW^]4/M'O1]H]Z +^_WHW^]4/M'O1]H]Z +^_WHW^]
M4/M'O1]H]Z +^_WHW^]4/M'O1]H]Z +^_P!Z-_O5#[1[T?:/>@"_O]Z-_O5#
M[1[T?:/>@"_O]Z-_O5#[1[T?:/>@"_O]Z-_O5#[1[T?:/>@"_O\ >C?[U0^T
M>]'VCWH O[_>C?[U0^T>]'VCWH O[_>C?[U0^T>]'VCWH O[_>C?[U0^T>]'
MVCWH O[_ 'HW^]4/M'O1]H]Z +^_WHW^]4/M'O1]H]Z +^_WHW^]4/M'O1]H
M]Z +^_WHW^]4/M'O1]H]Z +^_P!Z-_O5#[1[T?:/>@"_O]Z-_O5#[1[T?:/>
M@"_O]Z-_O5#[1[T?:/>@"_O]Z-_O5#[1[T?:/>@"_O\ >C?[U0^T>]'VCWH
MO[_>C?[U0^T>]'VCWH O[_>C?[U0^T>]'VCWH O[_>C?[U0^T>]'VCWH O[_
M 'HW^]4/M'O1]H]Z +^_WHW^]4/M'O1]H]Z +^_WHW^]4/M'O1]H]Z +^_WH
MW^]4/M'O1]H]Z +^_P!Z-_O5#[1[T?:/>@"_O]Z-_O5#[1[T?:/>@"_O]Z-_
MO5#[1[T?:/>@"_O]Z-_O5#[1[T?:/>@"_O\ >C?[U0^T>]'VCWH O[_>C?[U
M0^T>]'VCWH O[_>C?[U0^T>]'VCWH O[_>C?[U0^T>]'VCWH O[_ 'HW^]4/
MM'O1]H]Z +^_WHW^]4/M'O1]H]Z +^_WHW^]4/M'O1]H]Z +^_WHW^]4/M'O
M1]H]Z +^_P!Z-_O5#[1[T?:/>@"_O]Z-_O5#[1[T?:/>@"_O]Z-_O5#[1[T?
M:/>@"_O]Z-_O5#[1[T?:/>@"_O\ >C?[U0^T>]'VCWH O[_>C?[U0^T>]'VC
MWH O[_>C?[U0^T>]'VCWH O[_>C?[U0^T>]'VCWH O[_ 'HWU0^T>]+]H]Z
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M[T 7M_O1O]ZH_:/>C[1[T 7M_O1O]ZH_:/>C[1[T 7M_O1O]ZH_:/>C[1[T
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M VP_[^1__%T>1\6?^@;8?]_(_P#XNO8**/;?W4'L_-GC_D?%G_H&V'_?R/\
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M4'L_-GC_ )'Q9_Z!MA_W\C_^+H\CXL_] VP_[^1__%U[!11[;^Z@]GYL\?\
M(^+/_0-L/^_D?_Q='D?%G_H&V'_?R/\ ^+KV"BCVW]U![/S9X_Y'Q9_Z!MA_
MW\C_ /BZ/(^+/_0-L/\ OY'_ /%U[!11[;^Z@]GYL\?\CXL_] VP_P"_D?\
M\71Y'Q9_Z!MA_P!_(_\ XNO8**/;?W4'L_-GC_D?%G_H&V'_ '\C_P#BZ/(^
M+/\ T#;#_OY'_P#%U[!11[;^Z@]GYL\?\CXL_P#0-L/^_D?_ ,71Y'Q9_P"@
M;8?]_(__ (NO8**/;?W4'L_-GC_D?%G_ *!MA_W\C_\ BZ/(^+/_ $#;#_OY
M'_\ %U[!11[;^Z@]GYL\?\CXL_\ 0-L/^_D?_P 71Y'Q9_Z!MA_W\C_^+KV"
MBCVW]U![/S9X_P"1\6?^@;8?]_(__BZ/(^+/_0-L/^_D?_Q=>P44>V_NH/9^
M;/'_ "/BS_T#;#_OY'_\71Y'Q9_Z!MA_W\C_ /BZ]@HH]M_=0>S\V>/^1\6?
M^@;8?]_(_P#XNCR/BS_T#;#_ +^1_P#Q=>P44>V_NH/9^;/'_(^+/_0-L/\
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M?]_(_P#XNO8**/;?W4'L_-GC_D?%G_H&V'_?R/\ ^+H\CXL_] VP_P"_D?\
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MG_H&V'_?R/\ ^+KV"BCVW]U![/S9X_Y'Q9_Z!MA_W\C_ /BZ/(^+/_0-L/\
MOY'_ /%U[!11[;^Z@]GYL\?\CXL_] VP_P"_D?\ \71Y'Q9_Z!MA_P!_(_\
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M#;#_ +^1_P#Q=>P44>V_NH/9^;/'_(^+/_0-L/\ OY'_ /%T>1\6?^@;8?\
M?R/_ .+KV"BCVW]U![/S9X_Y'Q9_Z!MA_P!_(_\ XNCR/BS_ - VP_[^1_\
MQ=>P44>V_NH/9^;/'_(^+/\ T#;#_OY'_P#%T>1\6?\ H&V'_?R/_P"+KV"B
MCVW]U![/S9X_Y'Q9_P"@;8?]_(__ (NCR/BS_P! VP_[^1__ !=>P44>V_NH
M/9^;/'_(^+/_ $#;#_OY'_\ %T>1\6?^@;8?]_(__BZ]@HH]M_=0>S\V>/\
MD?%G_H&V'_?R/_XNCR/BS_T#;#_OY'_\77L%%'MO[J#V?FSQ_P CXL_] VP_
M[^1__%T>1\6?^@;8?]_(_P#XNO8**/;?W4'L_-GC_D?%G_H&V'_?R/\ ^+H\
MCXL_] VP_P"_D?\ \77L%%'MO[J#V?FSQ_R/BS_T#;#_ +^1_P#Q='D?%G_H
M&V'_ '\C_P#BZ]@HH]M_=0>S\V>/^1\6?^@;8?\ ?R/_ .+H\CXL_P#0-L/^
M_D?_ ,77L%%'MO[J#V?FSQ_R/BS_ - VP_[^1_\ Q='D?%G_ *!MA_W\C_\
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M ,4CH_\ UZ1?^@BND!XKFO!W_(I:1_UZ1?\ H(KI!TJ9_$RH[(BF-<'\*?\
MD=O&?_7S_P"U)*[J>N%^%'_(Z^,_^OG_ -J25I3^"7]=2)_%$]:HHHK$T"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>VL-8FDQ.90I3:I96QN5NI ->9:]XR^+/A_Q!;:'-X@M+K4;@@+#:6\+D$G
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M EP.<9[]3CTKT>O'?C/ FG>(/"/B"V&R^BU!(MR]77.<'UZ8_$U["IRBGU%
M'GGQ'\7ZSX1UKP[+:O%_95Y<^1=AXLD<C!#=N"?RKT!ID6W,Y8",)OS[8S7#
M_&'1CK'PXO\ RP3-9E;J,@<@KU_0FL?7O&07X$IJL;9N+RT6W3'7>WR_IUH
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M7?UV^7TV]L=/;M0!ZG17F6E>-;WQ'\)M:OY&:WU:R@FBF>$[<2*#\RXZ5C^
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M[:,$EG?T5NHQ7(ZQ)K/PU\9Z&EMXNU#6++4)A!<VFHW F=#D8(_NYW#H!TH
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MJ45YE_POOP)_S^7G_@*U=5X8\=>'O&$;'1]02611EH6&V11ZE3SB@#HZ***
M"BBB@ HHHH **** "BBLCQ)XETWPII7]I:K)(EMO6/*(6.3TX% &O138W66-
M9%^ZP!'T-.H **** "BBJVH7T&F:?<7UR2(+>,R2$#) ')XH LT5YE_POOP)
M_P _EY_X"M6AHWQC\%ZYJ,=C;:D\4TAPGVB(QJQ/  )[T =[1110 4444 %%
M%8WA[Q1IGB>&YETR21UMIC#)O0KAA]: -FBBL:S\4:9?>);S0())#?V<8DF4
MH0H4G'![]: -FBL;2_%&F:QK&I:79R2-=:<_EW 9" #['O6S0 4444 %%%%
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M9V=MI]I%:6D"06\2[8XXQA5'H!4-CH^G:9+<RV-E!;R7+[YVC0 R-ZGU- '
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M33TIU-/2@""2J%QWJ_)5"X[T >;V_P#R7S3_ /KT;_T6]>P5X_;_ /)?-/\
M^O1O_1;U[!6U;[/H9T^OJ%%%%8F@4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4AZ4M(WW30!POB"3S=>QVCA _,FLYA5[6QMUXD_Q
MQ?R)JFPKUJ'\-'F5OXC("*C85.PJ)A6QD5G=595/4TUA5JVL'O(Y)<'!X6JP
M##*.,.IP:SC4C*3BNA4J;C%2?4B85$PJP143"M"!D.1<Q$==XQ^=>OV9)MDS
MUQ7E.G0&?4H$'][)_"O5[1=L"_2N#&/WDCNPBT;)Z***XCK"BBB@#R?]H$A?
M EJQ. +Z,G\C6]%\7O 2PHI\1VX(4 _NI/\ XFL']H$!O MJ",@WT8/Y&NEA
M^%G@9H8R?#5B25!/RG_&@#SSQCXOT'Q5\1_ YT/48[P6]S)YNQ6&W=LQU ]#
M72>./^2P>"?]Y_YUS_C;PMH?AKXC^!AHNF060GN9/-\H$;L;,9_,_G70>./^
M2P>"?]Y_YT 9OQ5NM*LOB5X1N-;\G^SD5S-Y\>],<]5P<_E6G_PF'P:]= _\
M%O\ ]KJG\2=-L]7^*O@VQU"W2XM9@XDB?HPYKK?^%5^!?^A9L?\ OD_XT ;^
MAQZ1_9<,^B6]M%8W"B6/[-"(U<'H< "M&L/51J.A>'HX?"^CP7<L&V.*T:81
M*$_WCZ"L32-;^(%SJD,.J^$+.SLF)\V=-120IP<84=><4 1ZW\2&MM?DT+P[
MH5SKVHP<W"0RB)(A[L01GVK+O/C''IMH8=1\/W-IKHG2(Z9-,/F#' 99 I##
M\*K_  5.YO$[W'_'^=0/G;OO8YQ4/Q2CTU_B+X)%T5$AN#OX!.W^']<T >M0
MN\D$;NFQV4%DSG:<=,UP7QI_Y)AJ7U3^=>@5Y_\ &G_DF&I?5/\ T*@#0\+>
M%/#DWA'1I9= TJ21[&%G=[.,EB4&23CDUYY\4?#=KX!U33/''AR);*2*Z5+F
MWB^6.13[#H#T('K7K7A'_D3-#_[!\'_HM:\V^/=\EWI.E>&K9@^H7]VFV->3
MCIG'U(H ] \1^,]+\+Z/#?WID=KC @MX5W22L1T KEV^)^M:=$E[KW@34-.T
MDXW7:7*3% >A*  @>OI7,_$2WU5/B3X/L=.N+2&5+;%N]XI:(2 D<@=^*Z'4
M](^*%SI=W#?:]X8%I)"RS%K=P F.3DCCCO0!V>H^+='TSPN?$4USNTXQB1'0
M9+YZ #U-<<OQ5U2*U_M2^\#ZE;:(V2M[YZLVW^$F/&0#W]/>N(UW3GTCX<>%
M;";4[/4]/750)Y[.3="4SP,^QKW76$@.@WR3!?(^S.&!Z;=IH YSPYX_C\1>
M![_Q-'IYBCM/.(A\[=O$:Y^]M&,_2L'2_BQJ?B"UANM#\%7E[;X47$WVI46)
MSU RN7QZ@5D?#<(/@9X@$7^K_P!-VX]-G%=5\&X8X?AAI6Q0-X9F]R2<T 3>
M(/B'_9NM_P!@Z+HMQK>M*@DFMH)5C2)3_><]^G&.]5-%^)\EQXIA\.^(?#MU
MH5_<#-N))A,DGMN &/UK*'B>=O&>M1^!?!\&H7D3*FI7LMP(0[CH 3UQR/PK
MF/$DGB>;XH>"KCQ(EA;22WBF&TMFWO"N\9#-T;\* /4?%_CRU\+W%MI\-C/J
M>KW0S!96Y +#/5F_A'O@UY?\5/&UYJ?A%M(UOPY=Z'?O<12P+)*LR2J&YPZ@
M 'VKI].7=^T3JYNA\RV$?V7=_=VC=C\:7X_1VS> K=Y0OG)?1^43USSG],T
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M4K&3?;7*!XVQSCW]ZSO&G_(DZU_UYR?^@FJ_@7Q/9^+?"\.HV=K]D4,8I+?
M'EN.HX^M6/&G_(DZU_UYR?\ H)H \[^%4'@I_AQI3:K%H#7I$GF&Z6$R?ZQL
M9W<],5D_&:'P&OA$#2TTI=8,J_91IP0,?F&[.SCIGK^%0_#KX.^%O%'@+3M7
MU!;S[9<"3>8Y\+P[*.,>@%9^B>&=%^&?Q.BL/$E@MU9WC#^SM0E^Y&V>,CIG
M.!GM0![+#K\/AKX?V6JZ])(ABM8_-R,NSX' '<DUS%Q\4O$-MI[:J_P]OQI
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M>B0Z9:QQS^=&D**LV<[P ,-^/6LV#QCX9N;];&#7],ENV?8($ND+EO3&<YH
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MA[XSTYYY)7T"=K>TE8Y948[5Y]NM;MK\2]=L])&F7O@C77UZ)?)_=0!K9W'
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M.<CWP*Z'&*;;:L*R3N( %&!2T44AA1110 4444 %%%% !1110 4444 %%%%
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M7-K\Q*]2O_UNM>ES)TX4Y;-?B<5FIRFMTS*\)_\ ([:C]7_G56RA36/B)/\
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MH-Q76[(;<DF^ED=9XLU#^SO#UPZMB1QL3ZFN,O="-MX&LKU!B='\YB/1NGZ
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M8_@/_D2-*_ZY'_T(UK>)O^0%>?\ 7)OY5D^ _P#D2-*_ZY'_ -"- '14444
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MU%?0X7'4L0O=T?8\/$X*K0U>J[EVBBBNPY HHHH **** "N(^+G_ "3;4O\
M?A_]&K7;UQ'Q<_Y)MJ7^_#_Z-6M*7\2/J1/X60>#O^12TC_KTB_]!%=*.E<U
MX._Y%+2/^O2+_P!!%=*.E3/XF5'9$$]<+\*/^1U\9_\ 7S_[4DKNIZX7X4?\
MCKXS_P"OG_VI)6E/X)?UU(G\43UJBBBL30**** "BBB@ HHHH 3%&*6B@!,4
M8I:* $%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 >.1_P#)?-:_Z]E_]%Q5Z9;]*\SC_P"2^:U_
MU[+_ .BXJ],M^E;5MUZ(SI[/U+Z=*F'2H4Z5,.E8F@ZBBB@ IIZ4ZFGI0!!)
M5"X[U?DJA<=Z /-[?_DOFG_]>C?^BWKV"O'[?_DOFG_]>C?^BWKV"MJWV?0S
MI]?4****Q-"A=Z+IU_=QW5U;+)/& $<L1C!R.AJ\5#*58 @C!!I:*;DWN))(
MSK'0=,TV=I[.T6*1A@L&8_S-79[>&YB,4\221GJKKD5)13<I-W;!125D8B^$
M=!20.-.CW Y&68_IFMF.-(HQ'&BH@Z*HP!3J*)3E+XG<2C%;(H+HNG)J9U%;
M91=DY,NXYZ8Z9QTJ\RAE*L,@C!!I:*3DWN-)+8S;/0-+T^Y-Q:6@BE((+*S<
MY]LXI]GHNGV%U)<VMLL<TGWV#$Y_,U?HIN<GNQ*,5LC.30M,343J"VBBZ+%C
M)N/4^V<4Z?1=.N;]+Z:V5[E,;9-QXQT[XJ_11SR[ARQ[&>-$TY=2_M 6R_:R
M<^86)/Y9Q6A112<F]QI);&=!H.F6U\U[#:JEPV<N&;G/7C.*J'P?H!.3IR9/
M^VW^-;E%4JLUU8N2/8P_^$.T#_H')_WV_P#C6TB+&BHHPJC %.HI2G*7Q.X*
M,8[(****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** ,;Q-_R KS_KDW\JR? ?\ R)&E?]<C_P"A&M;Q-_R
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M*]1L+V'4+2.X@8,CC/TKZK 8U8F-I?$CYS&X-T)<T?A?]6+-%%,E?9&6]*]
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M.HI$U.\+HZYB'WACO7HU%%36J^UGS6L.E3Y(\H4445D:!1110 4444 %%%%
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M1K@"GT45U'*%%%% !1110 5Q'Q<_Y)MJ7^_#_P"C5KMZXCXN?\DVU+_?A_\
M1JUI2_B1]2)_"R#P=_R*6D?]>D7_ *"*Z4=*YKP=_P BEI'_ %Z1?^@BNE'2
MIG\3*CLB">N%^%'_ ".OC/\ Z^?_ &I)7=3UPOPH_P"1U\9_]?/_ +4DK2G\
M$OZZD3^*)ZU1116)H%%%% !37=(U+.P51U).*=6=?:)9ZBV;KS9!_=\PA?R'
M%.-KZB=[:&;J7C33+'*1,;F0=H^GYUQ^I>,]5OLI$XMHSVCZ_G7:?\(;H?\
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M3=6T_6;-;O3;R&ZMVZ21.&!JA/XO\.VPO#/K-G&+)_+N=T@'E-Z'WKD/AR?
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M88IXFBFC22-QAD=00P]"#7D?PDTC33XB\6RG3K0R6VH@0/Y*YB'S<*<?+^%
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MO*-2O9OM\D&/GP&W;<>N*]5L?!_AG3+Q+NP\/Z7:W,>=DT-HB.N1C@@9%;5
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M]&_]%O7L%>/V_P#R7S3_ /KT;_T6]>P5M6^SZ&=/KZA1116)H%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%(2%4LQ  &23VH \7^+7PCU/Q1K#>(-%N
M@]SY:J]K*<9VCC:>WTKSS0?B=XV^'=Z-,UJ&:YMHSM-M>@[E'^P_7^8KV;Q7
M\:/"OAKS((;G^TKQ>/*M2& /NW0?GFO"O%GC[Q%\3KH65OI:>4AWK#;Q;W '
M<MC.* /8Y/BMH'B_PQ=0V,S6]^\>&M9?O<]<'H152(!(44= H%>#^"K*>?Q7
M%&J'="DCO[!5)/\ *O<XI \*-ZJ#7SN=)^TCZ'NY5;V<O4FW4FZF%J:6KQ;'
MJW//?BI(4;1W"EBLKG:._P!VDF^(-Y)I\D!\-7BAHBF\L<#C&?N4?$PYN-$_
MZ[-_-:[.Z;_B2S?]>Y_]!KUE*G'#TN>-]^K74\WEG*O4Y96VZ>1PO@1O^*,U
MCW9O_0:=X)/_ !;[5OK+_P"@"HO YQX/UC_?;_T&G>"SCP!JOUE_] %=%=:U
M/\43"CM3_P +,OPCXKN-$TM[:+1KB\4R%O,C8@#V^Z:]$T36VU;3#>7%H]CA
MB"DK= ._(%<[\-3CP])_UV-=9=P1WEK+;2Y\N1=K8.#BN;'2INM*/+9WWO\
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MGG_Z&J/_ , 3_P#'*/\ AF>?_H:H_P#P!/\ \<KZ%HH ^>O^&9Y_^AJC_P#
M$_\ QRC_ (9GG_Z&J/\ \ 3_ /'*^A:* /GK_AF>?_H:H_\ P!/_ ,<H_P"&
M9Y_^AJC_ / $_P#QROH6B@#YZ_X9GG_Z&J/_ , 3_P#'*/\ AF>?_H:H_P#P
M!/\ \<KZ%HH ^>O^&9Y_^AJC_P# $_\ QRC_ (9GG_Z&J/\ \ 3_ /'*^A:*
M /GK_AF>?_H:H_\ P!/_ ,<H_P"&9Y_^AJC_ / $_P#QROH6B@#YZ_X9GG_Z
M&J/_ , 3_P#'*/\ AF>?_H:H_P#P!/\ \<KZ%HH ^>O^&9Y_^AJC_P# $_\
MQRC_ (9GG_Z&J/\ \ 3_ /'*^A:* /GK_AF>?_H:H_\ P!/_ ,<H_P"&9Y_^
MAJC_ / $_P#QROH6B@#YZ_X9GG_Z&J/_ , 3_P#'*/\ AF>?_H:H_P#P!/\
M\<KZ%HH ^>O^&9Y_^AJC_P# $_\ QRC_ (9GG_Z&J/\ \ 3_ /'*^A:* /GK
M_AF>?_H:H_\ P!/_ ,<K-U_X"0^&]%N-4U#Q?%'! N?^/$Y8]@/WG4U]+$@
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M/%VL$H,8,KIM)/\ LD5[?7CNL?#3QS_PF.K:UX<\2VFFQW\FXKE]Q'8'Y2*
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M37+^$F>U\8?$\VV59/G0#^]M<Y_.O1/ _A^X\+^$;'1[J6*6:W3:SQ9VGZ9
M-9GACP;=Z)XN\3ZO=3V\MOJ\B-'&F=R@9R&R,=^U 'G'PMD^("^$VE\.V?AI
M[>6X=I)+QI1,S]]VTXK<30_&MY\2=$UK77\-6<L V,EE<.LDT9Z_*W+5I?\
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M)!'0#) /2LOP#\+9?"/B[5M9N;J">.<LMFD>[,2,VX@Y&!VZ4 >EJH50JC
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M?M_^2^:?_P!>C?\ HMZ]@K:M]GT,Z?7U"BBBL30**** "BBB@ HHHH ****
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M"W6WL[>*"%?NI$@4#\!0!X=X5_9WMX]ESXFO3,W4VUN<+]"W4_A7?^*[;2/
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M-IK6FG*SKB20[FKM:I:?;""!5QCBKM?4TX*$5%=#YJ<W.3D^H44459 4444
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M?3I4PZ5"G2IATK$T'4444 %-/2G4T]* ()*H7'>K\E4+CO0!YO;_ /)?-/\
M^O1O_1;U[!7C]O\ \E\T_P#Z]&_]%O7L%;5OL^AG3Z^H4445B:!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJR X0$>F*Y._\-LA)0$>QKQ:^5U(:T_>7XGKT<QI5-)^Z_P.9+TTM5BXTZ>
MG*FJ3;E.&!%>>XM.ST9W;JZV'EJ:6J/=29IV%<L6_P UP@]Z]RTC_CPA'^P/
MY5XIH\#7&HQ(!GYA7N&GILM47T%>OE4=9R]#S,TE[L(^K_(?>#,#?2O'=0'E
M:A<)Z2&O99QF)A[5Y'XFA,&L3'& _P P_P _A59O"].,NS(RJ5IRCW1EEZ:7
MJ(O3"]>$D>Q<E+4(#(P5><U$N7; KK/#NA-(ZRR+] :WH8>5:?)'_AC.K6C1
MASS_ .'-#PUH1&V61?F/Z5WL$*Q1@ 5%96BV\0 %6Z^IHTHTH*$=D?-UJLJL
MW.6["BBBM#(**** "BBB@ HHHH *XCXN?\DVU+_?A_\ 1JUV]<1\7/\ DFVI
M?[\/_HU:TI?Q(^I$_A9!X._Y%+2/^O2+_P!!%=*.E<UX._Y%+2/^O2+_ -!%
M=*.E3/XF5'9$$]<+\*/^1U\9_P#7S_[4DKNIZX7X4?\ (Z^,_P#KY_\ :DE:
M4_@E_74B?Q1/6J***Q- HHHH **** "FO]TTZD/2@"'%&*DQ1BF(CQ1BI,48
MH 2,8)J2FJ.:=2&%%%% !1110 5\\?\ ">VO@3XO>++BYT^ZO!<OL"V^,K@Y
MYS7T/7DW@3_DM/C;\/\ T*@"@W[1&E%2/^$<U;D?[/\ C4_P*OXCX9U[4)/W
M4)O&F;=_"O)YKU]_N-]*\/\ A[9SZA\.O'5G:@F>:6X2,#J6*L!0!OZ=XB\=
M^//-U+PR]AI.C*Y2"2]B,CW&"1NQVK6\*^,=6/B:;PGXIMH8=6CA\Z"XA/[N
MY3."0.Q]O8UP/PQ\&V_B3PE \7C7Q-97,):.>QM;_P M82">B8X%;FA>&_#V
MF_%:U@3Q%XCUC6[.W:0M=3K-%&A!7:S8R.O3UQ0 ^+QIXSU?QWK_ (9T=+3_
M $:3$5S,GR6Z9ZMCEC[5!/XZ\<^%?%<?AO6;6SU>[OXPUC-:KY2Y/'/L,'/T
MK0^'X'_"T_'!P,^<.?QJ'QI_R7;P9_UP;^;T 1Z_XF^('@,VFK:]<:9J&DRS
MB.>&VB*/$&]SUQ75>./'#^&[2PM]-M!>ZMJ3;+2#.!GU/M6+\>/^2:S?]?,/
M_H8K*\<R+I?C[P-K-XN-/0")I&^ZC=<G\Z +VH7_ ,4?#&FC6]0FTK5+2$![
MFRMXMDB)CDAN^/:M[6?B/8:?\/XO%%K']H%RJBWAS@M(W 4_CUK4\:ZM8Z;X
M(U2[NIH_(>U=4RPQ(64@ >N<UXK=Z=>:?\'O">HSQ,(+345NI4()Q&3QD>E
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M:!!A8XD"@?@*LT 9&A^%]%\-VP@TG3H+90,%E7YC]3UK7HHH **** "BBB@
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M>BZ?8);1#CFGV=A';J,#FKU>Q0P\*$>6!Y%?$3KRYIA1116QB%%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSBV4$E"!OX./7'ZU?U>HNG6WS)]O3?7I?Y&_NI-U<#_PM?1O^?.__P"^$_\
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M2!<N_P!6/)_$UMT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP- 'C?B/XT:%XBT*ZT?0M+OM2O;Q#"L,D&% ;C<>O0XKM_!_A)K#X9V_AW5
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M* ()*H7'>K\E4+CO0!YO;_\ )?-/_P"O1O\ T6]>P5X_;_\ )?-/_P"O1O\
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MBW6G7D-S"PR'C;- %VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHM/MKQQ'#=6LWFQJQ[,>U:_C#QQ+H6H6&BZ1IYU+6]0R;>#=M0*.2S'L,9H
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M'((R* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QR/\
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M?:Y?]G\J/M<O^S^5 %^BJ'VN7_9_*C[7+_L_E0!?HJA]KE_V?RH^UR_[/Y4
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M)21TR03D>U=+XL\'6WB?PU'H:3_8H(WC9#''NVA.@QD4 :VEJJ:!9HHPJVJ
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M4+GZ4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QR/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJQ42W&@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M9_%GXAW_ (+2RMM,CC-S<@N9)%W!5''2O*_^%Y^-?^>]E_X#"NA_:'_Y"VC?
M]<'_ /0JZSX2^&- U+X<:;=7VB:;=7#M+NEFM4=CB1@,DC/2@#S+_A>?C7_G
MO9?^ PH_X7GXU_Y[V7_@,*^@_P#A"O"O_0M:/_X Q_\ Q-'_  A7A7_H6M'_
M / &/_XF@#Y\_P"%Y^-?^>]E_P" PH_X7GXU_P">]E_X#"OH/_A"O"O_ $+6
MC_\ @#'_ /$T?\(5X5_Z%K1__ &/_P")H ^?/^%Y^-?^>]E_X#"C_A>?C7_G
MO9?^ PKZ#_X0KPK_ -"UH_\ X Q__$T?\(5X5_Z%K1__  !C_P#B: /GS_A>
M?C7_ )[V7_@,*/\ A>?C7_GO9?\ @,*^@_\ A"O"O_0M:/\ ^ ,?_P 31_PA
M7A7_ *%K1_\ P!C_ /B: /GS_A>?C7_GO9?^ PH_X7GXU_Y[V7_@,*^@_P#A
M"O"O_0M:/_X Q_\ Q-'_  A7A7_H6M'_ / &/_XF@#Y\_P"%Y^-?^>]E_P"
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MX@^-?A]>#3]5AFEA0X-O> YQ_LM_7FO8_"GQ;\->)MD+W']GWK<>1<G:"?\
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MKN/\+<&K]>C"<9J\7='!.$H.TE9A1115$!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%-=UC4L[!5'4DUB7?BBSA)2 -<./[O3\ZRJUZ=%7J.Q
MK2H5*KM35S=HKBY]?U2X)V,D"GLHR?SJA+)<W'_'Q=32>Q;BO+J9U1C\";_
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MM.\275D1'<YN(?7^(?XUC[J:6K:C6J49<U-V,ZE.%6/+45T>DV=];WT(EMY
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MTFDR-C)Y,)/?Z5[Q#-'/"DL3!D<;E8'@B@!]%%% '@'[0_\ R%M&_P"N#_\
MH5>@_!C_ ))?I?\ O3?^C6KS[]H?_D+:-_UP?_T*O0?@Q_R2_2_]Z;_T:U '
M?4444 %%%% !1110 4444 %%%% !1110 5RWQ1_Y)?J7_72+_P!&K74URWQ1
M_P"27ZE_UTB_]&K6E+^)'U(G\+%\'?\ (I:1_P!>D7_H(KI1TKFO!W_(I:1_
MUZ1?^@BNE'2IG\3*CLB">N%^%'_(Z^,_^OG_ -J25W4]<+\*/^1U\9_]?/\
M[4DK2G\$OZZD3^*)ZU1116)H%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&7(S[FNRKT,K_P!W7J_S//S73$OT7Y!1117H'G!1110 4444 %%%% !1110
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M4]U<-XFMQ%K+NHP)5#_XU[&457&;I/9ZGFYG24J:J=5I\C$"T[;79_V/8?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(-<O=>#<RE[*Z\M2>5?/'Y5U=%17PM*NOWBN70Q56@_W;L<K:^#AY@:]NC*
M>%3/(_&MF_TM;C1GT^WVQ*0 N1P,'-:-%33P=&G%QBM]RJF-KU)J4I;:HXP>
M#;U1@7T8'L#5BS\*WEO>13->HRHV2.>:ZNBL8Y9AHM-+\6;RS3$R33:^Y&'>
MZ%+=:[!J"S(J1E25(.3@YK3O[.._LY+>3HPX/H:LT5U1P]./-9?%N<LL14ER
MW?P[&#H.@2Z1<2R23)('7: H-;U%%.C1A1AR0V)K5YUI\\]PHHHK4R"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@]**#TH XWQ2Q-[;^
M@!K$S6]XKB/[N8#[K<_2N=W5\GFD&L5*_6Q]-@))X:-NE_S'YI-U1EJ:6K@L
M==ROJS?\2>\_ZX/_ "->5>#]&UW4=-EETS6C90B3#("W)]>*]4OHVN+"XA3&
MZ2-E&>F2*P/!FB7>@:7+;7AB+O)N'EMD8_*O0P];V5":5KW6YQ5Z/M*T;[69
MQRV.HZ?\0],BU*_-Y-N4^82>GIS6GJ1_XNW8G_IF/Y-6KJ?A^]N_&EGJ\;1?
M9H=NX%CNX]L4V\\/7L_CJVUE6A^RQH P+'=T/;'O77]8A)IMKX&OF<_L)132
M7VD_D<]XEM[N\^)$<-E<_9KAHUV2C/R\'TKH]'T/Q%9:E'/?:\UU;KG=$2W/
MYTRY\/WLOCF'65:+[*B@$%CNX'IBNI+5A6Q'[N$(V?NZZ&M&A[\IRON<UK/C
M>'1]2>S?3[F9D .],8-<WJ#Q^(?'5C%=HPM6B5EC8^HSBO1RU<KXG\-SZG=0
M:CILZPWT.,%C@'\?6GA:M*,K6Y79J]PQ%*I)7O=73M8Y_P 2:+967C#2XK2-
M88IBK-$O !!ZXKTG.!@=J\^F\)Z]=SPZE>7\<VH1RKA<X4(/H/Z5W:LVQ=WW
ML<T8N2E&"YN9H>%BU*;Y;7)2U(6J,M0GS.![UQ6L=BU=CT;PDQ_LM0?[QK=N
MS,+.<VP!G\MO+!Z;L<?K61X;A,.GQ@CG&36[7UF%BXT81?9'S&*DI5YR7=GS
M5>R?&)[V8A=>4;S@0JP3\,=JKY^,7_4R?D]?3M%;F!\Q9^,7_4R?D]&?C%_U
M,GY/7T[10!\Q9^,7_4R?D]&?C%_U,GY/7T[10!\Q9^,7_4R?D]&?C%_U,GY/
M7T[1T&30!\KZH/BF^F7(U0:\;'RSYWG!MFWOG/:L#P/)K,?BZP.A;C>F0  =
M"O?/M7H/Q?\ B#)KE]_PC&BNSVRN%G:/DS/_ '1[9_.O0?A5\/4\(Z2+V^C4
MZM=*#(3_ ,LE_N#^M 'H47F>2GFX\S:-VWIGOBN7\6D[(/0/75US?BB R698
M#E3FN7&P<\/.*['5@IJ.(@WW.6S29J+?D9I"U?'6/J&2%J\U^* >34-$2-]C
MLSA6]#E,&O12U<CXO\/7NN7^ES6C1!;5RTGF,0>2IXX]C79@91IUU*3LM?R.
M3&1<Z+C%=OS,F\\->*X].FDE\2L\2QDLFYN1CI4/@P_\6_U8?[;_ /H(KO+V
M)Y],FMT(WO$4&3QG%<QX?\.7VE^%K[39VA,\[,4V,2O( Y./:NJ.)YZ+4[)W
M72QA+#\E5.-[6?F9WA4_\6UU3_<F_P#0*R?"FBZ]?Z1YVG:T;.#>1Y8+=?7B
MNIT3P]>Z=X0O=+F:+[1,L@4JQ*_,N!DXJUX1TBYT/1_LEV8S)O+?NVR.:TGB
M8Q51P:;<O4SA0<G34D[)%FS-YH/AZ634KEKZ:'+E@3EAZ<U@GQT-3L[R*VL;
MF"9;=W5WQ@$ FNR+5',B31/%(-R."K ]P:XH5(7;G&[^[\#LE3G9*$K+^NIY
M]X1T#3-1\+W-S=0K+<.7&]N2F.F/2K7PV@6.'4I-VYO,5,^PS4">$M>TZ6XM
M-+U)(].G;YMWWL?EU^A%:WA?0+OP_=7L;RI):R[2C9^;(]1CW->A7JQE3J6G
M?FLTCAH4Y1G"\+6NFSJBU)NJ,M32U>58].Y(6KEO%6#J-OZB'G\S72C+, .]
M<AK4XNM8F*G*I\@_"O0RR#>(OV3.+,))8=KNT=[HDND0?"3=K-I/=6O]ID!(
M)-C;M@P<_G6?I^H> SJ%N(=!U-9#(NTFZR <UF?V[9_\*\&A8E^U_;OM&=HV
M;=N.N>OX5AV,BV]]!,^=L<@8XZX!KZ,^?/4)!_Q?J0_[O_HI:S_ I@37_%;7
M*-) +2<R(IP67=R ?I5-O%NFM\3F\1!9_L1Q@;!OX0+TSZCUJEH'B*QTR]U^
M:=9BM_;2Q0[5!.6.1GGB@!S:AX"PP70-3#=C]JK,T;PKJ'B,W$FF)%Y43XQ+
M,JD YQUZUC8YI=M 'H_@+1+S0?&LUI>B,2_9';]VX<8(]15#PIKNG--;Z/<:
M:+4S PM>VLA25R>F[U%/^%/R>*I&QG%NYP?I3[75_!=MJ']M)8Z@NH*3(MF"
MI@63V/WL=Z .2U[2SHVNWFGE]_DR8#>HZC^=9^*O:I?RZMJEQ?SX\R=RQ [>
MU5<4 ,Q5>^!%ME?O;EQ]<U<Q3[.T.H:YIUBHSYLZEQ_L@Y- 'T99G-NOTJQ5
M>S&V!1[58H \ _:'_P"0MHW_ %P?_P!"KT'X,?\ )+]+_P!Z;_T:U>??M#_\
MA;1O^N#_ /H5>@_!C_DE^E_[TW_HUJ .^HHHH **** "BBB@ HHHH **** "
MBBB@ KEOBC_R2_4O^ND7_HU:ZFN6^*/_ "2_4O\ KI%_Z-6M*7\2/J1/X6+X
M._Y%+2/^O2+_ -!%=*.E<UX._P"12TC_ *](O_0172CI4S^)E1V1!/7"_"C_
M )'7QG_U\_\ M22NZGKA?A1_R.OC/_KY_P#:DE:4_@E_74B?Q1/6J***Q- H
MHHH **** "D/2EIK_=H 3-&:CW4;J8B3-&:CW4;J )5-.J.,Y-24AA1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!XY'_R7S6O^O9?_1<5>F6_2O,X_P#DOFM?]>R_^BXJ],M^E;5MUZ(S
MI[/U+Z=*F'2H4Z5,.E8F@ZBBB@ IIZ4ZFGI0!!)5"X[U?DJA<=Z /-%_Y+O9
M_P#7D_\ Z*>O3:\R7_DN]G_UY/\ ^BGKTVMJWV?0SI]?4****Q-"CK.K6VAZ
M1<ZE=MB&!-QQU)[ >Y-1Z#?W>IZ-;WM[:"TEG7>(=V2JGIGWQ7%>/Y6U?QGX
M9\,!CY,DOVRX [JOW?U!KJ/%_B:W\(>')M2DB,K+B.&%?XW/ % &_17G$5M\
M3[NT_M/^U].MF<>8NFFU#8'9-_6N@\$^*SXITVX-S;BUU&SF,%U #D*P[CV/
M]* .GHJ*ZN8K.UEN9FVQ1(7<GL!7FFDZMX\\;V[ZSH][9:1I99A;0RVXE:8
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M0B]6IJ+;LM6%TE=[%?4;X:=8M+G]\XVQ#W]:Y&-3C)Y)Y-237TFJW+3RG&.
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M2_4O^ND7_HU:TI?Q(^I$_A8O@[_D4M(_Z](O_0172CI7->#O^12TC_KTB_\
M0172CI4S^)E1V1!/7"_"C_D=?&?_ %\_^U)*[J>N%^%'_(Z^,_\ KY_]J25I
M3^"7]=2)_%$]:HHHK$T"BBB@ HHHH *9*<1FGU%<'$#&A 0;J-U5]]&^M+$W
M+&ZC=5??1OHL%R[ <L:GJG:-EV^E7*A[C04444AA1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'CD?_ "7S6O\
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M6)?A#X3DN'D6"[B1VW&&*Y98Q[;>F*ZZUTJQLM+_ +-M+=(+0(4$<8P #UH
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MHP% P!6XJA1@4  =*6@ HHHH \ _:'_Y"VC?]<'_ /0J]!^#'_)+]+_WIO\
MT:U>=_M"RQMK>D1JZET@;<H/(^;O7HGP8_Y)?I?^]-_Z-:@#OJ*** "BBB@
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M;>+6NW1HBK26@C!65U!"L3G@C([=J .$^)>A2^'/AGX5TV"7RHK>ZC\^4IN
M8C[S \'GUKL4\.?$F2%94^(]HT;+N##1X<$>M=OK6BV'B#2I]-U* 36TRX93
MU'N/0UP4?PKU>UM6TZS\>ZI#I&2%M#"K%4)^[OSG\: *7@S1XM*\*>-&C\1P
M:U).DK3O#;F(1R!'W#'3G/;TJ'P?#HMU\!HK;Q!<_9M.FWH\W.4)8X/ ->@Z
M=X0TW1O"MQH&FJT,$T4B-(WS,6<$%CZFJFB>!;'3/ X\*WDAOK0JRNS)L+ G
M/3)Q0!Q%EX6^)'AFQM?^$7\56NL:6"9([:^C'^KP-JASEB,=@5'YUU_P[\:S
M^,M*NFO;-;34+*;R;F.,DIN]5S]*QH?A=K5C;FPTSQ]JEKI8RJ6I@5RJ'JN\
MG/XUV'A?PMIOA+2OL&FJ^TMODDD;<\C'J2: -NBBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH \<C_ .2^:U_U[+_Z+BKTRWZ5YG'_ ,E\UK_KV7_T
M7%7IEOTK:MNO1&=/9^I?3I4PZ5"G2IATK$T'4444 %-/2G4T]* ()*H7'>K\
ME4+CO0!YHO\ R7>S_P"O)_\ T4]>FUYDO_)=[/\ Z\G_ /13UZ;6U;[/H9T^
MOJ%%%%8FAX5\3=0OO%GQ(L?!-O<-!9HR>;L/WF9=Q)^@/%7/&?P=T72/"5QJ
M6AM<07]C'YY<RD^8%&6^G&3Q4/Q.T+5] \>6?CC2K1[J$%3.D:DE648.<=BH
MZ]J9XI^,5OXH\.2Z)X=TJ_DU&_3RG5D!"*1\V-I);C([>M $MEXGN_$WP'U=
M[^0RW5K&87D/5L="??%9?PB^'FC^*=!EU76EEN!#<>5!$)"JIM 8\#KDM^E;
M:>$[CPE\"=5M[T!;RXB,TR#^ GHOU K:^!0 ^'G '-W)G\EH ]*CC6*-8T&$
M0!5 [ 4ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU)*[J>N%^%'_ ".OC/\ Z^?_ &I)6E/X)?UU(G\43UJBBBL30**** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVDNF:KK-Q>!88II0R,S 9% %>Z_Y*;:_]>U:?BIM*AL(KG5#Q!()(E!Y9AT
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MD;U S77'!O[3,'771'T5+\3?!T/W]:CZX^6*1OY+4?\ PM3P7_T&A_X#R_\
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M(IP '0 4 >;Z)\,V#+-JTPP.?)C.?S->A6EG;V-NL%M$L4:CA5%3T4 %%%%
M"$!@0P!!Z@UQNO\ P^LM39I[)A:SGDC'RG_"NSHH \/OO"&OZ5(6%K(ZCI)
M=W\N:IMJNMVB^6]S=Q =F)'\Z]\IABC;K&A^JB@#P?[;KNI ()+R?T";C_*M
M33/ 6MZDX:>+[-&>2\QY_+K7LJQHOW44?04Z@#GM \(:=H2AU7SKCO*XZ?0=
MJZ&BB@ HHHH S-8T&PUNW\N[A!8#Y9!PR_C7F^L?#?4K1FDT]ENHNRYPX_.O
M6Z* /!=NO:0V"M[;X]0P'^%+_P ))KA^7[?<'VS7O!16^\H/U%,\B+_GDG_?
M(H \)$&O:L^!'>SY]FQ_A71:/\-M0NF63476VC[H#N<_TKU<*J_=4#Z"EH S
MM)T2PT6W\JSA"_WG/WF_&M&BB@ HHHH Y[7_  ?IVN@NR^3<]I4'7ZCO7G6I
M^ =;TYRT$7VJ,<AHCS^76O9J* /!!=Z[IORE[V#'9@P_G7HWP[U+5-0L;HWY
M=XD9?*D<<D\Y'X<?G79F-&^\BGZBE554850!Z 4 +1110 4444 %<M\4?^27
MZE_UTB_]&K74URWQ1_Y)?J7_ %TB_P#1JUI2_B1]2)_"Q?!W_(I:1_UZ1?\
MH(KI1TKFO!W_ "*6D?\ 7I%_Z"*Z4=*F?Q,J.R()ZX7X4?\ (Z^,_P#KY_\
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M7_D<]7_Z^6KGS7KPH4W%.QPRJ3YGJ>@'XP:Z/^7:T_[Y/^--/QBUW_GVL_\
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M2?;-<)\,OAOX8\2>'[B[U2QDEF2Z>-66=U^4'C@&O='^XWTKS?X*?\BE>?\
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M_P#"3:#_ -!O3?\ P+C_ ,:/^$FT'_H-Z;_X%Q_XT<K[!=&I167_ ,)-H/\
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M2RG2I14:#BI:Q-!:*** "FGI3J:>E $$E4+CO5^2J%QWH \T7_DN]G_UY/\
M^BGKTVO,E_Y+O9_]>3_^BGKTWM6U;[/H9T^OJ>._&B4F?1HLG!:1L?0#_&O-
M+ ;M28_W4KTWXS0G&E7'9)63/U'_ -:O,; [=2(_O)79A_X2,*OQFV.E%%)6
MQD>FZY::!<:%X>.L:E<6D@L4V"*'>"*?'8:+X)TM?$.GRW.IO<(8[>0* D1(
MZMCO[?6N8\5ZE9W^F:#%:SK*]O9K'*!GY6]*F\%^(;:T6ZT75W']DWJ'<6&1
M&_9O\^@KFY)<GZ&W,N8LZ%*Y\ ^);F,?OY'4.1UVGK7#5T^C:U;>'-8O+9RM
M_I-P#%,%) =#W'O5I_#_ (3N)/M$'BD6]NWS"":W)E4=P2.,UHGRMWZDM<R1
M-II,OPHU@3#*17,9A)[,6 ./PIGPU>]_MJ5$VG33&?MGF?<">I]ZJ>(->L+C
M3K70-$1H=-BDW/++PTK]-S8[59UK6=.TGPW%H&@W"S><NZ]NE!'F'TYYQ4--
MIJVY6B=^Q:^):W,4NGQ6X0:&(0;,Q?=/KGWJ/X8:0UUK,VIM&'6RC+1AB #(
M>@R:A\-:[I]YH-SX;U^81VI!DM;A@3Y+^GT_^O3-3U*PTSP/#HFFWL=S/<3&
M2ZDC!' Z#FBSY>0-+\QUNB>&M;EMM;LM:6$Q:@#*I6=6(EZYP#7'> +>2U^(
MEI;RC$D32HP]PC5S>E7\FEZK;7T1P\,@85WG]K:##\3;'6X+Z);2>,O.<']T
MY0C!X^E)IJZ[H::=CS+Q3_K[S_KN?YUT^A[I/@SKBS<QI>J8LGHVT9Q5C6?#
M'AB\::63QQ:1)))N/^B.<<].M97BGQ#H\>@6_ACPVLK6$$IEGN9>&GDZ9X[8
M_I5I\UDA6MJRUXW!_P"$%\'G''V=QG\:S/AF"?'^F8'1\UI:9JV@^(_"-MX>
MUV\;3KJR<M:7NS>FT]58=:M:2WA/P+)+JL.NC6]0$;);100F-48CJV:+VBXV
MU%NTS'LO$MQX7\=ZO>16XN;>2>:*YA8</&7.16CY/PVU]HREU?Z'<22$,KKY
MB<^_1167X/\ &$&DZCJ<>KPM/IVJHRW0C^\"22&'YFKS>$_!3W7G1^-XH[0M
MN$+VS&4+Z;NF?PHEH];KT&MC#\8>&+WPS?01W%TMY;SQ"2VN48E70^E=%X9_
MY(]XK_ZZ0_\ H0K&\<>)['7&TZPTF*6/3--MQ# 9OOOQR35K0=:TZU^&7B/3
M9[I$O;EXC#"0<OAN<4/F<%?R$K<SL-^%F@?VWXPA>2/=;V8\^3/3(Z _4UZ/
MH?AWQ))XOURXUF.W_LS6(WC<"Z1BO9#@'L*\ZT_7-.T+X9WEK:7:/J^IR[94
M4'=%&.V?>N)M;B2TNX;F)MLD3AU/H0<BIE%S;92:BD6];TN71=;N].F4J\$I
M7GT[5VWQ6_X]?"W_ &"HZH_$;5-(U^;3=:L+J-KR> +>0 '*..YXQ2?$36M.
MU>W\/K8723FVTY(I@H/R..H.::NW%L6B31PM)2TE:DBABC!AU!S7UIH3E]&L
MV/>%#^@KY,B0RS1QCJS!?S-?6>AH8])M4/\ #$H_2N3$]#:EU-*@]**#TKD-
MCYO\:_\ (YZO_P!?+5SYKM?&'AO6)O%.IW,>GS-#).S(XQ@BN:;0M4!P;*6O
M9A./*M3SY1ES/0S#3#6F=#U/_GSE_*FG0M4_Y\I?RIN<>X<LNQE&F&M0Z#JO
M_/E+^5-.@:K_ ,^,OY"I<X]RE%]C*---6[RPNK$J+F!HBW3=WJH:5T]AC#7<
M>"?#+_:X=3O%90IW0Q]"?<U%X5\*FX=+V^C^3K'$1U]S7J^E:47*DK7'7K?9
MB;TX=6=)I4SO&-U:_:JEI;"%  *MUR&P4444 07=U'9VSS2'"J,UPE[?RZC<
MF:4G;_ G916EXIOC+<I:*WRH-S@=SVK"4UZ.%I)1YWNS@Q-5N7*MD3?>7![U
MU_AZ^^TV(C<_O(OE;Z=C7' U>TN\-CJ,<A.(Y/D?^AK3$4^>'FC.A4Y)G=US
M_B*\)"62'E^7QV6MF>Y2"V:9V 55R37%F9[F>2YD^]*<@>@["N/#4^:7,]D=
M>(J<L;+J3+@  =!3DDDM)Q=0?>7[RC^(5&IJ0&O2:35F<";3NCK+2YCN[9)H
MSE7&14]<YX?G,5S/9D_+_K$_'K71UY%6')-Q/4ISYXIA1116984444 %%%%
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M2'3[>S:&1RX!#$D].O>M#X@:->^(/!6H:9IZ*]U,JA%9@H."#U-=-10!XO\
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M'56# ?B*Z6B@#B?"OAO4M*\<^*-4NXD6UU"1&MV#@E@,YR.W6NVHHH ****
M"BBB@ HHHH *Y;XH_P#)+]2_ZZ1?^C5KJ:Y;XH_\DOU+_KI%_P"C5K2E_$CZ
MD3^%C_!O_(I:1_UZ1?\ H(KIT'%<QX-_Y%+2/^O2+_T$5U,?2IG\3*CLA66N
M*U'X9>&]0O[B]FMYA-.YD?9*0"QY)Q7<5$V*(RE'X6#BGN>>M\*?#(Z07'_?
M\TP_"OPU_P \+C_O^:[]L5&<57MJG<GV<.QP?_"K/#7_ #PN/^_YH_X57X;_
M .>-Q_W_ #7=\4G%'MJG</9P['"_\*K\-_\ /&X_[_FC_A5?AO\ YXW'_?\
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M-_\ /&X_[_FC_A5?AO\ YXW'_?\ -=UQ1Q1[:IW#V<.QPO\ PJOPW_SQN/\
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MPO\ A9OA;_H(M_X#R?\ Q-'_  LWPM_T$6_\!Y/_ (FMW_A#O#?_ $ M/_\
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M)_\ $T?\+-\+?]!%O_ >3_XFMW_A#O#?_0"T_P#\!U_PH_X0[PW_ - +3_\
MP'7_  HY*7F'-/R,+_A9OA;_ *"+?^ \G_Q-'_"S?"W_ $$6_P# >3_XFMW_
M (0[PW_T M/_ / =?\*/^$.\-_\ 0"T__P !U_PHY*7F'-/R,+_A9OA;_H(M
M_P" \G_Q-5[CX@>#;M=L]YO]S;29_P#0:Z7_ (0[PW_T M/_ / =?\*/^$.\
M-_\ 0"T__P !U_PI2IT)*TDW]PXU*L7>+L>?7?B+PBV6M=6=#_=>WDQ^>VJU
MKJVGWK%;:Z1SG@'*D_@>:]*_X0[PW_T M/\ _ =?\*4>#_#@.1H>GC_M@O\
MA7EXC)L)45Z=XO\ #[CU</G.*IZ3M)?C]YP:2/&VY&*MZ@XK7M/$E[;860B9
M!V;K^==1<>&=,FC"1VZP8&!Y0VX_"N?O?"5W!EK=A,OIT->-/+\;A'S4G=>7
M^1[$,PP6+7+55GY_YBW7BN=UVV\0CXY9CDUAW%W<73EII6<GU-:5KX:U*X?#
M0F%>Y?BNALO"EG;X:X)G?T/W?RJ5AL?C'[]TO/1?<-XG 8)>Y9ORU?WGGUU>
MVUDF^XG2,>YY/X4VT\0^&#AKK5BH_N);R$_GMKTJ3PGX?F<O)HMB['J6@4FF
M?\(=X;_Z 6G_ /@.O^%>OALDPT%>JW)_<CR<3G>(GI22BOO9RUKXZ\%V8_<W
M>#_>-O(3_P"@U<_X6;X6_P"@BW_@/)_\36[_ ,(=X;_Z 6G_ /@.O^%'_"'>
M&_\ H!:?_P" Z_X5Z\*5""M%-+Y'D3JU9N\G=F%_PLWPM_T$6_\  >3_ .)H
M_P"%F^%O^@BW_@/)_P#$UN_\(=X;_P"@%I__ (#K_A1_PAWAO_H!:?\ ^ Z_
MX57)2\R>:?D87_"S?"W_ $$6_P# >3_XFC_A9OA;_H(M_P" \G_Q-;O_  AW
MAO\ Z 6G_P#@.O\ A1_PAWAO_H!:?_X#K_A1R4O,.:?D87_"S?"W_01;_P !
MY/\ XFC_ (6;X6_Z"+?^ \G_ ,36[_PAWAO_ * 6G_\ @.O^%'_"'>&_^@%I
M_P#X#K_A1R4O,.:?D87_  LWPM_T$6_\!Y/_ (FC_A9OA;_H(M_X#R?_ !-;
MO_"'>&_^@%I__@.O^%'_  AWAO\ Z 6G_P#@.O\ A1R4O,.:?D87_"S?"W_0
M1;_P'D_^)H_X6;X6_P"@BW_@/)_\36[_ ,(=X;_Z 6G_ /@.O^%'_"'>&_\
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MP4961<).2U+B]*?4:GBI*R+%HHHH *:>E.IIZ4 0250N.]7Y*H7'>@#S1?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<M\4?\ DE^I?]=(O_1JUU-<M\4?
M^27ZE_UTB_\ 1JUI2_B1]2)_"QW@[_D4M(_Z](O_ $$5TJ]*YGP=_P BEI'_
M %Z1?^@BNE7I4S^)E1V1'*>*\V^''_(Z>,/^OH_^C)*]'FKSCX<?\CGXO_Z^
M3_Z,DK:C\,C.INCTRBBBD 4444 %%%% !1110 445%/<P6L9DGE2-1W8XII7
M$2T53M-5L;XD6]RCL/X<\_E5RAIK1@FGL%%%%(84444 %%%% !1110 4444
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MVGQP 845<  '%<E2K*H_>.J%.,%H &!@4M%%9EA1110 4444 %%%% !1110
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M\EWL_P#KR?\ ]%/7IM>9+_R7>S_Z\G_]%/7IM;5OL^AG3Z^H4445B:!1110
M4444 %)@4M% "8%&!2T4 )@48%+10 F!1@4M% "8%&!2T4 )@48%+10 F!1@
M4M% "8%&!2T4 )@4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !2;1Z4M% ";1Z48%+10 4444 %%%% !1110
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MW_KPC_\ 9:=X3_Y*_P"+/^N:_P Q2N.QZ51113$%%%% !1110 4444 %%%%
M!1110 4444 %%%% 'F%C_P ESUC_ *]A_P"@15ZE;]*\ML?^2YZQ_P!>P_\
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M+XKGMS=0*4MK.VYCA]\GJ:20[F?I'_)>==_Z\(__ &6G>$_^2O\ BS_KFO\
M,5KZ?X9U&V^*6J>(9!%]AN;5(HR'^;<,9R/PI=!\-:AIWQ U[6IQ%]DO4 AV
MOEN".H[4".RHHHJA!1110 4444 %%%% !1110 4444 %%%% !1110!YA8_\
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MW@B.Z,3)NVGVH NV_P#Q[Q?[@_E7BWQZ>*+5/"DD^/)661GR,C:&CSQ]*]L
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "N6^*/\ R2_4O^ND7_HU:ZFN6^*/_)+]2_ZZ1?\ HU:TI?Q(^I$_A8O@
M[_D4M(_Z](O_ $$5THZ5S7@[_D4M(_Z](O\ T$5THZ5,_B94=D03UYS\-_\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<M\4?^27ZE_UTB_\
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M12TC_KTB_P#0172CI4S^)E1V1!/7G/PW_P"1S\7_ /7R?_1DE>C3UYS\-_\
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MMG9^#?%\$+W%MI8C^T+&,D1L%!;]*T_%WQ'\.W'@V[33-0BO;N[A*16\)W2
MD?Q+U&/>O1(;>&V@2""&.*%!M6-%"JH] !6?;^&M"M&D:VT73H6E4K(8[5%+
M@]0<#D4 >:6EC<:C^S<MM;(7E-LS!0.2%F)/Z UM>'OB/X:@\%69DU&+[7#
M(VLP?WQ8#& G4UW]K:6UC;);6=O%;V\?"11($5>_ ' JG#X>T6WO_MT.CV$=
MYDG[0EL@DR>IW 9H \S^$EW?)X*\1W=O:"2]%]+(+>3C+;02IJ"*7X9>+].^
MU:Y'9:-JOF9N8S+Y$JN..IY(KURSTZRTY9%LK.WMED<NXAB"!F/4G Y/O52\
M\-:#J-RUS?:+IUU.PP99[5'8_B1F@#SOX5-=EO$$%I<W-UX?1V6QEGSDGOC/
M:H_A1K5K9^&]5TE;J$:REY</':.P#L0!C [C(KUF**.")8H8UCC085$& H]
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MO)__ $4]>EUM6^SZ&=/KZA1116)H%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<M\4?\ DE^I?]=(O_1JUU-<M\4?
M^27ZE_UTB_\ 1JUI2_B1]2)_"Q_@X?\ %(Z/_P!>D7_H(KI .*P/!J?\4AHY
M_P"G.+_T$5T07BIG\3*CLBK,*\X^''_(Z>,/^OD_^C)*],E7BO-/AS_R.OC#
M_KZ/_HR2MJ/PR,ZFZ/2Z***0!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI-![4PV_M5^W_NHGV7FSS#_A)/B9_P!"[8_]\_\ VRD_X23XE_\ 0NV/Y?\
MVRO3OL]'V?VH]O\ W4'LO-GF/_"2?$O_ *%VQ_+_ .V4?\))\2_^A=L?R_\
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MIWV?VH^S^U'M_P"Z@]EYL\Q_X23XE_\ 0NV/Y?\ VRC_ (23XE_]"[8_E_\
M;*].^S^U'V?VH]O_ '4'LO-GF/\ PDGQ+_Z%VQ_+_P"V4?\ "2?$O_H7;'\O
M_ME>G?9_:C[/[4>W_NH/9>;/,?\ A)/B7_T+MC^7_P!LH_X23XE_]"[8_E_]
MLKT[[/[4?9_:CV_]U![+S9YC_P ))\2_^A=L?R_^V4?\))\2_P#H7;'\O_ME
M>G?9_:C[/[4>W_NH/9>;/,?^$D^)?_0NV/Y?_;*/^$D^)?\ T+MC^7_VRO3O
ML_M1]G]J/;_W4'LO-GF/_"2?$O\ Z%VQ_+_[91_PDGQ+_P"A=L?R_P#ME>G?
M9_:C[/[4>W_NH/9>;/,?^$D^)?\ T+MC^7_VRC_A)/B7_P!"[8_E_P#;*].^
MS^U'V?VH]O\ W4'LO-GF/_"2?$O_ *%VQ_+_ .V4?\))\2_^A=L?R_\ ME>G
M?9_:C[/[4>W_ +J#V7FSS'_A)/B7_P!"[8_E_P#;*/\ A)/B7_T+MC^7_P!L
MKT[[/[4?9_:CV_\ =0>R\V>8_P#"2?$O_H7;'\O_ +91_P ))\2_^A=L?R_^
MV5Z=]G]J/L_M1[?^Z@]EYL\Q_P"$D^)?_0NV/Y?_ &RC_A)/B7_T+MC^7_VR
MO3OL_M1]G]J/;_W4'LO-GF/_  DGQ+_Z%VQ_+_[92_\ "2?$S_H7;'_OG_[9
M7IOV?VI?L]'M_P"Z@]EYL\Q_X2/XF?\ 0NV/Y?\ VRE'B'XG'IX<L?R_^V5Z
M<+?VJ18:/;_W4'LO-GF'@W1O$LWC^\U_7=-6T\^W*-L8;=WR@8&XGHM>K1KQ
M2+'4ZKBLZDW-W9<8\JL.45)2 <4ZH*"BBB@ HHHH 2D(IU)0!&5INRIL4F*
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A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gapk0ju0ozex000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gapk0ju0ozex000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -?!LT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M /5:*Y7PS\0-#\4X6RG"R'I&Y&ZNJH ***Y7Q1\0-$\**1>S!I0,^4A&[\J
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M%_C_ $CP;907-\7D\X_*D?+=,T =717,>#_&]GXSM&N;&UN8HE)&Z5< UT]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'&O7'A7XBMHR3.UM)<FW"9XSNZU]#W?CK0[70?[5-["R>7O"!P6Z>F<U\X>
MM)F\3?%$ZC;H_D179N-VW@C<: -?]HK_ )'>S_Z]1_.O5;#_ )(=8_\ 8/\
MZ&O*OVBO^1WL_P#KU'\Z]5L/^2'6/_8/_H: /"?A'X;M_$OBV.VO"3;A69E]
M2!7HWQH\"Z-I?AM;_3K.*V:$8/EKC=S7*_ '_D<_^ -_*O4OCI_R(EQ^'\Z
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M-=+73=;TF,W+#;YQBSC\:]C\8>+_  KHMC#8^)8II(Y(P0! 77D>M<7+\/\
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M.=K@DD#- 'V!17DMA\?O"CZ>C7KW$=UM^9$A)&?K7">)/CCJ=]KD?]@!Q;#
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MQ_Y$W6/^O5_Y4 ?./[/W_)2!_P!>LG\J^JJ^5?V?O^2D#_KUD_E7U50!'/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ[CN$]4-:%?'FDW6O?#[QO!:RS2C$HC96)VLN0"0,U]=V-TM[8PW*C"R+N%
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M&FZG9ZO91WEA.L]O(,JZ]"*MUQ'PG_Y$'3O^N2UV] &?J^N:;H-FUWJ=VEM
MO5WZ5SG_  MGP-_T,5I^9_PK!^.G_(B7'X?SKPSP+\+[_P =0S26E_;VPB )
M$JDY_*@#Z5A^*7@JXE$<6OVK.>  374VUU!>0+-;R"2-NC"OESQ#\#==\-Z3
M-J?]HP7"PJ69848$"NA^ ?B>_.JW6C74KRP(FY=QR0Q/J: /H"\OK;3X#/=3
M+%&.K-7,2?%'P5%-Y3Z_:A\XQDUX7\7/$^HZYXQ72;6>2.)3Y85&(RV?:GVO
MP \07FGI>G4[=6==PC9&W4 ?2.F:UIVL0^=I]TD\?JII^J:K9:-8O>ZA<+;V
MR?>D;H*^2=#U'7/A[XZCM9Y9<I*(61F.U@2 3@FOJ?6K*#Q!X7GAD7=')$6
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ME?C):^)]3L(++0;>X>-@?-,/7KQSFN<\)? VQU#P^MUXD6[74'!^4RE2I]Z
M/9])U[3-<A\[3;R.XC_O(:HZWXU\.^';@6^K:I!:RD A7)S@U\V:==WGPZ^)
MD5C%=N]JD@+(6)!7GCFO>]?^'/A[QTUOJ6JQW!E>)2/+E*C&* )/^%L^!O\
MH8K3\S_A3X?BGX*N)TAB\06K2.P55!/)-<%XK^$7@'PSH-QJ$T=Z"JG8#<GE
MO2O,?AIX*;Q7XI6XMXWCT^WDWAF.<8YQGUH ^MQ-&8/.##R\;MWM7,77Q*\'
MV5R;>XUVVCE!P5).<UQ?QM\42^'?#D.E6,ACEG (.>=H.#7*^!_A!IWB3P<F
MMZG+/)<7$1DB(E(QUZT >_:?JEEJMN+BQN$FB/1EJW7S%\-]<U'PE\1/[!GG
M9K61]KAR3@=L9Z5].*P90PZ$9% "T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ3(0?3<:^PH8D@A2*,81!@ 5\C^-+"X\%_$H7_E-A9_M"MC@DDFOH+PI\3M
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M>*%490'&"Q(X->W1^"O#,3AX]$LE8="(Q6U#!%;1".&-40<!5' H ^:_C_\
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M+*4Z*.F*POAI.]Q\1]/ED.69CF@#V#XC?"/6/&6N#4+*[MHHRJ\29STKC/\
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M ($BOJVB@#R&]^'6O3_""T\-(D']H1)A@91MZYZUH?"+P-K/@RUNH]66%6E
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ME@YPP-P%R/I7T710!YC\./A5%X3E.H7[";4&YR<'8?8UZ=110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1(D+R.J*.I8X H =15*VU?3;R7R[:_MII/[L<H8_I3Y=2L89Q!+=P),>B-(
MQ_"@"U10#D9%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCI4IPD" ISW+<U[Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *J:K_ ,@>]_Z]Y/\ T$U;JIJO_('O?^O>3_T$T <G\)?^
M2=:=]7_]"-=O7$?"7_DG6G?5_P#T(UV] !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!FZ[JMGHVEO>WX)@5E4X&>2<"K\3K)"DB?
M=901]#7+_$72+O6_!\]E9*&F:6-@"<<!LFNDLT:*QMXV^\D:J?J!0!/1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM7?R+MA]PC _,UU?BC7'T#09M1BB69HQPK' - &U17SG_P -*:G_ -"_:?\
M?UJ/^&E-3_Z%^T_[^M0!]&45\Z+^TGJ;,!_8%IR<?ZUJ][T746U72;>]>,(T
MJ!BH/ R,T :%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !535?^0/>_\ 7O)_Z":MU4U7
M_D#WO_7O)_Z": .3^$O_ "3K3OJ__H1KMZXCX2_\DZT[ZO\ ^A&NWH ****
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MI(DBAHW5E/0J<BG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.%_[T8*G]#5O_A'/B5_SZ:W_ -_&_P : /KH:3IJG*Z?:@CN(5_PJV    ,
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M_2@#YF\2?%72-5\$MX=T_19[52FT.SJ1GUXJM\*/B+;>#+F:">PEN#<@("C
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M.P)X^E>#^&_ FMQ?$J*>ZT&86 D.6>(;,5]'S"TT71I)(H8H(HTR0BA0/RH
M^5;56;XT6BH"6-X<8^K5]<6X(MXP>H49KY8^&&FMKGQ5EO3EA:7)FS[;B*^J
MZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %5-5_Y ][_U[R?^@FK=5-5_Y ][_P!>
M\G_H)H Y/X2_\DZT[ZO_ .A&NWKB/A+_ ,DZT[ZO_P"A&NWH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,KQ%K=MX>T>34+J,R1
M(RJ5'N<5I0R":".51A74,/Q%<U\0='N=>\)3V%KCS6D1AGV;-=%:1F*R@C;[
MR1JI_ 4 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 54U7_D#WO\ U[R?^@FK
M=5-5_P"0/>_]>\G_ *": .3^$O\ R3K3OJ__ *$:[>N(^$O_ "3K3OJ__H1K
MMZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#!\8
M:^?#7AZ74E0,4=%P1ZG%;-O+YUM%+_?0-^8K'\7Z ?$OAZ730Y3>ZMD>QS6Q
M;Q>3;11==B!?R% $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7S7#XBU*'6AJJ7+BZ#[]V>] 'W317FWPS^)EKXKL4M+J18]0C7!!/WO>O2:
M"BBB@ HHHH **** "BBB@ HK$NO%NBV=\UE/>*EPK;2A]:VE(90PZ$9% "T4
M44 %%%% !1110!R_Q!UFYT'PE/?VC%9ED100?5L5T5I(9;*"1OO/&K'\15'Q
M!H]KKNDO87F/)9E8Y]0<BM&*,10QQK]U%"CZ"@!]%%% !1110 4444 %%%%
M!1110 4444 %%%% !2,P52S$ #J2:1W6-"[D!1U)KQOXI?%JSL+";2-(E\V[
MD!5V7^#WH ]?BO;29RD5U#(XZJD@)%3U\N_ NZGN?'%T\LKL6CR<GOFOJ*@
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M_A0W@;_GUN__  (/^% ')?\ #2EM_P!"_+_W]%'_  TI;?\ 0OR_]_176_\
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M6N$905\GI^%?/'P3O#;^/);< XFE(Z].37T'XFNXX?"%Q.3E?*[?2OGGX.1
M>*+_ %'RV;[,Q88/3.: /5/C+XY'AW03I]G)_IMT"G!Y3C(->">)?"%QHOAJ
MSU6]R+J\E)(([$9!_6I+WQA%>_$%M8URWENX(9B# C 9"DCOQ6C\2/B18>-;
M&SM;+39K-;=ACS&!X QVH ]N^"/_ "(H_P"NI_E7I5?/?P?^)EI8V\'AQM/G
M:6648E#C:,^U?0E 'EWQUU>2P\"200MMEEE3GVR0:R/V>],6WT&\NROS3LK
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8*R:=;(P(98E!![' JQ110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\[RL''US7K/PP^'J>#])D:ZVR7=R/WN>GZUZ'10!F'PYHC,2=)LB2<DF!?\
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M4"#"QJ% ]A0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !535?^0/>_\ 7O)_Z":MU4U7_D#WO_7O)_Z": .3
M^$O_ "3K3OJ__H1KMZXCX2_\DZT[ZO\ ^A&NWH **** "BBB@ HHHH ****
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M]Y/_ $$T <G\)?\ DG6G?5__ $(UV]<1\)?^2=:=]7_]"-=O0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <]XUT&3Q)X:ETV-]C
M.Z-GZ'-;EM&8;6&(]415_(5S_CS6[CP]X5FU"V_UJ2(H_$XK?M9#-9P2MU>-
M6/XB@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ5QWQ2%P? UP+4.9?-CQL'/WJZNQS_9]MNZ^4N<_04 6**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"A^T'_R';;Z_TKUCX/?\D]M?^NC_ -*\G_:#_P"0[;?7^E>L?![_ ))[:_\
M71_Z4 ?/'B#_ )*E_P!O1_F:^MM&_P"0+9_]<A7R3X@_Y*E_V]'^9KZVT;_D
M"V?_ %R% %ZO*_COJ<EGX)>VB<H\KJ<CTS7JE>1_'VP>;P?]K7)$3*I 'J:
M//\ X!:/;7WB">^F0-);D;<CU%?3G08KYK_9[OH(-8N[:1P))2-H/? KZ4H
MH:AHNFZJ8S?V<5P8SE-XZ&I=D&F63&&+;'&,[$&:FDGAAQYLJ)G@;F S3+B\
MM[:TDN9)%\F-=S,#G H ^9M?N/%/CWQN^GE+VWL!+Y8S&P7;GKR*L^-O@RGA
M'0?[6T_4IY9T8;@X4 ?2M[Q+\=YDU&2PT33UFVL5$H)#9^E<=XEUGX@Z_I#S
M7;31:?U:-FX_44 =9\!_%^I7U[)I%[<//'@LA<_= '056_:4_P"/_0_^N3_S
MK'_9^_Y' _\ 7-_Y5L?M*?\ '_H?_7)_YT =Q\#?^1#MOH?YUS/[2G_(*T/_
M *[O_P"@UTWP-/\ Q0=M]#_.N5_:2F1K#1H@?G69R1_P&@#0^!5T++X?W%RP
MR(Y)&(_&O,M0UG4/'GCB33[_ %-[>S,QC +@ +GWKU#X"P)<^!)8)!E'DD!'
MXUY]XY^$&NZ=J]S>Z?'Y]K(YD#9P1D],4 ;'B#X)P:1I#:CX?UB2\N(AN*@J
M>!Z8ZUK_  5\5^(&U%M%UB"]:)E+I+-$P"8'3.,5Y+9^*/&/AMO*@NKVW6,X
M(V$#^5>P?#+XQ7&L:E'I&KQJ9&4XG)Y)% &C\:?B#=>'8(M*TR0I<7"DM(IY
M7!QBO(-)^''C+QK:C4X0DJ/\P>>7:3^E7/C3)-+\0+A"Q.V4B//;I6[X?T;X
MOG1;<Z/?LEB1^Z59EP!^5 '*V&N>*/AOXCC@NII%6-AOAW?(P^N*^L-"U2/6
M='M[Z,@B1 3CUP,U\VZS\,/B?XAN%GU54NI!T9YQ_A7NWPWTC4M#\'06.JQ+
M%=([$JK;ACC'- '6T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %5-5_Y ][_U[R?^@FK=
M5-5_Y ][_P!>\G_H)H Y/X2_\DZT[ZO_ .A&NWKB/A+_ ,DZT[ZO_P"A&NWH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,_6KZQ
MT_37N-1_X]PP!XSR3Q5V-E>)&3[K*"OTKE/B5IUUJO@RXM;1-\S2QD#/8-73
MV2&.PMT8898E!_(4 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9[C3V+DY^63 H \6'Q6\=>)_$"0Z)+);I,P"0A<@?C7TIHJ7D>DVXOY3+<E
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MGV=/_017S_\ 'GP_/;:S;ZRD;-$[;G8#[N*[32OBEH2?#_S7O46[CBVB O\
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M7T1X+T8Z!X4L=-;K"G- &?K/A_3=$\)7Z6-LD>4)+8&3^->$?!?_ )*'<?\
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MDYKI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2-M>D:7I5II%DEI9PK'$@P HQ5VB@#)U[P[IWB.Q:UU"!9%(X8C)7Z5Y['\
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M1<#H+]P/^^C0!Z/\==1F:+3-/)_<K"D@&>Y%=M\#O#%C:>&SJ+PH]U(V1)W
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ JIJO_('O?^O>3_T$U;JIJO\ R![W
M_KWD_P#030!R?PE_Y)UIWU?_ -"-=O7$?"7_ ))UIWU?_P!"-=O0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <QX_T6XU_PG-I]
MJ0)7D1AD>AS70VD9BLH(V^\D:J?P%8WC+7G\->'9=210S(Z+@CU.*VK:7SK6
M&4_QH&_,4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54U7_ ) ][_U[R?\
MH)JW535?^0/>_P#7O)_Z": .3^$O_).M.^K_ /H1KMZXCX2_\DZT[ZO_ .A&
MNWH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,/Q
M;H \2Z!+II<IO=6R/8YK8MXO)MHHO[B!?R%<S\0]7NM#\(3WUHQ699(U!!QP
M6Q726;F6RMY&^\\:L?Q% $U%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5-5_Y
M ][_ ->\G_H)JW535?\ D#WO_7O)_P"@F@#D_A+_ ,DZT[ZO_P"A&NWKB/A+
M_P DZT[ZO_Z$:[>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH RO$.C6VO:0]A=D"%F5B3['-:4,8B@CC7[J*%'X"N1^)]W<6/@F
MXGM7*2B6, CW:NJL6+:?;,WWC$I/Y"@">BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BB@G R: "BJK:C9HQ5KA 1VS2?VG9?\_,?Y
MT 6Z*J?VG9?\_,?YT?VG9?\ /S'^= %NBJG]IV7_ #\Q_G1_:=E_S\Q_G0!;
MHJI_:=E_S\Q_G1_:=E_S\Q_G0!;HJI_:=E_S\Q_G1_:=E_S\Q_G0!;HJI_:=
ME_S\Q_G1_:=E_P _,?YT 6Z*J?VG9?\ /S'^=']IV7_/S'^= %NBJG]IV7_/
MS'^=']IV7_/S'^= %NBJG]IV7_/S'^=']IV7_/S'^= %NBJG]IV7_/S'^=']
MIV7_ #\Q_G0!;HJI_:=E_P _,?YT?VG9?\_,?YT 6Z*J?VG9?\_,?YT?VG9?
M\_,?YT 6Z*J?VG9?\_,?YT?VG9?\_,?YT 6Z*J?VG9?\_,?YT?VG9?\ /S'^
M= %NBJG]IV7_ #\Q_G1_:=E_S\Q_G0!;HJI_:=E_S\Q_G1_:=E_S\Q_G0!;H
MJI_:=E_S\Q_G1_:=E_S\Q_G0!;HJI_:=E_S\Q_G1_:=E_P _,?YT 6Z*J?VG
M9?\ /S'^=']IV7_/S'^= %NBJG]IV7_/S'^=']IV7_/S'^= %NBJG]IV7_/S
M'^=']IV7_/S'^= %NBJG]IV7_/S'^=']IV7_ #\Q_G0!;HJI_:=E_P _,?YT
M?VG9?\_,?YT 6Z*J?VG9?\_,?YT?VG9?\_,?YT 6Z*J?VG9?\_,?YT?VG9?\
M_,?YT 6Z*J?VG9?\_,?YT?VG9?\ /S'^= %NBJG]IV7_ #\Q_G1_:=E_S\Q_
MG0!;HJI_:=E_S\Q_G1_:=E_S\Q_G0!;HJI_:=E_S\Q_G1_:=E_S\Q_G0!;JI
MJO\ R![W_KWD_P#031_:=E_S\Q_G574]1LWTJ\5;A"S0. ,]?E- '._"7_DG
M6G?5_P#T(UV]<'\+[F&R\ V$%S(L4JE\JW4?,:['^T[+_GYC_.@"W153^T[+
M_GYC_.C^T[+_ )^8_P Z +=%5/[3LO\ GYC_ #H_M.R_Y^8_SH MT54_M.R_
MY^8_SH_M.R_Y^8_SH MT54_M.R_Y^8_SH_M.R_Y^8_SH MT54_M.R_Y^8_SH
M_M.R_P"?F/\ .@"W153^T[+_ )^8_P Z/[3LO^?F/\Z +=%5/[3LO^?F/\Z/
M[3LO^?F/\Z +=%5/[3LO^?F/\Z/[3LO^?F/\Z +=%5/[3LO^?F/\Z/[3LO\
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MVG9?\_,?YT 6Z*J?VG9?\_,?YT?VG9?\_,?YT 6Z*J?VG9?\_,?YT?VG9?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#GBG_?-'V2W_YXI_WS4U% $/V2W_YXI_WS1]DM_P#GBG_?-344 0_9+?\
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M,810H]A3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*BN+B*U@>>9PD:#+,>PKSYOB7?7U_+#X>\.S:M#$2K312 #([<T >C45P_AG
MXBQ:QJDFE:G8MIFH(3B"1LD@=Z[B@ HJ"\N5L[.:X?D1H6QZX&:\QTCXKZUK
MZROI/@ZYNHXV(++,/6@#U6BN-T;Q1XEO]2BM[[PC<V-NYPT[R@A1794 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH \]^,>K-IG@>X5&*FX5H\@X[5
MI_#;38-/\'61B0!I8UD9NY)%<W\=H'F\&1LO1'9C^5=?X$8-X-TW!SB!/Y4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+LB@^T$960KD$ T >[T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTZ&RM/">LQPQC 5;? KO=#U8:UIB7HM9[7<Q'ESKM88]JT:* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2**^<F\>_%:&W_M:6Q8:6/F+>2OW?KFO3OAQ\2;;QI;/%(ODWT7WXR>>N,T
M=_17A/Q?^)?B7PEXN33])N8H[<P*Y#1ACDUZUX<U&YU#P=8:C<,&N)K82.P&
M 3B@#<JIJ.HVNE64EW>2B.%!RQKP+_A:WBK_ (6/-H_VN+[&MR(POE#.,CO2
M?&Z_\7K+<PO$Z:%O^60+C/IS0![+X6\8V/BQKHV!#0P$ ./XJZ2OE/X5WWCB
M"4IX?M6EL68>>PC!P*Z/XC_%7Q9X:\:3:98W44<$<<9V-$"<D<T ?1-%> GQ
MY\2M=,%[H6G.-/*JKR&)6!8#YCU]:Z_QU\3)/!^C6<31&75)HE+J,?*2.N*
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M;_\ 'G=?45IZWXSM-)G,")YTHZJ#TK+^'./L-WNZ<9K-UJ\\/V>I.T-K)/<
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M0#-?2=?.'Q&_Y'T?1:YL5\"/;R+2O+T-*R^"NJ7ME#=)JEJJRH& *-D9KKO
M?PRO_"?B'^T;B^@FC\IDVHI!YKO= _Y%^Q_ZXK6E50H05I(QQ&:XJHI4I/1Z
M;'FOQ&\:V^ASQ6D-I!<7;J<-)&K[>>G-<C#;^-O$VG-(VRUM2A8;(MH(_ T?
M%S1[V'Q!#?K$SPME]P' Y[U8L_B<S>%TTJQLI7O0FPD+Q6,I7FU-V/3H4>3#
M0GAXJ3>[?0Y7X;*4^(VGJQRRRL":](^,F@?:]'CU*)?FMR6D/MBO-O K-8?$
M2Q>[4QL)"6#<8S7T7K&GIK.C7%FV"LZ8YHHQYJ;B3F==T,;3JK:QX]I'C(1?
M"ZYM9)/]*;>BG/;C%6/@UHC2W,^LS(3NR@)]:\RU"SNK?59=+4,,3,%4=^:^
ME?!>D)H_AJUA48+H'8>Y%*C><U?H7F3AAL/)4]ZCO\CQ?XES27?C>&*4DH&V
M@9[9KW#PQ9P6WANRBBB4+Y0!X'/UKSGXJ^#KJXNH]8L(RY0895'.?6JF@_%D
M:-H\>GZE:2FXA78A"_SJXM4ZCYC"O3EB\'35#6VZ,#XFP1V?C826ZB-FER=O
M'<5L_$:>2Y\'Z1+*<L4.36-!I^J_$'Q;]L>!HX#)OW%< "NH^,%JEEHFG6\8
MPJ*16=KQG+H=:DHU:%%N\EO]Q?\ @Q9)'HLEUA2TG'3G@UT/Q#\.3>(/#_D6
M@ DB)<*!U)K)^#O_ "*R_4_SKH/&NI:YI6EBZT6*.5U),BLNXX]JW@E['4\G
M$3J?VBW!ZWZGB&E:CXI\$2&-+1HX@QW>9'G-=UX>^)VCZE>)#JFFP)<,<><T
M: 9_*J5C\5K;RV3Q-I(DGST2(?UKC-8;_A+/$D4NC:<\,3$* B8QSUXKG4N3
MX'?R/8E0^L-_6*?*_P"9,^F()(I84>$J8V&5*],5)69X>M);#P_8VLQS)%$%
M8^]:==ZV/DII*32/F;XB+N^)5\OK,H_E7T-H5@EEHMM!M0@(#P/45\]_$+_D
MIUY_UW3^E?2%G_QXV_\ UR7^5<U!>_(]W-I-8:@O+]$?/WQCN97\9O;$GRHX
MT91[D5[?X9T^VLO#UDD$2J'A5FXZD@9KSWXM>#;G46&KV2&211^\4#)( K.\
M/?%<Z)I0L=6M)C/&-J;1T]*46J=63EU+JTY8O!4HT-7'=&-\78(]-\9PO:J(
MR8@_ [U[-X< U#P58?:L,);8;R?>O%!:ZK\1/%D=VUNRP @;F7C;FO2?&?B*
M'P=X6BTZ!Q]H$8C4#J!TS2IM)RGT'C:<ITZ.&6LUN>+^,[.WTKQ1>0V,X,8<
MC"'[OM7JGP<TO3X]+:]1U>[?!89R4KB_!W@>X\6Q7FI79; !VDGECC@U6\,:
MQ>^!?%36EWN$0?;(M90]V2FUHSOQ2]O0EAJ<KSBE?S/4?B-XQMO#Z10BUAN+
ME\[?,C5]OYUQ-B/&WBNUS&J6EJ^<-'%L7]#3_BM8SW\MIJUHIFMY/FW)R!3M
M$^)QM/#*Z5:V<KWZ@A=J\9K24KS:D[(Y*%!PPL94(J4NM^AQG@^-X?B+IT4A
MRZ7FUCZD9S79_&RXD_M2&#/[L(K8]ZXWPX9;3X@Z?/>H8F-SYK!AC&<FO5?B
MMX:FUO3(M0LD,DBX) &25Q403=*21U8FI&&.I2GM8W_AQ:00>%+<I&H+J"QQ
MUXKRCXKV\4'BZ Q(%WY+8'4Y%:7@[XE_\([IYTW4+29Y%.$"#D5R'B_5KO6?
M$"7=U T2NV8E88.W-.I4BZ:2,L'A*U/&RJ3V=_F>KZI_R1JW_P!Q?YFN9^"O
M_(2O/]X5V3:=-JGPFMK: 9D,08#Z9KROP9XD?P5J\OVRVDVNWS*!S53?+.,G
ML8X>#JX:O2AK*[T.T^.W_'II/_71OY5J_#BQ.I?"9[)3@S22*#^(KSSXC>*+
MGQ*+25K22"U5B8BZXSQS7HGPUDO8OA7YFGA#=++(8PXR"<BG&2E6;\A5Z4Z.
M74XO1J7^9YI+H_B;P;K,US:VC]3B0IE2,UT^F?%>-Y8X=?TV*9NA8Q+Q^=2I
M\3]3L]0DA\3:8C0J<82+!/YUSOC/Q'IGBJ..'1-):)PP)(C )_*L[J"O!_(Z
M_9SQ$E'$4U_B3/<[/4+#4O#\MQIWEB%HC\L8 "\=*\!T;_DI#?\ 74_TKU?X
M;:)>Z9X.N(KH,)+@;E5NJ\=*\CNGD\->/)[F\A?9'*>@Z].E76;:C)G)EU.,
M:E>E!WTT/</&_B2T\/:+YMQ!'/(P^1'4-G\#7F&GZMXO\4"0Z;;PV]J?XHH
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MIT>G^&+&!53!A5^!QRHKSGXK?$:U\.7JZ?:V%K<W^T-OFA60 'IU%>IZ-_R
MM/\ ^O:/_P!!%?./QNT'4+7QDNJK TEMY:_,!D9H LR6OQ$\3Z#+=7)CL[(Q
M%PJP[ 5QVP:YWX.Q-!\25B9MS+&P)]:Z]?C VH>#DT+2]-N)+PP>2Q"9'3'%
M<;\*96T[XE*M^#%*%9&5N"&..* .K_:4_P"0[H?_ %[/_P"A5ZK\(/\ DE^B
M_P#7(_SKRK]I3_D.Z'_U[/\ ^A5ZK\(/^27Z+_UR/\Z .XHHHH **** "BBB
M@ HHHH **** "BBB@ KS;XF_\?MC_P!<V_G7I-8NM^&;+7I8I+II 8E*KL.*
MZ,+4C2JJ4MC*O!S@XHB\&?\ (JV?^Z:WZJ:;I\.EV$=G 6,<8P-QYJW6562E
M-R74N":BDSSOXCI-F!L-Y6[CTZ4GA37-)T_0V6Y6+SE8MA@,FNZU#3K?4[8P
M7"[E/3U%<^OP_P!(67?F8\YP6XKMAB*3HJG4OIV.:5*:J<\3SF6Z6Z\0"=1M
M1I<@>V:]BCA6YT98B 0\6!FLBY\#Z5<3)(?,0H,#8<5T-M MK;1P(2508!/6
MIQ6(A44>3H50I2@WS=3Q._CFT?5;BW&0%)7ZUW'P]TWRK22\=>9,%#6QJ?@[
M3=5O/M,YD#DY.TX%;%C91:?9QVT(^1!@9JZ^,C.ERK?J12P[C4N]CC?B#I,D
MT45W"C-LR7-1^#O%%G;:<ME>2+$4).YC@5WDD:31F.10RGJ"*YJZ\":3=2%V
M\Q23G"G%9TZ].5+V57H7.E-3YX'&^+M7CUS4DALU+J" I'.36Q?Z<^F^"8XG
M^\S;B/3(KH]-\(Z9IDHDB1G8=-_-:.IZ5;ZK:?9I]P3_ &3BKEBH+EA#X42J
M$GS2ENS@_AS_ ,?DGT-=[JM^--L6N6A>8 X*KUJEHWAFRT.1GM6D)(Q\QS6O
M)&DL91U#*1@@UAB*L*E7G6QK1A*%/E>YP::YX;UV8I=VQM?]IB!_*N9\20:1
M;7*?V1*7YY8/FN^N_ NDW<K2,)$)[(<"DMO >DVT@=?,8CLQS773Q-&#O%OT
M,)T:DE9I>I)X*:Z;08OM!)&3C/6NDID420QK'&H51T %/KSJD^>;EW.N$>6*
M1Y;\1?\ D,K_ +@K9\+^*[&'2?)NY1&\:\!CUQ6-\1?^0RO^X*U]&\*:=J^D
M12SAE; Y0XKU)>S^K0]IL<2Y_;2Y#D[^?^W/$FZW0[6DX^F:ZGQM;&T\/VUN
M3GRP!G\:Z/2O"VG:0^^!"S>K\U8UC0[76X1%<EPH_NG%8RQ<'4C;X8EJA+DE
M?=G*?#[_ )!=]C^[_2N1TZ6*T\2K)?+F-9#N#5ZOHV@6FAQ21VQ<J_7><U3U
M+P;I>IW#32JZ,>NPXIQQ=-5)M[2"5"?)%+='*^,M<TZZM([6Q"-CDL@&.E.\
M!0BZM;R#.-Z$?K72P^"-)@MI80KL)%P68\CZ58T?PO9:).\MJ\I+#!#-D4I8
MBDJ+IPN"HU'44Y'FL;-H/B7=.A"K)^8S7<:SXVM8-.62PGC>=OX>N*V-4\.V
M&K?Z^/#?WEX-947P^TB*0.#,<=BU$J]"K:52]T"I5874-F4=%O\ 5_$FFW/V
MW9Y(4[=J8R<<5R.ASQ:+KX^WPAD4D,K ?UKV"UM(;.W6&% J 8X'6LO5/"NF
MZK)OF0JW<IQFE3Q4$Y1:M%]ASH2:33U1S'B#Q590+&NE0VCNW4F)6_I6OI<E
MW<>&IKF[C@C9UX6.,)_*I+3P)I-I,)%\QR.SG(KH'M8GM3;XVQD8P*BI5I**
MC!?,J%.I=N1XI87IT_75N@,B.4L1^)KT'5O&&G2:'(J2!Y94V[0>0:LP^!-)
MAN3.#*S$Y(9LBFR> -(EF\TF4'.<!N*WJXC#U)*4KZ&4*5:$6EU.4\"6+W6L
M-<,#Y:J>?>J_BNQFT[Q$UZ4.QY?,![=:]1T_3+;3(?*MT 'KCFEO]-MM2A\J
MXC##UQS6?UW]]SVTV+^K?N^7J8-IXVT^32_/FF59PO,9/)-<)MF\2^)VGCC)
M#N"<=L5W#?#W2&DW[IA[!JVM+T.RTE<6\?/]X]:<:]"BFZ5[L'2JU+*>R+\2
M[(8U]% I]%%><=84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MF7/A[2+RX^T7.G6\LW]]DR:TZ*32>Y492B[Q=AL<:11K'&H5%& !VIU%%,D@
MNK*VO8_+NH$E3T<9JC;^&M%M9/,@TRVC?U5,5JT4K(M5)I63T,P^'=':Z^TG
M3K<S_P!_9S6D    , <"EHH22%*<I;NYF/X=T>2Z^TOIUNTX.=Y3FM)5"*%4
M8 X I:*$D@E.4MW<:Z+(I5U#*>H-94OA?0YY/,ETNV=_4I6O10TGN$9RC\+L
M5K6PM+%-MK;QQ+Z(,4V^TNPU-56]M8IPO02+G%6Z*++8.>5^:^I6LM/L].B\
MJSMXX(_[J# JPRJZE6 *GJ#2T4Q-MN[,F;POH=PY>;2[9V/4E*GM-$TRQ;=:
MV,,)]47%7Z*7*NQ;JU&K.3"BBBF9F7<>'-&N[IKJXTVWDG8Y,C)DDUIJ JA5
M& !@"EHI62*<Y25FQ&574JP!4]0:RIO#&AW$GF2Z7;.Q[E*UJ*&D]PC.4?A=
MBM::=9V"[;6VCA'H@Q4%]H>EZE('O;&&=@, NN:T**++8%.2?,GJ5[2QM;"'
MR;2!(8Q_"@P*J77AW1[VX,]SIUO+*3DNZ9)K3HHLAJI-.Z>I4.F636HM3;1F
M <"/'%58?#.B6\OFPZ9;(X.=RIS6K119 JDUHFS,D\.Z/-<BXDTZW:8='*<U
MH>6GE>7M&S&-O;%/HHLD)SE+=F2WAC0WF\YM+MC(3G<4YIT_AS1KID:?3;>0
MH,*63I6I11RKL5[6I_,_O(X;>&W@6"&-4B48"*. *SY_#>BW,OFS:;;R2?WF
M3FM2BBR9*G*+NF9D_A[2+F&.*;3K>2./[BLG JW96-KIUN+>S@2"$'(1!@9J
MQ119#<YM6;T,ZZT'2KY]UU803-ZNN:C@\-:+;.'@TRVC8="J5JT4<J[#]K4M
M;F8BJ%4*HP!T%9]WH&DW\ADN]/@F<]6=<FM&BAI/<F,I1=XNQ3M])L+6W:""
MTBCB;JBKP:J#POH0E\T:7;>9G.[9S6O11RH:JS6S9F7/A[1[P@W.G6\I'3<F
M<5>2V@B@\A(E6+&-@'&*EHHLA.<FK-F0_A?0I)?-?2[9GSG<4YK4BB2&)8XE
M"HHPJCH*?10DEL$IREI)W"BBBF2%%%% !1110 4444 %%%% !1110 5GZEH6
ME:OC^T;""YQT\Q<XK0HH K65A::= (+.WC@B'1$&!27^FV6J6QM[ZVCN(2<E
M)!D9JU10!F:=X<T;29#)I^FV]LYZF-,5>N+:"[A:*XB62-NJL,@U+10!A#P9
MX:683#1;,2 Y#>7S6U%%'#&(XD"(.@':GT4 5[NRM;^'R;N!)HS_  N,BLZV
M\*:!9R>9;:3:Q.?XE3!K9HH QO\ A$] %X;P:3:_:"VXR;/FSZUK2PQSQ&.5
M Z'JI'!I]% &&O@WPVL_GKHUF)0<[_+YI]YX3T#4+G[3=Z3:S3$ ;W3)XZ5L
MT4 -1%CC6-%"HH 4#L!5>]TVRU*+RKVVCGC_ +KC(JU10!CVGA70;"7S+32;
M6%_[R)@T?\(KH/VXWO\ 9-K]I+;C+L^8GUK8HH S=3\/Z1K,D<FI:=;W3QC"
M&5,[15NSLK;3[5+6S@2&",86-!@"IZ* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G]
M;\)V>N70GN)9$8 #"UJ:;I\>F6BV\3,RKW:KE%:.K-Q46]$2H13YDM0HHHK,
MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gapk0ju0ozex000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gapk0ju0ozex000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +Q!?$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<&.-V.2T>3MS^&*[>A^0:[,****0!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11574;P
MV%A+<K#),R#B.,9+&ANP+4M4W>@_B7\ZXG^QO%/B/]]J>J-I-JW*VEIR^/\
M:?CG\*@D^$.@7$@EN;O5)9A_&;H_X4:]0T.^!!Z'-+7##P+?Z4 ^A>)+V!UY
M$5R?-1O8C(K<T#4]4N&ELM8L?(NX<?O8SF.4>H/]*>X;&[1112 **** "BBB
M@ HHHH **** "BBB@#G_ !U_R(6O?]>,O_H)KE/@7_R3YO\ K]E_DM=7XZ_Y
M$+7O^O&7_P!!-<I\"_\ DGS?]?LO\EH ]+HHHH **** "HYX(KF%H9HUDC88
M96&0:DHH X6_^%'AV]N/-C%Q;Y.2D3@+^HK9T'P7HOAUO,LK<M-C'FRG<U=#
M12LC*-"E&7,HJX4444S4**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *IZIIT.K:9<6,XS',A4^WH?SJY12:NK#3L[F
M%X634;733I^I1$26C>7'-VE0?=/Y8'X5NT453=]62E8****0PHHHH Q]7\-V
M.M:CIM[=-,)=/E\V$(P )XZ\<]*DUK0+#Q!;Q07Z,\<3B15!QR/6M2B@!%4*
MH50 !P *RO$4E^ND2Q:; 9;J;]VI[)G@L?H.:UJ*&K[@M#,\/Z/%H>C06,?+
M*,R-_><G)/YFM.BBFW=W$E8****0PHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***KWR
M7,EC,EG(L=R4(C=AD*WK0]@18HKS;^Q?BI_T-.G?^ J__$T?V+\5/^AIT[_P
M%7_XF@#H=1FN$^(&D1+(X@>WF+(#\K$8ZBNHKA- \.^,$\26^H^(]8L[V&WC
M=46*$(06QZ >E=W3VBEZ_FP>KN%%%%( HHHH "0!D\4R.:.92T4B.H."58'F
MN3\2:)K>KR7.[6&L],2,E8K<8D<@=VZ@?0UG?!TL?! W.SM]HDRS')/S&B.M
MQM65SI/$/BBR\/)$DRR3W4YVPVT(R\A]JQQX^DLIHAKFA7VF6\K!4N)=C(,^
MNUCBJ/BV&;2O'ND>))8))M/BC:"4HI8Q$Y ; [<T>/=6L_$'APZ-I#)J%Y>D
M*BP_.(_]IB/NX]Z%LGOK_7^865[;>9Z CK(BNA#*PR".]1/?6D<PB>Z@60]$
M:0 _E7,Z]J4WA'P!YNX-=0PK$A/=R.*JZ7X"TZ?04?4A)<:E,F^2Z:1MZL?[
MISQ^%#W=MD);*_4[>BN,^'^J74T.HZ-?2M+<:9.81(QY=,G:3^&*[.F_(-=F
M<_XZ_P"1"U[_ *\9?_037*? O_DGS?\ 7[+_ "6NK\=?\B%KW_7C+_Z":Y3X
M%_\ )/F_Z_9?Y+2 ]+HHHH ***KSWUI;.$GNH(F(R%DD"G'XTTF]A-I*[+%(
M2 ,DX [FJG]K:;_T$+3_ +_+_C7%>/?$X2".PT^Y5O,&9)(G!P/3(K2E1E4D
MHHYL1BZ="FZC=['577BG1+.7RI]1B5QV )_D*N66IV6HIOL[F.8?[)Y_*OG_
M *G)JYINI76E7B7-K(493DC/#>QKT)9='E]UZGA4\_GS^_!<OEN>_P!%96GZ
M_I]YI\%PU[;1M(@)5I5!!^F:L_VMIO\ T$+3_O\ +_C7F.$D[6/HU6IM731<
MK@_$>MZZ/'VG:#I=]%:PW$#2.S0*YR/K7=(Z2(KQLKHPRK*<@BO-/$E];:?\
M8=%GNYTAB%HX+N<#H:2^))^?Y,MOW6U_6J-/6/$'B'PBT-UJJV]]I;.$EFB&
MUX\G&2N,8_&HO&.KW4?B+PA]BNYHK>[NOWBQN0)%^7@COUJOXTU@>++#_A'-
M"AEN9;EU$L_EL(XUSR=Q&#QZ5!XPM?L.O^!;7.?*N0F?IMHAK*-^Y3M9V[,]
M.'2BL36-%EU212^JW-K;*N#'"0N3ZENOZUQ^DW=SX>^(<&@PZK+?Z?=0EP)I
M/,:-AC^+DTEJ[$O17/2Z*XW4M2N];\7/X<LKI[6&WA$MU-&!N.>B@]NHJWI^
MA1^$XKW4'U6^NH5B+M'<REPN.21FE?3F>Q5M;+<Z>J6KR/%H]Y)&Q5UB8A@<
M$'%<)I.GW7B_3?[;U'7+FU:9BUM%;S>6L:CID C/XYJUX=UVYU/PWKFGW\RS
MW>FEH6E7'[P8.#Q]*4T^62ZI#C;F7:Y=^%]]=ZCX&L[F]N9;B=F;=)*Q9CSZ
MFNQKR?X<^'KC6? 5KYVK74%N2PCCMFV$<]2PP:V?"FIZCI/B?4O#.JW;W4=O
M%Y]O<2?>*<'!/?%:SMSM&</AN=_17GFD&^\?7%]>7-[<6NE0RF""&W<QL^.K
M%A@]??M4L=Y?^$?%UCI-S>R7>EZCE(#,<O&XQQNZD<CK4I:I/J4^K70[ZN>\
M0Z[-8W5EIFGHLFH7CX4'HB#DL?RQ^-=#7#^'G_M7XB:]?/\ ,+-5M8\_P]"?
MU%):RM\PVBV=L@8(H<Y8#D^IIU>?_$?5-4T_4/#\.F7/DM<W8C;/0CWJ/Q9X
M>U*PT.YUR#7[T:A:1F;[^(VP,XV=/THOIS/8:6O*MST2BN6T[QA:)X/T[6=3
M:1!<H,^5"TAS]%!-1_\ "R?#?_/:]_\  ";_ .)IM6;78E:JYUM17-Q%:6TE
MQ.X2*-2S,>P%5]+U6UUFQ6\LVD:%B0#)&R'CV8 UR^O2/XIUU/#MJY%E;D2W
M\BGKCD1Y]^,^QI-.]NHU;<M^#/&(\7+J$B6PAAMIS%&<\N,#D^G6I=>\5G3=
M2@TG3[-K[4YAN$2G"HOJQ["L/X;(D5_XCCC0(B7NU5 X "+46C2+'\8M:CN2
M!,]NGD;NI7+9Q3LFXI=5?\+ALI/L_P!;&K9^,KRVUJWTKQ%I@L)KG_431OOB
M<^F>N?PK5\3:C?Z191ZA:(LL$+@W,>.2G0D?3K^%87Q4@4^%H[P<2VES'*C#
MJ.<?UKK(]NI:(GF ,MQ;C</7<O\ ]>IO>+:W3_X(]%))]2:SNHKZSANH&#12
MH'4CT-3UQ'PSO'DT:]TZ0G.GW<D*Y_NY)'Z&NWJI))Z$J^SZ!1112&%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1XEUQ?#V
MB3:@8FF92%2->K,Q  _,UQ@U;XJ7"B:'0=(2-QN57FP0/?YNM=;XPDT^'PS=
MS:DQ6",!P0,D,""N/QQ7&V?Q)\0?8X=G@;4KI=O$ROM#CL<;3274I[(W?#=W
MX\FU4+XATW3K>QVG+V\NYMW;C<:[*N.\.>,=7UO51:7OA*^TR(J6^T3297([
M?=%=C5/9$=0HHHI#"BBB@"O?_P#(.N?^N3?RKAO@[_R)/_;S+_Z$:WO$,OB7
M>T&D:?:7%O)&59Y;C803[8KF? ^D>,O#%A%ILVG6+6YF9WE%UD@$YX&*<-WY
M_P"8Y/W;>?Z,O^)+RZUKQ?:^%8)C!:M%YUTZXW.O]T9]:K^)?#=MX3TB37?#
MJ"SN;)-\B@Y69!R0V?QZ5J^)?"][>:Q::[HMREOJ=L-A$BY25.X/(]:S]2T?
MQ;XIM1INJ?8]/L'8"<P/YCRKW Z;<_C4J]M-_P"OT#2^NQ0^(5VVM_#"UU*-
M2%>2*9QZ#G->BV4BRV,,B$%60$&J<VA64^@'1GC_ -$,7E;?:N7M=,\::3I_
M]CV<EE<6R@I%=RDAT7ME<\G\15-K5+O="5VHWZ%+PJ)[GQ/XTGL6Q(6,43=O
M, X]NM<U_97QK_Z"2?\ ?V#_  KU+POX=C\.:5]F$AFN)&,D\Q&#(YY)_,UM
MT6LE%=$%[MON>!:]IOQ<CT#4'U6_5]/6!S<KYD)S'CYN@ST]*[+X%_\ )/F_
MZ_9?Y+75^.O^1"U[_KQE_P#037*? O\ Y)\W_7[+_):0STNBBB@05Q_BKP9/
MXAU..[BO(X56(1[60GH2?ZUV%%73J2IRYH[F-?#T\1#DJ*Z/,O\ A5UW_P!!
M.#_OV:YWQ'X9N/#DT*2RK,LH)#JI X[5[?6?K&CVNM6+6URN0>58=5/K793Q
MU127.[H\O$9+0=-JDK2Z:L\$HZG KM;SX:ZI'*1:2PS)G@L=IQ6QX?\ AXMI
M<)<ZG*LC(0RQ)T!]SWKOEC**C=.YX5/*<5*?(XV\^AD6/PWO;RRAN&O8HC(N
M[8R$D58_X5==_P#03@_[]FO3    !@#I2UYKQU:^Y]$LFPB6L?Q94TJS;3])
MM+-G#M!$L98# .!BN!UZ"&X^,VBQSQ)*GV1_E=0PZ'L:])JE+I&GS:I%J<EJ
MC7L*E(YC]Y0>U<E_?YGY_DSTU%*'(O+]"S%!# ,11)&/1% KS_X@_P#(X>#?
M^OT_^RUZ)5*\TC3]0N;6YN[5)IK5]\#MU1O4?E0M))]B^C7='G^KW*:M\3?[
M&UB[>WTR&V$D4/F&,3-GN1@G\ZS)YM%T_P"+>CO8%([3RVB,H8LA?TW$\FO3
MM2T#2M7='U"QBG:/[K,.1^(J0Z-IICA0V4.V!MT8V_=/K2CI;R_'?_,F2YDU
MW.!>[C\)_%>[NM2?RK'5856*=^%# #@GH.E=EK!MM;T*^L+2ZBDEN+=U0(X)
MY!%:-[I]IJ,/DWEO'-'_ '7&:JZ;X?TK2)&DL+*.!FZE2?ZFE:\>5E7M+F1Y
M_P" K?PU<:"FG:DJQ:G:$QSQ2SNC=>N-PXKK?[.T.PT75CHZ0*7B/G&*0L2<
M'&>3[U?U'POHFK2>9?:;#,_]X@@_I5NUTJQLK5K:VMDCA889!T-.5Y)^8+1H
MX3X5:M8VG@>VM;NX2WFC!<I,=I*GD,,]1[TW0ROBGX@:OJ]KSI\5O]DCF'1V
MQ@X/?O7:WGAO1[^".&ZT^&2., (I&, ?2KMI9VUC;K!:PI#$O14&!3DU*3DR
M4K1LOZZG!_#J^BTA;_P[J#+;WEO<NZ+(<>8AY!&>M,U^6/Q1X_T.RT]A,FF2
M&XN94Y5,XP,^O!KM=1T'2]7Q]OLHIR.YR#^8J:QTRRTR+R[*VCA3N%'6A/5-
M]![)I=?U+?:N"\"H;;Q7XLMW/SM=B49]#G_&N]KBM54^'/&\&M;3]AOT%M<L
M.B-QM8_EC\:4?B]=/Z^X;^%KYF;\2_\ D/>$_P#K_6NF\<?\B/K'_7I)_P"@
MFM.]TC3M4DMI[RUCG>W?S(6;^!O458N[2"^M);6ZB66"52CHW1@>HI25Z?)Z
M_H$7:HI^AQ/A9=5;X:Z*-(BLI)_*&1=J2N/P(YJQY7CC_GS\._\ ?E__ (NN
MLLK*VTZSCM+.%8;>(;4C7HHJQ5S?-)R74E:*Q@2R:[;>%+AVM;9]5"D)%:@J
MA).!C)/UKEO#E]K>@Z<83X0O);F1C)/.;E,R.>IZ=*](H[5/=]Q]+'D'PZUS
M4TU36%70IYEGOB97$JCR> ,'CG%=YXA\'V?B">&]$TUEJ$/^KNK<@./8YR"/
MPJGX)\.W^@W&L/>B,"[NC+%L?/RD#K^5:&K3>*(KP_V7:V5Q;D#'FR;&![_6
MAVM'T7Y#^U+U9P/CS0=3L= C2^\37U^TUPD45NZ1A6.<\X4'MZUZI8P_9=,M
MX6X\J%5/X"N5LO"VIZCK<6K^)KJ*5K<YMK2!<1QGU.2<G\JV/%.K#2=%E*?-
M<SCR;=!U9VX'^/X4/2-NK_I"LG)>1S?PS0O-XBNP"(YM1?;[X ']*[^L3PGH
MQT/P];6C_P"N(,DQ]78DG]36W52TT72R^X5[MR[A1114C"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH **** "BBB@ HHHH *CG@BN8C%/&LD9ZJPR#4E% "*H10JC"@8
M':EHHH **** "BBB@ HHHH *AEM8)Y8Y)8D=XCE&8<J?:IJ* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"ZA1110 4444 %%%% !1110 4444 %%%% '/^.O^1"U[_KQE_P#037*? O\
MY)\W_7[+_):ZOQU_R(6O?]>,O_H)KE/@7_R3YO\ K]E_DM 'I=%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV'V\SNZ*X_P%K-W>V]]IFHR&2\TV<P-(>KJ"<'\J["FT+R9S_CK_ )$+7O\
MKQE_]!-<I\"_^2?-_P!?LO\ ):ZOQU_R(6O?]>,O_H)KE/@7_P D^;_K]E_D
MM(#TNBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#Q+XU?\CEX4_P![_P!J+7MM>)?&
MK_D<O"G^]_[46O;:!A1110(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH YGQ[:3WOA.X@@+@,Z>;L//E[QN_3--T_P
M1X4_L^W,>BV,B&,8=H58GCN<5JZ]I(U[1;C3Q=RVPF 'G0MAASG@UP2?!YXT
M")XOUQ5'0+/@"DNHWLCN[#PSHFEW/VFPTNTMI@,;XH54X^H%:M<5X9^'\GAW
M5A?-XBU2^ 0KY-S-N3GOBNUJF(****0!1110!7O_ /D'7/\ UR;^5<-\'?\
MD2?^WF7_ -"-;_B&\\01E[?2]$%[#)&093<(F"1Z,17+^ K+Q;X9TV/2[KP^
MAB:9G>8749V@DGINS3AN_/\ S')^[;S_ $8S5M,M-0^,5O!J*&2&6R)1"<*V
M,Y!'>KGCCP=HUKX8N]1TRR@T^]LHS-%-;((VRHSR16OXM\,W6JW%EJFE3)#J
MEBV8R_W77NI]CDUF:K9^+O%-@=)N[&#3+67Y;B<3*Y=>X4 G&?>IL^5):/\
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MV%<-\/[/PO"L\^C:H=3O'XGN9F)D/_?7.*[FJM9)"O=W"BBBD 4444 %%%%
M!1110 4444 %%%% '/\ CK_D0M>_Z\9?_037*? O_DGS?]?LO\EKJ_'7_(A:
M]_UXR_\ H)KE/@7_ ,D^;_K]E_DM 'I=%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO\EI >ET444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ71110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH \2^-7_(Y>%/][_VHM>VUXE\:O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU%KVV@84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M":Y3X%_\D^;_ *_9?Y+0!Z71110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 <WXZ:Z3PI<O:JS;60RJG4Q[AO_\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O%?
M/_)=O%7_ &\?^C5KVJO%? /_ "7;Q5_V\?\ HU: /:J*** "BBB@ HHHH **
M** "BBB@ HK.U#7=-TQ"UU=QJ1_"#EOR'-<[)XSO+]_*T/2I9R>!+("%_.M8
M49RU2T.>KBJ5-V;U[+5_<=D6"C+$ #N36-J/BK2--^62Z627M''\Q/\ 2L4>
M'-?UAM^KZHT,9_Y8P'!'L<5LZ;X4TC3,&.U623KOE^8_K5<E*/Q._I_F9^UQ
M%3X(\J[O_)?YF*?$NO:PVS1]*:&(\>=/@8_"G)X-O-2(?7=4DGSUAC8[:[(
M*,   =A2T>W:^!6_,%@U+^-)R_!?<OU,W3M!TS2U'V2TC1A_'MRWYUI445BY
M.3NSJA",%:*L@HHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ^<+W_DXI?^PK%_):^CZ^<+W_
M ).*7_L*Q?R6OH^@84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBL#Q5X6C\4V45M)?W=F(WW[K63:3P1@^
MW-)C1#X\LIM0\*7$$.[:70RA3R8PP+?IFI-.\+>&SIUN8=(L7C\L89H5)/'<
MXKB[[X4:586K3WGBG68X00I9[H8Y. .GO4T7P;L?*4Q^(];"$97;<#&/RIKJ
M#Z'?VFAZ583^=::=:P2XQOBB53CZ@5H5P/A_P7I_A3Q);O\ V[J5S<S1N(X;
MF;<K 8R<8[5WU-[(74****0!1110 4444 9FLZ]IV@6HGU"<1ACA% +,Y] H
MY-8UG\0M%N;N.VF6\LVE.(VN[9XE;\6 %8GBW;8_$C0M2U,9TH1M&'?[B2'.
M,_F*M?%":RN?"GV*,)-?73*+-$Y<MV(Q0MD_,=M>4[P$$ @Y!Z&EKF-1U:7P
MMX$%Y=?/<00!<'N^.!63I_@VZU+24U'4M5O?[6F3S \<FU8B><!>F/K0]&_(
M2U2;ZG>T5R?@77;K5+.[L=1;=?Z=,8)7QC?@D!OQ KK*;5@.?\=?\B%KW_7C
M+_Z":Y3X%_\ )/F_Z_9?Y+75^.O^1"U[_KQE_P#037*? O\ Y)\W_7[+_):0
M'I=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !116'JWBS2]))C>82S]!%&<G/I[5482D[11%2K"G'FF[(W*\(\1PFW\07
ML9(.),Y!S7H)_P"$E\3=!_9=BWJ/G84S4_AW;2::%LY7-ZO)DD;._P!C7=AI
M1H2]][GBYC3J8VG^ZCHM;O2_HCRVBKU_H]_IDC)=VTD>#]XKP?QJFB/(X1%+
M,>  .37KJ2:NCY:4)1ERR5F-KUWX=63VOAUI'!'VB4R 'TZ?TKDO#G@:]U">
M.>^C>WM0<D,,,WX5ZO##';P)#$H5$&% [5YF.Q$7'V<3Z+)<#4A/V]16[$E%
M%%>6?2!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !11T&36%J_BS3-)S&9#/<=HHAN-5&$
MINT49U*L*<>:;LC=Z5A:OXMTS228VE\ZX[11\G\:P@/$_B@_,?[+L&]#\[#^
MM;ND>$]+TC$D<7FS]Y9.3^'I6WLX4_C=WV7^9R^WK5OX,;+N_P!%_F86WQ/X
MH//_ !++!NW5R/ZUO:1X4TS2,.D7FS]Y9>36Y14RK2:Y8Z+R-*>$A&7//WI=
MW^G1!TZ4445B=0UXTD^^BM]1FO&/ 9W_ !P\3PMS'&)PBD<+^]7I7M->*^ ?
M^2[>*O\ MX_]&K3NQ<J>K1[51112&%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7TZ66._\S; ) "FYPW)QSTKZ9:UMW8LUO$S'J2@)-)]BM?\ GVA_[]B@#B_
MOQ-M_'&I7-E#IDMH8(?-+/*&SR!C@>]=W4<<$,1)CBC0GJ54"I* "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0HHHIFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZG>T5R_@GQ!<:U8W-O?@#4+"8P3[1@,02-WXXKJ*;5A'/^.O^1"U[_KQE_\
M037*? O_ ))\W_7[+_):ZOQU_P B%KW_ %XR_P#H)KE/@7_R3YO^OV7^2T@/
M2Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/,VC';.,\>M>[>%/BAHOC#6#IFGV][',(FES,BA< @=F/K0,[>BBB@04444
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M52S$ #J37-:KXUL+*3[/:*U[='@1P_,/S%7"G*;M%&56M3I+FF['2DA02Q
MZDUSNJ^,;"P<P6VZ\NCTCA&[]:RETKQ'XD;S-2NC86C=(8N&(_G^==+I?A_3
MM(C MK==_>1N6/XFM>2G3^)W?9?YG/[6O6_AKE7=[_)?YG.?V;XB\2_/J$_]
MGVAZ0QGYB/P_K70:3X<TW1D MH%,G>1^6/XFM:BHE6E)<JT79&E/"TX2YWK+
MN]_^!\@HHHK(Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;S.\HKFO!GB*77M.F2\14U"SE,%RJ]-P.,CV.*Z6FU8#G_'7_(A:]_UXR_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#P4H7.TW,8?Z<UW%H%%G"%^[L&*YV_\ #5]J_A&ZTG5=1%W<2Y*3^4J;3VX
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBBLCH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!SGCFQCO\ PO<)+)&D<;I*WF,%5@K D$GUQBI-.\0^
M'&TZW,>I:;$OEC"&=!M]L9K3U32[/6=/EL+^$2VTN-Z$D9P<]JY;_A4W@O\
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M"JBM3OR^E*57GMHCI0H484  =@*6BBM#WPHHHH **** "BBB@ HHHH ****
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M7_R3YO\ K]E_DM(9Z71110(**** "BBB@ HHHH **** "BBB@ HHHH ****
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MD\327VCT&BO/O^$A\>7S?Z)X>@AC)X:20 C\S0VF?$2_/SZM:6:D?=$8./Q
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M^M;M%%D5&C3CM%$$%G;6PQ!;QQC_ &% J>BBF:A1110 4444 %%%% !1110
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M&A26T448-%TRVQY-A;+CH?+&:N+&B#"(J_08IU%,T22V"BBB@84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 <9K?Q1\+^']7GTO4+F=+J @.JP,P&0".1[&O(]*\;:):?
M&6_\2RS2C39@X1Q$2QR@ ^7KU%>WZCX'\,:M?R7U_HUM<74N-\K@Y; P._H*
MJ_\ "M?!G_0O6?Y'_&@8WP[\1_#GBG5/[.TNXFDN/+,F'A91M&,\GZUUE8>D
M^#O#NA7OVS2])M[6XVE/,C!S@]1U]JW*!!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 'X7_"@#RW_AH'1_^@+??]]I1_PT#H__ $!;[_OM*]2_L?3/^@=9_P#?A?\
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MWW_?:4?\- Z/_P! 6^_[[2O4O['TS_H'6?\ WX7_  H_L?3/^@=9_P#?A?\
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MIG_0.L_^_"_X4?V/IG_0.L_^_"_X4 >6_P##0.C_ /0%OO\ OM*/^&@='_Z
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M * M]_WVE>I?V/IG_0.L_P#OPO\ A1_8^F?] ZS_ ._"_P"% 'EO_#0.C_\
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M .@+??\ ?:5ZE_8^F?\ 0.L_^_"_X4?V/IG_ $#K/_OPO^% 'EO_  T#H_\
MT!;[_OM*/^&@='_Z M]_WVE>I?V/IG_0.L_^_"_X4?V/IG_0.L_^_"_X4 >6
M_P##0.C_ /0%OO\ OM*/^&@='_Z M]_WVE>I?V/IG_0.L_\ OPO^%']CZ9_T
M#K/_ +\+_A0!Y;_PT#H__0%OO^^TH_X:!T?_ * M]_WVE>I?V/IG_0.L_P#O
MPO\ A1_8^F?] ZS_ ._"_P"% 'EO_#0.C_\ 0%OO^^TH_P"&@='_ .@+??\
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M M]_WVE>I?V/IG_0.L_^_"_X4?V/IG_0.L_^_"_X4 >6_P##0.C_ /0%OO\
MOM*/^&@='_Z M]_WVE>I?V/IG_0.L_\ OPO^%']CZ9_T#K/_ +\+_A0!Y;_P
MT#H__0%OO^^TH_X:!T?_ * M]_WVE>I?V/IG_0.L_P#OPO\ A1_8^F?] ZS_
M ._"_P"% 'EO_#0.C_\ 0%OO^^TH_P"&@='_ .@+??\ ?:5ZE_8^F?\ 0.L_
M^_"_X4?V/IG_ $#K/_OPO^% 'EO_  T#H_\ T!;[_OM*/^&@='_Z M]_WVE>
MI?V/IG_0.L_^_"_X4?V/IG_0.L_^_"_X4 >6_P##0.C_ /0%OO\ OM*/^&@=
M'_Z M]_WVE>I?V/IG_0.L_\ OPO^%']CZ9_T#K/_ +\+_A0!Y;_PT#H__0%O
MO^^TH_X:!T?_ * M]_WVE>I?V/IG_0.L_P#OPO\ A7SS\7;:"W^)\$4,,<49
MA@^1$ '4]A0,[3_AH'1_^@+??]]I1_PT#H__ $!;[_OM*]2_L?3/^@=9_P#?
MA?\ "C^Q],_Z!UG_ -^%_P *!'EO_#0.C_\ 0%OO^^TH_P"&@='_ .@+??\
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M M]_WVE>I?V/IG_0.L_^_"_X4?V/IG_0.L_^_"_X4 >6_P##0.C_ /0%OO\
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M!0.!3Z*BK6G5=Y,[,/A*.'C:DK!11161T!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4A^Z?I7/ZAXQL;&ZEMDMKV[FAX=+>+.._<@5)H?B[
M2O$$TEO:R/'=1#+V\R[77\*%KL#TW/-?@1&\=SXDWHRYDBQD8SR]>ST@ '0
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M/E\%Z7:PWUM)=1VH+0)*I=<>J@YJHJT9+T_4):J+]?T,:SN!\//$>J'4U/\
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M6BL#UU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XZ_
M^'EK?:[-JXUG58+F48_=2)A1Z#*G%6M-\''3K^*Z.OZM<>6<^5-(A1OKA173
MT4+38'KN,:&)CEHT)]2HKA/B%H]U?7F@M8V#S+%>AI3%'G:N#R<=J[ZBCJGV
M!ZIKN-5%0810H]ABG444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %5+[2['4PHO;6*<)]WS%SBK=% '#>./#>BVW@K5IH=-
MMXY$MG*LJ<@XJQ\.=)L(/!^DWD5I$ER]L-TH7YCFNP9592K $'J"*%544*H
M4= !33LGY@]4EV.0N_!MW;:M<:GX>U3^SYKDYFB=-\3GUQP<_C4FF^#Y1K,>
ML:YJ#:A?1+MA 7;''[A?7ZFNLHI+38'J%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
910 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gapk0ju0ozex000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gapk0ju0ozex000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .$!5L# 2(  A$! Q$!_\0
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MA>G-4D M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %':B@]* &&F]C3J2GL):IHA.4&X8"]R349O(7_P"6D7'JXK&\:WDE
MIX;NY87V,@X->6>'O#VN>(-,^V#560.[#[OO42G8Z*.%BZ;;/;Q>P ?ZV/\
M[Z%'VZW_ .>L?_?0KRG_ (5]K^/^0TW_ 'S1_P *^U__ *#3?]\UE[5FJP]+
M^8]6^W6__/6/_OH4?;K?_GK'_P!]"O*?^%?:_P#]!IO^^:/^%?:__P!!IO\
MOFCVK#ZO2_F/5OMT'_/6/_OH4?;H/^>L?_?0KRK_ (5[K_\ T&F_[YH_X5[K
M_P#T&F_[YI>U8?5Z7\QZK]N@_P">L?\ WT*/MT'_ #UC_P"^A7E7_"O=?_Z#
M3?\ ?-'_  KW7_\ H--_WS1[5A]7I?S'JOVZ#_GK'_WT*/MT'_/6/_OH5Y5_
MPKW7_P#H--_WS1_PKW7_ /H--_WS1[5A]7I?S'JOVZ#_ )ZQ_P#?0H^W0?\
M/6/_ +Z%>5?\*]U__H--_P!\T?\ "O=?_P"@TW_?-'M6'U>E_,>J_;H/^>L?
M_?0H^W0?\]8_^^A7E7_"O=?_ .@TW_?-'_"O=?\ ^@TW_?-'M6'U>E_,>J_;
MH/\ GK'_ -]"C[=!_P ]8_\ OH5Y5_PKW7_^@TW_ 'S1_P *]U__ *#3?]\T
M>U8?5Z7\QZK]N@_YZQ_]]"C[=!_SUC_[Z%>5?\*]U_\ Z#3?]\T?\*]U_P#Z
M#3?]\T>U8?5Z7\QZK]N@_P">L?\ WT*/MT'_ #UC_P"^A7E7_"O=?_Z#3?\
M?-'_  KW7_\ H--_WS1[5A]7I?S'JOVZ#_GK'_WT*/MT'_/6/_OH5Y5_PKW7
M_P#H--_WS1_PKW7_ /H--_WS1[5A]7I?S'JOVZ#_ )ZQ_P#?0H^W0?\ /6/_
M +Z%>5?\*]U__H--_P!\T?\ "O=?_P"@TW_?-'M6'U>E_,>J_;H/^>L?_?0H
M^W0?\]8_^^A7E7_"O=?_ .@TW_?-'_"O=?\ ^@TW_?-'M6'U>E_,>J_;H/\
MGK'_ -]"C[=!_P ]8_\ OH5Y5_PKW7_^@TW_ 'S1_P *]U__ *#3?]\T>U8?
M5Z7\QZK]N@_YZQ_]]"C[=!_SUC_[Z%>5?\*]U_\ Z#3?]\T?\*]U_P#Z#3?]
M\T>U8?5Z7\QZK]N@_P">L?\ WT*/MT'_ #UC_P"^A7E7_"O=?_Z#3?\ ?-'_
M  KW7_\ H--_WS1[5A]7I?S'JOVZ#_GK'_WT*/MT'_/6/_OH5Y5_PKW7_P#H
M--_WS1_PKW7_ /H--_WS1[5A]7I?S'JOVZ#_ )ZQ_P#?0H^W0?\ /6/_ +Z%
M>5?\*]U__H--_P!\T?\ "O=?_P"@TW_?-'M6'U>E_,>J_;H/^>L?_?0H^W0?
M\]8_^^A7E7_"O=?_ .@TW_?-'_"O=?\ ^@TW_?-'M6'U>E_,>J_;H/\ GK'_
M -]"C[=!_P ]8_\ OH5Y5_PKW7_^@TW_ 'S1_P *]U__ *#3?]\T>U8?5Z7\
MQZK]N@_YZQ_]]"C[=!_SUC_[Z%>5?\*]U_\ Z#3?]\T?\*]U_P#Z#3?]\T>U
M8?5Z7\QZK]N@_P">L?\ WT*/MT'_ #UC_P"^A7E7_"O=?_Z#3?\ ?-'_  KW
M7_\ H--_WS1[5A]7I?S'JOVZ#_GK'_WT*/MT'_/6/_OH5Y5_PKW7_P#H--_W
MS1_PKW7_ /H--_WS1[5A]7I?S'J37D/421'_ (&*?%<)(N=X(/H<UY#?>!M>
ML[.6Y.LL2BDXV^U:WPOU2ZN+"5+R0R-&0,GZ5:J7#ZM'D;3/3 !VJ0#BHHL,
MNX'@U,.E:)W.*,;(=1113&%%%% !1110 4444 %%%% !1110 4444 %%%%
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MKTG1-4DLY+&>21#@A7%9I_:#T13C^S+D,?61:\]N;[2]-^*]Q/JD0EMPP)#
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MJ\=\1?%;4=#\:S:+%:K-&N/+VIDDFJ4_Q1\4Z)?13Z[I\:6$S84I%AL=?Y4
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M-?AS\1IO%EW-I^HP^7>PY+;%P.*],7O0 ZBBB@ HHHH **** "BBB@ HHHH
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M?[/:7$X&6C4MCZ#-353U48TJY9?O>4V?R--(EG&^"?B(WBS4[BR:W6/R6P2
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MC_CX3'^\*DJX[..@S1[TBLK?ZN0-]#2X /7F@$%%%%(H**** "BBB@ HHHH
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MMVFJO*EM*K/$<.!VK4KYJ^#?B/4[?5I[>*SN+B&X?]]+G(7\Z^E$.44D8R*
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M10 4444 %%%% !1110 4444 9VM_\@>[_P"N3?RKRSX==+G_ 'Q_*O4];_Y
M]W_UR;^5>6?#GI<_[X_E3CN=$/X3/9M/_P!2/I5P53T__4CZ5<%=*V/-6P9H
M-%(QXH#J<-X]UU[2WBL;9L2R,0_TQ7"QJ(D)^\YY8GK6CXNF$_C!W)^5%7 K
M+=__ !XU\[C*C]K8]*C!6&L]5G;)ZTYVP2*KN]<3.I#9&[57)YZ5(S9-1FJ5
MT4*O$F?:G+M\W)YH"_NMU,'7-6DWN0TC2CF Z5;6YXK%$F*D$YK-Z/0G0TVD
M1P>!4 N[BW;=!/*&';=Q5,R%\88@]@.];6D^&-3U=@54QIZDXKII1J-W1G.4
M.ILZ#X\N;:>."\(920O'6O4H)Q<1)(@^5AGFN(TGX=VMO<)/=-YCKSS@UW,:
M"*)40851Q7MX?F2U//J.-]!['K7/>);*74=)DC@G\M@#\P.*WR2RG;UKD?&P
MO_[((TT%6YW <9KNI14Y\MS%5/9RYSR34K:[1WMKBY$FWONS6'<6EM"H:<'G
MI7IWASP>9(6U+67.Q1DJW>N<\51Z=K=XMMI\7E1QG[VW'2MI5\)@V^979TJI
M6Q7P.QR^DW4"7NQ%*MV)Z5LRON-1)I5O RC ++_%3Y% KYC'5H5JG- ]"E%Q
MC9D?:E X8'N*3H*7&XBO/DW<U0A \I>ORD8KVWP@[2>&+$MU,=>-E 6BC Y8
MBO:_#L)MM!M(R,;4Q7J8!-,Y,2]+&GWJ"Y!DMW )R!GBIS3<[>@SGK7J'$SD
MKJT>YA8QD*X/>J26XB7<<@A<-[FNHN]-,C[X&VD]15 :1-++^\X4'GWJD]3.
M2=M!?#2/Y<K=%/2ME1M5?7-,B@2UC$<7'K4APO'6LYLTIQTU,W4M.%S\Z<-[
M5E'2;MFP=N/7O72CGO3""3@-23$Z<4]$4K*P6SBZ_,3G-7X[ET.<Y'O4?U.:
M0_I2YV:1C&VQI0W2OU/)I+VU2]MFCR,D<5F<@\&IH[MXR"<D"KC4[F;IW.?G
MT:19BLD98#H5%7;'39I (MNR-6!Y'/%= ETDHR /QJ<8QG _"M4XF;4[<O00
M1#8%[4\( ,4M+3=^@EHK!1110""@T4&@;#J*,4#I2T ,=<XQ45S(8[>4@?=C
M8_I4S<9/M43+YD#+C[ZD'\: /+/AP?MOC+Q%>2C+^>,>W%4?C!!->>(O#MO;
M.$F:9@K9QCBK_A3.A?$G5M/F!1;J7=$>Q %)\5K'4CJ>C:AIEL+B2UE9V'/I
M[4 *O@KQ:R1E-64*4''F'TKKO"FD:EI=O(FI7)G)).2Q-<-%\2O$YVPIH(VJ
MH!;8_P#A74^$O%>L:Y=M;W^FBVC49#;6&?SH \UTM]=7XC>(&T-8@?M+Y#CV
MKI+W1/'7B.V^R7LUO#;N1O,>58BKO@O2;VT^(.O7$T16*6Y9D8C@C%>GY&[:
M": /*O'6@#P[\*)]/M03&B$R$=\D5V7@22WF\*69@*E @''8X&:V=5TVWU?3
M9["Y4-#*N&R*\CM5\4_#JYN+*"U6\TYF+H<EF4$YX H ]5U[RTT"^W\+Y+$G
M\*\^^"RL-/UB0 ^2UT-GN-M9U]J_BWQU$--L[/[';-Q,[Y0E>_45Z-X5T.'P
MUH,=C#C,2@2,?XL=Z ."N@UG\:K1X^EP7+#\*]>'05Y/IT3ZW\7+B\C!,%BY
M7=VY%>LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% #.!P*\?^/_ /R*MOV_TA:]@Z=!WKBOB'X-?QAI26HEV8D#=10 _P"'/'P]
MT[!+9MAU_&O+?#]E#=_'*^$R(ZB4\,,]J]G\,:&?#_AJVTQI-QAB\O.:YK2_
MATVG>.9O$'GD^8V[;D>E %OQ]XBL?"GAXR26<;^8"L<;("N1ZBO--0_X2;6_
M U[J+/9VMAL8B)1M)'L*]<\:^%+7Q?I!T^Y+*Q!".H^Z:X2T^$NI_89=/O-=
MNS9@$+$&!!_"@#+^%(4?"_6\-R%D)Y_V:9\ K2WG35;AH4<K, &(R1\M=KX6
M^'A\/:%J&EBY8Q72L <CC(Q4WP[\ MX(CO(?/9UGD#]1Z8H \VNX1#^T#NB
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M'GC4,P7WJ"S^*.@7=RD#>; SG ,N *XO.D_\+?U'^UXX3%Y4>WS/QK7\:_\
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M$#;#(V&(]*\WB CBP>2>]=_\28C]DA=1D;Q7G7F_)7B8^HE4U._"POL*[87
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M%,%.W>@H8AXH?.#CTI 2.:<, 9)SFJBB)F/<63398-CGIFH#$59%7[PZUO\
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M?_X5YI?_ #[C_OFD_P"%>:7_ ,^X_P"^:.5AS4?YCH?^%@Z!_P _/_CPI/\
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M,^X=*<;:V+;PZ;?3-1R72Y\NU0EO85C3PLJ3N=>)QD:]/EB6--7[1X@51R$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!O>B@T4;@]!,=STKG=8U$[O*0UKZC=+;VYR>2.*Y!G9Y6=^0>E<]>I9
M61TX:G=W9&5#C!^M5FC>0OGDCI5HC/YYIGS+)O7K7)!W9TUJ3>QBK'/&_F9,
M;@\&MJ!M.U95EU! DT'))/WJAG\R?@A1GT%1QVZH ,<UU_6'!61P_5E4E=C=
M1NI+^3(7R[=/E5![=ZIB$GY0-V>F*T#"<X R3VK?TC105\V5>>U9<\IZG2^2
MG&R*^DV+FS-K?+NAD' /:M+3]*MM)B:*V09;O6FL(5&7 P!7*7VHSQ71$;?*
M#7?2<N6QP3A3;YCJ(4.  .G4U;1:YJR\0 !1,./45NVVHVUPN5<#ZFEROJ*-
M1,O#I130X(R#GZ4;B1GI]:33+33'4M-)XX-.I( HHHI@%%%% !1110 4444
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M.E%*;DCJKPBI7B244F:,UNC&PM+3<TZF%@HHHI %%%% !1110 4444 %%%%
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M4[M7H+8\A@*6D%+0(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** (\<TM+@TN*3W"]RG?6,5["8W /I7$7^C7^ES%X,O%GIUKT
M#8<G'>D,89=K ,/>M.;0SG1C(\R_M3#8>%U;O33JDLAV0VSECWQ7HLFDV<G)
MMX\^N*?'IEK$!LMXP?7%"JO8YGA/,X;3O#]]J4RRW>5C!^[TKN;:S2SMUAA
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M,6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2HY1F,U)36&5Q2V
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MM-BDAEY!S717\;WL0BV8SP3BJHTA5( 08QZ5$YZ:%4<.[VD8VG.[0A)QD*<
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M)C&EB.5'H-I-Y]M'*/XE%6QTK/TQ=ME"O\(08^N*T1TI:W.C0**** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#>%0[-6STIP-4[6]CNDS&1FK:X_&LFC9.XZ@44#K4%V%HHHI@%%%% !1110
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M?<4<O86^Y(O ]:6D'3BEIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNZJ\%PMQ'NC(#=Q4Z^_6MTTQ:#LT9HHH$+1110 4444 %%%% !1110 4444
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M'T444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ3K6JW-]>7;27QN69 <],\5[H<%2 ,T 5)K^P61HIKF!67LT@!ID>K6$J_\
M'Y;KCIB5?\:\6708O$WQ:UNTO6=8XI\(N\\<"NJO/A)HPMG:&<Q3H,B3>>*
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10 E!SVI:*
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M!)KJ/&'@N:[TC37TT*+S3B'7<.&(4#\:Q9_$?B:>Q73XM#9+QAY;3&#Y?J*
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M ^?+AO[I:N?B&<C%%L"+AABKC-HPG33/1H[_ $^].Q)D$GL:N0SW=BV>94[
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MM3U'S5G22&WOH[E>JGFNVE.YPRIV/0QTI:AMY!- CCN*FKLW,@HHHI@%%%%
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M'S?[A_E7!^'?]?+_ +PKO+[_ )!\W^X?Y5P?AW_7R_[PK1_PF8R_B(])L?\
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M*W\9&Y1110:A1110(**** "BBB@ HHHI@'7C.,U5U/Y]*O%/.V%OF_"K6?F
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M,DG&!0 NTL"&VE,=/6LQ_#VEM/\ :?[/MR[')S&.?<^]:NT*.O6C=M7;GVH
MJKIUI%*)8K:-9%X!"BA+:VAN-\5ND3/]]@N,U:)*KM!'MDTQL@C&&]2W:@"-
MK2WFE666VC:13PS*,BG7%K!?PF*XA1T!^ZXR*ER57KD>IIISG<3UXQVH STT
M/285PFG6ZC/.V,<GUK2BC1$5478J]!BN<U/Q7::;X@M='DW^?.A<$+P,'%=&
M6)XSUH >PRN.,]JI2:?:2W*W,ENAG7HQ7FK"RER!@97K2DGH"#[DT +M+ JP
M4@CD8[5!#:Q6X<6L,<>]LMA<9J7?A]N,G')I!*I.5."O&&XS0!&]I;M<1SM
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ME6/^J'TJX.E5-/QY(^E7:Y&>C>^HM%%%, HHHH **** "BBB@ HHHH ****
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M^&M+OK._,YF-VQ!6(L/S%>N>(E \.7_=1$37 ?";3K*_T#4)+BV1V^UNN2*
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M+B@"N_[Q&!3';#=#7':A\-] UJ\>ZDCG@FSAS#*8P3^%=OY8QC)ZYI0BCH*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *0TM(: $I#1FD-3'8: U\[_%G_D;6^IKZ(-?._Q9_P"1L/N373@G[YS5
MT='\%?\ 6WG^Z/YU[.*\8^"G^MO/]T?SKV>EB_C*H+W1:*,T9KG;T-A:***H
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $H-)WHW#.* >A
M2NODCE8,/NGD]N*\J/\ 9]SJ3#4(KK>6^69/NG\:]/U8K#83LV2K*2>.^*\R
MAAUC4+=8XX+;[/DX<R8(K6)T44GN;-]>+9R1(EDLU@ ,[DR3QS3=(@AU5I;\
MVHMY$R(49<#(Z5F11ZC?W,-B+F-(K9MTC>8!D&MZ_O-.NT6RANG@D@4.TD>,
M$_6M$VC:5]C%UF_NYY%L+H1)*6#;\8XK'N8+82E[BZ=VMFVHF_*L.O2NMT?2
M;;4UEN+AY;AT)1&D7K4\WA:$7UK*UJC0^61(,=ZOVJZEJJDK,SM&U&\U241R
M0V\6EL,$[<406B1ZU--?1-LM@'A)'!/_ .JJ]_IP_M?^STNI;2S0YPO ]>]:
MUU>6.OZ:T-G=%9H5V@OA=V.*5U)F2O*6FQ4T[4K:;S-3O?\ 6*Y1(QZ#IQ6U
MH>LOJ&L9VF.$(< C%<7J3!I;>'3HDDEC8>;GOZUJ:7<W8U:%)8TBR. AJ:E-
M)7*J4K+4].7[X(Q@U)52VDW.4;ADX^M6ZYCA:L%%%% !1110 4444 %)ZTM)
MZT >/?&S_567^Y_6N4^%/_(XP_6NK^-G^JLO]S^M<I\*?^1QB^M=L?X)P2_B
MGT4*<*:*<*XD=XM%%% !1110 4444 %(>E+2-TH K7C&.!W'7%,CQY2.!\QJ
M:=1+ R?WA@5#:D-%CG"G%"!/4;J$GDZ?,^?F$9QCZ5\ZW\D]WK,\LLC$%NC&
MOH#7+N*PTN:>8!D"G.?I7S[K%Y#>RR7-HK*CG<N%QQ7)B9GT&2T]93-_P+:V
M=OXGBGD8%G/R\U[5<IYNG2Q]F7BO#/A[I%QJ>IQW1=5CB.?F;!KW%I@ZQPQY
M..&/:M,.K1./,I\U8\_\86>D?8%T\@)(YR3[FO.M1LCHZ0^2V47!'/6NH^)/
MF2>)8+>$%?E4Y/ KGM4999+2UD<[E9<^_-8U-9'JX).GAW-GMG@JY>\\+V,L
MB[6>,$\5T7*K@5D^'8HXM!M(X^%"<<5K ?+@5V1V/G*SYIMCU&!0:!P**9B
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M$&G2-M6Y0G/K6DDJ. 5.01D4)IB<)+=#Z*3<,XSS2TR0HHHH **** "BBB@
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M^OO6KJ.2*>)YU8UTQ]H7;SQR:MBH(XHTD)4<^M3UF8A12=Z6@ HHHH ****
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M;1]['%8PT9A'0U/#^KF;3KF9HF58W)7/<"M*'5HKF"&:$\RKNQZ5Q%P\UQ=
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MSFE1:T.G^&'B2?6=*,%PI+P?)N;//%/^(NEJ;%-01C',@QA?<UP5OXAO-#M
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MI!3J0;A1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;[GXTY>E01'X ;/:@MM?..,4-GM0WRX YSUH!GF7QO"_\(C&0<YE_I7 >%O
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M-2TUR ,D4 (3CCDT@_'\:0N%&YB /<U";N#.?M$?TWBG:Y+FD6<T55^V0?\
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M/")$G@&1GEJZ)S21R4X-L7P[80^3-J-SAH8P<+WW"K<&O+/*T=Y9JMF?N,J
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MFDMJWV]4=@7B@,7)'4#\C7,ZAIMQ:?#C3;F:-S!%([LGL37KFE^(M*?P];7
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M];+_ *ZK70>%/^/"T_ZYU4#>?\*)W,?W!3J;']P4ZMSA0'I6;JME'J-E-:R
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %!Z44AZ4 )1111T$M1CH66N#U3P/<7NH27"W"J&[;:[WY1WH(]*JG-Q
M>AG5H0J;GFO_  KR[_Y^5_[Y-'_"O+O_ )^5_P"^:]+Q1BMOK,SD_L^AV/-/
M^%>W?_/RO_?-(/AY=YYN5Q_NUZ9BC;3^LS%_9U'L>:CX>7?_ #\+_P!\FD/P
M\O#_ ,O*_P#?)KTRBE]9F']GT.QYG_PKR\[W*_\ ?-*/A[>8_P"/E<_[M>E4
M8-/ZS,/[/H]CS4_#V[(YN5SZ[:3_ (5Y=_\ /RO_ 'R:]+Q1BCZS,7]G47T/
M-1\/+O\ Y^5Y_P!FD_X5U=C[ETH]?E->EXHI?6)EK T4K6/-3\/+O"_Z2O Y
M^6D_X5Y=_P#/RO\ WS7I9'%-P?6G]:F*.74+['FW_"O+K_GY7_ODUU'AK09=
M$MVC>029).0,5T)XI<;A42JRDM32EA:5.>@@'(-2U%@ U+6-CKTOH%%%% PI
MO8TZF\\\4Q,\>^-G^JLO]S^M<I\*<'QC%SWKJ_C<?W5GQ_!_6N3^$_\ R.,/
M'>NV'\$XI?Q3Z,'2G"F]N*5<XYKA.WJ.HHHH&%-;'%.ICXQS0&G4H:G9/>V,
ML"G!<$9K@V^'EWN.+E?^^:]*!%+6L:DHG-4H4ZFYYG_PKR\_Y^5_[YI/^%>7
MG_/RO_?->FT5I]8F8?V?0/,_^%>7G_/RO_?-'_"O+O/-RO\ WS7I>TT8-'UF
M8OJ%'L>:+\/+P!@;E<$\?+TI?^%?7H Q<KD=]M>F8-&*/K4RO[.H=CS'_A7E
MU_S\C/\ NFC_ (5[>9R+I?\ ODUZ;Q2\4_K<T"P%-'F/_"O;SK]J7=Z[:#\/
M[TCFZ3/^Y7IW%)@4?6YL'@*;/,_^%>7G_/RO_?-'_"N[S_GY7_OFO3<>E'-+
MZS,G^SZ/8\R_X5W>?\_*_P#?)H_X5W>?\_*_]\UZ;S1S2^LS#^SZ'8\UB^'M
MTLJ,UTHVL#]TUZ#8P&WM8XB<E1C-6,4N*SG4<]SHI4(T_A 4N*04N:SV.G<6
MBBB@ HHHH **** "BBB@ HHHH *04M(* ,'QA_R*^H?]<C7)?"S_ ) 4_P#U
MV:NM\8?\BOJ'_7(UR7PL_P"0%/\ ]=FK&>YUT_X3.Z;[GXTY>E-;[GXTY>E0
M1'X ;Z _6J]S:17<+P3HLD,@VNC#(Q5DTE%PLF<#<_"C29;AY+>[NK=7Y*1'
M K;\/^"])\-MYELAEG/65QEOSKHZ3D<KRW0T[B:,K7?#MCXBA6*]7) ^5U'*
MUSEK\,=*AO5GN;FZNE0Y$<QW+7:R216\;N\@C1/OL3BN-OOBCH%K</!&UU*P
MX+1PEA^8HN+0V]:\-:?K<5I:SH$CMFW($'3C%1WGA'3KR_M+V1G\RU"J@]AT
MI-!\8:3X@+1VLN+A!G9*-I/YUOD\@L 2?3M1<-#FO$'@C2]?E$[[K>X!_P!;
M%PQ_&H-'\ :9I-X+N626YG7[IGYQ76 ')/!YXYI&QP9"2.X]*3 "V$4A<8["
ML;7?#-EKMU97-V7#VLGF(%ZYQBMG>5&\KQ_"*,&(%Q\S-TS2#0:B>6%C494+
M@$]17/ZSX-TW6=2M]0E9TN8.%9.IYSS718(ZG)(SBE&5YVJ.QYIW8]#G=>\'
M:?X@CC^U!DGC&%F3[WYUGZ9\-](L=02\N)IKMXSE1.=P%=E@CKWH*\8*CCK1
M=A9&%XB\)Z;XDB$=U&4:,?))&.5[<&LC3_AMIEI=QW,]S/=&/&U)3N48[_6N
MUYY'8#.*0X Z8&,\4[L+(\G^+-JEQJFDVQC)@9D7"CI\XKHU^&.E&>.1[NY>
M).1"6^7\JZB\T^QNPMQ>VJ2>4-RDC)XYKE;KXI^'[.Z>WG2\1D.#MMV(HN*R
M.JETJUN=-;3YH$-L5VE<=JY.3X6:26^6]NHXF;F-6P/I4<?QA\+L-^;QD/=+
M8FNKT+6[/7['[3:"4QY/^MC*D4Q:")H-E'HS:5'&([9DVL5&"U&AZ);>']/:
MUM 2A88W>E::Y8'=QZ48*IEN3VI:CT,6U\+Z?:ZY=:NFXW%RV74].F*QM2^&
MVE7U^UY!/-9R,<D0':#79]#D ''K2%"HW?>([4:AH8.@^$--T&*0PAGED&&D
MD^\?QI-/\):?IMM>P0LY2]9FDS_M=:Z'!8Y8!A[TB\DC %*['9'#'X6Z.JXM
M+FXM_P"]L.-U;VB>%[#P]$ZV2DN_WW<<M]:V\$\8&1ZTO)!W=^@HNPLC#TSP
MO8:5JUQJD!9I[C ?/3BL[6/A_I>JWS744DMG(X^8V_RYKK!\O('7HIZ4N"?D
M("GV-.[%H<UH/@G3- D:XA+3W+<>;+RWYUTF#P"W '>G%1_#U%)EMGS("?K2
MNP,2]\+V.HZS!JDV[[1 #M Z'-/UWPY8>(K+[/>QCY1A)5'S+]#6L65(_,=M
MNT<U7L[Z"_1A:N'0=&S3 Y.U^&FFP7L=S/=W-SY6"D4K97BMW6?#5CKEM!!<
M@I'"P9%3H"*V1G;\P&?4&BBXTB*V@2UMHK=!\L:[03UJ0TM(:GJ-;@WW:/X*
M&^[1_!3%/X3S3XM_\>ME_P!=5KH/"G_'A:?]<ZY_XM_\>ME_UU6N@\*?\>%I
M_N54#>?\*)W$?W!3Z9']P4^MS@6X4T@DTZEH&1>6161K'ANPUJ-DNH$)/\6.
M:W*,4/7<<).$N:+/+I_@]ISS;XYY4&?N@\5MZ%\.]-TB99L&213QNYKM<4=Z
MS]E&]SHEBZLE9L@\G&,< =!VI_(X/4\FI#3<<_A6MSE6A3O(4N[.2)AD,I%?
M-VO::^E:W<6T@P=V1CIS7TT5P*\H^*7A[(&IPK]SE\5RXJ"E"Y[&55_9UUYG
ME+CY=WZ55D&'&1U%6U._Y^W3%12*3S[\5Y/-;1GV%25DO,IR@@<>H-?1/PPG
M$OA2V4'E5YKY\$))8M^%>[_"96'AU2?08KOPTDMCPL[C:FCT.D8#!)Z4IHP"
MI!KT7JCY9I=3QSXM6$GVF&[4?NP ":\S!RV[^'UKZ1\2:##KVER6LN V#L/O
M7A>I^#-9T>1H?LWG1$Y!ZG]*\S$4FWH?3Y1CX1CR3,/( Y(!]*K[<OECQ71V
M7@K7-3D_=6HVG^*0[37;Z!\)]D@DU24N/[G!%90PT^IWXO-*'+N<?X1\*77B
M&\24QE+16PVX8S7O>G646G64=M$H$:  8I+2TL]+MA#;1I&BC!["L36O'6D:
M0#&9=\H_A49'Z5VT5"EN?-8K$U<6[6T.M5AZTI89KQJ^^+D^XBUM(B.W)%9_
M_"V=94Y:TBQ_OFK^L0N*&65IJZ1[I^--5PV?Y5YSX4^)MOK$PM;U5AG]NGYF
MO04<';*3G?P,>E:1GS;''6P\J3M(LBEIJ]*=5F04444 %%%% !1110 4444
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MY4<],'SGBGQ#\5P^*DMQ9VER/+7!WICO6+X)U(^'M>2^NK:8Q*>0J<U]"_\
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M:6BB\0N9VM;O['NR#_RR;^5>1?#\G==X/5Q_*O7]9_Y ]Y_UQ;^5>/\ P_\
MOW7^^/Y5T)_NF8OXCV+3^+51WJ]VJA8_ZD5>'2L7L:H=1110,**** "BBB@
MHHHH **** "D%+2"@#!\8?\ (KZA_P!<C7)?"S_D!3_]=FKK/&'_ "*^H?\
M7(UR7PM_Y 4__79JQGN==/\ A,[P_<_&E7I2'[GXTJ5!$?A%-)2FDI#6P4#[
MU%%,#.UK1K77M/>SO4#*PX([5YZG@7Q9HV;?1=7A6TSPLVYB/UKU.BG<7*>=
M>'_AS*FJKJWB"[-Y.ARB!CM!'L:U?%/A.[\2WUK$]RD>FPL',2Y!..U=A11S
M"Y3C?$O@2VUG3+:*TQ;W%JR^0XXP <X.*W(2=/\ #GE:W=PF98B'<<*QQ6M6
M#XE\-6_B6W6&>XGA"<?NSC-"8G$\[^&.@1R>*M1U%.8%8&W/;.><5V'Q!BT;
M4(K6TU&5;:XW_N)MVW#8]:Z#1-$M= TQ;&U'$8X<]35?Q'X;L?$EB+>Z&&'*
M2 ?,I]:=R+'EGB/P_?6^@R_VCKT,]L(R88XW8,W''UKKO!_AZ'4_AO#8WJ$+
M+&&3U!P<&G6_PRT^.6-[C4+NX6$@B-VR.*[BWB2"!(XD5(E&$4#H*+E):GF<
M/@KQ;IMFVEV&K0?9/NJ9-S,%^N:Z+1_!(TGP[<V'VEY;BY7#R.Y8?K77T4N8
MOE.<\%^&V\,Z*UA-*)"9GDW*?[QS5/3O",MIXSFUPRKY4D9C$??.>M=?11<.
M4/XJ@O+<W-G- K!3(I7)]Q4]%(=CDO WA.;PI;3PO,D@E8GCMSFD\3^$I==U
MO3+])E1;.82,O.6&,5UU%.XN4YWQ=X7B\4:(ED[;9(SNC;. #VS7+6O@_P 5
M/9+IESJ<"VB)Y?[L%21]:]+HHN'*CA/"W@*3PW9ZE9"X#PW7W#DDCC')K8\%
M^'6\*Z.UG)()6W,V5/J<UT=%','*CD[/PM/;>-[KQ"TJ%9X4C$8ZC:36'J7@
M+5[77)M4\/ZB(?/!+QSLS#)ZX%>D44<PK' >'/ ]_;:P=<URZCN;M(V1=F<
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M84\=<T[(#Z$\2^(K71/#LNIM<1!2A\ICT8XXQ7GOPN\?R>(3JG]IWD232/\
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M*** "D%+2"@# \8?\BOJ'_7(UR7PM_Y 4_\ UV:NM\9?\BMJ'_7(UR7PM_Y
M$W_79JQGN==+^&SO#]S\:$H/W:$Q4$1^$<:2E.*.*!K82BEXHXI#$HI>*.*
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MUW'G<"GI7"1_&:6\N9?LFD&6QC)4RACT]:Y'X=7\&K?&F\O8!@3>:ZJ?3 H
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MX[=ZM_&[2KZ_;1EL[=Y=K?,54G%>U[$SD*,^N*0J&X8 X]10!XA\5=!U>_\
M#&D/:1--%;J#+'Z_(!TKG]5O]9UWP?'I>G^'8[:.!/WC@,&.!@\$5](% 1@@
M$?2F^2F,!% ^E 'EO@BQNI_AA=631R),(RBJZD<[37%_"RYUGPMJE]HMSIC
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M:U% &3_PCVE*P;[%$,=,"M!(UCC"*@$8Z 5-10 4444 %%%% !1110 4444
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MC:6EQ1B@=D)12XHQ0%A**7%&* L)12XHQ0%A**7%&* L)12XHQ0%A**7%&*
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M@;QSSFK_ ,6/"VHPZMIVNZ5$THM0-ZJ,Y^;/]*R_%?C76_&?A.2TM-%N(0H
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M\>M<IXD\7P^'M6TVQ9,F[E\L'\,UU4APN37CGQ@O4L->\-W4P!2*Z+8_X":
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MZQUF_P!.NYI)$-A)OB5>F<8JCXC^'NFZ_.EV9)+>ZC4!98N&XH \Y.HZ_P"
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MWO0,YSFDI<T!<=129HS0%QO.>M*1CO11Q0%QU%)FC- 7%HI,T9H"XM%)FC-
M7%HI,TFZ@+HHZW_R!KS_ *XM_(UX]\/_ +]U_OBO8-:/_$GN_P#KDW\C7D'P
M_!\RZ'^V/Y5O!^XS-_Q$SV&P_P!2/I5P=*IZ?@P]:N@<5A%61JMQU%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVR(K+W!&:41$*!P-O0"@":BCM10 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** $-)@444(!<4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
E10 4444 %%%% !1110 4444 %%%% !@>E&!1128!2T44D!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gapk0ju0ozex000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gapk0ju0ozex000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /<!YX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M FKOZ* . _X6M8?] +7?_ )J/^%K6'_0"UW_ , FKOZ* . _X6M8?] +7?\
MP":C_A:UA_T M=_\ FKOZ* . _X6M8?] +7?_ )J/^%K6'_0"UW_ , FKOZ*
M . _X6M8?] +7?\ P":C_A:UA_T M=_\ FKOZ* . _X6M8?] +7?_ )J/^%K
M6'_0"UW_ , FKOZ* . _X6M8?] +7?\ P":C_A:UA_T M=_\ FKOZ* . _X6
MM8?] +7?_ )J/^%K6'_0"UW_ , FKOZ* . _X6M8?] +7?\ P":C_A:UA_T
MM=_\ FKOZ* . _X6M8?] +7?_ )J/^%K6'_0"UW_ , FKOZ* . _X6M8?] +
M7?\ P":C_A:UA_T M=_\ FKOZ* . _X6M8?] +7?_ )J/^%K6'_0"UW_ , F
MKOZ* . _X6M8?] +7?\ P":C_A:UA_T M=_\ FKOZ* . _X6M8?] +7?_ )J
M/^%K6'_0"UW_ , FKOZ* . _X6M8?] +7?\ P":C_A:UA_T M=_\ FKOZ* .
M _X6M8?] +7?_ )J/^%K6'_0"UW_ , FKOZ* . _X6M8?] +7?\ P":C_A:U
MA_T M=_\ FKOZ* . _X6M8?] +7?_ )J/^%K6'_0"UW_ , FKOZ* . _X6M8
M?] +7?\ P":C_A:UA_T M=_\ FKOZ* . _X6M8?] +7?_ )J/^%K6'_0"UW_
M , FKOZ* . _X6M8?] +7?\ P":C_A:UA_T M=_\ FKOZ* . _X6M8?] +7?
M_ )J/^%K6'_0"UW_ , FKOZ* . _X6M8?] +7?\ P":C_A:UA_T M=_\ FKO
MZ* . _X6M8?] +7?_ )J/^%K6'_0"UW_ , FKOZ* . _X6M8?] +7?\ P":C
M_A:UA_T M=_\ FKOZ* . _X6M8?] +7?_ )J/^%K6'_0"UW_ , FKOZ* . _
MX6M8?] +7?\ P":C_A:UA_T M=_\ FKOZ* . _X6M8?] +7?_ )J/^%K6'_0
M"UW_ , FKOZ* . _X6M8?] +7?\ P":C_A:UA_T M=_\ FKOZ* . _X6M8?]
M +7?_ )J/^%K6'_0"UW_ , FKOZ* . _X6M8?] +7?\ P":C_A:UA_T M=_\
M FKOZ* . _X6M8?] +7?_ )J/^%K6'_0"UW_ , FKOZ* . _X6M8?] +7?\
MP":C_A:UA_T M=_\ FKOZ* . _X6M8?] +7?_ )J/^%K6'_0"UW_ , FKOZ*
M . _X6M8?] +7?\ P":C_A:UA_T M=_\ FKOZ* . _X6M8?] +7?_ )J/^%K
M6'_0"UW_ , FKOZ* . _X6M8?] +7?\ P":C_A:UA_T M=_\ FKOZ* . _X6
MM8?] +7?_ )J/^%K6'_0"UW_ , FKOZ* . _X6M8?] +7?\ P":C_A:UA_T
MM=_\ FKOZ* . _X6M8?] +7?_ )J/^%K6'_0"UW_ , FKOZ* . _X6M8?] +
M7?\ P":C_A:UA_T M=_\ FKOZ* . _X6M8?] +7?_ )J/^%K6'_0"UW_ , F
MKOZ* . _X6M8?] +7?\ P":C_A:UA_T M=_\ FKOZ* . _X6M8?] +7?_ )J
M/^%K6'_0"UW_ , FKOZ* . _X6M8?] +7?\ P":C_A:UA_T M=_\ FKOZ* .
M _X6M8?] +7?_ )J/^%K6'_0"UW_ , FKOZ* . _X6M8?] +7?\ P":C_A:U
MA_T M=_\ FKOZ* . _X6M8?] +7?_ )J/^%K6'_0"UW_ , FKOZ* . _X6M8
M?] +7?\ P":C_A:UA_T M=_\ FKOZ* . _X6M8?] +7?_ )J/^%K6'_0"UW_
M , FKOZ* . _X6M8?] +7?\ P":C_A:UA_T M=_\ FKOZ* . _X6M8?] +7?
M_ )J/^%K6'_0"UW_ , FKOZ* . _X6M8?] +7?\ P":C_A:UA_T M=_\ FKO
MZ* . _X6M8?] +7?_ )J/^%K6'_0"UW_ , FKOZ* . _X6M8?] +7?\ P":C
M_A:UA_T M=_\ FKOZ* . _X6M8?] +7?_ )J/^%K6'_0"UW_ , FKOZ* . _
MX6M8?] +7?\ P":C_A:UA_T M=_\ FKOZ* . _X6M8?] +7?_ )J/^%K6'_0
M"UW_ , FKOZ* . _X6M8?] +7?\ P":C_A:UA_T M=_\ FKOZ* . _X6M8?]
M +7?_ )J/^%K6'_0"UW_ , FKOZ* . _X6M8?] +7?\ P":C_A:UA_T M=_\
M FKOZ* . _X6M8?] +7?_ )J/^%K6'_0"UW_ , FKOZ* . _X6M8?] +7?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_8AK4'VK_GCAM_Y8S6MJVMZ;H5J+G4[M+: G&]P<>O:O/$CC_P"&D9#L7/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJUK*;BW"QH)!O+9!QMZYKTD00B'R1$@BQC9M&W\JA_LVQQC[%;8_ZY+_ (4
M<W\/SH]]X/TJ>S%G--';HLCQJI9&QT/<&NNJ.&W@MP1!#'$"<D(H&?RJ2@#
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M=N(5N=.@$&[_ ):$<$+ZUZ+';01.7C@C1FZLJ $TK01/(LC1(TB_=8J"1^-
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MANH_%WAU/^)Q9H5FA' NX>Z'W]*[9[&SDD,CVL#.3DLT8)/XU8H YKP!(9O
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M%O&(8$8\R-_^ODUU$4,4*[8HTC7T10!39K:"X $\,<H'3>@;'YT >=Z+X_\
M!JWIF36HM0UJ_=4*PQL3UX1<@845K_%2X$/PUUD$9>6)8HT'5F9@ !74II]E
M&X=+2W5AR"L0!'Z5D:AH,VMZS;RZB\9TVSD$L%LO/F2#HSGV["@"?PG82:7X
M1TFQE_UD%K&C?4"MFBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /,-&_Y.(\1_\ 8)A_]IUZ?7F&
MC?\ )Q'B/_L$P_\ M.O3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH \P^!G_(G:E_V%I_Y+7I]>8? S_D3M2_["T_\EKT^@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \PT;_DXCQ'_V"8?_
M &G7I]>8:-_R<1XC_P"P3#_[3KT^@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /,/@9_R)VI?]A:?^2UZ?7F'P,_Y$[4O^PM/_ "6O
M3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S#1O^3B
M/$?_ &"8?_:=>GUYAHW_ "<1XC_[!,/_ +3KT^@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /,/@9_R)VI?]A:?^2UZ?7F'P,_Y$[4
MO^PM/_):]/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /,-&_Y.(\1_]@F'_P!IUZ?7F&C?\G$>(_\ L$P_^TZ]/H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S#X&?\B=J7_86G_DM>GUYA
M\#/^1.U+_L+3_P EKT^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH \PT;_DXCQ'_P!@F'_VG7I]>+W=SX@MOCYKS>';"SO;DZ;")$NI
MC&H3"<@COG%=4NJ_%#<-WAG0P,\_Z>W^% '?5Q?B3Q3XCL)+A]#\-_VA:6H_
M?S2S>66QR0@ZMBNTKE_'%OXGN=$EA\-/:)*R,)!-G<P]%/0=Z -#PMX@@\4^
M'+/6+:-HX[E,['ZJ0<$?G6!?>)/%USJ$X\-:!8WVGPN8OM%Q>>46<?>P,=/>
MI/AKJEMK/@>*"&R.GM:%[.:!3]QUX.#^.:YG6_"6K^ +277_  MJ]W-;V[&:
MYTZZ?>LBYRQ![&@#O-;\1IX;\.+J6IQCSSM000G.^5N BGOS6>OBN^T[5--M
M/$%E!:IJ9*V\L,A8+)C.Q\]#].*Y/XD7_P#:J> KA05MKO4$E=3T!PI&?QJ]
M\:25\/Z(\7_'PNL6_EXZYR?_ *U 'I=%,BR8D+==HS3Z "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#S#X&?\B=J7_86G_DM>GUYA\#/^1.U+_L+3_R6O3Z "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/NGWH ],HK,T/5UUC3_.:%H+B-C'/ _6)QU'_P!>M.@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S#X&?\B=
MJ7_86G_DM>GUYA\#/^1.U+_L+3_R6O3Z "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ\P^!G_(G:E_V%I_Y+7I] !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!YAHW_)Q'B/\ [!,/_M.O3Z\PT;_DXCQ'_P!@F'_VG7I] !11
M10 4444 %%%% !1110 4444 %5M1=XM+NY(B1(D+LI'4$*<5/(6$;%%#. =H
M)ZFO)K3XC^/[]KD6?@ 3+;S- [B[P-RGG&5% ':>$O$\.I^$;>_OY3;7%O O
MVU;GY&C;;]YL]CUS[US.B_$ ^,/B3:6VDV]U_85M#.IO"K".XEP.G; [9KD/
M%MOXU\8/"U]\/9X=C#SOL^HA//0'.Q^.1_*NE\'ZWXF'B_2=#OO"Z^'M*CM9
MC'#$^Y9" ,<].* /5@ .@Q2T44 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 >8? S_D3M2_["T_\ ):]/KS#X
M&?\ (G:E_P!A:?\ DM>GT %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'F&C?\G$>(_\ L$P_^TZ]/KS#1O\ DXCQ'_V"8?\ VG7I] !1
M110 4444 %%%% !1110 4444 (R[T922,C&0<&N630==T?<=&UA+F$G<;;4H
M\DG_ *ZH ?Q(:NJKSS0/'>K7%K=)/X;U6\:"\GA6Y@C79(JR,!CD=!Q^% &Y
M_P )9/I_RZ_HUW8 =;B(>?!_WTO('^\!6S9:AIFK+'=65Q;76T'9(C!BN>N/
M2L'_ (3*]_B\(ZX!W_<J?ZU8T&3P_JM_+J-C8+;:E$"DZO"8I5S_ 'UXS]30
M!TE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M17#?$;Q#KOABPMK_ $UK06[W,4+B1"S_ #-@X[5W- !17#)XAUV#XIVWAZ[:
MT-A/9R7"^4AW#:0!DFNYH **** /,/@9_P B=J7_ &%I_P"2UZ?7F'P,_P"1
M.U+_ +"T_P#):]/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ;Y3J.DJ#W '%=1X+\'ZKI5[/K/B353J6L3IY88#"0I_=44 =M1110 4444
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MG_DM>GUYA\#/^1.U+_L+3_R6O3Z "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M $J25?.5[^/Y[I.FY7R=P'H.E 'IM%%% !1110 4444 %%%% !1110 4444
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MH\:&[TE7!:&"/8T@'8X '\Z]9L[2"PLH;.V0)! @CC4=@!@4 3T444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO^3B/$?_ &"8?_:=>GUYAHW_ "<1XC_[!,/_ +3KT^@ HHHH **** "BBB@
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M>XJ>8[?J;MS?@=VK;D#8(R,X/:EJ.">.XB66)PZ-T(J2J.)Z,****!!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >8:-_R<1XC_ .P3#_[3KT^O%[NTU^\^/FO)X>U2WT^X&FPF22>W
M\X,N$X ['..:ZI=#^)FX9\8Z41GD?V8/\: .^KA]8G\=ZA-<S^'WL+*T@9EB
M2ZB+R7!7J?\ 9&>!7<5F:WJ9TZR(@0S7LWR6\*]7<_T'4F@#)\ ^*Y?%GAQK
MR[MA;7EO,]O<Q@_*'3@X]JQVOO%OB>^N;GPSX@TFTT^*0Q+%-;^<YV\%B0>
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MU61,_P#/(!/Y"LI8^DMKG=3X2QTOB<5\_P#)'T77)ZAXL.B>(E@U*2W.F7
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M%%1QS13%A&ZML.&P>AH"Q)139)$BC:21@J*,DGM2JRN@92"I&01WH"PM%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M110!YAHW_)Q'B/\ [!,/_M.O3Z\PT;_DXCQ'_P!@F'_VG7I] !1110 4444
M%%%% !1110 4444 %>5:1\._#OBR[U#Q%XE4ZA=75U*D<;SLBPHCE  %(_N_
MK7JM>-6GP2747N[_ %'6]2M)KF[GE$$#X5%,C$=^XP?QH Z3PAX8L?!?C'4=
M/TJX8:5=6JW*V[R;A%(&VG!/J*[.75[2+5;333)NN+I7= IS@*!G/YUYA_PH
M/3-V[_A(]8W8QGS.:N>&/A</"/CJQU:SU&ZO[=K>:*5KAMQC)QCGWH ]1HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@"M=:?:7LEO)<P+(]M)YL+'JC>HKF
M_&WB^X\.16UII>G2:EK%X2+>V3T'5F] *ZVN/\4WK>&]:M_$CV$UW9K;FVG,
M";GA&[<& [CL: .?T[Q+\3+!_M?B'PS:RZ<.9/L<H\V->YVY.<5Z7;7$5W:Q
M7,+!HI5#JP[@UY=>_&K3M14V'A?3;_4=3F_=QHT!148]VSV%>A^';"72_#FG
M6$[!IH+=$<CN0.: -.BBB@ HHHH **** "BBB@ HHHH \P^!G_(G:E_V%I_Y
M+7I]>8? S_D3M2_["T_\EKT^@ HHHH **** "H+NSMKZ#R;J%)HLAMKC(R.E
M3T4-7&I.+NMQ    !@#H!4+65J]['>-!&;F-2B2E?F /49J>BBP*36S"BBB@
M04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!4U#3K#48&2_M89XP.?,4''X]J\E'P_L_$VJ7,NC))8:;%E%EERW
MFO\ [(["O9:155%VHH4>@&*QJT(U&N8]+ YI7P49>R;N]M=%\MKGC\?@2S\*
M:K;RZS"=0TZ;"&9 0(7S_$.XKURWAA@@2.WC2.(#Y51< "I&577:ZAAZ$9I:
M=*C&G?EV)QV8U<:HNJ[M?=]W1A1116IYX4444 %%%% !1110!#<VL%[;O;W,
M*2PN,,CC(->4^+/A0R>9>: 2R]6M6/(_W3_2O7**RJT855:2._ 9GB,#/FHR
MTZKHSY>L=0U3PWJ7F6TDMK<QG#*1C/L1WKV#PI\4+#50EKJVVSO.@<G]V_X]
MC[5O^)?!FE>)H3]IB\NY ^2XC&&'U]17A7B7PQ=^&M4>RE=)L+Y@>/GY<]2.
MU><XUL*[K6)]E3K9?G\.2HN6JOO^3ZKR9Z!XO^*JIYECX?(9NC79' _W1W^M
M>:V.G:IXDU/R[=);JZE.7<G/XDUL^#?!4WBB^=))EMX(<&7/WR#TP/ZU[MHN
M@Z=H%DMKI]NL:_Q-_$Y]2:<*53%/GF[(G$8[!9'!X?"QYJG7_@O]$<MX1^&U
MCH02[U +=WW49&4C/L.Y]Z[NBBO2ITXTU:*/B<7C*V+J>TK2N_ZV"BBBK.8*
M*** "BBB@""[M+>^MGMKJ%)H7&&1QD&O(/&'PMFLO,OM"#30#EK<\LGT]17L
MU%8UJ$*JM(]'+LTQ& GS4GIU71GS)H?B'5/#-_YMG*T9!Q)"_P!UO8BO;_"G
MCW3?$L:Q%A;7P'S0N>O^Z>]0^+?A[IWB-&N( MK?XXD4</\ [P_K7B.K:1J'
MAS4S:W:M#.G*LC=1Z@BO/O5PC[Q/L.7+^((77N55]_\ P5^)] Z[XRT7P])%
M'>W(,DAQMC^8J/4@5Q6L?&.%-T>D6+2'M+.<#\J\QL-)U37;@K9VT]U(3\S
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M.2%% 'K%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?\B=J7_86G_DM>GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 -D#-&RHVUB" V,X/K6'HGA>VTRWG:Z(
MO;RZ.;FXF7)D]O8>U;U%2XIN[-85JD(.$79/?Y&#J?AF*ZU*TU.QF-E>P, 9
M(UXDC[JP[\=*WJ**%%)MH*E:=2,8S=[;!1115&04444 %%%% !1110 4444
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M2LB*E2=23G-W;"BBBF0%%%% !1110 A (P1D&EHHH 3 )!(Z=*6BB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN*H1^$[N]U73[[7]1COO[-R;6**'RUWD8WOR<MCZ#VH ZB($1(#U"@&GT44
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ME_V%I_Y+7I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRZA63"@$ D<C\#FN?E\1:-=?$[3M%L_L\U_;V\[SNG6$87Y<CC)[CFO+=?\
MB%X?M++[#X'\0_V59W16.YB:REQ"O0O%QPQ'4=^O6M[X::AX$C\2Z?I7AF*2
M^U P32W6IW,3)*QP,]>N3V[4 >TT444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5YQ\1-=T?PGXBT37K@R2ZG&KP):Q)N>6)OO8]"#TS7H]>:?$+7-"\+>,M
M US4A,;F..2)56$N&1NI!'1@?T- %6;XZ:5'!(X\->(<A21OM5 _$[NE=OX*
MO/[0\$Z->>3'#Y]I')Y<2[53(S@#L*Y";XY^#A!(<WS_ "GY?LCC=[<C%=AX
M+N8KWP5HUU!;K;Q2VB.D*DD(". ,\T ;M%%% !1110 4444 %%%% !1110!Y
MA\#/^1.U+_L+3_R6O3Z\P^!G_(G:E_V%I_Y+7I] !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M110 4444 >8:-_R<1XC_ .P3#_[3KT^O,-&_Y.(\1_\ 8)A_]IUZ?0 4444
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M7YM/N21?HHHKN/EPHHHH **** "JVH?\@VZ_ZXO_ "-6:K:A_P @VZ_ZXO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX+@G_D'R*8$^@;H?P->O^'/!_A[PQ"/[&TZ" E<&51EF'NU &]1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[K?SKEQG\%GN\-?\C*G\_P F>4U]2:'_ ,@&P_Z]T_D*^6Z^I-#_ .0#8?\
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M@1&&WT2ST/39./-O5#RX]@>0?RKKO G@.Y\'PG[1K]]J#,.8G;$2GU"UVU%
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M7+'(<_+L7&*LUW'RC5G8****!!1110 5Y%\:/]?I?^ZW\Z]=KR+XT?Z_2_\
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MD\RII^?Y,\MANKBW),$\L6[KL<KG\J^G]$9FT*Q9B2Q@0DD]>*^6Z^H]"_Y
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M?(!1110 4444 %>1?&C_ %^E_P"ZW\Z]=KR+XT?Z_2_]UOYURXS^"SW>&O\
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MBB@ HHHH \PT;_DXCQ'_ -@F'_VG7I]>8:-_R<1XC_[!,/\ [3KT^@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 >8:-_R<1XC_P"P3#_[3KT^O,-&_P"3B/$?_8)A_P#:=>GT %%%% !1110
M4444 %%%% !1110 5R6E^*_#=KJ$WA_3S<-=6\S^; EN[%69BQ)./4YKK:XC
MPUJFD:1HNL:A>7$,-REY.]Z78!\ACM![_="XH M>-/B'HW@A(5OA-/=S_P"J
MM;==TC#U]A4?A;Q5HGC>ZCO(;>XMM2L58?9[E=DB*^ 3CN#BN/\ AQILGC7Q
M9J/C_5H=T)<PZ;'(,A4'\0%=S>?9G^(NF>0%^U):2FX*]?+.-N?QS0!U%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNM/-(U-'/B/[2W]KK9B';\OD$YS6W116\596/,JU/:2YK)>@4444S,*R-?\
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M,9J*T0ZBBBF0%%%% !1110!\^_$__D>;K_<3^58GAC_D9]-_Z^%_G6W\3_\
MD>;K_<3^587AQUC\2:>[?=6=2?SKP*G\=^I^MX/_ )%</\'Z'T_16;_;MB3@
M.^1U^0U/:ZC;W;E(2Q(&3E2*]^Y^3NG-*[1;HHHH("BBB@ HHHH \^^+_P#R
M*D/_ %\"O#T7?(J]-Q KW#XO_P#(J0_]? KQ&#_CXC_WA_.O%QW\8_3.%O\
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MTO\ K7_WC7H/@W_D C_KHU>+@OXI^I9]_N:]5^IT]K_Q]P_[X_G7I%>;VO\
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M_D8TO4\2KZ-^'W_(C:7_ -<_ZU\Y5]&_#[_D1M+_ .N?]:\_+_XC]#Z_B_\
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M2GUFZ'I":-IRVXE>>9B7FG?[TKGJQK2H **** "BBB@ HHHH **** "BBB@
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MO^NE>+7_ -Y^:/U#*?\ D2Q_PR_4]2KKO"?_ !Y3?[_]*Y&NN\)_\>4W^_\
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M%% !1110!YA\#/\ D3M2_P"PM/\ R6O3Z\P^!G_(G:E_V%I_Y+7I] !1110
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M_P!<Q7E%>KZ-_P @:T_ZYBO+P/Q,_0^(_P"##U_0Z+P__P AF'\:[JN%\/\
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M0?2O8CN? 8[^&O4TJ***L\L**** "BBB@#S[XO\ _(J0_P#7P*\1@_X^(_\
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MA+2_^N+?SK@?#O\ R,%E_P!=*[[XT?\ (2TO_KBW\ZX'P[_R,%E_UTKQ:_\
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MNY)6R-WF#Y1Z 9Q^%5?"VMB+XV:SH6D2;]&:#S7C0Y2*8==OID^E 'K=%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'F'P,_Y$[4O^PM/_ "6O3Z\P^!G_ ")VI?\ 86G_ )+7I] !1110
M 4444 %%%% !1110 50US_D W_\ U[O_ "-7ZH:Y_P @&_\ ^O=_Y&IE\+-:
M'\6/JCY;KTKPG_R+\/U->:UZ5X3_ .1?A^IKQ\%_$^1^G\0?[JO7_,Z73O\
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M_P!S7JOU.GM?^/N'_?'\Z](KS>U_X^X?]\?SKTBO9B?G./WB%%%%4< 4444
M%%%% 'COQH_Y"6E_]<6_G7 ^'?\ D8++_KI7??&C_D):7_UQ;^=<#X=_Y&"R
M_P"NE>+7_P!Y^:/U#*?^1+'_  R_4]2KKO"?_'E-_O\ ]*Y&NN\)_P#'E-_O
M_P!*]:.Y\-C/X3.@HHHK0\@**** "BBB@#S#1O\ DXCQ'_V"8?\ VG7I]>8:
M-_R<1XC_ .P3#_[3KT^@ HHHH **** "BBB@ HHHH **** "JFHZI8:1:M=:
MC=PVL*]7E<*/_KU;KP.+X;^)_%FN7FN:O/;WMH;N9;:TOI9,!%D('"D<<=*
M-S7_ (F6_BEWTCPIX<?7Y2=OGS1XA0^N?_KBNB^'7ASQ;HD+OXAUA)87&4L4
M7<(?8,>>/2I].T_Q?I-JMMI^G^&K:%1@)$DBC^=1V[>+6\?Z0-92Q6Q^SW&W
M[%OQOPOWMWMTH [NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#S#X&?\ (G:E_P!A:?\ DM>GUYA\#/\
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M@/>O&Q_\7Y'Z3PE_N#_Q/\D>OVG_ !Y0?]<U_E70^%_^0M_P USUI_QY0?\
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M?J>I5UWA/_CRF_W_ .E<C77>$_\ CRF_W_Z5ZT=SX;&?PF=!1116AY 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3_#NP3_#NQ[5U=% #418XUC10J*,*H& !3J** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH \P^!G_(G:E_V%I_Y+7I]>8? S_D3M2_["T_\EKT^@ HHHH
M**** "BBB@ HHHH *H:Y_P @&_\ ^O=_Y&K]4-<_Y -__P!>[_R-3+X6:T/X
ML?5'RW7I7A/_ )%^'ZFO-:]*\)_\B_#]37CX+^)\C]/X@_W5>O\ F=+IW_(1
MM_\ ?%>B5YWIW_(1M_\ ?%>B5[$3\YQWQ(\B^-'_ !\:7_NM_.O.M"_Y#EG_
M -=!7HOQH_X^-+_W6_G7G6A?\ARS_P"N@KQ\1_O/S1^@Y-_R)H^DOU/5*ZSP
ME_QZW/\ OC^5<G76>$O^/6Y_WQ_*O6CN?$8O^$SHJ***T/'"BBB@ K%\7?\
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M4XO^OA:\/A_U\?\ O#^=>X?%[_D4XO\ KX6O#X?]?'_O#^=>-COXQ^F<+?\
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MK?"?_'E/_OC^5<E76^$_^/*?_?'\J]:.Y\-C/X3.AHHHK0\@*\C^-'^MTO\
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M /R*D/\ U\"O$8/^/B/_ 'A_.O;OB_\ \BI#_P!? KQ&#_CXC_WA_.O%QO\
M&/TSA?\ Y%OS9Z]%_JD_W171>%/^/Z;_ '/ZUSL7^J3_ '171>%/^/Z;_<_K
M7JQ/CL5_#D=?1116IX@4444 %%%% !7S%XF_Y&?4O^OAOYU].U\Q>)O^1GU+
M_KX;^=>=F/PQ/LN#OX]7T7YF_P"!/]5=_P"\*["N/\"?ZJ[_ -X5V%:87^$B
MLX_WV?R_)'I%I_QYP_[@_E4U0VG_ !YP_P"X/Y5-7:?&2W84444""BBB@ KR
M+XT?Z_2_]UOYUZ[7D7QH_P!?I?\ NM_.N7&?P6>[PU_R,J?S_)GG.A?\ARS_
M .N@KU6O*M"_Y#EG_P!=!7JM<V!^!GTO$7\:'I^IU?A+_CVN?]\?RKHZYSPE
M_P >US_OC^5='7I+8^$Q/\5A1113, HHHH *K:A_R#;K_KB_\C5FJVH?\@VZ
M_P"N+_R-)[%T_C1\L2_ZU_\ >->@^#?^0"/^NC5Y]+_K7_WC7H/@W_D C_KH
MU>+@OXI^I9]_N:]5^IT]K_Q]P_[X_G7I%>;VO_'W#_OC^=>D5[,3\YQ^\0HH
MHJC@"BBB@ HHHH \=^-'_(2TO_KBW\ZX'P[_ ,C!9?\ 72N^^-'_ "$M+_ZX
MM_.N!\._\C!9?]=*\6O_ +S\T?J&4_\ (EC_ (9?J>I5UWA/_CRF_P!_^E<C
M77>$_P#CRF_W_P"E>M'<^&QG\)G04445H>0%%%% !1110!YAHW_)Q'B/_L$P
M_P#M.O3Z\PT;_DXCQ'_V"8?_ &G7I] !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 >8? S_ )$[4O\ L+3_ ,EKT^O,/@9_R)VI?]A:
M?^2UZ?0 4444 %%%% !1110 4444 %4-<_Y -_\ ]>[_ ,C5^J&N?\@&_P#^
MO=_Y&IE\+-:'\6/JCY;KTKPG_P B_#]37FM>E>$_^1?A^IKQ\%_$^1^G\0?[
MJO7_ #.ET[_D(V_^^*]$KSO3O^0C;_[XKT2O8B?G..^)'D7QH_X^-+_W6_G7
MG6A?\ARS_P"N@KT7XT?\?&E_[K?SKSK0O^0Y9_\ 705X^(_WGYH_0<F_Y$T?
M27ZGJE=9X2_X];G_ 'Q_*N3KK/"7_'K<_P"^/Y5ZT=SXC%_PF=%1116AXX44
M44 %8OB[_D4M4_Z]VK:K%\7?\BEJG_7NU14^!G1@_P#>*?JOS/F:O4/#?_(O
MVG^Y7E]>H>&_^1?M/]RO)P/QOT/TGB+_ '>/K^C.CT;_ )#%K_OUZ!7G^C?\
MABU_WZ] KUX['YWCOC7H%%%%4<1RGQ'_ .1&U#Z#^=?.]?1'Q'_Y$;4/H/YU
M\[UX^8?Q%Z'Z-PA_N<O\7Z(]9TK_ )!5K_US%=%X<_Y#,?T-<[I7_(*M?^N8
MKHO#G_(9C^AKT:>R/FL;O4^9W%%%%;GSP5PGQ:_Y$L_]?"5W=<)\6O\ D2S_
M -?"5CB/X4O0]/)O^1A1_P 2/"4_UB_45Z_;_P#'M%_N#^5>0)_K%^HKU^W_
M ./:+_<'\J\_ ?:/M^)-J?S_ $.A\*_\A)_]RNQKCO"O_(2?_<KL:]2.Q^?X
MS^*%%%%4<IQ7Q5_Y$:?_ *[1_P Z\![U[]\5?^1&G_Z[1_SKP'O7C8_^+\C]
M)X2_W!_XG^2/7[3_ (\H/^N:_P JZ'PO_P A;_@!KGK3_CR@_P"N:_RKH?"_
M_(6_X :]2'0^4Q?PS^9V=%%%:G@A7G/QB_Y%NT_Z^/Z5Z-7G/QB_Y%NT_P"O
MC^E88K^#(];(O^1C2]3Q>V_X^H?]]?YUZ^OW%^E>06W_ !]0_P"^O\Z]?7[B
M_2N' ;2/LN)-Z?S_ $.C\)?\?=Q_N#^==97)^$O^/NX_W!_.NLKTX['P&+_B
ML****HYCS_XO?\BG%_U\+7A\/^OC_P!X?SKW#XO?\BG%_P!?"UX?#_KX_P#>
M'\Z\;'?QC],X6_Y%OS9Z_%_J4_W171>%/^/^;_<KG8O]2G^Z*Z+PI_Q_S?[E
M>I$^.Q7\.1U]%%%:GB!7EWQH_P"0;I?_ %V;^5>HUY=\:/\ D&Z7_P!=F_E7
M-B_X,CVN'O\ D94OG^3/)]._Y"5M_P!=%_G7K=>2:=_R$K;_ *Z+_.O6ZY,#
M\+/J^(_XE/T9TWA+K<_A745R_A+K<_A745Z<=CX+%?Q6%%%%,YSQ[XT?\A#2
M_P#KDW\ZX#P]_P C!9?]=*[_ .-'_(0TO_KDW\ZX#P]_R,%E_P!=*\6O_O/S
M1^H91_R)H_X9?J>I5UOA/_CRG_WQ_*N2KK?"?_'E/_OC^5>M'<^&QG\)G0T4
M45H>0%>1_&C_ %NE_P"ZU>N5Y'\:/];I?^ZU<N,_@L]WAO\ Y&5/Y_DSSC0_
M^0W9_P#705ZK7E6A_P#(;L_^N@KU6N; _ SZ;B/^-#T_4ZOPE_Q[W/\ OC^5
M='7.>$O^/>Y_WQ_*NCKTEL?!XG^*PHHHIF!XG\8_^1CL_P#KW_K7(^%O^1@M
M_P :Z[XQ_P#(QV?_ %[_ -:Y'PM_R,%O^->)4_WKYGZCE_\ R)8_X7^IZ979
M>%O^06W^^:XVNR\+?\@MO]\UZ\=SX3&?PC<HHHK0\D*\8^,W_(:TW_KW;_T*
MO9Z\8^,W_(:TW_KW;_T*N3&_P6?0<,?\C*'H_P CB?#7_(P6G^]7I]>8>&O^
M1@M/]ZO3ZPP/P/U/H.(O]XCZ?JSL/"O_ "#Y/]^MZL'PK_R#Y/\ ?K>KT5L?
M"XC^+(****9B%%%% !7,_$'_ )$;5/\ KE_6NFKF?B#_ ,B-JG_7+^M9UOX<
MO0[,N_WNE_B7YGSE7J^C?\@:T_ZYBO**]7T;_D#6G_7,5Y>!^)GZ'Q'_  8>
MOZ'1>'_^0S#^-=U7"^'_ /D,P_C7=5ZT=C\\QO\ $7H%%%%4<84444 %%%%
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M,\YT+_D.6?\ UT%>JUY5H7_(<L_^N@KU6N; _ SZ7B+^-#T_4ZOPE_Q[7/\
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M_O\ ]*Y&NN\)_P#'E-_O_P!*]:.Y\-C/X3.@HHHK0\@**** "BBB@#S#1O\
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M_6]7HK8^%Q'\604444S$**** "N9^(/_ "(VJ?\ 7+^M=-7,_$'_ )$;5/\
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M7.Q?ZI/]T5T7A3_C^F_W/ZUZL3X[%?PY'7T445J>(%%%% !1110 5\Q>)O\
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M10 4444 >8:-_P G$>(_^P3#_P"TZ]/KS#1O^3B/$?\ V"8?_:=>GT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4456U!KA=-NFM!FY$3&(?[6#C]: +-
M%>'Z7>Z'JO@>XD8RGQO&2C@L?M?VG/&WOM_0"O9-)%XND68U @W@A7SB/[V.
M: +E%%% 'F'P,_Y$[4O^PM/_ "6O3Z\P^!G_ ")VI?\ 86G_ )+7I] !1110
M 4444 %%%% !1110 50US_D W_\ U[O_ "-7ZH:Y_P @&_\ ^O=_Y&IE\+-:
M'\6/JCY;KTKPG_R+\/U->:UZ5X3_ .1?A^IKQ\%_$^1^G\0?[JO7_,Z73O\
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MN_\ @QDH_P"%0Z#_ -!'7?\ P8R5WN]/[R_G1O3^\OYT <%_PJ'0?^@CKO\
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M (5#H/\ T$==_P#!C)7>[T_O+^=&]/[R_G3,S@O^%0Z#_P!!'7?_  8R4?\
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MR_G2Y5>YI[:I;EOH>=?\*5\-?\_VM?\ @<W^%3)\'O#\:!5U#7 !Z:BXKO\
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MT;T_O+^= '!?\*AT'_H(Z[_X,9*/^%0Z#_T$==_\&,E=[O3^\OYT;T_O+^=
M'!?\*AT'_H(Z[_X,9*K77P3\,WA4S7NM-MZ;KXM_,&O1MZ?WE_.C>G]Y?SH:
MN5&3B[H\Q7X#^%$8,MWK 8="+O\ ^QJS_P *4\-?\_VM?^!S?X5Z+O3^\OYT
M;T_O+^=))+8J56<MV>?1?!SP]$"$O]<&?34''\JD_P"%0Z#_ -!'7?\ P8R5
MWN]/[R_G1O3^\OYTS,X+_A4.@_\ 01UW_P &,E'_  J'0?\ H(Z[_P"#&2N]
MWI_>7\Z-Z?WE_.@#@O\ A4.@_P#01UW_ ,&,E'_"H=!_Z".N_P#@QDKO=Z?W
ME_.C>G]Y?SH X+_A4.@_]!'7?_!C)2'X0: RD'4-<P1@_P#$Q>N^WI_>7\Z-
MZ?WE_.@#S#_A0OA(G_CZU?\ \"__ +&IHO@?X8A7:E[K07T%Z0/T%>D[T_O+
M^=&]/[R_G244C1UJDE9L\['P6\-@@B^UKC_I_:I_^%0Z#_T$==_\&,E=[O3^
M\OYT;T_O+^=,AMO<X+_A4.@_]!'7?_!C)1_PJ'0?^@CKO_@QDKO=Z?WE_.C>
MG]Y?SH$<%_PJ'0?^@CKO_@QDH_X5#H/_ $$==_\ !C)7>[T_O+^=&]/[R_G0
M!P7_  J'0?\ H(Z[_P"#&2C_ (5#H/\ T$==_P#!C)7>[T_O+^=&]/[R_G0!
MYQ=?!+PS>,K37NM,5&!NOBW\P:@7X#^%$8,MWK"L.A%WC_V6O3MZ?WE_.C>G
M]Y?SI<JW-%6FERIZ'G7_  I7PU_S_:U_X'-_A4L?P<\/1 A+_7 #Z:@X_E7H
M&]/[R_G1O3^\OYTR')LX+_A4.@_]!'7?_!C)1_PJ'0?^@CKO_@QDKO=Z?WE_
M.C>G]Y?SH$<%_P *AT'_ *".N_\ @QDH_P"%0Z#_ -!'7?\ P8R5WN]/[R_G
M1O3^\OYT <%_PJ'0?^@CKO\ X,9*/^%0Z#_T$==_\&,E=[O3^\OYT;T_O+^=
M '@^F?#GP[>?&?6M#U"&ZOK.WT^.:/S[N3>&.SJRD$]3Q7>+\%O *L&&B/D'
M(_TZ?_XNL[12#^T1XC((/_$IA_\ :=>GT %>:?#2W;1_%/C32;GY)S?_ &M
MW\<<F3N'L,XKTNLG5/#6DZQ<)<7MJ3.BE!+%,\3[3U4LA!*^QXH XSX;VSW7
MB[QEKP'^C75\(86[/L&&Q^(KTFH+*RM=.LX[2S@C@MXAM2.-<*HJ>@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** $)"@DD  9)-<C;>+[S7[ZXA\,V$5S;6SF.2]N9"D1<=0N 2V*M?
M$*YN;3X?:Y/9[A<):MLV]?0_I6;\(A;CX8:*;?'S1$R8_OYYS[T 6SXEUFQ\
M0:;I6J:/&JWTA1+NWEW1 A2<'(!!XKK*\Z\6>*]<TKQIHVB1Z7IERM_,6M)I
M)'!C(!Y88ZXST]:CU.\\0Q_%G3M&&M.EA>V,D[Q1Q@>60<?*>Y]S0!Z317GU
MUJ.I6?B;1? \>KSRW$\$EW=:A(H$IB!(55[ YXSZ"FS:QJOA+XB:/HEW?3:A
MI&N)(L#SX,L$J 9&1U!ROYT >AT5YWX4N=2D\?\ C'0+G5[VYM+..W%NTK@O
M'O3<2#CKDU6\(7NN:CI7BZU?6[AI[#4)(;:YE579$49QV% 'IM!.!D]!7EGA
M=_$?B7X66^M'Q#=1:GY4DD;(%VL5)X88YZ5K:3XNN->^%]OJCH$U"[7[+M7O
M*3MX_G0!T^@:A<:I:37DNT0O.XMP!C]V#@$_D:UJ\Y^(DFK>&/!^GRZ+J;6@
M@FAMW18P?,#'!.>U+XBO]7\.ZYX7N4U6>>/4+G[/=6\@'ED%<Y4=CF@#T6BL
MV\TZZN=6LKN+5)[>"WW>;:HH*3YZ;B>1CVK2H \P^!G_ ")VI?\ 86G_ )+7
MI]>8? S_ )$[4O\ L+3_ ,EKT^@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH \PT;_DXCQ'_ -@F'_VG7I]>8:-_R<1XC_[!,/\ [3KT
M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI-9&,*(WY^;:RYSQD Y'/2NC\?ZMXC\*Z/I=Q8:JDJM=Q6]P\]LADDWN!G(
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M HHHH *P=9\7:;H>JZ?IUXEUYU],D$+)"2F]C@ MT['WK>K@OB7_ ,?/@_\
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M,].>M;%<KX#\0:CKFE7<.LP)#JNFW36=UY?W'90#N7V((KJJ "BBB@ HHHH
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M]IUZ?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)1P?O(V.=I'<5%:>'+Z_\3)X@UT6L<\%LUM;6]I(SK&'^^Q=E4DGTP,5U=%
M'!6OA;Q#INA7GARV;2[C3)VD$=S.[B6)'))!C"D.1DX.X5V&D:;'H^CVFG0L
MS1VT2QJS=3@=:NT4 %%%% '#7&A^)W^)\'B2.VTG[!%:&PV->2"4QF3=YF/*
MQN_V<X]^]:'B/PU>7?B#2_$FC2P1ZK8*\1CN"1'<0OU1B 2I!Y! //8UU-%
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MJ*Y72_#^F:LJ7]_JC:_(?F!D8>0I_P!F(?+^>34.JR>5J4T:7_BN%5.!'8V
M>%?]T^2>/Q- '9UY[_PG/B/_ (3_ /X1'_A'M/\ M/V?[5Y_]HMY?EYQG_59
MSGC&*ECN&\Q?^)IXV/(X;30!^/[BLP\?M)+GOH''_?R@#N?$NHZCI.BSW^FV
M5O>/ K22133F+*@$G:0K9/L<?6L*^\4^(K'P.WB-]#T]BD'VF2V%^V1%M#<'
MR\%O;]:W_$W_ "*^J_\ 7K)_Z":Y_P 1\?!F]!_Z O\ [2% &CX,U_5/$VB0
M:M>Z;:V5O<Q[X5CNC*YY_B&P ?F:N>(;[5]-T][K2M/M;TQ*SR1S7)A. ,_+
M\K _CBLSX9_\DVT'_KU'\S6]J_\ R!;_ /Z]Y/\ T$T 8?@7QO9^-]%^V0Q_
M9[J)MEQ:ELF)OKQD'UIMSK_B&+Q?%HL6C6#V\L9F6Y:^8$1@X.5\O[WMG'O7
M&7&C7GAS3M(\<>'XBTL=JBZG:)_R\18Y;']X5U=AJ]GKOB_2=2L)1);SZ8[*
M1_O#@^] &I#K\UMXB&BZM%'%+<!GLIT/R3J.J\]''<?C6_7G'QFE?3_#.FZQ
M 2MS8:G#(C#K@Y##\:]$A<R0QN?XE!H \S^!G_(G:E_V%I_Y+7I]>8? S_D3
MM2_["T_\EKT^@ HHHH **** (+VZ%E:27!AFF"#/EPQEW;Z =:S?"_B6T\5Z
M,-3LHIXH3*\6V=0K95B#QGU%;-<%\(O^1*?_ *_[K_T:U &G>>.K.W%Y/!I]
M]>6-BY2ZO+=%,<1'WN"0S8[[0<5=U3Q9INF:+;:FGG7J7>/LL5FGF27&1D;0
M.O'-<-H$]YX'\(ZWHVMZ7=R1VQN98[M(]T4\;[FY?H#SC!K<^%.GO!\.=!FO
MH\7,<$AC9^J1R/N _P"^0OY4 :7A7QWIGBNYN[*&"[LM1M,&>RO8O+E13T..
M>*GUWQ?9Z!JNFV%U:7KMJ%Q';12QP_NP[G !8X'8G YK/T335U+Q[J?BU4V0
M&T33;5L8\Y5<L\GTW84'N%],53^)G^N\'_\ 8PVW_LU '6:UK5IH.FM>WC-Y
M88(JHNYG8G 4#N2:HV7BF.?5H=,OM.O--N[A"\"7(0B4#K@HQ&1Z'!JG\1+.
MQO?",\=[<R6S"1&MI8AEQ,&&S [G..*Y?PMJ6I2>-K6P\;PF+6X+=O[/=%'D
MR@CYVR/X\4 =UK?B;3]">&&<RS7EP<06ENA>63Z*.WN>*OZ?=RWEFL\]E/9N
MV?W,Q4N/KM)'ZUY9X537=<U;Q1XGLI[-;U+E[6W6YB:3:D?\ P1M!/?FN[\$
M>)F\6>&8M2D@$$XD>&:,'(5T.&Q[9H 72/%]GK/B'4-%BM+V"YL8TDD-Q%Y8
M(;., \]O2IM3\216&J1Z7;V=S?Z@\?G&WM@H*)G&YBQ"CGWKG=&_Y+1XF_[!
M]I_6J?C>VU*+QC9ZAX3F#^(H[4^?9N/W<MN"<;CV.>!Z_A0!VNB:]:Z[#<-
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M2=%O)$ET[59[*&3RYM0@MBUO&W0@MWQ[9K(\(ZG?S^-EL_&<!A\06]L5LRH
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M)_!>KG4[OQ)X=\0WEKJ;(I-M*0T$@0<)C' Z^O4U9L_&4NI^#=+NPL=MJFI
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M:)%IUNQ?:6>20C!=V.6;\37#_P#"<?$+_HG[_P#?^C_A./B%_P!$_?\ [_T
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MC/;.S*LBS\$J2#^H- '4>,_A[IOB#PG?Z7IFG:797MP$$=Q]F5=F'5CRHSR
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M^$X^(7_1/W_[_P! 'I]4M6CO9M+GBT[[/]I==J_:"0@SP<X!->>_\)Q\0O\
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M *)^_P#W_H_X3CXA?]$_?_O_ $ =[<>'M$NYVGN='T^:9SEI)+9&9OJ2*Q_
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MX7ET/3);.".X*^;)<%LJ%96 4*#Z5T>G"]%A"-1$'VH#$GD$E/PR >E>=?\
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M;(#37,L*6FX[Y"I7)+ 8'/05S7_"<?$+_HG[_P#?^C_A./B%_P!$_?\ [_T
M>GT5YA_PG'Q"_P"B?O\ ]_Z/^$X^(7_1/W_[_P! 'I]%>8?\)Q\0O^B?O_W_
M */^$X^(7_1/W_[_ - 'I]%>8?\ "<?$+_HG[_\ ?^C_ (3CXA?]$_?_ +_T
M &C?\G$>(_\ L$P_^TZ]/KRKP/9>)KWXI:OXEUO0WTR&ZL%@56?(W*4QC\%)
MKU6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#@/&?_)3OA[_ -=[W_T2*[^JESIEC>7UG>W%K')<V99K
M>5A\T188;'U'%6Z "BBB@ K@/A+_ ,@+6_\ L.WG_H8KOZJ:?IECI44L5A:Q
MV\<LK3.L8P&=N68^YH MT444 %<-\8_^23:]_P!<X_\ T:E=S574=-LM7T^6
MPU"VCN;28 212#*M@@C/X@4 2VO_ !Z0_P#7-?Y5+2*H50JC  P!2T %%%%
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M(- &-X'_ .2?^&_^P7:_^BEK?J*UMH+*TAM+:)8K>"-8XHU'"*HP /8 5+0
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M^PY>?^ABN_JII^F6.E0R16%K';QRRM,ZQC 9VY9C[F@"W1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***@O;I+&PN+N7_ %<$32M]%!)_E0!/17EGA;3'\:^"[OQ)J,LA
MU:]:9[297(-H%)$8C]!P#[YKJ/AQXEE\5^"+'4KG'VH;H9R!U="5)_'&?QH
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M9Z*I/ 8^M=/X9T?0K"U-SHLD=SYP >[6?SFEQZODYH WJ*** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQH HV]LDVI_\)-K3+;+#&8[.*8[?(0]6;/\ &WIV''7-97BV:/6_%FE>#[U
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M^&*9)T7>RX=3E3E2#QZ=* //?B3!?&'PAKE[;Q0C3]23[2L,IE2-7P-VXJO
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M;011K90B!HIS(9%VCE@57:?8%OK78U5TW3K72--MM.L8O*M;:,111[BVU0,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEZT@AEA%UN:-!T/W>>*G\!Z#XS\'7%SIDEI;7.@M.6M0UY^]MT)Z?=Y&.<4
M>G4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
2%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gapk0ju0ozex000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gapk0ju0ozex000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1L!T<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFW&OZ5:7/V>>^@CES@JT@!% &E13(I8YHQ)$ZNAZ,IR#2R2)$A>1U1%&2S'
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M:N A@"I!!Z$4 +114$][:6I N+J&$MT$D@7/YT 3T52_MC3/^@C9_P#?]?\
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M'0CT-?(/BKPM):^&-)UZ),QW*D2D#A2#@5ZS\!/&8O-/D\/W4N9H?FBR?X>
M * .!^.SO_PG\PW' 48'IP*^@?AH2?A[HQ)S_HR?RKY\^.W_ "4&?_='\A7T
M%\,_^2>Z-_U[)_*@#K:**R?$]\VF>&=0O5.&AA+ T >+?%OXMWEI?3:%H<WE
M[1B6=#S]!7G.A?#KQ5XSB%_&C;)#Q+-G#>]8VC6C^(?&L,,CEO-NMS$\Y&[F
MOM33["WTRQBL[:-4BB4*H Q0!\B^(/A9XH\+VQO9H?,CC()>')Q74_"WXMZC
M8:K;:1K%PT]G*P19)#_J_P#ZU?2E[:Q7UE-;3(K)*A4AAGJ,5\3>,--&B>,M
M2LHLJD%PRH1QP* /LGQ%<$>%K^>%L9M796'NIKXGTRQN]>UJWL87W7-U)L4L
M>I-?75O>F_\ A6\Y.2;%ES]$(KY;^'<B1?$+0WD=41;I268X ZT =8/@3XM(
M!W0<^YKU;X0> M8\'-=MJ;QD2C"A2?:O24U?3-B_\3&TZ?\ /=?\:LP7,%RI
M:WGCE4'!,;AA^E $M%%% 'R9\;WFF^*5W;AR1LB"+GH2!5*U^$7BN[M8[B*V
M)CD7<IP>E7?C.ZQ?%ZYD8X51"Q/L *]BT'XQ>"K;1K*TEU-EF2,*P\IN#0!Y
MIX-^$_BC3?%%G=W,)2*-LLW-?3E8VB>*=&\0Q>9IM['*/3.#^5;- !7S#\>?
M"CZ9XA&M0J?L]X<NW^V:^GJY;X@>&$\5>$[NQV S["82>S4 <'\!/%AU+0I-
M&N9-TUJ<H6/+ _X59^.WBO\ LCPT-*@DQ/>#:ZYYV&O#?!.NS>"/',<LI95B
MD:*53WYQFK?Q'UR;QGX_F2S)FC$AAMP.X[4 ='\"?";ZMXB;6)U)M[4<9Z,3
M_A4G[0]S,?%]G#YC>6+?(7/'WC7N?P^\,1>%O"=I9(H\QE\QSCG+<XKP?]H;
M_D=K3_KV_P#9C0!S7ACX7:_XKTA=2T]HO(9BHW$YX.*VO^%$>+?[T'YFNW^#
M_CSP]H'@>&RU&]\JX61R5VD\$UZ5IWQ(\+ZK?165IJ(>>5MJ+M(R: -K0K*7
M3M#L[29MTD42JQ]P *R_'NMKH'@[4;W?ME6(^7[M72UX1^T/XA\NTL]#C?#.
M?.;'IR,4 > SM<7LMQ>$,P+EG;TR:^@OV>O$9GT^[T2:3=)&WF1@GHH %8G@
M3P$-3^$FJW3Q#S;K)4D<CRR3Q7"_"[7'\/>/+)F)2.:012Y[*30!]D5\S?M$
MW,Q\66,/F-Y8MR=N>/O&OI='62-74Y5@"#[&OF+]HC_D<K+_ *]C_P"A4 <O
MX7^&&O\ BS2%U+3VC\AF*C<3G(.*JZMHWBGX>:@!(\UJV<I-'P&^E>Z_ G4+
M*V^'D23WEO$_G2?*\H4_>]S7,_'[Q-I%_96VEVLT<UU'('9D(( &>,T =?\
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M(O%-U<7OBO4GFD9W^TN@)/8,<"NG^&'B2]\+^-K>UDE=(9I!%+&3QSCFN:U
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MT ?,OAF1S\5-.8L23?+DU]F1_P"K7Z"OC'PO_P E2TW_ *_EK[.C_P!6OT%
M#J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;IK2RCDC&.Y4"O$/BI_R4K6O^NP_D*^J_#5NEW\/M,@D4,LE@@(/^[0!\]_
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M_P" UO\ QZT2?5/"$-S#$7-FY<X'(S@5Y#\(/'-OX/UYX[\E;.XX8XZ-P,T
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M [GXI^+_  GXH\&7%M;ZG!)=QC="H8=>*\L^#WB'^P?'=N'?]U< PD9X)8@
MUW+?LUW 4D>(8R0.GD'_ !KR'5M-N?!_BN2T=MT]E*"&QC)'- 'W"QS&Q'I7
MQ;\2O^2@ZO\ ]=?Z"OK7PAJZ:YX1LKU&W,T(#G_:QS7R5\2O^2@ZO_UU_H*
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MC)[$'_Z]>_T ?)_QY_Y*,W_7LG]:N>#/@Q)XK\-VVK+?>6)@3MSTYJG\>?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "H;NT@OK62VN8UDAD&&5NAJ:B@#P_Q3^S_:7UZ]SHEP+=7.3"V
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M!GZ5]"44 <-X[\$W7BWP5%HRSJEPC1DNQX.VL'X7?"R]\#:O>7EU<QRB>((
MASC!S7J]% $-W;I=VDUM(,I*A1OH1BO KWX :D=:EN[&]ACA\TO&"V"!GZ5]
M!T4 8ESI%Q=^$I=*FE!G>W,1?/?;BO(O"7P,U+0/%>GZK->0O':R[RJMR>"/
M2O>** .;\:>#[3QGH#:9=.T?(970#((Z5X7>?L[>(%N&%C?6AA[&1R#^@KZ8
MHH ^<M(_9VU-KI3J]_"L(//D-D_J*]V\-^&[#POI$>G:?&%C3J<<L?4UKT4
M4]3TNSUBPDLK^!)H''*..*\3\1?L]1SWK3:+=B*-CGRY, +["O>** /F2']G
M?Q*9L37MD(O]ESG^5=[X.^!>E:)<B[U9A>RJ?EC8 J*]>HH ;'&D4:QQJ%11
M@ =A7D7Q)^$=]XS\2)J=K=1QJ(@A5SCH:]?HH PO!^AR>'/#-KI<KAWA!RPZ
M5:U_1+7Q#HMSIEVN8ITVDXZ5IT4 ?.4_[.NHFZ8PW\/DEN,MSC\J]W\,Z/\
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M_?7_ -:OI*B@#YOC_9XUE)48W\'RL#]__P"M7T)I=F;#3+>U9MQB0*35RB@
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MX5\66^K7%W$\<08;5;DY'TKVVB@ KPKQ;\"+G5_$=Q?Z9<Q0PRG=M8X(;O\
MK7NM% '/>$=#O-#\*6NDWLXED@C$>X'->3VGP+U*W\5G53>PF+[29L;N<%L^
ME>\T4 %<+\2/AW;^.M.C4.(KN$YC?Z^M=U10!X+X6^!%_HWB6QU*ZO8FCMI1
M)M1N3C\*]Y P !VI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBDWJ&VEAN/;- "T5'+/% F^:5(UZ9=@!^M/5E=0
MR,&4\@@Y!H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BD9@JEF( '4DTR&>&X7=#+'(OJC
MC]* )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBD5E;[K X]#0 M%%% !1110 4444 %%%% !1110 444A(52S$ #J30 M
M%117$%P"89HY .NQ@<?E4M !1110 4444 %%%% !1110 4444 %%%% !1144
M=U;S.R13Q.R]0K@D4 2T444 %%%1"Y@:8PB>,RCJ@<;ORH EHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-J$(ANWC!E0?PMW%<C_PN;P1D ZHPR<<PM_A77IJ]G+HPU6.7=:-'YBOCJ*
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M*/6?[)AE&Y($?&!VZBH)O%/CSX;30MXH<:G82, TX8L5_ES7N:JJ(J* %48
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MKMM]EU6#@]<-^?>O3Z\'^(=N=$^,.AZC:*$-PX,A'\1R:]T@<R01N>K*#^E
M$E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#EQWQFNL^&^@WNB>"K?3=4@$<P!#H2#W-<-JW@'Q9X5\276L^")8W%T<O;R
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MX]X\\%^*H?&$/B?PGY<ER.&C8#'7.3GK0!Z7XF_Y%O4/^N#_ /H)KSWX"?\
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M<F/+E9]Q<XY/YT >KUX]\<_]7HO_ %]1_P#H8KV&N&^)W@ZY\7>'Q%8R*EW
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M4:A@/[V!G]: /GSXD^(/$6NVUMJ$_ABZL6LGW^>T1  'N:].N+Y?&GP?:>U
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M#)$R!RA(P&'44^B@#G/"_@ZQ\+_:7@=Y[FY<O+/(!N;DD#CTS71T44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!F3^'M(N=3CU*:PA>\B^Y,1\RUIT44 %%%% !1110 4444 %%%%
M !1110!6U&W>ZT^>!,;I$*C/N*XSX8^#=1\':=?6^H/"S3S>8OE-GC%=Y10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $5S;07<#P7
M$2R1N,,K#@BJVEZ-IVBVYM]-M([:$L6*)TR>35ZB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M )Z*JC4K G O;8D_]-5_QJ4W-N)!&9XA(>BEQD_A0!+1142W$#RF)9HVD'5
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M#WB7_KX;_P!#:ND^-7_(@7'U_I0!T U$ZIX#-Z3\\EGN8CUV<UX9\._#NO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %9?B/3YM5\.WUA;E1+/$47<<#-:E% '@^C> /BEX>MFM=,U
M6TAMR[,%$WJ<^E78?A3XK\27Z2>-=<-Q;QON6&-@P^G05[710!E76DJ/#DNE
MV:J@\@Q(#P/NXKFOA?X0U'P=H,UEJ+0M*\N\>4V1C%=U10!YGXZ^&4^M:LFN
MZ!>FQU9!C>N &^IKG&\ ?$[6D2QU[Q(/[/8;9O*D!9A]-M>WT4 8?A7PQ9>$
M]%CTZR&57EG(Y8GKFN&^('PWUK5_$$&O^&M0%KJ,?!W,% YSG.*]5HH X[P=
MHGB.#0Y[7Q;?B^GE!4G<& !_ 5Q4OPO\4^&M5EN/!6KB&UF?<]O*X51[#@U[
M-10!Y;I_A'QYJ-]"_B#Q"T-NC!C%;.&#8]<BNI\;>";+QIHOV&Z8I(O,<H'(
M-=310!XA;>!/BIIZ&QL_$JK8#Y4/FC<J_3;Z5Z5X5\.76@Z));7=_+>W4QWR
M2R8^]C':NEHH \[^'/@C5/"NIZQ<7[0%+R4O'Y;9."Q//YUK_$3PW>^*?"TN
MFV#1B9SP9&P.E=;10!S6E:%=V7@E=(E,?V@0&/(/RYVXK)^%_@_4?!^CW5IJ
M+0M)++O7RFR,8Q7=T4 <-\2_".H^+M-M+?3VA5XI0[>8V!C(/]*Z'^PXKOPR
MND7ZJZ-%Y;@<BMBB@#Q ?#+QWX:NI(O".OB+3W9F\J5PN,_A6IX<^%NL7.M0
MZUXSU5KZ\@;,<8(9!W]!7K=% '*?$#PW=^)?"<VEZ>8UE8KM\PX  (J_X2T>
M;1?"=AI=YL:6"+8^TY!Y-;E% 'CNO?"K7+#79]7\%:J;":X.9(RP5<]3V/K5
M>/X8^-/$EXB^,M>,MBC;A#$X8'V/ KVJB@#AO'=S8^%/AY-"+1)H4C$21D<'
MH,FO/?!W@_X@W'ANUN-/\2RV%G*NZ&"-EPJY/'(KVC7M"LO$6DS:=?(6AD'.
M#@C\:\R3X2>)-.=H]'\6M;VF?DBE#OM'H.: *$_B/QIX!\06-OKU_'J5K=N(
MUW/E@?7  ]:]K^6XM_F&5=>0:\VT'X3"VU>/5-?U235+F(YC!9MBGZ'->BWD
M,LMC+#;2+%*R%4<C(4_2@#YJT?PHE[\9Y=/1O-L8IFFD Z*22?YBOIM%"(JJ
M, # KAO GP^?PG>W]]>7J7MW=N6,@0C')/?ZUW= !7GOCWP5J?B7Q#HM]9-"
M(K)PTGF-@\-GBO0J* .4\<^'+SQ'X-FTJS:,7#JH!<X'!%7O!VD7&@^%;#3;
MLH9X(]KE#D9R:W:* /.O%?@C5-:\>:7K5LT MK4@N';#=,<"NA\9>$;7QAX>
M;3;EBC<,C@<AATKI** /$+'P!\3;*+^RX_$2II8.T%91N"?3'I6GH?PEN?#_
M (UL]3M)(GM8XF6:1V_>.Q(.<5ZY10!RGCKP/9^-=+6WF=H9XB6AF4#*M7#6
M?A;XK:;%]C@UJWDME^6-WF^95_*O9** .+\+^&=>T>VO+K4=8EO]1N$VA92-
MB>F"!69X$\ W^DZ[J&O^(7AGU.=SY;HV[:I'(_05Z/10!YCXV^'FHW_BFP\1
M>&WA@OXF'FEVVY4#_P"N:])MO-^S1B?;YH4;MIXS4M% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 444Q98W)".K$=0#G% #Z*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1E5QAE##T
M(I0 !@# HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MXKQ3_P C?HOX?^A5VM<5XI_Y&_1?P_\ 0J[6@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .*\4
M_P#(WZ+^'_H5=K7%>*?^1OT7\/\ T*NUH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#BO%/_(W
MZ+^'_H5=K7%>*?\ D;]%_#_T*NUH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#BO%/_(WZ+^'_
M *%7:UQ7BG_D;]%_#_T*NUH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#BO%/_ "-^B_A_Z%7:
MUQ7BG_D;]%_#_P!"KM: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HJ*XN8;6)I9Y%1%&237G/B7XA;MUKI73H93W^E
M1*:BM3>AAZE9V@B]\2[ZV;1H[595,PE#%0>0*\N[4L]Q-=2&6:1I&/5F.:;D
M>M<<Y\TKGTF&H>PIJ%[BT=J3(]:,CUJ#<]1^%?\ R";[_KN/_0:[ZN!^%?\
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M> #TXH Y'XVK(OAZQN5!VQ72LQ';K7H6B3+/H5C*K!@;=#G_ ("*SCX8CO\
MPC'H>LRF[/E>7+,#RQ]037+6'A#QUHUBVFZ;XCTT6 9A&)[9WD53T&[/84 8
M]A;G4/C=J<L)W)#"Z,1V;(.*7X/2F'7O$=E*=LBW#L$/N[5W?A#P?;^%[1R9
M&N+^<[[BX8Y+M[9YQ6/K7@*]'B-=?\,:A#87[C$XG0O&X'3Y1^- $/QE=?\
MA"'@S^\ED"(/4D&NJ\*6S6GA;38FSN%NF<_[HKF8O ^M:OK-M?>+=5M;V.UY
MB@M(VC3=G(+ YS7?*JH@50 JC  [4 +1110 5R-QX$BGN))CJ=PN]BV !QFN
MNHH \TO-$70_$^E1+<R3^8P;+CIS7I=<5XI_Y&_1?P_]"KM: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ*XN8;6%I9Y%1%&22:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 445#<W4-I"TL\BHBC))- TF]$35@
M:[XLT_1(B&D$D_9%Y_.N1\2_$)I-]MI7"]#+Z_2N#"W6I77 >:9S]2:YYUK:
M1/5PV6N7OU=$:>N^*+_7)B97*19^6-3P*=H7A6_UN8;(RD.>7;C\JZWPU\/<
M;+K5>O41>GUKT*"WBMHEBAC5$7H%&*F-)R=YFM?'TZ*]G01CZ'X5T_1(E\J,
M/-CF1AR:W:**Z4DE9'CSG*;YI.["BBBF0%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q7BG_D;]
M%_#_ -"KM:XKQ3_R-^B_A_Z%7:T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%0W
M-U!:0M+<2K&BC))KSCQ+\0FDWVNE\+T,OK]*B<U%:F]##5*SM%'6Z_XML-#B
M8%Q)/CA%YY]_2O)];\37^MS$S2%8L_+&#P*SE6[U*ZP \\SGZDFO0O#7P\QM
MNM4Z]1%Z?6N9RG5=EL>S&E0P4>:>LCDM!\*W^N2KL0QP9^:1N./;UKUC0O"]
MAHD(\J,/-CYI&')K7@MXK:(10QJB#HJC J6MX4E$\S$XZI6TV04445J<0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 <5XI_Y&_1?P_\ 0J[6N*\4_P#(WZ+^'_H5
M=K0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q
M7BG_ )&_1?P_]"KM:XKQ3_R-^B_A_P"A5VM !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOM(Z&N"\8>'=1\&:4-=TG7M2G:V8>9#=W!=7!/I0!ZU17.Z-XF2]\$6_B"X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 445!=7<%E TUQ(L:*.2:!I-NR)ZYSQ!X
MOL-%B9=XEN,<(O/YUR7B7XA//OMM+.U.AE]?I7#)'=:G=X4/-,Y^I-<\ZW2)
MZN&RUOWZVB[%_6O$E_K<Q:>0K'GY8P>!5C0/"5_K<P(0QP?Q.W'Y5UOAKX>K
M&$N=5&6ZB+T^M>@PP16\2Q0H$1>@ J847)WF:U\?"DO9T$9.A^&;#0X0L,8:
M3'S2,.36U1172DDK(\:<Y3?-)W84444R0HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH \X\=?#Z_U/4T\0>&[O[+K,0^4' 5SU
MY)K'A^)'B3PGJ5KI?C/24$3X#WT#&0$GIT&*["\^(VBZ3J]SI^MNVF&)CY<D
M_*RK_>&,\?6N+\?Z[9^/K6TT7PPW]I2/*K22PCB( @Y.<4 >O6\\=U;I/$VZ
M-QE3ZBO+_BAK#:W+!X/TK]]=7$BM.5Z(H(/)^F:M^-?$Q^'W@JUT^!FDO3'Y
M4;XSMZ_,:Q/ .L^#/#T#ZAJ?B.VN=8NOGEE97.W/.T97MG% '5>+-,30_A->
M:="3LM[-D!J3X3A!X L_+)(W-DD8YK6O7T[QKX4O(-/NDG@N8B@D4''/UK@?
M /BJU\%65QX<\42'3IK:5FB:4'$B,3C&,]J &?%T'_A*_#>T?-YRXQ]32_!
M+Y^NMN)D\]MP(Z?.:L /\1/']MJ%I"W]BZ8?EN6'RS,#D8[]#WJCHTG_  K+
MQQJ$6JJT.D:B=\5T1\@;)8CU[T ='\:!_P 4#/\ [W]#73^#01X2TW=G/D)U
M_P!T5P7B_7(/B%-9^'_#C&]@=P]S<H#LC7H0<X-=EKVOP>!/"T$\MK+=) B1
M;(2,GH.] '*?&S']BZ:&8A3=IG'XUZ/I.!HUB%Z?9X\?]\BN(\;Z;-X\^'L%
MYIUO(MP0+B&$_>)&<"HO#OQ0T&#P[#!JMV+/4;9/)>VD!W%E&.PQR10!@*#_
M ,+TO2H/_'N^<?459^#.PZGXB;<3(;E\@CMO-7_ >E7FL>)M1\7WUJ]M%=96
MVCDZF,XY_,5CZ3(?AGX[U!=55HM(U)M\=V1\@;)8CU[T =+\9AGP#<<?Q?T-
M='X*!'A#3-V<^0G7_=%<)XPUV#X@26?A[PXQO89'#W-S&#LC7H0<X->H:=:"
MPTVVM%Y$,2IGZ#% %JBBB@ KC;CQ?JL-S+$FBNZHY4-AN0#UZ5V5% 'F5UJU
MUJWB?2Y+JS-JR.%"G/(SUYKTVN*\4_\ (WZ+^'_H5=K0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 45!=7EO90M-<RK'&O4M
M7FWB7XA/,7M=,^5.AE]?I43FHK4Z*&&J5W:*.M\0>+['1(F7>);CLBG//OZ5
MY1K7B._UN<M-(1'GY4!X%48H;S5+O:BO/.Y^I)KT7PY\/$B"76IG<W41>GUK
MF;G5=EL>Q&GA\%'FEK(Y#0/"5_KDH*H8H,_,[#''MZUZQHGAFPT2$"&,-+CY
MG(Y-:T,$5O$(X45$'15& *DK>%)1/,Q.-J5W;9!1116IQ!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .*\4_\ (WZ+^'_H5=K7
M%>*?^1OT7\/_ $*NUH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .*\4_\ (WZ+^'_H5=K7
M%>*?^1OT7\/_ $*NUH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BF22QPH7D<*HZDFN8U;Q[I.G K%
M)]ID':,]/SI.26YI3I3J.T%<ZJLZ_P!<T[38R]Q<H,?PJ03^5>6:M\0-4O\
M<D#>1'V*\-7,N]U?SY<O-(Q[\DUA*NOLGITLKD]:CL>AZM\3%&Z/38=P[2-D
M$?A7$:CX@U+5'S<7+G/8'%:VD^ M6U$AI4^S1GO(.OY5W6E?#_2[#:\Z^?)W
MW<K4<M2IN='M,)A?AU9Y98:)J.IRA;>W=L_Q,"!^==MI/PS8[9-2FVGO&N"#
M^->C06\-M&(X(UC0= HP*EK2-"*W.*MF=6>D-$<U>>$K*/0+NRT^W19I8]JL
MQ[_4UP'_  KGQ".D5OC_ *["O9**N5*,C&CCJU).VM^YXW_PKGQ%_P \K?\
M[_"C_A7/B+_GE;_]_A7LE%3["!M_:E?R.$\#^%-3T+4KBXOEC57CVC8X;G-=
MW116D8J*LCBK5I5I\\MPHHHJC(**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#BO%/_(WZ+^'
M_H5=K7%>*?\ D;]%_#_T*NUH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HJ"[NX;*W:>=PD:CDFL[1_$MAK3.EN^)%_A)Y(]:I0DUS):$N23L;%%%
M%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'+B"S6"6_P!1G;$=G;D>81Z\\5Q_ASQAKNDZM-_PDNBZK;6]W)B&6X9=D?/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /$O%5T_@SXJKXAU*VEETR5"#*B%_*&>O'2O4M*\1Z#XDMH
M9;2[MIO,Y2)V7?\ ]\GFM&^L+/5+9K6]MX[B%N&C<9!KQGXG>#],\*?9O$6@
M Z?>)*B+';_*""0#Q0!ZEXJ\-_\ "3Z='8M=R6\(D#2!.KK_ '?:O+/[(L]$
M^.&E65E$(XD@_,[.M>O^'[F>\T"RN;E2LTD09U/4&O+]8_Y. T[_ *X_^R4
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M['.?\(+X?_Y\S_WV:CD\!:$WW+8K_P "-=/13]M4_F8O90['*?\ "O\ 1O\
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M$BY_ND51E^&NG'_53S#_ 'FH]OAY;K\ ]C76S,.+XD7Z??A5_P <5=B^)[Y
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M+OX6STP:S=.:W1:G%[,TZ*KQWUK-CRYT;/3!J?</45-FBKBT49'K12 ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"I_NL&KUI$6-0J !1V%.IJA%;F%3-:LOA5CB+'X:Z;!@W,C3_I726?A_3+
M06J#']X9K3HK50BMD<53$U:GQ2&JB(,(BK]!BN9\3^#H_$EU#.UT86C3;PN<
M\UU%%-Q4E9D4ZLZ<N:+U/.?^%5)_T%&_[]T?\*J3_H*-_P!^Z]&HJ/8P['1_
M:&(_F_(\Y_X55'_T$V_[]UW.DV TO2K:Q5]XA3:&QUJ[13C",=C*KB:M56F[
MA1115F 4444 %%%% !1110 4444 %(0#U /UI:* &F-",%%/X4WR(?\ GDG_
M 'R*DHH'=D7V6W_YX1?]\"F_8K4G)MH?^_8J>BBP<S*<FE6,IRUK%^""H9-
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M=NA)5!@9J:O55[:G0%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#BO%/_ "-^B_A_Z%7:UQ7BG_D;]%_#_P!"KM: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***1F"J2QP!UH 6BLB\\3Z/8Y$U]$''\.
M>:YN^^)EA%E+:"21NS<8J'.*W9O3PU:I\,3NZ9)-%$,R2(G^\P%>17WQ&U6Y
MRL*I$O8KG-<]=ZYJ=Z3]HO)7![%JS>(BMCMIY55?Q.Q[1?>*=(T\'SKI3C_G
MG\W\JYF^^)UI'D6=N9O0ME:\VM=.O;X_Z-;R2D_W170V/P_UJ\QYD7V;/_/4
M5'M:DOA1TK X6E_$D/OOB'J]SD0LL*GL #7/7.JW]Z^9;B5B>P8UZ'8_#"W7
M!O;EF(_YYFMP>'/#VAVQGN((MJ_QRBA4JDWJ#QN$HKW$>00Z9?W;?);RG_:9
M3C\Z9<6,EJ_ERE=W^RV:[#7_ !FTP:TTI?L]OT++P37-6&G7>K70BMHVD<GD
M@=*]*AED4N:JSR\1GU1OEHQ*"0%V"J"S'H *[GPSX#>[V76H*4AZA.Y_PKIO
M#G@JUTM5GN@LUQUY'"UUM$Y48>[1C\SE]MB:NM:;]"O:V5O9Q+'!$B*HP,#F
MK%%%<XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=CU-7HHDAC6.-0J*, "GUQ5L1*J_(ZZ5&-->84445SFP4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 451N-6MK:\CM9&P[]*O Y&1WJ5)-M+H 44450!137=8UW.P
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M-:_=FUTK6;6[G"[C'$V3CUK>H **** "BBB@#BO%/_(WZ+^'_H5=K7%>*?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4FM..U@B4!(D&/\ 9%2T5TQIPC\*'9!TZ44458PHHHH **** "BBB@ HHHH
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MBGSCDJH':O0*K7EA::A$(KRW29 <A7&14SCS1L70K>SJJ;UL?/.X4;A7N_\
MPBF@_P#0*MO^^*/^$4T'_H%6W_?%<_U>7<];^U:?\K/"-PKUGX8_\B[-_P!=
MS_(5O?\ "*:#_P! JV_[XK0L["UT^'RK2!(8R<[4&!FM*=)QE=G-B\?"M3Y(
MIEBBBBMSRPHHHH **** "BBLG6O$%EHD!>=P9,?+&#R:<8N3LA-I*[-&>XBM
M8FEFD5$49))KSCQ+X\>;?:Z:=L?0R8Y-<]KWBB]UN4AW*09XC!XHT'PO>ZW*
M"B%(.\A'%>E2PT::YZIPU*\JCY:9F6]M=ZG=;(U>61SR>37I?AKP-#8;+F_
MDG'(7LI_K6_HOA^RT2 +!&#)CYI".36M6-?%N7NPT1K1PRCK+<155%"J  .P
M%+117$=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1534KQ;&R
MDF8]!Q6'X=UR6\G>"Y;+'E2:RE6C&:@]V*^MCIZ***U&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444R26.(9=@H]
MZ 'T50EUK3H<[KJ/([9K/F\66,?W0S_[N*RE7IQWD*Z-^BN0F\9-_P L8?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M .*\4_\ (WZ+^'_H5=K7%>*?^1OT7\/_ $*NUH **** "BBB@ HHHH ****
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M2?C4#>#>NV;Z9H]GC(]0M(:GC1Q]ZUS_ ,"J=?&41QNMR/7FJ;^#;K^":/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 <5XI_P"1OT7\/_0J[6N*\4_\C?HOX?\ H5=K0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$,2_=C0?113Z*U44MD,  .@HHHJ@"BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!Q7BG_ )&_1?P_]"KM:XKQ3_R-^B_A_P"A5VM !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH XKQ3_ ,C?HOX?^A5VM<5XI_Y&_1?P_P#0J[6@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &LBN,,H8>XS6=J&@:
M=J,+1S6R#(ZH I_2M.BFI-.Z$TGN>*>(_#EQH5V1@M;L?E<5AYKWW4-/M]2M
M'MKA Z,._8^M<5I_P[6#5C+<R+):J<HG<_6O3I8R+C[^Z."IAGS>[L9?A#P@
M]_(M]>J5@4Y53_%7J,:+%&J(H55& !VHCC6*-40 *HP *=7#6K2JRNSLI4E3
M5D%%%%8F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1152]U2QT[R_MEU'!YAVIO.-QH MT444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '%>*?^1OT7\/\ T*NUKBO%/_(WZ+^'_H5=
MK0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% &%XM\2P^%- GU.:,R>6#M0?Q'TK
MSZ/PWXR\<6-KK%YK=O:;6,MO;_9@VT'E<GOQBN^\9^&U\5>&[G3=^QW4[&/0
M-7F^D>+O%7@&!M/\1:'<7.EVHPM[ A.1V&30!Z/X=DU^/2IDUX1FZB.%E0 "
M08ZX'2N#\*ZMXX\7SZBT'B&ULXK>X>-4-FK<!B!S^%=[X<\5:7XRT87>F3AM
MZ_-&3\T9]&]ZXCP_X4\=>$YK_P#LW^QYH;B9Y1YS/N&6)[?6@#MM!TWQ+9W+
M/K.N07\1&%2.U$9!^M9'C7QA>:7J%GH>BP";5+LX!)&(AUR0>O%0^&?'UW<^
M()?#OB*Q%GJ:\QL@/ER#_9SSUKGXBT_Q]D\R0$16Z;5;_=/2@#2UN3Q]X9TW
M^UYM:MM1@@.^>V2T6,E!UP:[7PSK]OXET.#4[<863AE_NL.HI?$ZA_#&HJPR
M# V17#? ]C_PB$Z9^5;N; ]/G- 'I5Q<1VMO)/*VV.-=S'T%>;:7K_BWQS=7
M5QHMU#I&FP2-$DDL(E,I4D'Z5T_Q"E>'P+JSQL586[<CZ5F_"2,1^ +7!5BT
MCL2/4T 9VE^+M;T+Q>OASQ1+'=&Y.;6[CC$8(Z8P/>I=2\6:UK?BR3P]X9:.
MW%NH:>^=0X7/;:?<5A?%[]WXK\-S)\LBS+AAU'S&E^"NZ;4->N)9 \K3,"3U
MX<T :&JZ_P"+/ NH6EQKM_!JFESL(W:. 1&-B>OO7IEM<)=6L5Q&<I*@=3[$
M9K@?C.BMX!G+ '#9'Y&NE\%LS^$-,+$D_9T'_CHH WJ*** "BBN5G\>:;!<2
M0M#.6C8J< =J *GBG_D;]%_#_P!"KM:\VO\ 7+?7/%&E2VZ.JQL%.\>]>DT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!D4 96N1Q>*_ ]T+%RZ7ENWE,1C.:Y'X2:[;6GA^;1-0E2UN[*9PRS'9D;L
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M^1OT7\/_ $*NUKBO%/\ R-^B_A_Z%7:T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q7BG_D;]
M%_#_ -"KM:XKQ3_R-^B_A_Z%7:T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q7BG_ )&_1?P_
M]"KM:XKQ3_R-^B_A_P"A5VM !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <5XI_Y&_1?P_]"KM:
MXKQ3_P C?HOX?^A5VM !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 <5XI_Y&_1?P_\ 0J[6N*\4
M_P#(WZ+^'_H5=K0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/_00M_\ ONC^W])_Z"%O_P!]T :-%9W]OZ3_ -!"W_[[H_M_2?\ H(6__?=
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M@A;_ /?= &C16=_;^D_]!"W_ .^Z/[?TG_H(6_\ WW0!HT5G?V_I/_00M_\
MONC^W])_Z"%O_P!]T :-%9W]OZ3_ -!"W_[[H_M_2?\ H(6__?= &C16=_;^
MD_\ 00M_^^Z/[?TG_H(6_P#WW0!HT5G?V_I/_00M_P#ONC^W])_Z"%O_ -]T
M :-%9W]OZ3_T$+?_ +[H_M_2?^@A;_\ ?= &C16=_;^D_P#00M_^^Z/[?TG_
M *"%O_WW0!HT5G?V_I/_ $$+?_ONC^W])_Z"%O\ ]]T :-%9W]OZ3_T$+?\
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MV_I/_00M_P#ONC^W])_Z"%O_ -]T :-%9W]OZ3_T$+?_ +[H_M_2?^@A;_\
M?= &C16=_;^D_P#00M_^^Z/[?TG_ *"%O_WW0!HT5G?V_I/_ $$+?_ONC^W]
M)_Z"%O\ ]]T :-%9W]OZ3_T$+?\ [[H_M_2?^@A;_P#?= &C16=_;^D_]!"W
M_P"^Z/[?TG_H(6__ 'W0!HT5G?V_I/\ T$+?_ONC^W])_P"@A;_]]T :-%9W
M]OZ3_P!!"W_[[H_M_2?^@A;_ /?= &C16=_;^D_]!"W_ .^Z/[?TG_H(6_\
MWW0!HT5G?V_I/_00M_\ ONC^W])_Z"%O_P!]T :-%9W]OZ3_ -!"W_[[H_M_
M2?\ H(6__?= &C16=_;^D_\ 00M_^^Z/[?TG_H(6_P#WW0!HT5G?V_I/_00M
M_P#ONC^W])_Z"%O_ -]T :-%9W]OZ3_T$+?_ +[H_M_2?^@A;_\ ?= &C16=
M_;^D_P#00M_^^Z/[?TG_ *"%O_WW0!HT5G?V_I/_ $$+?_ONC^W])_Z"%O\
M]]T :-%9W]OZ3_T$+?\ [[H_M_2?^@A;_P#?= &C16=_;^D_]!"W_P"^Z/[?
MTG_H(6__ 'W0!HT5G?V_I/\ T$+?_ONC^W])_P"@A;_]]T :-%9W]OZ3_P!!
M"W_[[H_M_2?^@A;_ /?= &C16=_;^D_]!"W_ .^Z/[?TG_H(6_\ WW0!HT5G
M?V_I/_00M_\ ONC^W])_Z"%O_P!]T :-%9W]OZ3_ -!"W_[[H_M_2?\ H(6_
M_?= &C16=_;^D_\ 00M_^^Z/[?TG_H(6_P#WW0!HT5G?V_I/_00M_P#ONC^W
M])_Z"%O_ -]T :-%9W]OZ3_T$+?_ +[H_M_2?^@A;_\ ?= &C16=_;^D_P#0
M0M_^^Z/[?TG_ *"%O_WW0!HT5G?V_I/_ $$+?_ONC^W])_Z"%O\ ]]T :-%9
MW]OZ3_T$+?\ [[H_M_2?^@A;_P#?= &C16=_;^D_]!"W_P"^Z/[?TG_H(6__
M 'W0!HT5G?V_I/\ T$+?_ONC^W])_P"@A;_]]T :-%9W]OZ3_P!!"W_[[H_M
M_2?^@A;_ /?= &C16=_;^D_]!"W_ .^Z/[?TG_H(6_\ WW0!HT5G?V_I/_00
MM_\ ONC^W])_Z"%O_P!]T :-%9W]OZ3_ -!"W_[[H_M_2?\ H(6__?= &C16
M=_;^D_\ 00M_^^ZN6UU!=Q>;;RK+'G&Y3D9H EHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ ILDB1+ND=47U8X%.JAK.DV^MZ9+8W0/ER=
MQU!'0T 1:GH&CZU;R)>V-O,)5*F0QJ6Q[-CBO'_ ]G<:+\2-5T70+A_[/$8(
M+L72-CGM]:LKH_B&/QTGA>#QOJPM!;-(6PFY<'&.E>F>&?"&F^%X)!:)ON93
MF:Y<?/(>O- &1'I'Q"$JE_%.F-'GE1I^"1^==G$)%A02L&D"@,P& 3W-/HH
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M:'_SSF_[^FNEHH YK_A!-#_YYS?]_31_P@FA_P#/.;_OZ:Z6B@#FO^$$T/\
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MR_!"^1K6JVJ,WDQ<(I;('S&NYKG- T*ZTS6-0NYV0QW!^3:>>I/- '1T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0BSMA<_:1;Q>
M?C'F[!NQ]>M3444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$<]*]&R N3P,9KPW6M(LM$^,'ABRL85BA0K@+W^5N:]NGB\^UDBSC>A7/U%
M'&7/Q!EGU>XT_P /Z+-J[VW$S1RB,(<X(YZT[2/B$MQKAT;6M,DTF^;F*.20
M/O'?!'%<)H_B"3X6>(]1L=?M9?[/O)6EM[J-<@DG."?H*FT^5OBEX\MM:L8S
M!I>F97S&&'<D@C^5 'M=%%% !1110 4444 %%%% !1110 4$@#). **AN[?[
M79S6_F-'YL;)O7JN1C(H X'QE\7=(\*7*6L4+W]P6VND38"#USTKO;*Y%Y90
MW(4J)4#X/;(S7B'Q0\(:=X6\%VZVJF2>2<F6X<?.YQWKV?1/^0'8_P#7!/\
MT$4 8FL>+;NTU$V&D:+/JEP@W2*KB,*/J>#6=IWQ'!UU='UW29=(NI/]4))
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M"%'?D52C^'^NQ1JD?Q!UM548 $<7'_CM==I^FR6NEBRO;V74#C#2S@;F^N*
M.>^&-]%>^!-/V/N:-"KC/(.37)^(D76OC1I$-N=XL]LDQ7D $$5O?\*R>SO;
MF70O$VHZ-;W#[VMK5$* _P# @36YX8\&V/AE9I4D>ZOIV)FO)0-\G?G''6@"
M_P"(1CPUJ ]+9_Y5PGP._P"10N?^OV7^E;VO>"]4UNZN'3QAJMG:S#!M84C*
M 8Z<C-96@_"V[\. 1Z?XRU:.W\PR-"(X]K$]<\4 >B-)&C!6=5)Z G&:R_$J
MV;>'[S[>L9@\LY\P C]:J^)/"P\0VT*IJ%Q8W4)!2Z@ +C'UXYK D^&U[>E8
M]6\8ZMJ5GG,EK.D820>AP : *'P26Y7PO<B0,+?SOW&?[N3TKTZJVGZ?:Z79
M1V=E"L,$8PJ+T%6: "BBB@ HHHH **** "BBB@ HHHH .U>.^!?^2R>)O^N7
M_L]>A^(M U#6FA-EXCO])" AA:JAW_7<#7'V?PBN;#5)]3M?&NKQ7EP,2S+'
M'EQG//% 'ILCK%&SNP55&23VKR'7M6O?B1XB_P"$<T@O'I-N_P#IEPO 8="
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M#VR* +?P]\&R:-!)J^JL9=8O/GE9N=F>P_(5@?&>*6&;0=1 /DP7),C#^$'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHC.H7-TY*"1B!&H)&!C'M7>^'O#L7AR":WMKF5[9W+1Q,.(A_='M0!M4444
M%%%% !1110 4444 %%,ED$43R-]U%+'\*\ZU#XGO!=/':644D:G 9V(S4RG&
M.YO1P]2L[01Z117EG_"U;[_H&V__ 'VU'_"U;[_H&V__ 'VU1[:!T?V;B.WX
ME[Q=XVU32-<DL;+RE5 "2Z;LY%8/_"Q_$/\ ?MO^_-86M:O)KFK27\L2Q,X
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M>WD&'1NXH P9M/\ !5O:"Y>PTGRR 05A0GGV KFOBV;9OAMNLU5;<J#&%7:
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M@:7HR3)I]FD"S,7D"Y^8GDFFZ=X=TG2;RXN[&RC@GN6W2NN<L<8H \^^*O\
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MC:9:^=)=QMS@*%/-=_69JVCQZLJ"29X]O]T5G4P5/D?(M?43BNAYP*#79?\
M"%6W_/W+_P!\BC_A"K;_ )^Y?^^17#]1K=B>5F+I6@-JL)D2Z1&!Y4J2:T/^
M$*G_ .?R/_O@UNZ1H<6D/(T<SR;Q@A@.*U:[:6"AR+VBU]2E%6U.-_X0J?\
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MK4],BN)U7:')(./P-:BZ;9II_P!@$"_9=NSRSR,8Q0!SUO9^"+G3DOX['23
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MO5BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
@B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gapk0ju0ozex000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gapk0ju0ozex000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /)!5\# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %(PW+C.*6D;[O7% &;?75O;VLWF2CA>]>+Q:C;/X]FD5U"D#G\37J>LZ
M/+?ADCD SUKF!\-E1O/5D$_<T =-K<4>K>'&M8)/,9E' ^E<%X$UF+1-5O;2
M\"Q_O-H+?A7H'A[2I].B_P!(D#L#Q]*H:UX'M-0G^T6R)',QR6]Z .2^)6I1
MZO)8V]@PE9+@%MOID59\7^'YKCP:FQ"7!4X'TKIM'\&6NGL)KM%EE]?>NEDM
MX[JW,3+\F,;30!Q7A#Q/9P:+Y4TZB2!0NTUQ+F3Q/XU+1+MCAF#!E[UW%WX
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]:<<;XZ &A!N8>E)L'DY]Z=D"5\]^E!7$6WOF@! @\Q12!1N?VIP(#JW8=:
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M.M"# ?/\/6@!-J[C1L&W;2JA8>9_":=P)-W\- #-@./:EVC\Z50 &![]*0X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *3M2TF<B@#G?%)_XES?C7B;
M-F[?_>->V^*!G3F_&O$W4"ZD/^T: (\?O.>.>/>AQE^GS=QZ4='YYST/I2G)
M;&>1U;UH &QLP*%YD5CU7H/6A?FDQTH'\3=UZ"@ 8?OBPZGJ/2@_>P*:I).[
MN>H]*>W!H 3 W ]N].'&<]^E-[;?6DSGC^[0  89?7-=1,#_ ,(U(/XLBN8S
M\RM[BNIE/_%.2/Z8H Y;(R,=NM*I&YL4S&&_WJ<!M)H 1!\V*3K&WM3AP-U&
M,(P]:  C=&E* !D'IB@'$?TICD_9U;N30 Z/'V=\]<TU\;H\'FG;< +V- 4$
MX/7L?2@!'*+(2S8)[4AVEL,=HK<TCP^VI,Q)W8&<UHMX75 2TBMCM0!RJD"-
MD'.>AIC-L4#TZUH3:7)%?)%&=^X]NU:]GX6D9G,S8W#C(H YG(D7(.%I&.W]
MSC[U;VJ>%;BTAW1,2H.>!6&PP-S??3B@!K+YFU0=NSKBG&2,GR@>G>K5I8OJ
M3!(#ACPV*W6\&2"T 5\S+RQ YH Y@)\^6)Q2':RLV?NU9.G7#WXM1G=]*Z#_
M (1"46N-WS,.F* .5QE X.<TH&[Z59NK"73I#"X/' JWI>AW5X-ZJVW'I0!F
M@[N".*3S0YV #Y:L7%I)#<&$ ELXK=LO"LC6PE;AG'&10!S2X9BF>@S4?)R?
M2M+4]'N-,<LX."<=*HJ-K#/0T *<;136X5<>M+D!CG\*,;B?:@!6XX[4B_*A
M7^]2-\R>^:67EX\=AS0 C<!13N^.U#TA_P!4#WS0 T\QDUU6@$'2[H^B?X5R
MK_=Q74Z"N--NO=* .<N/ED\P=6XJ-L_='>I9QF9E].:B5LG)[4 *W8^E!X&[
M^]TIK_>![=Z4GCGIVH &^5=M##Y-WI36SLYZTO\ #[=Z %'RKG^]TK9\-$B]
M=?\ 8-8W1>?PK:\,?\?CY^]L- %?6?\ C_&.N.E9@."V.?7VK3UCF_QT/K67
MCEL<8Z^] #CC:/[OK39 'ARA[]J=UC]O2FE?+LR5/.: .M\)%$N8BR@C/.:D
M\;VYED5K>,<MVJOX4R$);J3Q6Z@&H3S1%<^7TH K>!H(;96:Y5=VP]1[5B:W
M;_;M<"1C"DGI6W$#;7)CZ5,D5O\ VW!DKR.: ,-/#J' R2WI6;=Z/<1WQBV$
M+G%=;.S0ZD"IRN[M4QEBN+^7S% (&1F@#GT\.10JN7/F'G%:6KVOV86D*(#O
M7DUCZI+?-K*O$S^6!C K?O)'=['S 2VWO0!RE[IQGN!"6*8/:M"#P_!%&(S(
M6;WJQ?6CS7@\MMK;JT;6S>"=1-+D^] ',W6D-:7J1A<[N16BGAM!%OE8J9!P
M*U]:B"ZE;=\K63JU],;BTC1RH5N: ,K4]'DTNU$NTE2< FLI#NB(/#GH*[OQ
M(#+X9A)Y._.?RKA-R[M_0CC% #4#,CD_PU(,- C4B'*OCH>M(@*@Y^[VH T]
M#3=JRD^E3^(\F9![56T!F&I 'KBK>OX,B_2@#$<XC0"C=MY[T#DJ#1M!N64]
M * &OD+A?O'I2LAS'SU^]2J?FWGH*%WR%@,Y/2@!)!^\*(?E%$0YVFM.VT6=
MK;S3G..>*S=ICG(/:@!K-N;CM2C&"<Y-3V,(FE9">2:L:CIDEBBR\E6H SPF
M_P"<G%/1]_##IWK1L])EO;3SURJU0N%^]'&OS#C(H C)^;..%Z4Y&!)=N]-W
M@!8RN#T--=':78JG YH =N,8+#[W:E"_Q'OUHEW+AF4X II\R1,*IYH ?%Q)
M)G[I'%-AY!B;ZTJAA&%(PR]:3&(_.'7I0 9!SCM33\PIX38O/\7--Z T =]\
M/#B8#VKU1?NCZ5Y5\/@3.#[5ZJOW1]* %HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH H:O%=363):,%D(/)KYX\::5KUEJVZ\F1HS
MDX'I7TJ<8YKR/XLHJR!_]B@#T#PJQ;PQI_M%S6Q(%QDBL?PB0?#-C_UR%;9H
M @)&[$C+CW-2#<!G(V^U>?\ CG5KS2IM\/0#UK2\*>*AJ\*Q2,-X&#B@#L5P
M?F'>G4Q>#M]*?0 4ASD8I:* &;3O)H,8+[N]/HH A^="23\M*-K#?CK3W&5J
M-6XVT <GX[R-+R/[PJ_X1/\ Q+@"1R!5;QK9--I+%<G!S6#X#U9Y7D@8_<?;
M0!Z1N'/M0KANE- X)]:5  M #Z*0'-+0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4G04M-H Y[Q3G^SF_&O$VS]JD)Z;C7M?BH_\2UOQKQ.3)N)/]XT
M  Y+8_&A<$X["DV_,"/QI4&)G;^$CB@!%/[S?V%"\!\]3TI(UPI!]:4?<;U%
M  /E&>YZTA.#[4IYC3U[T$ G-  S;1S][M1CH1WZT.Q9/,Q\Z\ >M*&Q&&')
M/WO:@!#C>JCU%=5+M_X1R0=N*Y0,"RXZ9ZUU$P_XIR3\* .8VDMUZ=*4 G.3
MS3<'-.13EL^E "$?N-G\6:4\[<=NM-0;NI^7UI5!W<\'M[T #8&::_$"YZ9H
M4;F<'J*5N85'O0 [GA>Y'%,53\Q/;K3F.)D^E#*<%A0!Z+X! >WDV\9C(&?I
M3KO2-6 D=)X@,GJ?_KU!X*W"PDD'!$9/Z5S>J>)KU[AXE/ )'!H W?#-A*]^
M\EV5=D?@BJVL:W>RZS-:6;;?+;N*C\(:N3>^7,0"S5H:YHE]'J37MG"'$C9R
M: )DDU1M'VW#!FYY K@IH96NG)5B-QS@5ZM82S)HV+V)4;![5R%OJNF6M[(L
MS+DN< @4 8FD7C:/)+)@J7^[Q7<^'+R]OO,NY'4J\9X_"L=;;3==N=D;X.>
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M4T<J<'^*AR %0#H:  Y*;*7'R<=J"<2!L=NE .(WSWH 1.02>,?K2KTW$?\
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MSGK7J6"*XOQPLA5=N<;: -KPU([Z=&7.?EK9/'S"L3PTV-(@4]=M;@7Y<$T
M/!R*6D7I2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)BEI,&@#G/%0
M_P")<WXUXJX_?2?[QKVGQ6#_ &<WXUXI)GS9/]XT (.C8[=::?\ 5J?X2>*"
M3E>WMZTX']X3C_@/I0 8).#1]^"1NZ=*5?SIL?"NO]Z@!2<VT9[GK1VH' V'
MMTH/!Q0 ?PD=Z!V]J7_EJOIWI.C/GOTH 1N9%(_O"NINL_\ "./^%<J/X/\
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M ._^'O\ Q\#_ ':]37[HKRSX>@_:!_NUZFOW10 M%%% !1110 4444 %%%%
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2<TM(>E
M'.>*@?[.;GUKQ23B:0GGYC7M7BO_ )!S?C7B<F?.D_WC0 (P96)'W>E(K;D!
MQ@^M*_\ #MZ'[U*2!Q_#V% "!OFQC%&<'-./^L!]J;_RS>@!&7<0PXYIS'][
MN]NE(?\ 51_K1QO_  H /]GN>]#?/@#C;U]Z"#L*?\M#]TTAY"A>J_?H "<,
MAQ_$.*ZJX.[PX_&!QS7*,WSJ5^Z6%=7/SX;=.QQ0!RS<CKBD89C49H(W_P#
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M&9MSG<$<=* +'BYO%/RG2K/S!QWQ_2O+?&!\4.Z_VK9^2NWD@_\ UJ^E_E(
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M10 4E*>E(3\N: .=\58_LYOQKQ60 S2?[QKVCQ7G^R&?Z\5XIN'F2L3T8\4
M",,G=P5^[[TF[]XSXY(Z>E-;# MG&.E*6!MT/\6>: %0XA/KF@=*'=>HZ49
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MN[1@ 0O'3BE^V6W95W>FT4 >2?\ "(W>0&7(/M2#PC=DX1<8]J]=^W6><X7
MZ\"G"^M,Y4+S_LB@#R ^$M0#;2./I0?"5TK8"?-]*]>^V6^<E5Q]!0;ZR8Y
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M#[23US1YG%)@4$ \4 &=O>E"D'=FD=<4A+!: ',2/F]:53D<\5&"S*,TI;C
MH &D(; &:?G*\'FD7!7FF+D.?2@!RY!SN-*V2?O&DS32#0 \DX^]TH60AB0>
M330OK0H&:  R,!M'0TH=LC-!QF@C.,4 )@ABV3S3@6!W4WFE+$"@ 1B0V>*5
MF)4<]*:ARII3TH TM.S)@$]*Z%?NCZ5SVD_>%=".@H 6BBB@ HHHH **** "
MBLS4M<LM(@$M]*(E)QDUD?\ "Q/#?_/^N* .JII:N7_X6)X;#JIOURW2M>PU
MJRU3)M90XQD4 :0-&[FHU9\_=XIQ)WCB@!]%%% !1110 4444 %%%% "$X%>
M1_%W"C!_N5ZS*2%&T=Z\D^+ZDLI_Z9_TH [_ ,'\>%[#/_/(5NJV7([5A>%E
MSX2T_/&(?ZUN0?ZL4 24444 (V<<5&!E<=ZEJ,+^\S0!R_CP;?"EVH[BF^!.
M-&AS_<JUXTLWNO#EU'&"S$<"N'\*^)[VPN(M.N8%1,[ : /7*3'-1K(& *G(
MIQ< 9H ?135)/44Z@ HHHH **** &MG'%)SQFGTA7- $%T6,,@7^Z:\JEU%=
M*\7++*CY /(%>M; 0<]ZS)_#]G</O>-2WJ10!S4GCNV^7"R?]\TG_"=VO]V3
M_OFM_P#X1:QSG8O_ 'S2?\(K8YSM7\J ,+_A.X3]U7_[YHB\>6Z3+')N&[VK
M>'AFR7HBG_@-<;XUT:ULR)XSM95X % 'H%G=P7<"S)GYQFKL?W.*P/"Q#:/
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MI[*)T<\=J $N:K"K%T<-BJ_% "CI0AV]:,@4,N: %;YNE(!BE4!>](6.X8%
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M =&I*R8ZBM#</L+?+WJ@64'H<5?9U_L]N#0!2W _PTW.6Z8I5=?0T@8%S@4
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M 4444 %%%% #7Z5Y)\6DPOF$G<$X%>MN0%Y.*\A^+9,@VM\HV=: .^\*._\
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MG2@"H^F0N68]^M3I#&MLL 4 #N!S4NZC<* ($B2(8R3]:F!7&?3M28!IP44
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M%*,D=*  =*2D&_<1CBAMP/2@!U7K3_43?2J(Z5=M3B&7W% %3HE(K BG.#L
MJ,)@9% "@ASCTH)"G%(H"'(SS2E5;DYH 7:.M-*XE6G ]N:;O)8''2@!7.#4
M]HOSD^U5W.>2#5JUDQVH 2YJN!4UUNW=*A#8'(- "9P:,TC,G'!S3B,)D#F@
M!O-'-/. N>]+D%1US0 W=0>::0 V #3MPVY /% " <TYE I.2,XI-N0#SS0
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M$MH"V0Q%>T^!] O-#T](KNY,S!<<T =0^T'@_-3XLG[PI-H\S=BGXRP(/X4
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MK6MOGY7S[4;0$V=^M 7)  H :;6WQ]_/K[4"UM>N_P"7UIP4$-QC'7WI B[
M<<>E #S:V@'WA31;VN?O"AMJG&,TGRC^&@"0VMKC[P_*A;:UZ[Z9N4_PTUB!
MT% $@M+8'[]*+*VY^?K37& .*:V1MXZT .^R6B\&2D^S69_Y:4':.L>30#'_
M ,\J  6MF/\ EK3A:6F<^92,8P/]53=N1D# H D-G:G^.D%K:C^.A4&.E(=H
M- "_9K4'[XI#:VI_CI6";<X%(%4B@ ^R6N/OU/':P*O#]:K%1GI5@$!%XH B
M^R6_FL-_:D%K;;2-]*<>:6QUICKB8+CJ* 'FTM/[]+]DM,??II5:-JXH 46E
MIG[XIWV:T_O#\JC"KFD.,_=H >UM:8^\/RI\-O;+T85%\N/NU)&5'\- #IH;
M<MRPIAMK3 RP_*B5@7'R4UMN!\M "FULSCYQ^5)]EMC-MW]J3:..*7:HEW8[
M4 "V=JV?GZ4"RM1GY^E- Q%(V.E 7]V&]: '+:6A^;?2M8VH^4OR::$&S:.H
MIOWY _9>* 'K;VN"N\4?8[8*/GHV(,GCFF., <=Z )#:VWF#Y^U'V6VY&^FC
M'F#CM1QD\4 .6SMO[]!M+;^_3>/2DXSTH >;2VV_?I/LEL,?/UH.-G2EX9<X
MZ4  M;8R$;Z06=L3@O34QNW8ZTX[0^,4 .^Q6O\ ?Z4PV5KN)W]:.,-1@;%.
M* 'PVMLC\/2W%K 1R_S=J8@ DZ4^;!&['(Z4 -6UM]OW^>]+]DM=OW^*8>$!
M ^]UH0+C!Z4 *+6U*'YQ2K9VVTD/2!44[>.:#\O '6@ %K;!<L_6@6UF/^6E
M(2% #)D4.T8_Y94 'V2S!SYM*MK9@Y$F:1BFW/E4F5VC]WB@"3[-:?WA^5'V
M:T_O#\J:-O\ =H.W^[0 K6MJ1PXH%M:^6/GIHVX/&*7:OECB@!?LMKL/STC6
MML-HW"D"J$Z4K[?EPN: %-M:J/O"E%M:D9W"F%@1]R@, ,;* %^RVQ;.0<4&
MV@'<'/Z4BC()Z>U&PCOG/Z4 6;>&-#M!Z=ZOKTK.@X;9GG^]6B.E "T444 %
M%%% !1110!6,FV,@@[L5P>HZCI@\51VM_C>RY&3CTKO5WL#O4#(KRSQM\/KS
M6]>74+<RAE7 V,10!Z7;3V*P)Y4\ 7''SBK:/'(,JZL/]DYKQ)? /B,!55KC
M:/\ IHU>D>$M'N]+LU6[9RP7^)B: .CE<JGRT8;<I!X[T[(=,TX#)!':@!U+
M110 44F:,T +129HS0 M%%(* (;N?[/ TA!X&>*\'^(WBJ#5-3%HB29VXY%>
M]3J'B*D<'BO%/B9HMGI5S]I3[^W=R* /4?"IV^&-/4?\\A6XA/0]:P/">6\-
M6$AZ&($5NHN9"XZ&@"6BBB@ HQFBB@ K.U;2+;5+<I.F[ XK1IK=* .!_P"%
M<Z;)UAX^M17?P\TN.T9S">/>O0N=O JGJ)(L'R* /-O!,"6FK7$$((028(->
MJXQP.E>;>%+=EUJ[<CCS,UZ4#D9H 0'#[:5>]-ZR9IX&* %HHHH **** "BB
MB@ HHHH *3 I:* $"@=*\M\9EQX@&T_\M%_G7J=>;>--*U.743<V< ?Y@1GZ
MT =SI9"V$9/]T?RJYC)&.AKRX^*==TNT O+:-(UP,_Y%=UH6LIJMBKJ07V\X
MH V>G%.J-,[?FZT^@ I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH 1N!3#)M SWIYZ5$XXX[T 12_,,=_6J8PS8JXR@
M)LS^-4_X\]A0 P9+'/\ #TI[X""0?>;@T<$\\'^'WICYZ?Q]QZ4 .4;3STI!
M_$1^%#$>3\M&=K(OK0 JDX.[K2#/4=:63[^!2 X?% "YYW_PCK2!B"<]&^[0
M?^>?]ZC;O ']R@!2Q4 #[V:L?\L_^FG:JR_,^34[Y"^;Z<4 5SEY 1_#UISD
M [E[]:%PF?\ ;I-H+;6/2@ "C?M[8H7_ %;@^O%*(QG()JIJ%Z;&!FP/QH M
MJ4\L[B!@=S4,-Q%(Y7(.!V-<;_;DFL7+0*VW8?X3BM_3-.D@(D)8_4T :RG=
MEFZCH:0S1Q@C>NYO>DNV(LG"CYJ\_L%U#4KV]C&[:C8&&/M0!Z*'B,0S(A;_
M 'A21D%<+(A;V:O,H_[3BU:2R!8XXY8U9\^^T34U$Q;!&?F8T >C',8S.ZD?
M6FHT<S';*FU>@W"O/=9\2".:"-Y2JR#G!K.AU>*WNUDCN9",\@M0!ZH^ -Q8
M!_4FLG5]933I%57!R,G!KF+W7;O4V6*U (..0<54UK2;ZU:*60,8RN6))XH
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MX^,]L4 (?ND^E)T4'^]0G1L],TD9^_G_ (#0!/;+^]V'M6D.E9]IG8/[_>M
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M0XL(B$')JQX-7.BAB?XJ .BVC-2U"0"X^:IATH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IC<<TYONTT\I0!7?J6JD3L
MEP>]793B('WJI)@7*9Z8H AN(DO+.XBR067 Q7FEY\,SJ%V[>;,._$A_QKTX
MDB0X'&:5(XUD:0R8R.E 'F>B_#F73=16Y$DQ"\?,Y->D[(X[9+<D_,N#4B.=
M_E8X/.:C&<OD9(/% 'G>M_#Q]5U*6022A"<C#D56M?AH]K<*PDF+ YY<UZ<2
MS!=H^8=:>&,C\K@8ZT 5[.!+:P",3N4 55M[$PW339;#G/6K^3M;"Y.>!ZTX
M-\G3GN/2@ ?R^ O7-2]P.V*KAF.#M^7/6K3KB'?Z4 5U/+4IZ9]::G4^]+G+
ME?2@!Z#+;?:HU.8I#Z&GJ</GVIJ#]S)[F@!1_JU:E#;3YO\ >XIO_+,"D_@'
MI0 [9M!C_O<T@!! %*6^89ZT DMP* %&T,V[TIH^:,[?6C&Z1@:CGF6TM6?/
M2@"5%*CYOPI Q#,/6LVRU9;N.5P1B,XI+'68;B>X3(S&,T :8_=)YA[\4Y#M
MD&[OS7.7'B2+>8MP^7FI--\2VVJWB0HR[A\O% &K+>BVD9<_?X%6(\O:H1W-
M<E=7#S:HZ\[8FYJW)XGAA_T=67<M '2; 9 KD]*8$4EFR<+7.P^+(50K(5\S
MMFGVOB>%;D0N5_>GB@#5EU:T@D\MF(8G%6X<*OG*>37GWB.8_P!KPF)C@RCI
M7>VH/DH3]W:* (9;J)7\N7&&JPN BE/N]JQ?$L+_ &=I8LY [58T.]^TV4<3
M'YT'- &HY+GB@ @[OX!UH8%7X%!;+;?X3U-  5/4]^E*/W8SW-*20.>W2D&6
M 8]* &<NOEGZT]QM4$=J4D&<$>E)M(5MW>@!!RN?7K2A1C9_RS'(/O1@B/CH
M:%7,/ED_*.=U #=Q:%BW4<"K%N28CGTJ $-&2>,<8]:G5L1X'<4 1,N6R*@N
MI6@MVQ4PW>:P]!3707%NV?6@#!MM5L=1BN$N/O1G'2L+38U&NR?9L[0>*WKS
MPW%-(/)D*%OO;:OZ?I4>E@ J&8\%B.: .4\8SRW5\MF_W>#Q77Z1;+:Z;''C
M 91FJ]_H27%]]KSN..E::+N@$0XP,4 )CS,YZ1]*L0OYD0)^]4&[HG3;^M20
MC$A;H".E #I@ NX]*B)V[<_Q=*=+EFVG[IIBC()/\/2@!^>J]P*C .S\:>#Q
MN/4TB99MM "9*NH]:7!W'WI'!W@^E.?@+VS0 @;)\IN@YJEK$<DNFR>1_K.P
MJXX,;Y'(]:3!D<,XVX_A]: /-Y;7Q!8VUT_E1E'&<D4WP6VJ&_,KJH!'->DW
M21W,)A"@J1ACZ5G:?HT5A/(RM\K+@4 7YKAI4RN,@8K@K1[9]6F&H XW\<5V
M<5E+$&.2P)JK>Z!;WC*RG8W\1 H Y&[XUE!IH_=[QNSZ5Z,FW["@^E9-EHD-
MJ_\ >([D5K*/+?>W Z;: %R63#=>U+T4"FR<7"8Z$4HX+CKZ^U "#KL["A!\
M^#3?1<\ _>]:D)Q<+VXH 0?-+_NFA_\ 6D]C3?N;O>GJ-T?TH 6+_78]J=(#
ML8>M-A^8[Z5B<XH C(.Q!Z4<[\TK9I&R$!]Z %[Y%#?.RL/X.M#_ "+2K\D;
M _QCB@ 9M[%QT-(2J6S-WI(_ECVGJ!35&4*GH: .*MPTGB2-B. ]=GJ39LIE
M']TU4_LI4O$F4=\U<EB\X,A/48H Y3PFNW5&0>AKH+^PMKDDW X^E)9Z2FG3
M^<IY-7;Z+[1;E$^^1QB@#SVYMVNYKA(E^2W^[@5DR0YAC;<XE#9(S7I]C810
M*RF,$MPY(K.N?#D+ZDTJ']WV&.* '>'9))=-W2YX.*VV2,!0A/S=<U''&+>,
M6\<8"D=14F%R,'..OM0 H.Q2I_"DB_=C)ZTD@\W&. ISGUIQ/F_..HXQ0 U@
M<Y]:&SQG\*,\^U(21G/?[M $]ONW_P"U6DO2LRUW8 Q\W<5ICH* %HHHH **
M** "BBB@#DO&'AH>(+ 0QD),C;@]<%IGPZUB;4%&I:AYT(/W6':O9<KN)'7W
MJ/,+MV!H Y'Q'I=[-IL%A92%$5-AP.*O^$] ;2+%3,VZ4K@FM\8#?*RX[Y-/
M!<G@@CVH 4#='\PI(W.<8I6+=!3E&W@]Z 'T444 (QP*YG5?"&F:G+YTMLC2
M9SDUTS=.:.W% '+:?X)TNUF$OV9-XY!KHYH(IHO)D0%,8Q3P'S2G]: .4NO!
M&DRRLWV1/F.36MH_AZQTA2;:!4)'.*U^U,);- ".,FO)OBXGFIQP0G7\*];
MQS7DGQ<9MA _N4 =_P"%#CPEIZYW?N1_.MR(8C QBL'P=&5\+6#-S^Z%;ZG=
MR.E #J*** "BBB@ I" >M+10 8I,"EHH 9)TQCK30NY ,T]FP0/6F-F,.YZ
M9H @-C;B3S=@\SUJR  O!KD+KQ?;V^I^1(3BME-=LGA!#CD>M &LQSC#4-]T
M8-00217,89#G\:F*?+@T /'2EI  !Q2T %%%% !1110 4444 %)@9S2T4 )M
M&,8HQQBEHH X_P =.8["(@9 -0>"-7AGM1:\!LYQFNBUJPAU&T>.09V@FO-_
M#D'V+QE]FC^[C.* /6=HSG-/'2HP@*#UQ4@X% "T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% "'I3"W!&.E25&QZ^W6@"!B#
M'N(X]*HD[CD\GL:OEA@O_#5#. WUH %.58^E(0/+5R.IH'' _BZT['.SL.E
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M,XW;N*H:;*S7-X4^7Y>3ZUGZ)HNK:DU[]C954/SNKK-)T%],MICJ W.Z8RM
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M8Q0;F';@,,]Q2+/ $P66@!50,C)_>H5BRE?^>=*ES#G.Y<]A3?M, <X9>>M
M"9;:)#WJRO*9J$W, ^7<N*F,\7V1B&% $#'YJ:\9;!';FG+<P=V6@W4). PH
M '.Z'S/PI5(5E-(UQ $VAE(H%Q!C[RGVH 51^\=AWIC9 #=R>E.%U!S\P^E$
MEU!Y8PR]: 'Y (7L>],&\;@@R*474&\99:/M,()(<4 (&."I&*AF@CDM6$A.
M":G6[MU^8E3GBD>>#[FY<'F@"E8:;!8AVA8_,<FKAVS1O')P&& :=]JMMN R
MC%(+BVS]]: .=D\'6;3ES=3!CV!K3T[1[33D/E-NDSQD5HFXMSSYBYIOVBW
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MHR,]*=@GD4T;@>E  3[&CYMAP<4_?CTI"=R$T (Q?:.:0[]@YH.,"E8#RQ0
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M;FY)H"[&);HW-+T.1T- ";O:EX]*-Q/:E^8]J  =#MXIOSJ<9H.=PS3I%&:
M#Y@.M-.\ D&A^!3B  OO0 1ERG)H0,3R::2%.!2D8Z4 +']_!YI@/[YQBG\H
M<BFLQ!W8ZT ;6A*K7)R.U=&@ ' KGM#W9W>HKHESCF@!:*** "BBB@ HHHH
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M0X()KT>Y<"V<%#BO,/#Y'_"87Q5<?O* /6!D<T[))J/)XJ7B@ S2YJ/G-.%
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MI3]0^^* *K?=6FL,CDTYONK32NZ@!<Y&,8'K31E3_>I^\,-N,'UII_=]><T
M+N4<X&3VIDDT-N^ZXD"K[T^-0VYSV&17*WTDFH:V+1F^4CO0!TJ7MK<2!(I0
MY/I4P^5F0C_ZU<5<12:3?PM&W&><5UT%P)K1)L9+#)H D\V*U.7<$>]1I?6A
MR(YPS$]*Y;7;YYKW[- 2N2*2[TN?3?*G$G5=QQ0!U_"[68_>IAFC$[#?GCI6
M<;IKG3H]F=ZKS7-VE[=?V\\4A;: .M '< AT-)U^7/TI.D2X[BGX^7=Z4 )@
M*N#UI8_D'S'/UH"^8-V:: 9.,T . Z\Y/84GS<\4J$<KCYNS>E)AOF^?Z^]
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M^EZHL1.YONU!H,>HR6)9F0EE[UV.B^$Q_9]Q%-G<XXS5(^&KJPD:- VQN!0
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MGHW2CIPGZ4$GS,.<K1TD'EG [T '&1Z]Z&ZTAQO]^]#'F@!S=*3^&ANE'\-
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M[\[L>E)&1/D=".!F@ DSB-D'U H)W-N8<FDC$@=QN&!UI0P9R* %8*.@ICH
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MM0AXTZRTX3Q$X$@H F]J*C"E6W9R*DH 6EI*6@ HHHH **** "BBB@ HHHH
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M_P!V@#ECH4_931_8-Q_=/YUU'7VHQ[T <O\ V#<?W3^=-.A3@\J:ZK'O1^M
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MS1SZTZB@!O-'-.HH ;SZT<^M.HH ;SZTN#2T4 -&?6C#>M.HH ;@^M+S2T4
M)@^M)SZTZB@!.:,'UI:* $YI.?6G44 -Y]:.:=10 WFCFG44 -Y]:,'UIU%
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M4?+6%XBT%-7@5< $'- &?X>\1:9#IBI+< $5JKXGTTR!5G4YZ5R)^'TQ&$N
MH^E8_B#PS=:1+"ZW)8 9.* /6HYH[B,/$<@U)]Y>:Y[PC([Z;'O)8[:Z/% #
MATHHHR* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J3;MFS\S
M7E7CNPO[35EO-)D;S57[L8YKU>=R(25ZGBO)/$WB>Z\.^+XWD#-;[,D!<^E
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MMQ6#=*Y_PQ\GARP\M?E\OM6W&Q+D;<"@":BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *YSQB"VCL%Y(S71U5O;-;R(QOC!'
M>@#R_P"'.K06\SVL[[93*2!^->J[@VT@\&N:L?!]M9WWVA0N<YZ5T@7;M7L*
M ,/4?$UIIMR8YY H!Q5[3]:M=0A$D,@93WK(\0>'X[V&YG8C*J6%<CX :?\
MM,VSLWE@GKTH ]6W*5W9XI0PVYSQ4!!615'*]Z<TI5MH3(H F# ]*3>N[&>:
M;_#D#%# ;<CK0!)12+]T4M !1110 4444 0LK-(#CBE9#E<?C4M% "8XIH7'
M/>GTTT >=^)EWZ]:9[-7<:6"+*,'IBN&\2,?[?M?]ZN[TS_CQC^E %LT"EHH
M 2EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#S+XLZ-?:GI<(LHV9TEW#;]17F)_P"$
MV:(0?9KDJ!@?-7TO+&DBX<9%5OLL F 5!0!\Y6B>-;/<J65P _4YKV/P(VJF
MQ3^T8W#;>=YKKC;1#.Y1BG+$%4>7P* ),X/3 I  6R&H8X7D9J*.7+XV$>]
M%FBBB@ HHHH **** "BBB@!KYV\#->0_%S*)_>^3I7J6JO+'9.8<[\'&*^<?
M&5UK<VL%;UY##S]X=J /??"!(\)Z>=F/W(_G6W'D_-Z]JQO"X/\ PB^G -QY
M0K912&SNRM $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$NJV-W"LMLRK(V"2:]%TNX^UZ>DOK7'?$")(7LB@QEO\:Z?POG^PHL]: -?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%)FES0 44F:-U "T4F:,C% ".-PZXKR7XN8=< Y.RO3-
M2O6MK9F16) /05X!XZ\1W%[JGDM'*!@C+*: /<?"&X>%]/4@_P"J%;@/SE<5
MA^%7;_A&=.SWB%;0/[TB@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@Y_"@#OA>6H/^L&35DN"@9.0:\EUFRU31G622\=P!G%>CZ#(\NAP2N2Q9,T
M:L9W+NI]10',0.,>U2T %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%%% !1110 4444 %%%% !1110 4444 %%%(>!0 9HS11D4 -VJ#G'-+FEHH
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MO@[(T6 XS\M=*/[V*YOP:'328HW!!"]ZZ4G:* '4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4TKD]:=10 @XI:** "FN,CKBG4UR .: ,
M;Q'IT%_I4L4@7)'4UP?@V+[%K%S K[E#8%>DZDBM9MD=J\X\*;?^$FOAZ/\
MX4 >HHI'.:?FF@-OSGBESS0 M+2$T9 % !2TF11N% "TE&11D4 +2$XHW"D8
MC&/6@!K2@8QS2NQ5,@9IJH >10'!?;0!(IR,D8I::N><TZ@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSM9?_':7_A-;O/W3_P!\UW7]FV(/-K%_WS0-,L?^?6+_ +YH X4^-;O^Z?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 0W,4<T121-RGM7BGQ/\.:?8
M7(NH;=5<+G(KVZ3=M^7K7DOQ?WB+*]=G]* .[\)/YGAFP#(<"(8S6\BX<X/R
M^E87A28+X5TT.#DQ#I]36\F.HZ4 /HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EI*
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M* "BBB@!#UH%!&32T %%(3B@'(H 6BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH 8^,<G%>2_%Z1DA/ V[.OX5ZI?7*VMNTK#( S7@WQ#\51ZQ=FVV!>-
MN<T >P^%"3X2TYMHXA'\ZW(2S#<1C-8OA,+_ ,(KIZ!O^60_G6Q"I1RN[.*
M)Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@""ZMXKJ$QRKN4CI7AWQ'\,V&FW)N(H0
M#C/%>[MTKR3XMCRXB5Z[* .[\+!/^$7T]E7D1"MV+!^;'S&L+P<6_P"$6L"P
M_P"60K>0?-NH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ I:*:3S0 ZBBB@ HHHH **** $Q1BC-&: %HI,TM !1110 4444 %%(QP*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSWXGZ)+J&C,85+,&!KT)NQ%17-NES$4D4,#ZT >>>&/&NGV.E+;W<A62%0N
M/2N1S-XK\:>; @:"&4,&QVKT2X\"6<K2,K!2YS@"M;1/#UGI"GRT0R$<G'-
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M.9&4238'O_\ 7K6\*^&5T)KI@?FF?=TKJE; V@9;O0!P8^$VB>6?WLV<>O\
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MCGBO0/#D&DN\CV;G>#T9J .J,ACX8$YXS4D2 +4:%B=LE3JH48% "XQ2T44
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M;0=LJE07S7=CI5*RL4LXD1,! !Q5Z@ I,TM% !1110 4444 %%%% ##PV:"
M>1UH8X-)T88Z4 02VD=P5,B@[?45XYXV6WA\8, 0N'7@?6O2/%D&H2VRBQG>
M-CW6O*=0\!ZYJ$_VF:\D:7.=Q% 'L&E3LUA%N7;&$&6_"N';P]H>I:_)(+XF
M82?<]36CX/TO5K)%AO;B25 >C52\2>#+U[Y;O39V@;.X[1UH ROB%H=KI5E#
M-#<M%*'^ZO%=7\,[VXO?#8:<E\-C<QS7&'P/KNJW:G4+Z26,,#M85ZKX?TF/
M1=,6V0# YXH TXP03Q4M1KG.:DH ***.] !1110 4444 %,E3>F,XI]-8X%
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M$'(&*,9;/:D)SPM  2<XHP%Y Y-.R%'S4U2=V3T/2@!3EA2 [>*<<]J.#UH
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MCFF #>3GFI%YYH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,"EHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1\OK3=*U6'5D:2)0H'.:\R\>:M>ZEX7>X@;CRQG\J/A;=ZQ-"T<S@Q8 Z=J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQT??_J6VD ]:ZW6M97PUH<5K'''YA<#! [XJ_IOPNM[#66O3.'W-N"XZ5O\
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MZ"!?"L("*/G7D#Z5;O?"*7>JI<AA&%?<%Q6SK>@IJVFI:-+C:P.: /.[[#>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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K **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gs4n3b54niev000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gs4n3b54niev000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %> \D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **.U9DUVWVU$3
M.T]<4TKDRDH[FG134)*TZD4%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 45!=7 MXBY' I+>[CG0$$?2@"Q1110 444C,$4
ML>@H I:E?I90;F;&XX%5=+5I<RL.^17.ZS<2:IJ?V2(G",#Q]:["Q@\BV1?]
MD5;5D<E.;JU'V1:HHHJ#K"BD) ZT AAD'- "T44A('6@!:*0$'H:6@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2V,/Q9_R!)*^<-2_Y"$W^]7T?XL_Y DE?.&I?\A";_>K>AL9U"&W_P"/B/\
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M_P#=;\JGE0[LZ'_A,+W^^_YT?\)A>_WW_.N>\M_[K?E1Y;_W6_*CE079T/\
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M,&A-@XYKDM>5C>^AXKXBU![W4I2S$@.<5CJI9@H[G%/G??,S'N:=;$+<(S=
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M:W")A8SDUT6DRQW5BDJ@<TY-6N:*,MKCXXFFC99!UK$N8I=+N_-3.QCBNH
MZ"H;JV2YB*LH/'%2F:)60RRNTNH@RG/K5JL33[26RGV$DJ3FMNDRD%%%%(!#
MT->,_%G_ (^K>O9CT->,_%G_ (^K>M:7Q$3^$\OKI/!/_(QVO^]7-UTG@G_D
M8[7_ 'JZI;&*W/HZ#_5"I:B@_P!4*EK@.D**** "BBB@ HHHH \N^*?;_<KQ
MD]:]F^*?;_<KQD]:[*7PF$]SJ/ 7_(T6_P#GN*^BK?\ U*_2OG7P%_R-%O\
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MJ3 ]*6DV7&-@HHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% #7;:I)KE[RU.J:G&X^[&<&M[479(,KW.*CT^U6)2W4MSS5)
MVU,*L?:/E>Q;MX5@B$:C %2T45)NE;0**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!KHL@PPR*4*%& *
M6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>24
<FILENAME>fgen-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-01T20:53:06.3607201+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : c4cc8ad73bdd4a268962242d24ba2619 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:fgen="http://www.fibrogen.com/20201231" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.fibrogen.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.fibrogen.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical" id="Role_StatementConsolidatedStatementsOfOperationsParenthetical">
        <link:definition>100040 - Statement - Consolidated Statements of Operations (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100050 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" id="Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>100060 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" id="Role_StatementConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>100080 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureTheCompany" id="Role_DisclosureTheCompany">
        <link:definition>100090 - Disclosure - The Company</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntity" id="Role_DisclosureAcquisitionAndVariableInterestEntity">
        <link:definition>100110 - Disclosure - Acquisition and Variable Interest Entity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenues" id="Role_DisclosureCollaborationAgreementsAndRevenues">
        <link:definition>100120 - Disclosure - Collaboration Agreements and Revenues</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100130 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100140 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents" id="Role_DisclosureBalanceSheetComponents">
        <link:definition>100150 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligations" id="Role_DisclosureProductDevelopmentObligations">
        <link:definition>100160 - Disclosure - Product Development Obligations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100170 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensation" id="Role_DisclosureEquityAndStockBasedCompensation">
        <link:definition>100180 - Disclosure - Equity and Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100190 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFibrogenInc401KPlan" id="Role_DisclosureFibrogenInc401KPlan">
        <link:definition>100200 - Disclosure - FibroGen, Inc. 401(k) Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100210 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100220 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformation" id="Role_DisclosureSegmentAndGeographicInformation">
        <link:definition>100230 - Disclosure - Segment and Geographic Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccounts" id="Role_DisclosureScheduleIIValuationAndQualifyingAccounts">
        <link:definition>100240 - Disclosure - Schedule II - Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100260 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityTables" id="Role_DisclosureAcquisitionAndVariableInterestEntityTables">
        <link:definition>100270 - Disclosure - Acquisition and Variable Interest Entity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables" id="Role_DisclosureCollaborationAgreementsAndRevenuesTables">
        <link:definition>100280 - Disclosure - Collaboration Agreements and Revenues (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100290 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100300 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables" id="Role_DisclosureBalanceSheetComponentsTables">
        <link:definition>100310 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100320 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationTables" id="Role_DisclosureEquityAndStockBasedCompensationTables">
        <link:definition>100330 - Disclosure - Equity and Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100340 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100350 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationTables" id="Role_DisclosureSegmentAndGeographicInformationTables">
        <link:definition>100360 - Disclosure - Segment and Geographic Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail">
        <link:definition>100380 - Disclosure - Summary of Significant Accounting Policies - Schedule of Significant Balance of Accounts Receivable (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail" id="Role_DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail">
        <link:definition>100390 - Disclosure - Acquisition and Variable Interest Entity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail" id="Role_DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail">
        <link:definition>100400 - Disclosure - Acquisition and Variable Interest Entity - Summary of Equity Method Investment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail" id="Role_DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail">
        <link:definition>100410 - Disclosure - Collaboration Agreements and Revenues - Astellas Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail" id="Role_DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail">
        <link:definition>100420 - Disclosure - Collaboration Agreements and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail" id="Role_DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail">
        <link:definition>100430 - Disclosure - Collaboration Agreements and Revenues - Accounting for the Astellas Agreements - Additional Information 2 (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail" id="Role_DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail">
        <link:definition>100440 - Disclosure - Collaboration Agreements and Revenues - Accounting for the AstraZeneca Agreements - Additional Information 3 (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail" id="Role_DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail">
        <link:definition>100450 - Disclosure - Collaboration Agreements and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" id="Role_DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail">
        <link:definition>100460 - Disclosure - Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail" id="Role_DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail">
        <link:definition>100470 - Disclosure - Collaboration Agreements and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail" id="Role_DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail">
        <link:definition>100480 - Disclosure - Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail" id="Role_DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail">
        <link:definition>100490 - Disclosure - Collaboration Agreements and Revenues - Summary of Product Revenue, Net (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail" id="Role_DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail">
        <link:definition>100500 - Disclosure - Collaboration Agreements and Revenues - Product Revenue, Net - Additional Information 1 (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail" id="Role_DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail">
        <link:definition>100510 - Disclosure - Collaboration Agreements and Revenues - Roll-forward of Related Contract Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail" id="Role_DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail">
        <link:definition>100520 - Disclosure - Collaboration Agreements and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail" id="Role_DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail">
        <link:definition>100530 - Disclosure - Collaboration Agreements and Revenues - Drug Product Revenue - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail" id="Role_DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail">
        <link:definition>100540 - Disclosure - Collaboration Agreements and Revenues - Deferred Revenue - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" id="Role_DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail">
        <link:definition>100550 - Disclosure - Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
        <link:definition>100560 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail" id="Role_DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail">
        <link:definition>100570 - Disclosure - Fair Value Measurements - Fair Values of Financial Liabilities Carried at Historical Cost (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>100580 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" id="Role_DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail">
        <link:definition>100590 - Disclosure - Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail" id="Role_DisclosureLeasesComponentsOfLeaseExpenseDetail">
        <link:definition>100600 - Disclosure - Leases - Components of Lease Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail" id="Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail">
        <link:definition>100610 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail" id="Role_DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail">
        <link:definition>100620 - Disclosure - Leases - Schedule of Lease Term and Discount Rate (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" id="Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail">
        <link:definition>100630 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2" id="Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2">
        <link:definition>100640 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail">
        <link:definition>100650 - Disclosure - Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" id="Role_DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail">
        <link:definition>100660 - Disclosure - Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfContractualMaturitiesOfAvailableForSaleInvestmentsDetail" id="Role_DisclosureBalanceSheetComponentsSummaryOfContractualMaturitiesOfAvailableForSaleInvestmentsDetail">
        <link:definition>100670 - Disclosure - Balance Sheet Components - Summary of Contractual Maturities of Available-for-Sale Investments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" id="Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail">
        <link:definition>100680 - Disclosure - Balance Sheet Components - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfInventoryDetail">
        <link:definition>100690 - Disclosure - Balance Sheet Components - Schedule of Inventory (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>100700 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail">
        <link:definition>100710 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail">
        <link:definition>100720 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail">
        <link:definition>100730 - Disclosure - Balance Sheet Components - Schedule of Other Long-term Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail" id="Role_DisclosureProductDevelopmentObligationsAdditionalInformationDetail">
        <link:definition>100740 - Disclosure - Product Development Obligations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100750 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail">
        <link:definition>100760 - Disclosure - Commitments and Contingencies - Summary of Unconditional Purchase Obligations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail" id="Role_DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail">
        <link:definition>100770 - Disclosure - Equity and Stock-based Compensation - Subsidiary Stock and Non-Controlling Interests - Additional information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationCommonStockAdditionalInformationDetail" id="Role_DisclosureEquityAndStockBasedCompensationCommonStockAdditionalInformationDetail">
        <link:definition>100780 - Disclosure - Equity and Stock-based Compensation - Common Stock - Additional information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail" id="Role_DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail">
        <link:definition>100790 - Disclosure - Equity and Stock-based Compensation - Summary of Common Stock Reserved for Future Issuance (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail" id="Role_DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail">
        <link:definition>100800 - Disclosure - Equity and Stock-based Compensation - Stock Plans - Additional information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail" id="Role_DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail">
        <link:definition>100810 - Disclosure - Equity and Stock-based Compensation - Stock Plans - Summary of Stock Option Transactions (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail" id="Role_DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail">
        <link:definition>100820 - Disclosure - Equity and Stock-based Compensation - Summary of RSU Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail" id="Role_DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail">
        <link:definition>100830 - Disclosure - Equity and Stock-based Compensation - Employee Stock Purchase Plan - Additional information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail" id="Role_DisclosureEquityAndStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail">
        <link:definition>100840 - Disclosure - Equity and Stock-based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail" id="Role_DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail">
        <link:definition>100850 - Disclosure - Equity and Stock-based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Employee Stock Purchase Plans (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100860 - Disclosure - Equity and Stock-based Compensation - Stock-Based Compensation - Additional information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationWarrantsAdditionalInformationDetail" id="Role_DisclosureEquityAndStockBasedCompensationWarrantsAdditionalInformationDetail">
        <link:definition>100870 - Disclosure - Equity and Stock-based Compensation - Warrants - Additional information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail" id="Role_DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail">
        <link:definition>100880 - Disclosure - Net Loss Per Share - Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFibrogenInc401KPlanAdditionalInformationDetail" id="Role_DisclosureFibrogenInc401KPlanAdditionalInformationDetail">
        <link:definition>100890 - Disclosure - FibroGen, Inc. 401(k) Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail" id="Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail">
        <link:definition>100900 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail" id="Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail">
        <link:definition>100910 - Disclosure - Income Taxes - Schedule of Components of Provision For Income Taxes (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail">
        <link:definition>100920 - Disclosure - Income Taxes - Schedule of Reconciliation Between Statutory Federal Income Tax Rate and Effective Tax Rate (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail" id="Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail">
        <link:definition>100930 - Disclosure - Income Taxes - Schedule of Significant Components of Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100940 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail" id="Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail">
        <link:definition>100950 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Income Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
        <link:definition>100960 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetail" id="Role_DisclosureSegmentAndGeographicInformationAdditionalInformationDetail">
        <link:definition>100970 - Disclosure - Segment and Geographic Information - Additional information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail" id="Role_DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail">
        <link:definition>100980 - Disclosure - Segment and Geographic Information - Schedule of Revenue by Geographic Area (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfInventoryByGeographicAreaDetail" id="Role_DisclosureSegmentAndGeographicInformationScheduleOfInventoryByGeographicAreaDetail">
        <link:definition>100990 - Disclosure - Segment and Geographic Information - Schedule of Inventory by Geographic Area (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfLongLivedAssetsByGeographicAreaDetail" id="Role_DisclosureSegmentAndGeographicInformationScheduleOfLongLivedAssetsByGeographicAreaDetail">
        <link:definition>101000 - Disclosure - Segment and Geographic Information - Schedule of Long Lived Assets by Geographic Area (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationSummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationDetail" id="Role_DisclosureSegmentAndGeographicInformationSummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationDetail">
        <link:definition>101010 - Disclosure - Segment and Geographic Information - Summary of Finance and Operating Lease Right of Use Assets by Geographical Location (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail" id="Role_DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail">
        <link:definition>101020 - Disclosure - Segment and Geographic Information - Schedule of Customer Concentration by Collaboration Partners (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccountsDetail" id="Role_DisclosureScheduleIIValuationAndQualifyingAccountsDetail">
        <link:definition>101030 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" name="CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_RestrictedTimeDepositsNoncurrent" name="RestrictedTimeDepositsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" name="EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_AccruedProductDevelopmentCosts" name="AccruedProductDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_DueToRelatedPartiesDeferredRevenueCurrent" name="DueToRelatedPartiesDeferredRevenueCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_DueToRelatedPartiesDeferredRevenueNoncurrent" name="DueToRelatedPartiesDeferredRevenueNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_CostOfGoodsAndServicesSoldOperatingExpense" name="CostOfGoodsAndServicesSoldOperatingExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_UnconsolidatedVariableInterestEntityInvestmentLoss" name="UnconsolidatedVariableInterestEntityInvestmentLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_InterestAndOtherNetAbstract" name="InterestAndOtherNetAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_DevelopmentAndOtherRevenueMember" name="DevelopmentAndOtherRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_DrugProductRevenueMember" name="DrugProductRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_LicenseFeesAndMilestonesRevenue" name="LicenseFeesAndMilestonesRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_CollaborationServicesAndOtherRevenue" name="CollaborationServicesAndOtherRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_ProductRevenue" name="ProductRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_AstellasCollaborationAgreementMember" name="AstellasCollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" name="SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" name="AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_WarrantExercisedDuringPeriodShares" name="WarrantExercisedDuringPeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_WarrantsExercisedDuringPeriodValue" name="WarrantsExercisedDuringPeriodValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_UnrealizedLossGainOnEquityInvestments" name="UnrealizedLossGainOnEquityInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" name="InvestmentLossInUnconsolidatedVariableInterestEntity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_IncreaseDecreaseInLeaseObligations" name="IncreaseDecreaseInLeaseObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" name="IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" name="PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity" name="ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit" name="PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_RepaymentsOfFinanceLeaseLiabilities" name="RepaymentsOfFinanceLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_IncreaseDecreaseInAccountsPayableFromRelatedParty" name="IncreaseDecreaseInAccountsPayableFromRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_AcquisitionAndVariableInterestEntityTextBlock" name="AcquisitionAndVariableInterestEntityTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_AcquisitionAndVariableInterestEntityAbstract" name="AcquisitionAndVariableInterestEntityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock" name="CollaborativeArrangementAndRevenuesDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ProductDevelopmentObligationsDisclosureTextBlock" name="ProductDevelopmentObligationsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_OtherRisksAndUncertaintiesPolicyTextBlock" name="OtherRisksAndUncertaintiesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock" name="CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ClinicalTrialAccrualPolicyTextBlock" name="ClinicalTrialAccrualPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock" name="RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock" name="RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock" name="CollaborativeArrangementAndRevenuesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ProductRevenuePolicyPolicyTextBlock" name="ProductRevenuePolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_DrugProductRevenuePolicyTextBlock" name="DrugProductRevenuePolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_OtherRevenuesPolicyTextBlock" name="OtherRevenuesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ContractWithCustomerMilestoneMethodTableTextBlock" name="ContractWithCustomerMilestoneMethodTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_UnitedStatesRestOfWorldAndChinaMember" name="UnitedStatesRestOfWorldAndChinaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ScheduleOfDrugProductRevenueTableTextBlock" name="ScheduleOfDrugProductRevenueTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock" name="ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" name="ScheduleOfLeaseTermAndDiscountRateTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock" name="ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" name="ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" name="ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock" name="ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_InventoryByGeographicAreasTableTextBlock" name="InventoryByGeographicAreasTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock" name="SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_AccountingPolicyLineItems" name="AccountingPolicyLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AccountingPolicyTable" name="AccountingPolicyTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AccountsReceivableFromDistributorsMember" name="AccountsReceivableFromDistributorsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member" name="ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AstraZenecaAgreementsMember" name="AstraZenecaAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_HighlyLiquidInvestmentMaturityPeriod" name="HighlyLiquidInvestmentMaturityPeriod" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ShortTermInvestmentsMaximumMaturityPeriod" name="ShortTermInvestmentsMaximumMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_LongTermInvestmentsMinimumMaturityPeriod" name="LongTermInvestmentsMinimumMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_DescriptionOfSalesReturn" name="DescriptionOfSalesReturn" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_AcquisitionAndVariableInterestEntityLineItems" name="AcquisitionAndVariableInterestEntityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AcquisitionAndVariableInterestEntityTable" name="AcquisitionAndVariableInterestEntityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" name="BeijingKangdaYongfuPharmaceuticalCoLTDMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_FibroGenBeijingMember" name="FibroGenBeijingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AcquiredLicenseMember" name="AcquiredLicenseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_BeijingFalikangPharmaceuticalCoLtdMember" name="BeijingFalikangPharmaceuticalCoLtdMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AstraZenecaABMember" name="AstraZenecaABMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer" name="PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_EquityMethodInvestmentAdditions" name="EquityMethodInvestmentAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" name="EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" name="ProceedsFromUpfrontNonContingentAndTimeBasedPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_CommercialSalesMilestone" name="CommercialSalesMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_AdditionalConsiderationBasedOnNetSales" name="AdditionalConsiderationBasedOnNetSales" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_PotentialMilestones" name="PotentialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" name="CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_ClinicalDevelopmentMilestonesMember" name="ClinicalDevelopmentMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_RegulatoryMilestonesMember" name="RegulatoryMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_TransactionPriceAllocatedToPerformanceObligations" name="TransactionPriceAllocatedToPerformanceObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_PercentageOfFundingForCosts" name="PercentageOfFundingForCosts" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_DevelopmentAndRegulatoryApprovalMilestones" name="DevelopmentAndRegulatoryApprovalMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_EstimatedJointDevelopmentExtendedServicePeriod" name="EstimatedJointDevelopmentExtendedServicePeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" name="ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_UnitedStatesAndRestOfWorldMember" name="UnitedStatesAndRestOfWorldMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_DeferredApprovalMilestoneMember" name="DeferredApprovalMilestoneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_FibroGenIncMember" name="FibroGenIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AccruedAndOtherCurrentLiabilitiesMember" name="AccruedAndOtherCurrentLiabilitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_SharedDevelopmentCosts" name="SharedDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" name="ProceedsFromUpfrontNonContingentAndNonRefundablePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_CommercialSalesAndOtherEventsMilestone" name="CommercialSalesAndOtherEventsMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_CollaborativeArrangementAggregateConsideration" name="CollaborativeArrangementAggregateConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" name="ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_HistoricalCoPromotionCosts" name="HistoricalCoPromotionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_CoPromotionExpenses" name="CoPromotionExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_ReversalOfAccruedCoPromotionExpenses" name="ReversalOfAccruedCoPromotionExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" name="AccruedLongTermCoPromotionLiabilityNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_AccruedLongTermCoPromotionLiabilityCurrent" name="AccruedLongTermCoPromotionLiabilityCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_ProceedsFromNonContingentUpfrontPayments" name="ProceedsFromNonContingentUpfrontPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone" name="VariableConsiderationPaymentReceivedUponAchievementOfMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" name="VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_ProvisionForCoDevelopmentServices" name="ProvisionForCoDevelopmentServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_CoDevelopmentServicesEstimatedContinuationYear" name="CoDevelopmentServicesEstimatedContinuationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_VariableConsiderationRelatedToProfitShare" name="VariableConsiderationRelatedToProfitShare" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_UnitedStatesAndRestOfWorldAndChinaMember" name="UnitedStatesAndRestOfWorldAndChinaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_RoyaltyRateOnNetRevenue" name="RoyaltyRateOnNetRevenue" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="fgen_CashConsiderationReceivedUnderCollaborationAgreement" name="CashConsiderationReceivedUnderCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" name="CoDevelopmentInformationSharingAndCommitteeServicesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ChinaPerformanceObligationMember" name="ChinaPerformanceObligationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" name="VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_SuppliesNet" name="SuppliesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" name="RevenueGrossFromContractWithCustomerExcludingAssessedTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_PriceAdjustmentMember" name="PriceAdjustmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_NonKeyAccountHospitalListingAwardMember" name="NonKeyAccountHospitalListingAwardMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ContractualSalesRebateMember" name="ContractualSalesRebateMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_OtherDiscountsAndRebatesMember" name="OtherDiscountsAndRebatesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_RebatesAndDiscountsMember" name="RebatesAndDiscountsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_GrossAccountsReceivableMember" name="GrossAccountsReceivableMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ContractLiabilitiesMember" name="ContractLiabilitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ContractWithCustomerLiabilityAdditions" name="ContractWithCustomerLiabilityAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_ContractWithCustomerLiabilityDeduction" name="ContractWithCustomerLiabilityDeduction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" name="ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_ContractWithCustomerLiabilityGross" name="ContractWithCustomerLiabilityGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_ContractWithCustomerLiabilityNetOfAccountsReceivable" name="ContractWithCustomerLiabilityNetOfAccountsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_ContractWithCustomerLiabilityLineItems" name="ContractWithCustomerLiabilityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ContractWithCustomerLiabilityTable" name="ContractWithCustomerLiabilityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AstellasAgreementMember" name="AstellasAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_APIShipmentMember" name="APIShipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_EstimatedVariableConsiderationTransactionPrice" name="EstimatedVariableConsiderationTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_BondAndMutualFundsMember" name="BondAndMutualFundsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_LeaseObligationsMember" name="LeaseObligationsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_NumberOfFinanceLeases" name="NumberOfFinanceLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ShorensteinPropertiesLLCMember" name="ShorensteinPropertiesLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" name="BeijingEconomicTechnologicalDevelopmentAreaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_OfficeSpacesMember" name="OfficeSpacesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_LesseeFinanceLeaseExpirationPeriod" name="LesseeFinanceLeaseExpirationPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" name="LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" name="LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" name="PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_NumberOfOperatingLeases" name="NumberOfOperatingLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_LesseeOperatingLeaseExpirationPeriod" name="LesseeOperatingLeaseExpirationPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_FinanceLeaseRightOfUseAssetsCost" name="FinanceLeaseRightOfUseAssetsCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_FinanceLeaseAccumulatedAmortization" name="FinanceLeaseAccumulatedAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_OperatingLeaseRightOfUseAssetsCost" name="OperatingLeaseRightOfUseAssetsCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_OperatingLeaseAccumulatedAmortization" name="OperatingLeaseAccumulatedAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_FinanceLeaseAndOperatingLeaseAssets" name="FinanceLeaseAndOperatingLeaseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_FinanceLeaseAndOperatingLeaseLiability" name="FinanceLeaseAndOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" name="RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_WeightedAverageRemainingLeaseTermAbstract" name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_WeightedAverageDiscountRateAbstract" name="WeightedAverageDiscountRateAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear" name="AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" name="PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="fgen_NumberOfRegulatoryMilestones" name="NumberOfRegulatoryMilestones" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_AccruedPreclinicalAndClinicalTrialCurrent" name="AccruedPreclinicalAndClinicalTrialCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" name="AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" name="AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_AccruedCoPromotionExpensesCurrent" name="AccruedCoPromotionExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_AccruedProfitShareCurrent" name="AccruedProfitShareCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_PropertyTaxesAndOtherCurrent" name="PropertyTaxesAndOtherCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent" name="AccruedLongTermCoPromotionalLiabilityNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses" name="ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_NumberOfProductDevelopmentObligations" name="NumberOfProductDevelopmentObligations" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_BankOfFinlandInterestRateMember" name="BankOfFinlandInterestRateMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AccruedProductDevelopmentCostsExcludingInterest" name="AccruedProductDevelopmentCostsExcludingInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" name="ResearchAndPreClinicalStageDevelopmentProgramsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ManufactureAndSupplyOfRoxadustatMember" name="ManufactureAndSupplyOfRoxadustatMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ManufactureAndSupplyOfPamrevlumabMember" name="ManufactureAndSupplyOfPamrevlumabMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_OtherPurchasesMember" name="OtherPurchasesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_MaximumFutureMilestonePayments" name="MaximumFutureMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" name="ShareholdersEquityAndStockBasedCompensationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_FibrogenEuropeOyMember" name="FibrogenEuropeOyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_FibroGenCaymanMember" name="FibroGenCaymanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares" name="RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_PreferredSharesIssuedPricePerShare" name="PreferredSharesIssuedPricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="fgen_CommonStockSharesReserved" name="CommonStockSharesReserved" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="fgen_TwoThousandAndFiveStockPlanMember" name="TwoThousandAndFiveStockPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_TwoThousandAndFourteenEquityIncentivePlanMember" name="TwoThousandAndFourteenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear" name="StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" name="TwoThousandAndFourteenEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_StockOptionAwardsMember" name="StockOptionAwardsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod" name="ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost" name="EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets" name="EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets" name="EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted" name="EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_DeferredTaxAssetsIntangibleAssets" name="DeferredTaxAssetsIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_DeferredTaxLiabilitiesFixedAssets" name="DeferredTaxLiabilitiesFixedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_OtherTaxCreditCarryforwardsExpirationYear" name="OtherTaxCreditCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_ExperienceHistoricalOwnershipChanges" name="ExperienceHistoricalOwnershipChanges" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fgen_FederalAndStateMember" name="FederalAndStateMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_LicenseAndDevelopmentMember" name="LicenseAndDevelopmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_AstellasMember" name="AstellasMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_FalikangMember" name="FalikangMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_DrugProductRevenueFromRelatedParty" name="DrugProductRevenueFromRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fgen_MiscellaneousReceivables" name="MiscellaneousReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fgen_AllOtherMember" name="AllOtherMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fgen_ValuationAllowanceForRebatesAndDiscountsMember" name="ValuationAllowanceForRebatesAndDiscountsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>25
<FILENAME>fgen-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-01T20:53:06.3607201+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : c4cc8ad73bdd4a268962242d24ba2619 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="fgen-20201231.xsd#TemplateLink" roleURI="http://www.fibrogen.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="fgen-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RestrictedTimeDepositsNoncurrent" xlink:type="locator" xlink:label="fgen_RestrictedTimeDepositsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedProductDevelopmentCosts" xlink:type="locator" xlink:label="fgen_AccruedProductDevelopmentCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="fgen_AccruedProductDevelopmentCosts" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="fgen_RestrictedTimeDepositsNoncurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="10280.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10290.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="10300.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10310.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="fgen-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CostOfGoodsAndServicesSoldOperatingExpense" xlink:type="locator" xlink:label="fgen_CostOfGoodsAndServicesSoldOperatingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnconsolidatedVariableInterestEntityInvestmentLoss" xlink:type="locator" xlink:label="fgen_UnconsolidatedVariableInterestEntityInvestmentLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestExpense" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="fgen_UnconsolidatedVariableInterestEntityInvestmentLoss" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestAndOtherIncome" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="fgen_CostOfGoodsAndServicesSoldOperatingExpense" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="fgen-20201231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="fgen-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_IncreaseDecreaseInLeaseObligations" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInLeaseObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnrealizedLossGainOnEquityInvestments" xlink:type="locator" xlink:label="fgen_UnrealizedLossGainOnEquityInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit" xlink:type="locator" xlink:label="fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RepaymentsOfFinanceLeaseLiabilities" xlink:type="locator" xlink:label="fgen_RepaymentsOfFinanceLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLongTermCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLongTermCapitalLeaseObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromLongTermCapitalLeaseObligations" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="fgen_RepaymentsOfFinanceLeaseLiabilities" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="fgen_ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10210.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fgen_UnrealizedLossGainOnEquityInvestments" order="10220.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" order="10230.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="10240.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" order="10260.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" order="10270.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10280.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="10290.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10300.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10310.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10320.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10330.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10340.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fgen_IncreaseDecreaseInLeaseObligations" order="10350.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" order="10360.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="10370.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" xlink:type="locator" xlink:label="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CashConsiderationReceivedUnderCollaborationAgreement" xlink:type="locator" xlink:label="fgen_CashConsiderationReceivedUnderCollaborationAgreement" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_CashConsiderationReceivedUnderCollaborationAgreement" xlink:to="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_CashConsiderationReceivedUnderCollaborationAgreement" xlink:to="us-gaap_ContractWithCustomerLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FinanceLeaseAccumulatedAmortization" xlink:type="locator" xlink:label="fgen_FinanceLeaseAccumulatedAmortization" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FinanceLeaseRightOfUseAssetsCost" xlink:type="locator" xlink:label="fgen_FinanceLeaseRightOfUseAssetsCost" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OperatingLeaseAccumulatedAmortization" xlink:type="locator" xlink:label="fgen_OperatingLeaseAccumulatedAmortization" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OperatingLeaseRightOfUseAssetsCost" xlink:type="locator" xlink:label="fgen_OperatingLeaseRightOfUseAssetsCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FinanceLeaseAndOperatingLeaseAssets" xlink:type="locator" xlink:label="fgen_FinanceLeaseAndOperatingLeaseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FinanceLeaseAndOperatingLeaseLiability" xlink:type="locator" xlink:label="fgen_FinanceLeaseAndOperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_FinanceLeaseAndOperatingLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_FinanceLeaseAndOperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_FinanceLeaseAndOperatingLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_FinanceLeaseAndOperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_FinanceLeaseAndOperatingLeaseAssets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="fgen_OperatingLeaseRightOfUseAssetsCost" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="fgen_OperatingLeaseAccumulatedAmortization" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="fgen_FinanceLeaseRightOfUseAssetsCost" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="fgen_FinanceLeaseAccumulatedAmortization" order="10100.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_SubleaseIncome" order="10040.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2" xlink:href="fgen-20201231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:type="locator" xlink:label="us-gaap_Cash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_Cash" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfContractualMaturitiesOfAvailableForSaleInvestmentsDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfContractualMaturitiesOfAvailableForSaleInvestmentsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfContractualMaturitiesOfAvailableForSaleInvestmentsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear" xlink:type="locator" xlink:label="fgen_AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="fgen_AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecurities" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfInventoryDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies" xlink:type="locator" xlink:label="us-gaap_Supplies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_SuppliesNet" xlink:type="locator" xlink:label="fgen_SuppliesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="fgen_SuppliesNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_SuppliesNet" xlink:to="us-gaap_Supplies" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_SuppliesNet" xlink:to="us-gaap_ContractWithCustomerLiability" order="10050.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PropertyTaxesAndOtherCurrent" xlink:type="locator" xlink:label="fgen_PropertyTaxesAndOtherCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedProfitShareCurrent" xlink:type="locator" xlink:label="fgen_AccruedProfitShareCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedCoPromotionExpensesCurrent" xlink:type="locator" xlink:label="fgen_AccruedCoPromotionExpensesCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" xlink:type="locator" xlink:label="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" xlink:type="locator" xlink:label="fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedPreclinicalAndClinicalTrialCurrent" xlink:type="locator" xlink:label="fgen_AccruedPreclinicalAndClinicalTrialCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="fgen_AccruedPreclinicalAndClinicalTrialCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="fgen_AccruedCoPromotionExpensesCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="fgen_AccruedProfitShareCurrent" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="fgen_PropertyTaxesAndOtherCurrent" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" xlink:type="locator" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherSundryLiabilitiesNoncurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CommonStockSharesReserved" xlink:type="locator" xlink:label="fgen_CommonStockSharesReserved" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_CommonStockSharesReserved" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_CommonStockSharesReserved" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_CommonStockSharesReserved" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_CommonStockSharesReserved" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fgen_CommonStockSharesReserved" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted" xlink:type="locator" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets" xlink:type="locator" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets" xlink:type="locator" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="fgen_EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="fgen_EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="fgen_EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="fgen_EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10090.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DeferredTaxAssetsIntangibleAssets" xlink:type="locator" xlink:label="fgen_DeferredTaxAssetsIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DeferredTaxLiabilitiesFixedAssets" xlink:type="locator" xlink:label="fgen_DeferredTaxLiabilitiesFixedAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="fgen_DeferredTaxLiabilitiesFixedAssets" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="fgen_DeferredTaxAssetsIntangibleAssets" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10150.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>26
<FILENAME>fgen-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-01T20:53:06.3617359+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : c4cc8ad73bdd4a268962242d24ba2619 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="fgen-20201231.xsd#TemplateLink" roleURI="http://www.fibrogen.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="fgen-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnconsolidatedVariableInterestEntityInvestmentLoss" xlink:type="locator" xlink:label="fgen_UnconsolidatedVariableInterestEntityInvestmentLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_InterestAndOtherNetAbstract" xlink:type="locator" xlink:label="fgen_InterestAndOtherNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CostOfGoodsAndServicesSoldOperatingExpense" xlink:type="locator" xlink:label="fgen_CostOfGoodsAndServicesSoldOperatingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DevelopmentAndOtherRevenueMember" xlink:type="locator" xlink:label="fgen_DevelopmentAndOtherRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10130.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DevelopmentAndOtherRevenueMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="fgen_CostOfGoodsAndServicesSoldOperatingExpense" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_TypeOfCostGoodOrServiceExtensibleList" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_InterestAndOtherNetAbstract" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_InterestAndOtherNetAbstract" xlink:to="us-gaap_InterestExpense" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_InterestAndOtherNetAbstract" xlink:to="fgen_UnconsolidatedVariableInterestEntityInvestmentLoss" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_InterestAndOtherNetAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_InterestAndOtherNetAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11800.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical" xlink:href="fgen-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProductRevenue" xlink:type="locator" xlink:label="fgen_ProductRevenue" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CollaborationServicesAndOtherRevenue" xlink:type="locator" xlink:label="fgen_CollaborationServicesAndOtherRevenue" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LicenseFeesAndMilestonesRevenue" xlink:type="locator" xlink:label="fgen_LicenseFeesAndMilestonesRevenue" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_LicenseFeesAndMilestonesRevenue" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_CollaborationServicesAndOtherRevenue" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_ProductRevenue" order="10280.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="fgen-20201231.xsd#Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_WarrantExercisedDuringPeriodShares" xlink:type="locator" xlink:label="fgen_WarrantExercisedDuringPeriodShares" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_WarrantsExercisedDuringPeriodValue" xlink:type="locator" xlink:label="fgen_WarrantsExercisedDuringPeriodValue" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" xlink:type="locator" xlink:label="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" xlink:type="locator" xlink:label="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201601Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201802Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201802Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201802Member" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201601Member" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_WarrantsExercisedDuringPeriodValue" order="11940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_WarrantExercisedDuringPeriodShares" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12100.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ScheduleOfDrugProductRevenueTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfDrugProductRevenueTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerMilestoneMethodTableTextBlock" xlink:type="locator" xlink:label="fgen_ContractWithCustomerMilestoneMethodTableTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesRestOfWorldAndChinaMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_ContractWithCustomerMilestoneMethodTableTextBlock" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_ScheduleOfDrugProductRevenueTableTextBlock" order="11090.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DescriptionOfSalesReturn" xlink:type="locator" xlink:label="fgen_DescriptionOfSalesReturn" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:type="locator" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LongTermInvestmentsMinimumMaturityPeriod" xlink:type="locator" xlink:label="fgen_LongTermInvestmentsMinimumMaturityPeriod" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ShortTermInvestmentsMaximumMaturityPeriod" xlink:type="locator" xlink:label="fgen_ShortTermInvestmentsMaximumMaturityPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RestrictedTimeDepositsNoncurrent" xlink:type="locator" xlink:label="fgen_RestrictedTimeDepositsNoncurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_HighlyLiquidInvestmentMaturityPeriod" xlink:type="locator" xlink:label="fgen_HighlyLiquidInvestmentMaturityPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax" xlink:type="locator" xlink:label="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201601Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:type="locator" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201802Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201802Member" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member" xlink:type="locator" xlink:label="fgen_ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="fgen_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionForeignMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CreditConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccountsReceivableFromDistributorsMember" xlink:type="locator" xlink:label="fgen_AccountsReceivableFromDistributorsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccountingPolicyTable" xlink:type="locator" xlink:label="fgen_AccountingPolicyTable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccountingPolicyLineItems" xlink:type="locator" xlink:label="fgen_AccountingPolicyLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_AccountingPolicyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="fgen_AccountsReceivableFromDistributorsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_GeographicDistributionAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionForeignMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AccountingPolicyTable" xlink:to="srt_RangeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fgen_LaboratoryEquipmentMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AccountingPolicyTable" xlink:to="srt_StatementGeographicalAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AccountingPolicyTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="fgen_ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201802Member" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201601Member" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_HighlyLiquidInvestmentMaturityPeriod" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_RestrictedTimeDepositsNoncurrent" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_ShortTermInvestmentsMaximumMaturityPeriod" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_LongTermInvestmentsMinimumMaturityPeriod" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" order="11770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_DescriptionOfSalesReturn" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11920.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CreditConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccountingPolicyTable" xlink:type="locator" xlink:label="fgen_AccountingPolicyTable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccountingPolicyLineItems" xlink:type="locator" xlink:label="fgen_AccountingPolicyLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_AccountingPolicyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EquityMethodInvestmentAdditions" xlink:type="locator" xlink:label="fgen_EquityMethodInvestmentAdditions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Capital" xlink:type="locator" xlink:label="us-gaap_Capital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer" xlink:type="locator" xlink:label="fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaABMember" xlink:type="locator" xlink:label="fgen_AstraZenecaABMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BeijingFalikangPharmaceuticalCoLtdMember" xlink:type="locator" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquiredLicenseMember" xlink:type="locator" xlink:label="fgen_AcquiredLicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FibroGenBeijingMember" xlink:type="locator" xlink:label="fgen_FibroGenBeijingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" xlink:type="locator" xlink:label="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquisitionAndVariableInterestEntityTable" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityTable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="fgen_AcquisitionAndVariableInterestEntityTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_FibroGenBeijingMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fgen_AcquiredLicenseMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_2" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="fgen_BeijingFalikangPharmaceuticalCoLtdMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fgen_AstraZenecaABMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="srt_CounterpartyNameAxis" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_Capital" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="fgen_EquityMethodInvestmentAdditions" order="11640.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" xlink:type="locator" xlink:label="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EquityMethodInvestmentAdditions" xlink:type="locator" xlink:label="fgen_EquityMethodInvestmentAdditions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BeijingFalikangPharmaceuticalCoLtdMember" xlink:type="locator" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquisitionAndVariableInterestEntityTable" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityTable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="fgen_AcquisitionAndVariableInterestEntityTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="fgen_BeijingFalikangPharmaceuticalCoLtdMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="fgen_EquityMethodInvestmentAdditions" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" order="10280.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EstimatedJointDevelopmentExtendedServicePeriod" xlink:type="locator" xlink:label="fgen_EstimatedJointDevelopmentExtendedServicePeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies" xlink:type="locator" xlink:label="us-gaap_Supplies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PercentageOfFundingForCosts" xlink:type="locator" xlink:label="fgen_PercentageOfFundingForCosts" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DevelopmentAndRegulatoryApprovalMilestones" xlink:type="locator" xlink:label="fgen_DevelopmentAndRegulatoryApprovalMilestones" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:type="locator" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_TransactionPriceAllocatedToPerformanceObligations" xlink:type="locator" xlink:label="fgen_TransactionPriceAllocatedToPerformanceObligations" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AdditionalConsiderationBasedOnNetSales" xlink:type="locator" xlink:label="fgen_AdditionalConsiderationBasedOnNetSales" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CommercialSalesMilestone" xlink:type="locator" xlink:label="fgen_CommercialSalesMilestone" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PotentialMilestones" xlink:type="locator" xlink:label="fgen_PotentialMilestones" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" xlink:type="locator" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RegulatoryMilestonesMember" xlink:type="locator" xlink:label="fgen_RegulatoryMilestonesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ClinicalDevelopmentMilestonesMember" xlink:type="locator" xlink:label="fgen_ClinicalDevelopmentMilestonesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_ClinicalDevelopmentMilestonesMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_RegulatoryMilestonesMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_2" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_PotentialMilestones" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CommercialSalesMilestone" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_AdditionalConsiderationBasedOnNetSales" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_TransactionPriceAllocatedToPerformanceObligations" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_DevelopmentAndRegulatoryApprovalMilestones" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_PercentageOfFundingForCosts" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="12380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Supplies" order="12460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="12500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_EstimatedJointDevelopmentExtendedServicePeriod" order="12570.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedLongTermCoPromotionLiabilityCurrent" xlink:type="locator" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" xlink:type="locator" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CoPromotionExpenses" xlink:type="locator" xlink:label="fgen_CoPromotionExpenses" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ReversalOfAccruedCoPromotionExpenses" xlink:type="locator" xlink:label="fgen_ReversalOfAccruedCoPromotionExpenses" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_HistoricalCoPromotionCosts" xlink:type="locator" xlink:label="fgen_HistoricalCoPromotionCosts" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CollaborativeArrangementAggregateConsideration" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAggregateConsideration" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CommercialSalesAndOtherEventsMilestone" xlink:type="locator" xlink:label="fgen_CommercialSalesAndOtherEventsMilestone" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" xlink:type="locator" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EstimatedJointDevelopmentExtendedServicePeriod" xlink:type="locator" xlink:label="fgen_EstimatedJointDevelopmentExtendedServicePeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies" xlink:type="locator" xlink:label="us-gaap_Supplies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_TransactionPriceAllocatedToPerformanceObligations" xlink:type="locator" xlink:label="fgen_TransactionPriceAllocatedToPerformanceObligations" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AdditionalConsiderationBasedOnNetSales" xlink:type="locator" xlink:label="fgen_AdditionalConsiderationBasedOnNetSales" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_SharedDevelopmentCosts" xlink:type="locator" xlink:label="fgen_SharedDevelopmentCosts" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CommercialSalesMilestone" xlink:type="locator" xlink:label="fgen_CommercialSalesMilestone" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PotentialMilestones" xlink:type="locator" xlink:label="fgen_PotentialMilestones" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" xlink:type="locator" xlink:label="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedAndOtherCurrentLiabilitiesMember" xlink:type="locator" xlink:label="fgen_AccruedAndOtherCurrentLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableMember" xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FibroGenIncMember" xlink:type="locator" xlink:label="fgen_FibroGenIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DeferredApprovalMilestoneMember" xlink:type="locator" xlink:label="fgen_DeferredApprovalMilestoneMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RegulatoryMilestonesMember" xlink:type="locator" xlink:label="fgen_RegulatoryMilestonesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ClinicalDevelopmentMilestonesMember" xlink:type="locator" xlink:label="fgen_ClinicalDevelopmentMilestonesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesAndRestOfWorldMember" xlink:type="locator" xlink:label="fgen_UnitedStatesAndRestOfWorldMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesAndRestOfWorldMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_ClinicalDevelopmentMilestonesMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_RegulatoryMilestonesMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_DeferredApprovalMilestoneMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="fgen_FibroGenIncMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableMember" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="fgen_AccruedAndOtherCurrentLiabilitiesMember" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_PotentialMilestones" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CommercialSalesMilestone" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_SharedDevelopmentCosts" order="11930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_AdditionalConsiderationBasedOnNetSales" order="12050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_TransactionPriceAllocatedToPerformanceObligations" order="12120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="12140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Supplies" order="12180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_EstimatedJointDevelopmentExtendedServicePeriod" order="12230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" order="12330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CommercialSalesAndOtherEventsMilestone" order="12490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CollaborativeArrangementAggregateConsideration" order="12530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="12610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" order="12680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_HistoricalCoPromotionCosts" order="12790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ReversalOfAccruedCoPromotionExpenses" order="12830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CoPromotionExpenses" order="12870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" order="12910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_AccruedLongTermCoPromotionLiabilityCurrent" order="12950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="13060.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProvisionForCoDevelopmentServices" xlink:type="locator" xlink:label="fgen_ProvisionForCoDevelopmentServices" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CoDevelopmentServicesEstimatedContinuationYear" xlink:type="locator" xlink:label="fgen_CoDevelopmentServicesEstimatedContinuationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="locator" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" xlink:type="locator" xlink:label="fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone" xlink:type="locator" xlink:label="fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProceedsFromNonContingentUpfrontPayments" xlink:type="locator" xlink:label="fgen_ProceedsFromNonContingentUpfrontPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_2" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_2" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDiscountedCashFlowMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ProceedsFromNonContingentUpfrontPayments" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CoDevelopmentServicesEstimatedContinuationYear" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ProvisionForCoDevelopmentServices" order="10940.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CoDevelopmentServicesEstimatedContinuationYear" xlink:type="locator" xlink:label="fgen_CoDevelopmentServicesEstimatedContinuationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="locator" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RoyaltyRateOnNetRevenue" xlink:type="locator" xlink:label="fgen_RoyaltyRateOnNetRevenue" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_VariableConsiderationRelatedToProfitShare" xlink:type="locator" xlink:label="fgen_VariableConsiderationRelatedToProfitShare" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" xlink:type="locator" xlink:label="fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone" xlink:type="locator" xlink:label="fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProceedsFromNonContingentUpfrontPayments" xlink:type="locator" xlink:label="fgen_ProceedsFromNonContingentUpfrontPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesAndRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesAndRestOfWorldAndChinaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesAndRestOfWorldAndChinaMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDiscountedCashFlowMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ProceedsFromNonContingentUpfrontPayments" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_VariableConsiderationRelatedToProfitShare" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_RoyaltyRateOnNetRevenue" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CoDevelopmentServicesEstimatedContinuationYear" order="10660.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DevelopmentAndOtherRevenueMember" xlink:type="locator" xlink:label="fgen_DevelopmentAndOtherRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_ProductOrServiceAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DevelopmentAndOtherRevenueMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_StatementGeographicalAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesRestOfWorldAndChinaMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10740.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CashConsiderationReceivedUnderCollaborationAgreement" xlink:type="locator" xlink:label="fgen_CashConsiderationReceivedUnderCollaborationAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" xlink:type="locator" xlink:label="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ChinaPerformanceObligationMember" xlink:type="locator" xlink:label="fgen_ChinaPerformanceObligationMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" xlink:type="locator" xlink:label="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DevelopmentAndOtherRevenueMember" xlink:type="locator" xlink:label="fgen_DevelopmentAndOtherRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_StatementGeographicalAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_ProductOrServiceAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DevelopmentAndOtherRevenueMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesRestOfWorldAndChinaMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_ChinaPerformanceObligationMember" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="fgen_CashConsiderationReceivedUnderCollaborationAgreement" order="11000.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" xlink:type="locator" xlink:label="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesRestOfWorldAndChinaMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_SuppliesNet" xlink:type="locator" xlink:label="fgen_SuppliesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesAndRestOfWorldMember" xlink:type="locator" xlink:label="fgen_UnitedStatesAndRestOfWorldMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_StatementGeographicalAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesAndRestOfWorldMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="fgen_SuppliesNet" order="10260.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:type="locator" xlink:label="us-gaap_SalesReturnsAndAllowancesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OtherDiscountsAndRebatesMember" xlink:type="locator" xlink:label="fgen_OtherDiscountsAndRebatesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractualSalesRebateMember" xlink:type="locator" xlink:label="fgen_ContractualSalesRebateMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_NonKeyAccountHospitalListingAwardMember" xlink:type="locator" xlink:label="fgen_NonKeyAccountHospitalListingAwardMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PriceAdjustmentMember" xlink:type="locator" xlink:label="fgen_PriceAdjustmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_PriceAdjustmentMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_NonKeyAccountHospitalListingAwardMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_ContractualSalesRebateMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_OtherDiscountsAndRebatesMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_SalesReturnsAndAllowancesMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10420.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractLiabilitiesMember" xlink:type="locator" xlink:label="fgen_ContractLiabilitiesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_GrossAccountsReceivableMember" xlink:type="locator" xlink:label="fgen_GrossAccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RebatesAndDiscountsMember" xlink:type="locator" xlink:label="fgen_RebatesAndDiscountsMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PriceAdjustmentMember" xlink:type="locator" xlink:label="fgen_PriceAdjustmentMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractualSalesRebateMember" xlink:type="locator" xlink:label="fgen_ContractualSalesRebateMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_NonKeyAccountHospitalListingAwardMember" xlink:type="locator" xlink:label="fgen_NonKeyAccountHospitalListingAwardMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_NonKeyAccountHospitalListingAwardMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_ContractualSalesRebateMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_PriceAdjustmentMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_RebatesAndDiscountsMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="fgen_GrossAccountsReceivableMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="fgen_ContractLiabilitiesMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="10770.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityNetOfAccountsReceivable" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityNetOfAccountsReceivable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityGross" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityGross" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityDeduction" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityDeduction" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityAdditions" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityAdditions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityTable" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityTable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityLineItems" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_ContractWithCustomerLiabilityTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_ContractWithCustomerLiabilityTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityAdditions" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityDeduction" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityGross" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityNetOfAccountsReceivable" order="10440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EstimatedVariableConsiderationTransactionPrice" xlink:type="locator" xlink:label="fgen_EstimatedVariableConsiderationTransactionPrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesAndRestOfWorldMember" xlink:type="locator" xlink:label="fgen_UnitedStatesAndRestOfWorldMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_APIShipmentMember" xlink:type="locator" xlink:label="fgen_APIShipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TransactionTypeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="fgen_APIShipmentMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesAndRestOfWorldMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_EstimatedVariableConsiderationTransactionPrice" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11000.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityAbstract" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BondAndMutualFundsMember" xlink:type="locator" xlink:label="fgen_BondAndMutualFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fgen_BondAndMutualFundsMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquitySecuritiesMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10860.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LeaseObligationsMember" xlink:type="locator" xlink:label="fgen_LeaseObligationsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="fgen_LeaseObligationsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LesseeOperatingLeaseExpirationPeriod" xlink:type="locator" xlink:label="fgen_LesseeOperatingLeaseExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_NumberOfOperatingLeases" xlink:type="locator" xlink:label="fgen_NumberOfOperatingLeases" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" xlink:type="locator" xlink:label="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" xlink:type="locator" xlink:label="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" xlink:type="locator" xlink:label="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LesseeFinanceLeaseExpirationPeriod" xlink:type="locator" xlink:label="fgen_LesseeFinanceLeaseExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_NumberOfFinanceLeases" xlink:type="locator" xlink:label="fgen_NumberOfFinanceLeases" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OfficeSpacesMember" xlink:type="locator" xlink:label="fgen_OfficeSpacesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" xlink:type="locator" xlink:label="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ShorensteinPropertiesLLCMember" xlink:type="locator" xlink:label="fgen_ShorensteinPropertiesLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_ShorensteinPropertiesLLCMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fgen_OfficeSpacesMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_NumberOfFinanceLeases" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_LesseeFinanceLeaseExpirationPeriod" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseOptionToExtend" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_NumberOfOperatingLeases" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_LesseeOperatingLeaseExpirationPeriod" order="11110.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BondAndMutualFundsMember" xlink:type="locator" xlink:label="fgen_BondAndMutualFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fgen_BondAndMutualFundsMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquitySecuritiesMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="10890.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses" xlink:type="locator" xlink:label="fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent" xlink:type="locator" xlink:label="fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedLongTermCoPromotionLiabilityCurrent" xlink:type="locator" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" xlink:type="locator" xlink:label="fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies" xlink:type="locator" xlink:label="us-gaap_Supplies" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_NumberOfRegulatoryMilestones" xlink:type="locator" xlink:label="fgen_NumberOfRegulatoryMilestones" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" xlink:type="locator" xlink:label="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesAndRestOfWorldMember" xlink:type="locator" xlink:label="fgen_UnitedStatesAndRestOfWorldMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="srt_StatementGeographicalAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesAndRestOfWorldMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fgen_NumberOfRegulatoryMilestones" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_Supplies" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_Depreciation" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fgen_AccruedLongTermCoPromotionLiabilityCurrent" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses" order="10890.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="fgen_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fgen_LaboratoryEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10560.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureProductDevelopmentObligationsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedProductDevelopmentCostsExcludingInterest" xlink:type="locator" xlink:label="fgen_AccruedProductDevelopmentCostsExcludingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:type="locator" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRate" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_NumberOfProductDevelopmentObligations" xlink:type="locator" xlink:label="fgen_NumberOfProductDevelopmentObligations" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BankOfFinlandInterestRateMember" xlink:type="locator" xlink:label="fgen_BankOfFinlandInterestRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="fgen_BankOfFinlandInterestRateMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="fgen_NumberOfProductDevelopmentObligations" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LoansReceivableBasisSpreadOnVariableRate" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="fgen_AccruedProductDevelopmentCostsExcludingInterest" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" order="10330.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_MaximumFutureMilestonePayments" xlink:type="locator" xlink:label="fgen_MaximumFutureMilestonePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" xlink:type="locator" xlink:label="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="fgen_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="fgen_CommitmentsAndContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fgen_CommitmentsAndContingenciesLineItems" xlink:to="fgen_CommitmentsAndContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligation" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_CommitmentsAndContingenciesLineItems" xlink:to="fgen_MaximumFutureMilestonePayments" order="10170.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligation" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OtherPurchasesMember" xlink:type="locator" xlink:label="fgen_OtherPurchasesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ManufactureAndSupplyOfPamrevlumabMember" xlink:type="locator" xlink:label="fgen_ManufactureAndSupplyOfPamrevlumabMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ManufactureAndSupplyOfRoxadustatMember" xlink:type="locator" xlink:label="fgen_ManufactureAndSupplyOfRoxadustatMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="fgen_ManufactureAndSupplyOfRoxadustatMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="fgen_ManufactureAndSupplyOfPamrevlumabMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="fgen_OtherPurchasesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligation" order="10360.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PreferredSharesIssuedPricePerShare" xlink:type="locator" xlink:label="fgen_PreferredSharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:type="locator" xlink:label="us-gaap_PreferredStockVotingRights" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares" xlink:type="locator" xlink:label="fgen_RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FibroGenCaymanMember" xlink:type="locator" xlink:label="fgen_FibroGenCaymanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesHPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesGPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesFPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesEPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FibrogenEuropeOyMember" xlink:type="locator" xlink:label="fgen_FibrogenEuropeOyMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="fgen_FibrogenEuropeOyMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="fgen_FibroGenCaymanMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockRedemptionTerms" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fgen_RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockVotingRights" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fgen_PreferredSharesIssuedPricePerShare" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="11890.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CommonStockSharesReserved" xlink:type="locator" xlink:label="fgen_CommonStockSharesReserved" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10060.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fgen_CommonStockSharesReserved" order="10370.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="locator" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="fgen_TwoThousandAndFourteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_TwoThousandAndFiveStockPlanMember" xlink:type="locator" xlink:label="fgen_TwoThousandAndFiveStockPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fgen_TwoThousandAndFiveStockPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fgen_TwoThousandAndFourteenEquityIncentivePlanMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10850.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="fgen_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fgen_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10600.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11000.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_StockOptionAwardsMember" xlink:type="locator" xlink:label="fgen_StockOptionAwardsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fgen_StockOptionAwardsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible" xlink:type="locator" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ExperienceHistoricalOwnershipChanges" xlink:type="locator" xlink:label="fgen_ExperienceHistoricalOwnershipChanges" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OtherTaxCreditCarryforwardsExpirationYear" xlink:type="locator" xlink:label="fgen_OtherTaxCreditCarryforwardsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="fgen_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_IncomeTaxesTable" xlink:type="locator" xlink:label="fgen_IncomeTaxesTable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_IncomeTaxesLineItems" xlink:type="locator" xlink:label="fgen_IncomeTaxesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="fgen_IncomeTaxesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_IncomeTaxesTable" xlink:to="srt_RangeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_IncomeTaxesTable" xlink:to="srt_StatementGeographicalAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fgen_IncomeTaxesTable" xlink:to="us-gaap_TaxPeriodAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_2" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="fgen_OperatingLossCarryforwardsExpirationYear" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="fgen_OtherTaxCreditCarryforwardsExpirationYear" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="fgen_ExperienceHistoricalOwnershipChanges" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_OpenTaxYear" order="11430.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FederalAndStateMember" xlink:type="locator" xlink:label="fgen_FederalAndStateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="fgen_FederalAndStateMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_MiscellaneousReceivables" xlink:type="locator" xlink:label="fgen_MiscellaneousReceivables" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_SuppliesNet" xlink:type="locator" xlink:label="fgen_SuppliesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies" xlink:type="locator" xlink:label="us-gaap_Supplies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenueFromRelatedParty" xlink:type="locator" xlink:label="fgen_DrugProductRevenueFromRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_RevenueFromRelatedParties" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FalikangMember" xlink:type="locator" xlink:label="fgen_FalikangMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasMember" xlink:type="locator" xlink:label="fgen_AstellasMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_APIShipmentMember" xlink:type="locator" xlink:label="fgen_APIShipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LicenseAndDevelopmentMember" xlink:type="locator" xlink:label="fgen_LicenseAndDevelopmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_LicenseAndDevelopmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TransactionTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="fgen_APIShipmentMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_AstellasMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_StatementGeographicalAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_FalikangMember" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fgen_DrugProductRevenueFromRelatedParty" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="11910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_Supplies" order="11980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fgen_SuppliesNet" order="12020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="12170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InvestmentIncomeNet" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage" order="12320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="12360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fgen_MiscellaneousReceivables" order="12400.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureSegmentAndGeographicInformationAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10270.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AllOtherMember" xlink:type="locator" xlink:label="fgen_AllOtherMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_AllOtherMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfInventoryByGeographicAreaDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureSegmentAndGeographicInformationScheduleOfInventoryByGeographicAreaDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfInventoryByGeographicAreaDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InventoryNet" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfLongLivedAssetsByGeographicAreaDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureSegmentAndGeographicInformationScheduleOfLongLivedAssetsByGeographicAreaDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfLongLivedAssetsByGeographicAreaDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationSummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureSegmentAndGeographicInformationSummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationSummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="locator" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10360.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccountsDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureScheduleIIValuationAndQualifyingAccountsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccountsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ValuationAllowanceForRebatesAndDiscountsMember" xlink:type="locator" xlink:label="fgen_ValuationAllowanceForRebatesAndDiscountsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="locator" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="locator" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_ValuationAllowanceForRebatesAndDiscountsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions" order="10520.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>27
<FILENAME>fgen-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-01T20:53:06.3617359+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : c4cc8ad73bdd4a268962242d24ba2619 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" xlink:type="locator" xlink:label="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Total amount of revenue recognized for license and development services under the collaboration agreement as of a given date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" xlink:to="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RestrictedTimeDepositsNoncurrent" xlink:type="locator" xlink:label="fgen_RestrictedTimeDepositsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_RestrictedTimeDepositsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted time deposits noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RestrictedTimeDepositsNoncurrent" xlink:to="fgen_RestrictedTimeDepositsNoncurrent_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" />
    <link:label xml:lang="en-US" xlink:label="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity method investment in unconsolidated variable interest entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" xlink:to="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedProductDevelopmentCosts" xlink:type="locator" xlink:label="fgen_AccruedProductDevelopmentCosts" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedProductDevelopmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the long-term portion of the outstanding principal and accrued interest of advances in the form note agreements received by the entity to fund various product development efforts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccruedProductDevelopmentCosts" xlink:to="fgen_AccruedProductDevelopmentCosts_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net ($4,127 and $4,845 from a related party)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets ($889 and $125,210 from related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RestrictedTimeDepositsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted time deposits</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RestrictedTimeDepositsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Time Deposits Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method investment in unconsolidated variable interest entity</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment In Unconsolidated Variable Interest Entity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, stockholders&#8217; equity and non-controlling interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable ($1,118 and $0 to a related party)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities ($24 and $36,883 to a related party)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue ($2,907 and $249 to a related party)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liabilities, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedProductDevelopmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product development obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedProductDevelopmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Product Development Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current ($4,636 and $125 to a related party)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liabilities, non-current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies (Note 9)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at December 31, 2020 and 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.01 par value; 225,000 shares authorized at December 31, 2020 and 2019; 91,441 and 87,657 shares issued and outstanding at December 31, 2020 and 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Including Portion Attributable To Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, stockholders&#8217; equity and non-controlling interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DueToRelatedPartiesDeferredRevenueCurrent" xlink:type="locator" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Due to related parties deferred revenue current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DueToRelatedPartiesDeferredRevenueCurrent" xlink:to="fgen_DueToRelatedPartiesDeferredRevenueCurrent_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DueToRelatedPartiesDeferredRevenueNoncurrent" xlink:type="locator" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Due to related parties deferred revenue noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DueToRelatedPartiesDeferredRevenueNoncurrent" xlink:to="fgen_DueToRelatedPartiesDeferredRevenueNoncurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable from related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Related Parties Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets from related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due From Related Parties Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable to related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Related Parties Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities to related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue current to related party</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Deferred Revenue Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue non-current to related party</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Deferred Revenue Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CostOfGoodsAndServicesSoldOperatingExpense" xlink:type="locator" xlink:label="fgen_CostOfGoodsAndServicesSoldOperatingExpense" />
    <link:label xml:lang="en-US" xlink:label="fgen_CostOfGoodsAndServicesSoldOperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of goods and services sold operating expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CostOfGoodsAndServicesSoldOperatingExpense" xlink:to="fgen_CostOfGoodsAndServicesSoldOperatingExpense_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnconsolidatedVariableInterestEntityInvestmentLoss" xlink:type="locator" xlink:label="fgen_UnconsolidatedVariableInterestEntityInvestmentLoss" />
    <link:label xml:lang="en-US" xlink:label="fgen_UnconsolidatedVariableInterestEntityInvestmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unconsolidated variable interest entity investment loss.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_UnconsolidatedVariableInterestEntityInvestmentLoss" xlink:to="fgen_UnconsolidatedVariableInterestEntityInvestmentLoss_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_InterestAndOtherNetAbstract" xlink:type="locator" xlink:label="fgen_InterestAndOtherNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="fgen_InterestAndOtherNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest and other net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_InterestAndOtherNetAbstract" xlink:to="fgen_InterestAndOtherNetAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DevelopmentAndOtherRevenueMember" xlink:type="locator" xlink:label="fgen_DevelopmentAndOtherRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_DevelopmentAndOtherRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and other revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DevelopmentAndOtherRevenueMember" xlink:to="fgen_DevelopmentAndOtherRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DevelopmentAndOtherRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and Other Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DevelopmentAndOtherRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development And Other Revenue [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Revenue, Net [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_DrugProductRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Drug product revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DrugProductRevenueMember" xlink:to="fgen_DrugProductRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DrugProductRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Drug Product Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DrugProductRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Drug Product Revenue [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating costs and expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs And Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CostOfGoodsAndServicesSoldOperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of goods sold</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CostOfGoodsAndServicesSoldOperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Goods And Services Sold Operating Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost, Product and Service [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:to="us-gaap_TypeOfCostGoodOrServiceExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Cost Good Or Service Extensible List</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating costs and expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_InterestAndOtherNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other, net</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_InterestAndOtherNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_UnconsolidatedVariableInterestEntityInvestmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Investment loss in unconsolidated variable interest entity</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_UnconsolidatedVariableInterestEntityInvestmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unconsolidated Variable Interest Entity Investment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income and other, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total interest and other, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Expense Nonoperating Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share - basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of common shares used to calculate net loss per share - basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LicenseFeesAndMilestonesRevenue" xlink:type="locator" xlink:label="fgen_LicenseFeesAndMilestonesRevenue" />
    <link:label xml:lang="en-US" xlink:label="fgen_LicenseFeesAndMilestonesRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue from multiple-deliverable arrangements that include licensing fees and services revenue and the amount of consideration recognized during the period for milestones. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity&apos;s intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, non-specified, services during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_LicenseFeesAndMilestonesRevenue" xlink:to="fgen_LicenseFeesAndMilestonesRevenue_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CollaborationServicesAndOtherRevenue" xlink:type="locator" xlink:label="fgen_CollaborationServicesAndOtherRevenue" />
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborationServicesAndOtherRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognized from co-development services, manufacturing of clinical supplies, committee services and information services and other revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CollaborationServicesAndOtherRevenue" xlink:to="fgen_CollaborationServicesAndOtherRevenue_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProductRevenue" xlink:type="locator" xlink:label="fgen_ProductRevenue" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProductRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product revenue from a related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ProductRevenue" xlink:to="fgen_ProductRevenue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Astellas agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AstellasCollaborationAgreementMember" xlink:to="fgen_AstellasCollaborationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Astellas Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Astellas Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LicenseFeesAndMilestonesRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and milestone revenue from a related party</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LicenseFeesAndMilestonesRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Fees And Milestones Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborationServicesAndOtherRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration services and other revenue from a related party</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborationServicesAndOtherRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Services And Other Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProductRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product revenue from a related party</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProductRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustments (Note 2)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale investments:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Available For Sale Securities Adjustment Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on investments, net of tax effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other comprehensive income (loss), net of taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" xlink:type="locator" xlink:label="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" />
    <link:label xml:lang="en-US" xlink:label="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued from stock plans net of payroll taxes paid shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" xlink:to="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" xlink:type="locator" xlink:label="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" />
    <link:label xml:lang="en-US" xlink:label="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital shares issued from stock plans net of payroll taxes paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" xlink:to="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_WarrantExercisedDuringPeriodShares" xlink:type="locator" xlink:label="fgen_WarrantExercisedDuringPeriodShares" />
    <link:label xml:lang="en-US" xlink:label="fgen_WarrantExercisedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant exercised during period shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_WarrantExercisedDuringPeriodShares" xlink:to="fgen_WarrantExercisedDuringPeriodShares_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_WarrantsExercisedDuringPeriodValue" xlink:type="locator" xlink:label="fgen_WarrantsExercisedDuringPeriodValue" />
    <link:label xml:lang="en-US" xlink:label="fgen_WarrantsExercisedDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercised during period value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_WarrantsExercisedDuringPeriodValue" xlink:to="fgen_WarrantsExercisedDuringPeriodValue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling Interests [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Effect, Period of Adoption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect Period Of Adoption [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Effect, Period of Adoption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect Period Of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect Period Of Adoption Adjustment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201602 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201802Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201802Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201802Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2018-02 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201802Member" xlink:to="us-gaap_AccountingStandardsUpdate201802Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201802Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201802 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201601Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201601Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-01 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201601Member" xlink:to="us-gaap_AccountingStandardsUpdate201601Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201601Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201601 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in unrealized gain or loss on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Foreign currency translation adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment to issuance costs for Follow-on Offerings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued from stock plans, net of payroll taxes paid</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued from stock plans, net of payroll taxes paid, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued From Stock Plans Net Of Payroll Taxes Paid Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_WarrantsExercisedDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_WarrantsExercisedDuringPeriodValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercised During Period Value</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_WarrantExercisedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_WarrantExercisedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Exercised During Period Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnrealizedLossGainOnEquityInvestments" xlink:type="locator" xlink:label="fgen_UnrealizedLossGainOnEquityInvestments" />
    <link:label xml:lang="en-US" xlink:label="fgen_UnrealizedLossGainOnEquityInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrealized loss (gain) on equity investments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_UnrealizedLossGainOnEquityInvestments" xlink:to="fgen_UnrealizedLossGainOnEquityInvestments_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" />
    <link:label xml:lang="en-US" xlink:label="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment loss in unconsolidated variable interest entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" xlink:to="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_IncreaseDecreaseInLeaseObligations" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInLeaseObligations" />
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInLeaseObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in lease obligations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_IncreaseDecreaseInLeaseObligations" xlink:to="fgen_IncreaseDecreaseInLeaseObligations_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in accrued interest for finance lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" xlink:to="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" />
    <link:label xml:lang="en-US" xlink:label="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment made for investment in unconsolidated variable interest entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" xlink:to="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from equity transfer of unconsolidated variable interest entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity" xlink:to="fgen_ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit" xlink:type="locator" xlink:label="fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit" />
    <link:label xml:lang="en-US" xlink:label="fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments to acquire available for sale securities and term deposit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit" xlink:to="fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RepaymentsOfFinanceLeaseLiabilities" xlink:type="locator" xlink:label="fgen_RepaymentsOfFinanceLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="fgen_RepaymentsOfFinanceLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayments of finance lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RepaymentsOfFinanceLeaseLiabilities" xlink:to="fgen_RepaymentsOfFinanceLeaseLiabilities_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of finance lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Right Of Use Asset Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net accretion of discount on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_UnrealizedLossGainOnEquityInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized loss (gain) on equity investments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_UnrealizedLossGainOnEquityInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Loss Gain On Equity Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Investment loss in unconsolidated variable interest entity</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Loss In Unconsolidated Variable Interest Entity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss (gain) on disposal of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Disposition Of Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Realized foreign currency gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Gain Loss Realized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Realized loss (gain) on sales of available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable, net ($718, $42,365 and $(43,486) from a related party)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets ($124,321, $(125,210) and $0 from a related party)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable ($1,118, $0 and $0 from a related party)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other liabilities ($(36,859), $36,439 and $172 from a related party)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue ($7,169, $(3,137) and $(3,908) from a related party)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInLeaseObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInLeaseObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Lease Obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest for finance lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Interest For Finance Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment made for investment in unconsolidated variable interest entity</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Made For Investment In Unconsolidated Variable Interest Entity</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from equity transfer of unconsolidated variable interest entity</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Equity Transfer Of Unconsolidated Variable Interest Entity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of available-for-sale securities and term deposit</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Available For Sale Securities And Term Deposit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales of available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Available For Sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Maturity And Collections Of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLongTermCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLongTermCapitalLeaseObligations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromLongTermCapitalLeaseObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings under capital lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLongTermCapitalLeaseObligations" xlink:to="us-gaap_ProceedsFromLongTermCapitalLeaseObligations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromLongTermCapitalLeaseObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Long Term Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayments of capital lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Long Term Capital Lease Obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RepaymentsOfFinanceLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayments of finance lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RepaymentsOfFinanceLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Finance Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayments of lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Debt And Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash paid for payroll taxes on restricted stock unit releases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Related To Tax Withholding For Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate change on cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Total cash and cash equivalents at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Total cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance in accounts payable and accrued liabilities related to purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAssumed1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs recorded in accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAssumed1" xlink:to="us-gaap_LiabilitiesAssumed1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Assumed1</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in prepaid expenses and other current assets related parties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties" xlink:to="fgen_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_IncreaseDecreaseInAccountsPayableFromRelatedParty" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInAccountsPayableFromRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInAccountsPayableFromRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accounts payable from related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_IncreaseDecreaseInAccountsPayableFromRelatedParty" xlink:to="fgen_IncreaseDecreaseInAccountsPayableFromRelatedParty_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable from related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets from related party</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Expenses And Other Current Assets Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInAccountsPayableFromRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable from related party</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncreaseDecreaseInAccountsPayableFromRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable From Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other liabilities from related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue from related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Revenue</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquisitionAndVariableInterestEntityTextBlock" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquisition and variable interest entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AcquisitionAndVariableInterestEntityTextBlock" xlink:to="fgen_AcquisitionAndVariableInterestEntityTextBlock_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityAbstract" />
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquisition and variable interest entity abstract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:to="fgen_AcquisitionAndVariableInterestEntityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition And Variable Interest Entity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition and Variable Interest Entity</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition And Variable Interest Entity [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement and revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock" xlink:to="fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreements and Revenues</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement And Revenues Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases Of Lessee Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProductDevelopmentObligationsDisclosureTextBlock" xlink:type="locator" xlink:label="fgen_ProductDevelopmentObligationsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProductDevelopmentObligationsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product development obligation disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ProductDevelopmentObligationsDisclosureTextBlock" xlink:to="fgen_ProductDevelopmentObligationsDisclosureTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProductDevelopmentObligationsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Development Obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProductDevelopmentObligationsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Development Obligations Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity and Stock-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders Equity And Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FibroGen, Inc. 401(k) Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension And Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment and Geographic Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:type="locator" xlink:label="srt_ValuationAndQualifyingAccountsAbstract" />
    <link:label xml:lang="en-US" xlink:label="srt_ValuationAndQualifyingAccountsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation And Qualifying Accounts [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ValuationAndQualifyingAccountsAbstract" xlink:to="srt_ValuationAndQualifyingAccountsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="locator" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule II - Valuation and Qualifying Accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Valuation And Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="locator" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Interest Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Variable Interest Entity Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Translation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions And Translations Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:type="locator" xlink:label="fgen_OtherRisksAndUncertaintiesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_OtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Risks and Uncertainties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:to="fgen_OtherRisksAndUncertaintiesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_OtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_OtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Risks And Uncertainties Policy [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="fgen_CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents and restricted time deposits policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock" xlink:to="fgen_CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents and Restricted Time Deposits</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents And Restricted Time Deposits Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trade And Other Accounts Receivable Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Losses &#8211; Available-for-sale Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Loss Financial Instrument Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ClinicalTrialAccrualPolicyTextBlock" xlink:type="locator" xlink:label="fgen_ClinicalTrialAccrualPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ClinicalTrialAccrualPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical trial accrual.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ClinicalTrialAccrualPolicyTextBlock" xlink:to="fgen_ClinicalTrialAccrualPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ClinicalTrialAccrualPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Trial Accruals</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ClinicalTrialAccrualPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trial Accrual Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, General and Administrative Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock" xlink:type="locator" xlink:label="fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued and adopted accounting guidance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock" xlink:to="fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued and Adopted Accounting Guidance</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued And Adopted Accounting Guidance Policy [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock" xlink:type="locator" xlink:label="fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued accounting guidance not yet adopted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock" xlink:to="fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Guidance Not Yet Adopted</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Guidance Not Yet Adopted Policy [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement and revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock" xlink:to="fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Arrangements and Revenues</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement And Revenues Policy [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProductRevenuePolicyPolicyTextBlock" xlink:type="locator" xlink:label="fgen_ProductRevenuePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProductRevenuePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product revenue policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ProductRevenuePolicyPolicyTextBlock" xlink:to="fgen_ProductRevenuePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProductRevenuePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Revenue, Net</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProductRevenuePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Revenue Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenuePolicyTextBlock" xlink:type="locator" xlink:label="fgen_DrugProductRevenuePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_DrugProductRevenuePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Drug product revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DrugProductRevenuePolicyTextBlock" xlink:to="fgen_DrugProductRevenuePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DrugProductRevenuePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Drug Product Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DrugProductRevenuePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Drug Product Revenue Policy [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OtherRevenuesPolicyTextBlock" xlink:type="locator" xlink:label="fgen_OtherRevenuesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_OtherRevenuesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other revenues policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_OtherRevenuesPolicyTextBlock" xlink:to="fgen_OtherRevenuesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_OtherRevenuesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Revenues</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_OtherRevenuesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Revenues Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Significant Balance of Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedules Of Concentration Of Risk By Risk Factor [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Equity Method Investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerMilestoneMethodTableTextBlock" xlink:type="locator" xlink:label="fgen_ContractWithCustomerMilestoneMethodTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerMilestoneMethodTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer milestone method.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ContractWithCustomerMilestoneMethodTableTextBlock" xlink:to="fgen_ContractWithCustomerMilestoneMethodTableTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:label xml:lang="en-US" xlink:label="country_JP_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Japan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_JP" xlink:to="country_JP_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_JP_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">JAPAN</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_EuropeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Europe [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_EuropeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Europe [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">United States/Rest of World and China.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:to="fgen_UnitedStatesRestOfWorldAndChinaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S./RoW and China [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">United States Rest Of World And China [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerMilestoneMethodTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of License Revenue and Development Revenue Recognized under Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerMilestoneMethodTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Milestone Method Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Roll-forward of Related Contract Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset And Liability Table [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ScheduleOfDrugProductRevenueTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfDrugProductRevenueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfDrugProductRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of drug product revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ScheduleOfDrugProductRevenueTableTextBlock" xlink:to="fgen_ScheduleOfDrugProductRevenueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfDrugProductRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Drug Product Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfDrugProductRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Drug Product Revenue Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Values of Financial Assets Measured on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Values of Financial Liabilities Carried at Historical Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of lease assets and related lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock" xlink:to="fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Lease Assets and Related Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Lease Assets And Related Lease Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental cash flow information related to leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:to="fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Cash Flow Information Related to Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of lease term and discount rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" xlink:to="fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Lease Term and Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Lease Term And Discount Rate Table [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of maturities of finance and operating leases liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock" xlink:to="fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of Finance and Operating Leases Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Maturities Of Finance And Operating Leases Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash And Cash Equivalents Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Contractual Maturities of Available-for-Sale Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified By Contractual Maturity Date Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Inventory Current Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued and Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Long-term Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationsTextBlock" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Unconditional Purchase Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationsTextBlock" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recorded Unconditional Purchase Obligations [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of shares of common stock reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="fgen_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Common Stock Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Shares Of Common Stock Reserved For Future Issuance Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of RSU Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Recorded Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of share based payment award stock options and employee stock purchase plan valuation assumptions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options And Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of income loss before income tax domestic and foreign.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="fgen_ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Loss Before Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Income Loss Before Income Tax Domestic And Foreign Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Provision For Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation Between Statutory Federal Income Tax Rate and Effective Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Significant Components of Deferred Tax Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of the Beginning and Ending Amounts of Unrecognized Income Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Revenue by Geographic Area</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From External Customers By Geographic Areas Table [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_InventoryByGeographicAreasTableTextBlock" xlink:type="locator" xlink:label="fgen_InventoryByGeographicAreasTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_InventoryByGeographicAreasTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Inventory by geographic areas.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_InventoryByGeographicAreasTableTextBlock" xlink:to="fgen_InventoryByGeographicAreasTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_InventoryByGeographicAreasTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Inventory by Geographic Area</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_InventoryByGeographicAreasTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory By Geographic Areas Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Long Lived Assets by Geographic Area</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Lived Assets By Geographic Areas Table [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock" xlink:type="locator" xlink:label="fgen_SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fgen_SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of Finance and Operating Lease Right of Use Assets by Geographical Location.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock" xlink:to="fgen_SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Finance and Operating Lease Right of Use Assets by Geographical Location</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Finance And Operating Lease Right Of Use Assets By Geographical Location Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Customer Concentration by Collaboration Partners</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Revenue By Major Customers By Reporting Segments Table [Text Block]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccountingPolicyLineItems" xlink:type="locator" xlink:label="fgen_AccountingPolicyLineItems" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccountingPolicyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_AccountingPolicyLineItems_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccountingPolicyTable" xlink:type="locator" xlink:label="fgen_AccountingPolicyTable" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccountingPolicyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccountingPolicyTable" xlink:to="fgen_AccountingPolicyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccountingPolicyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policy [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccountingPolicyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policy [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccountsReceivableFromDistributorsMember" xlink:type="locator" xlink:label="fgen_AccountsReceivableFromDistributorsMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccountsReceivableFromDistributorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts receivable from distributors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccountsReceivableFromDistributorsMember" xlink:to="fgen_AccountsReceivableFromDistributorsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccountsReceivableFromDistributorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable from Distributors [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccountsReceivableFromDistributorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable From Distributors [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CreditConcentrationRiskMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Concentration Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeographicDistributionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographic Distribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeographicDistributionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeographicDistributionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographic Distribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeographicDistributionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionForeignMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeographicDistributionForeignMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign subsidiaries [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionForeignMember" xlink:to="us-gaap_GeographicDistributionForeignMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeographicDistributionForeignMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution Foreign [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="fgen_LaboratoryEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_LaboratoryEquipmentMember" xlink:to="fgen_LaboratoryEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Machinery [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Machinery And Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Application Period Cumulative Effect Transition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Application Period Cumulative Effect Transition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member" xlink:type="locator" xlink:label="fgen_ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member" />
    <link:label xml:lang="en-US" xlink:label="fgen_ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Impact of change in accounting principle upon adoption of ASU 2018-02.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member" xlink:to="fgen_ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact of change in accounting principle upon adoption of ASU 2018-02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impact Of Change In Accounting Principle Upon Adoption Of A S U201802 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:type="locator" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact of change in accounting principle upon adoption of ASU 2016-01 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:to="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Difference Between Revenue Guidance In Effect Before And After Topic606 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccountingPolicyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policy [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccountingPolicyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policy [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax" xlink:type="locator" xlink:label="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency translation adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax" xlink:to="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Translation Adjustment Functional To Reporting Currency Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstraZenecaAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Astra Zeneca agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AstraZenecaAgreementsMember" xlink:to="fgen_AstraZenecaAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstraZenecaAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AstraZeneca Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AstraZenecaAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Astra Zeneca Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Percentage1</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_HighlyLiquidInvestmentMaturityPeriod" xlink:type="locator" xlink:label="fgen_HighlyLiquidInvestmentMaturityPeriod" />
    <link:label xml:lang="en-US" xlink:label="fgen_HighlyLiquidInvestmentMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Highly liquid investment maturity period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_HighlyLiquidInvestmentMaturityPeriod" xlink:to="fgen_HighlyLiquidInvestmentMaturityPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_HighlyLiquidInvestmentMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Highly liquid investment maturity period</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_HighlyLiquidInvestmentMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Highly Liquid Investment Maturity Period</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ShortTermInvestmentsMaximumMaturityPeriod" xlink:type="locator" xlink:label="fgen_ShortTermInvestmentsMaximumMaturityPeriod" />
    <link:label xml:lang="en-US" xlink:label="fgen_ShortTermInvestmentsMaximumMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Short term investments maximum maturity period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ShortTermInvestmentsMaximumMaturityPeriod" xlink:to="fgen_ShortTermInvestmentsMaximumMaturityPeriod_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LongTermInvestmentsMinimumMaturityPeriod" xlink:type="locator" xlink:label="fgen_LongTermInvestmentsMinimumMaturityPeriod" />
    <link:label xml:lang="en-US" xlink:label="fgen_LongTermInvestmentsMinimumMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term investments minimum maturity period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_LongTermInvestmentsMinimumMaturityPeriod" xlink:to="fgen_LongTermInvestmentsMinimumMaturityPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ShortTermInvestmentsMaximumMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term investments maturity</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ShortTermInvestmentsMaximumMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments Maximum Maturity Period</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LongTermInvestmentsMinimumMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term Investments Maturity</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LongTermInvestmentsMinimumMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Investments Minimum Maturity Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets To Be Disposed Of</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount constrained related to drug product shipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:type="locator" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of payment term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Performance Obligation Description Of Payment Terms</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DescriptionOfSalesReturn" xlink:type="locator" xlink:label="fgen_DescriptionOfSalesReturn" />
    <link:label xml:lang="en-US" xlink:label="fgen_DescriptionOfSalesReturn_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of sales return.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DescriptionOfSalesReturn" xlink:to="fgen_DescriptionOfSalesReturn_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DescriptionOfSalesReturn_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of sales return</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DescriptionOfSalesReturn_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Sales Return</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityLineItems" />
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquisition and variable interest entity line items.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="fgen_AcquisitionAndVariableInterestEntityLineItems_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquisitionAndVariableInterestEntityTable" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityTable" />
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquisition and variable interest entity table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="fgen_AcquisitionAndVariableInterestEntityTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition And Variable Interest Entity [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition And Variable Interest Entity [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Acquiree [Domain]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" xlink:type="locator" xlink:label="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Beijing Kangda Yongfu Pharmaceutical Co., LTD.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" xlink:to="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Beijing Kangda Yongfu Pharmaceutical Co L T D [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FibroGenBeijingMember" xlink:type="locator" xlink:label="fgen_FibroGenBeijingMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_FibroGenBeijingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">FibroGen Beijing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_FibroGenBeijingMember" xlink:to="fgen_FibroGenBeijingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_FibroGenBeijingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FibroGen Beijing [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FibroGenBeijingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fibro Gen Beijing [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquiredLicenseMember" xlink:type="locator" xlink:label="fgen_AcquiredLicenseMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_AcquiredLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquired license.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AcquiredLicenseMember" xlink:to="fgen_AcquiredLicenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AcquiredLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AcquiredLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquired License [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Method Investment, Nonconsolidated Investee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Method Investment, Nonconsolidated Investee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BeijingFalikangPharmaceuticalCoLtdMember" xlink:type="locator" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Beijing Falikang Pharmaceutical Co. Ltd.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_BeijingFalikangPharmaceuticalCoLtdMember" xlink:to="fgen_BeijingFalikangPharmaceuticalCoLtdMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beijing Falikang Pharmaceutical Co. Ltd [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Beijing Falikang Pharmaceutical Co Ltd [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaABMember" xlink:type="locator" xlink:label="fgen_AstraZenecaABMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstraZenecaABMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">AstraZeneca AB.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AstraZenecaABMember" xlink:to="fgen_AstraZenecaABMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstraZenecaABMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AstraZeneca AB [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AstraZenecaABMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Astra Zeneca A B [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity Not Primary Beneficiary [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition And Variable Interest Entity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AcquisitionAndVariableInterestEntityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition And Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding shares acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Percentage Of Voting Interests Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Businesses Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Cost Of Acquired Entity Transaction Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Acquisition Related Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entire purchase price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Consideration Transferred1</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer" xlink:type="locator" xlink:label="fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer" />
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of outstanding shares of acquiree sold by acquirer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer" xlink:to="fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding shares sold in exchange for cash consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Outstanding Shares Of Acquiree Sold By Acquirer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash consideration for exchange of outstanding shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Sold Carrying Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding shares owned</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Capital" xlink:type="locator" xlink:label="us-gaap_Capital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Capital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Falikang&apos;s total registered capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Capital" xlink:to="us-gaap_Capital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Capital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EquityMethodInvestmentAdditions" xlink:type="locator" xlink:label="fgen_EquityMethodInvestmentAdditions" />
    <link:label xml:lang="en-US" xlink:label="fgen_EquityMethodInvestmentAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity method investment additions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_EquityMethodInvestmentAdditions" xlink:to="fgen_EquityMethodInvestmentAdditions_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_EquityMethodInvestmentAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EquityMethodInvestmentAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Additions</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" xlink:type="locator" xlink:label="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" />
    <link:label xml:lang="en-US" xlink:label="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity method investment increase (decrease) from currency translation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" xlink:to="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EquityMethodInvestmentAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Additions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Share of Net Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Equity Method Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency Translation</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Increase Decrease From Currency Translation</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" xlink:type="locator" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" xlink:to="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CommercialSalesMilestone" xlink:type="locator" xlink:label="fgen_CommercialSalesMilestone" />
    <link:label xml:lang="en-US" xlink:label="fgen_CommercialSalesMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of milestone payments related to commercial sales under the collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CommercialSalesMilestone" xlink:to="fgen_CommercialSalesMilestone_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AdditionalConsiderationBasedOnNetSales" xlink:type="locator" xlink:label="fgen_AdditionalConsiderationBasedOnNetSales" />
    <link:label xml:lang="en-US" xlink:label="fgen_AdditionalConsiderationBasedOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of additional consideration based on net sales of product as defined under a collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AdditionalConsiderationBasedOnNetSales" xlink:to="fgen_AdditionalConsiderationBasedOnNetSales_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PotentialMilestones" xlink:type="locator" xlink:label="fgen_PotentialMilestones" />
    <link:label xml:lang="en-US" xlink:label="fgen_PotentialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_PotentialMilestones" xlink:to="fgen_PotentialMilestones_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" />
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of aggregate consideration receivable under collaborative arrangement excluding drug product revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" xlink:to="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ClinicalDevelopmentMilestonesMember" xlink:type="locator" xlink:label="fgen_ClinicalDevelopmentMilestonesMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_ClinicalDevelopmentMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical development milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ClinicalDevelopmentMilestonesMember" xlink:to="fgen_ClinicalDevelopmentMilestonesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ClinicalDevelopmentMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical and Development Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ClinicalDevelopmentMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Development Milestones [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RegulatoryMilestonesMember" xlink:type="locator" xlink:label="fgen_RegulatoryMilestonesMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_RegulatoryMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RegulatoryMilestonesMember" xlink:to="fgen_RegulatoryMilestonesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_RegulatoryMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RegulatoryMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SEC Schedule, 12-09, Valuation Allowances and Reserves Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowances And Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SEC Schedule, 12-09, Valuation Allowances and Reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowances And Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront, non-contingent and time-based payments received</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Upfront Non Contingent And Time Based Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PotentialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PotentialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Potential Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CommercialSalesMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial sales milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CommercialSalesMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Sales Milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AdditionalConsiderationBasedOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional consideration based on net sales description</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AdditionalConsiderationBasedOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Consideration Based On Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate considerations received excluding drug product revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Aggregate Consideration Excluding Drug Product Revenue</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_TransactionPriceAllocatedToPerformanceObligations" xlink:type="locator" xlink:label="fgen_TransactionPriceAllocatedToPerformanceObligations" />
    <link:label xml:lang="en-US" xlink:label="fgen_TransactionPriceAllocatedToPerformanceObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction price allocated to performance obligations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_TransactionPriceAllocatedToPerformanceObligations" xlink:to="fgen_TransactionPriceAllocatedToPerformanceObligations_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_TransactionPriceAllocatedToPerformanceObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price and allocated to performance obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_TransactionPriceAllocatedToPerformanceObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Price Allocated To Performance Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:type="locator" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consideration associated with milestone included in transaction price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:to="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Significant Noncash Transaction Value Of Consideration Given1</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PercentageOfFundingForCosts" xlink:type="locator" xlink:label="fgen_PercentageOfFundingForCosts" />
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageOfFundingForCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_PercentageOfFundingForCosts" xlink:to="fgen_PercentageOfFundingForCosts_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DevelopmentAndRegulatoryApprovalMilestones" xlink:type="locator" xlink:label="fgen_DevelopmentAndRegulatoryApprovalMilestones" />
    <link:label xml:lang="en-US" xlink:label="fgen_DevelopmentAndRegulatoryApprovalMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DevelopmentAndRegulatoryApprovalMilestones" xlink:to="fgen_DevelopmentAndRegulatoryApprovalMilestones_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DevelopmentAndRegulatoryApprovalMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and regulatory approval milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DevelopmentAndRegulatoryApprovalMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development And Regulatory Approval Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageOfFundingForCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of joint development costs committed to fund</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageOfFundingForCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Funding For Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue during period from performance obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies" xlink:type="locator" xlink:label="us-gaap_Supplies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Supplies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unbilled contract asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Supplies" xlink:to="us-gaap_Supplies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Supplies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EstimatedJointDevelopmentExtendedServicePeriod" xlink:type="locator" xlink:label="fgen_EstimatedJointDevelopmentExtendedServicePeriod" />
    <link:label xml:lang="en-US" xlink:label="fgen_EstimatedJointDevelopmentExtendedServicePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated joint development extended service period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_EstimatedJointDevelopmentExtendedServicePeriod" xlink:to="fgen_EstimatedJointDevelopmentExtendedServicePeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_EstimatedJointDevelopmentExtendedServicePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated joint development extended service period</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EstimatedJointDevelopmentExtendedServicePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Joint Development Extended Service Period</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" xlink:type="locator" xlink:label="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" xlink:to="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesAndRestOfWorldMember" xlink:type="locator" xlink:label="fgen_UnitedStatesAndRestOfWorldMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_UnitedStatesAndRestOfWorldMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">United states and rest of world.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_UnitedStatesAndRestOfWorldMember" xlink:to="fgen_UnitedStatesAndRestOfWorldMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_UnitedStatesAndRestOfWorldMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S./RoW [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_UnitedStatesAndRestOfWorldMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">United States And Rest Of World [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DeferredApprovalMilestoneMember" xlink:type="locator" xlink:label="fgen_DeferredApprovalMilestoneMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_DeferredApprovalMilestoneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred approval milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DeferredApprovalMilestoneMember" xlink:to="fgen_DeferredApprovalMilestoneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DeferredApprovalMilestoneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Approval Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DeferredApprovalMilestoneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Approval Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_UnitedStatesAndRestOfWorldMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S./RoW [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FibroGenIncMember" xlink:type="locator" xlink:label="fgen_FibroGenIncMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_FibroGenIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">FibroGen, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_FibroGenIncMember" xlink:to="fgen_FibroGenIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_FibroGenIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FibroGen, Inc. [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FibroGenIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fibro Gen Inc [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:label xml:lang="en-US" xlink:label="country_CN_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">China [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_CN_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CHINA</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Noncurrent Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableMember" xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesMember" xlink:to="us-gaap_AccruedLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, General and Administrative Expenses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedAndOtherCurrentLiabilitiesMember" xlink:type="locator" xlink:label="fgen_AccruedAndOtherCurrentLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedAndOtherCurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccruedAndOtherCurrentLiabilitiesMember" xlink:to="fgen_AccruedAndOtherCurrentLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedAndOtherCurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and Other Current Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedAndOtherCurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued And Other Current Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront, non-contingent, non-refundable and time-based payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Upfront Non Contingent Non Refundable And Time Based Payments</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_SharedDevelopmentCosts" xlink:type="locator" xlink:label="fgen_SharedDevelopmentCosts" />
    <link:label xml:lang="en-US" xlink:label="fgen_SharedDevelopmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the total amount of development costs that will be shared under collaborative agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_SharedDevelopmentCosts" xlink:to="fgen_SharedDevelopmentCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_SharedDevelopmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shared development costs</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_SharedDevelopmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shared Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Drug product revenue</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" xlink:type="locator" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" xlink:to="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CommercialSalesAndOtherEventsMilestone" xlink:type="locator" xlink:label="fgen_CommercialSalesAndOtherEventsMilestone" />
    <link:label xml:lang="en-US" xlink:label="fgen_CommercialSalesAndOtherEventsMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial sales and other events milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CommercialSalesAndOtherEventsMilestone" xlink:to="fgen_CommercialSalesAndOtherEventsMilestone_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CollaborativeArrangementAggregateConsideration" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAggregateConsideration" />
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAggregateConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of aggregate consideration receivable under collaborative arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CollaborativeArrangementAggregateConsideration" xlink:to="fgen_CollaborativeArrangementAggregateConsideration_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from upfront, non-contingent and non-refundable payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Upfront Non Contingent And Non Refundable Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CommercialSalesAndOtherEventsMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial sales and other events milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CommercialSalesAndOtherEventsMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Sales And Other Events Milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAggregateConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate considerations received</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CollaborativeArrangementAggregateConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Aggregate Consideration</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability, milestone method revenue recognized.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" xlink:to="fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Milestone payment, revenue recognition</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Milestone Method Revenue Recognized</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_HistoricalCoPromotionCosts" xlink:type="locator" xlink:label="fgen_HistoricalCoPromotionCosts" />
    <link:label xml:lang="en-US" xlink:label="fgen_HistoricalCoPromotionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Historical co-promotion costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_HistoricalCoPromotionCosts" xlink:to="fgen_HistoricalCoPromotionCosts_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CoPromotionExpenses" xlink:type="locator" xlink:label="fgen_CoPromotionExpenses" />
    <link:label xml:lang="en-US" xlink:label="fgen_CoPromotionExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Co-promotion expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CoPromotionExpenses" xlink:to="fgen_CoPromotionExpenses_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ReversalOfAccruedCoPromotionExpenses" xlink:type="locator" xlink:label="fgen_ReversalOfAccruedCoPromotionExpenses" />
    <link:label xml:lang="en-US" xlink:label="fgen_ReversalOfAccruedCoPromotionExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reversal of accrued co-promotion expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ReversalOfAccruedCoPromotionExpenses" xlink:to="fgen_ReversalOfAccruedCoPromotionExpenses_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" xlink:type="locator" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued long term co promotion liability non current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" xlink:to="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedLongTermCoPromotionLiabilityCurrent" xlink:type="locator" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued long term co promotion liability current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccruedLongTermCoPromotionLiabilityCurrent" xlink:to="fgen_AccruedLongTermCoPromotionLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_HistoricalCoPromotionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Historical co-promotion costs</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_HistoricalCoPromotionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Historical Co Promotion Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ReversalOfAccruedCoPromotionExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reversal of accrued co-promotion expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ReversalOfAccruedCoPromotionExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reversal Of Accrued Co Promotion Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CoPromotionExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Co-promotion expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CoPromotionExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Co Promotion Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued long-term co-promotion expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Long Term Co Promotion Liability Non Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued long term co promotion liability current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Long Term Co Promotion Liability Current</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProceedsFromNonContingentUpfrontPayments" xlink:type="locator" xlink:label="fgen_ProceedsFromNonContingentUpfrontPayments" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromNonContingentUpfrontPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of non-contingent upfront payments included under the collaborative agreement as arrangement consideration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ProceedsFromNonContingentUpfrontPayments" xlink:to="fgen_ProceedsFromNonContingentUpfrontPayments_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone" xlink:type="locator" xlink:label="fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone" />
    <link:label xml:lang="en-US" xlink:label="fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Variable consideration payment received upon achievement of milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone" xlink:to="fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" xlink:type="locator" xlink:label="fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" />
    <link:label xml:lang="en-US" xlink:label="fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Variable consideration payment received related to co-development billings.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" xlink:to="fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Discount Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Discount Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Approach and Technique</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Approach and Technique</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discounted Cash Flow [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="us-gaap_ValuationTechniqueDiscountedCashFlowMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique Discounted Cash Flow [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromNonContingentUpfrontPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-contingent upfront payments received</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProceedsFromNonContingentUpfrontPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Non Contingent Upfront Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable consideration related to payments for milestones considered probable of being achieved</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Consideration Payment Received Upon Achievement Of Milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable consideration related to co-development billings</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Consideration Payment Received Related To Co Development Billings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="locator" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount rate applied</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Alternative Investment Measurement Input</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProvisionForCoDevelopmentServices" xlink:type="locator" xlink:label="fgen_ProvisionForCoDevelopmentServices" />
    <link:label xml:lang="en-US" xlink:label="fgen_ProvisionForCoDevelopmentServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Provision for co-development services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ProvisionForCoDevelopmentServices" xlink:to="fgen_ProvisionForCoDevelopmentServices_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CoDevelopmentServicesEstimatedContinuationYear" xlink:type="locator" xlink:label="fgen_CoDevelopmentServicesEstimatedContinuationYear" />
    <link:label xml:lang="en-US" xlink:label="fgen_CoDevelopmentServicesEstimatedContinuationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Co-development services, estimated continuation year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CoDevelopmentServicesEstimatedContinuationYear" xlink:to="fgen_CoDevelopmentServicesEstimatedContinuationYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_CoDevelopmentServicesEstimatedContinuationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Co-development services, currently estimated continuation year</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CoDevelopmentServicesEstimatedContinuationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Co Development Services Estimated Continuation Year</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProvisionForCoDevelopmentServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for co-development services</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ProvisionForCoDevelopmentServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Provision For Co Development Services</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_VariableConsiderationRelatedToProfitShare" xlink:type="locator" xlink:label="fgen_VariableConsiderationRelatedToProfitShare" />
    <link:label xml:lang="en-US" xlink:label="fgen_VariableConsiderationRelatedToProfitShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Variable consideration related to profit share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_VariableConsiderationRelatedToProfitShare" xlink:to="fgen_VariableConsiderationRelatedToProfitShare_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesAndRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesAndRestOfWorldAndChinaMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_UnitedStatesAndRestOfWorldAndChinaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">United states and rest of world and china.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_UnitedStatesAndRestOfWorldAndChinaMember" xlink:to="fgen_UnitedStatesAndRestOfWorldAndChinaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_UnitedStatesAndRestOfWorldAndChinaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S./RoW and China [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_UnitedStatesAndRestOfWorldAndChinaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">United States And Rest Of World And China [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_VariableConsiderationRelatedToProfitShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable consideration related to profit share</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_VariableConsiderationRelatedToProfitShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Consideration Related To Profit Share</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RoyaltyRateOnNetRevenue" xlink:type="locator" xlink:label="fgen_RoyaltyRateOnNetRevenue" />
    <link:label xml:lang="en-US" xlink:label="fgen_RoyaltyRateOnNetRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Implied royalty rate used to find the net present value of future cash flows.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RoyaltyRateOnNetRevenue" xlink:to="fgen_RoyaltyRateOnNetRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_RoyaltyRateOnNetRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty rate against projected net revenues</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RoyaltyRateOnNetRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Rate On Net Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition Multiple Deliverable Arrangements [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Multiple Deliverable Arrangements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DevelopmentAndOtherRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Development Revenue [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Multiple Deliverable Arrangements [Line Items]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CashConsiderationReceivedUnderCollaborationAgreement" xlink:type="locator" xlink:label="fgen_CashConsiderationReceivedUnderCollaborationAgreement" />
    <link:label xml:lang="en-US" xlink:label="fgen_CashConsiderationReceivedUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CashConsiderationReceivedUnderCollaborationAgreement" xlink:to="fgen_CashConsiderationReceivedUnderCollaborationAgreement_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" xlink:type="locator" xlink:label="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Co development information sharing and committee services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" xlink:to="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Co-development, information sharing &amp; committee services [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Co Development Information Sharing And Committee Services [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ChinaPerformanceObligationMember" xlink:type="locator" xlink:label="fgen_ChinaPerformanceObligationMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_ChinaPerformanceObligationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">China performance obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ChinaPerformanceObligationMember" xlink:to="fgen_ChinaPerformanceObligationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ChinaPerformanceObligationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">China performance obligation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ChinaPerformanceObligationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">China Performance Obligation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Revenue License And Development Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CashConsiderationReceivedUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CashConsiderationReceivedUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Consideration Received Under Collaboration Agreement</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" xlink:type="locator" xlink:label="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" />
    <link:label xml:lang="en-US" xlink:label="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Variable consideration payment received from estimated future co-development billing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" xlink:to="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in revenue due to prior period adjustment of performance obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price, variable consideration from estimated future co-development billing</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Consideration Payment Received From Estimated Future Co Development Billing</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_SuppliesNet" xlink:type="locator" xlink:label="fgen_SuppliesNet" />
    <link:label xml:lang="en-US" xlink:label="fgen_SuppliesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplies, net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_SuppliesNet" xlink:to="fgen_SuppliesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_SuppliesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net unbilled co-development revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_SuppliesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplies Net</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue gross from contract with customer excluding assessed tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" xlink:to="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Product [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PriceAdjustmentMember" xlink:type="locator" xlink:label="fgen_PriceAdjustmentMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_PriceAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Price adjustment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_PriceAdjustmentMember" xlink:to="fgen_PriceAdjustmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_PriceAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price Adjustment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PriceAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Price Adjustment [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_NonKeyAccountHospitalListingAwardMember" xlink:type="locator" xlink:label="fgen_NonKeyAccountHospitalListingAwardMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_NonKeyAccountHospitalListingAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-key account hospital listing award.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_NonKeyAccountHospitalListingAwardMember" xlink:to="fgen_NonKeyAccountHospitalListingAwardMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_NonKeyAccountHospitalListingAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-key Account Hospital Listing Award [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_NonKeyAccountHospitalListingAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Key Account Hospital Listing Award [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractualSalesRebateMember" xlink:type="locator" xlink:label="fgen_ContractualSalesRebateMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractualSalesRebateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual sales rebate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ContractualSalesRebateMember" xlink:to="fgen_ContractualSalesRebateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractualSalesRebateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual Sales Rebate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractualSalesRebateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Sales Rebate [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OtherDiscountsAndRebatesMember" xlink:type="locator" xlink:label="fgen_OtherDiscountsAndRebatesMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_OtherDiscountsAndRebatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other discounts and rebates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_OtherDiscountsAndRebatesMember" xlink:to="fgen_OtherDiscountsAndRebatesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_OtherDiscountsAndRebatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Discounts and Rebates [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_OtherDiscountsAndRebatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Discounts And Rebates [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:type="locator" xlink:label="us-gaap_SalesReturnsAndAllowancesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesReturnsAndAllowancesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Return [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesReturnsAndAllowancesMember" xlink:to="us-gaap_SalesReturnsAndAllowancesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesReturnsAndAllowancesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Returns And Allowances [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Gross From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RebatesAndDiscountsMember" xlink:type="locator" xlink:label="fgen_RebatesAndDiscountsMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_RebatesAndDiscountsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Rebates and discounts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RebatesAndDiscountsMember" xlink:to="fgen_RebatesAndDiscountsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_RebatesAndDiscountsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rebates and Discounts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RebatesAndDiscountsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Rebates And Discounts [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_GrossAccountsReceivableMember" xlink:type="locator" xlink:label="fgen_GrossAccountsReceivableMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_GrossAccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross accounts receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_GrossAccountsReceivableMember" xlink:to="fgen_GrossAccountsReceivableMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_GrossAccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Accounts Receivable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_GrossAccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gross Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractLiabilitiesMember" xlink:type="locator" xlink:label="fgen_ContractLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract liabilities,</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ContractLiabilitiesMember" xlink:to="fgen_ContractLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract Liabilities [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityAdditions" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityAdditions" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability additions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ContractWithCustomerLiabilityAdditions" xlink:to="fgen_ContractWithCustomerLiabilityAdditions_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityDeduction" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityDeduction" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityDeduction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability deduction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ContractWithCustomerLiabilityDeduction" xlink:to="fgen_ContractWithCustomerLiabilityDeduction_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer, liability, increase (decrease) from current translation and other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" xlink:to="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityGross" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityGross" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability gross.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ContractWithCustomerLiabilityGross" xlink:to="fgen_ContractWithCustomerLiabilityGross_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityNetOfAccountsReceivable" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityNetOfAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityNetOfAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability net of accounts receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ContractWithCustomerLiabilityNetOfAccountsReceivable" xlink:to="fgen_ContractWithCustomerLiabilityNetOfAccountsReceivable_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityLineItems" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityLineItems" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityLineItems_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityTable" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityTable" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract With Customer Liability [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ContractWithCustomerLiabilityTable" xlink:to="fgen_ContractWithCustomerLiabilityTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract With Customer Liability [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract with Customer Liability [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel">Balance at December 31, 2019</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Additions</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Additions</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityDeduction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deduction</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityDeduction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Deduction</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency Translation and Other</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Increase Decrease From Current Translation And Other</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Contract Liabilities Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityNetOfAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Presented Net Against Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ContractWithCustomerLiabilityNetOfAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Net Of Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel">Balance at December 31, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions to gross accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allowance For Doubtful Accounts Receivable</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Astellas agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AstellasAgreementMember" xlink:to="fgen_AstellasAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Astellas Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Astellas Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction [Domain]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_APIShipmentMember" xlink:type="locator" xlink:label="fgen_APIShipmentMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_APIShipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">API shipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_APIShipmentMember" xlink:to="fgen_APIShipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_APIShipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">API Shipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_APIShipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A P I Shipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Drug product revenue recognized</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EstimatedVariableConsiderationTransactionPrice" xlink:type="locator" xlink:label="fgen_EstimatedVariableConsiderationTransactionPrice" />
    <link:label xml:lang="en-US" xlink:label="fgen_EstimatedVariableConsiderationTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated variable consideration transaction price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_EstimatedVariableConsiderationTransactionPrice" xlink:to="fgen_EstimatedVariableConsiderationTransactionPrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_EstimatedVariableConsiderationTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated variable consideration transaction price</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EstimatedVariableConsiderationTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Variable Consideration Transaction Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract with Customer, Liability [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US treasury notes and bills [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BondAndMutualFundsMember" xlink:type="locator" xlink:label="fgen_BondAndMutualFundsMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_BondAndMutualFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bond and mutual funds.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_BondAndMutualFundsMember" xlink:to="fgen_BondAndMutualFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_BondAndMutualFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bond and mutual funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_BondAndMutualFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bond And Mutual Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity investments [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesMember" xlink:to="us-gaap_EquitySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certificate of deposit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Certificates Of Deposit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets fair value disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of assets from level 1 to 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level2 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of assets from level 2 to 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level1 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of assets into level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of assets out of level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Liability Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LeaseObligationsMember" xlink:type="locator" xlink:label="fgen_LeaseObligationsMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_LeaseObligationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease obligations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_LeaseObligationsMember" xlink:to="fgen_LeaseObligationsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_LeaseObligationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease obligations [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LeaseObligationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Obligations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities fair value disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of liabilities from level 1 to 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level1 To Level2 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of liabilities from level 2 to 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level2 To Level1 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of liabilities into level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of liabilities out of level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_NumberOfFinanceLeases" xlink:type="locator" xlink:label="fgen_NumberOfFinanceLeases" />
    <link:label xml:lang="en-US" xlink:label="fgen_NumberOfFinanceLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of finance leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_NumberOfFinanceLeases" xlink:to="fgen_NumberOfFinanceLeases_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BuildingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Building [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BuildingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Building [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ShorensteinPropertiesLLCMember" xlink:type="locator" xlink:label="fgen_ShorensteinPropertiesLLCMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_ShorensteinPropertiesLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shorenstein properties LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ShorensteinPropertiesLLCMember" xlink:to="fgen_ShorensteinPropertiesLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ShorensteinPropertiesLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shorenstein Properties LLC [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ShorensteinPropertiesLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shorenstein Properties L L C [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" xlink:type="locator" xlink:label="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Beijing economic-technological development area.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" xlink:to="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beijing Economic-Technological Development Area [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Beijing Economic Technological Development Area [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OfficeSpacesMember" xlink:type="locator" xlink:label="fgen_OfficeSpacesMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_OfficeSpacesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office spaces.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_OfficeSpacesMember" xlink:to="fgen_OfficeSpacesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_OfficeSpacesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Spaces [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_OfficeSpacesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Spaces [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_NumberOfFinanceLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of finance leases</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_NumberOfFinanceLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Finance Leases</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LesseeFinanceLeaseExpirationPeriod" xlink:type="locator" xlink:label="fgen_LesseeFinanceLeaseExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeFinanceLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, finance lease, expiration period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_LesseeFinanceLeaseExpirationPeriod" xlink:to="fgen_LesseeFinanceLeaseExpirationPeriod_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" xlink:type="locator" xlink:label="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" />
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, finance lease, option to extend the additional lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" xlink:to="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" xlink:type="locator" xlink:label="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, finance lease, additional lease expiration period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" xlink:to="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" xlink:type="locator" xlink:label="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage increases on each anniversary of rent commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" xlink:to="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, finance lease, initial lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Finance Lease Term Of Contract1</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeFinanceLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, finance lease, expiration period</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeFinanceLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Finance Lease Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, finance lease, option to extend the additional lease term</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Finance Lease Option To Extend Additional Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, finance lease, additional lease expiration period</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Finance Lease Additional Lease Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage increases on each anniversary of rent commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Increases On Each Anniversary Of Rent Commencement Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, finance lease, existence of option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Finance Lease Existence Of Option To Extend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeFinanceLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, finance lease, option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseOptionToExtend" xlink:to="us-gaap_LesseeFinanceLeaseOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeFinanceLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Finance Lease Option To Extend</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_NumberOfOperatingLeases" xlink:type="locator" xlink:label="fgen_NumberOfOperatingLeases" />
    <link:label xml:lang="en-US" xlink:label="fgen_NumberOfOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of operating leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_NumberOfOperatingLeases" xlink:to="fgen_NumberOfOperatingLeases_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LesseeOperatingLeaseExpirationPeriod" xlink:type="locator" xlink:label="fgen_LesseeOperatingLeaseExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeOperatingLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, expiration period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_LesseeOperatingLeaseExpirationPeriod" xlink:to="fgen_LesseeOperatingLeaseExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_NumberOfOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating leases</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_NumberOfOperatingLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Leases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeOperatingLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, expiration period</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LesseeOperatingLeaseExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Expiration Period</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FinanceLeaseRightOfUseAssetsCost" xlink:type="locator" xlink:label="fgen_FinanceLeaseRightOfUseAssetsCost" />
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseRightOfUseAssetsCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease, right-of-use assets - cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_FinanceLeaseRightOfUseAssetsCost" xlink:to="fgen_FinanceLeaseRightOfUseAssetsCost_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FinanceLeaseAccumulatedAmortization" xlink:type="locator" xlink:label="fgen_FinanceLeaseAccumulatedAmortization" />
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease accumulated amortization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_FinanceLeaseAccumulatedAmortization" xlink:to="fgen_FinanceLeaseAccumulatedAmortization_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OperatingLeaseRightOfUseAssetsCost" xlink:type="locator" xlink:label="fgen_OperatingLeaseRightOfUseAssetsCost" />
    <link:label xml:lang="en-US" xlink:label="fgen_OperatingLeaseRightOfUseAssetsCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease, right-of-use assets - cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_OperatingLeaseRightOfUseAssetsCost" xlink:to="fgen_OperatingLeaseRightOfUseAssetsCost_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OperatingLeaseAccumulatedAmortization" xlink:type="locator" xlink:label="fgen_OperatingLeaseAccumulatedAmortization" />
    <link:label xml:lang="en-US" xlink:label="fgen_OperatingLeaseAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease, accumulated amortization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_OperatingLeaseAccumulatedAmortization" xlink:to="fgen_OperatingLeaseAccumulatedAmortization_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FinanceLeaseAndOperatingLeaseAssets" xlink:type="locator" xlink:label="fgen_FinanceLeaseAndOperatingLeaseAssets" />
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseAndOperatingLeaseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease and operating lease assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_FinanceLeaseAndOperatingLeaseAssets" xlink:to="fgen_FinanceLeaseAndOperatingLeaseAssets_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FinanceLeaseAndOperatingLeaseLiability" xlink:type="locator" xlink:label="fgen_FinanceLeaseAndOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseAndOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance lease and operating lease liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_FinanceLeaseAndOperatingLeaseLiability" xlink:to="fgen_FinanceLeaseAndOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseRightOfUseAssetsCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets - cost</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseRightOfUseAssetsCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Right Of Use Assets Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance lease right-of-use assets, net</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_OperatingLeaseRightOfUseAssetsCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets - cost</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_OperatingLeaseRightOfUseAssetsCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Assets Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_OperatingLeaseAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_OperatingLeaseAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating lease right-of-use assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseAndOperatingLeaseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease assets</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseAndOperatingLeaseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease And Operating Lease Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Finance lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current Statement Of Financial Position Extensible List</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Finance lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseAndOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FinanceLeaseAndOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease And Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease cost:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization of right-of-use assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest on lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Sublease income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for amounts included in the measurement of lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="fgen_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="fgen_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets obtained in exchange for new lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" xlink:to="fgen_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows from operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows from finance leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Interest Payment On Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RepaymentsOfFinanceLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing cash flows from finance leases</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for new lease liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Assets Obtained In Exchange For New Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Finance Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_WeightedAverageRemainingLeaseTermAbstract" xlink:type="locator" xlink:label="fgen_WeightedAverageRemainingLeaseTermAbstract" />
    <link:label xml:lang="en-US" xlink:label="fgen_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted-average remaining lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_WeightedAverageRemainingLeaseTermAbstract" xlink:to="fgen_WeightedAverageRemainingLeaseTermAbstract_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_WeightedAverageDiscountRateAbstract" xlink:type="locator" xlink:label="fgen_WeightedAverageDiscountRateAbstract" />
    <link:label xml:lang="en-US" xlink:label="fgen_WeightedAverageDiscountRateAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted-average discount rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_WeightedAverageDiscountRateAbstract" xlink:to="fgen_WeightedAverageDiscountRateAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (years):</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_WeightedAverageDiscountRateAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate:</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_WeightedAverageDiscountRateAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Discount Rate [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liabilities Payments Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:type="locator" xlink:label="us-gaap_Cash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Cash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Cash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S. treasury notes and bills [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Holding Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Holding Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear" xlink:type="locator" xlink:label="fgen_AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear" />
    <link:label xml:lang="en-US" xlink:label="fgen_AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities bond and mutual funds maturing within one year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear" xlink:to="fgen_AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Within one year - Bond and mutual funds</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Bond And Mutual Funds Maturing Within One Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Equity Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfInvestmentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other-than-temporary impairment loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Than Temporary Impairment Losses Investments Availableforsale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Raw Materials</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work-in-progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Work In Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Finished Goods</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total inventories</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" xlink:type="locator" xlink:label="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" />
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of pre-launch inventory capitalized of aggregate inventory balance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" xlink:to="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of pre-launch inventory capitalized of aggregate inventory balance</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Pre Launch Inventory Capitalized Of Aggregate Inventory Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Supplies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unbilled contract assets</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred revenues from associated contracts</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_SuppliesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net unbilled contract assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_NumberOfRegulatoryMilestones" xlink:type="locator" xlink:label="fgen_NumberOfRegulatoryMilestones" />
    <link:label xml:lang="en-US" xlink:label="fgen_NumberOfRegulatoryMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of regulatory milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_NumberOfRegulatoryMilestones" xlink:to="fgen_NumberOfRegulatoryMilestones_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_NumberOfRegulatoryMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of regulatory milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_NumberOfRegulatoryMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Regulatory Milestones</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in progress [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedPreclinicalAndClinicalTrialCurrent" xlink:type="locator" xlink:label="fgen_AccruedPreclinicalAndClinicalTrialCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedPreclinicalAndClinicalTrialCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to pre-clinical and clinical trial activities, including those performed by third parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccruedPreclinicalAndClinicalTrialCurrent" xlink:to="fgen_AccruedPreclinicalAndClinicalTrialCurrent_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" xlink:type="locator" xlink:label="fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued active pharmaceutical ingredient product price adjustment current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" xlink:to="fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" xlink:type="locator" xlink:label="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued contract liabilities to pharmaceutical distributors current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" xlink:to="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedCoPromotionExpensesCurrent" xlink:type="locator" xlink:label="fgen_AccruedCoPromotionExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedCoPromotionExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued co-promotion expenses - current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccruedCoPromotionExpensesCurrent" xlink:to="fgen_AccruedCoPromotionExpensesCurrent_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedProfitShareCurrent" xlink:type="locator" xlink:label="fgen_AccruedProfitShareCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedProfitShareCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued profit share current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccruedProfitShareCurrent" xlink:to="fgen_AccruedProfitShareCurrent_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PropertyTaxesAndOtherCurrent" xlink:type="locator" xlink:label="fgen_PropertyTaxesAndOtherCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_PropertyTaxesAndOtherCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property taxes and other current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_PropertyTaxesAndOtherCurrent" xlink:to="fgen_PropertyTaxesAndOtherCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedPreclinicalAndClinicalTrialCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preclinical and clinical trial accruals</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedPreclinicalAndClinicalTrialCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Preclinical And Clinical Trial Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">API product price adjustment</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Active Pharmaceutical Ingredient Product Price Adjustment Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and related accruals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities to pharmaceutical distributors</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Contract Liabilities To Pharmaceutical Distributors Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedCoPromotionExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued co-promotion expenses - current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedCoPromotionExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Co Promotion Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedProfitShareCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Roxadustat profit share to AstraZeneca</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedProfitShareCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Profit Share Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PropertyTaxesAndOtherCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property taxes and other</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PropertyTaxesAndOtherCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Taxes And Other Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">API product price change in estimated variable consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Profit share liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax And Other Liabilities Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities, non-current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:to="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Sundry Liabilities Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other long-term liabilities</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent" xlink:type="locator" xlink:label="fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued long-term co-promotional liability non current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent" xlink:to="fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses" xlink:type="locator" xlink:label="fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses" />
    <link:label xml:lang="en-US" xlink:label="fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reversal of previously accrued long term co promotion expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses" xlink:to="fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued long-term co-promotional expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Long Term Co Promotional Liability Non Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reversal of previously accrued long-term co-promotion expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reversal Of Previously Accrued Long Term Co Promotion Expenses</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_NumberOfProductDevelopmentObligations" xlink:type="locator" xlink:label="fgen_NumberOfProductDevelopmentObligations" />
    <link:label xml:lang="en-US" xlink:label="fgen_NumberOfProductDevelopmentObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of product development obligations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_NumberOfProductDevelopmentObligations" xlink:to="fgen_NumberOfProductDevelopmentObligations_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BankOfFinlandInterestRateMember" xlink:type="locator" xlink:label="fgen_BankOfFinlandInterestRateMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_BankOfFinlandInterestRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bank of Finland interest rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_BankOfFinlandInterestRateMember" xlink:to="fgen_BankOfFinlandInterestRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_BankOfFinlandInterestRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bank of Finland Interest Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_BankOfFinlandInterestRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bank Of Finland Interest Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_NumberOfProductDevelopmentObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of product development obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_NumberOfProductDevelopmentObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Product Development Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:type="locator" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage points deducted to reference rate to compute effective interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:to="us-gaap_LoansReceivableBasisSpreadOnVariableRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loans Receivable Basis Spread On Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate on product development advances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedProductDevelopmentCostsExcludingInterest" xlink:type="locator" xlink:label="fgen_AccruedProductDevelopmentCostsExcludingInterest" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedProductDevelopmentCostsExcludingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Product Development Costs Excluding Interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AccruedProductDevelopmentCostsExcludingInterest" xlink:to="fgen_AccruedProductDevelopmentCostsExcludingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedProductDevelopmentCostsExcludingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued product development costs excluding interest</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AccruedProductDevelopmentCostsExcludingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Product Development Costs Excluding Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable Current And Noncurrent</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="fgen_CommitmentsAndContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="fgen_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CommitmentsAndContingenciesLineItems" xlink:to="fgen_CommitmentsAndContingenciesLineItems_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="fgen_CommitmentsAndContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="fgen_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CommitmentsAndContingenciesTable" xlink:to="fgen_CommitmentsAndContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Category of Item Purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Purchase Commitment By Category Of Item Purchased [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Purchase Commitment, Category of Item Purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Purchase Commitment Category Of Item Purchased [Domain]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" xlink:type="locator" xlink:label="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and pre-clinical stage development programs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" xlink:to="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Pre-Clinical Stage Development Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Pre Clinical Stage Development Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding non-cancelable contract obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract" xlink:type="locator" xlink:label="us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unconditional Purchase Obligations Excluding Capital Stock Redemptions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract" xlink:to="us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recorded Unconditional Purchase Obligation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recorded Unconditional Purchase Obligation [Table]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ManufactureAndSupplyOfRoxadustatMember" xlink:type="locator" xlink:label="fgen_ManufactureAndSupplyOfRoxadustatMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_ManufactureAndSupplyOfRoxadustatMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacture and Supply of Roxadustat.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ManufactureAndSupplyOfRoxadustatMember" xlink:to="fgen_ManufactureAndSupplyOfRoxadustatMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ManufactureAndSupplyOfRoxadustatMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacture and Supply of Roxadustat [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ManufactureAndSupplyOfRoxadustatMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacture And Supply Of Roxadustat [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ManufactureAndSupplyOfPamrevlumabMember" xlink:type="locator" xlink:label="fgen_ManufactureAndSupplyOfPamrevlumabMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_ManufactureAndSupplyOfPamrevlumabMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacture and supply of pamrevlumab.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ManufactureAndSupplyOfPamrevlumabMember" xlink:to="fgen_ManufactureAndSupplyOfPamrevlumabMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ManufactureAndSupplyOfPamrevlumabMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacture and Supply of Pamrevlumab [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ManufactureAndSupplyOfPamrevlumabMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacture And Supply Of Pamrevlumab [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OtherPurchasesMember" xlink:type="locator" xlink:label="fgen_OtherPurchasesMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_OtherPurchasesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Purchases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_OtherPurchasesMember" xlink:to="fgen_OtherPurchasesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_OtherPurchasesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Purchases [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_OtherPurchasesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Purchases [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recorded Unconditional Purchase Obligation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recorded Unconditional Purchase Obligation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase obligations due 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recorded Unconditional Purchase Obligation Due Within One Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase obligations due 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recorded Unconditional Purchase Obligation Due In Second Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligation" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total purchase obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligation" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recorded Unconditional Purchase Obligation</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_MaximumFutureMilestonePayments" xlink:type="locator" xlink:label="fgen_MaximumFutureMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="fgen_MaximumFutureMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum future milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_MaximumFutureMilestonePayments" xlink:to="fgen_MaximumFutureMilestonePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_MaximumFutureMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum future milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_MaximumFutureMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Future Milestone Payments</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:type="locator" xlink:label="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" />
    <link:label xml:lang="en-US" xlink:label="fgen_ShareholdersEquityAndStockBasedCompensationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shareholders equity and stock-based compensation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:to="fgen_ShareholdersEquityAndStockBasedCompensationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ShareholdersEquityAndStockBasedCompensationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders Equity And Stock Based Compensation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FibrogenEuropeOyMember" xlink:type="locator" xlink:label="fgen_FibrogenEuropeOyMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_FibrogenEuropeOyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fibro Gen Europe Oy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_FibrogenEuropeOyMember" xlink:to="fgen_FibrogenEuropeOyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_FibrogenEuropeOyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FibroGen Europe [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FibrogenEuropeOyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fibrogen Europe Oy [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series D Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesEPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series E [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesEPreferredStockMember" xlink:to="us-gaap_SeriesEPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series E Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesFPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesFPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series F [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesFPreferredStockMember" xlink:to="us-gaap_SeriesFPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesFPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series F Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesGPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesGPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series G [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesGPreferredStockMember" xlink:to="us-gaap_SeriesGPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesGPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series G Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesHPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesHPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series H [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesHPreferredStockMember" xlink:to="us-gaap_SeriesHPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesHPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series H Preferred Stock [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FibroGenCaymanMember" xlink:type="locator" xlink:label="fgen_FibroGenCaymanMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_FibroGenCaymanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">FibroGen Cayman.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_FibroGenCaymanMember" xlink:to="fgen_FibroGenCaymanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_FibroGenCaymanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FibroGen Cayman [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FibroGenCaymanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fibro Gen Cayman [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares" xlink:type="locator" xlink:label="fgen_RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares" />
    <link:label xml:lang="en-US" xlink:label="fgen_RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Required minimum shareholder percentage to call for redemption of preferred shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares" xlink:to="fgen_RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionTerms" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockRedemptionTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock redemption percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionTerms" xlink:to="us-gaap_PreferredStockRedemptionTerms_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockRedemptionTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Redemption Terms</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of shareholder&apos;s approval to call for redemption of preferred shares</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Required Minimum Shareholder Percentage To Call For Redemption Of Preferred Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:type="locator" xlink:label="us-gaap_PreferredStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, voting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Voting Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion rights, shares issued upon conversion of each preferred share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PreferredSharesIssuedPricePerShare" xlink:type="locator" xlink:label="fgen_PreferredSharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="fgen_PreferredSharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred shares issued, price per share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_PreferredSharesIssuedPricePerShare" xlink:to="fgen_PreferredSharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_PreferredSharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred shares issued, price per share</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_PreferredSharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Shares Issued Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash dividend percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividend Rate Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CommonStockSharesReserved" xlink:type="locator" xlink:label="fgen_CommonStockSharesReserved" />
    <link:label xml:lang="en-US" xlink:label="fgen_CommonStockSharesReserved_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock shares reserved.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_CommonStockSharesReserved" xlink:to="fgen_CommonStockSharesReserved_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved for future stock options and RSUs grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved for future ESPP offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CommonStockSharesReserved_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shares of common stock reserved</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_CommonStockSharesReserved_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Reserved</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_TwoThousandAndFiveStockPlanMember" xlink:type="locator" xlink:label="fgen_TwoThousandAndFiveStockPlanMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_TwoThousandAndFiveStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and five stock plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_TwoThousandAndFiveStockPlanMember" xlink:to="fgen_TwoThousandAndFiveStockPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_TwoThousandAndFiveStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2005 Stock Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_TwoThousandAndFiveStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Five Stock Plan [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="fgen_TwoThousandAndFourteenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_TwoThousandAndFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and fourteen equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:to="fgen_TwoThousandAndFourteenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_TwoThousandAndFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_TwoThousandAndFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Fourteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration period of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination date of equity incentive plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Expiration Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option vesting term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fair value exercise price grant date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of vesting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common stock reserved for issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance, Description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common stock reserved for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock repurchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period Shares</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear" xlink:type="locator" xlink:label="fgen_StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear" />
    <link:label xml:lang="en-US" xlink:label="fgen_StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares stock options exercised full year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear" xlink:to="fgen_StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, Beginning Balance, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised Full Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Expired, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, Ending Balance, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, Beginning Balance, Weighted Average Exercise per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Weighted Average Exercise per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised, Weighted Average Exercise per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expired, Weighted Average Exercise per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited, Weighted Average Exercise per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, Ending Balance, Weighted Average Exercise per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Weighted Average Exercise per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Weighted Average Exercise per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, Weighted Average Remaining Contractual Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Weighted Average Remaining Contractual Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Weighted Average Remaining Contractual Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total intrinsic value of options exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Unit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested, Shares, Beginning Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested, Shares, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested, Fair value at Grant, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Fair value at Grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested, Fair value at Grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited, Fair value at Grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested, Fair value at Grant, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="locator" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs released and issued net of shares withheld for taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Shares Issued Net Of Shares For Tax Withholdings</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average fair value of awards granted</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="fgen_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and fourteen employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:to="fgen_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 ESPP [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Fourteen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock shares at discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Purchase Date</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of fair value exercise price grant date</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of common stock reserved for future issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in number of shares of common stock reserved for future issuance, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares purchased by employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Compensation Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average estimated fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_StockOptionAwardsMember" xlink:type="locator" xlink:label="fgen_StockOptionAwardsMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_StockOptionAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock option awards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_StockOptionAwardsMember" xlink:to="fgen_StockOptionAwardsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_StockOptionAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_StockOptionAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option Awards [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-vested stock option awards granted that will be recognized on a straight-line basis over the weighted-average period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod" xlink:type="locator" xlink:label="fgen_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod" />
    <link:label xml:lang="en-US" xlink:label="fgen_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right number of warrants or rights exercised during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod" xlink:to="fgen_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase common stock exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Warrants Or Rights Exercised During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants to purchase common stock outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">RSUs [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities excluded from computation of net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, maximum annual contributions per employee, percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Maximum Annual Contributions Per Employee Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer matching contributions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Cost Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Income Tax Expense Benefit Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal State And Local Tax Expense Benefit [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current State And Local Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal State And Local Tax Expense Benefit [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State And Local Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total provision for income taxes</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation deduction expense share based compensation cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost" xlink:to="fgen_EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets" xlink:type="locator" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets" />
    <link:label xml:lang="en-US" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation benefit on intercompany transfer of assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets" xlink:to="fgen_EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets" xlink:type="locator" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets" />
    <link:label xml:lang="en-US" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation valuation allowance on intercompany transfer of assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets" xlink:to="fgen_EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted" xlink:type="locator" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted" />
    <link:label xml:lang="en-US" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation net operating losses not benefitted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted" xlink:to="fgen_EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax at statutory federal rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Deduction Expense Share Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Benefit due to intercompany transfer of assets</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Benefit On Intercompany Transfer Of Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance on intercompany transfer of assets</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Valuation Allowance On Intercompany Transfer Of Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses not benefitted</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Net Operating Losses Not Benefitted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign net operating losses not benefitted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deduction limitation on executive compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Deductions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DeferredTaxAssetsIntangibleAssets" xlink:type="locator" xlink:label="fgen_DeferredTaxAssetsIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="fgen_DeferredTaxAssetsIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets intangible assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DeferredTaxAssetsIntangibleAssets" xlink:to="fgen_DeferredTaxAssetsIntangibleAssets_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DeferredTaxLiabilitiesFixedAssets" xlink:type="locator" xlink:label="fgen_DeferredTaxLiabilitiesFixedAssets" />
    <link:label xml:lang="en-US" xlink:label="fgen_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities fixed assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DeferredTaxLiabilitiesFixedAssets" xlink:to="fgen_DeferredTaxLiabilitiesFixedAssets_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Assets And Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserves and accruals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DeferredTaxAssetsIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DeferredTaxAssetsIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Subtotal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Fixed Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_IncomeTaxesLineItems" xlink:type="locator" xlink:label="fgen_IncomeTaxesLineItems" />
    <link:label xml:lang="en-US" xlink:label="fgen_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes line items.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="fgen_IncomeTaxesLineItems_lbl" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_IncomeTaxesTable" xlink:type="locator" xlink:label="fgen_IncomeTaxesTable" />
    <link:label xml:lang="en-US" xlink:label="fgen_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_IncomeTaxesTable" xlink:to="fgen_IncomeTaxesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign net operating loss [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earliest Tax Year [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earliest Tax Year [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Latest Tax Year [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Latest Tax Year [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax asset for temporary difference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory" xlink:to="us-gaap_DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset Intra Entity Transfer Asset Other Than Inventory</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="fgen_OperatingLossCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="fgen_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_OperatingLossCarryforwardsExpirationYear" xlink:to="fgen_OperatingLossCarryforwardsExpirationYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OtherTaxCreditCarryforwardsExpirationYear" xlink:type="locator" xlink:label="fgen_OtherTaxCreditCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="fgen_OtherTaxCreditCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other tax credit carryforwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_OtherTaxCreditCarryforwardsExpirationYear" xlink:to="fgen_OtherTaxCreditCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Other</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_OtherTaxCreditCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other tax credit carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_OtherTaxCreditCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Tax Credit Carryforwards Expiration Year</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ExperienceHistoricalOwnershipChanges" xlink:type="locator" xlink:label="fgen_ExperienceHistoricalOwnershipChanges" />
    <link:label xml:lang="en-US" xlink:label="fgen_ExperienceHistoricalOwnershipChanges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Experience historical ownership changes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ExperienceHistoricalOwnershipChanges" xlink:to="fgen_ExperienceHistoricalOwnershipChanges_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ExperienceHistoricalOwnershipChanges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of ownership changes</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ExperienceHistoricalOwnershipChanges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Experience Historical Ownership Changes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest, unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Interest On Income Taxes Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits that would affect effective tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits That Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Contingency [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FederalAndStateMember" xlink:type="locator" xlink:label="fgen_FederalAndStateMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_FederalAndStateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal and state.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_FederalAndStateMember" xlink:to="fgen_FederalAndStateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_FederalAndStateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and State [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FederalAndStateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal And State [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Contingency [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase due to prior positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease due to prior positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase due to current year position</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible" xlink:type="locator" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Estimated Range Not Possible</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign statute of limitation generally remains open in the year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LicenseAndDevelopmentMember" xlink:type="locator" xlink:label="fgen_LicenseAndDevelopmentMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_LicenseAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_LicenseAndDevelopmentMember" xlink:to="fgen_LicenseAndDevelopmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_LicenseAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_LicenseAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Development [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasMember" xlink:type="locator" xlink:label="fgen_AstellasMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Astellas.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AstellasMember" xlink:to="fgen_AstellasMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Astellas [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Astellas [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FalikangMember" xlink:type="locator" xlink:label="fgen_FalikangMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_FalikangMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Falikang.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_FalikangMember" xlink:to="fgen_FalikangMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_FalikangMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Falikang [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_FalikangMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Falikang [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_RevenueFromRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and development revenue related to collaboration agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Related Parties</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenueFromRelatedParty" xlink:type="locator" xlink:label="fgen_DrugProductRevenueFromRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="fgen_DrugProductRevenueFromRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Drug product revenue from related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DrugProductRevenueFromRelatedParty" xlink:to="fgen_DrugProductRevenueFromRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DrugProductRevenueFromRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Drug product revenue from a related party</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_DrugProductRevenueFromRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Drug Product Revenue From Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense related to collaboration agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_SuppliesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unbilled contract asset</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued liabilities and accounts payable to related party</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_MiscellaneousReceivables" xlink:type="locator" xlink:label="fgen_MiscellaneousReceivables" />
    <link:label xml:lang="en-US" xlink:label="fgen_MiscellaneousReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Miscellaneous receivables.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_MiscellaneousReceivables" xlink:to="fgen_MiscellaneousReceivables_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Net</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method investments</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_MiscellaneousReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Miscellaneous receivables</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_MiscellaneousReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Miscellaneous Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Revenue Net [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure Of Entitys Reportable Segments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Segment Reporting Information By Segment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Segment Reporting Information By Segment [Table]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AllOtherMember" xlink:type="locator" xlink:label="fgen_AllOtherMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_AllOtherMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">All other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_AllOtherMember" xlink:to="fgen_AllOtherMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_AllOtherMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">All other [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AllOtherMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">All Other [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting Information [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Revenues From External Customers And Long Lived Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Revenues From External Customers And Long Lived Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues From External Customers And Long Lived Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues From External Customers And Long Lived Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total finance lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating lease right-of-use assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Entity Wide Revenue By Major Customers By Reporting Segments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Entity Wide Revenue By Major Customers By Reporting Segments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of Accounts Receivable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AstellasCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Astellas-Related party [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_AstraZenecaAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">AstraZeneca [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="locator" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Wide Revenue Major Customer [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Wide Revenue Major Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="locator" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation And Qualifying Accounts Disclosure [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation And Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Allowances for Deferred Tax Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Of Deferred Tax Assets [Member]</link:label>
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ValuationAllowanceForRebatesAndDiscountsMember" xlink:type="locator" xlink:label="fgen_ValuationAllowanceForRebatesAndDiscountsMember" />
    <link:label xml:lang="en-US" xlink:label="fgen_ValuationAllowanceForRebatesAndDiscountsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Valuation allowance for rebates and discounts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_ValuationAllowanceForRebatesAndDiscountsMember" xlink:to="fgen_ValuationAllowanceForRebatesAndDiscountsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_ValuationAllowanceForRebatesAndDiscountsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Allowance for Rebates and Discounts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fgen_ValuationAllowanceForRebatesAndDiscountsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance For Rebates And Discounts [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="locator" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation And Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation And Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at Beginning of Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowances And Reserves Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Charged (Credited) to Statement of Operation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowances And Reserves Charged To Cost And Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Charged to Other Accounts - Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowances And Reserves Charged To Other Accounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deductions, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowances And Reserves Deductions</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at End of Year</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>28
<FILENAME>fgen-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-01T20:53:06.3627208+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : c4cc8ad73bdd4a268962242d24ba2619 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/role/TemplateLink" xlink:href="fgen-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="fgen-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="fgen-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedProductDevelopmentCosts" xlink:type="locator" xlink:label="fgen_AccruedProductDevelopmentCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RestrictedTimeDepositsNoncurrent" xlink:type="locator" xlink:label="fgen_RestrictedTimeDepositsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="fgen_RestrictedTimeDepositsNoncurrent" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="fgen_AccruedProductDevelopmentCosts" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_PreferredStockValue" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_CommonStockValue" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquity" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_MinorityInterest" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="fgen-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DueToRelatedPartiesDeferredRevenueNoncurrent" xlink:type="locator" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueNoncurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DueToRelatedPartiesDeferredRevenueCurrent" xlink:type="locator" xlink:label="fgen_DueToRelatedPartiesDeferredRevenueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="fgen_DueToRelatedPartiesDeferredRevenueCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="fgen_DueToRelatedPartiesDeferredRevenueNoncurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="fgen-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnconsolidatedVariableInterestEntityInvestmentLoss" xlink:type="locator" xlink:label="fgen_UnconsolidatedVariableInterestEntityInvestmentLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_InterestAndOtherNetAbstract" xlink:type="locator" xlink:label="fgen_InterestAndOtherNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CostOfGoodsAndServicesSoldOperatingExpense" xlink:type="locator" xlink:label="fgen_CostOfGoodsAndServicesSoldOperatingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DevelopmentAndOtherRevenueMember" xlink:type="locator" xlink:label="fgen_DevelopmentAndOtherRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DevelopmentAndOtherRevenueMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="fgen_CostOfGoodsAndServicesSoldOperatingExpense" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_TypeOfCostGoodOrServiceExtensibleList" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_InterestAndOtherNetAbstract" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_InterestAndOtherNetAbstract" xlink:to="us-gaap_InterestExpense" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_InterestAndOtherNetAbstract" xlink:to="fgen_UnconsolidatedVariableInterestEntityInvestmentLoss" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_InterestAndOtherNetAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_InterestAndOtherNetAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical" xlink:href="fgen-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProductRevenue" xlink:type="locator" xlink:label="fgen_ProductRevenue" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CollaborationServicesAndOtherRevenue" xlink:type="locator" xlink:label="fgen_CollaborationServicesAndOtherRevenue" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LicenseFeesAndMilestonesRevenue" xlink:type="locator" xlink:label="fgen_LicenseFeesAndMilestonesRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_LicenseFeesAndMilestonesRevenue" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_CollaborationServicesAndOtherRevenue" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_ProductRevenue" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="fgen-20201231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="fgen-20201231.xsd#Role_StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_WarrantExercisedDuringPeriodShares" xlink:type="locator" xlink:label="fgen_WarrantExercisedDuringPeriodShares" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_WarrantsExercisedDuringPeriodValue" xlink:type="locator" xlink:label="fgen_WarrantsExercisedDuringPeriodValue" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" xlink:type="locator" xlink:label="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" xlink:type="locator" xlink:label="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201601Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201802Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201802Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201802Member" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201601Member" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_WarrantsExercisedDuringPeriodValue" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_WarrantExercisedDuringPeriodShares" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_li0l2" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="fgen-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAssumed1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RepaymentsOfFinanceLeaseLiabilities" xlink:type="locator" xlink:label="fgen_RepaymentsOfFinanceLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLongTermCapitalLeaseObligations" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLongTermCapitalLeaseObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit" xlink:type="locator" xlink:label="fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_IncreaseDecreaseInLeaseObligations" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInLeaseObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" xlink:type="locator" xlink:label="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnrealizedLossGainOnEquityInvestments" xlink:type="locator" xlink:label="fgen_UnrealizedLossGainOnEquityInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="fgen_UnrealizedLossGainOnEquityInvestments" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="fgen_InvestmentLossInUnconsolidatedVariableInterestEntity" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="fgen_IncreaseDecreaseInLeaseObligations" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="fgen_ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity" order="12240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="12600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLongTermCapitalLeaseObligations" order="12720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="12780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="fgen_RepaymentsOfFinanceLeaseLiabilities" order="12840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" order="12900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="12960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="13020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="13080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="13140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="13200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="13260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="13320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="13380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="13500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="13560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_LiabilitiesAssumed1" order="13620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="fgen-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_IncreaseDecreaseInAccountsPayableFromRelatedParty" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInAccountsPayableFromRelatedParty" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties" xlink:type="locator" xlink:label="fgen_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="fgen_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="fgen_IncreaseDecreaseInAccountsPayableFromRelatedParty" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureTheCompany" xlink:href="fgen-20201231.xsd#Role_DisclosureTheCompany" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureTheCompany">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="fgen-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntity" xlink:href="fgen-20201231.xsd#Role_DisclosureAcquisitionAndVariableInterestEntity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntity">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquisitionAndVariableInterestEntityTextBlock" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:to="fgen_AcquisitionAndVariableInterestEntityTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenues" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenues" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenues">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="fgen-20201231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeases" xlink:href="fgen-20201231.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligations" xlink:href="fgen-20201231.xsd#Role_DisclosureProductDevelopmentObligations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligations">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProductDevelopmentObligationsDisclosureTextBlock" xlink:type="locator" xlink:label="fgen_ProductDevelopmentObligationsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="fgen_ProductDevelopmentObligationsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="fgen-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensation" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="fgen-20201231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShare">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFibrogenInc401KPlan" xlink:href="fgen-20201231.xsd#Role_DisclosureFibrogenInc401KPlan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFibrogenInc401KPlan">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="fgen-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="fgen-20201231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformation" xlink:href="fgen-20201231.xsd#Role_DisclosureSegmentAndGeographicInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccounts" xlink:href="fgen-20201231.xsd#Role_DisclosureScheduleIIValuationAndQualifyingAccounts" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccounts">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="locator" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:type="locator" xlink:label="srt_ValuationAndQualifyingAccountsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsAbstract" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="fgen-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OtherRevenuesPolicyTextBlock" xlink:type="locator" xlink:label="fgen_OtherRevenuesPolicyTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenuePolicyTextBlock" xlink:type="locator" xlink:label="fgen_DrugProductRevenuePolicyTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProductRevenuePolicyPolicyTextBlock" xlink:type="locator" xlink:label="fgen_ProductRevenuePolicyPolicyTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock" xlink:type="locator" xlink:label="fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock" xlink:type="locator" xlink:label="fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ClinicalTrialAccrualPolicyTextBlock" xlink:type="locator" xlink:label="fgen_ClinicalTrialAccrualPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="fgen_CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:type="locator" xlink:label="fgen_OtherRisksAndUncertaintiesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="locator" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_OtherRisksAndUncertaintiesPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_ClinicalTrialAccrualPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_ProductRevenuePolicyPolicyTextBlock" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_DrugProductRevenuePolicyTextBlock" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_OtherRevenuesPolicyTextBlock" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="fgen-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityTables" xlink:href="fgen-20201231.xsd#Role_DisclosureAcquisitionAndVariableInterestEntityTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ScheduleOfDrugProductRevenueTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfDrugProductRevenueTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerMilestoneMethodTableTextBlock" xlink:type="locator" xlink:label="fgen_ContractWithCustomerMilestoneMethodTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesRestOfWorldAndChinaMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_ContractWithCustomerMilestoneMethodTableTextBlock" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fgen_ScheduleOfDrugProductRevenueTableTextBlock" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="fgen-20201231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesTables" xlink:href="fgen-20201231.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="fgen-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationsTextBlock" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationTables" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationTables">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="fgen_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="fgen-20201231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="fgen-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="fgen_ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="fgen_ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationTables" xlink:href="fgen-20201231.xsd#Role_DisclosureSegmentAndGeographicInformationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock" xlink:type="locator" xlink:label="fgen_SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_InventoryByGeographicAreasTableTextBlock" xlink:type="locator" xlink:label="fgen_InventoryByGeographicAreasTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="fgen_InventoryByGeographicAreasTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="fgen_SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DescriptionOfSalesReturn" xlink:type="locator" xlink:label="fgen_DescriptionOfSalesReturn" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:type="locator" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LongTermInvestmentsMinimumMaturityPeriod" xlink:type="locator" xlink:label="fgen_LongTermInvestmentsMinimumMaturityPeriod" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ShortTermInvestmentsMaximumMaturityPeriod" xlink:type="locator" xlink:label="fgen_ShortTermInvestmentsMaximumMaturityPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RestrictedTimeDepositsNoncurrent" xlink:type="locator" xlink:label="fgen_RestrictedTimeDepositsNoncurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_HighlyLiquidInvestmentMaturityPeriod" xlink:type="locator" xlink:label="fgen_HighlyLiquidInvestmentMaturityPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax" xlink:type="locator" xlink:label="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccountingPolicyLineItems" xlink:type="locator" xlink:label="fgen_AccountingPolicyLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201601Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:type="locator" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201802Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201802Member" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member" xlink:type="locator" xlink:label="fgen_ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="fgen_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionForeignMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:type="locator" xlink:label="us-gaap_GeographicDistributionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CreditConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccountsReceivableFromDistributorsMember" xlink:type="locator" xlink:label="fgen_AccountsReceivableFromDistributorsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccountingPolicyTable" xlink:type="locator" xlink:label="fgen_AccountingPolicyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_AccountingPolicyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="fgen_AccountsReceivableFromDistributorsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_GeographicDistributionAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionForeignMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fgen_LaboratoryEquipmentMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyTable" xlink:to="srt_StatementGeographicalAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" order="10030.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" order="10030.18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="fgen_ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201802Member" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201601Member" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyTable" xlink:to="fgen_AccountingPolicyLineItems" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_HighlyLiquidInvestmentMaturityPeriod" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_RestrictedTimeDepositsNoncurrent" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_ShortTermInvestmentsMaximumMaturityPeriod" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_LongTermInvestmentsMinimumMaturityPeriod" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="fgen_DescriptionOfSalesReturn" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccountingPolicyLineItems" xlink:type="locator" xlink:label="fgen_AccountingPolicyLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CreditConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccountingPolicyTable" xlink:type="locator" xlink:label="fgen_AccountingPolicyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fgen_AccountingPolicyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyTable" xlink:to="fgen_AccountingPolicyLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AccountingPolicyLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EquityMethodInvestmentAdditions" xlink:type="locator" xlink:label="fgen_EquityMethodInvestmentAdditions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Capital" xlink:type="locator" xlink:label="us-gaap_Capital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer" xlink:type="locator" xlink:label="fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaABMember" xlink:type="locator" xlink:label="fgen_AstraZenecaABMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BeijingFalikangPharmaceuticalCoLtdMember" xlink:type="locator" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquiredLicenseMember" xlink:type="locator" xlink:label="fgen_AcquiredLicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FibroGenBeijingMember" xlink:type="locator" xlink:label="fgen_FibroGenBeijingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" xlink:type="locator" xlink:label="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquisitionAndVariableInterestEntityTable" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityTable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:to="fgen_AcquisitionAndVariableInterestEntityTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_FibroGenBeijingMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fgen_AcquiredLicenseMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="fgen_BeijingFalikangPharmaceuticalCoLtdMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="fgen_AstraZenecaABMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="srt_CounterpartyNameAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="fgen_AcquisitionAndVariableInterestEntityLineItems" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_Capital" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="fgen_EquityMethodInvestmentAdditions" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments_li0l2" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" xlink:type="locator" xlink:label="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EquityMethodInvestmentAdditions" xlink:type="locator" xlink:label="fgen_EquityMethodInvestmentAdditions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BeijingFalikangPharmaceuticalCoLtdMember" xlink:type="locator" xlink:label="fgen_BeijingFalikangPharmaceuticalCoLtdMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquisitionAndVariableInterestEntityTable" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityTable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:type="locator" xlink:label="fgen_AcquisitionAndVariableInterestEntityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityAbstract" xlink:to="fgen_AcquisitionAndVariableInterestEntityTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="fgen_BeijingFalikangPharmaceuticalCoLtdMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityTable" xlink:to="fgen_AcquisitionAndVariableInterestEntityLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="fgen_EquityMethodInvestmentAdditions" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_AcquisitionAndVariableInterestEntityLineItems" xlink:to="us-gaap_EquityMethodInvestments_li0l2" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EstimatedJointDevelopmentExtendedServicePeriod" xlink:type="locator" xlink:label="fgen_EstimatedJointDevelopmentExtendedServicePeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies" xlink:type="locator" xlink:label="us-gaap_Supplies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PercentageOfFundingForCosts" xlink:type="locator" xlink:label="fgen_PercentageOfFundingForCosts" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DevelopmentAndRegulatoryApprovalMilestones" xlink:type="locator" xlink:label="fgen_DevelopmentAndRegulatoryApprovalMilestones" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:type="locator" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_TransactionPriceAllocatedToPerformanceObligations" xlink:type="locator" xlink:label="fgen_TransactionPriceAllocatedToPerformanceObligations" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AdditionalConsiderationBasedOnNetSales" xlink:type="locator" xlink:label="fgen_AdditionalConsiderationBasedOnNetSales" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CommercialSalesMilestone" xlink:type="locator" xlink:label="fgen_CommercialSalesMilestone" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PotentialMilestones" xlink:type="locator" xlink:label="fgen_PotentialMilestones" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" xlink:type="locator" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RegulatoryMilestonesMember" xlink:type="locator" xlink:label="fgen_RegulatoryMilestonesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ClinicalDevelopmentMilestonesMember" xlink:type="locator" xlink:label="fgen_ClinicalDevelopmentMilestonesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_ClinicalDevelopmentMilestonesMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_RegulatoryMilestonesMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_PotentialMilestones" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CommercialSalesMilestone" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_AdditionalConsiderationBasedOnNetSales" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_TransactionPriceAllocatedToPerformanceObligations" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_DevelopmentAndRegulatoryApprovalMilestones" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_PercentageOfFundingForCosts" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Supplies" order="12450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="12490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_EstimatedJointDevelopmentExtendedServicePeriod" order="12560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedLongTermCoPromotionLiabilityCurrent" xlink:type="locator" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" xlink:type="locator" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CoPromotionExpenses" xlink:type="locator" xlink:label="fgen_CoPromotionExpenses" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ReversalOfAccruedCoPromotionExpenses" xlink:type="locator" xlink:label="fgen_ReversalOfAccruedCoPromotionExpenses" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_HistoricalCoPromotionCosts" xlink:type="locator" xlink:label="fgen_HistoricalCoPromotionCosts" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CollaborativeArrangementAggregateConsideration" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAggregateConsideration" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CommercialSalesAndOtherEventsMilestone" xlink:type="locator" xlink:label="fgen_CommercialSalesAndOtherEventsMilestone" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" xlink:type="locator" xlink:label="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EstimatedJointDevelopmentExtendedServicePeriod" xlink:type="locator" xlink:label="fgen_EstimatedJointDevelopmentExtendedServicePeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies" xlink:type="locator" xlink:label="us-gaap_Supplies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_TransactionPriceAllocatedToPerformanceObligations" xlink:type="locator" xlink:label="fgen_TransactionPriceAllocatedToPerformanceObligations" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AdditionalConsiderationBasedOnNetSales" xlink:type="locator" xlink:label="fgen_AdditionalConsiderationBasedOnNetSales" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_SharedDevelopmentCosts" xlink:type="locator" xlink:label="fgen_SharedDevelopmentCosts" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" xlink:type="locator" xlink:label="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CommercialSalesMilestone" xlink:type="locator" xlink:label="fgen_CommercialSalesMilestone" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PotentialMilestones" xlink:type="locator" xlink:label="fgen_PotentialMilestones" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" xlink:type="locator" xlink:label="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedAndOtherCurrentLiabilitiesMember" xlink:type="locator" xlink:label="fgen_AccruedAndOtherCurrentLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableMember" xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FibroGenIncMember" xlink:type="locator" xlink:label="fgen_FibroGenIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesAndRestOfWorldMember" xlink:type="locator" xlink:label="fgen_UnitedStatesAndRestOfWorldMember_li0l2" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DeferredApprovalMilestoneMember" xlink:type="locator" xlink:label="fgen_DeferredApprovalMilestoneMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RegulatoryMilestonesMember" xlink:type="locator" xlink:label="fgen_RegulatoryMilestonesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ClinicalDevelopmentMilestonesMember" xlink:type="locator" xlink:label="fgen_ClinicalDevelopmentMilestonesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesAndRestOfWorldMember" xlink:type="locator" xlink:label="fgen_UnitedStatesAndRestOfWorldMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesAndRestOfWorldMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_ClinicalDevelopmentMilestonesMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_RegulatoryMilestonesMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fgen_DeferredApprovalMilestoneMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesAndRestOfWorldMember_li0l2" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="fgen_FibroGenIncMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableMember" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="fgen_AccruedAndOtherCurrentLiabilitiesMember" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_PotentialMilestones" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CommercialSalesMilestone" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_SharedDevelopmentCosts" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_AdditionalConsiderationBasedOnNetSales" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_TransactionPriceAllocatedToPerformanceObligations" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Supplies" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_EstimatedJointDevelopmentExtendedServicePeriod" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments" order="12320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CommercialSalesAndOtherEventsMilestone" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CollaborativeArrangementAggregateConsideration" order="12520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="12600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" order="12670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_HistoricalCoPromotionCosts" order="12780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ReversalOfAccruedCoPromotionExpenses" order="12820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CoPromotionExpenses" order="12860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" order="12900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_AccruedLongTermCoPromotionLiabilityCurrent" order="12940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="13050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProvisionForCoDevelopmentServices" xlink:type="locator" xlink:label="fgen_ProvisionForCoDevelopmentServices" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CoDevelopmentServicesEstimatedContinuationYear" xlink:type="locator" xlink:label="fgen_CoDevelopmentServicesEstimatedContinuationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="locator" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" xlink:type="locator" xlink:label="fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone" xlink:type="locator" xlink:label="fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProceedsFromNonContingentUpfrontPayments" xlink:type="locator" xlink:label="fgen_ProceedsFromNonContingentUpfrontPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDiscountedCashFlowMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ProceedsFromNonContingentUpfrontPayments" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CoDevelopmentServicesEstimatedContinuationYear" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ProvisionForCoDevelopmentServices" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CoDevelopmentServicesEstimatedContinuationYear" xlink:type="locator" xlink:label="fgen_CoDevelopmentServicesEstimatedContinuationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="locator" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RoyaltyRateOnNetRevenue" xlink:type="locator" xlink:label="fgen_RoyaltyRateOnNetRevenue" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_VariableConsiderationRelatedToProfitShare" xlink:type="locator" xlink:label="fgen_VariableConsiderationRelatedToProfitShare" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" xlink:type="locator" xlink:label="fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone" xlink:type="locator" xlink:label="fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ProceedsFromNonContingentUpfrontPayments" xlink:type="locator" xlink:label="fgen_ProceedsFromNonContingentUpfrontPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesAndRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesAndRestOfWorldAndChinaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesAndRestOfWorldAndChinaMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDiscountedCashFlowMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_ProceedsFromNonContingentUpfrontPayments" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_VariableConsiderationRelatedToProfitShare" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_RoyaltyRateOnNetRevenue" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_CoDevelopmentServicesEstimatedContinuationYear" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DevelopmentAndOtherRevenueMember" xlink:type="locator" xlink:label="fgen_DevelopmentAndOtherRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DevelopmentAndOtherRevenueMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesRestOfWorldAndChinaMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CashConsiderationReceivedUnderCollaborationAgreement" xlink:type="locator" xlink:label="fgen_CashConsiderationReceivedUnderCollaborationAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" xlink:type="locator" xlink:label="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ChinaPerformanceObligationMember" xlink:type="locator" xlink:label="fgen_ChinaPerformanceObligationMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" xlink:type="locator" xlink:label="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DevelopmentAndOtherRevenueMember" xlink:type="locator" xlink:label="fgen_DevelopmentAndOtherRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_StatementGeographicalAxis" order="10050.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_ProductOrServiceAxis" order="10050.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DevelopmentAndOtherRevenueMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesRestOfWorldAndChinaMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_ChinaPerformanceObligationMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="fgen_CashConsiderationReceivedUnderCollaborationAgreement" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" xlink:type="locator" xlink:label="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesRestOfWorldAndChinaMember" xlink:type="locator" xlink:label="fgen_UnitedStatesRestOfWorldAndChinaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesRestOfWorldAndChinaMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_SuppliesNet" xlink:type="locator" xlink:label="fgen_SuppliesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesAndRestOfWorldMember" xlink:type="locator" xlink:label="fgen_UnitedStatesAndRestOfWorldMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesAndRestOfWorldMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="fgen_SuppliesNet" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:type="locator" xlink:label="us-gaap_SalesReturnsAndAllowancesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OtherDiscountsAndRebatesMember" xlink:type="locator" xlink:label="fgen_OtherDiscountsAndRebatesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractualSalesRebateMember" xlink:type="locator" xlink:label="fgen_ContractualSalesRebateMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_NonKeyAccountHospitalListingAwardMember" xlink:type="locator" xlink:label="fgen_NonKeyAccountHospitalListingAwardMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PriceAdjustmentMember" xlink:type="locator" xlink:label="fgen_PriceAdjustmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_PriceAdjustmentMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_NonKeyAccountHospitalListingAwardMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_ContractualSalesRebateMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_OtherDiscountsAndRebatesMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_SalesReturnsAndAllowancesMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractLiabilitiesMember" xlink:type="locator" xlink:label="fgen_ContractLiabilitiesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_GrossAccountsReceivableMember" xlink:type="locator" xlink:label="fgen_GrossAccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RebatesAndDiscountsMember" xlink:type="locator" xlink:label="fgen_RebatesAndDiscountsMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PriceAdjustmentMember" xlink:type="locator" xlink:label="fgen_PriceAdjustmentMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractualSalesRebateMember" xlink:type="locator" xlink:label="fgen_ContractualSalesRebateMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_NonKeyAccountHospitalListingAwardMember" xlink:type="locator" xlink:label="fgen_NonKeyAccountHospitalListingAwardMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_NonKeyAccountHospitalListingAwardMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_ContractualSalesRebateMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_PriceAdjustmentMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_RebatesAndDiscountsMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="fgen_GrossAccountsReceivableMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="fgen_ContractLiabilitiesMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability_li0l2" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityNetOfAccountsReceivable" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityNetOfAccountsReceivable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityGross" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityGross" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityDeduction" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityDeduction" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityAdditions" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityAdditions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityLineItems" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ContractWithCustomerLiabilityTable" xlink:type="locator" xlink:label="fgen_ContractWithCustomerLiabilityTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="fgen_ContractWithCustomerLiabilityTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityTable" xlink:to="fgen_ContractWithCustomerLiabilityLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityAdditions" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityDeduction" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityGross" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="fgen_ContractWithCustomerLiabilityNetOfAccountsReceivable" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ContractWithCustomerLiabilityLineItems" xlink:to="us-gaap_ContractWithCustomerLiability_li0l2" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EstimatedVariableConsiderationTransactionPrice" xlink:type="locator" xlink:label="fgen_EstimatedVariableConsiderationTransactionPrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesAndRestOfWorldMember" xlink:type="locator" xlink:label="fgen_UnitedStatesAndRestOfWorldMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_APIShipmentMember" xlink:type="locator" xlink:label="fgen_APIShipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenueMember" xlink:type="locator" xlink:label="fgen_DrugProductRevenueMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_DrugProductRevenueMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TransactionTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="fgen_APIShipmentMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesAndRestOfWorldMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fgen_EstimatedVariableConsiderationTransactionPrice" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityAbstract" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BondAndMutualFundsMember" xlink:type="locator" xlink:label="fgen_BondAndMutualFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fgen_BondAndMutualFundsMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquitySecuritiesMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LeaseObligationsMember" xlink:type="locator" xlink:label="fgen_LeaseObligationsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="fgen_LeaseObligationsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LesseeOperatingLeaseExpirationPeriod" xlink:type="locator" xlink:label="fgen_LesseeOperatingLeaseExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_NumberOfOperatingLeases" xlink:type="locator" xlink:label="fgen_NumberOfOperatingLeases" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseOptionToExtend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" xlink:type="locator" xlink:label="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" xlink:type="locator" xlink:label="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" xlink:type="locator" xlink:label="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LesseeFinanceLeaseExpirationPeriod" xlink:type="locator" xlink:label="fgen_LesseeFinanceLeaseExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_NumberOfFinanceLeases" xlink:type="locator" xlink:label="fgen_NumberOfFinanceLeases" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OfficeSpacesMember" xlink:type="locator" xlink:label="fgen_OfficeSpacesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" xlink:type="locator" xlink:label="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ShorensteinPropertiesLLCMember" xlink:type="locator" xlink:label="fgen_ShorensteinPropertiesLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_ShorensteinPropertiesLLCMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_BeijingEconomicTechnologicalDevelopmentAreaMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fgen_OfficeSpacesMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_NumberOfFinanceLeases" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_LesseeFinanceLeaseExpirationPeriod" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseOptionToExtend" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_NumberOfOperatingLeases" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="fgen_LesseeOperatingLeaseExpirationPeriod" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FinanceLeaseAndOperatingLeaseLiability" xlink:type="locator" xlink:label="fgen_FinanceLeaseAndOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FinanceLeaseAndOperatingLeaseAssets" xlink:type="locator" xlink:label="fgen_FinanceLeaseAndOperatingLeaseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OperatingLeaseAccumulatedAmortization" xlink:type="locator" xlink:label="fgen_OperatingLeaseAccumulatedAmortization" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OperatingLeaseRightOfUseAssetsCost" xlink:type="locator" xlink:label="fgen_OperatingLeaseRightOfUseAssetsCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FinanceLeaseAccumulatedAmortization" xlink:type="locator" xlink:label="fgen_FinanceLeaseAccumulatedAmortization" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FinanceLeaseRightOfUseAssetsCost" xlink:type="locator" xlink:label="fgen_FinanceLeaseRightOfUseAssetsCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_FinanceLeaseRightOfUseAssetsCost" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_FinanceLeaseAccumulatedAmortization" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_OperatingLeaseRightOfUseAssetsCost" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_OperatingLeaseAccumulatedAmortization" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_FinanceLeaseAndOperatingLeaseAssets" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_FinanceLeaseAndOperatingLeaseLiability" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_SubleaseIncome" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="fgen_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RepaymentsOfFinanceLeaseLiabilities" xlink:type="locator" xlink:label="fgen_RepaymentsOfFinanceLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="fgen_RepaymentsOfFinanceLeaseLiabilities" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_WeightedAverageDiscountRateAbstract" xlink:type="locator" xlink:label="fgen_WeightedAverageDiscountRateAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_WeightedAverageRemainingLeaseTermAbstract" xlink:type="locator" xlink:label="fgen_WeightedAverageRemainingLeaseTermAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_WeightedAverageRemainingLeaseTermAbstract" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="fgen_WeightedAverageDiscountRateAbstract" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_WeightedAverageDiscountRateAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_WeightedAverageDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:type="locator" xlink:label="us-gaap_Cash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_Cash" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BondAndMutualFundsMember" xlink:type="locator" xlink:label="fgen_BondAndMutualFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:type="locator" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="fgen_BondAndMutualFundsMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquitySecuritiesMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfContractualMaturitiesOfAvailableForSaleInvestmentsDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfContractualMaturitiesOfAvailableForSaleInvestmentsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfContractualMaturitiesOfAvailableForSaleInvestmentsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear" xlink:type="locator" xlink:label="fgen_AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="fgen_AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecurities" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecurities" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses" xlink:type="locator" xlink:label="fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent" xlink:type="locator" xlink:label="fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedLongTermCoPromotionLiabilityCurrent" xlink:type="locator" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" xlink:type="locator" xlink:label="fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies" xlink:type="locator" xlink:label="us-gaap_Supplies" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_NumberOfRegulatoryMilestones" xlink:type="locator" xlink:label="fgen_NumberOfRegulatoryMilestones" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" xlink:type="locator" xlink:label="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_UnitedStatesAndRestOfWorldMember" xlink:type="locator" xlink:label="fgen_UnitedStatesAndRestOfWorldMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_UnitedStatesAndRestOfWorldMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fgen_NumberOfRegulatoryMilestones" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_Supplies" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_Depreciation" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fgen_AccruedLongTermCoPromotionLiabilityCurrent" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfInventoryDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_InventoryNet" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_SuppliesNet" xlink:type="locator" xlink:label="fgen_SuppliesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies" xlink:type="locator" xlink:label="us-gaap_Supplies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_Supplies" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="fgen_SuppliesNet" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="fgen_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fgen_LaboratoryEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PropertyTaxesAndOtherCurrent" xlink:type="locator" xlink:label="fgen_PropertyTaxesAndOtherCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedProfitShareCurrent" xlink:type="locator" xlink:label="fgen_AccruedProfitShareCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedCoPromotionExpensesCurrent" xlink:type="locator" xlink:label="fgen_AccruedCoPromotionExpensesCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" xlink:type="locator" xlink:label="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" xlink:type="locator" xlink:label="fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedPreclinicalAndClinicalTrialCurrent" xlink:type="locator" xlink:label="fgen_AccruedPreclinicalAndClinicalTrialCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="fgen_AccruedPreclinicalAndClinicalTrialCurrent" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="fgen_AccruedCoPromotionExpensesCurrent" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="fgen_AccruedProfitShareCurrent" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="fgen_PropertyTaxesAndOtherCurrent" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" xlink:type="locator" xlink:label="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="fgen_AccruedLongTermCoPromotionLiabilityNonCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherSundryLiabilitiesNoncurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureProductDevelopmentObligationsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AccruedProductDevelopmentCostsExcludingInterest" xlink:type="locator" xlink:label="fgen_AccruedProductDevelopmentCostsExcludingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:type="locator" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRate" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_NumberOfProductDevelopmentObligations" xlink:type="locator" xlink:label="fgen_NumberOfProductDevelopmentObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_BankOfFinlandInterestRateMember" xlink:type="locator" xlink:label="fgen_BankOfFinlandInterestRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="fgen_BankOfFinlandInterestRateMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="fgen_NumberOfProductDevelopmentObligations" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LoansReceivableBasisSpreadOnVariableRate" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="fgen_AccruedProductDevelopmentCostsExcludingInterest" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_MaximumFutureMilestonePayments" xlink:type="locator" xlink:label="fgen_MaximumFutureMilestonePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="fgen_CommitmentsAndContingenciesLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" xlink:type="locator" xlink:label="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="fgen_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="fgen_CommitmentsAndContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_CommitmentsAndContingenciesTable" xlink:to="fgen_CommitmentsAndContingenciesLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ContractualObligation" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_CommitmentsAndContingenciesLineItems" xlink:to="fgen_MaximumFutureMilestonePayments" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligation" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OtherPurchasesMember" xlink:type="locator" xlink:label="fgen_OtherPurchasesMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ManufactureAndSupplyOfPamrevlumabMember" xlink:type="locator" xlink:label="fgen_ManufactureAndSupplyOfPamrevlumabMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ManufactureAndSupplyOfRoxadustatMember" xlink:type="locator" xlink:label="fgen_ManufactureAndSupplyOfRoxadustatMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract" xlink:type="locator" xlink:label="us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="fgen_ManufactureAndSupplyOfRoxadustatMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="fgen_ManufactureAndSupplyOfPamrevlumabMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="fgen_OtherPurchasesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligation" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_PreferredSharesIssuedPricePerShare" xlink:type="locator" xlink:label="fgen_PreferredSharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:type="locator" xlink:label="us-gaap_PreferredStockVotingRights" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares" xlink:type="locator" xlink:label="fgen_RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FibroGenCaymanMember" xlink:type="locator" xlink:label="fgen_FibroGenCaymanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesHPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesHPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesGPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesFPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesEPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FibrogenEuropeOyMember" xlink:type="locator" xlink:label="fgen_FibrogenEuropeOyMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:type="locator" xlink:label="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="fgen_FibrogenEuropeOyMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="fgen_FibroGenCaymanMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockRedemptionTerms" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fgen_RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockVotingRights" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fgen_PreferredSharesIssuedPricePerShare" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationCommonStockAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationCommonStockAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationCommonStockAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockVotingRights" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_CommonStockSharesReserved" xlink:type="locator" xlink:label="fgen_CommonStockSharesReserved" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:type="locator" xlink:label="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="fgen_CommonStockSharesReserved" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="locator" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="fgen_TwoThousandAndFourteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_TwoThousandAndFiveStockPlanMember" xlink:type="locator" xlink:label="fgen_TwoThousandAndFiveStockPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:type="locator" xlink:label="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fgen_TwoThousandAndFiveStockPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fgen_TwoThousandAndFourteenEquityIncentivePlanMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear" xlink:type="locator" xlink:label="fgen_StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="fgen_StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:type="locator" xlink:label="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="fgen_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:type="locator" xlink:label="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fgen_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:type="locator" xlink:label="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:type="locator" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:type="locator" xlink:label="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_StockOptionAwardsMember" xlink:type="locator" xlink:label="fgen_StockOptionAwardsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:type="locator" xlink:label="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fgen_StockOptionAwardsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationWarrantsAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureEquityAndStockBasedCompensationWarrantsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationWarrantsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod" xlink:type="locator" xlink:label="fgen_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:type="locator" xlink:label="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:to="fgen_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_ShareholdersEquityAndStockBasedCompensationAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFibrogenInc401KPlanAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureFibrogenInc401KPlanAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFibrogenInc401KPlanAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted" xlink:type="locator" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets" xlink:type="locator" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets" xlink:type="locator" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="fgen_EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="fgen_EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="fgen_EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="fgen_EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="fgen_EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DeferredTaxLiabilitiesFixedAssets" xlink:type="locator" xlink:label="fgen_DeferredTaxLiabilitiesFixedAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DeferredTaxAssetsIntangibleAssets" xlink:type="locator" xlink:label="fgen_DeferredTaxAssetsIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="fgen_DeferredTaxAssetsIntangibleAssets" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="fgen_DeferredTaxLiabilitiesFixedAssets" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible" xlink:type="locator" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ExperienceHistoricalOwnershipChanges" xlink:type="locator" xlink:label="fgen_ExperienceHistoricalOwnershipChanges" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OtherTaxCreditCarryforwardsExpirationYear" xlink:type="locator" xlink:label="fgen_OtherTaxCreditCarryforwardsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="fgen_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_IncomeTaxesLineItems" xlink:type="locator" xlink:label="fgen_IncomeTaxesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_IncomeTaxesTable" xlink:type="locator" xlink:label="fgen_IncomeTaxesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="fgen_IncomeTaxesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_IncomeTaxesTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_IncomeTaxesTable" xlink:to="srt_StatementGeographicalAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_IncomeTaxesTable" xlink:to="us-gaap_TaxPeriodAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_IncomeTaxesTable" xlink:to="fgen_IncomeTaxesLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="fgen_OperatingLossCarryforwardsExpirationYear" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="fgen_OtherTaxCreditCarryforwardsExpirationYear" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="fgen_ExperienceHistoricalOwnershipChanges" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_IncomeTaxesLineItems" xlink:to="us-gaap_OpenTaxYear" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FederalAndStateMember" xlink:type="locator" xlink:label="fgen_FederalAndStateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="fgen_FederalAndStateMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits_li0l2" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
    <link:loc xlink:href="fgen-20201231.xsd#fgen_MiscellaneousReceivables" xlink:type="locator" xlink:label="fgen_MiscellaneousReceivables" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_SuppliesNet" xlink:type="locator" xlink:label="fgen_SuppliesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Supplies" xlink:type="locator" xlink:label="us-gaap_Supplies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_DrugProductRevenueFromRelatedParty" xlink:type="locator" xlink:label="fgen_DrugProductRevenueFromRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_RevenueFromRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_FalikangMember" xlink:type="locator" xlink:label="fgen_FalikangMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasMember" xlink:type="locator" xlink:label="fgen_AstellasMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_APIShipmentMember" xlink:type="locator" xlink:label="fgen_APIShipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_LicenseAndDevelopmentMember" xlink:type="locator" xlink:label="fgen_LicenseAndDevelopmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="fgen_LicenseAndDevelopmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TransactionTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="fgen_APIShipmentMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_AstellasMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_StatementGeographicalAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fgen_FalikangMember" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fgen_DrugProductRevenueFromRelatedParty" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_Supplies" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fgen_SuppliesNet" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InvestmentIncomeNet" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="fgen_MiscellaneousReceivables" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureSegmentAndGeographicInformationAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AllOtherMember" xlink:type="locator" xlink:label="fgen_AllOtherMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:type="locator" xlink:label="country_JP" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:type="locator" xlink:label="srt_EuropeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fgen_AllOtherMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfInventoryByGeographicAreaDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureSegmentAndGeographicInformationScheduleOfInventoryByGeographicAreaDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfInventoryByGeographicAreaDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InventoryNet" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfLongLivedAssetsByGeographicAreaDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureSegmentAndGeographicInformationScheduleOfLongLivedAssetsByGeographicAreaDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfLongLivedAssetsByGeographicAreaDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationSummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureSegmentAndGeographicInformationSummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationSummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:type="locator" xlink:label="country_CN" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="locator" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstraZenecaAgreementsMember" xlink:type="locator" xlink:label="fgen_AstraZenecaAgreementsMember" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_AstellasCollaborationAgreementMember" xlink:type="locator" xlink:label="fgen_AstellasCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstellasCollaborationAgreementMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fgen_AstraZenecaAgreementsMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_EntityWideRevenueMajorCustomerLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccountsDetail" xlink:href="fgen-20201231.xsd#Role_DisclosureScheduleIIValuationAndQualifyingAccountsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccountsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="locator" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems" />
    <link:loc xlink:href="fgen-20201231.xsd#fgen_ValuationAllowanceForRebatesAndDiscountsMember" xlink:type="locator" xlink:label="fgen_ValuationAllowanceForRebatesAndDiscountsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="locator" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:type="locator" xlink:label="srt_ValuationAndQualifyingAccountsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsAbstract" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="fgen_ValuationAllowanceForRebatesAndDiscountsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_li0l2" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>fgen-10k_20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:fgen="http://www.fibrogen.com/20201231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="fgen-20201231.xsd" xlink:type="simple"/>
    <context id="C_0000921299_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_0000921299_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <instant>2020-04-01</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_fgenAccountsReceivableFromDistributorsMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">fgen:AccountsReceivableFromDistributorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapGeographicDistributionAxis_us-gaapGeographicDistributionForeignMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapGeographicDistributionAxis_us-gaapGeographicDistributionForeignMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fgen:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fgen:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_fgenImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member_20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">fgen:ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fgen:BeijingKangdaYongfuPharmaceuticalCoLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FibroGenBeijingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200701_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fgen:BeijingKangdaYongfuPharmaceuticalCoLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FibroGenBeijingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAcquiredLicenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200701_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fgen:BeijingKangdaYongfuPharmaceuticalCoLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">fgen:AcquiredLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FibroGenBeijingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAstraZenecaABMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200915_20200915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fgen:BeijingKangdaYongfuPharmaceuticalCoLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">fgen:AstraZenecaABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FibroGenBeijingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-15</startDate>
            <endDate>2020-09-15</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FibroGenBeijingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FibroGenBeijingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtCounterpartyNameAxis_us-gaapVariableInterestEntityNotPrimaryBeneficiaryMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">fgen:BeijingFalikangPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20090228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-06-01</startDate>
            <endDate>2009-02-28</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-06-01</startDate>
            <endDate>2005-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-06-01</startDate>
            <endDate>2005-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-06-01</startDate>
            <endDate>2005-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190901_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180401_20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20090228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-04-01</startDate>
            <endDate>2009-02-28</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2006-04-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-04-01</startDate>
            <endDate>2006-04-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-04-01</startDate>
            <endDate>2006-04-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-04-01</startDate>
            <endDate>2006-04-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-29</startDate>
            <endDate>2013-07-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-29</startDate>
            <endDate>2013-07-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-29</startDate>
            <endDate>2013-07-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenDeferredApprovalMilestoneMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:DeferredApprovalMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-29</startDate>
            <endDate>2013-07-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20150101_20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibroGenIncMember_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20150101_20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibroGenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-29</startDate>
            <endDate>2013-07-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-29</startDate>
            <endDate>2013-07-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fgen:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-29</startDate>
            <endDate>2013-07-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20181216_20181217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-16</startDate>
            <endDate>2018-12-17</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20181228_20181229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-28</startDate>
            <endDate>2018-12-29</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201001_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapBalanceSheetLocationAxis_us-gaapAccountsPayableMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapBalanceSheetLocationAxis_us-gaapAccruedLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapBalanceSheetLocationAxis_fgenAccruedAndOtherCurrentLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueDiscountedCashFlowMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueDiscountedCashFlowMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueDiscountedCashFlowMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DevelopmentAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenCoDevelopmentInformationSharingAndCommitteeServicesMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:CoDevelopmentInformationSharingAndCommitteeServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenChinaPerformanceObligationMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:ChinaPerformanceObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesRestOfWorldAndChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenPriceAdjustmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:PriceAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenPriceAdjustmentMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:PriceAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNonKeyAccountHospitalListingAwardMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:NonKeyAccountHospitalListingAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNonKeyAccountHospitalListingAwardMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:NonKeyAccountHospitalListingAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenContractualSalesRebateMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ContractualSalesRebateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenContractualSalesRebateMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ContractualSalesRebateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenOtherDiscountsAndRebatesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:OtherDiscountsAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenOtherDiscountsAndRebatesMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:OtherDiscountsAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNonKeyAccountHospitalListingAwardMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:NonKeyAccountHospitalListingAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenContractualSalesRebateMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ContractualSalesRebateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenContractualSalesRebateMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ContractualSalesRebateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenPriceAdjustmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:PriceAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:RebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenGrossAccountsReceivableMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:GrossAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:RebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenGrossAccountsReceivableMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:GrossAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:RebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:ContractLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:RebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fgen:ContractLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:RebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fgen:APIShipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:DrugProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fgen:LeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fgen:LeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fgen:LeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fgen:LeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fgen:LeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fgen:LeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fgen:LeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fgen:LeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20061231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:ShorensteinPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2006-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20060101_20061231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:ShorensteinPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-01-01</startDate>
            <endDate>2006-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:ShorensteinPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20131231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:BeijingEconomicTechnologicalDevelopmentAreaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20130101_20131231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:BeijingEconomicTechnologicalDevelopmentAreaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenOfficeSpacesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fgen:OfficeSpacesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMinimumMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMaximumMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">fgen:BondAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_20180101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:UnitedStatesAndRestOfWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fgen:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fgen:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200701_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapVariableRateAxis_fgenBankOfFinlandInterestRateMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">fgen:BankOfFinlandInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfRoxadustatMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fgen:ManufactureAndSupplyOfRoxadustatMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfPamrevlumabMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fgen:ManufactureAndSupplyOfPamrevlumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenOtherPurchasesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fgen:OtherPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenResearchAndPreClinicalStageDevelopmentProgramsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fgen:ResearchAndPreClinicalStageDevelopmentProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesEPreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesEPreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibrogenEuropeOyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibroGenCaymanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibroGenCaymanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibroGenCaymanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibroGenCaymanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibroGenCaymanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibroGenCaymanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_deiLegalEntityAxis_fgenFibroGenCaymanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">fgen:FibroGenCaymanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20141119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-19</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFiveStockPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFiveStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_fgenTwoThousandAndFiveStockPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFiveStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20140901_20140930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-09-01</startDate>
            <endDate>2014-09-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20140901_20140930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-09-01</startDate>
            <endDate>2014-09-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20140930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-09-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fgen:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_fgenStockOptionAwardsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fgen:StockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAwardTypeAxis_fgenStockOptionAwardsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fgen:StockOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_stprCA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">fgen:FederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">fgen:FederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">fgen:FederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">fgen:FederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">fgen:FederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">fgen:FederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">fgen:FederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTaxPeriodAxis_us-gaapEarliestTaxYearMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTaxPeriodAxis_us-gaapLatestTaxYearMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenLicenseAndDevelopmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:LicenseAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenLicenseAndDevelopmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:LicenseAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtProductOrServiceAxis_fgenLicenseAndDevelopmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fgen:LicenseAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fgen:APIShipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fgen:APIShipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fgen:APIShipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:AstellasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">fgen:APIShipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20200901_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FalikangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fgen:FalikangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryJP_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenAllOtherMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:AllOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenAllOtherMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:AllOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_fgenAllOtherMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fgen:AllOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryUS_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryUS_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_srtStatementGeographicalAxis_countryCN_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstellasCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fgen:AstraZenecaAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ValuationAllowanceForRebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ValuationAllowanceForRebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ValuationAllowanceForRebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ValuationAllowanceForRebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">fgen:ValuationAllowanceForRebatesAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_fgenSegment">
        <measure>fgen:Segment</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_iso4217CNY">
        <measure>iso4217:CNY</measure>
    </unit>
    <unit id="U_fgenLease">
        <measure>fgen:Lease</measure>
    </unit>
    <unit id="U_fgenMilestone">
        <measure>fgen:Milestone</measure>
    </unit>
    <unit id="U_fgenDevelopmentObligation">
        <measure>fgen:DevelopmentObligation</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0000921299_20200101_20201231" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0000921299_20200101_20201231" id="F_000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0000921299_20200101_20201231" id="F_000007">0000921299</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0000921299_20200101_20201231" id="F_000008">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231"
      id="F_000630">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20200101_20201231"
      id="F_000632">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20200101_20201231"
      id="F_000634">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231"
      id="F_000636">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20190101_20191231"
      decimals="-6"
      id="F_000839"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenGrossAccountsReceivableMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20190101_20191231"
      decimals="-6"
      id="F_000841"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20190101_20191231"
      decimals="-6"
      id="F_000843"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LesseeFinanceLeaseExistenceOfOptionToExtend
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20060101_20061231"
      id="F_000941">true</us-gaap:LesseeFinanceLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeFinanceLeaseExistenceOfOptionToExtend
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20130101_20131231"
      id="F_000945">false</us-gaap:LesseeFinanceLeaseExistenceOfOptionToExtend>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_001454_2"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="C_0000921299_20181231"
      decimals="INF"
      id="F_001455"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_001454"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="C_0000921299_20181231"
      decimals="INF"
      id="F_001455_2"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0000921299_20201231"
      id="F_000079"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0000921299_20191231"
      id="F_000080"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="C_0000921299_20201231" id="F_000970">fgen:AccruedAndOtherCurrentLiabilitiesMember</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="C_0000921299_20191231" id="F_000971">fgen:AccruedAndOtherCurrentLiabilitiesMember</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="C_0000921299_20201231" id="F_000976">us-gaap:OtherNoncurrentLiabilitiesMember</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="C_0000921299_20191231" id="F_000977">us-gaap:OtherNoncurrentLiabilitiesMember</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0000921299_20201231" id="F_001000">P2Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0000921299_20191231" id="F_001001">P3Y7M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0000921299_20201231" id="F_001002">P1Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0000921299_20191231" id="F_001003">P2Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0000921299_20200101_20201231" id="F_001234">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="C_0000921299_20200101_20201231" id="F_001235">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_0000921299_20200101_20201231" id="F_001236">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      id="F_001275">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      id="F_001276">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      id="F_001277">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231"
      id="F_001290">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231"
      id="F_001291">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231"
      id="F_001292">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231"
      decimals="INF"
      id="F_001296"
      unitRef="U_xbrlipure">0.475</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231"
      decimals="INF"
      id="F_001297"
      unitRef="U_xbrlipure">0.481</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231"
      decimals="INF"
      id="F_001298"
      unitRef="U_xbrlipure">0.473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231"
      decimals="INF"
      id="F_001302"
      unitRef="U_xbrlipure">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231"
      decimals="INF"
      id="F_001303"
      unitRef="U_xbrlipure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231"
      decimals="INF"
      id="F_001304"
      unitRef="U_xbrlipure">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231"
      id="F_001293">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231"
      id="F_001294">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231"
      id="F_001295">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231"
      decimals="INF"
      id="F_001299"
      unitRef="U_xbrlipure">0.771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231"
      decimals="INF"
      id="F_001300"
      unitRef="U_xbrlipure">0.621</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231"
      decimals="INF"
      id="F_001301"
      unitRef="U_xbrlipure">0.753</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231"
      decimals="INF"
      id="F_001305"
      unitRef="U_xbrlipure">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231"
      decimals="INF"
      id="F_001306"
      unitRef="U_xbrlipure">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231"
      decimals="INF"
      id="F_001307"
      unitRef="U_xbrlipure">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="C_0000921299_20200101_20201231" id="F_000145">us-gaap:ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="C_0000921299_20190101_20191231" id="F_000146">us-gaap:ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="C_0000921299_20180101_20181231" id="F_000147">us-gaap:ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <dei:DocumentType contextRef="C_0000921299_20200101_20201231" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0000921299_20200101_20201231" id="F_000030">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0000921299_20200101_20201231" id="F_000002">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0000921299_20200101_20201231" id="F_000003">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0000921299_20200101_20201231" id="F_000031">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0000921299_20200101_20201231" id="F_000019">001-36740</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0000921299_20200101_20201231" id="F_000006">FIBROGEN, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000921299_20200101_20201231" id="F_000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000921299_20200101_20201231" id="F_000021">77-0357827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000921299_20200101_20201231" id="F_000022">409 Illinois Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0000921299_20200101_20201231" id="F_000023">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000921299_20200101_20201231" id="F_000024">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000921299_20200101_20201231" id="F_000025">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000921299_20200101_20201231" id="F_000026">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000921299_20200101_20201231" id="F_000027">978-1200&#160;</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0000921299_20200101_20201231" id="F_000017">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000921299_20200101_20201231" id="F_000005">FGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000921299_20200101_20201231" id="F_000018">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0000921299_20200101_20201231" id="F_000009">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0000921299_20200101_20201231" id="F_000011">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0000921299_20200101_20201231" id="F_000010">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0000921299_20200101_20201231" id="F_000016">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0000921299_20200101_20201231" id="F_000012">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0000921299_20200101_20201231" id="F_000014">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000921299_20200101_20201231" id="F_000015">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0000921299_20200101_20201231" id="F_000032">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0000921299_20200101_20201231" id="F_000013">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0000921299_20200630"
      decimals="-5"
      id="F_000029"
      unitRef="U_iso4217USD">2127600000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0000921299_20210131"
      decimals="INF"
      id="F_000028"
      unitRef="U_xbrlishares">91560468</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000523">
&lt;p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/p&gt;
&lt;p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K incorporate information by reference from the definitive proxy statement for the registrant&#x2019;s 2021 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than after 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000033"
      unitRef="U_iso4217USD">678393000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000034"
      unitRef="U_iso4217USD">126266000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">8144000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">407491000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000099"
      unitRef="U_iso4217USD">4127000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">4845000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">41883000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">28455000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">16530000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">6887000</us-gaap:InventoryNet>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">889000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">125210000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">10160000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">133391000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">755110000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">702490000</us-gaap:AssetsCurrent>
    <fgen:RestrictedTimeDepositsNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">2072000</fgen:RestrictedTimeDepositsNoncurrent>
    <fgen:RestrictedTimeDepositsNoncurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">2072000</fgen:RestrictedTimeDepositsNoncurrent>
    <us-gaap:LongTermInvestments
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">244000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">61118000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">33647000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">42743000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">29606000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">39602000</us-gaap:FinanceLeaseRightOfUseAsset>
    <fgen:EquityMethodInvestmentInUnconsolidatedVariableInterestEntity
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">2728000</fgen:EquityMethodInvestmentInUnconsolidatedVariableInterestEntity>
    <fgen:EquityMethodInvestmentInUnconsolidatedVariableInterestEntity
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">0</fgen:EquityMethodInvestmentInUnconsolidatedVariableInterestEntity>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">3433000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">9372000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">826840000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">857397000</us-gaap:Assets>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">1118000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">0</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">24789000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">6088000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">24000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">36883000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">119521000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">83816000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <fgen:DueToRelatedPartiesDeferredRevenueCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">2907000</fgen:DueToRelatedPartiesDeferredRevenueCurrent>
    <fgen:DueToRelatedPartiesDeferredRevenueCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">249000</fgen:DueToRelatedPartiesDeferredRevenueCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">6547000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">490000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">12330000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">12351000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">163187000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">102745000</us-gaap:LiabilitiesCurrent>
    <fgen:AccruedProductDevelopmentCosts
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">18697000</fgen:AccruedProductDevelopmentCosts>
    <fgen:AccruedProductDevelopmentCosts
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">16780000</fgen:AccruedProductDevelopmentCosts>
    <fgen:DueToRelatedPartiesDeferredRevenueNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">4636000</fgen:DueToRelatedPartiesDeferredRevenueNoncurrent>
    <fgen:DueToRelatedPartiesDeferredRevenueNoncurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">125000</fgen:DueToRelatedPartiesDeferredRevenueNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">138474000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">99449000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">25391000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">37610000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">39642000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">65407000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000077"
      unitRef="U_iso4217USD">385391000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000078"
      unitRef="U_iso4217USD">321991000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000111"
      unitRef="U_iso4217USD_xbrlishares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0000921299_20191231"
      decimals="INF"
      id="F_000112"
      unitRef="U_iso4217USD_xbrlishares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000113"
      unitRef="U_xbrlishares">125000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0000921299_20191231"
      decimals="INF"
      id="F_000114"
      unitRef="U_xbrlishares">125000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000115"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0000921299_20191231"
      decimals="INF"
      id="F_000116"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000117"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_20191231"
      decimals="INF"
      id="F_000118"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000081"
      unitRef="U_iso4217USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000082"
      unitRef="U_iso4217USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000119"
      unitRef="U_iso4217USD_xbrlishares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0000921299_20191231"
      decimals="INF"
      id="F_000120"
      unitRef="U_iso4217USD_xbrlishares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000121"
      unitRef="U_xbrlishares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0000921299_20191231"
      decimals="INF"
      id="F_000122"
      unitRef="U_xbrlishares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000123"
      unitRef="U_xbrlishares">91441000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000125"
      unitRef="U_xbrlishares">91441000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000124"
      unitRef="U_xbrlishares">87657000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000126"
      unitRef="U_xbrlishares">87657000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000083"
      unitRef="U_iso4217USD">914000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000084"
      unitRef="U_iso4217USD">877000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000085"
      unitRef="U_iso4217USD">1399774000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000086"
      unitRef="U_iso4217USD">1300725000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000087"
      unitRef="U_iso4217USD">-4499000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000088"
      unitRef="U_iso4217USD">-747000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000089"
      unitRef="U_iso4217USD">-974011000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">-784720000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000091"
      unitRef="U_iso4217USD">422178000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">516135000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000093"
      unitRef="U_iso4217USD">19271000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000094"
      unitRef="U_iso4217USD">19271000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000095"
      unitRef="U_iso4217USD">441449000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000096"
      unitRef="U_iso4217USD">535406000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000097"
      unitRef="U_iso4217USD">826840000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000098"
      unitRef="U_iso4217USD">857397000</us-gaap:LiabilitiesAndStockholdersEquity>
    <fgen:LicenseFeesAndMilestonesRevenue
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">14323000</fgen:LicenseFeesAndMilestonesRevenue>
    <fgen:LicenseFeesAndMilestonesRevenue
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">129405000</fgen:LicenseFeesAndMilestonesRevenue>
    <fgen:LicenseFeesAndMilestonesRevenue
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">14323000</fgen:LicenseFeesAndMilestonesRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20200101_20201231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">14323000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20190101_20191231"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">177086000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_20180101_20181231"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">22269000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fgen:CollaborationServicesAndOtherRevenue
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">19174000</fgen:CollaborationServicesAndOtherRevenue>
    <fgen:CollaborationServicesAndOtherRevenue
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">29393000</fgen:CollaborationServicesAndOtherRevenue>
    <fgen:CollaborationServicesAndOtherRevenue
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">20903000</fgen:CollaborationServicesAndOtherRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20200101_20201231"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">80592000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20190101_20191231"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">114115000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_20180101_20181231"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">125913000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">72498000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20190101_20191231"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">1700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20180101_20181231"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fgen:ProductRevenue
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">4281000</fgen:ProductRevenue>
    <fgen:ProductRevenue
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">-36324000</fgen:ProductRevenue>
    <fgen:ProductRevenue
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">64776000</fgen:ProductRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20200101_20201231"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">8906000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20190101_20191231"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">-36324000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20180101_20181231"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">64776000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">176319000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">256577000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">212958000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fgen:CostOfGoodsAndServicesSoldOperatingExpense
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">8869000</fgen:CostOfGoodsAndServicesSoldOperatingExpense>
    <fgen:CostOfGoodsAndServicesSoldOperatingExpense
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">1147000</fgen:CostOfGoodsAndServicesSoldOperatingExpense>
    <fgen:CostOfGoodsAndServicesSoldOperatingExpense
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">0</fgen:CostOfGoodsAndServicesSoldOperatingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">252924000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">209265000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">235839000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">106406000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">135479000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">63812000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">368199000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">345891000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">299651000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">-191880000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">-89314000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">-86693000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">2402000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">2876000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">10991000</us-gaap:InterestExpense>
    <fgen:UnconsolidatedVariableInterestEntityInvestmentLoss
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">202000</fgen:UnconsolidatedVariableInterestEntityInvestmentLoss>
    <fgen:UnconsolidatedVariableInterestEntityInvestmentLoss
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">0</fgen:UnconsolidatedVariableInterestEntityInvestmentLoss>
    <fgen:UnconsolidatedVariableInterestEntityInvestmentLoss
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">0</fgen:UnconsolidatedVariableInterestEntityInvestmentLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">5553000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">15548000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">11568000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">2949000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">12672000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">577000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">-188931000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">-76642000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">-86116000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">360000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">328000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">304000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">-189291000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">-76970000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">-86420000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0000921299_20200101_20201231"
      decimals="2"
      id="F_000181"
      unitRef="U_iso4217USD_xbrlishares">-2.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0000921299_20190101_20191231"
      decimals="2"
      id="F_000182"
      unitRef="U_iso4217USD_xbrlishares">-0.89</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0000921299_20180101_20181231"
      decimals="2"
      id="F_000183"
      unitRef="U_iso4217USD_xbrlishares">-1.03</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000184"
      unitRef="U_xbrlishares">89854000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000185"
      unitRef="U_xbrlishares">86633000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000186"
      unitRef="U_xbrlishares">84062000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">-189291000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">-76970000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">-86420000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">-3207000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">331000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">771000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">-545000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">592000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">-7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">-3752000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">923000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000207"
      unitRef="U_iso4217USD">764000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">-193043000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">-76047000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">-85656000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231"
      decimals="INF"
      id="F_000211"
      unitRef="U_xbrlishares">82498128</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">825000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231"
      decimals="-3"
      id="F_000213"
      unitRef="U_iso4217USD">1160094000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">-1795000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231"
      decimals="-3"
      id="F_000215"
      unitRef="U_iso4217USD">-630657000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20171231"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">19271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_20171231"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">547738000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">-1250000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">1250000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20171231"
      decimals="-3"
      id="F_000223"
      unitRef="U_iso4217USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_20171231"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231"
      decimals="-3"
      id="F_000229"
      unitRef="U_iso4217USD">-86420000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180101_20181231"
      decimals="-3"
      id="F_000230"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000231"
      unitRef="U_iso4217USD">-86420000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="-3"
      id="F_000232"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000234"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231"
      decimals="-3"
      id="F_000235"
      unitRef="U_iso4217USD">-7000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231"
      decimals="-3"
      id="F_000236"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180101_20181231"
      decimals="-3"
      id="F_000237"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000238"
      unitRef="U_iso4217USD">-7000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="-3"
      id="F_000239"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="-3"
      id="F_000240"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000241"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231"
      decimals="-3"
      id="F_000242"
      unitRef="U_iso4217USD">771000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231"
      decimals="-3"
      id="F_000243"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180101_20181231"
      decimals="-3"
      id="F_000244"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000245"
      unitRef="U_iso4217USD">771000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="-3"
      id="F_000246"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="-3"
      id="F_000247"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000248"
      unitRef="U_iso4217USD">11000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231"
      decimals="-3"
      id="F_000249"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231"
      decimals="-3"
      id="F_000250"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180101_20181231"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000252"
      unitRef="U_iso4217USD">11000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="INF"
      id="F_000253"
      unitRef="U_xbrlishares">2933974</fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="-3"
      id="F_000254"
      unitRef="U_iso4217USD">29000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000255"
      unitRef="U_iso4217USD">14206000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231"
      decimals="-3"
      id="F_000256"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180101_20181231"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">14235000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="-3"
      id="F_000260"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">52142000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231"
      decimals="-3"
      id="F_000264"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180101_20181231"
      decimals="-3"
      id="F_000265"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000266"
      unitRef="U_iso4217USD">52142000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="INF"
      id="F_000267"
      unitRef="U_xbrlishares">85432102</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000268"
      unitRef="U_iso4217USD">854000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231"
      decimals="-3"
      id="F_000269"
      unitRef="U_iso4217USD">1226453000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231"
      decimals="-3"
      id="F_000270"
      unitRef="U_iso4217USD">-2281000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231"
      decimals="-3"
      id="F_000271"
      unitRef="U_iso4217USD">-715827000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20181231"
      decimals="-3"
      id="F_000272"
      unitRef="U_iso4217USD">19271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_20181231"
      decimals="-3"
      id="F_000273"
      unitRef="U_iso4217USD">528470000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000274"
      unitRef="U_iso4217USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000275"
      unitRef="U_iso4217USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231"
      decimals="-3"
      id="F_000277"
      unitRef="U_iso4217USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231"
      decimals="-3"
      id="F_000278"
      unitRef="U_iso4217USD">8688000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20181231"
      decimals="-3"
      id="F_000279"
      unitRef="U_iso4217USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20181231"
      decimals="-3"
      id="F_000280"
      unitRef="U_iso4217USD">8688000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000281"
      unitRef="U_iso4217USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000282"
      unitRef="U_iso4217USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231"
      decimals="-3"
      id="F_000283"
      unitRef="U_iso4217USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231"
      decimals="-3"
      id="F_000284"
      unitRef="U_iso4217USD">611000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231"
      decimals="-3"
      id="F_000285"
      unitRef="U_iso4217USD">-611000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20181231"
      decimals="-3"
      id="F_000286"
      unitRef="U_iso4217USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_20181231"
      decimals="-3"
      id="F_000287"
      unitRef="U_iso4217USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000288"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000289"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000290"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="-3"
      id="F_000291"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000292"
      unitRef="U_iso4217USD">-76970000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190101_20191231"
      decimals="-3"
      id="F_000293"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000294"
      unitRef="U_iso4217USD">-76970000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000295"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000296"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000297"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="-3"
      id="F_000298"
      unitRef="U_iso4217USD">592000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000299"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190101_20191231"
      decimals="-3"
      id="F_000300"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000301"
      unitRef="U_iso4217USD">592000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000302"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000303"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000304"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="-3"
      id="F_000305"
      unitRef="U_iso4217USD">331000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000306"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190101_20191231"
      decimals="-3"
      id="F_000307"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000308"
      unitRef="U_iso4217USD">331000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000309"
      unitRef="U_xbrlishares">2220957</fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000310"
      unitRef="U_iso4217USD">23000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000311"
      unitRef="U_iso4217USD">7939000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="-3"
      id="F_000312"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000313"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190101_20191231"
      decimals="-3"
      id="F_000314"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000315"
      unitRef="U_iso4217USD">7962000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:WarrantExercisedDuringPeriodShares
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000316"
      unitRef="U_xbrlishares">4430</fgen:WarrantExercisedDuringPeriodShares>
    <fgen:WarrantsExercisedDuringPeriodValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000317"
      unitRef="U_iso4217USD">0</fgen:WarrantsExercisedDuringPeriodValue>
    <fgen:WarrantsExercisedDuringPeriodValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000318"
      unitRef="U_iso4217USD">66000</fgen:WarrantsExercisedDuringPeriodValue>
    <fgen:WarrantsExercisedDuringPeriodValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="-3"
      id="F_000319"
      unitRef="U_iso4217USD">0</fgen:WarrantsExercisedDuringPeriodValue>
    <fgen:WarrantsExercisedDuringPeriodValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000320"
      unitRef="U_iso4217USD">0</fgen:WarrantsExercisedDuringPeriodValue>
    <fgen:WarrantsExercisedDuringPeriodValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190101_20191231"
      decimals="-3"
      id="F_000321"
      unitRef="U_iso4217USD">0</fgen:WarrantsExercisedDuringPeriodValue>
    <fgen:WarrantsExercisedDuringPeriodValue
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000322"
      unitRef="U_iso4217USD">66000</fgen:WarrantsExercisedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000323"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000324"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000325"
      unitRef="U_iso4217USD">66267000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="-3"
      id="F_000326"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000327"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190101_20191231"
      decimals="-3"
      id="F_000328"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000329"
      unitRef="U_iso4217USD">66267000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000330"
      unitRef="U_xbrlishares">87657489</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000331"
      unitRef="U_iso4217USD">877000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000332"
      unitRef="U_iso4217USD">1300725000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231"
      decimals="-3"
      id="F_000333"
      unitRef="U_iso4217USD">-747000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000334"
      unitRef="U_iso4217USD">-784720000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191231"
      decimals="-3"
      id="F_000335"
      unitRef="U_iso4217USD">19271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000336"
      unitRef="U_iso4217USD">535406000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000337"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000338"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000339"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000340"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000341"
      unitRef="U_iso4217USD">-189291000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20201231"
      decimals="-3"
      id="F_000342"
      unitRef="U_iso4217USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000343"
      unitRef="U_iso4217USD">-189291000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000344"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000345"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000346"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000347"
      unitRef="U_iso4217USD">-545000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000348"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20201231"
      decimals="-3"
      id="F_000349"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000350"
      unitRef="U_iso4217USD">-545000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000351"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000352"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000353"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000354"
      unitRef="U_iso4217USD">-3207000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000355"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20201231"
      decimals="-3"
      id="F_000356"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000357"
      unitRef="U_iso4217USD">-3207000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000358"
      unitRef="U_xbrlishares">3783144</fgen:SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000359"
      unitRef="U_iso4217USD">37000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000360"
      unitRef="U_iso4217USD">26329000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000361"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000362"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20201231"
      decimals="-3"
      id="F_000363"
      unitRef="U_iso4217USD">0</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000364"
      unitRef="U_iso4217USD">26366000</fgen:AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000365"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000366"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000367"
      unitRef="U_iso4217USD">72720000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000368"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000369"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20201231"
      decimals="-3"
      id="F_000370"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000371"
      unitRef="U_iso4217USD">72720000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000372"
      unitRef="U_xbrlishares">91440633</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000373"
      unitRef="U_iso4217USD">914000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000374"
      unitRef="U_iso4217USD">1399774000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231"
      decimals="-3"
      id="F_000375"
      unitRef="U_iso4217USD">-4499000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000376"
      unitRef="U_iso4217USD">-974011000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20201231"
      decimals="-3"
      id="F_000377"
      unitRef="U_iso4217USD">19271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000378"
      unitRef="U_iso4217USD">441449000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000379"
      unitRef="U_iso4217USD">-189291000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000380"
      unitRef="U_iso4217USD">-76970000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000381"
      unitRef="U_iso4217USD">-86420000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000382"
      unitRef="U_iso4217USD">11678000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000383"
      unitRef="U_iso4217USD">11147000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000384"
      unitRef="U_iso4217USD">6562000</us-gaap:Depreciation>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000385"
      unitRef="U_iso4217USD">10369000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000386"
      unitRef="U_iso4217USD">10307000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000387"
      unitRef="U_iso4217USD">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000388"
      unitRef="U_iso4217USD">-103000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000389"
      unitRef="U_iso4217USD">3667000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000390"
      unitRef="U_iso4217USD">42000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <fgen:UnrealizedLossGainOnEquityInvestments
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000391"
      unitRef="U_iso4217USD">0</fgen:UnrealizedLossGainOnEquityInvestments>
    <fgen:UnrealizedLossGainOnEquityInvestments
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000392"
      unitRef="U_iso4217USD">88000</fgen:UnrealizedLossGainOnEquityInvestments>
    <fgen:UnrealizedLossGainOnEquityInvestments
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000393"
      unitRef="U_iso4217USD">-1120000</fgen:UnrealizedLossGainOnEquityInvestments>
    <fgen:InvestmentLossInUnconsolidatedVariableInterestEntity
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000394"
      unitRef="U_iso4217USD">-202000</fgen:InvestmentLossInUnconsolidatedVariableInterestEntity>
    <fgen:InvestmentLossInUnconsolidatedVariableInterestEntity
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000395"
      unitRef="U_iso4217USD">0</fgen:InvestmentLossInUnconsolidatedVariableInterestEntity>
    <fgen:InvestmentLossInUnconsolidatedVariableInterestEntity
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000396"
      unitRef="U_iso4217USD">0</fgen:InvestmentLossInUnconsolidatedVariableInterestEntity>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000397"
      unitRef="U_iso4217USD">-933000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000398"
      unitRef="U_iso4217USD">42000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000399"
      unitRef="U_iso4217USD">-53000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000400"
      unitRef="U_iso4217USD">72720000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000401"
      unitRef="U_iso4217USD">66267000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000402"
      unitRef="U_iso4217USD">52142000</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000403"
      unitRef="U_iso4217USD">0</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000404"
      unitRef="U_iso4217USD">0</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000405"
      unitRef="U_iso4217USD">1074000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000406"
      unitRef="U_iso4217USD">-258000</us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000407"
      unitRef="U_iso4217USD">0</us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000408"
      unitRef="U_iso4217USD">87000</us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000508"
      unitRef="U_iso4217USD">718000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000509"
      unitRef="U_iso4217USD">42365000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000510"
      unitRef="U_iso4217USD">-43486000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000409"
      unitRef="U_iso4217USD">11973000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000410"
      unitRef="U_iso4217USD">-35229000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000411"
      unitRef="U_iso4217USD">55232000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000412"
      unitRef="U_iso4217USD">9175000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000413"
      unitRef="U_iso4217USD">6887000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000414"
      unitRef="U_iso4217USD">0</us-gaap:IncreaseDecreaseInInventories>
    <fgen:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000511"
      unitRef="U_iso4217USD">124321000</fgen:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties>
    <fgen:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000512"
      unitRef="U_iso4217USD">-125210000</fgen:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties>
    <fgen:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000513"
      unitRef="U_iso4217USD">0</fgen:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000415"
      unitRef="U_iso4217USD">-123492000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000416"
      unitRef="U_iso4217USD">128598000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000417"
      unitRef="U_iso4217USD">129000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000418"
      unitRef="U_iso4217USD">-6843000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000419"
      unitRef="U_iso4217USD">3253000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000420"
      unitRef="U_iso4217USD">-1090000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <fgen:IncreaseDecreaseInAccountsPayableFromRelatedParty
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000514"
      unitRef="U_iso4217USD">1118000</fgen:IncreaseDecreaseInAccountsPayableFromRelatedParty>
    <fgen:IncreaseDecreaseInAccountsPayableFromRelatedParty
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000515"
      unitRef="U_iso4217USD">0</fgen:IncreaseDecreaseInAccountsPayableFromRelatedParty>
    <fgen:IncreaseDecreaseInAccountsPayableFromRelatedParty
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000516"
      unitRef="U_iso4217USD">0</fgen:IncreaseDecreaseInAccountsPayableFromRelatedParty>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000421"
      unitRef="U_iso4217USD">17731000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000422"
      unitRef="U_iso4217USD">-3051000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000423"
      unitRef="U_iso4217USD">3630000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000517"
      unitRef="U_iso4217USD">-36859000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000518"
      unitRef="U_iso4217USD">36439000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000519"
      unitRef="U_iso4217USD">172000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000424"
      unitRef="U_iso4217USD">31048000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000425"
      unitRef="U_iso4217USD">18288000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000426"
      unitRef="U_iso4217USD">5606000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000520"
      unitRef="U_iso4217USD">7169000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000521"
      unitRef="U_iso4217USD">-3137000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000522"
      unitRef="U_iso4217USD">-3908000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000427"
      unitRef="U_iso4217USD">45077000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000428"
      unitRef="U_iso4217USD">-49941000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000429"
      unitRef="U_iso4217USD">-5031000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <fgen:IncreaseDecreaseInLeaseObligations
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000430"
      unitRef="U_iso4217USD">0</fgen:IncreaseDecreaseInLeaseObligations>
    <fgen:IncreaseDecreaseInLeaseObligations
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000431"
      unitRef="U_iso4217USD">0</fgen:IncreaseDecreaseInLeaseObligations>
    <fgen:IncreaseDecreaseInLeaseObligations
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000432"
      unitRef="U_iso4217USD">32000</fgen:IncreaseDecreaseInLeaseObligations>
    <fgen:IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000433"
      unitRef="U_iso4217USD">-177000</fgen:IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities>
    <fgen:IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000434"
      unitRef="U_iso4217USD">194000</fgen:IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities>
    <fgen:IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000435"
      unitRef="U_iso4217USD">0</fgen:IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000436"
      unitRef="U_iso4217USD">-28236000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000437"
      unitRef="U_iso4217USD">52360000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000438"
      unitRef="U_iso4217USD">1636000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000439"
      unitRef="U_iso4217USD">81602000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000440"
      unitRef="U_iso4217USD">-78705000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000441"
      unitRef="U_iso4217USD">-76144000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000442"
      unitRef="U_iso4217USD">3994000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000443"
      unitRef="U_iso4217USD">5762000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000444"
      unitRef="U_iso4217USD">8020000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <fgen:PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000445"
      unitRef="U_iso4217USD">3896000</fgen:PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity>
    <fgen:PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000446"
      unitRef="U_iso4217USD">0</fgen:PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity>
    <fgen:PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000447"
      unitRef="U_iso4217USD">0</fgen:PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity>
    <fgen:ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000448"
      unitRef="U_iso4217USD">1063000</fgen:ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity>
    <fgen:ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000449"
      unitRef="U_iso4217USD">0</fgen:ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity>
    <fgen:ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000450"
      unitRef="U_iso4217USD">0</fgen:ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000451"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000452"
      unitRef="U_iso4217USD">7000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000453"
      unitRef="U_iso4217USD">184000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <fgen:PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000454"
      unitRef="U_iso4217USD">8192000</fgen:PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit>
    <fgen:PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000455"
      unitRef="U_iso4217USD">411299000</fgen:PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit>
    <fgen:PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000456"
      unitRef="U_iso4217USD">576880000</fgen:PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000457"
      unitRef="U_iso4217USD">10606000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000458"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000459"
      unitRef="U_iso4217USD">8167000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000460"
      unitRef="U_iso4217USD">456900000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000461"
      unitRef="U_iso4217USD">537072000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000462"
      unitRef="U_iso4217USD">54426000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000463"
      unitRef="U_iso4217USD">452487000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000464"
      unitRef="U_iso4217USD">120018000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000465"
      unitRef="U_iso4217USD">-522123000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromLongTermCapitalLeaseObligations
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000466"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromLongTermCapitalLeaseObligations>
    <us-gaap:ProceedsFromLongTermCapitalLeaseObligations
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000467"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromLongTermCapitalLeaseObligations>
    <us-gaap:ProceedsFromLongTermCapitalLeaseObligations
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000468"
      unitRef="U_iso4217USD">49000</us-gaap:ProceedsFromLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000469"
      unitRef="U_iso4217USD">0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000470"
      unitRef="U_iso4217USD">0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000471"
      unitRef="U_iso4217USD">6000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <fgen:RepaymentsOfFinanceLeaseLiabilities
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000472"
      unitRef="U_iso4217USD">12620000</fgen:RepaymentsOfFinanceLeaseLiabilities>
    <fgen:RepaymentsOfFinanceLeaseLiabilities
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000473"
      unitRef="U_iso4217USD">11925000</fgen:RepaymentsOfFinanceLeaseLiabilities>
    <fgen:RepaymentsOfFinanceLeaseLiabilities
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000474"
      unitRef="U_iso4217USD">0</fgen:RepaymentsOfFinanceLeaseLiabilities>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000475"
      unitRef="U_iso4217USD">403000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000476"
      unitRef="U_iso4217USD">403000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000477"
      unitRef="U_iso4217USD">403000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000478"
      unitRef="U_iso4217USD">11463000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000479"
      unitRef="U_iso4217USD">12750000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000480"
      unitRef="U_iso4217USD">15612000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000481"
      unitRef="U_iso4217USD">37829000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000482"
      unitRef="U_iso4217USD">20778000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000483"
      unitRef="U_iso4217USD">29847000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000484"
      unitRef="U_iso4217USD">13343000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000485"
      unitRef="U_iso4217USD">-4300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000486"
      unitRef="U_iso4217USD">13875000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000487"
      unitRef="U_iso4217USD">4695000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000488"
      unitRef="U_iso4217USD">-5000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000489"
      unitRef="U_iso4217USD">-8000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000490"
      unitRef="U_iso4217USD">552127000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000491"
      unitRef="U_iso4217USD">37008000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000492"
      unitRef="U_iso4217USD">-584400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000493"
      unitRef="U_iso4217USD">126266000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000921299_20181231"
      decimals="-3"
      id="F_000494"
      unitRef="U_iso4217USD">89258000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000921299_20171231"
      decimals="-3"
      id="F_000495"
      unitRef="U_iso4217USD">673658000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000496"
      unitRef="U_iso4217USD">678393000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000497"
      unitRef="U_iso4217USD">126266000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000921299_20181231"
      decimals="-3"
      id="F_000498"
      unitRef="U_iso4217USD">89258000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000499"
      unitRef="U_iso4217USD">135000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000500"
      unitRef="U_iso4217USD">174000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000501"
      unitRef="U_iso4217USD">218000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000502"
      unitRef="U_iso4217USD">884000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000503"
      unitRef="U_iso4217USD">460000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000504"
      unitRef="U_iso4217USD">276000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:LiabilitiesAssumed1
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000505"
      unitRef="U_iso4217USD">0</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000506"
      unitRef="U_iso4217USD">0</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_000507"
      unitRef="U_iso4217USD">24000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000524">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p id="NOTE_1_COMPANY" style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-weight:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;The Company&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;FibroGen, Inc. (&#x201c;FibroGen&#x201d; or the &#x201c;Company&#x201d;) is headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#x2019;s Republic of China (&#x201c;China&#x201d;). FibroGen is a leading biopharmaceutical company developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (&#x201c;HIF&#x201d;) biology, 2-oxoglutarate enzymology, connective tissue growth factor (&#x201c;CTGF&#x201d;) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Roxadustat, FibroGen&#x2019;s most advanced product, is an oral small molecule inhibitor of HIF prolyl hydroxylase&#160;&#160;activity that has received marketing authorization in China (tradename: &#x7231;&#x745e;&#x5353;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;) for the treatment of anemia caused by chronic kidney disease (&#x201c;CKD&#x201d;) in dialysis and non-dialysis patients. EVRENZO&#xae; (roxadustat) is also approved in Japan and Chile for the treatment of anemia associated with CKD in dialysis and non-dialysis patients. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s New Drug Application (&#x201c;NDA&#x201d;) filing in the United States (&#x201c;U.S.&#x201d;) for roxadustat for the treatment of anemia in dialysis and non-dialysis CKD patients was submitted in December 2019 to the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;). In December 2020, the FDA extended the review period of the NDA by three months for FibroGen to submit additional analyses of existing roxadustat clinical data, and set a new Prescription Drug User Fee Act goal date of March 20, 2021. On March 1, 2021, the FDA informed us that the Cardiovascular and Renal Drugs Advisory Committee will hold an advisory committee meeting to review the NDA for roxadustat. The date of the advisory committee meeting has not been set. As a result of this communication, we will not receive an approval decision by the PDUFA goal date. In Europe, the Marketing Authorization Application (&#x201c;MAA&#x201d;) filing for roxadustat for the treatment of anemia in dialysis and non-dialysis CKD patients was accepted for regulatory review by the European Medicines Agency (&#x201c;EMA&#x201d;) in May 2020 and Astellas expects an approval decision by the EMA mid-2021. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 3 development in China for anemia associated with myelodysplastic syndromes. Roxadustat is in Phase 2 clinical development for chemotherapy-induced anemia. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pamrevlumab, an anti-CTGF human monoclonal antibody, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis, locally advanced unresectable pancreatic cancer and Duchenne muscular dystrophy.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000525">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Summary of Significant Accounting Policies&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#x201c;U.S. GAAP&#x201d;). &lt;span style="color:#000000;"&gt;The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and its majority-owned subsidiaries, FibroGen Europe and FibroGen China Anemia Holdings, Ltd. (&#x201c;FibroGen Cayman&#x201d;). All inter-company transactions and balances have been eliminated in consolidation. For any variable interest entity for which FibroGen is not the primary beneficiary, the Company uses the equity method of accounting.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company operates in one segment &#x2014; the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable Interest Entity&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Accounting Standards Codification (&#x201c;ASC&#x201d;) 810, &lt;span style="font-style:italic;"&gt;Consolidation &lt;/span&gt;(&#x201c;ASC 810&#x201d;), when the Company obtains an economic interest in an entity, it evaluates the entity to determine if it should be deemed a variable interest entity (&#x201c;VIE&#x201d;), and, if so, whether the Company is the primary beneficiary and is therefore required to consolidate the VIE, based on significant judgment whether the Company (i) has the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) has the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On an ongoing basis, the Company re-evaluates &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the VIE assessment based on potential changes in facts and circumstances, including but not limited to, the shareholder loans to the entity and the execution of any future significant agreements between the entity and its shareholders and/or other third parties.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign Currency Translation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reporting currency of the Company and its subsidiaries is the U.S. dollar. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The functional currency of FibroGen Europe is the Euro. The assets and liabilities of FibroGen Europe are translated to U.S. dollars at exchange rates in effect at the balance sheet date. All income statement accounts are translated at monthly average exchange rates. Resulting foreign currency translation adjustments are recorded directly in accumulated other comprehensive income (loss) as a separate component of stockholders&#x2019; equity.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to April 1, 2020, the functional currency of the Company&#x2019;s subsidiary, FibroGen (China) Medical Technology Development Co., Ltd. (&#x201c;FibroGen Beijing&#x201d;), was the U.S. dollar. Accordingly, monetary assets and liabilities of FibroGen Beijing in the currencies other than U.S. dollar were remeasured using exchange rates in effect at the end of the period. Revenues and costs in its local currency, Renminbi Yuan (&#x201c;CNY&#x201d;), were remeasured using average exchange rates for the period, except for costs related to those balance sheet items that were remeasured using historical exchange rates. The resulting remeasurement gains and losses were included within interest income and other, net in the consolidated statements of operations as incurred. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 1, 2020, FibroGen Beijing adopted CNY as its functional currency based on reassessment of the primary economic operational environment of FibroGen Beijing that is mainly associated with its growing manufacturing and product sales activities conducted in CNY. As such, monetary assets and liabilities of FibroGen Beijing in currencies other than CNY are remeasured using exchange rates in effect at the end of the period. The assets and liabilities of FibroGen Beijing are translated to U.S. dollars at exchange rates in effect at the balance sheet date. All income statement accounts are translated at monthly average exchange rates. Resulting foreign currency translation adjustments are recorded directly in accumulated other comprehensive income (loss) as a separate component of stockholders&#x2019; equity. This change in FibroGen Beijing&#x2019;s functional currency was accounted for prospectively from April 1, 2020, and the prior consolidated financial statements were not restated. The related currency translation adjustment was $1.3 million at April 1, 2020 upon adoption.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The functional currency of FibroGen, Inc. and all other subsidiaries is the U.S. dollar. Accordingly, monetary assets and liabilities in the non-functional currency of these subsidiaries are remeasured using exchange rates in effect at the end of the period. Revenues and costs in local currency are remeasured using average exchange rates for the period, except for costs related to those balance sheet items that are remeasured using historical exchange rates. The resulting remeasurement gains and losses are included within interest income and other, net in the consolidated statements of operations as incurred and have not been material for all periods presented.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to risks associated with concentration of credit for cash and cash equivalents. Outside of short-term operating needs, the majority of cash on hand is invested in U.S. treasuries and money market funds. Any remaining cash is deposited with major financial institutions in the U.S., Finland, China and the Cayman Islands. At times, such deposits may be in excess of insured limits. The Company has not experienced any loss on its deposits of cash and cash equivalents. Included in current assets are significant balances of accounts receivable as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas Pharma Inc. (&#x201c;Astellas&#x201d;)&#x2014;Related party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AstraZeneca AB (&#x201c;AstraZeneca&#x201d;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company started selling roxadustat in China since late 2019 through a growing number of pharmaceutical distributors located in China. As of December 31, 2019, the aggregate accounts receivable from distributors was immaterial. As of December 31, 2020, along with the growing roxadustat sales in China, the aggregate accounts receivable from distributors represented 64% of the consolidated accounts receivable, with no material balance from any individual distributor.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s business is subject to risks and uncertainties, including those related to COVID-19 and the related shelter-in-place, stay-at-home and other similar governmental orders issued in response to the COVID-19 pandemic.&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#x2019;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, obtaining second source suppliers, &lt;span style="font-size:9.5pt;"&gt;regulatory approval from the FDA or other regulatory authorities, &lt;/span&gt;the results of clinical trials and the achievement of milestones, market acceptance of the Company&#x2019;s product candidates, competition from other products and larger companies, protection of proprietary technology, strategic relationships and dependence on key individuals.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Starting in the first quarter of 2020, the Company experienced slower enrollment in its clinical trials due to the interruption caused by COVID-19 in the worldwide healthcare system. The future impact of the COVID-19 pandemic on the Company&#x2019;s business is highly uncertain and difficult to predict. The COVID-19 pandemic may continue to affect enrollment in and initiation of the Company&#x2019;s clinical trials, and could affect the Company&#x2019;s supply chain if further social distancing and other business restrictions are put in place by various government entities, particularly in China and the U.S. COVID-19 may affect the health of the Company&#x2019;s employees limiting the Company&#x2019;s productivity. The COVID-19 pandemic may also impact the market for the Company&#x2019;s products and product candidates in the future, affecting sales of the Company&#x2019;s products. Such possible risks and uncertain impacts from the COVID-19 pandemic could have a material adverse effect on the Company&#x2019;s drug development, commercialization revenues, and other portions of its business, and in particular, could impact the Company&#x2019;s assumptions of accounts receivable collectability, fair value measurements of investments, liquidity, and development costs. The extent of the pandemic&#x2019;s effect on the Company&#x2019;s operational and financial performance will depend in large part on future developments, particularly with respect to the scope and severity of the pandemic, governmental restrictions put in place to fight the pandemic, and the development of vaccines and treatments for COVID-19. Due to the inherent uncertainty of the unprecedented and rapidly evolving situation, the Company is unable to estimate the likely impact of the COVID-19 pandemic on its future operations.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash, Cash Equivalents and Restricted Time Deposits&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with maturities of three months or less and that are used in the Company&#x2019;s cash management activities at the date of purchase to be cash equivalents. Cash and cash equivalents also include money market accounts and various deposit accounts. Restricted time deposits include an irrevocable standby letter of credit as security deposit for a long-term property lease with the Company&#x2019;s landlord. Restricted time deposits as of December&#160;31, 2020 and 2019 totaled $2.1 million and $2.1&#160;million, respectively. As of December&#160;31, 2020 and 2019, a total of $66.0 million and $11.9 million, respectively, of the Company&#x2019;s cash and cash equivalents was held outside of the U.S. in the Company&#x2019;s foreign subsidiaries to be used primarily for the Company&#x2019;s China operations.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, the Company&#x2019;s investments consist of diversified bond funds and marketable equity investments. Those investments with original maturities of greater than three months and remaining maturities of less than 12&#160;months (365 days) are considered short-term investments. Those investments with maturities greater than 12 months (365 days) from the balance sheet date are considered long-term investments. When such investments are held, the Company&#x2019;s investments classified as available-for-sale are recorded at fair value based upon quoted market prices at period end. Unrealized gains and losses for available-for-sale debt investments that are deemed temporary in nature are recorded in accumulated other comprehensive income (loss) as a separate component of stockholder&#x2019; equity. Marketable equity securities are equity securities with readily determinable fair value, and are measured and recorded at fair value. Realized and unrealized gains or losses resulting from changes in value and sale of the Company&#x2019;s marketable equity investments are recorded in other income (expenses) in the consolidated statement of operations.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Premiums and discounts are amortized (accreted) over the life of the related security as an adjustment to its yield. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of investments sold.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying amounts of certain of the Company&#x2019;s financial instruments including cash equivalents, investments, receivables, accounts payable and accrued liabilities approximate fair value (refer to Note 5, &lt;span style="font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;).&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade accounts receivable&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The allowance for doubtful accounts is based on the Company&#x2019;s assessment of the collectability of customer accounts. The Company makes estimates of expected credit losses for the allowance for doubtful accounts by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, current economic and regulatory conditions that may affect a customer&#x2019;s ability to pay, and estimates of expected future losses. The Company&#x2019;s bad debt expense for the years ended December&#160;31, 2020, 2019 and 2018 and the allowance for doubtful accounts as of December&#160;31, 2020 and 2019 were immaterial.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Credit losses &#x2013; Available-for-sale debt securities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company periodically assesses its available-for-sale investments for other-than-temporary impairment. For debt securities in an unrealized loss position, the Company first considers its intent to sell, or whether it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis. If either of these criteria are met, the amortized cost basis of such debt securities is written down to fair value through interest and other, net. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in the fair value of such debt securities has resulted from credit losses or other factors. The Company considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the securities, among other factors. If this assessment indicates that a credit loss may exist, the Company then compares the present value of cash flows expected to be collected from such securities to their amortized cost basis. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded through interest and other, net, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive income.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in the allowance for credit losses are recorded as provision for, or reversal of, credit loss expense. Losses are charged against the allowance when the Company believes that an available-for-sale security is confirmed uncollectable or when either of the criteria regarding intent or requirement to sell is met.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories are stated at the lower of cost or net realizable value, on a first-in, first-out, or FIFO, basis. The cost of the Company&#x2019;s inventories in China is determined using full absorption and standard costing method. The Company reviews the standard cost of raw materials, work-in-process and finished goods annually and more often as appropriate to ensure that its inventories approximate current actual cost. The cost of the Company&#x2019;s inventories in the U.S. uses actual costs to determine its cost basis. The cost of inventories includes direct material cost, direct labor and manufacturing overhead.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When the technical feasibility of the Company&#x2019;s future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, the Company capitalizes pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the status in the validation process in significant jurisdictions, regulatory application and approval process, and terms and condition for future sale of such inventory or future alternative use. The pre-launch inventory cost includes purchase cost of raw materials, &lt;span style="color:#000000;"&gt;cost paid to contract manufacturers for inventory manufacturing, freight and custom charges, and certain direct internal labor and overhead expenses.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company &lt;span style="color:#auto;"&gt;periodically&lt;/span&gt; reviews its inventories to identify obsolete, slow-moving, excess or otherwise unsaleable items. If obsolete, excess or unsaleable items are observed and there are no alternate uses for the &lt;span style="color:#auto;"&gt;inventory&lt;/span&gt;, an inventory valuation adjustment is recorded through a charge to cost of goods sold on the Company&#x2019;s consolidated statements of operations. The establishment of inventory valuation reserves, together with the calculation of the amount of such reserves, requires judgment including consideration of many factors, such as estimates of future product demand and product expiration period, among others.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Computer equipment, laboratory equipment, machinery and furniture and fixtures are depreciated over three to five years. Leasehold improvements are recorded at cost and amortized over the term of the lease or their useful life, whichever is shorter.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines if an arrangement is or contains a lease at inception date when it is given control of the underlying assets. The Company elected the practical expedient not to apply the lease recognition and measurement requirements to short-term leases, which is any lease with a term of 12 months or less as of the commencement date that does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s building leases previously accounted for as build-to-suit arrangements prior to the adoption of Accounting Standards Codification (&#x201c;ASC&#x201d;) 842 - &lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt; (&#x201c;ASC 842&#x201d;) are accounted for as finance leases under the requirements of ASC 842.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As its leases do not typically provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company reassesses the incremental borrowing rate periodically for application to any new leases or lease modifications, which approximates the rate at which the Company would borrow, on a secured basis, in the country where the lease was executed.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease ROU assets include any lease payments made and initial direct costs incurred. The Company has lease agreements with lease and non-lease components. The Company generally accounts for each lease component separately from the non-lease components, and excludes all non-lease components from the calculation of minimum lease payments in measuring the ROU asset and lease liability. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease terms. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Regarding leases denominated in a foreign currency, the related ROU assets and the corresponding ROU asset amortization costs are remeasured using the exchange rate in effect at the date of initial recognition; the related lease liabilities are remeasured using the exchange rate in effect at the end of the reporting period; the lease costs and interest expenses related to lease liability accretion are remeasured using average exchange rates for the reporting period.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance leases are included in finance lease ROU assets, finance lease liabilities, current and non-current on the Company&#x2019;s consolidated balance sheets. Operating leases are included in other assets, accrued and other current liabilities, and other long-term liabilities on the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. If the Company determines that an impairment trigger has been met, the Company evaluates the realizability of its long-lived assets based on a comparison of projected undiscounted cash flows from use and eventual disposition with the carrying value of the related asset. Any write-downs (which are measured based on the difference between the fair value and the carrying value of the asset) are treated as permanent reductions in the carrying amount of the assets (asset group). Based on this evaluation, the Company believes that, as of each of the balance sheet dates presented, none of the Company&#x2019;s long-lived assets were impaired. The Company&#x2019;s impairment of long-lived assets for the years ended December&#160;31, 2020, 2019 and 2018 were immaterial.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenues under collaboration agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s collaboration agreements include multiple performance obligations comprised of promised services, or bundles of services, that are distinct. Services that are not distinct are combined with other services in the agreement until they form a distinct bundle of services. The Company&#x2019;s process for identifying performance obligations and an enumeration of each obligation for each agreement is outlined in Note 4, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues&lt;/span&gt;. Determining the performance obligations within a collaboration agreement often involves significant judgment and is specific to the facts and circumstances contained in each agreement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has identified the following material promises under its collaboration agreements: (1) license of FibroGen technology, (2) the performance of co-development services, including manufacturing of clinical supplies and other services during the development period, and (3) manufacture of commercial supply. The evaluation as to whether these promises are distinct, and therefore represent separate performance obligations, is described in more details in Note 4, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For revenue recognition purposes, the Company determines that the term of its collaboration agreements begin on the effective date and ends upon the completion of all performance obligations contained in the agreements. In each agreement, the contract term is defined as the period in which parties to the contract have present and enforceable rights and obligations. The Company believes that the existence of what it considers to be substantive termination penalties on the part of the counterparty create sufficient incentive for the counterparty to avoid exercising its right to terminate the agreement unless in exceptionally rare situations.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price for each collaboration agreement is determined based on the amount of consideration the Company expects to be entitled for satisfying all performance obligations within the agreement. The Company&#x2019;s collaboration agreements include payments to the Company of one or more of the following: non-refundable upfront license fees; co-development billings; development, regulatory, and commercial milestone payments; payments from sales of active pharmaceutical ingredient (&#x201c;API&#x201d;); payments from sales of bulk drug product and royalties on net sales of licensed products. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upfront license fees are non-contingent and non-refundable in nature and are included in the transaction price at the point when the license fees become due to the Company. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Co-development billings resulting from the Company&#x2019;s research and development efforts, which are reimbursable under its collaboration agreements, are considered variable consideration. Determining the reimbursable amount of research and development efforts requires detailed analysis of the terms of the collaboration agreements and the nature of the research and development efforts incurred. Determining the amount of variable consideration from co-development billings requires the Company to make estimates of future research and development efforts, which involves significant judgment. Co-development billings are allocated entirely to the co-development services performance obligation when amounts are related specifically to research and development efforts necessary to satisfy the performance obligation, and such an allocation is consistent with the allocation objective.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Milestone payments are also considered variable consideration, which requires the Company to make estimates of when achievement of a particular milestone becomes probable. Similar to other forms of variable consideration, milestone payments are included in the transaction price when it becomes probable that such inclusion would not result in a significant revenue reversal. Milestone payments are therefore included in the transaction price when achievement of the milestone becomes probable.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For arrangements that include sales-based royalties and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from its collaboration arrangements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price is allocated to performance obligations based on their relative standalone selling price (&#x201c;SSP&#x201d;), with the exception of co-development billings allocated entirely to co-development services performance obligations. The SSP is determined based on observable prices at which the Company separately sells the products and services. If an SSP is not directly observable, then the Company will estimate the SSP considering marketing conditions, entity-specific factors, and information about the customer or class of customer that is reasonably available. The process for determining SSP involves significant judgment and includes consideration of multiple factors, including assumptions related to the market opportunity and the time needed to commercialize a product candidate pursuant to the relevant license, estimated direct expenses and other costs, which include the rates normally charged by contract research and contract manufacturing organizations for development and manufacturing obligations, and rates that would be charged by qualified outsiders for committee services.&#160;&#160; &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant judgment may be required in determining whether a performance obligation is distinct, determining the amount of variable consideration to be included in the transaction price, and estimating the SSP of each performance obligation. An enumeration of the Company&#x2019;s significant judgments is outlined in Note 4, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For each performance obligation identified within an arrangement, the Company determines the period over which the promised services are transferred and the performance obligation is satisfied. Service revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. For each performance obligation satisfied over time, the Company assesses the proper method to be used for revenue recognition, either an input method to measure progress toward the satisfaction of services or an output method of determining the progress of completion of performance obligation.&lt;span style="font-weight:bold;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Drug product revenue&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue includes commercial-grade API or bulk drug product sales to AstraZeneca and Astellas, and is recognized when the Company fulfills the shipment obligations. The drug product revenue is accounted for as variable consideration, estimated at the time of sale using the expected value method. The Company applies significant judgment in estimating the variable consideration, which involves the use of significant assumptions such as the future list price adjustments set by the Japanese Ministry of Health, Labour and Welfare, product mix, and timing of processing of API into bulk drug product.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2018, FibroGen and Astellas entered into an amendment to the Japan Agreement that allows Astellas to manufacture roxadustat drug product for commercialization in Japan (the &#x201c;Japan Amendment&#x201d;). Under this amendment, FibroGen would continue to manufacture and supply roxadustat API to Astellas for the roxadustat commercial launch in Japan. The drug product revenue represents variable consideration and is estimated based on the quantity of product shipped, actual listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and possible future changes to the listed price, adjusted for the timing of and estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk drug product tablets, and estimated yield from the manufacture of bulk product tablets, among others.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Europe Agreement with Astellas, Astellas has an option to purchase roxadustat bulk drug product in support of commercial supplies. The drug product revenue amount represents variable consideration and was estimated based on the quantity of product shipped and an estimated price. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price per strength, which is estimated to be realized by Astellas from the end sale of roxadustat in its approved territories.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2020, the Company entered into Commercial Supply Agreement under the U.S./RoW Agreement with AstraZeneca to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The drug product revenue amount represents variable consideration and was estimated based on the quantity of product shipped and an estimated price. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price per strength, which is estimated to be realized by AstraZeneca from the end sale of roxadustat in its approved territories.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the drug product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. Estimating variable consideration and the related constraint requires the use of significant management judgment. The Company reviews new information that may affect its variable consideration estimate at every reporting period and record revenue adjustment, if certain and material. Actual amounts of consideration ultimately received in the future may differ from the Company&#x2019;s estimates, for which the Company will adjust these estimates and affect the drug product revenue in the period such variances become known. The amount constrained as of December 31, 2020 was $6.0 million related to the drug product shipment to Astellas under the Europe Agreement in the fourth quarter of 2020. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As each of the Company&#x2019;s collaboration agreements provide for annual true up to the considerations paid for its commercial supplies, the Company will re-evaluate the transaction price in each reporting period and record adjustment to revenue as uncertain events are resolved or other changes in circumstances occur.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Product revenue, net&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company sells roxadustat in China through a number of pharmaceutical distributors located in China. These pharmaceutical distributors are the Company&#x2019;s customers. Hospitals order roxadustat through a distributor and the Company ships the product directly to the distributors. The delivery of roxadustat to a distributor represents a single performance obligation.&#160;Distributors are responsible for delivering product to end users, primarily hospitals. Distributors bear inventory risk once they receive and accept the product. Product revenue is recognized when control of the promised good is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for the product. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The period between the transfer of control of the promised goods and when the Company receives payment is based on a general 60-day payment term. As such, product revenue is not adjusted for the effects of a significant financing component. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue is recorded at the net sales prices (transaction price) which includes the following estimates of variable consideration:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Price adjustment:&lt;/span&gt;&lt;span style="color:#000000;"&gt; In December 2019, China&#x2019;s National Healthcare Security Administration released price guidance for roxadustat under the National Reimbursement Drug List (&#x201c;NRDL&#x201d;), effective January 1, 2020. Any channel inventories as of January 1, 2020 that had not been sold to hospitals by distributors, or to patients by hospitals, were eligible for a price adjustment under the price protection. The price adjustment is calculated based on estimated channel inventory levels at January 1, 2020. If price guidance changes in the future, the price adjustment will be calculated in the same manner;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Contractual sales rebate&lt;/span&gt;&lt;span style="color:#000000;"&gt;: The contractual sales rebate is calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. The contractual sales rebate is recorded as a reduction to revenue at the point of sale to the distributor;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Key account hospital sales rebate&lt;/span&gt;&lt;span style="color:#000000;"&gt;: An additional sales rebate is provided to a distributor for product sold to key account hospitals as a percentage of gross sales made by the distributor to eligible hospitals. This additional rebate is recorded as a reduction to revenue at the point of sale to the distributor; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Transfer fee discount&lt;/span&gt;&lt;span style="color:#000000;"&gt;: The transfer fee discount is offered to a distributor who has its downstream distributors supply to eligible hospitals. This discount is calculated based on a percentage of gross sales made to the downstream distributors, and recorded as a reduction to revenue as incurred; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Sales return&lt;/span&gt;&lt;span style="color:#000000;"&gt;: Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product&#x2019;s expiration date; and&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Non-key account hospital listing award: &lt;/span&gt;&lt;span style="color:#000000;"&gt;A one-time fixed-amount award is offered to a distributor who successfully lists the product with an eligible hospital, and who meets certain requirements. The Company considers this particular award to be an upfront payment to a customer within the definitions of ASC 606. The non-key account hospital listing award is capitalized when the distributor meets eligibility requirements, and amortized as reduction to product revenue over future sales orders made by the distributor until exhausted. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The calculation of the above variable consideration is based on gross sales to the distributor, or estimated utilizing best available information from the distributor, maximum known exposures and other available information including estimated channel inventory levels and estimated sales made by the distributor to hospitals, which involve a substantial degree of judgment. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The above rebates and discounts all together are eligible to be applied against the distributor&#x2019;s future sales order, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible and in the same period that the related revenue is recorded. Due to the distributor&#x2019;s legal right to offset, at each balance sheet date, the liability for rebates and discounts are presented as reductions of gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The distributor&#x2019;s legal right of offset is calculated at the individual distributor level.&lt;span style="font-weight:bold;color:#FF0000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses consist of independent research and development costs and the gross amount of costs associated with work performed under collaboration agreements. Research and development costs include employee-related expenses, expenses incurred under agreements with clinical research organizations, other clinical and preclinical costs and allocated direct and indirect overhead costs, such as facilities costs, information technology costs and other overhead. All research and development costs are expensed as incurred.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical Trial Accruals&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with clinical research organizations and clinical sites. The Company determines the costs to be recorded based upon validation with the external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, General and Administrative Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative (&#x201c;SG&amp;amp;A&#x201d;) expenses consist primarily of employee-related expenses for executive, operational, finance, legal, compliance and human resource functions. SG&amp;amp;A expenses also include facility-related costs, professional fees, accounting and legal services, other outside services including co-promotional expenses, recruiting fees and expenses associated with obtaining and maintaining patents.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company utilizes the asset and liability method of accounting for income taxes, which requires the recognition of deferred tax assets and liabilities for expected future consequences of temporary differences between the financial reporting and income tax bases of assets and liabilities using enacted tax rates. Management makes estimates, assumptions and judgments to determine the Company&#x2019;s provision for income taxes and for deferred tax assets and liabilities, and any valuation allowances recorded against the Company&#x2019;s deferred tax assets. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The calculation of the Company&#x2019;s current provision for income taxes involves the use of estimates, assumptions and judgments while taking into account current tax laws, interpretation of current tax laws and possible outcomes of future tax audits. The Company has established reserves to address potential exposures related to tax positions that could be challenged by tax authorities. Although the Company believes its estimates, assumptions and judgments to be reasonable, any changes in tax law or its interpretation of tax laws and the resolutions of potential tax audits could significantly impact the amounts provided for income taxes in the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The calculation of the Company&#x2019;s deferred tax asset balance involves the use of estimates, assumptions and judgments while taking into account estimates of the amounts and type of future taxable income. Actual future operating results and the underlying amount and type of income could differ materially from the Company&#x2019;s estimates, assumptions and judgments thereby impacting the Company&#x2019;s financial position and results of operations.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2020, the Company transferred certain intellectual property rights relating to its Chinese business between its wholly owned subsidiaries that are based in different tax jurisdictions. Refer to Note 13, &lt;span style="font-style:italic;"&gt;Income Taxes&lt;/span&gt;, for more information. The establishment of a deferred tax asset from the intra-entity transfer of intangible assets required the Company to make significant estimates and assumptions to determine the fair value of intellectual property rights transferred, which include but are not limited to, its expectations of discount rate, revenue volume and price.&lt;span style="Background-color:#F8F9FA;color:#202124;"&gt; The accuracy of these estimates could be affected by unforeseen events or actual results, and the sustainability of the Company&#x2019;s future tax benefits is dependent upon the acceptance of these valuation estimates and assumptions by the taxing authorities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has adopted ASC 740-10, &lt;span style="font-style:italic;"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;, that prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company&#x2019;s income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company includes interest and penalties related to unrecognized tax benefits within income tax expense in the Consolidated Statements of Operations. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company maintains equity incentive plans under which incentive and nonqualified stock options are granted to employees and non-employee consultants. Compensation expense relating to non-employee stock options has not been material for all the periods presented.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures and recognizes compensation expense for all stock options and restricted stock units (&#x201c;RSUs&#x201d;) granted to its employees and directors based on the estimated fair value of the award on the grant date. The Company uses the Black-Scholes valuation model to estimate the fair value of stock option awards. The fair value is recognized as expense, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis. The Company believes that the fair value of stock options granted to non-employees is more reliably measured than the fair value of the services received. The determination of the grant date fair value of options using an option pricing model is affected by the Company&#x2019;s estimated Common Stock fair value and requires management to make a number of assumptions including the expected life of the option, the volatility of the underlying stock, the risk-free interest rate and expected dividends.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive Income (Loss)&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is required to report all components of comprehensive income (loss), including net loss, in the consolidated financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation adjustments. Comprehensive gains (losses) have been reflected in the consolidated statements of comprehensive income (loss) for all periods presented.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recently Issued and Adopted Accounting Guidance&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2018-15, &lt;span style="font-style:italic;"&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. &lt;/span&gt;This guidance requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This guidance was effective for annual reporting periods beginning after December 15, 2019, including interim periods. The Company adopted this guidance on January 1, 2020 using the prospective method, and the adoption of this guidance did not have material impact to the Company&#x2019;s consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;span style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;(&#x201c;ASU 2016-13&#x201d;). This guidance is intended to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. This guidance requires the measurement of financial assets with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. This guidance requires an impairment model, known as the current expected credit loss model, which is based on expected losses rather than incurred losses. Entities are required to carry an allowance for expected credit losses for financial assets, including most debt instruments (except those carried at fair value) and trade receivables. In November 2019, the FASB issued ASU No. 2019-11, &lt;span style="font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments-Credit Losses &lt;/span&gt;(&#x201c;ASU 2019-11&#x201d;)&lt;span style="font-style:italic;"&gt;, &lt;/span&gt;which has the same effective dates and transition requirements as ASU 2016-13. ASU 2016-13 and ASU 2019-11 were effective for annual reporting periods beginning after December 15, 2019 including interim periods. The Company&#x2019;s investment portfolio primarily consists of U.S. Treasury bills and notes carried at fair value, which is required to follow the impairment model under Topic 326. The Company adopted this guidance on January 1, 2020. Based on the composition of the Company&#x2019;s trade receivables and investment portfolio, economic conditions and historical credit loss activity, the adoption of this guidance did not have material impact to the Company&#x2019;s consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;span style="font-style:italic;"&gt;Leases (Topic 842). &lt;/span&gt;The Company adopted the lease guidance under ASC 842 as of January 1, 2019, using the modified retrospective transition method, through a cumulative-effect adjustment. The adoption of this guidance resulted in a reduction of $8.7 million to the Company&#x2019;s accumulated deficit and also impacted various balance sheet line items in its consolidated balance sheet as of January 1, 2019 upon adoption. The adoption of this guidance did not have a material impact to the Company&#x2019;s consolidated statement of operations or consolidated statement of cash flows for the year ended December 31, 2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2018, the FASB issued ASU 2018-02, &lt;span style="font-style:italic;"&gt;Income Statement - Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income&lt;/span&gt;. The Company adopted this guidance on January 1, 2019 using the modified retrospective approach, with a reduction of $0.6 million to its accumulated other comprehensive loss and an increase of $0.6 million to its accumulated deficit as of January 1, 2019 upon adoption. The adoption of this guidance had no impact to the Company&#x2019;s consolidated statement of operations or consolidated statement of cash flows for the year ended December 31, 2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2016, the FASB issued ASU 2016-01, &lt;span style="font-style:italic;"&gt;Financial Instruments-Overall (Subtopic 825-10)&lt;/span&gt;. The Company adopted this guidance as of January 1, 2018 using the modified retrospective approach, with an increase of $1.3 million to its accumulated other comprehensive loss and a reduction of $1.3 million to its accumulated deficit as of January 1, 2018 upon adoption. The adoption of this guidance had no impact to the Company&#x2019;s consolidated statement of cash flows for the year ended December 31, 2018. &lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Guidance Not Yet Adopted&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the FASB issued ASU 2020-04, &lt;span style="font-style:italic;"&gt;Reference Rate Reform (Topic 848): &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt; (&#x201c;ASU&lt;span style="font-style:italic;"&gt; &lt;/span&gt;2020&lt;span style="font-style:italic;"&gt;-&lt;/span&gt;04&lt;span style="font-style:italic;"&gt;&#x201d;&lt;/span&gt;)&lt;span style="font-style:italic;"&gt;,&lt;/span&gt; which provides companies with optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform. This guidance is effective as of March 12, 2020 through December 31, 2022. Subsequently in January 2021, the FASB issued ASU 2021-01, &lt;span style="font-style:italic;"&gt;Reference Rate Reform (Topic 848): Scope&lt;/span&gt;, which clarifies ASU 2020-04 and provides certain optional expedients that allow derivative instruments impacted by changes in the interest rate used for margining, discounting or contract price alignment to qualify for certain optional relief. ASU 2021-01 is effective in the same timeframe as ASU 2020-04. The relief offered by this guidance, if adopted, is available to companies for the period March 12, 2020 through December 31, 2022. &lt;span style="Background-color:#FFFFFF;"&gt;The Company has certain lease arrangements that are linked to LIBOR. The Company is in the process of evaluating options for transitioning away from LIBOR and expects to complete by the time LIBOR is phased out. The Company did not elect to apply any of the expedients or exceptions as of and for the year ended December 31, 2020 and is currently evaluating the impact on its consolidated financial statements and related disclosures upon adoption of this guidance.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;span style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;. This guidance simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step up in the tax basis of goodwill, and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. This guidance is effective for annual reporting periods beginning after December 15, 2020 including interim periods, with early adoption permitted. The Company does not plan to early adopt this guidance and does not anticipate a material impact to its consolidated financial statements upon adoption of this guidance.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000540">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#x201c;U.S. GAAP&#x201d;). &lt;span style="color:#000000;"&gt;The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and its majority-owned subsidiaries, FibroGen Europe and FibroGen China Anemia Holdings, Ltd. (&#x201c;FibroGen Cayman&#x201d;). All inter-company transactions and balances have been eliminated in consolidation. For any variable interest entity for which FibroGen is not the primary beneficiary, the Company uses the equity method of accounting.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company operates in one segment &#x2014; the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. &lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0000921299_20200101_20201231"
      decimals="INF"
      id="F_000616"
      unitRef="U_fgenSegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="C_0000921299_20200101_20201231" id="F_000541">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable Interest Entity&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Accounting Standards Codification (&#x201c;ASC&#x201d;) 810, &lt;span style="font-style:italic;"&gt;Consolidation &lt;/span&gt;(&#x201c;ASC 810&#x201d;), when the Company obtains an economic interest in an entity, it evaluates the entity to determine if it should be deemed a variable interest entity (&#x201c;VIE&#x201d;), and, if so, whether the Company is the primary beneficiary and is therefore required to consolidate the VIE, based on significant judgment whether the Company (i) has the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) has the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On an ongoing basis, the Company re-evaluates &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the VIE assessment based on potential changes in facts and circumstances, including but not limited to, the shareholder loans to the entity and the execution of any future significant agreements between the entity and its shareholders and/or other third parties.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000542">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign Currency Translation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reporting currency of the Company and its subsidiaries is the U.S. dollar. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The functional currency of FibroGen Europe is the Euro. The assets and liabilities of FibroGen Europe are translated to U.S. dollars at exchange rates in effect at the balance sheet date. All income statement accounts are translated at monthly average exchange rates. Resulting foreign currency translation adjustments are recorded directly in accumulated other comprehensive income (loss) as a separate component of stockholders&#x2019; equity.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to April 1, 2020, the functional currency of the Company&#x2019;s subsidiary, FibroGen (China) Medical Technology Development Co., Ltd. (&#x201c;FibroGen Beijing&#x201d;), was the U.S. dollar. Accordingly, monetary assets and liabilities of FibroGen Beijing in the currencies other than U.S. dollar were remeasured using exchange rates in effect at the end of the period. Revenues and costs in its local currency, Renminbi Yuan (&#x201c;CNY&#x201d;), were remeasured using average exchange rates for the period, except for costs related to those balance sheet items that were remeasured using historical exchange rates. The resulting remeasurement gains and losses were included within interest income and other, net in the consolidated statements of operations as incurred. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 1, 2020, FibroGen Beijing adopted CNY as its functional currency based on reassessment of the primary economic operational environment of FibroGen Beijing that is mainly associated with its growing manufacturing and product sales activities conducted in CNY. As such, monetary assets and liabilities of FibroGen Beijing in currencies other than CNY are remeasured using exchange rates in effect at the end of the period. The assets and liabilities of FibroGen Beijing are translated to U.S. dollars at exchange rates in effect at the balance sheet date. All income statement accounts are translated at monthly average exchange rates. Resulting foreign currency translation adjustments are recorded directly in accumulated other comprehensive income (loss) as a separate component of stockholders&#x2019; equity. This change in FibroGen Beijing&#x2019;s functional currency was accounted for prospectively from April 1, 2020, and the prior consolidated financial statements were not restated. The related currency translation adjustment was $1.3 million at April 1, 2020 upon adoption.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The functional currency of FibroGen, Inc. and all other subsidiaries is the U.S. dollar. Accordingly, monetary assets and liabilities in the non-functional currency of these subsidiaries are remeasured using exchange rates in effect at the end of the period. Revenues and costs in local currency are remeasured using average exchange rates for the period, except for costs related to those balance sheet items that are remeasured using historical exchange rates. The resulting remeasurement gains and losses are included within interest income and other, net in the consolidated statements of operations as incurred and have not been material for all periods presented.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax
      contextRef="C_0000921299_20200401"
      decimals="-5"
      id="F_000617"
      unitRef="U_iso4217USD">1300000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax>
    <us-gaap:UseOfEstimates contextRef="C_0000921299_20200101_20201231" id="F_000543">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates.&lt;/p&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0000921299_20200101_20201231" id="F_000544">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to risks associated with concentration of credit for cash and cash equivalents. Outside of short-term operating needs, the majority of cash on hand is invested in U.S. treasuries and money market funds. Any remaining cash is deposited with major financial institutions in the U.S., Finland, China and the Cayman Islands. At times, such deposits may be in excess of insured limits. The Company has not experienced any loss on its deposits of cash and cash equivalents. Included in current assets are significant balances of accounts receivable as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas Pharma Inc. (&#x201c;Astellas&#x201d;)&#x2014;Related party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AstraZeneca AB (&#x201c;AstraZeneca&#x201d;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company started selling roxadustat in China since late 2019 through a growing number of pharmaceutical distributors located in China. As of December 31, 2019, the aggregate accounts receivable from distributors was immaterial. As of December 31, 2020, along with the growing roxadustat sales in China, the aggregate accounts receivable from distributors represented 64% of the consolidated accounts receivable, with no material balance from any individual distributor.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000572">The Company has not experienced any loss on its deposits of cash and cash equivalents. Included in current assets are significant balances of accounts receivable as follows:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas Pharma Inc. (&#x201c;Astellas&#x201d;)&#x2014;Related party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AstraZeneca AB (&#x201c;AstraZeneca&#x201d;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="2"
      id="F_000618"
      unitRef="U_xbrlipure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231"
      decimals="2"
      id="F_000619"
      unitRef="U_xbrlipure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231"
      decimals="2"
      id="F_000620"
      unitRef="U_xbrlipure">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231"
      decimals="2"
      id="F_000621"
      unitRef="U_xbrlipure">0.81</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_fgenAccountsReceivableFromDistributorsMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_20200101_20201231"
      decimals="2"
      id="F_000622"
      unitRef="U_xbrlipure">0.64</us-gaap:ConcentrationRiskPercentage1>
    <fgen:OtherRisksAndUncertaintiesPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000545">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s business is subject to risks and uncertainties, including those related to COVID-19 and the related shelter-in-place, stay-at-home and other similar governmental orders issued in response to the COVID-19 pandemic.&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#x2019;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, obtaining second source suppliers, &lt;span style="font-size:9.5pt;"&gt;regulatory approval from the FDA or other regulatory authorities, &lt;/span&gt;the results of clinical trials and the achievement of milestones, market acceptance of the Company&#x2019;s product candidates, competition from other products and larger companies, protection of proprietary technology, strategic relationships and dependence on key individuals.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Starting in the first quarter of 2020, the Company experienced slower enrollment in its clinical trials due to the interruption caused by COVID-19 in the worldwide healthcare system. The future impact of the COVID-19 pandemic on the Company&#x2019;s business is highly uncertain and difficult to predict. The COVID-19 pandemic may continue to affect enrollment in and initiation of the Company&#x2019;s clinical trials, and could affect the Company&#x2019;s supply chain if further social distancing and other business restrictions are put in place by various government entities, particularly in China and the U.S. COVID-19 may affect the health of the Company&#x2019;s employees limiting the Company&#x2019;s productivity. The COVID-19 pandemic may also impact the market for the Company&#x2019;s products and product candidates in the future, affecting sales of the Company&#x2019;s products. Such possible risks and uncertain impacts from the COVID-19 pandemic could have a material adverse effect on the Company&#x2019;s drug development, commercialization revenues, and other portions of its business, and in particular, could impact the Company&#x2019;s assumptions of accounts receivable collectability, fair value measurements of investments, liquidity, and development costs. The extent of the pandemic&#x2019;s effect on the Company&#x2019;s operational and financial performance will depend in large part on future developments, particularly with respect to the scope and severity of the pandemic, governmental restrictions put in place to fight the pandemic, and the development of vaccines and treatments for COVID-19. Due to the inherent uncertainty of the unprecedented and rapidly evolving situation, the Company is unable to estimate the likely impact of the COVID-19 pandemic on its future operations.&lt;/p&gt;</fgen:OtherRisksAndUncertaintiesPolicyTextBlock>
    <fgen:CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000546">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash, Cash Equivalents and Restricted Time Deposits&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with maturities of three months or less and that are used in the Company&#x2019;s cash management activities at the date of purchase to be cash equivalents. Cash and cash equivalents also include money market accounts and various deposit accounts. Restricted time deposits include an irrevocable standby letter of credit as security deposit for a long-term property lease with the Company&#x2019;s landlord. Restricted time deposits as of December&#160;31, 2020 and 2019 totaled $2.1 million and $2.1&#160;million, respectively. As of December&#160;31, 2020 and 2019, a total of $66.0 million and $11.9 million, respectively, of the Company&#x2019;s cash and cash equivalents was held outside of the U.S. in the Company&#x2019;s foreign subsidiaries to be used primarily for the Company&#x2019;s China operations.&lt;/p&gt;
</fgen:CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock>
    <fgen:HighlyLiquidInvestmentMaturityPeriod contextRef="C_0000921299_20200101_20201231" id="F_000623">three months or less</fgen:HighlyLiquidInvestmentMaturityPeriod>
    <fgen:RestrictedTimeDepositsNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-5"
      id="F_000624"
      unitRef="U_iso4217USD">2100000</fgen:RestrictedTimeDepositsNoncurrent>
    <fgen:RestrictedTimeDepositsNoncurrent
      contextRef="C_0000921299_20191231"
      decimals="-5"
      id="F_000625"
      unitRef="U_iso4217USD">2100000</fgen:RestrictedTimeDepositsNoncurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000921299_us-gaapGeographicDistributionAxis_us-gaapGeographicDistributionForeignMember_20201231"
      decimals="-5"
      id="F_000626"
      unitRef="U_iso4217USD">66000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000921299_us-gaapGeographicDistributionAxis_us-gaapGeographicDistributionForeignMember_20191231"
      decimals="-5"
      id="F_000627"
      unitRef="U_iso4217USD">11900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000547">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, the Company&#x2019;s investments consist of diversified bond funds and marketable equity investments. Those investments with original maturities of greater than three months and remaining maturities of less than 12&#160;months (365 days) are considered short-term investments. Those investments with maturities greater than 12 months (365 days) from the balance sheet date are considered long-term investments. When such investments are held, the Company&#x2019;s investments classified as available-for-sale are recorded at fair value based upon quoted market prices at period end. Unrealized gains and losses for available-for-sale debt investments that are deemed temporary in nature are recorded in accumulated other comprehensive income (loss) as a separate component of stockholder&#x2019; equity. Marketable equity securities are equity securities with readily determinable fair value, and are measured and recorded at fair value. Realized and unrealized gains or losses resulting from changes in value and sale of the Company&#x2019;s marketable equity investments are recorded in other income (expenses) in the consolidated statement of operations.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Premiums and discounts are amortized (accreted) over the life of the related security as an adjustment to its yield. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of investments sold.&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <fgen:ShortTermInvestmentsMaximumMaturityPeriod contextRef="C_0000921299_20200101_20201231" id="F_000628">P12M</fgen:ShortTermInvestmentsMaximumMaturityPeriod>
    <fgen:LongTermInvestmentsMinimumMaturityPeriod contextRef="C_0000921299_20200101_20201231" id="F_000629">P12M</fgen:LongTermInvestmentsMinimumMaturityPeriod>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="C_0000921299_20200101_20201231" id="F_000548">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying amounts of certain of the Company&#x2019;s financial instruments including cash equivalents, investments, receivables, accounts payable and accrued liabilities approximate fair value (refer to Note 5, &lt;span style="font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;).&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="C_0000921299_20200101_20201231" id="F_000549">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade accounts receivable&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The allowance for doubtful accounts is based on the Company&#x2019;s assessment of the collectability of customer accounts. The Company makes estimates of expected credit losses for the allowance for doubtful accounts by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, current economic and regulatory conditions that may affect a customer&#x2019;s ability to pay, and estimates of expected future losses. The Company&#x2019;s bad debt expense for the years ended December&#160;31, 2020, 2019 and 2018 and the allowance for doubtful accounts as of December&#160;31, 2020 and 2019 were immaterial.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000550">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Credit losses &#x2013; Available-for-sale debt securities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company periodically assesses its available-for-sale investments for other-than-temporary impairment. For debt securities in an unrealized loss position, the Company first considers its intent to sell, or whether it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis. If either of these criteria are met, the amortized cost basis of such debt securities is written down to fair value through interest and other, net. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in the fair value of such debt securities has resulted from credit losses or other factors. The Company considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the securities, among other factors. If this assessment indicates that a credit loss may exist, the Company then compares the present value of cash flows expected to be collected from such securities to their amortized cost basis. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded through interest and other, net, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive income.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in the allowance for credit losses are recorded as provision for, or reversal of, credit loss expense. Losses are charged against the allowance when the Company believes that an available-for-sale security is confirmed uncollectable or when either of the criteria regarding intent or requirement to sell is met.&lt;/p&gt;
</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000551">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories are stated at the lower of cost or net realizable value, on a first-in, first-out, or FIFO, basis. The cost of the Company&#x2019;s inventories in China is determined using full absorption and standard costing method. The Company reviews the standard cost of raw materials, work-in-process and finished goods annually and more often as appropriate to ensure that its inventories approximate current actual cost. The cost of the Company&#x2019;s inventories in the U.S. uses actual costs to determine its cost basis. The cost of inventories includes direct material cost, direct labor and manufacturing overhead.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When the technical feasibility of the Company&#x2019;s future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, the Company capitalizes pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the status in the validation process in significant jurisdictions, regulatory application and approval process, and terms and condition for future sale of such inventory or future alternative use. The pre-launch inventory cost includes purchase cost of raw materials, &lt;span style="color:#000000;"&gt;cost paid to contract manufacturers for inventory manufacturing, freight and custom charges, and certain direct internal labor and overhead expenses.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company &lt;span style="color:#auto;"&gt;periodically&lt;/span&gt; reviews its inventories to identify obsolete, slow-moving, excess or otherwise unsaleable items. If obsolete, excess or unsaleable items are observed and there are no alternate uses for the &lt;span style="color:#auto;"&gt;inventory&lt;/span&gt;, an inventory valuation adjustment is recorded through a charge to cost of goods sold on the Company&#x2019;s consolidated statements of operations. The establishment of inventory valuation reserves, together with the calculation of the amount of such reserves, requires judgment including consideration of many factors, such as estimates of future product demand and product expiration period, among others.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000552">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Computer equipment, laboratory equipment, machinery and furniture and fixtures are depreciated over three to five years. Leasehold improvements are recorded at cost and amortized over the term of the lease or their useful life, whichever is shorter.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231"
      id="F_000631">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20200101_20201231"
      id="F_000633">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20200101_20201231"
      id="F_000635">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231"
      id="F_000637">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000553">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines if an arrangement is or contains a lease at inception date when it is given control of the underlying assets. The Company elected the practical expedient not to apply the lease recognition and measurement requirements to short-term leases, which is any lease with a term of 12 months or less as of the commencement date that does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s building leases previously accounted for as build-to-suit arrangements prior to the adoption of Accounting Standards Codification (&#x201c;ASC&#x201d;) 842 - &lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt; (&#x201c;ASC 842&#x201d;) are accounted for as finance leases under the requirements of ASC 842.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As its leases do not typically provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company reassesses the incremental borrowing rate periodically for application to any new leases or lease modifications, which approximates the rate at which the Company would borrow, on a secured basis, in the country where the lease was executed.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease ROU assets include any lease payments made and initial direct costs incurred. The Company has lease agreements with lease and non-lease components. The Company generally accounts for each lease component separately from the non-lease components, and excludes all non-lease components from the calculation of minimum lease payments in measuring the ROU asset and lease liability. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease terms. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Regarding leases denominated in a foreign currency, the related ROU assets and the corresponding ROU asset amortization costs are remeasured using the exchange rate in effect at the date of initial recognition; the related lease liabilities are remeasured using the exchange rate in effect at the end of the reporting period; the lease costs and interest expenses related to lease liability accretion are remeasured using average exchange rates for the reporting period.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance leases are included in finance lease ROU assets, finance lease liabilities, current and non-current on the Company&#x2019;s consolidated balance sheets. Operating leases are included in other assets, accrued and other current liabilities, and other long-term liabilities on the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <fgen:ShortTermInvestmentsMaximumMaturityPeriod contextRef="C_0000921299_20200101_20201231" id="F_000638">P12M</fgen:ShortTermInvestmentsMaximumMaturityPeriod>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000554">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. If the Company determines that an impairment trigger has been met, the Company evaluates the realizability of its long-lived assets based on a comparison of projected undiscounted cash flows from use and eventual disposition with the carrying value of the related asset. Any write-downs (which are measured based on the difference between the fair value and the carrying value of the asset) are treated as permanent reductions in the carrying amount of the assets (asset group). Based on this evaluation, the Company believes that, as of each of the balance sheet dates presented, none of the Company&#x2019;s long-lived assets were impaired. The Company&#x2019;s impairment of long-lived assets for the years ended December&#160;31, 2020, 2019 and 2018 were immaterial.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_0000921299_20200101_20201231"
      decimals="INF"
      id="F_000639"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000555">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenues under collaboration agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s collaboration agreements include multiple performance obligations comprised of promised services, or bundles of services, that are distinct. Services that are not distinct are combined with other services in the agreement until they form a distinct bundle of services. The Company&#x2019;s process for identifying performance obligations and an enumeration of each obligation for each agreement is outlined in Note 4, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues&lt;/span&gt;. Determining the performance obligations within a collaboration agreement often involves significant judgment and is specific to the facts and circumstances contained in each agreement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has identified the following material promises under its collaboration agreements: (1) license of FibroGen technology, (2) the performance of co-development services, including manufacturing of clinical supplies and other services during the development period, and (3) manufacture of commercial supply. The evaluation as to whether these promises are distinct, and therefore represent separate performance obligations, is described in more details in Note 4, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For revenue recognition purposes, the Company determines that the term of its collaboration agreements begin on the effective date and ends upon the completion of all performance obligations contained in the agreements. In each agreement, the contract term is defined as the period in which parties to the contract have present and enforceable rights and obligations. The Company believes that the existence of what it considers to be substantive termination penalties on the part of the counterparty create sufficient incentive for the counterparty to avoid exercising its right to terminate the agreement unless in exceptionally rare situations.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price for each collaboration agreement is determined based on the amount of consideration the Company expects to be entitled for satisfying all performance obligations within the agreement. The Company&#x2019;s collaboration agreements include payments to the Company of one or more of the following: non-refundable upfront license fees; co-development billings; development, regulatory, and commercial milestone payments; payments from sales of active pharmaceutical ingredient (&#x201c;API&#x201d;); payments from sales of bulk drug product and royalties on net sales of licensed products. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upfront license fees are non-contingent and non-refundable in nature and are included in the transaction price at the point when the license fees become due to the Company. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Co-development billings resulting from the Company&#x2019;s research and development efforts, which are reimbursable under its collaboration agreements, are considered variable consideration. Determining the reimbursable amount of research and development efforts requires detailed analysis of the terms of the collaboration agreements and the nature of the research and development efforts incurred. Determining the amount of variable consideration from co-development billings requires the Company to make estimates of future research and development efforts, which involves significant judgment. Co-development billings are allocated entirely to the co-development services performance obligation when amounts are related specifically to research and development efforts necessary to satisfy the performance obligation, and such an allocation is consistent with the allocation objective.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Milestone payments are also considered variable consideration, which requires the Company to make estimates of when achievement of a particular milestone becomes probable. Similar to other forms of variable consideration, milestone payments are included in the transaction price when it becomes probable that such inclusion would not result in a significant revenue reversal. Milestone payments are therefore included in the transaction price when achievement of the milestone becomes probable.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For arrangements that include sales-based royalties and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from its collaboration arrangements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price is allocated to performance obligations based on their relative standalone selling price (&#x201c;SSP&#x201d;), with the exception of co-development billings allocated entirely to co-development services performance obligations. The SSP is determined based on observable prices at which the Company separately sells the products and services. If an SSP is not directly observable, then the Company will estimate the SSP considering marketing conditions, entity-specific factors, and information about the customer or class of customer that is reasonably available. The process for determining SSP involves significant judgment and includes consideration of multiple factors, including assumptions related to the market opportunity and the time needed to commercialize a product candidate pursuant to the relevant license, estimated direct expenses and other costs, which include the rates normally charged by contract research and contract manufacturing organizations for development and manufacturing obligations, and rates that would be charged by qualified outsiders for committee services.&#160;&#160; &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant judgment may be required in determining whether a performance obligation is distinct, determining the amount of variable consideration to be included in the transaction price, and estimating the SSP of each performance obligation. An enumeration of the Company&#x2019;s significant judgments is outlined in Note 4, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For each performance obligation identified within an arrangement, the Company determines the period over which the promised services are transferred and the performance obligation is satisfied. Service revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. For each performance obligation satisfied over time, the Company assesses the proper method to be used for revenue recognition, either an input method to measure progress toward the satisfaction of services or an output method of determining the progress of completion of performance obligation.&lt;span style="font-weight:bold;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Drug product revenue&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue includes commercial-grade API or bulk drug product sales to AstraZeneca and Astellas, and is recognized when the Company fulfills the shipment obligations. The drug product revenue is accounted for as variable consideration, estimated at the time of sale using the expected value method. The Company applies significant judgment in estimating the variable consideration, which involves the use of significant assumptions such as the future list price adjustments set by the Japanese Ministry of Health, Labour and Welfare, product mix, and timing of processing of API into bulk drug product.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2018, FibroGen and Astellas entered into an amendment to the Japan Agreement that allows Astellas to manufacture roxadustat drug product for commercialization in Japan (the &#x201c;Japan Amendment&#x201d;). Under this amendment, FibroGen would continue to manufacture and supply roxadustat API to Astellas for the roxadustat commercial launch in Japan. The drug product revenue represents variable consideration and is estimated based on the quantity of product shipped, actual listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and possible future changes to the listed price, adjusted for the timing of and estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk drug product tablets, and estimated yield from the manufacture of bulk product tablets, among others.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Europe Agreement with Astellas, Astellas has an option to purchase roxadustat bulk drug product in support of commercial supplies. The drug product revenue amount represents variable consideration and was estimated based on the quantity of product shipped and an estimated price. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price per strength, which is estimated to be realized by Astellas from the end sale of roxadustat in its approved territories.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2020, the Company entered into Commercial Supply Agreement under the U.S./RoW Agreement with AstraZeneca to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The drug product revenue amount represents variable consideration and was estimated based on the quantity of product shipped and an estimated price. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price per strength, which is estimated to be realized by AstraZeneca from the end sale of roxadustat in its approved territories.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the drug product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. Estimating variable consideration and the related constraint requires the use of significant management judgment. The Company reviews new information that may affect its variable consideration estimate at every reporting period and record revenue adjustment, if certain and material. Actual amounts of consideration ultimately received in the future may differ from the Company&#x2019;s estimates, for which the Company will adjust these estimates and affect the drug product revenue in the period such variances become known. The amount constrained as of December 31, 2020 was $6.0 million related to the drug product shipment to Astellas under the Europe Agreement in the fourth quarter of 2020. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As each of the Company&#x2019;s collaboration agreements provide for annual true up to the considerations paid for its commercial supplies, the Company will re-evaluate the transaction price in each reporting period and record adjustment to revenue as uncertain events are resolved or other changes in circumstances occur.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Product revenue, net&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company sells roxadustat in China through a number of pharmaceutical distributors located in China. These pharmaceutical distributors are the Company&#x2019;s customers. Hospitals order roxadustat through a distributor and the Company ships the product directly to the distributors. The delivery of roxadustat to a distributor represents a single performance obligation.&#160;Distributors are responsible for delivering product to end users, primarily hospitals. Distributors bear inventory risk once they receive and accept the product. Product revenue is recognized when control of the promised good is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for the product. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The period between the transfer of control of the promised goods and when the Company receives payment is based on a general 60-day payment term. As such, product revenue is not adjusted for the effects of a significant financing component. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue is recorded at the net sales prices (transaction price) which includes the following estimates of variable consideration:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Price adjustment:&lt;/span&gt;&lt;span style="color:#000000;"&gt; In December 2019, China&#x2019;s National Healthcare Security Administration released price guidance for roxadustat under the National Reimbursement Drug List (&#x201c;NRDL&#x201d;), effective January 1, 2020. Any channel inventories as of January 1, 2020 that had not been sold to hospitals by distributors, or to patients by hospitals, were eligible for a price adjustment under the price protection. The price adjustment is calculated based on estimated channel inventory levels at January 1, 2020. If price guidance changes in the future, the price adjustment will be calculated in the same manner;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Contractual sales rebate&lt;/span&gt;&lt;span style="color:#000000;"&gt;: The contractual sales rebate is calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. The contractual sales rebate is recorded as a reduction to revenue at the point of sale to the distributor;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Key account hospital sales rebate&lt;/span&gt;&lt;span style="color:#000000;"&gt;: An additional sales rebate is provided to a distributor for product sold to key account hospitals as a percentage of gross sales made by the distributor to eligible hospitals. This additional rebate is recorded as a reduction to revenue at the point of sale to the distributor; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Transfer fee discount&lt;/span&gt;&lt;span style="color:#000000;"&gt;: The transfer fee discount is offered to a distributor who has its downstream distributors supply to eligible hospitals. This discount is calculated based on a percentage of gross sales made to the downstream distributors, and recorded as a reduction to revenue as incurred; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Sales return&lt;/span&gt;&lt;span style="color:#000000;"&gt;: Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product&#x2019;s expiration date; and&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Non-key account hospital listing award: &lt;/span&gt;&lt;span style="color:#000000;"&gt;A one-time fixed-amount award is offered to a distributor who successfully lists the product with an eligible hospital, and who meets certain requirements. The Company considers this particular award to be an upfront payment to a customer within the definitions of ASC 606. The non-key account hospital listing award is capitalized when the distributor meets eligibility requirements, and amortized as reduction to product revenue over future sales orders made by the distributor until exhausted. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The calculation of the above variable consideration is based on gross sales to the distributor, or estimated utilizing best available information from the distributor, maximum known exposures and other available information including estimated channel inventory levels and estimated sales made by the distributor to hospitals, which involve a substantial degree of judgment. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The above rebates and discounts all together are eligible to be applied against the distributor&#x2019;s future sales order, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible and in the same period that the related revenue is recorded. Due to the distributor&#x2019;s legal right to offset, at each balance sheet date, the liability for rebates and discounts are presented as reductions of gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The distributor&#x2019;s legal right of offset is calculated at the individual distributor level.&lt;span style="font-weight:bold;color:#FF0000;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000640"
      unitRef="U_iso4217USD">6000000.0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms contextRef="C_0000921299_20200101_20201231" id="F_000641">The period between the transfer of control of the promised goods and when the Company receives payment is based on a general 60-day payment term.</us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms>
    <fgen:DescriptionOfSalesReturn contextRef="C_0000921299_20200101_20201231" id="F_000642">Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product&#x2019;s expiration date</fgen:DescriptionOfSalesReturn>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0000921299_20200101_20201231" id="F_000556">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses consist of independent research and development costs and the gross amount of costs associated with work performed under collaboration agreements. Research and development costs include employee-related expenses, expenses incurred under agreements with clinical research organizations, other clinical and preclinical costs and allocated direct and indirect overhead costs, such as facilities costs, information technology costs and other overhead. All research and development costs are expensed as incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <fgen:ClinicalTrialAccrualPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000557">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical Trial Accruals&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with clinical research organizations and clinical sites. The Company determines the costs to be recorded based upon validation with the external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.&lt;/p&gt;</fgen:ClinicalTrialAccrualPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000558">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, General and Administrative Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative (&#x201c;SG&amp;amp;A&#x201d;) expenses consist primarily of employee-related expenses for executive, operational, finance, legal, compliance and human resource functions. SG&amp;amp;A expenses also include facility-related costs, professional fees, accounting and legal services, other outside services including co-promotional expenses, recruiting fees and expenses associated with obtaining and maintaining patents.&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000559">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company utilizes the asset and liability method of accounting for income taxes, which requires the recognition of deferred tax assets and liabilities for expected future consequences of temporary differences between the financial reporting and income tax bases of assets and liabilities using enacted tax rates. Management makes estimates, assumptions and judgments to determine the Company&#x2019;s provision for income taxes and for deferred tax assets and liabilities, and any valuation allowances recorded against the Company&#x2019;s deferred tax assets. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The calculation of the Company&#x2019;s current provision for income taxes involves the use of estimates, assumptions and judgments while taking into account current tax laws, interpretation of current tax laws and possible outcomes of future tax audits. The Company has established reserves to address potential exposures related to tax positions that could be challenged by tax authorities. Although the Company believes its estimates, assumptions and judgments to be reasonable, any changes in tax law or its interpretation of tax laws and the resolutions of potential tax audits could significantly impact the amounts provided for income taxes in the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The calculation of the Company&#x2019;s deferred tax asset balance involves the use of estimates, assumptions and judgments while taking into account estimates of the amounts and type of future taxable income. Actual future operating results and the underlying amount and type of income could differ materially from the Company&#x2019;s estimates, assumptions and judgments thereby impacting the Company&#x2019;s financial position and results of operations.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2020, the Company transferred certain intellectual property rights relating to its Chinese business between its wholly owned subsidiaries that are based in different tax jurisdictions. Refer to Note 13, &lt;span style="font-style:italic;"&gt;Income Taxes&lt;/span&gt;, for more information. The establishment of a deferred tax asset from the intra-entity transfer of intangible assets required the Company to make significant estimates and assumptions to determine the fair value of intellectual property rights transferred, which include but are not limited to, its expectations of discount rate, revenue volume and price.&lt;span style="Background-color:#F8F9FA;color:#202124;"&gt; The accuracy of these estimates could be affected by unforeseen events or actual results, and the sustainability of the Company&#x2019;s future tax benefits is dependent upon the acceptance of these valuation estimates and assumptions by the taxing authorities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has adopted ASC 740-10, &lt;span style="font-style:italic;"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;, that prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company&#x2019;s income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company includes interest and penalties related to unrecognized tax benefits within income tax expense in the Consolidated Statements of Operations. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0000921299_20200101_20201231" id="F_000560">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company maintains equity incentive plans under which incentive and nonqualified stock options are granted to employees and non-employee consultants. Compensation expense relating to non-employee stock options has not been material for all the periods presented.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures and recognizes compensation expense for all stock options and restricted stock units (&#x201c;RSUs&#x201d;) granted to its employees and directors based on the estimated fair value of the award on the grant date. The Company uses the Black-Scholes valuation model to estimate the fair value of stock option awards. The fair value is recognized as expense, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis. The Company believes that the fair value of stock options granted to non-employees is more reliably measured than the fair value of the services received. The determination of the grant date fair value of options using an option pricing model is affected by the Company&#x2019;s estimated Common Stock fair value and requires management to make a number of assumptions including the expected life of the option, the volatility of the underlying stock, the risk-free interest rate and expected dividends.&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates the fair value of stock options using the Black-Scholes option valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair market value of common stock is based on the closing price of the Company&#x2019;s common stock as reported on the NASDAQ Global Select Market on the date of the grant.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of employee stock-based compensation is estimated using the following assumptions:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Expected Term.&lt;/span&gt;&lt;span style="color:#000000;"&gt; Expressed as a weighted-average, the expected life of the options is based on the average period the stock options are expected to be outstanding and was based on the Company&#x2019;s historical information of the option exercise patterns and post-vesting termination behavior as well as contractual terms of the instruments.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Expected Volatility.&lt;/span&gt;&lt;span style="color:#000000;"&gt; The Company considers its historical volatility data for volatility considerations for its ESPP. &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Historically, the expected volatility for all other stock-based compensation was based upon a blend of the Company&#x2019;s and comparable public entities&#x2019;&#160;historical volatility. Since the third quarter of 2020, the&lt;/span&gt;&lt;span style="color:#000000;"&gt; expected volatility for all other stock-based compensation is currently based upon the Company&#x2019;s historical volatility data.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Risk-Free Interest Rate.&lt;/span&gt;&lt;span style="color:#000000;"&gt; Expressed as a weighted-average, the risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company&#x2019;s stock options.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Expected Dividend Yield.&lt;/span&gt;&lt;span style="color:#000000;"&gt; The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000561">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive Income (Loss)&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is required to report all components of comprehensive income (loss), including net loss, in the consolidated financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation adjustments. Comprehensive gains (losses) have been reflected in the consolidated statements of comprehensive income (loss) for all periods presented.&lt;/p&gt;
</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <fgen:RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000562">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recently Issued and Adopted Accounting Guidance&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2018-15, &lt;span style="font-style:italic;"&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. &lt;/span&gt;This guidance requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This guidance was effective for annual reporting periods beginning after December 15, 2019, including interim periods. The Company adopted this guidance on January 1, 2020 using the prospective method, and the adoption of this guidance did not have material impact to the Company&#x2019;s consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;span style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;(&#x201c;ASU 2016-13&#x201d;). This guidance is intended to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. This guidance requires the measurement of financial assets with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. This guidance requires an impairment model, known as the current expected credit loss model, which is based on expected losses rather than incurred losses. Entities are required to carry an allowance for expected credit losses for financial assets, including most debt instruments (except those carried at fair value) and trade receivables. In November 2019, the FASB issued ASU No. 2019-11, &lt;span style="font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments-Credit Losses &lt;/span&gt;(&#x201c;ASU 2019-11&#x201d;)&lt;span style="font-style:italic;"&gt;, &lt;/span&gt;which has the same effective dates and transition requirements as ASU 2016-13. ASU 2016-13 and ASU 2019-11 were effective for annual reporting periods beginning after December 15, 2019 including interim periods. The Company&#x2019;s investment portfolio primarily consists of U.S. Treasury bills and notes carried at fair value, which is required to follow the impairment model under Topic 326. The Company adopted this guidance on January 1, 2020. Based on the composition of the Company&#x2019;s trade receivables and investment portfolio, economic conditions and historical credit loss activity, the adoption of this guidance did not have material impact to the Company&#x2019;s consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;span style="font-style:italic;"&gt;Leases (Topic 842). &lt;/span&gt;The Company adopted the lease guidance under ASC 842 as of January 1, 2019, using the modified retrospective transition method, through a cumulative-effect adjustment. The adoption of this guidance resulted in a reduction of $8.7 million to the Company&#x2019;s accumulated deficit and also impacted various balance sheet line items in its consolidated balance sheet as of January 1, 2019 upon adoption. The adoption of this guidance did not have a material impact to the Company&#x2019;s consolidated statement of operations or consolidated statement of cash flows for the year ended December 31, 2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2018, the FASB issued ASU 2018-02, &lt;span style="font-style:italic;"&gt;Income Statement - Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income&lt;/span&gt;. The Company adopted this guidance on January 1, 2019 using the modified retrospective approach, with a reduction of $0.6 million to its accumulated other comprehensive loss and an increase of $0.6 million to its accumulated deficit as of January 1, 2019 upon adoption. The adoption of this guidance had no impact to the Company&#x2019;s consolidated statement of operations or consolidated statement of cash flows for the year ended December 31, 2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2016, the FASB issued ASU 2016-01, &lt;span style="font-style:italic;"&gt;Financial Instruments-Overall (Subtopic 825-10)&lt;/span&gt;. The Company adopted this guidance as of January 1, 2018 using the modified retrospective approach, with an increase of $1.3 million to its accumulated other comprehensive loss and a reduction of $1.3 million to its accumulated deficit as of January 1, 2018 upon adoption. The adoption of this guidance had no impact to the Company&#x2019;s consolidated statement of cash flows for the year ended December 31, 2018. &lt;/p&gt;
</fgen:RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0000921299_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101"
      decimals="-5"
      id="F_000643"
      unitRef="U_iso4217USD">-8700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_fgenImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member_20190101"
      decimals="-5"
      id="F_000644"
      unitRef="U_iso4217USD">-600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201802Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_fgenImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member_20190101"
      decimals="-5"
      id="F_000645"
      unitRef="U_iso4217USD">600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20180101"
      decimals="-5"
      id="F_000646"
      unitRef="U_iso4217USD">1300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0000921299_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201601Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20180101"
      decimals="-5"
      id="F_000647"
      unitRef="U_iso4217USD">-1300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <fgen:RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000563">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Guidance Not Yet Adopted&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the FASB issued ASU 2020-04, &lt;span style="font-style:italic;"&gt;Reference Rate Reform (Topic 848): &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt; (&#x201c;ASU&lt;span style="font-style:italic;"&gt; &lt;/span&gt;2020&lt;span style="font-style:italic;"&gt;-&lt;/span&gt;04&lt;span style="font-style:italic;"&gt;&#x201d;&lt;/span&gt;)&lt;span style="font-style:italic;"&gt;,&lt;/span&gt; which provides companies with optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform. This guidance is effective as of March 12, 2020 through December 31, 2022. Subsequently in January 2021, the FASB issued ASU 2021-01, &lt;span style="font-style:italic;"&gt;Reference Rate Reform (Topic 848): Scope&lt;/span&gt;, which clarifies ASU 2020-04 and provides certain optional expedients that allow derivative instruments impacted by changes in the interest rate used for margining, discounting or contract price alignment to qualify for certain optional relief. ASU 2021-01 is effective in the same timeframe as ASU 2020-04. The relief offered by this guidance, if adopted, is available to companies for the period March 12, 2020 through December 31, 2022. &lt;span style="Background-color:#FFFFFF;"&gt;The Company has certain lease arrangements that are linked to LIBOR. The Company is in the process of evaluating options for transitioning away from LIBOR and expects to complete by the time LIBOR is phased out. The Company did not elect to apply any of the expedients or exceptions as of and for the year ended December 31, 2020 and is currently evaluating the impact on its consolidated financial statements and related disclosures upon adoption of this guidance.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;span style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;. This guidance simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step up in the tax basis of goodwill, and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. This guidance is effective for annual reporting periods beginning after December 15, 2020 including interim periods, with early adoption permitted. The Company does not plan to early adopt this guidance and does not anticipate a material impact to its consolidated financial statements upon adoption of this guidance.&lt;/p&gt;</fgen:RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock>
    <fgen:AcquisitionAndVariableInterestEntityTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000526">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Acquisition and Variable Interest Entity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 8, 2020, FibroGen Cayman, FibroGen Beijing, and FibroGen International (Hong Kong) Limited (collectively, &#x201c;FibroGen China&#x201d;) and AstraZeneca entered into an amendment, effective July 1, 2020, to the collaboration agreement for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in China (&#x201c;China Agreement&#x201d;), relating to the development and commercialization of roxadustat in China (the &#x201c;China Amendment&#x201d;). &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The China Amendment provides for the establishment of a jointly owned entity that will perform roxadustat distribution, as well as conduct sales and marketing through AstraZeneca. To prepare for the establishment of this jointly owned entity, in July 2020, FibroGen Beijing acquired 100% of the outstanding shares of Beijing Kangda Yongfu Pharmaceutical Co., LTD (&#x201c;Kangda&#x201d;) in exchange for cash consideration of CNY15.0 million (approximately $2.1 million). The purpose of the acquisition was to acquire a distribution license owned by Kangda for commercializing and distributing roxadustat in China. FibroGen Beijing continues to hold all of the regulatory licenses issued by China regulatory authorities and continues to be primarily responsible for regulatory, clinical, manufacturing, medical affairs and pharmacovigilance. The transaction costs related to the execution of the acquisition, primarily legal expenses, totaled CNY5.0 million and were shared equally with AstraZeneca. Therefore, the acquisition costs for FibroGen Beijing were CNY2.5 million (approximately $0.4 million).&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the ASU No. 2017-01, &lt;span style="font-style:italic;"&gt;Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/span&gt;, the Company determined that the all of the value of Kangda was attributable to the acquired license, and therefore the transaction was accounted for as an asset acquisition. The Company allocated the entire purchase price of $2.5 million to the acquired license that was recorded as an intangible asset, to be amortized over the duration of expected sales of roxadustat. There was no excess consideration over the estimated fair value. Through September 15, 2020, Kangda was consolidated as a wholly owned subsidiary of the Company. The amortization of the license was immaterial during the short period of time before Kangda was deconsolidated upon the establishment of the jointly owned entity described below.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 15, 2020, FibroGen Beijing and AstraZeneca entered into an equity transfer agreement and shareholders agreement, under which FibroGen Beijing sold 48.9% of the outstanding shares of Kangda to AstraZeneca in exchange for cash consideration of CNY7.3 million (approximately $1.0 million). Concurrently with the equity transfer, the two parties renamed Kangda to Beijing Falikang Pharmaceutical Co. Ltd. (&#x201c;Falikang&#x201d;). Following the sale, FibroGen Beijing owns 51.1% of the outstanding shares of Falikang. The gain (loss) resulting from the equity transfer was immaterial.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, based on the shareholders&#x2019; resolutions of Falikang, in December 2020, FibroGen Beijing made cash contribution of CNY8.9 million (approximately $1.4 million) to Falikang, representing 51.1% of Falikang&#x2019;s registered capital of CNY17.5 million. AstraZeneca completed its cash contribution of 48.9% of Falikang&#x2019;s registered capital in December 2020 as well.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the guidance under ASC 810, the Company concluded that Falikang qualifies as a VIE. As Falikang is a distribution entity for roxadustat and AstraZeneca is the final decision maker for all the roxadustat commercialization activities, the Company lacks the power criterion while AstraZeneca meets both the power and economic criteria under ASC 810, to direct the activities of Falikang that most significantly impact its performance. Therefore, the Company is not the primary beneficiary of this VIE. As a result, the Company accounted for its investment in Falikang under the equity method, and Falikang is not consolidated into the Company&#x2019;s consolidated financial statements. Accordingly, The Company recorded its total investments in Falikang of CNY19.2 million (approximately $2.8 million), which is the total of the 51.1% of Falikang&#x2019;s equity and the acquisition costs, as an investment in unconsolidated subsidiary in other assets in the consolidated balance sheet. In addition, the Company recognized its proportionate share of the reported profits or losses of Falikang, beginning September 15, 2020, as other income (loss) in the consolidated statement of operations, and as an adjustment to its investment in unconsolidated subsidiary in the consolidated balance sheet. Falikang has not incurred material profit or loss to date. The Company may be required to provide shareholder loans to Falikang to meet necessary financial obligations as part of its operations. To date, these loans have been immaterial. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s&#160;equity&#160;method&#160;investment&#160;in Falikang was as follows for the year ended December 31, 2020 (in thousands):&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Entity&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ownership Percentage&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share of Net Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Translation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Falikang&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,825&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(202&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Falikang is considered as a related party to the Company. See Note 14, &lt;span style="font-style:italic;"&gt;Related Party Transactions&lt;/span&gt;, for related disclosures.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On an ongoing basis, the Company will re-evaluate the VIE assessment based on changes in facts and circumstances, including but not limited to, the shareholder loans received by Falikang and the execution of any future significant agreements between Falikang and its shareholders and/or other third parties.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will assess the impairment of its equity method&#160;investment whenever events or changes in circumstances indicate that a decrease in value of the investment has occurred that is other than temporary.&lt;/p&gt;</fgen:AcquisitionAndVariableInterestEntityTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200731"
      decimals="INF"
      id="F_000648"
      unitRef="U_xbrlipure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200701_20200731"
      decimals="-5"
      id="F_000649"
      unitRef="U_iso4217CNY">15000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200701_20200731"
      decimals="-5"
      id="F_000650"
      unitRef="U_iso4217USD">2100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200731"
      decimals="-5"
      id="F_000651"
      unitRef="U_iso4217CNY">5000000.0</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200701_20200731"
      decimals="-5"
      id="F_000652"
      unitRef="U_iso4217CNY">2500000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200701_20200731"
      decimals="-5"
      id="F_000653"
      unitRef="U_iso4217USD">400000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAcquiredLicenseMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200701_20200731"
      decimals="-5"
      id="F_000654"
      unitRef="U_iso4217USD">2500000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <fgen:PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer
      contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAstraZenecaABMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200915_20200915"
      decimals="3"
      id="F_000655"
      unitRef="U_xbrlipure">0.489</fgen:PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAstraZenecaABMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200915_20200915"
      decimals="-5"
      id="F_000656"
      unitRef="U_iso4217CNY">7300000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAstraZenecaABMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200915_20200915"
      decimals="-5"
      id="F_000657"
      unitRef="U_iso4217USD">1000000.0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="C_0000921299_us-gaapBusinessAcquisitionAxis_fgenBeijingKangdaYongfuPharmaceuticalCoLTDMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fgenAstraZenecaABMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200915_20200915"
      decimals="3"
      id="F_000658"
      unitRef="U_xbrlipure">0.511</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200101_20201231"
      decimals="-5"
      id="F_000659"
      unitRef="U_iso4217CNY">8900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200101_20201231"
      decimals="-5"
      id="F_000660"
      unitRef="U_iso4217USD">1400000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20200101_20201231"
      decimals="3"
      id="F_000661"
      unitRef="U_xbrlipure">0.511</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:Capital
      contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20201231"
      decimals="-5"
      id="F_000662"
      unitRef="U_iso4217CNY">17500000</us-gaap:Capital>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFibroGenBeijingMember_20201231"
      decimals="3"
      id="F_000663"
      unitRef="U_xbrlipure">0.489</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <fgen:EquityMethodInvestmentAdditions
      contextRef="C_0000921299_srtCounterpartyNameAxis_us-gaapVariableInterestEntityNotPrimaryBeneficiaryMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20200101_20201231"
      decimals="-5"
      id="F_000664"
      unitRef="U_iso4217CNY">19200000</fgen:EquityMethodInvestmentAdditions>
    <fgen:EquityMethodInvestmentAdditions
      contextRef="C_0000921299_srtCounterpartyNameAxis_us-gaapVariableInterestEntityNotPrimaryBeneficiaryMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20200101_20201231"
      decimals="-5"
      id="F_000665"
      unitRef="U_iso4217USD">2800000</fgen:EquityMethodInvestmentAdditions>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20200101_20201231"
      decimals="3"
      id="F_000666"
      unitRef="U_xbrlipure">0.511</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000573">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s&#160;equity&#160;method&#160;investment&#160;in Falikang was as follows for the year ended December 31, 2020 (in thousands):&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Entity&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ownership Percentage&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share of Net Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Translation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Falikang&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,825&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(202&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20201231"
      decimals="3"
      id="F_000667"
      unitRef="U_xbrlipure">0.511</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20191231"
      decimals="-3"
      id="F_000668"
      unitRef="U_iso4217USD">0</us-gaap:EquityMethodInvestments>
    <fgen:EquityMethodInvestmentAdditions
      contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20200101_20201231"
      decimals="-3"
      id="F_000669"
      unitRef="U_iso4217USD">2825000</fgen:EquityMethodInvestmentAdditions>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20200101_20201231"
      decimals="-3"
      id="F_000670"
      unitRef="U_iso4217USD">202000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <fgen:EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation
      contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20200101_20201231"
      decimals="-3"
      id="F_000671"
      unitRef="U_iso4217USD">105000</fgen:EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation>
    <us-gaap:EquityMethodInvestments
      contextRef="C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20201231"
      decimals="-3"
      id="F_000672"
      unitRef="U_iso4217USD">2728000</us-gaap:EquityMethodInvestments>
    <fgen:CollaborativeArrangementAndRevenuesDisclosureTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000527">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Collaboration Agreements and Revenues&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas Agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Japan Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2005, the Company entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (&#x201c;Japan Agreement&#x201d;). Under this agreement, Astellas paid license fees and other consideration totaling $40.1&#160;million (such amounts were fully received as of February 2009). Under the Japan Agreement, the Company is also eligible to receive from Astellas an aggregate of approximately $132.5&#160;million in potential milestone payments, comprised of (i)&#160;up to $22.5&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of July 2016), (ii)&#160;up to $95.0&#160;million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $15.0&#160;million in milestone payments upon the achievement of specified commercial sales milestone. The Japan Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range of the list price published by the Japanese Ministry of Health, Labour and Welfare, adjusted for certain elements, after commercial launch. The aggregate amount of the considerations received under the Japan Agreement, through December&#160;31, 2020 totals $105.1 million, excluding drug product revenue that is discussed separately below.&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the fourth quarter of 2020, the Japanese Ministry of Health, Labour and Welfare approved EVRENZO&#xae; (roxadustat) for the treatment of anemia of CKD in adult patients not on dialysis. This approval triggered a $15.0 million milestone payable to the Company by Astellas under the Japan Agreement. Accordingly, the consideration of $15.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the Japan Agreement in the fourth quarter of 2020, substantially all of which was recognized as revenue during the year ended December 31, 2020 from performance obligations satisfied or partially satisfied.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In Septembe&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;r 2019, the Japanese Ministry of Health, Labour and Welfare approved EVRENZO&#xae; (generic name: roxadustat; tradename EVRENZO&#xae; in Japan) for the treatment of anemia associated with CKD in dialysis patients. This approval triggered a $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.5 million&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; milestone &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;payable to the Company by Astellas under the Japan Agreement. Accordingly, the consideration of $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.5&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million associated with this milestone was included in the transaction price and allocated to performance obligations under the Japan Agreement in the t&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;hird quarter of 2019, substantially all of which was recognized as revenue during the year ended December 31, 2019 from performance obligations satisfied or partially satisfied.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the second quarter of 2018, Astellas reported positive results from the final phase 3 CKD-dialysis trial of roxadustat in Japan, indicating that Astellas was ready to make an NDA submission for the treatment of anemia with roxadustat in CKD-dialysis patients in 2018. The Company evaluated the regulatory milestone payment associated with NDA submission in Japan based on variable consideration requirements under the current revenue standards and concluded that this milestone became probable of being achieved in the second quarter of 2018. Accordingly, the consideration of $15.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the Japan Agreement in the second quarter of 2018, substantially all of which was recognized as revenue during the year ended December 31, 2018 from performance obligations satisfied or partially satisfied. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2018, FibroGen and Astellas entered into an amendment to the Japan Agreement that allows Astellas to manufacture roxadustat drug product for commercialization in Japan (the &#x201c;Japan Amendment&#x201d;). Under this amendment, FibroGen would continue to manufacture and supply roxadustat API&lt;span style="font-weight:bold;"&gt; &lt;/span&gt;to Astellas for the roxadustat commercial launch in Japan. The commercial terms of the Japan Agreement relating to the transfer price for roxadustat for commercial use remain substantially the same, reflecting an adjustment for the manufacture of drug product by Astellas rather than FibroGen. The Company fulfilled shipment obligations under the term of the Japan Amendment in the second quarter of 2020 and in 2018. The related drug product revenue, as described in details under &lt;span style="font-style:italic;"&gt;Drug Product Revenue&lt;/span&gt; section below, were $4.3 million, $(36.3) million and $64.8 million in the years ended December 31, 2020, 2019 and 2018, respectively. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Europe Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2006, the Company entered into a separate collaboration agreement with Astellas for the development and commercialization of roxadustat for the treatment of anemia in Europe, the Middle East, the Commonwealth of Independent States and South Africa (&#x201c;Europe Agreement&#x201d;). Under the terms of the Europe Agreement, Astellas paid license fees and other upfront consideration totaling $320.0 million (such amounts were fully received as of February 2009). The Europe Agreement also provides for additional development and regulatory approval milestone payments up to $425.0 million, comprised of (i)&#160;up to $90.0&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of 2012), (ii)&#160;up to $335.0&#160;million in milestone payments upon achievement of specified regulatory milestone events. Under the Europe Agreement, Astellas committed to fund 50% of joint development costs for Europe and North America, and all territory-specific costs. The Europe Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range. The aggregate amount of the considerations received under the Europe Agreement through December&#160;31, 2020 totals $540.0 million, excluding drug product revenue that is discussed separately below.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the second quarter of 2019, the Company received positive topline results from analyses of pooled major adverse cardiovascular event (&#x201c;MACE&#x201d;) and MACE+ data from its Phase 3 trials evaluating roxadustat as a treatment for dialysis and non-dialysis CKD patients, enabling Astellas to prepare for an MAA submission to the EMA in the second quarter of 2020, following the Company&#x2019;s NDA submission to the FDA that was accepted for review in February 2020. The Company evaluated the two regulatory milestone payments associated with the planned MAA submission and concluded that these milestones became probable of being achieved in the second quarter of 2019. Accordingly, the total consideration of $130.0 million associated with these milestones was included in the transaction price and allocated to performance obligations under the Europe Agreement in the second quarter of 2019, of which $128.8 million was recognized as revenue during the year ended December 31, 2019 and $0.8 million was recognized as revenue during the year ended December 31, 2020, from performance obligations satisfied or partially satisfied. According to the Europe Agreement, these milestone payments are billable to Astellas upon the submission of an MAA, therefore this $130.0 million was an unbilled contract asset as of December 31, 2019, and billed to Astellas upon the submission of an MAA in the second quarter of 2020 with the total $130.0 million received during the same quarter. &lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the fourth quarter of 2018, the Company was engaged in the final stages of review with its partners over the proposed development of roxadustat for the treatment of chemotherapy-induced anemia (&#x201c;CIA&#x201d;).&#160;AstraZeneca and Astellas approved the program in December 2018 and January 2019, respectively. Costs associated with the development of this indication are expected to be shared 50-50 between the Company&#x2019;s two partners.&#160;For revenue recognition purposes, the Company concluded that this new indication represents a modification to the Europe agreements and will be accounted for separately, meaning the development costs associated with the new indications are distinct from the original development costs. The development service period for roxadustat for the treatment of CIA under the Europe Agreement is estimated to continue through the second quarter of 2024 to allow for development of this indication.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Europe Agreement, Astellas has an option to purchase roxadustat bulk drug product in support of commercial supplies. The Company fulfilled a shipment obligation under the term of the Europe Amendment in the fourth quarter of 2020, as described in details under &lt;span style="font-style:italic;"&gt;Drug Product Revenue&lt;/span&gt; section below.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;AstraZeneca Agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;U.S./Rest of World (&#x201c;RoW&#x201d;) Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective July&#160;30, 2013, the Company entered into a collaboration agreement with AstraZeneca for the development and commercialization of roxadustat for the treatment of anemia in the U.S. and all other countries in the world, other than China, not previously licensed under the Astellas Europe and Astellas Japan Agreements (&#x201c;U.S./RoW Agreement&#x201d;). It also excludes China, which is covered by a separate agreement with AstraZeneca described below. Under the terms of the U.S./RoW Agreement, AstraZeneca paid upfront, non-contingent, non-refundable and time-based payments totaling $374.0 million (such amounts were fully received as of June 2016). Under the U.S./RoW Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $875.0 million in potential milestone payments, comprised of (i)&#160;up to $65.0 million in milestone payments upon achievement of specified clinical and development milestone events, (ii)&#160;up to $325.0 million in milestone payments upon achievement of specified regulatory milestone events, (iii)&#160;up to $160.0&#160;million in milestone payments related to activity by potential competitors and (iv)&#160;up to approximately $325.0 million in milestone payments upon the achievement of specified commercial sales events. The aggregate amount of the considerations received under the U.S./RoW Agreement through December&#160;31, 2020 totals $439.0 million, excluding drug product revenue that is discussed separately below.&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the U.S./RoW Agreement, the Company and AstraZeneca will share equally in the development costs of roxadustat not already paid for by Astellas, up to a total of $233.0 million (i.e. the Company&#x2019;s share of development costs is $116.5 million, which was reached in 2015). Development costs incurred by FibroGen during the development period in excess of the $233.0 million (aggregated spend) are fully reimbursed by AstraZeneca. AstraZeneca will pay the Company tiered royalty payments on AstraZeneca&#x2019;s future net sales (as defined in the agreement) of roxadustat in the low 20% range. In addition, the Company will receive a transfer price for shipment of commercial product based on a percentage of AstraZeneca&#x2019;s net sales (as defined in the agreement) in the low- to mid-single digit range.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As mentioned above, during the second quarter of 2019, the Company received positive topline results from analyses of pooled MACE and MACE+ data from its Phase 3 trials for roxadustat, enabling the Company&#x2019;s NDA submission to the FDA. The Company evaluated the regulatory milestone payment associated with this planned NDA submission and concluded that this milestone became probable of being achieved in the second quarter of 2019. Accordingly, the consideration of $50.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the combined arrangement in the second quarter of 2019, of which $42.4 million was recognized as revenue during the year ended December 31, 2019 and $0.6 million was recognized as revenue during the year ended December 31, 2020, from performance obligations satisfied or partially satisfied. The Company submitted such NDA in December 2019, which was accepted by FDA in February 2020. According to the U.S/RoW Agreement, this milestone payment is billable to AstraZeneca when the NDA is accepted by the FDA, therefore this $50.0 million was an unbilled contract asset as of December 31, 2019, and was billed during the first quarter of 2020, the payment of which was fully received in April 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As mentioned above, AstraZeneca and Astellas approved the development of roxadustat for the treatment of CIA in December 2018 and January 2019, respectively. Costs associated with the development of this indication are expected to be shared 50/50 between AstraZeneca and Astellas.&#160;In addition, in December 2018, anemia of chronic inflammation and multiple myeloma was approved for development by AstraZeneca and is expected to be fully funded by them.&#160;For revenue recognition purposes, the Company concluded that the addition of these new indications represents a modification to the collaboration agreements and will be accounted for separately, meaning the development costs associated with the new indications are distinct from the original development costs. The development service period for roxadustat for the treatment of CIA, anemia of chronic inflammation and multiple myeloma under the AstraZeneca agreements is estimated to continue through the end of 2024, to allow for development of these additional indications.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2020, the Company entered into Commercial Supply Agreement under the U.S./RoW Agreement with AstraZeneca to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. The Company shipped bulk drug product to AstraZeneca as pre-commercial supply for process validation purposes during the year ended December 31, 2020 and recognized related drug product revenue of $4.6 million, as described in details under &lt;span style="font-style:italic;"&gt;Drug Product Revenue&lt;/span&gt; section below.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;China Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective July&#160;30, 2013, the Company (through its subsidiaries affiliated with China) entered into a collaboration agreement with AstraZeneca for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in China (&#x201c;China Agreement&#x201d;). Under the terms of the China Agreement, AstraZeneca agreed to pay upfront consideration totaling $28.2&#160;million (such amounts were fully received in 2014). Under the China Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $348.5 million in potential milestone payments, comprised of (i)&#160;up to $15.0 million in milestone payments upon achievement of specified clinical and development milestone events, (ii)&#160;up to $146.0 million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $187.5 million in milestone payments upon the achievement of specified commercial sales and other events. The China Agreement is structured as a 50/50 profit or loss share (as defined), which was amended under the China Amendment discussed below in the third quarter of 2020, and provides for joint development costs (including capital and equipment costs for construction of the manufacturing plant in China), to be shared equally during the development. The aggregate amount of the considerations received under the China Agreement through December&#160;31, 2020 totals $77.2 million.&lt;/p&gt;
&lt;p id="C2" style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, roxadustat has been included on the updated NRDL released by China&#x2019;s National Healthcare Security Administration for the treatment of anemia in CKD, covering patients who are non-dialysis dependent as well as those who are dialysis-dependent. The inclusion on the NRDL triggered a total of $22.0 million milestones payable to the Company by AstraZeneca. Accordingly, the total consideration of $22.0 million associated with these milestones was included in the transaction price and allocated to performance obligations under the combined arrangement, of which $18.7 million was recognized as revenue during the year ended December 31, 2019. The Company continued to recognize related revenue during the year ended December 31, 2020, from performance obligations satisfied or partially satisfied, and the amount was not material. This milestone payment was received during the first quarter of 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 17, 2018, FibroGen Beijing, received marketing authorization from the NMPA for roxadustat, a first-in-class HIF prolyl hydroxylase inhibitor, for the treatment of anemia caused by CKD in patients on dialysis. This approval triggered a $6.0 million milestone payable to the Company by AstraZeneca. On December 29, 2018, FibroGen Beijing received First Manufacturing Approval for a Product in the Field in the Territory, which allows production for Phase 4 clinical studies, patients&#x2019; early experience programs, donation programs, as well as to supply products for testing and assessments required prior to launch. This approval triggered a $6.0 million milestone payable to the Company by AstraZeneca. Approximately $9.9 million of the total $12.0 million milestone payables was recognized as revenue during the year ended December 31, 2018. The Company continued to recognize related revenues during the years ended December 31, 2019 and 2020, from performance obligations satisfied or partially satisfied, and the amounts were not material.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;China Amendment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 8, 2020, FibroGen China and AstraZeneca (together with FibroGen China, the &#x201c;Parties&#x201d;) entered into the China Amendment, effective July 1, 2020, relating to the development and commercialization of roxadustat in China. While the responsibilities of the Parties under the China Agreement remain largely the same, certain changes were made. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the China Amendment, in September 2020, FibroGen Beijing and AstraZeneca completed the establishment of a jointly owned entity, Falikang, which will perform roxadustat distribution, as well as conduct sales and marketing through AstraZeneca. See Note 3,&lt;span style="font-style:italic;"&gt; Acquisition and Variable Interest Entity&lt;/span&gt;, for details. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with the China Amendment, the Company is currently in the interim period. Under the China Amendment, the interim period is defined as the period from April 1, 2020 to the time when Falikang is fully operational, which commenced in January 2021. During the interim period, FibroGen continues to sell product directly to the distributors, who remain as the Company&#x2019;s customers. Under the China Amendment, the calculation for profit or loss share has changed related to sales of roxadustat in China for the period from April 1, 2020 onwards. With effect from April 1, 2020, the Parties have changed the method under which commercial expenses incurred by AstraZeneca are calculated and billed. AstraZeneca&#x2019;s co-promotion expenses for their sales and marketing efforts are now subject to a cap of a percentage of net sales. Once AstraZeneca has been fully reimbursed for their sales and marketing costs under the cap, AstraZeneca will bill the co-promotion expenses based on actual costs on a prospective basis. In addition, the China Amendment has allowed for a higher cost of manufacturing incurred by FibroGen Beijing to be included in the profit or loss share calculation, subject to an annual cap, among other changes. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Once Falikang is fully operational, substantially all direct product sales will be made by Falikang while the Company continues to sell product directly in few provinces in China. AstraZeneca will bill the co-promotion expenses to Falikang and to FibroGen Beijing, respectively, for its services provided to the respective entity. In addition, FibroGen Beijing will sell commercial product to Falikang based on an agreed upon transfer price. Development costs will continue to be shared 50/50 between the Parties.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result, the interim period primarily includes the following activities:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.36%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Co-promotion expenses: The China Amendment revised the payment arrangements and calculation of the historical unpaid co-promotion expenses to AstraZeneca for its sales and marketing efforts associated with the commercial sales for roxadustat in China since the product launch. Under the previous China Agreement, payment of these historical co-promotion expenses was subject to certain profitability and cash flow thresholds. No amount of the historical co-promotion costs had been paid prior to the China Amendment as these thresholds had not yet been met. Under the China Amendment, a portion of the historical unpaid co-promotion expenses was adjusted to reduce the amount owed by FibroGen Beijing and the current period co-promotion expenses are capped at a percentage of net roxadustat sales in China. As a result, in the third quarter of 2020, the Company reversed approximately $84.4 million of previously accrued co-promotion expenses payable, which was recorded as a reduction to selling, general and administrative expenses, where these expenses were initially recorded during the periods from the initiation of commercial activities in the first quarter of 2019 to the second quarter of 2020. The co-promotion expenses for the year ended December 31, 2020, capped at a percentage of net roxadustat sales in China, were $27.2 million, included in the selling, general and administrative expenses. After this adjustment, as of December 31, 2020, $16.9 million and $11.5 million of the recalculated accrued co-promotion expenses were recorded in accounts payable and accrued liabilities, respectively, as they were anticipated to be paid within the next 12 months; and $27.4 million of the recalculated accrued co-promotion expenses adjusted under the China Amendment remained in the long-term liabilities, as it is not anticipated to be paid within the next 12 months.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.36%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Profit share: Profit/loss share between FibroGen Beijing and AstraZeneca is based on a calculation of the current period net roxadustat sales in China and deductible expenses pursuant to the China Agreement. Based on the calculation revised under the China Amendment, profit was achieved during the third and fourth quarter of 2020. As a result, the Company recorded a profit share liability of $7.0 million to AstraZeneca as of December 31, 2020 in the accrued and other current liabilities, which correspondingly reduced the deferred revenue related to the performance obligation in accordance with the China Agreement.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.36%;white-space:nowrap" valign="top"/&gt;
&lt;td valign="top"&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounting for the Astellas Agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For each of the Astellas agreements, the Company has evaluated the promised services within the respective arrangements and has identified performance obligations representing those services and bundles of services that are distinct.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Promised services that were not distinct have been combined with other promised services to form a distinct bundle of promised services, with revenue being recognized on the bundle of services rather than the individual services. There are no right-of-return provisions for the delivered items in the Astellas agreements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, the transaction price for the Japan Agreement, excluding manufacturing services that is discussed separately below, included $40.1 million of non-contingent upfront payments, $65.0 million of variable consideration related to payments for milestones considered probable of being achieved, and $11.7 million of variable consideration related to co-development billings. The transaction price for the Europe Agreement, excluding manufacturing services that is discussed separately below, included $320.0 million of non-contingent upfront payments, $220.0 million of variable consideration related to payments for milestones considered probable of being achieved, and $225.9 million of variable consideration related to co-development billings. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For revenue recognition purposes, the Company determined that the term of each collaboration agreement with Astellas begins on the effective date and ends upon the completion of all performance obligations contained in the agreement. The contract term is defined as the period in which parties to the contract have present and enforceable rights and obligations. The Company believes that the requirement to continue funding development for a substantive period of time and loss of product rights, along with non-refundable upfront payments already remitted by Astellas, create significant disincentive for Astellas to exercise its right to terminate the agreements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Astellas agreements, the Company allocated the transaction price to the various performance obligations based on the relative SSP of each performance obligation, with the exception of co-development billings allocated entirely to co-development services performance obligations.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the technology license under the Japan Agreement and the Europe Agreement, SSP was determined primarily by using the discounted cash flow (&#x201c;DCF&#x201d;) method, which aggregates the present value of future cash flows to determine the valuation as of the effective date of each of the agreements. The DCF method involves the following key steps: 1) the determination of cash flow forecasts and 2) the selection of a range of comparative risk-adjusted discount rates to apply against the cash flow forecasts. The discount rates selected were based on expectations of the total rate of return, the rate at which capital would be attracted to the Company and the level of risk inherent within the Company. The discounts applied in the DCF analysis ranged from 17.5% to 20.0%. The Company&#x2019;s cash flow forecasts were derived from probability-adjusted revenue and expense projections by territory. Such projections included consideration of taxes and cash flow adjustments. The probability adjustments were made after considering the likelihood of technical success at various stages of clinical trials and regulatory approval phases. SSP also considered certain future royalty payments associated with commercial performance of the Company&#x2019;s compounds, transfer prices and expected gross margins.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The promised services that were analyzed, along with their general timing of satisfaction and recognition as revenue, are as follows:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;License to the Company&#x2019;s technology existing at the effective date of the agreements.&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt; For both of the Astellas agreements, the license was delivered at the beginning of the agreement term. In both cases, the Company concluded at the time of the agreement that its collaboration partner, Astellas, would have the knowledge and capabilities to fully exploit the licenses without the Company&#x2019;s further involvement. However, the Japan Agreement has contractual limitations that might affect Astellas&#x2019; ability to fully exploit the license and therefore, potentially, the conclusion as to whether the license is capable of being distinct. In the Japan Agreement, Astellas does not have the right to manufacture commercial supplies of the drug. In order to determine whether this characteristic of the agreement should lead to a conclusion that the license was not distinct in the context of the agreement, the Company considered the ability of Astellas to benefit from the license together with other resources readily available to Astellas. Finally, the Company considered the fact that at the time of delivery of the license, the development services were beyond the preclinical development phase and any remaining development work in either agreement would not be expected to result in any significant modification or customization to the licensed technology. As such, the development services are separately identifiable from the licensed technology, indicating that the license is a distinct performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing rights.&lt;/span&gt;&lt;span style="font-style:normal;"&gt; In the case of the Japan Agreement, the Company retained manufacturing rights largel&lt;/span&gt;&lt;span style="font-style:normal;"&gt;y because of the way the parties chose for FibroGen to be compensated under the agreement. At the time the agreement was signed, the Company believed that it was more advantageous upon commercialization to have a transfer price revenue model in place as op&lt;/span&gt;&lt;span style="font-style:normal;"&gt;posed to a traditional sales-based model. The manufacturing process does not require specialized knowledge or expertise uniquely held by FibroGen, and notwithstanding contractual restrictions, Astellas could employ manufacturing services from readily avail&lt;/span&gt;&lt;span style="font-style:normal;"&gt;able third parties in order to benefit from the license. Therefore, along with the foregoing paragraph, the Company determined that the license in Japan is a distinct performance obligation despite the retention of manufacturing rights by the Company.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In summary, the Company concludes that item (1) represents a performance obligation. The portion of the transaction price allocated to this performance obligation based on a relative SSP basis is recognized as revenue in its entirety at the point in time the license transfers to Astellas.&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.42%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;Co-development services (Europe Agreement). &lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;This promise relates to co-development services that were reasonably expected to be performed by the Company at the time the collaboration agreement was signed and is considered distinct. Co-development billings are allocated entirely to the co-development services performance obligation as amounts are related specifically to research and development efforts necessary to satisfy the performance obligation, and such an allocation is consistent with the allocation objective. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours and out-of-pocket expenses incurred relative to total expected costs to be incurred. The measure of progress is updated each reporting period. Co-development services are expected to continue over the development period that is currently estimated to continue through the end of 2021. In addition, the Company concluded that the new indication related to CIA approved in January 2019 represents a modification to the Europe agreements at that time and will be accounted for separately, for which the development service period is estimated to continue through the second quarter of 2024. There was no provision for co-development services in the Japan Agreement. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;License to the Company&#x2019;s technology developed during the term of the agreement and development (referred to as &#x201c;when and if available&#x201d;) and information sharing services. &lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;These promises are generally satisfied throughout the term of the agreements.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;Manufacturing of clinical supplies of products.&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt; This promise is satisfied as supplies for clinical product are delivered for use in the Company&#x2019;s clinical trial programs during the development period, or pre-commercialization period.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(5)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;Committee service&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;. This promise is satisfied throughout the course of the agreements as meetings are attended.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0.04%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Items (2)-(5) are bundled into a single performance obligation that is distinct given the fact that all are highly interrelated during the development period (pre-commercial phase of development) such that satisfying them independently is not practicable. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours or full time equivalents and out-of-pocket expenses incurred relative to total expected costs to be incurred. The measure of progress is updated each reporting period.&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(6)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;Manufacturing commercial supplies of products.&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt; This promised service is distinct as services are not interrelated with any of the other performance obligations. Payments received for commercial supplies of products represent sales-based payments related predominately to the license of intellectual property under both Astellas agreements. Revenue is recognized as supplies are shipped for commercial use during the commercialization period. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Japan Amendment the drug product revenue represents variable consideration and is estimated based on the quantity of product shipped, actual listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and possible future changes to the listed price, adjusted for estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk drug product tablets, and estimated yield from the manufacture of bulk product tablets, among others.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Europe Agreement, the drug product revenue amount represents variable consideration and is estimated based on the quantity of product shipped and an estimated price. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price per strength, which is estimated to be realized by Astellas from the end sale of roxadustat in its approved territories.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the drug product revenue only to the extent that &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;it is probable that a significant re&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;versal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. Estimating variable consideration and the related constraint requires the &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;use of significant management judgment. The Company reviews new information that may affect its variable consideration estimate at every reporting period and records an adjustment to revenue, if certain and material&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. Actual amounts of consideration &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ultimately received in the future may differ from the Company&#x2019;s estimates, for which the Company will adjust these estimates and affect the drug product revenue in the period such variances become known.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As each of the agreements provides for annual true up to the considerations paid for its commercial supplies, the Company will re-evaluate the transaction price in each reporting period and record adjustment to revenue as uncertain events are resolved or other changes in circumstances occur. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounting for the AstraZeneca Agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluated whether the U.S./RoW Agreement and the China Agreement should be accounted for as a single or separate arrangements and concluded that the agreements should be accounted for as a single arrangement with the presumption that two or more agreements executed with a single customer at or around the same time should be presumed to be a single arrangement. The key points the Company considered in reaching this conclusion are as follows: &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;While the two agreements were largely negotiated separately, those negotiations proceeded concurrently, and were intended to be completed contemporaneously, presuming AstraZeneca&lt;/span&gt;&lt;span style="font-weight:bold;color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;decided to proceed with licenses in all regions available. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;2.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Throughout negotiations for both agreements, the Company and the counterparties understood and considered the possibility that one arrangement may be executed without the execution of the other arrangement. However, the preference for the Company and the counterparties during the negotiations was to execute both arrangements concurrently.&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;The two agreements were executed as separate agreements because different development, regulatory and commercial approaches required certain terms of the agreements to be structured differently, rather than because the Company or the counterparties considered the agreements to be fundamentally separate negotiations.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accordingly, as the agreements are being accounted for as a single arrangement, upfront and other non-contingent consideration received and to be received has been and will be pooled together and allocated to each of the performance obligations in both the U.S./RoW Agreement and the China Agreement based on their relative SSPs.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For each of the AstraZeneca agreements, the Company has evaluated the promised services within the respective arrangements and has identified performance obligations representing those services and bundled services that are distinct.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Promised services that were not distinct have been combined with other promised services to form a distinct bundle of promised services, with revenue being recognized on the bundle of services rather than the individual promised services. There are no right-of-return provisions for the delivered items in the AstraZeneca agreements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, the transaction price for the U.S./RoW Agreement and the China Agreement, excluding manufacturing services that is discussed separately below, included $402.2 million of non-contingent upfront payments, $114.0 million of variable consideration related to payments for milestones considered probable of being achieved, $564.9 million of variable consideration related to co-development billings, offset by $7.0 million of variable consideration related to profit share under the China Amendment.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the AstraZeneca agreements, the Company allocated the transaction price to the various performance obligations based on the relative SSP of each performance obligation, with the exception of co-development billings and commercial sale of product. Co-development billings under the U.S./RoW Agreement were allocated entirely to the U.S./RoW co-development services performance obligation, and co-development billings under the China Agreement were allocated entirely to the combined performance obligation under the China Agreement. Commercial sale of product under the U.S./ROW Agreement is entirely allocated to the manufacturing commercial supply of products performance obligation, and commercial sale of product under the China Agreement is allocated entirely to the combined China performance obligation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For revenue recognition purposes, the Company determined that the term of its collaboration agreements with AstraZeneca begin on the effective date and ends upon the completion of all performance obligations c&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ontained in the agreements. T&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;he contract term is defined as the period in which parties to the contract have present and enforceable rights and obligations. The Company believes that the requirement to continue funding development for a substantive period &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;of time and the loss of product rights, along with non-refundable upfront payments already remitted by AstraZeneca, represent substantive termination penalties that create significant disincentive for AstraZeneca to exercise its right to terminate the agre&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ement.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the technology license under the AstraZeneca U.S./RoW Agreement, SSP was determined based on a two-step process. The first step involved determining an implied royalty rate that would result in the net present value of future cash flows to equal to zero (i.e. where the implied royalty rate on the transaction would equal the target return for the investment). This results in an upper bound estimation of the magnitude of royalties that a hypothetical acquirer would reasonably pay for the forecasted cash flow stream. The Company&#x2019;s cash flow forecasts were derived from probability-adjusted revenue and expense projections. Such projections included consideration of taxes and cash flow adjustments. The probability adjustments were made after considering the likelihood of technical success at various stages of clinical trials and regulatory approval phases. The second step involved applying the implied royalty rate, which was determined to be 40%, against the probability-adjusted projected net revenues by territory and determining the value of the license as the net present value of future cash flows after adjusting for taxes. The discount rate utilized was 17.5%.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;U.S./RoW Agreement:&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The promised services that were analyzed, along with their general timing of satisfaction and recognition as revenue, are as follows:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;License to the Company&#x2019;s technology existing at the effective date of the agreements.&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt; For the U.S./RoW Agreement, the license was delivered at the beginning of the agreement term. The Company concluded that AstraZeneca has the knowledge and capabilities to fully exploit the license under the U.S./RoW Agreement without the Company&#x2019;s further involvement. Finally, the Company considered the fact that at the time of delivery of the license, the development services were beyond the preclinical development phase and any remaining development work would not be expected to result in any significant modification or customization to the licensed technology. As such, the development services are separately identifiable from the licensed technology, indicating that the license is a distinct performance obligation. Therefore, the Company has concluded that the license is distinct and represents a performance obligation. The portion of the transaction price allocated to this performance obligation based on a relative SSP basis is recognized as revenue in its entirety at the point in time the license transfers to AstraZeneca.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;Co-development services. &lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;This promise relates to co-development services that were reasonably expected to be performed by the Company at the time the collaboration agreement was signed and is distinct. Co-development billings are allocated entirely to the co-development services performance obligation as amounts are related specifically to research and development efforts necessary to satisfy the performance obligation, and such an allocation is consistent with the allocation objective. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours or full time equivalents and out-of-pocket expenses incurred relative to total expected costs to be incurred. Co-development services are expected to continue over the development period that is currently estimated to continue through the end of the first quarter of 2021. In addition, the Company concluded that the addition of the new indications related to CIA, anemia of chronic inflammation and multiple myeloma approved during the fourth quarter of 2018 represents a modification to the collaboration agreements and will be accounted for separately, for which the joint development service period is estimated to continue through the end of 2024. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;Manufacturing of clinical supplies of products.&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt; This promise is satisfied as supplies for clinical product are delivered for use in the Company&#x2019;s clinical trial programs during the development period, or pre-commercialization period.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;Information sharing and committee service.&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt; These promises are satisfied throughout the course of the agreement as services are provided.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Items (2)-(4) are bundled into a single performance obligation that is distinct given the fact that all are highly interrelated during the development period (pre-commercial phase of development) such that delivering them independently is not practicable. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours or full time equivalents and out-of-pocket expenses incurred relative to total expected costs to be incurred. The measure of progress is updated each reporting period.&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(5)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="text-decoration:none;Background-color:#auto;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;Manufacturing commercial supplies of products. &lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;This promise is distinct as services are not interrelated with any of the other&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt; performance obligations. Revenue is recognized as supplies are shipped for commercial use during the commercialization period. &lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;The drug product revenue amount represents variable consideration and is estimated based on the quantity of product shipped and &lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;an estimated price for each individual purchase order. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price, which is estimated to be realized by AstraZeneca from the end sale o&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;f roxadustat in its approved territories.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the drug product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. Estimating variable consideration and the related constraint requires the use of significant management judgment. The Company reviews new information that may affect its variable consideration estimate at every reporting period and records an adjustment to revenue, if certain and material. Actual amounts of consideration ultimately received in the future may differ from the Company&#x2019;s estimates, for which the Company will adjust these estimates and affect the drug product revenue in the period such variances become known.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As the agreement provides for an annual true up to the considerations paid for its commercial supplies, the Company will re-evaluate the transaction price in each reporting period and record an adjustment to revenue as uncertain events are resolved or other changes in circumstances occur. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;China Agreement:&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The promised services that were analyzed are consistent with the U.S./RoW Agreement, except for license to the Company&#x2019;s technology existing at the effective date of the agreement, described as follows:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-style:italic;color:#000000;"&gt;License to the Company&#x2019;s technology existing at the effective date of the agreement.&lt;/span&gt;&lt;span style="color:#000000;"&gt; The license was delivered at the beginning of the agreement term. However, the China Agreement with AstraZeneca has contractual limitations that might affect AstraZeneca&#x2019;s ability to fully exploit the license and therefore, potentially, the conclusion as to whether the license is distinct in the context of the agreement. In the China Agreement, AstraZeneca does not have the right to manufacture commercial supplies of the drug. In order to determine whether this characteristic of the arrangement should lead to a conclusion that the license was not distinct in the context of the agreement, the Company considered the ability of AstraZeneca to benefit from the license on its own or together with other resources readily available to AstraZeneca.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the China Agreement, the Company retained manufacturing rights as an essential part of a strategy to pursue domestic regulatory pathway for product approval which requires the regulatory licensure of the manufacturing facility in order to commence commercial shipment. The prospects for the collaboration as a whole would have been substantially different had manufacturing rights been provided to AstraZeneca. We hold the rights to manufacture commercial drug product in China. Therefore, AstraZeneca cannot benefit from the license on its own or together with other readily available resources. Accordingly, all the promises identified, including the license, co-development services and manufacturing of commercial supplies,, under the China Agreement have been bundled into a single performance obligation and amounts of the transaction price allocable to this performance obligation are deferred until control of the manufactured commercial drug product has begun to transfer to AstraZeneca. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with the China Amendment, once Falikang is fully operational, which commenced in January 2021, substantially all product sales will be made by Falikang directly to the distributors in China, while the Company continues to sell directly in few provinces in China. Revenue will be recognized upon the transfer of control of commercial drug product to Falikang. For the Company&#x2019;s direct sales of commercial drug product, revenue will be recognized when control of the promised good is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for the product.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Summary of revenue recognized under the collaboration agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The table below summarizes the accounting treatment for the various performance obligations pursuant to each of the Astellas and AstraZeneca agreements. License amounts identified below are included in the &#x201c;License revenue&#x201d; line item in the consolidated statements of operations. All other elements identified&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; below are included in the &#x201c;Development and other revenue&#x201d; line item in the consolidated statements of operations.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts recognized as license revenue and development revenue under the Japan Agreement with Astellas were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance Obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Japan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,935&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,220&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,222&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Japan Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&#160;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&#160;at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&#160;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&#160;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,350&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total license and development&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;116,697&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;116,827&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The revenue recognized under the Japan Agreement for the year ended December 31, 2020 included an increase of $15.1 million resulting from changes to estimated variable consideration in the current year relating to performance obligations satisfied or partially satisfied in previous periods. The Company does not expect material variable consideration from estimated future co-development billing beyond development period in the transaction price related to the Japan Agreement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts recognized as license revenue and development revenue under the Europe Agreement with Astellas were as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance Obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Europe&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;117,470&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,954&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,172&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,503&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Europe Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&#160;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&#160;at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&#160;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&#160;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;487,951&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;487,951&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;248,962&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,429&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;250,391&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total license and development&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;736,913&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,429&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;738,342&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:2.68%;text-indent:-2.68%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The revenue recognized under the Europe Agreement for the year ended December 31, 2020 included an increase in revenue of $1.5 million resulting from changes to estimated variable consideration in the current year relating to performance obligations satisfied or partially satisfied in previous periods. The remainder of the transaction price related to the Europe Agreement includes $27.6 million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts recognized as license revenue and development revenue under the U.S./RoW and China Agreements with AstraZeneca were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance Obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S.&#160;/&#160;RoW&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;and China&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,681&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,946&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,508&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;84,629&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,970&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China performance obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(90&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement, along with any associated deferred revenue as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S.&#160;/&#160;RoW and China Agreements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&#160;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&#160;at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&#160;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&#160;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;341,844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;341,844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Co-development, information sharing &amp;amp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;committee services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;554,775&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,276&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;557,051&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China performance obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137,338&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137,338&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total license and development&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;896,619&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;139,614&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,036,233&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:92.86%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;* &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the consolidated balance sheets. As of December 31, 2020, deferred revenue included $137.5 million related to the U.S./RoW and China Agreement, which represents the net of $139.6 million of deferred revenue presented above and a $2.1 million unbilled co-development revenue under the China Amendment with AstraZeneca.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The revenue recognized under the U.S./RoW Agreement and China Agreement for the year ended December 31, 2020 included a reduction in revenue of $2.9 million resulting from changes to estimated variable consideration in the current year relating to performance obligations satisfied or partially satisfied in previous periods. The remainder of the transaction price related to the U.S./RoW Agreement and China Agreement includes $37.9 million of variable consideration from estimated future co-development billing. The amount allocated to the U.S./RoW Agreement is expected to be recognized over the remaining development service period. The amount allocated to the China performance obligation is expected to be recognized as the Company transfers control of the commercial drug product to Falikang.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product Revenue, Net&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue from roxadustat commercial sales in China is recognized in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products, net of various sales rebates and discounts. Product revenue, net was as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,027&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price adjustment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(936&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-key account hospital listing award&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,325&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual sales rebate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,189&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(149&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other discounts and rebates&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(923&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales return&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,498&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the second quarter of 2020, the Company amended the agreement with its pharmaceutical distributors, which triggered accounting modifications particularly related to the non-key account hospital listing award. For the year ended December 31, 2020, the non-key account hospital listing award was $9.3 million, which was recorded as a reduction to the revenue and calculated based on eligible non-key account hospital listings to date achieved by each distributor with certain requirements met during the period. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December 31, 2020 and 2019, the contractual sales rebate was $6.2 million and $0.1 million, respectively, which were calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. All other rebates and discounts, including sales return allowance were immaterial for the periods presented. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December 31, 2019, a $0.9 million of price adjustment was recorded based on government-listed price guidance and estimated channel inventory levels.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The rebates and discounts that the Company&#x2019;s pharmaceutical distributors have earned are eligible to be applied against future sales orders, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible in the same period that the related revenue is recorded. Due to the distributor&#x2019;s legal right to offset, at each balance sheet date, the rebates and discounts are presented as reductions to gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The distributor&#x2019;s legal right of offset is calculated at the individual distributor level. The following table includes a roll-forward of the related contract liabilities (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deduction&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Translation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Presented Net&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Against&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue - Contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,102&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,497&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,184&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(270&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,685&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;548&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the total rebates and discounts as reductions to gross accounts receivable was $0.5 million, and the total contract liabilities was $15.1 million, which was included in accrued and other current liabilities in the consolidated balance sheet. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reductions to gross accounts receivable, including the above-mentioned contra-accounts receivable items related to product revenue, totaled $0.8 million and $1.1 million as of December 31, 2020 and 2019, respectively.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug Product Revenue&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue was as follows (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,281&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(36,324&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,776&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AstraZeneca&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,906&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(36,324&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,776&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company fulfilled all the shipment obligations under the term of the Japan Amendment during the year ended December 31, 2018, and recognized the related product revenue of $64.8 million in the same period&lt;span style="font-weight:bold;"&gt; &lt;/span&gt;based on a transaction price that was subject to potential future adjustments, which represented a form of variable consideration. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A change in estimated variable consideration incurred in 2019 related to the above API shipments in 2018, at the time the actual listed price for roxadustat was issued by the Japanese Ministry of Health, Labour and Welfare, which resulted in a total difference of $36.3 million between the estimated and the actual listed price and yield from the manufacture of bulk product tablets. &lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, during the year ended December 31, 2020, the Company recorded another $4.0 million reduction to drug product revenue related to the above API shipments, due to a change in estimated variable consideration. Specifically, the change in estimated variable consideration was based on the API held by Astellas at March 31, 2020 adjusted to reflect the updated listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and changes in the estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk product tablets, and estimated yield from the manufacture of bulk product tablets, among others. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the second quarter of 2020, the Company fulfilled shipment obligations under the term of Japan Amendment with Astellas, and recognized related drug product revenue of $8.2 million in the same period. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the fourth quarter of 2020, the Company shipped bulk drug product from process validation supplies for commercial purposes under the term of the Europe Agreement with Astellas. The Company constrained the consideration from this shipment due to a high degree of uncertainty associated to the final consideration. As a result, the Company recorded $1.4 million as current deferred revenue and $4.6 million as long-term deferred revenue as of December 31, 2020. The deferred revenue will be recognized as and when uncertainty is resolved. The following table includes a roll-forward of the related contract liabilities (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue - Astellas - contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,984&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,984&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2020, the Company shipped bulk drug product to AstraZeneca as pre-commercial supply for process validation purposes, under the term of Commercial Supply Agreement under the U.S./RoW Agreement with AstraZeneca, and recognized drug product revenue of $4.6 million.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other Revenues&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other revenues consist primarily of collagen material sold for research purposes. Other revenues were immaterial for each of the three years ended December&#160;31, 2020.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Revenue&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue represents amounts billed, or in certain cases, yet to be billed to the Company&#x2019;s collaboration partners for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying performance obligations. The long-term portion of deferred revenue represents amounts to be recognized after one year through the end of the non-contingent performance period of the underlying performance obligations. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue includes amounts allocated to the China performance obligation under the AstraZeneca arrangement as revenue recognition associated with this unit of accounting is tied to the commercial launch of the products within China and to when the control of the manufactured commercial drug product is transferred to AstraZeneca. As of December 31, 2020, approximately $3.5 million of the deferred revenue related to the China unit of accounting was included in short-term deferred revenue, which represents the amount of deferred revenue associated with the China unit of accounting that is expected to be recognized within the next 12 months, associated with the commercial sales in China.&lt;/p&gt;</fgen:CollaborativeArrangementAndRevenuesDisclosureTextBlock>
    <fgen:CollaborativeArrangementAndRevenuesPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000564">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas Agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Japan Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2005, the Company entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (&#x201c;Japan Agreement&#x201d;). Under this agreement, Astellas paid license fees and other consideration totaling $40.1&#160;million (such amounts were fully received as of February 2009). Under the Japan Agreement, the Company is also eligible to receive from Astellas an aggregate of approximately $132.5&#160;million in potential milestone payments, comprised of (i)&#160;up to $22.5&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of July 2016), (ii)&#160;up to $95.0&#160;million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $15.0&#160;million in milestone payments upon the achievement of specified commercial sales milestone. The Japan Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range of the list price published by the Japanese Ministry of Health, Labour and Welfare, adjusted for certain elements, after commercial launch. The aggregate amount of the considerations received under the Japan Agreement, through December&#160;31, 2020 totals $105.1 million, excluding drug product revenue that is discussed separately below.&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the fourth quarter of 2020, the Japanese Ministry of Health, Labour and Welfare approved EVRENZO&#xae; (roxadustat) for the treatment of anemia of CKD in adult patients not on dialysis. This approval triggered a $15.0 million milestone payable to the Company by Astellas under the Japan Agreement. Accordingly, the consideration of $15.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the Japan Agreement in the fourth quarter of 2020, substantially all of which was recognized as revenue during the year ended December 31, 2020 from performance obligations satisfied or partially satisfied.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In Septembe&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;r 2019, the Japanese Ministry of Health, Labour and Welfare approved EVRENZO&#xae; (generic name: roxadustat; tradename EVRENZO&#xae; in Japan) for the treatment of anemia associated with CKD in dialysis patients. This approval triggered a $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.5 million&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; milestone &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;payable to the Company by Astellas under the Japan Agreement. Accordingly, the consideration of $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.5&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million associated with this milestone was included in the transaction price and allocated to performance obligations under the Japan Agreement in the t&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;hird quarter of 2019, substantially all of which was recognized as revenue during the year ended December 31, 2019 from performance obligations satisfied or partially satisfied.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the second quarter of 2018, Astellas reported positive results from the final phase 3 CKD-dialysis trial of roxadustat in Japan, indicating that Astellas was ready to make an NDA submission for the treatment of anemia with roxadustat in CKD-dialysis patients in 2018. The Company evaluated the regulatory milestone payment associated with NDA submission in Japan based on variable consideration requirements under the current revenue standards and concluded that this milestone became probable of being achieved in the second quarter of 2018. Accordingly, the consideration of $15.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the Japan Agreement in the second quarter of 2018, substantially all of which was recognized as revenue during the year ended December 31, 2018 from performance obligations satisfied or partially satisfied. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2018, FibroGen and Astellas entered into an amendment to the Japan Agreement that allows Astellas to manufacture roxadustat drug product for commercialization in Japan (the &#x201c;Japan Amendment&#x201d;). Under this amendment, FibroGen would continue to manufacture and supply roxadustat API&lt;span style="font-weight:bold;"&gt; &lt;/span&gt;to Astellas for the roxadustat commercial launch in Japan. The commercial terms of the Japan Agreement relating to the transfer price for roxadustat for commercial use remain substantially the same, reflecting an adjustment for the manufacture of drug product by Astellas rather than FibroGen. The Company fulfilled shipment obligations under the term of the Japan Amendment in the second quarter of 2020 and in 2018. The related drug product revenue, as described in details under &lt;span style="font-style:italic;"&gt;Drug Product Revenue&lt;/span&gt; section below, were $4.3 million, $(36.3) million and $64.8 million in the years ended December 31, 2020, 2019 and 2018, respectively. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Europe Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2006, the Company entered into a separate collaboration agreement with Astellas for the development and commercialization of roxadustat for the treatment of anemia in Europe, the Middle East, the Commonwealth of Independent States and South Africa (&#x201c;Europe Agreement&#x201d;). Under the terms of the Europe Agreement, Astellas paid license fees and other upfront consideration totaling $320.0 million (such amounts were fully received as of February 2009). The Europe Agreement also provides for additional development and regulatory approval milestone payments up to $425.0 million, comprised of (i)&#160;up to $90.0&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of 2012), (ii)&#160;up to $335.0&#160;million in milestone payments upon achievement of specified regulatory milestone events. Under the Europe Agreement, Astellas committed to fund 50% of joint development costs for Europe and North America, and all territory-specific costs. The Europe Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range. The aggregate amount of the considerations received under the Europe Agreement through December&#160;31, 2020 totals $540.0 million, excluding drug product revenue that is discussed separately below.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the second quarter of 2019, the Company received positive topline results from analyses of pooled major adverse cardiovascular event (&#x201c;MACE&#x201d;) and MACE+ data from its Phase 3 trials evaluating roxadustat as a treatment for dialysis and non-dialysis CKD patients, enabling Astellas to prepare for an MAA submission to the EMA in the second quarter of 2020, following the Company&#x2019;s NDA submission to the FDA that was accepted for review in February 2020. The Company evaluated the two regulatory milestone payments associated with the planned MAA submission and concluded that these milestones became probable of being achieved in the second quarter of 2019. Accordingly, the total consideration of $130.0 million associated with these milestones was included in the transaction price and allocated to performance obligations under the Europe Agreement in the second quarter of 2019, of which $128.8 million was recognized as revenue during the year ended December 31, 2019 and $0.8 million was recognized as revenue during the year ended December 31, 2020, from performance obligations satisfied or partially satisfied. According to the Europe Agreement, these milestone payments are billable to Astellas upon the submission of an MAA, therefore this $130.0 million was an unbilled contract asset as of December 31, 2019, and billed to Astellas upon the submission of an MAA in the second quarter of 2020 with the total $130.0 million received during the same quarter. &lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the fourth quarter of 2018, the Company was engaged in the final stages of review with its partners over the proposed development of roxadustat for the treatment of chemotherapy-induced anemia (&#x201c;CIA&#x201d;).&#160;AstraZeneca and Astellas approved the program in December 2018 and January 2019, respectively. Costs associated with the development of this indication are expected to be shared 50-50 between the Company&#x2019;s two partners.&#160;For revenue recognition purposes, the Company concluded that this new indication represents a modification to the Europe agreements and will be accounted for separately, meaning the development costs associated with the new indications are distinct from the original development costs. The development service period for roxadustat for the treatment of CIA under the Europe Agreement is estimated to continue through the second quarter of 2024 to allow for development of this indication.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Europe Agreement, Astellas has an option to purchase roxadustat bulk drug product in support of commercial supplies. The Company fulfilled a shipment obligation under the term of the Europe Amendment in the fourth quarter of 2020, as described in details under &lt;span style="font-style:italic;"&gt;Drug Product Revenue&lt;/span&gt; section below.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;AstraZeneca Agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;U.S./Rest of World (&#x201c;RoW&#x201d;) Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective July&#160;30, 2013, the Company entered into a collaboration agreement with AstraZeneca for the development and commercialization of roxadustat for the treatment of anemia in the U.S. and all other countries in the world, other than China, not previously licensed under the Astellas Europe and Astellas Japan Agreements (&#x201c;U.S./RoW Agreement&#x201d;). It also excludes China, which is covered by a separate agreement with AstraZeneca described below. Under the terms of the U.S./RoW Agreement, AstraZeneca paid upfront, non-contingent, non-refundable and time-based payments totaling $374.0 million (such amounts were fully received as of June 2016). Under the U.S./RoW Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $875.0 million in potential milestone payments, comprised of (i)&#160;up to $65.0 million in milestone payments upon achievement of specified clinical and development milestone events, (ii)&#160;up to $325.0 million in milestone payments upon achievement of specified regulatory milestone events, (iii)&#160;up to $160.0&#160;million in milestone payments related to activity by potential competitors and (iv)&#160;up to approximately $325.0 million in milestone payments upon the achievement of specified commercial sales events. The aggregate amount of the considerations received under the U.S./RoW Agreement through December&#160;31, 2020 totals $439.0 million, excluding drug product revenue that is discussed separately below.&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the U.S./RoW Agreement, the Company and AstraZeneca will share equally in the development costs of roxadustat not already paid for by Astellas, up to a total of $233.0 million (i.e. the Company&#x2019;s share of development costs is $116.5 million, which was reached in 2015). Development costs incurred by FibroGen during the development period in excess of the $233.0 million (aggregated spend) are fully reimbursed by AstraZeneca. AstraZeneca will pay the Company tiered royalty payments on AstraZeneca&#x2019;s future net sales (as defined in the agreement) of roxadustat in the low 20% range. In addition, the Company will receive a transfer price for shipment of commercial product based on a percentage of AstraZeneca&#x2019;s net sales (as defined in the agreement) in the low- to mid-single digit range.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As mentioned above, during the second quarter of 2019, the Company received positive topline results from analyses of pooled MACE and MACE+ data from its Phase 3 trials for roxadustat, enabling the Company&#x2019;s NDA submission to the FDA. The Company evaluated the regulatory milestone payment associated with this planned NDA submission and concluded that this milestone became probable of being achieved in the second quarter of 2019. Accordingly, the consideration of $50.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the combined arrangement in the second quarter of 2019, of which $42.4 million was recognized as revenue during the year ended December 31, 2019 and $0.6 million was recognized as revenue during the year ended December 31, 2020, from performance obligations satisfied or partially satisfied. The Company submitted such NDA in December 2019, which was accepted by FDA in February 2020. According to the U.S/RoW Agreement, this milestone payment is billable to AstraZeneca when the NDA is accepted by the FDA, therefore this $50.0 million was an unbilled contract asset as of December 31, 2019, and was billed during the first quarter of 2020, the payment of which was fully received in April 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As mentioned above, AstraZeneca and Astellas approved the development of roxadustat for the treatment of CIA in December 2018 and January 2019, respectively. Costs associated with the development of this indication are expected to be shared 50/50 between AstraZeneca and Astellas.&#160;In addition, in December 2018, anemia of chronic inflammation and multiple myeloma was approved for development by AstraZeneca and is expected to be fully funded by them.&#160;For revenue recognition purposes, the Company concluded that the addition of these new indications represents a modification to the collaboration agreements and will be accounted for separately, meaning the development costs associated with the new indications are distinct from the original development costs. The development service period for roxadustat for the treatment of CIA, anemia of chronic inflammation and multiple myeloma under the AstraZeneca agreements is estimated to continue through the end of 2024, to allow for development of these additional indications.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2020, the Company entered into Commercial Supply Agreement under the U.S./RoW Agreement with AstraZeneca to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. The Company shipped bulk drug product to AstraZeneca as pre-commercial supply for process validation purposes during the year ended December 31, 2020 and recognized related drug product revenue of $4.6 million, as described in details under &lt;span style="font-style:italic;"&gt;Drug Product Revenue&lt;/span&gt; section below.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;China Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective July&#160;30, 2013, the Company (through its subsidiaries affiliated with China) entered into a collaboration agreement with AstraZeneca for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in China (&#x201c;China Agreement&#x201d;). Under the terms of the China Agreement, AstraZeneca agreed to pay upfront consideration totaling $28.2&#160;million (such amounts were fully received in 2014). Under the China Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $348.5 million in potential milestone payments, comprised of (i)&#160;up to $15.0 million in milestone payments upon achievement of specified clinical and development milestone events, (ii)&#160;up to $146.0 million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $187.5 million in milestone payments upon the achievement of specified commercial sales and other events. The China Agreement is structured as a 50/50 profit or loss share (as defined), which was amended under the China Amendment discussed below in the third quarter of 2020, and provides for joint development costs (including capital and equipment costs for construction of the manufacturing plant in China), to be shared equally during the development. The aggregate amount of the considerations received under the China Agreement through December&#160;31, 2020 totals $77.2 million.&lt;/p&gt;
&lt;p id="C2" style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, roxadustat has been included on the updated NRDL released by China&#x2019;s National Healthcare Security Administration for the treatment of anemia in CKD, covering patients who are non-dialysis dependent as well as those who are dialysis-dependent. The inclusion on the NRDL triggered a total of $22.0 million milestones payable to the Company by AstraZeneca. Accordingly, the total consideration of $22.0 million associated with these milestones was included in the transaction price and allocated to performance obligations under the combined arrangement, of which $18.7 million was recognized as revenue during the year ended December 31, 2019. The Company continued to recognize related revenue during the year ended December 31, 2020, from performance obligations satisfied or partially satisfied, and the amount was not material. This milestone payment was received during the first quarter of 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 17, 2018, FibroGen Beijing, received marketing authorization from the NMPA for roxadustat, a first-in-class HIF prolyl hydroxylase inhibitor, for the treatment of anemia caused by CKD in patients on dialysis. This approval triggered a $6.0 million milestone payable to the Company by AstraZeneca. On December 29, 2018, FibroGen Beijing received First Manufacturing Approval for a Product in the Field in the Territory, which allows production for Phase 4 clinical studies, patients&#x2019; early experience programs, donation programs, as well as to supply products for testing and assessments required prior to launch. This approval triggered a $6.0 million milestone payable to the Company by AstraZeneca. Approximately $9.9 million of the total $12.0 million milestone payables was recognized as revenue during the year ended December 31, 2018. The Company continued to recognize related revenues during the years ended December 31, 2019 and 2020, from performance obligations satisfied or partially satisfied, and the amounts were not material.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;China Amendment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 8, 2020, FibroGen China and AstraZeneca (together with FibroGen China, the &#x201c;Parties&#x201d;) entered into the China Amendment, effective July 1, 2020, relating to the development and commercialization of roxadustat in China. While the responsibilities of the Parties under the China Agreement remain largely the same, certain changes were made. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the China Amendment, in September 2020, FibroGen Beijing and AstraZeneca completed the establishment of a jointly owned entity, Falikang, which will perform roxadustat distribution, as well as conduct sales and marketing through AstraZeneca. See Note 3,&lt;span style="font-style:italic;"&gt; Acquisition and Variable Interest Entity&lt;/span&gt;, for details. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with the China Amendment, the Company is currently in the interim period. Under the China Amendment, the interim period is defined as the period from April 1, 2020 to the time when Falikang is fully operational, which commenced in January 2021. During the interim period, FibroGen continues to sell product directly to the distributors, who remain as the Company&#x2019;s customers. Under the China Amendment, the calculation for profit or loss share has changed related to sales of roxadustat in China for the period from April 1, 2020 onwards. With effect from April 1, 2020, the Parties have changed the method under which commercial expenses incurred by AstraZeneca are calculated and billed. AstraZeneca&#x2019;s co-promotion expenses for their sales and marketing efforts are now subject to a cap of a percentage of net sales. Once AstraZeneca has been fully reimbursed for their sales and marketing costs under the cap, AstraZeneca will bill the co-promotion expenses based on actual costs on a prospective basis. In addition, the China Amendment has allowed for a higher cost of manufacturing incurred by FibroGen Beijing to be included in the profit or loss share calculation, subject to an annual cap, among other changes. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Once Falikang is fully operational, substantially all direct product sales will be made by Falikang while the Company continues to sell product directly in few provinces in China. AstraZeneca will bill the co-promotion expenses to Falikang and to FibroGen Beijing, respectively, for its services provided to the respective entity. In addition, FibroGen Beijing will sell commercial product to Falikang based on an agreed upon transfer price. Development costs will continue to be shared 50/50 between the Parties.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result, the interim period primarily includes the following activities:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.36%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Co-promotion expenses: The China Amendment revised the payment arrangements and calculation of the historical unpaid co-promotion expenses to AstraZeneca for its sales and marketing efforts associated with the commercial sales for roxadustat in China since the product launch. Under the previous China Agreement, payment of these historical co-promotion expenses was subject to certain profitability and cash flow thresholds. No amount of the historical co-promotion costs had been paid prior to the China Amendment as these thresholds had not yet been met. Under the China Amendment, a portion of the historical unpaid co-promotion expenses was adjusted to reduce the amount owed by FibroGen Beijing and the current period co-promotion expenses are capped at a percentage of net roxadustat sales in China. As a result, in the third quarter of 2020, the Company reversed approximately $84.4 million of previously accrued co-promotion expenses payable, which was recorded as a reduction to selling, general and administrative expenses, where these expenses were initially recorded during the periods from the initiation of commercial activities in the first quarter of 2019 to the second quarter of 2020. The co-promotion expenses for the year ended December 31, 2020, capped at a percentage of net roxadustat sales in China, were $27.2 million, included in the selling, general and administrative expenses. After this adjustment, as of December 31, 2020, $16.9 million and $11.5 million of the recalculated accrued co-promotion expenses were recorded in accounts payable and accrued liabilities, respectively, as they were anticipated to be paid within the next 12 months; and $27.4 million of the recalculated accrued co-promotion expenses adjusted under the China Amendment remained in the long-term liabilities, as it is not anticipated to be paid within the next 12 months.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.36%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Profit share: Profit/loss share between FibroGen Beijing and AstraZeneca is based on a calculation of the current period net roxadustat sales in China and deductible expenses pursuant to the China Agreement. Based on the calculation revised under the China Amendment, profit was achieved during the third and fourth quarter of 2020. As a result, the Company recorded a profit share liability of $7.0 million to AstraZeneca as of December 31, 2020 in the accrued and other current liabilities, which correspondingly reduced the deferred revenue related to the performance obligation in accordance with the China Agreement.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.36%;white-space:nowrap" valign="top"/&gt;
&lt;td valign="top"&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounting for the Astellas Agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For each of the Astellas agreements, the Company has evaluated the promised services within the respective arrangements and has identified performance obligations representing those services and bundles of services that are distinct.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Promised services that were not distinct have been combined with other promised services to form a distinct bundle of promised services, with revenue being recognized on the bundle of services rather than the individual services. There are no right-of-return provisions for the delivered items in the Astellas agreements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, the transaction price for the Japan Agreement, excluding manufacturing services that is discussed separately below, included $40.1 million of non-contingent upfront payments, $65.0 million of variable consideration related to payments for milestones considered probable of being achieved, and $11.7 million of variable consideration related to co-development billings. The transaction price for the Europe Agreement, excluding manufacturing services that is discussed separately below, included $320.0 million of non-contingent upfront payments, $220.0 million of variable consideration related to payments for milestones considered probable of being achieved, and $225.9 million of variable consideration related to co-development billings. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For revenue recognition purposes, the Company determined that the term of each collaboration agreement with Astellas begins on the effective date and ends upon the completion of all performance obligations contained in the agreement. The contract term is defined as the period in which parties to the contract have present and enforceable rights and obligations. The Company believes that the requirement to continue funding development for a substantive period of time and loss of product rights, along with non-refundable upfront payments already remitted by Astellas, create significant disincentive for Astellas to exercise its right to terminate the agreements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Astellas agreements, the Company allocated the transaction price to the various performance obligations based on the relative SSP of each performance obligation, with the exception of co-development billings allocated entirely to co-development services performance obligations.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the technology license under the Japan Agreement and the Europe Agreement, SSP was determined primarily by using the discounted cash flow (&#x201c;DCF&#x201d;) method, which aggregates the present value of future cash flows to determine the valuation as of the effective date of each of the agreements. The DCF method involves the following key steps: 1) the determination of cash flow forecasts and 2) the selection of a range of comparative risk-adjusted discount rates to apply against the cash flow forecasts. The discount rates selected were based on expectations of the total rate of return, the rate at which capital would be attracted to the Company and the level of risk inherent within the Company. The discounts applied in the DCF analysis ranged from 17.5% to 20.0%. The Company&#x2019;s cash flow forecasts were derived from probability-adjusted revenue and expense projections by territory. Such projections included consideration of taxes and cash flow adjustments. The probability adjustments were made after considering the likelihood of technical success at various stages of clinical trials and regulatory approval phases. SSP also considered certain future royalty payments associated with commercial performance of the Company&#x2019;s compounds, transfer prices and expected gross margins.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The promised services that were analyzed, along with their general timing of satisfaction and recognition as revenue, are as follows:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;License to the Company&#x2019;s technology existing at the effective date of the agreements.&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt; For both of the Astellas agreements, the license was delivered at the beginning of the agreement term. In both cases, the Company concluded at the time of the agreement that its collaboration partner, Astellas, would have the knowledge and capabilities to fully exploit the licenses without the Company&#x2019;s further involvement. However, the Japan Agreement has contractual limitations that might affect Astellas&#x2019; ability to fully exploit the license and therefore, potentially, the conclusion as to whether the license is capable of being distinct. In the Japan Agreement, Astellas does not have the right to manufacture commercial supplies of the drug. In order to determine whether this characteristic of the agreement should lead to a conclusion that the license was not distinct in the context of the agreement, the Company considered the ability of Astellas to benefit from the license together with other resources readily available to Astellas. Finally, the Company considered the fact that at the time of delivery of the license, the development services were beyond the preclinical development phase and any remaining development work in either agreement would not be expected to result in any significant modification or customization to the licensed technology. As such, the development services are separately identifiable from the licensed technology, indicating that the license is a distinct performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing rights.&lt;/span&gt;&lt;span style="font-style:normal;"&gt; In the case of the Japan Agreement, the Company retained manufacturing rights largel&lt;/span&gt;&lt;span style="font-style:normal;"&gt;y because of the way the parties chose for FibroGen to be compensated under the agreement. At the time the agreement was signed, the Company believed that it was more advantageous upon commercialization to have a transfer price revenue model in place as op&lt;/span&gt;&lt;span style="font-style:normal;"&gt;posed to a traditional sales-based model. The manufacturing process does not require specialized knowledge or expertise uniquely held by FibroGen, and notwithstanding contractual restrictions, Astellas could employ manufacturing services from readily avail&lt;/span&gt;&lt;span style="font-style:normal;"&gt;able third parties in order to benefit from the license. Therefore, along with the foregoing paragraph, the Company determined that the license in Japan is a distinct performance obligation despite the retention of manufacturing rights by the Company.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In summary, the Company concludes that item (1) represents a performance obligation. The portion of the transaction price allocated to this performance obligation based on a relative SSP basis is recognized as revenue in its entirety at the point in time the license transfers to Astellas.&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.42%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;Co-development services (Europe Agreement). &lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;This promise relates to co-development services that were reasonably expected to be performed by the Company at the time the collaboration agreement was signed and is considered distinct. Co-development billings are allocated entirely to the co-development services performance obligation as amounts are related specifically to research and development efforts necessary to satisfy the performance obligation, and such an allocation is consistent with the allocation objective. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours and out-of-pocket expenses incurred relative to total expected costs to be incurred. The measure of progress is updated each reporting period. Co-development services are expected to continue over the development period that is currently estimated to continue through the end of 2021. In addition, the Company concluded that the new indication related to CIA approved in January 2019 represents a modification to the Europe agreements at that time and will be accounted for separately, for which the development service period is estimated to continue through the second quarter of 2024. There was no provision for co-development services in the Japan Agreement. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;License to the Company&#x2019;s technology developed during the term of the agreement and development (referred to as &#x201c;when and if available&#x201d;) and information sharing services. &lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;These promises are generally satisfied throughout the term of the agreements.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;Manufacturing of clinical supplies of products.&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt; This promise is satisfied as supplies for clinical product are delivered for use in the Company&#x2019;s clinical trial programs during the development period, or pre-commercialization period.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(5)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;Committee service&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;. This promise is satisfied throughout the course of the agreements as meetings are attended.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0.04%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Items (2)-(5) are bundled into a single performance obligation that is distinct given the fact that all are highly interrelated during the development period (pre-commercial phase of development) such that satisfying them independently is not practicable. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours or full time equivalents and out-of-pocket expenses incurred relative to total expected costs to be incurred. The measure of progress is updated each reporting period.&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(6)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;Manufacturing commercial supplies of products.&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt; This promised service is distinct as services are not interrelated with any of the other performance obligations. Payments received for commercial supplies of products represent sales-based payments related predominately to the license of intellectual property under both Astellas agreements. Revenue is recognized as supplies are shipped for commercial use during the commercialization period. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Japan Amendment the drug product revenue represents variable consideration and is estimated based on the quantity of product shipped, actual listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and possible future changes to the listed price, adjusted for estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk drug product tablets, and estimated yield from the manufacture of bulk product tablets, among others.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Europe Agreement, the drug product revenue amount represents variable consideration and is estimated based on the quantity of product shipped and an estimated price. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price per strength, which is estimated to be realized by Astellas from the end sale of roxadustat in its approved territories.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the drug product revenue only to the extent that &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;it is probable that a significant re&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;versal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. Estimating variable consideration and the related constraint requires the &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;use of significant management judgment. The Company reviews new information that may affect its variable consideration estimate at every reporting period and records an adjustment to revenue, if certain and material&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. Actual amounts of consideration &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ultimately received in the future may differ from the Company&#x2019;s estimates, for which the Company will adjust these estimates and affect the drug product revenue in the period such variances become known.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As each of the agreements provides for annual true up to the considerations paid for its commercial supplies, the Company will re-evaluate the transaction price in each reporting period and record adjustment to revenue as uncertain events are resolved or other changes in circumstances occur. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounting for the AstraZeneca Agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluated whether the U.S./RoW Agreement and the China Agreement should be accounted for as a single or separate arrangements and concluded that the agreements should be accounted for as a single arrangement with the presumption that two or more agreements executed with a single customer at or around the same time should be presumed to be a single arrangement. The key points the Company considered in reaching this conclusion are as follows: &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;While the two agreements were largely negotiated separately, those negotiations proceeded concurrently, and were intended to be completed contemporaneously, presuming AstraZeneca&lt;/span&gt;&lt;span style="font-weight:bold;color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;decided to proceed with licenses in all regions available. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;2.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Throughout negotiations for both agreements, the Company and the counterparties understood and considered the possibility that one arrangement may be executed without the execution of the other arrangement. However, the preference for the Company and the counterparties during the negotiations was to execute both arrangements concurrently.&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;The two agreements were executed as separate agreements because different development, regulatory and commercial approaches required certain terms of the agreements to be structured differently, rather than because the Company or the counterparties considered the agreements to be fundamentally separate negotiations.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accordingly, as the agreements are being accounted for as a single arrangement, upfront and other non-contingent consideration received and to be received has been and will be pooled together and allocated to each of the performance obligations in both the U.S./RoW Agreement and the China Agreement based on their relative SSPs.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For each of the AstraZeneca agreements, the Company has evaluated the promised services within the respective arrangements and has identified performance obligations representing those services and bundled services that are distinct.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Promised services that were not distinct have been combined with other promised services to form a distinct bundle of promised services, with revenue being recognized on the bundle of services rather than the individual promised services. There are no right-of-return provisions for the delivered items in the AstraZeneca agreements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, the transaction price for the U.S./RoW Agreement and the China Agreement, excluding manufacturing services that is discussed separately below, included $402.2 million of non-contingent upfront payments, $114.0 million of variable consideration related to payments for milestones considered probable of being achieved, $564.9 million of variable consideration related to co-development billings, offset by $7.0 million of variable consideration related to profit share under the China Amendment.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the AstraZeneca agreements, the Company allocated the transaction price to the various performance obligations based on the relative SSP of each performance obligation, with the exception of co-development billings and commercial sale of product. Co-development billings under the U.S./RoW Agreement were allocated entirely to the U.S./RoW co-development services performance obligation, and co-development billings under the China Agreement were allocated entirely to the combined performance obligation under the China Agreement. Commercial sale of product under the U.S./ROW Agreement is entirely allocated to the manufacturing commercial supply of products performance obligation, and commercial sale of product under the China Agreement is allocated entirely to the combined China performance obligation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For revenue recognition purposes, the Company determined that the term of its collaboration agreements with AstraZeneca begin on the effective date and ends upon the completion of all performance obligations c&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ontained in the agreements. T&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;he contract term is defined as the period in which parties to the contract have present and enforceable rights and obligations. The Company believes that the requirement to continue funding development for a substantive period &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;of time and the loss of product rights, along with non-refundable upfront payments already remitted by AstraZeneca, represent substantive termination penalties that create significant disincentive for AstraZeneca to exercise its right to terminate the agre&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ement.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the technology license under the AstraZeneca U.S./RoW Agreement, SSP was determined based on a two-step process. The first step involved determining an implied royalty rate that would result in the net present value of future cash flows to equal to zero (i.e. where the implied royalty rate on the transaction would equal the target return for the investment). This results in an upper bound estimation of the magnitude of royalties that a hypothetical acquirer would reasonably pay for the forecasted cash flow stream. The Company&#x2019;s cash flow forecasts were derived from probability-adjusted revenue and expense projections. Such projections included consideration of taxes and cash flow adjustments. The probability adjustments were made after considering the likelihood of technical success at various stages of clinical trials and regulatory approval phases. The second step involved applying the implied royalty rate, which was determined to be 40%, against the probability-adjusted projected net revenues by territory and determining the value of the license as the net present value of future cash flows after adjusting for taxes. The discount rate utilized was 17.5%.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;U.S./RoW Agreement:&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The promised services that were analyzed, along with their general timing of satisfaction and recognition as revenue, are as follows:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;License to the Company&#x2019;s technology existing at the effective date of the agreements.&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt; For the U.S./RoW Agreement, the license was delivered at the beginning of the agreement term. The Company concluded that AstraZeneca has the knowledge and capabilities to fully exploit the license under the U.S./RoW Agreement without the Company&#x2019;s further involvement. Finally, the Company considered the fact that at the time of delivery of the license, the development services were beyond the preclinical development phase and any remaining development work would not be expected to result in any significant modification or customization to the licensed technology. As such, the development services are separately identifiable from the licensed technology, indicating that the license is a distinct performance obligation. Therefore, the Company has concluded that the license is distinct and represents a performance obligation. The portion of the transaction price allocated to this performance obligation based on a relative SSP basis is recognized as revenue in its entirety at the point in time the license transfers to AstraZeneca.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;Co-development services. &lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;This promise relates to co-development services that were reasonably expected to be performed by the Company at the time the collaboration agreement was signed and is distinct. Co-development billings are allocated entirely to the co-development services performance obligation as amounts are related specifically to research and development efforts necessary to satisfy the performance obligation, and such an allocation is consistent with the allocation objective. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours or full time equivalents and out-of-pocket expenses incurred relative to total expected costs to be incurred. Co-development services are expected to continue over the development period that is currently estimated to continue through the end of the first quarter of 2021. In addition, the Company concluded that the addition of the new indications related to CIA, anemia of chronic inflammation and multiple myeloma approved during the fourth quarter of 2018 represents a modification to the collaboration agreements and will be accounted for separately, for which the joint development service period is estimated to continue through the end of 2024. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;Manufacturing of clinical supplies of products.&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt; This promise is satisfied as supplies for clinical product are delivered for use in the Company&#x2019;s clinical trial programs during the development period, or pre-commercialization period.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;Information sharing and committee service.&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt; These promises are satisfied throughout the course of the agreement as services are provided.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Items (2)-(4) are bundled into a single performance obligation that is distinct given the fact that all are highly interrelated during the development period (pre-commercial phase of development) such that delivering them independently is not practicable. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours or full time equivalents and out-of-pocket expenses incurred relative to total expected costs to be incurred. The measure of progress is updated each reporting period.&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(5)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="text-decoration:none;Background-color:#auto;"/&gt;&lt;span style="font-style:normal;color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;Manufacturing commercial supplies of products. &lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;This promise is distinct as services are not interrelated with any of the other&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt; performance obligations. Revenue is recognized as supplies are shipped for commercial use during the commercialization period. &lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;The drug product revenue amount represents variable consideration and is estimated based on the quantity of product shipped and &lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;an estimated price for each individual purchase order. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price, which is estimated to be realized by AstraZeneca from the end sale o&lt;/span&gt;&lt;span style="font-style:normal;color:#000000;"&gt;f roxadustat in its approved territories.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the drug product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. Estimating variable consideration and the related constraint requires the use of significant management judgment. The Company reviews new information that may affect its variable consideration estimate at every reporting period and records an adjustment to revenue, if certain and material. Actual amounts of consideration ultimately received in the future may differ from the Company&#x2019;s estimates, for which the Company will adjust these estimates and affect the drug product revenue in the period such variances become known.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As the agreement provides for an annual true up to the considerations paid for its commercial supplies, the Company will re-evaluate the transaction price in each reporting period and record an adjustment to revenue as uncertain events are resolved or other changes in circumstances occur. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;China Agreement:&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The promised services that were analyzed are consistent with the U.S./RoW Agreement, except for license to the Company&#x2019;s technology existing at the effective date of the agreement, described as follows:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.86%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-style:italic;color:#000000;"&gt;License to the Company&#x2019;s technology existing at the effective date of the agreement.&lt;/span&gt;&lt;span style="color:#000000;"&gt; The license was delivered at the beginning of the agreement term. However, the China Agreement with AstraZeneca has contractual limitations that might affect AstraZeneca&#x2019;s ability to fully exploit the license and therefore, potentially, the conclusion as to whether the license is distinct in the context of the agreement. In the China Agreement, AstraZeneca does not have the right to manufacture commercial supplies of the drug. In order to determine whether this characteristic of the arrangement should lead to a conclusion that the license was not distinct in the context of the agreement, the Company considered the ability of AstraZeneca to benefit from the license on its own or together with other resources readily available to AstraZeneca.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the China Agreement, the Company retained manufacturing rights as an essential part of a strategy to pursue domestic regulatory pathway for product approval which requires the regulatory licensure of the manufacturing facility in order to commence commercial shipment. The prospects for the collaboration as a whole would have been substantially different had manufacturing rights been provided to AstraZeneca. We hold the rights to manufacture commercial drug product in China. Therefore, AstraZeneca cannot benefit from the license on its own or together with other readily available resources. Accordingly, all the promises identified, including the license, co-development services and manufacturing of commercial supplies,, under the China Agreement have been bundled into a single performance obligation and amounts of the transaction price allocable to this performance obligation are deferred until control of the manufactured commercial drug product has begun to transfer to AstraZeneca. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with the China Amendment, once Falikang is fully operational, which commenced in January 2021, substantially all product sales will be made by Falikang directly to the distributors in China, while the Company continues to sell directly in few provinces in China. Revenue will be recognized upon the transfer of control of commercial drug product to Falikang. For the Company&#x2019;s direct sales of commercial drug product, revenue will be recognized when control of the promised good is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for the product.&lt;/p&gt;
</fgen:CollaborativeArrangementAndRevenuesPolicyTextBlock>
    <fgen:ProceedsFromUpfrontNonContingentAndTimeBasedPayments
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20090228"
      decimals="-5"
      id="F_000673"
      unitRef="U_iso4217USD">40100000</fgen:ProceedsFromUpfrontNonContingentAndTimeBasedPayments>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630"
      decimals="-5"
      id="F_000674"
      unitRef="U_iso4217USD">132500000</fgen:PotentialMilestones>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630"
      decimals="-5"
      id="F_000675"
      unitRef="U_iso4217USD">22500000</fgen:PotentialMilestones>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630"
      decimals="-5"
      id="F_000676"
      unitRef="U_iso4217USD">95000000.0</fgen:PotentialMilestones>
    <fgen:CommercialSalesMilestone
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20050630"
      decimals="-5"
      id="F_000677"
      unitRef="U_iso4217USD">15000000.0</fgen:CommercialSalesMilestone>
    <fgen:AdditionalConsiderationBasedOnNetSales
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      id="F_000678">the low 20% range of the list price</fgen:AdditionalConsiderationBasedOnNetSales>
    <fgen:CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-5"
      id="F_000679"
      unitRef="U_iso4217USD">105100000</fgen:CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201201_20201231"
      decimals="-5"
      id="F_000680"
      unitRef="U_iso4217USD">15000000.0</fgen:PotentialMilestones>
    <fgen:TransactionPriceAllocatedToPerformanceObligations
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-5"
      id="F_000681"
      unitRef="U_iso4217USD">15000000.0</fgen:TransactionPriceAllocatedToPerformanceObligations>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190901_20190930"
      decimals="-5"
      id="F_000682"
      unitRef="U_iso4217USD">12500000</fgen:PotentialMilestones>
    <fgen:TransactionPriceAllocatedToPerformanceObligations
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190930"
      decimals="-5"
      id="F_000683"
      unitRef="U_iso4217USD">12500000</fgen:TransactionPriceAllocatedToPerformanceObligations>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180401_20180630"
      decimals="-5"
      id="F_000684"
      unitRef="U_iso4217USD">15000000.0</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231"
      decimals="-5"
      id="F_000685"
      unitRef="U_iso4217USD">4300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20190101_20191231"
      decimals="-5"
      id="F_000686"
      unitRef="U_iso4217USD">-36300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231"
      decimals="-5"
      id="F_000687"
      unitRef="U_iso4217USD">64800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fgen:ProceedsFromUpfrontNonContingentAndTimeBasedPayments
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20090228"
      decimals="-5"
      id="F_000688"
      unitRef="U_iso4217USD">320000000.0</fgen:ProceedsFromUpfrontNonContingentAndTimeBasedPayments>
    <fgen:DevelopmentAndRegulatoryApprovalMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060430"
      decimals="-5"
      id="F_000689"
      unitRef="U_iso4217USD">425000000.0</fgen:DevelopmentAndRegulatoryApprovalMilestones>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430"
      decimals="-5"
      id="F_000690"
      unitRef="U_iso4217USD">90000000.0</fgen:PotentialMilestones>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430"
      decimals="-5"
      id="F_000691"
      unitRef="U_iso4217USD">335000000.0</fgen:PotentialMilestones>
    <fgen:PercentageOfFundingForCosts
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20060401_20060430"
      decimals="2"
      id="F_000692"
      unitRef="U_xbrlipure">0.50</fgen:PercentageOfFundingForCosts>
    <fgen:AdditionalConsiderationBasedOnNetSales
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      id="F_000693">low 20% range</fgen:AdditionalConsiderationBasedOnNetSales>
    <fgen:CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-5"
      id="F_000694"
      unitRef="U_iso4217USD">540000000.0</fgen:CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue>
    <fgen:TransactionPriceAllocatedToPerformanceObligations
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190630"
      decimals="-5"
      id="F_000695"
      unitRef="U_iso4217USD">130000000.0</fgen:TransactionPriceAllocatedToPerformanceObligations>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20191231"
      decimals="-5"
      id="F_000696"
      unitRef="U_iso4217USD">128800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-5"
      id="F_000697"
      unitRef="U_iso4217USD">800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:Supplies
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20191231"
      decimals="-5"
      id="F_000698"
      unitRef="U_iso4217USD">130000000.0</us-gaap:Supplies>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200401_20200630"
      decimals="-5"
      id="F_000699"
      unitRef="U_iso4217USD">130000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <fgen:EstimatedJointDevelopmentExtendedServicePeriod
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      id="F_000700">2024</fgen:EstimatedJointDevelopmentExtendedServicePeriod>
    <fgen:ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000701"
      unitRef="U_iso4217USD">374000000.0</fgen:ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000702"
      unitRef="U_iso4217USD">875000000.0</fgen:PotentialMilestones>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000703"
      unitRef="U_iso4217USD">65000000.0</fgen:PotentialMilestones>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000704"
      unitRef="U_iso4217USD">325000000.0</fgen:PotentialMilestones>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenDeferredApprovalMilestoneMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000705"
      unitRef="U_iso4217USD">160000000.0</fgen:PotentialMilestones>
    <fgen:CommercialSalesMilestone
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000706"
      unitRef="U_iso4217USD">325000000.0</fgen:CommercialSalesMilestone>
    <fgen:CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-5"
      id="F_000707"
      unitRef="U_iso4217USD">439000000.0</fgen:CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue>
    <fgen:SharedDevelopmentCosts
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20150101_20151231"
      decimals="-5"
      id="F_000708"
      unitRef="U_iso4217USD">233000000.0</fgen:SharedDevelopmentCosts>
    <fgen:SharedDevelopmentCosts
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibroGenIncMember_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20150101_20151231"
      decimals="-5"
      id="F_000709"
      unitRef="U_iso4217USD">116500000</fgen:SharedDevelopmentCosts>
    <fgen:SharedDevelopmentCosts
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20150101_20151231"
      decimals="-5"
      id="F_000710"
      unitRef="U_iso4217USD">233000000.0</fgen:SharedDevelopmentCosts>
    <fgen:AdditionalConsiderationBasedOnNetSales
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231"
      id="F_000711">low 20% range</fgen:AdditionalConsiderationBasedOnNetSales>
    <fgen:TransactionPriceAllocatedToPerformanceObligations
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190630"
      decimals="-5"
      id="F_000712"
      unitRef="U_iso4217USD">50000000.0</fgen:TransactionPriceAllocatedToPerformanceObligations>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20191231"
      decimals="-5"
      id="F_000713"
      unitRef="U_iso4217USD">42400000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-5"
      id="F_000714"
      unitRef="U_iso4217USD">600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:Supplies
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20191231"
      decimals="-5"
      id="F_000715"
      unitRef="U_iso4217USD">50000000.0</us-gaap:Supplies>
    <fgen:EstimatedJointDevelopmentExtendedServicePeriod
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231"
      id="F_000716">2024</fgen:EstimatedJointDevelopmentExtendedServicePeriod>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231"
      decimals="-5"
      id="F_000717"
      unitRef="U_iso4217USD">4600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fgen:ProceedsFromUpfrontNonContingentAndNonRefundablePayments
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000718"
      unitRef="U_iso4217USD">28200000</fgen:ProceedsFromUpfrontNonContingentAndNonRefundablePayments>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000719"
      unitRef="U_iso4217USD">348500000</fgen:PotentialMilestones>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenClinicalDevelopmentMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000720"
      unitRef="U_iso4217USD">15000000.0</fgen:PotentialMilestones>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fgenRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000721"
      unitRef="U_iso4217USD">146000000.0</fgen:PotentialMilestones>
    <fgen:CommercialSalesAndOtherEventsMilestone
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20130729_20130730"
      decimals="-5"
      id="F_000722"
      unitRef="U_iso4217USD">187500000</fgen:CommercialSalesAndOtherEventsMilestone>
    <fgen:CollaborativeArrangementAggregateConsideration
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-5"
      id="F_000723"
      unitRef="U_iso4217USD">77200000</fgen:CollaborativeArrangementAggregateConsideration>
    <fgen:PotentialMilestones
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231"
      decimals="-5"
      id="F_000724"
      unitRef="U_iso4217USD">22000000.0</fgen:PotentialMilestones>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231"
      decimals="-5"
      id="F_000725"
      unitRef="U_iso4217USD">18700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <fgen:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20181216_20181217"
      decimals="-5"
      id="F_000726"
      unitRef="U_iso4217USD">6000000.0</fgen:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized>
    <fgen:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20181228_20181229"
      decimals="-5"
      id="F_000727"
      unitRef="U_iso4217USD">6000000.0</fgen:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized>
    <fgen:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20180101_20181231"
      decimals="-5"
      id="F_000728"
      unitRef="U_iso4217USD">9900000</fgen:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized>
    <fgen:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231"
      decimals="-5"
      id="F_000729"
      unitRef="U_iso4217USD">12000000.0</fgen:ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized>
    <fgen:HistoricalCoPromotionCosts
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231"
      decimals="INF"
      id="F_000730"
      unitRef="U_iso4217USD">0</fgen:HistoricalCoPromotionCosts>
    <fgen:ReversalOfAccruedCoPromotionExpenses
      contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201001_20201231"
      decimals="-5"
      id="F_000731"
      unitRef="U_iso4217USD">84400000</fgen:ReversalOfAccruedCoPromotionExpenses>
    <fgen:CoPromotionExpenses
      contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231"
      decimals="-5"
      id="F_000732"
      unitRef="U_iso4217USD">27200000</fgen:CoPromotionExpenses>
    <fgen:AccruedLongTermCoPromotionLiabilityCurrent
      contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_us-gaapAccountsPayableMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-5"
      id="F_000734"
      unitRef="U_iso4217USD">16900000</fgen:AccruedLongTermCoPromotionLiabilityCurrent>
    <fgen:AccruedLongTermCoPromotionLiabilityCurrent
      contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_us-gaapAccruedLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-2"
      id="F_000735"
      unitRef="U_iso4217USD">11500</fgen:AccruedLongTermCoPromotionLiabilityCurrent>
    <fgen:AccruedLongTermCoPromotionLiabilityNonCurrent
      contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-5"
      id="F_000733"
      unitRef="U_iso4217USD">27400000</fgen:AccruedLongTermCoPromotionLiabilityNonCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapBalanceSheetLocationAxis_fgenAccruedAndOtherCurrentLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-5"
      id="F_000736"
      unitRef="U_iso4217USD">7000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <fgen:ProceedsFromNonContingentUpfrontPayments
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000737"
      unitRef="U_iso4217USD">40100000</fgen:ProceedsFromNonContingentUpfrontPayments>
    <fgen:VariableConsiderationPaymentReceivedUponAchievementOfMilestone
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000738"
      unitRef="U_iso4217USD">65000000.0</fgen:VariableConsiderationPaymentReceivedUponAchievementOfMilestone>
    <fgen:VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000739"
      unitRef="U_iso4217USD">11700000</fgen:VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings>
    <fgen:ProceedsFromNonContingentUpfrontPayments
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000740"
      unitRef="U_iso4217USD">320000000.0</fgen:ProceedsFromNonContingentUpfrontPayments>
    <fgen:VariableConsiderationPaymentReceivedUponAchievementOfMilestone
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000741"
      unitRef="U_iso4217USD">220000000.0</fgen:VariableConsiderationPaymentReceivedUponAchievementOfMilestone>
    <fgen:VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000742"
      unitRef="U_iso4217USD">225900000</fgen:VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueDiscountedCashFlowMember_20201231"
      decimals="INF"
      id="F_000743"
      unitRef="U_xbrlipure">17.5</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueDiscountedCashFlowMember_20201231"
      decimals="INF"
      id="F_000744"
      unitRef="U_xbrlipure">20.0</us-gaap:AlternativeInvestmentMeasurementInput>
    <fgen:CoDevelopmentServicesEstimatedContinuationYear
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      id="F_000745">2024</fgen:CoDevelopmentServicesEstimatedContinuationYear>
    <fgen:ProvisionForCoDevelopmentServices
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="INF"
      id="F_000746"
      unitRef="U_iso4217USD">0</fgen:ProvisionForCoDevelopmentServices>
    <fgen:ProceedsFromNonContingentUpfrontPayments
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231"
      decimals="-5"
      id="F_000747"
      unitRef="U_iso4217USD">402200000</fgen:ProceedsFromNonContingentUpfrontPayments>
    <fgen:VariableConsiderationPaymentReceivedUponAchievementOfMilestone
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231"
      decimals="-5"
      id="F_000748"
      unitRef="U_iso4217USD">114000000.0</fgen:VariableConsiderationPaymentReceivedUponAchievementOfMilestone>
    <fgen:VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231"
      decimals="-5"
      id="F_000749"
      unitRef="U_iso4217USD">564900000</fgen:VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings>
    <fgen:VariableConsiderationRelatedToProfitShare
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231"
      decimals="-5"
      id="F_000750"
      unitRef="U_iso4217USD">7000000.0</fgen:VariableConsiderationRelatedToProfitShare>
    <fgen:RoyaltyRateOnNetRevenue
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="2"
      id="F_000751"
      unitRef="U_xbrlipure">0.40</fgen:RoyaltyRateOnNetRevenue>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="C_0000921299_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputDiscountRateMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationTechniqueAxis_us-gaapValuationTechniqueDiscountedCashFlowMember_20201231"
      decimals="1"
      id="F_000752"
      unitRef="U_xbrlipure">17.5</us-gaap:AlternativeInvestmentMeasurementInput>
    <fgen:CoDevelopmentServicesEstimatedContinuationYear
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231"
      id="F_000753">2024</fgen:CoDevelopmentServicesEstimatedContinuationYear>
    <fgen:ContractWithCustomerMilestoneMethodTableTextBlock
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_20200101_20201231"
      id="F_000574">Amounts recognized as license revenue and development revenue under the Japan Agreement with Astellas were as follows (in thousands):
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance Obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Japan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,935&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,220&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,222&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</fgen:ContractWithCustomerMilestoneMethodTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000754"
      unitRef="U_iso4217USD">14323000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000755"
      unitRef="U_iso4217USD">11935000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231"
      decimals="-3"
      id="F_000756"
      unitRef="U_iso4217USD">14323000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000757"
      unitRef="U_iso4217USD">1220000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000758"
      unitRef="U_iso4217USD">1222000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231"
      decimals="-3"
      id="F_000759"
      unitRef="U_iso4217USD">2400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_20200101_20201231"
      id="F_000575">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Japan Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&#160;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&#160;at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&#160;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&#160;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,350&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total license and development&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;116,697&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;116,827&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000760"
      unitRef="U_iso4217USD">100347000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000763"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000766"
      unitRef="U_iso4217USD">100347000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000761"
      unitRef="U_iso4217USD">16350000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000764"
      unitRef="U_iso4217USD">130000</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000767"
      unitRef="U_iso4217USD">16480000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000762"
      unitRef="U_iso4217USD">116697000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000765"
      unitRef="U_iso4217USD">130000</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000768"
      unitRef="U_iso4217USD">116827000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000769"
      unitRef="U_iso4217USD">15100000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_20200101_20201231"
      decimals="INF"
      id="F_000770"
      unitRef="U_iso4217USD">0</fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling>
    <fgen:ContractWithCustomerMilestoneMethodTableTextBlock
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20200101_20201231"
      id="F_000576">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts recognized as license revenue and development revenue under the Europe Agreement with Astellas were as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance Obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Europe&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;117,470&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,954&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,172&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,503&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</fgen:ContractWithCustomerMilestoneMethodTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000771"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000772"
      unitRef="U_iso4217USD">117470000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231"
      decimals="-3"
      id="F_000773"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000774"
      unitRef="U_iso4217USD">17954000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000775"
      unitRef="U_iso4217USD">28172000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231"
      decimals="-3"
      id="F_000776"
      unitRef="U_iso4217USD">18503000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20200101_20201231"
      id="F_000577">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Europe Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&#160;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&#160;at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&#160;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&#160;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;487,951&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;487,951&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;248,962&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,429&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;250,391&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total license and development&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;736,913&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,429&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;738,342&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:2.68%;text-indent:-2.68%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000777"
      unitRef="U_iso4217USD">487951000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000780"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000783"
      unitRef="U_iso4217USD">487951000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000778"
      unitRef="U_iso4217USD">248962000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000781"
      unitRef="U_iso4217USD">1429000</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000784"
      unitRef="U_iso4217USD">250391000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000779"
      unitRef="U_iso4217USD">736913000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000782"
      unitRef="U_iso4217USD">1429000</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000785"
      unitRef="U_iso4217USD">738342000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000786"
      unitRef="U_iso4217USD">1500000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20200101_20201231"
      decimals="-5"
      id="F_000787"
      unitRef="U_iso4217USD">27600000</fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling>
    <fgen:ContractWithCustomerMilestoneMethodTableTextBlock
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_20200101_20201231"
      id="F_000578">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts recognized as license revenue and development revenue under the U.S./RoW and China Agreements with AstraZeneca were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance Obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S.&#160;/&#160;RoW&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;and China&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,681&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,946&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Development revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,508&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;84,629&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;104,970&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China performance obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(90&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</fgen:ContractWithCustomerMilestoneMethodTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231"
      decimals="-3"
      id="F_000788"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231"
      decimals="-3"
      id="F_000789"
      unitRef="U_iso4217USD">47681000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20180101_20181231"
      decimals="-3"
      id="F_000790"
      unitRef="U_iso4217USD">7946000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231"
      decimals="-3"
      id="F_000791"
      unitRef="U_iso4217USD">61508000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231"
      decimals="-3"
      id="F_000792"
      unitRef="U_iso4217USD">84629000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDevelopmentAndOtherRevenueMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20180101_20181231"
      decimals="-3"
      id="F_000793"
      unitRef="U_iso4217USD">104970000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231"
      decimals="-3"
      id="F_000794"
      unitRef="U_iso4217USD">-90000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231"
      decimals="-3"
      id="F_000795"
      unitRef="U_iso4217USD">90000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20180101_20181231"
      decimals="-3"
      id="F_000796"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_20200101_20201231"
      id="F_000579">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement, along with any associated deferred revenue as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S.&#160;/&#160;RoW and China Agreements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cumulative&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&#160;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&#160;at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&#160;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consideration&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Through&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&#160;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;341,844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;341,844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Co-development, information sharing &amp;amp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;committee services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;554,775&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,276&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;557,051&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China performance obligation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137,338&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137,338&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total license and development&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;896,619&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;139,614&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,036,233&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:92.86%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;* &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the consolidated balance sheets. As of December 31, 2020, deferred revenue included $137.5 million related to the U.S./RoW and China Agreement, which represents the net of $139.6 million of deferred revenue presented above and a $2.1 million unbilled co-development revenue under the China Amendment with AstraZeneca.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-3"
      id="F_000797"
      unitRef="U_iso4217USD">341844000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-3"
      id="F_000801"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-3"
      id="F_000805"
      unitRef="U_iso4217USD">341844000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenCoDevelopmentInformationSharingAndCommitteeServicesMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-3"
      id="F_000798"
      unitRef="U_iso4217USD">554775000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenCoDevelopmentInformationSharingAndCommitteeServicesMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-3"
      id="F_000802"
      unitRef="U_iso4217USD">2276000</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenCoDevelopmentInformationSharingAndCommitteeServicesMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-3"
      id="F_000806"
      unitRef="U_iso4217USD">557051000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenChinaPerformanceObligationMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-3"
      id="F_000799"
      unitRef="U_iso4217USD">0</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenChinaPerformanceObligationMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-3"
      id="F_000803"
      unitRef="U_iso4217USD">137338000</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenChinaPerformanceObligationMember_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-3"
      id="F_000807"
      unitRef="U_iso4217USD">137338000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-3"
      id="F_000800"
      unitRef="U_iso4217USD">896619000</fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-3"
      id="F_000804"
      unitRef="U_iso4217USD">139614000</us-gaap:ContractWithCustomerLiability>
    <fgen:CashConsiderationReceivedUnderCollaborationAgreement
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-3"
      id="F_000808"
      unitRef="U_iso4217USD">1036233000</fgen:CashConsiderationReceivedUnderCollaborationAgreement>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-5"
      id="F_000809"
      unitRef="U_iso4217USD">137500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-5"
      id="F_000810"
      unitRef="U_iso4217USD">139600000</us-gaap:ContractWithCustomerLiability>
    <fgen:SuppliesNet
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-5"
      id="F_000811"
      unitRef="U_iso4217USD">2100000</fgen:SuppliesNet>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000813"
      unitRef="U_iso4217USD">-2900000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesRestOfWorldAndChinaMember_20200101_20201231"
      decimals="-5"
      id="F_000812"
      unitRef="U_iso4217USD">37900000</fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling>
    <fgen:ProductRevenuePolicyPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000565">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product Revenue, Net&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue from roxadustat commercial sales in China is recognized in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products, net of various sales rebates and discounts. Product revenue, net was as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,027&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price adjustment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(936&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-key account hospital listing award&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,325&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual sales rebate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,189&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(149&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other discounts and rebates&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(923&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales return&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,498&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the second quarter of 2020, the Company amended the agreement with its pharmaceutical distributors, which triggered accounting modifications particularly related to the non-key account hospital listing award. For the year ended December 31, 2020, the non-key account hospital listing award was $9.3 million, which was recorded as a reduction to the revenue and calculated based on eligible non-key account hospital listings to date achieved by each distributor with certain requirements met during the period. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December 31, 2020 and 2019, the contractual sales rebate was $6.2 million and $0.1 million, respectively, which were calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. All other rebates and discounts, including sales return allowance were immaterial for the periods presented. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December 31, 2019, a $0.9 million of price adjustment was recorded based on government-listed price guidance and estimated channel inventory levels.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The rebates and discounts that the Company&#x2019;s pharmaceutical distributors have earned are eligible to be applied against future sales orders, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible in the same period that the related revenue is recorded. Due to the distributor&#x2019;s legal right to offset, at each balance sheet date, the rebates and discounts are presented as reductions to gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The distributor&#x2019;s legal right of offset is calculated at the individual distributor level. The following table includes a roll-forward of the related contract liabilities (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deduction&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Translation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Presented Net&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Against&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue - Contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,102&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,497&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,184&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(270&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,685&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;548&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the total rebates and discounts as reductions to gross accounts receivable was $0.5 million, and the total contract liabilities was $15.1 million, which was included in accrued and other current liabilities in the consolidated balance sheet. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reductions to gross accounts receivable, including the above-mentioned contra-accounts receivable items related to product revenue, totaled $0.8 million and $1.1 million as of December 31, 2020 and 2019, respectively.&lt;/p&gt;</fgen:ProductRevenuePolicyPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000580">Product revenue, net was as follows (in thousands):
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,027&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price adjustment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(936&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-key account hospital listing award&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,325&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual sales rebate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,189&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(149&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other discounts and rebates&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(923&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales return&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,498&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231"
      decimals="-3"
      id="F_000814"
      unitRef="U_iso4217USD">89027000</fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax>
    <fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20190101_20191231"
      decimals="-3"
      id="F_000815"
      unitRef="U_iso4217USD">2803000</fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenPriceAdjustmentMember_20200101_20201231"
      decimals="-3"
      id="F_000816"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenPriceAdjustmentMember_20190101_20191231"
      decimals="-3"
      id="F_000817"
      unitRef="U_iso4217USD">-936000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNonKeyAccountHospitalListingAwardMember_20200101_20201231"
      decimals="-3"
      id="F_000818"
      unitRef="U_iso4217USD">-9325000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNonKeyAccountHospitalListingAwardMember_20190101_20191231"
      decimals="-3"
      id="F_000819"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenContractualSalesRebateMember_20200101_20201231"
      decimals="-3"
      id="F_000820"
      unitRef="U_iso4217USD">-6189000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenContractualSalesRebateMember_20190101_20191231"
      decimals="-3"
      id="F_000821"
      unitRef="U_iso4217USD">-149000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenOtherDiscountsAndRebatesMember_20200101_20201231"
      decimals="-3"
      id="F_000822"
      unitRef="U_iso4217USD">-923000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenOtherDiscountsAndRebatesMember_20190101_20191231"
      decimals="-3"
      id="F_000823"
      unitRef="U_iso4217USD">-18000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20200101_20201231"
      decimals="-3"
      id="F_000824"
      unitRef="U_iso4217USD">-92000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapSalesReturnsAndAllowancesMember_20190101_20191231"
      decimals="-3"
      id="F_000825"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231"
      decimals="-3"
      id="F_000826"
      unitRef="U_iso4217USD">72498000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20190101_20191231"
      decimals="-3"
      id="F_000827"
      unitRef="U_iso4217USD">1700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenNonKeyAccountHospitalListingAwardMember_20200101_20201231"
      decimals="-5"
      id="F_000828"
      unitRef="U_iso4217USD">9300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenContractualSalesRebateMember_20200101_20201231"
      decimals="-5"
      id="F_000829"
      unitRef="U_iso4217USD">6200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenContractualSalesRebateMember_20190101_20191231"
      decimals="-5"
      id="F_000830"
      unitRef="U_iso4217USD">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenPriceAdjustmentMember_20200101_20201231"
      decimals="-5"
      id="F_000831"
      unitRef="U_iso4217USD">900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000581">. The following table includes a roll-forward of the related contract liabilities (in thousands):
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deduction&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Currency&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Translation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Presented Net&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Against&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product revenue - Contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,102&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,497&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,184&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(270&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,685&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;548&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20191231"
      decimals="-3"
      id="F_000832"
      unitRef="U_iso4217USD">1102000</us-gaap:ContractWithCustomerLiability>
    <fgen:ContractWithCustomerLiabilityAdditions
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231"
      decimals="-3"
      id="F_000833"
      unitRef="U_iso4217USD">16497000</fgen:ContractWithCustomerLiabilityAdditions>
    <fgen:ContractWithCustomerLiabilityDeduction
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231"
      decimals="-3"
      id="F_000834"
      unitRef="U_iso4217USD">2184000</fgen:ContractWithCustomerLiabilityDeduction>
    <fgen:ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231"
      decimals="-3"
      id="F_000835"
      unitRef="U_iso4217USD">-270000</fgen:ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther>
    <fgen:ContractWithCustomerLiabilityGross
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20201231"
      decimals="-3"
      id="F_000836"
      unitRef="U_iso4217USD">-15685000</fgen:ContractWithCustomerLiabilityGross>
    <fgen:ContractWithCustomerLiabilityNetOfAccountsReceivable
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20201231"
      decimals="-3"
      id="F_000837"
      unitRef="U_iso4217USD">548000</fgen:ContractWithCustomerLiabilityNetOfAccountsReceivable>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20201231"
      decimals="-3"
      id="F_000838"
      unitRef="U_iso4217USD">15137000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenGrossAccountsReceivableMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20200101_20201231"
      decimals="-5"
      id="F_000840"
      unitRef="U_iso4217USD">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_fgenContractLiabilitiesMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenRebatesAndDiscountsMember_20200101_20201231"
      decimals="-5"
      id="F_000842"
      unitRef="U_iso4217USD">15100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20201231"
      decimals="-5"
      id="F_000844"
      unitRef="U_iso4217USD">800000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20191231"
      decimals="-5"
      id="F_000845"
      unitRef="U_iso4217USD">1100000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <fgen:DrugProductRevenuePolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000566">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug Product Revenue&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue was as follows (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,281&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(36,324&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,776&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AstraZeneca&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,906&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(36,324&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,776&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company fulfilled all the shipment obligations under the term of the Japan Amendment during the year ended December 31, 2018, and recognized the related product revenue of $64.8 million in the same period&lt;span style="font-weight:bold;"&gt; &lt;/span&gt;based on a transaction price that was subject to potential future adjustments, which represented a form of variable consideration. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A change in estimated variable consideration incurred in 2019 related to the above API shipments in 2018, at the time the actual listed price for roxadustat was issued by the Japanese Ministry of Health, Labour and Welfare, which resulted in a total difference of $36.3 million between the estimated and the actual listed price and yield from the manufacture of bulk product tablets. &lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, during the year ended December 31, 2020, the Company recorded another $4.0 million reduction to drug product revenue related to the above API shipments, due to a change in estimated variable consideration. Specifically, the change in estimated variable consideration was based on the API held by Astellas at March 31, 2020 adjusted to reflect the updated listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and changes in the estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk product tablets, and estimated yield from the manufacture of bulk product tablets, among others. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the second quarter of 2020, the Company fulfilled shipment obligations under the term of Japan Amendment with Astellas, and recognized related drug product revenue of $8.2 million in the same period. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the fourth quarter of 2020, the Company shipped bulk drug product from process validation supplies for commercial purposes under the term of the Europe Agreement with Astellas. The Company constrained the consideration from this shipment due to a high degree of uncertainty associated to the final consideration. As a result, the Company recorded $1.4 million as current deferred revenue and $4.6 million as long-term deferred revenue as of December 31, 2020. The deferred revenue will be recognized as and when uncertainty is resolved. The following table includes a roll-forward of the related contract liabilities (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue - Astellas - contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,984&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,984&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2020, the Company shipped bulk drug product to AstraZeneca as pre-commercial supply for process validation purposes, under the term of Commercial Supply Agreement under the U.S./RoW Agreement with AstraZeneca, and recognized drug product revenue of $4.6 million.&lt;/p&gt;</fgen:DrugProductRevenuePolicyTextBlock>
    <fgen:ScheduleOfDrugProductRevenueTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000582">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue was as follows (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,281&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(36,324&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,776&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AstraZeneca&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,906&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(36,324&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,776&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fgen:ScheduleOfDrugProductRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231"
      decimals="-3"
      id="F_000846"
      unitRef="U_iso4217USD">4281000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20190101_20191231"
      decimals="-3"
      id="F_000847"
      unitRef="U_iso4217USD">-36324000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231"
      decimals="-3"
      id="F_000848"
      unitRef="U_iso4217USD">64776000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231"
      decimals="-3"
      id="F_000849"
      unitRef="U_iso4217USD">4625000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20190101_20191231"
      decimals="-3"
      id="F_000850"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231"
      decimals="-3"
      id="F_000851"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231"
      decimals="-3"
      id="F_000852"
      unitRef="U_iso4217USD">8906000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20190101_20191231"
      decimals="-3"
      id="F_000853"
      unitRef="U_iso4217USD">-36324000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231"
      decimals="-3"
      id="F_000854"
      unitRef="U_iso4217USD">64776000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20180101_20181231"
      decimals="-5"
      id="F_000855"
      unitRef="U_iso4217USD">64800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fgen:EstimatedVariableConsiderationTransactionPrice
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20191231"
      decimals="-5"
      id="F_000856"
      unitRef="U_iso4217USD">36300000</fgen:EstimatedVariableConsiderationTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231"
      decimals="-5"
      id="F_000857"
      unitRef="U_iso4217USD">4000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200401_20200630"
      decimals="-5"
      id="F_000858"
      unitRef="U_iso4217USD">8200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20201231"
      decimals="-5"
      id="F_000859"
      unitRef="U_iso4217USD">1400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20201231"
      decimals="-5"
      id="F_000860"
      unitRef="U_iso4217USD">4600000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_20200101_20201231"
      id="F_000583">The following table includes a roll-forward of the related contract liabilities (in thousands):
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Drug product revenue - Astellas - contract liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,984&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,984&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20191231"
      decimals="-3"
      id="F_000861"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiability>
    <fgen:ContractWithCustomerLiabilityAdditions
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000862"
      unitRef="U_iso4217USD">5984000</fgen:ContractWithCustomerLiabilityAdditions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenDrugProductRevenueMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231"
      decimals="-3"
      id="F_000863"
      unitRef="U_iso4217USD">5984000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231"
      decimals="-2"
      id="F_000864"
      unitRef="U_iso4217USD">4600</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <fgen:OtherRevenuesPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000567">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other Revenues&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other revenues consist primarily of collagen material sold for research purposes. Other revenues were immaterial for each of the three years ended December&#160;31, 2020.&lt;/p&gt;</fgen:OtherRevenuesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000568">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Revenue&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue represents amounts billed, or in certain cases, yet to be billed to the Company&#x2019;s collaboration partners for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying performance obligations. The long-term portion of deferred revenue represents amounts to be recognized after one year through the end of the non-contingent performance period of the underlying performance obligations. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue includes amounts allocated to the China performance obligation under the AstraZeneca arrangement as revenue recognition associated with this unit of accounting is tied to the commercial launch of the products within China and to when the control of the manufactured commercial drug product is transferred to AstraZeneca. As of December 31, 2020, approximately $3.5 million of the deferred revenue related to the China unit of accounting was included in short-term deferred revenue, which represents the amount of deferred revenue associated with the China unit of accounting that is expected to be recognized within the next 12 months, associated with the commercial sales in China.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-5"
      id="F_000865"
      unitRef="U_iso4217USD">3500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000528">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with the authoritative guidance on fair value measurements and disclosures under U.S. GAAP, the Company presents all financial assets and liabilities and any other assets and liabilities that are recognized or disclosed at fair value on a nonrecurring basis. The guidance defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair-value measurements. The guidance also requires fair value measurements be classified and disclosed in one of the following three categories:&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;span style="font-style:normal;"&gt;: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;span style="font-style:normal;"&gt;: Observable inputs other than quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;span style="font-style:normal;"&gt;: Unobservable inputs.&lt;/span&gt;&lt;/p&gt;
&lt;p id="T0" style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company values certain assets and liabilities, focusing on the inputs used to measure fair value, particularly in instances where the measurement uses significant unobservable (Level 3) inputs. The Company&#x2019;s financial instruments are valued using quoted prices in active markets (Level 1) or based upon other observable inputs (Level 2). The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability. In addition, the categories presented do not suggest how prices may be affected by the size of the purchases or sales, particularly with the largest highly liquid financial issuers who are in markets continuously with non-equity instruments, or how any such financial assets may be impacted by other factors such as U.S. government guarantees. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. &lt;/span&gt;&lt;span style="color:#000000;"&gt;The availability of observable data is monitored to assess &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;appropriate&lt;/span&gt;&lt;span style="color:#000000;"&gt; classification of financial instruments within the fair value hierarchy. Depending upon the availability of such inputs, specific securities may &lt;/span&gt;&lt;span style="color:#000000;"&gt;transfer between levels. In such instances, the transfer is reported at the end of the reporting period.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair values of the Company&#x2019;s financial assets that are measured on a recurring basis are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bond and mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590,591&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;598,735&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury notes and bills&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;347,383&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,123&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;427,506&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bond and mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,816&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,816&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certificate of deposit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;444,005&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,155&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;554,160&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s Level 2 investments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar investments, issuer credit spreads, benchmark investments, prepayment/default projections based on historical data and other observable inputs. There were no transfers of assets between levels for the years ended December&#160;31, 2020 and 2018. During the fourth quarter of 2019, there was a $29.8 million transfer of assets from Level 1 to Level 2 as such US treasury notes and bills were changed to off-the-run when they were issued before the most recent issue and were still outstanding at measurement day.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair values of the Company&#x2019;s financial liabilities that are carried at historical cost are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,141&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,141&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of the Company&#x2019;s financial liabilities were derived by using an income approach, which required Level 3 inputs such as discounted estimated future cash flows. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no transfers of liabilities between levels for the years ended December&#160;31, 2020, 2019 and 2018.&lt;/p&gt;
</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000569">Fair Value Measurements
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with the authoritative guidance on fair value measurements and disclosures under U.S. GAAP, the Company presents all financial assets and liabilities and any other assets and liabilities that are recognized or disclosed at fair value on a nonrecurring basis. The guidance defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair-value measurements. The guidance also requires fair value measurements be classified and disclosed in one of the following three categories:&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;span style="font-style:normal;"&gt;: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;span style="font-style:normal;"&gt;: Observable inputs other than quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;span style="font-style:normal;"&gt;: Unobservable inputs.&lt;/span&gt;&lt;/p&gt;
&lt;p id="T0" style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company values certain assets and liabilities, focusing on the inputs used to measure fair value, particularly in instances where the measurement uses significant unobservable (Level 3) inputs. The Company&#x2019;s financial instruments are valued using quoted prices in active markets (Level 1) or based upon other observable inputs (Level 2). The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability. In addition, the categories presented do not suggest how prices may be affected by the size of the purchases or sales, particularly with the largest highly liquid financial issuers who are in markets continuously with non-equity instruments, or how any such financial assets may be impacted by other factors such as U.S. government guarantees. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. &lt;/span&gt;&lt;span style="color:#000000;"&gt;The availability of observable data is monitored to assess &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;appropriate&lt;/span&gt;&lt;span style="color:#000000;"&gt; classification of financial instruments within the fair value hierarchy. Depending upon the availability of such inputs, specific securities may &lt;/span&gt;&lt;span style="color:#000000;"&gt;transfer between levels. In such instances, the transfer is reported at the end of the reporting period.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000584">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair values of the Company&#x2019;s financial assets that are measured on a recurring basis are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bond and mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590,591&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;598,735&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury notes and bills&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;347,383&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,123&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;427,506&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bond and mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,816&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,816&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certificate of deposit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;444,005&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,155&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;554,160&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231"
      decimals="-3"
      id="F_000866"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231"
      decimals="-3"
      id="F_000867"
      unitRef="U_iso4217USD">8144000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231"
      decimals="-3"
      id="F_000868"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231"
      decimals="-3"
      id="F_000869"
      unitRef="U_iso4217USD">8144000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_000870"
      unitRef="U_iso4217USD">244000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_000871"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_000872"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_000873"
      unitRef="U_iso4217USD">244000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000874"
      unitRef="U_iso4217USD">590347000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000875"
      unitRef="U_iso4217USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000876"
      unitRef="U_iso4217USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000877"
      unitRef="U_iso4217USD">590347000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000878"
      unitRef="U_iso4217USD">590591000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000879"
      unitRef="U_iso4217USD">8144000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000880"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000881"
      unitRef="U_iso4217USD">598735000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231"
      decimals="-3"
      id="F_000882"
      unitRef="U_iso4217USD">347383000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231"
      decimals="-3"
      id="F_000883"
      unitRef="U_iso4217USD">80123000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231"
      decimals="-3"
      id="F_000884"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231"
      decimals="-3"
      id="F_000885"
      unitRef="U_iso4217USD">427506000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231"
      decimals="-3"
      id="F_000886"
      unitRef="U_iso4217USD">10816000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231"
      decimals="-3"
      id="F_000887"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231"
      decimals="-3"
      id="F_000888"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231"
      decimals="-3"
      id="F_000889"
      unitRef="U_iso4217USD">10816000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231"
      decimals="-3"
      id="F_000890"
      unitRef="U_iso4217USD">255000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231"
      decimals="-3"
      id="F_000891"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231"
      decimals="-3"
      id="F_000892"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231"
      decimals="-3"
      id="F_000893"
      unitRef="U_iso4217USD">255000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000894"
      unitRef="U_iso4217USD">85551000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000895"
      unitRef="U_iso4217USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000896"
      unitRef="U_iso4217USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000897"
      unitRef="U_iso4217USD">85551000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231"
      decimals="-3"
      id="F_000898"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231"
      decimals="-3"
      id="F_000899"
      unitRef="U_iso4217USD">30032000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231"
      decimals="-3"
      id="F_000900"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231"
      decimals="-3"
      id="F_000901"
      unitRef="U_iso4217USD">30032000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000902"
      unitRef="U_iso4217USD">444005000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000903"
      unitRef="U_iso4217USD">110155000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000904"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000905"
      unitRef="U_iso4217USD">554160000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000907"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_0000921299_20181231"
      decimals="INF"
      id="F_000908"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000909"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_0000921299_20181231"
      decimals="INF"
      id="F_000910"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_0000921299_20200101_20201231"
      decimals="INF"
      id="F_000911"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_0000921299_20200101_20201231"
      decimals="INF"
      id="F_000913"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_0000921299_20180101_20181231"
      decimals="INF"
      id="F_000912"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_0000921299_20180101_20181231"
      decimals="INF"
      id="F_000914"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_0000921299_20191231"
      decimals="-5"
      id="F_000906"
      unitRef="U_iso4217USD">29800000</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000585">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair values of the Company&#x2019;s financial liabilities that are carried at historical cost are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,141&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,141&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20201231"
      decimals="-3"
      id="F_000915"
      unitRef="U_iso4217USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20201231"
      decimals="-3"
      id="F_000916"
      unitRef="U_iso4217USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20201231"
      decimals="-3"
      id="F_000917"
      unitRef="U_iso4217USD">1141000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20201231"
      decimals="-3"
      id="F_000918"
      unitRef="U_iso4217USD">1141000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20191231"
      decimals="-3"
      id="F_000919"
      unitRef="U_iso4217USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20191231"
      decimals="-3"
      id="F_000920"
      unitRef="U_iso4217USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20191231"
      decimals="-3"
      id="F_000921"
      unitRef="U_iso4217USD">1544000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0000921299_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20191231"
      decimals="-3"
      id="F_000922"
      unitRef="U_iso4217USD">1544000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000923"
      unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="C_0000921299_20191231"
      decimals="INF"
      id="F_000924"
      unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="C_0000921299_20181231"
      decimals="INF"
      id="F_000925"
      unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_000926"
      unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="C_0000921299_20191231"
      decimals="INF"
      id="F_000927"
      unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="C_0000921299_20181231"
      decimals="INF"
      id="F_000928"
      unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_0000921299_20200101_20201231"
      decimals="INF"
      id="F_000929"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_0000921299_20190101_20191231"
      decimals="INF"
      id="F_000930"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_0000921299_20180101_20181231"
      decimals="INF"
      id="F_000931"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_0000921299_20200101_20201231"
      decimals="INF"
      id="F_000932"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_0000921299_20190101_20191231"
      decimals="INF"
      id="F_000933"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_0000921299_20180101_20181231"
      decimals="INF"
      id="F_000934"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000529">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Leases&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company currently has two building leases treated as finance leases. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2006, the Company entered into a long-term property lease with Alexandria for its corporate headquarters in San Francisco, California, with an initial term of 15&#160;years, scheduled to expire in 2023. The Company has an option to extend the lease for an additional 10 years through 2033. The lease contract provides for a fixed annual rent, with scheduled increases of two percent that occur on each anniversary of the rent commencement date. This lease requires the Company to pay all costs of ownership, operation, and maintenance of the premises, including without limitation all operating costs, insurance costs, and taxes.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2013, the Company entered into a long-term property lease with Beijing Economic-Technological Development Area (&#x201c;BDA&#x201d;) Management Committee for a pilot plant located in Beijing Yizhuang Biomedical Park of BDA. The building is leased for an initial lease term of eight years, scheduled to expire in 2021. Renewal options are not specified within the lease contract. The lease contract provides for fixed quarterly rent payments, with scheduled increases that occur as detailed in the lease contract. This lease requires the Company to pay all operating and maintenance costs, and a fixed amount for property management fees.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company currently has six additional real estate leases for office spaces in Shanghai and Beijing, China, which are treated as operating leases. These leases have lease terms ranging from two to three years, expiring in 2023. These lease contracts provide for fixed quarterly rent payments, and require the Company to pay operating and maintenance costs, and a fixed amount for property management fees.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, the Company has several immaterial lease arrangements in China and U.S. for office equipment, scientific devices and automobile leases, with contracted lease terms ranging from two to four years, treated as finance leases or operating leases, respectively.&#160;&#160; &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s lease assets and related lease liabilities were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Sheet Line Item&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets - cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,477&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,909&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,871&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,307&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease right-of-use assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,602&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets - cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,934&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,736&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,891&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(805&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,043&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,931&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,649&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,533&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities, current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,330&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,351&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,188&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;983&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,391&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,610&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other long-term liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;853&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;942&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,762&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,886&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease expense were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Statement of Operations Line Item&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of goods sold;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,307&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,932&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,373&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of goods sold;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;891&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,201&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,385&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental cash flow information related to leases were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;951&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;914&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows from finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,896&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing cash flows from finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,620&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,925&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets obtained in exchange for new lease liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;662&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,909&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,072&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,736&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease term and discount rate were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term (years):&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001000"&gt;2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001001"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001002"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001003"&gt;2.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.39&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.74&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturities of lease liabilities as of December&#160;31, 2020 are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance&#160;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&#160;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,689&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,142&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,886&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;839&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,526&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,101&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,124&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,380&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(83&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,721&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,041&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <fgen:NumberOfFinanceLeases
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20200101_20201231"
      decimals="INF"
      id="F_000935"
      unitRef="U_fgenLease">2</fgen:NumberOfFinanceLeases>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20061231"
      id="F_000936">P15Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <fgen:LesseeFinanceLeaseExpirationPeriod
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20060101_20061231"
      id="F_000937">2023</fgen:LesseeFinanceLeaseExpirationPeriod>
    <us-gaap:LesseeFinanceLeaseOptionToExtend
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20200101_20201231"
      id="F_000942">The Company has an option to extend the lease for an additional 10 years through 2033.</us-gaap:LesseeFinanceLeaseOptionToExtend>
    <fgen:LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20060101_20061231"
      id="F_000938">P10Y</fgen:LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm>
    <fgen:LesseeFinanceLeaseAdditionalLeaseExpirationPeriod
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20060101_20061231"
      id="F_000939">2033</fgen:LesseeFinanceLeaseAdditionalLeaseExpirationPeriod>
    <fgen:PercentageIncreasesOnEachAnniversaryOfRentCommencementDate
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenShorensteinPropertiesLLCMember_20060101_20061231"
      decimals="2"
      id="F_000940"
      unitRef="U_xbrlipure">0.02</fgen:PercentageIncreasesOnEachAnniversaryOfRentCommencementDate>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20131231"
      id="F_000943">P8Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <fgen:LesseeFinanceLeaseExpirationPeriod
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenBeijingEconomicTechnologicalDevelopmentAreaMember_20130101_20131231"
      id="F_000944">2021</fgen:LesseeFinanceLeaseExpirationPeriod>
    <fgen:NumberOfOperatingLeases
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenOfficeSpacesMember_20200101_20201231"
      decimals="INF"
      id="F_000946"
      unitRef="U_fgenLease">6</fgen:NumberOfOperatingLeases>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_20201231"
      id="F_000947">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_20201231"
      id="F_000948">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <fgen:LesseeOperatingLeaseExpirationPeriod
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenOfficeSpacesMember_20200101_20201231"
      id="F_000949">2023</fgen:LesseeOperatingLeaseExpirationPeriod>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231"
      id="F_000950">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231"
      id="F_000951">P4Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <fgen:ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000586">
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s lease assets and related lease liabilities were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Sheet Line Item&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets - cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,477&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,909&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,871&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,307&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease right-of-use assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,602&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets - cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,934&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,736&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,891&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(805&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,043&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,931&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,649&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,533&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities, current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,330&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,351&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,188&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;983&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,391&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,610&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other long-term liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;853&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;942&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,762&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,886&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fgen:ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock>
    <fgen:FinanceLeaseRightOfUseAssetsCost
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000952"
      unitRef="U_iso4217USD">50477000</fgen:FinanceLeaseRightOfUseAssetsCost>
    <fgen:FinanceLeaseRightOfUseAssetsCost
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000953"
      unitRef="U_iso4217USD">49909000</fgen:FinanceLeaseRightOfUseAssetsCost>
    <fgen:FinanceLeaseAccumulatedAmortization
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000954"
      unitRef="U_iso4217USD">20871000</fgen:FinanceLeaseAccumulatedAmortization>
    <fgen:FinanceLeaseAccumulatedAmortization
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000955"
      unitRef="U_iso4217USD">10307000</fgen:FinanceLeaseAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000956"
      unitRef="U_iso4217USD">29606000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000957"
      unitRef="U_iso4217USD">39602000</us-gaap:FinanceLeaseRightOfUseAsset>
    <fgen:OperatingLeaseRightOfUseAssetsCost
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000958"
      unitRef="U_iso4217USD">3934000</fgen:OperatingLeaseRightOfUseAssetsCost>
    <fgen:OperatingLeaseRightOfUseAssetsCost
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000959"
      unitRef="U_iso4217USD">2736000</fgen:OperatingLeaseRightOfUseAssetsCost>
    <fgen:OperatingLeaseAccumulatedAmortization
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000960"
      unitRef="U_iso4217USD">1891000</fgen:OperatingLeaseAccumulatedAmortization>
    <fgen:OperatingLeaseAccumulatedAmortization
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000961"
      unitRef="U_iso4217USD">805000</fgen:OperatingLeaseAccumulatedAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000962"
      unitRef="U_iso4217USD">2043000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000963"
      unitRef="U_iso4217USD">1931000</us-gaap:OperatingLeaseRightOfUseAsset>
    <fgen:FinanceLeaseAndOperatingLeaseAssets
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000964"
      unitRef="U_iso4217USD">31649000</fgen:FinanceLeaseAndOperatingLeaseAssets>
    <fgen:FinanceLeaseAndOperatingLeaseAssets
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000965"
      unitRef="U_iso4217USD">41533000</fgen:FinanceLeaseAndOperatingLeaseAssets>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000966"
      unitRef="U_iso4217USD">12330000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000967"
      unitRef="U_iso4217USD">12351000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000968"
      unitRef="U_iso4217USD">1188000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000969"
      unitRef="U_iso4217USD">983000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000972"
      unitRef="U_iso4217USD">25391000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000973"
      unitRef="U_iso4217USD">37610000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000974"
      unitRef="U_iso4217USD">853000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000975"
      unitRef="U_iso4217USD">942000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <fgen:FinanceLeaseAndOperatingLeaseLiability
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_000978"
      unitRef="U_iso4217USD">39762000</fgen:FinanceLeaseAndOperatingLeaseLiability>
    <fgen:FinanceLeaseAndOperatingLeaseLiability
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_000979"
      unitRef="U_iso4217USD">51886000</fgen:FinanceLeaseAndOperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000587">
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease expense were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Statement of Operations Line Item&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of goods sold;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,307&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,932&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,373&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of goods sold;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;891&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,201&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,385&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000980"
      unitRef="U_iso4217USD">10369000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000981"
      unitRef="U_iso4217USD">10307000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000982"
      unitRef="U_iso4217USD">1932000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000983"
      unitRef="U_iso4217USD">2373000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000984"
      unitRef="U_iso4217USD">1151000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000985"
      unitRef="U_iso4217USD">891000</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000986"
      unitRef="U_iso4217USD">1201000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000987"
      unitRef="U_iso4217USD">1385000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000988"
      unitRef="U_iso4217USD">12251000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000989"
      unitRef="U_iso4217USD">12186000</us-gaap:LeaseCost>
    <fgen:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000588">
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental cash flow information related to leases were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;951&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;914&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows from finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,896&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing cash flows from finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,620&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,925&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets obtained in exchange for new lease liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;662&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,909&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,072&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,736&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fgen:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000990"
      unitRef="U_iso4217USD">951000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000991"
      unitRef="U_iso4217USD">914000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000992"
      unitRef="U_iso4217USD">1896000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000993"
      unitRef="U_iso4217USD">2196000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <fgen:RepaymentsOfFinanceLeaseLiabilities
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000994"
      unitRef="U_iso4217USD">12620000</fgen:RepaymentsOfFinanceLeaseLiabilities>
    <fgen:RepaymentsOfFinanceLeaseLiabilities
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000995"
      unitRef="U_iso4217USD">11925000</fgen:RepaymentsOfFinanceLeaseLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000996"
      unitRef="U_iso4217USD">662000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000997"
      unitRef="U_iso4217USD">49909000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_000998"
      unitRef="U_iso4217USD">1072000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_000999"
      unitRef="U_iso4217USD">2736000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <fgen:ScheduleOfLeaseTermAndDiscountRateTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000589">
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease term and discount rate were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term (years):&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001000"&gt;2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001001"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001002"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001003"&gt;2.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.39&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.74&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fgen:ScheduleOfLeaseTermAndDiscountRateTableTextBlock>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0000921299_20201231"
      decimals="4"
      id="F_001004"
      unitRef="U_xbrlipure">0.0439</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0000921299_20191231"
      decimals="4"
      id="F_001005"
      unitRef="U_xbrlipure">0.0442</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0000921299_20201231"
      decimals="4"
      id="F_001006"
      unitRef="U_xbrlipure">0.0474</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0000921299_20191231"
      decimals="4"
      id="F_001007"
      unitRef="U_xbrlipure">0.0475</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <fgen:ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000590">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturities of lease liabilities as of December&#160;31, 2020 are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance&#160;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&#160;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,689&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,142&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,886&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;839&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,526&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,101&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,124&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,380&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(83&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,721&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,041&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fgen:ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001008"
      unitRef="U_iso4217USD">13689000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001014"
      unitRef="U_iso4217USD">1142000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001009"
      unitRef="U_iso4217USD">13886000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001015"
      unitRef="U_iso4217USD">839000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001010"
      unitRef="U_iso4217USD">12526000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001016"
      unitRef="U_iso4217USD">143000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001011"
      unitRef="U_iso4217USD">40101000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001017"
      unitRef="U_iso4217USD">2124000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001012"
      unitRef="U_iso4217USD">2380000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001018"
      unitRef="U_iso4217USD">83000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001013"
      unitRef="U_iso4217USD">37721000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001019"
      unitRef="U_iso4217USD">2041000</us-gaap:OperatingLeaseLiability>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000530">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Balance Sheet Components&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,046&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;678,393&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s investments consist of available-for-sale debt investments, marketable equity investments, term deposit and certificate of deposit. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#x2019;s investments by major investments type are summarized in the tables below (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&#160;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&#160;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&#160;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bond and mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,147&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,272&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,388&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&#160;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&#160;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&#160;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury notes and bills&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;426,995&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;536&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;427,506&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bond and mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,730&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,816&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;467,850&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;784&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;468,609&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The contractual maturities of the available-for-sale investments were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Within one year - Bond and mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,388&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company periodically reviews its available-for-sale investments and term deposit for other-than-temporary impairment. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period and its intent to sell. For debt securities, the Company also considers whether (i)&#160;it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. During the three years ended December 31, 2020, the Company did not recognize any other-than-temporary impairment loss.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,303&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;325&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Work-in-progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,264&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,298&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total inventories&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,530&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,887&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company started capitalizing inventory costs in June 2019 when FibroGen Beijing began productions of roxadustat for commercial sales purposes. The Company started capitalizing pre-launch inventory costs in the U.S. the second quarter of 2020 prior to regulatory approval. As of December 31, 2020, pre-launch inventory capitalized was 29% of the total inventory balance. The provision to write-down excess and obsolete inventory was nominal for the years ended December&#160;31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unbilled contract assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,147&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;180,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenues from associated contracts&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,147&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(54,790&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net unbilled contract assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125,210&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,464&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,807&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,717&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,160&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;133,391&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The unbilled contract assets as of December 31, 2020 were related to unbilled co-development revenue under the China Amendment with AstraZeneca. The unbilled contract assets as of December 31, 2019 were related to two regulatory milestones totaling $130.0 million under the Europe Agreement with Astellas associated with the planned MAA submission in Europe, and a $50.0 million regulatory milestone under the U.S./RoW Agreement with AstraZeneca associated with the NDA submission in the U.S., which was submitted in December 2019 and accepted for review in February 2020. See Note 4, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues&lt;/span&gt;, for details.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,006&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;101,548&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,143&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,329&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Machinery&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,312&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,217&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,545&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,399&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;760&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,792&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,894&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143,107&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(111,247&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(100,364&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,647&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,743&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense for the years ended December&#160;31, 2020, 2019 and 2018 was $11.7 million, $11.1 million, and $6.6 million, respectively.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued and Other Current Liabilities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued and other current liabilities consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preclinical and clinical trial accruals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,279&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;API product price adjustment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,324&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and related accruals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,784&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities to pharmaceutical distributors&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued co-promotion expenses - current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,537&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Roxadustat profit share to AstraZeneca&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property taxes and other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,970&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,869&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,842&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,088&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,543&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119,521&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;83,816&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The API product price adjustment of $36.3 million accrued as of December 31, 2019 was related to the change in estimated variable consideration of API product at the time the roxadustat listed price was issued by the Japanese Ministry of Health, Labour and Welfare in the fourth quarter of 2019. This amount was fully paid during the first quarter of 2020. Refer to Note 4, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues&lt;/span&gt;, for details.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 8, 2020, the Parties entered into an amendment to the China Agreement, relating to the development and commercialization of roxadustat in China, which revised, among other things, the arrangements and calculation of the estimated co-promotion expenses payable to AstraZeneca for its sales and marketing efforts associated with the commercial sales for roxadustat in China. As a result, the previously accrued long-term co-promotion expenses were significantly reduced during the third quarter of 2020. $11.5 million of the recalculated accrued co-promotion expenses is anticipated to be paid within the next 12 months, therefore was recorded as a current liability as of December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The profit share liability of $7.0 million to AstraZeneca as of December 31, 2020 represented the profit/loss share between FibroGen Beijing and AstraZeneca that is calculated pursuant to the China Agreement. This liability correspondingly reduced the deferred revenue related to the performance obligation in accordance with the China Agreement.&lt;span style="font-weight:bold;color:#FF0000;"&gt; &lt;/span&gt;Refer to Note 4, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues&lt;/span&gt;, for details.&lt;span style="font-weight:bold;color:#FF0000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other Long-term Liabilities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other long-term liabilities consisted of the following (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued long-term co-promotion expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,424&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,071&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other long-term tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,675&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,913&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;853&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;942&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,690&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,481&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other long-term liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,642&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,407&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The a&lt;span style="color:#000000;"&gt;ccrued long-term co-promotional expenses &lt;/span&gt;of $53.1 million &lt;span style="color:#000000;"&gt;as of December 31, 2019 was related to the estimated amount payable to AstraZeneca for its sales and marketing efforts related to the commercial launch for roxadustat in China. &lt;/span&gt;As mentioned above, the China Amendment revised the arrangements and calculation of the estimated co-promotion expenses payable to AstraZeneca. As a result, we reversed approximately $84.4 million of previously accrued long-term co-promotion expenses during the third quarter of 2020. $27.4 million of the recalculated accrued co-promotion expenses remained in the long-term liabilities as of December 31, 2020, as it is not anticipated to be paid within the next 12 months.&lt;span style="color:#000000;"&gt; &lt;/span&gt; &lt;/p&gt;
</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000591">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,046&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;678,393&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:Cash
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001020"
      unitRef="U_iso4217USD">88046000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001021"
      unitRef="U_iso4217USD">40715000</us-gaap:Cash>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001022"
      unitRef="U_iso4217USD">590347000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001023"
      unitRef="U_iso4217USD">85551000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001024"
      unitRef="U_iso4217USD">678393000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001025"
      unitRef="U_iso4217USD">126266000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000592">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s investments consist of available-for-sale debt investments, marketable equity investments, term deposit and certificate of deposit. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#x2019;s investments by major investments type are summarized in the tables below (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&#160;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&#160;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&#160;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bond and mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,147&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,272&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,388&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&#160;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&#160;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&#160;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&#160;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury notes and bills&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;426,995&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;536&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;427,506&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bond and mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,730&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,816&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;467,850&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;784&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;468,609&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231"
      decimals="-3"
      id="F_001026"
      unitRef="U_iso4217USD">8147000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231"
      decimals="-3"
      id="F_001034"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231"
      decimals="-3"
      id="F_001042"
      unitRef="U_iso4217USD">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20201231"
      decimals="-3"
      id="F_001050"
      unitRef="U_iso4217USD">8144000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_001027"
      unitRef="U_iso4217USD">125000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_001035"
      unitRef="U_iso4217USD">119000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_001043"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_001051"
      unitRef="U_iso4217USD">244000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001028"
      unitRef="U_iso4217USD">8272000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001036"
      unitRef="U_iso4217USD">119000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001044"
      unitRef="U_iso4217USD">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001052"
      unitRef="U_iso4217USD">8388000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231"
      decimals="-3"
      id="F_001029"
      unitRef="U_iso4217USD">426995000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231"
      decimals="-3"
      id="F_001037"
      unitRef="U_iso4217USD">536000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231"
      decimals="-3"
      id="F_001045"
      unitRef="U_iso4217USD">25000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231"
      decimals="-3"
      id="F_001053"
      unitRef="U_iso4217USD">427506000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231"
      decimals="-3"
      id="F_001030"
      unitRef="U_iso4217USD">30000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231"
      decimals="-3"
      id="F_001038"
      unitRef="U_iso4217USD">32000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231"
      decimals="-3"
      id="F_001046"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapCertificatesOfDepositMember_20191231"
      decimals="-3"
      id="F_001054"
      unitRef="U_iso4217USD">30032000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231"
      decimals="-3"
      id="F_001031"
      unitRef="U_iso4217USD">10730000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231"
      decimals="-3"
      id="F_001039"
      unitRef="U_iso4217USD">86000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231"
      decimals="-3"
      id="F_001047"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_fgenBondAndMutualFundsMember_20191231"
      decimals="-3"
      id="F_001055"
      unitRef="U_iso4217USD">10816000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231"
      decimals="-3"
      id="F_001032"
      unitRef="U_iso4217USD">125000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231"
      decimals="-3"
      id="F_001040"
      unitRef="U_iso4217USD">130000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231"
      decimals="-3"
      id="F_001048"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20191231"
      decimals="-3"
      id="F_001056"
      unitRef="U_iso4217USD">255000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001033"
      unitRef="U_iso4217USD">467850000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001041"
      unitRef="U_iso4217USD">784000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001049"
      unitRef="U_iso4217USD">25000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001057"
      unitRef="U_iso4217USD">468609000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000593">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The contractual maturities of the available-for-sale investments were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Within one year - Bond and mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.58%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;244&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,388&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <fgen:AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001058"
      unitRef="U_iso4217USD">8144000</fgen:AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear>
    <us-gaap:AvailableForSaleSecuritiesEquitySecurities
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001059"
      unitRef="U_iso4217USD">244000</us-gaap:AvailableForSaleSecuritiesEquitySecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001060"
      unitRef="U_iso4217USD">8388000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
      contextRef="C_0000921299_20180101_20201231"
      decimals="INF"
      id="F_001061"
      unitRef="U_iso4217USD">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000594">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,303&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;325&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Work-in-progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,264&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,298&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total inventories&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,530&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,887&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001062"
      unitRef="U_iso4217USD">2303000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001063"
      unitRef="U_iso4217USD">325000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001064"
      unitRef="U_iso4217USD">8114000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001065"
      unitRef="U_iso4217USD">2264000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001066"
      unitRef="U_iso4217USD">6113000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001067"
      unitRef="U_iso4217USD">4298000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001068"
      unitRef="U_iso4217USD">16530000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001069"
      unitRef="U_iso4217USD">6887000</us-gaap:InventoryNet>
    <fgen:PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance
      contextRef="C_0000921299_20201231"
      decimals="2"
      id="F_001070"
      unitRef="U_xbrlipure">0.29</fgen:PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000595">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unbilled contract assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,147&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;180,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenues from associated contracts&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,147&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(54,790&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net unbilled contract assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125,210&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,464&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,807&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,717&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,160&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;133,391&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:Supplies
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001071"
      unitRef="U_iso4217USD">2147000</us-gaap:Supplies>
    <us-gaap:Supplies
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001072"
      unitRef="U_iso4217USD">180000000</us-gaap:Supplies>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001073"
      unitRef="U_iso4217USD">2147000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001074"
      unitRef="U_iso4217USD">54790000</us-gaap:ContractWithCustomerLiability>
    <fgen:SuppliesNet
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001075"
      unitRef="U_iso4217USD">0</fgen:SuppliesNet>
    <fgen:SuppliesNet
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001076"
      unitRef="U_iso4217USD">125210000</fgen:SuppliesNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001077"
      unitRef="U_iso4217USD">8353000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001078"
      unitRef="U_iso4217USD">6464000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001079"
      unitRef="U_iso4217USD">1807000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001080"
      unitRef="U_iso4217USD">1717000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001081"
      unitRef="U_iso4217USD">10160000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001082"
      unitRef="U_iso4217USD">133391000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <fgen:NumberOfRegulatoryMilestones
      contextRef="C_0000921299_20190101_20191231"
      decimals="INF"
      id="F_001083"
      unitRef="U_fgenMilestone">2</fgen:NumberOfRegulatoryMilestones>
    <us-gaap:Supplies
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20191231"
      decimals="-5"
      id="F_001084"
      unitRef="U_iso4217USD">130000000.0</us-gaap:Supplies>
    <us-gaap:Supplies
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20191231"
      decimals="-5"
      id="F_001085"
      unitRef="U_iso4217USD">50000000.0</us-gaap:Supplies>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000596">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,006&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;101,548&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,143&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,329&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Machinery&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,312&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,217&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,545&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,399&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;760&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,792&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;144,894&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143,107&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(111,247&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(100,364&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,647&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,743&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_001086"
      unitRef="U_iso4217USD">102006000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231"
      decimals="-3"
      id="F_001087"
      unitRef="U_iso4217USD">101548000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20201231"
      decimals="-3"
      id="F_001088"
      unitRef="U_iso4217USD">18143000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_fgenLaboratoryEquipmentMember_20191231"
      decimals="-3"
      id="F_001089"
      unitRef="U_iso4217USD">17329000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20201231"
      decimals="-3"
      id="F_001090"
      unitRef="U_iso4217USD">8312000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20191231"
      decimals="-3"
      id="F_001091"
      unitRef="U_iso4217USD">8217000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231"
      decimals="-3"
      id="F_001092"
      unitRef="U_iso4217USD">9545000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231"
      decimals="-3"
      id="F_001093"
      unitRef="U_iso4217USD">8399000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231"
      decimals="-3"
      id="F_001094"
      unitRef="U_iso4217USD">6128000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231"
      decimals="-3"
      id="F_001095"
      unitRef="U_iso4217USD">5822000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231"
      decimals="-3"
      id="F_001096"
      unitRef="U_iso4217USD">760000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231"
      decimals="-3"
      id="F_001097"
      unitRef="U_iso4217USD">1792000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001098"
      unitRef="U_iso4217USD">144894000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001099"
      unitRef="U_iso4217USD">143107000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001100"
      unitRef="U_iso4217USD">111247000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001101"
      unitRef="U_iso4217USD">100364000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001102"
      unitRef="U_iso4217USD">33647000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001103"
      unitRef="U_iso4217USD">42743000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_0000921299_20200101_20201231"
      decimals="-5"
      id="F_001104"
      unitRef="U_iso4217USD">11700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0000921299_20190101_20191231"
      decimals="-5"
      id="F_001105"
      unitRef="U_iso4217USD">11100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0000921299_20180101_20181231"
      decimals="-5"
      id="F_001106"
      unitRef="U_iso4217USD">6600000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000597">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued and other current liabilities consisted of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preclinical and clinical trial accruals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,279&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;API product price adjustment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,324&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and related accruals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,784&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities to pharmaceutical distributors&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued co-promotion expenses - current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,537&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Roxadustat profit share to AstraZeneca&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property taxes and other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,970&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,869&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,842&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,088&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,543&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119,521&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;83,816&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <fgen:AccruedPreclinicalAndClinicalTrialCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001107"
      unitRef="U_iso4217USD">44113000</fgen:AccruedPreclinicalAndClinicalTrialCurrent>
    <fgen:AccruedPreclinicalAndClinicalTrialCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001108"
      unitRef="U_iso4217USD">16279000</fgen:AccruedPreclinicalAndClinicalTrialCurrent>
    <fgen:AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001109"
      unitRef="U_iso4217USD">0</fgen:AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent>
    <fgen:AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001110"
      unitRef="U_iso4217USD">36324000</fgen:AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001111"
      unitRef="U_iso4217USD">22800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001112"
      unitRef="U_iso4217USD">19784000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <fgen:AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001113"
      unitRef="U_iso4217USD">15137000</fgen:AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent>
    <fgen:AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001114"
      unitRef="U_iso4217USD">0</fgen:AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent>
    <fgen:AccruedCoPromotionExpensesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001115"
      unitRef="U_iso4217USD">11537000</fgen:AccruedCoPromotionExpensesCurrent>
    <fgen:AccruedCoPromotionExpensesCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001116"
      unitRef="U_iso4217USD">0</fgen:AccruedCoPromotionExpensesCurrent>
    <fgen:AccruedProfitShareCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001117"
      unitRef="U_iso4217USD">7007000</fgen:AccruedProfitShareCurrent>
    <fgen:AccruedProfitShareCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001118"
      unitRef="U_iso4217USD">0</fgen:AccruedProfitShareCurrent>
    <fgen:PropertyTaxesAndOtherCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001119"
      unitRef="U_iso4217USD">5970000</fgen:PropertyTaxesAndOtherCurrent>
    <fgen:PropertyTaxesAndOtherCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001120"
      unitRef="U_iso4217USD">2044000</fgen:PropertyTaxesAndOtherCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001121"
      unitRef="U_iso4217USD">4869000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001122"
      unitRef="U_iso4217USD">4842000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001123"
      unitRef="U_iso4217USD">8088000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001124"
      unitRef="U_iso4217USD">4543000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001125"
      unitRef="U_iso4217USD">119521000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001126"
      unitRef="U_iso4217USD">83816000</us-gaap:AccruedLiabilitiesCurrent>
    <fgen:AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent
      contextRef="C_0000921299_20191231"
      decimals="-5"
      id="F_001127"
      unitRef="U_iso4217USD">36300000</fgen:AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent>
    <fgen:AccruedLongTermCoPromotionLiabilityCurrent
      contextRef="C_0000921299_20201231"
      decimals="-5"
      id="F_001128"
      unitRef="U_iso4217USD">11500000</fgen:AccruedLongTermCoPromotionLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-5"
      id="F_001129"
      unitRef="U_iso4217USD">7000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000598">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other long-term liabilities consisted of the following (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued long-term co-promotion expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,424&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,071&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other long-term tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,675&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,913&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, non-current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;853&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;942&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,690&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,481&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other long-term liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,642&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,407&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <fgen:AccruedLongTermCoPromotionLiabilityNonCurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001130"
      unitRef="U_iso4217USD">27424000</fgen:AccruedLongTermCoPromotionLiabilityNonCurrent>
    <fgen:AccruedLongTermCoPromotionLiabilityNonCurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001131"
      unitRef="U_iso4217USD">53071000</fgen:AccruedLongTermCoPromotionLiabilityNonCurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001132"
      unitRef="U_iso4217USD">8675000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001133"
      unitRef="U_iso4217USD">8913000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001134"
      unitRef="U_iso4217USD">853000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001135"
      unitRef="U_iso4217USD">942000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001136"
      unitRef="U_iso4217USD">2690000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001137"
      unitRef="U_iso4217USD">2481000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001138"
      unitRef="U_iso4217USD">39642000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001139"
      unitRef="U_iso4217USD">65407000</us-gaap:OtherLiabilitiesNoncurrent>
    <fgen:AccruedLongTermCoPromotionalLiabilityNonCurrent
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20191231"
      decimals="-5"
      id="F_001140"
      unitRef="U_iso4217USD">53100000</fgen:AccruedLongTermCoPromotionalLiabilityNonCurrent>
    <fgen:ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses
      contextRef="C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200701_20200930"
      decimals="-5"
      id="F_001142"
      unitRef="U_iso4217USD">84400000</fgen:ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses>
    <fgen:AccruedLongTermCoPromotionalLiabilityNonCurrent
      contextRef="C_0000921299_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentLiabilitiesMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231"
      decimals="-5"
      id="F_001141"
      unitRef="U_iso4217USD">27400000</fgen:AccruedLongTermCoPromotionalLiabilityNonCurrent>
    <fgen:ProductDevelopmentObligationsDisclosureTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000531">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Product Development Obligations&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Technology Development Center of the Republic of Finland (&#x201c;TEKES&#x201d;) product development obligations consist of 11 separate advances (each in the form of a note agreement) received by FibroGen Europe between 1996 and 2008 from TEKES. These advances are granted on a project-by-project basis to fund various product development efforts undertaken by FibroGen Europe only. Each separate note is denominated in EUR and bears interest (not compounded) calculated as one percentage point less than the Bank of Finland rate in effect at the time of the note, but no less than 3.0%.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If the research work funded by TEKES does not result in an economically profitable business or does not meet its technological objectives, TEKES may, on application from FibroGen Europe, forgive each of these loans, including accrued interest, either in full or in part. As of December&#160;31, 2020 and 2019, the Company had U.S. Dollar equivalent of $11.6 million and $10.6 million of principal outstanding, respectively, and $7.1 million and $6.2 million of interest accrued, respectively, which were presented in the product development obligations line on the consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is not a guarantor of these loans, and these loans are not repayable by FibroGen Europe until it has distributable funds.&lt;/p&gt;</fgen:ProductDevelopmentObligationsDisclosureTextBlock>
    <fgen:NumberOfProductDevelopmentObligations
      contextRef="C_0000921299_20200101_20201231"
      decimals="INF"
      id="F_001143"
      unitRef="U_fgenDevelopmentObligation">11</fgen:NumberOfProductDevelopmentObligations>
    <us-gaap:LoansReceivableBasisSpreadOnVariableRate
      contextRef="C_0000921299_us-gaapVariableRateAxis_fgenBankOfFinlandInterestRateMember_20201231"
      decimals="2"
      id="F_001144"
      unitRef="U_xbrlipure">0.01</us-gaap:LoansReceivableBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_20201231"
      decimals="INF"
      id="F_001145"
      unitRef="U_xbrlipure">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <fgen:AccruedProductDevelopmentCostsExcludingInterest
      contextRef="C_0000921299_20201231"
      decimals="-5"
      id="F_001146"
      unitRef="U_iso4217USD">11600000</fgen:AccruedProductDevelopmentCostsExcludingInterest>
    <fgen:AccruedProductDevelopmentCostsExcludingInterest
      contextRef="C_0000921299_20191231"
      decimals="-5"
      id="F_001147"
      unitRef="U_iso4217USD">10600000</fgen:AccruedProductDevelopmentCostsExcludingInterest>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_0000921299_20201231"
      decimals="-5"
      id="F_001148"
      unitRef="U_iso4217USD">7100000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_0000921299_20191231"
      decimals="-5"
      id="F_001149"
      unitRef="U_iso4217USD">6200000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000532">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Commitments and Contingencies&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract Obligations &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, the Company had outstanding total non-cancelable purchase obligations of $86.0 million. The Company expects to fulfill our commitments under these agreements in the normal course of business, and as such, no liability has been recorded. The unconditional purchase obligations consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchase Obligations&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due In The Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacture and supply of roxadustat&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,951&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,065&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacture and supply of pamrevlumab&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,063&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,543&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other purchases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,418&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,418&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total purchase obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,012&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,014&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86,026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Some of the Company&#x2019;s license agreements provide for periodic maintenance fees over specified time periods, as well as payments by the Company upon the achievement of development, regulatory and commercial milestones. Future milestone payments for research and pre-clinical stage development programs consisted of up to approximately $10.9 million in total potential future milestone payments under the Company&#x2019;s license agreements with Dana-Farber Cancer Institute, University of Miami and Medarex, Inc. These milestone payments generally become due and payable only upon the achievement of certain developmental, clinical, regulatory and/or commercial milestones. The event triggering such payment or obligation has not yet occurred.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legal Proceedings&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, the Company is a party to various legal actions, both inside and outside the U.S., arising in the ordinary course of its business or otherwise. The Company accrues amounts, to the extent they can be reasonably estimated, that the Company believes will result in a probable loss (including, among other things, probable settlement value), to adequately address any liabilities related to legal proceedings and other loss contingencies. A loss or a range of loss is disclosed when it is reasonably possible that a material loss will incur and can be estimated, or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 20, 2020, in response to an invalidation action brought against certain FibroGen United Kingdom patents by Akebia, the United Kingdom court handed down a decision invalidating United Kingdom designations of European Patent Nos. 1463823, 1633333, 2298301, 2322153, and 2322155. The United Kingdom designation to European Patent No. 2289531 was held to be valid in amended form, but not infringed by Akebia. The Company and its partner Astellas have filed an appeal of the decision in the United Kingdom Court of Appeal. The Company did not have material accruals for any currently active legal action in its consolidated balance sheets as of December&#160;31, 2020, as it could not predict the ultimate outcome of these matters, or reasonably estimate the potential exposure.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Indemnification Agreements&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into standard indemnification arrangements in the ordinary course of business, including for example, service, manufacturing and collaboration agreements. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, including in connection with intellectual property infringement claims by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the extent permissible under applicable law. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these arrangements is minimal.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ContractualObligation
      contextRef="C_0000921299_20201231"
      decimals="-5"
      id="F_001150"
      unitRef="U_iso4217USD">86000000.0</us-gaap:ContractualObligation>
    <us-gaap:RecordedUnconditionalPurchaseObligationsTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000599">The unconditional purchase obligations consisted of the following (in thousands):
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchase Obligations&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due In The Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacture and supply of roxadustat&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,951&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,065&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacture and supply of pamrevlumab&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,063&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,543&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other purchases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,418&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,418&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total purchase obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,012&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,014&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86,026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:RecordedUnconditionalPurchaseObligationsTextBlock>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear
      contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfRoxadustatMember_20201231"
      decimals="-3"
      id="F_001151"
      unitRef="U_iso4217USD">14114000</us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear
      contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfRoxadustatMember_20201231"
      decimals="-3"
      id="F_001155"
      unitRef="U_iso4217USD">10951000</us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear>
    <us-gaap:RecordedUnconditionalPurchaseObligation
      contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfRoxadustatMember_20201231"
      decimals="-3"
      id="F_001159"
      unitRef="U_iso4217USD">25065000</us-gaap:RecordedUnconditionalPurchaseObligation>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear
      contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfPamrevlumabMember_20201231"
      decimals="-3"
      id="F_001152"
      unitRef="U_iso4217USD">24480000</us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear
      contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfPamrevlumabMember_20201231"
      decimals="-3"
      id="F_001156"
      unitRef="U_iso4217USD">33063000</us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear>
    <us-gaap:RecordedUnconditionalPurchaseObligation
      contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenManufactureAndSupplyOfPamrevlumabMember_20201231"
      decimals="-3"
      id="F_001160"
      unitRef="U_iso4217USD">57543000</us-gaap:RecordedUnconditionalPurchaseObligation>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear
      contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenOtherPurchasesMember_20201231"
      decimals="-3"
      id="F_001153"
      unitRef="U_iso4217USD">3418000</us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear
      contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenOtherPurchasesMember_20201231"
      decimals="-3"
      id="F_001157"
      unitRef="U_iso4217USD">0</us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear>
    <us-gaap:RecordedUnconditionalPurchaseObligation
      contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenOtherPurchasesMember_20201231"
      decimals="-3"
      id="F_001161"
      unitRef="U_iso4217USD">3418000</us-gaap:RecordedUnconditionalPurchaseObligation>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001154"
      unitRef="U_iso4217USD">42012000</us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001158"
      unitRef="U_iso4217USD">44014000</us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear>
    <us-gaap:RecordedUnconditionalPurchaseObligation
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001162"
      unitRef="U_iso4217USD">86026000</us-gaap:RecordedUnconditionalPurchaseObligation>
    <fgen:MaximumFutureMilestonePayments
      contextRef="C_0000921299_us-gaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_fgenResearchAndPreClinicalStageDevelopmentProgramsMember_20200101_20201231"
      decimals="-5"
      id="F_001163"
      unitRef="U_iso4217USD">10900000</fgen:MaximumFutureMilestonePayments>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000533">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Equity and Stock-based Compensation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subsidiary Stock and Non-Controlling Interests&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;FibroGen Europe&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020 and 2019, respectively, FibroGen Europe had a total of 42,619,022&#160;shares of Preferred Stock outstanding, of which there were 1,700,845 shares of Series&#160;A Preferred Stock, 1,875,000&#160;shares of Series&#160;B Preferred Stock, 1,599,503&#160;shares of Series&#160;C Preferred Stock, 1,520,141&#160;shares of Series&#160;D Preferred Stock, 459,565&#160;shares of Series&#160;E Preferred Stock, 5,714,332&#160;shares of Series&#160;F Preferred Stock, 9,927,500&#160;shares of Series&#160;G Preferred Stock and 19,822,136&#160;shares of Series&#160;H Preferred Stock, all of which shares no longer have any right to be exchanged for FibroGen, Inc. Common Stock. The holders of FibroGen Europe&#x2019;s shares of Preferred Stock (&#x201c;Preferred Shares&#x201d;) have the following rights, preferences and privileges:&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.36%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Dividend Rights &lt;span style="font-style:normal;"&gt;&#x2014; When the assets of FibroGen Europe are distributed (except for distribution in a liquidation), Preferred Shares shall have the same rights to dividend or other forms of distribution as shares of Common Stock of FibroGen Europe. In the event of a merger, holders of Preferred Shares do not have the right to demand FibroGen Europe to redeem all or part of their Preferred Shares. FibroGen Europe may repurchase shares of Common Stock or Preferred Shares for consideration.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.36%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Pre-emptive Right &lt;span style="font-style:normal;"&gt;&#x2014; Preferred Shares shall have pre-emptive subscription right in accordance with the Finnish Limited Liability Companies Act if additional shares are issued, option rights are given, or convertible loan is taken, &lt;/span&gt;provided&lt;span style="font-style:normal;"&gt;, &lt;/span&gt;however&lt;span style="font-style:normal;"&gt;, that the foregoing pre-emptive right does not apply to a directed share issue, for which two thirds (2/3)&#160;of the voting shares represented at a general meeting of shareholders approve for an important legitimate cause.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.36%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Redemption Right &lt;span style="font-style:normal;"&gt;&#x2014; If a Preferred Share can be redeemed by a majority shareholder owning more than ninety percent (90%)&#160;of the shares of FibroGen Europe in accordance with the provisions of the Finnish Limited Liability Companies Act, the minority holders of Preferred Shares have the right to request redemption of their shares.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.36%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Voting Right &lt;span style="font-style:normal;"&gt;&#x2014; Each share has one vote. Preferred Shares have voting rights only in situations that are specifically provided in the Articles of Association, which include a merger transaction and directed share issue. In addition, Preferred Shares have right to vote in a general shareholder meeting for amending the Articles of Association if the amendment will affect the rights of Preferred Shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.36%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Conversion Right&lt;span style="font-style:normal;"&gt; (1-for-1 basis into Common Stock of FibroGen Europe):&lt;/span&gt;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.43%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.42%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Voluntary conversion right: Preferred Shares can be converted into common shares upon the written request of a shareholder provided that the conversion is feasible within the maximum and minimum amounts of shares of classes of FibroGen Europe as set forth in its Articles of Association. Such request can be withdrawn before the notification of conversion is filed with the Finnish Trade Register.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.36%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.46%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Compulsory conversion right: Preferred Shares will be converted into common shares if (i)&#160;FibroGen Europe&#x2019;s shares are listed in a stock exchange or other trading system in the European Economic Area, or (ii)&#160;FibroGen Europe&#x2019;s recombinant collagen and gelatin production technology is being put into commercial use in the area of Europe and certain other European states. Commercial use means there is income generated from the first commercial sale of the products incorporating the above mentioned technology and does not include license fees, development financing, milestone payments or income from test products or equipment used in research. The board of directors of FibroGen Europe shall notify the shareholders of the compulsory conversion in writing, and the shareholders shall request to convert their shares within the timeframe provided in the notification. Should the shareholders fail to make the conversion request within the time limit, FibroGen Europe may redeem the shares of such shareholders.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Liquidation Right &lt;span style="font-style:normal;"&gt;&#x2014; In the event of a dissolution of FibroGen Europe, holders of Preferred Shares are entitled to be paid in an amount equal to the subscription price of the shares before any distribution is made to holders of common shares. Among holders of Preferred Shares, holders of shares of Series F Preferred Stock are entitled to be paid in an amount equal to the subscription price of Series F Preferred Stock before any distribution is made to holders of other Preferred Shares.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;FibroGen Cayman&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;FibroGen Cayman had 6,758,000 Series A Preference Shares outstanding as of December&#160;31, 2020 and 2019, respectively. The holders of the FibroGen Cayman Series A Preference Shares have the following rights, preferences and privileges:&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Liquidation &lt;span style="font-style:normal;"&gt;&#x2014; In the event of liquidation, dissolution, or winding up of the Company, either voluntary or involuntary, including by means of a merger, the holders of FibroGen Cayman Series A Preference Shares are entitled to be paid an amount equal to the product of the number of shares held by a holder of shares of FibroGen Cayman Series A Preference Shares and the original issue price of $1.00 (subject to equitable adjustment for any stock dividend, combination, split, reclassification, recapitalization) plus all declared and unpaid dividends thereon.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Conversion &lt;span style="font-style:normal;"&gt;&#x2014; Each share of FibroGen Cayman Series A Preference Shares is convertible into the number of fully paid and non-assessable shares of Common Stock of FibroGen Cayman that results from dividing the original issue price by the conversion price in effect at the time of the conversion, subject to adjustments for stock splits, stock dividends, reclassifications and like events. The FibroGen Cayman Series A Preference Shares have a conversion price that is equal to the original issuance price such that the conversion ratio to FibroGen Cayman Common Stock is 1:1 as of all periods presented.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Voting &lt;span style="font-style:normal;"&gt;&#x2014; The holders of FibroGen Cayman Series A Preference Shares are entitled to vote together with the FibroGen Cayman Common Stock holders on all matters submitted for a vote of the stockholders. The holder of each share of FibroGen Cayman Series A Preference Shares has the number of votes equal to the number of shares of FibroGen Cayman Common Stock into which it is convertible.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Dividends &lt;span style="font-style:normal;"&gt;&#x2014; The holders of FibroGen Cayman Series A Preference Shares are entitled to receive cash dividends when and if declared, at a rate of 6%.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Non-Controlling Interests&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-controlling interest positions related to the issuance of subsidiary stock as described above are reported as a separate component of consolidated equity from the equity attributable to the Company&#x2019;s stockholders at December&#160;31, 2020 and 2019. In addition, the Company does not allocate losses to the non-controlling interests as the outstanding shares representing the non-controlling interest do not represent a residual equity interest in the subsidiary. Upon the initial public offering and as described above, all eligible FibroGen Europe preferred shares were exchanged for 958,996 shares of FibroGen Common Stock. No other FibroGen Europe shares have the right to be exchanged for FibroGen, Inc. Common Stock.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common Stock&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Each share of Common Stock is entitled to one vote. The holders of Common Stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares of Common Stock outstanding, shares of stock plans outstanding and shares reserved for future issuance related to stock options and RSU grants and the Company&#x2019;s Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) purchases are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87,657&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,290&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,893&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for future stock options and RSUs grant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,910&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,725&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for future ESPP offering&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,070&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total shares of common stock reserved&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;114,604&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,220&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock Plans&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock Option and RSU Plans&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Company&#x2019;s Amended and Restated 2005 Stock Plan (&#x201c;2005 Stock Plan&#x201d;), the Company may issue shares of Common Stock and options to purchase Common Stock and other forms of equity incentives to employees, directors and consultants. Options granted under the 2005 Stock Plan may be incentive stock options or nonqualified stock options. Incentive stock options (&#x201c;ISO&#x201d;) may be granted only to employees and officers of the Company. Nonqualified stock options (&#x201c;NSO&#x201d;) and stock purchase rights may be granted to employees, directors and consultants. The board of directors has the authority to determine to whom options will be granted, the number of options, the term and the exercise price. Options are to be granted at an exercise price not less than fair market value for an ISO or an NSO. Options generally vest over four years. Options expire no more than 10 years after the date of grant. Upon the effective date of the registration statement related to the Company&#x2019;s initial public offering, the 2005 Plan was amended to cease the grant of any additional awards thereunder, although the Company will continue to issue common stock upon the exercise of previously granted stock options under the 2005 Plan.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2014, the Company adopted a 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;) which became effective on November&#160;13, 2014. The 2014 Plan is the successor equity compensation plan to the 2005 Plan. The 2014 Plan will terminate on November&#160;12, 2024. The 2014 Plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock awards, stock appreciation rights, performance stock awards, performance cash awards, restricted stock units and other stock awards to employees, directors and consultants. Stock options granted must be at prices not less than 100% of the fair market value at date of grant. Option vesting schedules are determined by the Company at the time of issuance and generally have a four year vesting schedule (25% vesting on the first anniversary of the vesting base date and quarterly thereafter over the next 3 years). Options generally expire ten years from the date of grant unless the optionee is a 10% stockholder, in which case the term will be five years from the date of grant. Unvested options exercised are subject to the Company&#x2019;s repurchase right. Shares reserved for issuance increases on January&#160;1 of each year commencing on January&#160;1, 2016 and ending on January&#160;1, 2024 by the lesser of (i)&#160;the amount equal to 4% of the number of shares issued and outstanding on December&#160;31 immediately prior to the date of increase or (ii)&#160;such lower number of shares as may be determined by the board of directors. As of December&#160;31, 2020, the Company has reserved 7,909,854 shares of its common stock that remains unissued for issuance under the 2014 Plan.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of shares upon share option exercise or share unit conversion is made through issuance of new shares authorized under the plan.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain Common Stock option holders have the right to exercise unvested options, subject to a right held by the Company to repurchase the stock, at the original exercise price, in the event of voluntary or involuntary termination of employment of the stockholder. The shares are generally released from repurchase provisions ratably over four years. The Company accounts for the cash received in consideration for the early exercised options as a liability. At December&#160;31, 2020 and 2019, no shares of Common Stock were subject to repurchase by the Company.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock option transactions, including forfeited options granted under the 2014 Plan as well as prior plans, are summarized below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&#160;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26.63&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,692&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31.55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.73&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(73&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39.92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(234&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40.11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,290&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32.94&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001234"&gt;6.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86,013&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest, December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,929&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32.76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001235"&gt;6.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;84,125&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,576&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001236"&gt;5.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total intrinsic value of options exercised during the years ended December&#160;31, 2020, 2019 and 2018 was $89.6 million, $59.2 million, and $97.5 million, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes RSU activity:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&#160;at&#160;Grant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49.05&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,354&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29.99&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(813&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45.55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(131&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.14%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,893&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.14%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Among the vested RSUs during the year ended December&#160;31, 2020, 526,055 shares were released and issued, while the remaining was withheld for the related payroll taxes. The estimated weighted-average fair value of the awards granted during the years ended December&#160;31, 2020, 2019 and 2018 was $29.99, $54.74 and $53.69, respectively.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;ESPP&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2014, the Company adopted a 2014 ESPP that became effective on November&#160;13, 2014. The 2014 ESPP is designed to enable eligible employees to periodically purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan or IRS limitations. At the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the last day of the offering period. Purchases are accomplished through participation in discrete offering periods. The 2014 ESPP is intended to qualify as an ESPP under Section&#160;423 of the Internal Revenue Code. The Company has reserved 1,600,000 shares of its common stock for issuance under the 2014 ESPP and shares reserved for issuance increases January&#160;1 of each year commencing January&#160;1, 2016 by the lesser of (i)&#160;a number of shares equal to 1% of the total number of outstanding shares of common stock on December&#160;31 immediately prior to the date of increase; (ii)&#160;1,200,000 shares or (iii)&#160;such number of shares as may be determined by the board of directors. There were 143,876 shares, 135,115 shares and 230,317 shares purchased by employees under the 2014 Purchased Plan for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The expected term of 2014 ESPP shares is the average of the remaining purchase periods under each offering period.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense was recorded directly to research and development and selling, general and administrative expense for the years ended December&#160;31, 2020, 2019 and 2018 was as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,229&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,015&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,491&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,491&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,651&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,720&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,267&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,142&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates the fair value of stock options using the Black-Scholes option valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair market value of common stock is based on the closing price of the Company&#x2019;s common stock as reported on the NASDAQ Global Select Market on the date of the grant.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of employee stock-based compensation is estimated using the following assumptions:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Expected Term.&lt;/span&gt;&lt;span style="color:#000000;"&gt; Expressed as a weighted-average, the expected life of the options is based on the average period the stock options are expected to be outstanding and was based on the Company&#x2019;s historical information of the option exercise patterns and post-vesting termination behavior as well as contractual terms of the instruments.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Expected Volatility.&lt;/span&gt;&lt;span style="color:#000000;"&gt; The Company considers its historical volatility data for volatility considerations for its ESPP. &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Historically, the expected volatility for all other stock-based compensation was based upon a blend of the Company&#x2019;s and comparable public entities&#x2019;&#160;historical volatility. Since the third quarter of 2020, the&lt;/span&gt;&lt;span style="color:#000000;"&gt; expected volatility for all other stock-based compensation is currently based upon the Company&#x2019;s historical volatility data.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Risk-Free Interest Rate.&lt;/span&gt;&lt;span style="color:#000000;"&gt; Expressed as a weighted-average, the risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company&#x2019;s stock options.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Expected Dividend Yield.&lt;/span&gt;&lt;span style="color:#000000;"&gt; The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions used to estimate the fair value of stock options granted and ESPPs using the Black-Scholes option valuation model were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001275"&gt;5.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001276"&gt;5.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001277"&gt;5.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average estimated fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31.98&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32.12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;ESPPs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001290"&gt;0.5 - 2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001291"&gt;0.5 - 2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001292"&gt;0.5 - 2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001296"&gt;47.5 - 77.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001297"&gt;48.1 - 62.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001298"&gt;47.3 - 75.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001302"&gt;0.1 - 2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001303"&gt;1.3 - 2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001304"&gt;0.8 - 2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average estimated fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.27&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.27&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, there was $63.9 million of total unrecognized compensation costs, net of estimated forfeitures, related to non-vested stock option awards granted that will be recognized on a straight-line basis over the weighted-average period of 2.59 years. As of December&#160;31, 2020, there was $55.5 million of total unrecognized compensation costs, net of estimated forfeitures, related to non-vested RSUs granted that will be recognized on a straight-line basis over the weighted-average period of 2.73 years.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2019, a warrant to purchase 4,430 shares of our common stock was exercised and there was no warrant to purchase shares of Common Stock outstanding at December&#160;31, 2020 and 2019.&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_20201231"
      decimals="INF"
      id="F_001164"
      unitRef="U_xbrlishares">42619022</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_20191231"
      decimals="INF"
      id="F_001165"
      unitRef="U_xbrlishares">42619022</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20201231"
      decimals="INF"
      id="F_001166"
      unitRef="U_xbrlishares">1700845</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231"
      decimals="INF"
      id="F_001167"
      unitRef="U_xbrlishares">1700845</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231"
      decimals="INF"
      id="F_001168"
      unitRef="U_xbrlishares">1875000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231"
      decimals="INF"
      id="F_001169"
      unitRef="U_xbrlishares">1875000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20201231"
      decimals="INF"
      id="F_001170"
      unitRef="U_xbrlishares">1599503</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231"
      decimals="INF"
      id="F_001171"
      unitRef="U_xbrlishares">1599503</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20201231"
      decimals="INF"
      id="F_001172"
      unitRef="U_xbrlishares">1520141</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesDPreferredStockMember_20191231"
      decimals="INF"
      id="F_001173"
      unitRef="U_xbrlishares">1520141</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesEPreferredStockMember_20201231"
      decimals="INF"
      id="F_001174"
      unitRef="U_xbrlishares">459565</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesEPreferredStockMember_20191231"
      decimals="INF"
      id="F_001175"
      unitRef="U_xbrlishares">459565</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20201231"
      decimals="INF"
      id="F_001176"
      unitRef="U_xbrlishares">5714332</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesFPreferredStockMember_20191231"
      decimals="INF"
      id="F_001177"
      unitRef="U_xbrlishares">5714332</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20201231"
      decimals="INF"
      id="F_001178"
      unitRef="U_xbrlishares">9927500</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesGPreferredStockMember_20191231"
      decimals="INF"
      id="F_001179"
      unitRef="U_xbrlishares">9927500</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20201231"
      decimals="INF"
      id="F_001180"
      unitRef="U_xbrlishares">19822136</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesHPreferredStockMember_20191231"
      decimals="INF"
      id="F_001181"
      unitRef="U_xbrlishares">19822136</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockRedemptionTerms
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_20200101_20201231"
      id="F_001182">Redemption Right &#x2014; If a Preferred Share can be redeemed by a majority shareholder owning more than ninety percent (90%)&#160;of the shares of FibroGen Europe in accordance with the provisions of the Finnish Limited Liability Companies Act, the minority holders of Preferred Shares have the right to request redemption of their shares.</us-gaap:PreferredStockRedemptionTerms>
    <fgen:RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_20200101_20201231"
      decimals="INF"
      id="F_001183"
      unitRef="U_xbrlipure">0.90</fgen:RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares>
    <us-gaap:PreferredStockVotingRights
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_20200101_20201231"
      id="F_001184">one vote</us-gaap:PreferredStockVotingRights>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibrogenEuropeOyMember_20201231"
      decimals="INF"
      id="F_001185"
      unitRef="U_xbrlishares">1</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibroGenCaymanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20201231"
      decimals="INF"
      id="F_001186"
      unitRef="U_xbrlishares">6758000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibroGenCaymanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231"
      decimals="INF"
      id="F_001187"
      unitRef="U_xbrlishares">6758000</us-gaap:PreferredStockSharesOutstanding>
    <fgen:PreferredSharesIssuedPricePerShare
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibroGenCaymanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20201231"
      decimals="INF"
      id="F_001188"
      unitRef="U_iso4217USD_xbrlishares">1.00</fgen:PreferredSharesIssuedPricePerShare>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibroGenCaymanMember_20201231"
      decimals="INF"
      id="F_001189"
      unitRef="U_xbrlishares">1</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="C_0000921299_deiLegalEntityAxis_fgenFibroGenCaymanMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20200101_20201231"
      decimals="INF"
      id="F_001190"
      unitRef="U_xbrlipure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_0000921299_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20141119"
      decimals="INF"
      id="F_001191"
      unitRef="U_xbrlishares">958996</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:CommonStockVotingRights contextRef="C_0000921299_20200101_20201231" id="F_001192">one vote</us-gaap:CommonStockVotingRights>
    <fgen:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000600">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares of Common Stock outstanding, shares of stock plans outstanding and shares reserved for future issuance related to stock options and RSU grants and the Company&#x2019;s Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) purchases are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87,657&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,290&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,893&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for future stock options and RSUs grant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,910&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,725&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved for future ESPP offering&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,070&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total shares of common stock reserved&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;114,604&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,220&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</fgen:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001193"
      unitRef="U_xbrlishares">91441000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001194"
      unitRef="U_xbrlishares">87657000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001195"
      unitRef="U_xbrlishares">9290000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001196"
      unitRef="U_xbrlishares">10018000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001197"
      unitRef="U_xbrlishares">1893000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001198"
      unitRef="U_xbrlishares">1483000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001199"
      unitRef="U_xbrlishares">7910000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001200"
      unitRef="U_xbrlishares">7725000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0000921299_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231"
      decimals="-3"
      id="F_001201"
      unitRef="U_xbrlishares">4070000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0000921299_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191231"
      decimals="-3"
      id="F_001202"
      unitRef="U_xbrlishares">3337000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <fgen:CommonStockSharesReserved
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001203"
      unitRef="U_xbrlishares">114604000</fgen:CommonStockSharesReserved>
    <fgen:CommonStockSharesReserved
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001204"
      unitRef="U_xbrlishares">110220000</fgen:CommonStockSharesReserved>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFiveStockPlanMember_20200101_20201231"
      id="F_001205">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_fgenTwoThousandAndFiveStockPlanMember_20200101_20201231"
      id="F_001206">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20200101_20201231"
      id="F_001207">2024-11-12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_001209"
      unitRef="U_xbrlipure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20200101_20201231"
      id="F_001208">Option vesting schedules are determined by the Company at the time of issuance and generally have a four year vesting schedule (25% vesting on the first anniversary of the vesting base date and quarterly thereafter over the next 3 years).</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231"
      decimals="2"
      id="F_001210"
      unitRef="U_xbrlipure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20200101_20201231"
      id="F_001215">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20200101_20201231"
      id="F_001214">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20200101_20201231"
      id="F_001212">Shares reserved for issuance increases on January&#160;1 of each year commencing on January&#160;1, 2016 and ending on January&#160;1, 2024 by the lesser of (i)&#160;the amount equal to 4% of the number of shares issued and outstanding on December&#160;31 immediately prior to the date of increase or (ii)&#160;such lower number of shares as may be determined by the board of directors. As of December&#160;31, 2020, the Company has reserved 7,909,854 shares of its common stock that remains unissued for issuance under the 2014 Plan.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20140901_20140930"
      decimals="INF"
      id="F_001213"
      unitRef="U_xbrlipure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_001211"
      unitRef="U_xbrlishares">7909854</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_001216"
      unitRef="U_xbrlishares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20190101_20191231"
      decimals="INF"
      id="F_001217"
      unitRef="U_xbrlishares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000601">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock option transactions, including forfeited options granted under the 2014 Plan as well as prior plans, are summarized below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&#160;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26.63&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,692&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31.55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.73&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(73&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39.92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(234&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40.11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,290&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32.94&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001234"&gt;6.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86,013&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest, December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,929&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32.76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001235"&gt;6.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;84,125&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,576&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001236"&gt;5.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001218"
      unitRef="U_xbrlishares">10018000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0000921299_20191231"
      decimals="2"
      id="F_001226"
      unitRef="U_iso4217USD_xbrlishares">26.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001219"
      unitRef="U_xbrlishares">2692000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0000921299_20200101_20201231"
      decimals="2"
      id="F_001227"
      unitRef="U_iso4217USD_xbrlishares">31.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <fgen:StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001220"
      unitRef="U_xbrlishares">3113000</fgen:StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0000921299_20200101_20201231"
      decimals="2"
      id="F_001228"
      unitRef="U_iso4217USD_xbrlishares">10.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001221"
      unitRef="U_xbrlishares">73000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0000921299_20200101_20201231"
      decimals="2"
      id="F_001229"
      unitRef="U_iso4217USD_xbrlishares">39.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001222"
      unitRef="U_xbrlishares">234000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0000921299_20200101_20201231"
      decimals="2"
      id="F_001230"
      unitRef="U_iso4217USD_xbrlishares">40.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001223"
      unitRef="U_xbrlishares">9290000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0000921299_20201231"
      decimals="2"
      id="F_001231"
      unitRef="U_iso4217USD_xbrlishares">32.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001237"
      unitRef="U_iso4217USD">86013000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001224"
      unitRef="U_xbrlishares">8929000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_0000921299_20201231"
      decimals="2"
      id="F_001232"
      unitRef="U_iso4217USD_xbrlishares">32.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001238"
      unitRef="U_iso4217USD">84125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001225"
      unitRef="U_xbrlishares">5576000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0000921299_20201231"
      decimals="2"
      id="F_001233"
      unitRef="U_iso4217USD_xbrlishares">29.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001239"
      unitRef="U_iso4217USD">66943000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20201231"
      decimals="-5"
      id="F_001240"
      unitRef="U_iso4217USD">89600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20191231"
      decimals="-5"
      id="F_001241"
      unitRef="U_iso4217USD">59200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEquityIncentivePlanMember_20181231"
      decimals="-5"
      id="F_001242"
      unitRef="U_iso4217USD">97500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000602">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes RSU activity:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&#160;at&#160;Grant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49.05&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,354&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29.99&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(813&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45.55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(131&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.14%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,893&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.14%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231"
      decimals="-3"
      id="F_001243"
      unitRef="U_xbrlishares">1483000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231"
      decimals="2"
      id="F_001248"
      unitRef="U_iso4217USD_xbrlishares">49.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="-3"
      id="F_001244"
      unitRef="U_xbrlishares">1354000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="2"
      id="F_001249"
      unitRef="U_iso4217USD_xbrlishares">29.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="-3"
      id="F_001245"
      unitRef="U_xbrlishares">813000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="2"
      id="F_001250"
      unitRef="U_iso4217USD_xbrlishares">45.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="-3"
      id="F_001246"
      unitRef="U_xbrlishares">131000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="2"
      id="F_001251"
      unitRef="U_iso4217USD_xbrlishares">39.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231"
      decimals="-3"
      id="F_001247"
      unitRef="U_xbrlishares">1893000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231"
      decimals="2"
      id="F_001252"
      unitRef="U_iso4217USD_xbrlishares">37.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_0000921299_20200101_20201231"
      decimals="INF"
      id="F_001253"
      unitRef="U_xbrlishares">526055</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_20200101_20201231"
      decimals="2"
      id="F_001254"
      unitRef="U_iso4217USD_xbrlishares">29.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_20190101_20191231"
      decimals="2"
      id="F_001255"
      unitRef="U_iso4217USD_xbrlishares">54.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_20180101_20181231"
      decimals="2"
      id="F_001256"
      unitRef="U_iso4217USD_xbrlishares">53.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20140901_20140930"
      decimals="2"
      id="F_001257"
      unitRef="U_xbrlipure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20140901_20140930"
      decimals="2"
      id="F_001258"
      unitRef="U_xbrlipure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20200101_20201231"
      id="F_001260">The Company has reserved 1,600,000 shares of its common stock for issuance under the 2014 ESPP and shares reserved for issuance increases January&#160;1 of each year commencing January&#160;1, 2016 by the lesser of (i)&#160;a number of shares equal to 1% of the total number of outstanding shares of common stock on December&#160;31 immediately prior to the date of increase; (ii)&#160;1,200,000 shares or (iii)&#160;such number of shares as may be determined by the board of directors.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20140930"
      decimals="INF"
      id="F_001259"
      unitRef="U_xbrlishares">1600000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20140901_20140930"
      decimals="INF"
      id="F_001261"
      unitRef="U_xbrlipure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20140901_20140930"
      decimals="INF"
      id="F_001262"
      unitRef="U_xbrlishares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="INF"
      id="F_001263"
      unitRef="U_xbrlishares">143876</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20190101_20191231"
      decimals="INF"
      id="F_001264"
      unitRef="U_xbrlishares">135115</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20180101_20181231"
      decimals="INF"
      id="F_001265"
      unitRef="U_xbrlishares">230317</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000603">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense was recorded directly to research and development and selling, general and administrative expense for the years ended December&#160;31, 2020, 2019 and 2018 was as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.76%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,229&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,015&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,491&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,491&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,651&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,720&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66,267&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,142&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_001266"
      unitRef="U_iso4217USD">46229000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_001267"
      unitRef="U_iso4217USD">41015000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231"
      decimals="-3"
      id="F_001268"
      unitRef="U_iso4217USD">30491000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231"
      decimals="-3"
      id="F_001269"
      unitRef="U_iso4217USD">26491000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20190101_20191231"
      decimals="-3"
      id="F_001270"
      unitRef="U_iso4217USD">25252000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20180101_20181231"
      decimals="-3"
      id="F_001271"
      unitRef="U_iso4217USD">21651000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001272"
      unitRef="U_iso4217USD">72720000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_001273"
      unitRef="U_iso4217USD">66267000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_001274"
      unitRef="U_iso4217USD">52142000</us-gaap:AllocatedShareBasedCompensationExpense>
    <fgen:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000604">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions used to estimate the fair value of stock options granted and ESPPs using the Black-Scholes option valuation model were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001275"&gt;5.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001276"&gt;5.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001277"&gt;5.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average estimated fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31.98&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32.12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;ESPPs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001290"&gt;0.5 - 2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001291"&gt;0.5 - 2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001292"&gt;0.5 - 2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001296"&gt;47.5 - 77.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001297"&gt;48.1 - 62.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001298"&gt;47.3 - 75.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001302"&gt;0.1 - 2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001303"&gt;1.3 - 2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001304"&gt;0.8 - 2.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average estimated fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.27&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.27&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fgen:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="3"
      id="F_001278"
      unitRef="U_xbrlipure">0.671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="3"
      id="F_001279"
      unitRef="U_xbrlipure">0.680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="3"
      id="F_001280"
      unitRef="U_xbrlipure">0.679</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="3"
      id="F_001281"
      unitRef="U_xbrlipure">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="3"
      id="F_001282"
      unitRef="U_xbrlipure">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="3"
      id="F_001283"
      unitRef="U_xbrlipure">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="2"
      id="F_001284"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="2"
      id="F_001285"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="2"
      id="F_001286"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="2"
      id="F_001287"
      unitRef="U_iso4217USD_xbrlishares">18.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="2"
      id="F_001288"
      unitRef="U_iso4217USD_xbrlishares">31.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="2"
      id="F_001289"
      unitRef="U_iso4217USD_xbrlishares">32.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231"
      decimals="2"
      id="F_001308"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231"
      decimals="2"
      id="F_001309"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231"
      decimals="2"
      id="F_001310"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20200101_20201231"
      decimals="2"
      id="F_001311"
      unitRef="U_iso4217USD_xbrlishares">17.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20190101_20191231"
      decimals="2"
      id="F_001312"
      unitRef="U_iso4217USD_xbrlishares">19.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapStockCompensationPlanMember_20180101_20181231"
      decimals="2"
      id="F_001313"
      unitRef="U_iso4217USD_xbrlishares">16.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0000921299_us-gaapAwardTypeAxis_fgenStockOptionAwardsMember_20201231"
      decimals="-5"
      id="F_001314"
      unitRef="U_iso4217USD">63900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0000921299_us-gaapAwardTypeAxis_fgenStockOptionAwardsMember_20200101_20201231"
      id="F_001315">P2Y7M2D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231"
      decimals="-5"
      id="F_001316"
      unitRef="U_iso4217USD">55500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      id="F_001317">P2Y8M23D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <fgen:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod
      contextRef="C_0000921299_20190101_20191231"
      decimals="INF"
      id="F_001318"
      unitRef="U_xbrlishares">4430</fgen:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0000921299_20191231"
      decimals="INF"
      id="F_001320"
      unitRef="U_xbrlishares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0000921299_20201231"
      decimals="INF"
      id="F_001319"
      unitRef="U_xbrlishares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000534">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Net Loss Per Share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following weighted impacts of outstanding securities were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the three years presented (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,694&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,602&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,815&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;564&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,187&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;820&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ESPP&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;306&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;260&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,564&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,050&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,834&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000605">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following weighted impacts of outstanding securities were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the three years presented (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,694&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,602&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,815&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;564&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,187&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;820&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ESPP&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;306&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;260&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,564&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,050&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,834&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="-3"
      id="F_001321"
      unitRef="U_xbrlishares">6694000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="-3"
      id="F_001322"
      unitRef="U_xbrlishares">7602000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="-3"
      id="F_001323"
      unitRef="U_xbrlishares">7815000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="-3"
      id="F_001324"
      unitRef="U_xbrlishares">564000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20190101_20191231"
      decimals="-3"
      id="F_001325"
      unitRef="U_xbrlishares">1187000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20180101_20181231"
      decimals="-3"
      id="F_001326"
      unitRef="U_xbrlishares">820000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20200101_20201231"
      decimals="-3"
      id="F_001327"
      unitRef="U_xbrlishares">306000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20190101_20191231"
      decimals="-3"
      id="F_001328"
      unitRef="U_xbrlishares">260000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockMember_20180101_20181231"
      decimals="-3"
      id="F_001329"
      unitRef="U_xbrlishares">195000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20201231"
      decimals="-3"
      id="F_001330"
      unitRef="U_xbrlishares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20190101_20191231"
      decimals="-3"
      id="F_001331"
      unitRef="U_xbrlishares">1000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20180101_20181231"
      decimals="-3"
      id="F_001332"
      unitRef="U_xbrlishares">4000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001333"
      unitRef="U_xbrlishares">7564000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_001334"
      unitRef="U_xbrlishares">9050000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_001335"
      unitRef="U_xbrlishares">8834000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000535">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;FibroGen,&#160;Inc. 401(k) Plan&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Substantially all of the Company&#x2019;s full-time U.S.-based employees are eligible to make contributions to the Company&#x2019;s 401(k) Plan. Under this plan, participating employees may defer up to 60% of their pretax salary during the year, but not more than statutory limits. The Company may elect to match employee contributions. Matching contributions of $3.2 million, $3.0 million and $2.9 million were made during years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="C_0000921299_20200101_20201231"
      decimals="INF"
      id="F_001336"
      unitRef="U_xbrlipure">0.60</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_0000921299_20200101_20201231"
      decimals="-5"
      id="F_001337"
      unitRef="U_iso4217USD">3200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_0000921299_20190101_20191231"
      decimals="-5"
      id="F_001338"
      unitRef="U_iso4217USD">3000000.0</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_0000921299_20180101_20181231"
      decimals="-5"
      id="F_001339"
      unitRef="U_iso4217USD">2900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000536">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Income Taxes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of loss before income taxes are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(195,617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38,472&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,686&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(79,180&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(47,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss before provision for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(188,931&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(76,642&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(86,116&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The provision for income taxes consists of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;328&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;328&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total provision for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;328&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is the reconciliation between the statutory federal income tax rate and the Company&#x2019;s effective tax rate:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax at statutory federal rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State tax&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Benefit due to intercompany transfer of assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance on intercompany transfer of assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses not benefitted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign net operating losses not benefitted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deduction limitation on executive compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&#x2019;s deferred tax assets are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal and state net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;134,033&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,267&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62,465&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,417&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,786&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,399&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,698&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reserves and accruals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,875&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,550&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;284&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;342,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;222,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(337,824&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(213,847&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,073&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,073&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,073&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A valuation allowance has been provided to reduce the deferred tax assets to an amount management believes is more likely than not to be realized. Expected realization of the deferred tax assets for which a valuation allowance has not been recognized is based on upon the reversal of existing temporary differences and future taxable income.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The valuation allowance increased by $124.0 million, $19.9 million and $34.4 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Due to uncertainty surrounding the realization of the favorable tax attributes in the future tax returns, the Company has established a valuation allowance against its otherwise recognizable net deferred tax assets.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2020, the Company transferred certain intellectual property rights relating to its Chinese business between its wholly owned subsidiaries that are based in different tax jurisdictions. The transferor entity was not subject to income taxes in its local jurisdiction. The acquiring entity of the intellectual property is entitled to amortize the acquisition price of the intangible assets for tax purposes. In accordance with ASU 2016-16, &lt;span style="font-style:italic;"&gt;Intra-Entity Transfers of Assets Other Than Inventory&lt;/span&gt;, the Company recognized a deferred tax asset of $78.7 million for the temporary difference arising from the acquirer&#x2019;s excess tax basis. Furthermore, based upon the weight of available evidence, the Company recognized a full valuation allowance against this deferred tax asset since it does not currently believe that realization of this gross deductible temporary difference is more likely than not. Accordingly, this inter-company transfer did not have a material impact to the Company&#x2019;s consolidated financial statements.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&#160;31, 2020, the Company had net operating loss carryforwards available to offset future taxable income of approximately $606.8 million and $133.6 million for federal and state tax purposes, respectively. These carryforwards will begin to expire in 2026 for federal and 2021 for state purposes, if not utilized before these dates. The Company also had foreign net operating loss carryforwards of approximately $172.9 million which expire between 2021 and 2030 if not utilized.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&#160;31, 2020, the Company had approximately $66.9&#160;million of federal and $32.9&#160;million of California research and development tax credit and other tax credit carryforwards available to offset future taxable income. The federal credits begin to expire in 2021 and the California research credits have no expiration dates.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal and state tax laws impose substantial restrictions on the utilization of net operating loss and credit carryforwards in the event of an &#x201c;ownership change&#x201d; for tax purposes, as defined in IRC Section&#160;382. The Company reviewed its stock ownership for year ended December&#160;31, 2020 and concluded no ownership changes occurred which would result in a reduction of its net operating loss or in its research and development credits expiring unused. If additional ownership change occurs, the utilization of net operating loss and credit carryforwards could be significantly reduced.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Uncertain Tax Positions&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had unrecognized tax benefits of approximately $48.6 million as of December&#160;31, 2020. Approximately $0.5 million of unrecognized tax benefits, if recognized, would affect the effective tax rate. The interest accrued as of December&#160;31, 2020 and 2019 was immaterial.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the beginning and ending amounts of unrecognized income tax benefits during the three years ended December&#160;31, 2020 is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&#160;and&#160;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,361&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase due to prior positions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;379&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase due to current year position&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,216&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,956&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Decrease due to prior positions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(111&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase due to current year position&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,418&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,263&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Decrease due to prior positions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase due to current year position&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,448&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,574&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. The Company does not anticipate a material change to its unrecognized tax benefits over the next twelve months that would affect the Company&#x2019;s effective tax rate.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies interest and penalties as a component of tax expense, if any.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company files income tax returns in the U.S. federal jurisdiction, U.S. state and other foreign jurisdictions. The U.S. federal and U.S. state taxing authorities may choose to audit tax returns for tax years beyond the statute of limitation period due to significant tax attribute carryforwards from prior years, making adjustments only to carryforward attributes. The foreign statute of limitation generally remains open from 2011 to 2020. The Company is not currently under audit in any tax jurisdiction.&lt;/p&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
    <fgen:ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000606">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of loss before income taxes are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(195,617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38,472&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,686&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(79,180&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(47,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss before provision for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(188,931&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(76,642&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(86,116&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fgen:ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001340"
      unitRef="U_iso4217USD">-195617000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_001341"
      unitRef="U_iso4217USD">2538000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_001342"
      unitRef="U_iso4217USD">-38472000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001343"
      unitRef="U_iso4217USD">6686000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_001344"
      unitRef="U_iso4217USD">-79180000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_001345"
      unitRef="U_iso4217USD">-47644000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001346"
      unitRef="U_iso4217USD">-188931000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_001347"
      unitRef="U_iso4217USD">-76642000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_001348"
      unitRef="U_iso4217USD">-86116000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000607">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The provision for income taxes consists of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;328&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;328&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total provision for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;328&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001349"
      unitRef="U_iso4217USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_001350"
      unitRef="U_iso4217USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_001351"
      unitRef="U_iso4217USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001352"
      unitRef="U_iso4217USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_001353"
      unitRef="U_iso4217USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_001354"
      unitRef="U_iso4217USD">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001355"
      unitRef="U_iso4217USD">360000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_001356"
      unitRef="U_iso4217USD">328000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_001357"
      unitRef="U_iso4217USD">302000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001358"
      unitRef="U_iso4217USD">360000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_001359"
      unitRef="U_iso4217USD">328000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_001360"
      unitRef="U_iso4217USD">304000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001361"
      unitRef="U_iso4217USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_001362"
      unitRef="U_iso4217USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_001363"
      unitRef="U_iso4217USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001364"
      unitRef="U_iso4217USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_001365"
      unitRef="U_iso4217USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_001366"
      unitRef="U_iso4217USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001367"
      unitRef="U_iso4217USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_001368"
      unitRef="U_iso4217USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_001369"
      unitRef="U_iso4217USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001370"
      unitRef="U_iso4217USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_001371"
      unitRef="U_iso4217USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_001372"
      unitRef="U_iso4217USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001373"
      unitRef="U_iso4217USD">360000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_001374"
      unitRef="U_iso4217USD">328000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_001375"
      unitRef="U_iso4217USD">304000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000608">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following is the reconciliation between the statutory federal income tax rate and the Company&#x2019;s effective tax rate:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax at statutory federal rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State tax&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Benefit due to intercompany transfer of assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance on intercompany transfer of assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses not benefitted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign net operating losses not benefitted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deduction limitation on executive compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0000921299_20200101_20201231"
      decimals="3"
      id="F_001376"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0000921299_20190101_20191231"
      decimals="3"
      id="F_001377"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0000921299_20180101_20181231"
      decimals="3"
      id="F_001378"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0000921299_20200101_20201231"
      decimals="2"
      id="F_001379"
      unitRef="U_xbrlipure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0000921299_20190101_20191231"
      decimals="2"
      id="F_001380"
      unitRef="U_xbrlipure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0000921299_20180101_20181231"
      decimals="2"
      id="F_001381"
      unitRef="U_xbrlipure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <fgen:EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost
      contextRef="C_0000921299_20200101_20201231"
      decimals="3"
      id="F_001382"
      unitRef="U_xbrlipure">0.024</fgen:EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost>
    <fgen:EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost
      contextRef="C_0000921299_20190101_20191231"
      decimals="3"
      id="F_001383"
      unitRef="U_xbrlipure">0.063</fgen:EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost>
    <fgen:EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost
      contextRef="C_0000921299_20180101_20181231"
      decimals="3"
      id="F_001384"
      unitRef="U_xbrlipure">0.145</fgen:EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost>
    <fgen:EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets
      contextRef="C_0000921299_20200101_20201231"
      decimals="3"
      id="F_001385"
      unitRef="U_xbrlipure">0.417</fgen:EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets>
    <fgen:EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets
      contextRef="C_0000921299_20190101_20191231"
      decimals="2"
      id="F_001386"
      unitRef="U_xbrlipure">0</fgen:EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets>
    <fgen:EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets
      contextRef="C_0000921299_20180101_20181231"
      decimals="2"
      id="F_001387"
      unitRef="U_xbrlipure">0</fgen:EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets>
    <fgen:EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets
      contextRef="C_0000921299_20200101_20201231"
      decimals="3"
      id="F_001388"
      unitRef="U_xbrlipure">-0.417</fgen:EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets>
    <fgen:EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets
      contextRef="C_0000921299_20190101_20191231"
      decimals="2"
      id="F_001389"
      unitRef="U_xbrlipure">0</fgen:EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets>
    <fgen:EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets
      contextRef="C_0000921299_20180101_20181231"
      decimals="2"
      id="F_001390"
      unitRef="U_xbrlipure">0</fgen:EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets>
    <fgen:EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted
      contextRef="C_0000921299_20200101_20201231"
      decimals="3"
      id="F_001391"
      unitRef="U_xbrlipure">-0.232</fgen:EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted>
    <fgen:EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted
      contextRef="C_0000921299_20190101_20191231"
      decimals="3"
      id="F_001392"
      unitRef="U_xbrlipure">-0.029</fgen:EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted>
    <fgen:EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted
      contextRef="C_0000921299_20180101_20181231"
      decimals="3"
      id="F_001393"
      unitRef="U_xbrlipure">-0.232</fgen:EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_0000921299_20200101_20201231"
      decimals="3"
      id="F_001394"
      unitRef="U_xbrlipure">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_0000921299_20190101_20191231"
      decimals="3"
      id="F_001395"
      unitRef="U_xbrlipure">-0.217</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_0000921299_20180101_20181231"
      decimals="3"
      id="F_001396"
      unitRef="U_xbrlipure">-0.116</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="C_0000921299_20200101_20201231"
      decimals="3"
      id="F_001397"
      unitRef="U_xbrlipure">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="C_0000921299_20190101_20191231"
      decimals="3"
      id="F_001398"
      unitRef="U_xbrlipure">-0.025</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="C_0000921299_20180101_20181231"
      decimals="3"
      id="F_001399"
      unitRef="U_xbrlipure">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0000921299_20200101_20201231"
      decimals="3"
      id="F_001400"
      unitRef="U_xbrlipure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0000921299_20190101_20191231"
      decimals="3"
      id="F_001401"
      unitRef="U_xbrlipure">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0000921299_20180101_20181231"
      decimals="3"
      id="F_001402"
      unitRef="U_xbrlipure">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0000921299_20200101_20201231"
      decimals="3"
      id="F_001403"
      unitRef="U_xbrlipure">-0.002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0000921299_20190101_20191231"
      decimals="3"
      id="F_001404"
      unitRef="U_xbrlipure">-0.004</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0000921299_20180101_20181231"
      decimals="3"
      id="F_001405"
      unitRef="U_xbrlipure">-0.004</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000609">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&#x2019;s deferred tax assets are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal and state net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;134,033&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,267&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62,465&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,417&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,786&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,399&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,159&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,698&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reserves and accruals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,875&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,550&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;284&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;342,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;222,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(337,824&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(213,847&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,073&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,073&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,073&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001406"
      unitRef="U_iso4217USD">134033000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001407"
      unitRef="U_iso4217USD">91267000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001408"
      unitRef="U_iso4217USD">62465000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001409"
      unitRef="U_iso4217USD">52243000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001410"
      unitRef="U_iso4217USD">32417000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001411"
      unitRef="U_iso4217USD">37786000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001412"
      unitRef="U_iso4217USD">10399000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001413"
      unitRef="U_iso4217USD">11159000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001414"
      unitRef="U_iso4217USD">8243000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001415"
      unitRef="U_iso4217USD">10698000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001416"
      unitRef="U_iso4217USD">5875000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001417"
      unitRef="U_iso4217USD">5353000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001418"
      unitRef="U_iso4217USD">13550000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001419"
      unitRef="U_iso4217USD">13323000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <fgen:DeferredTaxAssetsIntangibleAssets
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001420"
      unitRef="U_iso4217USD">75915000</fgen:DeferredTaxAssetsIntangibleAssets>
    <fgen:DeferredTaxAssetsIntangibleAssets
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001421"
      unitRef="U_iso4217USD">0</fgen:DeferredTaxAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001422"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001423"
      unitRef="U_iso4217USD">284000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001424"
      unitRef="U_iso4217USD">342897000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001425"
      unitRef="U_iso4217USD">222113000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001426"
      unitRef="U_iso4217USD">337824000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001427"
      unitRef="U_iso4217USD">213847000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001428"
      unitRef="U_iso4217USD">5073000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001429"
      unitRef="U_iso4217USD">8266000</us-gaap:DeferredTaxAssetsNet>
    <fgen:DeferredTaxLiabilitiesFixedAssets
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001430"
      unitRef="U_iso4217USD">5073000</fgen:DeferredTaxLiabilitiesFixedAssets>
    <fgen:DeferredTaxLiabilitiesFixedAssets
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001431"
      unitRef="U_iso4217USD">8266000</fgen:DeferredTaxLiabilitiesFixedAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001432"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001433"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001434"
      unitRef="U_iso4217USD">5073000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001435"
      unitRef="U_iso4217USD">8266000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001436"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001437"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0000921299_20200101_20201231"
      decimals="-5"
      id="F_001438"
      unitRef="U_iso4217USD">124000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0000921299_20190101_20191231"
      decimals="-5"
      id="F_001439"
      unitRef="U_iso4217USD">19900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0000921299_20180101_20181231"
      decimals="-5"
      id="F_001440"
      unitRef="U_iso4217USD">34400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory
      contextRef="C_0000921299_20201231"
      decimals="-5"
      id="F_001441"
      unitRef="U_iso4217USD">78700000</us-gaap:DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_001442"
      unitRef="U_iso4217USD">606800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231"
      decimals="-5"
      id="F_001443"
      unitRef="U_iso4217USD">133600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <fgen:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"
      id="F_001444">2026</fgen:OperatingLossCarryforwardsExpirationYear>
    <fgen:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231"
      id="F_001445">2021</fgen:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20201231"
      decimals="-5"
      id="F_001446"
      unitRef="U_iso4217USD">172900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <fgen:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0000921299_srtRangeAxis_srtMinimumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20200101_20201231"
      id="F_001447">2021</fgen:OperatingLossCarryforwardsExpirationYear>
    <fgen:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0000921299_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20200101_20201231"
      id="F_001448">2030</fgen:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther
      contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_001449"
      unitRef="U_iso4217USD">66900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther
      contextRef="C_0000921299_srtStatementGeographicalAxis_stprCA_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231"
      decimals="-5"
      id="F_001450"
      unitRef="U_iso4217USD">32900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <fgen:OtherTaxCreditCarryforwardsExpirationYear
      contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"
      id="F_001451">2021</fgen:OtherTaxCreditCarryforwardsExpirationYear>
    <fgen:ExperienceHistoricalOwnershipChanges
      contextRef="C_0000921299_20200101_20201231"
      decimals="INF"
      id="F_001452"
      unitRef="U_xbrlipure">0</fgen:ExperienceHistoricalOwnershipChanges>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0000921299_20201231"
      decimals="-5"
      id="F_001453"
      unitRef="U_iso4217USD">48600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_0000921299_20201231"
      decimals="-5"
      id="F_001456"
      unitRef="U_iso4217USD">500000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000610">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the beginning and ending amounts of unrecognized income tax benefits during the three years ended December&#160;31, 2020 is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&#160;and&#160;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,361&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase due to prior positions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;379&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase due to current year position&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,216&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,956&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Decrease due to prior positions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(111&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase due to current year position&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,418&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,263&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Decrease due to prior positions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase due to current year position&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,448&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,574&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20171231"
      decimals="-3"
      id="F_001457"
      unitRef="U_iso4217USD">23361000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20180101_20181231"
      decimals="-3"
      id="F_001458"
      unitRef="U_iso4217USD">379000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20180101_20181231"
      decimals="-3"
      id="F_001459"
      unitRef="U_iso4217USD">4216000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20181231"
      decimals="-3"
      id="F_001460"
      unitRef="U_iso4217USD">27956000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20190101_20191231"
      decimals="-3"
      id="F_001461"
      unitRef="U_iso4217USD">111000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20190101_20191231"
      decimals="-3"
      id="F_001462"
      unitRef="U_iso4217USD">4418000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20191231"
      decimals="-3"
      id="F_001463"
      unitRef="U_iso4217USD">32263000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20200101_20201231"
      decimals="-3"
      id="F_001464"
      unitRef="U_iso4217USD">137000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20200101_20201231"
      decimals="-3"
      id="F_001465"
      unitRef="U_iso4217USD">16448000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20201231"
      decimals="-3"
      id="F_001466"
      unitRef="U_iso4217USD">48574000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible contextRef="C_0000921299_20200101_20201231" id="F_001467">The Company does not anticipate a material change to its unrecognized tax benefits over the next twelve months that would affect the Company&#x2019;s effective tax rate.</us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible>
    <us-gaap:OpenTaxYear
      contextRef="C_0000921299_us-gaapTaxPeriodAxis_us-gaapEarliestTaxYearMember_20200101_20201231"
      id="F_001468">2011</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="C_0000921299_us-gaapTaxPeriodAxis_us-gaapLatestTaxYearMember_20200101_20201231"
      id="F_001469">2020</us-gaap:OpenTaxYear>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000537">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Related Party Transactions&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas is an equity investor in the Company and considered a related party. During the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded license and development revenue related to collaboration agreements with Astellas of $33.5 million, $158.8 million, and $35.2 million, respectively. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December&#160;31, 2020, 2019 and 2018, the Company also recorded drug product revenue from Astellas of $4.3 million, $(36.3) million, and $64.8 million, respectively. The drug product revenue from Astellas for the year ended December 31, 2020 included $8.2 million under the Japan Agreement, and a $4.0 million reduction to revenue as a change in estimated variable consideration at the time an updated listed price for roxadustat was issued by the Japanese Ministry of Health, Labour and Welfare related to roxadustat API sales in 2018. The drug product revenue from Astellas for the year ended December 31, 2019 included a change in estimated variable consideration that resulted in a $36.3 million reduction to revenue related to the product revenue of $64.8 million for API recorded in 2018. See Note 4, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues&lt;/span&gt;, for details. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded expense related to collaboration agreements with Astellas of $0.5&#160;million, $2.8&#160;million and $1.5&#160;million, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020 and 2019, accounts receivable from Astellas were $4.1&#160;million and $4.8&#160;million, respectively. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020 and 2019, total deferred revenue from Astellas were $7.5&#160;million and $0.4&#160;million, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019, prepaid expenses and other current assets from Astellas was $125.2 million of net unbilled contract assets, representing a $130.0 million unbilled contract asset related to two regulatory milestones under the Europe Agreement with Astellas associated with the planned MAA submission to the EMA, net of $4.8 million of associated deferred revenue. According to the Europe Agreement, this $130.0 million is not billable to Astellas until the submission of an MAA, therefore the net contract asset was included in the prepaid expenses and other current assets line on the Company&#x2019;s consolidated balance sheet as of December 31, 2019. The $130.0 million was billed to Astellas upon the submission of an MAA in the second quarter of 2020. There was no such contract asset balance as of December 31, 2020. See Note 4, &lt;span style="font-style:italic;"&gt;Collaboration Agreements and Revenues&lt;/span&gt;, for details.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020 and 2019, amounts due to Astellas were $1.1&#160;million and $36.9&#160;million, respectively. The amounts due are included in accrued liabilities and accounts payable on the consolidated balance sheets. The amount as of December 31, 2019 included the above-mentioned $36.3 million of a change in estimated variable consideration related to the API product revenue recognized in 2018, which was fully paid during the first quarter of 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2020, FibroGen Beijing and AstraZeneca completed the establishment of a jointly owned entity, Falikang, which was determined to be an unconsolidated VIE. As such, Falikang is accounted for as an equity method investment, and considered as a related party to the Company. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s total investments in Falikang was &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;approximately $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.8&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million, &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;which is the total of the &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51.1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;% of Falikang&#x2019;s equity and the acquisition costs. In addition, &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the Company recognized its proportionate share of the reported profits or losses of Falikang, &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;b&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;eginning September 15, 2020, as other income (loss) in the consolidated statement of operations, and as an adjustment to its investment in unconsolidated subsidiary in the &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;condensed &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;consolidated balance sheet. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Falikang has not incurred material profit or loss to date. As of December 31, 2020, the &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Company&#x2019;s &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;equity method &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;investment in Falikang was $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.7&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, and&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; prepaid expenses and other current assets&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; included its miscellaneous receivables of $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.9&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million from Falikang. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;See Note 3, &lt;/span&gt;&lt;span style="font-style:italic;"&gt;Acquisition and Variable Interest Entity&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;,&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; for details&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenLicenseAndDevelopmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231"
      decimals="-5"
      id="F_001470"
      unitRef="U_iso4217USD">33500000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenLicenseAndDevelopmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231"
      decimals="-5"
      id="F_001471"
      unitRef="U_iso4217USD">158800000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_0000921299_srtProductOrServiceAxis_fgenLicenseAndDevelopmentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231"
      decimals="-5"
      id="F_001472"
      unitRef="U_iso4217USD">35200000</us-gaap:RevenueFromRelatedParties>
    <fgen:DrugProductRevenueFromRelatedParty
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20200101_20201231"
      decimals="-5"
      id="F_001473"
      unitRef="U_iso4217USD">4300000</fgen:DrugProductRevenueFromRelatedParty>
    <fgen:DrugProductRevenueFromRelatedParty
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20190101_20191231"
      decimals="-5"
      id="F_001474"
      unitRef="U_iso4217USD">-36300000</fgen:DrugProductRevenueFromRelatedParty>
    <fgen:DrugProductRevenueFromRelatedParty
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20180101_20181231"
      decimals="-5"
      id="F_001475"
      unitRef="U_iso4217USD">64800000</fgen:DrugProductRevenueFromRelatedParty>
    <fgen:DrugProductRevenueFromRelatedParty
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20200101_20201231"
      decimals="-5"
      id="F_001476"
      unitRef="U_iso4217USD">8200000</fgen:DrugProductRevenueFromRelatedParty>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_20200101_20201231"
      decimals="-5"
      id="F_001477"
      unitRef="U_iso4217USD">-4000000.0</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_20190101_20191231"
      decimals="-5"
      id="F_001478"
      unitRef="U_iso4217USD">-36300000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_20180101_20181231"
      decimals="-5"
      id="F_001479"
      unitRef="U_iso4217USD">64800000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231"
      decimals="-5"
      id="F_001480"
      unitRef="U_iso4217USD">500000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231"
      decimals="-5"
      id="F_001481"
      unitRef="U_iso4217USD">2800000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231"
      decimals="-5"
      id="F_001482"
      unitRef="U_iso4217USD">1500000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231"
      decimals="-5"
      id="F_001483"
      unitRef="U_iso4217USD">4100000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231"
      decimals="-5"
      id="F_001484"
      unitRef="U_iso4217USD">4800000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231"
      decimals="-5"
      id="F_001485"
      unitRef="U_iso4217USD">7500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231"
      decimals="-5"
      id="F_001486"
      unitRef="U_iso4217USD">400000</us-gaap:ContractWithCustomerLiability>
    <fgen:SuppliesNet
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20191231"
      decimals="-5"
      id="F_001489"
      unitRef="U_iso4217USD">125200000</fgen:SuppliesNet>
    <us-gaap:Supplies
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20191231"
      decimals="-5"
      id="F_001487"
      unitRef="U_iso4217USD">130000000.0</us-gaap:Supplies>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20191231"
      decimals="-5"
      id="F_001491"
      unitRef="U_iso4217USD">4800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Supplies
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20191231"
      decimals="-5"
      id="F_001488"
      unitRef="U_iso4217USD">130000000.0</us-gaap:Supplies>
    <us-gaap:Supplies
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20200630"
      decimals="-5"
      id="F_001492"
      unitRef="U_iso4217USD">130000000.0</us-gaap:Supplies>
    <fgen:SuppliesNet
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20201231"
      decimals="INF"
      id="F_001490"
      unitRef="U_iso4217USD">0</fgen:SuppliesNet>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20201231"
      decimals="-5"
      id="F_001493"
      unitRef="U_iso4217USD">1100000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20191231"
      decimals="-5"
      id="F_001494"
      unitRef="U_iso4217USD">36900000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_0000921299_us-gaapTransactionTypeAxis_fgenAPIShipmentMember_20190101_20191231"
      decimals="-5"
      id="F_001495"
      unitRef="U_iso4217USD">36300000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20200901_20200930"
      decimals="-5"
      id="F_001496"
      unitRef="U_iso4217USD">2800000</us-gaap:InvestmentIncomeNet>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20200901_20200930"
      decimals="3"
      id="F_001497"
      unitRef="U_xbrlipure">0.511</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20201231"
      decimals="-5"
      id="F_001498"
      unitRef="U_iso4217USD">2700000</us-gaap:EquityMethodInvestments>
    <fgen:MiscellaneousReceivables
      contextRef="C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenFalikangMember_20201231"
      decimals="-5"
      id="F_001499"
      unitRef="U_iso4217USD">900000</fgen:MiscellaneousReceivables>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000538">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:3.57%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Segment and Geographic Information&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has determined that the chief executive officer is the chief operating decision maker (&#x201c;CODM&#x201d;). The CODM reviews financial information presented for the Company&#x2019;s various clinical trial programs as well as results on a consolidated basis. License revenues and development revenues received are not allocated to various programs for purposes of determining a profit measure and resource allocation decisions are made by the CODM based primarily on consolidated results. As such, the Company has concluded that it operates as one segment. Supplemental enterprise-wide information has been presented below.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Geographic Revenues&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Geographic revenues, which are based on the bill-to region, are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Europe&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67,161&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;112,916&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Japan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,660&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;122,475&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,002&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,498&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;176,319&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;256,577&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;212,958&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Geographic Assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory by geographic location are as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,815&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,887&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,530&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,887&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net by geographic location are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,673&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,325&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,974&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,418&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,647&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,743&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease right-of-use assets and operating lease right-of-use assets, net by geographic location are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,237&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;365&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,602&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,856&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,043&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,931&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer Concentration&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s revenues to date have been generated from the following collaboration partners that respectively accounted for 10% or more of the Company&#x2019;s total revenue and accounts receivable:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.84%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Percentage&#160;of&#160;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Percentage&#160;of&#160;Accounts&#160;Receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas&#x2014;Related party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AstraZeneca&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company started selling roxadustat in China since late 2019 through a growing number of pharmaceutical distributors located in China. For the year ended December 31, 2020, the aggregate revenue from distributors represented 42% of the consolidated revenue, with no individual distributor representing over 10% of the total revenue. As of December 31, 2020, the aggregate accounts receivable from distributors represented 64% of the consolidated accounts receivable, with no material balance from any individual distributor. The aggregate revenue from distributors for the year ended December 31, 2019 and the aggregate accounts receivable from distributors as of December 31, 2019 were immaterial.&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0000921299_20200101_20201231"
      decimals="INF"
      id="F_001500"
      unitRef="U_fgenSegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000611">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Geographic revenues, which are based on the bill-to region, are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Europe&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67,161&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;112,916&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Japan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,660&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;122,475&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,002&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.68%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,498&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;176,319&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;256,577&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;212,958&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20200101_20201231"
      decimals="-3"
      id="F_001501"
      unitRef="U_iso4217USD">67161000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20190101_20191231"
      decimals="-3"
      id="F_001502"
      unitRef="U_iso4217USD">132400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0000921299_srtStatementGeographicalAxis_srtEuropeMember_20180101_20181231"
      decimals="-3"
      id="F_001503"
      unitRef="U_iso4217USD">112916000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_20200101_20201231"
      decimals="-3"
      id="F_001504"
      unitRef="U_iso4217USD">36660000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_20190101_20191231"
      decimals="-3"
      id="F_001505"
      unitRef="U_iso4217USD">122475000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryJP_20180101_20181231"
      decimals="-3"
      id="F_001506"
      unitRef="U_iso4217USD">100002000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20200101_20201231"
      decimals="-3"
      id="F_001507"
      unitRef="U_iso4217USD">72498000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20190101_20191231"
      decimals="-3"
      id="F_001508"
      unitRef="U_iso4217USD">1700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20180101_20181231"
      decimals="-3"
      id="F_001509"
      unitRef="U_iso4217USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenAllOtherMember_20200101_20201231"
      decimals="-3"
      id="F_001510"
      unitRef="U_iso4217USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenAllOtherMember_20190101_20191231"
      decimals="-3"
      id="F_001511"
      unitRef="U_iso4217USD">2000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0000921299_srtStatementGeographicalAxis_fgenAllOtherMember_20180101_20181231"
      decimals="-3"
      id="F_001512"
      unitRef="U_iso4217USD">40000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0000921299_20200101_20201231"
      decimals="-3"
      id="F_001513"
      unitRef="U_iso4217USD">176319000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0000921299_20190101_20191231"
      decimals="-3"
      id="F_001514"
      unitRef="U_iso4217USD">256577000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0000921299_20180101_20181231"
      decimals="-3"
      id="F_001515"
      unitRef="U_iso4217USD">212958000</us-gaap:Revenues>
    <fgen:InventoryByGeographicAreasTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000612">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory by geographic location are as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,815&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,887&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,530&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,887&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fgen:InventoryByGeographicAreasTableTextBlock>
    <us-gaap:InventoryNet
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryUS_20201231"
      decimals="-3"
      id="F_001516"
      unitRef="U_iso4217USD">4715000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryUS_20191231"
      decimals="-3"
      id="F_001517"
      unitRef="U_iso4217USD">0</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20201231"
      decimals="-3"
      id="F_001518"
      unitRef="U_iso4217USD">11815000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20191231"
      decimals="-3"
      id="F_001519"
      unitRef="U_iso4217USD">6887000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001520"
      unitRef="U_iso4217USD">16530000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001521"
      unitRef="U_iso4217USD">6887000</us-gaap:InventoryNet>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000613">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net by geographic location are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,673&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,325&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,974&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,418&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,647&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,743&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryUS_20201231"
      decimals="-3"
      id="F_001522"
      unitRef="U_iso4217USD">20673000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryUS_20191231"
      decimals="-3"
      id="F_001523"
      unitRef="U_iso4217USD">27325000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20201231"
      decimals="-3"
      id="F_001524"
      unitRef="U_iso4217USD">12974000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20191231"
      decimals="-3"
      id="F_001525"
      unitRef="U_iso4217USD">15418000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001526"
      unitRef="U_iso4217USD">33647000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001527"
      unitRef="U_iso4217USD">42743000</us-gaap:PropertyPlantAndEquipmentNet>
    <fgen:SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000614">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finance lease right-of-use assets and operating lease right-of-use assets, net by geographic location are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,237&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;365&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,602&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;China&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,856&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,043&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,931&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fgen:SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryUS_20201231"
      decimals="-3"
      id="F_001528"
      unitRef="U_iso4217USD">29551000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryUS_20191231"
      decimals="-3"
      id="F_001529"
      unitRef="U_iso4217USD">39237000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20201231"
      decimals="-3"
      id="F_001530"
      unitRef="U_iso4217USD">55000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20191231"
      decimals="-3"
      id="F_001531"
      unitRef="U_iso4217USD">365000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001532"
      unitRef="U_iso4217USD">29606000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001533"
      unitRef="U_iso4217USD">39602000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryUS_20201231"
      decimals="-3"
      id="F_001534"
      unitRef="U_iso4217USD">47000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryUS_20191231"
      decimals="-3"
      id="F_001535"
      unitRef="U_iso4217USD">75000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20201231"
      decimals="-3"
      id="F_001536"
      unitRef="U_iso4217USD">1996000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000921299_srtStatementGeographicalAxis_countryCN_20191231"
      decimals="-3"
      id="F_001537"
      unitRef="U_iso4217USD">1856000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000921299_20201231"
      decimals="-3"
      id="F_001538"
      unitRef="U_iso4217USD">2043000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000921299_20191231"
      decimals="-3"
      id="F_001539"
      unitRef="U_iso4217USD">1931000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000615">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s revenues to date have been generated from the following collaboration partners that respectively accounted for 10% or more of the Company&#x2019;s total revenue and accounts receivable:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.84%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Percentage&#160;of&#160;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Percentage&#160;of&#160;Accounts&#160;Receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas&#x2014;Related party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AstraZeneca&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="2"
      id="F_001540"
      unitRef="U_xbrlipure">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231"
      decimals="2"
      id="F_001541"
      unitRef="U_xbrlipure">0.48</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20180101_20181231"
      decimals="2"
      id="F_001542"
      unitRef="U_xbrlipure">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231"
      decimals="2"
      id="F_001543"
      unitRef="U_xbrlipure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20190101_20191231"
      decimals="2"
      id="F_001544"
      unitRef="U_xbrlipure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231"
      decimals="2"
      id="F_001545"
      unitRef="U_xbrlipure">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231"
      decimals="2"
      id="F_001546"
      unitRef="U_xbrlipure">0.52</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20180101_20181231"
      decimals="2"
      id="F_001547"
      unitRef="U_xbrlipure">0.53</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20200101_20201231"
      decimals="2"
      id="F_001548"
      unitRef="U_xbrlipure">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190101_20191231"
      decimals="2"
      id="F_001549"
      unitRef="U_xbrlipure">0.81</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="2"
      id="F_001550"
      unitRef="U_xbrlipure">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="2"
      id="F_001551"
      unitRef="U_xbrlipure">0.64</us-gaap:ConcentrationRiskPercentage1>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="C_0000921299_20200101_20201231" id="F_000539">
&lt;p id="SCHEDULE_II" style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Schedule II: Valuation and Qualifying Accounts&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Charged&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Charged&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;to Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&#160;at&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Credited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts -&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning&#160;of&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;to Statement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deductions,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance&#160;at&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.78%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Operation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and Equity&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;End&#160;of&#160;Year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowances for deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;213,847&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;123,977&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;337,824&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;193,987&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,860&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;213,847&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December&#160;31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;159,540&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,447&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;193,987&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allowances for rebates and discounts&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,102&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,497&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,867&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,184&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;548&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,102&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,102&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20191231"
      decimals="-3"
      id="F_001552"
      unitRef="U_iso4217USD">213847000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20200101_20201231"
      decimals="-3"
      id="F_001557"
      unitRef="U_iso4217USD">123977000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20200101_20201231"
      decimals="-3"
      id="F_001562"
      unitRef="U_iso4217USD">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20200101_20201231"
      decimals="-3"
      id="F_001567"
      unitRef="U_iso4217USD">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20201231"
      decimals="-3"
      id="F_001572"
      unitRef="U_iso4217USD">337824000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20181231"
      decimals="-3"
      id="F_001553"
      unitRef="U_iso4217USD">193987000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20190101_20191231"
      decimals="-3"
      id="F_001558"
      unitRef="U_iso4217USD">19860000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20190101_20191231"
      decimals="-3"
      id="F_001563"
      unitRef="U_iso4217USD">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20190101_20191231"
      decimals="-3"
      id="F_001568"
      unitRef="U_iso4217USD">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20191231"
      decimals="-3"
      id="F_001573"
      unitRef="U_iso4217USD">213847000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20171231"
      decimals="-3"
      id="F_001554"
      unitRef="U_iso4217USD">159540000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20180101_20181231"
      decimals="-3"
      id="F_001559"
      unitRef="U_iso4217USD">34447000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20180101_20181231"
      decimals="-3"
      id="F_001564"
      unitRef="U_iso4217USD">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20180101_20181231"
      decimals="-3"
      id="F_001569"
      unitRef="U_iso4217USD">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20181231"
      decimals="-3"
      id="F_001574"
      unitRef="U_iso4217USD">193987000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20191231"
      decimals="-3"
      id="F_001555"
      unitRef="U_iso4217USD">1102000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20200101_20201231"
      decimals="-3"
      id="F_001560"
      unitRef="U_iso4217USD">16497000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20200101_20201231"
      decimals="-3"
      id="F_001565"
      unitRef="U_iso4217USD">-14867000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20200101_20201231"
      decimals="-3"
      id="F_001570"
      unitRef="U_iso4217USD">2184000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20201231"
      decimals="-3"
      id="F_001575"
      unitRef="U_iso4217USD">548000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20181231"
      decimals="-3"
      id="F_001556"
      unitRef="U_iso4217USD">0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20190101_20191231"
      decimals="-3"
      id="F_001561"
      unitRef="U_iso4217USD">1102000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20190101_20191231"
      decimals="-3"
      id="F_001566"
      unitRef="U_iso4217USD">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20190101_20191231"
      decimals="-3"
      id="F_001571"
      unitRef="U_iso4217USD">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenValuationAllowanceForRebatesAndDiscountsMember_20191231"
      decimals="-3"
      id="F_001576"
      unitRef="U_iso4217USD">1102000</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650139656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FGEN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FIBROGEN, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000921299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0357827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">409 Illinois Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">978-1200&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,560,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,127.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.86%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Items 10, 11, 12, 13 and 14 of Part III of this Annual Report on Form 10-K incorporate information by reference from the definitive proxy statement for the registrant&#8217;s 2021 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than after 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090649932552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 678,393<span></span>
</td>
<td class="nump">$ 126,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">8,144<span></span>
</td>
<td class="nump">407,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net ($4,127 and $4,845 from a related party)</a></td>
<td class="nump">41,883<span></span>
</td>
<td class="nump">28,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">16,530<span></span>
</td>
<td class="nump">6,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets ($889 and $125,210 from related parties)</a></td>
<td class="nump">10,160<span></span>
</td>
<td class="nump">133,391<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">755,110<span></span>
</td>
<td class="nump">702,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_RestrictedTimeDepositsNoncurrent', window );">Restricted time deposits</a></td>
<td class="nump">2,072<span></span>
</td>
<td class="nump">2,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">61,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">33,647<span></span>
</td>
<td class="nump">42,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">29,606<span></span>
</td>
<td class="nump">39,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity', window );">Equity method investment in unconsolidated variable interest entity</a></td>
<td class="nump">2,728<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3,433<span></span>
</td>
<td class="nump">9,372<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">826,840<span></span>
</td>
<td class="nump">857,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable ($1,118 and $0 to a related party)</a></td>
<td class="nump">24,789<span></span>
</td>
<td class="nump">6,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other current liabilities ($24 and $36,883 to a related party)</a></td>
<td class="nump">119,521<span></span>
</td>
<td class="nump">83,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue ($2,907 and $249 to a related party)</a></td>
<td class="nump">6,547<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities, current</a></td>
<td class="nump">12,330<span></span>
</td>
<td class="nump">12,351<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">163,187<span></span>
</td>
<td class="nump">102,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedProductDevelopmentCosts', window );">Product development obligations</a></td>
<td class="nump">18,697<span></span>
</td>
<td class="nump">16,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current ($4,636 and $125 to a related party)</a></td>
<td class="nump">138,474<span></span>
</td>
<td class="nump">99,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, non-current</a></td>
<td class="nump">25,391<span></span>
</td>
<td class="nump">37,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">39,642<span></span>
</td>
<td class="nump">65,407<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">385,391<span></span>
</td>
<td class="nump">321,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at December 31, 2020 and 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 225,000 shares authorized at December 31, 2020 and 2019; 91,441 and 87,657 shares issued and outstanding at December 31, 2020 and 2019</a></td>
<td class="nump">914<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,399,774<span></span>
</td>
<td class="nump">1,300,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,499)<span></span>
</td>
<td class="num">(747)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(974,011)<span></span>
</td>
<td class="num">(784,720)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">422,178<span></span>
</td>
<td class="nump">516,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="nump">19,271<span></span>
</td>
<td class="nump">19,271<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">441,449<span></span>
</td>
<td class="nump">535,406<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, stockholders&#8217; equity and non-controlling interests</a></td>
<td class="nump">$ 826,840<span></span>
</td>
<td class="nump">$ 857,397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedProductDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the long-term portion of the outstanding principal and accrued interest of advances in the form note agreements received by the entity to fund various product development efforts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedProductDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment in unconsolidated variable interest entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_RestrictedTimeDepositsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted time deposits noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_RestrictedTimeDepositsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650491608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from related party</a></td>
<td class="nump">$ 4,127<span></span>
</td>
<td class="nump">$ 4,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Prepaid expenses and other current assets from related parties</a></td>
<td class="nump">889<span></span>
</td>
<td class="nump">125,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable to related party</a></td>
<td class="nump">1,118<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accrued and other current liabilities to related party</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">36,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DueToRelatedPartiesDeferredRevenueCurrent', window );">Deferred revenue current to related party</a></td>
<td class="nump">2,907<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DueToRelatedPartiesDeferredRevenueNoncurrent', window );">Deferred revenue non-current to related party</a></td>
<td class="nump">$ 4,636<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">225,000,000<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">91,441,000<span></span>
</td>
<td class="nump">87,657,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">91,441,000<span></span>
</td>
<td class="nump">87,657,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_DueToRelatedPartiesDeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Due to related parties deferred revenue current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_DueToRelatedPartiesDeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_DueToRelatedPartiesDeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Due to related parties deferred revenue noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_DueToRelatedPartiesDeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650877560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 176,319<span></span>
</td>
<td class="nump">$ 256,577<span></span>
</td>
<td class="nump">$ 212,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CostOfGoodsAndServicesSoldOperatingExpense', window );">Cost of goods sold</a></td>
<td class="nump">$ 8,869<span></span>
</td>
<td class="nump">$ 1,147<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList', window );">Cost, Product and Service [Extensible List]</a></td>
<td class="text">us-gaap:ProductMember<span></span>
</td>
<td class="text">us-gaap:ProductMember<span></span>
</td>
<td class="text">us-gaap:ProductMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 252,924<span></span>
</td>
<td class="nump">$ 209,265<span></span>
</td>
<td class="nump">$ 235,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">106,406<span></span>
</td>
<td class="nump">135,479<span></span>
</td>
<td class="nump">63,812<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">368,199<span></span>
</td>
<td class="nump">345,891<span></span>
</td>
<td class="nump">299,651<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(191,880)<span></span>
</td>
<td class="num">(89,314)<span></span>
</td>
<td class="num">(86,693)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_InterestAndOtherNetAbstract', window );"><strong>Interest and other, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,402)<span></span>
</td>
<td class="num">(2,876)<span></span>
</td>
<td class="num">(10,991)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_UnconsolidatedVariableInterestEntityInvestmentLoss', window );">Investment loss in unconsolidated variable interest entity</a></td>
<td class="num">(202)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income and other, net</a></td>
<td class="nump">5,553<span></span>
</td>
<td class="nump">15,548<span></span>
</td>
<td class="nump">11,568<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Total interest and other, net</a></td>
<td class="nump">2,949<span></span>
</td>
<td class="nump">12,672<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(188,931)<span></span>
</td>
<td class="num">(76,642)<span></span>
</td>
<td class="num">(86,116)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (189,291)<span></span>
</td>
<td class="num">$ (76,970)<span></span>
</td>
<td class="num">$ (86,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted</a></td>
<td class="num">$ (2.11)<span></span>
</td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="num">$ (1.03)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares used to calculate net loss per share - basic and diluted</a></td>
<td class="nump">89,854<span></span>
</td>
<td class="nump">86,633<span></span>
</td>
<td class="nump">84,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 14,323<span></span>
</td>
<td class="nump">$ 177,086<span></span>
</td>
<td class="nump">$ 22,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember', window );">Development and Other Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">80,592<span></span>
</td>
<td class="nump">114,115<span></span>
</td>
<td class="nump">125,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">72,498<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 8,906<span></span>
</td>
<td class="num">$ (36,324)<span></span>
</td>
<td class="nump">$ 64,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CostOfGoodsAndServicesSoldOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of goods and services sold operating expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CostOfGoodsAndServicesSoldOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_InterestAndOtherNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and other net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_InterestAndOtherNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_UnconsolidatedVariableInterestEntityInvestmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unconsolidated variable interest entity investment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_UnconsolidatedVariableInterestEntityInvestmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of cost from product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121551570&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfCostGoodOrServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090635958920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Parenthetical) - Astellas Agreement [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_LicenseFeesAndMilestonesRevenue', window );">License and milestone revenue from a related party</a></td>
<td class="nump">$ 14,323<span></span>
</td>
<td class="nump">$ 129,405<span></span>
</td>
<td class="nump">$ 14,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CollaborationServicesAndOtherRevenue', window );">Collaboration services and other revenue from a related party</a></td>
<td class="nump">19,174<span></span>
</td>
<td class="nump">29,393<span></span>
</td>
<td class="nump">20,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProductRevenue', window );">Product revenue from a related party</a></td>
<td class="nump">$ 4,281<span></span>
</td>
<td class="num">$ (36,324)<span></span>
</td>
<td class="nump">$ 64,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CollaborationServicesAndOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized from co-development services, manufacturing of clinical supplies, committee services and information services and other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CollaborationServicesAndOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_LicenseFeesAndMilestonesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue and the amount of consideration recognized during the period for milestones. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, non-specified, services during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_LicenseFeesAndMilestonesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ProductRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product revenue from a related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ProductRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650088328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (189,291)<span></span>
</td>
<td class="num">$ (76,970)<span></span>
</td>
<td class="num">$ (86,420)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments (Note 2)</a></td>
<td class="num">(3,207)<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Available-for-sale investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments, net of tax effect</a></td>
<td class="num">(545)<span></span>
</td>
<td class="nump">592<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(3,752)<span></span>
</td>
<td class="nump">923<span></span>
</td>
<td class="nump">764<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (193,043)<span></span>
</td>
<td class="num">$ (76,047)<span></span>
</td>
<td class="num">$ (85,656)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650078008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Cumulative Effect, Period of Adoption, Adjustment [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Cumulative Effect, Period of Adoption, Adjustment [Member]</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th">
<div>Accumulated Other Comprehensive Loss [Member] </div>
<div>Cumulative Effect, Period of Adoption, Adjustment [Member]</div>
</th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th">
<div>Accumulated Deficit [Member] </div>
<div>Cumulative Effect, Period of Adoption, Adjustment [Member]</div>
</th>
<th class="th"><div>Noncontrolling Interests [Member]</div></th>
<th class="th">
<div>Noncontrolling Interests [Member] </div>
<div>Cumulative Effect, Period of Adoption, Adjustment [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 547,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,160,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,795)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (630,657)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance (ASU 2016-01 [Member]) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,498,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(86,420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized gain or loss on investments</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustment to issuance costs for Follow-on Offerings</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid', window );">Shares issued from stock plans, net of payroll taxes paid</a></td>
<td class="nump">14,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares', window );">Shares issued from stock plans, net of payroll taxes paid, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,933,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">52,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">528,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(715,827)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance (ASU 2016-02 [Member]) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance (ASU 2018-02 [Member]) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (611)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,432,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(76,970)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,970)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized gain or loss on investments</a></td>
<td class="nump">592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid', window );">Shares issued from stock plans, net of payroll taxes paid</a></td>
<td class="nump">7,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares', window );">Shares issued from stock plans, net of payroll taxes paid, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,220,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_WarrantsExercisedDuringPeriodValue', window );">Warrants exercised</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_WarrantExercisedDuringPeriodShares', window );">Warrants exercised, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">66,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">535,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(747)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(784,720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,657,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(189,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(189,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized gain or loss on investments</a></td>
<td class="num">(545)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(545)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(3,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid', window );">Shares issued from stock plans, net of payroll taxes paid</a></td>
<td class="nump">26,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares', window );">Shares issued from stock plans, net of payroll taxes paid, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,783,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">72,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 441,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,399,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,499)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (974,011)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,440,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital shares issued from stock plans net of payroll taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued from stock plans net of payroll taxes paid shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_WarrantExercisedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant exercised during period shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_WarrantExercisedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_WarrantsExercisedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised during period value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_WarrantsExercisedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201802Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201802Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650759032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (189,291)<span></span>
</td>
<td class="num">$ (76,970)<span></span>
</td>
<td class="num">$ (86,420)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">11,678<span></span>
</td>
<td class="nump">11,147<span></span>
</td>
<td class="nump">6,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease right-of-use assets</a></td>
<td class="nump">10,369<span></span>
</td>
<td class="nump">10,307<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion of discount on investments</a></td>
<td class="nump">103<span></span>
</td>
<td class="num">(3,667)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_UnrealizedLossGainOnEquityInvestments', window );">Unrealized loss (gain) on equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_InvestmentLossInUnconsolidatedVariableInterestEntity', window );">Investment loss in unconsolidated variable interest entity</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss (gain) on disposal of property and equipment</a></td>
<td class="nump">933<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">72,720<span></span>
</td>
<td class="nump">66,267<span></span>
</td>
<td class="nump">52,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Realized foreign currency gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,074)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Realized loss (gain) on sales of available-for-sale securities</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net ($718, $42,365 and $(43,486) from a related party)</a></td>
<td class="num">(11,973)<span></span>
</td>
<td class="nump">35,229<span></span>
</td>
<td class="num">(55,232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(9,175)<span></span>
</td>
<td class="num">(6,887)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets ($124,321, $(125,210) and $0 from a related party)</a></td>
<td class="nump">123,492<span></span>
</td>
<td class="num">(128,598)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">6,843<span></span>
</td>
<td class="num">(3,253)<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable ($1,118, $0 and $0 from a related party)</a></td>
<td class="nump">17,731<span></span>
</td>
<td class="num">(3,051)<span></span>
</td>
<td class="nump">3,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other liabilities ($(36,859), $36,439 and $172 from a related party)</a></td>
<td class="nump">31,048<span></span>
</td>
<td class="nump">18,288<span></span>
</td>
<td class="nump">5,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue ($7,169, $(3,137) and $(3,908) from a related party)</a></td>
<td class="nump">45,077<span></span>
</td>
<td class="num">(49,941)<span></span>
</td>
<td class="num">(5,031)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_IncreaseDecreaseInLeaseObligations', window );">Lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities', window );">Accrued interest for finance lease liabilities</a></td>
<td class="num">(177)<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(28,236)<span></span>
</td>
<td class="nump">52,360<span></span>
</td>
<td class="nump">1,636<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">81,602<span></span>
</td>
<td class="num">(78,705)<span></span>
</td>
<td class="num">(76,144)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(3,994)<span></span>
</td>
<td class="num">(5,762)<span></span>
</td>
<td class="num">(8,020)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity', window );">Payment made for investment in unconsolidated variable interest entity</a></td>
<td class="num">(3,896)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity', window );">Proceeds from equity transfer of unconsolidated variable interest entity</a></td>
<td class="nump">1,063<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit', window );">Purchases of available-for-sale securities and term deposit</a></td>
<td class="num">(8,192)<span></span>
</td>
<td class="num">(411,299)<span></span>
</td>
<td class="num">(576,880)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities', window );">Proceeds from sales of available-for-sale securities</a></td>
<td class="nump">10,606<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities of investments</a></td>
<td class="nump">456,900<span></span>
</td>
<td class="nump">537,072<span></span>
</td>
<td class="nump">54,426<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">452,487<span></span>
</td>
<td class="nump">120,018<span></span>
</td>
<td class="num">(522,123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermCapitalLeaseObligations', window );">Borrowings under capital lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Repayments of capital lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_RepaymentsOfFinanceLeaseLiabilities', window );">Repayments of finance lease liabilities</a></td>
<td class="num">(12,620)<span></span>
</td>
<td class="num">(11,925)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Repayments of lease obligations</a></td>
<td class="num">(403)<span></span>
</td>
<td class="num">(403)<span></span>
</td>
<td class="num">(403)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Cash paid for payroll taxes on restricted stock unit releases</a></td>
<td class="num">(11,463)<span></span>
</td>
<td class="num">(12,750)<span></span>
</td>
<td class="num">(15,612)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">37,829<span></span>
</td>
<td class="nump">20,778<span></span>
</td>
<td class="nump">29,847<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">13,343<span></span>
</td>
<td class="num">(4,300)<span></span>
</td>
<td class="nump">13,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate change on cash and cash equivalents</a></td>
<td class="nump">4,695<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">552,127<span></span>
</td>
<td class="nump">37,008<span></span>
</td>
<td class="num">(584,400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash and cash equivalents at beginning of period</a></td>
<td class="nump">126,266<span></span>
</td>
<td class="nump">89,258<span></span>
</td>
<td class="nump">673,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash and cash equivalents at end of period</a></td>
<td class="nump">678,393<span></span>
</td>
<td class="nump">126,266<span></span>
</td>
<td class="nump">89,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest payments</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Balance in accounts payable and accrued liabilities related to purchases of property and equipment</a></td>
<td class="nump">884<span></span>
</td>
<td class="nump">460<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Deferred offering costs recorded in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accrued interest for finance lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_IncreaseDecreaseInLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_IncreaseDecreaseInLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_InvestmentLossInUnconsolidatedVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment loss in unconsolidated variable interest entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_InvestmentLossInUnconsolidatedVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment made for investment in unconsolidated variable interest entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to acquire available for sale securities and term deposit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from equity transfer of unconsolidated variable interest entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_RepaymentsOfFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments of finance lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_RepaymentsOfFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_UnrealizedLossGainOnEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized loss (gain) on equity investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_UnrealizedLossGainOnEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from proceeds received from lessor related to a long-term capital lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090644259432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement Of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Accounts receivable from related party</a></td>
<td class="nump">$ 718<span></span>
</td>
<td class="nump">$ 42,365<span></span>
</td>
<td class="num">$ (43,486)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties', window );">Prepaid expenses and other current assets from related party</a></td>
<td class="nump">124,321<span></span>
</td>
<td class="num">(125,210)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_IncreaseDecreaseInAccountsPayableFromRelatedParty', window );">Accounts payable from related party</a></td>
<td class="nump">1,118<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accrued and other liabilities from related party</a></td>
<td class="num">(36,859)<span></span>
</td>
<td class="nump">36,439<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue from related party</a></td>
<td class="nump">$ 7,169<span></span>
</td>
<td class="num">$ (3,137)<span></span>
</td>
<td class="num">$ (3,908)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_IncreaseDecreaseInAccountsPayableFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accounts payable from related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_IncreaseDecreaseInAccountsPayableFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in prepaid expenses and other current assets related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090642211800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">The Company</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</span></p></td>
<td valign="top">
<p id="NOTE_1_COMPANY" style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-weight:normal;color:#000000;"/><span style="color:#000000;">The Company</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc. (&#8220;FibroGen&#8221; or the &#8220;Company&#8221;) is headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#8217;s Republic of China (&#8220;China&#8221;). FibroGen is a leading biopharmaceutical company developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (&#8220;HIF&#8221;) biology, 2-oxoglutarate enzymology, connective tissue growth factor (&#8220;CTGF&#8221;) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat, FibroGen&#8217;s most advanced product, is an oral small molecule inhibitor of HIF prolyl hydroxylase&#160;&#160;activity that has received marketing authorization in China (tradename: &#29233;&#29790;&#21331;<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>) for the treatment of anemia caused by chronic kidney disease (&#8220;CKD&#8221;) in dialysis and non-dialysis patients. EVRENZO&#174; (roxadustat) is also approved in Japan and Chile for the treatment of anemia associated with CKD in dialysis and non-dialysis patients. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s New Drug Application (&#8220;NDA&#8221;) filing in the United States (&#8220;U.S.&#8221;) for roxadustat for the treatment of anemia in dialysis and non-dialysis CKD patients was submitted in December 2019 to the U.S. Food and Drug Administration (&#8220;FDA&#8221;). In December 2020, the FDA extended the review period of the NDA by three months for FibroGen to submit additional analyses of existing roxadustat clinical data, and set a new Prescription Drug User Fee Act goal date of March 20, 2021. On March 1, 2021, the FDA informed us that the Cardiovascular and Renal Drugs Advisory Committee will hold an advisory committee meeting to review the NDA for roxadustat. The date of the advisory committee meeting has not been set. As a result of this communication, we will not receive an approval decision by the PDUFA goal date. In Europe, the Marketing Authorization Application (&#8220;MAA&#8221;) filing for roxadustat for the treatment of anemia in dialysis and non-dialysis CKD patients was accepted for regulatory review by the European Medicines Agency (&#8220;EMA&#8221;) in May 2020 and Astellas expects an approval decision by the EMA mid-2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 3 development in China for anemia associated with myelodysplastic syndromes. Roxadustat is in Phase 2 clinical development for chemotherapy-induced anemia. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pamrevlumab, an anti-CTGF human monoclonal antibody, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis, locally advanced unresectable pancreatic cancer and Duchenne muscular dystrophy.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650029320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Summary of Significant Accounting Policies</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;). <span style="color:#000000;">The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and its majority-owned subsidiaries, FibroGen Europe and FibroGen China Anemia Holdings, Ltd. (&#8220;FibroGen Cayman&#8221;). All inter-company transactions and balances have been eliminated in consolidation. For any variable interest entity for which FibroGen is not the primary beneficiary, the Company uses the equity method of accounting.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one segment &#8212; the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Variable Interest Entity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Accounting Standards Codification (&#8220;ASC&#8221;) 810, <span style="font-style:italic;">Consolidation </span>(&#8220;ASC 810&#8221;), when the Company obtains an economic interest in an entity, it evaluates the entity to determine if it should be deemed a variable interest entity (&#8220;VIE&#8221;), and, if so, whether the Company is the primary beneficiary and is therefore required to consolidate the VIE, based on significant judgment whether the Company (i) has the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) has the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an ongoing basis, the Company re-evaluates </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the VIE assessment based on potential changes in facts and circumstances, including but not limited to, the shareholder loans to the entity and the execution of any future significant agreements between the entity and its shareholders and/or other third parties.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency Translation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reporting currency of the Company and its subsidiaries is the U.S. dollar. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of FibroGen Europe is the Euro. The assets and liabilities of FibroGen Europe are translated to U.S. dollars at exchange rates in effect at the balance sheet date. All income statement accounts are translated at monthly average exchange rates. Resulting foreign currency translation adjustments are recorded directly in accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to April 1, 2020, the functional currency of the Company&#8217;s subsidiary, FibroGen (China) Medical Technology Development Co., Ltd. (&#8220;FibroGen Beijing&#8221;), was the U.S. dollar. Accordingly, monetary assets and liabilities of FibroGen Beijing in the currencies other than U.S. dollar were remeasured using exchange rates in effect at the end of the period. Revenues and costs in its local currency, Renminbi Yuan (&#8220;CNY&#8221;), were remeasured using average exchange rates for the period, except for costs related to those balance sheet items that were remeasured using historical exchange rates. The resulting remeasurement gains and losses were included within interest income and other, net in the consolidated statements of operations as incurred. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 1, 2020, FibroGen Beijing adopted CNY as its functional currency based on reassessment of the primary economic operational environment of FibroGen Beijing that is mainly associated with its growing manufacturing and product sales activities conducted in CNY. As such, monetary assets and liabilities of FibroGen Beijing in currencies other than CNY are remeasured using exchange rates in effect at the end of the period. The assets and liabilities of FibroGen Beijing are translated to U.S. dollars at exchange rates in effect at the balance sheet date. All income statement accounts are translated at monthly average exchange rates. Resulting foreign currency translation adjustments are recorded directly in accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity. This change in FibroGen Beijing&#8217;s functional currency was accounted for prospectively from April 1, 2020, and the prior consolidated financial statements were not restated. The related currency translation adjustment was $1.3 million at April 1, 2020 upon adoption.<span style="font-size:12pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of FibroGen, Inc. and all other subsidiaries is the U.S. dollar. Accordingly, monetary assets and liabilities in the non-functional currency of these subsidiaries are remeasured using exchange rates in effect at the end of the period. Revenues and costs in local currency are remeasured using average exchange rates for the period, except for costs related to those balance sheet items that are remeasured using historical exchange rates. The resulting remeasurement gains and losses are included within interest income and other, net in the consolidated statements of operations as incurred and have not been material for all periods presented.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks associated with concentration of credit for cash and cash equivalents. Outside of short-term operating needs, the majority of cash on hand is invested in U.S. treasuries and money market funds. Any remaining cash is deposited with major financial institutions in the U.S., Finland, China and the Cayman Islands. At times, such deposits may be in excess of insured limits. The Company has not experienced any loss on its deposits of cash and cash equivalents. Included in current assets are significant balances of accounts receivable as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas Pharma Inc. (&#8220;Astellas&#8221;)&#8212;Related party</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca AB (&#8220;AstraZeneca&#8221;)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company started selling roxadustat in China since late 2019 through a growing number of pharmaceutical distributors located in China. As of December 31, 2019, the aggregate accounts receivable from distributors was immaterial. As of December 31, 2020, along with the growing roxadustat sales in China, the aggregate accounts receivable from distributors represented 64% of the consolidated accounts receivable, with no material balance from any individual distributor.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s business is subject to risks and uncertainties, including those related to COVID-19 and the related shelter-in-place, stay-at-home and other similar governmental orders issued in response to the COVID-19 pandemic.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, obtaining second source suppliers, <span style="font-size:9.5pt;">regulatory approval from the FDA or other regulatory authorities, </span>the results of clinical trials and the achievement of milestones, market acceptance of the Company&#8217;s product candidates, competition from other products and larger companies, protection of proprietary technology, strategic relationships and dependence on key individuals.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Starting in the first quarter of 2020, the Company experienced slower enrollment in its clinical trials due to the interruption caused by COVID-19 in the worldwide healthcare system. The future impact of the COVID-19 pandemic on the Company&#8217;s business is highly uncertain and difficult to predict. The COVID-19 pandemic may continue to affect enrollment in and initiation of the Company&#8217;s clinical trials, and could affect the Company&#8217;s supply chain if further social distancing and other business restrictions are put in place by various government entities, particularly in China and the U.S. COVID-19 may affect the health of the Company&#8217;s employees limiting the Company&#8217;s productivity. The COVID-19 pandemic may also impact the market for the Company&#8217;s products and product candidates in the future, affecting sales of the Company&#8217;s products. Such possible risks and uncertain impacts from the COVID-19 pandemic could have a material adverse effect on the Company&#8217;s drug development, commercialization revenues, and other portions of its business, and in particular, could impact the Company&#8217;s assumptions of accounts receivable collectability, fair value measurements of investments, liquidity, and development costs. The extent of the pandemic&#8217;s effect on the Company&#8217;s operational and financial performance will depend in large part on future developments, particularly with respect to the scope and severity of the pandemic, governmental restrictions put in place to fight the pandemic, and the development of vaccines and treatments for COVID-19. Due to the inherent uncertainty of the unprecedented and rapidly evolving situation, the Company is unable to estimate the likely impact of the COVID-19 pandemic on its future operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Restricted Time Deposits</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with maturities of three months or less and that are used in the Company&#8217;s cash management activities at the date of purchase to be cash equivalents. Cash and cash equivalents also include money market accounts and various deposit accounts. Restricted time deposits include an irrevocable standby letter of credit as security deposit for a long-term property lease with the Company&#8217;s landlord. Restricted time deposits as of December&#160;31, 2020 and 2019 totaled $2.1 million and $2.1&#160;million, respectively. As of December&#160;31, 2020 and 2019, a total of $66.0 million and $11.9 million, respectively, of the Company&#8217;s cash and cash equivalents was held outside of the U.S. in the Company&#8217;s foreign subsidiaries to be used primarily for the Company&#8217;s China operations.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company&#8217;s investments consist of diversified bond funds and marketable equity investments. Those investments with original maturities of greater than three months and remaining maturities of less than 12&#160;months (365 days) are considered short-term investments. Those investments with maturities greater than 12 months (365 days) from the balance sheet date are considered long-term investments. When such investments are held, the Company&#8217;s investments classified as available-for-sale are recorded at fair value based upon quoted market prices at period end. Unrealized gains and losses for available-for-sale debt investments that are deemed temporary in nature are recorded in accumulated other comprehensive income (loss) as a separate component of stockholder&#8217; equity. Marketable equity securities are equity securities with readily determinable fair value, and are measured and recorded at fair value. Realized and unrealized gains or losses resulting from changes in value and sale of the Company&#8217;s marketable equity investments are recorded in other income (expenses) in the consolidated statement of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Premiums and discounts are amortized (accreted) over the life of the related security as an adjustment to its yield. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of investments sold.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying amounts of certain of the Company&#8217;s financial instruments including cash equivalents, investments, receivables, accounts payable and accrued liabilities approximate fair value (refer to Note 5, <span style="font-style:italic;">Fair Value Measurements</span>).</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Trade accounts receivable</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The allowance for doubtful accounts is based on the Company&#8217;s assessment of the collectability of customer accounts. The Company makes estimates of expected credit losses for the allowance for doubtful accounts by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, current economic and regulatory conditions that may affect a customer&#8217;s ability to pay, and estimates of expected future losses. The Company&#8217;s bad debt expense for the years ended December&#160;31, 2020, 2019 and 2018 and the allowance for doubtful accounts as of December&#160;31, 2020 and 2019 were immaterial.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Credit losses &#8211; Available-for-sale debt securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company periodically assesses its available-for-sale investments for other-than-temporary impairment. For debt securities in an unrealized loss position, the Company first considers its intent to sell, or whether it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis. If either of these criteria are met, the amortized cost basis of such debt securities is written down to fair value through interest and other, net. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in the fair value of such debt securities has resulted from credit losses or other factors. The Company considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the securities, among other factors. If this assessment indicates that a credit loss may exist, the Company then compares the present value of cash flows expected to be collected from such securities to their amortized cost basis. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded through interest and other, net, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive income.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in the allowance for credit losses are recorded as provision for, or reversal of, credit loss expense. Losses are charged against the allowance when the Company believes that an available-for-sale security is confirmed uncollectable or when either of the criteria regarding intent or requirement to sell is met.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories are stated at the lower of cost or net realizable value, on a first-in, first-out, or FIFO, basis. The cost of the Company&#8217;s inventories in China is determined using full absorption and standard costing method. The Company reviews the standard cost of raw materials, work-in-process and finished goods annually and more often as appropriate to ensure that its inventories approximate current actual cost. The cost of the Company&#8217;s inventories in the U.S. uses actual costs to determine its cost basis. The cost of inventories includes direct material cost, direct labor and manufacturing overhead.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When the technical feasibility of the Company&#8217;s future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, the Company capitalizes pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the status in the validation process in significant jurisdictions, regulatory application and approval process, and terms and condition for future sale of such inventory or future alternative use. The pre-launch inventory cost includes purchase cost of raw materials, <span style="color:#000000;">cost paid to contract manufacturers for inventory manufacturing, freight and custom charges, and certain direct internal labor and overhead expenses.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company <span style="color:#auto;">periodically</span> reviews its inventories to identify obsolete, slow-moving, excess or otherwise unsaleable items. If obsolete, excess or unsaleable items are observed and there are no alternate uses for the <span style="color:#auto;">inventory</span>, an inventory valuation adjustment is recorded through a charge to cost of goods sold on the Company&#8217;s consolidated statements of operations. The establishment of inventory valuation reserves, together with the calculation of the amount of such reserves, requires judgment including consideration of many factors, such as estimates of future product demand and product expiration period, among others.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Computer equipment, laboratory equipment, machinery and furniture and fixtures are depreciated over three to five years. Leasehold improvements are recorded at cost and amortized over the term of the lease or their useful life, whichever is shorter.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is or contains a lease at inception date when it is given control of the underlying assets. The Company elected the practical expedient not to apply the lease recognition and measurement requirements to short-term leases, which is any lease with a term of 12 months or less as of the commencement date that does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s building leases previously accounted for as build-to-suit arrangements prior to the adoption of Accounting Standards Codification (&#8220;ASC&#8221;) 842 - <span style="font-style:italic;">Leases</span> (&#8220;ASC 842&#8221;) are accounted for as finance leases under the requirements of ASC 842.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease right-of-use (&#8220;ROU&#8221;) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As its leases do not typically provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company reassesses the incremental borrowing rate periodically for application to any new leases or lease modifications, which approximates the rate at which the Company would borrow, on a secured basis, in the country where the lease was executed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease ROU assets include any lease payments made and initial direct costs incurred. The Company has lease agreements with lease and non-lease components. The Company generally accounts for each lease component separately from the non-lease components, and excludes all non-lease components from the calculation of minimum lease payments in measuring the ROU asset and lease liability. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease terms. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regarding leases denominated in a foreign currency, the related ROU assets and the corresponding ROU asset amortization costs are remeasured using the exchange rate in effect at the date of initial recognition; the related lease liabilities are remeasured using the exchange rate in effect at the end of the reporting period; the lease costs and interest expenses related to lease liability accretion are remeasured using average exchange rates for the reporting period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases are included in finance lease ROU assets, finance lease liabilities, current and non-current on the Company&#8217;s consolidated balance sheets. Operating leases are included in other assets, accrued and other current liabilities, and other long-term liabilities on the Company&#8217;s consolidated balance sheets.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. If the Company determines that an impairment trigger has been met, the Company evaluates the realizability of its long-lived assets based on a comparison of projected undiscounted cash flows from use and eventual disposition with the carrying value of the related asset. Any write-downs (which are measured based on the difference between the fair value and the carrying value of the asset) are treated as permanent reductions in the carrying amount of the assets (asset group). Based on this evaluation, the Company believes that, as of each of the balance sheet dates presented, none of the Company&#8217;s long-lived assets were impaired. The Company&#8217;s impairment of long-lived assets for the years ended December&#160;31, 2020, 2019 and 2018 were immaterial.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenues under collaboration agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s collaboration agreements include multiple performance obligations comprised of promised services, or bundles of services, that are distinct. Services that are not distinct are combined with other services in the agreement until they form a distinct bundle of services. The Company&#8217;s process for identifying performance obligations and an enumeration of each obligation for each agreement is outlined in Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>. Determining the performance obligations within a collaboration agreement often involves significant judgment and is specific to the facts and circumstances contained in each agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified the following material promises under its collaboration agreements: (1) license of FibroGen technology, (2) the performance of co-development services, including manufacturing of clinical supplies and other services during the development period, and (3) manufacture of commercial supply. The evaluation as to whether these promises are distinct, and therefore represent separate performance obligations, is described in more details in Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For revenue recognition purposes, the Company determines that the term of its collaboration agreements begin on the effective date and ends upon the completion of all performance obligations contained in the agreements. In each agreement, the contract term is defined as the period in which parties to the contract have present and enforceable rights and obligations. The Company believes that the existence of what it considers to be substantive termination penalties on the part of the counterparty create sufficient incentive for the counterparty to avoid exercising its right to terminate the agreement unless in exceptionally rare situations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price for each collaboration agreement is determined based on the amount of consideration the Company expects to be entitled for satisfying all performance obligations within the agreement. The Company&#8217;s collaboration agreements include payments to the Company of one or more of the following: non-refundable upfront license fees; co-development billings; development, regulatory, and commercial milestone payments; payments from sales of active pharmaceutical ingredient (&#8220;API&#8221;); payments from sales of bulk drug product and royalties on net sales of licensed products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront license fees are non-contingent and non-refundable in nature and are included in the transaction price at the point when the license fees become due to the Company. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-development billings resulting from the Company&#8217;s research and development efforts, which are reimbursable under its collaboration agreements, are considered variable consideration. Determining the reimbursable amount of research and development efforts requires detailed analysis of the terms of the collaboration agreements and the nature of the research and development efforts incurred. Determining the amount of variable consideration from co-development billings requires the Company to make estimates of future research and development efforts, which involves significant judgment. Co-development billings are allocated entirely to the co-development services performance obligation when amounts are related specifically to research and development efforts necessary to satisfy the performance obligation, and such an allocation is consistent with the allocation objective.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone payments are also considered variable consideration, which requires the Company to make estimates of when achievement of a particular milestone becomes probable. Similar to other forms of variable consideration, milestone payments are included in the transaction price when it becomes probable that such inclusion would not result in a significant revenue reversal. Milestone payments are therefore included in the transaction price when achievement of the milestone becomes probable.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For arrangements that include sales-based royalties and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from its collaboration arrangements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is allocated to performance obligations based on their relative standalone selling price (&#8220;SSP&#8221;), with the exception of co-development billings allocated entirely to co-development services performance obligations. The SSP is determined based on observable prices at which the Company separately sells the products and services. If an SSP is not directly observable, then the Company will estimate the SSP considering marketing conditions, entity-specific factors, and information about the customer or class of customer that is reasonably available. The process for determining SSP involves significant judgment and includes consideration of multiple factors, including assumptions related to the market opportunity and the time needed to commercialize a product candidate pursuant to the relevant license, estimated direct expenses and other costs, which include the rates normally charged by contract research and contract manufacturing organizations for development and manufacturing obligations, and rates that would be charged by qualified outsiders for committee services.&#160;&#160; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant judgment may be required in determining whether a performance obligation is distinct, determining the amount of variable consideration to be included in the transaction price, and estimating the SSP of each performance obligation. An enumeration of the Company&#8217;s significant judgments is outlined in Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each performance obligation identified within an arrangement, the Company determines the period over which the promised services are transferred and the performance obligation is satisfied. Service revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. For each performance obligation satisfied over time, the Company assesses the proper method to be used for revenue recognition, either an input method to measure progress toward the satisfaction of services or an output method of determining the progress of completion of performance obligation.<span style="font-weight:bold;font-style:italic;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Drug product revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue includes commercial-grade API or bulk drug product sales to AstraZeneca and Astellas, and is recognized when the Company fulfills the shipment obligations. The drug product revenue is accounted for as variable consideration, estimated at the time of sale using the expected value method. The Company applies significant judgment in estimating the variable consideration, which involves the use of significant assumptions such as the future list price adjustments set by the Japanese Ministry of Health, Labour and Welfare, product mix, and timing of processing of API into bulk drug product.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, FibroGen and Astellas entered into an amendment to the Japan Agreement that allows Astellas to manufacture roxadustat drug product for commercialization in Japan (the &#8220;Japan Amendment&#8221;). Under this amendment, FibroGen would continue to manufacture and supply roxadustat API to Astellas for the roxadustat commercial launch in Japan. The drug product revenue represents variable consideration and is estimated based on the quantity of product shipped, actual listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and possible future changes to the listed price, adjusted for the timing of and estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk drug product tablets, and estimated yield from the manufacture of bulk product tablets, among others.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Europe Agreement with Astellas, Astellas has an option to purchase roxadustat bulk drug product in support of commercial supplies. The drug product revenue amount represents variable consideration and was estimated based on the quantity of product shipped and an estimated price. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price per strength, which is estimated to be realized by Astellas from the end sale of roxadustat in its approved territories.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, the Company entered into Commercial Supply Agreement under the U.S./RoW Agreement with AstraZeneca to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The drug product revenue amount represents variable consideration and was estimated based on the quantity of product shipped and an estimated price. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price per strength, which is estimated to be realized by AstraZeneca from the end sale of roxadustat in its approved territories.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of variable consideration that is included in the transaction price may be constrained, and is included in the drug product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. Estimating variable consideration and the related constraint requires the use of significant management judgment. The Company reviews new information that may affect its variable consideration estimate at every reporting period and record revenue adjustment, if certain and material. Actual amounts of consideration ultimately received in the future may differ from the Company&#8217;s estimates, for which the Company will adjust these estimates and affect the drug product revenue in the period such variances become known. The amount constrained as of December 31, 2020 was $6.0 million related to the drug product shipment to Astellas under the Europe Agreement in the fourth quarter of 2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As each of the Company&#8217;s collaboration agreements provide for annual true up to the considerations paid for its commercial supplies, the Company will re-evaluate the transaction price in each reporting period and record adjustment to revenue as uncertain events are resolved or other changes in circumstances occur.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product revenue, net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sells roxadustat in China through a number of pharmaceutical distributors located in China. These pharmaceutical distributors are the Company&#8217;s customers. Hospitals order roxadustat through a distributor and the Company ships the product directly to the distributors. The delivery of roxadustat to a distributor represents a single performance obligation.&#160;Distributors are responsible for delivering product to end users, primarily hospitals. Distributors bear inventory risk once they receive and accept the product. Product revenue is recognized when control of the promised good is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for the product. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The period between the transfer of control of the promised goods and when the Company receives payment is based on a general 60-day payment term. As such, product revenue is not adjusted for the effects of a significant financing component. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue is recorded at the net sales prices (transaction price) which includes the following estimates of variable consideration:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Price adjustment:</span><span style="color:#000000;"> In December 2019, China&#8217;s National Healthcare Security Administration released price guidance for roxadustat under the National Reimbursement Drug List (&#8220;NRDL&#8221;), effective January 1, 2020. Any channel inventories as of January 1, 2020 that had not been sold to hospitals by distributors, or to patients by hospitals, were eligible for a price adjustment under the price protection. The price adjustment is calculated based on estimated channel inventory levels at January 1, 2020. If price guidance changes in the future, the price adjustment will be calculated in the same manner;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Contractual sales rebate</span><span style="color:#000000;">: The contractual sales rebate is calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. The contractual sales rebate is recorded as a reduction to revenue at the point of sale to the distributor;&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Key account hospital sales rebate</span><span style="color:#000000;">: An additional sales rebate is provided to a distributor for product sold to key account hospitals as a percentage of gross sales made by the distributor to eligible hospitals. This additional rebate is recorded as a reduction to revenue at the point of sale to the distributor; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Transfer fee discount</span><span style="color:#000000;">: The transfer fee discount is offered to a distributor who has its downstream distributors supply to eligible hospitals. This discount is calculated based on a percentage of gross sales made to the downstream distributors, and recorded as a reduction to revenue as incurred; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Sales return</span><span style="color:#000000;">: Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product&#8217;s expiration date; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Non-key account hospital listing award: </span><span style="color:#000000;">A one-time fixed-amount award is offered to a distributor who successfully lists the product with an eligible hospital, and who meets certain requirements. The Company considers this particular award to be an upfront payment to a customer within the definitions of ASC 606. The non-key account hospital listing award is capitalized when the distributor meets eligibility requirements, and amortized as reduction to product revenue over future sales orders made by the distributor until exhausted. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The calculation of the above variable consideration is based on gross sales to the distributor, or estimated utilizing best available information from the distributor, maximum known exposures and other available information including estimated channel inventory levels and estimated sales made by the distributor to hospitals, which involve a substantial degree of judgment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above rebates and discounts all together are eligible to be applied against the distributor&#8217;s future sales order, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible and in the same period that the related revenue is recorded. Due to the distributor&#8217;s legal right to offset, at each balance sheet date, the liability for rebates and discounts are presented as reductions of gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The distributor&#8217;s legal right of offset is calculated at the individual distributor level.<span style="font-weight:bold;color:#FF0000;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of independent research and development costs and the gross amount of costs associated with work performed under collaboration agreements. Research and development costs include employee-related expenses, expenses incurred under agreements with clinical research organizations, other clinical and preclinical costs and allocated direct and indirect overhead costs, such as facilities costs, information technology costs and other overhead. All research and development costs are expensed as incurred.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trial Accruals</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with clinical research organizations and clinical sites. The Company determines the costs to be recorded based upon validation with the external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Selling, General and Administrative Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses consist primarily of employee-related expenses for executive, operational, finance, legal, compliance and human resource functions. SG&amp;A expenses also include facility-related costs, professional fees, accounting and legal services, other outside services including co-promotional expenses, recruiting fees and expenses associated with obtaining and maintaining patents.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes the asset and liability method of accounting for income taxes, which requires the recognition of deferred tax assets and liabilities for expected future consequences of temporary differences between the financial reporting and income tax bases of assets and liabilities using enacted tax rates. Management makes estimates, assumptions and judgments to determine the Company&#8217;s provision for income taxes and for deferred tax assets and liabilities, and any valuation allowances recorded against the Company&#8217;s deferred tax assets. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The calculation of the Company&#8217;s current provision for income taxes involves the use of estimates, assumptions and judgments while taking into account current tax laws, interpretation of current tax laws and possible outcomes of future tax audits. The Company has established reserves to address potential exposures related to tax positions that could be challenged by tax authorities. Although the Company believes its estimates, assumptions and judgments to be reasonable, any changes in tax law or its interpretation of tax laws and the resolutions of potential tax audits could significantly impact the amounts provided for income taxes in the Company&#8217;s consolidated financial statements.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The calculation of the Company&#8217;s deferred tax asset balance involves the use of estimates, assumptions and judgments while taking into account estimates of the amounts and type of future taxable income. Actual future operating results and the underlying amount and type of income could differ materially from the Company&#8217;s estimates, assumptions and judgments thereby impacting the Company&#8217;s financial position and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, the Company transferred certain intellectual property rights relating to its Chinese business between its wholly owned subsidiaries that are based in different tax jurisdictions. Refer to Note 13, <span style="font-style:italic;">Income Taxes</span>, for more information. The establishment of a deferred tax asset from the intra-entity transfer of intangible assets required the Company to make significant estimates and assumptions to determine the fair value of intellectual property rights transferred, which include but are not limited to, its expectations of discount rate, revenue volume and price.<span style="Background-color:#F8F9FA;color:#202124;"> The accuracy of these estimates could be affected by unforeseen events or actual results, and the sustainability of the Company&#8217;s future tax benefits is dependent upon the acceptance of these valuation estimates and assumptions by the taxing authorities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has adopted ASC 740-10, <span style="font-style:italic;">Accounting for Uncertainty in Income Taxes</span>, that prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company&#8217;s income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company includes interest and penalties related to unrecognized tax benefits within income tax expense in the Consolidated Statements of Operations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains equity incentive plans under which incentive and nonqualified stock options are granted to employees and non-employee consultants. Compensation expense relating to non-employee stock options has not been material for all the periods presented.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures and recognizes compensation expense for all stock options and restricted stock units (&#8220;RSUs&#8221;) granted to its employees and directors based on the estimated fair value of the award on the grant date. The Company uses the Black-Scholes valuation model to estimate the fair value of stock option awards. The fair value is recognized as expense, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis. The Company believes that the fair value of stock options granted to non-employees is more reliably measured than the fair value of the services received. The determination of the grant date fair value of options using an option pricing model is affected by the Company&#8217;s estimated Common Stock fair value and requires management to make a number of assumptions including the expected life of the option, the volatility of the underlying stock, the risk-free interest rate and expected dividends.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Income (Loss)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to report all components of comprehensive income (loss), including net loss, in the consolidated financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation adjustments. Comprehensive gains (losses) have been reflected in the consolidated statements of comprehensive income (loss) for all periods presented.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued and Adopted Accounting Guidance</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-15, <span style="font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. </span>This guidance requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This guidance was effective for annual reporting periods beginning after December 15, 2019, including interim periods. The Company adopted this guidance on January 1, 2020 using the prospective method, and the adoption of this guidance did not have material impact to the Company&#8217;s consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span>(&#8220;ASU 2016-13&#8221;). This guidance is intended to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. This guidance requires the measurement of financial assets with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. This guidance requires an impairment model, known as the current expected credit loss model, which is based on expected losses rather than incurred losses. Entities are required to carry an allowance for expected credit losses for financial assets, including most debt instruments (except those carried at fair value) and trade receivables. In November 2019, the FASB issued ASU No. 2019-11, <span style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments-Credit Losses </span>(&#8220;ASU 2019-11&#8221;)<span style="font-style:italic;">, </span>which has the same effective dates and transition requirements as ASU 2016-13. ASU 2016-13 and ASU 2019-11 were effective for annual reporting periods beginning after December 15, 2019 including interim periods. The Company&#8217;s investment portfolio primarily consists of U.S. Treasury bills and notes carried at fair value, which is required to follow the impairment model under Topic 326. The Company adopted this guidance on January 1, 2020. Based on the composition of the Company&#8217;s trade receivables and investment portfolio, economic conditions and historical credit loss activity, the adoption of this guidance did not have material impact to the Company&#8217;s consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02, <span style="font-style:italic;">Leases (Topic 842). </span>The Company adopted the lease guidance under ASC 842 as of January 1, 2019, using the modified retrospective transition method, through a cumulative-effect adjustment. The adoption of this guidance resulted in a reduction of $8.7 million to the Company&#8217;s accumulated deficit and also impacted various balance sheet line items in its consolidated balance sheet as of January 1, 2019 upon adoption. The adoption of this guidance did not have a material impact to the Company&#8217;s consolidated statement of operations or consolidated statement of cash flows for the year ended December 31, 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, the FASB issued ASU 2018-02, <span style="font-style:italic;">Income Statement - Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</span>. The Company adopted this guidance on January 1, 2019 using the modified retrospective approach, with a reduction of $0.6 million to its accumulated other comprehensive loss and an increase of $0.6 million to its accumulated deficit as of January 1, 2019 upon adoption. The adoption of this guidance had no impact to the Company&#8217;s consolidated statement of operations or consolidated statement of cash flows for the year ended December 31, 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2016, the FASB issued ASU 2016-01, <span style="font-style:italic;">Financial Instruments-Overall (Subtopic 825-10)</span>. The Company adopted this guidance as of January 1, 2018 using the modified retrospective approach, with an increase of $1.3 million to its accumulated other comprehensive loss and a reduction of $1.3 million to its accumulated deficit as of January 1, 2018 upon adoption. The adoption of this guidance had no impact to the Company&#8217;s consolidated statement of cash flows for the year ended December 31, 2018. </p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Guidance Not Yet Adopted</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the FASB issued ASU 2020-04, <span style="font-style:italic;">Reference Rate Reform (Topic 848): </span><span style="font-style:italic;color:#000000;">Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span> (&#8220;ASU<span style="font-style:italic;"> </span>2020<span style="font-style:italic;">-</span>04<span style="font-style:italic;">&#8221;</span>)<span style="font-style:italic;">,</span> which provides companies with optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform. This guidance is effective as of March 12, 2020 through December 31, 2022. Subsequently in January 2021, the FASB issued ASU 2021-01, <span style="font-style:italic;">Reference Rate Reform (Topic 848): Scope</span>, which clarifies ASU 2020-04 and provides certain optional expedients that allow derivative instruments impacted by changes in the interest rate used for margining, discounting or contract price alignment to qualify for certain optional relief. ASU 2021-01 is effective in the same timeframe as ASU 2020-04. The relief offered by this guidance, if adopted, is available to companies for the period March 12, 2020 through December 31, 2022. <span style="Background-color:#FFFFFF;">The Company has certain lease arrangements that are linked to LIBOR. The Company is in the process of evaluating options for transitioning away from LIBOR and expects to complete by the time LIBOR is phased out. The Company did not elect to apply any of the expedients or exceptions as of and for the year ended December 31, 2020 and is currently evaluating the impact on its consolidated financial statements and related disclosures upon adoption of this guidance.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span>. This guidance simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step up in the tax basis of goodwill, and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. This guidance is effective for annual reporting periods beginning after December 15, 2020 including interim periods, with early adoption permitted. The Company does not plan to early adopt this guidance and does not anticipate a material impact to its consolidated financial statements upon adoption of this guidance.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650357464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition and Variable Interest Entity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AcquisitionAndVariableInterestEntityAbstract', window );"><strong>Acquisition And Variable Interest Entity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AcquisitionAndVariableInterestEntityTextBlock', window );">Acquisition and Variable Interest Entity</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Acquisition and Variable Interest Entity</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 8, 2020, FibroGen Cayman, FibroGen Beijing, and FibroGen International (Hong Kong) Limited (collectively, &#8220;FibroGen China&#8221;) and AstraZeneca entered into an amendment, effective July 1, 2020, to the collaboration agreement for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in China (&#8220;China Agreement&#8221;), relating to the development and commercialization of roxadustat in China (the &#8220;China Amendment&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The China Amendment provides for the establishment of a jointly owned entity that will perform roxadustat distribution, as well as conduct sales and marketing through AstraZeneca. To prepare for the establishment of this jointly owned entity, in July 2020, FibroGen Beijing acquired 100% of the outstanding shares of Beijing Kangda Yongfu Pharmaceutical Co., LTD (&#8220;Kangda&#8221;) in exchange for cash consideration of CNY15.0 million (approximately $2.1 million). The purpose of the acquisition was to acquire a distribution license owned by Kangda for commercializing and distributing roxadustat in China. FibroGen Beijing continues to hold all of the regulatory licenses issued by China regulatory authorities and continues to be primarily responsible for regulatory, clinical, manufacturing, medical affairs and pharmacovigilance. The transaction costs related to the execution of the acquisition, primarily legal expenses, totaled CNY5.0 million and were shared equally with AstraZeneca. Therefore, the acquisition costs for FibroGen Beijing were CNY2.5 million (approximately $0.4 million).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the ASU No. 2017-01, <span style="font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</span>, the Company determined that the all of the value of Kangda was attributable to the acquired license, and therefore the transaction was accounted for as an asset acquisition. The Company allocated the entire purchase price of $2.5 million to the acquired license that was recorded as an intangible asset, to be amortized over the duration of expected sales of roxadustat. There was no excess consideration over the estimated fair value. Through September 15, 2020, Kangda was consolidated as a wholly owned subsidiary of the Company. The amortization of the license was immaterial during the short period of time before Kangda was deconsolidated upon the establishment of the jointly owned entity described below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 15, 2020, FibroGen Beijing and AstraZeneca entered into an equity transfer agreement and shareholders agreement, under which FibroGen Beijing sold 48.9% of the outstanding shares of Kangda to AstraZeneca in exchange for cash consideration of CNY7.3 million (approximately $1.0 million). Concurrently with the equity transfer, the two parties renamed Kangda to Beijing Falikang Pharmaceutical Co. Ltd. (&#8220;Falikang&#8221;). Following the sale, FibroGen Beijing owns 51.1% of the outstanding shares of Falikang. The gain (loss) resulting from the equity transfer was immaterial.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, based on the shareholders&#8217; resolutions of Falikang, in December 2020, FibroGen Beijing made cash contribution of CNY8.9 million (approximately $1.4 million) to Falikang, representing 51.1% of Falikang&#8217;s registered capital of CNY17.5 million. AstraZeneca completed its cash contribution of 48.9% of Falikang&#8217;s registered capital in December 2020 as well.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the guidance under ASC 810, the Company concluded that Falikang qualifies as a VIE. As Falikang is a distribution entity for roxadustat and AstraZeneca is the final decision maker for all the roxadustat commercialization activities, the Company lacks the power criterion while AstraZeneca meets both the power and economic criteria under ASC 810, to direct the activities of Falikang that most significantly impact its performance. Therefore, the Company is not the primary beneficiary of this VIE. As a result, the Company accounted for its investment in Falikang under the equity method, and Falikang is not consolidated into the Company&#8217;s consolidated financial statements. Accordingly, The Company recorded its total investments in Falikang of CNY19.2 million (approximately $2.8 million), which is the total of the 51.1% of Falikang&#8217;s equity and the acquisition costs, as an investment in unconsolidated subsidiary in other assets in the consolidated balance sheet. In addition, the Company recognized its proportionate share of the reported profits or losses of Falikang, beginning September 15, 2020, as other income (loss) in the consolidated statement of operations, and as an adjustment to its investment in unconsolidated subsidiary in the consolidated balance sheet. Falikang has not incurred material profit or loss to date. The Company may be required to provide shareholder loans to Falikang to meet necessary financial obligations as part of its operations. To date, these loans have been immaterial. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s&#160;equity&#160;method&#160;investment&#160;in Falikang was as follows for the year ended December 31, 2020 (in thousands):</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Entity</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership Percentage</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share of Net Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Currency</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Translation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,825</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(202</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,728</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang is considered as a related party to the Company. See Note 14, <span style="font-style:italic;">Related Party Transactions</span>, for related disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an ongoing basis, the Company will re-evaluate the VIE assessment based on changes in facts and circumstances, including but not limited to, the shareholder loans received by Falikang and the execution of any future significant agreements between Falikang and its shareholders and/or other third parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will assess the impairment of its equity method&#160;investment whenever events or changes in circumstances indicate that a decrease in value of the investment has occurred that is other than temporary.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AcquisitionAndVariableInterestEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition and variable interest entity abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AcquisitionAndVariableInterestEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AcquisitionAndVariableInterestEntityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition and variable interest entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AcquisitionAndVariableInterestEntityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090649880200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock', window );">Collaboration Agreements and Revenues</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaboration Agreements and Revenues</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Astellas Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Japan Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2005, the Company entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (&#8220;Japan Agreement&#8221;). Under this agreement, Astellas paid license fees and other consideration totaling $40.1&#160;million (such amounts were fully received as of February 2009). Under the Japan Agreement, the Company is also eligible to receive from Astellas an aggregate of approximately $132.5&#160;million in potential milestone payments, comprised of (i)&#160;up to $22.5&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of July 2016), (ii)&#160;up to $95.0&#160;million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $15.0&#160;million in milestone payments upon the achievement of specified commercial sales milestone. The Japan Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range of the list price published by the Japanese Ministry of Health, Labour and Welfare, adjusted for certain elements, after commercial launch. The aggregate amount of the considerations received under the Japan Agreement, through December&#160;31, 2020 totals $105.1 million, excluding drug product revenue that is discussed separately below.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fourth quarter of 2020, the Japanese Ministry of Health, Labour and Welfare approved EVRENZO&#174; (roxadustat) for the treatment of anemia of CKD in adult patients not on dialysis. This approval triggered a $15.0 million milestone payable to the Company by Astellas under the Japan Agreement. Accordingly, the consideration of $15.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the Japan Agreement in the fourth quarter of 2020, substantially all of which was recognized as revenue during the year ended December 31, 2020 from performance obligations satisfied or partially satisfied.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Septembe</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r 2019, the Japanese Ministry of Health, Labour and Welfare approved EVRENZO&#174; (generic name: roxadustat; tradename EVRENZO&#174; in Japan) for the treatment of anemia associated with CKD in dialysis patients. This approval triggered a $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.5 million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> milestone </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payable to the Company by Astellas under the Japan Agreement. Accordingly, the consideration of $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.5</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million associated with this milestone was included in the transaction price and allocated to performance obligations under the Japan Agreement in the t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hird quarter of 2019, substantially all of which was recognized as revenue during the year ended December 31, 2019 from performance obligations satisfied or partially satisfied.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2018, Astellas reported positive results from the final phase 3 CKD-dialysis trial of roxadustat in Japan, indicating that Astellas was ready to make an NDA submission for the treatment of anemia with roxadustat in CKD-dialysis patients in 2018. The Company evaluated the regulatory milestone payment associated with NDA submission in Japan based on variable consideration requirements under the current revenue standards and concluded that this milestone became probable of being achieved in the second quarter of 2018. Accordingly, the consideration of $15.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the Japan Agreement in the second quarter of 2018, substantially all of which was recognized as revenue during the year ended December 31, 2018 from performance obligations satisfied or partially satisfied. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, FibroGen and Astellas entered into an amendment to the Japan Agreement that allows Astellas to manufacture roxadustat drug product for commercialization in Japan (the &#8220;Japan Amendment&#8221;). Under this amendment, FibroGen would continue to manufacture and supply roxadustat API<span style="font-weight:bold;"> </span>to Astellas for the roxadustat commercial launch in Japan. The commercial terms of the Japan Agreement relating to the transfer price for roxadustat for commercial use remain substantially the same, reflecting an adjustment for the manufacture of drug product by Astellas rather than FibroGen. The Company fulfilled shipment obligations under the term of the Japan Amendment in the second quarter of 2020 and in 2018. The related drug product revenue, as described in details under <span style="font-style:italic;">Drug Product Revenue</span> section below, were $4.3 million, $(36.3) million and $64.8 million in the years ended December 31, 2020, 2019 and 2018, respectively. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Europe Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2006, the Company entered into a separate collaboration agreement with Astellas for the development and commercialization of roxadustat for the treatment of anemia in Europe, the Middle East, the Commonwealth of Independent States and South Africa (&#8220;Europe Agreement&#8221;). Under the terms of the Europe Agreement, Astellas paid license fees and other upfront consideration totaling $320.0 million (such amounts were fully received as of February 2009). The Europe Agreement also provides for additional development and regulatory approval milestone payments up to $425.0 million, comprised of (i)&#160;up to $90.0&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of 2012), (ii)&#160;up to $335.0&#160;million in milestone payments upon achievement of specified regulatory milestone events. Under the Europe Agreement, Astellas committed to fund 50% of joint development costs for Europe and North America, and all territory-specific costs. The Europe Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range. The aggregate amount of the considerations received under the Europe Agreement through December&#160;31, 2020 totals $540.0 million, excluding drug product revenue that is discussed separately below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2019, the Company received positive topline results from analyses of pooled major adverse cardiovascular event (&#8220;MACE&#8221;) and MACE+ data from its Phase 3 trials evaluating roxadustat as a treatment for dialysis and non-dialysis CKD patients, enabling Astellas to prepare for an MAA submission to the EMA in the second quarter of 2020, following the Company&#8217;s NDA submission to the FDA that was accepted for review in February 2020. The Company evaluated the two regulatory milestone payments associated with the planned MAA submission and concluded that these milestones became probable of being achieved in the second quarter of 2019. Accordingly, the total consideration of $130.0 million associated with these milestones was included in the transaction price and allocated to performance obligations under the Europe Agreement in the second quarter of 2019, of which $128.8 million was recognized as revenue during the year ended December 31, 2019 and $0.8 million was recognized as revenue during the year ended December 31, 2020, from performance obligations satisfied or partially satisfied. According to the Europe Agreement, these milestone payments are billable to Astellas upon the submission of an MAA, therefore this $130.0 million was an unbilled contract asset as of December 31, 2019, and billed to Astellas upon the submission of an MAA in the second quarter of 2020 with the total $130.0 million received during the same quarter. </p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the fourth quarter of 2018, the Company was engaged in the final stages of review with its partners over the proposed development of roxadustat for the treatment of chemotherapy-induced anemia (&#8220;CIA&#8221;).&#160;AstraZeneca and Astellas approved the program in December 2018 and January 2019, respectively. Costs associated with the development of this indication are expected to be shared 50-50 between the Company&#8217;s two partners.&#160;For revenue recognition purposes, the Company concluded that this new indication represents a modification to the Europe agreements and will be accounted for separately, meaning the development costs associated with the new indications are distinct from the original development costs. The development service period for roxadustat for the treatment of CIA under the Europe Agreement is estimated to continue through the second quarter of 2024 to allow for development of this indication.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Europe Agreement, Astellas has an option to purchase roxadustat bulk drug product in support of commercial supplies. The Company fulfilled a shipment obligation under the term of the Europe Amendment in the fourth quarter of 2020, as described in details under <span style="font-style:italic;">Drug Product Revenue</span> section below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">U.S./Rest of World (&#8220;RoW&#8221;) Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective July&#160;30, 2013, the Company entered into a collaboration agreement with AstraZeneca for the development and commercialization of roxadustat for the treatment of anemia in the U.S. and all other countries in the world, other than China, not previously licensed under the Astellas Europe and Astellas Japan Agreements (&#8220;U.S./RoW Agreement&#8221;). It also excludes China, which is covered by a separate agreement with AstraZeneca described below. Under the terms of the U.S./RoW Agreement, AstraZeneca paid upfront, non-contingent, non-refundable and time-based payments totaling $374.0 million (such amounts were fully received as of June 2016). Under the U.S./RoW Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $875.0 million in potential milestone payments, comprised of (i)&#160;up to $65.0 million in milestone payments upon achievement of specified clinical and development milestone events, (ii)&#160;up to $325.0 million in milestone payments upon achievement of specified regulatory milestone events, (iii)&#160;up to $160.0&#160;million in milestone payments related to activity by potential competitors and (iv)&#160;up to approximately $325.0 million in milestone payments upon the achievement of specified commercial sales events. The aggregate amount of the considerations received under the U.S./RoW Agreement through December&#160;31, 2020 totals $439.0 million, excluding drug product revenue that is discussed separately below.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the U.S./RoW Agreement, the Company and AstraZeneca will share equally in the development costs of roxadustat not already paid for by Astellas, up to a total of $233.0 million (i.e. the Company&#8217;s share of development costs is $116.5 million, which was reached in 2015). Development costs incurred by FibroGen during the development period in excess of the $233.0 million (aggregated spend) are fully reimbursed by AstraZeneca. AstraZeneca will pay the Company tiered royalty payments on AstraZeneca&#8217;s future net sales (as defined in the agreement) of roxadustat in the low 20% range. In addition, the Company will receive a transfer price for shipment of commercial product based on a percentage of AstraZeneca&#8217;s net sales (as defined in the agreement) in the low- to mid-single digit range.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As mentioned above, during the second quarter of 2019, the Company received positive topline results from analyses of pooled MACE and MACE+ data from its Phase 3 trials for roxadustat, enabling the Company&#8217;s NDA submission to the FDA. The Company evaluated the regulatory milestone payment associated with this planned NDA submission and concluded that this milestone became probable of being achieved in the second quarter of 2019. Accordingly, the consideration of $50.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the combined arrangement in the second quarter of 2019, of which $42.4 million was recognized as revenue during the year ended December 31, 2019 and $0.6 million was recognized as revenue during the year ended December 31, 2020, from performance obligations satisfied or partially satisfied. The Company submitted such NDA in December 2019, which was accepted by FDA in February 2020. According to the U.S/RoW Agreement, this milestone payment is billable to AstraZeneca when the NDA is accepted by the FDA, therefore this $50.0 million was an unbilled contract asset as of December 31, 2019, and was billed during the first quarter of 2020, the payment of which was fully received in April 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As mentioned above, AstraZeneca and Astellas approved the development of roxadustat for the treatment of CIA in December 2018 and January 2019, respectively. Costs associated with the development of this indication are expected to be shared 50/50 between AstraZeneca and Astellas.&#160;In addition, in December 2018, anemia of chronic inflammation and multiple myeloma was approved for development by AstraZeneca and is expected to be fully funded by them.&#160;For revenue recognition purposes, the Company concluded that the addition of these new indications represents a modification to the collaboration agreements and will be accounted for separately, meaning the development costs associated with the new indications are distinct from the original development costs. The development service period for roxadustat for the treatment of CIA, anemia of chronic inflammation and multiple myeloma under the AstraZeneca agreements is estimated to continue through the end of 2024, to allow for development of these additional indications.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, the Company entered into Commercial Supply Agreement under the U.S./RoW Agreement with AstraZeneca to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. The Company shipped bulk drug product to AstraZeneca as pre-commercial supply for process validation purposes during the year ended December 31, 2020 and recognized related drug product revenue of $4.6 million, as described in details under <span style="font-style:italic;">Drug Product Revenue</span> section below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">China Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective July&#160;30, 2013, the Company (through its subsidiaries affiliated with China) entered into a collaboration agreement with AstraZeneca for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in China (&#8220;China Agreement&#8221;). Under the terms of the China Agreement, AstraZeneca agreed to pay upfront consideration totaling $28.2&#160;million (such amounts were fully received in 2014). Under the China Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $348.5 million in potential milestone payments, comprised of (i)&#160;up to $15.0 million in milestone payments upon achievement of specified clinical and development milestone events, (ii)&#160;up to $146.0 million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $187.5 million in milestone payments upon the achievement of specified commercial sales and other events. The China Agreement is structured as a 50/50 profit or loss share (as defined), which was amended under the China Amendment discussed below in the third quarter of 2020, and provides for joint development costs (including capital and equipment costs for construction of the manufacturing plant in China), to be shared equally during the development. The aggregate amount of the considerations received under the China Agreement through December&#160;31, 2020 totals $77.2 million.</p>
<p id="C2" style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, roxadustat has been included on the updated NRDL released by China&#8217;s National Healthcare Security Administration for the treatment of anemia in CKD, covering patients who are non-dialysis dependent as well as those who are dialysis-dependent. The inclusion on the NRDL triggered a total of $22.0 million milestones payable to the Company by AstraZeneca. Accordingly, the total consideration of $22.0 million associated with these milestones was included in the transaction price and allocated to performance obligations under the combined arrangement, of which $18.7 million was recognized as revenue during the year ended December 31, 2019. The Company continued to recognize related revenue during the year ended December 31, 2020, from performance obligations satisfied or partially satisfied, and the amount was not material. This milestone payment was received during the first quarter of 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 17, 2018, FibroGen Beijing, received marketing authorization from the NMPA for roxadustat, a first-in-class HIF prolyl hydroxylase inhibitor, for the treatment of anemia caused by CKD in patients on dialysis. This approval triggered a $6.0 million milestone payable to the Company by AstraZeneca. On December 29, 2018, FibroGen Beijing received First Manufacturing Approval for a Product in the Field in the Territory, which allows production for Phase 4 clinical studies, patients&#8217; early experience programs, donation programs, as well as to supply products for testing and assessments required prior to launch. This approval triggered a $6.0 million milestone payable to the Company by AstraZeneca. Approximately $9.9 million of the total $12.0 million milestone payables was recognized as revenue during the year ended December 31, 2018. The Company continued to recognize related revenues during the years ended December 31, 2019 and 2020, from performance obligations satisfied or partially satisfied, and the amounts were not material.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">China Amendment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 8, 2020, FibroGen China and AstraZeneca (together with FibroGen China, the &#8220;Parties&#8221;) entered into the China Amendment, effective July 1, 2020, relating to the development and commercialization of roxadustat in China. While the responsibilities of the Parties under the China Agreement remain largely the same, certain changes were made. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the China Amendment, in September 2020, FibroGen Beijing and AstraZeneca completed the establishment of a jointly owned entity, Falikang, which will perform roxadustat distribution, as well as conduct sales and marketing through AstraZeneca. See Note 3,<span style="font-style:italic;"> Acquisition and Variable Interest Entity</span>, for details. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the China Amendment, the Company is currently in the interim period. Under the China Amendment, the interim period is defined as the period from April 1, 2020 to the time when Falikang is fully operational, which commenced in January 2021. During the interim period, FibroGen continues to sell product directly to the distributors, who remain as the Company&#8217;s customers. Under the China Amendment, the calculation for profit or loss share has changed related to sales of roxadustat in China for the period from April 1, 2020 onwards. With effect from April 1, 2020, the Parties have changed the method under which commercial expenses incurred by AstraZeneca are calculated and billed. AstraZeneca&#8217;s co-promotion expenses for their sales and marketing efforts are now subject to a cap of a percentage of net sales. Once AstraZeneca has been fully reimbursed for their sales and marketing costs under the cap, AstraZeneca will bill the co-promotion expenses based on actual costs on a prospective basis. In addition, the China Amendment has allowed for a higher cost of manufacturing incurred by FibroGen Beijing to be included in the profit or loss share calculation, subject to an annual cap, among other changes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once Falikang is fully operational, substantially all direct product sales will be made by Falikang while the Company continues to sell product directly in few provinces in China. AstraZeneca will bill the co-promotion expenses to Falikang and to FibroGen Beijing, respectively, for its services provided to the respective entity. In addition, FibroGen Beijing will sell commercial product to Falikang based on an agreed upon transfer price. Development costs will continue to be shared 50/50 between the Parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, the interim period primarily includes the following activities:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.36%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Co-promotion expenses: The China Amendment revised the payment arrangements and calculation of the historical unpaid co-promotion expenses to AstraZeneca for its sales and marketing efforts associated with the commercial sales for roxadustat in China since the product launch. Under the previous China Agreement, payment of these historical co-promotion expenses was subject to certain profitability and cash flow thresholds. No amount of the historical co-promotion costs had been paid prior to the China Amendment as these thresholds had not yet been met. Under the China Amendment, a portion of the historical unpaid co-promotion expenses was adjusted to reduce the amount owed by FibroGen Beijing and the current period co-promotion expenses are capped at a percentage of net roxadustat sales in China. As a result, in the third quarter of 2020, the Company reversed approximately $84.4 million of previously accrued co-promotion expenses payable, which was recorded as a reduction to selling, general and administrative expenses, where these expenses were initially recorded during the periods from the initiation of commercial activities in the first quarter of 2019 to the second quarter of 2020. The co-promotion expenses for the year ended December 31, 2020, capped at a percentage of net roxadustat sales in China, were $27.2 million, included in the selling, general and administrative expenses. After this adjustment, as of December 31, 2020, $16.9 million and $11.5 million of the recalculated accrued co-promotion expenses were recorded in accounts payable and accrued liabilities, respectively, as they were anticipated to be paid within the next 12 months; and $27.4 million of the recalculated accrued co-promotion expenses adjusted under the China Amendment remained in the long-term liabilities, as it is not anticipated to be paid within the next 12 months.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.36%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Profit share: Profit/loss share between FibroGen Beijing and AstraZeneca is based on a calculation of the current period net roxadustat sales in China and deductible expenses pursuant to the China Agreement. Based on the calculation revised under the China Amendment, profit was achieved during the third and fourth quarter of 2020. As a result, the Company recorded a profit share liability of $7.0 million to AstraZeneca as of December 31, 2020 in the accrued and other current liabilities, which correspondingly reduced the deferred revenue related to the performance obligation in accordance with the China Agreement.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.36%;white-space:nowrap" valign="top"/>
<td valign="top">
</td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accounting for the Astellas Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each of the Astellas agreements, the Company has evaluated the promised services within the respective arrangements and has identified performance obligations representing those services and bundles of services that are distinct.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Promised services that were not distinct have been combined with other promised services to form a distinct bundle of promised services, with revenue being recognized on the bundle of services rather than the individual services. There are no right-of-return provisions for the delivered items in the Astellas agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the transaction price for the Japan Agreement, excluding manufacturing services that is discussed separately below, included $40.1 million of non-contingent upfront payments, $65.0 million of variable consideration related to payments for milestones considered probable of being achieved, and $11.7 million of variable consideration related to co-development billings. The transaction price for the Europe Agreement, excluding manufacturing services that is discussed separately below, included $320.0 million of non-contingent upfront payments, $220.0 million of variable consideration related to payments for milestones considered probable of being achieved, and $225.9 million of variable consideration related to co-development billings. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For revenue recognition purposes, the Company determined that the term of each collaboration agreement with Astellas begins on the effective date and ends upon the completion of all performance obligations contained in the agreement. The contract term is defined as the period in which parties to the contract have present and enforceable rights and obligations. The Company believes that the requirement to continue funding development for a substantive period of time and loss of product rights, along with non-refundable upfront payments already remitted by Astellas, create significant disincentive for Astellas to exercise its right to terminate the agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the Astellas agreements, the Company allocated the transaction price to the various performance obligations based on the relative SSP of each performance obligation, with the exception of co-development billings allocated entirely to co-development services performance obligations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the technology license under the Japan Agreement and the Europe Agreement, SSP was determined primarily by using the discounted cash flow (&#8220;DCF&#8221;) method, which aggregates the present value of future cash flows to determine the valuation as of the effective date of each of the agreements. The DCF method involves the following key steps: 1) the determination of cash flow forecasts and 2) the selection of a range of comparative risk-adjusted discount rates to apply against the cash flow forecasts. The discount rates selected were based on expectations of the total rate of return, the rate at which capital would be attracted to the Company and the level of risk inherent within the Company. The discounts applied in the DCF analysis ranged from 17.5% to 20.0%. The Company&#8217;s cash flow forecasts were derived from probability-adjusted revenue and expense projections by territory. Such projections included consideration of taxes and cash flow adjustments. The probability adjustments were made after considering the likelihood of technical success at various stages of clinical trials and regulatory approval phases. SSP also considered certain future royalty payments associated with commercial performance of the Company&#8217;s compounds, transfer prices and expected gross margins.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promised services that were analyzed, along with their general timing of satisfaction and recognition as revenue, are as follows:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">License to the Company&#8217;s technology existing at the effective date of the agreements.</span><span style="font-style:normal;color:#000000;"> For both of the Astellas agreements, the license was delivered at the beginning of the agreement term. In both cases, the Company concluded at the time of the agreement that its collaboration partner, Astellas, would have the knowledge and capabilities to fully exploit the licenses without the Company&#8217;s further involvement. However, the Japan Agreement has contractual limitations that might affect Astellas&#8217; ability to fully exploit the license and therefore, potentially, the conclusion as to whether the license is capable of being distinct. In the Japan Agreement, Astellas does not have the right to manufacture commercial supplies of the drug. In order to determine whether this characteristic of the agreement should lead to a conclusion that the license was not distinct in the context of the agreement, the Company considered the ability of Astellas to benefit from the license together with other resources readily available to Astellas. Finally, the Company considered the fact that at the time of delivery of the license, the development services were beyond the preclinical development phase and any remaining development work in either agreement would not be expected to result in any significant modification or customization to the licensed technology. As such, the development services are separately identifiable from the licensed technology, indicating that the license is a distinct performance obligation.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Manufacturing rights.</span><span style="font-style:normal;"> In the case of the Japan Agreement, the Company retained manufacturing rights largel</span><span style="font-style:normal;">y because of the way the parties chose for FibroGen to be compensated under the agreement. At the time the agreement was signed, the Company believed that it was more advantageous upon commercialization to have a transfer price revenue model in place as op</span><span style="font-style:normal;">posed to a traditional sales-based model. The manufacturing process does not require specialized knowledge or expertise uniquely held by FibroGen, and notwithstanding contractual restrictions, Astellas could employ manufacturing services from readily avail</span><span style="font-style:normal;">able third parties in order to benefit from the license. Therefore, along with the foregoing paragraph, the Company determined that the license in Japan is a distinct performance obligation despite the retention of manufacturing rights by the Company.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In summary, the Company concludes that item (1) represents a performance obligation. The portion of the transaction price allocated to this performance obligation based on a relative SSP basis is recognized as revenue in its entirety at the point in time the license transfers to Astellas.</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.42%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">Co-development services (Europe Agreement). </span><span style="font-style:normal;color:#000000;">This promise relates to co-development services that were reasonably expected to be performed by the Company at the time the collaboration agreement was signed and is considered distinct. Co-development billings are allocated entirely to the co-development services performance obligation as amounts are related specifically to research and development efforts necessary to satisfy the performance obligation, and such an allocation is consistent with the allocation objective. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours and out-of-pocket expenses incurred relative to total expected costs to be incurred. The measure of progress is updated each reporting period. Co-development services are expected to continue over the development period that is currently estimated to continue through the end of 2021. In addition, the Company concluded that the new indication related to CIA approved in January 2019 represents a modification to the Europe agreements at that time and will be accounted for separately, for which the development service period is estimated to continue through the second quarter of 2024. There was no provision for co-development services in the Japan Agreement. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">License to the Company&#8217;s technology developed during the term of the agreement and development (referred to as &#8220;when and if available&#8221;) and information sharing services. </span><span style="font-style:normal;color:#000000;">These promises are generally satisfied throughout the term of the agreements.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">Manufacturing of clinical supplies of products.</span><span style="font-style:normal;color:#000000;"> This promise is satisfied as supplies for clinical product are delivered for use in the Company&#8217;s clinical trial programs during the development period, or pre-commercialization period.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(5)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">Committee service</span><span style="font-style:normal;color:#000000;">. This promise is satisfied throughout the course of the agreements as meetings are attended.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0.04%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Items (2)-(5) are bundled into a single performance obligation that is distinct given the fact that all are highly interrelated during the development period (pre-commercial phase of development) such that satisfying them independently is not practicable. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours or full time equivalents and out-of-pocket expenses incurred relative to total expected costs to be incurred. The measure of progress is updated each reporting period.</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(6)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">Manufacturing commercial supplies of products.</span><span style="font-style:normal;color:#000000;"> This promised service is distinct as services are not interrelated with any of the other performance obligations. Payments received for commercial supplies of products represent sales-based payments related predominately to the license of intellectual property under both Astellas agreements. Revenue is recognized as supplies are shipped for commercial use during the commercialization period. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Japan Amendment the drug product revenue represents variable consideration and is estimated based on the quantity of product shipped, actual listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and possible future changes to the listed price, adjusted for estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk drug product tablets, and estimated yield from the manufacture of bulk product tablets, among others.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Europe Agreement, the drug product revenue amount represents variable consideration and is estimated based on the quantity of product shipped and an estimated price. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price per strength, which is estimated to be realized by Astellas from the end sale of roxadustat in its approved territories.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of variable consideration that is included in the transaction price may be constrained, and is included in the drug product revenue only to the extent that </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it is probable that a significant re</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">versal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. Estimating variable consideration and the related constraint requires the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use of significant management judgment. The Company reviews new information that may affect its variable consideration estimate at every reporting period and records an adjustment to revenue, if certain and material</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Actual amounts of consideration </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ultimately received in the future may differ from the Company&#8217;s estimates, for which the Company will adjust these estimates and affect the drug product revenue in the period such variances become known.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As each of the agreements provides for annual true up to the considerations paid for its commercial supplies, the Company will re-evaluate the transaction price in each reporting period and record adjustment to revenue as uncertain events are resolved or other changes in circumstances occur. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accounting for the AstraZeneca Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluated whether the U.S./RoW Agreement and the China Agreement should be accounted for as a single or separate arrangements and concluded that the agreements should be accounted for as a single arrangement with the presumption that two or more agreements executed with a single customer at or around the same time should be presumed to be a single arrangement. The key points the Company considered in reaching this conclusion are as follows: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">While the two agreements were largely negotiated separately, those negotiations proceeded concurrently, and were intended to be completed contemporaneously, presuming AstraZeneca</span><span style="font-weight:bold;color:#000000;"> </span><span style="color:#000000;">decided to proceed with licenses in all regions available. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Throughout negotiations for both agreements, the Company and the counterparties understood and considered the possibility that one arrangement may be executed without the execution of the other arrangement. However, the preference for the Company and the counterparties during the negotiations was to execute both arrangements concurrently.&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">The two agreements were executed as separate agreements because different development, regulatory and commercial approaches required certain terms of the agreements to be structured differently, rather than because the Company or the counterparties considered the agreements to be fundamentally separate negotiations.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, as the agreements are being accounted for as a single arrangement, upfront and other non-contingent consideration received and to be received has been and will be pooled together and allocated to each of the performance obligations in both the U.S./RoW Agreement and the China Agreement based on their relative SSPs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each of the AstraZeneca agreements, the Company has evaluated the promised services within the respective arrangements and has identified performance obligations representing those services and bundled services that are distinct.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Promised services that were not distinct have been combined with other promised services to form a distinct bundle of promised services, with revenue being recognized on the bundle of services rather than the individual promised services. There are no right-of-return provisions for the delivered items in the AstraZeneca agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the transaction price for the U.S./RoW Agreement and the China Agreement, excluding manufacturing services that is discussed separately below, included $402.2 million of non-contingent upfront payments, $114.0 million of variable consideration related to payments for milestones considered probable of being achieved, $564.9 million of variable consideration related to co-development billings, offset by $7.0 million of variable consideration related to profit share under the China Amendment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the AstraZeneca agreements, the Company allocated the transaction price to the various performance obligations based on the relative SSP of each performance obligation, with the exception of co-development billings and commercial sale of product. Co-development billings under the U.S./RoW Agreement were allocated entirely to the U.S./RoW co-development services performance obligation, and co-development billings under the China Agreement were allocated entirely to the combined performance obligation under the China Agreement. Commercial sale of product under the U.S./ROW Agreement is entirely allocated to the manufacturing commercial supply of products performance obligation, and commercial sale of product under the China Agreement is allocated entirely to the combined China performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For revenue recognition purposes, the Company determined that the term of its collaboration agreements with AstraZeneca begin on the effective date and ends upon the completion of all performance obligations c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ontained in the agreements. T</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he contract term is defined as the period in which parties to the contract have present and enforceable rights and obligations. The Company believes that the requirement to continue funding development for a substantive period </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of time and the loss of product rights, along with non-refundable upfront payments already remitted by AstraZeneca, represent substantive termination penalties that create significant disincentive for AstraZeneca to exercise its right to terminate the agre</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ement.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the technology license under the AstraZeneca U.S./RoW Agreement, SSP was determined based on a two-step process. The first step involved determining an implied royalty rate that would result in the net present value of future cash flows to equal to zero (i.e. where the implied royalty rate on the transaction would equal the target return for the investment). This results in an upper bound estimation of the magnitude of royalties that a hypothetical acquirer would reasonably pay for the forecasted cash flow stream. The Company&#8217;s cash flow forecasts were derived from probability-adjusted revenue and expense projections. Such projections included consideration of taxes and cash flow adjustments. The probability adjustments were made after considering the likelihood of technical success at various stages of clinical trials and regulatory approval phases. The second step involved applying the implied royalty rate, which was determined to be 40%, against the probability-adjusted projected net revenues by territory and determining the value of the license as the net present value of future cash flows after adjusting for taxes. The discount rate utilized was 17.5%.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">U.S./RoW Agreement:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promised services that were analyzed, along with their general timing of satisfaction and recognition as revenue, are as follows:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">License to the Company&#8217;s technology existing at the effective date of the agreements.</span><span style="font-style:normal;color:#000000;"> For the U.S./RoW Agreement, the license was delivered at the beginning of the agreement term. The Company concluded that AstraZeneca has the knowledge and capabilities to fully exploit the license under the U.S./RoW Agreement without the Company&#8217;s further involvement. Finally, the Company considered the fact that at the time of delivery of the license, the development services were beyond the preclinical development phase and any remaining development work would not be expected to result in any significant modification or customization to the licensed technology. As such, the development services are separately identifiable from the licensed technology, indicating that the license is a distinct performance obligation. Therefore, the Company has concluded that the license is distinct and represents a performance obligation. The portion of the transaction price allocated to this performance obligation based on a relative SSP basis is recognized as revenue in its entirety at the point in time the license transfers to AstraZeneca.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">Co-development services. </span><span style="font-style:normal;color:#000000;">This promise relates to co-development services that were reasonably expected to be performed by the Company at the time the collaboration agreement was signed and is distinct. Co-development billings are allocated entirely to the co-development services performance obligation as amounts are related specifically to research and development efforts necessary to satisfy the performance obligation, and such an allocation is consistent with the allocation objective. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours or full time equivalents and out-of-pocket expenses incurred relative to total expected costs to be incurred. Co-development services are expected to continue over the development period that is currently estimated to continue through the end of the first quarter of 2021. In addition, the Company concluded that the addition of the new indications related to CIA, anemia of chronic inflammation and multiple myeloma approved during the fourth quarter of 2018 represents a modification to the collaboration agreements and will be accounted for separately, for which the joint development service period is estimated to continue through the end of 2024. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">Manufacturing of clinical supplies of products.</span><span style="font-style:normal;color:#000000;"> This promise is satisfied as supplies for clinical product are delivered for use in the Company&#8217;s clinical trial programs during the development period, or pre-commercialization period.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">Information sharing and committee service.</span><span style="font-style:normal;color:#000000;"> These promises are satisfied throughout the course of the agreement as services are provided.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Items (2)-(4) are bundled into a single performance obligation that is distinct given the fact that all are highly interrelated during the development period (pre-commercial phase of development) such that delivering them independently is not practicable. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours or full time equivalents and out-of-pocket expenses incurred relative to total expected costs to be incurred. The measure of progress is updated each reporting period.</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(5)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">Manufacturing commercial supplies of products. </span><span style="font-style:normal;color:#000000;">This promise is distinct as services are not interrelated with any of the other</span><span style="font-style:normal;color:#000000;"> performance obligations. Revenue is recognized as supplies are shipped for commercial use during the commercialization period. </span><span style="font-style:normal;color:#000000;">The drug product revenue amount represents variable consideration and is estimated based on the quantity of product shipped and </span><span style="font-style:normal;color:#000000;">an estimated price for each individual purchase order. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price, which is estimated to be realized by AstraZeneca from the end sale o</span><span style="font-style:normal;color:#000000;">f roxadustat in its approved territories.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of variable consideration that is included in the transaction price may be constrained, and is included in the drug product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. Estimating variable consideration and the related constraint requires the use of significant management judgment. The Company reviews new information that may affect its variable consideration estimate at every reporting period and records an adjustment to revenue, if certain and material. Actual amounts of consideration ultimately received in the future may differ from the Company&#8217;s estimates, for which the Company will adjust these estimates and affect the drug product revenue in the period such variances become known.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the agreement provides for an annual true up to the considerations paid for its commercial supplies, the Company will re-evaluate the transaction price in each reporting period and record an adjustment to revenue as uncertain events are resolved or other changes in circumstances occur. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">China Agreement:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promised services that were analyzed are consistent with the U.S./RoW Agreement, except for license to the Company&#8217;s technology existing at the effective date of the agreement, described as follows:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-style:italic;color:#000000;">License to the Company&#8217;s technology existing at the effective date of the agreement.</span><span style="color:#000000;"> The license was delivered at the beginning of the agreement term. However, the China Agreement with AstraZeneca has contractual limitations that might affect AstraZeneca&#8217;s ability to fully exploit the license and therefore, potentially, the conclusion as to whether the license is distinct in the context of the agreement. In the China Agreement, AstraZeneca does not have the right to manufacture commercial supplies of the drug. In order to determine whether this characteristic of the arrangement should lead to a conclusion that the license was not distinct in the context of the agreement, the Company considered the ability of AstraZeneca to benefit from the license on its own or together with other resources readily available to AstraZeneca.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the China Agreement, the Company retained manufacturing rights as an essential part of a strategy to pursue domestic regulatory pathway for product approval which requires the regulatory licensure of the manufacturing facility in order to commence commercial shipment. The prospects for the collaboration as a whole would have been substantially different had manufacturing rights been provided to AstraZeneca. We hold the rights to manufacture commercial drug product in China. Therefore, AstraZeneca cannot benefit from the license on its own or together with other readily available resources. Accordingly, all the promises identified, including the license, co-development services and manufacturing of commercial supplies,, under the China Agreement have been bundled into a single performance obligation and amounts of the transaction price allocable to this performance obligation are deferred until control of the manufactured commercial drug product has begun to transfer to AstraZeneca. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the China Amendment, once Falikang is fully operational, which commenced in January 2021, substantially all product sales will be made by Falikang directly to the distributors in China, while the Company continues to sell directly in few provinces in China. Revenue will be recognized upon the transfer of control of commercial drug product to Falikang. For the Company&#8217;s direct sales of commercial drug product, revenue will be recognized when control of the promised good is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for the product.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Summary of revenue recognized under the collaboration agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes the accounting treatment for the various performance obligations pursuant to each of the Astellas and AstraZeneca agreements. License amounts identified below are included in the &#8220;License revenue&#8221; line item in the consolidated statements of operations. All other elements identified</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> below are included in the &#8220;Development and other revenue&#8221; line item in the consolidated statements of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts recognized as license revenue and development revenue under the Japan Agreement with Astellas were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Obligation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,323</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,935</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,323</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,220</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,222</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,400</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Japan Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#160;at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,350</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,480</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,697</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,827</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue recognized under the Japan Agreement for the year ended December 31, 2020 included an increase of $15.1 million resulting from changes to estimated variable consideration in the current year relating to performance obligations satisfied or partially satisfied in previous periods. The Company does not expect material variable consideration from estimated future co-development billing beyond development period in the transaction price related to the Japan Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts recognized as license revenue and development revenue under the Europe Agreement with Astellas were as follows (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.32%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Obligation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117,470</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,954</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,172</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,503</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Europe Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#160;at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487,951</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487,951</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248,962</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,429</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250,391</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">736,913</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,429</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">738,342</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:2.68%;text-indent:-2.68%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue recognized under the Europe Agreement for the year ended December 31, 2020 included an increase in revenue of $1.5 million resulting from changes to estimated variable consideration in the current year relating to performance obligations satisfied or partially satisfied in previous periods. The remainder of the transaction price related to the Europe Agreement includes $27.6 million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts recognized as license revenue and development revenue under the U.S./RoW and China Agreements with AstraZeneca were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.32%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Obligation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.&#160;/&#160;RoW</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and China</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,681</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,946</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,508</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,629</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,970</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China performance obligation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(90</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement, along with any associated deferred revenue as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U.S.&#160;/&#160;RoW and China Agreements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#160;at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">341,844</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">341,844</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-development, information sharing &amp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;committee services</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">554,775</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,276</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">557,051</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China performance obligation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137,338</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137,338</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">896,619</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,614</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,036,233</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:92.86%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* </span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the consolidated balance sheets. As of December 31, 2020, deferred revenue included $137.5 million related to the U.S./RoW and China Agreement, which represents the net of $139.6 million of deferred revenue presented above and a $2.1 million unbilled co-development revenue under the China Amendment with AstraZeneca.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue recognized under the U.S./RoW Agreement and China Agreement for the year ended December 31, 2020 included a reduction in revenue of $2.9 million resulting from changes to estimated variable consideration in the current year relating to performance obligations satisfied or partially satisfied in previous periods. The remainder of the transaction price related to the U.S./RoW Agreement and China Agreement includes $37.9 million of variable consideration from estimated future co-development billing. The amount allocated to the U.S./RoW Agreement is expected to be recognized over the remaining development service period. The amount allocated to the China performance obligation is expected to be recognized as the Company transfers control of the commercial drug product to Falikang.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Product Revenue, Net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue from roxadustat commercial sales in China is recognized in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products, net of various sales rebates and discounts. Product revenue, net was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,027</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,803</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Price adjustment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(936</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-key account hospital listing award</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,325</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual sales rebate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,189</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(149</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other discounts and rebates</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(923</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales return</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,498</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the second quarter of 2020, the Company amended the agreement with its pharmaceutical distributors, which triggered accounting modifications particularly related to the non-key account hospital listing award. For the year ended December 31, 2020, the non-key account hospital listing award was $9.3 million, which was recorded as a reduction to the revenue and calculated based on eligible non-key account hospital listings to date achieved by each distributor with certain requirements met during the period. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020 and 2019, the contractual sales rebate was $6.2 million and $0.1 million, respectively, which were calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. All other rebates and discounts, including sales return allowance were immaterial for the periods presented. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2019, a $0.9 million of price adjustment was recorded based on government-listed price guidance and estimated channel inventory levels.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rebates and discounts that the Company&#8217;s pharmaceutical distributors have earned are eligible to be applied against future sales orders, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible in the same period that the related revenue is recorded. Due to the distributor&#8217;s legal right to offset, at each balance sheet date, the rebates and discounts are presented as reductions to gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The distributor&#8217;s legal right of offset is calculated at the individual distributor level. The following table includes a roll-forward of the related contract liabilities (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deduction</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Currency</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Translation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contract</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Presented Net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Against</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Receivable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue - Contract liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,102</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,497</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,184</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(270</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,685</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">548</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,137</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the total rebates and discounts as reductions to gross accounts receivable was $0.5 million, and the total contract liabilities was $15.1 million, which was included in accrued and other current liabilities in the consolidated balance sheet. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reductions to gross accounts receivable, including the above-mentioned contra-accounts receivable items related to product revenue, totaled $0.8 million and $1.1 million as of December 31, 2020 and 2019, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Drug Product Revenue<span style="font-weight:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue was as follows (in thousands): </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,281</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,324</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,776</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,625</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,906</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,324</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,776</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company fulfilled all the shipment obligations under the term of the Japan Amendment during the year ended December 31, 2018, and recognized the related product revenue of $64.8 million in the same period<span style="font-weight:bold;"> </span>based on a transaction price that was subject to potential future adjustments, which represented a form of variable consideration. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in estimated variable consideration incurred in 2019 related to the above API shipments in 2018, at the time the actual listed price for roxadustat was issued by the Japanese Ministry of Health, Labour and Welfare, which resulted in a total difference of $36.3 million between the estimated and the actual listed price and yield from the manufacture of bulk product tablets. </p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, during the year ended December 31, 2020, the Company recorded another $4.0 million reduction to drug product revenue related to the above API shipments, due to a change in estimated variable consideration. Specifically, the change in estimated variable consideration was based on the API held by Astellas at March 31, 2020 adjusted to reflect the updated listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and changes in the estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk product tablets, and estimated yield from the manufacture of bulk product tablets, among others. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2020, the Company fulfilled shipment obligations under the term of Japan Amendment with Astellas, and recognized related drug product revenue of $8.2 million in the same period. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fourth quarter of 2020, the Company shipped bulk drug product from process validation supplies for commercial purposes under the term of the Europe Agreement with Astellas. The Company constrained the consideration from this shipment due to a high degree of uncertainty associated to the final consideration. As a result, the Company recorded $1.4 million as current deferred revenue and $4.6 million as long-term deferred revenue as of December 31, 2020. The deferred revenue will be recognized as and when uncertainty is resolved. The following table includes a roll-forward of the related contract liabilities (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue - Astellas - contract liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,984</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,984</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the Company shipped bulk drug product to AstraZeneca as pre-commercial supply for process validation purposes, under the term of Commercial Supply Agreement under the U.S./RoW Agreement with AstraZeneca, and recognized drug product revenue of $4.6 million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Revenues</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other revenues consist primarily of collagen material sold for research purposes. Other revenues were immaterial for each of the three years ended December&#160;31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue represents amounts billed, or in certain cases, yet to be billed to the Company&#8217;s collaboration partners for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying performance obligations. The long-term portion of deferred revenue represents amounts to be recognized after one year through the end of the non-contingent performance period of the underlying performance obligations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue includes amounts allocated to the China performance obligation under the AstraZeneca arrangement as revenue recognition associated with this unit of accounting is tied to the commercial launch of the products within China and to when the control of the manufactured commercial drug product is transferred to AstraZeneca. As of December 31, 2020, approximately $3.5 million of the deferred revenue related to the China unit of accounting was included in short-term deferred revenue, which represents the amount of deferred revenue associated with the China unit of accounting that is expected to be recognized within the next 12 months, associated with the commercial sales in China.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement and revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090637452856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value Measurements</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the authoritative guidance on fair value measurements and disclosures under U.S. GAAP, the Company presents all financial assets and liabilities and any other assets and liabilities that are recognized or disclosed at fair value on a nonrecurring basis. The guidance defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair-value measurements. The guidance also requires fair value measurements be classified and disclosed in one of the following three categories:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 1<span style="font-style:normal;">: Quoted prices in active markets for identical assets or liabilities.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 2<span style="font-style:normal;">: Observable inputs other than quoted prices in active markets for identical assets or liabilities.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 3<span style="font-style:normal;">: Unobservable inputs.</span></p>
<p id="T0" style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company values certain assets and liabilities, focusing on the inputs used to measure fair value, particularly in instances where the measurement uses significant unobservable (Level 3) inputs. The Company&#8217;s financial instruments are valued using quoted prices in active markets (Level 1) or based upon other observable inputs (Level 2). The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability. In addition, the categories presented do not suggest how prices may be affected by the size of the purchases or sales, particularly with the largest highly liquid financial issuers who are in markets continuously with non-equity instruments, or how any such financial assets may be impacted by other factors such as U.S. government guarantees. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. </span><span style="color:#000000;">The availability of observable data is monitored to assess </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">appropriate</span><span style="color:#000000;"> classification of financial instruments within the fair value hierarchy. Depending upon the availability of such inputs, specific securities may </span><span style="color:#000000;">transfer between levels. In such instances, the transfer is reported at the end of the reporting period.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of the Company&#8217;s financial assets that are measured on a recurring basis are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,144</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,144</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590,591</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,144</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598,735</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury notes and bills</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">347,383</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,123</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">427,506</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,816</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,816</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,551</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,551</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificate of deposit</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">444,005</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,155</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">554,160</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Level 2 investments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar investments, issuer credit spreads, benchmark investments, prepayment/default projections based on historical data and other observable inputs. There were no transfers of assets between levels for the years ended December&#160;31, 2020 and 2018. During the fourth quarter of 2019, there was a $29.8 million transfer of assets from Level 1 to Level 2 as such US treasury notes and bills were changed to off-the-run when they were issued before the most recent issue and were still outstanding at measurement day.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of the Company&#8217;s financial liabilities that are carried at historical cost are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease obligations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,141</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,141</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease obligations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,544</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,544</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the Company&#8217;s financial liabilities were derived by using an income approach, which required Level 3 inputs such as discounted estimated future cash flows. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no transfers of liabilities between levels for the years ended December&#160;31, 2020, 2019 and 2018.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090736768664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Leases</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently has two building leases treated as finance leases. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2006, the Company entered into a long-term property lease with Alexandria for its corporate headquarters in San Francisco, California, with an initial term of 15&#160;years, scheduled to expire in 2023. The Company has an option to extend the lease for an additional 10 years through 2033. The lease contract provides for a fixed annual rent, with scheduled increases of two percent that occur on each anniversary of the rent commencement date. This lease requires the Company to pay all costs of ownership, operation, and maintenance of the premises, including without limitation all operating costs, insurance costs, and taxes.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2013, the Company entered into a long-term property lease with Beijing Economic-Technological Development Area (&#8220;BDA&#8221;) Management Committee for a pilot plant located in Beijing Yizhuang Biomedical Park of BDA. The building is leased for an initial lease term of eight years, scheduled to expire in 2021. Renewal options are not specified within the lease contract. The lease contract provides for fixed quarterly rent payments, with scheduled increases that occur as detailed in the lease contract. This lease requires the Company to pay all operating and maintenance costs, and a fixed amount for property management fees.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently has six additional real estate leases for office spaces in Shanghai and Beijing, China, which are treated as operating leases. These leases have lease terms ranging from two to three years, expiring in 2023. These lease contracts provide for fixed quarterly rent payments, and require the Company to pay operating and maintenance costs, and a fixed amount for property management fees.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company has several immaterial lease arrangements in China and U.S. for office equipment, scientific devices and automobile leases, with contracted lease terms ranging from two to four years, treated as finance leases or operating leases, respectively.&#160;&#160; </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s lease assets and related lease liabilities were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Line Item</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets - cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,477</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,909</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,871</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,307</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,606</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,602</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets - cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,934</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,736</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,891</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(805</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,043</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,931</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,649</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,533</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,330</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,351</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,188</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">983</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, non-current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,391</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,610</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">853</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">942</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,762</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,886</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease expense were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of Operations Line Item</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease cost:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,369</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,307</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,932</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,373</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,151</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">891</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,201</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,385</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,251</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to leases were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">951</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">914</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from finance leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,896</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,196</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flows from finance leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,620</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,925</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for new lease liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,909</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,072</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,736</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease term and discount rate were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (years):</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001000">2.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001001">3.6</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001002">1.8</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001003">2.1</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.39</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.42</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.74</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of lease liabilities as of December&#160;31, 2020 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance&#160;Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating&#160;Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,689</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,142</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,886</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">839</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,526</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,101</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,124</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Interest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,380</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(83</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,721</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,041</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650453160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Balance Sheet Components</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,046</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,715</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590,347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,551</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">678,393</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,266</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s investments consist of available-for-sale debt investments, marketable equity investments, term deposit and certificate of deposit. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#8217;s investments by major investments type are summarized in the tables below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,147</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,144</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,272</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,388</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury notes and bills</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">426,995</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">536</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">427,506</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,730</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,816</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">467,850</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">784</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">468,609</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contractual maturities of the available-for-sale investments were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within one year - Bond and mutual funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,144</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,388</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company periodically reviews its available-for-sale investments and term deposit for other-than-temporary impairment. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period and its intent to sell. For debt securities, the Company also considers whether (i)&#160;it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. During the three years ended December 31, 2020, the Company did not recognize any other-than-temporary impairment loss.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,303</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work-in-progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,114</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,264</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,113</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,298</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,530</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,887</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company started capitalizing inventory costs in June 2019 when FibroGen Beijing began productions of roxadustat for commercial sales purposes. The Company started capitalizing pre-launch inventory costs in the U.S. the second quarter of 2020 prior to regulatory approval. As of December 31, 2020, pre-launch inventory capitalized was 29% of the total inventory balance. The provision to write-down excess and obsolete inventory was nominal for the years ended December&#160;31, 2020 and 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unbilled contract assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,147</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues from associated contracts</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,147</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,790</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net unbilled contract assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,210</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,353</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,464</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,807</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,717</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,160</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,391</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unbilled contract assets as of December 31, 2020 were related to unbilled co-development revenue under the China Amendment with AstraZeneca. The unbilled contract assets as of December 31, 2019 were related to two regulatory milestones totaling $130.0 million under the Europe Agreement with Astellas associated with the planned MAA submission in Europe, and a $50.0 million regulatory milestone under the U.S./RoW Agreement with AstraZeneca associated with the NDA submission in the U.S., which was submitted in December 2019 and accepted for review in February 2020. See Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, for details.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,006</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,548</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,143</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,329</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,312</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,217</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,545</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,399</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,128</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,822</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">760</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,792</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,894</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,107</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(111,247</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100,364</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,647</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,743</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense for the years ended December&#160;31, 2020, 2019 and 2018 was $11.7 million, $11.1 million, and $6.6 million, respectively.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accrued and Other Current Liabilities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and clinical trial accruals</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,113</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,279</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">API product price adjustment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,324</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and related accruals</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,800</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,784</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities to pharmaceutical distributors</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,137</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued co-promotion expenses - current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,537</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat profit share to AstraZeneca</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,007</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property taxes and other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,970</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,044</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional services</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,869</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,842</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,088</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,543</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued and other current liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119,521</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,816</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The API product price adjustment of $36.3 million accrued as of December 31, 2019 was related to the change in estimated variable consideration of API product at the time the roxadustat listed price was issued by the Japanese Ministry of Health, Labour and Welfare in the fourth quarter of 2019. This amount was fully paid during the first quarter of 2020. Refer to Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, for details.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 8, 2020, the Parties entered into an amendment to the China Agreement, relating to the development and commercialization of roxadustat in China, which revised, among other things, the arrangements and calculation of the estimated co-promotion expenses payable to AstraZeneca for its sales and marketing efforts associated with the commercial sales for roxadustat in China. As a result, the previously accrued long-term co-promotion expenses were significantly reduced during the third quarter of 2020. $11.5 million of the recalculated accrued co-promotion expenses is anticipated to be paid within the next 12 months, therefore was recorded as a current liability as of December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The profit share liability of $7.0 million to AstraZeneca as of December 31, 2020 represented the profit/loss share between FibroGen Beijing and AstraZeneca that is calculated pursuant to the China Agreement. This liability correspondingly reduced the deferred revenue related to the performance obligation in accordance with the China Agreement.<span style="font-weight:bold;color:#FF0000;"> </span>Refer to Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, for details.<span style="font-weight:bold;color:#FF0000;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Long-term Liabilities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities consisted of the following (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued long-term co-promotion expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,424</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,071</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,675</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,913</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, non-current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">853</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">942</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,690</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,481</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other long-term liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,642</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,407</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The a<span style="color:#000000;">ccrued long-term co-promotional expenses </span>of $53.1 million <span style="color:#000000;">as of December 31, 2019 was related to the estimated amount payable to AstraZeneca for its sales and marketing efforts related to the commercial launch for roxadustat in China. </span>As mentioned above, the China Amendment revised the arrangements and calculation of the estimated co-promotion expenses payable to AstraZeneca. As a result, we reversed approximately $84.4 million of previously accrued long-term co-promotion expenses during the third quarter of 2020. $27.4 million of the recalculated accrued co-promotion expenses remained in the long-term liabilities as of December 31, 2020, as it is not anticipated to be paid within the next 12 months.<span style="color:#000000;"> </span> </p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090637453880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Development Obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProductDevelopmentObligationsDisclosureTextBlock', window );">Product Development Obligations</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Product Development Obligations</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Technology Development Center of the Republic of Finland (&#8220;TEKES&#8221;) product development obligations consist of 11 separate advances (each in the form of a note agreement) received by FibroGen Europe between 1996 and 2008 from TEKES. These advances are granted on a project-by-project basis to fund various product development efforts undertaken by FibroGen Europe only. Each separate note is denominated in EUR and bears interest (not compounded) calculated as one percentage point less than the Bank of Finland rate in effect at the time of the note, but no less than 3.0%.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the research work funded by TEKES does not result in an economically profitable business or does not meet its technological objectives, TEKES may, on application from FibroGen Europe, forgive each of these loans, including accrued interest, either in full or in part. As of December&#160;31, 2020 and 2019, the Company had U.S. Dollar equivalent of $11.6 million and $10.6 million of principal outstanding, respectively, and $7.1 million and $6.2 million of interest accrued, respectively, which were presented in the product development obligations line on the consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not a guarantor of these loans, and these loans are not repayable by FibroGen Europe until it has distributable funds.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ProductDevelopmentObligationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product development obligation disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ProductDevelopmentObligationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090735086072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract Obligations </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had outstanding total non-cancelable purchase obligations of $86.0 million. The Company expects to fulfill our commitments under these agreements in the normal course of business, and as such, no liability has been recorded. The unconditional purchase obligations consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchase Obligations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Due In The Year Ending December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacture and supply of roxadustat</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,114</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,951</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,065</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacture and supply of pamrevlumab</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,480</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,063</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,543</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other purchases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,418</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,418</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total purchase obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,012</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,014</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,026</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the Company&#8217;s license agreements provide for periodic maintenance fees over specified time periods, as well as payments by the Company upon the achievement of development, regulatory and commercial milestones. Future milestone payments for research and pre-clinical stage development programs consisted of up to approximately $10.9 million in total potential future milestone payments under the Company&#8217;s license agreements with Dana-Farber Cancer Institute, University of Miami and Medarex, Inc. These milestone payments generally become due and payable only upon the achievement of certain developmental, clinical, regulatory and/or commercial milestones. The event triggering such payment or obligation has not yet occurred.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Legal Proceedings</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company is a party to various legal actions, both inside and outside the U.S., arising in the ordinary course of its business or otherwise. The Company accrues amounts, to the extent they can be reasonably estimated, that the Company believes will result in a probable loss (including, among other things, probable settlement value), to adequately address any liabilities related to legal proceedings and other loss contingencies. A loss or a range of loss is disclosed when it is reasonably possible that a material loss will incur and can be estimated, or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 20, 2020, in response to an invalidation action brought against certain FibroGen United Kingdom patents by Akebia, the United Kingdom court handed down a decision invalidating United Kingdom designations of European Patent Nos. 1463823, 1633333, 2298301, 2322153, and 2322155. The United Kingdom designation to European Patent No. 2289531 was held to be valid in amended form, but not infringed by Akebia. The Company and its partner Astellas have filed an appeal of the decision in the United Kingdom Court of Appeal. The Company did not have material accruals for any currently active legal action in its consolidated balance sheets as of December&#160;31, 2020, as it could not predict the ultimate outcome of these matters, or reasonably estimate the potential exposure.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Indemnification Agreements</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into standard indemnification arrangements in the ordinary course of business, including for example, service, manufacturing and collaboration agreements. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, including in connection with intellectual property infringement claims by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the extent permissible under applicable law. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these arrangements is minimal.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090644075848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Equity and Stock-based Compensation</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Equity and Stock-based Compensation</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Subsidiary Stock and Non-Controlling Interests</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">FibroGen Europe</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, respectively, FibroGen Europe had a total of 42,619,022&#160;shares of Preferred Stock outstanding, of which there were 1,700,845 shares of Series&#160;A Preferred Stock, 1,875,000&#160;shares of Series&#160;B Preferred Stock, 1,599,503&#160;shares of Series&#160;C Preferred Stock, 1,520,141&#160;shares of Series&#160;D Preferred Stock, 459,565&#160;shares of Series&#160;E Preferred Stock, 5,714,332&#160;shares of Series&#160;F Preferred Stock, 9,927,500&#160;shares of Series&#160;G Preferred Stock and 19,822,136&#160;shares of Series&#160;H Preferred Stock, all of which shares no longer have any right to be exchanged for FibroGen, Inc. Common Stock. The holders of FibroGen Europe&#8217;s shares of Preferred Stock (&#8220;Preferred Shares&#8221;) have the following rights, preferences and privileges:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.36%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dividend Rights <span style="font-style:normal;">&#8212; When the assets of FibroGen Europe are distributed (except for distribution in a liquidation), Preferred Shares shall have the same rights to dividend or other forms of distribution as shares of Common Stock of FibroGen Europe. In the event of a merger, holders of Preferred Shares do not have the right to demand FibroGen Europe to redeem all or part of their Preferred Shares. FibroGen Europe may repurchase shares of Common Stock or Preferred Shares for consideration.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.36%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pre-emptive Right <span style="font-style:normal;">&#8212; Preferred Shares shall have pre-emptive subscription right in accordance with the Finnish Limited Liability Companies Act if additional shares are issued, option rights are given, or convertible loan is taken, </span>provided<span style="font-style:normal;">, </span>however<span style="font-style:normal;">, that the foregoing pre-emptive right does not apply to a directed share issue, for which two thirds (2/3)&#160;of the voting shares represented at a general meeting of shareholders approve for an important legitimate cause.</span></p><p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.36%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Redemption Right <span style="font-style:normal;">&#8212; If a Preferred Share can be redeemed by a majority shareholder owning more than ninety percent (90%)&#160;of the shares of FibroGen Europe in accordance with the provisions of the Finnish Limited Liability Companies Act, the minority holders of Preferred Shares have the right to request redemption of their shares.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.36%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Voting Right <span style="font-style:normal;">&#8212; Each share has one vote. Preferred Shares have voting rights only in situations that are specifically provided in the Articles of Association, which include a merger transaction and directed share issue. In addition, Preferred Shares have right to vote in a general shareholder meeting for amending the Articles of Association if the amendment will affect the rights of Preferred Shares.</span></p>

<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.36%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Conversion Right<span style="font-style:normal;"> (1-for-1 basis into Common Stock of FibroGen Europe):</span></p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.43%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.42%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Voluntary conversion right: Preferred Shares can be converted into common shares upon the written request of a shareholder provided that the conversion is feasible within the maximum and minimum amounts of shares of classes of FibroGen Europe as set forth in its Articles of Association. Such request can be withdrawn before the notification of conversion is filed with the Finnish Trade Register.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.36%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Compulsory conversion right: Preferred Shares will be converted into common shares if (i)&#160;FibroGen Europe&#8217;s shares are listed in a stock exchange or other trading system in the European Economic Area, or (ii)&#160;FibroGen Europe&#8217;s recombinant collagen and gelatin production technology is being put into commercial use in the area of Europe and certain other European states. Commercial use means there is income generated from the first commercial sale of the products incorporating the above mentioned technology and does not include license fees, development financing, milestone payments or income from test products or equipment used in research. The board of directors of FibroGen Europe shall notify the shareholders of the compulsory conversion in writing, and the shareholders shall request to convert their shares within the timeframe provided in the notification. Should the shareholders fail to make the conversion request within the time limit, FibroGen Europe may redeem the shares of such shareholders.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Liquidation Right <span style="font-style:normal;">&#8212; In the event of a dissolution of FibroGen Europe, holders of Preferred Shares are entitled to be paid in an amount equal to the subscription price of the shares before any distribution is made to holders of common shares. Among holders of Preferred Shares, holders of shares of Series F Preferred Stock are entitled to be paid in an amount equal to the subscription price of Series F Preferred Stock before any distribution is made to holders of other Preferred Shares.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">FibroGen Cayman</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen Cayman had 6,758,000 Series A Preference Shares outstanding as of December&#160;31, 2020 and 2019, respectively. The holders of the FibroGen Cayman Series A Preference Shares have the following rights, preferences and privileges:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Liquidation <span style="font-style:normal;">&#8212; In the event of liquidation, dissolution, or winding up of the Company, either voluntary or involuntary, including by means of a merger, the holders of FibroGen Cayman Series A Preference Shares are entitled to be paid an amount equal to the product of the number of shares held by a holder of shares of FibroGen Cayman Series A Preference Shares and the original issue price of $1.00 (subject to equitable adjustment for any stock dividend, combination, split, reclassification, recapitalization) plus all declared and unpaid dividends thereon.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Conversion <span style="font-style:normal;">&#8212; Each share of FibroGen Cayman Series A Preference Shares is convertible into the number of fully paid and non-assessable shares of Common Stock of FibroGen Cayman that results from dividing the original issue price by the conversion price in effect at the time of the conversion, subject to adjustments for stock splits, stock dividends, reclassifications and like events. The FibroGen Cayman Series A Preference Shares have a conversion price that is equal to the original issuance price such that the conversion ratio to FibroGen Cayman Common Stock is 1:1 as of all periods presented.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Voting <span style="font-style:normal;">&#8212; The holders of FibroGen Cayman Series A Preference Shares are entitled to vote together with the FibroGen Cayman Common Stock holders on all matters submitted for a vote of the stockholders. The holder of each share of FibroGen Cayman Series A Preference Shares has the number of votes equal to the number of shares of FibroGen Cayman Common Stock into which it is convertible.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dividends <span style="font-style:normal;">&#8212; The holders of FibroGen Cayman Series A Preference Shares are entitled to receive cash dividends when and if declared, at a rate of 6%.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Non-Controlling Interests</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling interest positions related to the issuance of subsidiary stock as described above are reported as a separate component of consolidated equity from the equity attributable to the Company&#8217;s stockholders at December&#160;31, 2020 and 2019. In addition, the Company does not allocate losses to the non-controlling interests as the outstanding shares representing the non-controlling interest do not represent a residual equity interest in the subsidiary. Upon the initial public offering and as described above, all eligible FibroGen Europe preferred shares were exchanged for 958,996 shares of FibroGen Common Stock. No other FibroGen Europe shares have the right to be exchanged for FibroGen, Inc. Common Stock.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each share of Common Stock is entitled to one vote. The holders of Common Stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares of Common Stock outstanding, shares of stock plans outstanding and shares reserved for future issuance related to stock options and RSU grants and the Company&#8217;s Employee Stock Purchase Plan (&#8220;ESPP&#8221;) purchases are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock outstanding</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,441</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,657</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,290</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs outstanding</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,893</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,483</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for future stock options and RSUs grant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,910</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,725</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for future ESPP offering</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,070</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,337</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares of common stock reserved</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,604</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,220</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock Plans</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Option and RSU Plans</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Company&#8217;s Amended and Restated 2005 Stock Plan (&#8220;2005 Stock Plan&#8221;), the Company may issue shares of Common Stock and options to purchase Common Stock and other forms of equity incentives to employees, directors and consultants. Options granted under the 2005 Stock Plan may be incentive stock options or nonqualified stock options. Incentive stock options (&#8220;ISO&#8221;) may be granted only to employees and officers of the Company. Nonqualified stock options (&#8220;NSO&#8221;) and stock purchase rights may be granted to employees, directors and consultants. The board of directors has the authority to determine to whom options will be granted, the number of options, the term and the exercise price. Options are to be granted at an exercise price not less than fair market value for an ISO or an NSO. Options generally vest over four years. Options expire no more than 10 years after the date of grant. Upon the effective date of the registration statement related to the Company&#8217;s initial public offering, the 2005 Plan was amended to cease the grant of any additional awards thereunder, although the Company will continue to issue common stock upon the exercise of previously granted stock options under the 2005 Plan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2014, the Company adopted a 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) which became effective on November&#160;13, 2014. The 2014 Plan is the successor equity compensation plan to the 2005 Plan. The 2014 Plan will terminate on November&#160;12, 2024. The 2014 Plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock awards, stock appreciation rights, performance stock awards, performance cash awards, restricted stock units and other stock awards to employees, directors and consultants. Stock options granted must be at prices not less than 100% of the fair market value at date of grant. Option vesting schedules are determined by the Company at the time of issuance and generally have a four year vesting schedule (25% vesting on the first anniversary of the vesting base date and quarterly thereafter over the next 3 years). Options generally expire ten years from the date of grant unless the optionee is a 10% stockholder, in which case the term will be five years from the date of grant. Unvested options exercised are subject to the Company&#8217;s repurchase right. Shares reserved for issuance increases on January&#160;1 of each year commencing on January&#160;1, 2016 and ending on January&#160;1, 2024 by the lesser of (i)&#160;the amount equal to 4% of the number of shares issued and outstanding on December&#160;31 immediately prior to the date of increase or (ii)&#160;such lower number of shares as may be determined by the board of directors. As of December&#160;31, 2020, the Company has reserved 7,909,854 shares of its common stock that remains unissued for issuance under the 2014 Plan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of shares upon share option exercise or share unit conversion is made through issuance of new shares authorized under the plan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain Common Stock option holders have the right to exercise unvested options, subject to a right held by the Company to repurchase the stock, at the original exercise price, in the event of voluntary or involuntary termination of employment of the stockholder. The shares are generally released from repurchase provisions ratably over four years. The Company accounts for the cash received in consideration for the early exercised options as a liability. At December&#160;31, 2020 and 2019, no shares of Common Stock were subject to repurchase by the Company.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option transactions, including forfeited options granted under the 2014 Plan as well as prior plans, are summarized below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic&#160;Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,018</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.63</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,692</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.55</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,113</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.73</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39.92</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(234</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40.11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,290</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.94</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001234">6.60</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,013</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest, December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,929</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.76</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001235">6.50</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,125</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,576</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001236">5.10</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,943</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total intrinsic value of options exercised during the years ended December&#160;31, 2020, 2019 and 2018 was $89.6 million, $59.2 million, and $97.5 million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes RSU activity:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value&#160;at&#160;Grant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,483</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.05</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,354</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.99</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(813</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45.55</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(131</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.14%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39.25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,893</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.14%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37.60</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among the vested RSUs during the year ended December&#160;31, 2020, 526,055 shares were released and issued, while the remaining was withheld for the related payroll taxes. The estimated weighted-average fair value of the awards granted during the years ended December&#160;31, 2020, 2019 and 2018 was $29.99, $54.74 and $53.69, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ESPP</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2014, the Company adopted a 2014 ESPP that became effective on November&#160;13, 2014. The 2014 ESPP is designed to enable eligible employees to periodically purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan or IRS limitations. At the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last day of the offering period. Purchases are accomplished through participation in discrete offering periods. The 2014 ESPP is intended to qualify as an ESPP under Section&#160;423 of the Internal Revenue Code. The Company has reserved 1,600,000 shares of its common stock for issuance under the 2014 ESPP and shares reserved for issuance increases January&#160;1 of each year commencing January&#160;1, 2016 by the lesser of (i)&#160;a number of shares equal to 1% of the total number of outstanding shares of common stock on December&#160;31 immediately prior to the date of increase; (ii)&#160;1,200,000 shares or (iii)&#160;such number of shares as may be determined by the board of directors. There were 143,876 shares, 135,115 shares and 230,317 shares purchased by employees under the 2014 Purchased Plan for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expected term of 2014 ESPP shares is the average of the remaining purchase periods under each offering period.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was recorded directly to research and development and selling, general and administrative expense for the years ended December&#160;31, 2020, 2019 and 2018 was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,229</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,015</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,491</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,491</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,252</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,651</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,720</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,267</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,142</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the fair value of stock options using the Black-Scholes option valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair market value of common stock is based on the closing price of the Company&#8217;s common stock as reported on the NASDAQ Global Select Market on the date of the grant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of employee stock-based compensation is estimated using the following assumptions:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Expected Term.</span><span style="color:#000000;"> Expressed as a weighted-average, the expected life of the options is based on the average period the stock options are expected to be outstanding and was based on the Company&#8217;s historical information of the option exercise patterns and post-vesting termination behavior as well as contractual terms of the instruments.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Expected Volatility.</span><span style="color:#000000;"> The Company considers its historical volatility data for volatility considerations for its ESPP. </span><span style="Background-color:#FFFFFF;">Historically, the expected volatility for all other stock-based compensation was based upon a blend of the Company&#8217;s and comparable public entities&#8217;&#160;historical volatility. Since the third quarter of 2020, the</span><span style="color:#000000;"> expected volatility for all other stock-based compensation is currently based upon the Company&#8217;s historical volatility data.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Risk-Free Interest Rate.</span><span style="color:#000000;"> Expressed as a weighted-average, the risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company&#8217;s stock options.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Expected Dividend Yield.</span><span style="color:#000000;"> The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to estimate the fair value of stock options granted and ESPPs using the Black-Scholes option valuation model were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001275">5.7</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001276">5.3</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001277">5.4</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.9</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average estimated fair value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.36</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.98</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ESPPs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001290">0.5 - 2.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001291">0.5 - 2.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001292">0.5 - 2.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001296">47.5 - 77.1</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001297">48.1 - 62.1</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001298">47.3 - 75.3</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001302">0.1 - 2.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001303">1.3 - 2.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001304">0.8 - 2.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average estimated fair value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.53</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.27</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.27</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, there was $63.9 million of total unrecognized compensation costs, net of estimated forfeitures, related to non-vested stock option awards granted that will be recognized on a straight-line basis over the weighted-average period of 2.59 years. As of December&#160;31, 2020, there was $55.5 million of total unrecognized compensation costs, net of estimated forfeitures, related to non-vested RSUs granted that will be recognized on a straight-line basis over the weighted-average period of 2.73 years.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2019, a warrant to purchase 4,430 shares of our common stock was exercised and there was no warrant to purchase shares of Common Stock outstanding at December&#160;31, 2020 and 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090649887768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net Loss Per Share</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following weighted impacts of outstanding securities were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the three years presented (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,694</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,602</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,815</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">564</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,187</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">820</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">260</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,564</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,050</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,834</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650384280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FibroGen, Inc. 401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">FibroGen, Inc. 401(k) Plan</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">FibroGen,&#160;Inc. 401(k) Plan</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company&#8217;s full-time U.S.-based employees are eligible to make contributions to the Company&#8217;s 401(k) Plan. Under this plan, participating employees may defer up to 60% of their pretax salary during the year, but not more than statutory limits. The Company may elect to match employee contributions. Matching contributions of $3.2 million, $3.0 million and $2.9 million were made during years ended December&#160;31, 2020, 2019 and 2018, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090643903832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of loss before income taxes are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Domestic</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(195,617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,538</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,472</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,686</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79,180</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,644</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before provision for income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(188,931</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76,642</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(86,116</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision for income taxes consists of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">304</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total provision for income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">304</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is the reconciliation between the statutory federal income tax rate and the Company&#8217;s effective tax rate:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax at statutory federal rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefit due to intercompany transfer of assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance on intercompany transfer of assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses not benefitted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign net operating losses not benefitted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11.6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deduction limitation on executive compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and state net operating loss carryforwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134,033</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,267</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,465</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,243</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign net operating loss carryforwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,417</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,786</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,399</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,159</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease obligations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,243</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,698</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserves and accruals</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,875</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,353</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,550</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,323</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,915</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">342,897</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222,113</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(337,824</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(213,847</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,073</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,266</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,073</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,266</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,073</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,266</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A valuation allowance has been provided to reduce the deferred tax assets to an amount management believes is more likely than not to be realized. Expected realization of the deferred tax assets for which a valuation allowance has not been recognized is based on upon the reversal of existing temporary differences and future taxable income.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The valuation allowance increased by $124.0 million, $19.9 million and $34.4 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Due to uncertainty surrounding the realization of the favorable tax attributes in the future tax returns, the Company has established a valuation allowance against its otherwise recognizable net deferred tax assets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, the Company transferred certain intellectual property rights relating to its Chinese business between its wholly owned subsidiaries that are based in different tax jurisdictions. The transferor entity was not subject to income taxes in its local jurisdiction. The acquiring entity of the intellectual property is entitled to amortize the acquisition price of the intangible assets for tax purposes. In accordance with ASU 2016-16, <span style="font-style:italic;">Intra-Entity Transfers of Assets Other Than Inventory</span>, the Company recognized a deferred tax asset of $78.7 million for the temporary difference arising from the acquirer&#8217;s excess tax basis. Furthermore, based upon the weight of available evidence, the Company recognized a full valuation allowance against this deferred tax asset since it does not currently believe that realization of this gross deductible temporary difference is more likely than not. Accordingly, this inter-company transfer did not have a material impact to the Company&#8217;s consolidated financial statements.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020, the Company had net operating loss carryforwards available to offset future taxable income of approximately $606.8 million and $133.6 million for federal and state tax purposes, respectively. These carryforwards will begin to expire in 2026 for federal and 2021 for state purposes, if not utilized before these dates. The Company also had foreign net operating loss carryforwards of approximately $172.9 million which expire between 2021 and 2030 if not utilized.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020, the Company had approximately $66.9&#160;million of federal and $32.9&#160;million of California research and development tax credit and other tax credit carryforwards available to offset future taxable income. The federal credits begin to expire in 2021 and the California research credits have no expiration dates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and state tax laws impose substantial restrictions on the utilization of net operating loss and credit carryforwards in the event of an &#8220;ownership change&#8221; for tax purposes, as defined in IRC Section&#160;382. The Company reviewed its stock ownership for year ended December&#160;31, 2020 and concluded no ownership changes occurred which would result in a reduction of its net operating loss or in its research and development credits expiring unused. If additional ownership change occurs, the utilization of net operating loss and credit carryforwards could be significantly reduced.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Uncertain Tax Positions</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had unrecognized tax benefits of approximately $48.6 million as of December&#160;31, 2020. Approximately $0.5 million of unrecognized tax benefits, if recognized, would affect the effective tax rate. The interest accrued as of December&#160;31, 2020 and 2019 was immaterial.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending amounts of unrecognized income tax benefits during the three years ended December&#160;31, 2020 is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Federal&#160;and&#160;State</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2017</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,361</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase due to prior positions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">379</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase due to current year position</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,216</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,956</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease due to prior positions</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(111</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase due to current year position</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,418</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,263</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease due to prior positions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(137</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase due to current year position</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,448</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,574</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. The Company does not anticipate a material change to its unrecognized tax benefits over the next twelve months that would affect the Company&#8217;s effective tax rate.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies interest and penalties as a component of tax expense, if any.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the U.S. federal jurisdiction, U.S. state and other foreign jurisdictions. The U.S. federal and U.S. state taxing authorities may choose to audit tax returns for tax years beyond the statute of limitation period due to significant tax attribute carryforwards from prior years, making adjustments only to carryforward attributes. The foreign statute of limitation generally remains open from 2011 to 2020. The Company is not currently under audit in any tax jurisdiction.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650642440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Related Party Transactions</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas is an equity investor in the Company and considered a related party. During the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded license and development revenue related to collaboration agreements with Astellas of $33.5 million, $158.8 million, and $35.2 million, respectively. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2020, 2019 and 2018, the Company also recorded drug product revenue from Astellas of $4.3 million, $(36.3) million, and $64.8 million, respectively. The drug product revenue from Astellas for the year ended December 31, 2020 included $8.2 million under the Japan Agreement, and a $4.0 million reduction to revenue as a change in estimated variable consideration at the time an updated listed price for roxadustat was issued by the Japanese Ministry of Health, Labour and Welfare related to roxadustat API sales in 2018. The drug product revenue from Astellas for the year ended December 31, 2019 included a change in estimated variable consideration that resulted in a $36.3 million reduction to revenue related to the product revenue of $64.8 million for API recorded in 2018. See Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, for details. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded expense related to collaboration agreements with Astellas of $0.5&#160;million, $2.8&#160;million and $1.5&#160;million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, accounts receivable from Astellas were $4.1&#160;million and $4.8&#160;million, respectively. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, total deferred revenue from Astellas were $7.5&#160;million and $0.4&#160;million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019, prepaid expenses and other current assets from Astellas was $125.2 million of net unbilled contract assets, representing a $130.0 million unbilled contract asset related to two regulatory milestones under the Europe Agreement with Astellas associated with the planned MAA submission to the EMA, net of $4.8 million of associated deferred revenue. According to the Europe Agreement, this $130.0 million is not billable to Astellas until the submission of an MAA, therefore the net contract asset was included in the prepaid expenses and other current assets line on the Company&#8217;s consolidated balance sheet as of December 31, 2019. The $130.0 million was billed to Astellas upon the submission of an MAA in the second quarter of 2020. There was no such contract asset balance as of December 31, 2020. See Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>, for details.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, amounts due to Astellas were $1.1&#160;million and $36.9&#160;million, respectively. The amounts due are included in accrued liabilities and accounts payable on the consolidated balance sheets. The amount as of December 31, 2019 included the above-mentioned $36.3 million of a change in estimated variable consideration related to the API product revenue recognized in 2018, which was fully paid during the first quarter of 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, FibroGen Beijing and AstraZeneca completed the establishment of a jointly owned entity, Falikang, which was determined to be an unconsolidated VIE. As such, Falikang is accounted for as an equity method investment, and considered as a related party to the Company. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s total investments in Falikang was </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approximately $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which is the total of the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51.1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of Falikang&#8217;s equity and the acquisition costs. In addition, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company recognized its proportionate share of the reported profits or losses of Falikang, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eginning September 15, 2020, as other income (loss) in the consolidated statement of operations, and as an adjustment to its investment in unconsolidated subsidiary in the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condensed </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated balance sheet. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang has not incurred material profit or loss to date. As of December 31, 2020, the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company&#8217;s </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">equity method </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investment in Falikang was $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> prepaid expenses and other current assets</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> included its miscellaneous receivables of $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million from Falikang. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 3, </span><span style="font-style:italic;">Acquisition and Variable Interest Entity</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for details</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090642249560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Segment and Geographic Information</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has determined that the chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). The CODM reviews financial information presented for the Company&#8217;s various clinical trial programs as well as results on a consolidated basis. License revenues and development revenues received are not allocated to various programs for purposes of determining a profit measure and resource allocation decisions are made by the CODM based primarily on consolidated results. As such, the Company has concluded that it operates as one segment. Supplemental enterprise-wide information has been presented below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Geographic Revenues</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Geographic revenues, which are based on the bill-to region, are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,161</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,400</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,916</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,660</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122,475</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,002</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,498</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,319</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256,577</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,958</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Geographic Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory by geographic location are as follows (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,715</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,815</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,887</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventory</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,530</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,887</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net by geographic location are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.08%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,673</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,325</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,974</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,418</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,647</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,743</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets and operating lease right-of-use assets, net by geographic location are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.08%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,551</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,237</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">365</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total finance lease right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,606</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,602</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,996</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,856</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,043</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,931</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Customer Concentration</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s revenues to date have been generated from the following collaboration partners that respectively accounted for 10% or more of the Company&#8217;s total revenue and accounts receivable:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.84%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage&#160;of&#160;Revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage&#160;of&#160;Accounts&#160;Receivable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas&#8212;Related party</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company started selling roxadustat in China since late 2019 through a growing number of pharmaceutical distributors located in China. For the year ended December 31, 2020, the aggregate revenue from distributors represented 42% of the consolidated revenue, with no individual distributor representing over 10% of the total revenue. As of December 31, 2020, the aggregate accounts receivable from distributors represented 64% of the consolidated accounts receivable, with no material balance from any individual distributor. The aggregate revenue from distributors for the year ended December 31, 2019 and the aggregate accounts receivable from distributors as of December 31, 2019 were immaterial.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090644470664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>Valuation And Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule II - Valuation and Qualifying Accounts</a></td>
<td class="text">
<p id="SCHEDULE_II" style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Schedule II: Valuation and Qualifying Accounts</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Charged</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Charged</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">to Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance&#160;at</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Credited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts -</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beginning&#160;of</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">to Statement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deductions,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance&#160;at</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.78%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Operation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Equity</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.56%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End&#160;of&#160;Year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowances for deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year ended December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213,847</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123,977</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337,824</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year ended December&#160;31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193,987</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,860</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213,847</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year ended December&#160;31, 2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,540</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,447</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193,987</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Allowances for rebates and discounts</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year ended December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,102</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,497</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,867</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,184</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">548</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.78%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year ended December&#160;31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,102</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,102</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090651742008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;). <span style="color:#000000;">The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and its majority-owned subsidiaries, FibroGen Europe and FibroGen China Anemia Holdings, Ltd. (&#8220;FibroGen Cayman&#8221;). All inter-company transactions and balances have been eliminated in consolidation. For any variable interest entity for which FibroGen is not the primary beneficiary, the Company uses the equity method of accounting.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one segment &#8212; the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entity</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Variable Interest Entity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Accounting Standards Codification (&#8220;ASC&#8221;) 810, <span style="font-style:italic;">Consolidation </span>(&#8220;ASC 810&#8221;), when the Company obtains an economic interest in an entity, it evaluates the entity to determine if it should be deemed a variable interest entity (&#8220;VIE&#8221;), and, if so, whether the Company is the primary beneficiary and is therefore required to consolidate the VIE, based on significant judgment whether the Company (i) has the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) has the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an ongoing basis, the Company re-evaluates </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the VIE assessment based on potential changes in facts and circumstances, including but not limited to, the shareholder loans to the entity and the execution of any future significant agreements between the entity and its shareholders and/or other third parties.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency Translation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reporting currency of the Company and its subsidiaries is the U.S. dollar. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of FibroGen Europe is the Euro. The assets and liabilities of FibroGen Europe are translated to U.S. dollars at exchange rates in effect at the balance sheet date. All income statement accounts are translated at monthly average exchange rates. Resulting foreign currency translation adjustments are recorded directly in accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to April 1, 2020, the functional currency of the Company&#8217;s subsidiary, FibroGen (China) Medical Technology Development Co., Ltd. (&#8220;FibroGen Beijing&#8221;), was the U.S. dollar. Accordingly, monetary assets and liabilities of FibroGen Beijing in the currencies other than U.S. dollar were remeasured using exchange rates in effect at the end of the period. Revenues and costs in its local currency, Renminbi Yuan (&#8220;CNY&#8221;), were remeasured using average exchange rates for the period, except for costs related to those balance sheet items that were remeasured using historical exchange rates. The resulting remeasurement gains and losses were included within interest income and other, net in the consolidated statements of operations as incurred. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 1, 2020, FibroGen Beijing adopted CNY as its functional currency based on reassessment of the primary economic operational environment of FibroGen Beijing that is mainly associated with its growing manufacturing and product sales activities conducted in CNY. As such, monetary assets and liabilities of FibroGen Beijing in currencies other than CNY are remeasured using exchange rates in effect at the end of the period. The assets and liabilities of FibroGen Beijing are translated to U.S. dollars at exchange rates in effect at the balance sheet date. All income statement accounts are translated at monthly average exchange rates. Resulting foreign currency translation adjustments are recorded directly in accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity. This change in FibroGen Beijing&#8217;s functional currency was accounted for prospectively from April 1, 2020, and the prior consolidated financial statements were not restated. The related currency translation adjustment was $1.3 million at April 1, 2020 upon adoption.<span style="font-size:12pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of FibroGen, Inc. and all other subsidiaries is the U.S. dollar. Accordingly, monetary assets and liabilities in the non-functional currency of these subsidiaries are remeasured using exchange rates in effect at the end of the period. Revenues and costs in local currency are remeasured using average exchange rates for the period, except for costs related to those balance sheet items that are remeasured using historical exchange rates. The resulting remeasurement gains and losses are included within interest income and other, net in the consolidated statements of operations as incurred and have not been material for all periods presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks associated with concentration of credit for cash and cash equivalents. Outside of short-term operating needs, the majority of cash on hand is invested in U.S. treasuries and money market funds. Any remaining cash is deposited with major financial institutions in the U.S., Finland, China and the Cayman Islands. At times, such deposits may be in excess of insured limits. The Company has not experienced any loss on its deposits of cash and cash equivalents. Included in current assets are significant balances of accounts receivable as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas Pharma Inc. (&#8220;Astellas&#8221;)&#8212;Related party</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca AB (&#8220;AstraZeneca&#8221;)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company started selling roxadustat in China since late 2019 through a growing number of pharmaceutical distributors located in China. As of December 31, 2019, the aggregate accounts receivable from distributors was immaterial. As of December 31, 2020, along with the growing roxadustat sales in China, the aggregate accounts receivable from distributors represented 64% of the consolidated accounts receivable, with no material balance from any individual distributor.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_OtherRisksAndUncertaintiesPolicyTextBlock', window );">Other Risks and Uncertainties</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s business is subject to risks and uncertainties, including those related to COVID-19 and the related shelter-in-place, stay-at-home and other similar governmental orders issued in response to the COVID-19 pandemic.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, obtaining second source suppliers, <span style="font-size:9.5pt;">regulatory approval from the FDA or other regulatory authorities, </span>the results of clinical trials and the achievement of milestones, market acceptance of the Company&#8217;s product candidates, competition from other products and larger companies, protection of proprietary technology, strategic relationships and dependence on key individuals.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Starting in the first quarter of 2020, the Company experienced slower enrollment in its clinical trials due to the interruption caused by COVID-19 in the worldwide healthcare system. The future impact of the COVID-19 pandemic on the Company&#8217;s business is highly uncertain and difficult to predict. The COVID-19 pandemic may continue to affect enrollment in and initiation of the Company&#8217;s clinical trials, and could affect the Company&#8217;s supply chain if further social distancing and other business restrictions are put in place by various government entities, particularly in China and the U.S. COVID-19 may affect the health of the Company&#8217;s employees limiting the Company&#8217;s productivity. The COVID-19 pandemic may also impact the market for the Company&#8217;s products and product candidates in the future, affecting sales of the Company&#8217;s products. Such possible risks and uncertain impacts from the COVID-19 pandemic could have a material adverse effect on the Company&#8217;s drug development, commercialization revenues, and other portions of its business, and in particular, could impact the Company&#8217;s assumptions of accounts receivable collectability, fair value measurements of investments, liquidity, and development costs. The extent of the pandemic&#8217;s effect on the Company&#8217;s operational and financial performance will depend in large part on future developments, particularly with respect to the scope and severity of the pandemic, governmental restrictions put in place to fight the pandemic, and the development of vaccines and treatments for COVID-19. Due to the inherent uncertainty of the unprecedented and rapidly evolving situation, the Company is unable to estimate the likely impact of the COVID-19 pandemic on its future operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Time Deposits</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash, Cash Equivalents and Restricted Time Deposits</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with maturities of three months or less and that are used in the Company&#8217;s cash management activities at the date of purchase to be cash equivalents. Cash and cash equivalents also include money market accounts and various deposit accounts. Restricted time deposits include an irrevocable standby letter of credit as security deposit for a long-term property lease with the Company&#8217;s landlord. Restricted time deposits as of December&#160;31, 2020 and 2019 totaled $2.1 million and $2.1&#160;million, respectively. As of December&#160;31, 2020 and 2019, a total of $66.0 million and $11.9 million, respectively, of the Company&#8217;s cash and cash equivalents was held outside of the U.S. in the Company&#8217;s foreign subsidiaries to be used primarily for the Company&#8217;s China operations.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company&#8217;s investments consist of diversified bond funds and marketable equity investments. Those investments with original maturities of greater than three months and remaining maturities of less than 12&#160;months (365 days) are considered short-term investments. Those investments with maturities greater than 12 months (365 days) from the balance sheet date are considered long-term investments. When such investments are held, the Company&#8217;s investments classified as available-for-sale are recorded at fair value based upon quoted market prices at period end. Unrealized gains and losses for available-for-sale debt investments that are deemed temporary in nature are recorded in accumulated other comprehensive income (loss) as a separate component of stockholder&#8217; equity. Marketable equity securities are equity securities with readily determinable fair value, and are measured and recorded at fair value. Realized and unrealized gains or losses resulting from changes in value and sale of the Company&#8217;s marketable equity investments are recorded in other income (expenses) in the consolidated statement of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Premiums and discounts are amortized (accreted) over the life of the related security as an adjustment to its yield. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of investments sold.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carrying amounts of certain of the Company&#8217;s financial instruments including cash equivalents, investments, receivables, accounts payable and accrued liabilities approximate fair value (refer to Note 5, <span style="font-style:italic;">Fair Value Measurements</span>).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade Accounts Receivable</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Trade accounts receivable</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The allowance for doubtful accounts is based on the Company&#8217;s assessment of the collectability of customer accounts. The Company makes estimates of expected credit losses for the allowance for doubtful accounts by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, current economic and regulatory conditions that may affect a customer&#8217;s ability to pay, and estimates of expected future losses. The Company&#8217;s bad debt expense for the years ended December&#160;31, 2020, 2019 and 2018 and the allowance for doubtful accounts as of December&#160;31, 2020 and 2019 were immaterial.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Credit Losses &#8211; Available-for-sale Debt Securities</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Credit losses &#8211; Available-for-sale debt securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company periodically assesses its available-for-sale investments for other-than-temporary impairment. For debt securities in an unrealized loss position, the Company first considers its intent to sell, or whether it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis. If either of these criteria are met, the amortized cost basis of such debt securities is written down to fair value through interest and other, net. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in the fair value of such debt securities has resulted from credit losses or other factors. The Company considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the securities, among other factors. If this assessment indicates that a credit loss may exist, the Company then compares the present value of cash flows expected to be collected from such securities to their amortized cost basis. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded through interest and other, net, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive income.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in the allowance for credit losses are recorded as provision for, or reversal of, credit loss expense. Losses are charged against the allowance when the Company believes that an available-for-sale security is confirmed uncollectable or when either of the criteria regarding intent or requirement to sell is met.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories are stated at the lower of cost or net realizable value, on a first-in, first-out, or FIFO, basis. The cost of the Company&#8217;s inventories in China is determined using full absorption and standard costing method. The Company reviews the standard cost of raw materials, work-in-process and finished goods annually and more often as appropriate to ensure that its inventories approximate current actual cost. The cost of the Company&#8217;s inventories in the U.S. uses actual costs to determine its cost basis. The cost of inventories includes direct material cost, direct labor and manufacturing overhead.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When the technical feasibility of the Company&#8217;s future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, the Company capitalizes pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the status in the validation process in significant jurisdictions, regulatory application and approval process, and terms and condition for future sale of such inventory or future alternative use. The pre-launch inventory cost includes purchase cost of raw materials, <span style="color:#000000;">cost paid to contract manufacturers for inventory manufacturing, freight and custom charges, and certain direct internal labor and overhead expenses.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company <span style="color:#auto;">periodically</span> reviews its inventories to identify obsolete, slow-moving, excess or otherwise unsaleable items. If obsolete, excess or unsaleable items are observed and there are no alternate uses for the <span style="color:#auto;">inventory</span>, an inventory valuation adjustment is recorded through a charge to cost of goods sold on the Company&#8217;s consolidated statements of operations. The establishment of inventory valuation reserves, together with the calculation of the amount of such reserves, requires judgment including consideration of many factors, such as estimates of future product demand and product expiration period, among others.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Computer equipment, laboratory equipment, machinery and furniture and fixtures are depreciated over three to five years. Leasehold improvements are recorded at cost and amortized over the term of the lease or their useful life, whichever is shorter.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is or contains a lease at inception date when it is given control of the underlying assets. The Company elected the practical expedient not to apply the lease recognition and measurement requirements to short-term leases, which is any lease with a term of 12 months or less as of the commencement date that does not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s building leases previously accounted for as build-to-suit arrangements prior to the adoption of Accounting Standards Codification (&#8220;ASC&#8221;) 842 - <span style="font-style:italic;">Leases</span> (&#8220;ASC 842&#8221;) are accounted for as finance leases under the requirements of ASC 842.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease right-of-use (&#8220;ROU&#8221;) assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As its leases do not typically provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company reassesses the incremental borrowing rate periodically for application to any new leases or lease modifications, which approximates the rate at which the Company would borrow, on a secured basis, in the country where the lease was executed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease ROU assets include any lease payments made and initial direct costs incurred. The Company has lease agreements with lease and non-lease components. The Company generally accounts for each lease component separately from the non-lease components, and excludes all non-lease components from the calculation of minimum lease payments in measuring the ROU asset and lease liability. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease terms. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regarding leases denominated in a foreign currency, the related ROU assets and the corresponding ROU asset amortization costs are remeasured using the exchange rate in effect at the date of initial recognition; the related lease liabilities are remeasured using the exchange rate in effect at the end of the reporting period; the lease costs and interest expenses related to lease liability accretion are remeasured using average exchange rates for the reporting period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases are included in finance lease ROU assets, finance lease liabilities, current and non-current on the Company&#8217;s consolidated balance sheets. Operating leases are included in other assets, accrued and other current liabilities, and other long-term liabilities on the Company&#8217;s consolidated balance sheets.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. If the Company determines that an impairment trigger has been met, the Company evaluates the realizability of its long-lived assets based on a comparison of projected undiscounted cash flows from use and eventual disposition with the carrying value of the related asset. Any write-downs (which are measured based on the difference between the fair value and the carrying value of the asset) are treated as permanent reductions in the carrying amount of the assets (asset group). Based on this evaluation, the Company believes that, as of each of the balance sheet dates presented, none of the Company&#8217;s long-lived assets were impaired. The Company&#8217;s impairment of long-lived assets for the years ended December&#160;31, 2020, 2019 and 2018 were immaterial.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenues under collaboration agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s collaboration agreements include multiple performance obligations comprised of promised services, or bundles of services, that are distinct. Services that are not distinct are combined with other services in the agreement until they form a distinct bundle of services. The Company&#8217;s process for identifying performance obligations and an enumeration of each obligation for each agreement is outlined in Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>. Determining the performance obligations within a collaboration agreement often involves significant judgment and is specific to the facts and circumstances contained in each agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified the following material promises under its collaboration agreements: (1) license of FibroGen technology, (2) the performance of co-development services, including manufacturing of clinical supplies and other services during the development period, and (3) manufacture of commercial supply. The evaluation as to whether these promises are distinct, and therefore represent separate performance obligations, is described in more details in Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For revenue recognition purposes, the Company determines that the term of its collaboration agreements begin on the effective date and ends upon the completion of all performance obligations contained in the agreements. In each agreement, the contract term is defined as the period in which parties to the contract have present and enforceable rights and obligations. The Company believes that the existence of what it considers to be substantive termination penalties on the part of the counterparty create sufficient incentive for the counterparty to avoid exercising its right to terminate the agreement unless in exceptionally rare situations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price for each collaboration agreement is determined based on the amount of consideration the Company expects to be entitled for satisfying all performance obligations within the agreement. The Company&#8217;s collaboration agreements include payments to the Company of one or more of the following: non-refundable upfront license fees; co-development billings; development, regulatory, and commercial milestone payments; payments from sales of active pharmaceutical ingredient (&#8220;API&#8221;); payments from sales of bulk drug product and royalties on net sales of licensed products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront license fees are non-contingent and non-refundable in nature and are included in the transaction price at the point when the license fees become due to the Company. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-development billings resulting from the Company&#8217;s research and development efforts, which are reimbursable under its collaboration agreements, are considered variable consideration. Determining the reimbursable amount of research and development efforts requires detailed analysis of the terms of the collaboration agreements and the nature of the research and development efforts incurred. Determining the amount of variable consideration from co-development billings requires the Company to make estimates of future research and development efforts, which involves significant judgment. Co-development billings are allocated entirely to the co-development services performance obligation when amounts are related specifically to research and development efforts necessary to satisfy the performance obligation, and such an allocation is consistent with the allocation objective.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Milestone payments are also considered variable consideration, which requires the Company to make estimates of when achievement of a particular milestone becomes probable. Similar to other forms of variable consideration, milestone payments are included in the transaction price when it becomes probable that such inclusion would not result in a significant revenue reversal. Milestone payments are therefore included in the transaction price when achievement of the milestone becomes probable.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For arrangements that include sales-based royalties and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from its collaboration arrangements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is allocated to performance obligations based on their relative standalone selling price (&#8220;SSP&#8221;), with the exception of co-development billings allocated entirely to co-development services performance obligations. The SSP is determined based on observable prices at which the Company separately sells the products and services. If an SSP is not directly observable, then the Company will estimate the SSP considering marketing conditions, entity-specific factors, and information about the customer or class of customer that is reasonably available. The process for determining SSP involves significant judgment and includes consideration of multiple factors, including assumptions related to the market opportunity and the time needed to commercialize a product candidate pursuant to the relevant license, estimated direct expenses and other costs, which include the rates normally charged by contract research and contract manufacturing organizations for development and manufacturing obligations, and rates that would be charged by qualified outsiders for committee services.&#160;&#160; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant judgment may be required in determining whether a performance obligation is distinct, determining the amount of variable consideration to be included in the transaction price, and estimating the SSP of each performance obligation. An enumeration of the Company&#8217;s significant judgments is outlined in Note 4, <span style="font-style:italic;">Collaboration Agreements and Revenues</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each performance obligation identified within an arrangement, the Company determines the period over which the promised services are transferred and the performance obligation is satisfied. Service revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. For each performance obligation satisfied over time, the Company assesses the proper method to be used for revenue recognition, either an input method to measure progress toward the satisfaction of services or an output method of determining the progress of completion of performance obligation.<span style="font-weight:bold;font-style:italic;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Drug product revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue includes commercial-grade API or bulk drug product sales to AstraZeneca and Astellas, and is recognized when the Company fulfills the shipment obligations. The drug product revenue is accounted for as variable consideration, estimated at the time of sale using the expected value method. The Company applies significant judgment in estimating the variable consideration, which involves the use of significant assumptions such as the future list price adjustments set by the Japanese Ministry of Health, Labour and Welfare, product mix, and timing of processing of API into bulk drug product.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, FibroGen and Astellas entered into an amendment to the Japan Agreement that allows Astellas to manufacture roxadustat drug product for commercialization in Japan (the &#8220;Japan Amendment&#8221;). Under this amendment, FibroGen would continue to manufacture and supply roxadustat API to Astellas for the roxadustat commercial launch in Japan. The drug product revenue represents variable consideration and is estimated based on the quantity of product shipped, actual listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and possible future changes to the listed price, adjusted for the timing of and estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk drug product tablets, and estimated yield from the manufacture of bulk product tablets, among others.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Europe Agreement with Astellas, Astellas has an option to purchase roxadustat bulk drug product in support of commercial supplies. The drug product revenue amount represents variable consideration and was estimated based on the quantity of product shipped and an estimated price. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price per strength, which is estimated to be realized by Astellas from the end sale of roxadustat in its approved territories.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, the Company entered into Commercial Supply Agreement under the U.S./RoW Agreement with AstraZeneca to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The drug product revenue amount represents variable consideration and was estimated based on the quantity of product shipped and an estimated price. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price per strength, which is estimated to be realized by AstraZeneca from the end sale of roxadustat in its approved territories.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of variable consideration that is included in the transaction price may be constrained, and is included in the drug product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. Estimating variable consideration and the related constraint requires the use of significant management judgment. The Company reviews new information that may affect its variable consideration estimate at every reporting period and record revenue adjustment, if certain and material. Actual amounts of consideration ultimately received in the future may differ from the Company&#8217;s estimates, for which the Company will adjust these estimates and affect the drug product revenue in the period such variances become known. The amount constrained as of December 31, 2020 was $6.0 million related to the drug product shipment to Astellas under the Europe Agreement in the fourth quarter of 2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As each of the Company&#8217;s collaboration agreements provide for annual true up to the considerations paid for its commercial supplies, the Company will re-evaluate the transaction price in each reporting period and record adjustment to revenue as uncertain events are resolved or other changes in circumstances occur.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product revenue, net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sells roxadustat in China through a number of pharmaceutical distributors located in China. These pharmaceutical distributors are the Company&#8217;s customers. Hospitals order roxadustat through a distributor and the Company ships the product directly to the distributors. The delivery of roxadustat to a distributor represents a single performance obligation.&#160;Distributors are responsible for delivering product to end users, primarily hospitals. Distributors bear inventory risk once they receive and accept the product. Product revenue is recognized when control of the promised good is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for the product. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The period between the transfer of control of the promised goods and when the Company receives payment is based on a general 60-day payment term. As such, product revenue is not adjusted for the effects of a significant financing component. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue is recorded at the net sales prices (transaction price) which includes the following estimates of variable consideration:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Price adjustment:</span><span style="color:#000000;"> In December 2019, China&#8217;s National Healthcare Security Administration released price guidance for roxadustat under the National Reimbursement Drug List (&#8220;NRDL&#8221;), effective January 1, 2020. Any channel inventories as of January 1, 2020 that had not been sold to hospitals by distributors, or to patients by hospitals, were eligible for a price adjustment under the price protection. The price adjustment is calculated based on estimated channel inventory levels at January 1, 2020. If price guidance changes in the future, the price adjustment will be calculated in the same manner;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Contractual sales rebate</span><span style="color:#000000;">: The contractual sales rebate is calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. The contractual sales rebate is recorded as a reduction to revenue at the point of sale to the distributor;&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Key account hospital sales rebate</span><span style="color:#000000;">: An additional sales rebate is provided to a distributor for product sold to key account hospitals as a percentage of gross sales made by the distributor to eligible hospitals. This additional rebate is recorded as a reduction to revenue at the point of sale to the distributor; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Transfer fee discount</span><span style="color:#000000;">: The transfer fee discount is offered to a distributor who has its downstream distributors supply to eligible hospitals. This discount is calculated based on a percentage of gross sales made to the downstream distributors, and recorded as a reduction to revenue as incurred; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Sales return</span><span style="color:#000000;">: Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product&#8217;s expiration date; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Non-key account hospital listing award: </span><span style="color:#000000;">A one-time fixed-amount award is offered to a distributor who successfully lists the product with an eligible hospital, and who meets certain requirements. The Company considers this particular award to be an upfront payment to a customer within the definitions of ASC 606. The non-key account hospital listing award is capitalized when the distributor meets eligibility requirements, and amortized as reduction to product revenue over future sales orders made by the distributor until exhausted. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The calculation of the above variable consideration is based on gross sales to the distributor, or estimated utilizing best available information from the distributor, maximum known exposures and other available information including estimated channel inventory levels and estimated sales made by the distributor to hospitals, which involve a substantial degree of judgment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above rebates and discounts all together are eligible to be applied against the distributor&#8217;s future sales order, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible and in the same period that the related revenue is recorded. Due to the distributor&#8217;s legal right to offset, at each balance sheet date, the liability for rebates and discounts are presented as reductions of gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The distributor&#8217;s legal right of offset is calculated at the individual distributor level.<span style="font-weight:bold;color:#FF0000;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of independent research and development costs and the gross amount of costs associated with work performed under collaboration agreements. Research and development costs include employee-related expenses, expenses incurred under agreements with clinical research organizations, other clinical and preclinical costs and allocated direct and indirect overhead costs, such as facilities costs, information technology costs and other overhead. All research and development costs are expensed as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ClinicalTrialAccrualPolicyTextBlock', window );">Clinical Trial Accruals</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trial Accruals</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with clinical research organizations and clinical sites. The Company determines the costs to be recorded based upon validation with the external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Selling, General and Administrative Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses consist primarily of employee-related expenses for executive, operational, finance, legal, compliance and human resource functions. SG&amp;A expenses also include facility-related costs, professional fees, accounting and legal services, other outside services including co-promotional expenses, recruiting fees and expenses associated with obtaining and maintaining patents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes the asset and liability method of accounting for income taxes, which requires the recognition of deferred tax assets and liabilities for expected future consequences of temporary differences between the financial reporting and income tax bases of assets and liabilities using enacted tax rates. Management makes estimates, assumptions and judgments to determine the Company&#8217;s provision for income taxes and for deferred tax assets and liabilities, and any valuation allowances recorded against the Company&#8217;s deferred tax assets. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The calculation of the Company&#8217;s current provision for income taxes involves the use of estimates, assumptions and judgments while taking into account current tax laws, interpretation of current tax laws and possible outcomes of future tax audits. The Company has established reserves to address potential exposures related to tax positions that could be challenged by tax authorities. Although the Company believes its estimates, assumptions and judgments to be reasonable, any changes in tax law or its interpretation of tax laws and the resolutions of potential tax audits could significantly impact the amounts provided for income taxes in the Company&#8217;s consolidated financial statements.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The calculation of the Company&#8217;s deferred tax asset balance involves the use of estimates, assumptions and judgments while taking into account estimates of the amounts and type of future taxable income. Actual future operating results and the underlying amount and type of income could differ materially from the Company&#8217;s estimates, assumptions and judgments thereby impacting the Company&#8217;s financial position and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, the Company transferred certain intellectual property rights relating to its Chinese business between its wholly owned subsidiaries that are based in different tax jurisdictions. Refer to Note 13, <span style="font-style:italic;">Income Taxes</span>, for more information. The establishment of a deferred tax asset from the intra-entity transfer of intangible assets required the Company to make significant estimates and assumptions to determine the fair value of intellectual property rights transferred, which include but are not limited to, its expectations of discount rate, revenue volume and price.<span style="Background-color:#F8F9FA;color:#202124;"> The accuracy of these estimates could be affected by unforeseen events or actual results, and the sustainability of the Company&#8217;s future tax benefits is dependent upon the acceptance of these valuation estimates and assumptions by the taxing authorities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has adopted ASC 740-10, <span style="font-style:italic;">Accounting for Uncertainty in Income Taxes</span>, that prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company&#8217;s income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company includes interest and penalties related to unrecognized tax benefits within income tax expense in the Consolidated Statements of Operations. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains equity incentive plans under which incentive and nonqualified stock options are granted to employees and non-employee consultants. Compensation expense relating to non-employee stock options has not been material for all the periods presented.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures and recognizes compensation expense for all stock options and restricted stock units (&#8220;RSUs&#8221;) granted to its employees and directors based on the estimated fair value of the award on the grant date. The Company uses the Black-Scholes valuation model to estimate the fair value of stock option awards. The fair value is recognized as expense, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective award, on a straight-line basis. The Company believes that the fair value of stock options granted to non-employees is more reliably measured than the fair value of the services received. The determination of the grant date fair value of options using an option pricing model is affected by the Company&#8217;s estimated Common Stock fair value and requires management to make a number of assumptions including the expected life of the option, the volatility of the underlying stock, the risk-free interest rate and expected dividends.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the fair value of stock options using the Black-Scholes option valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair market value of common stock is based on the closing price of the Company&#8217;s common stock as reported on the NASDAQ Global Select Market on the date of the grant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of employee stock-based compensation is estimated using the following assumptions:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Expected Term.</span><span style="color:#000000;"> Expressed as a weighted-average, the expected life of the options is based on the average period the stock options are expected to be outstanding and was based on the Company&#8217;s historical information of the option exercise patterns and post-vesting termination behavior as well as contractual terms of the instruments.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Expected Volatility.</span><span style="color:#000000;"> The Company considers its historical volatility data for volatility considerations for its ESPP. </span><span style="Background-color:#FFFFFF;">Historically, the expected volatility for all other stock-based compensation was based upon a blend of the Company&#8217;s and comparable public entities&#8217;&#160;historical volatility. Since the third quarter of 2020, the</span><span style="color:#000000;"> expected volatility for all other stock-based compensation is currently based upon the Company&#8217;s historical volatility data.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Risk-Free Interest Rate.</span><span style="color:#000000;"> Expressed as a weighted-average, the risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company&#8217;s stock options.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="text-decoration:underline;color:#000000;">Expected Dividend Yield.</span><span style="color:#000000;"> The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future.</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Income (Loss)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to report all components of comprehensive income (loss), including net loss, in the consolidated financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency translation adjustments. Comprehensive gains (losses) have been reflected in the consolidated statements of comprehensive income (loss) for all periods presented.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock', window );">Recently Issued and Adopted Accounting Guidance</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued and Adopted Accounting Guidance</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-15, <span style="font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. </span>This guidance requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This guidance was effective for annual reporting periods beginning after December 15, 2019, including interim periods. The Company adopted this guidance on January 1, 2020 using the prospective method, and the adoption of this guidance did not have material impact to the Company&#8217;s consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span>(&#8220;ASU 2016-13&#8221;). This guidance is intended to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. This guidance requires the measurement of financial assets with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. This guidance requires an impairment model, known as the current expected credit loss model, which is based on expected losses rather than incurred losses. Entities are required to carry an allowance for expected credit losses for financial assets, including most debt instruments (except those carried at fair value) and trade receivables. In November 2019, the FASB issued ASU No. 2019-11, <span style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments-Credit Losses </span>(&#8220;ASU 2019-11&#8221;)<span style="font-style:italic;">, </span>which has the same effective dates and transition requirements as ASU 2016-13. ASU 2016-13 and ASU 2019-11 were effective for annual reporting periods beginning after December 15, 2019 including interim periods. The Company&#8217;s investment portfolio primarily consists of U.S. Treasury bills and notes carried at fair value, which is required to follow the impairment model under Topic 326. The Company adopted this guidance on January 1, 2020. Based on the composition of the Company&#8217;s trade receivables and investment portfolio, economic conditions and historical credit loss activity, the adoption of this guidance did not have material impact to the Company&#8217;s consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02, <span style="font-style:italic;">Leases (Topic 842). </span>The Company adopted the lease guidance under ASC 842 as of January 1, 2019, using the modified retrospective transition method, through a cumulative-effect adjustment. The adoption of this guidance resulted in a reduction of $8.7 million to the Company&#8217;s accumulated deficit and also impacted various balance sheet line items in its consolidated balance sheet as of January 1, 2019 upon adoption. The adoption of this guidance did not have a material impact to the Company&#8217;s consolidated statement of operations or consolidated statement of cash flows for the year ended December 31, 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, the FASB issued ASU 2018-02, <span style="font-style:italic;">Income Statement - Reporting Comprehensive Income: Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</span>. The Company adopted this guidance on January 1, 2019 using the modified retrospective approach, with a reduction of $0.6 million to its accumulated other comprehensive loss and an increase of $0.6 million to its accumulated deficit as of January 1, 2019 upon adoption. The adoption of this guidance had no impact to the Company&#8217;s consolidated statement of operations or consolidated statement of cash flows for the year ended December 31, 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2016, the FASB issued ASU 2016-01, <span style="font-style:italic;">Financial Instruments-Overall (Subtopic 825-10)</span>. The Company adopted this guidance as of January 1, 2018 using the modified retrospective approach, with an increase of $1.3 million to its accumulated other comprehensive loss and a reduction of $1.3 million to its accumulated deficit as of January 1, 2018 upon adoption. The adoption of this guidance had no impact to the Company&#8217;s consolidated statement of cash flows for the year ended December 31, 2018. </p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock', window );">Recently Issued Accounting Guidance Not Yet Adopted</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Guidance Not Yet Adopted</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the FASB issued ASU 2020-04, <span style="font-style:italic;">Reference Rate Reform (Topic 848): </span><span style="font-style:italic;color:#000000;">Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span> (&#8220;ASU<span style="font-style:italic;"> </span>2020<span style="font-style:italic;">-</span>04<span style="font-style:italic;">&#8221;</span>)<span style="font-style:italic;">,</span> which provides companies with optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform. This guidance is effective as of March 12, 2020 through December 31, 2022. Subsequently in January 2021, the FASB issued ASU 2021-01, <span style="font-style:italic;">Reference Rate Reform (Topic 848): Scope</span>, which clarifies ASU 2020-04 and provides certain optional expedients that allow derivative instruments impacted by changes in the interest rate used for margining, discounting or contract price alignment to qualify for certain optional relief. ASU 2021-01 is effective in the same timeframe as ASU 2020-04. The relief offered by this guidance, if adopted, is available to companies for the period March 12, 2020 through December 31, 2022. <span style="Background-color:#FFFFFF;">The Company has certain lease arrangements that are linked to LIBOR. The Company is in the process of evaluating options for transitioning away from LIBOR and expects to complete by the time LIBOR is phased out. The Company did not elect to apply any of the expedients or exceptions as of and for the year ended December 31, 2020 and is currently evaluating the impact on its consolidated financial statements and related disclosures upon adoption of this guidance.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span>. This guidance simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step up in the tax basis of goodwill, and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. This guidance is effective for annual reporting periods beginning after December 15, 2020 including interim periods, with early adoption permitted. The Company does not plan to early adopt this guidance and does not anticipate a material impact to its consolidated financial statements upon adoption of this guidance.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock', window );">Collaboration Arrangements and Revenues</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Astellas Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Japan Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2005, the Company entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (&#8220;Japan Agreement&#8221;). Under this agreement, Astellas paid license fees and other consideration totaling $40.1&#160;million (such amounts were fully received as of February 2009). Under the Japan Agreement, the Company is also eligible to receive from Astellas an aggregate of approximately $132.5&#160;million in potential milestone payments, comprised of (i)&#160;up to $22.5&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of July 2016), (ii)&#160;up to $95.0&#160;million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $15.0&#160;million in milestone payments upon the achievement of specified commercial sales milestone. The Japan Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range of the list price published by the Japanese Ministry of Health, Labour and Welfare, adjusted for certain elements, after commercial launch. The aggregate amount of the considerations received under the Japan Agreement, through December&#160;31, 2020 totals $105.1 million, excluding drug product revenue that is discussed separately below.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fourth quarter of 2020, the Japanese Ministry of Health, Labour and Welfare approved EVRENZO&#174; (roxadustat) for the treatment of anemia of CKD in adult patients not on dialysis. This approval triggered a $15.0 million milestone payable to the Company by Astellas under the Japan Agreement. Accordingly, the consideration of $15.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the Japan Agreement in the fourth quarter of 2020, substantially all of which was recognized as revenue during the year ended December 31, 2020 from performance obligations satisfied or partially satisfied.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Septembe</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r 2019, the Japanese Ministry of Health, Labour and Welfare approved EVRENZO&#174; (generic name: roxadustat; tradename EVRENZO&#174; in Japan) for the treatment of anemia associated with CKD in dialysis patients. This approval triggered a $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.5 million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> milestone </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payable to the Company by Astellas under the Japan Agreement. Accordingly, the consideration of $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.5</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million associated with this milestone was included in the transaction price and allocated to performance obligations under the Japan Agreement in the t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hird quarter of 2019, substantially all of which was recognized as revenue during the year ended December 31, 2019 from performance obligations satisfied or partially satisfied.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2018, Astellas reported positive results from the final phase 3 CKD-dialysis trial of roxadustat in Japan, indicating that Astellas was ready to make an NDA submission for the treatment of anemia with roxadustat in CKD-dialysis patients in 2018. The Company evaluated the regulatory milestone payment associated with NDA submission in Japan based on variable consideration requirements under the current revenue standards and concluded that this milestone became probable of being achieved in the second quarter of 2018. Accordingly, the consideration of $15.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the Japan Agreement in the second quarter of 2018, substantially all of which was recognized as revenue during the year ended December 31, 2018 from performance obligations satisfied or partially satisfied. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, FibroGen and Astellas entered into an amendment to the Japan Agreement that allows Astellas to manufacture roxadustat drug product for commercialization in Japan (the &#8220;Japan Amendment&#8221;). Under this amendment, FibroGen would continue to manufacture and supply roxadustat API<span style="font-weight:bold;"> </span>to Astellas for the roxadustat commercial launch in Japan. The commercial terms of the Japan Agreement relating to the transfer price for roxadustat for commercial use remain substantially the same, reflecting an adjustment for the manufacture of drug product by Astellas rather than FibroGen. The Company fulfilled shipment obligations under the term of the Japan Amendment in the second quarter of 2020 and in 2018. The related drug product revenue, as described in details under <span style="font-style:italic;">Drug Product Revenue</span> section below, were $4.3 million, $(36.3) million and $64.8 million in the years ended December 31, 2020, 2019 and 2018, respectively. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Europe Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2006, the Company entered into a separate collaboration agreement with Astellas for the development and commercialization of roxadustat for the treatment of anemia in Europe, the Middle East, the Commonwealth of Independent States and South Africa (&#8220;Europe Agreement&#8221;). Under the terms of the Europe Agreement, Astellas paid license fees and other upfront consideration totaling $320.0 million (such amounts were fully received as of February 2009). The Europe Agreement also provides for additional development and regulatory approval milestone payments up to $425.0 million, comprised of (i)&#160;up to $90.0&#160;million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of 2012), (ii)&#160;up to $335.0&#160;million in milestone payments upon achievement of specified regulatory milestone events. Under the Europe Agreement, Astellas committed to fund 50% of joint development costs for Europe and North America, and all territory-specific costs. The Europe Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range. The aggregate amount of the considerations received under the Europe Agreement through December&#160;31, 2020 totals $540.0 million, excluding drug product revenue that is discussed separately below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2019, the Company received positive topline results from analyses of pooled major adverse cardiovascular event (&#8220;MACE&#8221;) and MACE+ data from its Phase 3 trials evaluating roxadustat as a treatment for dialysis and non-dialysis CKD patients, enabling Astellas to prepare for an MAA submission to the EMA in the second quarter of 2020, following the Company&#8217;s NDA submission to the FDA that was accepted for review in February 2020. The Company evaluated the two regulatory milestone payments associated with the planned MAA submission and concluded that these milestones became probable of being achieved in the second quarter of 2019. Accordingly, the total consideration of $130.0 million associated with these milestones was included in the transaction price and allocated to performance obligations under the Europe Agreement in the second quarter of 2019, of which $128.8 million was recognized as revenue during the year ended December 31, 2019 and $0.8 million was recognized as revenue during the year ended December 31, 2020, from performance obligations satisfied or partially satisfied. According to the Europe Agreement, these milestone payments are billable to Astellas upon the submission of an MAA, therefore this $130.0 million was an unbilled contract asset as of December 31, 2019, and billed to Astellas upon the submission of an MAA in the second quarter of 2020 with the total $130.0 million received during the same quarter. </p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the fourth quarter of 2018, the Company was engaged in the final stages of review with its partners over the proposed development of roxadustat for the treatment of chemotherapy-induced anemia (&#8220;CIA&#8221;).&#160;AstraZeneca and Astellas approved the program in December 2018 and January 2019, respectively. Costs associated with the development of this indication are expected to be shared 50-50 between the Company&#8217;s two partners.&#160;For revenue recognition purposes, the Company concluded that this new indication represents a modification to the Europe agreements and will be accounted for separately, meaning the development costs associated with the new indications are distinct from the original development costs. The development service period for roxadustat for the treatment of CIA under the Europe Agreement is estimated to continue through the second quarter of 2024 to allow for development of this indication.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Europe Agreement, Astellas has an option to purchase roxadustat bulk drug product in support of commercial supplies. The Company fulfilled a shipment obligation under the term of the Europe Amendment in the fourth quarter of 2020, as described in details under <span style="font-style:italic;">Drug Product Revenue</span> section below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">U.S./Rest of World (&#8220;RoW&#8221;) Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective July&#160;30, 2013, the Company entered into a collaboration agreement with AstraZeneca for the development and commercialization of roxadustat for the treatment of anemia in the U.S. and all other countries in the world, other than China, not previously licensed under the Astellas Europe and Astellas Japan Agreements (&#8220;U.S./RoW Agreement&#8221;). It also excludes China, which is covered by a separate agreement with AstraZeneca described below. Under the terms of the U.S./RoW Agreement, AstraZeneca paid upfront, non-contingent, non-refundable and time-based payments totaling $374.0 million (such amounts were fully received as of June 2016). Under the U.S./RoW Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $875.0 million in potential milestone payments, comprised of (i)&#160;up to $65.0 million in milestone payments upon achievement of specified clinical and development milestone events, (ii)&#160;up to $325.0 million in milestone payments upon achievement of specified regulatory milestone events, (iii)&#160;up to $160.0&#160;million in milestone payments related to activity by potential competitors and (iv)&#160;up to approximately $325.0 million in milestone payments upon the achievement of specified commercial sales events. The aggregate amount of the considerations received under the U.S./RoW Agreement through December&#160;31, 2020 totals $439.0 million, excluding drug product revenue that is discussed separately below.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the U.S./RoW Agreement, the Company and AstraZeneca will share equally in the development costs of roxadustat not already paid for by Astellas, up to a total of $233.0 million (i.e. the Company&#8217;s share of development costs is $116.5 million, which was reached in 2015). Development costs incurred by FibroGen during the development period in excess of the $233.0 million (aggregated spend) are fully reimbursed by AstraZeneca. AstraZeneca will pay the Company tiered royalty payments on AstraZeneca&#8217;s future net sales (as defined in the agreement) of roxadustat in the low 20% range. In addition, the Company will receive a transfer price for shipment of commercial product based on a percentage of AstraZeneca&#8217;s net sales (as defined in the agreement) in the low- to mid-single digit range.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As mentioned above, during the second quarter of 2019, the Company received positive topline results from analyses of pooled MACE and MACE+ data from its Phase 3 trials for roxadustat, enabling the Company&#8217;s NDA submission to the FDA. The Company evaluated the regulatory milestone payment associated with this planned NDA submission and concluded that this milestone became probable of being achieved in the second quarter of 2019. Accordingly, the consideration of $50.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the combined arrangement in the second quarter of 2019, of which $42.4 million was recognized as revenue during the year ended December 31, 2019 and $0.6 million was recognized as revenue during the year ended December 31, 2020, from performance obligations satisfied or partially satisfied. The Company submitted such NDA in December 2019, which was accepted by FDA in February 2020. According to the U.S/RoW Agreement, this milestone payment is billable to AstraZeneca when the NDA is accepted by the FDA, therefore this $50.0 million was an unbilled contract asset as of December 31, 2019, and was billed during the first quarter of 2020, the payment of which was fully received in April 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As mentioned above, AstraZeneca and Astellas approved the development of roxadustat for the treatment of CIA in December 2018 and January 2019, respectively. Costs associated with the development of this indication are expected to be shared 50/50 between AstraZeneca and Astellas.&#160;In addition, in December 2018, anemia of chronic inflammation and multiple myeloma was approved for development by AstraZeneca and is expected to be fully funded by them.&#160;For revenue recognition purposes, the Company concluded that the addition of these new indications represents a modification to the collaboration agreements and will be accounted for separately, meaning the development costs associated with the new indications are distinct from the original development costs. The development service period for roxadustat for the treatment of CIA, anemia of chronic inflammation and multiple myeloma under the AstraZeneca agreements is estimated to continue through the end of 2024, to allow for development of these additional indications.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, the Company entered into Commercial Supply Agreement under the U.S./RoW Agreement with AstraZeneca to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. The Company shipped bulk drug product to AstraZeneca as pre-commercial supply for process validation purposes during the year ended December 31, 2020 and recognized related drug product revenue of $4.6 million, as described in details under <span style="font-style:italic;">Drug Product Revenue</span> section below.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">China Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective July&#160;30, 2013, the Company (through its subsidiaries affiliated with China) entered into a collaboration agreement with AstraZeneca for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in China (&#8220;China Agreement&#8221;). Under the terms of the China Agreement, AstraZeneca agreed to pay upfront consideration totaling $28.2&#160;million (such amounts were fully received in 2014). Under the China Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $348.5 million in potential milestone payments, comprised of (i)&#160;up to $15.0 million in milestone payments upon achievement of specified clinical and development milestone events, (ii)&#160;up to $146.0 million in milestone payments upon achievement of specified regulatory milestone events, and (iii)&#160;up to approximately $187.5 million in milestone payments upon the achievement of specified commercial sales and other events. The China Agreement is structured as a 50/50 profit or loss share (as defined), which was amended under the China Amendment discussed below in the third quarter of 2020, and provides for joint development costs (including capital and equipment costs for construction of the manufacturing plant in China), to be shared equally during the development. The aggregate amount of the considerations received under the China Agreement through December&#160;31, 2020 totals $77.2 million.</p>
<p id="C2" style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, roxadustat has been included on the updated NRDL released by China&#8217;s National Healthcare Security Administration for the treatment of anemia in CKD, covering patients who are non-dialysis dependent as well as those who are dialysis-dependent. The inclusion on the NRDL triggered a total of $22.0 million milestones payable to the Company by AstraZeneca. Accordingly, the total consideration of $22.0 million associated with these milestones was included in the transaction price and allocated to performance obligations under the combined arrangement, of which $18.7 million was recognized as revenue during the year ended December 31, 2019. The Company continued to recognize related revenue during the year ended December 31, 2020, from performance obligations satisfied or partially satisfied, and the amount was not material. This milestone payment was received during the first quarter of 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 17, 2018, FibroGen Beijing, received marketing authorization from the NMPA for roxadustat, a first-in-class HIF prolyl hydroxylase inhibitor, for the treatment of anemia caused by CKD in patients on dialysis. This approval triggered a $6.0 million milestone payable to the Company by AstraZeneca. On December 29, 2018, FibroGen Beijing received First Manufacturing Approval for a Product in the Field in the Territory, which allows production for Phase 4 clinical studies, patients&#8217; early experience programs, donation programs, as well as to supply products for testing and assessments required prior to launch. This approval triggered a $6.0 million milestone payable to the Company by AstraZeneca. Approximately $9.9 million of the total $12.0 million milestone payables was recognized as revenue during the year ended December 31, 2018. The Company continued to recognize related revenues during the years ended December 31, 2019 and 2020, from performance obligations satisfied or partially satisfied, and the amounts were not material.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">China Amendment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 8, 2020, FibroGen China and AstraZeneca (together with FibroGen China, the &#8220;Parties&#8221;) entered into the China Amendment, effective July 1, 2020, relating to the development and commercialization of roxadustat in China. While the responsibilities of the Parties under the China Agreement remain largely the same, certain changes were made. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the China Amendment, in September 2020, FibroGen Beijing and AstraZeneca completed the establishment of a jointly owned entity, Falikang, which will perform roxadustat distribution, as well as conduct sales and marketing through AstraZeneca. See Note 3,<span style="font-style:italic;"> Acquisition and Variable Interest Entity</span>, for details. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the China Amendment, the Company is currently in the interim period. Under the China Amendment, the interim period is defined as the period from April 1, 2020 to the time when Falikang is fully operational, which commenced in January 2021. During the interim period, FibroGen continues to sell product directly to the distributors, who remain as the Company&#8217;s customers. Under the China Amendment, the calculation for profit or loss share has changed related to sales of roxadustat in China for the period from April 1, 2020 onwards. With effect from April 1, 2020, the Parties have changed the method under which commercial expenses incurred by AstraZeneca are calculated and billed. AstraZeneca&#8217;s co-promotion expenses for their sales and marketing efforts are now subject to a cap of a percentage of net sales. Once AstraZeneca has been fully reimbursed for their sales and marketing costs under the cap, AstraZeneca will bill the co-promotion expenses based on actual costs on a prospective basis. In addition, the China Amendment has allowed for a higher cost of manufacturing incurred by FibroGen Beijing to be included in the profit or loss share calculation, subject to an annual cap, among other changes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once Falikang is fully operational, substantially all direct product sales will be made by Falikang while the Company continues to sell product directly in few provinces in China. AstraZeneca will bill the co-promotion expenses to Falikang and to FibroGen Beijing, respectively, for its services provided to the respective entity. In addition, FibroGen Beijing will sell commercial product to Falikang based on an agreed upon transfer price. Development costs will continue to be shared 50/50 between the Parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, the interim period primarily includes the following activities:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.36%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Co-promotion expenses: The China Amendment revised the payment arrangements and calculation of the historical unpaid co-promotion expenses to AstraZeneca for its sales and marketing efforts associated with the commercial sales for roxadustat in China since the product launch. Under the previous China Agreement, payment of these historical co-promotion expenses was subject to certain profitability and cash flow thresholds. No amount of the historical co-promotion costs had been paid prior to the China Amendment as these thresholds had not yet been met. Under the China Amendment, a portion of the historical unpaid co-promotion expenses was adjusted to reduce the amount owed by FibroGen Beijing and the current period co-promotion expenses are capped at a percentage of net roxadustat sales in China. As a result, in the third quarter of 2020, the Company reversed approximately $84.4 million of previously accrued co-promotion expenses payable, which was recorded as a reduction to selling, general and administrative expenses, where these expenses were initially recorded during the periods from the initiation of commercial activities in the first quarter of 2019 to the second quarter of 2020. The co-promotion expenses for the year ended December 31, 2020, capped at a percentage of net roxadustat sales in China, were $27.2 million, included in the selling, general and administrative expenses. After this adjustment, as of December 31, 2020, $16.9 million and $11.5 million of the recalculated accrued co-promotion expenses were recorded in accounts payable and accrued liabilities, respectively, as they were anticipated to be paid within the next 12 months; and $27.4 million of the recalculated accrued co-promotion expenses adjusted under the China Amendment remained in the long-term liabilities, as it is not anticipated to be paid within the next 12 months.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.36%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Profit share: Profit/loss share between FibroGen Beijing and AstraZeneca is based on a calculation of the current period net roxadustat sales in China and deductible expenses pursuant to the China Agreement. Based on the calculation revised under the China Amendment, profit was achieved during the third and fourth quarter of 2020. As a result, the Company recorded a profit share liability of $7.0 million to AstraZeneca as of December 31, 2020 in the accrued and other current liabilities, which correspondingly reduced the deferred revenue related to the performance obligation in accordance with the China Agreement.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.36%;white-space:nowrap" valign="top"/>
<td valign="top">
</td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accounting for the Astellas Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each of the Astellas agreements, the Company has evaluated the promised services within the respective arrangements and has identified performance obligations representing those services and bundles of services that are distinct.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Promised services that were not distinct have been combined with other promised services to form a distinct bundle of promised services, with revenue being recognized on the bundle of services rather than the individual services. There are no right-of-return provisions for the delivered items in the Astellas agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the transaction price for the Japan Agreement, excluding manufacturing services that is discussed separately below, included $40.1 million of non-contingent upfront payments, $65.0 million of variable consideration related to payments for milestones considered probable of being achieved, and $11.7 million of variable consideration related to co-development billings. The transaction price for the Europe Agreement, excluding manufacturing services that is discussed separately below, included $320.0 million of non-contingent upfront payments, $220.0 million of variable consideration related to payments for milestones considered probable of being achieved, and $225.9 million of variable consideration related to co-development billings. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For revenue recognition purposes, the Company determined that the term of each collaboration agreement with Astellas begins on the effective date and ends upon the completion of all performance obligations contained in the agreement. The contract term is defined as the period in which parties to the contract have present and enforceable rights and obligations. The Company believes that the requirement to continue funding development for a substantive period of time and loss of product rights, along with non-refundable upfront payments already remitted by Astellas, create significant disincentive for Astellas to exercise its right to terminate the agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the Astellas agreements, the Company allocated the transaction price to the various performance obligations based on the relative SSP of each performance obligation, with the exception of co-development billings allocated entirely to co-development services performance obligations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the technology license under the Japan Agreement and the Europe Agreement, SSP was determined primarily by using the discounted cash flow (&#8220;DCF&#8221;) method, which aggregates the present value of future cash flows to determine the valuation as of the effective date of each of the agreements. The DCF method involves the following key steps: 1) the determination of cash flow forecasts and 2) the selection of a range of comparative risk-adjusted discount rates to apply against the cash flow forecasts. The discount rates selected were based on expectations of the total rate of return, the rate at which capital would be attracted to the Company and the level of risk inherent within the Company. The discounts applied in the DCF analysis ranged from 17.5% to 20.0%. The Company&#8217;s cash flow forecasts were derived from probability-adjusted revenue and expense projections by territory. Such projections included consideration of taxes and cash flow adjustments. The probability adjustments were made after considering the likelihood of technical success at various stages of clinical trials and regulatory approval phases. SSP also considered certain future royalty payments associated with commercial performance of the Company&#8217;s compounds, transfer prices and expected gross margins.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promised services that were analyzed, along with their general timing of satisfaction and recognition as revenue, are as follows:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">License to the Company&#8217;s technology existing at the effective date of the agreements.</span><span style="font-style:normal;color:#000000;"> For both of the Astellas agreements, the license was delivered at the beginning of the agreement term. In both cases, the Company concluded at the time of the agreement that its collaboration partner, Astellas, would have the knowledge and capabilities to fully exploit the licenses without the Company&#8217;s further involvement. However, the Japan Agreement has contractual limitations that might affect Astellas&#8217; ability to fully exploit the license and therefore, potentially, the conclusion as to whether the license is capable of being distinct. In the Japan Agreement, Astellas does not have the right to manufacture commercial supplies of the drug. In order to determine whether this characteristic of the agreement should lead to a conclusion that the license was not distinct in the context of the agreement, the Company considered the ability of Astellas to benefit from the license together with other resources readily available to Astellas. Finally, the Company considered the fact that at the time of delivery of the license, the development services were beyond the preclinical development phase and any remaining development work in either agreement would not be expected to result in any significant modification or customization to the licensed technology. As such, the development services are separately identifiable from the licensed technology, indicating that the license is a distinct performance obligation.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Manufacturing rights.</span><span style="font-style:normal;"> In the case of the Japan Agreement, the Company retained manufacturing rights largel</span><span style="font-style:normal;">y because of the way the parties chose for FibroGen to be compensated under the agreement. At the time the agreement was signed, the Company believed that it was more advantageous upon commercialization to have a transfer price revenue model in place as op</span><span style="font-style:normal;">posed to a traditional sales-based model. The manufacturing process does not require specialized knowledge or expertise uniquely held by FibroGen, and notwithstanding contractual restrictions, Astellas could employ manufacturing services from readily avail</span><span style="font-style:normal;">able third parties in order to benefit from the license. Therefore, along with the foregoing paragraph, the Company determined that the license in Japan is a distinct performance obligation despite the retention of manufacturing rights by the Company.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In summary, the Company concludes that item (1) represents a performance obligation. The portion of the transaction price allocated to this performance obligation based on a relative SSP basis is recognized as revenue in its entirety at the point in time the license transfers to Astellas.</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.42%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">Co-development services (Europe Agreement). </span><span style="font-style:normal;color:#000000;">This promise relates to co-development services that were reasonably expected to be performed by the Company at the time the collaboration agreement was signed and is considered distinct. Co-development billings are allocated entirely to the co-development services performance obligation as amounts are related specifically to research and development efforts necessary to satisfy the performance obligation, and such an allocation is consistent with the allocation objective. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours and out-of-pocket expenses incurred relative to total expected costs to be incurred. The measure of progress is updated each reporting period. Co-development services are expected to continue over the development period that is currently estimated to continue through the end of 2021. In addition, the Company concluded that the new indication related to CIA approved in January 2019 represents a modification to the Europe agreements at that time and will be accounted for separately, for which the development service period is estimated to continue through the second quarter of 2024. There was no provision for co-development services in the Japan Agreement. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">License to the Company&#8217;s technology developed during the term of the agreement and development (referred to as &#8220;when and if available&#8221;) and information sharing services. </span><span style="font-style:normal;color:#000000;">These promises are generally satisfied throughout the term of the agreements.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">Manufacturing of clinical supplies of products.</span><span style="font-style:normal;color:#000000;"> This promise is satisfied as supplies for clinical product are delivered for use in the Company&#8217;s clinical trial programs during the development period, or pre-commercialization period.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(5)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">Committee service</span><span style="font-style:normal;color:#000000;">. This promise is satisfied throughout the course of the agreements as meetings are attended.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0.04%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Items (2)-(5) are bundled into a single performance obligation that is distinct given the fact that all are highly interrelated during the development period (pre-commercial phase of development) such that satisfying them independently is not practicable. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours or full time equivalents and out-of-pocket expenses incurred relative to total expected costs to be incurred. The measure of progress is updated each reporting period.</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(6)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">Manufacturing commercial supplies of products.</span><span style="font-style:normal;color:#000000;"> This promised service is distinct as services are not interrelated with any of the other performance obligations. Payments received for commercial supplies of products represent sales-based payments related predominately to the license of intellectual property under both Astellas agreements. Revenue is recognized as supplies are shipped for commercial use during the commercialization period. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Japan Amendment the drug product revenue represents variable consideration and is estimated based on the quantity of product shipped, actual listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and possible future changes to the listed price, adjusted for estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk drug product tablets, and estimated yield from the manufacture of bulk product tablets, among others.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Europe Agreement, the drug product revenue amount represents variable consideration and is estimated based on the quantity of product shipped and an estimated price. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price per strength, which is estimated to be realized by Astellas from the end sale of roxadustat in its approved territories.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of variable consideration that is included in the transaction price may be constrained, and is included in the drug product revenue only to the extent that </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it is probable that a significant re</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">versal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. Estimating variable consideration and the related constraint requires the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use of significant management judgment. The Company reviews new information that may affect its variable consideration estimate at every reporting period and records an adjustment to revenue, if certain and material</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Actual amounts of consideration </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ultimately received in the future may differ from the Company&#8217;s estimates, for which the Company will adjust these estimates and affect the drug product revenue in the period such variances become known.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As each of the agreements provides for annual true up to the considerations paid for its commercial supplies, the Company will re-evaluate the transaction price in each reporting period and record adjustment to revenue as uncertain events are resolved or other changes in circumstances occur. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accounting for the AstraZeneca Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluated whether the U.S./RoW Agreement and the China Agreement should be accounted for as a single or separate arrangements and concluded that the agreements should be accounted for as a single arrangement with the presumption that two or more agreements executed with a single customer at or around the same time should be presumed to be a single arrangement. The key points the Company considered in reaching this conclusion are as follows: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">While the two agreements were largely negotiated separately, those negotiations proceeded concurrently, and were intended to be completed contemporaneously, presuming AstraZeneca</span><span style="font-weight:bold;color:#000000;"> </span><span style="color:#000000;">decided to proceed with licenses in all regions available. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Throughout negotiations for both agreements, the Company and the counterparties understood and considered the possibility that one arrangement may be executed without the execution of the other arrangement. However, the preference for the Company and the counterparties during the negotiations was to execute both arrangements concurrently.&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">The two agreements were executed as separate agreements because different development, regulatory and commercial approaches required certain terms of the agreements to be structured differently, rather than because the Company or the counterparties considered the agreements to be fundamentally separate negotiations.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, as the agreements are being accounted for as a single arrangement, upfront and other non-contingent consideration received and to be received has been and will be pooled together and allocated to each of the performance obligations in both the U.S./RoW Agreement and the China Agreement based on their relative SSPs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each of the AstraZeneca agreements, the Company has evaluated the promised services within the respective arrangements and has identified performance obligations representing those services and bundled services that are distinct.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Promised services that were not distinct have been combined with other promised services to form a distinct bundle of promised services, with revenue being recognized on the bundle of services rather than the individual promised services. There are no right-of-return provisions for the delivered items in the AstraZeneca agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the transaction price for the U.S./RoW Agreement and the China Agreement, excluding manufacturing services that is discussed separately below, included $402.2 million of non-contingent upfront payments, $114.0 million of variable consideration related to payments for milestones considered probable of being achieved, $564.9 million of variable consideration related to co-development billings, offset by $7.0 million of variable consideration related to profit share under the China Amendment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the AstraZeneca agreements, the Company allocated the transaction price to the various performance obligations based on the relative SSP of each performance obligation, with the exception of co-development billings and commercial sale of product. Co-development billings under the U.S./RoW Agreement were allocated entirely to the U.S./RoW co-development services performance obligation, and co-development billings under the China Agreement were allocated entirely to the combined performance obligation under the China Agreement. Commercial sale of product under the U.S./ROW Agreement is entirely allocated to the manufacturing commercial supply of products performance obligation, and commercial sale of product under the China Agreement is allocated entirely to the combined China performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For revenue recognition purposes, the Company determined that the term of its collaboration agreements with AstraZeneca begin on the effective date and ends upon the completion of all performance obligations c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ontained in the agreements. T</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he contract term is defined as the period in which parties to the contract have present and enforceable rights and obligations. The Company believes that the requirement to continue funding development for a substantive period </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of time and the loss of product rights, along with non-refundable upfront payments already remitted by AstraZeneca, represent substantive termination penalties that create significant disincentive for AstraZeneca to exercise its right to terminate the agre</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ement.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the technology license under the AstraZeneca U.S./RoW Agreement, SSP was determined based on a two-step process. The first step involved determining an implied royalty rate that would result in the net present value of future cash flows to equal to zero (i.e. where the implied royalty rate on the transaction would equal the target return for the investment). This results in an upper bound estimation of the magnitude of royalties that a hypothetical acquirer would reasonably pay for the forecasted cash flow stream. The Company&#8217;s cash flow forecasts were derived from probability-adjusted revenue and expense projections. Such projections included consideration of taxes and cash flow adjustments. The probability adjustments were made after considering the likelihood of technical success at various stages of clinical trials and regulatory approval phases. The second step involved applying the implied royalty rate, which was determined to be 40%, against the probability-adjusted projected net revenues by territory and determining the value of the license as the net present value of future cash flows after adjusting for taxes. The discount rate utilized was 17.5%.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">U.S./RoW Agreement:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promised services that were analyzed, along with their general timing of satisfaction and recognition as revenue, are as follows:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">License to the Company&#8217;s technology existing at the effective date of the agreements.</span><span style="font-style:normal;color:#000000;"> For the U.S./RoW Agreement, the license was delivered at the beginning of the agreement term. The Company concluded that AstraZeneca has the knowledge and capabilities to fully exploit the license under the U.S./RoW Agreement without the Company&#8217;s further involvement. Finally, the Company considered the fact that at the time of delivery of the license, the development services were beyond the preclinical development phase and any remaining development work would not be expected to result in any significant modification or customization to the licensed technology. As such, the development services are separately identifiable from the licensed technology, indicating that the license is a distinct performance obligation. Therefore, the Company has concluded that the license is distinct and represents a performance obligation. The portion of the transaction price allocated to this performance obligation based on a relative SSP basis is recognized as revenue in its entirety at the point in time the license transfers to AstraZeneca.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">Co-development services. </span><span style="font-style:normal;color:#000000;">This promise relates to co-development services that were reasonably expected to be performed by the Company at the time the collaboration agreement was signed and is distinct. Co-development billings are allocated entirely to the co-development services performance obligation as amounts are related specifically to research and development efforts necessary to satisfy the performance obligation, and such an allocation is consistent with the allocation objective. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours or full time equivalents and out-of-pocket expenses incurred relative to total expected costs to be incurred. Co-development services are expected to continue over the development period that is currently estimated to continue through the end of the first quarter of 2021. In addition, the Company concluded that the addition of the new indications related to CIA, anemia of chronic inflammation and multiple myeloma approved during the fourth quarter of 2018 represents a modification to the collaboration agreements and will be accounted for separately, for which the joint development service period is estimated to continue through the end of 2024. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">Manufacturing of clinical supplies of products.</span><span style="font-style:normal;color:#000000;"> This promise is satisfied as supplies for clinical product are delivered for use in the Company&#8217;s clinical trial programs during the development period, or pre-commercialization period.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">Information sharing and committee service.</span><span style="font-style:normal;color:#000000;"> These promises are satisfied throughout the course of the agreement as services are provided.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Items (2)-(4) are bundled into a single performance obligation that is distinct given the fact that all are highly interrelated during the development period (pre-commercial phase of development) such that delivering them independently is not practicable. Revenue is recognized over time based on progress toward complete satisfaction of the performance obligation. The Company uses an input method to measure progress toward the satisfaction of the performance obligation, which is based on costs of labor hours or full time equivalents and out-of-pocket expenses incurred relative to total expected costs to be incurred. The measure of progress is updated each reporting period.</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.46%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(5)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;"/><span style="font-style:normal;color:#000000;"/><span style="color:#000000;">Manufacturing commercial supplies of products. </span><span style="font-style:normal;color:#000000;">This promise is distinct as services are not interrelated with any of the other</span><span style="font-style:normal;color:#000000;"> performance obligations. Revenue is recognized as supplies are shipped for commercial use during the commercialization period. </span><span style="font-style:normal;color:#000000;">The drug product revenue amount represents variable consideration and is estimated based on the quantity of product shipped and </span><span style="font-style:normal;color:#000000;">an estimated price for each individual purchase order. The estimated price is based on the contractual transfer price percentage applied on the estimated weighted average net sales price, which is estimated to be realized by AstraZeneca from the end sale o</span><span style="font-style:normal;color:#000000;">f roxadustat in its approved territories.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.42%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of variable consideration that is included in the transaction price may be constrained, and is included in the drug product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period when the uncertainty associated with the variable consideration is subsequently resolved. Estimating variable consideration and the related constraint requires the use of significant management judgment. The Company reviews new information that may affect its variable consideration estimate at every reporting period and records an adjustment to revenue, if certain and material. Actual amounts of consideration ultimately received in the future may differ from the Company&#8217;s estimates, for which the Company will adjust these estimates and affect the drug product revenue in the period such variances become known.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the agreement provides for an annual true up to the considerations paid for its commercial supplies, the Company will re-evaluate the transaction price in each reporting period and record an adjustment to revenue as uncertain events are resolved or other changes in circumstances occur. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">China Agreement:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promised services that were analyzed are consistent with the U.S./RoW Agreement, except for license to the Company&#8217;s technology existing at the effective date of the agreement, described as follows:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.86%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-style:italic;color:#000000;">License to the Company&#8217;s technology existing at the effective date of the agreement.</span><span style="color:#000000;"> The license was delivered at the beginning of the agreement term. However, the China Agreement with AstraZeneca has contractual limitations that might affect AstraZeneca&#8217;s ability to fully exploit the license and therefore, potentially, the conclusion as to whether the license is distinct in the context of the agreement. In the China Agreement, AstraZeneca does not have the right to manufacture commercial supplies of the drug. In order to determine whether this characteristic of the arrangement should lead to a conclusion that the license was not distinct in the context of the agreement, the Company considered the ability of AstraZeneca to benefit from the license on its own or together with other resources readily available to AstraZeneca.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the China Agreement, the Company retained manufacturing rights as an essential part of a strategy to pursue domestic regulatory pathway for product approval which requires the regulatory licensure of the manufacturing facility in order to commence commercial shipment. The prospects for the collaboration as a whole would have been substantially different had manufacturing rights been provided to AstraZeneca. We hold the rights to manufacture commercial drug product in China. Therefore, AstraZeneca cannot benefit from the license on its own or together with other readily available resources. Accordingly, all the promises identified, including the license, co-development services and manufacturing of commercial supplies,, under the China Agreement have been bundled into a single performance obligation and amounts of the transaction price allocable to this performance obligation are deferred until control of the manufactured commercial drug product has begun to transfer to AstraZeneca. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the China Amendment, once Falikang is fully operational, which commenced in January 2021, substantially all product sales will be made by Falikang directly to the distributors in China, while the Company continues to sell directly in few provinces in China. Revenue will be recognized upon the transfer of control of commercial drug product to Falikang. For the Company&#8217;s direct sales of commercial drug product, revenue will be recognized when control of the promised good is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled to in exchange for the product.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProductRevenuePolicyPolicyTextBlock', window );">Product Revenue, Net</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Product Revenue, Net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue from roxadustat commercial sales in China is recognized in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products, net of various sales rebates and discounts. Product revenue, net was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,027</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,803</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Price adjustment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(936</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-key account hospital listing award</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,325</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual sales rebate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,189</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(149</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other discounts and rebates</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(923</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales return</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,498</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the second quarter of 2020, the Company amended the agreement with its pharmaceutical distributors, which triggered accounting modifications particularly related to the non-key account hospital listing award. For the year ended December 31, 2020, the non-key account hospital listing award was $9.3 million, which was recorded as a reduction to the revenue and calculated based on eligible non-key account hospital listings to date achieved by each distributor with certain requirements met during the period. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020 and 2019, the contractual sales rebate was $6.2 million and $0.1 million, respectively, which were calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. All other rebates and discounts, including sales return allowance were immaterial for the periods presented. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2019, a $0.9 million of price adjustment was recorded based on government-listed price guidance and estimated channel inventory levels.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rebates and discounts that the Company&#8217;s pharmaceutical distributors have earned are eligible to be applied against future sales orders, limited to certain maximums until such rebates and discounts are exhausted. These rebates and discounts are recorded as contract liabilities at the time they become eligible in the same period that the related revenue is recorded. Due to the distributor&#8217;s legal right to offset, at each balance sheet date, the rebates and discounts are presented as reductions to gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The distributor&#8217;s legal right of offset is calculated at the individual distributor level. The following table includes a roll-forward of the related contract liabilities (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deduction</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Currency</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Translation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contract</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Presented Net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Against</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Receivable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue - Contract liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,102</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,497</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,184</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(270</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,685</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">548</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,137</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the total rebates and discounts as reductions to gross accounts receivable was $0.5 million, and the total contract liabilities was $15.1 million, which was included in accrued and other current liabilities in the consolidated balance sheet. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reductions to gross accounts receivable, including the above-mentioned contra-accounts receivable items related to product revenue, totaled $0.8 million and $1.1 million as of December 31, 2020 and 2019, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DrugProductRevenuePolicyTextBlock', window );">Drug Product Revenue</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Drug Product Revenue<span style="font-weight:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue was as follows (in thousands): </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,281</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,324</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,776</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,625</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,906</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,324</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,776</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company fulfilled all the shipment obligations under the term of the Japan Amendment during the year ended December 31, 2018, and recognized the related product revenue of $64.8 million in the same period<span style="font-weight:bold;"> </span>based on a transaction price that was subject to potential future adjustments, which represented a form of variable consideration. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in estimated variable consideration incurred in 2019 related to the above API shipments in 2018, at the time the actual listed price for roxadustat was issued by the Japanese Ministry of Health, Labour and Welfare, which resulted in a total difference of $36.3 million between the estimated and the actual listed price and yield from the manufacture of bulk product tablets. </p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, during the year ended December 31, 2020, the Company recorded another $4.0 million reduction to drug product revenue related to the above API shipments, due to a change in estimated variable consideration. Specifically, the change in estimated variable consideration was based on the API held by Astellas at March 31, 2020 adjusted to reflect the updated listed price for roxadustat issued by the Japanese Ministry of Health, Labour and Welfare and changes in the estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk product tablets, and estimated yield from the manufacture of bulk product tablets, among others. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2020, the Company fulfilled shipment obligations under the term of Japan Amendment with Astellas, and recognized related drug product revenue of $8.2 million in the same period. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fourth quarter of 2020, the Company shipped bulk drug product from process validation supplies for commercial purposes under the term of the Europe Agreement with Astellas. The Company constrained the consideration from this shipment due to a high degree of uncertainty associated to the final consideration. As a result, the Company recorded $1.4 million as current deferred revenue and $4.6 million as long-term deferred revenue as of December 31, 2020. The deferred revenue will be recognized as and when uncertainty is resolved. The following table includes a roll-forward of the related contract liabilities (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue - Astellas - contract liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,984</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,984</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the Company shipped bulk drug product to AstraZeneca as pre-commercial supply for process validation purposes, under the term of Commercial Supply Agreement under the U.S./RoW Agreement with AstraZeneca, and recognized drug product revenue of $4.6 million.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_OtherRevenuesPolicyTextBlock', window );">Other Revenues</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Revenues</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other revenues consist primarily of collagen material sold for research purposes. Other revenues were immaterial for each of the three years ended December&#160;31, 2020.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Deferred Revenue</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue represents amounts billed, or in certain cases, yet to be billed to the Company&#8217;s collaboration partners for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying performance obligations. The long-term portion of deferred revenue represents amounts to be recognized after one year through the end of the non-contingent performance period of the underlying performance obligations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue includes amounts allocated to the China performance obligation under the AstraZeneca arrangement as revenue recognition associated with this unit of accounting is tied to the commercial launch of the products within China and to when the control of the manufactured commercial drug product is transferred to AstraZeneca. As of December 31, 2020, approximately $3.5 million of the deferred revenue related to the China unit of accounting was included in short-term deferred revenue, which represents the amount of deferred revenue associated with the China unit of accounting that is expected to be recognized within the next 12 months, associated with the commercial sales in China.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the authoritative guidance on fair value measurements and disclosures under U.S. GAAP, the Company presents all financial assets and liabilities and any other assets and liabilities that are recognized or disclosed at fair value on a nonrecurring basis. The guidance defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair-value measurements. The guidance also requires fair value measurements be classified and disclosed in one of the following three categories:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 1<span style="font-style:normal;">: Quoted prices in active markets for identical assets or liabilities.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 2<span style="font-style:normal;">: Observable inputs other than quoted prices in active markets for identical assets or liabilities.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 3<span style="font-style:normal;">: Unobservable inputs.</span></p>
<p id="T0" style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company values certain assets and liabilities, focusing on the inputs used to measure fair value, particularly in instances where the measurement uses significant unobservable (Level 3) inputs. The Company&#8217;s financial instruments are valued using quoted prices in active markets (Level 1) or based upon other observable inputs (Level 2). The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability. In addition, the categories presented do not suggest how prices may be affected by the size of the purchases or sales, particularly with the largest highly liquid financial issuers who are in markets continuously with non-equity instruments, or how any such financial assets may be impacted by other factors such as U.S. government guarantees. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. </span><span style="color:#000000;">The availability of observable data is monitored to assess </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">appropriate</span><span style="color:#000000;"> classification of financial instruments within the fair value hierarchy. Depending upon the availability of such inputs, specific securities may </span><span style="color:#000000;">transfer between levels. In such instances, the transfer is reported at the end of the reporting period.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and restricted time deposits policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ClinicalTrialAccrualPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical trial accrual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ClinicalTrialAccrualPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement and revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_DrugProductRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Drug product revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_DrugProductRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_OtherRevenuesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_OtherRevenuesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_OtherRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Risks and Uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_OtherRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ProductRevenuePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product revenue policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ProductRevenuePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting guidance not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently issued and adopted accounting guidance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 35<br> -Paragraph 7A<br> -URI http://asc.fasb.org/extlink&amp;oid=121565518&amp;loc=SL120269220-210453<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3D<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL120267969-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922895-210455<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 35<br> -Paragraph 13A<br> -URI http://asc.fasb.org/extlink&amp;oid=121565518&amp;loc=SL120267917-210453<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 35<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=121648281&amp;loc=SL120267834-210445<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 30<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=121647444&amp;loc=SL120269210-210444<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919260-210447<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL120267845-210446<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919253-210447<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919272-210447<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 30<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=121647444&amp;loc=SL120254536-210444<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3C<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL120267966-210447<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 30<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121614247&amp;loc=SL120267897-210452<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919244-210447<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3D<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL120267862-210455<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3C<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL120267859-210455<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL120267853-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090637495768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Significant Balance of Accounts Receivable</a></td>
<td class="text">The Company has not experienced any loss on its deposits of cash and cash equivalents. Included in current assets are significant balances of accounts receivable as follows:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas Pharma Inc. (&#8220;Astellas&#8221;)&#8212;Related party</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca AB (&#8220;AstraZeneca&#8221;)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650860824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition and Variable Interest Entity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AcquisitionAndVariableInterestEntityAbstract', window );"><strong>Acquisition And Variable Interest Entity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Summary of Equity Method Investment</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s&#160;equity&#160;method&#160;investment&#160;in Falikang was as follows for the year ended December 31, 2020 (in thousands):</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Entity</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership Percentage</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share of Net Loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Currency</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Translation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Falikang</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,825</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(202</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,728</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AcquisitionAndVariableInterestEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition and variable interest entity abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AcquisitionAndVariableInterestEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090635832152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net</a></td>
<td class="text">Product revenue, net was as follows (in thousands):
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,027</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,803</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Price adjustment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(936</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-key account hospital listing award</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,325</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual sales rebate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,189</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(149</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other discounts and rebates</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(923</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales return</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,498</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Roll-forward of Related Contract Liabilities</a></td>
<td class="text">. The following table includes a roll-forward of the related contract liabilities (in thousands):
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deduction</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Currency</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Translation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contract</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Presented Net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Against</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Receivable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue - Contract liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,102</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,497</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,184</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(270</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,685</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">548</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,137</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ScheduleOfDrugProductRevenueTableTextBlock', window );">Schedule of Drug Product Revenue</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue was as follows (in thousands): </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,281</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,324</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,776</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,625</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,906</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,324</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,776</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Roll-forward of Related Contract Liabilities</a></td>
<td class="text">The following table includes a roll-forward of the related contract liabilities (in thousands):
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug product revenue - Astellas - contract liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,984</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,984</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerMilestoneMethodTableTextBlock', window );">Summary of License Revenue and Development Revenue Recognized under Agreement</a></td>
<td class="text">Amounts recognized as license revenue and development revenue under the Japan Agreement with Astellas were as follows (in thousands):
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Obligation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,323</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,935</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,323</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,220</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,222</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,400</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Japan Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#160;at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,350</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,480</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,697</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,827</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerMilestoneMethodTableTextBlock', window );">Summary of License Revenue and Development Revenue Recognized under Agreement</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts recognized as license revenue and development revenue under the Europe Agreement with Astellas were as follows (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.32%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Obligation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117,470</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,954</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,172</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,503</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement with Astellas, along with any associated deferred revenue as follows (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Europe Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#160;at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487,951</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487,951</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248,962</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,429</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250,391</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">736,913</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,429</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">738,342</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:2.68%;text-indent:-2.68%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember', window );">U.S./RoW and China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerMilestoneMethodTableTextBlock', window );">Summary of License Revenue and Development Revenue Recognized under Agreement</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts recognized as license revenue and development revenue under the U.S./RoW and China Agreements with AstraZeneca were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.32%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance Obligation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.&#160;/&#160;RoW</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and China</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,681</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,946</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,508</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,629</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,970</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China performance obligation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(90</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement, along with any associated deferred revenue as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U.S.&#160;/&#160;RoW and China Agreements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cumulative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue&#160;at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consideration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Through</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,&#160;2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">341,844</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">341,844</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-development, information sharing &amp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;committee services</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">554,775</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,276</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">557,051</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China performance obligation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137,338</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137,338</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total license and development</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">896,619</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,614</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,036,233</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:92.86%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.57%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* </span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the consolidated balance sheets. As of December 31, 2020, deferred revenue included $137.5 million related to the U.S./RoW and China Agreement, which represents the net of $139.6 million of deferred revenue presented above and a $2.1 million unbilled co-development revenue under the China Amendment with AstraZeneca.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ContractWithCustomerMilestoneMethodTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer milestone method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ContractWithCustomerMilestoneMethodTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ScheduleOfDrugProductRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of drug product revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ScheduleOfDrugProductRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090637366648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Values of Financial Assets Measured on Recurring Basis</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of the Company&#8217;s financial assets that are measured on a recurring basis are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,144</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,144</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590,591</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,144</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598,735</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury notes and bills</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">347,383</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,123</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">427,506</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,816</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,816</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,551</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,551</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificate of deposit</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">444,005</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,155</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">554,160</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair Values of Financial Liabilities Carried at Historical Cost</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair values of the Company&#8217;s financial liabilities that are carried at historical cost are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease obligations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,141</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,141</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease obligations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,544</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,544</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090635950840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock', window );">Schedule of Lease Assets and Related Lease Liabilities</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s lease assets and related lease liabilities were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Line Item</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets - cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,477</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,909</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,871</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,307</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,606</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,602</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets - cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,934</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,736</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,891</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(805</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,043</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,931</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,649</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,533</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,330</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,351</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,188</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">983</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease liabilities, non-current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,391</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,610</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">853</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">942</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.26%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,762</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,886</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease expense were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of Operations Line Item</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease cost:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,369</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,307</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,932</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,373</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,151</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">891</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,201</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,385</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.9%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,251</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to leases were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">951</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">914</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from finance leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,896</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,196</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flows from finance leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,620</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,925</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for new lease liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,909</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,072</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,736</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock', window );">Schedule of Lease Term and Discount Rate</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease term and discount rate were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (years):</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001000">2.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001001">3.6</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001002">1.8</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001003">2.1</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.39</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.42</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.74</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock', window );">Schedule of Maturities of Finance and Operating Leases Liabilities</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of lease liabilities as of December&#160;31, 2020 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance&#160;Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating&#160;Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,689</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,142</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,886</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">839</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,526</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,101</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,124</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Interest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,380</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(83</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,721</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,041</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of lease assets and related lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of lease term and discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of maturities of finance and operating leases liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental cash flow information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650466792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,046</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,715</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590,347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,551</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.52%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">678,393</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,266</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Investments</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s investments consist of available-for-sale debt investments, marketable equity investments, term deposit and certificate of deposit. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#8217;s investments by major investments type are summarized in the tables below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,147</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,144</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,272</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,388</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized&#160;Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross&#160;Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding&#160;Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury notes and bills</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">426,995</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">536</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">427,506</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond and mutual funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,730</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,816</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.86%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">467,850</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">784</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">468,609</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Contractual Maturities of Available-for-Sale Investments</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contractual maturities of the available-for-sale investments were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.74%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:73.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within one year - Bond and mutual funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.58%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,144</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:73.64%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.58%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,388</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,303</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work-in-progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,114</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,264</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,113</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,298</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventories</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,530</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,887</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unbilled contract assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,147</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues from associated contracts</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,147</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,790</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net unbilled contract assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,210</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,353</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,464</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,807</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,717</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,160</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,391</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,006</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,548</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,143</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,329</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,312</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,217</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,545</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,399</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,128</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,822</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">760</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,792</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144,894</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,107</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(111,247</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100,364</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,647</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,743</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued and Other Current Liabilities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other current liabilities consisted of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and clinical trial accruals</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,113</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,279</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">API product price adjustment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,324</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and related accruals</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,800</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,784</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities to pharmaceutical distributors</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,137</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued co-promotion expenses - current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,537</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat profit share to AstraZeneca</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,007</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property taxes and other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,970</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,044</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional services</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,869</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,842</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,088</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,543</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued and other current liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119,521</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,816</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of Other Long-term Liabilities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities consisted of the following (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued long-term co-promotion expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,424</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,071</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,675</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,913</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.72%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, non-current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">853</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">942</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,690</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,481</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.72%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other long-term liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,642</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,407</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090644635480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationsTextBlock', window );">Summary of Unconditional Purchase Obligations</a></td>
<td class="text">The unconditional purchase obligations consisted of the following (in thousands):
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchase Obligations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Due In The Year Ending December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacture and supply of roxadustat</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,114</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,951</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,065</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacture and supply of pamrevlumab</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,480</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,063</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,543</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other purchases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,418</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,418</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.26%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total purchase obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,012</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,014</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,026</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unconditional purchase obligation recognized as liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25383-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650893480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Summary of Common Stock Reserved for Future Issuance</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares of Common Stock outstanding, shares of stock plans outstanding and shares reserved for future issuance related to stock options and RSU grants and the Company&#8217;s Employee Stock Purchase Plan (&#8220;ESPP&#8221;) purchases are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock outstanding</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,441</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,657</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,290</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs outstanding</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,893</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,483</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for future stock options and RSUs grant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,910</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,725</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved for future ESPP offering</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,070</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,337</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares of common stock reserved</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,604</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,220</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Transactions</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option transactions, including forfeited options granted under the 2014 Plan as well as prior plans, are summarized below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic&#160;Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,018</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.63</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,692</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.55</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,113</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.73</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39.92</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(234</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40.11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,290</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.94</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001234">6.60</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,013</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest, December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,929</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.76</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001235">6.50</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,125</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,576</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001236">5.10</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,943</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes RSU activity:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value&#160;at&#160;Grant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,483</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.05</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,354</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.99</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(813</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45.55</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(131</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.14%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39.25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,893</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.14%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37.60</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Recorded Stock-Based Compensation Expense</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was recorded directly to research and development and selling, general and administrative expense for the years ended December&#160;31, 2020, 2019 and 2018 was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.76%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,229</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,015</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,491</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,491</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,252</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,651</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.76%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,720</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,267</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,142</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Employee Stock Purchase Plans</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to estimate the fair value of stock options granted and ESPPs using the Black-Scholes option valuation model were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001275">5.7</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001276">5.3</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001277">5.4</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.9</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average estimated fair value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.36</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.98</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ESPPs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001290">0.5 - 2.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001291">0.5 - 2.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001292">0.5 - 2.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001296">47.5 - 77.1</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001297">48.1 - 62.1</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001298">47.3 - 75.3</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001302">0.1 - 2.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001303">1.3 - 2.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001304">0.8 - 2.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average estimated fair value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.53</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.27</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.74%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.27</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of share based payment award stock options and employee stock purchase plan valuation assumptions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of shares of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090637487640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following weighted impacts of outstanding securities were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the three years presented (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,694</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,602</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,815</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">564</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,187</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">820</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">260</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.28%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,564</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,050</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,834</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090637389944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of Loss Before Income Taxes</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of loss before income taxes are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Domestic</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(195,617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,538</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,472</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,686</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79,180</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,644</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before provision for income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(188,931</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76,642</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(86,116</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Provision For Income Taxes</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision for income taxes consists of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">304</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total provision for income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">304</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation Between Statutory Federal Income Tax Rate and Effective Tax Rate</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is the reconciliation between the statutory federal income tax rate and the Company&#8217;s effective tax rate:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax at statutory federal rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefit due to intercompany transfer of assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance on intercompany transfer of assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses not benefitted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign net operating losses not benefitted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11.6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deduction limitation on executive compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of Deferred Tax Assets</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and state net operating loss carryforwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134,033</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,267</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,465</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,243</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign net operating loss carryforwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,417</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,786</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,399</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,159</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease obligations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,243</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,698</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserves and accruals</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,875</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,353</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,550</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,323</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,915</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">284</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">342,897</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222,113</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(337,824</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(213,847</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,073</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,266</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,073</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,266</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,073</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,266</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of the Beginning and Ending Amounts of Unrecognized Income Tax Benefits</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending amounts of unrecognized income tax benefits during the three years ended December&#160;31, 2020 is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Federal&#160;and&#160;State</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2017</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,361</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase due to prior positions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">379</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase due to current year position</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,216</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,956</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease due to prior positions</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(111</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase due to current year position</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,418</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,263</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease due to prior positions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(137</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase due to current year position</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,448</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,574</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of income loss before income tax domestic and foreign.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650684584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue by Geographic Area</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Geographic revenues, which are based on the bill-to region, are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,161</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,400</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,916</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,660</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122,475</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,002</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.68%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,498</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.68%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,319</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256,577</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,958</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_InventoryByGeographicAreasTableTextBlock', window );">Schedule of Inventory by Geographic Area</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory by geographic location are as follows (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,715</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,815</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,887</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total inventory</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,530</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,887</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of Long Lived Assets by Geographic Area</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net by geographic location are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.08%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,673</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,325</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,974</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,418</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,647</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,743</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock', window );">Summary of Finance and Operating Lease Right of Use Assets by Geographical Location</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease right-of-use assets and operating lease right-of-use assets, net by geographic location are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.08%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,551</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,237</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">365</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total finance lease right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,606</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,602</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">China</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,996</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,856</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,043</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,931</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Customer Concentration by Collaboration Partners</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s revenues to date have been generated from the following collaboration partners that respectively accounted for 10% or more of the Company&#8217;s total revenue and accounts receivable:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.84%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage&#160;of&#160;Revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage&#160;of&#160;Accounts&#160;Receivable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas&#8212;Related party</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_InventoryByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory by geographic areas.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_InventoryByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Finance and Operating Lease Right of Use Assets by Geographical Location.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090639995080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Apr. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax', window );">Currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_HighlyLiquidInvestmentMaturityPeriod', window );">Highly liquid investment maturity period</a></td>
<td class="text">three months or less<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_RestrictedTimeDepositsNoncurrent', window );">Restricted time deposits</a></td>
<td class="nump">$ 2,072,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,072,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 678,393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,266,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ShortTermInvestmentsMaximumMaturityPeriod', window );">Short term investments maturity</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_LongTermInvestmentsMinimumMaturityPeriod', window );">Long term Investments Maturity</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms', window );">Description of payment term</a></td>
<td class="text">The period between the transfer of control of the promised goods and when the Company receives payment is based on a general 60-day payment term.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DescriptionOfSalesReturn', window );">Description of sales return</a></td>
<td class="text">Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product&#8217;s expiration date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (974,011,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(784,720,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,499,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(747,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201802Member', window );">ASU 2018-02 [Member] | Impact of change in accounting principle upon adoption of ASU 2018-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">ASU 2016-01 [Member] | Impact of change in accounting principle upon adoption of ASU 2016-01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,300,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment [Member] | ASU 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member] | Astellas Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Amount constrained related to drug product shipment</a></td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Machinery [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Machinery [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember', window );">Foreign subsidiaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 66,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=fgen_AccountsReceivableFromDistributorsMember', window );">Accounts Receivable from Distributors [Member] | Credit Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccountingPolicyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccountingPolicyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_DescriptionOfSalesReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of sales return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_DescriptionOfSalesReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_HighlyLiquidInvestmentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Highly liquid investment maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_HighlyLiquidInvestmentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_LongTermInvestmentsMinimumMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term investments minimum maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_LongTermInvestmentsMinimumMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_RestrictedTimeDepositsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted time deposits noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_RestrictedTimeDepositsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ShortTermInvestmentsMaximumMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short term investments maximum maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ShortTermInvestmentsMaximumMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative translation gain (loss), after tax, from translating foreign currency financial statements into the reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201802Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201802Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=fgen_ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=fgen_ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fgen_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fgen_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=fgen_AccountsReceivableFromDistributorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=fgen_AccountsReceivableFromDistributorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090637257112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Significant Balance of Accounts Receivable (Detail) - Accounts Receivable [Member] - Credit Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Astellas Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">AstraZeneca Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccountingPolicyLineItems', window );"><strong>Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccountingPolicyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccountingPolicyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650806104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition and Variable Interest Entity - Additional Information (Detail)<br> $ in Thousands, &#165; in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 15, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=fgen_BeijingFalikangPharmaceuticalCoLtdMember', window );">Beijing Falikang Pharmaceutical Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AcquisitionAndVariableInterestEntityLineItems', window );"><strong>Acquisition And Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Percentage of outstanding shares owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.10%<span></span>
</td>
<td class="nump">51.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_EquityMethodInvestmentAdditions', window );">Investment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=fgen_BeijingFalikangPharmaceuticalCoLtdMember', window );">Beijing Falikang Pharmaceutical Co. Ltd [Member] | Variable Interest Entity, Not Primary Beneficiary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AcquisitionAndVariableInterestEntityLineItems', window );"><strong>Acquisition And Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_EquityMethodInvestmentAdditions', window );">Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">&#165; 19.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_FibroGenBeijingMember', window );">FibroGen Beijing [Member] | Beijing Falikang Pharmaceutical Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AcquisitionAndVariableInterestEntityLineItems', window );"><strong>Acquisition And Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of outstanding shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">&#165; 8.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Percentage of outstanding shares owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.10%<span></span>
</td>
<td class="nump">51.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Capital', window );">Falikang's total registered capital | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 17.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember', window );">Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] | FibroGen Beijing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AcquisitionAndVariableInterestEntityLineItems', window );"><strong>Acquisition And Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of outstanding shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">&#165; 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">&#165; 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember', window );">Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] | FibroGen Beijing [Member] | Acquired License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AcquisitionAndVariableInterestEntityLineItems', window );"><strong>Acquisition And Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Entire purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember', window );">Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] | FibroGen Beijing [Member] | AstraZeneca AB [Member] | Beijing Falikang Pharmaceutical Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AcquisitionAndVariableInterestEntityLineItems', window );"><strong>Acquisition And Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer', window );">Percentage of outstanding shares sold in exchange for cash consideration</a></td>
<td class="nump">48.90%<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Cash consideration for exchange of outstanding shares</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">&#165; 7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Percentage of outstanding shares owned</a></td>
<td class="nump">51.10%<span></span>
</td>
<td class="nump">51.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AcquisitionAndVariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition and variable interest entity line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AcquisitionAndVariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_EquityMethodInvestmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment additions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_EquityMethodInvestmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding shares of acquiree sold by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Capital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of total capital as defined by regulatory framework.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117337116&amp;loc=SL5958568-112826<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47080-110998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Capital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=fgen_BeijingFalikangPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=fgen_BeijingFalikangPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_FibroGenBeijingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_FibroGenBeijingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=fgen_AcquiredLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=fgen_AcquiredLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=fgen_AstraZenecaABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=fgen_AstraZenecaABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090636052904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition and Variable Interest Entity - Summary of Equity Method Investment (Detail) - Beijing Falikang Pharmaceutical Co. Ltd [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AcquisitionAndVariableInterestEntityLineItems', window );"><strong>Acquisition And Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership Percentage</a></td>
<td class="nump">51.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_EquityMethodInvestmentAdditions', window );">Additions</a></td>
<td class="nump">2,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of Net Loss</a></td>
<td class="num">(202)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation', window );">Currency Translation</a></td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending balance</a></td>
<td class="nump">$ 2,728<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AcquisitionAndVariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition and variable interest entity line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AcquisitionAndVariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_EquityMethodInvestmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment additions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_EquityMethodInvestmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment increase (decrease) from currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=fgen_BeijingFalikangPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=fgen_BeijingFalikangPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090641460568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Astellas Agreements - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">35 Months Ended</th>
<th class="th" colspan="1">45 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Apr. 30, 2006</div></th>
<th class="th"><div>Jun. 30, 2005</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2009</div></th>
<th class="th"><div>Feb. 28, 2009</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,319<span></span>
</td>
<td class="nump">$ 256,577<span></span>
</td>
<td class="nump">$ 212,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Unbilled contract asset</a></td>
<td class="nump">$ 2,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,147<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,906<span></span>
</td>
<td class="num">(36,324)<span></span>
</td>
<td class="nump">64,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan [Member] | Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Unbilled contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments', window );">Upfront, non-contingent and time-based payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CommercialSalesMilestone', window );">Commercial sales milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AdditionalConsiderationBasedOnNetSales', window );">Additional consideration based on net sales description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the low 20% range of the list price<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue', window );">Aggregate considerations received excluding drug product revenue</a></td>
<td class="nump">105,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_TransactionPriceAllocatedToPerformanceObligations', window );">Transaction price and allocated to performance obligations</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1', window );">Consideration associated with milestone included in transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Japan [Member] | Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="num">(36,300)<span></span>
</td>
<td class="nump">$ 64,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Japan [Member] | Clinical and Development Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Japan [Member] | Regulatory Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments', window );">Upfront, non-contingent and time-based payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AdditionalConsiderationBasedOnNetSales', window );">Additional consideration based on net sales description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">low 20% range<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue', window );">Aggregate considerations received excluding drug product revenue</a></td>
<td class="nump">540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_TransactionPriceAllocatedToPerformanceObligations', window );">Transaction price and allocated to performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DevelopmentAndRegulatoryApprovalMilestones', window );">Development and regulatory approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PercentageOfFundingForCosts', window );">Percentage of joint development costs committed to fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue during period from performance obligations</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">128,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Unbilled contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_EstimatedJointDevelopmentExtendedServicePeriod', window );">Estimated joint development extended service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Europe [Member] | Clinical and Development Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Europe [Member] | Regulatory Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AdditionalConsiderationBasedOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional consideration based on net sales of product as defined under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AdditionalConsiderationBasedOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate consideration receivable under collaborative arrangement excluding drug product revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CommercialSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payments related to commercial sales under the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CommercialSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_DevelopmentAndRegulatoryApprovalMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_DevelopmentAndRegulatoryApprovalMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_EstimatedJointDevelopmentExtendedServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated joint development extended service period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_EstimatedJointDevelopmentExtendedServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_PercentageOfFundingForCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_PercentageOfFundingForCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_PotentialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_PotentialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_TransactionPriceAllocatedToPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction price allocated to performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_TransactionPriceAllocatedToPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_ClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_ClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090637884280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2018</div></th>
<th class="th"><div>Dec. 17, 2018</div></th>
<th class="th"><div>Jul. 30, 2013</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Unbilled contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,147,000<span></span>
</td>
<td class="nump">$ 2,147,000<span></span>
</td>
<td class="nump">$ 180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,319,000<span></span>
</td>
<td class="nump">256,577,000<span></span>
</td>
<td class="nump">$ 212,958,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedLongTermCoPromotionLiabilityNonCurrent', window );">Accrued long-term co-promotion expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,424,000<span></span>
</td>
<td class="nump">27,424,000<span></span>
</td>
<td class="nump">53,071,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedLongTermCoPromotionLiabilityCurrent', window );">Accrued long term co promotion liability current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue ($2,907 and $249 to a related party)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,547,000<span></span>
</td>
<td class="nump">6,547,000<span></span>
</td>
<td class="nump">490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,906,000<span></span>
</td>
<td class="num">(36,324,000)<span></span>
</td>
<td class="nump">64,776,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_TransactionPriceAllocatedToPerformanceObligations', window );">Transaction price and allocated to performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue during period from performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">42,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Unbilled contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_EstimatedJointDevelopmentExtendedServicePeriod', window );">Estimated joint development extended service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_HistoricalCoPromotionCosts', window );">Historical co-promotion costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ReversalOfAccruedCoPromotionExpenses', window );">Reversal of accrued co-promotion expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CoPromotionExpenses', window );">Co-promotion expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedLongTermCoPromotionLiabilityNonCurrent', window );">Accrued long-term co-promotion expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,400,000<span></span>
</td>
<td class="nump">27,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedLongTermCoPromotionLiabilityCurrent', window );">Accrued long term co promotion liability current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,900,000<span></span>
</td>
<td class="nump">16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | Accrued Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedLongTermCoPromotionLiabilityCurrent', window );">Accrued long term co promotion liability current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,625,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments', window );">Upfront, non-contingent, non-refundable and time-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 374,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CommercialSalesMilestone', window );">Commercial sales milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue', window );">Aggregate considerations received excluding drug product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439,000,000.0<span></span>
</td>
<td class="nump">$ 439,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SharedDevelopmentCosts', window );">Shared development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AdditionalConsiderationBasedOnNetSales', window );">Additional consideration based on net sales description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">low 20% range<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Unbilled contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW [Member] | FibroGen, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SharedDevelopmentCosts', window );">Shared development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW [Member] | Clinical and Development Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW [Member] | Regulatory Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW [Member] | Deferred Approval Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,000)<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments', window );">Proceeds from upfront, non-contingent and non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CommercialSalesAndOtherEventsMilestone', window );">Commercial sales and other events milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CollaborativeArrangementAggregateConsideration', window );">Aggregate considerations received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,200,000<span></span>
</td>
<td class="nump">77,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized', window );">Milestone payment, revenue recognition</a></td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue ($2,907 and $249 to a related party)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | China [Member] | Accrued and Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue ($2,907 and $249 to a related party)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | China [Member] | Clinical and Development Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | China [Member] | Regulatory Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PotentialMilestones', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedLongTermCoPromotionLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued long term co promotion liability current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedLongTermCoPromotionLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedLongTermCoPromotionLiabilityNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued long term co promotion liability non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedLongTermCoPromotionLiabilityNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AdditionalConsiderationBasedOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional consideration based on net sales of product as defined under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AdditionalConsiderationBasedOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CoPromotionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-promotion expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CoPromotionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CollaborativeArrangementAggregateConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate consideration receivable under collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CollaborativeArrangementAggregateConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate consideration receivable under collaborative arrangement excluding drug product revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CommercialSalesAndOtherEventsMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial sales and other events milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CommercialSalesAndOtherEventsMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CommercialSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payments related to commercial sales under the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CommercialSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability, milestone method revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_EstimatedJointDevelopmentExtendedServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated joint development extended service period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_EstimatedJointDevelopmentExtendedServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_HistoricalCoPromotionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Historical co-promotion costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_HistoricalCoPromotionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_PotentialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_PotentialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ReversalOfAccruedCoPromotionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reversal of accrued co-promotion expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ReversalOfAccruedCoPromotionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_SharedDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total amount of development costs that will be shared under collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_SharedDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_TransactionPriceAllocatedToPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction price allocated to performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_TransactionPriceAllocatedToPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=fgen_FibroGenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=fgen_FibroGenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_ClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_ClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_DeferredApprovalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_DeferredApprovalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=fgen_AccruedAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=fgen_AccruedAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090725891480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Accounting for the Astellas Agreements - Additional Information 2 (Detail) - Astellas Agreement [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CoDevelopmentServicesEstimatedContinuationYear', window );">Co-development services, currently estimated continuation year</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Minimum [Member] | Measurement Input Discount Rate [Member] | Discounted Cash Flow [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Discount rate applied</a></td>
<td class="nump">17.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Maximum [Member] | Measurement Input Discount Rate [Member] | Discounted Cash Flow [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Discount rate applied</a></td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProceedsFromNonContingentUpfrontPayments', window );">Non-contingent upfront payments received</a></td>
<td class="nump">$ 40,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone', window );">Variable consideration related to payments for milestones considered probable of being achieved</a></td>
<td class="nump">65,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings', window );">Variable consideration related to co-development billings</a></td>
<td class="nump">11,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProvisionForCoDevelopmentServices', window );">Provision for co-development services</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProceedsFromNonContingentUpfrontPayments', window );">Non-contingent upfront payments received</a></td>
<td class="nump">320,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone', window );">Variable consideration related to payments for milestones considered probable of being achieved</a></td>
<td class="nump">220,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings', window );">Variable consideration related to co-development billings</a></td>
<td class="nump">$ 225,900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CoDevelopmentServicesEstimatedContinuationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-development services, estimated continuation year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CoDevelopmentServicesEstimatedContinuationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ProceedsFromNonContingentUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of non-contingent upfront payments included under the collaborative agreement as arrangement consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ProceedsFromNonContingentUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ProvisionForCoDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision for co-development services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ProvisionForCoDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable consideration payment received related to co-development billings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable consideration payment received upon achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090635865736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Accounting for the AstraZeneca Agreements - Additional Information 3 (Detail) - AstraZeneca Agreements [Member]<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_RoyaltyRateOnNetRevenue', window );">Royalty rate against projected net revenues</a></td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CoDevelopmentServicesEstimatedContinuationYear', window );">Co-development services, currently estimated continuation year</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">Measurement Input Discount Rate [Member] | Discounted Cash Flow [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Discount rate applied</a></td>
<td class="nump">17.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">U.S./RoW and China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ProceedsFromNonContingentUpfrontPayments', window );">Non-contingent upfront payments received</a></td>
<td class="nump">$ 402.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone', window );">Variable consideration related to payments for milestones considered probable of being achieved</a></td>
<td class="nump">114.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings', window );">Variable consideration related to co-development billings</a></td>
<td class="nump">564.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_VariableConsiderationRelatedToProfitShare', window );">Variable consideration related to profit share</a></td>
<td class="nump">$ 7.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CoDevelopmentServicesEstimatedContinuationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-development services, estimated continuation year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CoDevelopmentServicesEstimatedContinuationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ProceedsFromNonContingentUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of non-contingent upfront payments included under the collaborative agreement as arrangement consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ProceedsFromNonContingentUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_RoyaltyRateOnNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Implied royalty rate used to find the net present value of future cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_RoyaltyRateOnNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable consideration payment received related to co-development billings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable consideration payment received upon achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_VariableConsiderationRelatedToProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable consideration related to profit share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_VariableConsiderationRelatedToProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldAndChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldAndChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090731502728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 176,319<span></span>
</td>
<td class="nump">$ 256,577<span></span>
</td>
<td class="nump">$ 212,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">14,323<span></span>
</td>
<td class="nump">177,086<span></span>
</td>
<td class="nump">22,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember', window );">Development Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">80,592<span></span>
</td>
<td class="nump">114,115<span></span>
</td>
<td class="nump">125,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | License Revenue [Member] | Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">14,323<span></span>
</td>
<td class="nump">11,935<span></span>
</td>
<td class="nump">14,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">117,470<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Development Revenue [Member] | Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,220<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Development Revenue [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">17,954<span></span>
</td>
<td class="nump">28,172<span></span>
</td>
<td class="nump">18,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="num">(90)<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW and China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,681<span></span>
</td>
<td class="nump">7,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 61,508<span></span>
</td>
<td class="nump">$ 84,629<span></span>
</td>
<td class="nump">$ 104,970<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090726195544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">$ 2,147<span></span>
</td>
<td class="nump">$ 54,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">116,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">116,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Japan [Member] | License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">100,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">100,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Japan [Member] | Development Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">16,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">16,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">736,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">1,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">738,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Europe [Member] | License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">487,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">487,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Europe [Member] | Development Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">248,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">1,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">250,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW and China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">896,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">139,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">1,036,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">341,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">341,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | Co-development, information sharing &amp; committee services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">554,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">2,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">557,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | China performance obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized', window );">Cumulative Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue</a></td>
<td class="nump">137,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement', window );">Total Consideration</a></td>
<td class="nump">$ 137,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CashConsiderationReceivedUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CashConsiderationReceivedUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of revenue recognized for license and development services under the collaboration agreement as of a given date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fgen_ChinaPerformanceObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fgen_ChinaPerformanceObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090726354584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling', window );">Transaction price, variable consideration from estimated future co-development billing</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan [Member] | Astellas Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Changes in revenue due to prior period adjustment of performance obligations</a></td>
<td class="nump">15,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling', window );">Transaction price, variable consideration from estimated future co-development billing</a></td>
<td class="nump">27,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member] | Astellas Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Changes in revenue due to prior period adjustment of performance obligations</a></td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember', window );">U.S./RoW and China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling', window );">Transaction price, variable consideration from estimated future co-development billing</a></td>
<td class="nump">37,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember', window );">U.S./RoW and China [Member] | Astellas Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Changes in revenue due to prior period adjustment of performance obligations</a></td>
<td class="num">$ (2,900,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable consideration payment received from estimated future co-development billing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090761812792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 138,474<span></span>
</td>
<td class="nump">$ 99,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">2,147<span></span>
</td>
<td class="nump">54,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SuppliesNet', window );">Net unbilled co-development revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 125,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">137,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">139,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SuppliesNet', window );">Net unbilled co-development revenue</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_SuppliesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplies, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_SuppliesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090651398760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Summary of Product Revenue, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 176,319<span></span>
</td>
<td class="nump">$ 256,577<span></span>
</td>
<td class="nump">$ 212,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_PriceAdjustmentMember', window );">Price Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_NonKeyAccountHospitalListingAwardMember', window );">Non-key Account Hospital Listing Award [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_ContractualSalesRebateMember', window );">Contractual Sales Rebate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">6,200<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax', window );">Gross revenue</a></td>
<td class="nump">89,027<span></span>
</td>
<td class="nump">2,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">72,498<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Price Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(936)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Non-key Account Hospital Listing Award [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="num">(9,325)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Contractual Sales Rebate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="num">(6,189)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Other Discounts and Rebates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="num">(923)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Sales Return [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="num">$ (92)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue gross from contract with customer excluding assessed tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_PriceAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_PriceAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_NonKeyAccountHospitalListingAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_NonKeyAccountHospitalListingAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_ContractualSalesRebateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_ContractualSalesRebateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_OtherDiscountsAndRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_OtherDiscountsAndRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090651533624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Product Revenue, Net - Additional Information 1 (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 176,319<span></span>
</td>
<td class="nump">$ 256,577<span></span>
</td>
<td class="nump">$ 212,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">72,498<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Reductions to gross accounts receivable</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_NonKeyAccountHospitalListingAwardMember', window );">Non-key Account Hospital Listing Award [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_NonKeyAccountHospitalListingAwardMember', window );">Non-key Account Hospital Listing Award [Member] | Product Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="num">(9,325)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_ContractualSalesRebateMember', window );">Contractual Sales Rebate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">6,200<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_ContractualSalesRebateMember', window );">Contractual Sales Rebate [Member] | Product Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="num">(6,189)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_PriceAdjustmentMember', window );">Price Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_PriceAdjustmentMember', window );">Price Adjustment [Member] | Product Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(936)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_RebatesAndDiscountsMember', window );">Rebates and Discounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_RebatesAndDiscountsMember', window );">Rebates and Discounts [Member] | Gross Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_RebatesAndDiscountsMember', window );">Rebates and Discounts [Member] | Contract Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 15,100<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_NonKeyAccountHospitalListingAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_NonKeyAccountHospitalListingAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_ContractualSalesRebateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_ContractualSalesRebateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_PriceAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_PriceAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_RebatesAndDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_RebatesAndDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=fgen_GrossAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=fgen_GrossAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=fgen_ContractLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=fgen_ContractLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090651008824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Roll-forward of Related Contract Liabilities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityLineItems', window );"><strong>Contract with Customer Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2019</a></td>
<td class="num">$ (54,790)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2020</a></td>
<td class="num">(2,147)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityLineItems', window );"><strong>Contract with Customer Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2019</a></td>
<td class="num">(1,102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="num">(16,497)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityDeduction', window );">Deduction</a></td>
<td class="nump">2,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther', window );">Currency Translation and Other</a></td>
<td class="num">(270)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityGross', window );">Gross Contract Liabilities Balance</a></td>
<td class="num">(15,685)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityNetOfAccountsReceivable', window );">Balance Presented Net Against Accounts Receivable</a></td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2020</a></td>
<td class="num">(15,137)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member] | Astellas Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityLineItems', window );"><strong>Contract with Customer Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="num">(5,984)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2020</a></td>
<td class="num">$ (5,984)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability additions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ContractWithCustomerLiabilityDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability deduction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ContractWithCustomerLiabilityDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ContractWithCustomerLiabilityGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ContractWithCustomerLiabilityGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer, liability, increase (decrease) from current translation and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ContractWithCustomerLiabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ContractWithCustomerLiabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ContractWithCustomerLiabilityNetOfAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability net of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ContractWithCustomerLiabilityNetOfAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650348936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue</a></td>
<td class="nump">$ 176,319<span></span>
</td>
<td class="nump">$ 256,577<span></span>
</td>
<td class="nump">$ 212,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue</a></td>
<td class="nump">8,906<span></span>
</td>
<td class="num">(36,324)<span></span>
</td>
<td class="nump">64,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member] | Astellas Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue</a></td>
<td class="nump">4,281<span></span>
</td>
<td class="num">(36,324)<span></span>
</td>
<td class="nump">64,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member] | AstraZeneca Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue</a></td>
<td class="nump">$ 4,625<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090726365720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Drug Product Revenue - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,319,000<span></span>
</td>
<td class="nump">$ 256,577,000<span></span>
</td>
<td class="nump">$ 212,958,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue ($2,907 and $249 to a related party)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,547,000<span></span>
</td>
<td class="nump">490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,474,000<span></span>
</td>
<td class="nump">99,449,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember', window );">U.S./RoW [Member] | AstraZeneca Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,906,000<span></span>
</td>
<td class="num">(36,324,000)<span></span>
</td>
<td class="nump">64,776,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_EstimatedVariableConsiderationTransactionPrice', window );">Estimated variable consideration transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member] | AstraZeneca Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,625,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member] | API Shipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member] | Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue recognized</a></td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member] | Japan [Member] | Astellas Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug product revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="num">$ (36,300,000)<span></span>
</td>
<td class="nump">$ 64,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember', window );">Drug Product Revenue [Member] | Europe [Member] | Astellas Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue ($2,907 and $249 to a related party)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_EstimatedVariableConsiderationTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated variable consideration transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_EstimatedVariableConsiderationTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=fgen_APIShipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=fgen_APIShipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650561352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements and Revenues - Deferred Revenue - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract with Customer, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 2,147<span></span>
</td>
<td class="nump">$ 54,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract with Customer, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090651843720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">$ 8,388<span></span>
</td>
<td class="nump">$ 468,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">US treasury notes and bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=fgen_BondAndMutualFundsMember', window );">Bond and mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">8,144<span></span>
</td>
<td class="nump">10,816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of financial assets</a></td>
<td class="nump">598,735<span></span>
</td>
<td class="nump">554,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | US treasury notes and bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Bond and mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">8,144<span></span>
</td>
<td class="nump">10,816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Equity investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">590,347<span></span>
</td>
<td class="nump">85,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Certificate of deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of financial assets</a></td>
<td class="nump">590,591<span></span>
</td>
<td class="nump">444,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | US treasury notes and bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Bond and mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Equity investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">590,347<span></span>
</td>
<td class="nump">85,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Certificate of deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of financial assets</a></td>
<td class="nump">8,144<span></span>
</td>
<td class="nump">110,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | US treasury notes and bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Bond and mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">8,144<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Equity investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Certificate of deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | US treasury notes and bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Bond and mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Equity investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets fair value disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Certificate of deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=fgen_BondAndMutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=fgen_BondAndMutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650418552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Transfers of assets from level 1 to 2</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 29,800,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Transfers of assets from level 2 to 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Transfers of assets into level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers of assets out of level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Transfers of liabilities from level 1 to 2</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Transfers of liabilities from level 2 to 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Transfers of liabilities into level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfers of liabilities out of level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090644104376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Values of Financial Liabilities Carried at Historical Cost (Detail) - Lease obligations [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities fair value disclosure</a></td>
<td class="nump">$ 1,141<span></span>
</td>
<td class="nump">$ 1,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities fair value disclosure</a></td>
<td class="nump">$ 1,141<span></span>
</td>
<td class="nump">$ 1,544<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=fgen_LeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=fgen_LeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090652383336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail) - Lease<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2006</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, lease term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, lease term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_ShorensteinPropertiesLLCMember', window );">Shorenstein Properties LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Lessee, finance lease, initial lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_LesseeFinanceLeaseExpirationPeriod', window );">Lessee, finance lease, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm', window );">Lessee, finance lease, option to extend the additional lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod', window );">Lessee, finance lease, additional lease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate', window );">Percentage increases on each anniversary of rent commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend', window );">Lessee, finance lease, existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseOptionToExtend', window );">Lessee, finance lease, option to extend</a></td>
<td class="text">The Company has an option to extend the lease for an additional 10 years through 2033.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_BeijingEconomicTechnologicalDevelopmentAreaMember', window );">Beijing Economic-Technological Development Area [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Lessee, finance lease, initial lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_LesseeFinanceLeaseExpirationPeriod', window );">Lessee, finance lease, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend', window );">Lessee, finance lease, existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_NumberOfFinanceLeases', window );">Number of finance leases</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fgen_OfficeSpacesMember', window );">Office Spaces [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_NumberOfOperatingLeases', window );">Number of operating leases</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_LesseeOperatingLeaseExpirationPeriod', window );">Lessee, operating lease, expiration period</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, lease term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, lease term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, finance lease, additional lease expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_LesseeFinanceLeaseExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, finance lease, expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_LesseeFinanceLeaseExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, finance lease, option to extend the additional lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_LesseeOperatingLeaseExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_LesseeOperatingLeaseExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_NumberOfFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of finance leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_NumberOfFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_NumberOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_NumberOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage increases on each anniversary of rent commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's finance lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_ShorensteinPropertiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_ShorensteinPropertiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_BeijingEconomicTechnologicalDevelopmentAreaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_BeijingEconomicTechnologicalDevelopmentAreaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fgen_OfficeSpacesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fgen_OfficeSpacesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650411864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_FinanceLeaseRightOfUseAssetsCost', window );">Right-of-use assets - cost</a></td>
<td class="nump">$ 50,477<span></span>
</td>
<td class="nump">$ 49,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_FinanceLeaseAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(20,871)<span></span>
</td>
<td class="num">(10,307)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets, net</a></td>
<td class="nump">29,606<span></span>
</td>
<td class="nump">39,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_OperatingLeaseRightOfUseAssetsCost', window );">Right-of-use assets - cost</a></td>
<td class="nump">3,934<span></span>
</td>
<td class="nump">2,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_OperatingLeaseAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,891)<span></span>
</td>
<td class="num">(805)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">2,043<span></span>
</td>
<td class="nump">1,931<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_FinanceLeaseAndOperatingLeaseAssets', window );">Total lease assets</a></td>
<td class="nump">31,649<span></span>
</td>
<td class="nump">41,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">12,330<span></span>
</td>
<td class="nump">12,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 1,188<span></span>
</td>
<td class="nump">$ 983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">fgen:AccruedAndOtherCurrentLiabilitiesMember<span></span>
</td>
<td class="text">fgen:AccruedAndOtherCurrentLiabilitiesMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">$ 25,391<span></span>
</td>
<td class="nump">$ 37,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 853<span></span>
</td>
<td class="nump">$ 942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherNoncurrentLiabilitiesMember<span></span>
</td>
<td class="text">us-gaap:OtherNoncurrentLiabilitiesMember<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_FinanceLeaseAndOperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 39,762<span></span>
</td>
<td class="nump">$ 51,886<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_FinanceLeaseAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_FinanceLeaseAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_FinanceLeaseAndOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease and operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_FinanceLeaseAndOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_FinanceLeaseAndOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease and operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_FinanceLeaseAndOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_FinanceLeaseRightOfUseAssetsCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance lease, right-of-use assets - cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_FinanceLeaseRightOfUseAssetsCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_OperatingLeaseAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease, accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_OperatingLeaseAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_OperatingLeaseRightOfUseAssetsCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease, right-of-use assets - cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_OperatingLeaseRightOfUseAssetsCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090637155032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 10,369<span></span>
</td>
<td class="nump">$ 10,307<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">1,932<span></span>
</td>
<td class="nump">2,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="nump">891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(1,201)<span></span>
</td>
<td class="num">(1,385)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 12,251<span></span>
</td>
<td class="nump">$ 12,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090751130088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 951<span></span>
</td>
<td class="nump">$ 914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">1,896<span></span>
</td>
<td class="nump">2,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_RepaymentsOfFinanceLeaseLiabilities', window );">Financing cash flows from finance leases</a></td>
<td class="nump">12,620<span></span>
</td>
<td class="nump">11,925<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract', window );"><strong>Right-of-use assets obtained in exchange for new lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">662<span></span>
</td>
<td class="nump">49,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">$ 1,072<span></span>
</td>
<td class="nump">$ 2,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_RepaymentsOfFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments of finance lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_RepaymentsOfFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets obtained in exchange for new lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090635817080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Lease Term and Discount Rate (Detail)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted-average remaining lease term (years):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted-average discount rate:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">4.39%<span></span>
</td>
<td class="nump">4.42%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">4.74%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average remaining lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090725868584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 13,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">13,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">12,526<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">40,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(2,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">37,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">1,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">2,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 2,041<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650157352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash And Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 88,046<span></span>
</td>
<td class="nump">$ 40,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">590,347<span></span>
</td>
<td class="nump">85,551<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 678,393<span></span>
</td>
<td class="nump">$ 126,266<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090644503000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 8,272<span></span>
</td>
<td class="nump">$ 467,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">8,388<span></span>
</td>
<td class="nump">468,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury notes and bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">426,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=fgen_BondAndMutualFundsMember', window );">Bond and mutual funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">8,147<span></span>
</td>
<td class="nump">10,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">8,144<span></span>
</td>
<td class="nump">10,816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">$ 255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=fgen_BondAndMutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=fgen_BondAndMutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090651505832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Contractual Maturities of Available-for-Sale Investments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available For Sale Securities Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear', window );">Within one year - Bond and mutual funds</a></td>
<td class="nump">$ 8,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesEquitySecurities', window );">Equity investments</a></td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Total investments</a></td>
<td class="nump">$ 8,388<span></span>
</td>
<td class="nump">$ 468,609<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities bond and mutual funds maturing within one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity securities categorized neither as held-to-maturity nor as trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090642877336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Other-than-temporary impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance', window );">Percentage of pre-launch inventory capitalized of aggregate inventory balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_NumberOfRegulatoryMilestones', window );">Number of regulatory milestones | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Unbilled contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,147,000<span></span>
</td>
<td class="nump">$ 180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,147,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,678,000<span></span>
</td>
<td class="nump">11,147,000<span></span>
</td>
<td class="nump">$ 6,562,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent', window );">API product price change in estimated variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,324,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedLongTermCoPromotionLiabilityCurrent', window );">Accrued long term co promotion liability current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Profit share liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,547,000<span></span>
</td>
<td class="nump">490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,547,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Unbilled contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember', window );">Astellas Agreement [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Unbilled contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Unbilled contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent', window );">Accrued long-term co-promotional expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses', window );">Reversal of previously accrued long-term co-promotion expenses</a></td>
<td class="nump">$ 84,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent', window );">Accrued long-term co-promotional expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | U.S./RoW [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Unbilled contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember', window );">AstraZeneca Agreements [Member] | China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Profit share liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued active pharmaceutical ingredient product price adjustment current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedLongTermCoPromotionLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued long term co promotion liability current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedLongTermCoPromotionLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued long-term co-promotional liability non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_NumberOfRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_NumberOfRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of pre-launch inventory capitalized of aggregate inventory balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reversal of previously accrued long term co promotion expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090751210088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Inventory (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsAbstract', window );"><strong>Schedule Of Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 2,303<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-progress</a></td>
<td class="nump">8,114<span></span>
</td>
<td class="nump">2,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">6,113<span></span>
</td>
<td class="nump">4,298<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 16,530<span></span>
</td>
<td class="nump">$ 6,887<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090641436856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Unbilled contract assets</a></td>
<td class="nump">$ 2,147<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenues from associated contracts</a></td>
<td class="num">(2,147)<span></span>
</td>
<td class="num">(54,790)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SuppliesNet', window );">Net unbilled contract assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">125,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid assets</a></td>
<td class="nump">8,353<span></span>
</td>
<td class="nump">6,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,807<span></span>
</td>
<td class="nump">1,717<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 10,160<span></span>
</td>
<td class="nump">$ 133,391<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_SuppliesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplies, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_SuppliesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090652014952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 144,894<span></span>
</td>
<td class="nump">$ 143,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(111,247)<span></span>
</td>
<td class="num">(100,364)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">33,647<span></span>
</td>
<td class="nump">42,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">102,006<span></span>
</td>
<td class="nump">101,548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fgen_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">18,143<span></span>
</td>
<td class="nump">17,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">8,312<span></span>
</td>
<td class="nump">8,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">9,545<span></span>
</td>
<td class="nump">8,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">6,128<span></span>
</td>
<td class="nump">5,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 760<span></span>
</td>
<td class="nump">$ 1,792<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fgen_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fgen_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650891336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedPreclinicalAndClinicalTrialCurrent', window );">Preclinical and clinical trial accruals</a></td>
<td class="nump">$ 44,113<span></span>
</td>
<td class="nump">$ 16,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent', window );">API product price adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related accruals</a></td>
<td class="nump">22,800<span></span>
</td>
<td class="nump">19,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent', window );">Contract liabilities to pharmaceutical distributors</a></td>
<td class="nump">15,137<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedCoPromotionExpensesCurrent', window );">Accrued co-promotion expenses - current</a></td>
<td class="nump">11,537<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedProfitShareCurrent', window );">Roxadustat profit share to AstraZeneca</a></td>
<td class="nump">7,007<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PropertyTaxesAndOtherCurrent', window );">Property taxes and other</a></td>
<td class="nump">5,970<span></span>
</td>
<td class="nump">2,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">4,869<span></span>
</td>
<td class="nump">4,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">8,088<span></span>
</td>
<td class="nump">4,543<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued and other current liabilities</a></td>
<td class="nump">$ 119,521<span></span>
</td>
<td class="nump">$ 83,816<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued active pharmaceutical ingredient product price adjustment current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedCoPromotionExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued co-promotion expenses - current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedCoPromotionExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued contract liabilities to pharmaceutical distributors current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedPreclinicalAndClinicalTrialCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to pre-clinical and clinical trial activities, including those performed by third parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedPreclinicalAndClinicalTrialCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedProfitShareCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued profit share current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedProfitShareCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_PropertyTaxesAndOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property taxes and other current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_PropertyTaxesAndOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090637375992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Other Long-term Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrentAbstract', window );"><strong>Other Liabilities Noncurrent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedLongTermCoPromotionLiabilityNonCurrent', window );">Accrued long-term co-promotion expenses</a></td>
<td class="nump">$ 27,424<span></span>
</td>
<td class="nump">$ 53,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Other long-term tax liabilities</a></td>
<td class="nump">8,675<span></span>
</td>
<td class="nump">8,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">853<span></span>
</td>
<td class="nump">942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">2,690<span></span>
</td>
<td class="nump">2,481<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other long-term liabilities</a></td>
<td class="nump">$ 39,642<span></span>
</td>
<td class="nump">$ 65,407<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedLongTermCoPromotionLiabilityNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued long term co promotion liability non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedLongTermCoPromotionLiabilityNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090641441736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Development Obligations - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>DevelopmentObligation</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_NumberOfProductDevelopmentObligations', window );">Number of product development obligations | DevelopmentObligation</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_AccruedProductDevelopmentCostsExcludingInterest', window );">Accrued product development costs excluding interest</a></td>
<td class="nump">$ 11.6<span></span>
</td>
<td class="nump">$ 10.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued Interest</a></td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=fgen_BankOfFinlandInterestRateMember', window );">Bank of Finland Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansReceivableBasisSpreadOnVariableRate', window );">Percentage points deducted to reference rate to compute effective interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on product development advances</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_AccruedProductDevelopmentCostsExcludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Product Development Costs Excluding Interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_AccruedProductDevelopmentCostsExcludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_NumberOfProductDevelopmentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of product development obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_NumberOfProductDevelopmentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansReceivableBasisSpreadOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage points (also referred to as 'margin') added to the reference rate as stated in the loan agreement and used to compute the variable rate on the loans receivable. For instance, the loan agreement might state that the interest rate the borrower is obligated to pay is the London Interbank Offered Rate (LIBOR) plus three quarters (3/4) of a percentage point adjusted quarterly (each three months). LIBOR in this example is the index or reference rate, 3/4 percentage point is the margin, the reference rate plus the margin is the fully indexed rate. This element would be used to report separately the margin.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansReceivableBasisSpreadOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=fgen_BankOfFinlandInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=fgen_BankOfFinlandInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090651943128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Outstanding non-cancelable contract obligations</a></td>
<td class="nump">$ 86.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember', window );">Research and Pre-Clinical Stage Development Programs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_MaximumFutureMilestonePayments', window );">Maximum future milestone payments</a></td>
<td class="nump">$ 10.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_MaximumFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum future milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_MaximumFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090644748792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Unconditional Purchase Obligations (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear', window );">Purchase obligations due 2021</a></td>
<td class="nump">$ 42,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear', window );">Purchase obligations due 2022</a></td>
<td class="nump">44,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligation', window );">Total purchase obligations</a></td>
<td class="nump">86,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_ManufactureAndSupplyOfRoxadustatMember', window );">Manufacture and Supply of Roxadustat [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear', window );">Purchase obligations due 2021</a></td>
<td class="nump">14,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear', window );">Purchase obligations due 2022</a></td>
<td class="nump">10,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligation', window );">Total purchase obligations</a></td>
<td class="nump">25,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_ManufactureAndSupplyOfPamrevlumabMember', window );">Manufacture and Supply of Pamrevlumab [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear', window );">Purchase obligations due 2021</a></td>
<td class="nump">24,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear', window );">Purchase obligations due 2022</a></td>
<td class="nump">33,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligation', window );">Total purchase obligations</a></td>
<td class="nump">57,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_OtherPurchasesMember', window );">Other Purchases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear', window );">Purchase obligations due 2021</a></td>
<td class="nump">3,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear', window );">Purchase obligations due 2022</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligation', window );">Total purchase obligations</a></td>
<td class="nump">$ 3,418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the recorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25383-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recorded unconditional purchase obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25383-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25383-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_ManufactureAndSupplyOfRoxadustatMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_ManufactureAndSupplyOfRoxadustatMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_ManufactureAndSupplyOfPamrevlumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_ManufactureAndSupplyOfPamrevlumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_OtherPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=fgen_OtherPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090726212136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Stock-based Compensation - Subsidiary Stock and Non-Controlling Interests - Additional information (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 19, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion rights, shares issued upon conversion of each preferred share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=fgen_FibrogenEuropeOyMember', window );">FibroGen Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">42,619,022<span></span>
</td>
<td class="nump">42,619,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionTerms', window );">Preferred stock redemption percentage</a></td>
<td class="text">Redemption Right &#8212; If a Preferred Share can be redeemed by a majority shareholder owning more than ninety percent (90%)&#160;of the shares of FibroGen Europe in accordance with the provisions of the Finnish Limited Liability Companies Act, the minority holders of Preferred Shares have the right to request redemption of their shares.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares', window );">Minimum percentage of shareholder's approval to call for redemption of preferred shares</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock, voting rights</a></td>
<td class="text">one vote<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion rights, shares issued upon conversion of each preferred share</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=fgen_FibrogenEuropeOyMember', window );">FibroGen Europe [Member] | Series A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">1,700,845<span></span>
</td>
<td class="nump">1,700,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=fgen_FibrogenEuropeOyMember', window );">FibroGen Europe [Member] | Series B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">1,875,000<span></span>
</td>
<td class="nump">1,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=fgen_FibrogenEuropeOyMember', window );">FibroGen Europe [Member] | Series C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">1,599,503<span></span>
</td>
<td class="nump">1,599,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=fgen_FibrogenEuropeOyMember', window );">FibroGen Europe [Member] | Series D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">1,520,141<span></span>
</td>
<td class="nump">1,520,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=fgen_FibrogenEuropeOyMember', window );">FibroGen Europe [Member] | Series E [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">459,565<span></span>
</td>
<td class="nump">459,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=fgen_FibrogenEuropeOyMember', window );">FibroGen Europe [Member] | Series F [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">5,714,332<span></span>
</td>
<td class="nump">5,714,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=fgen_FibrogenEuropeOyMember', window );">FibroGen Europe [Member] | Series G [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">9,927,500<span></span>
</td>
<td class="nump">9,927,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=fgen_FibrogenEuropeOyMember', window );">FibroGen Europe [Member] | Series H [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">19,822,136<span></span>
</td>
<td class="nump">19,822,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=fgen_FibroGenCaymanMember', window );">FibroGen Cayman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion rights, shares issued upon conversion of each preferred share</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=fgen_FibroGenCaymanMember', window );">FibroGen Cayman [Member] | Series A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">6,758,000<span></span>
</td>
<td class="nump">6,758,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_PreferredSharesIssuedPricePerShare', window );">Preferred shares issued, price per share</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Cash dividend percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_PreferredSharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred shares issued, price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_PreferredSharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Required minimum shareholder percentage to call for redemption of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The redemption terms of preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity. The redemption features of this capital stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=fgen_FibrogenEuropeOyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=fgen_FibrogenEuropeOyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=fgen_FibroGenCaymanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=fgen_FibroGenCaymanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090649908072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Stock-based Compensation - Common Stock - Additional information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">one vote<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090639848968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity and Stock-based Compensation - Summary of Common Stock Reserved for Future Issuance (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">91,441<span></span>
</td>
<td class="nump">87,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="nump">9,290<span></span>
</td>
<td class="nump">10,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding</a></td>
<td class="nump">1,893<span></span>
</td>
<td class="nump">1,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares reserved for future stock options and RSUs grant</a></td>
<td class="nump">7,910<span></span>
</td>
<td class="nump">7,725<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_CommonStockSharesReserved', window );">Total shares of common stock reserved</a></td>
<td class="nump">114,604<span></span>
</td>
<td class="nump">110,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future ESPP offering</a></td>
<td class="nump">4,070<span></span>
</td>
<td class="nump">3,337<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_CommonStockSharesReserved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares reserved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_CommonStockSharesReserved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090651876232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Stock-based Compensation - Stock Plans - Additional information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Total intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">RSUs released and issued net of shares withheld for taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.99<span></span>
</td>
<td class="nump">$ 54.74<span></span>
</td>
<td class="nump">$ 53.69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fgen_TwoThousandAndFiveStockPlanMember', window );">2005 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fgen_TwoThousandAndFiveStockPlanMember', window );">2005 Stock Plan | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fgen_TwoThousandAndFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Termination date of equity incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 12,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Option vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Option vesting schedules are determined by the Company at the time of issuance and generally have a four year vesting schedule (25% vesting on the first anniversary of the vesting base date and quarterly thereafter over the next 3 years).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,909,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription', window );">Common stock reserved for future issuance, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Shares reserved for issuance increases on January&#160;1 of each year commencing on January&#160;1, 2016 and ending on January&#160;1, 2024 by the lesser of (i)&#160;the amount equal to 4% of the number of shares issued and outstanding on December&#160;31 immediately prior to the date of increase or (ii)&#160;such lower number of shares as may be determined by the board of directors. As of December&#160;31, 2020, the Company has reserved 7,909,854 shares of its common stock that remains unissued for issuance under the 2014 Plan.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of common stock reserved for future issuance</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Number of common stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Total intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,600<span></span>
</td>
<td class="nump">$ 59,200<span></span>
</td>
<td class="nump">$ 97,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fgen_TwoThousandAndFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan | First Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fgen_TwoThousandAndFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of fair value exercise price grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sets forth the nature of any other increase or decrease in the number of shares reserved for issuance under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fgen_TwoThousandAndFiveStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fgen_TwoThousandAndFiveStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fgen_TwoThousandAndFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fgen_TwoThousandAndFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090644429352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Stock-based Compensation - Stock Plans - Summary of Stock Option Transactions (Detail)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning Balance, Shares | shares</a></td>
<td class="nump">10,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, Shares | shares</a></td>
<td class="nump">2,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear', window );">Exercised, Shares | shares</a></td>
<td class="num">(3,113)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired, Shares | shares</a></td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited, Shares | shares</a></td>
<td class="num">(234)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending Balance, Shares | shares</a></td>
<td class="nump">9,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, Shares | shares</a></td>
<td class="nump">8,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Shares | shares</a></td>
<td class="nump">5,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning Balance, Weighted Average Exercise per Share | $ / shares</a></td>
<td class="nump">$ 26.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted Average Exercise per Share | $ / shares</a></td>
<td class="nump">31.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted Average Exercise per Share | $ / shares</a></td>
<td class="nump">10.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, Weighted Average Exercise per Share | $ / shares</a></td>
<td class="nump">39.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, Weighted Average Exercise per Share | $ / shares</a></td>
<td class="nump">40.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending Balance, Weighted Average Exercise per Share | $ / shares</a></td>
<td class="nump">32.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, Weighted Average Exercise per Share | $ / shares</a></td>
<td class="nump">32.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted Average Exercise per Share | $ / shares</a></td>
<td class="nump">$ 29.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted Average Remaining Contractual Life</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 86,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, Aggregate Intrinsic Value | $</a></td>
<td class="nump">84,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 66,943<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock options exercised full year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090726313768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Stock-based Compensation - Summary of RSU Activity (Detail) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, Shares, Beginning Balance</a></td>
<td class="nump">1,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, Shares, Ending Balance</a></td>
<td class="nump">1,893<span></span>
</td>
<td class="nump">1,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Fair value at Grant</a></td>
<td class="nump">$ 29.99<span></span>
</td>
<td class="nump">$ 54.74<span></span>
</td>
<td class="nump">$ 53.69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, Shares, Beginning Balance</a></td>
<td class="nump">1,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, Shares</a></td>
<td class="nump">1,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, Shares</a></td>
<td class="num">(813)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, Shares</a></td>
<td class="num">(131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, Shares, Ending Balance</a></td>
<td class="nump">1,893<span></span>
</td>
<td class="nump">1,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, Fair value at Grant, Beginning Balance</a></td>
<td class="nump">$ 49.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Fair value at Grant</a></td>
<td class="nump">29.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Fair value at Grant</a></td>
<td class="nump">45.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, Fair value at Grant</a></td>
<td class="nump">39.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, Fair value at Grant, Ending Balance</a></td>
<td class="nump">$ 37.60<span></span>
</td>
<td class="nump">$ 49.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090651817576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Stock-based Compensation - Employee Stock Purchase Plan - Additional information (Detail) - 2014 ESPP [Member] - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Purchase of common stock shares at discount</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of fair value exercise price grant date</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock reserved for issuance</a></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription', window );">Common stock reserved for future issuance, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has reserved 1,600,000 shares of its common stock for issuance under the 2014 ESPP and shares reserved for issuance increases January&#160;1 of each year commencing January&#160;1, 2016 by the lesser of (i)&#160;a number of shares equal to 1% of the total number of outstanding shares of common stock on December&#160;31 immediately prior to the date of increase; (ii)&#160;1,200,000 shares or (iii)&#160;such number of shares as may be determined by the board of directors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of common stock reserved for future issuance</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Increase in number of shares of common stock reserved for future issuance, shares</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares purchased by employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,876<span></span>
</td>
<td class="nump">135,115<span></span>
</td>
<td class="nump">230,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sets forth the nature of any other increase or decrease in the number of shares reserved for issuance under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fgen_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fgen_TwoThousandAndFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650543288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Stock-based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 72,720<span></span>
</td>
<td class="nump">$ 66,267<span></span>
</td>
<td class="nump">$ 52,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">46,229<span></span>
</td>
<td class="nump">41,015<span></span>
</td>
<td class="nump">30,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 26,491<span></span>
</td>
<td class="nump">$ 25,252<span></span>
</td>
<td class="nump">$ 21,651<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650604168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Stock-based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Employee Stock Purchase Plans (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">67.10%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">67.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value</a></td>
<td class="nump">$ 18.36<span></span>
</td>
<td class="nump">$ 31.98<span></span>
</td>
<td class="nump">$ 32.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee stock purchase plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">47.50%<span></span>
</td>
<td class="nump">48.10%<span></span>
</td>
<td class="nump">47.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">77.10%<span></span>
</td>
<td class="nump">62.10%<span></span>
</td>
<td class="nump">75.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value</a></td>
<td class="nump">$ 17.53<span></span>
</td>
<td class="nump">$ 19.27<span></span>
</td>
<td class="nump">$ 16.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee stock purchase plans [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee stock purchase plans [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090649805848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Stock-based Compensation - Stock-Based Compensation - Additional information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=fgen_StockOptionAwardsMember', window );">Stock Option Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation costs</a></td>
<td class="nump">$ 63.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Non-vested stock option awards granted that will be recognized on a straight-line basis over the weighted-average period</a></td>
<td class="text">2 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Non-vested stock option awards granted that will be recognized on a straight-line basis over the weighted-average period</a></td>
<td class="text">2 years 8 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs</a></td>
<td class="nump">$ 55.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fgen_StockOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fgen_StockOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090725921992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Stock-based Compensation - Warrants - Additional information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ShareholdersEquityAndStockBasedCompensationAbstract', window );"><strong>Shareholders Equity And Stock Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod', window );">Warrants to purchase common stock exercised</a></td>
<td class="nump">4,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase common stock outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ShareholdersEquityAndStockBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shareholders equity and stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ShareholdersEquityAndStockBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090638061512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of net loss per share</a></td>
<td class="nump">7,564<span></span>
</td>
<td class="nump">9,050<span></span>
</td>
<td class="nump">8,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of net loss per share</a></td>
<td class="nump">6,694<span></span>
</td>
<td class="nump">7,602<span></span>
</td>
<td class="nump">7,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of net loss per share</a></td>
<td class="nump">564<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of net loss per share</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of net loss per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090643068808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FibroGen, Inc. 401(k) Plan - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined contribution plan, maximum annual contributions per employee, percent</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, employer matching contributions</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090635763000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Loss Before Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Components Of Income Tax Expense Benefit Continuing Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (195,617)<span></span>
</td>
<td class="nump">$ 2,538<span></span>
</td>
<td class="num">$ (38,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">6,686<span></span>
</td>
<td class="num">(79,180)<span></span>
</td>
<td class="num">(47,644)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (188,931)<span></span>
</td>
<td class="num">$ (76,642)<span></span>
</td>
<td class="num">$ (86,116)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090649992664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Provision For Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="nump">$ 360<span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
<td class="nump">$ 304<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090644413592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation Between Statutory Federal Income Tax Rate and Effective Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at statutory federal rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">14.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets', window );">Benefit due to intercompany transfer of assets</a></td>
<td class="nump">41.70%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets', window );">Valuation allowance on intercompany transfer of assets</a></td>
<td class="num">(41.70%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted', window );">Net operating losses not benefitted</a></td>
<td class="num">(23.20%)<span></span>
</td>
<td class="num">(2.90%)<span></span>
</td>
<td class="num">(23.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign net operating losses not benefitted</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="num">(21.70%)<span></span>
</td>
<td class="num">(11.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Deduction limitation on executive compensation</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation benefit on intercompany transfer of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation deduction expense share based compensation cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation net operating losses not benefitted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation valuation allowance on intercompany transfer of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090644756216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Significant Components of Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Components Of Deferred Tax Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state net operating loss carryforwards</a></td>
<td class="nump">$ 134,033<span></span>
</td>
<td class="nump">$ 91,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">62,465<span></span>
</td>
<td class="nump">52,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign net operating loss carryforwards</a></td>
<td class="nump">32,417<span></span>
</td>
<td class="nump">37,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">10,399<span></span>
</td>
<td class="nump">11,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Lease obligations</a></td>
<td class="nump">8,243<span></span>
</td>
<td class="nump">10,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Reserves and accruals</a></td>
<td class="nump">5,875<span></span>
</td>
<td class="nump">5,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">13,550<span></span>
</td>
<td class="nump">13,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DeferredTaxAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">75,915<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Subtotal</a></td>
<td class="nump">342,897<span></span>
</td>
<td class="nump">222,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(337,824)<span></span>
</td>
<td class="num">(213,847)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">5,073<span></span>
</td>
<td class="nump">8,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DeferredTaxLiabilitiesFixedAssets', window );">Fixed assets</a></td>
<td class="num">(5,073)<span></span>
</td>
<td class="num">(8,266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(5,073)<span></span>
</td>
<td class="num">(8,266)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_DeferredTaxAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_DeferredTaxAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_DeferredTaxLiabilitiesFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities fixed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_DeferredTaxLiabilitiesFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090726227576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 124,000,000.0<span></span>
</td>
<td class="nump">$ 19,900,000<span></span>
</td>
<td class="nump">$ 34,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory', window );">Deferred tax asset for temporary difference</a></td>
<td class="nump">78,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state net operating loss carryforwards</a></td>
<td class="nump">134,033,000<span></span>
</td>
<td class="nump">91,267,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign net operating loss carryforwards</a></td>
<td class="nump">$ 32,417,000<span></span>
</td>
<td class="nump">$ 37,786,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_ExperienceHistoricalOwnershipChanges', window );">Percentage of ownership changes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 48,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Accrued interest, unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would affect effective tax rate</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible', window );">Unrecognized tax benefits description</a></td>
<td class="text">The Company does not anticipate a material change to its unrecognized tax benefits over the next twelve months that would affect the Company&#8217;s effective tax rate.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Foreign statute of limitation generally remains open in the year</a></td>
<td class="text">2011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember', window );">Latest Tax Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Foreign statute of limitation generally remains open in the year</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign net operating loss [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign net operating loss carryforwards</a></td>
<td class="nump">$ 172,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign net operating loss [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign net operating loss [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state net operating loss carryforwards</a></td>
<td class="nump">$ 606,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Other tax credit carryforwards</a></td>
<td class="nump">$ 66,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_OtherTaxCreditCarryforwardsExpirationYear', window );">Other tax credit carryforwards expiration year</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state net operating loss carryforwards</a></td>
<td class="nump">$ 133,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member] | California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Other tax credit carryforwards</a></td>
<td class="nump">$ 32,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_ExperienceHistoricalOwnershipChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Experience historical ownership changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_ExperienceHistoricalOwnershipChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_OtherTaxCreditCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other tax credit carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_OtherTaxCreditCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from intra-entity transfer of asset within consolidated group. Excludes intra-entity transfer of inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A statement that a range of reasonably possible change cannot be made for a tax position taken for which it is reasonably possible that the total amount of unrecognized tax benefit will significantly increase or decrease within 12 months of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090640234536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Income Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending Balance</a></td>
<td class="nump">$ 48,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=fgen_FederalAndStateMember', window );">Federal and State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">32,263<span></span>
</td>
<td class="nump">$ 27,956<span></span>
</td>
<td class="nump">$ 23,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase due to prior positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decrease due to prior positions</a></td>
<td class="num">(137)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase due to current year position</a></td>
<td class="nump">16,448<span></span>
</td>
<td class="nump">4,418<span></span>
</td>
<td class="nump">4,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending Balance</a></td>
<td class="nump">$ 48,574<span></span>
</td>
<td class="nump">$ 32,263<span></span>
</td>
<td class="nump">$ 27,956<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=fgen_FederalAndStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=fgen_FederalAndStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090639866440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,127,000<span></span>
</td>
<td class="nump">$ 4,845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,147,000<span></span>
</td>
<td class="nump">54,790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Unbilled contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,147,000<span></span>
</td>
<td class="nump">180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SuppliesNet', window );">Net unbilled contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">125,210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accrued liabilities and accounts payable to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">36,883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Unbilled contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_AstellasMember', window );">Astellas [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DrugProductRevenueFromRelatedParty', window );">Drug product revenue from a related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="num">(36,300,000)<span></span>
</td>
<td class="nump">$ 64,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accrued liabilities and accounts payable to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">36,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_AstellasMember', window );">Astellas [Member] | Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DrugProductRevenueFromRelatedParty', window );">Drug product revenue from a related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_AstellasMember', window );">Astellas [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Unbilled contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_SuppliesNet', window );">Net unbilled contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">125,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_AstellasMember', window );">Astellas [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expense related to collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_FalikangMember', window );">Falikang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Percentage of outstanding shares owned</a></td>
<td class="nump">51.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_MiscellaneousReceivables', window );">Miscellaneous receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=fgen_APIShipmentMember', window );">API Shipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">License and development revenue related to collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=fgen_APIShipmentMember', window );">API Shipment [Member] | Astellas [Member] | Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">License and development revenue related to collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000,000.0)<span></span>
</td>
<td class="num">(36,300,000)<span></span>
</td>
<td class="nump">64,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fgen_LicenseAndDevelopmentMember', window );">License and Development [Member] | Astellas [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">License and development revenue related to collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,500,000<span></span>
</td>
<td class="nump">158,800,000<span></span>
</td>
<td class="nump">$ 35,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,137,000<span></span>
</td>
<td class="nump">$ 1,102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_DrugProductRevenueFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Drug product revenue from related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_DrugProductRevenueFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_MiscellaneousReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Miscellaneous receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_MiscellaneousReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_SuppliesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplies, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_SuppliesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_AstellasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_AstellasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_FalikangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_FalikangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=fgen_APIShipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=fgen_APIShipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fgen_LicenseAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fgen_LicenseAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090650677784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information - Additional information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Percentage of Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Percentage of Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">64.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090643829032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information - Schedule of Revenue by Geographic Area (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue recognized</a></td>
<td class="nump">$ 176,319<span></span>
</td>
<td class="nump">$ 256,577<span></span>
</td>
<td class="nump">$ 212,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue recognized</a></td>
<td class="nump">67,161<span></span>
</td>
<td class="nump">132,400<span></span>
</td>
<td class="nump">112,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue recognized</a></td>
<td class="nump">36,660<span></span>
</td>
<td class="nump">122,475<span></span>
</td>
<td class="nump">100,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue recognized</a></td>
<td class="nump">72,498<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fgen_AllOtherMember', window );">All other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fgen_AllOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fgen_AllOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090636106776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment and Geographic Information - Schedule of Inventory by Geographic Area (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 16,530<span></span>
</td>
<td class="nump">$ 6,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">4,715<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 11,815<span></span>
</td>
<td class="nump">$ 6,887<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090644482856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment and Geographic Information - Schedule of Long Lived Assets by Geographic Area (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues From External Customers And Long Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 33,647<span></span>
</td>
<td class="nump">$ 42,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues From External Customers And Long Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">20,673<span></span>
</td>
<td class="nump">27,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues From External Customers And Long Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 12,974<span></span>
</td>
<td class="nump">$ 15,418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090637421608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment and Geographic Information - Summary of Finance and Operating Lease Right of Use Assets by Geographical Location (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Total finance lease right-of-use assets</a></td>
<td class="nump">$ 29,606<span></span>
</td>
<td class="nump">$ 39,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Total operating lease right-of-use assets</a></td>
<td class="nump">2,043<span></span>
</td>
<td class="nump">1,931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Total finance lease right-of-use assets</a></td>
<td class="nump">29,551<span></span>
</td>
<td class="nump">39,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Total operating lease right-of-use assets</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Total finance lease right-of-use assets</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Total operating lease right-of-use assets</a></td>
<td class="nump">$ 1,996<span></span>
</td>
<td class="nump">$ 1,856<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090725947656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information - Schedule of Customer Concentration by Collaboration Partners (Detail) - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Percentage of Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Entity Wide Revenue Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Percentage of Revenue [Member] | Astellas-Related party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Entity Wide Revenue Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Percentage of Revenue [Member] | AstraZeneca [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Entity Wide Revenue Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Percentage of Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Entity Wide Revenue Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Percentage of Accounts Receivable [Member] | Astellas-Related party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Entity Wide Revenue Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Percentage of Accounts Receivable [Member] | AstraZeneca [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Entity Wide Revenue Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090642159752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">Valuation Allowances for Deferred Tax Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation And Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Year</a></td>
<td class="nump">$ 213,847<span></span>
</td>
<td class="nump">$ 193,987<span></span>
</td>
<td class="nump">$ 159,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged (Credited) to Statement of Operation</a></td>
<td class="nump">123,977<span></span>
</td>
<td class="nump">19,860<span></span>
</td>
<td class="nump">34,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to Other Accounts - Liabilities and Equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions, Net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End of Year</a></td>
<td class="nump">337,824<span></span>
</td>
<td class="nump">213,847<span></span>
</td>
<td class="nump">193,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_ValuationAllowanceForRebatesAndDiscountsMember', window );">Valuation Allowance for Rebates and Discounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation And Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Year</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged (Credited) to Statement of Operation</a></td>
<td class="nump">16,497<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to Other Accounts - Liabilities and Equity</a></td>
<td class="num">(14,867)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions, Net</a></td>
<td class="num">(2,184)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End of Year</a></td>
<td class="nump">$ 548<span></span>
</td>
<td class="nump">$ 1,102<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_ValuationAllowanceForRebatesAndDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_ValuationAllowanceForRebatesAndDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>133
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MX0(E?,OJ3'X63[_SSB%/]1>+K&K^HJ?.UEF@N*ZDR+O&H"!/B_8_^]$%8M0
MNS,-2-> G-J =@UHXVBKK''KEDFVN2K%$RJ5-?2F+IK8-*W!F[10K_%>EO!K
M"NWDYD84E<C2A$F>H/<L8T7,T;WJKD(K]/7^%KTY>XO.4%J@+SM15ZQ(JJNU
MA)%5^W7<C?*^'87,C'++XW-$\1(1ASB&YC<G-\?1<?,U^-L[37JG2=,?G7.Z
M+DM>2,2J"OR\L/1(^QYITZ,[UR.K=@AB@V)UP;_7Z8%E,(0Q5FU70=.56F:'
MC1^$-*)7Z\,X)KH9)C[Q_=[L2*G;*W6M2N]WHI0KR<L<WNF!5S*?D]GVXXW&
M#['K3D3J1JX3N!$VB_1ZD9Y5Y+LX%C7(@D01<PCE0\:7J("D]N;,76(2-*&&
MR]#UT+84.6)@F35S>,]*^?S6Y(^G2\5A.(VZ;D5@%,_LC]_[XUO]^0B1+J0H
M4VZ,M*^-B7V/.A-ENI4?AH%96- +"ZS"[DJ^9VF"^ _@0L6K)K!"[G@)R6>\
M2"#R81BU<<?$6Q+LM)$?QQW<,T8^T/USL#_USV!%*9V;2F'O86CU\(N0+)LX
M8](8:J,'GH?Q5*3!S"%NY)A%1KW(R"KR,ZS#,HU5'"5 $CBT%U5J%AKI$]0)
MR$3F*T9'(K$SL,*QROQ#%(\GI8ZNGZ/QM=1A,/(QQN&,RA'1\"MS&HH<2 +-
M9%6I>*]T-OG#J!5K,BCUW6"J5C=S2>#2&;4#BC"QJOV0%@US,P[%""I5U;$2
MVU4--_.3M>OS*+Z1[_A3S;H9!;.Y>3# #MMI]QL$%>*;<[D3R6@NJ"JA+N)Q
M27%@9:K2-_P$$P?L$-A!8Z-75/<J(.'4*=UJ9O7A@8G8#L6_FHQGB;>..>K2
M*3H,5A&=774#"[$=AFT&LXC3D142/W2GJ<MDYP4TFD$('N"&_9/*J0S>=)JE
M"@.VF@H/<,)V.O5EP)X]-Y/HS1E>0H9H,>0@*4X"/];)0MP@C*;QT<U\)YQ+
M1P-_L!U X$19@SZ=K*-X@6?$;=VB_A*JDI-]TX&$<>01/'5.MPMIB&>*23R
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M]WGS&]-/7!HB8(.FP=T8?>C#%\-A8-6VW'2OE<4M?'F:X5<6:"? ^QNE[-O
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M/73[O:H?=EG3S2IB+_.*+-XQ2K,6$!KM/ O(\R?8#&8/W6[_%VM3AG7N\:C
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M#Z/3XW5T0ZY)^6E]E;.K4>UE$:<D*V*:@9PL3P:OX,M+C+G!%O%73.Z*O>^
M#^4+I5_YQ<7B9&#QC$A"YB5W$;&/6S(F2<(]L3R^54X'=4QNN/_]P?OY=O!L
M,%^B@HQI\CE>E*N3@3\ "[*,-DGY@=Y-234@A_N;TZ38_@5W%=8:@/FF*&E:
M&;,,TCC;?4;?*R+V#"#N,$"5 1(,G*## %<&6#! J,/ K@QLP:!S#$YEX @&
MV.TP<"L#MV\$KS+P! .[*X)?&?A](P2502"RU$4KM!YFSNH; ]:3+<XVMKM,
M'J8;BO/='>5APN%VQD>[9W'[($^B,CH]SND=R#F>^>-?MJMA:\^>WSCC"_>Z
MS-G=F-F5IV.:%32)%U%)%N"Z9!]L598%H$LP7D79#2E G+$;=/YU19,%R8L_
MP=FW35S>@R'X=#T!S_YX#O[@F(\KNBFB;%$<CTJ6&'<_FE=)O-XE@3J2^$C+
M*%&8C?5FXTVZ22*^\,'9<LDJP1&X(GE,%SS[5PNZYJ7AB'W[ES')AP7^OB3I
M%Y+_HX@U,<2B:4HK(G1NSA[AYJ#C.-<G\&JQB+F[* %74;P8LHD;1^N8\:]S
M^N;)3@\ZQJDAG?E\%XT]TN_+%<D!HYUM:RN^W[ $0EH4.O<7!W1_T''/^B<V
M(<MX'FN]O7V\MX..*M3G\8YF<YJ5.4W8G1MPD94D)T6IG<'+)[H\U/A&K!K7
M)1G5)1EML[,[LGL=)5$V)R J&>_S%P##(X LZ*GJZLZ3M_7$-=KMJ6-['O:/
M1[?[M4V&^<AI8\YE#(2N905V&S>5<4/H!8*WF0+E8LMUO#8N5$0-D =K5(M!
M7#.(>S'X[-7U)TZ=.[1@/4//^Q [QE)>5COS,R/BC1%Q(2.&$#D"ZJV,DD&7
MNF M$NV:1+L/B4?@>A6QU=&'M<G.H]-ZSNS A\A7Y^+4N3C:7-ZQ#B9F:S9E
M<YJP\OI<M18<*?C0=VTD$#5Q3+-R+CL2$%,C8M8OF5#GJ,646S/E:IG:B3:N
MQS89:^22^#]6OF]8 P=H#CAU@,F/.+LEN[JE%&NNG+NP;"<R1"31B)B:P\R,
M3D(=HD6@5Q/H:0ED[2!K]C*FOO.<9/-[4.915O#-@+>9=<%7$N=)R7A[I6S'
MG(P1F3,BICWBS(Q>0AVB19U?4^=KJ=O;#DL*XJ+8;*OPG/*M=<F>OW.VX=*[
M(2/R/=M5<[;W*FGTI<2@R*(,$5DT.YD:G<R,B%"':)$8U"0&6A*K:LO98RMW
MF=,4%-MN8<W*<7$$,E8*F0A91_=<OH R^L[0:Z:Z54P&,@DVPL)>/0FDBH@"
M@4VE(\L5")51(J%&1*A#M B%5M/B6C^'TH>]3]DN6E*B*, X\.R.=/<Z<JA/
ME^<VY*=1"[9VTC5K*[;51]E70RD+![&I$6:X@NDVO7Z>I@J8.,=F2*B%M&EK
M5#-\E&SVE;0AQ6!]VQ.U E0(9\<6F9.=081<V\$B=S)PB) O5FX5S(..CT3M
MK K<+9YAHY[A#\MGU"V?502/JP@M)>CZ0EMRID")&MH,N3!#WO9*YU+KJ,UE
M(Z)A+Q5=<^D_@DO;V(N8(6_,D L%Q!4WS;<*T%!"76JCM:EL>@"H;P(,#8F*
MNPF4!39;P!A!"W6DTPAMJ%?:O7H2J!*Y;B 7&M=<H,V*V@R9]4PHU+IJ,]8H
M:ZB7UH?H3:"L6IU VN[,(ML,F?8)-3/[";60-I6-TH9ZJ?V4+@7*FA5C46 K
M0!*%1LBT3ZB9V4^HA;0I;'0V_(5"&\JRU0M<Z;E4*&TLLJKRA .16+/4-D-"
M+:1]=MF(;?0;Q#92B&V$K&#O.+&=;B.VD5YL?XYRMG)8?TJ^DWP>,\VM/&:5
M]:HK-#\39-;8/=Q,%1AQ9LV04 MI4[5W+*T7V#)5VBF3Q:EMXZXD&FV*]-KT
M1YHC).LYUT6N>):%C.>TY_T\314P:>Z,D% +:=/6R%#43X8*FBE0TB:?XCK8
ML<5N?X)DC>=[GLB<[ QBR_+$?S],%<"A9XL'@DH4:]RD@U55W.[>"#4B%#U)
MA*H(G2"%"/5<Q[/]H".=1H2B XA0I-!\T ]0(&[ZR*Q"%;[$3=\,F?7-*-3Z
M:G/6R%#T\V4HDC7=T+'%@S4%2N+3K$-[Q9J9'85:2)O,1HBBGR=$D:SJAAA9
M4GTV2U$S9-HOV,SL*=1"VC0V8A3]0C&*9%F'7"P+%EF-8JE\*UV)Q\-3!4Q:
M\F8YJH6T_Q'<R%'\&^0HEN4H]GP,[8ZS7]S(47RXLU\L:SP/23OA!)MU:3]/
M4P5,G&4S)-1"VK0UTA0_YNR7#T!!FWRF:]MLZ@*1-QD70/'L5P&". @\3WQK
M0@$<LIB!R)\"%GBV)1ZPA:K FA<G]MZ<Z'7VVZ%OE(Q.L"Q8&5-,,&(LI#/:
M>U&1OQ=\&>4W<5: A"R9J?7"8S[RW:NVNXN2KK?O+GZA94G3[=<5B18DYP!V
M?TEI^7#!7X>L7W@^_1]02P,$%     @ 4H)A4CR>E5D;"@  ERT  !@   !X
M;"]W;W)K<VAE971S+W-H965T."YX;6REFMMNV[@6AE^%"'*1 '8M'G0JT@!-
M/,4>8 Y!,]W[6I'I6+NRZ)'DI)FGGT5*MFQRB79F;AK9_4GK)Q?7^DCIYE75
MWYN5E"WYL2ZKYM/%JFTW'V>S)E_)==9\4!M9P?\L5;W.6OA8/\^:32VSA6FT
M+F<L"*+9.BNJB]L;\]U#?7NCMFU95/*A)LUVO<[JMSM9JM=/%_1B]\77XGG5
MZB]FMS>;[%D^RO;;YJ&&3[-]+XMB+:NF4!6IY?+3Q6?Z<1Z:!D;QWT*^-@?7
M1%MY4NJ[_O#SXM-%H.](EC)O=1<9_'F1][(L=4]P'W_VG5[L?U,W/+S>]?[%
MF <S3UDC[U7YOV+1KCY=)!=D(9?9MFR_JM?_R-Y0J/O+5=F8?\EKKPTN2+YM
M6K7N&\,=K(NJ^YO]Z ?BH &-1AJPO@&S&XB1!KQOP,]M(/H&PHQ,9\6,PSQK
ML]N;6KV26JNA-WUA!M.T!OM%I>?]L:WA?PMHU][>JZI19;'(6KD@CRW\@4EM
M&Z*6Y#YK5N0+!$9#IN3;XYQ<75Z32U)4Y(^5VC99M6AN9BW<@^YIEO>_=]?]
M'AOY/<K(KZIJ5PWYJ5K(Q7$',[CYO0.V<W#'O#W.9?Z!<#HA+& !<D/W9S>G
M*=)\?G[SQ..&[^>#F_[X2'^_;V2=M47UW*V(HBUDX^E6[+L5IELQTNUOD$%*
MU: 3UK6,34N=)EYNIS1)64IO9B^'XXCHXBB-@V/9')$ED6"#[,A N#<0>L?E
M\^+_L!BZV&P59)Q<57E12E+USO2W^CK74;NIU4L!X46>WLC5MH&+HKHF"AG;
MCY[!C?;W%GD'=RXAY>9%IA,9-L!=Z_!@1"B-XL0:7DQ%16R-KJN*PHCA8QOO
M[S_VWO_GM:K;XB]S_WKA+XLJJW))2@D)E=0Z<T[5<@KC2+*FD2T:1;%[^P&/
M4LLDJ@ILDZYJ)'J2O</D9/AG>5[+G<5%T>1J6[4$/A;5B^Q#"S.68+=LV7(U
M4QY%MBU$)4:F+MT;2[W&OE50[,OB+XAPLPBNGC,3Z161?VZ+]NV4N=0STITU
M5S%-K-"=NQI*QQ8\#8;*%'B]_;R_]<X;%)YME1_6JY>L+K(G2 )%U<H:Q 3$
MX!HM2X%SDU P++.(R$YO7LFQTX,:3+U.?SF>.@C.C6JR4@<J9#+(6C"14&[-
MG&[T@* &J7-C*;<#%1$=QF!OT16%?,0C&SPRK\?'5N7?IQK1%B17:^#69C1A
M]ET=WD#,8F:')B*+(N8L.T06,CJV\NA0J2GW.OJZ6WE WX"7%>!:7<LJ?R-Z
M)E%?_.1R.RV9(Y(I#6(QXF= !.IGA*\CF00B41H@S%ZRHM3K;0J.I_IKTD@P
MC4!*[U>X:RZTZQXB<AR[DFD2C_@=B(+ZD>)^E57/TN25 S(P!<ZLMA)R2U&>
MI 0Z8 +U<\+GW-2<1M.++%[T2$X,LUQ=QC29D$O!)CP*S8]?7@D^$4ET39:U
M6I,,VI0FYVTRR ;7Z&B[;#"E-(V='.#J>,A8:@\ZTET8,CZV;@;:H'[<T'F]
M:E4]%C1N]9^F- YM%X@L2A)G\9_-$G2 ">JGB8=:;K("TO$/G<5D%RVJ7<FZ
M3P'M+HRN+BD3$\Y@?W!Y15DX832X[N8W>,?$(@C"N$B=ZH4 !F5)F-KU&A>F
M(^,RL CUP\CO9@C&$9&ZG! EP@E/A#@X"[GM 8&.(!V96S9 !_-#QWZ-;K(W
M@Q8PA1-J5F?P[HEC+BO0..;VQ@J137D06K(Y(N,1'W,\P ?SPP<XKK=@8PCB
M@\0']J]X-($8NH81@"O!TVX8:,S>,1 N47 :"+L4(#*:, <W$5D8!='(0 R$
MPOR$,I=+":MW 7X@06WUU,<3&J5Z[?()Y7&_<N%#&B3O2,S,!1 1!G%LNW=E
M4Y&FPHD#1!<&!U%U['_@&>;GF5_,=D\]E<6S(3-T#;/3"'-:,D<D8W6%#?S"
M_/RR"^3]9@ HQ=K+'D0V:@[A#.K.DZNBJ; =^JCFV.  +"P\([^6JGJ>@L/U
M23>AZX8EC$>V'U<'93YRYLR5T8B/K;H!BI@?BGY[_YD-:M:EE81&S@8/D4WC
M) Y"VRRFBZ@8@6PVP ^+O=#9;6K//M]C Y2P$U"RK?-5UG2D?OZND6%'%ZD=
MSO>8+(PC>^>(R9)@["B #63!_&3QD+V9<X!UMI!F60_'&O_R6(!AM)&DSAHY
M>5 R]TJ.SX('&N%^&GFH52[EHNEJ37^DT]99U4"ITA/]+YQS!$Z"R*8Q1&4;
M]TJ.C0]0POU0<FS<;#7?%=;<102[3"$2>_. 2&@RD@+XP!G<SQE'*]6[IS8^
M3:I?R(UJ"MPJ@@,)=38'F$Q0H'Y[WX<)8:DGR=BD'CS:\ .&.ZG_[%B!N_0
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M$IQHV6S<34.+VFYE<Z%Q8[2/!9YU0!H!OE\(H=\:)D%[>AK_ 5!+ P04
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ME3$#YM9XJU6>GF8F%]>./)F0%CZNQ$(9:3(EM;C%(B'Y@A=_S)8^.*3/G\\
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M%OVN7X'1MCOVC$H];*^=Q/:,[31MMFGJB9WL='?V T1"(F(28 #0LOKK]UP
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M7J*''TY7_L4UIA^G2_\U%YBI#6W ^D(#R?$'*6C_3\;Y_P!02P,$%     @
M4H)A4A^I9"3Q(0  GH4  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M[5U;<]M&EG[WKT!I/%-2+46)E&19OE4IOFR<B1.7G9E4S=8^-($FV38((&A
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MPRMB\FP3@C([N.M%QN0K6P"-/E6C:!Q"-0Q\,:*PGS5[(>W?$!H :RBF0$:
M#9"'G""ZP", .LY/OP+H,-TGDT<1,#-$^FV;(@*ON+,OXO%Y!QWXNKZ(1W?%
M&&X,A73 C>DW[7((.QP>3AY=C_?4,K>.@AKT5$-5,<]49*!L$+30IH?B:DL+
MQ8V7=KL>"HO;W VIZ(OH#;"*TY.+>\8J;JXSQI0YM:!PAD*R1()G0MTT]K,?
MNL1F&LVHR+E4148$[790^1S9[33!.F:@TY.3T#JHL1P/AGY,$+S1)X+RD\DC
M7Q4=114,$ #VHF!-SL":O.H/4%!IB4RM@^.#C"&<TH1/V(CR)97:&=7N0IP
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MNCF<C0VV,GYD(V+NH3/MEH$586N*E T?4QJ(?X).6&,![23,7;NC="/8P_,
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MC0T0Y3,SG.ZWNM(LJX;9[@\;H5=8M5:U-$YAH8V<RQPXHCW:H9'5BZ\4!O^
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M%'HP>V(V"!I0&?3"N6G$7:M!:\R> I@W)Z&]#0YS",Q]NJ:24+94_$Q"(?.
MT=T4Y*R*M)KU,C$,EW/\K%%"T@8YWL$@1^\C]AJZ@!4L#R^U<*"LF:#RBCU
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M-8X1,PDB[L,!1WBAGP4I_J9AVL;=^JE.) L#/YQ05(9QC%H]M'%Y3%?BQD,
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MXQ.FW1=N]\.HM?VJ/%/&J)5]7 J.XH F8'RND$#;'[1!_]\,+OX'4$L#!!0
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M+6&L\[P []<.H>YN6$'_&?/JOU!+ P04    " !2@F%2C779#QP8   @3
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M_';97<W'Z.5BYH_'X_[HUT.C9ZN5/QM/^J/?#(Z.QGXX#?NCW_9'3V=8>3Y
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MS=78_KWW(53; D7<N(J3DN.=Q29&4&"GNEC'B]4'VC*<&70)\5BJW*RV#2S
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MU=CG/GRJ\GJMQ%=YI^R[<P>*-'Z>M[L_^MWQD=U1+'ZK*[>RXN>J4,4^@7-
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MK';:^6GP[=K5^??75!P*#EW4+"^UNJ-W4!^E6):-$OQ&Z6B"QT=5J:5VHFC
MH88&G#*Y%U<@-546=B+/EM8J9X,T&DV/</]=EHUG)\D&LLJ5P,=S%,^8Y*MA
MFG]'.X#"#]6022D!(>"JVL&.#-O!@\[B9!03@;-X-/?/=J!U15&]@,J8Y3J+
M6S!G433*Z.5*%8TOW*5>:^<%9)6JO&$7Z&LZ.!N/9BV6"3_'_OD/N)&AKZ0=
MS?I/=G;ZBMO1M/<4UY!!+W4N*W>0D8=\LXLL=DVOX^<2]!%W;?, 1X%E%WRL
M2)%+8^X1G%MI"@K**$G#<9+@;1Z%<39E?\^!!SZVOS:+PS2;!),XC-/D"5L=
M;$NP#84AF893Y/YC+A]$XS"9SX,H"J/)//A5886H%Z6^X6D;S)@K5F7S6?!%
M665NJ9)!5)GGII&E#2;A; I\83))=MD1^>1658V"G.%D,J9'$B>HG$Y6-WI1
MJLZMIY-P'DUVKNSMO\O-LS2X;A:.S9ZD<3B;3X,XCE%P$F"U]HT8B"840$@]
MBZF^P5&3<)92@:08&3 Z@(^G"<F99<$O^@Z37<3Y&1#QDZ\.T'7/1X211!?(
MI$ZK(2(^8U='T P5K@MQ.Y S5I(J-W(T)W]*I\A+AL)0L<,/.3A62-!8UPUB
M9"TK]/'HV"G 2ZW(L*@&:^H%2OU=E<A#*RRG#("-"RH2LM3_5<5(_(Q,F3NV
M,PVUX;X\RIC*TG:E\Y601X7QF4957(L0RF!$>+S38G6#B&YKU:TR%DH$0W6'
MGH)"P"E$O,%!110:90=U.V\===DX:B*!1I+C^>(UXG9E" KFC6*>BWMQ&L7I
M:(Q.OBRQ*L3W?#3O/IGZ:9*.TMT(R4D0[[G*J4=5COMD^HWFO)M*70B![,87
MRO)^)*Y\B6D QCB<T]P]SF#&P&8%"[I20UI?REN(3P*RVITS>M$X,JE7VH,6
ML!NOE0W[>9$M@+82%#2.)\41.\D; +).:$JL% U;;=7.8,S^B&>37(;P>PWT
M67?5CC:T,G,Y+.DLV/CV!JD.>C!T:+/@5_J\1Y48WY<K=.G L6@LO=A=^T*3
MVQ72^;VHMQ7(VV9A=:&E06R2=SO.^=[%P+5S'<? _P!@6V@N:]8[3 <59L8J
M#4C;UG-!^0_ ]<U!K^W5'D59YQ"D3]$3E/F?C6:]M/1:<P[+KZU?5OIH1R ;
MASCA'4S):C;8QFCJ*G:D]I.N]U((N&G,ID:1'XE/=.#.:U.PE;?:K<3%]3=R
MS^QUE(68A^2O?_80O[9*X-IZX4ER:H1$R!>?*J1^;MDNW)#S[WM=\6PI$_)6
MZM*[=@V62S <#FINES;0UIU>HP[#ZJ?9.!O-]@,V2I)1MA>QRT<5O*^=P_B$
MV>!K^Q"WH :ONZ%@JZF/U'SX(XFS1RPP&/&@Y_7 1R_9E= O<9KM#F:.&198
MVWIAISU4WYI5N'QA5S"@H&@:]S*:S]$M_BZ*&*\'GHP/08Y>:.5#NV0]KD#5
MU\]I$N]/7B+;081*2S(%4BO5$2PL4 C*>K/N K;MGVB*DU-_\ ==RBN\0^=I
MV2.6CAX.0@. N[TKB6:X:K?Z_-J:]G$CR=V$1"NJU^0BG+X0S$[3.0C9VK3)
M2;25T1ME5Q<&W(%H#VJD+1/4MCEVDTI0_Q&/WU+F-':E-R)'>-\H'H[>/LHB
M(?7.R/RZ\LGTTY=+<=W>YB6S>-]U4<.UVM)"J,12=RH>^!!EJJ#'"JB7 N?5
MLJ%Y*/,0(S22\^F]:%UZ6S<E=2NV*1V!D[Y5ZC1%* :TQ8=IGCSJ=YU9V9RT
ML:D:2V'Q"3HL"L['U*H< /3XVAK\?Y@M9[G0F]F'TT]YW_:!0/&MZR+X3NUS
M[0N$W;,%A6=3];HNLFI[YAM*&>FLES\EKWAD(J2%_4TXX/5#^B@_SH(/<V%K
M.<E7"=Y%']TJ>-?B$S2"PI],N(\?A-8U7G.NW7I-" TB"I /KT':"LKA7I$Q
M:*OR?9COHNTC87J7(SL=%K[U(5IN9=0S_2&5^2>.H?TTX>^8/LK2=V=# N,0
M>!K$.']E$=U<<F_;76.@3X"+;SJOP&EQ_FA->PGF [);&J1A'&7/,)X%\32<
M3S(Z.#_)]BR*Z&+QI9Q34'Z:\YR.OW&6O(!S,GTQ9S1":?H,ZYCNVM)9.)FF
MP;>C,;66]UT>Z+E&I>[@X5M5PK77_IZ>K_-PM-DUJ]1NMZD:W9JNZ,"#'& L
M-S]= [R?:XNZO<>ARI'K#5_9B<[M.R!M+_U$(KA5YAA.1O<H4I^_#]P'FI=H
M4)'$N&WN@AE>OE%(H72<)IW+A\L=CD]0:N_M.'6 SC[1I2Z9WL.5I3_^=&K\
M-KH>[0I\OT$/_92OQ \]1==K#9P.]DC1CAX!<.:LT2"4#=\-M%Y04V&G9KZA
M[-X'V!58GRP6ZKYNVPM_*<H6[]VVH6+HNNA<N%</]D^$!P5D:>IU&Q;,)P2L
M[XRT^*.Q;NWOT"JZ#*CWMO;.F&V3U"IF&-T-W AJX=I$_SY:*G&59X^(C8B\
M+QQ]XVGON&T\8C,.P;"!UQ65<3H^'AS51D-_$IWW_G-;*W/#_RQR^:R<__MM
M-[K[\_+"_V?WL-S_\_F;-#>$OU1+;!V/II,3?S#M/ER]X7_P%K5S]9I?5TH"
M-RW _+*N7?=!#'9_Z7[X'U!+ P04    " !2@F%20Z#MG0X'  !6%   &0
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ME$7J<]T2SV>A:0'^;Y6RXX VF![DIW\!4$L#!!0    ( %*"85*:%OK'!@,
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M@VK+HA>D'7P#Q32KYGQ,P;00+*24H.X:V"3QOB+ S<3DO05_"2=N$'40_I<
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M%!\O56M]A.#"&)$NY!VTL6HS"VU8;P:C?:UZZR:_X;@*!1P7[;:(8L#H"_S
M-I&AMKVVP# D(-DOP/.S^[/,'/IG8TI/79.O6#D^F03HVS9?NOSQ#G!23Y*\
MG%W62CD'*&4+0TL<#$!D;+87_>6V\H\#1;OLN1$?1)1/%[H<Z)JIV F@Y^T#
M:TIA#D!G0L'P!CN",2&(K0 C+_L=-GWA[3-B]^+.)H4!M5^;8*+^V)E^Z\]M
MSKX2CM$X#I2"H ;O9B[*Y[((66(YQS$ZH4N3U&"\>;D#D(>J  ^]I[GX8-(
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MH-V$\(V]DWWK;N;M:*1"ZC6E LVT..DXR< E/J!YH,"R^.KJLUI-+U$CW25
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M4"WRY5V^G8(10LQ!.Y<?!":@=#:"E25EMA%J&-O>4*3MR.$UNA!O@MFF9,O
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M;(;S)EQ>E#\4&[V<@\G96K=E#XU>I);,XX*1@MAE>P,&MA\&1,0OY?*+@TR
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M%RBLGTB#G9$_CQR9OL-MF8Q!UF!K=>R4Q4O E9#$MR)"31']59@0J]:Z\J7
MG1JO=7CKSFV?K]P7#P6ZA<UV5/_X4!!Z0/Y7X8J8'<+%$#VK;2.T>%>BCBV'
M\E-&1K/N*!3P+O&]C@\T#GFJ]!:7I/T "E E"B,T:>BUV?'7A>!;%3271>':
M60L>]LF_48K@9=&F8':]:KCPH^^HO22:]7DT^$]<,5.GM]]*(?RMT-83I[<P
M,UKN-#1]IJ*'V+E@$+"#&@ 5Z#@@]L@H+3K1F>DAHS%9(4W&OJ3M2IM>=F!3
M5,ZBGWJD7"C6Y;4&W37D<6_9?=B4(H4P(>$I'ML=XY>F/DBA,[FX*4L"@X=
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MPWB)1Z-+/*(EA+\[YQC Z(T+2*9$P1,<<(%-[?RQ$5KBZ7V;?\A>2.T3L3O
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MD?"B[$W4GV3W<+KRBI/X.'<QM+N3&1O*8]D&CRVA)$(;K)\%]X&,K:9S(7!
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M7ZXZYNS4C=IS-A;F9>O1(%"U<5(!0,DU#A*\$CW!4MHDKDFB*I<MN28.A@A
MR:>,/E F,+>UD.*GCOKCH.H%.(!V@.Y<ZR8O1\C5Z"EF1ZL2Q Q@R VJSEAX
M@H3L!TA&VR/8,W7./()W/-VO%(1TV<0:)-"4$JI[I@6$99G6E?@\^930YO"A
M=6,F# HL4OK2/3*0G@/HOO\6U*RKXEE1552D7H.2@WX&]UOT?H,^=?SD;'[W
M'KSI'__^VPT0^\_<G@=V?PFO'AT^O'^7TP'TA[[9X))8J= W:_KGJLB!!^ #
M\/?+!MBA_( ?0)E/V_O^_P!02P,$%     @ 4H)A4F<_?&#- @  Y 4  !D
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M\5I9F@I^6](81NT<Z+Y0RNX/CJ ;[-,_4$L#!!0    ( %*"85*F>QHMM0(
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M@$F9-S>MS8=DE;[=W# I6:&+*26@OVH _[>,R>Y##=#?=U_\!U!+ P04
M" !2@F%2YFBY@)0#  !6"0  &0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6RM5MMNVS@0??=7$-IBL04$ZVX[J6T@3AJT0 ($2=H^+/:!ED86$8IT22JN
M_WZ'E*PXC>.TBWTQR=%<S@SG>#C=2/6@*P!#?M1<Z)E7&;,^#0*=5U!3/91K
M$/BEE*JF!H]J%>BU EHXHYH'<1B.@IHRX<VG3G:CYE/9&,X$W"BBF[JF:KL
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MX KP(Q &G+NI.1;_X!E)>;CC2O\X(<%QN.M'[SB&26\7?DO+';S1<9"0M_"
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MEYQE7.$"F)]+:=8O**#];^/L'U!+ P04    " !2@F%2/).MN-,'  #Y%0
M&0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6RU6&MOVS@6_:Y?07@'BP10
M8KT?G31 DK8S!=)-T+138!?[@99H6U-)]%!4'O/KYUQ*EI496\U@NU]LBB+O
MX]QS+R]U]B#5UV8MA&:/55DWKV=KK3>OYO,F6XN*-Z=R(VJ\64I5<8U'M9HW
M&R5X;C95Y=QSG&A>\:*>G9^9N5MU?B9;71:UN%6L::N*JZ=+4<J'US-WMIWX
M6*S6FB;FYV<;OA)W0G_>W"H\S0<I>5&)NBEDS918OIY=N*\N7;/!K/BE$ _-
M:,S(E8647^GA??YZYI!%HA29)A$<?_?B2I0E28(=O_5"9X-.VC@>;Z6_,\[#
MF05OQ)4LOQ2Y7K^>)3.6BR5O2_U1/OPL>H="DI?)LC&_[*%?Z\Q8UC9:5OUF
M6% 5=??/'WL@7K+!ZS=XQNY.D;'R#=?\_$S)!Z9H-:31P+AJ=L.XHJ:HW&F%
MMP7VZ?-+7O(Z$^S.4.!*5AM9BUHW[.@37Y2B.3Z;:ZBAQ?.L%WG9B?0.B'0]
M]D'6>MVPMW4N\N<"YK!O,-+;&GGI34I\([)3YKLV\QS/F9#G#T[[1IY_0-Z-
M6O&Z^)T;7ES)NI%ED7=/%W7.;I5H@$$W<;-D[XH:&!6\9'>8%)7!YS\7BT8K
MD.J_$P8%@T&!,2@X8- =DBUO2\'DDEWQ9LTXS#"#M[^UQ3TO2>6^2$R+'41E
M-! [42R#TT6C14X:]5JPI2R1H$6]8D=%C1G9-MC8'+^R +ZH%D)1 "P* '[<
MU"+9U@]6DMA.$&$0.';LAA8B+YY 4/45=%JV$&&%J6/[06PEH1V&KO5):B"9
M'3(-HJ(XL?W4Q\CU(MN+H@F$PP'A<!KAKNJ0NQ>55+KX';Y?R4;;["<EFX9]
MKE'42C/]LRQS0N(G%+6&2<6NL4 TMK'W'2\4^X67K0G6^_I>-+HZ%)YIFSX!
M=\HX7C_]\Q^)Y\8_-JS8"=P&B?3P>UZ4E) G*,0G#:!"Z5GH\7*[1YU6&4#U
MT_/76J@*NS:R*70'O0 .RR(#ITE'_^J4D5U\ "DS(*T,2.T.I'4/TFH+4CD"
M:4D@W6]!TM_P<T&$^14BQI/Z:0,KE.C/"Z/3,%,PXR*VT9$R25=3+ZSG\;:F
MPWWX=4<":Q=_ZU+"57*W:G4+3G=T1T[8+NC^@V6<]7[$Z,BWCOL7@?7V+[$!
MST/+15)M=WA8UN7)>!4)\&*/\@)K1U+])/FSWUCP?_/[\^G=*=-8V+3(J%IJ
M!(-@6!1E258&R-HT#3$*?2H-1_#NV,S'=NA$UM6.=\V(>);OV([C6+XWX$ S
M>-P/M(N*XSM6$@W+,9.XT4& L7@ . SW AQ$L9V$#D9Q$HQ-CQ([<M*)0A0-
MA2AZ:2'"R6-.$'+I ]>M*G31(7+Q+-WO*-V_46FFE5)&9R-MU3-ME%-["LPX
M&Q\$,I$W_3'1O"#KOA1ZC44X#MB3X(J=L*ETV9L5A[, A)\(13R$(G[QJ4OP
MUEJJIWW@3HO9;B4T__=S]2-_H/ (A7Z#G/5LWZ&CT <3OZ#!/2GJDXV2*_0H
M#4'G!ECB18&%+J5 'YBSE93 -<(KWPIL+TU&(/9V4@F)[- GHD=VDL03:"8#
MFLF+T40'M>%%SMX^XO;0].7A!G@H=M4J!3/8!:K*?BI/J]F*%F/1THC.>M'<
MB/X.L?A<4TDS9V"7.[UH$Y:NQKM)5[3>B*6 ]APW%:#<PJZEDA6ME^@<]4A&
M@Z)B-A];1V%@QZF#T;_0+;6'M WES0MMSW6L+03]:Z1#Z"., 4APLP<(R[43
M)\9O[,8]%38O!9$\=&PW(J*XOH^VS)V@2CI0)?T;5,$-4R'SR00J AM*\WV\
MF);Y3([8ROD.)+C&.2>HVV%%A<2[%]LRY#H>0A^9D6N'06)=\X54G*K(S@(P
M!-'V+3>V?2^U/O ,95&H)PJ;Z]&)CJA0=]0BYT?;4D@,:5&:6N]:51>HV*)K
MKHI'&IL4]Q(KM!//L^@6HU7;777AV% B8L0.H4^](?3[<"(G@L!.TL",?-L%
M8ZZQ_Q7NS5E;M:7A,$YJ)8C/T&(=N:YK>QV170<]/OAW;.V/@\UJ04I H<CD
M3>#9<>!/<,EU=C=8Y\5LNL@RU8I\3[VY+CC2RYQY>Z^TTSK&<I_G2;F3^QW(
MAM3.H!N]4=FUZ-L'3><!Q4*UW;F :%&!-X7<B]'MW;ZGV.:@ /X+7.EY_FO;
M'9J[?BH""0/KEC\I6&8T*-&%=A#M>2@7X$QJ4PNT[5&>^:DEVZRYJG@F6FW,
MR^&V*A8MN(]Z$]JN'P]*M]AED@ZN2AJ*#I7G9(LDFEJ<2+MM'^4CS^$ )W_D
M$G>69DWW 2B_H)OWOT4M,F[%R,'=IH%]FC^.RQJR)(V!,2ZK 2U:@MHP Y8W
M0MT#K09'91*E]!MX71E%\CEHK ,DHM\G#W\)#;K^W X]EWH5GUK2*9Z/OM2X
M+^9YQ^UK6:].S+7N6^R>EMQ)*P=IWY?3V_COY.]E AVJL1UX@;DWV$[L6G^V
M"T%]!C1Z\IAJ9(I$N$'<49=@5DD%>[P.Q4?6)UN:)3@LTR'&GAVEQ(L@V7Z9
MD(?!H *6HH#1%2P*[<#9VS?-1U_C*J%6YILC =G6NOLP-\P.WS4ONJ]YN^7=
M1]$/7*WH>EV*);8ZIW$X8ZK[SM@]:+DQW_864FM9F>%:\%PH6H#W2XG;6?]
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M00W:.>#Y2BF[6[@ _>B?_ 502P,$%     @ 4H)A4NYI4+2D!@  8A$  !D
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M^ ?"F?MN_C'<_?OP7J@55%*TEDN8"@4.%)W*?=&[!]-M[%?T=6?@F]PVUU)
M[8@#X/VRZ\SN 1<8_U8Y_0]02P,$%     @ 4H)A4DRQJJ4  P  + 8  !D
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M<;7 <_KB$\]$!>2>/8(BPWLV*T&=G(TUBC8;QEDK9MJ(H0?$^)1\$5PO%?G
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M-TSQD0-E#7!_*:793RQ!^6P.?@%02P,$%     @ 4H)A4O0G24AD!P  _2<
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MN/[$0=GZ1'W!L?H4ZO1O4$L#!!0    ( %*"85+$C!.HZP,  ",/   9
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MEQ,D2I4=63DQ,G==T$8:[*G<,,4N%I1=@.^W4IKCQ&Y0]\6+?P%02P,$%
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M*!RA!.9TG<DGMOD5ZH*\,MZ,94)_HDUM:X_0;"TDRVMGE4&>%M4W_5$WHN6
M_0,.I'8@70?W@(-3.SBG.KBU@ZL[4Y6B^Q!322=CSC:(E]8J6GF@FZF]5?EI
M47)_EES=396?G*A^973*.-44;A<<0%&5 M$B04_P"L4:!/J GJO_!6)S]#F=
M*>ZPO:LM8W6<L57IVEQ_@AE;%.D_D*!UD0 WT=';&"1-LW<J\,MSC-Z^>8?>
MH+1 7Y9L+50\,;:D*JY,T9K5A=Q5A9 #A6""'E@AEP)]5#^6[ :P5%>:UI!M
M:^[(8,089E?(P>\1L8G=D]#]R>XXZG&/3W</!ZIQ&M".CN<<B->A4N)^CQ[4
MZDA7&7Q((%/+C]-I!NB6<UHLZK_!M\\J#OHD(1=_#F3A-EFX.@OW0!9?F*29
MFA<ZES[(E7N@W<N9]3K!@>^4#7QMMW[?C'B^%P2[9G&/&2:1%S9F.T5X31'>
M8!'=!?#M ?(I\*'^^$UH_X*4@B:+X#Q*E;O7IN0ZQ.E ZK$* COT.Y#VS0@A
M?M3/*&Q*" =+Z!M()W"*FO#1!3EAVTQO^SQ2M7^[NZ'M1:2#JL<,8Q=CK\.J
MSXYX$7;Z:>&6#.'!0FZ%5-I/14LDMKC0OWN2T[KU&UW1XA2TF)A<R"7AFHF-
MG3/A.B>MPSXS'#E[;(]%VRW#C'P\//-_&NW'-5?/MR>Q-:,;>Y=D:^8\]L]D
MZ^_1L+M<]TTP#MS [H(="K6;OU$(/"P1PU"'IN__6K-FW./PDER-+N#H3*Y1
MSP0E>VA[K4@7[+X5<>T#;(D1%3(L*F>Q/7W1$B,.!%\0+C'"0,AY<&O_W4>>
MR',[='O,2(B#+MZ^:*%G'QC(Q.@*&=85Q9?3/Z" &6V_\;4@WB_3@I[$T*@
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M<VAE970T-RYX;6S%F5MOVS84@/\*811#"Z21>)%D=XX!U]FP#@T6Y+("*_I
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MRM)UP#\6= %#[2;0^[52=M]Q"[17NOF_4$L#!!0    ( %*"85+0G> N(0,
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MP",%K.B&FX7<O88VH<3RY9)K]TMV[=K (_E&&UFW8%10,]%\Z??6B - &)\
M1"T@^EM OP7T7:*-,I?6C!HZ'BJY(\JN1C;;<-XX-&;#A"WCK5$XRQ!GQI@^
MITNIJ#-U4BH +)+1A(J"+& +8@.:7)(/B@I-&^OGBN6 DYP:*(B19"JQK 6T
M) O( 4M3.(I)GLN-Y6M&Z9(#F7 N\SUV#LIM1H&4[Y><E8X$XW,I2C3#5&2B
MM<R9 \Q@!4I!)XU<S*E"O148EE/^G%S,P%"&C4MR=SLC%\^>DV>$"?*ADAN-
M@O30-VB;3=[/6XM>-A9%)RR:0=XC_? %B8(H> 0^_6MXF#V$^UBLKF)15['(
M\?5/\.TS1T-E*9AUZP6YP5W+UAPN"^#HO6I\5EBTLJWGY[?(0]X8J/67,RKZ
MG8J^4Q&?S*HMA&KD/&9KPY Z!GN<;,=A?Q"G\=#?'MIWO"S+XCCK5CW0%W?Z
MXB?K:QB2@\!1&*=_J#M>E,1I%CRN+NG4)6?5O</S>2.6C'-4F$NLVA8/U+6M
MU#G!R9&6X ^UR;'E41*%)^1>=7*OSLJ=:*/H)Q"0T\,CXO,-U$M07\A/<M>[
M[?D+>=^-G=EB:1<U_8\;?="I&#QY(PV.ZA+VTR0XX7K61<Z>'#E[)')V=2IR
M&/R^%8)_L4%;UO3!7^I(C7]P7=FWP@U5)<,CG\,*84$OQ7Q4<_TV'2/7[@9;
M2H/WH6M6^&0!91?@_$I*L^_82[%[!(U_ 5!+ P04    " !2@F%2@)7D 3T$
M  !S$P  &0   'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6RUF%MOVS84Q[\*
M(?2A!9I(I&Q= MN $V]K@:8UXEX>BCW0%FUKD42/I.(6V(<?2<FBK=N\>7Z)
M=3D7GO\A?XPXVE/VS+>$"/ C33(^MK9"[.YLFZ^V),7\ENY()M^L*4NQD+=L
M8_,=(SC23FEB(\?Q[!3'F349Z6=S-AG17"1Q1N8,\#Q-,?MY3Q*Z'UO0.CQX
MBC=;H1[8D]$.;\B"B"^[.9-W=A4EBE.2\9AF@)'UV)K"NYF+E(.V^!J3/3^Z
M!JJ4):7/ZN9]-+8<-2*2D)50(;#\>2$/)$E4)#F./\N@5I53.1Y?'Z+_JHN7
MQ2PQ)P\T^19'8CNV @M$9(WS1#S1_3M2%C14\58TX?HOV)>VC@56.1<T+9WE
M"-(X*W[QCU*((P?H=3B@T@'5'08=#F[IX)[K,"@=!EJ9HA2MPPP+/!DQN@=,
M6<MHZD*+J;UE^7&F^KX03+Z-I9^82+T2O*0,ZRY,-XP0V57! <XB\$1>2)83
M#F[ HI@7@*[!G-$H7XG#V[?@HYR>KV=$X#AY(TV_+&;@]:LWX!6(,_!Y2W,N
M8_&1+>1P55)[50[MOA@:ZA@:1."19F++P2]91*+3 +:LLRH6'8J]1[T19V1U
M"USX%B '.2T#>CC;'88M[K/SW8.>:MRJ=:Z.YW;%BSG>R(9MBMY]6A\Z KY_
MD*;@O2 I_[TGT:!*--")!AV)/E.!$[G(=?"V/A;NOG97H'F90-]SE48OQ^HV
MS=#0&_K^J=FLQ0RB<!A49B=%#*LBAKU%S%F\(F :_2'7E)KAX/LC29>$]0GD
M5;&]ZW;"KQ+YEW6B<!\>:1<Z3KMP094SZ,WYD68WS^0GF*Y6-)>ZO:-\%ZMA
M?(BYB+,-F.XQB\Z1,ZPRAM>5$SJ&?LYE@I;^)XJZ79+"(^K"WKP/$FQ,[GFY
MS+[ B43L$UEB0<Z1$2*3!5U92,,BZ%XHI-L0TD-'0A:(:+&"G6H;?L%^@!UV
MK'/$-3R!PRN+:_ "O=[Q_\8HY[WB>@W9@M!!?EW=IAD*'+=#7@,E>"&58!-+
M/AJ$07UX33/HUZ?(K+0ZWA^Z)HA!'.QG7'V"@+_ ?]DOH"$<O#+BD$$<NA!Q
MJ(FX^K)L,;D)7:]==F0HB/HIV"+[_[?;((-)=&5,(H-)="$F41. 4FDTK#>D
M:=:Q")"A)/IWE)3=N&2;0H:DZ,HD18:DJ)^D_ZQ_$Y$W'@SJ_\JVF<%!V-$"
M0U+43]*6%GP26\* E$BOA\-WF6H"/ZL+AH$HN'(7#/U0>&$7PI95@-QZ$UJL
M8,=G@FMXZ?;SLJ4'AZDO<I:=([IK".C"ZXKN&LJYZ#+12W__5/2:YBU&=?#8
M1Z<1*6$;?:K#@9Z_Q;=Z];0Z.9KJ\Y+:\WMX-RO.?TR8XCCJ$;--G'&0D+4,
MZ=SZ<@ZPXH2GN!%TI\\\EE0(FNK++<$18<I OE]3*@XW*D%USC;Y&U!+ P04
M    " !2@F%25#48#XL$   _%P  &0   'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6S-6%V/VC@4_2L6ZD,K=2:Q0P*,&"0&=K<C=:H1,]T^5'TPB0>\D\2L
M;:"5^N/7=D*<(1]$8A]X@23<<SGW'OO8\7C/^*M8$R+!SR1.Q6UO+>7FQG%$
MN"8)%M=L0U+URPOC"9;JEJ\<L>$$1P:4Q YRW<!),$U[D[%Y]L@G8[:5,4W)
M(P=BFR28_[HC,=O?]F#O\&!!5VNI'SB3\0:OR!.17S>/7-TY19:()B05E*6
MDY?;WA3>S#U? TS$WY3L1>D:Z%*6C+WJF_OHMN=J1B0FH=0IL/K:D1F)8YU)
M\?@W3]HK_E,#R]>'['^:XE4Q2RS(C,7?:"37M[UA#T3D!6]CN6#[3R0OR! ,
M62S,)]CGL6X/A%LA69*#%8.$IMDW_IDWH@2 00, Y0!T#.@W +P<X'4%]'-
MWW0F*\7T88XEGHPYVP.NHU4V?6&::="J?)IJW9\D5[]2A9,3U:\8+QG'1H7I
MBA.B5)4"X#0""[(CZ98(< 4>.8NVH3P\^@B^J#%Y!:911#42Q^ ^S4:AS@/!
M^SF1F,8?5,S7ISEX_^X#> =H"I[7;"M4;C%VI**O23AA3O4NHXH:J$($'E@J
MUP+\D48D>IO 4747Q:-#\7>H->.<A-? @Q\!<I%;0VC6&0Y'-?!Y=_BPI1JO
MD-(S^;S34NX(F'*.TU5)S"\LO0J;0L"SNA38S$4!OG]6J<&])(GXT4*L7Q#K
M&V+]!F+/3*KQP;.14Z=[!A\8N#:JW00. D_W=%=6HQJ&_, ?#-Z&S6O"(!KY
MPR+L31%^483?6D3M!/C^0)(EX6U-"HK\P66I-RB(#<Y3+X/[I7X/4'\T/!*O
M&@4'KGLDW: BG5NOVK @/VPEOR!:--,6R<"*,Z':&89LJ_O*24CH#B_CVK*&
M%<+#8[ZS:@R$;@/E44%YU$I9*_U*?H%I1A-\8F)#M02?J9 T78'I'O.HR]"#
MKET$W,L:?+"T/L'SAE^.+XLP\II$@,C^+_H_90"_ZY?(+C)9@X<7YO#06CP\
MT^-S?%FFJY&'_*,951/6)*5U;MANW3.U:^"J\JUB^(1CM9]9D"66I),XUK_A
MA1DXM X.S[1P6'7G %7<KB:JT>V@=6C8;M$GU3EG:EG3A:/+4@]9<T;N>>KE
M^#=3*X##X^U371CLC^KU0]:@4;M!/W(:JG9$_ZB7%=.-#KH@:\,(79@NUHV1
M=Z8N7G5E:IHOR#HM:G?:QGZ?,4^0]5+D7Y@>UH!1<*8>0<O:DL^1:HA:I8(&
MS:P!HW8#SAPM:]&<BGS_V448:Z-H>&'"6&]%[3O:4\+,<GR'1=^SKNFUNV9[
MR]5<^<N\#$P/+P.+XF6@BRZ>M4</7I8NGO56KWV+>W+"Y/BR+GYE5U 3U"1>
MZ22CW5I/BG?8-*C=.%[2F$I*.LTGS]JLU[\PW:P'>^W[V=.Z^=4#%1]6E:N&
M'2OGE$X6$\)7YH16 "-(=LY6/"U.@:?F[//H^1V\F6=GN39-=K3\@/F*JC;%
MY$6E=*\'BA7/3FNS&\DVYOQRR:1DB;E<$QP1K@/4[R^,R<.-_H/BS'SR'U!+
M P04    " !2@F%2A/59$8T#   7#   &0   'AL+W=O<FMS:&5E=',O<VAE
M970U,BYX;6R]5]N.VS80_15"R$,"=%>B?%5@&_"EEP#9UO F[4/0!UH:6T0H
MT24I.POTXSND9,G)2D(:!'FQ>)LS9X;DX7AVD>JC3@$,^92)7,^]U)C3:]_7
M<0H9T_?R!#G.'*3*F,&N.OKZI( ESB@3?A@$8S]C//<6,S>V58N9+(S@.6P5
MT466,?6T B$O<X]ZUX$=/Z;&#OB+V8D=X1',^]-68<^O41*>0:ZYS(F"P]Q;
MTM<K&ED#M^)/#A=]TR8VE+V4'VWG33+W LL(!,3&0C#\G&$-0E@DY/%/!>K5
M/JWA;?N*_HL+'H/9,PUK*?[BB4GGWM0C"1Q8(<Q.7GZ#*J"1Q8NET.Z77*JU
M@4?B0AN95<;((.-Y^66?JD3<&(2TPR"L#$+'NW3D6&Z888N9DA>B[&I$LPT7
MJK-&<CRWN_)H%,YRM#,+C$:PO53,Y6AY5 "8<Z,)RQ.R@S/D!6AR1W:X[@X/
MP86IA,@#3@EF("%KF1N%J25O.=MSP0W'Y2\W8!@7K\@+PG/R+I6%1C@]\PTR
MMG[]N&*W*MF%'>QH2![00:K)SWD"R>< /H9:QQM>XUV%O8@;B._)@/Y$PB ,
MWC]NR,L7KWI@!W4:!PYVT)G&*@T7;E*R=OL&JD[*$_GP%BW(&P.9_KO'W[#V
M-W3^AAW^5DRP/ ;"#,&((-NCLS(J&K6EN42;.#1[4<^+N]%P$@4S_]S"8E2S
M&'TCBS!H8U&BC6Y9A'0X:2<QKDF,>TELE4P*S/R'!T>@+[N3&G+R0W9S6ON;
M?M?=G#[/(Z5!V)['J"81]9)8)@FW(M!Z3:,6C^-AU+%U-&C4)^AUN@&[=^BU
M51N"9UY#.AUV^+Q1/-KK<UTH!7G\1-XIEFM1*I^5NS],"JJ5"&TYN)..RT/#
MADC82^17);5N5]#J1+22"5OV8C2>CCKH-!)&!U]U"K<*-#X!*.Z_8U6P/.+3
MKO$;Q[*P#\,.3R@_L[UH9S=XQFXTG'90:]2.?JO<M0M-!?=%CNB@Z[PV@D?[
M%6^CBB.Y*D[U/-;*0_XE2VVPP&"Z>4F_1I=HHW5T_$.4B3922"??59LJN-O4
M=UV41AYIOS[V2A-M4<-1U"D3C1S2?CW\WV<N:GECG_/P;VHUW+JCJT@U<9>K
M+-OJT;KJ79:U7K.\+)D?F#KBW20"#F@:W$\P!ZJL0LN.D2=7^>VEP7/BFBE6
M[J#L IP_2&FN'>N@_B^P^ ]02P,$%     @ 4H)A4BC]\%TH P  J@L  !D
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M!0%L \Q%L!""2 %PE8-;4F!)\O;&>XK7M*"2JL37UT1B6KQ1%3ZOKL'K5V_
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M$1.=F!EZ5@_\BA8-UDR$DJ0/.XQ*DW.R'ET%>4]$-09ST;GJCPNPK#DGE;P
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M"HS, UD=^=5$B]*=FFNAS1GLAKFY)5':#>;]1@A]G-B#N+EWIV]02P,$%
M  @ 4H)A4OXN#^K> @  6 D  !D   !X;"]W;W)K<VAE971S+W-H965T-C0N
M>&ULG59O;Z(P&/\J#=F++;D)+2AL49/;S')+MIR9V]WKJE6;E99KBV[?_MK"
M$$_ G&^$EO[^89^G#'="OJL-(1I\I(RKD;?1.KOU?;78D!2KGL@(-T]60J98
MFZ%<^RJ3!"\=*&4^"H*!GV+*O?'0S4WE>"ARS2@G4PE4GJ98?MX1)G8C#WI?
M$R]TO=%VPA\/,[PF,Z+?LJDT([]B6=*4<$4%!Y*L1MYW>'L'^Q;@5ORB9*=J
M]\!&F0OQ;@>/RY$76$>$D86V%-A<MN2>,&:9C(\_):E7:5I@_?Z+_<&%-V'F
M6)%[P7[3I=Z,O,0#2[+".=,O8O>#E(&<P85@ROV"7;$VCCVPR)46:0DV#E+*
MBRO^*%]$#8!@"P"5 .1\%T+.Y01K/!Y*L0/2KC9L]L9%=6ACCG+[K\RT-$^I
MP>GQ$S&1%+@&,_-_+W-&@%B!9ZQS234U#\S(+0%/%,\I*R8O)T1CRJ[ !: <
MO&Y$KC!?JJ&OC2/+ZR]*];M"';6H3\BB!T+X#:  !6^S";B\N#ID\4V>*A2J
M0B%'&[;0/E".^8(4SE4'85@1AHXP:B$T]F!3N@(5.Y3=_]LQ# ?)S=#?-HA%
ME5AT2@PUB16H_H%8D@R:Q?J56/^46-@DUC\60WW4(C:HQ :=8J]"8P96N=E=
M!#"WK3+\:6I<-^Z=P9&'*( !;/805Q[B3@]/1*E;\,@UD43I)MGX2/8:A4G0
M+)M4LDFG[-2HF9Q@BUGN:JR(S_95U60E.;(2QC%J>0,WE96;SNKXF1&)->7K
MT_4!@WT;"<ZJD!)VL)%@A)H3P%K7@F?52 FKRR5A2SW"?3N!Z*PB*6$'X:*P
M16W?:V!WL_G/*BG9ZB801%&+BWT3@MU=Z'2=P..&=)VTI=_W(]C=D,XKE)*T
MWHE1$/U;*'[MG+3?',]8KBE71F)E8$$O-BRR.,:+@1:9.SKG0IN#V-UNS*</
MD7:!>;X20G\-[&E<?4R-_P)02P,$%     @ 4H)A4C*H>!QA @  VP4  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C4N>&ULC51-;]LP#/TK@M%#"VSQ=Y(6
MCH$VV; ="@1-NQV&'12;CH7*DBO)2?OO)\F.YS8?Z,4F);['1XI2LN/B698
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M>P5NR..95BM&MK*J\;TJF@,6M\07GMA=]$TZ'@R'DW#SCIQA+V?XH9ROSXW
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M" A-"L'P9PL3$")%0C_^*4!;Y9RIX>[U,_IU1A[)S)F&B11?^,*L+UK]%EG
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M=UKB5X8ZO;JGG%89D)WMF8THCZ*"2BORENRP9?*: Q$'LLXR64-.:)63C[H
M23:UE&A(_F1TSSC3#!1Y_0":,OX&Q9]W#^3UJS?D%6$5^52(6J%4+5R-S":R
MF[5\]PU?,,'W -D="?W?2. %WHA\\\MR?_ZCW,5*=>4*NG(%UE\XX>]2AW[6
METK\O=XK+;$O_[D1*.P"A390-!%H*R'#.991;HO>#;1D9LIP4#Y:T,9Q8AV;
M5?R\BB+?#Q?N<[]N0RM_%B3SSNH'ZJBCCFY2K[?OR5&*O,XT/AGV%<W_Q2;&
M=:_'4!MO<0_"N\(<6H2S,(C&,>,.,[Y=7/HB!6\**X%3;3K[1D7C 400I-XU
MZM#*GR?I!.JL0YW=1-V(RO84X;V.TX(<"XJ;6 :UMEV1,VP]MJ^UD*,9S(9L
ML1\F5QD,K;QQ^J2C3V[W0[M<,O$6VZ(4=N>&,YY!"LP6DS5+9XPX&1+[\8!X
M:#5!G';$Z4WB1W&F.78L-0TL#DP3A94&4_*U6=U?H8*,C@&G Y3$\ZYYAT83
MO/..=_Z3?0)/=*E?B*9G+*GI:&'VYS'"^2!X/$^NNWAH%'C11!/[WO=3QOL9
MY@&4.?NQ617(9]P;QD\#;Q _2F?S*\A1JRB8H.R=A?Y-RH]3E6MU_7BIEZ;7
M5$.K*(["":KO1XX?W*3Z)/1EQV]/8/L/7Q9/?V<890^&.[T_CP/_FGYHEX:I
M/[O"=WMW#7/1^T#E$ZL4X7! G7>78/JRN3LU RV.]OJQ%QHO,_:UP/LF2&.
MWP]"Z,O W&BZ&^SJ?U!+ P04    " !2@F%2)8*F)+H"  !2!P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970W,RYX;6R-E5U/VS 4AO^*%7$!$B5I/BEJ*T&K
M:9-@0Q2VBVD7;G+:6#AV9CNT^_>SG1!"FQ9N$CLY[SG/>>TXXPT7SS('4&A;
M4"8G3JY4>>6Z,LVAP/*"E\#TFQ47!59Z*M:N+ 7@S(H*ZOJ>%[L%)LR9CNVS
M>S$=\TI1PN!>(%D5!1;_;H#RS<09.J\/'L@Z5^:!.QV7> T+4$_EO= SM\V2
MD0*8))PA :N)<SV\FB4FW@;\)+"1G3$RG2PY?S:3;]G$\0P04$B5R8#U[05F
M0*E)I#'^-CF=MJ01=L>OV;_8WG4O2RQAQNDODJE\XEPZ*(,5KJAZX)NOT/03
MF7PII])>T::)]1R45E+QHA%K@H*P^HZWC0\=P3 \(/ ;@?]90= ( MMH36;;
MFF.%IV/!-TB8:)W-#*PW5JV[(<RLXD()_99HG9K>8(I9"FAAM\R,%R5GP)1$
M [30.R:K*""^0C]4#@+=<K8>*! %NB5X22A1!"0ZG8/"A)YIR=-BCDY/SM )
M(@P]YKR2F&5R["I-:NJY:4-U4U/Y!ZCFD%Z@8'B.?,_W>N2S3\N'H_=R5_O3
MFN2W)ODV7W @7]-]I^?OG*65$-HI]/MZ*970V_'/D4I!6RFPE<(#E:[35%20
M(=HZG?)!*7C![::'K?YZ)?0Z6B=.;&+S[;Y,_23TP['[TC5N/RH*O&381KVC
M#EOJ\"AU[<\;L\);1-_<ZJ.M$T8=CLLXB79@>X)&PZ"?-6I9H^.L)0BL"%LC
M"OKS[W*>(\;9H%G7/NAHGR<*=ICW8T:AWX\<M\CQQ_;V\<1[M?QXY.T ]02%
MEP<6/&F)DJ-$CUQABOC.LG^PY,G>U@M&<<>;&G<_*HY"+]GA=3LGGOG;W&&Q
M)DSJ-5UIG7>1Z'Y%?8+7$\5+>P@NN=)'JAWF^J<'P@3H]RO.U>O$G*OM;W3Z
M'U!+ P04    " !2@F%20N#[O2L#  " "0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970W-"YX;6RU5LENVS 0_15":($$:*W%L;/ -N"E00W4K9$@[2'H@9;&
M-A&*5$G*3H%^?(>4(BN)+.22B\5EYO&]F3&'@[U4#WH+8,ACRH4>>EMCLBO?
MU_$64JH[,@.!.VNI4FIPJC:^SA30Q#FEW(^"H.^GE EO-'!K2S4:R-QP)F"I
MB,[3E*J_$^!R/_1"[VGAAFVVQB[XHT%&-W +YBY;*ISY%4K"4A":24$4K(?>
M.+R:AI%U<!8_&>QU;4RLE)64#W8R3X9>8!D!A]A8"(J?'4R!<XN$//Z4H%YU
MIG6LCY_0KYUX%+.B&J:2_V*)V0Z]"X\DL*8Y-S=R_Q5*03V+%TNNW2_9E[:!
M1^)<&YF6SL@@9:+XTL<R$#6'L^B(0U0Z1"\<HO"(0[=TZ#JA!3,G:T8-'0V4
MW!-EK1'-#EQLG#>J8<*F\=8HW&7H9T9+)9,\-F0&.TQIA@DRY,>*LPVU4=;D
M,QDG";-CRLE<%'5CXW\R T,9/R4?"!-DP3BW]@/?("D+[<<E@4E!(#I"((S(
M0@JSU>2+2"!Y#N"CFDI2]"1I$K4BSB#ND&[XB41!%-S=SLC)A].:O(.Z!K+3
M-T.'ER5T"^-NE82N@^T>A5T9#*XV*G<)N/^&!F1N(-6_6^#/*O@S!W]V!/Y[
MGJY $;DF69GMI)9M6<OV/_+60$V*(WON2'M7[$9A./!W#31[%<U>*\UQ'*L<
MDD:2L=1&$WB,>9XPL<&2,Z! FR9FQ2G]9\PZ_8I;D><&HZ!F]$Q OQ+0?Y.
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MJDV (N#VE,,V)-N8DX5G)B7+S.6:X(1P_8"ZOV1,[AK:0'76-/\74$L#!!0
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M-G+>EN'5%]JZW_):6K5U5;#/5D'@!:U]J_%GJZ;G^EYIM1=:LPRM>3*T*0C
M/(S-]Q3!6EVK*Y/;ET=(Y\!/I2\H]PB^K<2MTL?6%TF<\S8KLOB!YW4.)*ZQ
M<AVW>2#Q9ZN&XW?<>HG;96CMDZ'-5(DB='F-?@(%KJ+44@\B=343(3G656QW
M 8IS9.^4^W:^K>RN\U%-G"\2OB"N?I!>4%4K5[[.K*E^!]+7F;E!\U![NU(X
M4^!+TX (Y7-&95Y"RM6RR1F8TGZP/M3-CRG('S1YY_2(^9)0@1)8*$KGMJ7.
M(\^;D7PBV<J4YSF3JMB;8:P:..#:0+U?,"9W$[U!V1+V_P-02P,$%     @
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M,\(GMI#QJE7;RSRV618;:H@-(G!/$['AX"X)2% EL*50A5KHJ-8,&1E]LK2
M"S\!Y""G9D'SSG XKH'[W>&>(1JWV'M7\_6;]OZX"5QO LWWZ><]B9\(^]?@
MH5]XZ&L/;H.'1[5S8/8VI6Z93(8UD05$@-D!G-HM\$$_OMUC%H"??TM*\%60
MF)L6-"@6-#"'_+*5!4<E+6$Q^! FX$ PXQ_KDLO,-,B0P -QEF,RVP)\J$O3
M>3<FMV#RFIC\;DS](Q/JUS!5A!L6P@V[";>CD=S"2!:-.LW,),.1!9T_ZQ1J
MP7F64XOS6_V-7^,JT8^*Z$=&HH>0/U^MF/Q7"64)D\5( ";+79T"9B+'\NH%
M,,.0U:^/OPTV,H;O%>%[W38_"'=A0&3]/H0D"NK"-Q,Y#?LXOPSFGPVKA#\N
MPA\;>7[HX4%UKAUA<A@")&]W 5BI?K=3_:Y.C(S6T[1J -M-H6>YPXF].XW]
MK94+K;%7M?)KK) %46%5B0PZ9?MWSND!VV,CWNI&W*$5P)-) [Z/9@!1N21T
M;E7[I*:L,$[CVGG#3-<?68/Z_&X#>@V%T6_WZ!IS');# &R9!FJUP"^-6ICI
M1HVUO@4X1(U:M'@<M&E1CBVP?TF]-^>&F=)IE,.,@V^#RM5H\_>FTU3%*$<F
M:)XJFL4P)(>9$KWMR[D8E^'\\W%5,<HQ"':<@]I;80M38R^\$.>?CZMJ4 Y#
MT#Q67-P/<]Y*0Y0ETWW5$.O,QA8:O>J(=6;#4[-J>.6P UNFG4XM$?P'[K-B
MT*E+EK,&'+^/+HG*&0&US AG?#2U4 WS+Y/:;^>+H?Y%T*H:Y1B#X/^4'EEY
M[)(>J)Q8$'HGZ5$.#JCCX- E/<Q4*(/69L>E2/\29":%?7*N%A.VUN>3'"QI
MFHCLT*AX6IR!WNJ3OU?/9_#:STXR2YKL8/4>LW4H\R8B*TGI6"/9R%AV5IG=
M"+K5IW=/5 @:Z\L-P0%ARD"^7U$JCC?*07%B//T-4$L#!!0    ( %*"85)B
M?F/M_P(  +P(   9    >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;-5646_:
M,!#^*Z>H#ZTT2 B%T@J0H'1:I76KBM@>JCV8Y"!6'9O:!LI^_<Y.2-E$LSWL
M87L!^\[W^?M\/E_Z6Z6?3(9HX247T@R"S-K551B:),.<F:9:H23/0NF<69KJ
M96A6&EGJ@W(1QE'4#7/&93#L>]N]'O;5V@HN\5Z#6><YT[LQ"K4=!*U@;WC@
MR\PZ0SCLK]@2IVAGJWM-L[!"27F.TG E0>-B$(Q:5^-6Y +\BB\<M^9@#$[*
M7*DG-[E-!T'D&*' Q#H(1G\;O$8A'!+Q>"Y!@VI/%W@XWJ._]^))S)P9O%;B
M*T]M-@AZ :2X8&MA']3V Y:".@XO4<+X7]B6:Z, DK6Q*B^#B4'.9?'/7LJ#
M. B(.V\$Q&5 ['D7&WF6$V;9L*_5%K1;36ANX*7Z:"+'I<O*U&KR<HJSPYOG
M-;<[8#*%J57)4\-)3.%:Y91WP_S)-4K7^)AKE*;<#9D +HM;XARG$[2,BS,X
M(3/<<2'(:OJA)<YNYS I^8T+?O$;_%HQW"EI,P,W,L7T9X"0Q%:*X[WB<5R+
M.,&D">W6.XBC.)I-)W!Z<E8#VZX.LNUAS]^ ]4<$GU=>_6C+=&K@\0[S.>IO
M-?#G%?RYAV^_!9\QC7 D R.MF5PB%8J%\0X.U]VSG3=[-O#XD2#AUF)NZ@AU
M*D*=6KTSJ3%12\F_TT[)(:-$&7LTTP5@UP.ZUV(S[+:;E_UP<X1&MZ+1K:7Q
M2<G&!HTE$L9G0!498$4&EG0XSF<S9JFRA( YP@%QMY("-7/%VW#@KL:Y ;5!
M35$(6U_7F#886>B=@A5JKM)C^NJ9QK!#I@U<0%Y<Z!A2MC,UJ;BHSN"B%OF!
M]&N>.)W%+9Q);O_D\O6J#7K_QN6[K A=_C=9KV>ZSWJORGK[=VEO1:]O=_2W
M:[!$/"S"3J?9^:4(PX.&DJ->^K9I"'4M;=%;*FO5FD=%0WI=7O3U.Z:77!H0
MN*#0J'E!KX N6F4QL6KEV]-<66IV?IC1YP5JMX#\"Z7L?N(VJ#Y8AC\ 4$L#
M!!0    ( %*"85*U"_]M:0(  -@%   9    >&PO=V]R:W-H965T<R]S:&5E
M=#@W+GAM;*54RV[;,!#\%4*G%F@B6;+3-K %^)&B/00(8K0Y%#W0TMHBS(="
MKN+D[[.D9,5-8J- +Q(?.[.S0W+'.V.WK@) ]JBD=I.H0JPOX]@5%2CNSDT-
MFG;6QBJ.-+6;V-46>!E 2L9IDES$B@L=Y>.P=F/SL6E0"@TWEKE&*6Z?9B#-
M;A(-HOW"K=A4Z!?B?%SS#2P!?]8WEF9QSU(*!=H)HYF%]22:#B[G(Q\? GX)
MV+F#,?.5K(S9^LF/<A(E7A!(*- S</H]P!RD]$0DX[[CC/J4'G@XWK-_"[53
M+2ON8&[DG2BQFD1?(E;"FC<2;\WN.W3U!(&%D2Y\V:Z+32)6- Z-ZL"D0 G=
M_OECY\,!8'!Q!)!V@/0U8'@$D'6 +!3:*@ME+3CR?&S-CED?36Q^$+P):*I&
M:'^*2[2T*PB'^=5](_")<5VR)9IB>^8]*=G<*+HGC@>KS]@=MY9K=#2<EJ7P
MJUPRH=M;Y&,^+ "YD!\IPE7<@AO'2/)\DKCHI,Q:*>D1*8.471N-E6-7NH3R
M;X*8ZNJ+2_?%S=*3C LHSEDV^,329/#U'4'S?X:GR0DY6>]U%OBR(WQ+;TQE
M9 F6:FR-G^Z-9[.WQO^>KAQ:NNE_3F0?]MF'(?OP2/;^#-&PNK%%1?E8892B
M1"XH@$>PA7"OK6^=;LE'@=RWAH=\.,S(E8=W)(UZ2:/_E$1]QR%=3J$W[XD:
MO1'UHJ@]X5,1K>;XX/$HL)O04QS):#2V[ZA?[=O6-+S6^"6\[7G7W&Z$=DS"
MFJ#)^6?*:]L^TD[0U.$IK@S2PP[#BEHO6!] ^VMC<#_Q"?IFGC\#4$L#!!0
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MAR5^6T"[!%Q?*66W@2O0?:W2/U!+ P04    " !2@F%2.+30$,L"  !R!P
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MKG0%M<U</XH@3(">SSA7NXY9H'UFI_\ 4$L#!!0    ( %*"85*87AV3&@,
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M*'!%U2/?_PZ-H!O#EW$J[2_:-\^&'LHJJ7C9@'4$)6'U/SXT1IP HDD/(&X
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M\5OIS7I "4EQ?H+MD<KS8NS''G?8XR#VS,CJZ<RUM!K9FK9]7E/7*7V8XQX
MCI.R/,'T2&&<E7[,O,/,@YAW8 F1G'.V;/&\:<Q[GHOCS[K#ZPOA>%P6?KRB
MPRN"> ^@03W;VG5E1JM*;2CW(A;]I5?DI^O3(Y1D \NS[ C+(&'7>!0\@]B
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M'#>!'8#?3Y0R3S=V@O6/*V?_ 5!+ P04    " !2@F%2?-\O-#P#   '"@
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M4'JRJR]3/:V#- !]?R^$.BY,@&[^7_T 4$L#!!0    ( %*"85(LFXGN?P(
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MV%'5B?S>NP#<K=W7G'PW1*PHDY#C4N.\LU@G*.K3I)XH7MH-><&5ML@.,WT
MHS %^OV2<_4Z,7M\>Z2/7@!02P,$%     @ 4H)A4MY7?+K! @  K @  !H
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M<?]3Q9,<(SYD<(.6<'"LP0TZ[J)H*X N)(SW))"T@I/CS2SIO K\)-E^7^P
M#:)X2[6[L9>8??R>RB7C"N5DV.9=]-&TK/?&NM"BLMO+7&C<K.PRQ\\)D :
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MY8 I@/R^H52\#%2 ZG8X_Q=02P,$%     @ 4H)A4A?747EA @  5@T   T
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M6WP]/\8)*JE:M,D =O9W').2S=M9=^8@FEF=_<ULS_7J@MV;5/@74$L#!!0
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MJG< Z!U4[P#0.ZC> :!WJ/ZL!.@=5.\ T#NHW@&@=U"] T#OH'H'@-Y1]8X
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 4H)A4IE<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" !2@F%20GPA!.,&  ":&@  &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 4H)A4I@_=OLA!P  ]1P  !@
M             ("!)@\  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( %*"85()0Z5.L@,  ,,-   8              " @7T6  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !2@F%2+?+3V!<&  !A
M&0  &               @(%E&@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ 4H)A4I@R>J#% @  80<  !@              ("!LB
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( %*"85( M#OQ
M7@,  !8*   8              " @:TC  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " !2@F%2A9=3!N '  #\+   &
M@(%!)P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 4H)A
M4CR>E5D;"@  ERT  !@              ("!5R\  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( %*"85*\PABD&0,  $D)   8
M      " @:@Y  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %*"85)<:K>5.0@  , 5   9              "
M@5V7  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ 4H)A
M4IBW&T=9"   !18  !D              ("!S9\  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " !2@F%2>9FU4D<,  !R(   &0
M        @(%=J   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( %*"85)QTW,!:00  )T)   9              " @=NT  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ 4H)A4BUA\H;+"   TA0
M !D              ("!>[D  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " !2@F%2C779#QP8   @3   &0              @(%]P@
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( %*"85*(;9$N
MV0(  - %   9              " @=#:  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ 4H)A4HB.\[?V @  9P8  !D
M ("!X-T  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !2
M@F%2_]3X0=\*  #>'0  &0              @($-X0  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( %*"85)#H.V=#@<  %84   9
M          " @2/L  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#
M%     @ 4H)A4LMNR6="!@  G \  !D              ("!:/,  'AL+W=O
M<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !2@F%2FA;ZQP8#   Z
M!P  &0              @('A^0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM
M;%!+ 0(4 Q0    ( %*"85*4"<]H?UP  $=M 0 9              " @1[]
M  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ 4H)A4F<_
M?&#- @  Y 4  !D              ("!U%D! 'AL+W=O<FMS:&5E=',O<VAE
M970R-RYX;6Q02P$"% ,4    " !2@F%2IGL:+;4"  #%!0  &0
M    @('87 $ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M %*"85(4@W"WHP<  /L>   9              " @<1? 0!X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ 4H)A4N9HN8"4 P  5@D  !D
M             ("!GF<! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    " !2@F%24"=S&_$%  #G$   &0              @(%I:P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( %*"85(\DZVXTP<
M /D5   9              " @9%Q 0!X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ 4H)A4L'[N='0 @  !@8  !D              ("!
MFWD! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !2@F%2
M[FE0M*0&  !B$0  &0              @(&B? $ >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( %*"85),L:JE  ,  "P&   9
M      " @7V# 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ 4H)A4D'.?(5+!@  %!(  !D              ("!M(8! 'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !2@F%24]T56LL$  #:#
M&0              @($VC0$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( %*"85(+SQ4]H0<  -,D   9              " @3B2 0!X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ 4H)A4L<9G(BC
M @  I@<  !D              ("!$)H! 'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    " !2@F%2FF#\K> $  " %@  &0
M@('JG $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( %*"
M85+:(T 0VP(  $('   9              " @0&B 0!X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ 4H)A4O0G24AD!P  _2<  !D
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M=#0V+GAM;%!+ 0(4 Q0    ( %*"85(8P7FI2 4  -L>   9
M  " @8C" 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @
M4H)A4H!4"I.% P  W@T  !D              ("!!\@! 'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"% ,4    " !2@F%2T)W@+B$#   0"0  &0
M            @('#RP$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4
M Q0    ( %*"85* E>0!/00  ',3   9              " @1O/ 0!X;"]W
M;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ 4H)A4E0U& ^+!
M/Q<  !D              ("!C],! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6Q02P$"% ,4    " !2@F%2A/59$8T#   7#   &0              @(%1
MV $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( %*"85(H
M_?!=* ,  *H+   9              " @17< 0!X;"]W;W)K<VAE971S+W-H
M965T-3,N>&UL4$L! A0#%     @ 4H)A4I6#Y%VA!   C!8  !D
M     ("!=-\! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %*"85*K8G2PK@0  "D6   9              "
M@?;S 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ 4H)A
M4M41(Y;9 P  D0X  !D              ("!V_@! 'AL+W=O<FMS:&5E=',O
M<VAE970V,"YX;6Q02P$"% ,4    " !2@F%2&>64I=P"   Y"   &0
M        @('K_ $ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0
M   ( %*"85)'Z@NG(@,  #@)   9              " @?[_ 0!X;"]W;W)K
M<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ 4H)A4GMS0\YR @  @P<
M !D              ("!5P," 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q0
M2P$"% ,4    " !2@F%2_BX/ZMX"  !8"0  &0              @($ !@(
M>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( %*"85(RJ'@<
M80(  -L%   9              " @14) @!X;"]W;W)K<VAE971S+W-H965T
M-C4N>&UL4$L! A0#%     @ 4H)A4MG[QW96!   =Q,  !D
M ("!K0L" 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " !2
M@F%29*BAS70"  #0!0  &0              @($Z$ ( >&PO=V]R:W-H965T
M<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( %*"85)367@(7@4  )$7   9
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M970W,BYX;6Q02P$"% ,4    " !2@F%2)8*F)+H"  !2!P  &0
M    @('E)0( >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    (
M %*"85)"X/N]*P,  ( )   9              " @=8H @!X;"]W;W)K<VAE
M971S+W-H965T-S0N>&UL4$L! A0#%     @ 4H)A4IL$42>5 @  %@8  !D
M             ("!."P" 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"
M% ,4    " !2@F%2E[O1)R4#  "A#   &0              @($$+P( >&PO
M=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( %*"85*[XANC[04
M !,=   9              " @6 R @!X;"]W;W)K<VAE971S+W-H965T-S<N
M>&UL4$L! A0#%     @ 4H)A4L!4_@<. @  B00  !D              ("!
MA#@" 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4    " !2@F%2
M5"*BV_4"  #8"   &0              @(').@( >&PO=V]R:W-H965T<R]S
M:&5E=#<Y+GAM;%!+ 0(4 Q0    ( %*"85(\V VV= 8  )08   9
M      " @?4] @!X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%
M  @ 4H)A4I9**E9]!   =Q(  !D              ("!H$0" 'AL+W=O<FMS
M:&5E=',O<VAE970X,2YX;6Q02P$"% ,4    " !2@F%2 R;)3:P#  #8#0
M&0              @(%420( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+
M 0(4 Q0    ( %*"85+?'T[;300  ,@,   9              " @3=- @!X
M;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @ 4H)A4I7A.5HE
M P  '@H  !D              ("!NU$" 'AL+W=O<FMS:&5E=',O<VAE970X
M-"YX;6Q02P$"% ,4    " !2@F%2%2K>7K $   ]%@  &0
M@($750( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( %*"
M85)B?F/M_P(  +P(   9              " @?Y9 @!X;"]W;W)K<VAE971S
M+W-H965T.#8N>&UL4$L! A0#%     @ 4H)A4K4+_VUI @  V 4  !D
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M=#DQ+GAM;%!+ 0(4 Q0    ( %*"85(36_#9W ,  ,</   9
M  " @<%L @!X;"]W;W)K<VAE971S+W-H965T.3(N>&UL4$L! A0#%     @
M4H)A4N7@LX43!   :PX  !D              ("!U' " 'AL+W=O<FMS:&5E
M=',O<VAE970Y,RYX;6Q02P$"% ,4    " !2@F%2.+L3:'T%  !H&0  &0
M            @($>=0( >&PO=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4
M Q0    ( %*"85)\WR\T/ ,   <*   9              " @=)Z @!X;"]W
M;W)K<VAE971S+W-H965T.34N>&UL4$L! A0#%     @ 4H)A4CIIGO+>!0
M/AX  !D              ("!17X" 'AL+W=O<FMS:&5E=',O<VAE970Y-BYX
M;6Q02P$"% ,4    " !2@F%21*IA?&P"  !C!@  &0              @(%:
MA ( >&PO=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+ 0(4 Q0    ( %*"85+1
M%YN12 ,   L,   9              " @?V& @!X;"]W;W)K<VAE971S+W-H
M965T.3@N>&UL4$L! A0#%     @ 4H)A4BR;B>Y_ @  8 <  !D
M     ("!?(H" 'AL+W=O<FMS:&5E=',O<VAE970Y.2YX;6Q02P$"% ,4
M" !2@F%27@GV0JL"  #>!P  &@              @($RC0( >&PO=V]R:W-H
M965T<R]S:&5E=#$P,"YX;6Q02P$"% ,4    " !2@F%2WE=\NL$"  "L"
M&@              @($5D ( >&PO=V]R:W-H965T<R]S:&5E=#$P,2YX;6Q0
M2P$"% ,4    " !2@F%2O7=CC6P#  !@#P  &@              @($.DP(
M>&PO=V]R:W-H965T<R]S:&5E=#$P,BYX;6Q02P$"% ,4    " !2@F%2\W@A
MB^0#   I#@  &@              @(&RE@( >&PO=V]R:W-H965T<R]S:&5E
M=#$P,RYX;6Q02P$"% ,4    " !2@F%2%]=1>6$"  !6#0  #0
M    @ '.F@( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( %*"85*7BKL<P
M !,"   +              "  5J= @!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M %*"85(EA<L#K@8  #1$   /              "  4.> @!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " !2@F%2"DA2;NL"  "&/   &@
M@ $>I0( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !2
M@F%2A'6;AV,"  !A.@  $P              @ %!J ( 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     ;P!O (0>  #5J@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>467</ContextCount>
  <ElementCount>604</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>127</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>Consolidated Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureTheCompany</Role>
      <ShortName>The Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Acquisition and Variable Interest Entity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntity</Role>
      <ShortName>Acquisition and Variable Interest Entity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Collaboration Agreements and Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenues</Role>
      <ShortName>Collaboration Agreements and Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Product Development Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligations</Role>
      <ShortName>Product Development Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Equity and Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensation</Role>
      <ShortName>Equity and Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - FibroGen, Inc. 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFibrogenInc401KPlan</Role>
      <ShortName>FibroGen, Inc. 401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Segment and Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformation</Role>
      <ShortName>Segment and Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Schedule II - Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccounts</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Acquisition and Variable Interest Entity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityTables</Role>
      <ShortName>Acquisition and Variable Interest Entity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Collaboration Agreements and Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables</Role>
      <ShortName>Collaboration Agreements and Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenues</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Equity and Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationTables</Role>
      <ShortName>Equity and Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Segment and Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationTables</Role>
      <ShortName>Segment and Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Summary of Significant Accounting Policies - Schedule of Significant Balance of Accounts Receivable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Significant Balance of Accounts Receivable (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Acquisition and Variable Interest Entity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail</Role>
      <ShortName>Acquisition and Variable Interest Entity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Acquisition and Variable Interest Entity - Summary of Equity Method Investment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail</Role>
      <ShortName>Acquisition and Variable Interest Entity - Summary of Equity Method Investment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Collaboration Agreements and Revenues - Astellas Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration Agreements and Revenues - Astellas Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Collaboration Agreements and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail</Role>
      <ShortName>Collaboration Agreements and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Collaboration Agreements and Revenues - Accounting for the Astellas Agreements - Additional Information 2 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail</Role>
      <ShortName>Collaboration Agreements and Revenues - Accounting for the Astellas Agreements - Additional Information 2 (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Collaboration Agreements and Revenues - Accounting for the AstraZeneca Agreements - Additional Information 3 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail</Role>
      <ShortName>Collaboration Agreements and Revenues - Accounting for the AstraZeneca Agreements - Additional Information 3 (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Collaboration Agreements and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail</Role>
      <ShortName>Collaboration Agreements and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail</Role>
      <ShortName>Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Collaboration Agreements and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail</Role>
      <ShortName>Collaboration Agreements and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail</Role>
      <ShortName>Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Collaboration Agreements and Revenues - Summary of Product Revenue, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail</Role>
      <ShortName>Collaboration Agreements and Revenues - Summary of Product Revenue, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Collaboration Agreements and Revenues - Product Revenue, Net - Additional Information 1 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail</Role>
      <ShortName>Collaboration Agreements and Revenues - Product Revenue, Net - Additional Information 1 (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Collaboration Agreements and Revenues - Roll-forward of Related Contract Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail</Role>
      <ShortName>Collaboration Agreements and Revenues - Roll-forward of Related Contract Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Collaboration Agreements and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail</Role>
      <ShortName>Collaboration Agreements and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Collaboration Agreements and Revenues - Drug Product Revenue - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail</Role>
      <ShortName>Collaboration Agreements and Revenues - Drug Product Revenue - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Collaboration Agreements and Revenues - Deferred Revenue - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail</Role>
      <ShortName>Collaboration Agreements and Revenues - Deferred Revenue - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Fair Value Measurements - Fair Values of Financial Liabilities Carried at Historical Cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail</Role>
      <ShortName>Fair Value Measurements - Fair Values of Financial Liabilities Carried at Historical Cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Leases - Components of Lease Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail</Role>
      <ShortName>Leases - Components of Lease Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail</Role>
      <ShortName>Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Leases - Schedule of Lease Term and Discount Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail</Role>
      <ShortName>Leases - Schedule of Lease Term and Discount Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail</Role>
      <ShortName>Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Balance Sheet Components - Summary of Contractual Maturities of Available-for-Sale Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfContractualMaturitiesOfAvailableForSaleInvestmentsDetail</Role>
      <ShortName>Balance Sheet Components - Summary of Contractual Maturities of Available-for-Sale Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Balance Sheet Components - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail</Role>
      <ShortName>Balance Sheet Components - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Balance Sheet Components - Schedule of Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Inventory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Balance Sheet Components - Schedule of Other Long-term Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Other Long-term Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>100740 - Disclosure - Product Development Obligations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail</Role>
      <ShortName>Product Development Obligations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Commitments and Contingencies - Summary of Unconditional Purchase Obligations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Unconditional Purchase Obligations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>100770 - Disclosure - Equity and Stock-based Compensation - Subsidiary Stock and Non-Controlling Interests - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail</Role>
      <ShortName>Equity and Stock-based Compensation - Subsidiary Stock and Non-Controlling Interests - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>100780 - Disclosure - Equity and Stock-based Compensation - Common Stock - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationCommonStockAdditionalInformationDetail</Role>
      <ShortName>Equity and Stock-based Compensation - Common Stock - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>100790 - Disclosure - Equity and Stock-based Compensation - Summary of Common Stock Reserved for Future Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail</Role>
      <ShortName>Equity and Stock-based Compensation - Summary of Common Stock Reserved for Future Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>100800 - Disclosure - Equity and Stock-based Compensation - Stock Plans - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail</Role>
      <ShortName>Equity and Stock-based Compensation - Stock Plans - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>100810 - Disclosure - Equity and Stock-based Compensation - Stock Plans - Summary of Stock Option Transactions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail</Role>
      <ShortName>Equity and Stock-based Compensation - Stock Plans - Summary of Stock Option Transactions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>100820 - Disclosure - Equity and Stock-based Compensation - Summary of RSU Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail</Role>
      <ShortName>Equity and Stock-based Compensation - Summary of RSU Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>100830 - Disclosure - Equity and Stock-based Compensation - Employee Stock Purchase Plan - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail</Role>
      <ShortName>Equity and Stock-based Compensation - Employee Stock Purchase Plan - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>100840 - Disclosure - Equity and Stock-based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail</Role>
      <ShortName>Equity and Stock-based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>100850 - Disclosure - Equity and Stock-based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Employee Stock Purchase Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail</Role>
      <ShortName>Equity and Stock-based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Employee Stock Purchase Plans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>100860 - Disclosure - Equity and Stock-based Compensation - Stock-Based Compensation - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Equity and Stock-based Compensation - Stock-Based Compensation - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>100870 - Disclosure - Equity and Stock-based Compensation - Warrants - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationWarrantsAdditionalInformationDetail</Role>
      <ShortName>Equity and Stock-based Compensation - Warrants - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>100880 - Disclosure - Net Loss Per Share - Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail</Role>
      <ShortName>Net Loss Per Share - Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>100890 - Disclosure - FibroGen, Inc. 401(k) Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFibrogenInc401KPlanAdditionalInformationDetail</Role>
      <ShortName>FibroGen, Inc. 401(k) Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>100900 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Components of Loss Before Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>100910 - Disclosure - Income Taxes - Schedule of Components of Provision For Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Schedule of Components of Provision For Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>100920 - Disclosure - Income Taxes - Schedule of Reconciliation Between Statutory Federal Income Tax Rate and Effective Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation Between Statutory Federal Income Tax Rate and Effective Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>100930 - Disclosure - Income Taxes - Schedule of Significant Components of Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Schedule of Significant Components of Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>100940 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>100950 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Income Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Income Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>100960 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>100970 - Disclosure - Segment and Geographic Information - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetail</Role>
      <ShortName>Segment and Geographic Information - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>100980 - Disclosure - Segment and Geographic Information - Schedule of Revenue by Geographic Area (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail</Role>
      <ShortName>Segment and Geographic Information - Schedule of Revenue by Geographic Area (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>100990 - Disclosure - Segment and Geographic Information - Schedule of Inventory by Geographic Area (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfInventoryByGeographicAreaDetail</Role>
      <ShortName>Segment and Geographic Information - Schedule of Inventory by Geographic Area (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>101000 - Disclosure - Segment and Geographic Information - Schedule of Long Lived Assets by Geographic Area (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfLongLivedAssetsByGeographicAreaDetail</Role>
      <ShortName>Segment and Geographic Information - Schedule of Long Lived Assets by Geographic Area (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>101010 - Disclosure - Segment and Geographic Information - Summary of Finance and Operating Lease Right of Use Assets by Geographical Location (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationSummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationDetail</Role>
      <ShortName>Segment and Geographic Information - Summary of Finance and Operating Lease Right of Use Assets by Geographical Location (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>101020 - Disclosure - Segment and Geographic Information - Schedule of Customer Concentration by Collaboration Partners (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail</Role>
      <ShortName>Segment and Geographic Information - Schedule of Customer Concentration by Collaboration Partners (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="fgen-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>101030 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccountsDetail</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccounts</ParentRole>
      <Position>103</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="fgen-10k_20201231.htm">fgen-10k_20201231.htm</File>
    <File>fgen-20201231.xsd</File>
    <File>fgen-20201231_cal.xml</File>
    <File>fgen-20201231_def.xml</File>
    <File>fgen-20201231_lab.xml</File>
    <File>fgen-20201231_pre.xml</File>
    <File>fgen-ex1035_604.htm</File>
    <File>fgen-ex1036_605.htm</File>
    <File>fgen-ex1044_204.htm</File>
    <File>fgen-ex211_241.htm</File>
    <File>fgen-ex231_10.htm</File>
    <File>fgen-ex311_14.htm</File>
    <File>fgen-ex312_9.htm</File>
    <File>fgen-ex321_13.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gapk0ju0ozex000001.jpg</File>
    <File>gapk0ju0ozex000002.jpg</File>
    <File>gapk0ju0ozex000003.jpg</File>
    <File>gapk0ju0ozex000004.jpg</File>
    <File>gapk0ju0ozex000005.jpg</File>
    <File>gapk0ju0ozex000006.jpg</File>
    <File>gapk0ju0ozex000007.jpg</File>
    <File>gapk0ju0ozex000008.jpg</File>
    <File>gapk0ju0ozex000009.jpg</File>
    <File>gapk0ju0ozex000010.jpg</File>
    <File>gapk0ju0ozex000011.jpg</File>
    <File>gapk0ju0ozex000012.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>139
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "fgen-10k_20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 39,
   "contextCount": 467,
   "dts": {
    "calculationLink": {
     "local": [
      "fgen-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "fgen-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "fgen-10k_20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fgen-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fgen-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "fgen-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 854,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 50,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 54
   },
   "keyCustom": 135,
   "keyStandard": 469,
   "memberCustom": 53,
   "memberStandard": 70,
   "nsprefix": "fgen",
   "nsuri": "http://www.fibrogen.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - The Company",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureTheCompany",
     "shortName": "The Company",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "101000 - Disclosure - Segment and Geographic Information - Schedule of Long Lived Assets by Geographic Area (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfLongLivedAssetsByGeographicAreaDetail",
     "shortName": "Segment and Geographic Information - Schedule of Long Lived Assets by Geographic Area (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_srtStatementGeographicalAxis_countryUS_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "101010 - Disclosure - Segment and Geographic Information - Summary of Finance and Operating Lease Right of Use Assets by Geographical Location (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationSummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationDetail",
     "shortName": "Segment and Geographic Information - Summary of Finance and Operating Lease Right of Use Assets by Geographical Location (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_srtStatementGeographicalAxis_countryUS_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "101020 - Disclosure - Segment and Geographic Information - Schedule of Customer Concentration by Collaboration Partners (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail",
     "shortName": "Segment and Geographic Information - Schedule of Customer Concentration by Collaboration Partners (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "101030 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccountsDetail",
     "shortName": "Schedule II - Valuation and Qualifying Accounts (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_us-gaapValuationAllowanceOfDeferredTaxAssetsMember_20171231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:AcquisitionAndVariableInterestEntityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Acquisition and Variable Interest Entity",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntity",
     "shortName": "Acquisition and Variable Interest Entity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:AcquisitionAndVariableInterestEntityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:CollaborativeArrangementAndRevenuesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Collaboration Agreements and Revenues",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenues",
     "shortName": "Collaboration Agreements and Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:CollaborativeArrangementAndRevenuesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Fair Value Measurements",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Leases",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Balance Sheet Components",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:ProductDevelopmentObligationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Product Development Obligations",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligations",
     "shortName": "Product Development Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:ProductDevelopmentObligationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Commitments and Contingencies",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Equity and Stock-based Compensation",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensation",
     "shortName": "Equity and Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Net Loss Per Share",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - FibroGen, Inc. 401(k) Plan",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFibrogenInc401KPlan",
     "shortName": "FibroGen, Inc. 401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Income Taxes",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Related Party Transactions",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Segment and Geographic Information",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformation",
     "shortName": "Segment and Geographic Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Schedule II - Valuation and Qualifying Accounts",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccounts",
     "shortName": "Schedule II - Valuation and Qualifying Accounts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Acquisition and Variable Interest Entity (Tables)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityTables",
     "shortName": "Acquisition and Variable Interest Entity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "fgen:ProductRevenuePolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Collaboration Agreements and Revenues (Tables)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
     "shortName": "Collaboration Agreements and Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "fgen:ProductRevenuePolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableRelatedPartiesCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DueFromRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Leases (Tables)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RecordedUnconditionalPurchaseObligationsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RecordedUnconditionalPurchaseObligationsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Equity and Stock-based Compensation (Tables)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationTables",
     "shortName": "Equity and Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Segment and Geographic Information (Tables)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationTables",
     "shortName": "Segment and Geographic Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "U_fgenSegment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200401",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Summary of Significant Accounting Policies - Schedule of Significant Balance of Accounts Receivable (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Significant Balance of Accounts Receivable (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCreditConcentrationRiskMember_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "fgen:CostOfGoodsAndServicesSoldOperatingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20200101_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:VariableInterestEntityOwnershipPercentage",
      "reportCount": 1,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Acquisition and Variable Interest Entity - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail",
     "shortName": "Acquisition and Variable Interest Entity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_srtCounterpartyNameAxis_us-gaapVariableInterestEntityNotPrimaryBeneficiaryMember_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20200101_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "fgen:EquityMethodInvestmentAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Acquisition and Variable Interest Entity - Summary of Equity Method Investment (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail",
     "shortName": "Acquisition and Variable Interest Entity - Summary of Equity Method Investment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_fgenBeijingFalikangPharmaceuticalCoLtdMember_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Collaboration Agreements and Revenues - Astellas Agreements - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
     "shortName": "Collaboration Agreements and Revenues - Astellas Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "fgen:CollaborativeArrangementAndRevenuesPolicyTextBlock",
       "fgen:CollaborativeArrangementAndRevenuesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20050601_20090228",
      "decimals": "-5",
      "lang": null,
      "name": "fgen:ProceedsFromUpfrontNonContingentAndTimeBasedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Supplies",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Collaboration Agreements and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
     "shortName": "Collaboration Agreements and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20190630",
      "decimals": "-5",
      "lang": null,
      "name": "fgen:TransactionPriceAllocatedToPerformanceObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:CoDevelopmentServicesEstimatedContinuationYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Collaboration Agreements and Revenues - Accounting for the Astellas Agreements - Additional Information 2 (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
     "shortName": "Collaboration Agreements and Revenues - Accounting for the Astellas Agreements - Additional Information 2 (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fgen:CoDevelopmentServicesEstimatedContinuationYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "fgen:RoyaltyRateOnNetRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Collaboration Agreements and Revenues - Accounting for the AstraZeneca Agreements - Additional Information 3 (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail",
     "shortName": "Collaboration Agreements and Revenues - Accounting for the AstraZeneca Agreements - Additional Information 3 (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "fgen:RoyaltyRateOnNetRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Collaboration Agreements and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
     "shortName": "Collaboration Agreements and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_srtProductOrServiceAxis_us-gaapLicenseMember_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
     "shortName": "Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_srtStatementGeographicalAxis_countryJP_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "fgen:CumulativeRevenueLicenseAndDevelopmentRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_srtStatementGeographicalAxis_countryJP_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Collaboration Agreements and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
     "shortName": "Collaboration Agreements and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_srtStatementGeographicalAxis_countryJP_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "fgen:VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail",
     "shortName": "Collaboration Agreements and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_srtStatementGeographicalAxis_fgenUnitedStatesAndRestOfWorldMember_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fgen:LicenseFeesAndMilestonesRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Operations (Parenthetical)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical",
     "shortName": "Consolidated Statements of Operations (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasCollaborationAgreementMember_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fgen:LicenseFeesAndMilestonesRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Collaboration Agreements and Revenues - Summary of Product Revenue, Net (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail",
     "shortName": "Collaboration Agreements and Revenues - Summary of Product Revenue, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "fgen:ProductRevenuePolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "fgen:RevenueGrossFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Collaboration Agreements and Revenues - Product Revenue, Net - Additional Information 1 (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail",
     "shortName": "Collaboration Agreements and Revenues - Product Revenue, Net - Additional Information 1 (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Collaboration Agreements and Revenues - Roll-forward of Related Contract Liabilities (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
     "shortName": "Collaboration Agreements and Revenues - Roll-forward of Related Contract Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "fgen:ContractWithCustomerLiabilityAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Collaboration Agreements and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
     "shortName": "Collaboration Agreements and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfDrugProductRevenueTableTextBlock",
       "fgen:DrugProductRevenuePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapTypeOfArrangementAxis_fgenAstellasAgreementMember_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Collaboration Agreements and Revenues - Drug Product Revenue - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
     "shortName": "Collaboration Agreements and Revenues - Drug Product Revenue - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "fgen:DrugProductRevenuePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapValuationAllowancesAndReservesTypeAxis_fgenDrugProductRevenueMember_20191231",
      "decimals": "-5",
      "lang": null,
      "name": "fgen:EstimatedVariableConsiderationTransactionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Collaboration Agreements and Revenues - Deferred Revenue - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
     "shortName": "Collaboration Agreements and Revenues - Deferred Revenue - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_srtStatementGeographicalAxis_countryCN_us-gaapTypeOfArrangementAxis_fgenAstraZenecaAgreementsMember_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecurities",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Fair Value Measurements - Fair Values of Financial Liabilities Carried at Historical Cost (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail",
     "shortName": "Fair Value Measurements - Fair Values of Financial Liabilities Carried at Historical Cost (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapFairValueByLiabilityClassAxis_fgenLeaseObligationsMember_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_srtRangeAxis_srtMinimumMember_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_srtRangeAxis_srtMinimumMember_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fgen:FinanceLeaseRightOfUseAssetsCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail",
     "shortName": "Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fgen:FinanceLeaseRightOfUseAssetsCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Leases - Components of Lease Expense (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail",
     "shortName": "Leases - Components of Lease Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FinanceLeaseInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail",
     "shortName": "Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfLeaseTermAndDiscountRateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Leases - Schedule of Lease Term and Discount Rate (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail",
     "shortName": "Leases - Schedule of Lease Term and Discount Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfLeaseTermAndDiscountRateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail",
     "shortName": "Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail",
     "shortName": "Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fgen:AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Balance Sheet Components - Summary of Contractual Maturities of Available-for-Sale Investments (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfContractualMaturitiesOfAvailableForSaleInvestmentsDetail",
     "shortName": "Balance Sheet Components - Summary of Contractual Maturities of Available-for-Sale Investments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fgen:AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20180101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Balance Sheet Components - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
     "shortName": "Balance Sheet Components - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20180101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Balance Sheet Components - Schedule of Inventory (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail",
     "shortName": "Balance Sheet Components - Schedule of Inventory (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Supplies",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
     "shortName": "Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fgen:AccruedPreclinicalAndClinicalTrialCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail",
     "shortName": "Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fgen:AccruedPreclinicalAndClinicalTrialCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "fgen:AccruedLongTermCoPromotionLiabilityNonCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100730 - Disclosure - Balance Sheet Components - Schedule of Other Long-term Liabilities (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail",
     "shortName": "Balance Sheet Components - Schedule of Other Long-term Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "fgen:ProductDevelopmentObligationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "fgen:NumberOfProductDevelopmentObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_fgenDevelopmentObligation",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100740 - Disclosure - Product Development Obligations - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail",
     "shortName": "Product Development Obligations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "fgen:ProductDevelopmentObligationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "fgen:NumberOfProductDevelopmentObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_fgenDevelopmentObligation",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100750 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100760 - Disclosure - Commitments and Contingencies - Summary of Unconditional Purchase Obligations (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail",
     "shortName": "Commitments and Contingencies - Summary of Unconditional Purchase Obligations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "us-gaap:PreferredStockSharesIssued",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100770 - Disclosure - Equity and Stock-based Compensation - Subsidiary Stock and Non-Controlling Interests - Additional information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail",
     "shortName": "Equity and Stock-based Compensation - Subsidiary Stock and Non-Controlling Interests - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20141119",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100780 - Disclosure - Equity and Stock-based Compensation - Common Stock - Additional information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationCommonStockAdditionalInformationDetail",
     "shortName": "Equity and Stock-based Compensation - Common Stock - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100790 - Disclosure - Equity and Stock-based Compensation - Summary of Common Stock Reserved for Future Issuance (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail",
     "shortName": "Equity and Stock-based Compensation - Summary of Common Stock Reserved for Future Issuance (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100800 - Disclosure - Equity and Stock-based Compensation - Stock Plans - Additional information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail",
     "shortName": "Equity and Stock-based Compensation - Stock Plans - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100810 - Disclosure - Equity and Stock-based Compensation - Stock Plans - Summary of Stock Option Transactions (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail",
     "shortName": "Equity and Stock-based Compensation - Stock Plans - Summary of Stock Option Transactions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100820 - Disclosure - Equity and Stock-based Compensation - Summary of RSU Activity (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail",
     "shortName": "Equity and Stock-based Compensation - Summary of RSU Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20140901_20140930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100830 - Disclosure - Equity and Stock-based Compensation - Employee Stock Purchase Plan - Additional information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail",
     "shortName": "Equity and Stock-based Compensation - Employee Stock Purchase Plan - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapPlanNameAxis_fgenTwoThousandAndFourteenEmployeeStockPurchasePlanMember_20140901_20140930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100840 - Disclosure - Equity and Stock-based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail",
     "shortName": "Equity and Stock-based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100850 - Disclosure - Equity and Stock-based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Employee Stock Purchase Plans (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail",
     "shortName": "Equity and Stock-based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Employee Stock Purchase Plans (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapAwardTypeAxis_fgenStockOptionAwardsMember_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100860 - Disclosure - Equity and Stock-based Compensation - Stock-Based Compensation - Additional information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail",
     "shortName": "Equity and Stock-based Compensation - Stock-Based Compensation - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapAwardTypeAxis_fgenStockOptionAwardsMember_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20190101_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "fgen:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100870 - Disclosure - Equity and Stock-based Compensation - Warrants - Additional information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationWarrantsAdditionalInformationDetail",
     "shortName": "Equity and Stock-based Compensation - Warrants - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20190101_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "fgen:ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100880 - Disclosure - Net Loss Per Share - Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail",
     "shortName": "Net Loss Per Share - Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100890 - Disclosure - FibroGen, Inc. 401(k) Plan - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFibrogenInc401KPlanAdditionalInformationDetail",
     "shortName": "FibroGen, Inc. 401(k) Plan - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100900 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail",
     "shortName": "Income Taxes - Components of Loss Before Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100910 - Disclosure - Income Taxes - Schedule of Components of Provision For Income Taxes (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail",
     "shortName": "Income Taxes - Schedule of Components of Provision For Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100920 - Disclosure - Income Taxes - Schedule of Reconciliation Between Statutory Federal Income Tax Rate and Effective Tax Rate (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail",
     "shortName": "Income Taxes - Schedule of Reconciliation Between Statutory Federal Income Tax Rate and Effective Tax Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100930 - Disclosure - Income Taxes - Schedule of Significant Components of Deferred Tax Assets (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail",
     "shortName": "Income Taxes - Schedule of Significant Components of Deferred Tax Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100940 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100950 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Income Tax Benefits (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail",
     "shortName": "Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Income Tax Benefits (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapIncomeTaxAuthorityAxis_fgenFederalAndStateMember_20171231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableRelatedPartiesCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100960 - Disclosure - Related Party Transactions - Additional Information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
     "shortName": "Related Party Transactions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fgenAstellasMember_20200101_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "fgen:DrugProductRevenueFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "U_fgenSegment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100970 - Disclosure - Segment and Geographic Information - Additional information (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetail",
     "shortName": "Segment and Geographic Information - Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100980 - Disclosure - Segment and Geographic Information - Schedule of Revenue by Geographic Area (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail",
     "shortName": "Segment and Geographic Information - Schedule of Revenue by Geographic Area (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryNet",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100990 - Disclosure - Segment and Geographic Information - Schedule of Inventory by Geographic Area (Detail)",
     "role": "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfInventoryByGeographicAreaDetail",
     "shortName": "Segment and Geographic Information - Schedule of Inventory by Geographic Area (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fgen:InventoryByGeographicAreasTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fgen-10k_20201231.htm",
      "contextRef": "C_0000921299_srtStatementGeographicalAxis_countryUS_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InventoryNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 127,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China [Member]"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfInventoryByGeographicAreaDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfLongLivedAssetsByGeographicAreaDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationSummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan [Member]"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfInventoryByGeographicAreaDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfLongLivedAssetsByGeographicAreaDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationSummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r677",
      "r678",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r677",
      "r678",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "fgen_APIShipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "API shipment.",
        "label": "A P I Shipment [Member]",
        "terseLabel": "API Shipment [Member]"
       }
      }
     },
     "localname": "APIShipmentMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_AccountingPolicyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policy.",
        "label": "Accounting Policy [Line Items]",
        "terseLabel": "Accounting Policy [Line Items]"
       }
      }
     },
     "localname": "AccountingPolicyLineItems",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_AccountingPolicyTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policy.",
        "label": "Accounting Policy [Table]",
        "terseLabel": "Accounting Policy [Table]"
       }
      }
     },
     "localname": "AccountingPolicyTable",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_AccountsReceivableFromDistributorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable from distributors.",
        "label": "Accounts Receivable From Distributors [Member]",
        "terseLabel": "Accounts Receivable from Distributors [Member]"
       }
      }
     },
     "localname": "AccountsReceivableFromDistributorsMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued active pharmaceutical ingredient product price adjustment current.",
        "label": "Accrued Active Pharmaceutical Ingredient Product Price Adjustment Current",
        "terseLabel": "API product price adjustment",
        "verboseLabel": "API product price change in estimated variable consideration"
       }
      }
     },
     "localname": "AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_AccruedAndOtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued and other current liabilities.",
        "label": "Accrued And Other Current Liabilities [Member]",
        "terseLabel": "Accrued and Other Current Liabilities [Member]"
       }
      }
     },
     "localname": "AccruedAndOtherCurrentLiabilitiesMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_AccruedCoPromotionExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued co-promotion expenses - current.",
        "label": "Accrued Co Promotion Expenses Current",
        "terseLabel": "Accrued co-promotion expenses - current"
       }
      }
     },
     "localname": "AccruedCoPromotionExpensesCurrent",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued contract liabilities to pharmaceutical distributors current.",
        "label": "Accrued Contract Liabilities To Pharmaceutical Distributors Current",
        "terseLabel": "Contract liabilities to pharmaceutical distributors"
       }
      }
     },
     "localname": "AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_AccruedLongTermCoPromotionLiabilityCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued long term co promotion liability current.",
        "label": "Accrued Long Term Co Promotion Liability Current",
        "terseLabel": "Accrued long term co promotion liability current"
       }
      }
     },
     "localname": "AccruedLongTermCoPromotionLiabilityCurrent",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_AccruedLongTermCoPromotionLiabilityNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued long term co promotion liability non current.",
        "label": "Accrued Long Term Co Promotion Liability Non Current",
        "terseLabel": "Accrued long-term co-promotion expenses"
       }
      }
     },
     "localname": "AccruedLongTermCoPromotionLiabilityNonCurrent",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_AccruedLongTermCoPromotionalLiabilityNonCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued long-term co-promotional liability non current.",
        "label": "Accrued Long Term Co Promotional Liability Non Current",
        "terseLabel": "Accrued long-term co-promotional expenses"
       }
      }
     },
     "localname": "AccruedLongTermCoPromotionalLiabilityNonCurrent",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_AccruedPreclinicalAndClinicalTrialCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to pre-clinical and clinical trial activities, including those performed by third parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Preclinical And Clinical Trial Current",
        "terseLabel": "Preclinical and clinical trial accruals"
       }
      }
     },
     "localname": "AccruedPreclinicalAndClinicalTrialCurrent",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_AccruedProductDevelopmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the long-term portion of the outstanding principal and accrued interest of advances in the form note agreements received by the entity to fund various product development efforts.",
        "label": "Accrued Product Development Costs",
        "terseLabel": "Product development obligations"
       }
      }
     },
     "localname": "AccruedProductDevelopmentCosts",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_AccruedProductDevelopmentCostsExcludingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Product Development Costs Excluding Interest.",
        "label": "Accrued Product Development Costs Excluding Interest",
        "terseLabel": "Accrued product development costs excluding interest"
       }
      }
     },
     "localname": "AccruedProductDevelopmentCostsExcludingInterest",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_AccruedProfitShareCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued profit share current.",
        "label": "Accrued Profit Share Current",
        "terseLabel": "Roxadustat profit share to AstraZeneca"
       }
      }
     },
     "localname": "AccruedProfitShareCurrent",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_AcquiredLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired license.",
        "label": "Acquired License [Member]",
        "terseLabel": "Acquired License [Member]"
       }
      }
     },
     "localname": "AcquiredLicenseMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_AcquisitionAndVariableInterestEntityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition and variable interest entity abstract.",
        "label": "Acquisition And Variable Interest Entity [Abstract]"
       }
      }
     },
     "localname": "AcquisitionAndVariableInterestEntityAbstract",
     "nsuri": "http://www.fibrogen.com/20201231",
     "xbrltype": "stringItemType"
    },
    "fgen_AcquisitionAndVariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition and variable interest entity line items.",
        "label": "Acquisition And Variable Interest Entity [Line Items]",
        "terseLabel": "Acquisition And Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "AcquisitionAndVariableInterestEntityLineItems",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_AcquisitionAndVariableInterestEntityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition and variable interest entity table.",
        "label": "Acquisition And Variable Interest Entity [Table]",
        "terseLabel": "Acquisition And Variable Interest Entity [Table]"
       }
      }
     },
     "localname": "AcquisitionAndVariableInterestEntityTable",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_AcquisitionAndVariableInterestEntityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition and variable interest entity.",
        "label": "Acquisition And Variable Interest Entity [Text Block]",
        "terseLabel": "Acquisition and Variable Interest Entity"
       }
      }
     },
     "localname": "AcquisitionAndVariableInterestEntityTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_AdditionalConsiderationBasedOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of additional consideration based on net sales of product as defined under a collaboration agreement.",
        "label": "Additional Consideration Based On Net Sales",
        "terseLabel": "Additional consideration based on net sales description"
       }
      }
     },
     "localname": "AdditionalConsiderationBasedOnNetSales",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital shares issued from stock plans net of payroll taxes paid.",
        "label": "Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid",
        "terseLabel": "Shares issued from stock plans, net of payroll taxes paid"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_AllOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All other.",
        "label": "All Other [Member]",
        "terseLabel": "All other [Member]"
       }
      }
     },
     "localname": "AllOtherMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_AstellasAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Astellas agreement.",
        "label": "Astellas Agreement [Member]",
        "terseLabel": "Astellas Agreement"
       }
      }
     },
     "localname": "AstellasAgreementMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_AstellasCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Astellas agreements.",
        "label": "Astellas Collaboration Agreement [Member]",
        "terseLabel": "Astellas Agreement [Member]",
        "verboseLabel": "Astellas-Related party [Member]"
       }
      }
     },
     "localname": "AstellasCollaborationAgreementMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_AstellasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Astellas.",
        "label": "Astellas [Member]",
        "terseLabel": "Astellas [Member]"
       }
      }
     },
     "localname": "AstellasMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_AstraZenecaABMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca AB.",
        "label": "Astra Zeneca A B [Member]",
        "terseLabel": "AstraZeneca AB [Member]"
       }
      }
     },
     "localname": "AstraZenecaABMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_AstraZenecaAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Astra Zeneca agreements.",
        "label": "Astra Zeneca Agreements [Member]",
        "terseLabel": "AstraZeneca Agreements [Member]",
        "verboseLabel": "AstraZeneca [Member]"
       }
      }
     },
     "localname": "AstraZenecaAgreementsMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfContractualMaturitiesOfAvailableForSaleInvestmentsDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities bond and mutual funds maturing within one year.",
        "label": "Available For Sale Securities Bond And Mutual Funds Maturing Within One Year",
        "terseLabel": "Within one year - Bond and mutual funds"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfContractualMaturitiesOfAvailableForSaleInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_BankOfFinlandInterestRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank of Finland interest rate.",
        "label": "Bank Of Finland Interest Rate [Member]",
        "terseLabel": "Bank of Finland Interest Rate [Member]"
       }
      }
     },
     "localname": "BankOfFinlandInterestRateMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_BeijingEconomicTechnologicalDevelopmentAreaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beijing economic-technological development area.",
        "label": "Beijing Economic Technological Development Area [Member]",
        "terseLabel": "Beijing Economic-Technological Development Area [Member]"
       }
      }
     },
     "localname": "BeijingEconomicTechnologicalDevelopmentAreaMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_BeijingFalikangPharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beijing Falikang Pharmaceutical Co. Ltd.",
        "label": "Beijing Falikang Pharmaceutical Co Ltd [Member]",
        "terseLabel": "Beijing Falikang Pharmaceutical Co. Ltd [Member]"
       }
      }
     },
     "localname": "BeijingFalikangPharmaceuticalCoLtdMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beijing Kangda Yongfu Pharmaceutical Co., LTD.",
        "label": "Beijing Kangda Yongfu Pharmaceutical Co L T D [Member]",
        "terseLabel": "Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member]"
       }
      }
     },
     "localname": "BeijingKangdaYongfuPharmaceuticalCoLTDMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_BondAndMutualFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond and mutual funds.",
        "label": "Bond And Mutual Funds [Member]",
        "terseLabel": "Bond and mutual funds [Member]"
       }
      }
     },
     "localname": "BondAndMutualFundsMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents and restricted time deposits policy.",
        "label": "Cash And Cash Equivalents And Restricted Time Deposits Policy Policy [Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Time Deposits"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndRestrictedTimeDepositsPolicyPolicyTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_CashConsiderationReceivedUnderCollaborationAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition.",
        "label": "Cash Consideration Received Under Collaboration Agreement",
        "totalLabel": "Total Consideration"
       }
      }
     },
     "localname": "CashConsiderationReceivedUnderCollaborationAgreement",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_ChinaPerformanceObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "China performance obligation.",
        "label": "China Performance Obligation [Member]",
        "terseLabel": "China performance obligation [Member]"
       }
      }
     },
     "localname": "ChinaPerformanceObligationMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right number of warrants or rights exercised during period.",
        "label": "Class Of Warrant Or Right Number Of Warrants Or Rights Exercised During Period",
        "terseLabel": "Warrants to purchase common stock exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationWarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "fgen_ClinicalDevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical development milestone.",
        "label": "Clinical Development Milestones [Member]",
        "terseLabel": "Clinical and Development Milestone [Member]"
       }
      }
     },
     "localname": "ClinicalDevelopmentMilestonesMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_ClinicalTrialAccrualPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical trial accrual.",
        "label": "Clinical Trial Accrual Policy [Text Block]",
        "terseLabel": "Clinical Trial Accruals"
       }
      }
     },
     "localname": "ClinicalTrialAccrualPolicyTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co development information sharing and committee services.",
        "label": "Co Development Information Sharing And Committee Services [Member]",
        "terseLabel": "Co-development, information sharing &amp; committee services [Member]"
       }
      }
     },
     "localname": "CoDevelopmentInformationSharingAndCommitteeServicesMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_CoDevelopmentServicesEstimatedContinuationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co-development services, estimated continuation year.",
        "label": "Co Development Services Estimated Continuation Year",
        "terseLabel": "Co-development services, currently estimated continuation year"
       }
      }
     },
     "localname": "CoDevelopmentServicesEstimatedContinuationYear",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail"
     ],
     "xbrltype": "gYearItemType"
    },
    "fgen_CoPromotionExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co-promotion expenses.",
        "label": "Co Promotion Expenses",
        "terseLabel": "Co-promotion expenses"
       }
      }
     },
     "localname": "CoPromotionExpenses",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_CollaborationServicesAndOtherRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognized from co-development services, manufacturing of clinical supplies, committee services and information services and other revenue.",
        "label": "Collaboration Services And Other Revenue",
        "terseLabel": "Collaboration services and other revenue from a related party"
       }
      }
     },
     "localname": "CollaborationServicesAndOtherRevenue",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_CollaborativeArrangementAggregateConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of aggregate consideration receivable under collaborative arrangement.",
        "label": "Collaborative Arrangement Aggregate Consideration",
        "terseLabel": "Aggregate considerations received"
       }
      }
     },
     "localname": "CollaborativeArrangementAggregateConsideration",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of aggregate consideration receivable under collaborative arrangement excluding drug product revenue.",
        "label": "Collaborative Arrangement Aggregate Consideration Excluding Drug Product Revenue",
        "terseLabel": "Aggregate considerations received excluding drug product revenue"
       }
      }
     },
     "localname": "CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_CollaborativeArrangementAndRevenuesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and revenues.",
        "label": "Collaborative Arrangement And Revenues Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements and Revenues"
       }
      }
     },
     "localname": "CollaborativeArrangementAndRevenuesDisclosureTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_CollaborativeArrangementAndRevenuesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and revenues.",
        "label": "Collaborative Arrangement And Revenues Policy [Text Block]",
        "terseLabel": "Collaboration Arrangements and Revenues"
       }
      }
     },
     "localname": "CollaborativeArrangementAndRevenuesPolicyTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_CommercialSalesAndOtherEventsMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial sales and other events milestone.",
        "label": "Commercial Sales And Other Events Milestone",
        "terseLabel": "Commercial sales and other events milestone"
       }
      }
     },
     "localname": "CommercialSalesAndOtherEventsMilestone",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_CommercialSalesMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of milestone payments related to commercial sales under the collaborative agreement.",
        "label": "Commercial Sales Milestone",
        "terseLabel": "Commercial sales milestone"
       }
      }
     },
     "localname": "CommercialSalesMilestone",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_CommonStockSharesReserved": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock shares reserved.",
        "label": "Common Stock Shares Reserved",
        "totalLabel": "Total shares of common stock reserved"
       }
      }
     },
     "localname": "CommonStockSharesReserved",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "fgen_ContractLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract liabilities,",
        "label": "Contract Liabilities [Member]",
        "terseLabel": "Contract Liabilities [Member]"
       }
      }
     },
     "localname": "ContractLiabilitiesMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_ContractWithCustomerLiabilityAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability additions.",
        "label": "Contract With Customer Liability Additions",
        "negatedLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAdditions",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ContractWithCustomerLiabilityDeduction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability deduction.",
        "label": "Contract With Customer Liability Deduction",
        "terseLabel": "Deduction"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDeduction",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ContractWithCustomerLiabilityGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability gross.",
        "label": "Contract With Customer Liability Gross",
        "terseLabel": "Gross Contract Liabilities Balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityGross",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer, liability, increase (decrease) from current translation and other.",
        "label": "Contract With Customer Liability Increase Decrease From Current Translation And Other",
        "terseLabel": "Currency Translation and Other"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseFromCurrentTranslationAndOther",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ContractWithCustomerLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability.",
        "label": "Contract With Customer Liability [Line Items]",
        "terseLabel": "Contract with Customer Liability [Line Items]"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityLineItems",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability, milestone method revenue recognized.",
        "label": "Contract With Customer Liability Milestone Method Revenue Recognized",
        "verboseLabel": "Milestone payment, revenue recognition"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ContractWithCustomerLiabilityNetOfAccountsReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability net of accounts receivable.",
        "label": "Contract With Customer Liability Net Of Accounts Receivable",
        "terseLabel": "Balance Presented Net Against Accounts Receivable"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNetOfAccountsReceivable",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ContractWithCustomerLiabilityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer Liability [Table]",
        "label": "Contract With Customer Liability [Table]",
        "terseLabel": "Contract With Customer Liability [Table]"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityTable",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_ContractWithCustomerMilestoneMethodTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer milestone method.",
        "label": "Contract With Customer Milestone Method Table [Text Block]",
        "terseLabel": "Summary of License Revenue and Development Revenue Recognized under Agreement"
       }
      }
     },
     "localname": "ContractWithCustomerMilestoneMethodTableTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_ContractualSalesRebateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual sales rebate.",
        "label": "Contractual Sales Rebate [Member]",
        "terseLabel": "Contractual Sales Rebate [Member]"
       }
      }
     },
     "localname": "ContractualSalesRebateMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_CostOfGoodsAndServicesSoldOperatingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10100.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of goods and services sold operating expense.",
        "label": "Cost Of Goods And Services Sold Operating Expense",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldOperatingExpense",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail": {
       "order": 10010.0,
       "parentTag": "fgen_CashConsiderationReceivedUnderCollaborationAgreement",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of revenue recognized for license and development services under the collaboration agreement as of a given date.",
        "label": "Cumulative Revenue License And Development Revenue Recognized",
        "terseLabel": "Cumulative Revenue"
       }
      }
     },
     "localname": "CumulativeRevenueLicenseAndDevelopmentRevenueRecognized",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_DeferredApprovalMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred approval milestone.",
        "label": "Deferred Approval Milestone [Member]",
        "terseLabel": "Deferred Approval Milestone [Member]"
       }
      }
     },
     "localname": "DeferredApprovalMilestoneMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_DeferredTaxAssetsIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail": {
       "order": 10140.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets intangible assets.",
        "label": "Deferred Tax Assets Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsIntangibleAssets",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_DeferredTaxLiabilitiesFixedAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities fixed assets.",
        "label": "Deferred Tax Liabilities Fixed Assets",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFixedAssets",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_DescriptionOfSalesReturn": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of sales return.",
        "label": "Description Of Sales Return",
        "terseLabel": "Description of sales return"
       }
      }
     },
     "localname": "DescriptionOfSalesReturn",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_DevelopmentAndOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and other revenue.",
        "label": "Development And Other Revenue [Member]",
        "terseLabel": "Development and Other Revenue [Member]",
        "verboseLabel": "Development Revenue [Member]"
       }
      }
     },
     "localname": "DevelopmentAndOtherRevenueMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_DevelopmentAndRegulatoryApprovalMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement.",
        "label": "Development And Regulatory Approval Milestones",
        "terseLabel": "Development and regulatory approval milestones"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryApprovalMilestones",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_DrugProductRevenueFromRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Drug product revenue from related party.",
        "label": "Drug Product Revenue From Related Party",
        "terseLabel": "Drug product revenue from a related party"
       }
      }
     },
     "localname": "DrugProductRevenueFromRelatedParty",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_DrugProductRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Drug product revenue.",
        "label": "Drug Product Revenue [Member]",
        "terseLabel": "Drug Product Revenue [Member]"
       }
      }
     },
     "localname": "DrugProductRevenueMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_DrugProductRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Drug product revenue.",
        "label": "Drug Product Revenue Policy [Text Block]",
        "terseLabel": "Drug Product Revenue"
       }
      }
     },
     "localname": "DrugProductRevenuePolicyTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_DueToRelatedPartiesDeferredRevenueCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due to related parties deferred revenue current.",
        "label": "Due To Related Parties Deferred Revenue Current",
        "terseLabel": "Deferred revenue current to related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesDeferredRevenueCurrent",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_DueToRelatedPartiesDeferredRevenueNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due to related parties deferred revenue noncurrent.",
        "label": "Due To Related Parties Deferred Revenue Noncurrent",
        "terseLabel": "Deferred revenue non-current to related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesDeferredRevenueNoncurrent",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation benefit on intercompany transfer of assets.",
        "label": "Effective Income Tax Rate Reconciliation Benefit On Intercompany Transfer Of Assets",
        "terseLabel": "Benefit due to intercompany transfer of assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "fgen_EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation deduction expense share based compensation cost.",
        "label": "Effective Income Tax Rate Reconciliation Deduction Expense Share Based Compensation Cost",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "fgen_EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation net operating losses not benefitted.",
        "label": "Effective Income Tax Rate Reconciliation Net Operating Losses Not Benefitted",
        "terseLabel": "Net operating losses not benefitted"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "fgen_EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation valuation allowance on intercompany transfer of assets.",
        "label": "Effective Income Tax Rate Reconciliation Valuation Allowance On Intercompany Transfer Of Assets",
        "terseLabel": "Valuation allowance on intercompany transfer of assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "fgen_EquityMethodInvestmentAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment additions.",
        "label": "Equity Method Investment Additions",
        "terseLabel": "Investment",
        "verboseLabel": "Additions"
       }
      }
     },
     "localname": "EquityMethodInvestmentAdditions",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_EquityMethodInvestmentInUnconsolidatedVariableInterestEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10250.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment in unconsolidated variable interest entity.",
        "label": "Equity Method Investment In Unconsolidated Variable Interest Entity",
        "terseLabel": "Equity method investment in unconsolidated variable interest entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentInUnconsolidatedVariableInterestEntity",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment increase (decrease) from currency translation.",
        "label": "Equity Method Investment Increase Decrease From Currency Translation",
        "terseLabel": "Currency Translation"
       }
      }
     },
     "localname": "EquityMethodInvestmentIncreaseDecreaseFromCurrencyTranslation",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_EstimatedJointDevelopmentExtendedServicePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated joint development extended service period.",
        "label": "Estimated Joint Development Extended Service Period",
        "terseLabel": "Estimated joint development extended service period"
       }
      }
     },
     "localname": "EstimatedJointDevelopmentExtendedServicePeriod",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "gYearItemType"
    },
    "fgen_EstimatedVariableConsiderationTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated variable consideration transaction price.",
        "label": "Estimated Variable Consideration Transaction Price",
        "terseLabel": "Estimated variable consideration transaction price"
       }
      }
     },
     "localname": "EstimatedVariableConsiderationTransactionPrice",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ExperienceHistoricalOwnershipChanges": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Experience historical ownership changes.",
        "label": "Experience Historical Ownership Changes",
        "terseLabel": "Percentage of ownership changes"
       }
      }
     },
     "localname": "ExperienceHistoricalOwnershipChanges",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "fgen_FalikangMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Falikang.",
        "label": "Falikang [Member]",
        "terseLabel": "Falikang [Member]"
       }
      }
     },
     "localname": "FalikangMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_FederalAndStateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal and state.",
        "label": "Federal And State [Member]",
        "terseLabel": "Federal and State [Member]"
       }
      }
     },
     "localname": "FederalAndStateMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_FibroGenBeijingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FibroGen Beijing.",
        "label": "Fibro Gen Beijing [Member]",
        "terseLabel": "FibroGen Beijing [Member]"
       }
      }
     },
     "localname": "FibroGenBeijingMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_FibroGenCaymanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FibroGen Cayman.",
        "label": "Fibro Gen Cayman [Member]",
        "terseLabel": "FibroGen Cayman [Member]"
       }
      }
     },
     "localname": "FibroGenCaymanMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_FibroGenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FibroGen, Inc.",
        "label": "Fibro Gen Inc [Member]",
        "terseLabel": "FibroGen, Inc. [Member]"
       }
      }
     },
     "localname": "FibroGenIncMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_FibrogenEuropeOyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fibro Gen Europe Oy.",
        "label": "Fibrogen Europe Oy [Member]",
        "terseLabel": "FibroGen Europe [Member]"
       }
      }
     },
     "localname": "FibrogenEuropeOyMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_FinanceLeaseAccumulatedAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10100.0,
       "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease accumulated amortization.",
        "label": "Finance Lease Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FinanceLeaseAccumulatedAmortization",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_FinanceLeaseAndOperatingLeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease and operating lease assets.",
        "label": "Finance Lease And Operating Lease Assets",
        "totalLabel": "Total lease assets"
       }
      }
     },
     "localname": "FinanceLeaseAndOperatingLeaseAssets",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_FinanceLeaseAndOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease and operating lease liability.",
        "label": "Finance Lease And Operating Lease Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseAndOperatingLeaseLiability",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_FinanceLeaseRightOfUseAssetsCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10090.0,
       "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance lease, right-of-use assets - cost.",
        "label": "Finance Lease Right Of Use Assets Cost",
        "terseLabel": "Right-of-use assets - cost"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetsCost",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_GrossAccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross accounts receivable.",
        "label": "Gross Accounts Receivable [Member]",
        "terseLabel": "Gross Accounts Receivable [Member]"
       }
      }
     },
     "localname": "GrossAccountsReceivableMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_HighlyLiquidInvestmentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Highly liquid investment maturity period.",
        "label": "Highly Liquid Investment Maturity Period",
        "terseLabel": "Highly liquid investment maturity period"
       }
      }
     },
     "localname": "HighlyLiquidInvestmentMaturityPeriod",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_HistoricalCoPromotionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Historical co-promotion costs.",
        "label": "Historical Co Promotion Costs",
        "terseLabel": "Historical co-promotion costs"
       }
      }
     },
     "localname": "HistoricalCoPromotionCosts",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impact of change in accounting principle upon adoption of ASU 2018-02.",
        "label": "Impact Of Change In Accounting Principle Upon Adoption Of A S U201802 [Member]",
        "terseLabel": "Impact of change in accounting principle upon adoption of ASU 2018-02 [Member]"
       }
      }
     },
     "localname": "ImpactOfChangeInAccountingPrincipleUponAdoptionOfASU201802Member",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes line items.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_IncreaseDecreaseInAccountsPayableFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in accounts payable from related party.",
        "label": "Increase Decrease In Accounts Payable From Related Party",
        "terseLabel": "Accounts payable from related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableFromRelatedParty",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10360.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in accrued interest for finance lease liabilities.",
        "label": "Increase Decrease In Accrued Interest For Finance Lease Liabilities",
        "terseLabel": "Accrued interest for finance lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_IncreaseDecreaseInLeaseObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10350.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in lease obligations.",
        "label": "Increase Decrease In Lease Obligations",
        "terseLabel": "Lease obligations"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseObligations",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in prepaid expenses and other current assets related parties.",
        "label": "Increase Decrease In Prepaid Expenses And Other Current Assets Related Parties",
        "terseLabel": "Prepaid expenses and other current assets from related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_InterestAndOtherNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and other net.",
        "label": "Interest And Other Net [Abstract]",
        "terseLabel": "Interest and other, net"
       }
      }
     },
     "localname": "InterestAndOtherNetAbstract",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_InventoryByGeographicAreasTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory by geographic areas.",
        "label": "Inventory By Geographic Areas Table [Text Block]",
        "terseLabel": "Schedule of Inventory by Geographic Area"
       }
      }
     },
     "localname": "InventoryByGeographicAreasTableTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_InvestmentLossInUnconsolidatedVariableInterestEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10230.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment loss in unconsolidated variable interest entity.",
        "label": "Investment Loss In Unconsolidated Variable Interest Entity",
        "negatedLabel": "Investment loss in unconsolidated variable interest entity"
       }
      }
     },
     "localname": "InvestmentLossInUnconsolidatedVariableInterestEntity",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_LeaseObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease obligations.",
        "label": "Lease Obligations [Member]",
        "terseLabel": "Lease obligations [Member]"
       }
      }
     },
     "localname": "LeaseObligationsMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_LesseeFinanceLeaseAdditionalLeaseExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, finance lease, additional lease expiration period.",
        "label": "Lessee Finance Lease Additional Lease Expiration Period",
        "terseLabel": "Lessee, finance lease, additional lease expiration period"
       }
      }
     },
     "localname": "LesseeFinanceLeaseAdditionalLeaseExpirationPeriod",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "fgen_LesseeFinanceLeaseExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, finance lease, expiration period.",
        "label": "Lessee Finance Lease Expiration Period",
        "terseLabel": "Lessee, finance lease, expiration period"
       }
      }
     },
     "localname": "LesseeFinanceLeaseExpirationPeriod",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "fgen_LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, finance lease, option to extend the additional lease term.",
        "label": "Lessee Finance Lease Option To Extend Additional Lease Term",
        "terseLabel": "Lessee, finance lease, option to extend the additional lease term"
       }
      }
     },
     "localname": "LesseeFinanceLeaseOptionToExtendAdditionalLeaseTerm",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "fgen_LesseeOperatingLeaseExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease, expiration period.",
        "label": "Lessee Operating Lease Expiration Period",
        "terseLabel": "Lessee, operating lease, expiration period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExpirationPeriod",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "fgen_LicenseAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and development.",
        "label": "License And Development [Member]",
        "terseLabel": "License and Development [Member]"
       }
      }
     },
     "localname": "LicenseAndDevelopmentMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_LicenseFeesAndMilestonesRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from multiple-deliverable arrangements that include licensing fees and services revenue and the amount of consideration recognized during the period for milestones. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, non-specified, services during the reporting period.",
        "label": "License Fees And Milestones Revenue",
        "terseLabel": "License and milestone revenue from a related party"
       }
      }
     },
     "localname": "LicenseFeesAndMilestonesRevenue",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_LongTermInvestmentsMinimumMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term investments minimum maturity period.",
        "label": "Long Term Investments Minimum Maturity Period",
        "terseLabel": "Long term Investments Maturity"
       }
      }
     },
     "localname": "LongTermInvestmentsMinimumMaturityPeriod",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "fgen_ManufactureAndSupplyOfPamrevlumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacture and supply of pamrevlumab.",
        "label": "Manufacture And Supply Of Pamrevlumab [Member]",
        "terseLabel": "Manufacture and Supply of Pamrevlumab [Member]"
       }
      }
     },
     "localname": "ManufactureAndSupplyOfPamrevlumabMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_ManufactureAndSupplyOfRoxadustatMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacture and Supply of Roxadustat.",
        "label": "Manufacture And Supply Of Roxadustat [Member]",
        "terseLabel": "Manufacture and Supply of Roxadustat [Member]"
       }
      }
     },
     "localname": "ManufactureAndSupplyOfRoxadustatMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_MaximumFutureMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum future milestone payments.",
        "label": "Maximum Future Milestone Payments",
        "terseLabel": "Maximum future milestone payments"
       }
      }
     },
     "localname": "MaximumFutureMilestonePayments",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_MiscellaneousReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Miscellaneous receivables.",
        "label": "Miscellaneous Receivables",
        "terseLabel": "Miscellaneous receivables"
       }
      }
     },
     "localname": "MiscellaneousReceivables",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_NonKeyAccountHospitalListingAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-key account hospital listing award.",
        "label": "Non Key Account Hospital Listing Award [Member]",
        "terseLabel": "Non-key Account Hospital Listing Award [Member]"
       }
      }
     },
     "localname": "NonKeyAccountHospitalListingAwardMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_NumberOfFinanceLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of finance leases.",
        "label": "Number Of Finance Leases",
        "terseLabel": "Number of finance leases"
       }
      }
     },
     "localname": "NumberOfFinanceLeases",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "fgen_NumberOfOperatingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating leases.",
        "label": "Number Of Operating Leases",
        "terseLabel": "Number of operating leases"
       }
      }
     },
     "localname": "NumberOfOperatingLeases",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "fgen_NumberOfProductDevelopmentObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of product development obligations.",
        "label": "Number Of Product Development Obligations",
        "terseLabel": "Number of product development obligations"
       }
      }
     },
     "localname": "NumberOfProductDevelopmentObligations",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "fgen_NumberOfRegulatoryMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of regulatory milestones.",
        "label": "Number Of Regulatory Milestones",
        "terseLabel": "Number of regulatory milestones"
       }
      }
     },
     "localname": "NumberOfRegulatoryMilestones",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "fgen_OfficeSpacesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office spaces.",
        "label": "Office Spaces [Member]",
        "terseLabel": "Office Spaces [Member]"
       }
      }
     },
     "localname": "OfficeSpacesMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_OperatingLeaseAccumulatedAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_OperatingLeaseRightOfUseAsset",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease, accumulated amortization.",
        "label": "Operating Lease Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "OperatingLeaseAccumulatedAmortization",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_OperatingLeaseRightOfUseAssetsCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_OperatingLeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease, right-of-use assets - cost.",
        "label": "Operating Lease Right Of Use Assets Cost",
        "terseLabel": "Right-of-use assets - cost"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetsCost",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "fgen_OtherDiscountsAndRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other discounts and rebates.",
        "label": "Other Discounts And Rebates [Member]",
        "terseLabel": "Other Discounts and Rebates [Member]"
       }
      }
     },
     "localname": "OtherDiscountsAndRebatesMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_OtherPurchasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Purchases.",
        "label": "Other Purchases [Member]",
        "terseLabel": "Other Purchases [Member]"
       }
      }
     },
     "localname": "OtherPurchasesMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_OtherRevenuesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues policy.",
        "label": "Other Revenues Policy [Text Block]",
        "terseLabel": "Other Revenues"
       }
      }
     },
     "localname": "OtherRevenuesPolicyTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_OtherRisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Risks and Uncertainties.",
        "label": "Other Risks And Uncertainties Policy [Text Block]",
        "terseLabel": "Other Risks and Uncertainties"
       }
      }
     },
     "localname": "OtherRisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_OtherTaxCreditCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other tax credit carryforwards expiration year.",
        "label": "Other Tax Credit Carryforwards Expiration Year",
        "terseLabel": "Other tax credit carryforwards expiration year"
       }
      }
     },
     "localname": "OtherTaxCreditCarryforwardsExpirationYear",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "fgen_PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment made for investment in unconsolidated variable interest entity.",
        "label": "Payment Made For Investment In Unconsolidated Variable Interest Entity",
        "negatedLabel": "Payment made for investment in unconsolidated variable interest entity"
       }
      }
     },
     "localname": "PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to acquire available for sale securities and term deposit.",
        "label": "Payments To Acquire Available For Sale Securities And Term Deposit",
        "negatedLabel": "Purchases of available-for-sale securities and term deposit"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_PercentageIncreasesOnEachAnniversaryOfRentCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage increases on each anniversary of rent commencement date.",
        "label": "Percentage Increases On Each Anniversary Of Rent Commencement Date",
        "terseLabel": "Percentage increases on each anniversary of rent commencement date"
       }
      }
     },
     "localname": "PercentageIncreasesOnEachAnniversaryOfRentCommencementDate",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "fgen_PercentageOfFundingForCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs.",
        "label": "Percentage Of Funding For Costs",
        "terseLabel": "Percentage of joint development costs committed to fund"
       }
      }
     },
     "localname": "PercentageOfFundingForCosts",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "fgen_PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of outstanding shares of acquiree sold by acquirer.",
        "label": "Percentage Of Outstanding Shares Of Acquiree Sold By Acquirer",
        "terseLabel": "Percentage of outstanding shares sold in exchange for cash consideration"
       }
      }
     },
     "localname": "PercentageOfOutstandingSharesOfAcquireeSoldByAcquirer",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "fgen_PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of pre-launch inventory capitalized of aggregate inventory balance.",
        "label": "Percentage Of Pre Launch Inventory Capitalized Of Aggregate Inventory Balance",
        "terseLabel": "Percentage of pre-launch inventory capitalized of aggregate inventory balance"
       }
      }
     },
     "localname": "PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "fgen_PotentialMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement.",
        "label": "Potential Milestones",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "PotentialMilestones",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_PreferredSharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares issued, price per share.",
        "label": "Preferred Shares Issued Price Per Share",
        "terseLabel": "Preferred shares issued, price per share"
       }
      }
     },
     "localname": "PreferredSharesIssuedPricePerShare",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "fgen_PriceAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price adjustment.",
        "label": "Price Adjustment [Member]",
        "terseLabel": "Price Adjustment [Member]"
       }
      }
     },
     "localname": "PriceAdjustmentMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from equity transfer of unconsolidated variable interest entity.",
        "label": "Proceeds From Equity Transfer Of Unconsolidated Variable Interest Entity",
        "terseLabel": "Proceeds from equity transfer of unconsolidated variable interest entity"
       }
      }
     },
     "localname": "ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ProceedsFromNonContingentUpfrontPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of non-contingent upfront payments included under the collaborative agreement as arrangement consideration.",
        "label": "Proceeds From Non Contingent Upfront Payments",
        "terseLabel": "Non-contingent upfront payments received"
       }
      }
     },
     "localname": "ProceedsFromNonContingentUpfrontPayments",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.",
        "label": "Proceeds From Upfront Non Contingent And Non Refundable Payments",
        "terseLabel": "Proceeds from upfront, non-contingent and non-refundable payments"
       }
      }
     },
     "localname": "ProceedsFromUpfrontNonContingentAndNonRefundablePayments",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration.",
        "label": "Proceeds From Upfront Non Contingent And Time Based Payments",
        "terseLabel": "Upfront, non-contingent and time-based payments received"
       }
      }
     },
     "localname": "ProceedsFromUpfrontNonContingentAndTimeBasedPayments",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.",
        "label": "Proceeds From Upfront Non Contingent Non Refundable And Time Based Payments",
        "terseLabel": "Upfront, non-contingent, non-refundable and time-based payments"
       }
      }
     },
     "localname": "ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ProductDevelopmentObligationsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product development obligation disclosure.",
        "label": "Product Development Obligations Disclosure [Text Block]",
        "terseLabel": "Product Development Obligations"
       }
      }
     },
     "localname": "ProductDevelopmentObligationsDisclosureTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_ProductRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product revenue from a related party.",
        "label": "Product Revenue",
        "terseLabel": "Product revenue from a related party"
       }
      }
     },
     "localname": "ProductRevenue",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ProductRevenuePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product revenue policy.",
        "label": "Product Revenue Policy Policy [Text Block]",
        "terseLabel": "Product Revenue, Net"
       }
      }
     },
     "localname": "ProductRevenuePolicyPolicyTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_PropertyTaxesAndOtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property taxes and other current.",
        "label": "Property Taxes And Other Current",
        "terseLabel": "Property taxes and other"
       }
      }
     },
     "localname": "PropertyTaxesAndOtherCurrent",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ProvisionForCoDevelopmentServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision for co-development services.",
        "label": "Provision For Co Development Services",
        "terseLabel": "Provision for co-development services"
       }
      }
     },
     "localname": "ProvisionForCoDevelopmentServices",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_RebatesAndDiscountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rebates and discounts.",
        "label": "Rebates And Discounts [Member]",
        "terseLabel": "Rebates and Discounts [Member]"
       }
      }
     },
     "localname": "RebatesAndDiscountsMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently issued accounting guidance not yet adopted.",
        "label": "Recently Issued Accounting Guidance Not Yet Adopted Policy [Text Block]",
        "terseLabel": "Recently Issued Accounting Guidance Not Yet Adopted"
       }
      }
     },
     "localname": "RecentlyIssuedAccountingGuidanceNotYetAdoptedPolicyTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently issued and adopted accounting guidance.",
        "label": "Recently Issued And Adopted Accounting Guidance Policy [Text Block]",
        "terseLabel": "Recently Issued and Adopted Accounting Guidance"
       }
      }
     },
     "localname": "RecentlyIssuedAndAdoptedAccountingGuidancePolicyTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone.",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestone [Member]"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_RepaymentsOfFinanceLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments of finance lease liabilities.",
        "label": "Repayments Of Finance Lease Liabilities",
        "negatedLabel": "Repayments of finance lease liabilities",
        "terseLabel": "Financing cash flows from finance leases"
       }
      }
     },
     "localname": "RepaymentsOfFinanceLeaseLiabilities",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Required minimum shareholder percentage to call for redemption of preferred shares.",
        "label": "Required Minimum Shareholder Percentage To Call For Redemption Of Preferred Shares",
        "terseLabel": "Minimum percentage of shareholder's approval to call for redemption of preferred shares"
       }
      }
     },
     "localname": "RequiredMinimumShareholderPercentageToCallForRedemptionOfPreferredShares",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "fgen_ResearchAndPreClinicalStageDevelopmentProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and pre-clinical stage development programs.",
        "label": "Research And Pre Clinical Stage Development Programs [Member]",
        "terseLabel": "Research and Pre-Clinical Stage Development Programs [Member]"
       }
      }
     },
     "localname": "ResearchAndPreClinicalStageDevelopmentProgramsMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_RestrictedTimeDepositsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10210.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted time deposits noncurrent.",
        "label": "Restricted Time Deposits Noncurrent",
        "terseLabel": "Restricted time deposits"
       }
      }
     },
     "localname": "RestrictedTimeDepositsNoncurrent",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_RevenueGrossFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue gross from contract with customer excluding assessed tax.",
        "label": "Revenue Gross From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Gross revenue"
       }
      }
     },
     "localname": "RevenueGrossFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ReversalOfAccruedCoPromotionExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reversal of accrued co-promotion expenses.",
        "label": "Reversal Of Accrued Co Promotion Expenses",
        "terseLabel": "Reversal of accrued co-promotion expenses"
       }
      }
     },
     "localname": "ReversalOfAccruedCoPromotionExpenses",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reversal of previously accrued long term co promotion expenses.",
        "label": "Reversal Of Previously Accrued Long Term Co Promotion Expenses",
        "terseLabel": "Reversal of previously accrued long-term co-promotion expenses"
       }
      }
     },
     "localname": "ReversalOfPreviouslyAccruedLongTermCoPromotionExpenses",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets obtained in exchange for new lease liabilities.",
        "label": "Right Of Use Assets Obtained In Exchange For New Lease Liabilities [Abstract]",
        "terseLabel": "Right-of-use assets obtained in exchange for new lease liabilities:"
       }
      }
     },
     "localname": "RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_RoyaltyRateOnNetRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Implied royalty rate used to find the net present value of future cash flows.",
        "label": "Royalty Rate On Net Revenue",
        "terseLabel": "Royalty rate against projected net revenues"
       }
      }
     },
     "localname": "RoyaltyRateOnNetRevenue",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail"
     ],
     "xbrltype": "percentItemType"
    },
    "fgen_ScheduleOfDrugProductRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of drug product revenue.",
        "label": "Schedule Of Drug Product Revenue Table [Text Block]",
        "terseLabel": "Schedule of Drug Product Revenue"
       }
      }
     },
     "localname": "ScheduleOfDrugProductRevenueTableTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of income loss before income tax domestic and foreign.",
        "label": "Schedule Of Income Loss Before Income Tax Domestic And Foreign Table [Text Block]",
        "terseLabel": "Schedule of Components of Loss Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of lease assets and related lease liabilities.",
        "label": "Schedule Of Lease Assets And Related Lease Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Lease Assets and Related Lease Liabilities"
       }
      }
     },
     "localname": "ScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesTableTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_ScheduleOfLeaseTermAndDiscountRateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of lease term and discount rate.",
        "label": "Schedule Of Lease Term And Discount Rate Table [Text Block]",
        "terseLabel": "Schedule of Lease Term and Discount Rate"
       }
      }
     },
     "localname": "ScheduleOfLeaseTermAndDiscountRateTableTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of maturities of finance and operating leases liabilities.",
        "label": "Schedule Of Maturities Of Finance And Operating Leases Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Maturities of Finance and Operating Leases Liabilities"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfFinanceAndOperatingLeasesLiabilitiesTableTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of share based payment award stock options and employee stock purchase plan valuation assumptions.",
        "label": "Schedule Of Share Based Payment Award Stock Options And Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Employee Stock Purchase Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of shares of common stock reserved for future issuance.",
        "label": "Schedule Of Shares Of Common Stock Reserved For Future Issuance Table [Text Block]",
        "terseLabel": "Summary of Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental cash flow information related to leases.",
        "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_SharedDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total amount of development costs that will be shared under collaborative agreement.",
        "label": "Shared Development Costs",
        "terseLabel": "Shared development costs"
       }
      }
     },
     "localname": "SharedDevelopmentCosts",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ShareholdersEquityAndStockBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholders equity and stock-based compensation.",
        "label": "Shareholders Equity And Stock Based Compensation [Abstract]"
       }
      }
     },
     "localname": "ShareholdersEquityAndStockBasedCompensationAbstract",
     "nsuri": "http://www.fibrogen.com/20201231",
     "xbrltype": "stringItemType"
    },
    "fgen_SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued from stock plans net of payroll taxes paid shares.",
        "label": "Shares Issued From Stock Plans Net Of Payroll Taxes Paid Shares",
        "terseLabel": "Shares issued from stock plans, net of payroll taxes paid, Shares"
       }
      }
     },
     "localname": "SharesIssuedFromStockPlansNetOfPayrollTaxesPaidShares",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "fgen_ShorensteinPropertiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shorenstein properties LLC.",
        "label": "Shorenstein Properties L L C [Member]",
        "terseLabel": "Shorenstein Properties LLC [Member]"
       }
      }
     },
     "localname": "ShorensteinPropertiesLLCMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_ShortTermInvestmentsMaximumMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term investments maximum maturity period.",
        "label": "Short Term Investments Maximum Maturity Period",
        "terseLabel": "Short term investments maturity"
       }
      }
     },
     "localname": "ShortTermInvestmentsMaximumMaturityPeriod",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "fgen_StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares stock options exercised full year.",
        "label": "Stock Issued During Period Shares Stock Options Exercised Full Year",
        "negatedLabel": "Exercised, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "fgen_StockOptionAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option awards.",
        "label": "Stock Option Awards [Member]",
        "terseLabel": "Stock Option Awards [Member]"
       }
      }
     },
     "localname": "StockOptionAwardsMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Finance and Operating Lease Right of Use Assets by Geographical Location.",
        "label": "Summary Of Finance And Operating Lease Right Of Use Assets By Geographical Location Table [Text Block]",
        "terseLabel": "Summary of Finance and Operating Lease Right of Use Assets by Geographical Location"
       }
      }
     },
     "localname": "SummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationTableTextBlock",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fgen_SuppliesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplies, net.",
        "label": "Supplies Net",
        "terseLabel": "Net unbilled contract asset",
        "totalLabel": "Net unbilled contract assets",
        "verboseLabel": "Net unbilled co-development revenue"
       }
      }
     },
     "localname": "SuppliesNet",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_TransactionPriceAllocatedToPerformanceObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction price allocated to performance obligations.",
        "label": "Transaction Price Allocated To Performance Obligations",
        "terseLabel": "Transaction price and allocated to performance obligations"
       }
      }
     },
     "localname": "TransactionPriceAllocatedToPerformanceObligations",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_TwoThousandAndFiveStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and five stock plan.",
        "label": "Two Thousand And Five Stock Plan [Member]",
        "terseLabel": "2005 Stock Plan"
       }
      }
     },
     "localname": "TwoThousandAndFiveStockPlanMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_TwoThousandAndFourteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen employee stock purchase plan.",
        "label": "Two Thousand And Fourteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 ESPP [Member]"
       }
      }
     },
     "localname": "TwoThousandAndFourteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_TwoThousandAndFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen equity incentive plan.",
        "label": "Two Thousand And Fourteen Equity Incentive Plan [Member]",
        "terseLabel": "2014 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndFourteenEquityIncentivePlanMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_UnconsolidatedVariableInterestEntityInvestmentLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10060.0,
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unconsolidated variable interest entity investment loss.",
        "label": "Unconsolidated Variable Interest Entity Investment Loss",
        "negatedLabel": "Investment loss in unconsolidated variable interest entity"
       }
      }
     },
     "localname": "UnconsolidatedVariableInterestEntityInvestmentLoss",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_UnitedStatesAndRestOfWorldAndChinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United states and rest of world and china.",
        "label": "United States And Rest Of World And China [Member]",
        "terseLabel": "U.S./RoW and China [Member]"
       }
      }
     },
     "localname": "UnitedStatesAndRestOfWorldAndChinaMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_UnitedStatesAndRestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United states and rest of world.",
        "label": "United States And Rest Of World [Member]",
        "terseLabel": "U.S./RoW [Member]",
        "verboseLabel": "U.S./RoW [Member]"
       }
      }
     },
     "localname": "UnitedStatesAndRestOfWorldMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_UnitedStatesRestOfWorldAndChinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United States/Rest of World and China.",
        "label": "United States Rest Of World And China [Member]",
        "verboseLabel": "U.S./RoW and China [Member]"
       }
      }
     },
     "localname": "UnitedStatesRestOfWorldAndChinaMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_UnrealizedLossGainOnEquityInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10220.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized loss (gain) on equity investments.",
        "label": "Unrealized Loss Gain On Equity Investments",
        "negatedLabel": "Unrealized loss (gain) on equity investments"
       }
      }
     },
     "localname": "UnrealizedLossGainOnEquityInvestments",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_ValuationAllowanceForRebatesAndDiscountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance for rebates and discounts.",
        "label": "Valuation Allowance For Rebates And Discounts [Member]",
        "terseLabel": "Valuation Allowance for Rebates and Discounts [Member]"
       }
      }
     },
     "localname": "ValuationAllowanceForRebatesAndDiscountsMember",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable consideration payment received from estimated future co-development billing.",
        "label": "Variable Consideration Payment Received From Estimated Future Co Development Billing",
        "terseLabel": "Transaction price, variable consideration from estimated future co-development billing"
       }
      }
     },
     "localname": "VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable consideration payment received related to co-development billings.",
        "label": "Variable Consideration Payment Received Related To Co Development Billings",
        "terseLabel": "Variable consideration related to co-development billings"
       }
      }
     },
     "localname": "VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable consideration payment received upon achievement of milestone.",
        "label": "Variable Consideration Payment Received Upon Achievement Of Milestone",
        "terseLabel": "Variable consideration related to payments for milestones considered probable of being achieved"
       }
      }
     },
     "localname": "VariableConsiderationPaymentReceivedUponAchievementOfMilestone",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_VariableConsiderationRelatedToProfitShare": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable consideration related to profit share.",
        "label": "Variable Consideration Related To Profit Share",
        "terseLabel": "Variable consideration related to profit share"
       }
      }
     },
     "localname": "VariableConsiderationRelatedToProfitShare",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_WarrantExercisedDuringPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant exercised during period shares.",
        "label": "Warrant Exercised During Period Shares",
        "terseLabel": "Warrants exercised, Shares"
       }
      }
     },
     "localname": "WarrantExercisedDuringPeriodShares",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "fgen_WarrantsExercisedDuringPeriodValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercised during period value.",
        "label": "Warrants Exercised During Period Value",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "WarrantsExercisedDuringPeriodValue",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fgen_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average discount rate.",
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted-average discount rate:"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "fgen_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average remaining lease term.",
        "label": "Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted-average remaining lease term (years):"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.fibrogen.com/20201231",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r64",
      "r125",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r143",
      "r150",
      "r246",
      "r402",
      "r403",
      "r404",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect Period Of Adoption Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment [Member]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r143",
      "r150",
      "r246",
      "r402",
      "r403",
      "r404",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect Period Of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r143",
      "r150",
      "r246",
      "r402",
      "r403",
      "r404",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect Period Of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Continent of Europe.",
        "label": "Europe [Member]",
        "terseLabel": "Europe [Member]"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r363",
      "r365",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r623",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r363",
      "r365",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r623",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r211",
      "r330",
      "r333",
      "r562",
      "r622",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r211",
      "r330",
      "r333",
      "r562",
      "r622",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r342",
      "r363",
      "r365",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r623",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r342",
      "r363",
      "r365",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r623",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r138",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "Schedule Of Valuation And Qualifying Accounts Disclosure [Text Block]",
        "terseLabel": "Schedule II - Valuation and Qualifying Accounts"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccounts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r212",
      "r213",
      "r330",
      "r334",
      "r625",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfInventoryByGeographicAreaDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfLongLivedAssetsByGeographicAreaDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationSummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r212",
      "r213",
      "r330",
      "r334",
      "r625",
      "r660",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfInventoryByGeographicAreaDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfLongLivedAssetsByGeographicAreaDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationSummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation And Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Valuation And Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "Valuation And Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r138",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of valuation and qualifying accounts and reserves.",
        "label": "Valuation And Qualifying Accounts Disclosure [Table]",
        "terseLabel": "Valuation And Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "California [Member]"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201601Member": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.",
        "label": "Accounting Standards Update201601 [Member]",
        "terseLabel": "ASU 2016-01 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201601Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update201602 [Member]",
        "terseLabel": "ASU 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201802Member": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-02 Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.",
        "label": "Accounting Standards Update201802 [Member]",
        "terseLabel": "ASU 2018-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201802Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable ($1,118 and $0 to a related party)"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts Payable [Member]",
        "terseLabel": "Accounts Payable [Member]"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r44",
      "r129",
      "r548",
      "r549"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Related Parties Current",
        "terseLabel": "Accounts payable to related party"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]",
        "verboseLabel": "Percentage of Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r26",
      "r219",
      "r220"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10290.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable, net ($4,127 and $4,845 from a related party)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r55",
      "r129",
      "r547",
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable Related Parties Current",
        "terseLabel": "Accounts receivable from related party"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion Amortization Of Discounts And Premiums Investments",
        "negatedLabel": "Net accretion of discount on investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities And Other Liabilities",
        "terseLabel": "Accrued and other current liabilities ($24 and $36,883 to a related party)"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "totalLabel": "Total accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued Liabilities [Member]"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r46"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r42",
      "r288"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r29",
      "r70",
      "r71",
      "r72",
      "r608",
      "r634",
      "r638"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r69",
      "r72",
      "r73",
      "r140",
      "r141",
      "r142",
      "r477",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r27",
      "r405"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r445",
      "r446",
      "r447",
      "r448",
      "r564",
      "r565",
      "r566",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r367",
      "r369",
      "r408",
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r304",
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs",
        "terseLabel": "Adjustment to issuance costs for Follow-on Offerings"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r369",
      "r395",
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r225",
      "r252",
      "r255",
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Allowance For Doubtful Accounts Receivable",
        "terseLabel": "Reductions to gross accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure alternative investment.",
        "label": "Alternative Investment Measurement Input",
        "terseLabel": "Discount rate applied"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation of net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r121",
      "r194",
      "r200",
      "r207",
      "r241",
      "r473",
      "r479",
      "r505",
      "r581",
      "r606"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r63",
      "r121",
      "r241",
      "r473",
      "r479",
      "r505"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10200.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "terseLabel": "Total fair value of financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      },
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfContractualMaturitiesOfAvailableForSaleInvestmentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available For Sale Securities",
        "terseLabel": "Fair Value",
        "totalLabel": "Total investments",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfContractualMaturitiesOfAvailableForSaleInvestmentsDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Gross Unrealized Holding Gains"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Gross Unrealized Holding Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Available For Sale Securities Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available For Sale Securities Debt Maturities [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesEquitySecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfContractualMaturitiesOfAvailableForSaleInvestmentsDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity securities categorized neither as held-to-maturity nor as trading.",
        "label": "Available For Sale Securities Equity Securities",
        "terseLabel": "Equity investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesEquitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfContractualMaturitiesOfAvailableForSaleInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10270.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.",
        "label": "Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments",
        "negatedLabel": "Realized loss (gain) on sales of available-for-sale securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r370",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r362",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r362",
      "r364",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition Cost Of Acquired Entity Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition Percentage Of Voting Interests Acquired",
        "terseLabel": "Percentage of outstanding shares acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination Acquisition Related Costs",
        "terseLabel": "Acquisition costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r465",
      "r466",
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination Consideration Transferred1",
        "terseLabel": "Entire purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r139",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description And Basis Of Presentation [Text Block]",
        "terseLabel": "The Company"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureTheCompany"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Capital": {
     "auth_ref": [
      "r602",
      "r658",
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of total capital as defined by regulatory framework.",
        "label": "Capital",
        "terseLabel": "Falikang's total registered capital"
       }
      }
     },
     "localname": "Capital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r113",
      "r114",
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Balance in accounts payable and accrued liabilities related to purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r38",
      "r640",
      "r641"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash And Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r38",
      "r111"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10270.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Total cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure",
        "terseLabel": "Assets fair value disclosure"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r105",
      "r111",
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Total cash and cash equivalents at end of period",
        "periodStartLabel": "Total cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r105",
      "r509"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates Of Deposit [Member]",
        "terseLabel": "Certificate of deposit [Member]"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r120",
      "r121",
      "r155",
      "r156",
      "r157",
      "r159",
      "r161",
      "r168",
      "r169",
      "r170",
      "r241",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Outstanding",
        "verboseLabel": "Warrants to purchase common stock outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationWarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r51",
      "r297",
      "r588",
      "r613"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r293",
      "r294",
      "r296",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail": {
       "order": 10050.0,
       "parentTag": "fgen_CommonStockSharesReserved",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Shares reserved for future ESPP offering",
        "verboseLabel": "Number of common stock reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r24",
      "r304"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail": {
       "order": 10010.0,
       "parentTag": "fgen_CommonStockSharesReserved",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.01 par value; 225,000 shares authorized at December 31, 2020 and 2019; 91,441 and 87,657 shares issued and outstanding at December 31, 2020 and 2019"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock Voting Rights",
        "terseLabel": "Common stock voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationCommonStockAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Assets And Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Income Tax Expense Benefit Continuing Operations [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r76",
      "r78",
      "r79",
      "r89",
      "r593",
      "r618"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r178",
      "r179",
      "r217",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r217",
      "r502",
      "r503",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk By Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark",
        "verboseLabel": "Percentage of Accounts Receivable [Member]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r217",
      "r502",
      "r503",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk By Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r173",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r178",
      "r179",
      "r217",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk Percentage1",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r178",
      "r179",
      "r217",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r117",
      "r478",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation Variable Interest Entity Policy",
        "terseLabel": "Variable Interest Entity"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction in progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract With Customer Asset And Liability Table [Text Block]",
        "terseLabel": "Roll-forward of Related Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r314",
      "r315",
      "r331"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10050.0,
       "parentTag": "fgen_SuppliesNet",
       "weight": -1.0
      },
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail": {
       "order": 10020.0,
       "parentTag": "fgen_CashConsiderationReceivedUnderCollaborationAgreement",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract With Customer Liability",
        "negatedLabel": "Deferred revenues from associated contracts",
        "negatedPeriodEndLabel": "Balance at December 31, 2020",
        "negatedPeriodStartLabel": "Balance at December 31, 2019",
        "positiveLabel": "Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract With Customer Liability [Abstract]",
        "terseLabel": "Contract with Customer, Liability [Abstract]"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.",
        "label": "Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized",
        "terseLabel": "Changes in revenue due to prior period adjustment of performance obligations"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price",
        "terseLabel": "Amount constrained related to drug product shipment"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r314",
      "r315",
      "r331"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "positiveLabel": "Profit share liability",
        "terseLabel": "Deferred revenue ($2,907 and $249 to a related party)"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r314",
      "r315",
      "r331"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "terseLabel": "Deferred revenue, net of current ($4,636 and $125 to a related party)",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract With Customer Liability Revenue Recognized",
        "terseLabel": "Milestone payment received"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Outstanding non-cancelable contract obligations"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r22",
      "r23",
      "r305",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock Shares Issued Upon Conversion",
        "verboseLabel": "Conversion rights, shares issued upon conversion of each preferred share"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk [Member]"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.",
        "label": "Credit Loss Financial Instrument Policy [Text Block]",
        "terseLabel": "Credit Losses \u2013 Available-for-sale Debt Securities"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal State And Local Tax Expense Benefit [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r122",
      "r441",
      "r451"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense Benefit",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r128",
      "r441"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense Benefit",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r122",
      "r441",
      "r451",
      "r453"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense Benefit",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r122",
      "r441",
      "r451"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State And Local Tax Expense Benefit",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r177",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Interest rate on product development advances"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r49",
      "r126",
      "r305",
      "r309",
      "r310",
      "r311",
      "r519",
      "r520",
      "r522",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Debt Instrument [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r122",
      "r442",
      "r451"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense Benefit",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal State And Local Tax Expense Benefit [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r122",
      "r442",
      "r451"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense Benefit",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r109",
      "r122",
      "r442",
      "r451",
      "r452",
      "r453"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense Benefit",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r122",
      "r442",
      "r451"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State And Local Income Tax Expense Benefit",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.",
        "label": "Deferred Tax And Other Liabilities Noncurrent",
        "terseLabel": "Other long-term tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory": {
     "auth_ref": [
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from intra-entity transfer of asset within consolidated group. Excludes intra-entity transfer of inventory.",
        "label": "Deferred Tax Asset Intra Entity Transfer Asset Other Than Inventory",
        "terseLabel": "Deferred tax asset for temporary difference"
       }
      }
     },
     "localname": "DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail": {
       "order": 10130.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "totalLabel": "Total net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Federal and state net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards Foreign",
        "terseLabel": "Foreign net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail": {
       "order": 10150.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r438",
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": {
     "auth_ref": [
      "r438",
      "r439",
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Other",
        "terseLabel": "Other tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail": {
       "order": 10100.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail": {
       "order": 10120.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals",
        "terseLabel": "Reserves and accruals"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail": {
       "order": 10110.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent",
        "terseLabel": "Lease obligations"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r418",
      "r435"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities",
        "negatedTotalLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r439",
      "r440"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfSignificantComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan Cost Recognized",
        "terseLabel": "Defined contribution plan, employer matching contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFibrogenInc401KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan Maximum Annual Contributions Per Employee Percent",
        "terseLabel": "Defined contribution plan, maximum annual contributions per employee, percent"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFibrogenInc401KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r109",
      "r286"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.",
        "label": "Difference Between Revenue Guidance In Effect Before And After Topic606 [Member]",
        "terseLabel": "Impact of change in accounting principle upon adoption of ASU 2016-01 [Member]"
       }
      }
     },
     "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation Of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation Of Revenue [Line Items]",
        "terseLabel": "Disaggregation Of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r330",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue [Table]",
        "terseLabel": "Disaggregation Of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue Table [Text Block]",
        "terseLabel": "Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r5",
      "r16",
      "r25",
      "r123",
      "r547"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due From Related Parties Current",
        "terseLabel": "Prepaid expenses and other current assets from related parties"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r44",
      "r129",
      "r547"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due To Related Parties Current",
        "terseLabel": "Accrued and other current liabilities to related party",
        "verboseLabel": "Accrued liabilities and accounts payable to related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarliestTaxYearMember": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earliest identified tax year.",
        "label": "Earliest Tax Year [Member]",
        "terseLabel": "Earliest Tax Year [Member]"
       }
      }
     },
     "localname": "EarliestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share - basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r509"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "terseLabel": "Effect of exchange rate change on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r420"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r420",
      "r455"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "verboseLabel": "Tax at statutory federal rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": {
     "auth_ref": [
      "r420",
      "r455"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.",
        "label": "Effective Income Tax Rate Reconciliation Deductions",
        "terseLabel": "Deduction limitation on executive compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r420",
      "r455"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential",
        "terseLabel": "Foreign net operating losses not benefitted"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r420",
      "r455"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail": {
       "order": 10090.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r420",
      "r455"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "terseLabel": "State tax"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Payroll and related accruals"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Non-vested stock option awards granted that will be recognized on a straight-line basis over the weighted-average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee stock options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Wide Revenue Major Customer [Line Items]",
        "terseLabel": "Entity Wide Revenue Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r145",
      "r152",
      "r154",
      "r167",
      "r246",
      "r304",
      "r312",
      "r402",
      "r403",
      "r404",
      "r447",
      "r448",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r516",
      "r629",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r0",
      "r121",
      "r241",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r0",
      "r121",
      "r241",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment Ownership Percentage",
        "terseLabel": "Ownership Percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentSoldCarryingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the entity's equity method investment which has been sold.",
        "label": "Equity Method Investment Sold Carrying Amount",
        "terseLabel": "Cash consideration for exchange of outstanding shares"
       }
      }
     },
     "localname": "EquityMethodInvestmentSoldCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r39",
      "r195",
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Text Block]",
        "terseLabel": "Summary of Equity Method Investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r17",
      "r20",
      "r237",
      "r604",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity investments [Member]"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r489",
      "r490",
      "r491",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value Assets Level1 To Level2 Transfers Amount",
        "terseLabel": "Transfers of assets from level 1 to 2"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value Assets Level2 To Level1 Transfers Amount",
        "terseLabel": "Transfers of assets from level 2 to 1"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value Assets Measured On Recurring Basis [Text Block]",
        "terseLabel": "Fair Values of Financial Assets Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r358",
      "r490",
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Fair Value By Liability Class [Axis]",
        "terseLabel": "Liability Class"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r489",
      "r490",
      "r493",
      "r494",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r343",
      "r345",
      "r350",
      "r358",
      "r490",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r343",
      "r345",
      "r350",
      "r358",
      "r490",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r358",
      "r490",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value Liabilities Level1 To Level2 Transfers Amount",
        "terseLabel": "Transfers of liabilities from level 1 to 2"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value Liabilities Level2 To Level1 Transfers Amount",
        "terseLabel": "Transfers of liabilities from level 2 to 1"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]",
        "terseLabel": "Fair Values of Financial Liabilities Carried at Historical Cost"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement Policy Policy [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3",
        "terseLabel": "Transfers of liabilities into level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3",
        "terseLabel": "Transfers of liabilities out of level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3",
        "terseLabel": "Transfers of assets into level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3",
        "terseLabel": "Transfers of assets out of level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r358",
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r497",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r117",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value Of Financial Instruments Policy",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r528",
      "r534",
      "r543"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r529",
      "r537"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease Interest Payment On Liability",
        "terseLabel": "Operating cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Liabilities Payments Due [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r526",
      "r542"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2": {
       "order": 10040.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease Liability",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "fgen_FinanceLeaseAndOperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10190.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease Liability Current",
        "terseLabel": "Finance lease liabilities, current",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10030.0,
       "parentTag": "fgen_FinanceLeaseAndOperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease Liability Noncurrent",
        "terseLabel": "Finance lease liabilities, non-current",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease Liability Payments Due",
        "totalLabel": "Total future lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease Liability Payments Due Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease Liability Payments Due Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2": {
       "order": 10030.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r525"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_OperatingLeaseRightOfUseAsset",
       "weight": 1.0
      },
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10240.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease Right Of Use Asset",
        "terseLabel": "Finance lease right-of-use assets",
        "totalLabel": "Finance lease right-of-use assets, net",
        "verboseLabel": "Total finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationSummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r528",
      "r534",
      "r543"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      },
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease Right Of Use Asset Amortization",
        "terseLabel": "Amortization of finance lease right-of-use assets",
        "verboseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r540",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r539",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r278",
      "r279",
      "r281",
      "r282",
      "r563",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r278",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Country [Member]",
        "terseLabel": "Foreign net operating loss [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossRealized": {
     "auth_ref": [
      "r507",
      "r508"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10260.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain Loss Realized",
        "negatedLabel": "Realized foreign currency gain"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossRealized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions And Translations Policy [Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r109",
      "r285",
      "r290"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10240.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain Loss On Disposition Of Assets",
        "negatedLabel": "Loss (gain) on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeographicDistributionAxis": {
     "auth_ref": [
      "r262",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.",
        "label": "Geographic Distribution [Axis]",
        "terseLabel": "Geographic Distribution"
       }
      }
     },
     "localname": "GeographicDistributionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeographicDistributionDomain": {
     "auth_ref": [
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities.",
        "label": "Geographic Distribution [Domain]",
        "terseLabel": "Geographic Distribution"
       }
      }
     },
     "localname": "GeographicDistributionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicDistributionForeignMember": {
     "auth_ref": [
      "r263",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation of business activity identified as foreign.",
        "label": "Geographic Distribution Foreign [Member]",
        "terseLabel": "Foreign subsidiaries [Member]"
       }
      }
     },
     "localname": "GeographicDistributionForeignMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r109",
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment Of Long Lived Assets To Be Disposed Of",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r283",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r127",
      "r454"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r85",
      "r194",
      "r199",
      "r203",
      "r206",
      "r209",
      "r580",
      "r590",
      "r596",
      "r620"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r127",
      "r454"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r86",
      "r109",
      "r192",
      "r238",
      "r589",
      "r615"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income Loss From Equity Method Investments",
        "negatedLabel": "Share of Net Loss"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntitySummaryOfEquityMethodInvestmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r425",
      "r430",
      "r432",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r421",
      "r431",
      "r437",
      "r449",
      "r456",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r122",
      "r153",
      "r154",
      "r193",
      "r419",
      "r450",
      "r457",
      "r621"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Total provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r80",
      "r117",
      "r416",
      "r417",
      "r431",
      "r432",
      "r436",
      "r443",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10320.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable ($1,118, $0 and $0 from a related party)"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase Decrease In Accounts Payable Related Parties",
        "terseLabel": "Accrued and other liabilities from related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10280.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable, net ($718, $42,365 and $(43,486) from a related party)"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase Decrease In Accounts Receivable Related Parties",
        "terseLabel": "Accounts receivable from related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10330.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities",
        "terseLabel": "Accrued and other liabilities ($(36,859), $36,439 and $172 from a related party)"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10340.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue ($7,169, $(3,137) and $(3,908) from a related party)"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Deferred Revenue",
        "terseLabel": "Deferred revenue from related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10290.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase Decrease In Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10370.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase Decrease In Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10310.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase Decrease In Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10300.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets ($124,321, $(125,210) and $0 from a related party)"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Axis]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Domain]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10070.0,
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest And Other Income",
        "terseLabel": "Interest income and other, net"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r83",
      "r191",
      "r518",
      "r521",
      "r594"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10050.0,
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10040.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income Expense Nonoperating Net",
        "totalLabel": "Total interest and other, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r103",
      "r106",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "terseLabel": "Interest payments"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r587",
      "r614"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable Current And Noncurrent",
        "terseLabel": "Accrued Interest"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory Finished Goods",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r60"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10300.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories",
        "verboseLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfInventoryByGeographicAreaDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r61",
      "r117",
      "r166",
      "r271",
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory Policy [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory Raw Materials",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory Work In Process",
        "terseLabel": "Work-in-progress"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r92",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income Net",
        "terseLabel": "Investment"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r240",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment Policy [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified By Contractual Maturity Date Table [Text Block]",
        "terseLabel": "Summary of Contractual Maturities of Available-for-Sale Investments"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LatestTaxYearMember": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Latest identified tax year.",
        "label": "Latest Tax Year [Member]",
        "terseLabel": "Latest Tax Year [Member]"
       }
      }
     },
     "localname": "LatestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r541",
      "r543"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Cost [Abstract]",
        "terseLabel": "Finance lease cost:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease Cost Table [Text Block]",
        "terseLabel": "Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases Of Lessee Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeFinanceLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend finance lease.",
        "label": "Lessee Finance Lease Existence Of Option To Extend",
        "terseLabel": "Lessee, finance lease, existence of option to extend"
       }
      }
     },
     "localname": "LesseeFinanceLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeFinanceLeaseOptionToExtend": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's finance lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Finance Lease Option To Extend",
        "terseLabel": "Lessee, finance lease, option to extend"
       }
      }
     },
     "localname": "LesseeFinanceLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Finance Lease Term Of Contract1",
        "terseLabel": "Lessee, finance lease, initial lease term"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee Lease Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee Lease Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Lessee, operating lease, lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r45",
      "r121",
      "r201",
      "r241",
      "r474",
      "r479",
      "r480",
      "r505"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r32",
      "r121",
      "r241",
      "r505",
      "r584",
      "r611"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities, stockholders\u2019 equity and non-controlling interests"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities, stockholders\u2019 equity and non-controlling interests"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r113",
      "r114",
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities Assumed1",
        "terseLabel": "Deferred offering costs recorded in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r47",
      "r121",
      "r241",
      "r474",
      "r479",
      "r480",
      "r505"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities Fair Value Disclosure",
        "terseLabel": "Liabilities fair value disclosure"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialLiabilitiesCarriedAtHistoricalCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License Revenue [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansReceivableBasisSpreadOnVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage points (also referred to as 'margin') added to the reference rate as stated in the loan agreement and used to compute the variable rate on the loans receivable. For instance, the loan agreement might state that the interest rate the borrower is obligated to pay is the London Interbank Offered Rate (LIBOR) plus three quarters (3/4) of a percentage point adjusted quarterly (each three months). LIBOR in this example is the index or reference rate, 3/4 percentage point is the margin, the reference rate plus the margin is the fully indexed rate. This element would be used to report separately the margin.",
        "label": "Loans Receivable Basis Spread On Variable Rate",
        "terseLabel": "Percentage points deducted to reference rate to compute effective interest rate"
       }
      }
     },
     "localname": "LoansReceivableBasisSpreadOnVariableRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long Lived Assets By Geographic Areas Table [Text Block]",
        "terseLabel": "Schedule of Long Lived Assets by Geographic Area"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10220.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long Term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of items purchased under a long-term purchase commitment.",
        "label": "Long Term Purchase Commitment By Category Of Item Purchased [Axis]",
        "terseLabel": "Category of Item Purchased"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.",
        "label": "Long Term Purchase Commitment Category Of Item Purchased [Domain]",
        "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery And Equipment [Member]",
        "terseLabel": "Machinery [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input Discount Rate [Member]",
        "terseLabel": "Measurement Input Discount Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r56",
      "r121",
      "r241",
      "r505",
      "r583",
      "r610"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Minority Interest",
        "terseLabel": "Non-controlling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds At Carrying Value",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r105",
      "r107",
      "r110"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r74",
      "r77",
      "r87",
      "r110",
      "r121",
      "r144",
      "r148",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r158",
      "r194",
      "r199",
      "r203",
      "r206",
      "r209",
      "r241",
      "r505",
      "r591",
      "r616"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r312",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in CCYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Foreign statute of limitation generally remains open in the year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs And Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10090.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r194",
      "r199",
      "r203",
      "r206",
      "r209"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10030.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r535",
      "r543"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Payments Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "fgen_FinanceLeaseAndOperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease Liability Current Statement Of Financial Position Extensible List",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10040.0,
       "parentTag": "fgen_FinanceLeaseAndOperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r530",
      "r537"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r525"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail": {
       "order": 10050.0,
       "parentTag": "fgen_FinanceLeaseAndOperatingLeaseAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Total operating lease right-of-use assets",
        "totalLabel": "Operating lease right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseAssetsAndRelatedLeaseLiabilitiesDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationSummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r540",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r539",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfLeaseTermAndDiscountRateDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r46"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail": {
       "order": 10090.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10260.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Available For Sale Securities Adjustment Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Available-for-sale investments:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r67",
      "r68",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax",
        "terseLabel": "Change in unrealized gain or loss on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 10030.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax",
        "terseLabel": "Foreign currency translation adjustments (Note 2)",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r75",
      "r78",
      "r81",
      "r88",
      "r304",
      "r510",
      "r515",
      "r516",
      "r592",
      "r617"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income Loss Net Of Tax",
        "totalLabel": "Other comprehensive income (loss), net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r67",
      "r70"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 10040.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Unrealized gain (loss) on investments, net of tax effect"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Total other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Noncurrent [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Other Long-term Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1": {
     "auth_ref": [
      "r113",
      "r114",
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Other Significant Noncash Transaction Value Of Consideration Given1",
        "terseLabel": "Consideration associated with milestone included in transaction price"
       }
      }
     },
     "localname": "OtherSignificantNoncashTransactionValueOfConsiderationGiven1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesNoncurrent": {
     "auth_ref": [
      "r21",
      "r582",
      "r607"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.",
        "label": "Other Sundry Liabilities Noncurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongTermLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.",
        "label": "Other Than Temporary Impairment Losses Investments Availableforsale Securities",
        "terseLabel": "Other-than-temporary impairment loss"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payments Related To Tax Withholding For Share Based Compensation",
        "negatedLabel": "Cash paid for payroll taxes on restricted stock unit releases"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r97",
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments To Acquire Businesses Gross",
        "terseLabel": "Cash consideration"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r342",
      "r344",
      "r350",
      "r351",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Pension And Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "FibroGen, Inc. 401(k) Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFibrogenInc401KPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r370",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock Dividend Rate Percentage",
        "verboseLabel": "Cash dividend percentage"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockRedemptionTerms": {
     "auth_ref": [
      "r303",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The redemption terms of preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity. The redemption features of this capital stock are solely within the control of the issuer.",
        "label": "Preferred Stock Redemption Terms",
        "terseLabel": "Preferred stock redemption percentage"
       }
      }
     },
     "localname": "PreferredStockRedemptionTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at December 31, 2020 and 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockVotingRights": {
     "auth_ref": [
      "r23",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Preferred Stock Voting Rights",
        "terseLabel": "Preferred stock, voting rights"
       }
      }
     },
     "localname": "PreferredStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r36",
      "r37"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10310.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets ($889 and $125,210 from related parties)",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense And Other Assets Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r6",
      "r9",
      "r275",
      "r276"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense Current",
        "terseLabel": "Prepaid assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermCapitalLeaseObligations": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from proceeds received from lessor related to a long-term capital lease obligation.",
        "label": "Proceeds From Long Term Capital Lease Obligations",
        "terseLabel": "Borrowings under capital lease obligations"
       }
      }
     },
     "localname": "ProceedsFromLongTermCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds From Sale Maturity And Collections Of Investments",
        "terseLabel": "Proceeds from maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r94",
      "r229"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.",
        "label": "Proceeds From Sale Of Available For Sale Securities",
        "terseLabel": "Proceeds from sales of available-for-sale securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds From Sale Of Property Plant And Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product Revenue, Net [Member]",
        "verboseLabel": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r74",
      "r77",
      "r104",
      "r121",
      "r144",
      "r153",
      "r154",
      "r194",
      "r199",
      "r203",
      "r206",
      "r209",
      "r241",
      "r472",
      "r475",
      "r476",
      "r485",
      "r486",
      "r505",
      "r596"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r42",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r41",
      "r287"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r18",
      "r19",
      "r289",
      "r612"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10230.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfLongLivedAssetsByGeographicAreaDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r40",
      "r117",
      "r289",
      "r662",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r18",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r18",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property and equipment estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligation": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the recorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).",
        "label": "Recorded Unconditional Purchase Obligation",
        "terseLabel": "Total purchase obligations"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recorded unconditional purchase obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Recorded Unconditional Purchase Obligation Due In Second Year",
        "terseLabel": "Purchase obligations due 2022"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Recorded Unconditional Purchase Obligation Due Within One Year",
        "terseLabel": "Purchase obligations due 2021"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationDueWithinOneYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Recorded Unconditional Purchase Obligation [Line Items]",
        "terseLabel": "Recorded Unconditional Purchase Obligation [Line Items]"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationTable": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes each recorded unconditional purchase obligation arrangement to purchase goods and services that extend over multiple periods, any assets pledged to secure payment, and the fixed or determinable amount of payments due in each of the next five years and thereafter.",
        "label": "Recorded Unconditional Purchase Obligation [Table]",
        "terseLabel": "Recorded Unconditional Purchase Obligation [Table]"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfUnconditionalPurchaseObligationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationsTextBlock": {
     "auth_ref": [
      "r295",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unconditional purchase obligation recognized as liability.",
        "label": "Recorded Unconditional Purchase Obligations [Text Block]",
        "terseLabel": "Summary of Unconditional Purchase Obligations"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r352",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction Expenses From Transactions With Related Party",
        "terseLabel": "Expense related to collaboration agreements"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r352",
      "r546",
      "r549",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r544",
      "r545",
      "r547",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.",
        "label": "Repayments Of Debt And Capital Lease Obligations",
        "negatedLabel": "Repayments of lease obligations"
       }
      }
     },
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).",
        "label": "Repayments Of Long Term Capital Lease Obligations",
        "negatedLabel": "Repayments of capital lease obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research And Development Arrangement Contract To Perform For Others By Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r412",
      "r673"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10110.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r117",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Restricted Stock Shares Issued Net Of Shares For Tax Withholdings",
        "terseLabel": "RSUs released and issued net of shares withheld for taxes"
       }
      }
     },
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Unit [Member]",
        "verboseLabel": "RSUs [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r28",
      "r312",
      "r405",
      "r609",
      "r633",
      "r638"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r145",
      "r152",
      "r154",
      "r246",
      "r402",
      "r403",
      "r404",
      "r447",
      "r448",
      "r629",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r189",
      "r190",
      "r198",
      "r204",
      "r205",
      "r211",
      "r212",
      "r217",
      "r329",
      "r330",
      "r562"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10080.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "positiveVerboseLabel": "Drug product revenue recognized",
        "terseLabel": "Total revenue",
        "verboseLabel": "Drug product revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r118",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue From External Customers By Geographic Areas Table [Text Block]",
        "terseLabel": "Schedule of Revenue by Geographic Area"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r90",
      "r642"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue From Related Parties",
        "terseLabel": "License and development revenue related to collaboration agreements"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.",
        "label": "Revenue Performance Obligation Description Of Payment Terms",
        "terseLabel": "Description of payment term"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue Recognition Multiple Deliverable Arrangements [Line Items]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.",
        "label": "Revenue Recognition Multiple Deliverable Arrangements [Table]",
        "terseLabel": "Revenue Recognition Multiple Deliverable Arrangements [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue Remaining Performance Obligation",
        "terseLabel": "Revenue during period from performance obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r84",
      "r121",
      "r189",
      "r190",
      "r198",
      "r204",
      "r205",
      "r211",
      "r212",
      "r217",
      "r241",
      "r505",
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues From External Customers And Long Lived Assets [Line Items]",
        "terseLabel": "Revenues From External Customers And Long Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfLongLivedAssetsByGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r538",
      "r543"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Finance Lease Liability",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r538",
      "r543"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns And Allowances [Member]",
        "terseLabel": "Sales Return [Member]"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r178",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Sales Revenue Net [Member]",
        "verboseLabel": "Percentage of Revenue [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Available For Sale Securities [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule Of Available For Sale Securities Reconciliation Table [Text Block]",
        "terseLabel": "Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule Of Available For Sale Securities [Table]",
        "terseLabel": "Schedule Of Available For Sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule Of Cash And Cash Equivalents Table [Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]",
        "terseLabel": "Schedule of Components of Provision For Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Significant Components of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Reconciliation Between Statutory Federal Income Tax Rate and Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r369",
      "r394",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r369",
      "r394",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Schedule of Recorded Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule Of Entity Wide Revenue By Major Customers By Reporting Segments [Table]",
        "terseLabel": "Schedule Of Entity Wide Revenue By Major Customers By Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r14",
      "r33",
      "r34",
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule Of Inventory Current Table [Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Investments [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r42",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r124",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions By Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule Of Revenue By Major Customers By Reporting Segments Table [Text Block]",
        "terseLabel": "Schedule of Customer Concentration by Collaboration Partners"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r84",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule Of Revenues From External Customers And Long Lived Assets [Table]",
        "terseLabel": "Schedule Of Revenues From External Customers And Long Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfLongLivedAssetsByGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r194",
      "r196",
      "r202",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule Of Segment Reporting Information By Segment [Table]",
        "terseLabel": "Schedule Of Segment Reporting Information By Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfInventoryByGeographicAreaDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r370",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]",
        "terseLabel": "Summary of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r375",
      "r385",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Stock Option Transactions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r52",
      "r120",
      "r168",
      "r169",
      "r300",
      "r301",
      "r302",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r430",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]",
        "terseLabel": "Schedule of Reconciliation of the Beginning and Ending Amounts of Unrecognized Income Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r176",
      "r178",
      "r179",
      "r180",
      "r502",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules Of Concentration Of Risk By Risk Factor [Text Block]",
        "terseLabel": "Schedule of Significant Balance of Accounts Receivable"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure Of Entitys Reportable Segments [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r185",
      "r187",
      "r188",
      "r194",
      "r197",
      "r203",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r216",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment and Geographic Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfInventoryByGeographicAreaDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfRevenueByGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10120.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling General And Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling General And Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfRecordedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling General And Administrative Expenses Policy [Text Block]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B [Member]"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C [Member]"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series D preferred stock or outstanding series D preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series D Preferred Stock [Member]",
        "terseLabel": "Series D [Member]"
       }
      }
     },
     "localname": "SeriesDPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesEPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series E preferred stock or outstanding series E preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series E Preferred Stock [Member]",
        "terseLabel": "Series E [Member]"
       }
      }
     },
     "localname": "SeriesEPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesFPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series F preferred stock or outstanding series F preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series F Preferred Stock [Member]",
        "terseLabel": "Series F [Member]"
       }
      }
     },
     "localname": "SeriesFPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesGPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series G preferred stock or outstanding series G preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series G Preferred Stock [Member]",
        "terseLabel": "Series G [Member]"
       }
      }
     },
     "localname": "SeriesGPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesHPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series H preferred stock or outstanding series H preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series H Preferred Stock [Member]",
        "terseLabel": "Series H [Member]"
       }
      }
     },
     "localname": "SeriesHPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10250.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Vesting period of stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights",
        "terseLabel": "Option vesting term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Purchase Date",
        "terseLabel": "Purchase of common stock shares at discount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "negatedLabel": "Forfeited, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited, Fair value at Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "terseLabel": "Granted, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted, Fair value at Grant",
        "verboseLabel": "Weighted-average fair value of awards granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail": {
       "order": 10030.0,
       "parentTag": "fgen_CommonStockSharesReserved",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Unvested, Shares, Ending Balance",
        "periodStartLabel": "Unvested, Shares, Beginning Balance",
        "terseLabel": "RSUs outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested, Fair value at Grant, Ending Balance",
        "periodStartLabel": "Unvested, Fair value at Grant, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Vested, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested, Fair value at Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the equity-based award expires, in CCYY-MM-DD format.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Expiration Date",
        "terseLabel": "Termination date of equity incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail": {
       "order": 10040.0,
       "parentTag": "fgen_CommonStockSharesReserved",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Shares reserved for future stock options and RSUs grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Exercisable, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Exercisable, Weighted Average Exercise per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period",
        "negatedLabel": "Expired, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Forfeited, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Granted, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average estimated fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sets forth the nature of any other increase or decrease in the number of shares reserved for issuance under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period Description",
        "terseLabel": "Common stock reserved for future issuance, Description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r377",
      "r397"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail": {
       "order": 10020.0,
       "parentTag": "fgen_CommonStockSharesReserved",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Outstanding, Ending Balance, Shares",
        "periodStartLabel": "Outstanding, Beginning Balance, Shares",
        "terseLabel": "Stock options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease",
        "verboseLabel": "Increase in number of shares of common stock reserved for future issuance, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Ending Balance, Weighted Average Exercise per Share",
        "periodStartLabel": "Outstanding, Beginning Balance, Weighted Average Exercise per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Vested and expected to vest, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest, Weighted Average Exercise per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum",
        "terseLabel": "Percentage of common stock reserved for future issuance",
        "verboseLabel": "Percentage of common stock reserved for future issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r368",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockBasedCompensationAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfRSUActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Exercised, Weighted Average Exercise per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Expired, Weighted Average Exercise per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Forfeited, Weighted Average Exercise per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Granted, Weighted Average Exercise per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche One [Member]",
        "terseLabel": "First Anniversary [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r117",
      "r370",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage",
        "terseLabel": "Percentage of vesting rights"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Expiration period of stock options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r389",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Exercisable, Aggregate Intrinsic Value",
        "verboseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Exercisable, Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Outstanding, Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Vested and expected to vest, Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansSummaryOfStockOptionTransactionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Percentage of fair value exercise price grant date",
        "verboseLabel": "Percentage of fair value exercise price grant date"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r313",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders Equity And Share Based Payments [Text Block]",
        "terseLabel": "Equity and Stock-based Compensation"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r20",
      "r585",
      "r586",
      "r605"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10280.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A statement that a range of reasonably possible change cannot be made for a tax position taken for which it is reasonably possible that the total amount of unrecognized tax benefit will significantly increase or decrease within 12 months of the balance sheet date.",
        "label": "Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Estimated Range Not Possible",
        "terseLabel": "Unrecognized tax benefits description"
       }
      }
     },
     "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r120",
      "r121",
      "r155",
      "r156",
      "r157",
      "r159",
      "r161",
      "r168",
      "r169",
      "r170",
      "r241",
      "r304",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r54",
      "r140",
      "r141",
      "r142",
      "r145",
      "r152",
      "r154",
      "r167",
      "r246",
      "r304",
      "r312",
      "r402",
      "r403",
      "r404",
      "r447",
      "r448",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r516",
      "r629",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationSummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Income And Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r167",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTables",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationSummaryOfFinanceAndOperatingLeaseRightOfUseAssetsByGeographicalLocationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Stock Compensation Plan [Member]",
        "terseLabel": "Employee stock purchase plans [Member]"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEmployeeStockPurchasePlansDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r23",
      "r24",
      "r304",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "verboseLabel": "Shares purchased by employees"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationEmployeeStockPurchasePlanAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r23",
      "r24",
      "r304",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period Shares",
        "terseLabel": "Number of common stock repurchased"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r24",
      "r30",
      "r31",
      "r121",
      "r227",
      "r241",
      "r505"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r121",
      "r140",
      "r141",
      "r142",
      "r145",
      "r152",
      "r241",
      "r246",
      "r312",
      "r402",
      "r403",
      "r404",
      "r447",
      "r448",
      "r470",
      "r471",
      "r484",
      "r505",
      "r510",
      "r511",
      "r516",
      "r630",
      "r631"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r536",
      "r543"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSubsidiaryStockAndNonControllingInterestsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationSummaryOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Supplies": {
     "auth_ref": [
      "r7",
      "r9",
      "r274",
      "r276"
     ],
     "calculation": {
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10040.0,
       "parentTag": "fgen_SuppliesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Supplies",
        "terseLabel": "Unbilled contract assets",
        "verboseLabel": "Unbilled contract asset"
       }
      }
     },
     "localname": "Supplies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Trade And Other Accounts Receivable Policy",
        "terseLabel": "Trade Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]",
        "terseLabel": "Transaction"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]",
        "terseLabel": "Transaction Type"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax": {
     "auth_ref": [
      "r70",
      "r511"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative translation gain (loss), after tax, from translating foreign currency financial statements into the reporting currency.",
        "label": "Translation Adjustment Functional To Reporting Currency Net Of Tax",
        "terseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r445",
      "r446",
      "r447",
      "r448",
      "r564",
      "r565",
      "r566",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDeferredRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesRollForwardOfRelatedContractLiabilitiesDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfLicenseRevenueAndDevelopmentRevenueRecognizedUnderAgreementDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfRevenueRecognizedUnderCollaborationAgreementsAdditionalInformation4Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesTransactionPriceRelatedToConsiderationReceivedAndAccountsReceivableAllocatedToPerformanceObligationsAlongWithAssociatedDeferredRevenueParentheticalDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSegmentAndGeographicInformationScheduleOfCustomerConcentrationByCollaborationPartnersDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfSignificantBalanceOfAccountsReceivableDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfCostGoodOrServiceExtensibleList": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of cost from product sold and service rendered.",
        "label": "Type Of Cost Good Or Service Extensible List",
        "terseLabel": "Cost, Product and Service [Extensible List]"
       }
      }
     },
     "localname": "TypeOfCostGoodOrServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r343",
      "r358",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "U S Treasury Securities [Member]",
        "terseLabel": "US treasury notes and bills [Member]",
        "verboseLabel": "U.S. treasury notes and bills [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAmortizedCostGrossUnrealizedHoldingGainsOrLossesAndFairValueOfAvailableForSaleInvestmentsDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsFairValuesOfFinancialAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unconditional Purchase Obligations Excluding Capital Stock Redemptions [Abstract]"
       }
      }
     },
     "localname": "UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r415",
      "r426"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions",
        "negatedLabel": "Decrease due to prior positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Increase due to current year position"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions",
        "terseLabel": "Increase due to prior positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfBeginningAndEndingAmountsOfUnrecognizedIncomeTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "auth_ref": [
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits Interest On Income Taxes Accrued",
        "terseLabel": "Accrued interest, unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits That Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would affect effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r171",
      "r172",
      "r174",
      "r175",
      "r181",
      "r182",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r435"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "Valuation Allowance Of Deferred Tax Assets [Member]",
        "terseLabel": "Valuation Allowances for Deferred Tax Assets [Member]"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r130",
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "Valuation Allowances And Reserves Balance",
        "periodEndLabel": "Balance at End of Year",
        "periodStartLabel": "Balance at Beginning of Year"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "Valuation Allowances And Reserves Charged To Cost And Expense",
        "terseLabel": "Charged (Credited) to Statement of Operation"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r134"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "Valuation Allowances And Reserves Charged To Other Accounts",
        "terseLabel": "Charged to Other Accounts - Liabilities and Equity"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "Valuation Allowances And Reserves Deductions",
        "negatedLabel": "Deductions, Net"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "Valuation Allowances And Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "Valuation Allowances And Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstellasAgreementsAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAstrazenecaAgreementsAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesDrugProductRevenueSummaryOfDrugProductRevenueDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesProductRevenueNetAdditionalInformation1Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesSummaryOfProductRevenueNetDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccountsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating present value of future cash flows.",
        "label": "Valuation Technique Discounted Cash Flow [Member]",
        "terseLabel": "Discounted Cash Flow [Member]"
       }
      }
     },
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstellasAgreementsAdditionalInformation2Detail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAndRevenuesAccountingForAstrazenecaAgreementsAdditionalInformation3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity Not Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary [Member]"
       }
      }
     },
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
        "label": "Variable Interest Entity Ownership Percentage",
        "terseLabel": "Percentage of outstanding shares owned"
       }
      }
     },
     "localname": "VariableInterestEntityOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureAcquisitionAndVariableInterestEntityAdditionalInformationDetail",
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureProductDevelopmentObligationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureEquityAndStockBasedCompensationStockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfWeightedImpactsOfOutstandingAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted average number of common shares used to calculate net loss per share - basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.fibrogen.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(ColumnA))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647444&loc=SL120269210-210444"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647444&loc=SL120254536-210444"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121648281&loc=SL120267834-210445"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL120267845-210446"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919260-210447"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919272-210447"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL120267966-210447"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL120267969-210447"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121614247&loc=SL120267897-210452"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121565518&loc=SL120267917-210453"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121565518&loc=SL120269220-210453"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267853-210455"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267859-210455"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267862-210455"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25383-109308"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21564-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759068-111685"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=120240428&loc=SL75039408-165497"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)(1)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6490092&loc=d3e47080-110998"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r674": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r675": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r676": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r677": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r678": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r679": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r680": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r681": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r682": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r683": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r684": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r685": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09"
  },
  "r686": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(7)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657190&loc=SL116659633-172590"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>140
<FILENAME>0001564590-21-009871-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-009871-xbrl.zip
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M383^>AYW73ZPKH7'/%LPUVK&/=T#T=@'5M5UK0;>%E@-'G#YQ)T#\]1N"",
MH^ %YR\MZ8I?/Z2DAM\<^++SL5(J'7X$"8;P OXA=;TSO"%]\?%'_6-\:;O#
MO9$GMT5+^O"E&@KH1ZE<.2S'5T?!?CCH\R"YH\V"EGIT_(NZ!89F?^2F#F/]
MJ??@#U-N"<*^'&U^P.V#CO_T$7^!&\JG8S?(<%;+DI^FO4>&4V^8=JFP9[1(
MV%,N]YBP@^DWJ)^P#R>CM_ 7NSO]#OQEVCNBWG10.*'\B%W^"%=P*>SD!D#D
MZ_?XWO[8?0X7^T'H3&^<^7%*^_ 7T/?YMYH+IM\^\[8IE]N1E,!0@^GWQ+].
MN]&/O%#.ND__..6V%V"V'R.R?#Y4DBR?G9U]5+\F&A#*F=I[]A%^C2^<>.2H
MGN//+18D>BX"_ZA2/IG'#/J*I,V!F-9BN+3\\;]O;YIVE_?8_CB=B)=9;R@C
M]R##(\$/+P^G7S^\]&,HF1>T?=E3](Y/^K1?JNQ7CE,/V8<Q&'E0/":O/>=T
M.$JSQP?I]8/B6<X<_+?'0Z8,TS[_5R2>?OUPZ7LAHO,1M.*#9>M/OWX(^4OX
M4=UM?<3[0A&Z'/Y )MTOEWY\CTGS "Z"WS_&%_SR,7X5&HR[KV S/#"P(9?6
M$YJDRL&GV'2U?&?PY1='/%E!.'#YKQ\<$?1=-D -YMCJ_^L7\7*.C^,2/^F/
MPG&XISZJSW#MG=9C2X "7G\OX?] ,A[KX2.Y.*^"/7;0)E^[K&/Z^!(V>!MZ
MKRX_JY0K9V>J2Z5RJ9ST[<.7-G,#_LO'D?>\]NZC]+MC=^ :/ ;F/L"UOG,-
MWP7+M>/ZKR4;<9)N1,V#T1E<0C,D<^N>PU]^YX/E&C#\=<F&G*8;<JGXR0CC
M+\YDS7/0Z5FN+?O[Y0J ?ZF&'!^6XH88@WS^(/T^ '/PX#(OK'I.#12BCV/U
M+>#MR+T1[7GM OO98%Z'5U]$@!]NA2=Z4>^6]UI<?C?OF/F*BP'JF[K77'KI
M]_H1:$ERB7G2E/X_'"Z'AN/#2D;[CFQRPUJ^9*$O!VOI^E%&NVXNO65V%VA>
M#M*7K;+_Q]GN_W4D/1%"( 6778,YA+^"-W?_6C);!5(1/%.U_=MWXQM\:UY]
M&(KE]/!L7"P-_L2]B%]+OX<F$9_TIPB[EU$0^O"FVHOM1A@65H. P_^=1_8R
M1TSFJ7\P-U(V&R(@_QF]C0#Z:6*@8$0-&KP%1(@_8W")_MA0#N4S(X?RF8Y3
M'&Z+'IBF7S_L'P,WQS*)^_]&H1R5-R*4"^:B))I=SL,;W];RB<7P5?I!4+6U
M !K<YN*)M5P^BJ^<B?5P^V*-7W,C6$NX(A2)EF5(I!/L=3:)R!L4"-=3#?R&
M0YA0@W:!SVKS^_9]'Y_YZ-=>X OG=9$UN L]<1X8<-4C^MBZ4<'%(/U+TO%F
MUP?O!5XF/,-P(,:;F\ND]Z5CT_O2L>:K4$;+>8]G1Y^RU.,++OX&'-;@L7Y/
MV(_<[GJ^ZW<$N&]7 &+75[1>E9P-(7 80^!P01]Z454J'WTZ^C[ARGSS)+?]
MCB?^K13E@GN\+<*@#H( 6Q+>>W7/!JV"GS@2"XS(/#D-YX*&R*W?7:^*#: +
M$P.\Z@Z43]?;@0F/*G<CL'X0K74,(+J;<%\@?.B)$)41B1GI'O06. (8:B%9
MOP3BW!,N!/[0MP]?5M3.TXF@ZZWMC.W),NV<9->3B?;< XTS;(-BUM@\#DR@
MV@R!$[&Q]^UD=OO!#P2^2E%N(, YN0$Z7D3(7Y!2SPU\H/?W89=+\Z8)P[R<
MV3B9,)0;Z9@9E75V;")^F=&Q.]^SUS)HR7NQ4\.WO+=?)]OJ5SQFZ^A7&5XT
MWJ^TY_(GQU4@P,@3]+7#&[S'('XT77[DLE=>:$@>*G^52[>5HZLEVS:A)"ML
M6RQ6"%%/;H^7;=F$01I%PZKD5O[K[+9\NFSC)N*7E38N$1P,ZK*"JTQ.[S2[
M3')</G!P1@V40D<U4N*LA9Z#&%[RP ;*?WUFTM&N=' ?A;@N@.'7K([%P53$
M7.Q>9;G9RX?CY0%2.9SP&M_;SS_ K5%D77OI<QO^?/3QJ^6[_QKT)KM_?+MD
MYR=LP'L[7WOATA8!SBRLJ9>?W@#FD]4-\C43$D-Z7@V"J!=WV@ST*]TQ+U?/
M&9^NJ_7ZKC_@O!GZ]@\MS#FS=9_^.KTM5Y:5PNI&>QM2&)\!02D<+DVZE4G_
M(%]2.(VE<)I(X6AIBUTYF_ FMB*%A2:]I\I(R2;=4IP2GZ,QRU+CV81+4R@!
M32K3T@*:\*R*): )/9LOH&FAN\J[ZD>2?TC+;3H+7[PNMXMEY/:'[\)C,,YI
M0'!CI/)&/EI.UR:F9@Z.3CXM/>TQ77;3N3N_LILSJQ_+[K2\(MF=%DUV8QHZ
M#7>'*Y'=X604N5+9-43PXUIR'D^*;E]CX8(526XBQ,VUY%[75^CSBB0W/0#/
MK>1>U=92Z72I26=HT'1P;=T%82]K<F(K2^6H0.-6-XF310%-.K%+"R@;$P-K
M$]"$$SM?0(L[$Q/+9)MP)K14MF023TY691*GA][YE=WK1O&XLBK938_*<RR[
M5\WBR:=5.133N6ZM#L56-;94.5N1Y-8;LF]:<@LXL2N3W'H#]HU+[G4G]A7)
M3:Q7ER?STK!-]^U+/PB_^KYS+YM</@F;+[7"/N8YIE*4G<@.W["N7CZ:4(+W
MMW/"@5M%.R<@MX)VCOM1"[=3?9?:68/-EKS-<3,9#TQ7<%_6>: V3\';+;7W
MZQPWT_WZ(1"]OHL[J=1W78F-4SN%DEU"+X$3_\RD+7W<[K/P#K E-J$MNK?L
MRR\?1_LSE,-8Q[4L C^20U$H%CDW0Z%&]35HJ_OB&[G:CV.^B[\4#G[=%EQ:
MJE%\ZJZPR_KOHYMQQF^.W_1QRJO,F_IJ%]+8ZX.0R1#WXGR)-P'BY,KX;Z/W
M<+U[1]]A]N2,_C+:F/2+X^^,$$<$BWRMI&KX.D"J#<:$V.,,-V!_,4U4E\0/
MC7\;>1,^=>'Q*V/Z:@Z&3>]B#+_H[>+EU!#$O[Q["%*I?=-'P%QP#E>L;@#T
MEJU<#0!HS?'^86DU S!7-CGAE!'9C/##VF03F^@<R:9\MDK93%7<.33JB"?H
MS%CC\"'*/\!]>?%ORZK]J.)//"[UJBN.VPN\>2][E>5'WS;YQ/C7='^7)Z9
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MSVFT><DEPM=F(0_NVU>\[P?Q&!56B>;T.;^:1'%G%M5[VW$GJ3>I-T6@A8U
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M!=H=8-H=!6T!F/;K[C+MU*X7'[0%8-I9H-T!IMU1T!: :7_;7::=VO7B@[8
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MP*?UI?^$[]1AL<N>(4*>1D!3'&4]%&-#61D?R16,V_N&:=0E?M?(#95L1MQ
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M0=>/W(E'X'!-].BE/^5^ )<C)K^VIS[5#[D"OCN(?_&E4GX/X*6VY  DX'/
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M^,5J2[]G1D:H7O>C%O@T<!TX!0JS4XV)*_X5"4<=F R/"K"]\):.])_#KAH
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MEOB6^':]?(MSMHL\.Y7&A\[L]575NL3U5F#!0.VC,-L8,$WJ2D:=P*HZ3R)
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MW!!X@+E;NGX3C F1*)$HD2B1Z)KW0)G39%0=9"\^6GEDK4UE<=GF""=U5D@
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M4U7WJ^.K>[W(,W2UE]2-Q1L-[:DVQ\3G<%L$*'A3)T))>2C=?&MW'7$P2.G
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M2D?]E\\FD:!R6H(/&*/D&<^/:K%V*H343&I,>QC:CTSC&#"IE4@US1+GUF@
MF><(/&D/\VKTBD=K$%/$U!2<%"IQK?;A7C,<&,O$_  U*:/ GG!RTYP,@#S^
M_[/WKEV-&]G>^%?12J;G@75LQQ>NZ>><M0C0"1F:9J"3/)EWLE6VE98E'\F"
M=E[\/_M_WZI4DFV@;R#;E1<S--A2U=Y5^[Y_&P-)HRCI(S3V/,:A>APK0*L;
M4V9)/AK#=0E4\2!]R$4W6:9?"7VG,*\6\@=A/(Q\L-NX .C:V-\\Y<"6#/-I
MR.$$:?DF[H0</2M6- C3@2Y0LM0KWEBM/V?>%/QD5#5X_RP? YT!4('*Y_#'
M=#S/J#X-!0$!Y$J!4V3/["*^CG,X:%@1XD]U9HR+[ 9VQSH#CM,*QB'2$N0_
M>"3@-PS!W^'A7EP9%22Q\!L#29.I'Z)M$^4XHE9T7\,\K@C'*)PIN^G!CX,U
M"GYLK*SO/D'6[_6.;%E_I&7]0ICEA7;W:*"D]E?AISG/3O S\+HK>L>NU(3[
M@4+5.!6W)T75D4\H&1$/A]%FT5+E0S(RR6=D,J5L&E'UUX.J1100]JL;"1XD
M&=>LW6,%J-]/L&AXK(H"T@7)R\J,"PJR/ C(,)Y0D!LE)+[4+)XD,NS19$,J
ME+$#YUJ:HL^#<W*R),IQJ"P^,%""?3FGNNH^&.**%PI;)0&.^Z!@!E)42K\G
M.%J"48=UV94%+I?Y0VQ/9#N>K<HBP>G/> R&KBK$M>IP"45'R'G3A2GL($7^
MX /[(K8-\K"R)\5+2Y;QDY$O_@HJ+;%YP>G 1E+R5E=J[-7KG'$V6AX.7P5W
M<UK1[K2$6,%Z)X@@>O&[,+(H4[. "$I%PWP]\HS4*E Q7GBV93D$2<N[2N24
M^]:+\,'\T-+S)@QGFLT(-U!75N,WP/R"XT\&6]%S6LEH%@X<=72A)R"5C[H<
M@PK-%#@D:YU$H]*><#A4*87Q</]/#PVRFXS6I66M+ABSR7U<K2DG']D?C.DF
M^II5'.I=*#;'F@@RY$RHD<8+<G#1I[O(&393A%MDO(J<=4-,=99T @>)E;4#
MQ6"0Q770^V,BH5N/$[:SQ2OX(.?KG27YR8K'#KV3HJA RJW_Q>769UQNO<;A
MQM/E]>/HTG%,6;*R^@\+>5R,4"!":)2P:)0'F> 527^2P!C5R/G B%[2G]48
M\RDZ,[ 5G\9TH+K2K^71;3PF3NIS\.CJ)]!>00;'C'.:IW>PYA;'T.G89UZG
M^PK_UMDSA>'H!1*6%I;>39.I>*7\M5 D)$9C_$BJ%XH\^0".!J@Q=&QS#M2B
ME-2SBU-_&@84V_% PB/S1Q+$+]PCGEQ<!C!87SFI;PA'FB9%)9X42DNO$DVU
M\C+%F$ 3*8@NT'C,9 &CZ,AN0(P@@>B>590D1XHQMBJ.+P6EM(O?X%,\4R$]
MN_I5J3!(B9$2B42\(?DCQ0+0%-0RNZ4E05\-J'RG"%)$<UT8 ;RMWH% 806"
MXK6&BQ#CCVK3!J[2KF^U:9P5NE:&@.%M 5+AFM!$RTK&V1"^-,K!'1\D(XSZ
MXN4N2BI,FUL&ZB.E$H92P.]_X09+00C6>:R[<M>X&J7FD=ZQ!\N),(_T9:U"
M'>D2^K*G\$/*58REO"S<*Y5QD#WP#O3:D47WXV0BD20ZN%^XDNY7W,]ZA_?_
MP&P+6?;WU+J%0YS9#0/.=(Z/CLEO 7V:^F@TL4-(%TGI3(S4K2XQS2LEJ]K>
MHN+B @/2KF4""310Y8?PR]B0XP<5%J?5_S1<H4:YYE'\*PK[BV0"2U -K/E:
M)4&DE=M88315ZW5RC:,(%2$F&]AFSJP$V01S1%,4-?#19$*F1;DZ,+/<N2P?
MC13U@XF?R5CF[*!*IW"H!$K.+\KKV964K,PH#P-5"&532@RV*VH1KJX@!$^R
M5,@6,)/#[HH^(5B0.<FKL'.^&7).EX!S$#8'(4]*82GY4X&@(1]:AJPCKY&+
M=IM$8>!UIC//@@)Y>GC1AAA:N+/&+">!40DIKC%4:?MQ2**G@4^^4)"P+L'*
MKZ)NE\.!/<;"@M]KP3+OI_!#/[GS?O*P,BAJ>1+U_)F=FE2-=%=7X,6Z:[>?
MIQA3!+FUHFVX<WS<;G;;G4.OB78Z :O[7-JK.QRE:E;>\Y-YHKC"WBW55.,S
M=*L=A3,OL?@51'#O>-_;P6:>W1^]P_9QL]?#L&._Y75ZWAO\?VH+=N+ B8,O
M%@?=K1('7$T#QN=^BT,<)7\![!G&7>%8WPXC#OC&:\<L0*P"MMU,@KQPJ>$J
M'[7W7GN=KC?Z(;@D1QT\8 [SFC_VS!_A3X]=X@U-W!ZN4>+VA0OEZ\Y*S$/-
M* ' RJ\9J*FBA5GAP@;7UIJ;ELW0]>$V79/^N4=WT7+%J&R8*COP$5)+82*;
M Q_;698@8W2.R(>!FTM>)]5T[^^WJ:A[99-C.50 #DXZPDEX?R6IQ'$H2, !
MUJ*I2GJMUMM+?U_0JASAZ70/B6C@X8;$SP5(!"0;$KP4H3U3&)5C?QA3HT!^
M[18ONO$+,3L*@(M;6LV6K<"9:' ZK[/7.GA5RE'*ZGAOE,_1L40Z;],T1#LM
MT76=I<!YG,SPDW!0.;'M@[3VXP6YC^\[;HE(ER[[6<@EY=;AXN>O.Z[1>TIW
M6XFQ<)2G*GO"OC%##]R>$5S8.+GG:E_-$JN*'R\V#2.?<6:@!,M1('&8H,A]
M*1F?"@9 OWJ4NR;>!T8M9FO( "X]W%K$L@ B_"VFO$S#ZVLK@DYX<2"P@FSN
M#4!B8.RIW,C96PC5I(I@7739A*$4BC-#81*)_D)L:N$4POHCE4G^N].FXUBJ
M$-! &Q(,HH*W% -@?IA)C WOA(ZB82K**D;P1L0IJC]304A+PP>:=0JA2@3-
MU&Q&D';4DFKP3/6,^%@*'/3*4!D@-E"8P<>(4'1&FBO:U9<># I35W"Q\533
M5\MX(EP<3.V44@HAH3$IFX1#9BHYBFJ54G\!8J#E_4$.(D)AIB:,_Y*@GU7\
M2#$Q3(YC!21V$,TP9U"Z)FS/95QP. 6?DW#PIIA!) @<-D-7;[A8GERH3ZPS
M7C?C\6C]C,<U2.;7I.6QJ-71@A,%LV043[4,O>9&KH?K]IZ!S^*E?6X\A9?U
M(V%0?Z782G\!X?H-_?=:7E_$G/4O;HC+[=;AOO7+]T@I_A6_OM=N'>R]>NV5
MP^ 9A<'Y@Y(8\5%Y?VI0H!H/7PB(OZ2\J03?GY_VG5;WZ*5)_Q+"X$'"\XZ^
M/>WW6_N?3?S/ ,UV[/AF5\'B1HHOVSQF *E1(?[W=YV][YZ/,_I7/Q5TU!U>
MK<XCW"JRIYM[;ZY,9ZCN:7KA.[0L\;+1:N,',9F>UW!:>2^>8$LMOQ?KS!5.
M>=YB/T&2-CR^%,ZHJL'M>$X)M/)./,'.V@9=<8HS(5)$;'!V5BT8\K"=U:V#
MF=5IMXZZ!;.0J$OOS;;?+0SC.\MK<W7+,LGU69=AJQUZ)]O6D96,.N>DFY-N
M&W_4G=3:&%92>^>+"ZVGF@).N#GAYH2;$VY/9"6A_CKA5@=6?*V,P.F;-^TW
MI]\^(_!$T;?.++EZ=]4\NSBY_//VXO:SL@#?C!>LA3:'TE^FV;\=F<L!?Z?M
M:\2:)3=@\X/Z-:#[$Z[#ENGI6O#E^&D&[Z.L<<+K>2Z1NR-.9VP-W9W.J"5?
MG,Y8(V8YG>%TQC;1W>F,6O+%Z8PU8I;3&4YG;!/=G<ZH)5^<SE@C9FV?SJAG
MY]4F=:>_P;GK/ZO8:WIO?CZ];.[M'W>;[8.VMW-R=79^N_LB+58ODERM(3K
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M_589YY/Z2L7>*$WNJ<WLCI)2V%H&]D6@!F"L5FO%3 9?B76V8CUXHN#88^,
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M!?,V\#K3F?<])>W:^)S/!S>LPE:5LVX+,(^\V"H U"K*(E#7-Z(M7 A!\5K
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M&5%.HU:L=EC#A.$?X*<@'\SD*B)UB+'?J@SK&3RU4P-+)E;\&CM@)RA=_Z-
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M+ 9@^*88HX/PM&(*?*".,*S$$LP1 DT(^SGIHUEBIJ,\L+4;/PAUMP(3%:4
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MK+_!HK7D+/%Q(1^LG#:Y U=L4CE':W]<3M_]?G'6!)T*BB-0F+"CA!<U?2_
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M%2+W88':(KD>(]-.K]?J8;>[[HQ=#-;S9B6T_]A.#UN'KW9;')E=__AL!?0
ML371K)&FC:)$JQJR](%9HX?.(A,7<3=!DZ"(-[_8N3KG?MBCUOZ!"6Y.FUA-
MJ P,P5Z'H9YUW\@LN<>*XM4KLM71,BE%[UR<JX1+V^D"4WMZ47OM58LZ/#C
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M;0;+N^X5,[7G%E)-9YF-?ZR^E9@\%%8.=1\?M (/!I>N2YE/S@F+JEAS1')
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M#HFS4*/AJ6'CB52I>N=B5DPAL#-N7"!,%/00^!Q!E-('&^WP%N?6=CJVN#Y
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MW0FAM >+Y.7&%PRSG0VWK-RQ6EE,AT?P*Z;4<G"W8ZZ;]0W_>CHEDU7,%1?
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M/'$J$E)UWI!<CE+)N@"7/AP0<NBXCM9/DT]B5Y,1;ZN=M49(%&A#!W0!5=*
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M2O@7E3NGVJD>*'9^F&DL:VEOR8*RB>3>'C6%5P1AA@V+=3+V'#-T)'I"%@H
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MV,[9]A,>1K"5ZS7GY\2!T@>+4K/G6\WQS<M&YTJR>?!CX6",B);!.6H(:,*
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M8&*M, M4:Z.@ _G5,']BLAS<AD,T[!"T)CKX[  ,ZT+II91N1&E$;]<.Y8S
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MFE] G>%JTW OAYG=1$""^<YQ!9<@/?20)37QGM+>-6ZWGE;A4QZV]KF)E[]
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M&(>C8Z,2[5XX_P1G!$<;F*M*TV=S)6G$>P#HRY!JW%%*G2-6T#-@,XKA(O5
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MF<<MNC$NGZ_N^VCJ%6SQ#W >)41_!LY^QYD+N)G>"X$RN*(K$I6%"],.H""
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MZQK2*&(6?,MS;V+T0_Z@GKG 901G -C ,S>H6=WF\^#YF#3D@&<%?#;>U11
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MU:ILJI)K*O_V+X^>?J._HB'CO?ZR^:2O%#W #]OJ(DN^SSY\J)(?\CHO?31
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M%XX(%/++&AI#=OHJ_8QVC!@16S)^5:D=^GV-G,WFS)WV-1+IA/_& J;AG,Z
M<TJ,'U3XG/@J7",_3%YU-=H M)'IOM&0%^4+\YGBDY1R,)0N4RH-7_>Y<GL:
M3E4XPHCHRU<K&9X6"I:B'-^O+.PM68I5N]4FZB0V-^!P5!#5%!4S=;;YK%IL
M><<IPU8E' YEH\F$ @E./'5'*VRWN,J:-5(AK2LX4;O"!>ILLPAHA,,:.4S>
M"H'BH*YW[L:XTV!&\*TJWL B[&03(;CG<"5H9]D/X,? >M%4,H,?O!7[X<6#
MAX]3\,[7%/>"OWXZ)SZ21CZ2G'S[^N#+!X\?L.4@,_S%"4)7%GE5]ZYV\N[-
MP='CHUL.[5KV#Z7K'&I:-"9*&MSEX+@CW3G54O W]7@/NYEBR@)T,$!").R$
M1<T^U3A2(6KA-D$_EFD8QM![%J7 TL7RZNV/K]Z]_NGM?TN!;0:K@BYM 6CH
M7\.44)I@64$TEV3S?)$FCP^618=F>YXCG^1'L!@;ZC=@O Z<I+#(YYGPP7&'
M!T$SJ"/!%(7LC<E@G[GU'%YQEJM1S68'FPR,5YM]= *S,T!8V77OLF7F"BF9
M^#4*_AWU1^2S+YZ?O#YX<O2(.2(PK;+.YA_\!Q'&#.XE#O=A\AT]0:9/@"1&
MO8<@3]D$-0/(@:).,-%]0%#EJ/*Z=FU&M*GSL6FZS1OJN2OPG+-8^D C,JNS
MCQ!^?5I/*IJ9^U20]=MVO"-44*F\%N ?7_(BQ6\&#!O6K7L@-; .F@&&G_'X
MQKV/].G9PMWN:;NF-__BS8N]WORXM6*>I$ OQ0 3,\24,_ Y2-W:?70@',!_
M+SW5I*#%WY;)J=NT7)0XHD:'HR>& EWO<@J[<]/&K=+QN:;QLWS2(U=>?JS*
MQ;9)'A_]R?7[_HVN77"K-P6L-E="%!"N'QU#?LRCDX2KT,FZ:WVUA=C/MA#L
M5AN$^M(NS,#@*"&L@^OCQ9L/^69#;&#P?LS8[6WR1VK3@ID^>D21?PQ)@%FG
M++1FJW4L Q8:-L49@U41W:> .D3S\*3*C30IR-!]/P@!0OWR#<%OPXQRF4EO
MB*@$^%<E4/=E!XX8<M#8,50$)[S%OSYZ^L "-1F1;N:7YOWGK7SWT2>;W[.J
MJ!8\O_M0QB]@_/0MGUD(HD)!T $%J[3&!@U,A,!9X6=> 3'#J7YDIIJC(,1H
M=%JLBB?\Z>>ZAF"63<?&<)R.USQ.7SZ&7WWY].$WR;UYUH"YNO0]HT:_3_:>
M7S[^).]YFZWWR?OGD4%3=UY#BO=XE2*KRS]+BY7XM6WV/"+7M-G6>G;18?NE
MSLT%[5T(88?=3D]T&:AV 4T?A;NA:1R!.',WJVRC^-'3 UB42+M(/18*OX*C
M"Z%V7&H3W)_%*^*OOX?C"\Z3QI-TD0P&RKBM-&T15C!.A(),-Q42^R>>GI+Z
MOQ@TCWD8TIO"O[Z=MY6\WU=13SPRL[5-^ JLYUWS"*/JD+;=-X/1XV"E6G>"
MRD4(M[0WL'(3]5/Q!0Z3X]'^:&D4LK%$59Y5U$['!%W_@&7D>72M*H@C'YGV
MI]H'.1FPNXZ_PL:E;YL^V1D=$_SEK6\F5,D-2ALA"RT_;'0X0P2 -.#*'!R,
M&'+[4!.W0P+)GO]$C;L+>^)'(X!;H^I:P\=/']PRO"'<X8[#P[Z:X&%W&AYV
MTLM[[$F(2C&&@HI+R;D,P%93I>2,#C*E8YT=*:;DU:E)QQ.E8'N(D%_H%YFQ
M00'2?4S&Z!-J4H$B3YLBPI=E<%R:G*"6<ILFWV58R1/Z(#&#-XX;B!_:0WN'
M;:ETWM^TAWYU\.#)LT?/GCU\DM+A>7S\\[,$R\,'_?!*<V3H2*"Q[OFX#PYE
MND+.],>?#K[Z\NF#9]QIP7/H_XI](F'BD^^^?7#T"")9R2=I3_9(_O=.$#40
M^XLPBA-@CZG]O=Q ,]H0<V[XL$F11P)0M 3K3<:"2@-6\' ASK_ZNYHSN2=>
M1"3<8W?U)'TBI!6:LDC4(D8MQL4T6\ :;SSK&ZB1WC-5^((_S9$QFJJIK&$V
MK/J(5)1!II,Y(]5@+<,2GZAY-)5$R,I@<:URT<Q).>MBD >]U5'5FZIVS/Q.
M#.R>NY[70*6] +'VD;:8@%L/GYZ[(,BVJ Z3']%W[3/N1VU+AB@\Y>O# TL]
MBO3CJ& 3'U1.V-U9;H8A%4,UFM2>>Z'*&_K7Z/?C8@#I.)>^QR0:8&\/VA/+
M745:;82BX04>$\SW4OM,..X+4O L:^S5HL78I'Y+96=GR*3)>Q]A+"H?P.U3
MMC3-8$H[TB:9OXLMF?:X-*AQ]%'LG4V3Z-1%8290&400=NE&/0I-7D<CVN,8
M;=R<YRUJ^TR3,URW)5F,@+CAYAPAXECE&\FZ?'!;GZWC3D71,3>\*;+$>!7$
MYH<_&Y:>56[8M103D4>$*\PZ%F2+GHMFCQ'E,OA>63U.)'*6*?!9<X'+]*^A
M][AGES;P'BZENAL1M<0W0)GXF8@>FVWL$9GAZO%A,)+<QI.,C_&";SQ:SO4-
M^'%ONX<F-5K*YQC89\II'E74(>"YPC#0S,L[HBW/VXY5&Y+7+!R&\*3=PAQ:
MM]1L@VXY1]+0O.."<$X>ULKPP*YPR^*M9B@&BJ<N?@Z!V.6</R?)I*!ZQ>AL
MH:K+%A(_BR[U?D6Q&ZYF\U/EU8V(HL&V;I/_T'0U4:Z1 @DB9.00&BQ]CE#*
M;<K)K[Q>'.#L;6$.MWA2L0X5Q1Y&_*1A>$/6DH7 (X9@-9)QH-4X0C%^JZ5Q
MI%,EFR,Q2*:6F/KSU>L<#*Z(.)/*3<^0D.GJ35M_LOQE8&J,8::.W,%$J6V!
ME:\+'+\7[2J1WS%S0Q#,M=>L)$5VY.=JF!* N00V-N_I85%['JG')8!I14?\
MU/)^;%;L9R3S&E\R&[XGO:(,:+<A8&3HYV;:Z($>&WW15/816*G  3*['2=Q
M YHK;[Z6E;K(SW6M<BH,B?QA-<"?2'H^F9$'_)^?/?B,>%$@F$+PIO]Y@W&
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MX1C4.7<C>%L?AU+RV!0K\XG!.-ZE/4_YM-!U<,71T4;>=IB3W/<ZDMFU?\?
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M(C5Z-.3=FU1N)$43.)STH!H(0-3P<[XA=*62B:EDAG23<5-:JQ*L6.X=:[]
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M6N<82Y*V!$<^C3;G8W0!DY3A&K*!A)?7H 3P/1-^X\]P2[1@]S4:V%UEC]<
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M$8B5&SW[]Z0C;O-6_#:OC/-'!^/HAO#S(M8_6<$C%,(,Y3X:NO0FE/6H2AS
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MXR+97R!/K=5+)CC&^RYT:*0.!)?=6T0GE4#;*>E=0IDG 0:MO(* /,;(J0&
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MYY%*D^&7UR( #@^A"NV:XTL.R9S9'.ZP+U5<387CPCKCEO/7\\4N/IHWR&'
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M.Z%;N;T&JWH;-<\IL9_DV)S$"IK/&NY,9@XNOEBZQ=(MEFZQ=*=:.D8W&RW
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MRXFMU71(X^H2$"[9-T9=N4;@EKBXA(*A:C;U2 $#G^D3UAO^93D.$JMQ5YO
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M1<NFW<"A(TFMF?T2X2)Q-_)ZC#@;B*AUCJL.*50GVZ5C)""C0_;)1$T^*:N
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M/7T"CO!OWE[R [W\2X:D15F)Y6QP4_8['CLC&HNI9P&LP8TN,NX=T0Z-V^O
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MX>%.,F[H%U,FMANX@V1/]*/7;-:8+8U)1$(G8$#A4)7QB@^ <3B"#RYD[#B
MX_\>-/-CY=U8#RT?#KOU'>4V O*XB'FJJ6^!$A5'!O6I7\R/Y#%*?<+G10D'
M5K'6>B\,/8X@)M(?D3>J3"^/8IO==*A\OR=+\M!EZ"P[]E#P7TH=V@N4K@Z3
M";,^7N8"780JMCMA A>L(B43GWQ*J^8+C+=^@#7=\ZYY40E5_7/P@ :PQ"4&
M(B.UI4NR4-8*.<D(#<&6-G%+<-T,/9'D=M@MY'OGCDZK#A_N!UWFN"QUFV9D
M0SJC3)&-=.?+?>&W!+T8OP]<XA*)<&O3Q<L^0RDFI(I'VJ8=2?W@KR<# 4/
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M#W762B"O[CU")ED3]!C:LEJCDF/3M".5(ZN&(G2:.8BP<-O\Z54B5^W\'1&
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M^X0J\P6&B7_$P"JET-0WJGHG-\XF5+56,"WX"$O@$F]GGZS"<(O&_0]PS&'
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MZF5.<=--YY.R^SS@&,TU;K+(F6OW(GB]*RJ"^T\O($X1*C>YY#,E)YL0R@,
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MG:8E^"BP)!9%KK!'*^)LF#'@[.'>=2T.=[QZ9A62=B1NLN.7\J>A(",XC88
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M\R+EK!4&1Z%1YN%5KHAL=UHULC\::>272P[&P>I2I5T'5S$>A*Z2-HG$%VT
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M\%V$LCX>A4J:9\$0(.JN@]5:%@;W*@;VG  V9GD(CT9GBXQR9%[-,A<?"X?
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MP9W>6*BIK7@ P,%04( C40?GQ3,<RT;'>1>'$LH3M.B$R6*H-DTFCY.O4BZ
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M*3,FNPUH6S-33RA6M@/XY_;!?-MJ=3N(Z!P?N;WME6OM,0L\S'EB&<\RWG+
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M)2_S(*&H;['U69P&5)4#FZ-*&U4'(;G4BY!2I.Z<Q3$F*ZD\#+T@ 3::,_*
M8N)K+Y5>G_1[=$3]]].S\V+&,"(:O_C_'-_+//EXC+/,C4T!OR3,98KX,2:V
M@ZD9>4.RADL7!H@L$9@O5Y'K%6=M*-JJ@R3*R6+^%!DFRV?6RZ%])SH3##*
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M#.:TC7I#JMF:H>Z)\Q167%2$&]D**D@5LTP/+JGNSNSJD!/A,,\0^ &J!&G
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M%$?'+2D+:SF_F*>7F*O0KL%"?59I'ZKPMVQ^52W/AC4AC2E<6?U)%8OYX=(
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MUA@(P8:"M=A;<Z0'6Q(UYZ-TCAX2(WT< <F6A!U%,JRN=D3@L;K:9>RQNGI
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M(6 30EL# ;T?KA[2\N@[STE!<P;C8.0IORL!4:$?7VZ*#(A\FH.O@(;"7+R
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M*J[% ;X<?B2H]5OMXF(O3>-10-?3RO".]V].'6\V2V(0J?!RYQ_>S(,K1Y,
MWN@[?IZ 1*0KQ[!5N.D_N9=DN/$Q+?A)P53%T#JPZG1:A^L#J]>^ UJ)N,KA
M&7%RBY>)-(,;4WP1_C@+O0B?\_OIJ9/FPVF0IO@< .IYGL0SX9*D6877_OI+
M[1H7KXW7EO-Y4DJW]0CR!E "G),%L.A;6.<X%9DSO(6](/SE@^#YH_C +"T<
MXM*BJ]3<B/'G!"0.O&0J_& $Z_/&8R](4B"[++@.L@!@*LD&5R>!YYQJ>FFQ
M@$1F2;S_$Y$8>::,[/9:O:JR&GQ7&>DZLR0 < ,@05((O*]<SYI4D1%%EM<
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MT0B F#F3.)T%F1<Z89!F  ;'N_$2GUNC=D[M<LU!XP"_EQ%+M]?MVX>*QO/
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MPTHEH&]F2,M,1Z^[<^%NJRSM4Y9O*0-TV-1_F,R5ARG&5)NYXH7IV!>LWWE
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M@U<;1U\&4Y$O6DY(94KNJD:E38U,TD [4$[%XTOC.!]:,1@]_GSID#<:QE,
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M*E8AGRR4 U OT7B#.?92,L0 6P")@$^(B]"0J0^9O8;X%Q7WX1.21M#4"8_
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M8C+WF\Q^#,WOQB<IW"&LS)I2 0:44>,;X9(($!,F'NDG,M# TDA4B2V<S[$
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M+8B42N>1=@@0-$V-8<!O<(^ 53ENPRQA50!83KX'32,WTD78"K"<UBP*UB[
ME5C'S?#U/#ZG#9L.I1IP<G+#X!L3%'.)YJL*7@KI0B$V.2\<#KW4<LQ_3P"?
MOV#8(M9K-#,T-,IQC%,S,;5W9AWC(I6SNM-ZQQ4_E3O0^T:T\*F99^ZR>#
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MDKUB?M+\**\ZB61D9S:.!2WABF-2V"RL-S"GGTAN$?IIG>R)S/C46.[+]]=
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M98H6<F=R/BD),8U!I)06U BS5N)D24S'LF>1-MB5ATKIB8[)V0U=(3Q5Q'9
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MA$ANE>6F+QP(=IA$/T2OECU4_31&SQ#GND)D0!@B,#%( (#21W@%/4%TCJ=
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M#7IL >@V$SX9!8!]&CS!]US0_%#*'.!\0D G@PDNA#7T:Q*1,." :"$ DA:
MIW^I$G0H#6),)'J-&':-8!A^AM$EFM61^8K(#,]>TEL:;V%P. YJ%D4M]VW7
MA) <]B !2>)D/ZI2*>_R!!3Z$R47BA7>$X6M4 I\/9@(@%2Z&LX!-C4P@P?D
MF@":-CWP+0P54)RB3BMBOH;D8%%"E<8"XR*'BJ4?A*L9<*U42@+@L4LOC)#6
MEZZ+M@F5Y.<4Z ]T/V"D!<?D,IVF@##];F^D0>-MOG-1FNM'=(IY#([ OT+X
M3^%Q7W[\5^YF2TVNVM<^1^3)9>]=?OR<OT9:#=V?],X<ML4.#+0YE8"ORJ3R
M_!R&WD)B.!;X1#?(FQ^NT5D/N'_R&<3X8SA)%FA6GGU,Q\ ;Z;+!6??DM/O\
M);L""H#,Z_?.7ZGR%% MK^>13TMTC4Q7H0(UN\Z6U@@Z[,H/4P]^F4<IO7:)
MNRE3O:[_A(;C&OV3CWK-#L_I-6@>/?P$JU9P!K5 95Z. J\IHHG_A4W*ZBA<
M&D6^P <8-*L''> C>R$S"N"ND\HI@(2:P>OD<Q4#-1;5+$RT;:I[WX1[GR.$
MEX>-D"PF$^WV&CP+<+</G+@PIMY,"!T0&W0BH/YQPZ5 *Y0!$(8+QPR#)HZC
MD//L90W<1A^3R@B +/_AT"5X  ;U&)K^J08I\!3,>@R<]F06>D[A<6)S9HU7
M;;*"W#EJ R^X2WMP:VA<M_/7^CVU"[NGUNH]-3 4_TD#@:HY-&8"D#]'_(^?
M,Q0?GO3 S]MV.[VP-;@O%*<:A4[8%7HF"?L%7&V8Y;-/&J[[0\#J7\$% ?\B
M"YA6GPP#5M]DPW8T2F8P(UIF#E=!52K"/_)I 6X:-I%\,W4=] !YP6W4$=MY
M&!=N,QJ32>JC3X[-Z'7/&/Q.DBL=DH#)NIJS?L[9H@]9XBQY\#I*'\[G,C&&
M+(2&D&I9,[14 -^?EXP1NJRPO@231U&DX@<$\@9N[-6Z"$BS>54G"D*93!#B
M0<.FPXT-QH#94CL>L9CX J/\&V1 +[0SUPCWLCT1\\QL<UPU<]Q"(H=&!X_,
M<D4O]%0:(8?I<UGX0%CTQW)_^0)'K6ID/@1TD, /D#$1?AYZPG?8EX 6UIHQ
M9BU7.Z'L!1T7A@[&'+.6PJ!XVLP;YHCR#30*"G]/_]9A;U"(I=GNR<)CM.<%
MGMV2%J]9G@^Y9!MHBS^MRDW9!YN#NP@:/$XJRO=,?'4%)@;., B#/6*R!+!R
M E2A5"/Q7/M8,7 &0R]"WB#]F[=O?HW98C?:"=4.Z"U6[N*DU]O>REV%GIQ(
M5PL;K"7B\$;D,)7;-J?>=)U4+5S#J+9BR) NF2';ECJWT'$_<\HV:K0**SX7
MI55-L4E,C5%,/U,[8Y 424K#)H5>1L.&=-*P\?0&#1M0XS"RY*[JH%BA]6R!
M>W@/M?J_;?'_#A;<,K@1)@T6VY[ XCO$75Q8R@%9LCPWBH-^[GP$ QZ3A[1D
M8^G[6GUA34\!EAJ35;+)98,*O8 A)5!8-?LF%R['\GN%*!K&Y [[5^:(Z.SA
M>9::G&VGK!ES(F@=3YQ\*Q5YHG= ]=-%ED;%)Z*0-SCESB-%9;YG7MDC1*JO
M/EQ_NKZZ_(5=7EV]^_S;I^O??F;OW_UR?77]YB.[_.TU>_/QT_6OEY_>?#S@
M(/4[2@4*N Y2YC%:3/1/%>W#4!)2P/TE:'TFI 7#<\DS"PC<(M:/16;YH)WG
MW/^NOE[(RWH.1X3;TUD,V'7#V 1"<;W%BQBRR2]!32FR5N%W0?B0[2(14%&<
M$AOEA>#C+DSM>8)\)9*2*SGG7T2Q;*'9_I%ZTU)HEQ,^F[P(U%)125S+W'Y?
M<@!*6E;H$&F14V;BI>:4!68&8]9:F">VE<X>E%K)MJUJM1"Q4NAC"8*>VC0%
MXB#\J[,+@%U2OSRF.K*5%S&QM4 8'#[ /!UUT.NS!)/F3 ;)C>8M_IWM,^N
MP@3 )(P-Z1;(<A]S]<R.8VEQJ=&?T%+&;CK'%"(7:6<24#*!T^)#*TW\A69
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MW]/<B<,BY\Q5?$V.N9UU"&9C;F=MH,)D[%UY/-VGEQ.I.9V[[\'6-COM\C(
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M\5L)#52MECDDU-L<>EY>&3CA'-$ZQ(N_<RU\X ]F3$775%=H,]=%V0K#B9@
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M><0)08P4/YQ+>KBXE=>Q%_,HC+@-Y B4E$LKFA9MUJMH: ZZY4U#@#EHN#D
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M_?L6Z)68(!,U,:!7R+ZN*" P7(!><[7CJIQ>:9=JP;XTVKZ 6R'[NJ( ;BW
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MVZ\)T=(N,(-E:;1E :M"]G5% :Q:@%4'-6'5.A2=P;XTVKZ 6R'[NJ( ;BW
MK<,*N;6\N]-V%P1)3!0QIJQZ#*1J'MPX(9MP+7R8,2^4XP+IU7#";4'EK*8H
MP&W)[[;TBG5M$YZ+M(9'*6/XA?$C?<AW_XH%W]TQNV2!ZT^^L+%_Y\E/^8<S
MG3/,Z("1J;&1 <%"]G5% 01;@&"+-74#P<+(Z&ED0+"0?5U10/E3 8(MUNVM
M>H+=1SE4US:MC@WJ)2;D1,T/J!>RKRL**(<J0+WMNE)OW<JC8'P:;7Q O)!]
M75% 4+D \79J2KRTRZ5@:1IM:<"RD'U=40#+%F#9;DU9M@[E4[ WC;8WX%K(
MOJXH@&L+<&V/$-?B[E4KHU'9V*^5VBGCQ@\F+$CV>.+/;Z;,L _Y"PVYLAF7
M=2\J'YCT!M_XT\EV2!6%Y9,S%2/W#"<RCME8NJI&VS)W, N+QGI7)F$).U-5
MF67:7]-<!HF68UM+8,2.AO[4G1CJ34:R0R\AE[Q&;RM/ DKE&NX'34W]RV<&
M=/7Z3QU,57Y_,8_"R/$$7#M-G,\[=FO0-3MM[D&VRO,@2V**S6D"!D<K$@<4
MH'$]H 2-5Q4F&F187/#L/3\RL"!4K'SFC:=S@=NE'XA/'451X-[,(X=O_K6_
M_FYDK]2_.AALT*4S61,,3]86@>')0 &&;SZ4JA(/#+]_AA^29OC7B_:*M]\S
M;;MG=KIMN -UD&RX X "[H F4 Y7KFCA#A2%]VUN?Z"?:5!'RQ_(54FX-A(@
M1?M@0R?!-NV!!0>A#K+^#KX! 12($@I\@\9 B<N RGR#3&\]4K[!"\6.VSL"
M?:MK#NP^7($ZB#9< 0HH$.4/N *-@1*N0$6W!OU,$T!2GL"K!9G%+PV&)G>#
MX 740:IQ8P HX IH B5<@:I<@4Q3PIV[ EN6B0[,3K\%"J^#-&(67_48G#UP
M48L,_]9P)OY,&@7_=@=UHE36NU(I.KHZ,@8=V_@[US<O66SZ&V7UY)N/;\_]
MB"OKN[__+%Y(L.@<_4&J*?5/>R3P'6G"E/4=X1=N[Q=F>F;NW"\,@^A(98>X
MW]G)[2T;1ZH7R<7M**8N&27:Y'6+;BAQU&B1C[KHDG+J!WR[1^,QE]%(K"'P
M/?[/L8Q./4U:B5]S)4I?G6 2?IU-G(AQ1[;7LE>_H>3"%W07JY.6$360\![@
M/0 F> ][]!XRO4#A/<![@/=01P,)[P'> V#:N/ 5WL/VWD.FNRF\A]*\A^U+
M<N%)4-<XHL82G@0\"<"T<<TL/(GM/8EL&TMX$J5Y$EL7\\*KJ)/V$36<\"K@
M50 FW&[LT:O8?UM-?;R*G&7 &R4-#\S>8 !_@IC>$369\"?@3P F^!-[]"?V
MW\13'W]BZV)B!":H*QQ16PE' HX$8((CL3]'8K#_[I_U=B005=# WE4VL!8U
MQ\;XWO'NF.%ZNE0<.PN[8\P"UQN[LRG39>US?OQ*5YD;HZNONJQ=,,E!:V^5
MYKLS33BT5-/)2&^.)H&".I/@R)'KR+'_IL)U/'(,&E'I!?O7:/L'[H?LZXH"
MN+\ ]^^_C3"X']Q?;RTC:O_ _9!]75%01=S@_ES<O_^^P?IP/^4:;=C"1MM"
M^ &0?5U14"78\ -R^0'H$[M#/V#[<<F+;*6>16?N$>P@:3L('P"RKRL*N <H
M,%EX@':ONW,"BLY%!O535K+*9AR#]6GMNEYB3Q0%L'Z!DS^ZM.Z.] E7+<,4
M-MH4P@V [.N* MR  FX 6JSF<P/ WDW0$XPVKAZ#<Q894S\,Z97<PX="HP--
M48 /5<"'RC24Y:9-W>]_YO;M!5=HZXJ"8<MJ6?(?Z(-6=[DC:A' AI!]75$
M&Q9@PTP[5+ A+$)3+ +8$+*O*PHHM,O/AL-,3\]=L.&K%6=@QN;((%'K &:$
M[.N* DK/"C!CIO7<3I@Q3PT66+(Y\DC44H E(?NZHH!H:H'BK&&F2]LN:/+Y
M*J67.7%1KK31R(5^SQSV6Z!*8D)9N)@)+-DH^ZR9V!-% 2Q9X"R9:6>V"Y)\
MK:H'Q\?FB"!1XP!BA.SKB@*(L<CQ,=/@:U-FQ-E/!UU_5TH-#$;M%=S^HV3
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M #\.JN''+0N)EB'O7@_42$P(B9H'4"-D7U<44"I4@!J'%5%CW2I_8#L:;3O
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M29RH:CJ.X9!]75$ RQ4YAMLET]QK0^.60W/*:S\%S:XXK@Q":Y8IU4OLJ:(
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MKG/C3J7JOJ=W?X00. T<]+)75%& \T(6&B@(!11PLH7LZXH"R($L-% 0"BB
M'"#[NJ( <B +C>X*@CS9?6,P&H_Y5D:A$; Q<[^+,+YI>"PRWOZ4]VJ@F[T:
M.//& 7-"=LS4_YYYR?=]67S=%S85PRDOG4#$';=*'UNVWK2RJ6&F46!%F3[G
M):^HC/YK'=ML][J9]<J([D^Y+WBZ5J9_:MEK+K/A>Z=M=@:]S.+?&;>!_V X
M7*SE<QDS_F"/A2=O(*^;!O/B$J[9*, U+7(C7XBD=M[^VK+,8;^\<1Q0_8JG
M3R$'K5FV5B^QIXH"&"]_<G:Q$\I6\Q1SG4G:7=.VAV ^8G)&U02 _B#[NJ(
M^BMPX+,RDQ^VY[\R^F-SVFNC/S8U^6IVPC7Y"Y8S[SM_)C_8HJL(4JIIT"#N
M?9N- IR1(LY(9CQ'UAE)V<"=AYV'IM7/7H;2$S:]5+YPU!DI@,VRL7J)/544
MP'1%F"XS\J$XTY4R=]$<E%C?#)4'T]5RPZG:6+W$GBH*8+H"]ZN9:0];$-WF
M@64,>* N24C8KQZ#RX#-''=BL!]B\BE3C3M\T4HG'KH8)1T]"F3P+V^6;N^8
MMT;MXV\_B;]\Y$UD%Q_5!C\:R2\N+Z%_LSQ#NV.V;6M=OG^!Y'=[OQM0:MZ)
M97=-VVIED^&%QC97(Y154O]510_Y86_O&?9-&UAEP41A V4II(>#[AX*#11P
M#"EP#,D,W7G6+A^S6\8M<6*?$_.L[/+^.M+S3S [0Z3 4!,]JE8!@3G(OJXH
M@!&+7$%E9KCL@!++N)NR[('9'6(^"S61J\=!L4$;3M7\ZB7V5%$ "18AP<QL
MEEV0X*81.@N5?N1D"B4/E6Z_U+'X%HK>E2T"TS1PT,LD444!'DB!P/0&?>ZD
M#;Q(AFSL.Q#=,P>=\EKOP 8TVP;@! [9UQ4%\%^1$_@&'>=R$V 98>>V:7?!
M>]0$#"41,+8:BCU5%$!Y^8]\]@8MY_(S7IF-L"VS-<QFB]*3/MUM "HF*AMQ
M,',>12.L0H41G5<2Q),ON53?<1KX#ZE\\,?=5T&85DDS#Y9IESM8ZFOU#B\E
MOA=,[>_M<CG(X\=U"6YP]4$!OG,!WSE'N\K8".^>+OMFOYVM&:0G<%!["B@@
M7 39UQ4%4%Z!&Q)[@ZZ(>3BOW/D$)C\6@?N("5D]SGX-VG"J!E<OL:>* FBO
MP$EO@PZ)N5BOA*D$;;/7+N]>!%I/ZUX$:?I;W8L$<S9)-9":NLZ-.W5%^QKC
M;9'N21M4YCS1_Q*G/^?S@7OFH)NMW'E7Z,8DQ]SK_,LN)2^J9W;:V=46O5+)
M,7"TP'HWKKSJ9SMME'NK@B(4&EX>LA&:C0)\[0*^]@9-6F.&_[RD]:0"=I&F
ME/K;SB]=VI;9ZI37$P)6H=E6 =$GR+ZN*( 1"S#B!OT"2V3$4MHD#4Q[ $:D
M)GI4K0(8$;*O*PI@Q *,N$&[P#(9L8PATF:OU0,A$I,\E+%4CT'2R\P(V'?F
MS0N5L6Q2QI9\SQ?U-3N/"O5-JY>]FB@TO6.33.,\RRLYZ\IJ9\?UO5-W, 76
MND&&6:ZUEEF,V#:'K>RQYAUJ7FB:%JHY.+J3+ T4X'D7\+PWR(0XXM\E/O"?
M;G1_- _Y)K$@<;5W7S#:Z9JM?GGC8V$$FFT$$'J"[.N* @BP2 7,!DEQQ1FP
MU)-99V@..RB(H29S]3@8-FC#J=I?O<2>*@I@P2(LN$&J]!8L6&;,CI\'T1&!
MG,AAE$6EV_]9J*CAW_!]=H0^8)Y%Y9!035#0RRY110%>2OY@=;OU2HL\:04O
MED:PK.#T7RSP)TYX+\1IP-__ 8D?Q&2)JIKC( [9UQ4%4%P!BK/*I+@<J?^@
M..JR1%7-07&0?5U1 ,45H#B[5(K;M M'.]N$@YX\Z:[5R-:OJKF2*\*O+(R$
M4VC<NI[CC9DQE5'E5+<E>K<LB"K3P$%WRT4#!?@C!>Z^V^W7)Z\(&WD6F\A3
M/SA5!E)Z*B5UIEE<@J<;AR'OF9IX(=D+IE9#L:>* @BOP %\@QEQ)?#=QB/4
MK&$'-$=,J*CJ.[BNN;*?WLT;?SK9#I:F85 AT]$ )C_/;3 @M R>V[R;S.XN
M6:'[N]']:C*95Z+/QHT?3%B0;&_H3]V)H5YHR&7-G(#O8Z.CU!>J[;_/MXGK
MZD,9(>ER,%(.23&($*>NY(;M);"2?8.K7SU2RN$I!:TF'_\+Q+LWZ+8G#>ZY
M[XWG@;!<9<>X-RKTL@>FW:;38V\C Y*V]CH9D<I&EVQ/PPU"@:HI!^G6!2F0
M[HYB$1OTV2K(N67T=^_:9KM7WO1!4&UC30?XE@P4X-OZ(P6^W1'?;M#5JRC?
MEM ]WC)[.-G60_2H)*GO^T[ [A^VNZ21.6>1,7;">V,6^-_="9L8-X_&VWDH
ML]G?&7XR%L(0ZO6]TOQU7!;4\LY]"9;8T[6T#$>K'E"N.EJ[A1.>6-H3RW26
MXW;[B)OMR]AJ?WK\&HHDC,48G]'"7.^\N?B .V*M\@H#2Z().&+T+ OB'F2@
M %]K "7XNJKT@$YF]E9)A%UJ+_3^P.RWNF#N.LA@935S(.T:6'J0=F.@!&E7
M1MJ9B9)ED7:9K=O[/=/JT"GV VEOV]"]NIO3[5OST-Y^JA?6Z+=# X<-:%8G
M:T45I@T](JV]':K8H>*? @JH^ >] ";02^.P [U00 'T GH!3*"7QF&G.[TT
MKI7X>@#2&UE=XYPS[SL+B>1:(W9)_9I0=]-$ X7_S]Z[-Z>19'G#7Z6BWYWG
ML2-  P@0ZGZV(V39ZM&L;3DLN2=F_YDHJ$14-U0Q=;'-?/KW7/)6%Q!(R"JD
MW(CML22HRCPG\]S/[SCHU,:RQEV0)G#!N8;N[+]4+CCET%C6N O2!"XXY>#.
M_DOE@E,.C67-2[\@3X/7_&*K%#_ER63FI_".>(HP#$N19"O/CP)/_#L/EPM8
M</,BXRX,V P^O'19U0PN.&5^GW:+7KG=XI._0FF7WL1G$Q!]B?@DI>&G.;SL
M+ K>*8'XZ* &QZW3/4Y4<O?_P!&2G0_;+*J_K&/?5"XXM7<?M7?\2&IO+QC&
MK9/A_J!\W/UW:N\@"=Y4@?NRCGU3N>#4WGW47O^QU-X>H(1'+? 5G=IKV"';
MJGO^F96B-H7V\G)Z"S\0>(>\D*I3Z7<A7G>XD53'[F<"F0'?'\\%_(G'@'KP
MN3!;-2^WX^+6S>##RY)D3>6"LV3N8\D41R)+2?D!!.5%G%QJ,7D9?2D(R=^E
MC%23DM^1A/P!@>S1Z?ZF)#B!<.!H?LZC;Q;57]:Q;RH7G![<'9.^/_Q1:G"'
MP/9_1!('?CK#HS:"[__B-%_#SEE318!3?^[LOU0N./5W#_5W\L/4W_8!;J?^
MFG[.7+7U4P>VDW@B1)!ZTR1>4(5UMF)\XJE(L +[D4/;KB2[&=K4)>F>-Q><
M37,/FV94M&FDJ+P 2?F.!.6-E)-7TT;$MKNMSO#8I>T;=NR:*A&<A^_._DOE
M@M.&]]"&IS].&S8BQ.V$P/,6 DX!NK/_4KG@%.#N"G#0^8$*L E!;B<$FA7D
M=M7;>PERI_Y<[!];Q-5H-T-GNLS<\^:"LUSN8;E4)KG:QLLUR,.KZ:-CB[AD
M?-//55.OO'/4W=E_J5QPZNX>ZJZ*I+4G=7='7-J:2NZ46\-.45,ON%-N[NR_
M5"XXY78/Y5;%R]J7<ML<<[;JC$;[@X)T5[Q9,6972'W?&+,-6^U_]<,YIGS:
M\+TV!9Q3,<D3&F)'\>9,) NX8,LX#1V<]9,SKZEIVI<NPYK!!6>FW ,69-"O
M:P@SZ&9G2D1>Q E:+==:/H+!<@/2\2T+QT>OFAZUNJ<.X[-I!\YA?#KA^P*/
M?5.YX%3@?51@+3+6GE7@/F"N^]UN"Y[FE&##CIQ3@D[\OL!CWU0N."5X'R58
MBXNU;R6X!]#KP<FP-1HYV.NF'3D'>_V$0>U*X?3=X>WF98)<-+L9?'A9<JNI
M7'!6S#V2[B=W)]W7&S*/#_S1:0T[#M6Z:<>LJ1+ ^?#N[+]4+CCM=P_M-WHT
M[=<(H ]WYY_WG7?ZSIW]E\H%I^_NH>].'T_?[64Z8W?H^HN:=LJ:4H!="$Q[
MXS@)1*((3(@T'G^009Z7?@*4?+Y<*0:PX6ZI&NQX:HUPO'?,>C_,8@/E?KQR
M@>PG2<!M8I:BV\N6?LW@%)L_>^&6,Y$L$VG8N<M$^L"R=G46!>?Q?"[HP>G5
MU,P">?RX>'\P;)UVFI/2WTI\V++>B9##T<2.%4[O.DXYO?NX>O=.)*^'ZMU]
MU),/CD]:G9/F-%4YO=M8$>+T;F-8X?3NX7/*Z=U'TKMW0HH]6._NHX2]W^KW
M]E<'YM3N >0+'IJ_^='Y@M[)T?&@T9SY*#)OXJ<S! C_&@8B\,8K[U6>PC_"
MZ+5,&P 5/;Q>7Y^TYMWE#PXR*6^8A32M5<_.X#H,5A8-KL=EI[/(;(NL@H,'
M<OL<Q/8G*;7?K+Z R+Z,+I6\/M/B^@<D'GJM_J@Y11K.$FNL:'$!D,:PPBGL
M%\!*I["?2F'W'TEA[R-CT>UU6IWNR"GL0SAZ3F$[5CB%_5)8Z13V4T'W# >/
MI;'O0)JG(]?>-NG1Z[7@*4YU'\(AW K,Y^GRI\\=SZ>I:6N'T-,,/FRA9U^2
MM&HJF[8TB5ZTN=-4WKWTKLAF<,%! CCUXMCDU,NSXYU3+TW@@E,O3KTX-CGU
M\NQX]]+5RPO!'[<).8[GP<,X<E_R7X21'TV:46GM8I=-SQ.^=-'4#"XXO+G&
MLL9=D"9PP;F&[NR_5"XXY=!8UK@+T@0N..7@SOY+Y8)3#HUES4N_(*Y0\4?S
MX$V<)/$WV'KJ 3E%XDW\99CY<V\N_%1X\1@8X!/"2O-BY"X@V P^O'2IU0PN
M.+5^CU;)X2:TJ?=Q=(N#D<]9)+Y'B7AE!.*^P T>;]Z2N_+/^\H[+]:=_9?*
M!:?N[J'N-D[7?8BZ:\1X07?EG_>5=^K.G?V7R@6G[NZA[C:.TWV0NKNCK][@
MTYTZ[=:P8[3'J//!E9LVA0>?Q=)?$50WS@?<>\C9U: V0QVZ1-GSYH(S2NYA
ME%1F'AMA>#4]^)"SN_+/^\H[']R=_9?*!:?N=E=W)Y7YM?M2=XT(.;LK_[RO
MO%-W[NR_5"XX=7</*->3RMS8O>F[;6/.^YM+YV[X#P1CW8QLX J<]Q)JGA+2
M@9"AYGGHC\/Y@^ .7'5S,]2@RXX];RXX8^0^QH@>ICN]%5'!$F'(%T$6R'LC
M!A]]8%NWUQKV.BXIWK"S];IY#'"NMSOV+Y4+3MO=1]L=[U7;[67:6;=UVALX
M;=>PL^6TG9.S+_#8-Y4+3MO=(Z_:WZ^RVQQ<=OT[AW287BR:;E,84(PYN[+F
MQC&HJ2G7ERZGFL$%9X_<Q_NNS#"U;9*W8IR=1<$CE#5;O5:=YLPF=5?\@9ZV
M*^EZ7C+U91W[IG+!:;;[:+8*2-2>--L=$6:GV9I\CIQF<S+U!1[[IG+!:;;[
M:+8*'M2^--O6^!A.LS7N'&U5K?QTP?SG'CP^]].9M_3# +,N\(]5$L_G7N9_
MA[?"I4Y$FB7A)!,![#V>_$FW''Y+4697QOSD[&MJDO5ER;"F<L&9*?<Q4ZHX
M7M)(^2SF/DC"F_C&__Z/,)O-XCD2_B).KF=^(MZ 2 S.X\521"E9+8]?WMQM
M]8?[,VF<.' %7P=)\*;*WY=U[)O*!:<%[Z,%*\!1CZ(%]U+VW&N=#%R33]/.
MG-."3OZ^P&/?5"XX+7@/+3BJX$D]CA;<OAYZO18<M(;=GM."#3MS>P#C<(71
M]Z2]PE_WIDF\\,(TS0F- S&@X\4"[C^%M)N7 ')![&;PX65)JJ9RP1DNN_=K
MC2JX8/8LBDLI":^FYR0'KU$,/GJP^OBD->KM;T"%N_;/^]H[7]V=_9?*!:?R
M[J'R>OM5>?N(3/<ZK9.3D5-Y#3M;3;WV3N6YL_]2N>!4WCU4WO&>5=X>PM"]
MT]:H?^)47L/.UKY .AZ:%B@$GKUQG 0B401.XWD8>/Q!C[:U]!.@Y$.XTCLY
M.AXTFC,?1>9-J @[B;^&@0B\\<I[E:?PCS!Z+2&D@8H>WJ2O3XH>;9LI]^.=
M"V,_2<)-,0MI6N"4(MHF;JK/O&QQV0Q6LI7T8]CI3"W;U.J732V0V]@[\TE*
M[3>K+R"R+Z,+):_/M+A^_#+PX]9QOSEEX!6Q<Y>.<)+E<#2X8X73UXZ53E\W
MOG*O A"V)X5]%XP*';GVEIJ[WSKN-*=RW2GN)I:S.YU] (+>Z>QGPTJGLY_*
MQZX@G^U+9>^CO/ZX-3IISFP-IZH/ )'\1R<[FLV5=].IF&18?2^^3V9^="N\
MQ,^$)_\-$H+2('X4\#_$O_,0^(3--D^5/70)CX.L)7#&V+-AI3/&GLH8JX#U
ML?R^FKZ3TOLS".^K".TS_/]W1EI_UIAA^(>S*"C^POKD9329Y\CYMV&ZC%-_
M_AL<JR5\ WY&>RZ,<A%<+47R<.#V+<,QP]/]V7A[TC[.QFN>P'(QF<:PPID!
M+X"5S@QXLCQ*!0VOX7; MOD9H_6=QC^(L_MD$/A.V1^ AG#*_MFPTBG[)U/V
M%="_IBO[.Y#_J\J^.=V83MD_+FR2&PGP@(Z4,)HD-$CV%=PH^M=K^-W^,S1N
M$D SM/F35L:\),'65#9M:72]:(-J9WOJM (?^2#+Z9-(PCBXE*+YK13,VIZR
M;32VVQX]83(8]%K=WO[:?1WJY/.6,@[APJE@QR:G@G^@"JX@(39(!>\#8^KX
MI-7I["^JX33P\Q8R3@,[#>S8Y#3P#\PJG%:0&9ND@K?,(&SG#H_ZK7Z#&CJ=
M,MY;-L'U@NR3(3=QYL_79Q,\/_/& O82 16Q8V1)=_YP"T!<YN%)2T)<Q4>S
M.56TNUQ!Q]Z"'Q6 T.94;CQDWN.PU1L.72''(9Q9UZ?A6.'T]#/AE-/3CZ2G
M*^B2S='3]X?,&)VV>@-7;WD01]:I:<<*IZ:?":><FGXD-5W!E&R.FCZYMYH>
MGARWADY/'\:9/80Y'D&<C^?"ZQV]&)6]13I#P.\?G,AX1"C1+9GF$AG-K![9
MQ,V7:)K]5_.X>+^VUOMQTIEMMME6P15MC-GV@-:+X<FH=7S:_*D?:Q7+2Q)'
MC9WZ\?)L-:?DGPTKG9)W2EXK^0I>96.4?(-*'9R2?[::Q2GYQK#"*7FGY)V2
M?PPE7P&C;(Z2;TR=A-/QC<B_/%W^][GC4S4U[>X0IYK!AZ)J?O$&5%/95+6B
M'*L:RJJ7U2W:5"XXZ :G31R;G#8Y=%8Y;=($+CAMXK2)8Y/3)H?.JI>N35X(
M.+Y-R'$\#Q[&D?N2_SI?+N=B :M2]=[3>?S-"R,.](=Q]'/STE4N+MD,/KQT
M2=4,+K!J=YQX>DXX+C2!"\X/=&?_I7+!Z8*F<,)QH0E<<+K G?V7R@6G"YK"
MB9?.A741O448!'/A*@KWSX-+#(&)-/.6_FKQD'&6KKBP&<+)I1N>N/GBL5-S
MKF]BI[Z)REQO)?$^^6'P43QH4*35K7@\: R*E+O!S9:CF_79L[NR367#R[H,
M3ITUD2N[JK-!IS)6>1=U=L?014N=G?2=.FO866FJ''7JK!%L>%F7P:FS)G)E
M=W56&5&\DSJ[8X"A5F>];G,P?MT-WGOP]^ J.IO"@S?^W(\FP@LCSY],@*19
MBG%@'\N]$<T7?IGD(O#FH3\.YV$6PFH2,?<S^%T6>\L\F<S\%'X93Y&1SY1*
M?%+YO]XRB9<BR59$'P0Z7F+4?(TP>;J3Z_+9+G_W8KG@++%[6&(UDZJ78>;/
MWWU?BB@(LQRLLLMHDB>)"-[DV<<X^Z<@*VT_ ?31:'\1!W>_G_?]=A&'1K#!
M788F<,$INWLHNYKAP'M0=EN'U_O#CE-V#3M$3;W?3MDU@@WN,C2!"T[9W4/9
MU4S8W8>RVSKX?M(<$'=WOUWE=5-X\%9,!5XY+Y["/X $<-O2# /L$\1>"7:)
MRM\W_NPPEEP1P.%RP14!-)$KNQLHE=G"[XUD.TO3?"&"[D.BS#84_7]$$@=^
M.L,[/(+O_^(* QIV?IHJ6YTCW@@VO*S+X%1<$[FRNXJKS&'=5<7=$5MV*NZ0
MSD]39:M3<8U@P\NZ#$[%-9$KNZNXRA32G57<UA%EUYQTUW'I/KDHE0'EOV88
MMX3?!N'7W39?V.M?K+T-EUGAC0\$AJA]#Y$!DR3AY&XZ,L4[BN1%LNY Q)N9
MH(CO8NE'*PP(1W$&;_,3C/MZ(6SG-O'GWM)/,B^>>ME,I,([CR,:P4A%V1=A
MY$>3$#YTG<$O"-#C:&L:(46ZO2*%[)\M&M81[=XD>M#) U$A-SA+U Z7_JUH
MCQ/A_]GVI[#!G_WY-W^5_N3]]>%'<+M=%L_G(YQ0&P]Z5^K?E]07EV\^7_WV
M[F/+N_QXOOVQ:OS&2(M]O+IY=_VOFZM_W?SMW;_.KSY>7[V_?'MV\^[MORZN
M?_J5_NK=7'GP5\_^JW=Q^?'LX_GEV7OO^@9^\>'=QYOKQY)*N-O3#=+O!QUH
M:1M\!)6>A!/+!NA54LUO\C2,1)J^%>DD"9>HJ\^BX(V?ANG5]%," BS*"#S\
M!E;V9AY/_MPMT N/]9=(X207I%Q!S2AJ,,%1>;+>)4TD!QO\]T\=>)&8SU$]
M@ZC5/TN%3C\KJX%'(8"JG?O+5/RL_O&+)U5]IR.]IHU(]/SAXZ/!29UIL-:R
MI/77VP46G^NO3N$^2%/!S[.X]O*L.0=;7Z.YR.!DMR5!?^9#\__@QTCM:HM%
MTML"S( RI#R][DW%;*--/,F&NB#W<$_K+$[D^ ]EY4.VL\O]UT+R7UT0CQ\^
MG7W\9XF]:]A4RU+XJB3CN@-2W*HT<.N_5OX,VE'G;$65F45FZ9U&*3)GV'"[
MYR(<)_%O(@)E'$V.O%<8Z^MU?E&_IA^[OWAQ@G:B)_\JJ2+_^-H+4V\F_.#?
M.9B4(N&:@VL@+/A58$:FD[CEG</9A<5$H=\">9?-O#0?IV$0^LD**Q?""6P:
MOO5&A'^@R8H%"M<S/[J=^6'+^R3BY5Q0&/+DE]3[+);Y&$QJM%[/9V"KZF73
M3VI91Y[:!2[0]^:P1'SV.(R7,Q_V/Q%Y%DYP#@7O!SS%KV(>+]4"X->@FM .
M#O]#O_.6X5+,01/AFZ=ADB(3VY.YGZ9('I"_],3TR+/.CN<OEW-L>0RQ  ..
MKN R#?$=.P##E/HF9ZME_#WT\4SDDQ 5S!1<4J"ZVMG?+B\TN6$#\_AVU?)Z
M[?A[?#O/,Q\NA?!$])_50OX)M%\DP*G]*CQX1YH+#^[4-Z![Z;GG-[_5/)AV
M#QLEZDBJH!> [9I^\%5V>T;Q5Y_> #YY.$$%C0%D.B@96,T9?0,HY4=B@7R?
M(CN /EX N_93(=^#3TN.O#56R$%X#Y_C[WZ0IV"#M#S[ZM!Q7<1IIJ@68.<G
ML!@^AV<R@HL%%$[A*7/XW%Q,\CE2=A:.0^02$ \8C]^9K^9P2((D_KZ"XR;L
M9E*,77P-LQ40WL^\F4^U/P+X$GA LS]%1F<WSV9Q$OZ'A">>.'EQ8'] /S"V
M?H;+W3OM'1__@O][<HI/[W6/C[N__+\T7Q9$*T>2!G_Y!:]">\9D[/: !5_Q
M1,.9D9J*M!@L\J0/!A\\Y=?7FPX(G(0\A46/5]YDEL1P^+P_PR 2*W5>S*']
MG[=&]D3P9W^^2HF> ? D:NM?+&&[Y+QZ[W[__.[C_U[Q8KQ7B68822]_GL9X
M3Y/X*TNOO_NH&/!Y0">\C1N6#;<_!B&!CC-)-EC=MJLZY#-OB3A]U/'E;Y/\
MUCM#F3?APZ:X]O'MF>;:-)SCJ00R(56_1"%2CX(-J?[\EZ/K(_,%8(!AVD9^
M;*0],D?1W_L&=P7TT"+,,F;[6[@XB[%(/$R0H;"CU<$ZO(LX#NAIO+U@ <(Q
MS9+B#B_,#H] G]J/ZW5:]##X"$C^3$18FH>_2,37$*@&NB", QF/\8!4> VR
M62) N@+]9RQ:M4*#I?'"/70T<!$@1OP(-TE]]/ .6!Z2V"*:D>A^YK/P304\
MP8M@ >A%*=^*-_DEA95?P +.)IEW&_/W2/5]\)/)S,,MP<:Z1]Y5)'_5Y=^8
MK?)<)]AJGK)XPC^<^TD0@NY(0=KY":WCL\ -X&M3(.[7,(W!+H#31:P1<*]
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M^+:ZP#;9X!5?@4/(;OZ[FC[.$*SJ?!YY;VUIC]/3X,O&+--KS:,E\CE@QYS
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M-6X-OL%E;CC5EA,4EB&<;;'HL4EBD1TGB_7($\ XH3UY4Y4=M=2[_IW[7!+
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M'K56(ESJ?8-_PNY!-'V+J!C)F%RJN4F[3,7AR$>;9OLUWIW>_1PQPX.8F+_
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M+C7%0U?ZX;JM^0)Z[ BU83(F(D&B7)][P\Z0WQIM16%V9ND/180<FTR\0:8
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MN:A3O,]8<_)94 I0AW-'K^M'%E0?51YB<,'P9(7J<17?@!_KWUO(0NMHBER
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M8X?M2;?B:OI[C'M4,I$_!2^^.V-5\UQ=?""W\3]@S ;^/T%P3/-/,Q^X/1%
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M]" !$QXE[ 6T%=&MH5FKZD^M F1OY94IND&[QJ &@T*BRXXV79GP"H%-I]K
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M%6\%_R\: :JHWJHT/R0#H-MQ(8##.-)-" $X*Z )O'!6P/.V ES*_^G,@,K
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M3_/Y?&5L>)]GNXAQDN/\$7RKQ53AE?A>F4(&ZXH] >H/9VVCUR>?S).G]3'
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M/)V3!4VM.JLMKMQFBEX$2QB+@_3CNP>9SV7Z"@8N=/Z/+.$TEBR"E*UY_)G
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M#)<12L< UP7A?G'P(,^S/K25G8&J*FNL3@Z]R68MRM7$"0;["?&<%2>GXD"
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MD88VQO*LK]2YJ+$\3IYUL9:?X\*_A-6;"7K+PID7W']C7F0H"&-H&AQ\/7Y
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M&/1/N(K+IXL,#XKE^>[7MPFP:D9DBH#U#  0D:6*5LL@(^JU1;ZMR'1MX4O
M*_M%\J0*$$M]1E\7/M-44KC6A+VQ-2';()G=Y:(2:E$Z,BC'<+2HT2R<ZI3J
M*LW9X[]X/CP\F+)?R'H>N.<9[P2_?+,)@Q4IWG=[#7FR=9_R]+"0@YJ$C7<B
MF<B7$Y-2(A<_C^& K9:"!W02D[!IUC,)]YB[=!]#D.3,Q<$.>N!;# >H8L3@
M7)39.LI#"Y[5ZPNCVS72T$<:9FN4"4/2SMMM'7CG>^-6MW/WO//_"Z>2R'J3
M.(<RZ<%A].9TWH:F^^8#KW=9M-K-F]1FTJ3!$@V O7!K[.%YU6YK*,% *XX&
MFGVBA7"J,>IG<$2"\MY\,BTFJ=R7ZW5KNW745C"&S1BV2DFRT[;'QK 9PU9S
M-3<&JRZ2!(,UNKG!,C/MM.IBWS=8MJ?EJW9"DJ6S]:N$I9*HTT)K6BN>BH+=
MA<[_G"SZT$XF1ODU:I0P31#7;X+8RR*9!H==Y:!VNG*85_MBT6=>@>&;;UBT
M#$)YB"("_W<_.]^N,JHB781XC1)B,T=*?Y77%38,/AM\-OAL\/E$?.[<.S[;
M8X[/]OB$]L5AHS?4AZ# P+5V"Y\#UZ:OP "X 7 #X*<!>&8&\]T!^$@ ^,@<
ML"NH\A4J8:_WLNNQTF:AKUIZ7J>5KL:(T[JMNJ;Z77_@/-JKO^1TF(&9#K.'
MTYX9K78=I_WT^3 :9,F*HW##QKC?,^-B;K\A=(4$@[U&PPWVWCGV9ABR[QU[
MSY$!ZXP:]K!CL/?V&T)72# ),*/S!HT-&J?0>&#0^.AT5O%)>-3HM[L&C=4-
M88BSRXBSBSEAA^D-^MJ+G"=06\;;\G[&]XQ>5+"Z,\%^WD7>FV0-#CE5,N6&
M=:9322,+/Z7\K7,GLB:$+"W'A^47%R'.=(Z,W\@9R\A@81L64D;ORR_;@)L$
M<!WZ0V2*=J(HF'KTIBZ9D3"$OT@R6T-#6VH"<P<9UYL *JU=MV8:R X.,@0I
MNO(-M(]B2ZN5H.+!K>E1W[5ZS8]Q K^V[_AY#AOG:5[K=U3GDC ;8YC)[H+
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M/_R'X[-2R0<LLL0R;]YY!=\G$39NR/)Z:GL?I.D])A9PN8%1QJK4S:K<60#
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M^-["XTZM<$ 6SC=OL5E$%KK$ +@;L#/Y3TUO^FWN;")J$N#UHJ(7Q(^J7I>
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MG#B#M->_]4OOFB5JE^Q(1*T\N%.&W*K#1EOY4%\X]&R0S!J]#C=/_.FYJ?P
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M';45C&'3QK -3I?F71@V,\S8&+;:J[DQ6'61)!BLT<T-EJ%:UHIJN7!/\;A
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M9>I\C91(8H*9D!X?2E'IH3Z/P6+E++?6;.///!]'ZSB^3^?V1'-OA0E%*YB
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MONY'&>2]FR([#/6AI'EW-FO *@_PV0/7_VGCL=\CA0T*Y"L5R$(1"'5JW-A
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MZY9V82DS)C<^#KSWXECCO1R5\(.;*2[M#N.[J3SVQR\?5JQG(Q F6M!'H-!
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MO11'6QNV.W1DHII J:KL1'4D_?6%@:BN"-4-RZ2Z(](##*W?IB0ZY01*E>P
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M/$Q*BL]R!3>  O78=B,NC<7"*G2-X1^6Z89_6#VSU3.L86/8;[<:'4/T&WS
M.PUC-&H)0W2'O?$P-@;P$&'=A.L/&'6&8Z&+06-LP/]US$ZG,>2&WA"\;1JM
MD3[H]SL'JDAYDU_*86;J@URA:6G[;KT@O$?!OH?7OW4\\\<3&Y26WM(S.Q4!
M5FZ&0NY'8N.$=PAUUBATF@-@RNP:-.)?51G<G A8B^D,/N*& ?/&2:!3_)H)
M%_[[*'S!>  <X#C>8\">VRX+)UX4<-<*7KQ*U*28D2QC/;)R 0-!NX5,@V@G
MEO\?SUH MW <M.W $HN?$]:0/Z\,_Q6/0N]UPAM@LQT^"\2K]!^O6<(MK5:2
MV9^+T)_I*,48-H<5'GA?[):FI)3*8;--Z09J8*$W!U5FMV:75*6>@0 $C 2F
M#4CTGBF06&#TG[)8Z9K5IMOF_PKN!^P]C,MB[X0IIB/AQTBV=:WRHWKJN%E7
M=C\*A*NAE^W%)9YD_\V6[&KTY7O(0S'%IA2P9TAB39X;L$^V*]A'^!-Y!)5C
MM-LC,%3P"'2C4/BXWCX#AB;(-;B0ANAEV;/NL6JRW>!=L:J0";Q.7/&LBDS@
M)>Z.3G82'6^8KC?0MEKNS?2"XE7L3U=S;V5;M-64U<9,J9I[(W='A(+Z&5!U
MIA@U0-HSO^F0W"72KVNJ"T08[&2:;JXB,FD",0V!1$QS1=#5FVD4:V1W="!
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MZ/,OX7L6UF%](]/.C=?$F*H)IZJFFQB3I)\8LZ:,^?Q@RNSDKL,5H4P\UZN
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M3Q4';I=8'9CX3[%K3R>+=%W]+OU?GO\#1M:8^=Z#+X+*;G.3+Z+6;6"R1&K
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M?-%P>.2:DTVCPQJDOS>_-^4_ F%B-]T_(WR,C^- ;QJ>8&,%;X_YXB%RN'P
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MA+&G]/[W;W(:(\'] 'N/"]A;A.PY>D&P69IAY$=8+[+];,%3VB$?OT:^8\^
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M<%!)4'V!,L!<1TZ(X^1HCD=2JQP/QO3<=DTG0K@U?#M,1@Z1X9') PQD\>E
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M>+RI;0)'"2X/<Y[;3XT BT!-1[:+QQ72EL-&3'+F UX"AS< ]UI1O(-<5B1
MHAH)>3H3A<O))]7L(GEE/ [OP$B6-8SBDA!)=:5X2HO!X^5\/*&\77W.%/X6
M)+>HY!9/UL:)(U#R.KDLL88'1K:/O+O\=L"=16G,9!+Q]_V9%) D/L5'>'2#
M$2B8(KH8RTG*N%EZUI1&V-+:A%@I4UNI,#G&533E]:\-Y07C$A,X^'C(Z"4L
MAH75-/Z,[/@Y41#+05K=,DYG&'E8PD,>2B\*%N0]EOB,47H8\V4(/1/.CIVG
M3<(.;T1'+*[!YEKY;\?/3CT<";D4_Y5(=]8%PVH38Q]/V]>CF5D7"#RGB:R
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M;GGT=7-E7*2ZZ=,V!C]7@GY\+E.]Q+VM4G0\UYG?GB_%?C'=26L\R I)(DF
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M0?O_PYHUB=T8$O@7+_NLW..0J5&?',PAST0.DI-G(CG7;A\?/?:H!TVRW'>
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MH-\997L\'#'B:2NY+E@,4BJYQC&Y,N.=D%R]SC!/M#+#G+:-11H?##$")*P
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M=W=OJW?!U[_3T T/95=DZ/F4FCQV1Y+Q?S9$X_\<SF>;!7!F:4=$O1&&=.M
MJ]UR9>(((RX(XH5O,VC,-U+5IJ(Y6)F]'?AZQ)>QI@U?)P=J93T2%* +2\8I
M=#D*8%.TV\+=7$G(IW[:C<G_S.;C^&!!A)#7F]_^$$\Q?&#>HG/(^Q3XBH>C
MG4T^(ET1-&=F.YISV.+&:S4=T;9F*_.>1+LDU,03$B/XPE^EX1&GOJ_G+;HX
MQ#8YSQAO8^+$K=1#-Z%J;L$S <L ARQ'.-5H?%-+@Y<PS[!P)*..3'?$H-&E
MZX-8H(U&T\QGYXHO3]E<?\*AR/#R9["J^+_H,:'_S<=:PV?]^!66 V@>8@F4
MW]G4!NX"9AQ ,O)DY,G(DY$OS<C_P[7AL[85O!QFZI.G)+!KO@5O /,=I*SI
MT^JAZ,OK?&IBXG?Q]W1ARO&O^  <E-M1\E:1I5Y46_GJS?]=O=5^V<"9Q!OQ
M%? )Q84/>-O=[C5BA$M^V *+ZIC;3CJ( _AUW>.6=QE.;<M0P)A;@<7\Z&/B
M+)U+FXYR;SEPD,)G!W/+,Y7_A#H<E3PQ.AA'2,*?#N+*"7L&Y#5"#T,N]DMR
M\WL <X/%!%\$7P1?!%\7@J^OEO^]_=%C3+G#5"'XX<I7/6 EGE8\?,,,WV#%
M;_ P++4.O&3.+-\Z]QWEP6.Z'WHO2=]>>9Z[<(#@4^&?Q7G !TN*\X>?K6">
M1JUX=GR>_4T=@<CDDLDEDTLF]](GAO?6$SCOX/O^RV*V>?RI80X6T&&8L8#W
MVKJ'!M13EKH%]A@/%;H_5\SH'<+)-EV@F^,&RM*&=P0N?#CS.<N)(N0XZIUQ
MPS8+@]!CAYA)GN9*YK7B/'"4]UJGN8;=5;YW]LB<FWMCSLS09I]GZVSO%_T%
MS?XMYEKXR/K/PF#?.N:'*/+/?_TE] P@!OL"N_I'G">Z70?V'W"%#\"@MS9\
M^KC";.8;^A+YZX5L:T:N%JF31*9#"7T1[(MS(WNS<SQ[A$ /4H3'RV/S=> <
M>+B$*/.RRK5<.@\K</P4S!;+NN$V9!]^3[;"]X7N//9[';GNR]>V<JRL_@4T
MO?KH(7IJ7X8I>H-^Y\#;\8UAV[^8[OG*!U@7.#/,X#?(!2M[:DNNH?$26L'*
MV4<&L5ZL,62;*CK2:*KH<7REF?'5J]&%":Z=KB9GO99)G(HY!3^<C5%7;-,(
MJZZ3KWCCD;"J41;P0*PB#A &U8!UDF$0?*!/&'0T!HTKQR"9N@;*P189+"5A
MU6%-&ZN[3"W"KN=A@*";%< FC5(O/1_! YY[5J*<M'Q7V7EDM1+Q/X+XU5B@
MJQ_N25S:R:7^8=AQ3 >'RWI>#>:=/#&!YC)!^%Y$](L2G8<&B.:$Y\0EPO/K
MX1WA>?5,(#PG/&\$S0G/Z\"ER6&9$H)S^5A'<"X!$YH&YY65EU\Z]2%-=]</
MJ4O6OUB.\H)W 7ZM:CKHI;,@TC!"UEF2EX$!8L-!@9&&=Z).7JAN^\QH6S_:
M<[!(S+F)6D\/7KT9=$:[[\N3,C5<F<[D5=6#[-4A^'G")/6@.MF<IK.! /P@
M !\B@/<(P.5@F*3*1 !. -X882>;(P4;1"J#\'L/?H\0O_N$WW(P3%)=:AY^
M-^9.AS0\^)#M_UW5)%#*:<B55244D(,-%!+9.5WSQ]2SK67HL=1PS?'F<,W\
MF9JW'KS^D6'7U;<O^8U8/^J6ATU66:+!:FPUUS,PL(GXCD:KT2KX Q]>ENSV
MA^7'OTRU=A6WZ_[DK>7RVK.NYWGV5C,[V]JK-\-11Y5F9">9%+E-RK4[EC]+
MY\)03(C,37/90!Y, 0]F<AT>C#J))Y)/]G@PXTZ7/!C9Q%92DT(>#'DP39!S
M,C=2L(&R6L<[,./NE3@PX]B!&>\-P4S(@9%-;"6U*(UR8.B^TJ7)_S5_"*5T
MM5*4VJ,"CP:S@0)C!?Q*]:Q^)5I.G \<CP>N.K'7[8Q+<RK)GERW/6F44RF%
M_T)1,3(WS64#N2\%W!?M&MR7@[-Z&E:YD_LBE\Q*:D_(?2'WI0ER3N9&"C90
M4J^ ]]*["N_ET)2>ADURR'N12V8E-2>-\E[HHEYE%_5,Z\F"]9G*B\5L4[HZ
M,<KH45E'@]E (;$"3F7_(I5B[R/#>?F,GO9*0:+IP=]?63^"F_\RSS5U?XY2
M/(:7OJ:J,=E$6%+S<NT^YFD=G:CV_:J$G6R.'&P@EZ: 2S.X!I=F1Y:/7)JZ
MB;"DYH5<&G)I&B/L9'.D8 -E_@IX-,.K\&BV9_[(HZF;"$MJ79KGT=#]ODOS
MX)_\4<Q4]"?FZ8],87X =@Q_,P/KBAP(Z;9?]9HAA3(T#1=^DH\#%$/;Z7%:
MOMO7U-&W^_?"^?31;_13[N>H-/=3N(3^[_#!P+]SOC#/<LW8H-X*>\K_^![L
MZ<I7O73&\(TZ[O2&5'TFFQ1+:N.;YW1*X=%0&(UL#CDTY- 4<&C*ZU NC4.S
M,U_XIJ=V)M3+0#HIEM3&DT-##DUCA+UI-D<^AX92@J?Z,^7U*Y?'G]F5+7S3
MTSJJ1OZ,;%(LJ8EOGC]#6<'J>2"%3TEI/S+\#68#A<KDY0VIB QL:)YO) 4N
M4ZR';$YSV4"P+"]O2$5D8 /!,L%R8X2=;(X4;* \C+2L(0V1@@W-0^7&-!M,
MT,T*8)-&J5PYIMG@_9<OOG1WUL^41TB2:NK:YHE$O[+;C!>R^L0$68,5Q!E2
M#\F9<":7J Y$O[8.,G6@.5F;9C.!P%A6SI!Z5,\$ F,"XT8(.ED;"9A08;Z
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M!J&&'*A!8<,L:HSY6:.'9XU!IT>H(0?C"#6J1PVJ.KPT^;]:_O?VS&-,L9R
M><P/%$\/:."I%-9'LA0@G0 WL;S7Y2E E:< )Y0"E(-ME *L'LFE  TZ_U4M
M\X09.9C1>_5&Y<<_P@QIV$:809A!F"$'9E#,,(L9?3QGC DS9&(;84;UF$%5
MAI55&9K6DP7K,Y47B]FF=,F_1D8,JQ=_ @$YV$!#67:.X>6S=Y>AQQ*3=WO=
M<6F3=U?#=&]]/UR(,;RQY7P?&<ZO>E!TUBZ?L9M<TA=;7T_;U;K1M%VMFYVV
MJR#9].#OKZP?P<U_F>>:NC]'.1[#:U^7-H67#,QU&YAK]S(;U9ZN'E0GF]-T
M-I!34\"IF5R'4Z-.(J=&G9!34W<AEM3 D%-#3DUCA)ULCA1LH#E]Q_LT:O=*
M?)IQ[-.,R:>INQ!+:E^:Y]/0+8)+\^"?_%',5/0GYNF/3&%^ '8,?S,#^XH<
M".E.0?6:(84R- T7?I*/ Q1'V^ES6K[;U]31M_OWPOWTT7/T4PZH6IH#^EGX
MG+_#!P/_SOG"/,LU8X-Z*^PI_^-[L*<K;_7R><,WZJ@SZ)7F=I)YN6XKWSRW
M4PJ?AD)I9'/(I2&7IH!+HUVC2[,S:_A&G72T$;DTLLFQI%:>7!IR:1HC[$VS
M.?*Y-)08/-6CZ5VE1[,K9_A&'9)'(Z$<2VKD+^?1"-+&E-W%A$ND!G\+]*G-
MX+>F]?0FUI9/X0+4VL@C!FY=U99YMC6U^9^KE+%;7W%GRGMF<$LA]MY36PJ&
M<UM*,&<>4YYU7_GI(*.:,J3]34/Z8;&TW1?&[IGW9!DLWZY^<ITGYJ.!1"OG
M/[B!;B?__L[U@T]N\"\&;S?<1P<H8W+;%UG;8\WG[)$YB>^+MR:"VYOFLCT
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ML*([)O_D.W>QU)T7GF,>O?85%O-C]=&;2.<N+4[P2C1W"%#(_P@P_OZJ"P+
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M&\A%*>*B[.\R=Y"+<JY#^J U'M&-=>GD3%8;0 A(TM]<-A "%D' _1WC3D?
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M"TMW]4L_"DNKG*%&6-J0)/RE P8UO!MMKY6VJA ;N3]U"*H?<,^(_*.:\/+
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MK4+M@[G"E6P[,"+E2R%IL14>I?"1>BE<OY2D@JTVQP]<Z>/6ELW)/MGTU@]
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M5NMJ+Q7F^D34YD6B<"E=(V].#H:ND9?N4&F9N2P'.E2GQ2:&K4%/GH&K=;E
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MF613)L6 23([YJV,(J?VRH8F3?#@UC0(.S+PE65D'3KIY9#@#G0Q=SO7S7L
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M5%MA:Y$Y%=\\EWPXC,+L(6NS6XO A8BY([@0-@[QLWI"28@?%<+&(3)^8+L
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MX7:'%O!9\%E^5D\HH8+/PA'8AG^N?!9XEKWI \]R;^P0Z:R!;I%2 >B6;0V
M;E%Q - MEO('W;+M  SHE@NT1:$*(Q1V@+86H:U:I=&LU_=ZK4JK7:L:M%5;
M@6S-(RE=_(FC?X_]]%;_0HE(74$.HL*>(5WFJ6]3NI4.9"P-X@(Z(N:Z0$=O
MCX[V#F@I@:/=$TI9@$=P!+8)@"<\JM%2 NP>Y.@-[-[9<UR@(VIM*Z C4BH
M.K*M : C*@X =,12_D!'MAV  3JJ AU1*,,(A1V@HR714?V9Z&@X"J);*8L=
M3&-U(5Z2$23P(6+^"3X$/L31[@GE)? A. +;!,"3#]5I*0%V#SX$/@0^!#YD
M7P7@0[8U #Y$Q0' AUC*'WS(M@,PX$,U\"$*91BAL ,^I,%09881U1NU>KOB
M5BJNVZK7]_I7,MS5@,BY=-J5M2'1213N3AC1)S^6W32*Q6$T',DP,6\4WZ+
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M@$'\K)Y0%@(,@B.P#?\\89"#H]2Y&SYH$/=&")%.%&@0*16 !MG6 &@0%0<
M#6(I?] @VP[ @ :U__*GENO6'JH*T(-FVHT#$](PJ#+#A>J-6KU=<2N5NE-U
MZGO]*QGN&BATZ53<Y;G0810$7B?_Y71756F9HX*35*HW)_G6)/.'^YN\IF<M
MFPU>E3I0$S$W!VIZ\SRW^S=:.N!H]H2R&S_6A(>7DO$#VU4-3]1$2PFP>Y"F
M-[![9Z^^YZJ:!4T60ETND"92*@!ILJT!D"8J#@#2Q%+^/$F3^H_7":3ZWYY_
MO=RJ4-^ZX\Z+8O;G^\*BV0IWFE4M#77/@[BXZ9%W)7<[L?2^[WI]=<_[7G#C
MW28[8L\B YC5G;J*7%%&;Z(3Q3T9_[13V1%=&6AGZBKKGOR<6[OY>>[:][UQ
M&GW(WJU=*_!&B=PO_O%!%#&IDGL$PY6R)4 SBT_(7)6&I._\]Q-.FK,4<!3K
M#05"&12X=#$N==J52JW=;$]Q:=N_=&K.\KQT^E!5_5Q41Y\^^?H(=?;X1@>G
M-Y+T?E#4MZ>HO]/2P>N8_9K+4YJ)":03MOJHK=HN:EC22%U0T-(#S!/0,#-/
M=\]MZNUI;4!#0@U+0$-2*@ TM*T!0$,J#@!HR%+^/*$AST60Q1-"L#^-3LN5
M4/0!<%GVS,(5]J8=A'+H>^*+K\K:1!I@\NJLY6 4^T%F;6[+;%AK +40\WN@
M%IR-R,_J"64[?A0'9R/2<03;=0Y+1.2XM+0 PP=\PMF(@$^ 3]95 /AD6P.
M3U0< /")I?P!GVP[  ?XY  ^T2G&"$4?P*=EX5-UG8T^:22LD*CQU3A),]NK
M.D!1)*, 4!10%#^K)Y3[@*+@"&S#/U,45:6E!1@^4!10%% 44)1U%0!%V=8
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M0:[@"&S#/UMR!7#%WO8!KKCW;(@TS0"N2*D X,JV!@"NJ#@ P!5+^0-<V78
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M. +;\,\98(%@L3=_$"SNS1LBW3->Y1<=H=-B5J_5L2&M OMB9VCW]H6^J/'
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M4%Y.Q/13#9 /;/516[5= ;#$,E67EA9@G& G^0;,/4U.W J:!H2Z-B GI%0
M<F); R G5!P Y(2E_$%.;#L !W+B@)Q0Z+02BCL@)TN3D^JE6WO%9P4=!;Z7
MB-^C<7?@??^7?X><>.'8BV^%6S-[<6J )\1<&O $\(1HSX]0M@$\@:U2[D\S
MA2=56EJ <0*> )Z0;=P GI!2 >");0T GE!Q , 3EO('/+'M !S@B0MX0J'3
M2BCN )XL#4]JEV[-?45X$L;^O\=2'$:Z!@ZC>7KR27;SH\R:.,J,I%,#GP"?
M$.WZ$<HWP">P5<H=:J;XI$9+"S!.X!/@$[*M&^ 34BH /K&M > 3*@X ?,)2
M_L GMAV  SZI I]0Z+02BCO )P_BDVJSV:A,\8ESZ;PB/+D8>*$4_U"O]^\<
MV/75NQ4&F:CB&<B$EB,#F>#I+T0[?81R#) );)5R5YHG,G%H*0&V"6*2V69K
MKP%B0JU; V)"2@4@)K8U &)"Q0% 3%C*'\3$M@-P(":U_P8RH=!I)11XMAF9
M3&A'K7;I5FJOQSN^>O%W<>0GH7[Y+.XX[::1WB;BNF >)#T1S./-M=!R'9>8
M&CA:/J$<Q ^IP N(>('MJH,?K('IP_29LJ %IL^W"T*D#0441$H%0$&V-0 4
M1,4!@()8RA\HR+8#<$!!=2XDZ/E#<X1BPS;3FA<^'ZQ^V6BN\%CZS^IZ-+$Y
M^B&[XU1]J3CM]_VNC,7AP NOI/!#<Q98' 4&^9S+:ZGNKRO%P54LY5")DA_;
M>;YO@;_@F"ZBIDDH[/,#)-ASLDEAE"'&T,=TU6EI <8)T) 9)X[I(MCE &D@
MI0*0!ML: &F@X@ @#2SE#])@VP&VG31H"_MO)LU0,D*G'G:V&6+D_,%UG-6>
M[7X^[B1^SU<?+,W&D?E-)OS( FUG K6P/SEI7PT<+9]0&N$'1> %1+S =MG
M#[? ]&'Z3&$.=HW0ZR.!Y9!2 5B.;0V Y5!Q + <EO('R['M %O/<JI@.31J
M,$)AAP/+J3J7*KLMC7(.HS!1]Z$ISK?8[\H;3U6D@VB<R,,H&LDX$5^^? /2
M(>930#KVVQKVU<#1\@EE$R => '/^ ^D0T,/,'T@'2 =(!T"51B0CG45 .D
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M^.0<,(I"&48H\KP6C"*C@.,P\$,I_O?CV1=Q'":I%W:E^!1UQT-UK? & MX
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M'A!II9ZL=4++-M!ROEJ'\3/&W(V(U3YTXI&'P$'UF! V[,%:2B6$D3Y+!CE
MGFF(?%EO5>S(0-K8),!M^#'>K=M*128$ZF%]2Q^G; E)>03]B4X_7>%[$03.
MZ.IJQ:8IZ:<4[MJ=IQFAG1\K9XN5N57ZGLYE,K8GW>K=-IG8O81<)GSK>Q+]
M\:V([P$&X ZAU*!VYEF=*J:>T(.?W>APV=-$<GNK%^W7;2R->U5B@JR^^]%C
M_=+D?:<)P4NB[C>40+<?.P1CP]:$K*&[&++N"4GC(NDCSN#ZS U.[I8HP>6
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M*UDW(:W.2@EL Z8"?BV9_A=?$2E)93]8'5J3%%WV')V%::A2BD<0&AUE:W4
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M6#TE(D!,I[?XQ=!X$[B;8$:QZP%M&"%N[$3\ MPS]U]QDMBEV&5:3>G-8NS
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MP=JR[4_:+EJ8_H+]\PPZ_:__#U!+ P04    " !3@F%2_G0E.LI4  !(SP8
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M.T\ Y?M\M)1XKXV^"]SR==-1TQ0F)3, 3=8@-[@,;104^0/%G$"3MN./D$_
M2U3-#M48'A"0JYN0"EF(*A>XB"+#^6]X6$D[V_PL0R<!CLAVQF^ >PC8R[LJ
MWZQ*06QQ ?;%>@@Y+(_#\C@L3X=BFI>-;9@>/G.".8R?90@>.8+;A=?IWOEP
MIU=A$PJ'6\X>[P_4]<H:F?D]>2:_[B4M4?ZVHYDYK:TD"MM]EC:FQY6D!FU\
ML1"&Q=)=A]K?L T4*>+40L.6K;W_5V\WM_$484]+,& 8E'=1[ 2EC6D?)M%M
M!V8>6&LM.]QXL8S-;HG"3KJ)*4*W"\#EU8^BA[H6S/<-.A./FWX@3Y:7B6Z^
MWR]#]$\-HK_3O3VJ>NM'NZ*;/^%Y UIRD#B59O:FBTD#&(L):7LU1@M";G_Z
M:LE'.K*N3/LRP\="S;)^3K97:LG!8.]/'Y_Q$/NL+X[MK8"&5&\(],0Q60L\
MI3>5R)]MWW*X*Z*8R =E'P=5NJUU=GQD3+>H\R"AJ=HL1LV%VK2:MZQT3?(
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M:YT:/3)/"FO_$"Q0_@K6 $I^-H6(C]53\B*C-[_SI[-VGQ';C7<6&S"CUDY
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MRV0&""K8&/<IH'GY_+:V6EBE#*> &M_V41)L:-Q JXH&%<?P D3Z-^0!>OX
MR2IIE!&F*(YRJW05/1%W.Z\00AZ=.O3'JVB9@6[MX20H]%Y^]^* ACLV3J)E
M[(,<"Q 9D\SJL(B3;VC[-,BA"_Q32\90H\GX?4F6LC\/R*#TXYLIO.7VT&$&
MM\3>B&>5,:Y!G:^["2KM)/B _'D4_"-#U Q3VTI6MY?,+T/\$]YO!D)5DY3B
MW1]W:-@N@:J6J[OC"W>IW**@@OOM_6 ]H^^(/86O$!YJ.J02ZX_7164?I%"U
M0IHX@*Z1=AICM8/[ZCT'BVS!OP@:'AJ--W)D@?.V^=!8O-W1 S6,LXU'1N4+
MTLZO]L!8/%UD,5X"E;7YS,@MN?]ZR\-6_=NNHZ39'27SF$)S* +>6I*#F.LQ
M*5]>UV/2]9AT/29=CTG78[+5%K@>D]P[UH'UF.3P65RS2==L\D":3=:/;L9T
ME)0AV.Y1F75T=*V6UAJJQ3A8YSC=52N]JW@WE(,; DDV= ML"YCAQI"=,<W]
M!DBT&2!E$KF=MN[$M8>[*XV],V>S[6IJT1O\[Y&ZH;6A]B8_7 Z[','K8IOK
M;@ R5AU2-V4+F?2NRW5C.\"MG#'3EVX</I]YZ,F>=TK<9!IT ^MA72"%A:XW
M1-5M#0&='MM@'MT2MX)LF [,-XW*JA2[T5>5RC[J=A\TJVPH[(XI4O=QR0)%
M]N$SF3)UQV+UEQ=PPG9M:'>KJ#@*AN5F[70/?.%R8/:9KKC7I<E%++'WSZWK
MI1I+*MXJJF,18\?.4A:@K*Y69']J1>[PR@O3%3W5YQVFJJYEG"^@]7EY51V5
M?T)LXC1(\RYBW/P!*+I:&U=KXVIM7*V-&;4VKD[%U:G87M_18G/;K\\DOYW-
M@\@#@IWY"3H O-D ^/8[ACFG0B<-!W>7+Z^#NSNXNX.[.[B[@[L[N/MNNL3!
MW3OA[NVNBD.Y.Y3[@:#<@4<X8X#PAJP, "I5>[]P/=C,M^:#L$;$9NKN<&[8
M,NG%9KZUP@63BE(TN&)!&4I1=XV# 8 3*$I1.XK9 G =%TKQO6ZGU0)%<J,4
MWQ\X<@R >& ZT[WGZ6YYWX9B81HZW.U!%/OJ+NT0Q+Y^L+(I^7VV6'CQZF9Z
M3>2,$E1^3KY14\/.Y23?(R)T16\D;*=\UNS >4J46T%>2>@N-/[TD1#YD3OX
MG7WCD:#^[<& "[EH"V&HA440 -<L4JZJ'%9& E:F9L#7=_:5!@ZX6OH)J< 4
ME!L4'!.S]>!8[[^\TYMNKFM/#C9G.PB,S/--7 X(F:[-S[JVI@[G92/.:]/%
MI:K[FH5I0'SW<Q22HUU,XR5UK8.Q7*(C&"G][I%V# U<:\9B25!+TU7JP EP
M(.BJ@2O0(:@<@NJ &H8.7RWM/IQ%2*E.!Q;W^M6V@*3ZSQ:X];QC#!A*AHR<
MYU$FLV8+IW@]<\$?=:?DU<(?=3>+':W)[['9)FMHDU_=_0*-07<;W!M-'+_+
M ]XU.)\.7KDT+\.2M^:^T5%/OK"\FD!/,9-RW;7U?QL39Z8&3MH W130)?)@
MV7$G*3[*]1OF\90<DX/BO,=.Y*.;QS"8Y0\G)R&.9E231''8#^A7S]$4Q3%:
MLS%2MMQ$X>S(MQNE.:$N35XR;^0UQP0T*X [=B]&7$U%ZZ[=N@Z\QR D%@D2
M!.TA))0_.<L669@CD,KW6QX!>U <_*]%E+Z8--0;:)S9P$Q0/R$Q_NJ@K5KO
M,XJ8I)L8\6?P8A&D*4+K@RR4<?$1'/CC,,$?#@/@, !V8  <3,G!E!SXPX$_
M'/C#@3\<^(,?_,$1-'3@#P[P!W?ES+Z#/\P-KVL"?QS9<J^DPF2Q[DI9Q;UR
MS$TZ#KP1]K!P$#VXIF/C9[4L7-.QV1-:"J[IV%P4XVBXIF-S-V\IX ]S03N*
MP1][\)Z%P!\?]L!P#<WE, 2$V;, H(S>C!R[%LU\$R G0C LP\KTI;NH036H
MJ">1;M,U<3(GDA""8JVLHS?<B'^3L%95$XOF1A5M!)HN,'LW=G\1Z2S:@7L:
M0?ZQ[JFB,,6J!\]EEN;R[384X\Y)21U3.];I;$ZMT%7T0,ZPT]A;H,;M_)[\
M-YD&%> ,!CI2Q,B^8&6L0Z6XE*]+^0Y*^3K\R 'B1URNW^7ZAQW%K,GUNT8/
M4K*79C=ZD)Z]-+B=P[#LI6ZH@H$P%K,3\PIA+ :G['7!6/; #'3D!O>A[ETH
M)?;.7,$U1/B'AW]LNJ1"8H9 :CA2X'X*DQ('9E3CWGHQX6N.TMQ8['/%=H>D
M=J0QS%6C2!SV/ELNPP EWQ!_B?;&,]JS$=*R"0;(0F^3R.*8LUX>3')PMF/S
MSL4!B8YF0B[(:D*0U:*Z:Y>?,38_X\+T+DSOPO2''J9W_9A=/^:&6.8^W6BO
ML!+/^%[,[M9ZV*WU-J8R% 9XZV=7<RKWC%)173&Z]U"E,>R-(!33@=V78I9E
M-.7G1+2QH>@] ]H1D>V5QEU+R1_F*4?Z$N,DD2W-P %4'+OOO9"F8M,LCN@4
MHY'ZGS0X+Q 0ZB4E]'[RFF"Z.O*<0KX*'JEC 8S$]9$1;(M9O,K,"TOA*4UP
MY\LN(D)\$3_B/]&JS,/\AI-ED'KA=9"D=(;]]&)H))N;GA"W>5;I9/+W;'UW
M-HBWEJ=5K)W?O;"XJ9I-]<+=1?$3I LBC)Y^R6A8 !I7Y:6H0KIRVX1;N*T'
M74M-O2TUA\\$LB%X,^)B%6GHJE(/'%COIJ-1$J$@>3\M+:%P;A$Q[XLYD+ V
MURSG:R-D=MQ:9ALA@P/3X#9"6_N6?3%GWAD,]3;,";)QY6. ;AFW0FSJH27D
M?./NPX(-?;4&R<U]@+.AV]8@372?MBOQWYK?BD=(_+XP"%. N<DH405PQZF8
M$LPW@Q"G>& XDJG%_.(!D;/"L"O;WG%[$"9E8G8R"(WM9XY&2LL(C6Y'C@8F
MF@HDZ-K,7>+X'&>/Z30+=Y'Z(  H)T6%Z$&+TE$NE.E"F5S)I37T(1"X4ZV5
M@A!'N<^PN\*!7/504;%J3KV0VJW[.4+I->64F&)XNJ:+BBXIH&F9=AJ"R?3'
M$O15G3& LZ.#@BW)19<LEI$L=BG:0T[1WOMS-,E"=#.MN=I/:!>*[;?\N8[+
M!J?SQAA=3:WE8&YW3\A<!9DRQ]627!Q%=7C<*74@Z<L1;<&0E)'9J5#E*2.#
M\Z6*4R>ZLZJ:4R<6E'2,DSO<TY11QXG,F+RI87M)^ZF:Y5"L !STAAAZA-[9
M)2S(J'$$AS!?*(M);?[>")"Z(ZS()+8%632N0>! U+TSOLA5%J+.X&9^TA!U
M[\RW;V.?= >FT<W'%HRM0-Z\*KLKC7M[,0EZ<$>^022D1RB*S\B;RC5L+2-!
M#X1&MP-Z !-M2"JCN8@=I3=3,63! .*#4C*-0^7.G1RN2U+R>;R*_!AY"3I'
MQ;^YT2TZ".3F)BQF27FSJAQAH&/*E_H<T;VWYM(-$ZA&3CZO:]B/I)E4(Z>]
M>2,L0S"@$:6[4LFU[)/=LJ]E3IW'V6P3N@><1^T$'!S,P<$DP,$:+2AWAIN;
ME'P>=\\\@_B\UI0P%A%T.W+6I?@]3^I"Y[(K2[4FS;HW9:G2[GYO=P:,R9:.
ML6!['#,F.W?SLCUO@GID[H0?>BH1O-#)X&2ZH .P1]T-1W.!:M$-I@=S$P*C
MZ:$6D3(',*!!#]!0(U.6[IU%@[+*(+,YB64-.FA-#S"M<)M5DW)ENXYDU0-T
M]T\C9<P&\&!'WDQ$0%?:"HK7Z[Q0IR>+,#1QX'(%+E=@5:[ E<;)DLV5QKG2
M.%<:YTKC]@V][$KC7&E<5V401WI#=RK'L)74FQ'1';,Q)B-B;JV [(Q(>Q)$
M=V[0F+OQCLPWH&9751QSVQ6SHYZ-3?24Q3LY1K<UTMDEFFZ<L=9+XA7(=R99
MN#,^R5JB6A=)&BQHR<CO7AQ0/X:,E03$CN13HF:O\GIX[E@7E*QK&@EX9_T7
M;G*^I7Y"-D;^Q;&_%UF,EX"P[NXSKK+!92N,R%:<W%[=SX.ER 3:?5*)]MA;
M@R<C&AZVC^<_CY5S+9(<:7R\G^]DS7B"_%<S_/0Z1VW$JX+O\I=MELN/__SK
M+0^']6^/M47T7XO=LU]T$!B-Y]YKR_MX;B?@4JDNE>I2J2Z5ZE*I&J*$+I5J
M> +(I5)!"G&I5)=*;:@&[7 _+4FE\GGAN/>$8$/"E.^4A#>/:\8D00V9]IV'
M;7.*I=BD1U,O"]-F574%')IE90$1<VZHY,-*"(IJUUV4[7$OW!Y$-.:N2=.6
M> ](Z+WN2D!30$+O#P(? RF;?F^N>\SM!>SFT"KQ/ICKY*@%1'W0O?=)>,^<
M"6?6Y=3\U6XV".RC;N=0GP*%("B5XCZ9;W;&GGE\@*-*8Y\/=ZJ!\6=KI1V]
ML1.DB::(2#+1@= $#VT)/)-?+MW816F@10-PF">/2?Y':3(Q@B.C(<Z^0= 0
M]-L.#6$P&L)$N*0#^QD)]G,X"(>#<#B('>?;X2 LCW'; 7M0$..V /"@)N3I
MX \._G 8\ =Z/C,&_F!Z)(V=L9G*; @^0N(0(MV#N7/$ZF*)EUX04W <^HH\
M^GL^1ZH/DYOI91!YD1\0*Y DB&X!^=<F-]$=HM'2()J=>DD@=B/<.(.;$$^4
M+)F*T$#.1\4B$P44!&@GHN3PYR5S8M_H/Q?_R((G+]Q0NYA, *)*0CA/9$)0
M!^02Q_3&]WLZ7_*[ T$OJH.*DC>%XC28DBTWI8OA'"UQ$@C<D-1)1H4<7W&$
M5E^]^ =*+[-H(A W:Z.@@GLZG],5>_=P[MLH"(583W$T(2OM:Y9F7@A49P\!
M%=K\?O\0YV9\D$:[J*B0XBIZ0DF:^X*$VS.RLF;$6?EGGM^"2\-#;1^E4E4E
MO,D)-+K=]+0*KJO-\RI:9FERC9Y0^!;^&CK)Z)+C6(X<Q[KE.)(CQY$6.1J]
M[M\"%)/CX'P%K_T%$CX<6579N6K\T]4N*_E$@]H^7HK:WF5U$!RP$#OIZ9+L
M,D;_R%#D2YJ;.^3V4RX-*ZV)F0'+K)V<4KF*& 4Y)JQ#=+F#O1-^*>*D\48T
M!IQ%ESBH+3K:C1HKTM.UYO3Y.,K#HTRF TF;RU_S3:^CR[*9F#OO*@*%6/\F
M773O7TP;NA-H7$B"\91A%Y8 XNSTZ&'7"[4/2Z#*JG0>2TS$%' :%IX#7-\T
MZCJ/,M7HKM&&6IDQ-6,'+F-8=*-)-TVQ*)N '*-HXGA7$W9N0X,U\797$VX?
M:DD-"-Q<H'7/Z4B.M$K:ELPQYQ)TKDU%ENAUP<W?-0!9OIH6NC*N3'KS=PJ8
M]#T)<R:X^1N#V&MO@RZ8T\MH+,G;("<V-3<2D[P3+V1,ZR.(+S16L+$+(,;N
M;?_@% 6 ![).,4YO75!1UN.#6T\F J9K"COSB%;0Y"3]+4A2(HKOA6<X24<&
M34,9L LXS2V=@L19C9>!:.,^2D+ RFNB2W3S& 8S#UC=W?FXTI1DM_G)[<WW
M"#_2AKYTV\J/^.3/F,R5,,CY/EVQYCBAEPA< :" &:=3V<QH $YLLC$ ,M%$
MR $T'4#3 30M FCN-V31P:D<G,K!J1R<2CGPP2!$E5'9?4L!12-D]W4CB@S*
M[IL?T%>5W;?E6@-5QK;IB,FT98Z-Y027=1R]F^0?,^A@#LH(NE,9HD1+X4FC
M1]5P3US6&"B3"7FFOH Z2_=SVSIUR:;\#2?RVG=STS,A%=3/K%@NA$PT=+/,
M;QB(9OD@%\_+H&C]?8O(VY]L:J$S,\)#3$6LH8F3!Q0O:,.["-Q!FX>:4";J
M6T9-P<UTDS17<*/[>74Z+A*0Q>R\R2W# [[(9SY<PUVT]$AT039[,KZ/J([E
M"==!5F@>D:7EDP."-R/;IQ_G<^ FNO#\^4D4!4\H3KQX=3.](U\YPXL%'9B>
M)\Z]E"O>.'@(P2SMMM:8[9-AID"4)4FP^;*W1J4698 ,'+0E22%1\3IWASH?
MF];\:-CJWB$V:&^H4X;O#%M/J]#NS70:^(BBOS:N4N37: N!L>Y6^.H]!XML
MP<]GPT.C\4:<2SAOFP^-Q=L=[9(*XVSCD5'Y@MR-47M :*46\_5^Z?F0#F>M
MCXHUBT/!WXG_=^'3LT/@/R!_'N$0S_(VOC3VA_.U=$)V;F@7.3AE(0GNYSA&
M$7&+@NB6WJP8TS/J]?49D-T^,BHLX!T*Z1UNMUZ<"B3OFYY6S76]\?'IJOX7
M:)8>0E6%E*=9$$Z$V@AM/ZF"VW(*KVY#CRRQ:%)MBA3F#Y]:7.2TRG6Z$NG<
MQT5.G6>9>UOG*/'CH'#*H<B.3C+ZY-B-+ K+<JT93\$K(.9\*0>">>"9WQBX
M+BV#,$!,%X\JZJ;7)M0"9&O"[;NH,?"$L=8 Q $RL8U)QU(0\!A;%&-C4XX.
M+Q]S'D;,R8E+$5?@J&A3E2G0XK4>\%G!J"WH&TZ3MQ5,,:<PMO>BI]V8$6Z(
M6#&!S$42M$7F<&-LL)+HO;F0N#Z)-B.Q3**],R@]\7$FN;FS4^#XU97.J$3^
MR'V7E TB U)+3 /FGQB@+YTG7<CDW[])+Y3C9=T"S+7H\A32F[AGZC!_.X"J
M8P@D@^G%_).'%,O9 ;EANM@K&\J/K6(*V#\CV@J16PM-CI[[)#0$L\A4L%=&
M (!%K33 7Q*D#NY\ZH5TR=[/$:(6?(DC6@1TGRT6N6$_6> X#?Z))K2YRY<8
M)\GWB.P"(?WH-YP'6;\0K28W\37Y&Z)@\@KR39[>ZFC%.HB)75YJ!K,F +4U
M:\)=NCE8BA/?SQ99'N[<>D'TE9RB*8[1@_<L1UCNP4S5"9VMRG2R-9AFG=27
MLB3)-TFZ:T]MN_9T7Z[R==>W[DICYO6MMEQS>N_/T20+&YP8-C? 2"D 45-D
MW#VS2)+S6C.F2DQX+/0R0: A>_%6\#7#>VF!=H21KL;]VJ$U6AOW'YF?*!NS
ME[GV#AZZ[BTXT@W!T'9OP=$GXR4?O'%RGR=MNLUA3*WPQA=L0/QHU==6C(KU
M]#]H?0FEU'0G%N3U51&F;V[X7G;?E3N4)^C#F^EMC)X"G"7ABJPR<O(@2RJ:
MT4S=&;XE\Q73@2Z>E\19!I1_BY(7BMBU$V;7$JR^X>@LB^/BO,4G!)BNDOA>
MF3W](TCG9UF2X@6*67LJ?@EA]"2_%Q&&P22'\'SBI\$3NIU[9*7Y*$LI@OPJ
MFL5H$A#:9-!)YI-_ A^=3/Z>%5ZCH"R#AE(QX\A9)D9^T0H-,K,VGU,2_<J6
MRQ"8!63/#.J2<8=FU#_!\>IK$))C!+':\&89S40&=N3)3?"UET7^G)YP(DK^
MS%L&:>% $>]C1B;;C/A6U9_++8B;?SF#*>D-DLY1_##WH@=$=M;8BU=7BZ47
MQ'11%>GN6D*[\J_(AIL(IYFE#:E,/V1+\PL#L]'\#]Q&I9>6DGK[FCMU3?FE
M?A.X<+V+BBXIH'F7=AK]$B1K$1+DOYKAI]<^SHC?L"HD*'_99K[\^,^S;SQL
MUK\M9/*^$_\<3>Y3&H$[B29W9$W=3/_ <3@!)G#["8W5.N8BHQ49L)XVF\^,
MQ=E]D:OX@O L]I;SO**.>Q7U$!B-9_H&MP>%-.;I("#F7";$U?YO%"'?.R';
M8-%4&S@Y.VF(<H7"T$O.,/GO(RX BA5M.'L<Q)3 9N*8%FT5VVK>IM9CG]2K
MA>$[&YBT"GEIT)KX5XP1Z/[00L"4M+5+S;O4/# UO]>M4 :EYEO6NF6M4+I-
M'AY@L,V!*?3G$40W.@S:LHWIDZ)&(^T^EC&WN(QK*7K\7W, ';V]%?J/ ;CW
MB&)#HQ2^8QIN.C7:<+$'MWB<9W@;KN7@EKD>/&$M;?;:0/6'M1AX0C?DCLN;
MZ8WQ]0B]8ZMTM_?AV*DYHK,8$E%FLIMKIZ6=B:1E%IC6]ABK)C%395./GV'Z
MZLY,,CWL\;S9310SD)GN?46!V)M9?":ZN8ZBG)DO YW!F@.9CWZ6HBTN7 [3
MR@%8#3YX%4-K[K%%$</4V=0H:)AJ1#&3%D)]F:+6+0CKW0=E]O\ #&0N^)=+
M"IVW)GQ#(,QI-QTER6%64%!W<,C/(<H-1C0I*U>*=CUM#(.RQM+&U'I#1EZ
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M52\&4Z(&9_F(\C >>HNA=B:.R_+/^NXX1,$<IWZ*?AWM J^35:):J6$NOYI
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MM8*OE13L*Z1<L4V)*!][F^1_/\]PG!3PDV80.4S&*NX8(NOC27&#&1B]8(:
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MIO-,<?O3&DII@5YP44Y] 4YS9A8R,-,9@+)8:QB;[_J<G4F$F$CEA.!\SCN
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M'E6QZ.8C3;.VYHPW"@Z9.K /6R%FG"\:HJ+SB D$!Q %^K<DA^Z<<!=[3O-
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MJ"XMETBU:?^W1XU@-^I1?7H,':<1CZK=23!TM6^ /IXX>895#Z[.+Q*H0O4
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M>Y8RH$0*@3"7 A%X6I. '"%XOAGHU%SM1A>.*GSNX2.G9BDI>C1)SN&PYEC
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M-5ZK "%\U"7W7)?YE-;3SW14JQ^AT?V]UJ_;Q\@6<GZ[;3,N,*:O/B"(AH8
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M@CU*<O[ 'BXWAY;8*=CJG*7&XR9,MVS7\C'(\%B3:Z?EQMC::$]C9CO)&25
MGF$V0;##LKJUN8S0H$[;6G$!_>&,@R3]HX,5[<1#C:JC1)(M*OBJ7?AG6YVJ
MJ?N@@HP>SC:E[&8#;IC3QUA\6N+:L7FJJ]5E8=BZF:KEKSV/;4]PY.?63\UI
MNSJ.FL-78:X5K?'M/$#T[['S8-EQZ#C6:\$EM[V)4B6S=9\9^1M55TZ4<T2,
M)<AD2-7)@WCAV5$RU$K9RT3:PNG#)T-]N.HE0YU:71:&>LE0U5&E )"2H9%^
M:D[;TP0ZB:\N,!G2]%<[W2X-2]UD"(+7=E2.Y-5B-R>C74P;JF[B<3\7?_/I
M&I"'6F#9,9?J:',YN+7.H6H12LX94=8PTMSB7$Q1RE?\(WO^CJ-W_(7$V9M1
M:;$Y;;?P]O%R[YQ4P0.+RCE=4@O3 <<<UN?2\.MUTG/519D$2(B A S 7/7O
M.$B>OQ.7'EJ0] >L9.'%'W]>AC_6@3-PPXKV%@*2B=,QQM3I"$17HPRMN^4,
M$/6,)&/BQ>'^O""'J\!GZG*E!A<#E;G;,=[ ',^EO_G$SE<CB/TI.R5Y+[K\
M*L8RG,[&UWR[V.2>!<&=OL7YF1'>W?[8XC05=UY'^U8W8<<(=C'RT3-H3:G_
M9W&M"K"K#<(ZY'?]6ET&A'H>J3)'@KN\]PW!/T?[H7.P?#3%?* DV/W$]R"B
M"4=;HP' OJ;M4UY\9PH? ='!?OR9@!E=U]W!ISH7J!WZ /$<*TP'F[_[.1V8
M'K^.\SIX)P0L <*XXTZ/HY,">QYCNLO9\;SDDX/16!-7^ETJKE&Y:L"X^^89
ML*,%79U9'#$8D_:/_ <X<K %U,)_'1U!S *>E;?.="9AI"#3LPD+XA-!?>EG
M%?:PVOJJB[.+F2 <X:\S'&;H*LF'HTX![@<\Y#"&U,))I_+-^5P2DA^Z. VQ
M9. )XH]^.C(.;EV']75:,@>TAJX,YOC$0<\D#_V0O+:_6>8ABD%O(T]]BZ;H
M203E>4;6T'H5[]A_;O]Y"JEQL(G7YOADB)(]'OV4W??W9L]G\A\4;MI/#$[E
M)IK $3,U]G<8<F=RIH8UUGS\-,B'8PE=>(\-A>YT%^FHS8N]?2$Q/G\)DM]Q
M=G>*=^DJNPZ2Y$QC[Z]L*C0QQ4%2]IH>(.W>@#E#=. <Z3*:LH1ASKIP$4/=
M 8<F4E$1S!#GAE89RODASM#)&[<=LX$7JVOLVO#>W &=9OD/N.0_<6A8;;?)
MB2Y0RQSX6KR";I, :1"SM\%!XDZM4'*K5!A(?N 2(7T,B;$ZITB'GK9O>'>*
M\&:_>@]".M"(]45]HO[PA+>GA OWS'YK8HL&1$>\#JG+Q/WDE;-F75T+YKR!
M*V./2O[H-RX!$%LUQYI8JWLQN$9>(-4<Z[>GYP2S%YO.)8,O^/""$Q][,-_^
M]/0GE$F&*"89'0V;!FD0BNBX!..IB[9TX%Z',;[/\,&H4LN0L%^#+1AY#$9$
ML=S/>Y)\3NN6RZ1 7(P%1:0F^(91J:;[10%M'IVT,/:3SG8J974@21;^"^],
MWSS6)CDBM=5CX7XM4I ?>.%WTFS6$$)BJ<>%P)6O1WH]3A?'J7UNNST=3A$[
M ?TE(6GZ+:83?\3D_"4(XRM,)PC\'/QPY(VZS+P K\?<_<S+N:&2'?HKB79L
MGX3Q!;*?Y<Y ]'S=!(O%&X->?"@E0@V+84(A(16B8BT@>JSIOR:+'C5FTQI,
MA;F/DI3.^,$X0SD0=V<C(P-("QS+M0=G 80)I15 G"C'0Z/ ($R&SA7T7IKI
MEOJ*Q+M5O/MRRDY!Q$\UO@09_5O\^K<P>POC3<RK?W6"F2M.EN^>C.;LY0V;
MTGS9TYY\UR$MS?>%2L:WF0Y<-G'8APY2.O2=BX<(7;6R-U,@O'CCSI*(6]RF
M.!#H%O4&OV1"./7%5#<I0!=M'Q&^G=>$ 9T)@$H)X)UIV9J U@S?I_YEA\7*
MZP?5L(8^HZNV.#C^%00@8]<R?*X"5M\F9)(5!KE42.J,RL5OPH!9#+$*A4PY
MH7$3\II4?02[.A?WEBXXH#!^QVD&Z *,!9Y:\:M=H\O!3LM3):CE;Y:QL&B4
M^FA9I>=SS?M2!IND:8"0B^.L%L+>CJ\47N 2'SW,6H\?.U4X1<Z^R=YP\OP6
MQ,_X<"1)D)SO#T>ZL&;BB+TD5;S<">EB+:TXH8E5.F,YXJ*$&Q$\-#EB@GW.
MJ&2?LUPT%!:RH8@*!\/@71L.\83.A1A)I-@'8D*A0BI4BB6W?RN1LBZ9ULSL
M)=8PJ6(:%\Z/P7>:N>,D#"*CR-%!P![B5H+NO9I29[M6@CP,]^W'@FBI"*3>
MI:,4'!!3_I=AY?NU^+^1Y/?[^"$A[!ZIE<G7*#C0?86BAVT,2OYS&'\^)N25
MTH)F]^V(M!E^BYY@:K]A^HP'G0N0Y#*7\=^%<9C2;/<70G9VQE^CX$#]%8I>
M'K'BY-$KHP_,]-OQ:#/]%BW!U'W#] L ?AD&P%3^K]A#35^YZ<!XF"1G'8>:
M\M6[X)4N,1\2:IBG>/M6C.$Z.(:9. C>[%>O-$*S\H+BSU=!Q!KF:I]KNF%F
MN8?O@KF7T\U2,%9A?4PP=4\F6P'S&6U+Z=AG@EP^Y2,O0D((QYM.;8HXAV_Q
M]J-.(4Z-9_QA$1PE10W];/8TQ<%(R(3*24"1BI>_%_HI/W(UI!\OJ1&5EB[9
M=[<_CCA.\2K>\77]BJ[=LS$7.8W(VD_D!FS<(B[X(LF8'P>*#1'!&^Q-3QNX
MR0A]C]C8/QV/D9>=S6\QNRM&'9'JBXN* CX -W?")4UV#'Q]2C-RP(FK]C>M
M]9<W>(^IXG<HP322G'"*&.)L2&0;\G*[?)@.SNES4+SDG90H.AEC,T%4E)9M
M'_\* JXBG23H8:J7@4W'(^:)674P.J-314<@%=\QF4@>4S=W:T1RXY.TVK='
MGG=4J'DZWT);.4]#LO<>).I'4RTZ@J?URH%1-3]R,N5J)"6^-DF.TG6QX"UN
MHA,CR]+;0OEZ8M?:-_M'_,J*Z.EZX4L889I>Q'HGWAI$+)>L?42];&4(AFR5
MF10LT:'@"6%S0@LMHJU L,BH\70 EO&YI__A1)61T&5ZR0I]T1B)IU24''&2
MG1^H>C(:W%A1V_%@O2P?)#8F4QH@[CAK$MP09\=7X 5#@,MN71")L3ZG;;#4
M*=2(_DI#-%U4!_;S\-M=J=]48397TL2YM8Q01]=+P31R#:>GEOM!BM](M+L_
M'!/RCGF]E6B%9.*2O63&]%CO).O>\0IFK%BQX*;1&&I*/]/!BQ@H$# V41V6
M>S-8_/1/)C&=0D];MJ+@I2^\+LC<8?KIC.@9W$/70Q]FA1L*8Y3720%S&BW0
MB(D2(0,4M6 C"JATL9EV.;*V:6^G0\W#@F3MKY%=?W*PAM:[S@!.G97)VE67
MNJF@TUI,:J$VK;?Q%AI./$U2\@ 5I^S1P]A>*\Z9?4*O"9@;*9JPZ7B4HD38
M$.EXTB_]$/GJ3YXWGKG!QP2S0W$ZE]*?(\Q^H!+*YG?\]YVJ,G$V=SQ'=3MW
M(H._9\P"I2703A$1A@\[MQOB"YO%VTBC<7YA%JI4J!"+1Q55L-XM&4=GC!U#
M]U()TS7%Q=C-:%2U^NC178%-GHV.[HPEGAMXH(3IA\-M$+&G-^2/S^Q*E4'9
M@BE%VY8NNAR\')2*(VJR1]D;1MO\^1/^=EV*@C3_BZS+1>D;QAG:L:)4^A?R
M$H6OG%"*PI@?9N_HQQ-R>GVC_PWD)YF!'H-ST3=+_5J"A1-GA-<,YRH0CY;D
M_\B8%NA4D(7O_"+H)\8M.O$.@MD;82_2XH12/E!"+V?ZJS!A'!/VV3^A;ZF@
M3PTGPMM,C%0>O!]9?*#V)X>I/-*'_K [X7K/+D2EE[]B'X\I2Z:]XHVY[7E+
MQQCN443B5YS\$<(YL[E/$#O+[#]CZO?8%<,6/[P%5*%;?,H8A_OXE=I32.G3
M4+<[;>E_PBU>[?YQ$G>%+5UY%*MQ/CZ"M9]V=O+Y&>Y9U(DJ@E$?RR5CFWU,
M-/I?*AL*"N%R/P)DYRXLB3B&;8QGY+7"RA,ZSZ0JRTV8T@CY<J)V;U*6YX++
M.'^PX^K5%8J28G4J8)-3U3=VBE@ G6"DT1!W,(TS?>I;!\( DG5[]N;=36FL
M"7=1]FRF[**ZX%L6%GX&:8J#(#;,K5^E8TR*4MZ'V1.U79."_2$*8S/_.D6O
MIG/D[&@F3_D!M)<>A!IY:;O>K.PC7TT_!S]PFI<'FYI(/Q';ZYX]1/U< \XW
M%C+&L5FM#,%8M. BVAI<QM*]=@>G?ZU,)1OLW@-PC.7^'@]6ZC#Y<^'Y/SAG
M)S<$0"W05(A7#_>="Z_+&7$-<"$/J@J$2HF0% EQF5 IU$PWHFX/QXB<,7X4
M^UC-ATY-CH0TB-GOXP\2]Q"D@C/]G0A0^4:?7F2:Z@!''SYBK$GP4$G7R[DA
MR:[M-6)G\6;.)7^MG,UTG7\1.JB%VT(-*N;/I!Y_57$\F(3?)71E3M5;/R]F
M; TX4<$OORKL'C!?"]9*#TKR(]C1J3W(J@M6ZJ(K=K'E?^,8;P/P0VJDLWPH
MG(\[6/RO$%M+JVK+PR6,HUY_Q#DIC5GFR2$5&\1I2ETWB.ZP50(Y1&E4%4@/
M92]65C!"*4[>:;8/)&?4A(N8*0\V-"UQK$"',9NU'X40:MS2:XC2V(X)790]
M]:R X2F:\#0:5O0K"S84D8("ROW%:$7E<XX9YR1>_,.W:S3Z<01YU4.C#8>R
M%H3A0$:^X\UMIO$8*U]9VFYGM02RN<.[?:/C8 TQ$4ZS\,"W8]Z#).2U<]1@
MTG#':\V&"J!=-*)S.O C24.F>R6]*]9TN=N=Y\@>%'/[2N*M?3=+'6HCIZY>
MZAZF+]452X;@&F<8X%A/-30T.D7KC+P_(UV/YNO>5LE,[%&?IKU5ZO+PU9F-
ME=E^IK\^L,T(>-.W,:S$5K5+@5"&EZ(?*>6J;+^TQQLG,]TFK]'F/0:*.<[U
M^*KS>\$418RK:J"?4$SBSX,C]#?O/9WB77(>'66&:8V<\WIH7_[:60>D^I0V
MJ##H@%12$,'-:V3P/6LU%J"D-G=IS5M&98YK2ON9DE:.GZ@,2M"S+'[4ISNN
MHDJ7C]="R1(@];20XE>L5U@,AU059XL^&:-]JW++1TQGRC2(^.,,[R$YI=&Y
MFWM^DJEMKK;D+:W6CIT7X\U%D8]P2&&*/2]FTTC:-&J>@$,PXI&F01Q@LJ3@
MU5;=T!FY<IR=;:A-.];Z3B$S9L:]4O= AUD(P'(%=YN(<[IYI39BV,>;Z#O$
M?DX]1#45B+=T<A7T6T91$>.JT;;<,+ZAPD2$7[_?E%>;M2<K36HC&SSW4O?<
M@SO?X]Z5S-5+X!!F'3-(ZVVY-90[S3;B2W;/6\%9-=MM_?J8G:4&.?>QD#%!
M)1=8G7+[\" :B@*H^\A2[5[L_5=Y,O889'CU(S3J==;\KKVVZ[3<FWG. 3$6
M,(R[4_ED2#'0%!VUZ!C]QNC/:= WY!"$L:U)Y]]VHVM![<.9=0V"#L-6E0-/
MW>W&+3CHFW='(GP5Q+]O]G=A3,>WNX\IM#C-& ?]+LEZ="R3WP&Z7M)>QI,E
MO9(K"B5;E%"^$%)=7="(B1(A Z1&G#HZ.4_I%UJ]K,$,+%+&M+$?TP1KD;5-
MX^=.$J[RXK6_%L^-!'D-K:OS$$"="Y2UJ_[-7L'H6JAHXP!L<Z7]&:V!G95%
MC3"J#$Z\H<('IS!%&YW!^7D^A01Q^HBW.'QGB=15D(;ITS'!P6X3J\F;2833
MISGB\0Y-'EZ?A#^2D+WDL<,,T*(=(YVE6%-)EABQWVS)X7BB/^+]'HLV )7<
M"4;8-#8#8@O%4B"7?LN9HI(KXFR1X(LV,=)<[$V0C:CYV%/&BJQ+4[5/4/JI
MNIHF^[BX=^%[U0$1B5LGG&#WSIK#@BFZ-(:Z,]495O9R8.U(B*J+!<$:E;R=
M=62NIP_7),W2VQ^RC6\NA6E!DC[=T3W:M/AX+4AJRX>X&*B0HX 3PD:#+?;-
M/F\&NE\2SFVU&VT!=LM!Q@7(>5KDLOW!A,.NE7&8F/7$:4/.]D%T+Y>5)*MX
M9U<LK47.?D;1(._/;H<1FC(), &.6&AP 2!%M0Q.,LS+H?BU"YU2:KUY_IH<
M#B&_+\DZ=[![A=1MZ>HNQ*G1WI\!,<M(KT/<RS2N,!8M&U76$.9K(PR)L3JM
M"H5[R&O7MV@2<F]/#NLN+LB6&G4P!FH$C5&UOUP)$&]<JO+4JU*",[#(R9@\
M[<J*@M,'.J:W(,6EC%?G:[J6?27)>;-G42C_Q,ZT4LB:Q9@-/"N6'LQ8,F-G
M#8P=*OC!R//&PD\<Z7RA4!=;MWFY=,X#E6*@JS,JS&!3-X-YZJ2ZE=:A,O-B
M*FL6/DRAEZ5[KU\7-PA:[.$36FY0T+,.K:"@ <E"+4$K*/1%!$?%98\XQ13U
M-YIJ/"0X[_S^Q':EE:VB!_;6>7"H/_$^?$/0AKCU_4!S9IYN!PI!Q)-\ZGM[
M*3^F53<=CU(<"*N)4:9 1J.P.-BKM\44S*D<GXLW%+@DE6W77!:'A7#S*2&J
MC7\EQH^F'?]TVTT&R\^URR*HZ4:HMP[5&IR7M#1OIW8*HK).R23I["!@GTBT
M$O30-^64T0DDYD<UO*\-JP>(\J9UHL.\=EG:5&EB/UI$2XD@D2G<I."@E,U-
M[!+?8HK$+A07L_,<42GB*X[XKH-CF+&)@6Q_?\0[?#CRO]MTXG/'TQY>5S(X
MM8B*4&5:KXBE'+E*P1"7#"FB@>O_Y]S&B"\<I[@$_(BW)-GAW8#DQK>#S>C:
M>XX)'Q_9LN".!GT%UE5C*]3)&*TO">'(/;AZ>QA?@OBT9W-P@FFF^G0Z'J/S
M9E\^;F*X:Z%+SG+!JD?>R\Z$PIHO5 5SML-8LH>P$V$(*+'0[ + 4R.F#G(.
MU]-3#C-JCG!5CG!C.,(Q$>,A."3X/3H=@A<G(:.%GE.S:]"?)&BDA>D=2_YP
MHT8WJ/UAHT.Y2P!0+W HS+U'#D\#'0P=9F/4BQV\E6F>S9B>B+1_V=*HVHAY
M"0&B2VS!"8*S]Z) !A4$3N/-MNL%&X?>Z4_^R%;T.9?G:YL+\^:TO2_BUO[.
M.$Q6<VMHM^^MS<!\S;YV=5]_'L@MUNY::,_IW3<GS)[<">--C/^. ZU)>C0+
M[\#767JX49ZCK1PFH=T)(PK'3XMR[$X+,/?O=K4O%&US;Z=R("$(HI(@)@I8
MI[^/GS#[C#^?KW*8P@A4CM-Z_,]+\_A6^*T<OJGT94)MY^[W,1*" /9V#^X]
M <CN'5@\>7)L<>-%>>\(=YW(/V=RR/'[W3_"P^EP=V)[9%_""*<9B?%#<.;U
M70;;W/UDK#='^\AZVM3F+-&>\T2'G"DZ2JX0]K@T42,&:@2,4'77>@ >%QO5
M_H<454<C>*&"&7H8'(V>>S^Q%U[?2+2C*KS]YRG,SFSOG17)7+'+ M?DP)YD
MX*9O4NIE3]O2S"QX>8D.JAP(<T'$T1<3Y?,+OX"Q582!$"S&V  9J_^EX2T=
MLX*S$$ <(/%J/"X#4H70*LKSD@\_;=_P[A3AS5ZHYWP=!:G^Y7PM,O;)4P]9
M]W-#SHR=[TF@SH@SA%4LI@,9,= A8'BB\<CH371WX4M"Z ^WIX0<\>9L>/K:
M]77+\-5.SLN,Q%FA7W",!#.T.4.8= ;P(!J* JA[-=IP/HK>W9W%^AQ!I C_
MJAK-7 >RO.4AOUK+PH$,1*8](GJ(C B.740]W!?CH9#(X ADEAH$AFCK"BP(
M^?R4<Y&34C%-S=)>01VJ>>>$MF^/N"?5H/8QK+\' S*L'7CZCE15E^9MVBO
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M!\*I'SSWS=C*M1C(/J+O'GX\8Q*GF#MG5409F[[623E,I:JD?;VU%2\JM>U
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M?C-"C\MPL]00S()\'/Z&F?_HQ?F,6%NM )PMUATL UAX>\0I3MYQ*E]R'+<
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MT9O_;O^/A$4R7]]'GH=V;VY<W_)MU_+>/.8S_9]O;GW[ES?GGO?F@7X6OGE
M(0I>D/-+1M4CN/W%R\$C:^2'R5__^E,)O=?GP/L%!ZM?STY.WOZ:__9/V:^_
M5G[_Q]ODMT\_?_[\:_*OQ:^&;MTO$K*GO_[OKW>/]AIMK)_)4I%=8-,!0O<O
M8?+#.VPG:\3!UYO&WZ!_^SG_M9_ICWX^/?OY[>DOKZ'S$T'CS9L4CP![Z $M
MW]#_?G^XW1MSZ3X'>(7\9!.1%3@Y/7M[^BO]S5^?T&;KD2UTE\XX(;4.T/*O
M/RW)!S_GOTQ'^V]UOQOMMF37AR[Y%S+W7WLQ%%FOV,>;7<I9?BCR_Y[[SK4?
MN='NUE_B8),@V\7Q R'T!X10\W2V =F%?I3\-@5@[P/T&B'?04Y.ADY@F DG
M'.4\>=C> X .&)(1DQT4(ON7%7[YU4%N,B+]0X(.$0_9_OEOY$<%/"$Y=CC8
MXH"LL'.Q(TN' B+MT!.9W 49Z6#)/;JY<9#_T+.>D??7GX $?Y4_G5M[&9S'
MCDMX.X\B%*8K=N-9*U[^VR@,P' .UU-@^:%+AWI !+0("G?U^P&9/??]V/+$
M&-W_=@ FTU-S'S][KGWC88N;PYH/!V/O$F\VV'^,R#EX7%M$N"SB*%$DB'(!
MX[>=T@ 3H/>:=[\F^LZW>/., EYVJ]\-P-PE0>2<*$>7V$&\C.U_,]B2GSL.
M69WP'I/5\?[+W4)8;*,P-,./1 *B17 ?X!<W57'@+%=H#,TT7=-%\(1_^$+\
MEC\?FM7L/T2K0*="S.X3&(S=)^OUUB$"W%VZJ6(+._X=1 9CFZDA+A639!]>
MXMB/@AW\_'60&FP*-ZX'E+75[P9@[A'9<4"&N7ZUUY:_0M^L#3>@]=\.R.3I
MV?.3&WE@!MEW ^[0" 56:B>P(NLR#HBB#-1:FF@,QO3U!@4KHF)\"?"/:$V4
MD*WE[V \-Y 8C.7'C>5Y%W%(Y&08PE@]^'0X%M?(\X3 W/]R4%$47!+)M\(!
MD,.#3P=C\3?L$:%L!>F P(6N?#S<"R ]HNE#B)P">I_$0&Z;: S&].]DD_W=
M)VK1([)"HLD[MV$80Z^E1B)#O =2A&[<D#P^_H&LX-IWJ,V4^VW0^/UP&X.,
M%UC>K>^@U[\CX"&K?#P8FP]HY89D+#^"W/OUWP[ Y%-@T1?PXV[SC#U>[@X^
M&M""DFZH>Q2XV+DA/^,^^"T$!F>7[O\>S)8^'Y#5%!+@,6_X>  VS\DP3H()
MP"9Y\-&09DC""=CTF'PSA/#&+R@X?Z:2PN;6AP\^VF>K;,8_#^P]DE9@Y^3(
M'RLV_'V_3/8;OVXM>CW\;*]=KS#_+P.\J>4E&PW7P8<#!P5__>GTY.3TY)>3
MDY_>;,E.I ^0O_YT]M.;."3,X"UEV_+HOU%K>H"<NW3>C6PF/)*708B2WYPR
M' =[G.'Q=IYX-(@DALO[>>-2N5,8,A\-,@>J </F\SRQ.=#L"CQ.9RIMZ_5P
M!LM,A6[#(XKA,E.AV_P,9M#,5.IVV#08/C.5O.V6J@*>LUD+XHK9D>$R:TE\
M8#-FJ,Q4#M?9^ADHLY; !RX:ALJLY6Z#CZU Y^VLQ6Z3UY3!,U/I6_5^,TAF
M*GKK(Q88++,6ON5($P;)K"5O1[!0@=*[64O@QG@PAL],17!+B!_#9J:RN#%6
MDR$S:W'<%'7+X)FU:*Z/HR[ >3]3B;P?!\_@F*D KN8K,$AF+7?;,TX82+,6
MP7MI1 R3F<K=^N2O I8/,Y6XS<E[#)J92M^V-$P&SDSE,"#'EF&E0!S_QZ\5
MJ,B3Y4^):>&)2DNG?HEI=037269N>33Y_G&-4%3$)K8FA?.3&3,EG(/+SJ"[
M/.9N:87/R?K%X<\KR]JF@7?(B\+\)X<1>-F/_[ASK6?7(]()A>>^DUS[:^R1
M715>_RLF&XDG,(^?5G<88?\95<<EY\B+J?YR3]V3Y(!'4> ^QY'U[*$G_ V3
M8^9'9$T(*ZO$:$P$$F3>LD94@<Y7UT\$A,@\J]^.LY[]UD8-UP\HLEP?.==6
MX)-%#L]M(M1C6F'#N4)+UW9!R/-04S&KTKB+:(T"ZG(*T!H1_>8%T>MJ@^YP
M&'Y#T6+Y9+U"I@@FK62^CN.FU^>]Y3JW_J6U=2.+*^.@DX0*_DN/N=\L+^8*
M_F[^5@7'][F2(L9T[>?'<^M PN&'&EG5OG2C1,DEF@)1@&C4$-%MB>8 W:*-
M9%3,HZ3Q""I*:OA,)&II5+H'^!.1>:BHF$5:4 S=(8N\3#(V=F)3Z22EYA3X
MR9G[W8W6EW$8D2LNZ#DO;I+M\ZL^K.A/Z!T=Q,BY#[ 3V]$5>D$>WJ9/F/#P
M457/)Q<9Q2<7D)+?]O5H)T" _W8ZH^]]@1GQT5.D(]/=O?\8/A2=0,V8AZ"B
MN=$PA_#>VE%E0F"=FBB,<^9%]*TV*HIG46MEZ3FG#II*=ED85FQT';LJ^T*9
M+I4.V$.-JA(0NI'3Y?F*HC4F;\L7HLC3>_36_TYU_,*J^)L5N/2TY<I^ZL3B
MOJ_[#:+Z7DP*RRZ6WT.48"QZ+5;(J'G]XBT*HMV]9Z4U0@GRB6;T#3:1=CI*
MI!3V5T\HV+#] GLAU7TN=$(>R/>!:Y,-^N1NT!7:XM"%GEQ.0NIDH\C%N_^A
M(EO.UG*=Z]<M\LDQRI06X1EPD5,Q+[HI?<+G#G@J][]3J:\](!NY+U0ZDZ%[
M:&WU=)38U]8XB'H(E/KOE;QTK'!-K5/D/U0,OUA>8J^*+JT@V+G^"FZ8Y2.H
M7!J)*)X-!-3Q+LZT6FX+;_%B6=35O\=I6(F8U9B'WFA!$D+3QLU+Q-(6SK0,
M*NG8U!5D*B>.!0^?S "@)HF%P5*6X?;)X-9\T;(8R3F</PZ8VC4J!M<' U=5
M=69A;T98\3^-&&KO#&HU3V*&CWQ1CB/+FQ8^=<!PVCD*H#[.09BW[:!:,Q6#
M9P["NUTLM9DA"YP^S4&*M^'4:G=F,,U!;#>*I7Y." ;B'-3TMKW6X'TJ /H\
M=YF>^Q(9(O+%^)34 5$3"[_/.$?R]$1O00_VS->CV6B;H3?E3/ #O* /(TD*
MM$[U5K_ :/$$$17@G<WFJ/+8 KF"RQAV>BMJ,.S:0PT99D:TM8>7%D@-X,&8
MDCHB<HER114S &=S+X"U$.[P\0),S=U%?<#LS#%@(,[FP@"#V)9SPO";S>71
MYUU1 FP +]RQWR%,!+;DE#$ S1W2Z "6G(]88*ZYLV^@#-)]+V$U.9;!J[<0
M'1[>:L)T@:WFCK+AL6W,HF<0ZRV1%4 ,+<!00*^Y_VYXZ'G*>S"T]7XL#(]V
M74D8AJ[>L1_#HULM$E1@J[EK<8R=*U9HBJV(WJY-20_GAF)F.8IG [@U*RA.
MH?C>?0+X&D6NS6H@]:S$5TMSVF7Y]EE66\6IIB1O&0'NBDXU=!37HTHY2!JI
M.;TFD9,8A?_S.%J3,__OGG,HDU$\#[*;%T&RZ9WDU7J/@H0GP?DTDU-?/:S7
M8>DD-=9\X$>FC<I8LQ [.%V4U,]&QO'AI2B4_WX5$T7P 26/24*:ZC-7V7 /
MZ 7Y,1+(A8<1'8AO0!XSE***?53#CD!F=AN5$2H"]9X/'SU%ZW-#7A,R5JB%
MSCA5 *0M4R=)DQL]N<!=[K5C?>7U[.#0%\CVD\W0T[./@:QMV"[I&8IZ-E>1
ML <;[W_6G5S/-B.BV$&U08:CGDV/!L:Q-LU(TX[P?8\S[U-0]U[I<G&L&@IT
M;R ^!'ZYR4CW_ME#8%??1$_3MM)] >0R)^O>8EDBB"WB3],>P]+!J\@^37OL
M2@>NH7NH@IMC)(]Y\<-PL5QL4=HAOD??NG9ZD_.4-["KP KX.Z*5,Y!S_D)&
M765M?1?+9!N6=N&%%;KVN>]<N5X<P;Q/HB.HL('FH8/Y!=ECFIVD5,SG&XI8
MS"F$^X,/U=0#IN,]6:]9_:T+Y*,EK,%;(PEU_%.\J#DS37F)R0Y@Y_<"+7&
M"B91>/U*K@ BSLG=$.QNR8D/^[=1')0--3BFHZ4,9BM)&,+I!/P5N%XT#SV5
M,\MK!J0<B<SED(*0;YBGY@^K$<0K081)JUR!;!>(0%]\*H3YX0*2O0?QK773
M4-*[(S\Y8G=+[>=*^<[64(QK]K$2KRQ*1/ 7<I,%ED>6_-S9N+Y+ESMR7Y#
M1N:EJ*:_:XC(<XJ6""Z5&A"85 <A%7-Y(FPNEK1,PA>,G47PB((7UR9X1C3Y
MAXB_.Q=VDW,2%))#E.IB2>DF<=DIY? 1>\[A/N<62Q"22D][4KF"UDW,#JY(
M, ,',37G)?$%Y9K=89&)Z]<LCX%67R/_YP"[!PN1G\"\15:4FZ32V)L[UT>)
M!BX4:5/Z6BQ:,(A76>67#)ZOB+[.^8,#&PDHZOM$1^;GN>%#,>S8M9,K9H(8
M=A)2TQ_/IO(-CN7!AP*\AD%4XI/\[9!'\J-\R<I7S17>6*[/PVL'@8%Y+F[R
M\U>7ZYPW?ZM4-CW1-YR07,J^5&>%*486N1D:28SN3^B:'&[&GD7?Z)[X7+M;
M<=LI8MCHZ<?KE#VX4R0RB/2L;\)WI>#&:XY%PNA9Q8$;'TX5AN&E9S8[>#\=
MJ* ,'SW%-7 _-3XK&$ZZ%ZYINM;:'H$,'3VE-L?S&0N\^&<7UM@'MGJCT.SB
MREHAY+ >LG8W>@/&;Y7% G9EUJ!$[Z!:$(I ?P+#4&_I)X1AAY^)=3O1\R79
M"SM>QR-KU*&W* 3>'<SOS "2'_D^I<)30(#*X02L?8G\B^!X(.H.%V$XZ2GL
MN8-N]KJD'D3ZL)X'\@32YQ0D'ZUHA-0QP20<X,5@E">VCA?&KI ^5I9?3U6V
M#U;MH9P,.?DR[7ADOY)X8%;)7[Z^>ZQ0UX2?L^KP1J.MY!8P<(PVRY$VPDJU
MZWDOP. 2329B*"K0>R>50R>I_"R ^)%DUP$*TC:$@.V[J+@#O@X_$PSH]0A-
MG,XE-Y(>.%\!H;P\Q(3XS/SF-R@A^-7UB!Z!?11"6>RD,Z.PS?,P0F3!PKUE
M.U\%**$.##_D(Z:DX%X06/X*Y4VDB YJL9\\D3^%Y)E 3RX\2!%,6ET"08DU
MWOC #@(F2-"4.H1/FR>6\$3/X!W^H(N&$\< TEM';Y=8N(>\90CJ'=<C>L=A
MT&W-T)Q)')!8E-1<0J-K7]1\6K7NH=( K/@>2;,KU=@,V.$[ET&CH(#;!&PP
M>ZT RTGS_:POC60G;7>I<JVF8<OVH!DC:\3(K^ZWDE&2VLS569)_0GSTQIS9
M=S] ED?+[OT->]2B^\5R?<K>@HA>.P[2#F.!&Y)_NB)_]5?WB$@31R8:_7D8
M$\'S%\OUJ%IT@X-'RT,EEIU_QJF?/N<TY9M\1R8<HBN4_E<H;UX!-V.?.#(%
MY*[\M-"UO2MI[40;2/[FI3=Q96:RSF@?#L9&3]V>@XQFBK,U6LRR ^P[=<>Z
MG_&,C_1T=%T@&-T^\!EUN1!%3L;I9J]8O1]E$N4NYPKTN8G8>U!OJ^F AT"F
M6C67+#B%"C/'"O9_9,PE]6Y:Z[;_5&9KH'=,VSAKT&I_&;(Z^E3ZB>\9TM;4
M713>^G7-U:78%[L'F+:EL85_%2^G/NV3*Q__X;DGWIFJ-]\A7N2LI;G>]SA(
MI$P4!>YS'-&3_H3[UZZ6,Z)*C)@X"Y_PN>.XJ62YMUPBT2ZMK4LD1K*(ST2F
M)5H>D5K):7A 9(*A&Z',=92*P0=DXY6?4$DZM8""F@;G12@Z[??$HQU=OZ+
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MI^FA('0/\1)5(]%K']("\VHGI&(NI>ZT</YK/E;2V#/1^NDFP#X1__SBMX.
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MO(6V:>)^RS676B@]#@JN/]ZL>(#T<B@3RRV6@]TP5P%;!;VKJPQZD>,F%:5
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M,NTQWFRL8+=8/KHKWUVZ-HU33Z]&UU_=$]#MTD.(4][!B$Y#%G+RK.+%UL:
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MZ5EAZ"Y=Y%SL<D=?;'G9#;J[$K)"R!E'L>1ZL5R/<G"#@T?+0X_4-)G(&EJ
MT[>)X$EN*RGR3' LM8C45^Z7,7\^RB9F?)8QX\!=,A<[A0+ 1<727.P@@RU!
MOWMR+G83!2>@2SF;BZ5E,*C[OP#FTJ!JL"7@>7C.I8^5BDNUTW8QE]Y6@X'-
M;PQ3VA5+;;69S<:-\J(J5'%P??*Q<'$^;GK3,/%VLZO@+4F59+*_:(M [#MN
MNHWNX\!>6R%:/'MN&G4N%DTH0%Q-89I&X$MUQP3>R4#"HPLW,2!PKP76MG96
M6C:,IE1%9**5Q@9"$@U$<QI2C8_EGJ%;1>N(>VN7%$/_807I@&G_"+J=KPD.
M>(=0\N-\3U+]D09ZIJ<L#.--^OO]P[L&9TFM';5@-<T/K&_6<>XEV&1924G'
M)_HL0N1$IX^EGB97Z4RHQ;">7]9"-MD&-*\Y3#;+N1VY+[U*HDD?>@IX[9VA
MP2'B&:UOX"D=.*EVN]ED ]+F7\$+<FYP<!-'1(K2]AG4_R]'+@D.IJA87G9Q
M)#R6MFH2=I4<X&0.SR79*N3$Z#O2Z-J:)*AJ(N!Z[)&Y>#+D@2]3$LW%B:$>
M??!5.1>'QI!+(5W?FXOK8]BK8=!GC;9AJ]]0TCF=;,P$1*'W?RN-:;SWZUE4
M&P7E1Z[C>C'MD,;<_]>OMA>3>:8-A3;;.#?47UN![_HKQG+/N"AIHZO0MP^'
M%]&DFVF,+@@[IU?O[I*VA-I:-XONMH*^F<;OIR'%JNPIE6#?:5)YILD0)BZ0
MCY9$X208>N0%1J]<&18/^"AJ[3]YG 7AK4C\DQR4#QQ"L<UUN43T=<%V(TV<
MDA_)*S*.XBC>(N.%AC=E3&;]R+-M*R6D%SY,3]M?.@I5F"[0$I?DSA7Y3QBY
M-MF/Y"PB=R6PTO+&4A//G[/3R^?:2F9T?81GDM575X^5FXL]CA-8*6=^+E8V
M84Q%+I2YV,N$006J*G,Q=0GC"==^M35-956WR89BA;=+)0_$.N-":$[CT<?'
MLE+%-ZNP>;'[:OT3!WGATO!B]X"V.*#A61G34EY#XJ.)J<%Y"^*F\@8/[FH=
MD9.:%WZYV)4+P]]E9G]1Q7B8T974_\&$17*].E7&S@/">H^"34#*0NM>)*A(
M8!Q(4,7JE!K77Q,!%9#KH'24I"U5KV&4/-]365'(#I'77#.-T16/SNEA26LU
MER<<#Z# XSZ7EQID+T)%_%P>9MS;;R#%82X/-LA>E:&:ZOMJR_?AHTM>L4NR
MM\C;Q4X*K!$X[K'GTL2-<R?/PR@]9:Y09+D>]$4G:[R)O/9Z3T>!#D48BC=Q
M$K23) A2:V6 UL@/"^L:-0M_0T3>/%FO$-4*3%J-[DR0]9&3N]1+3%XALD8N
M2'ODH2;6K1F%=N!N4_<_K3(1DJ'B@*N-:P<!A2^4>Q0D6YK<82PW:X^S+,B+
MEF\$M<46'&"L+O1% YC+='N0 W!I1?;Z^_;<^6><%K5XPMFD+M>6OR('Y#J,
M7"(.R-WT%%A^2$B2&=T'K@WJ,:N$'27NN\W6<@/*VF)YH&(^X0M:>'^+0R)J
MEB!G'C_148OG$55O&7MW[A*T]ESDA.03Q8J>J5)-EJ^N[V[B35Z#)8V/Y997
M_ 3%+(%KHL,=TK=>>S ,H*A$ZM26@3J/+JT@V)&K*6DV 9(;? 2%5H/%NC^Y
M&W1%%.S0C4)6FX![$;H)"?'W-_*^\G9W+IFWPY97<*/P$5-T,]F(W@9)I+8;
M_DD&IS^P5N@4>*6TT%$QD^0&\M)'97%CW<2^G6K2].[*'FUIB2)[)Z+ ]AE%
M!0K?8MH9<[$LC /Y"Q4RR18B0F?GX(5#-OYAQ[>N ]-"006J;/C'R/(=*W#"
M[UN'*#YDIA].3O-VI*!W$ ]!-<F/RR6B.Q5=H.@'0GZFXWTALHDJT43+2R(K
MTB@@(O[/EQ$*GO#6M3^<?(!/7<YX8Z_ZIY,SN:M>(BCFWR):JTTD3:Z:ETY,
MX/JVN_70]RT56CA[!9T_?H?.0]) :@+[W,BUO//MEHB+1%QGR5G%ZR;=98D\
M3XPM!\V'N:+^1,>8)@)[3:H'F7\ZPMAG]X/LL_M![=Y^(NR28Y4=,/A4ZK]7
MLBJ%RA3>X. ;^E$6'M@G?[2SHF7 K0@D+##7,(A*\R1_.YPC[6E^N//3\\"P
M9FSRKYH8W;%FR"]%(=1&6R_.;<A/2TQ_#B/D>59XB<G_/N/TD76^"A"";24
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M=>,U:-$,R]F]2/$6!=&.X$++QFWI2WZ@%VC70,?RXFR<AQ*=,1W]GC 9E5D
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MSMMT&^#:^TCWH@I=:.QK#G,))>V0'<UJW[X8.=,6H$9EN0&=2HT2S:-E6YY
MF/>I-I="!YR'K?'!/9<(XBZCQ6&3[ X["X--;U<;!VQP<]J0KHXC!0]B;YU+
M%0/>(PLVRS, 9R_S0,X8%BVLX/&KTD5YB3<;-VONYB<Y(V2_(-]VD40'9;]!
MIN&>%)R#B%$_>SS=Q+0(TU?7(YL3^XCLSV1T;IM^%QF5[:9BRV-*!,2:UD!
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M\E+9]$!NC^ %.40EO(FI1DB%F.7#NKL($)]T-\I"1M-Z$DFV8SZ][-2 =])
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M$Z0>.*Q()LTFV$'!_=*Y9G,,@^!654PYI;ZP<<<H2*^0,;$6YKWWW-S".D0
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M7PT.GYWU0%'PJ;CYV)["5PE(6/862VO]@I!#NA#RD)898Z8E[\H;!R#2R?@
MW9FE;P.(_0KW02]!TU\/ZL1 @T49<+Q^FB]>O3$C)4J6DIXZ4!)'#7$$9ZS,
M5$/.2A O9JS<!@]KY"@[E5@/F"V1,<&PC13@W2@AL[XB&S\,4QN75:H/5^P?
MV94^OEM7EULIX;#H5&/"AQG'Y,+(-4_SI&-3GP+_57 ^<F3Q,DIU)?LN<1*P
MJ]V[5&=<)Q%3)CFGRLA5&F>Q_SHFC>YQ1'1N2-M8[YD2' 0;9'^36S?#(8/L
MS^Z8=<VNOWDMKU29+_?'I@'&^;==D)0;=5$%.CT4LM=VN$N]J+5SJ)^R0_UP
MJQKLB \0XISRS3KE SZ)[0[Z\*7MG/6=L_Y ?M6B<W5VKOJH#=AN%7'W<SNI
M/9R5B>'D7YV=Z49LFUTATC4=[6S##7EQXB"_=LL2 "_RQL[AU><5-,V,KL.N
M7P%=Q#WT9V+@* )\("$Y;MI?07+U^C9<C<;W/Y" ;8[[5,'G'F=>%@NF,;NK
M0@_3X.AE)B##['Q(>R1!X(6$)NPU@/@OS(2"YZ3J%F DO]._2;HG/I#44%XQ
M+\5XQV(<4/1(IP@S&<TBG\%U>+W/O3!+/Y%4HR[9BMN@^!*$4#/\R0'47$DB
M2UFW-C>2 B4AGVAE'_HD+@XZS/!%4J2XV,=DNPT..;^!F[36QD@ZG*)##%*\
MC9FJEF'&;OWE[YZODWB7KJSHD%$=E32Q1Y")N2R6R^R1EJM?Y64+%FEB?AV'
M85$1+&8F:/6,9%^BV@0S;^6NY.JA1\GF/J*K9+E[("\D3 CK"#L'L"@SWZRM
M<Z1*$ @9<=T=V_7R"^M6]67."_PO7KC!/LDUF@V5MNUM$M$M,I]<O8U$-LAE
MGH\C'UWQ/\W!%3]^^NT>,JSJ7[O,D)/-#"EA!*0WE\^4>;"_D$44,6=$-AI\
MSK@^24;, -XMJROS,;TE\I]43RW\]-"BC22<30=^MZX,#9UXMEV E")>Q#MV
M#49@V]K,]+&&=X=H:SWB81Q?[:N_P2X!C%2Y=7'__C&]=..T2E=+([N*HR"1
M>/JXL>$QLSV-U@-MS4V,NS#4\?JXT5!J9=[Z2W:G2=7Y36IF!U1FC0IE#&5U
M%)-G!]$CB5[2(<0X2TD@8. QWT5%AQ@CJ;VM$1IG^4Q629 >DC ]B7;MDNQ@
MS/-&QO>K7];H#UC@Z5+EKS<7#S&UW4-%F]]VO[%>E4E[-;GM[F*PDY!"#FK;
M/<; 4'685P-ZA[V0Z#,='R%M*DMH4MN>U!1R'6G'Z$AI69X[N/N22;MOO[;G
M"-:^"3'DANVI0A5HI Y$C_:LI0F* ;0A[6 S;<]6K/_8;&>D9Y-U5,CH4X7W
M"+X2[31Q5=^ */PIBZ<&MEO?:;F^@Y-SO[$.1^W)N2_M7&_@Y-Q5+P3;LRW#
M,Y8?>8S,)<TRP!YKNOG8G@;,U WJ]CAR\.QB/JM-Z M70Z_3?8_#9G=D&P8V
ML/]F"=YK.T]$M36GZ,!;@ON3G?GG5, %>X67(+ZQ^Z"1 ;$G8*"$[F>WN8\>
MG,L0$8Z2]ETZL2<9] E2"_8YX'3^2GN8_LFO)E%H5HF;_K>&$UY?PIB\$C+]
M(<LGO]00(9DEC!=NQS9A[(S5Y:"YZT3M,.@.S^:0&2B)8S*[0$$;+<(59XXJ
MP?+ZD@RH=S2-7 ,*\S 3J,MT8UYEXL&/OW!E>8;QP13+,>%1^C%A+-S=NJS;
M4@"/\E47"#'B$7P@](]5#L3=MZ7U. '2$B%0G3*,X.X%+.E.1@BEUA9^^!T"
M#(7:UW?>%0F7SU^]Z L^P*1?UC@SVI?CP :?],LR,J."B#@:C40H9)^H4;X0
M<RW0L-RJ8D9::3(13D(Q1L\-?(A(HZ61T>9GZ@/9THB=L3(Q']TR1K]%]$Z/
M=L,_F^"-]@5+@7O*]@ -C'X285;5I[9';&#.)HHX3VT/WU#:D@U;:BXA"& +
M58A>T[:>2W@"^,9">R]8 P8M3.PA00:T[DLUQTV[4IL8;OUJK8TVF4O4@8!P
MHB!6C -E]WL*#"@Q"\JQ,F"!3>A-H.HOF"GPJSW_NT5$O"'>!Y"=GL1; 71.
MYA(0RN0;-,6)-*[A%1SEV'60/+DL1D&050''IC!J-!LXF=_U1\C(JG\]F^R"
M)A(QNKR'IY+WD*MI@<ZXVA>_5,CJ@Q _AL;EY]K=.G?)B?/?L2$=3$@=Y"^R
MH_&-22U M:8*0BR)V7#-"ML1&V=H'XK:XPPMI9]UA-19RC"KA6!:6C,.#0HS
MJ#DH=JIL,"BM]Y^Y\.>*!QKN0CN;M$ 8NN X"K.&E)&@F4D2?,QM/$P-][U9
MB@_8[8F1?'VS,E1=*AN"1%DIWFZN=)]]E-L?CY@!L;]VQ)8CMARQY8@M1VQ-
M[1[@B"U'; U!5+!3WU%:0O;&3DIK9'["<F4OR4_4;V(<+>U*_60XBEL:;F[]
M%[):Q#'9Q6:9"E3G)\97P.9FIO#3ED2[_7W@9>-FB0VR7.=(%D,LQV"=URRQ
MUMOTLT;IQCQ$++ ,M W(I9@.^3X<^^'8CSFR'\@=HU2W2Z8GQXG,@Q.16QWS
MHT>4]JMC2AQ3XI@2QY1,6T6I&_-S(5*4KU04>D$<D&R9=KQ7\O6K%^WOUN_\
MT N7K"QB&3EX2[R8//B;Y]W=^H^8'#,%7G#+S$%_F*QQ@PSM-&@:K3,W<,$0
MC@YS@>@19.*R5&"N.A.A&%OSTSD*R5%(UE!()YVGRU$\QB@>EQ;,43".@G$4
MC*-@QE,YH/Q MD?%@-+>".\EAL-B)@]6SW64)PF:5^$ 3H6V9F2\VE<*Y]*0
ME6A@U3V&==:1'\EI4$(J$W6U"1 SR2\!?_DK4K#/'[Q_:,3+DTF0*6"1<AF)
MV-WD;Q*2I;?81"2O>(U-3R22(3LJ5FTEKJW+4C9^> !A1NHG2%85AY15P(HV
M,5^6D+>[#CU@5AT"7*T+5^M"X51PM2[TS,C5N@!]'%?K0M4-\\@$NMK7C*"L
M#'E!R1Y85P5?3(7N'%MO-5NO8XG,AN+7N'U=N1!7+D0[9JY<R,3VL;D:(Q/C
MDUV5$5=EY 1  U09.==NTTP,MX&T80?155>!E]9N83%12!5H3KXR[3ZE9:EE
MBB+)2S0OM/L*3&R?:\"S^TV$P^C4I92Z!+^)<:3MMH&P[X[X4D87KRWS4BA6
MYOOW?WI!DG^K</5[X@7^>L^*N1;&CISC@93PB?@2X,9N@/#DXP@"^A]S0&(J
M^2&%)'HA\947L!]AB$V0P*? ?Q6<FZ%TQ0.Z2;]'?MCHFV15YO@SO'[VH@U9
M?:)9FN_#"M,WVR[Y$YKY-8VSP,)O6Q+&&E=S9P?CSWVHG3M<6$J/1BQUZ/&!
MVQ.N(B%8RK'F&+]W-'H@G[U=!B3K*.L1Z6*#%3O.VKM;WQ3VR2?O6Q[[B'^J
M1HD=?X_AWZ]A\L:?F<R;-E3BV/H#_'@M(72<N6'>GS'21HVU0$Z92GTOV]^+
MY?<%Q6_LN3P0(U4G&,FY/1JC#E<AB@(K82XOR5@PI4Q+VU\]E=2EY%6#/Z+8
M&2*H=K4#*\_R>LKQ/-.-YY:DHE:/.R_:S0353H*#4]?:49[3JNWBSDIX+QV\
M"O!6B=@2TM?Z(/TYAS0DF_3$7,T$U :%7^+ZXT#Z]FU81[;[(:OX#?O/9R\F
MO_P/4$L#!!0    ( %."85)4N9,2/,(  "2'"0 3    9F=E;BUE>#$P,S5?
M-C T+FAT;>R]:V_;2+8N_/T [W_@R6!OV U&L7/M)+,;4-M.VG-R<6QG>C<:
M@T&)*LF<4*2&1=K1_/IWK547%BG*IFPYENS5'SJ61!:+Q>*S[L_ZZ__=_[QW
M^L?10?#;Z<</P='77S\<[@6/'C]Y\ONSO2=/]D_W]0_/>SN[P6DN4A47<9:*
MY,F3@T^/@D=G13%]\^3)Q<5%[^)9+\O'3TZ/GYP5D^3YDR3+E.P-B^&C7_Z_
M__-7_([^E6*(_Q9QD4CX8S26Z6/Y?7?GV8M_OMQYWH/CX-<G]N>_/K$G_-_'
MCX-/[X.]+#V7>2'SX/Q%;Z?WM/=B)WC\& \89,,9_/M__CH-5#%+Y/\\*N3W
MXK%(XG'ZYE^E*N+1[.U$Y.,X?3S(BB*;O-E].BWL5T4V?;,#'^FD.!W*M'BS
M\U]O1UE:/+Z0\?BL>#/(DJ'^0L7_D?IL^C@2DSB9O3F-)U(%G^1%<)Q-1&H.
MQ;F\2;-\(A(]>('+.((OX-M4ZJ/.11X+N&)@#GSTRY\__2/XGV /[E7$:1!E
MZ2C&.<4B">(4SQ;X(/ '/$ .X=N@.(M5,,RB<@)'A@'<V3?X83 +!KF(OLE"
MA<&94,% RC3()G%1X*\R$J6205P$<#(LS%FP%6_#/ HX']89+RC2(7P)WUYD
M93(,DOB;3&:!/B_*)E,)CRL^ES!X/@F*#.:AOQ?I+(A'P;0<)'$$9PQC%26P
M*X:]OSZ9_M+^I')<ZL9SVEG?QW3P_2P>P-KM[O2>O6C<U;5NXM))TOW@F8]^
M^>]TH*9O%Z]C!(/*_'H+R7/@.? <> X\!Y[#W<T!K^AK:-Z<UD7Z?^R?G!X<
M!R<'QW\_W#LX"?KOCP\./AY\.KU']SB0Q04HC/?HCD[Z'T^^@BWQZ^'G#Y_?
M'^Z=!'N?>V'PX73_$KUTX^X2E/9[=#?O#G\]_OS^X%,8''[:Z_R8U@'&> X\
M!YX#SX'GP'/@.<S-X5I7U*/N7CFJ4VR2.)6/S[3>LNM=Y I-Y\H[>V5U'J,3
M&7WE1JK.T]W=G1<_OWK^,CC_N7%;'6[C^L_+7TKTU.?VJE,QEH\'N13?'HL1
M[)(W(KD0,_7V(AX69S /&/?1/?'F_N_!WM?3P\^?P"(X^N/.W;EW=L7:^/I)
M)G)T'?L@RI(L?_,74199\]6]M:=X*@:)#+(1!HL*F)BZ3<@9QN<!K1"\G;!$
M^"(4=/U!E@]E_C^/=AX%D4P2-151G([=YZD8#NUG,R]]QF-8LD1,E7QC_W@;
M--ZT(L?_#8-S<V&8]Z/ CF*.?=[;?;KXO6R/A[4LA?F(MT:?ZVN#7RS[5%>(
ME"<'>_2R[N*C^.N38GCULO2>_OSC5N7J5[&YGSK=Q*N?>T^?+[Z+!6_J)CW8
M_8-WAY\.\=F>/*Q'^Z*W<\E-=)2F:_UHGWEK\40#&:-9#<V>/JPM?__1[/C@
M0__T8+^*#IP$_4_[P<'__G;XZ^$I(]P]0[C='8:X*R#NV</:\_<?XC[V/_7?
M$[8%G]_9>.C#>L@/ -AV&=BN +;G#VO/WW]@LZD=#^NY/@ L>\Y8=@66O7A8
M>_[!8%FP?W"R=WQXQ.ZU^XAK+QC7KL"UEP]KS]]_7-O[K?_I_<%)</HY./WM
M(#@Y.M@[?'>XUR> "P,P33_\<0J?/P0?#TY_^[P/WX&]^O5=?^_TZ_'AI_?!
MT?%G4/'@:_CJ\,/AZ1_!Y^/@X,O7PR.;R_MPMLO]A\BG3QDBKX#(5P]KS]]_
MB#P^>/_U0__T\_$?0?\(X.[O_0\Z"''X">&2D++WL![Z P ZMG&O KJ?']:>
MO_] ]^5KGQ2XO<\?CSX<]C]Q%()1[<&AVNN'M>?O/ZKM@7IVN']P3"8MZ6U'
M_3\HVGIZ</R1G7CW#>)>,L1= 7&U))L'L.D?!,:] XS[='I(&MS#>KP/ -->
M,:9=A6E<QW#/,.WS[Y\.CD]^.SS"K+B/?5#6#BO'V^G!AP_PY,%@Q0#$T<$Q
M@]Z] [W7#'I7@1Z7.]PST/N]?WS<!S7N@",*]PW/GG%IPY5XQK4-]PS/#C_M
M'WS\Y#)*'M;C?0"8QE4-5V(:ES7<,TS;/SS9^] __'APC)8IAA<.OGS5OK=@
MO_^Q__[@Y&WPX?#CX:D..<!!'P[[OQZR9^X> B#GPUT)@%P+<<\ $..FY(?#
M/PX_.92K,?@^G ?^ %".B4>N1#FNC+AG*-<__O7P])C-UON(9YPC<B6><1G#
M/<.SCV"V'GSXT/]T\/DK9[W=-T2;SQ!Y0E2:\-TP/O?O_,H;K=W7DJ3!FS1J
ML5SGAMMD8][YP=OESY^"^]XACUF8YUF85W-;&T;+[-WT38C:%SS,6R5COD:+
M)"N1:VSG+UI!;A50^@.N_$,]6PAQ'X7"'JDG,C^/([A<?YQ+B9CW5SS+WOG<
MIGCT2_#7)_CM+UN$E/_]EY^?/MUY>]5)'T_ZYC0Z8??M-B)E[:Q$ I;FCPT+
M]IO'.SU:UT>_T'8F< 98!.C-1@2.0T!6^W<"-Q,H>#ZB*',)>)QD%R%!+EQ%
MCD8R(FRED\T\@L]1D0U@!9[MA,'3G:<['6>SA=>S=ZV'NOSF%XYTX.:U#[?2
M-M;"4]TBFK- /.'-FD9<P;MXD&?O91H&AVG4@X4(]F4B+D2.(B6?9KF6>V?B
M'(8%J:6":1ZG43P%.35-1$3K.B@5['&E E$$SW=>!X<)[/D,UO.D@)T"HO%$
MP)5@PT4@D;(PV(,7!+9>&HLP^'K2#UX_WWWQ<[!UU<XP2[F7Q/"<S7V9N]K6
MC_!$3%0)\_PUSI)L'$<JV,NP&5<QI%NS0O(B!K&;C4:TFV'.V!ZWZ]5/?OW0
MN'1/ X'^OYZ<GLRO'P)<1Y5-0&+C>YK+D<QQ?\+N/(.-"CH$O.7Q>3PL10("
M&S:="#K.XTCDQ:P^$[HJ\KSKO:('Q#VXQ)"Q5/5!+VF/=5^@]1))MN"UNC4!
M]_MO!\<'_9.%#\P=""]1?:?5H \?^@"W%KP+IS(Z2_%UF.F>V[ %*P37KT(%
M>X24)W):R D"WN[/!O"VZC!V>MJ_>HH6>=X&U#U.8]8:;Z:'NW<N8G6&F$1[
MR C/"M1S$ @H!-19/ TN$+= ANC3$A ">0;X)>V0M)\B8T8-' S#S94C$8'(
MQ2T)UWV2Y<%0 DAE4]J'RB@7(6(66EER N*ET/84;F?8<KU@ W;1K4/2K>V?
M3Y]_#Y'SZ/C@W>?C@_#J?11H2UG!XS=J@M&Q)F51"MH:DUCA,XVR<YG"U11M
M.6'11QDI2"8H;($B@$G"_L&#X*\ K&/X_EPD)35!J5TKI"L9D:6'Q*TS O&7
M7:@W/WBG^,_K1^X=WP?WO/?B^7_59O=8?]683V-+E-.IS".AY(*=UWFK+=A6
M?Q5!*B9PP_\\S:+G+UZ]>/7ZU;,=^/Z)J*NP-*^AC(S.^::$F\AQ2=[6FK/,
MZ[[-$VF3H_S9?;GS]O+_=QFNFD?;R]3H+W)KN^XZ3[I-U;L+&*M9HK</9%TV
MQX&(SBQ<:<Q P12):5S 0OP'=7293Q1"2JD\=Q]8IR$*04(F^A(4?#BU3 3@
M50XV49F+) S4&6CT:#9).B27:FI4K(D4*9R@/+PC([2WMI"UBJY4]G9NUI:J
M%L1XV=MY^5]O+\[B0I*2A5OE(A?3JV(SRR_?G8GDRPVWQ4#UH^:WV]OU=FU[
MZ.E'/8UKW4)';ZI^)SI+JZN</743R4FA?A2!Y2722'8VK@A-E(L @,GAJ6'5
M>,%1GD5R2 ZOF5'5>\TG1V&RA5&RE0LQ_?HNHW8S#C$.+<*AIXQ#MX!#%6XL
MBTB5DW;WU5L5? %[,"YF05^I,J>1<WD>RXL0 Y9B.DWB"-]D[<6%SWD&CPYQ
MS+A;:9!?10%*V['4?H%]$W@%\Q+#MO$(AM!N_GXJDIF*E1ZM\>,>PF1,4Q 1
MK!KYR(S+K)I($+W_>!3D98+6:RY1O2,7""AVL#!#D0_ASZE=''.E+_T^'/OO
M,LZEF1B  LRXF$UA5'3P D;#+^AUKG1._P[AWB188CA/86[73.WN,/NA(/3<
MRES'1<@(O1"AGRV%T+?Y-.X!0I/#'D"0HD#=L1GS5>3(YJ^<H$4*ZN+NJ]ZS
MN]8&=W=Z3Q^0.LA@<[M@\YS!9I5@$X/&5"RM V*HW4LB"&W\'30G@*U4YA11
M<GY^3+<#%5'K3$-0HJ("5*8LIQBY_A12:"C/$M"M8F4_)#I*A$>J@&Z8%"V3
MK@<'Z*B4T&A),8<BJT7MWZ'GKH29*FF21BQ2QGKFHI8-T9RR=O8-4*D=@VH(
MTQ'5Y'3 2Q]_V2"@",=%D%W PF%LK/7^W>T'DRQ'SZ)(*7G!&/SG68%74T46
M?:O&AR'-4L<4(U:%/?Z2Z81TX5$ 2P)K0D&<18\$1YIF%W JZ*KZ:SQ$YRM2
M^@U]Y\>'1"K&.OZ,>O,T ZT[EJK#M/!S[7HR,9<#W3V#^VM?F F%L]T%QMFY
MS-$)"Z)B..MP6=:[611NJBA\P:)P=:*P<A!\$!?J.@*1'!P@+3Q?0P)#A:W.
M!O,AR^&\LCC+<H3 <1D/R7_A7!$!.0Q@\'^5>:R&L09;+4@Q \V[EG$GN%Q.
M+ZY%* J#')WT5; <X-VD@.!Y&YI=!\#,CM8YS8]6 V=U/'OVK/?LOM>['1^\
M>Q/L[.P\^_GG9SN][L3(EZ]-UT3S&RW-'AQ4YK.5+\G\:[[@63SZI7)RB&5.
MF],O;K;:]Z& :\\KP;G=4JXKA<O+Q4D\MW/!5PT9NHKU?/+DB4[V'LLT>.PR
MI1?F]@=;!@&V3<K[IM[X[FZP\R+PRH ^'/0_!>\./_4_K*Q>;=4[A(O@N CN
MAQ7!_; *M(VS4A^4N=1JOQ1G M_)&3JWX&77A0+!*,_@G8/1\<7K;$KA"9T/
MUA%5[5B+TR@IAY+,)K!YBK) 0TFF(BI,G!7^(N=.(L>Q2JBR*S1F%45XT5Q:
M8&(!Z.CHL/Z(QI7$I^H<7OI[\_>YU"G,M/N4-;LZW]5Q9<_UK3T7=C]=WWS-
M&ESJ;'0+RN_1F4C'L#Y*1F N4OJT;V>"?A M,VR1QX,RQ9S'00;&*#D.HZS,
M"VM/HNZ?8S0_IZ=GW6^D9,!W218AW#OSUKG>JL/@=^LD30-5@E7K&[JJ\U27
M=..MY.5N!+DXQL6.O14Y]EZR8V]ECKU?05<=YQF,%!P>7<>M=Y@6D@HOL?#E
M*,^F$D--N<E5HH(J^'981H6M?L):6E!F0QO2^.A*I"C_AV#.G!*2[,6,=:S3
ML&E%H#IC:&=H!ZQ'PVRT:YK'66X5Y*.3?E"O):8Z&_]:0568)8<$Q@.C[,.@
M^D :-RL++,;!J<)!J+KK.K$JFPJ6@&R&-)(NIH9N1O* :C^CEO(8G8/A<#6L
M1/6M?UC;RO: :[4OM0GB:-%!4^24!H;[>P3WKQCN5PCW171VG23[?Y?"Q*%'
M#C ]X":0I-)80NA<JC(!F"=[25"=$+S+>>D"X5Y@YF.M0I;R;I6Z:X7U8>7H
M,X+=+H+]S BV6@0+CG',X77S/QL(]*7?KR5%W;'Z]'/O]<^,/8P]J\&>UXP]
M*\>>1AW.LOI47>.QPV@SC_Q\TVF6NUS%A64R1@V[N;7'QAW#TYV54>\P/JT.
MGPSSU1]2Y-U!R25Q+]:0CD[Z##,,,QL,,\O1-3#,U*'BSY_^4;.0ELR29?<,
M@\,Z@\-R' H,#I?I('OPT@0?8(AEK2+$& Y<,:[<(USARO]5XDHKU<D*7<!L
MX##6;"[6<.'_K6%-Q9S$:,-HPV@#:,.UU2M$&TI+ORF7T<O>+F,*8\H&8PJG
M=:\04X@U\2;JRC278@*O)OMD&&7N$\IP-O&J42;X:$J7ETZ$,><#THRE[9&B
MZQAL-;2B;!@X;%CQ=P>FAJ0XB_,A,:K-[%%4[S&07N<"Q_A"[&=TS]1IAXI*
M /5&94X7;*#?D2[7>*+YM18E"A[J@R.7DK.?EV.7'DUE'LTE,M%V^"MSY9UT
MUDDY4)IZV%Q7+X30%2M3K/8&R"@+)-2%,\>Y',8^UR[6JF8Y_8,U*0/9EI[-
M8,Y@?I_ G!.K5P[F5=>\9='\&[P!C\^PJ6CAQL":<R5%'IUYX.Y3:J![S4J!
M>A5=$SG#]DJ1T,"H9IL4R4PCY$069QERE?_;$+!;1DSF]V)^+^;W6H3P"XFZ
MJO "\WO=;-&9WVNUZ\G\7LSOQ?Q>S._%_%[,[]6=WTNX5DG8G](GPJ+)8 &6
MQ@1BXRK SAK+6H^C[H1>G8^T+:4)93J?95S]G2\"D(*%^AH'4Q,]I#X!=:*2
MRNW5>>RCDWYW2JKNPRYILW%<DYU4Z^2DX@K<%3BI_C0G_/2/[FXI5,]T$PQJ
M/.SU':Z\_)PSP=BRN=CRE*MG5^H 3\EW; )X2[/A-0-Y65X/"#KVNC;BI&F9
M*^18,I1Y1@MSIWAQS2H0"C F*@>[*LKA3).-ED,D-R4.6] I;0=V,!J%4O"P
M57!6PA)3[#2.8C M"^J]A$2 4R)WI=_IJO#L**Z(W87.I$B*L\>6W(^Z*IVC
M'9WI8R5LO!*39A%<-64NC)::\Y Y#PQ9N2RY$V,N8^XZ82Z7$J\0<[$O<![%
M=X6Z[D?$LA1-[U&FF^B962F14$8&<73"2088\1L\,IY4G@+X*+]7'V'$#/F@
MTR*G%F\YDDT34@XE@K"!4)V)PIHHH^)FHR+74-\&*H+*=BR%RE)ZSPY&:+XN
MG69'SCU0$U$-)/4RU6EEF!:A]<I(Y#GFV"$9L4^A[.FDUCD8FI2W/)^A38UG
M6-)F-RCII<,8GB9JJ;"$*67=$8KB25+?!WT#\\K*'"-T%.3(_69M"X^;9"FL
MC)_E1^D=, &\FI<D E,;Q)B)$D<JV(KK^7H@ +9U3T_Z&@Z<2[,;PE[,9W-G
M:OU[&]=*AV80X>TRFVGBI$$>8"D9G*1BV%K"\%%GRF.Z)L;FP&R *YZ\?:[&
M$:U0NY],"Z/6Z\8"(WK4(&?B04R9+X[HNA"*NJ/Z#]]ZOW6>S @W@9Q,DVPF
MY9;:MDW[LLAEZU0WJ,68(?D>GI/PA?F,X8CY/=<^@0'LGF$&8VD:;;HI6NA"
M?#./3^A6!Q1'^_.G?X0Z=D9_P4CP07_J!<Q)PO+T'LE3Y@Y8H3S%;B\ Z-U#
M3<?BXAII[6'0N"ZL?#:!&Z5^ OMR2"7%P^!ZHQ,8UR_PF?(IKSG<'.\;1CNQ
M><%C:SH-A,(TAIG.QT0/T*D4DYI:\*+WC L/&6HW&FJ9.F&5IDM[_Y+KM);Q
M\[0H+V,HL7=7+JD$"%3-*1@MA0#]?"@*$;H$]/94<RR4D?0EI:>3@D\-7."I
MV"]"ZNJ22F/_D ,=L\!LJI7&0OA2_[Z%-45Q2CE6A)'UM=C7IU&R.A[?>0VV
M72^P"[0=!I+<YG1_J;6-O'XO5\WC6$82].UK3$/&=!7:%[I73TG-9VI/V=PF
MMN^IDBP'NN'W0!87F"!'T5:,-E![.1*"@@(-)W):R,D AG\6!D]W=E_@]V)"
MOCC2\%W9UJ49*U4';_SS2[]/S>Y$/DS0&('KX#;0]5%HC.(W0S?M,(A[LE?M
MC^IQPR4O4'=(Q[H3$3;?R<%8&L4).1KUYC(VI'XBA4C',4H6:_;BH\S1G@N#
M\QCD)EIV_@EQVCBE%WS*"KP]:G-.%1%GU*Y(CC.:"9D[+')9Y&ZNR&7^D%6*
MW+S91<=FO2]K#*#L]8MF30PY1X(2W<S'ID("@.++"B9"^@UPC>JSYEQO\X6M
M2"N 3C[K32)D \F5U&(V5*%[@</#O]X5*> \ 3,*!(A:< %_G)Z&RI4P2S)<
M,ES>&5PR-<J*X1+]&#=E7'JV&:X/KF7E6E:N9?6+4BOEDVM9;[;H7,NZVO7D
M6E:N9>5:5JYEY5I6MD/7T0YE\KP5VJ%EGJ,(?Y]EPSEJ(\QZ6LI_E^6-H$_T
M_N/1LD&WR$QIC%.J>_.F=DHF&6]<)KI@VB\4-@CO)5K[[<+)E2AR2A*;E,F8
MHD 4)\)4-QHPRV=!ORS.LCPN9C5F)U4[2P>$<":8:AAA+V!R %)0"*443N-K
M[Z07O)-P)$BJ=W!+H78.XFE[F9J <(J"/GH;3^,"9O]TUWHDZ<R];$C3MR,<
M5_<<4BQ+P1D[(?QO-PQ>[NS@_W9I\)?X-8G%7";R'#,E#KX&B1S'*C&AR.K.
M#LH\FZ+;=3_.=9D.J'([SYZ\?O[D8(\"E'0*2O?)-)&N4ZC2DX4E=2>&)AW.
M775<@FJ N[3&DH5W"/-Y[WZD#,'+MB$=\!'35\A5:QZH"K8.RB$LC?P>_#U+
M>L%SNOM^FLKOY#F6N2RR;9S5^79PB+:ENQ<T'.!GRM=/@]] /<C2^#]:<[ED
M)GK2-)V^7JNC6L:F@LLX9D2MG9R;),9T1O1@V3@K%56"4BZC]TBKQ=(U5'"6
MR(<*MYYQ_H3:!5X <M!6AW]#NX'=FK?M9-!_*/SZ+[@;!:NHO=_G)J8ZE.<R
MR:96-?/>';\2P:Z.V:*^I[QZ T-74$"9JD+19RK$,O%6NB"6:%%"9OT=QV7U
MQJ9W%;ZZ@ >%ZB1^1QK:;3N\V&W.ZLI*U!6FAUR=NK(O)F")+5U[@-@XU*>&
M "(*34W,BD\5?C'2L@D^B@1S0S#1WHJIO,I^%[#:>2IGRC3"#D;2*"(T(H@8
M,!Z5^2J)!26^QUQHRO"UT?#%Q"$KA*]83<OBQEU6=E?29H5)M!EFU@9FGC&'
MR IAQLL^6KZ2'> F5F>Z6L3/=0J&F<(4*$IB)9O?>/?GR]_!CI6I-/FF6%Z'
M_OI4(E,VK%M"3A4L%\S IJSR:'V2#YN5ZNQHUJ(8WC88WIBN8\7PYK!F>5O0
MMC.IT,46(%>5W,Z3ALG\M@+#T7,4&;9L09BT/5%T=3<&(VU5L6N>,B3/J'6
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M%JFWI !P6"B&V-J8XI*J$*-1'=H)<*?V6AZ5T%;E8P6<5&52"(0_8US ^D0
M?FI;XQ>-XI,#.:;:JM,O" $+RU2I.DCBL6&7JB&S&?$LHQ8\Y11/'"+G!(H6
MN)^J$7 .@HHX&_3Y>,O3##!T1B,T\33XE!4X3\># -". =1QE?")MP6W;HN_
MC'A#)"+!5FLKY-<Z.?((KG3A2A>N=%F^TN4Y5[IPI<M:%GQPI0M7NG"E"U>Z
M<-.<[B;T@[+E6BVQH511'@_TJ^[R>@(QR,[E$HU7=*BD.T$!OOQH!6&I?O<V
M#GE.G59'U! VK_JC5E8AX,29.)>F-VGN[)TZD=U@B9865Y$9=AYH!52S7!_"
M3K'U<8IQ<XFV:'HYL$ZG:\9##"JBKJ2JP33Q29;[669.I[>IA93NY[AX'(?-
M*,]T@$&CM,5"CTZS3+W,1QSM3";#$!/V>T%0*]$@;UTU+779O/QPS0#1.C8L
M0,:CIO/_3)1]9"HUO,'A]ZKMN$*E#_3)"YF;*)%C>:L"ZX62R:@6:<%;6-O(
M-.,PX_#-<9@IWUHIW\YEDE'S/E(VZSFW)[!AKP?/7],$4WFK!)F*HMH 694A
M0UG6%3I50*B#"_HL2C:J)S7?!6 Q/#$\W0X\,8E 6P^R&ASM&^\:';<"_L#K
M:YXMN3673-64;Q1Y*75R"!+$@U[G,T5^DW)ZY3B8FE/D<50XGV0DO3%02T6W
MX%7#6!W2T+W7RD<JE1$.,@@\IT#"3_H4/^9;561<L5KXX<KI%0&6T9A:9]U>
MU/;SM/[6N=2AX"NFXUPX0DM=!@S:MA$YM/9%(XF'SJ9TU;">R4H.$JH\HN(=
M*FBF&F6LS[UD_DUR9?E=1E3]^ZLHP)PXQNTY5+:+TZC,:26'<E1YDB]-BC*3
M)%+*1&4T4)1-8Z\APJ6S(VNE>BPYS<?TAS5/R-0<TT1#C-6+T+FVJX(@O05\
MA[B9?"+2<2G&LHKLM]Z52:)5674<>I':,K%F-G0?79%;%YRVO=,@&[/\S5]V
MZ+]V+,C,LRIP;;TN#=;.A-FA>8EV(]I]@);=?6.7;7;+8>K1;YJ,[O::_&O>
M'JQR@G&#HOT^*9<CSPI;N[<PY&%9R>G11[0357=W)N52Q[DA+<>V4LAG2ADD
MA&)X+EY"OREVQRGOC0I;6C:'YGBOTL_MW02.!(WFF^Y[[+YV':LI";R<VH+!
MT%81PL$P1S'!IFDFI0]? S3.TR(K<4ZYN*BB-/H=P<-<71YY#>0@R[![L4F2
ME-_A/A2&:V"RF$=#Y9&PQVIO>->\%KT[3SX?*>T&,>V.[6$:*/[[+S\_W7WU
M5E4)FH;WU>V\NG,A2T%4%])K5_Z$'EN>E>.S 'VZL% I7(76(\^R"7H<AA@L
MK16&5GL+8V 8VJK7"P &(<K0['TNA$F&5 C.%T,Y0/ MV!!4UPDXAURU9UF1
MC4%%/9-#)XW(SL@EO2T%Q;G8G\$&P[TU&%ZQP3!O,'S5W8L ZP"I98'P _#@
MY] $AY4XLYF8P=6RJU*8K):-LAF_K0FU6;#E*=,:Z;8)[+WI+)*NH17Y_O&V
M)'SKXDS:D0LC->SQWO4K 5EIH<TA+YD":?WFBDY 5$X;%!"D',(";%NM;N)5
M NBUIPIMZVW7Y0J^QQW33PW%_KRK?2"=9]TV"$/=Q6L-MI$1PKO/ZU^'$N_G
MURSQ?M'%VO_!)=Z/38UWL']PLG=\>(03/?&WYKJS#K!RP<I%^_Q>< EX:_^O
M>9Z4Y=J FA(QYQ#[)@W93Y69(\Y%G-!;V(AV-$SW1=VBI2ZNUL,69I;:>U*G
M8!'(+:1KW!94[!V=]'MUEY@;#\F-L R0ZN9,AD]P@O:J(/O:G%4MF/OJH[&8
MC5&]!W@2?(#EM4,NF M2]X1>Z3>>^V]TE^@[F"OEIM)MK51P"0>7<' )Q_(E
M'"^XA(-+.-:RDH%+.+B$@TLXN(2#2SBXA*-["8=]'0W!I#--NH<OVSI@4KS;
MA"+A+<4^S9XU0G0L7LE(YVLM$53=W:UH>*X^&N\=SGAVC7J,*P^=)ZFWB1<H
MB8GIJRS F/W/$G4E?W8^\J?.1_ZC^W*AP[N5'K5Q9WBS6\*YQ/42(-\KL<TD
M\APC^]$9U>70P9HH%_:B'0F$0>YBM;:/JDL?0E%!CG?,(1=)(U6E\_U,<Q K
M1;)$,1$(,D ",LT[GT/$^W#SW7=[IA?%)EL@/S&":?<!<&G:%K+S"'@6^JL)
M'3J?]23+N^\E'=ON/B78>IV/-5MK*I2ZH/2B&$,Y0^VJ43*R+$V;\MZ1RC38
MKF]S %=]'X9DT,6/W./&IZATYE8Y!:'TF'A&T$UT'N<E1I)&Q04F8\2I@M<(
M.R5DJ=.WRH(2L0RYE#*,UA$%P[R7CQ,+[J_O__85%6Z?L'G!$ Z'M(5#.J-Y
M7U%N@JU[NU2?,@7/Q#>H<V*M3K6?E^/@I!Q@6IQ)>Z:O;+[!T4E?:19<EP@7
MI\$B:GYEDK*;12:]UIE0HJU/E5O%7%Q/ )*TY11EA"8\M,$2<]M5]C)>/YA(
M4/&&RL0]6@F!ZVRW<!(@=*S.6O-I,5C#<NG>RB6&X1=,-ML&PBX\_-%KZT'@
M=6!SG*]7YG+0PIUM@96J)UQZF&;7FT].QDD00:HNN*@*KIU?WO;TL,RIK="+
M1Z.6?H%J?Y6X/4=IJQKI["V,L30G8H3U+DNYR^B_];+^=3H\64V6+!"I#]W%
M!W*6$7TM3$E'F6,U-R/AN&7K.(W,YZ:SSSZ8)SH)ON(>U+;.$#//)RC^J%[C
M%!>9/+N:T!;K MHFYJ]":'E\4=HYW]50BL0T_3'$M7O&=JQ1"MLJA%[[GG /
MWZ.@7]1$T%^4,/@=S*^S3"=0:IY<<IA4"?F.:]=4HV"^-TI,_!=?=C3IX$_8
MA/$@I^IXDPR0:.DZ<BV4X'R9XB3Q:J:&E%:3!24+RGLL*)F&MT50'HN+*OF(
M5>7[BP#LPF%(G(=$=N$LJ*\WS137H)S>:=Q^*;*H,EVES?AT/25KF%Y5$1L-
M\,I.0K8+Q;S2V@M04=2J:U,S'\6@<F,,DZP=N/JXBM2US@LK1BDI9 _Y3I!#
MO?9[J'-#]F";91,8EPH:]^505S$VCS6Y)'#"9ZH&:OQLZW-,@6YM=L0.A<$/
M8KR:YG%%02!-+X[&[31HIRQ1%A5MZ[X@4R2@,NM&Y@D-TS!P_,<]GP:-62VE
M\=#I2[0N;>LS-(9'^T.$5R? GJ&F&(L*[MT4<["2XFGA2N8;5Z/Z4W('6O,K
M2&)-)E!_N*9D24RTI:'K5N'])',8_@V;R0+FYDW(RMK&SB9^2Q?T5\RT#FOU
MFK;M3V<P8P-23'I0]/3JT\;W*(JGEEQ,-Q=5Y:3R+7ZL5W5) 8M$==9SO&&U
M3FC<69SU*M:K'I!>Q5[9*XS-X 2[*,LE$LWF8E ^L&.420^((C278Y%3D6_M
MDDJ,9('M8;+HFY;P&*/"PTA 5<ZR<Q!;&3)<5&P0U/ *1:)W&>>4\Y0QW:,%
M8!:>8TZM:*CZARXW!MFOQ4@JK 2A,AX4?A%1#M?F2_5)!25=M,D?TQFZ3BS4
MF*+.K1U8X@KC%JS:,9I&+W/2ZZZ=@2RR-AD16&1MH,AB_^B5(LL&^LANO#/?
MP"5BT&NP:S+XZG-V3H"&@5RQ8EA^"LK>MF%3D<RTB6[2,T)*Z8!I-(G.["CN
M9R)-JI%YM'.D@9T5R3RU['"8U&$B8R"M<S$V)CE7K7+5*E>M+E^U6M&H<M7J
MS5:=JU97NYY<M<I5JURURE6K7+7*?H)K^PD>E+G::A\:U^;2-8:Z:BR7\V'B
M.CUS]_*\^=Q.4XG0>0A'F1[6J<"]7G-+%>UY<^E\SI=^*Z?TY5;\W?E*N5?;
MYK[<["S=0&<IMZ]K90)4A6;6'08'L!;EPI8D[3C:3(#"IIDZ$N?%YFS7HRHO
MQJ?B-3E3ILJ!\NB]24DWJ?:<)*%J31>Z^D\U=08J^N\_'JG+I5:]V8,N6W!?
MM?J#+UOQNP[3<<;N)K_8+'DV4/)PP[XV1FP=)+IIKJVA!%'E"!#?!=E4&6M
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M!V*ZCF79Q\F?=KU3.)XT%UIU[>]PNP"3 F$:<.NDI X2(]*5I^&BOP6=@(V
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M$BWE8&-IAE2HA_6,BCBB8)WN_R!^8J-WE*,S8/0U0&'9%)(5BD\K% ^M4&S
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MYNIQU 2>0^J6,]K\DFA!39?[H/I"JN;#='-Y,]TC2BCH/7OVU=@4USGGE<&
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M&2R=J&"IV2A3'8(2$UZ%!NL7B#=@L2/ITRBJ=>ZJXJ.I>L?\1;6?FM5E:RI
MK"Y;7UT6;)8NZP])-2'TS+\FPA&=.2F+#^:6NK,"U$EEV?,W'"-#"4AE+/.4
ME9"8JLGKY2 9EO$@*BX5+.!U.>)R.6:;4K8IY35**1_9E'(CSN9"0EZ<[V 2
MGGGC91NWE5P<#> 5-(1#[#">,,3&51<Q&5R(3)M8O0>BB\ X#4B:!EZ-6AD6
M7$'@848=2C)'KI8?"UTL=:["^97X5\!7N?+?1"0)3L!T#._-=:)DE,@BK$ @
MDKDVVIQROIF",YZH^_ VZ)5:+Z-RD6'9LJ(,R[KH!82$YS=:%NFTD0[/G:<)
MNDULZ)9&[@5WA\?"^ZY,T6"Q/HRLT)^2>Z#2G%XC0_D%?>]<=F10B>[6/I0M
M)+.%9+:0;/%"LO>V)XDM)EO+FBI;3&:+R6PQF2TFL\5DMIBL?3%9Z7"T!C03
MJV[[JYFJEWP9S-"WOI&]&W2F*MZ5]+CF>#T@KS"QA&FE>)25[N#?$I "SF6>
M^#\<\):IA\$",R$)1H-57<:Y;0TZ\QNOU$<_2W(<&<ED) Y")HJTS,-46*J=
M31TT)-<:]T@ZD/R+$@-.W"^8T>%]J>1<.)$E16<!'G>YA9)QN&G'W-EJ&2+=
MTS=)1CE;)&,CFJ\[HOG.1C0;^AK#OR>"OC=-BYZDC1+_6<C3K@R.2XR"8GPM
M1:%83M/ &9 HC67-8LT"%E6:>]G ! .!FO >4]P@,8D^$V'+L4BSZW#B2G*L
M&XI="(5S8%MZB)W?P;P6K@&.!I.\\$,0^,P$ACH3QH''YK=H8ELQ:\7LQHC9
M]U;,-HG97(SX]RL4K3+QH]F&!1-U,Q4CFX4496J06U*PE29N5@S^0+SLV,OS
MDK57,1-F!79[$@$F/Y!*,!4W85)@+D-&$<H$SGA<Q.#-,!2XZ<FRUU$V8=J+
MN4]7V2(3GCS5G4+P9TKO9$Q0. ,,$,[5596DV8IJ*ZI?M:C>>;M)LMJD%][?
M/7J_<W1XN+<HO3#(QP!EY$?G-P_[VJU!+X\[:3 ,)($7@:C4M.Y@M8Z3(!Q*
MT5OAEC5XB+7]7*)093QAC(E_@X65H*H_A5](- +6AJBBS*"&_\4)"-T%H")T
MSQ!V6J29;"3H1;+@!8M*)-EK'>< UGQ(Y? "X^&R; .Q6ZXD*&&C7W+MFT0B
M$ON U9*$.FAJB@6ZP@%#GRAR;^F=XWB@#L/X/T6872MV$L(WS'OJ3'^J9,!%
MHV7S JV<*C.4J#1Z<.!LR:7+^40:F(%8Z+A<![V+4 *O\S3QZ,WQY? <4J7T
MBVTGB4WL\AQ<!6\U04UTZP[>"\4YS3M'@U4.BY=IE0T/Q>-F[+:I@(TQK8]D
M%>\K5[P[FZ1XVRK72R(B'X116;&]V@"4JD(!YXU!6^#$1%RP4>D(56] ^*LB
MU0\E,SDB;4#B89%)"FZ6-[EV$8]&35)02XP'30U70J++YV?*O^%H\#0" 2(:
M3;+"#X1A!12QU(/<V(4ISQ>< 7+KCROM?R.A.LMR$RFL8@FJKE>5=!X&1$'F
M-F95%GR5VIS!2I3V:2SN&8Q3QX4%B9"=@]$08MY_+P.%I&IMR7$%K>]3LR!C
M858A687TRA62[;?;H)".V0OP5QRV*Q62[O'E^<BS&(E@)$LT09I-F6(,$QFA
M'TZ\O,R$J#YA* :I.3@V!4]G-$Y%B75!)8P*@B K1>8V\$+*K+7A,(T\M/#+
M!AIP5RK#=]+U8Y>!G0KIX-3ZRP<I@G^"JDM:>I/4BX3FAT%%[3E9.6WE]"N7
MT[;;[ISL"C4M7W6"12!+2MD!Z5IX 6&:9 B$LB,I<U[YU)$\Y/:5<31EZ!01
M?;,]/\28'<>SD%>,V4G"6$E:S0,CEZ[R'=)\-U(=96JF(M^_<QB/J,A_YH;_
MX$?"PXI[B2["CK37(J:66D56R:Y_<+:\[?_Z\\[AVX\4/*+Z<TG=)6%,DG(+
MIUKY TQ7_:DYZ :7)>F$WA<Z$5Z4):X:8E#DI'>B<$Q=WO-D]C&J9HBNH9<N
MK_GH; WF35I2NZC1C-^&<=-O!U/U2WQY<*3"&QG?3)T,'AQYJ7P 4;88YP!F
MX==FH08&_VYV.8C?4[\="R_.:CZHZT1B1*:!]+N(&*[(B3,!?O;(^8.W*?N!
MN@:^#SS!)("_@K8/,*R)%Q81WXE>+'PWJ8 ?_RB"$8,@PO@/R=Z#X.(XD"W-
M&$Q7GX@\1RI.ZLVALG.VC,0=Q8"Q-5X:#HJ8. P(;$'+#+.(=WF0!-/RN37.
M.^4N;X5RG\O'LLM;Q'G*%*HBA0DD"-=#<#-?37X[<NNY_"W1_M%-<)DO27ML
M19:MR+(560M79.V7>4=;D?6P7;<568^[G[8BRU9DV8HL6Y%E*[)L15;[BBQV
M0$H:ZWEDV?"E5OR+8@)S51S<Z,UL2YZX0%U%^31B^Y2<;'5O\3:,(NV$II(C
MCDM_Z-"4T [C)G*Y3==5^^ 4&,GR)%%YQ1!D2*J=6G;VD-\"9!K,O$BKW9J[
M,_,-0%00IUY^G37G AMW]#^%E\)"%JA9@]E-A8<U :FHS0%>B8!YIW(R^D<U
M*_T+]51Z6?JW-&QEF;^I@ @SIQ &M20O5(&3$D63HJ<.7B0ZLMP4?/8OU7AZ
M8^/V!:K?6E^J(4JB_?#,AQMY4U(7B[C MM^<C;B_L(C[OHVX-V5&"PH\@[A\
MWEHQQ[FJ02,UYA2M[-N$]2:A6U/! 3LY3Y<AISK_B)K32#UB8P^P5T.*-F*$
MF0"-ZF*CW684&144#FR\1L409J8,0W;*N3;!:"=@' P+^#6O &V% 3;22%GX
M*&?!88_"V9H$PVW7&7H^198YX*HG3,D#!RYAK*RZ!IN*DI:>*81C[5[1_<A%
M9@(WC1TI!UI%CG6^[S<KS.=_B2_Z,;-1PL=^\+.ZT%>_]IR+WFFW?_:Y=^%\
M^^)<_=J_=,Z[7WO.2>_+E?/II'OV-Z=_=M4[0W^L>W+R^[]>Z\;?'1&QV0*;
M+=CP;,&.S1;8;,%:!LUMML!F"VRVP&8+9K,%C[.L9=('SY^P6,QPFV<^+_1Z
MVP4T'O1Z^V?.;_VKL][EI?/;K[V+WK<O;H66@'#*.OB@X7T:;Q>!$G 8&34T
M_'!583D047+;>8T^ZV.$4ULZ&@<U/P/^#J/"@_?^=)>A=Z<4>FR7PSR[,+\D
M_?#GM_0_SQ;%_-+_=/'M:^_,!8?ZV.@3IPR_%E[:SOO.WO[S[=FC]:*IKF+W
M-2SBZ%UG;_<%K,*>K9>WB-=ZMJ3J43/.DB@,G+>=(]!]W,UUXF$_S5<>AKI4
M1LB'!4_UNFW?TY[^NU:K5/>CKO1PW0[*+]DOSFGH7WLB<D[1W(W!/ M?@&Q?
MS79A%Z!%/ZG7]:G@I)[^.UF[%S_[C;C.^77G<\=^*G-V["K,X3[G!7XL;>%$
MZVAGK<C<^/NYZUP)_SHF3.1G<>,ZG]-BA/\243+!V*:UZ1ZXR9^]_%6;<T_Q
MV5D#[^V!<Y;<B/% I)2(>@'ZZM6[[4]YTE=NGSWBPNT!?1GO::TL('O^[/E[
ME>?/9KP:78_NZ>7WLZ_.I_ZWDV]?^\>7SO&WCNN<7+T(U]Q^R9OX)=OSMZ[O
MR9X_&W'9L"R:#;L\55[MRA/.KU[L_"T<OP!58!-J-J'VG-'LM&,_D-9IM(W\
M0E[WB[VHMLGY'*8"&UW*EL$BH](!:\+9I)G%0#UUBNS]/2FRUA0G]^[#4AA^
M8PQ;'ORRQ9$M#WY0>?"N+0^VY<$/?J M#[;EP;8\^"G*@__?+\ALB%7"OUSG
MXPC^\?\!4$L#!!0    ( %."85+3ZMZ@,!D  "R  0 3    9F=E;BUE>#$P
M,S9?-C U+FAT;>U=6W/;.+)^WZKS'[#>FBE[2J8DWV-GIDJVE<2[OJVEG#E3
M4U-;$ E)F) $EP"M:'[]Z09(BI1E6XYLAY*1AUB\ 8T&\/4%0/?[OY]>G71_
MNVZ33]V+<W+]^?C\[(2L;=;KOVZ?U.NGW5/S8,=I-$DWIJ'DBHN0^O5Z^W*-
MK V5B@[K]=%HY(RV'1$/ZMV;^E %_D[=%T(RQU/>VB__\[?W>$__9=3#OXHK
MG\&/_H"%F^QKL[&]]Y^]QJX#[\'3>O;X?3W[X.^;F^3R(SD1X2V+%8O)[:[3
M<+:<W0;9W,07>L(;P]^_O8^(5&.?_;RFV%>U27T^" ]C/ABJHX#& QYN]H12
M(CAL1/D=)2)]J;_@H<="==CXX:@O0K79IP'WQX=='C!)+MF(W(B AN:9Y'^Q
MPV83OM27(X;5'(8B#JB?OH&D9'=T\0JYV(<;<#=DYJU;&G,*=9+TQ;5?VO_7
M/OG</;NZ)"=7U[^]KT>_O&K#TI;TA.\= 34_ACT9'=U/Q9^)5+P_GJ*CN34?
M(<7*IMCJ,P5]O2DCZO)PH$MXB/:IUS<;3G,W^^1;>X+\_M,?Y&=R J..\I"X
M(NQS))]3G_ 0/Z<X)? !OL \N$O4D$OB"3<)X,T: 29\@0>],>G%U/W"E*R1
M(96DQUA(1,"!:GC*7)I(1K@B\#'P<$C6^080HN![:!962$,/;L+=D4A\C_C\
M"_/'Q'SGBB!B,''X+8/"XX H 728^S0<$]XG4=+SN0M?>%RZ/LQ/SWGUH?6"
M<^;KD/> >\V&L[UW?[M<H)3%+SQG"DW%6?#X%%J$JCL3Z G\_U9F=UH7G<\
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MDM62K)8TI26]K_>$-T9EJ3Y4@0\__A]02P,$%     @ 4X)A4FM#7CEJ&0
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M?T91N$:0"!CI<N<@POG^P\I;AY4XC&R]2QU(4!D8WD^''[[(AI/^Z<FS$N*
M'[)+X= NP3$A$WX9M2XEZ9PW;O<EE"TS 03:DV+^-8W%!HBWJ70ABB$E=-B'
MNH15_*_G$"L4#Y"V"7@%2;?-+_10(A= %V>4++@/BF9.%A(.( -D+!,AJVG:
MJ7&4ND,0N)#G TG0GT,A--MA4<W!I;Q1G%(5S I*K$H 5L2"LEX'\2L3)(AL
M@O6B>"![[ -=LKMTV3D$-UBS>_#N3!X0;BH+X@1WN(-1EN(.?**B3T3AMEB
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MS\M#Q3&2D1+!T>E;9"^8KM/87B;]6.$>!G%"0>*.W-D6^R-B+N\\' %+DR#
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M_[CB?_>&_S'>(*OY9V!$VPDA(S_7L81U/K:L*%ADB_T53I"!UB/#]/"(6<:
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M^[S;=D?K_-A7+NTO@_0=$8L4W26S\(MD5=8/#1U<5@D%B97W4<68:%G8A?\
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MSLJ7FS6[?;\>K4@M^,GUH/R:NS]NU<R]<W1T^AG:ML)0VDF\Y-CP[*@W2![
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ME@?=O1S^2L'1I.X5?*>ENDZ-,I"'/^'^37.8XM06?H30T81+-NX.%UP40DI
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MFHYIB-Q2?JB$2HT__=PBYRLMFLR8-$N.Z!U0(7)MO_ANHLZE9DT\FSIY>.8
M+6SO$Y!LCB0SO>W$R,ICMG/!!3A3JUR+X#;'XZWWN@9_V')^Q:\_;6.>H*KW
MLK6L<LF.:$>I*L.[AK?/,4+.ZQ/_%*S<,?$LTW;"]<M^I<+*MDC%P<_+"[@
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M!DR9JWPA R?SYT[R$D#\Z2944H&!!XZX>NW1+W-3,K=WZ#W>ET?'IP=;LU"
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M#HZ$W,+W,M3M=:WGLJ@-D8(QU24'*CZ:R0(Q93/1(CZ)WP!Z,Q@GN-#R69O
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M5=Z\X4(DXK=@.<N!>MB,[OCOF/ZN1Q_YY:(1]8*1^#O:43,**W7SW][SN47
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MT%)^:U%, 'H6E?JM$'7;ZOY9]FI!3BW/G?TYTV-A[-FBXK;EY%O(S2X!HK&
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M*_F@!VX/;@^&EKJRDL)RR .=S9-\KLJ?1KPF1:="!A++\X@ZUT1*EN>KY:J
M'<REPO8&[#*W$K"/6#Z)LO]++%4C]X@C)MCL.5/01W@RZ]J5QRP7)#0^/SF7
M^)1%V,@1@2R,LA>G6;X&:F0J*:XW)CSUP.D9HP+NV6TP2!O%B !&[XP91H>*
MV_H $0?$FZ_52".-IA_\'^R]!U 4W;HN/(A*!D5R&A4$!0')B," 2)8<1K*
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MQ%@.\(!OXFMX*-,$3[1Q_<:C'X#F=GXZP^7_+8'J/]NTM1P3[ETF3XT +!T
M:;+R?VE#WC=ASM['6U_V8SFP(F(;58\DS=%+I _U%^-='U;:%Q*S;W*[ ,3-
M[RG<YP_7Y:UQW#]7:"VX*2FGG,.7T(29O'6'B*.CWOC83 6B-6/Q;F.PUT%_
M*'#CC/I%@VC%L^IA1-#GO'R-&DVFZ^9^D9K]2M[.Q94<Q@04,*T*]Z+O8;@
MB+70^![Q<^*E;P$W:9;,[V4VHUBB5*X&6IJC$3D]^A;RYHT&[':""KU]=[9;
M9)&[0*@(<0!?IR?1DB,CV=HMI,UG6VZ.T<5 [C??"Y^Z!5T 'EP 0*&&+A3#
M477"PGG&KV(];/X2P3I,@7H3MVGZH8*4,HK>I^])C5=S<5EK[0V5C?N1^U>K
MOH8G.NPJXYE^%MD/ADM? -!]-%3V3YR2%(]CU\PVKQ7J!%U1M+&OQ *NF"#S
M,M5$T[^RQ^UYYG<73BW5$>9FN?#?X,T_38Z-G*9IT76%H:!;[4QY0DKWWL;2
M666U,Z5?CGH.CX=GPCW_(V>P/_8"0+:%#)85A);.KVC5UC,*?N-O%*Y^N"*V
M+^,C$0Q:+,=-8G[75+T4$CC(HJ,+0K.-U@ W+P#16AA>/"?ZBY]VPI%V2L>G
M*ACYK@_2 E8]JT;X__!*]W4@=;VGG2-9JH,S[0.I)-YF[:OX+_."[+B]OI%Z
MX4,6S:AB73)!*V&9#C+6DHF*>KX%]F<XN L9+F>"R=,>O9=>_0:_O23R6FXS
MH"':%43IS^HRKT4FAX6BVL; #Y)B_%A-+@#\EC=3W\5<<;8W9\4<IF"-QRYC
M&=\>1#O_G,[B]Y3JH[.7-RO\]6-C&$4'P-4[+,A8=/I> ,(\/,H);RCANFEO
MVIU:NP+K)-G1RW@I;'^H/Q@8=I!B(F.^C7\P)F*,_% C[;[YP'V_B"9\#M8R
MC/W>W/_YX9DCD 76Y86Q.W=U6=XGXFB:=WG+02P.KVQPRW%D>5KV=B5LXG;L
M-1=W%/TH=*&3!EVG3A$@/F"^/I'PLCQ$DOE =C02NX!7+9P]V*/!A_'Q=0H+
M)"_L$$,D(J-E .^R7&JC43Q[Z103! ;2#J1TR#09X1ZJ4%>1\TOA@U:JO(M1
M<<8=%FW9S<N$I6'P@G3&G8?!K_+YT3\I5*:N@&*-1[#%1=8Y.$[]NEHXZ-:6
MF=Y]H5LV-XDV/J,BIM=0<-CW';)UD;86"@U%Y^S'9&TOL'%K<NQ3R6GTHEO\
M!Y-EV1KD>8G[Y;&T2@UN35]OZL]08S4S%VA"I<;R\H29*\V4ZJX)T"DW-^_T
M><$KRQ *:+\BC>VOXK;3GVRFQ+_=7  :[VF%QM^?O2JVIFUIML-$(V>=3G$!
MH/;LL: ZHP\WK.?IJC1B"QZ-60B261,]W8DPOS,,J[K//53>8Q3^R<E:VF31
MH_-RE=/,04^GG<S*YG"DAYW0P\0/W@;^\(/^J^MC4LFO/>IZC#)V&8;$_!^T
MV>A?HLD1DF,.),=^3KTW7$$!.=6Q*W38M*JK^BDGN2X3[0-K,4$R.W(P!DBT
M<G=WS$QXBYA/YV V-;WRSTF7:V'A\0)Y6)*.B;Z//],X?51OGZ-<=(Y9O)NI
ME'Y:7-&P9GMWF"OP0C@G\.6-]S!>P"0F-LHS9-XOEA17S,0YFA'^\_4\->V2
MR AUY^2O$3PS5@F1[R^/%8CVP*;(2,?>Y 4HR_3[KA0O:K@<A@ZS:KU7@YM%
MGA<-+-Y[2*2Z]CE.#\>)5SN*;BPX6R4&/<:FQ9SI(:'ABD/141;/&^+%&E(%
MX[DH'Q</'GV<VS.19<:ZO'MY!IVYAK4;YZF&WQ KFB[=H@;\%#\GRH>1!.''
M?T_1PY%6T#O$!FC7M9&- &3N70#VKZ;3Z"$%JQ/K-;!#%#P/2P?N]YX^8DXC
M3L.1(;61O)CD$XE."Z96P>Z][Y0E(6=J@,MX#R*:+>*;X2TL'EFTM,<FQ(U7
M](#EFA\ 0$ST^BQN!S=Z 8B%[?(YP ZOJ1UXGF:NR0&EIL_D*K K[5I7NYP0
M9D:1)F&&C$S'5=8YLHF#_NHC+AY-D7B6-(UR1N\BQ\'OUR6O]%P3#N E<.MC
M/G.B"T#Q$$PL!S>&']; +:!5=\QH.5_^8#^Y]&QNX/))<0WVQG>OP0WC3;@M
M(OO2E1'QDI=^KBHKH/:8Q-7UL<"; ZV6MF4-(5\7A;\56\PW(NQL,"MZJDL:
M1SIOTV.E?[3% ':,&R^7IFEB!*(=/-.D'MG0I/T,>A@;<E3:FKV>RE+CY5!N
M,L[_H:1+:'&+P,CWX;M-8=8_"?(Q9CM39[$R7?O!J@J/V/J'/VW&T[_X_V=*
M,HNE>1<[5#XI/'(KH$'_U'B*8.+K^I7[6,\KHN:KHOL-W*S6TTBH[>=8^8@L
MO.3G"T#^</,%(* @QB>&X5'O1HS9N^3QTY]#$6B".I1HO "DD3;M9&IIL6F"
MQM;F+@#5HQ1B+4T5..%4HW=;N,R*C)JWTBZ(QLM8#2+9 CBJ?&Q_<KB2HGJ\
MJ>XSRQHB(E-O+MZ6_D%%WIF.;2B=YYJB!QOZ'Z(5N_6)Y>2OQF)CB "J0K[1
M+%>^3FGPJ<+XY$XE9O1334)Z]6=+Y0'O=!KGZIK70R2IR_;HT*O&JDR\N4?<
M]<AV&,?9HXQ/_/NA3H9KT%[8?;D+0+TO'H"*ZT3X*^&*O+@^3JL[U85_^#BG
ME;YF_A6M-7ZJ./S8%+)7F>GZ4$BPYQJH%R]*M"R1RH\+QS[&3#Q3?O6<AT,#
M_B$:-@/#WJZS(,?_G,I&10CN:G&/_5K!G\ P_6,-8[_#@_AU)SK&6.VO65J_
MNQ2,(R^38V8!ANY;4$V2BGZ1HK AOI(8:'T@ S'_1SG12L.8;G]1!.BF:48\
M?Y51LETO%?N9R(R?CJAY&JK&\W.5#D^?+!ABU7^]^H3E@#;"3X_R+NR-H6ZF
MI@6=3A9$/V;(+A%XM7--XOQ 2^NJ<EK=K9,*W]CQ!?QJNCP3_KK>@3&H._*D
MSV79+G42*DO_</=J@)98!03]X:E_A.SKVA*6F)'J2Q51G,#09]UZ'QIYW 4F
ME<-NRNH8WR-7>@#(NYO/]8_*@OUGV^/T WI#/Z8<MMP"#VT2,3_TOJM7;K'C
M4<M"VO3"FGEBU(C6)<E%\I_9+)X&.<40S0HU38R7]*N%5N>L+?JGJXP/5V%J
MAT8>U2_PUPV:2F[]](J83S)2;&"U .W5C+/]+#7.PELL64=B&H,&3,E,7TF!
MLQ[7<5Y*KRR-F?)/-ZC=S%2BL^PBCJEP&$N3;K-,O%U_ >@P-E$_W3<M/3@!
MIX]2/>YRMN*D V>RC$S=&;EKF,@2X;8*A80IA#%EQ]R[\YQ>2W9T=AIG9FSU
M)$#+L0*!L[%^[F4]4V^_9.!3.%%U,'#(8:><M/:(P/I"+@" YH$SZ9_KNP(!
MT;X":<^3!JD?(L9_*3MG$L,;S-LII>\J)Y'$65R7VEW^2*"#)6__7J3\";XF
M$AI9A)"Z(H#[+H&' #Z4_R%:^?E:X/5AT=CKZ\9;)6E;\-B3\YW$C=2KDD7K
M=XE(?W".?3L30?-+M+A.M^=\ZIY^:IO0%S KM#_GUN<\*,>F5((I:/5MS./.
M:'(:WB:P;>.)@.]O5 *>$8U52HO,;;&VN*K ;>I\"'*SJ/I358_@:9_)OO95
M[D2TV2,EE)B,^4C?89%BE5;#;LTAT_RG7)SRTU%I'00T;*[_<$M&K;4"\_'A
MNE"_GLF(]E7!"&E!!*Y.R8E/3X3"UM-]L7&L^W.,JV. 7NN);476%Q'="O44
MLW2GP$SV[P=%4G>)^S?QU#CSB65F[@"UD[N:NA.[FUW7.!$],:-^\^*ETF)S
MXSQFU#*:;59\D:_4\MN@/$%0^G%=X8(\0^UNZ,V8<B)TPEH3^<MRB5$T:F8>
M>+?GZL>3L -#3MY&K1DFGJ]K9K"6Z*LJ@4PI)CBN($<-T2)F5B-=^=C6B+7G
M&(E0?A>&71KJM9*I3!<CPW$%XHW/8/F!Y]I7E4+01:#66DI?,7C=> ZZTHKI
M\T$_?8_I&1NF_DA/G1*>^%E/?*6BHNX>F0S>U'O'/%@18.<@Q9#R=2T2X9#T
MSLDQD_5:(&*F>A$G@G[VTKJRRDEI.N[C>09%4?PW'DDN:B6M;%]Z.J)0=!JI
M/9ZV'"I:\*KH5F_9C\FL#R=EWAOJ.5 ]S:%Z^3R(88=+Q3J/R(X_<DZHW5E'
MCLD<B$E-01=$JT&(Q<^5EHKM]BQ<9Z;=.B\E+;3 /5&1+\_4;Z5L'<:)ZJ#Q
M3Q_<7+2>':NZFWZI'M4ICD0WL:S./'SG[IBYR1)#,AW=W[WR2\*BI8$WHZ;R
M]>Z$.N1CO/T=721KL4'PIB+ "I?24@N.%MV !"CF/%"^W<\<>ACOYR5MB)NS
MRGQ-6O0\AI3SV7R4TQ.=H,P!_0]$(850A:<HL2T^HSJ1\X*G5F.G0(J$J&VF
ME6Q#+$E0N>"-#8:3I +*!/7+_.2=3:3Z)U%VH&B/?6T2BIPS;LQ86EZ[_S+^
M&/TP[-%D J\2=$G9NMT%5V81WLK!5#^RR!JE,W^W$^S>DGORF7PR'^7K^>7X
MS?1$^\/7\O?-K<)^+632*,BQ];>Z4/6AF\@>)X?@N26BG(N[-I9!7('L(/*-
MU3]OJE^].XFWHK/B7F=$Q6NIM0V[+08)0])&_8WLGC\U7-@" Z<5FD_@*Q5-
MM'WYC^1M^^C3YZKGNBX 8X4&!O*A]',+(H&&:(4= F.=;%ERG!K%[^P)S$"D
M<C*TTCRL"!RV1S)0Y_@@GX(.,B@OBTC0ZN.&?,\S]&1?WO:[%O6\Z(K-(C]S
MSG*"&#$[_.FPNRK\_JVVD9=O-=U>2UUO9\Z:UOSNQR)N?)B'N+YD^LD:N/O3
M)>5@PRPF8;Z'7?GZT\ ^M_-.:>!7I'2?T#=?U->P7KX!KP:4[2OP]\&BVK+M
M6-N-H8B]!N)VW5]2DQ8/XW]AV';U")+&/)3MW7W'U>^)8?+L[0$"C(Q:USGL
M=WYAA"2-T$L.3H,Q!**=M?S7MY/^_JH&@ Y\?1X9@6? I$,1C28I[;\SJ%HW
ME*WZT734Z[4!6<Z,Y@MB-\\O36]FOM_2K]+= RU,8M)ITOV5%V#4.$.& !/=
M"![BM_K;[R\ S<H'R!M8\!99[NPC8ZAQZ^:/V;O5GUT2&R,D@44ZF)7F)EI<
MA$TCEGWX6<>*.YGF<0IF"X>J@)J@8T//N"/&O"CX?[!-:4K4$/ K ,//@T;$
M!MXRY\<C[P\\7N&>/X]QPW?#-*_X"8;*DN%,6H.Y:T,KU-M7>FN -V6[AO?Z
M?+7D"1)#7'+H[ICDH Z=I8$2@*/ER_],L8#_5&ME24W7?:,SH)?[CQ-/_&GB
M<?]A1=4N:8WY669H9'M5*B-&>'+B/!SH.,*#9]AGODPTN9W6TN!<G]S62(&-
M>3<_V4^+8UAGA&P[OUSAO%*7ZDJS(L<L89S<WD^D<%Y2;/H+ K>Z)L 9R9II
M>HY^\S2P2>U0!J@?8CRX)<9G_='9FE:P$M+129B<-U8?DTH[S:U]+;<54O?@
M?,YU\P 0G15 Y0&Z[JQ[U"SE'7$F<^]>3C_[YN,;%49$Q\'$E2+'VB2Y.N:>
M6,ZV5+O6#9?-+I.?8[VND\+ %,A<O&P0ZAZ6ME-O^& G?$(@$<;?\-WHILA5
M'A)2YH8?79RB1-OTO;B]=F$HJ)4F7^%E%:U/'FV!.(!_ZN2<KU_:>TX>34.C
M.A_ :#RJIU]NR17+W^7&'7A$$JR.?=4Q:X%SRL3%S/56:28MWE9Y;"5?O>@M
MNT\TYJ^*I49DGMVO'BN?3"N=O1R<]$3;:]N3A"B8G:RX23E5_0M+MT^*1_SC
MJ+Z8K(A="P[HJYY6V"5!=(E?LA&^G\]G]Q.U.N+I/L>H8P\Z_!#U)GVD(AJB
MZV2V]22N7N]##(<PW<VYX*$@&:^(70+17S^9G,-G%Z['!V3LJ"696'(>O"\>
MJ#E[1M-2T\"":C'G'!X&8V-C!BM,XNI;&7)N7:/N"O+3)FD8-%?%[+7K*<X[
M@5O>%74BC2>_KS@<06Z^ @-=XU!LY(O[ZD@J*-)@%-B9RE5?.II1_4*%8W52
MF4UN[HH,V>%A.LW7C<^8I;1W115FMAJO\!0I]^RF$9T<(G3^F$"=?LWE7"BC
M_*C'=4_*VGE'N,C<+^=70TH-P3*DG0WN:53;Q2GMLJ#6+CY%O],L6R[BL&8Z
MHO5R\,^3*_UATF"?W+X%).V,T0;9H[MAZF5.;/;4 /..!NOF6@9D>J>WBV=1
M3EXVP]7OD0SQHIM9^YQ,Z=0M_\4<,#1L_UOLI[G=WR>YJ2RJW5?R. S,WO^=
MSH;\=TAHVX#G;Y0INH_0TU(#O/[M0X#L(E#C 9*4R=\T>_@"L#'8M&^"^@:.
M_;L=AJ.-_5^_R#:F0^F_X\J>07HR$7*+"LSG:R0[0+4-L0(T8@W,R#XH>;)/
MO[2J22'4(S35.=,(DVRKEM>--3NG<>%MS5,=2]9H4+T*:)XC%]$@**?E0K^0
M,E5X\ZB_@5T6A '^$O-SS\S:^B:KLN0*=WD%*VY_6M:ORP N"7:_O*Y< =FT
M+?)L;/-3J=NH7.H=]@:#7.8G^=*H>HJY)"Y-R(P_OKH7VPDLN@XM_@FC;*S]
M]I/_ ZUV<%-(K&E@!0R<6^M9U9OFHG&P!HMKJDWP= 5A*O9=CO>:+@"--RX
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M]] (++2!PTXLNUY3%LJ=T/JX_  C'6HUTS(G^2N_V%$5WGQ^7X5D94..@X)
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MR-N_S ?PH19K-UA-GR0\41[OV;82L>4/80X0<<634.%A4FAO-PO.SSP'T7Y
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M7^_;LNEKZ+?%()K[J>P?\8QHKR=;?^X%>2'&81T-XDRWJ]Y9A8G&B#&19P+
M<5"%A<-W!<=>$_L\3^ND?0J20F/W+% ;YA4./DX!SE4,"9W2 L)(UJLD6/J2
M=S+_K85W_P?:GR;%]=A?4UQK2)6YE*O+J)9YKJB ZI:_6?QPTQ1OS/!>M7,T
M%QF^[\WUU/D%>^;:,0$U0(?U&[L?MTR(3,@V??%*PX39_R7'-+:IH_1, 1W
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M%*BZVR:A7KBY.=>98-FIH)4U&$0[GJI&*BQ4M,JUPYN,GXSV+D?>")XYG:;
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M!,$[1PD[TP!B0J%@?&@1\ ( L+X S-L3K_3_X6IW_V8<C2&_D7Y+TSZ__04
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M%&("5A.?*4GW%9"+YJN9ED36BM[-151'3$PC$EL(ZR3_@_'!F[&A*67.<IV
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MV>I)U"OW50@;?X B;TG!%<F7_9\+U/1ST#(#S?=^(9P05N4BS)7)3B G27Z
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MC&HYD<Y^8SECZT7_[8H/M_18%@S,[F0(1:UH74*HCE<5B(C1D"(^L<$A/D^
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MFI&XHE[(;R;<DTRBG(T\F=FO5'[_/PA<_#_*A_NG)I_,*XXO_=QJ$,#QO^I
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M !F@)\=WWY#?(:H,*#VR'_+V7F^617+=L1)C2N/DVDUST,@YD#/_&BTI:P-
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M&=M=8@#4WH01"2K-AXW'>G(3S]V#.N6:+;5B_!1"NL4^T*+-Q*.POFK2W;A
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M:U4&,\<,%@BK6*%*G8^UNQCF*\&%BZV7!$37N!BH^"7[[[MI\?OS.YCOR==
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MY6\K[#]TV+QR!)Y1#UBUO#8((XE4V? L\WV@7N-8&"$PKT=S,H'PN-SCIQ,
M0H/7[+.-]=[Q><I!^85"'!]\7CVGO: 8N:^43&/1[Z<HDS3GA**#,C!&TAC&
M=9H6QN^KXIK%3]Y2[^9KCT]>=^<PN1Q._'G UTKKZ_4XGBEJ4%!BZ?=M^6H
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MU V6^?(#9$3@%CFZ;UF?7 ,:702"7>H?Z"$D"I52%:AB5=K7PCGH*7)OOL/
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MD+;Y<XA(0P*0E$)5';2RN;;F_[1WW4%-;MO^0YK42.]%P(,(2!>EA2($1$1
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MP]UKR;0LPA(^4G& .6V.<7946[]<F\*ME"Q(8[9V%E0 BR1OA"K=_E*]W'M
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MZ2$#W<LO@!\"6W>3U)>UWB^ !RSAW[^4_EO/?^OY;SW_Q^A)-9=?4,%[ 7P
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M=, <'HRCB#/PSARL-),>3G$>\YA3WZ=F*4/X58##U].JTB,N>\16]\V/.C>
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M@\6?M5H;K[9M?R,! EQOMUV.NGF/5DU :TVO)/MJ!:#30WO;&S[DBLTI(([
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M&^I,1#J>AHX$WXMGRN?L!RZ$Z&7+/^@>V2?'N=278,WUZHT5=S>KK=DGTC.
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M5+_'=R+N2!,VIUT\:E=&98O;^3!L]_2N!2S)K]4J9R"83(]Q)D.9%\\5_P)
M'R"BDHE>I?B0T"8RW>V?/\C<H84#2SY#X&'PM_2";VZZB A(^%+XEMS,_H##
M/D[\-0E<XI]_ZT<):JN=>)+O?<(<L3&D(QC!C@B3/:@:D*8.L"GJ\$D]0P__
M7:7XZ)9MZFY+AM<\J3OTXNHY?<'9 G6CV=\;!V=KTH$!<F3T5<?PB?FR%(M<
MYWE^P=7\_)(B,A4%.52$&EQ__Z<]!!#3W"=(+$,V:VT7FM9,0E#-E"CP0NN$
MA&H?F=JW")Z$I!B@DGD5=YIAZ^7ZB#;AV>>'#2:Y?&I,XO*T<DIM!3AD,$0Z
M(V^L V%B<ME3\R-SI<(@QJX9";E6'^.<,2<3C@^AR-TNR MOF!D _"JA)ZZ>
M<QG92A)ZN)WU2W%WI2ILBNTV^DP]&P/ZJCY<O.\Z&<;#&1:5NCG>FUI7N/H>
M)!)@P@W;'WD:]?G[V(P)M)?U0Q;,LK^CLVX_ZB&)Z.%387$*Z,XSN$^*Z"F>
M"'-K#$H;%\L[)MGGY@$)*&QQ0\BT _'451)*D#]KEM)G0?_Z3'RC5@P,!ZGO
M"0JEK_\"0R?8"^!9@?UOB)2^8OT'1/+]%0WR2=-10*0A96K/E1_-%LJJPA+:
MR;*?$EO6%#N:Z_&'GF<Q?8%BWQ>B>&FB#@LP!:-"O)RV#XS@>2^,Q*9CKS?0
M;]G%1X>NDIL03I7";FP7N_A=W*=SBT>^2PI!S1GW1)F6)92HZO:CK=MYF!<U
MQ-&/9HE^<0[QCO=Z+]/E\0UMVU U?SV18@L?-'\U?^!7G/*6_HW":\Z4 *\J
MUF<:ORBM,/;3,R:!>A%,?=[WP65UGI2']97]A4:2!U_M8\3.*H5\05LFHR"<
MAW84PK'339;YXDO54Z9UT[<B*+:Q%\=Z6KMGPO*7<61Q]?XJ-%+Z.C4>[N(Z
MEH=B_4G8YPL?1I<E><VMF(?,?%97+-:!&+?PGFWL1&NG<88ZPG$<>Y=)R]69
MW^3#)A([87_=%'?6Y_K[4??1F[G7Z9<&\ZY44<W&&KDDMW?Q(.-W$O3KDC$2
MM\R$L%@G8E%.AUVFQ,(3#^"O&"J_!7ZDNS*.9Y8?Q+ZL"/YU_#D(7( :;C&M
M)\[?2H_F(NKF^H%!TR/-3\XO %2_RY^GSFX.MW>(,M;]EH&^%0?T67GY!.4"
MSARN#8J#;/KSRPCNO['<GXD[.F:EJ)1\?;N+P90K;E8F/?C+F4/9B&(%&IWS
M/KRJPZSD;S%P[:?EG)%QB(S,AKTY[-(Y^H$JY_Q@2#&LR>D]PZ) :32<0\)H
M6XWKFG']XK7%JT%G*P(F$LW="L6+SP1&7+X=BLW VM7@TF^I9.UZ^4XSKE&
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M)63;T4V 06U<$,,F[7S3HR,3*B<#IM\)8-ALK#YJEQMW%9BMF/R.PZ:S-T6
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M6TU2V @/6+RC-S$]<5/B4:6T???K/;T?^'7P5]!72;^J6HP=KPMBOAQ[HA?
MS&G]96WH_N52D;__;;[$>D);*= <+E6K<8G&N6]K55D[J-?W<)(8@Z(GZQ R
MH*%D)3'&=24.OI"B+FF <7VCM>#H$TX<[*8BN0PXIB)OFZU9FTHPM&<F.35]
MDL* $B6#)&N2*Z*OCV,X.OD;)<O:C*8NF]QKAW!>803W*/OS)MZQ<2,#O%X
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M*VMF4D,=HPQUJA1XM:I\X38N[#0;A[JC#)W1:3LJ!;T52\PIFR^=,]/TT>.
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M<_=)72UB@&7KOM[6U=7GO&)=*9[5RQ!907%I4K*WD)ZC#]'+K2C7)"^HG#H
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M)/T&"&W<_RS8,CM7O3?Q_LMS?_T*[@\MK_=WMP^O1/T;%JE)-O4Q^=MO0&!
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M0VEN:SZ06^47<7MG&)VR?K,Y6;J)KNWV3-/*N5,(YXK!,K5[L=W2PK; <VA
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M:WV=3L>7G%-B*!JY"S=? &&8'O[&MKKVT 0938QD<G:\U2J&_&"9\X0VQ^D
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M0W8P$J3X0&1(C2V,\NT+@* ]T/XS4R@;KWP9&^? 53;Z4SHZ?S89 YN3M+"
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MW_Y\D<>"XGSM.N%!\TV6S0(]L<44#BT48.9Q^\G_3G>^7LE,>+6N>H!2\BV
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M[%CYR?-\,JJYNB%N)>4/]54H4V7$;O6O3QE%O$G-NHP86V>YEJV:?[3YGI"
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MYT]+&2N6WM]/J;6M!$-Y'>>K7>FTN_UQJ(B\"38AF&.$_*\2U8$X'I&;CRM
MTV[]D7?)NS(1O+8KSD.ESV23W*R8=QFM4A4RN[DT@[G]Z(*.8GA"^-">+7*"
M(Z_,?)^]H)T^;/9!51DHYY9RO&WNX9);:6'PJ^%%"\F GR)!^4T_YGWPMEK:
M%)3K$@Z'KT<3I",;0X508K8F]&![;2#FW9J?2WID[S27C-L -"T9[EMDL="U
M%) %@SQ])[_1<UT>3+M["7B>E-B'"9;%3%[N=Q N&8AZ$BSJ*3IXN DON=6R
M8HGB;$$@94R'V4&W*M]9,UN "A207RGL#2PLD$<#O$2#W%F_7LUN_Y9(<#PQ
M> 'T$UBD=3%I"VIM\6Q/$AT(4=D+IX:6V>X95I(PE!%7.&J[EK.@F2EDCOLD
MQ\N2#9"H(LGT'"3XOP)&?5N".09.UY]6Y,R<[#2U9E"&LG\G;3]E'+K:AVGW
M;"V9ZLKYFJ)3LN68YN;-#H"?*58ES;A;%@^:?F]:,,@^3"+&@I=^07QIYE>$
MY])K4//1:AL99[BUU><_MTTJ?\</9DU1>[>8KR4F/O *<BCT>:.IXBJ:^VHR
M]U+Y_8+#9KBJ*%%?5J\?36:?RUTMCT(_F;ZBR;U?;@ G:1U?.Y8042WV\A!:
MKVR[NQ;)7 <6[#Q,B<*,6,3X#N_+X0-2,6O/7$WJ[<*:N<6 VH!>9:6U7M0+
MX&U9F3JE'8[=[@#57C;Z;<_'+(PES$ZTX'NM89)*12VC8+OY!^8RI^BR$@Y1
ME#F->+&WLD#K[%<%"AFMZ-Z?DD(#.+@SF(SU/O/%H?X&18.G-_=X+DA#5 "W
ME;(#W(&E.M_23MA9]-L^J^-+26M9\9?\@@WE*5W8Q\NH"I<.B6'*#ZZ*/Y6N
M('WX:K(OZ@M*AZ%'%XA;, ^)52YJIVIE?#_8/#J,W[=N1'$$0[#]9M+-X>1(
MS#Y<)D_ ETL$&C04]3D+8RC5]B8 .AL);_#F/;0>IJ<1]D="GP]L]K<(!_O>
M=4:&$I1&+;%E<$U(Q[P 5-H$L<VQO8F:4&_=F#,ME#NUTSB:5P:H6>N:X]#<
M]%B:T+J)085+&ZXTS3FZ>>/EDE6+NC9J!D\M_2^ T[D5LS9G)#H6<]97.;HR
MQ$H*]B4JUB@K\(,8>F>%NEP.C=Q-T^9P\U$/FOJ@1A8S[>BN%<ZHJU+A4@OJ
M(5(I"FC!7R5*ZW^JI!-W!<V^R@DD$P:B9)FIY":ZA4.:QCU*YJERE3<=%DN,
ML/BFM*GN8A@U^D0OX)L>4$;/LYX"S5X GJ4%S(^<H26_+_Y*'$KG_*T%X;^Z
MX-L/HNTSN--010YZ[^>/H#=PFBFHI1*1Q[P9N8G)<H* UG['S43IN1X4(X)M
MP"/W 8DG':NKZ)GLCG)"_[RJ?>Y#IK9)'YX%E:W>>4C=J#%*!44"DJY; &Z,
M%]&O=H+E,?N-H@07\WB\ZGS3^.+N)X'SC7G7#.7NASU=)ML(]GYJBM@T4I"D
M9.T+X*O55F^S87J%;2:B;=EN5:*>,2ISA1GL7?TM%A=#SPZUF:BPC'#M"2S*
M@ G;4^(5,:S?68P0^U=8+_D[FGH(4*J9L0IE!R%XNN)NNZ?^&2=S1G]JS9K0
M_%.\D417 R_4:A7D_$OTW8>6&*1,*N+2KP8;.'I&5/.G0N[^MM"#% WF:CY/
M(ZG30F%K+(6!3.I'OTKHHJ'LE![;[U]:2_JQ:KIKE"WGU4 :6S*Y1-5ZPRE3
M)W=>1;,V%S+>2>CT=32O07TUJ,CT!6!(:+BXC4=6N#7"6/KZI%84+;9AJ)-#
MOQBN[1<A6=.6]_(+ !GXKB7*V4B1>;69!$M?(*S'EX45:6BW=6M/T.GX&7@?
MCI0+,PHL6O< *;6#7\\_C/5.X (#' 3@CC3/_"CE'#>!3-G39R)K,((5W.WX
M8#%"/_RYW4D_S)757K=A%!J5+\&Z[>0MYTE+(K\M@1;MJ31:./$3=H):ZR%"
M_*ZE3QS-,Y81N5ETCP9FR:]F]3#"F;B$Z71 9"2LGO;Q>Z^1R +1[]Q+#;AO
M*J&ZLM/ZGF++_((_^CJZFW[SV-+TWSPL]+G=JAD,<9Y\WUO*D=L&G_J\=RZQ
ML?K49LA!3+!$P?P"<,)-P+C3^FC$&-$W5PBN14IPL7Q#[1#8Y.V:SUETCA82
M AZA22LNWZW-CROI/7DZJEV^[10"@(;]"($+\4<+S5&.<O:%_/8,A*$85%$H
MUZKBJ+V8\NFQ7OD*0J7=+X +S;K1?8I*\A!S8"99;&\6-K<L*TW24C?X./(]
MJ5SY&:J>P0",4S=31]<L+KI"QHC^&:6^.6R+IO9"XJ/TAQZLVW:S/I:\R;RM
M$7'[<N SU@PT@5':-4'"(.'3S=B7N[#-\52KS2'J*N!64X,Q%W]2^@EA43LE
MD-<1=&-$71VRB\D1@87DIZ9V9(Q%/7NE535S-9)5M\K2;<B!2X8F+-8Y6]=2
M;KQQH<05]2%B*_J[,KJ<\)&[])T_=,WCPX>6%/=,G1'/4(T^R\-,HM8I$1Q]
MW?#1!E9J:4T$H=#*CU-4KN=?Y0]"+V+PR69?[SYCK:THY1OH#>\FO#%4Y:6%
MJS+Z*J(NNT,VMV_\IKR"N=P5KS$B/FH:*_YYU8M%$IV#OP3G3^@<)/%O[,=K
MUHX=<M['L'MMY,WUZXL70"MC:_L+(,YG_91\UX \S']AY/F\G/S\>U1'>*S<
M?T^/EKB)'H9-5Z G]T_(2_[*_?OW8_]ABOF(/I(Y $[X3B,VN(T+&/MN-L'7
M1UF!1("JS0I#UFR;%F+EGOM:_@?[<:23)7?]:M:.=2U_-Z/ZQQZDP*1Z3<6R
M*Y /Q,@&%JN8%Z LNB/O[WW[/-&RP#YRFQC8RT"C]XW>@RPUU9[$U&8Q<X<C
M[BC]U DNBE$7G3AB."84@A$K'H.Y;,,>:D>04,9OEM+6!3$?277X?@/QM:JU
M+Z)'!7_S@@$_M+'M%GFV$]>YXLDS8N30AA\UOJ:%[KSO(&.H;8Z&EMIF>N29
M+>P39K^EC8-3U6^ 4MG1VF3*",TY>\-%CNHF27@)Q#FJ#_!F7!8LQ)+[D$R^
M"N?;E8BYNKSUTPNQ4YL+:K4;6788$__PNU66\/0]6CHN!QP84/?C=%-L0D/9
MU-UM26!.ES6G(4J)>BH\K>GS@[K>NIY!QH^5_OOG(W@E@*[%+P=.A5IT0=>M
M[,8F66).V:I^9-2QJ,=/#L9+J\&[!A\)2'PJWG#!.62E1EU.<,,AQFV'3SC.
M)Q=$(U''PV>>=JJAK=;FF6MCL1OE&! !XBQP+_1GN)YN.P\TB3]5Z?)PC[Y?
MJ(=I,$:HXL:1.2?SXP(NAUZ1 =>]#^FCW%!#2.: =?J"EI\@6]3.3X(#N'!?
M@M-O1*$T;#^I$B=GS)I"'=L)J>*]DTT<Y3Z<E'DWK'QDG\7'!93DVT7'G#[-
MM*NS\0W8A#*.>'<]1I@YKX."I)@J21O7N<#!Y)[AY"$ V:[P>Y$#DCT(I6HX
MW(K8-O? W6,OAZX'T(XK<DZW%Y:SN)TC-/\""&/9:YUDMJ.YAUH,T01PPU_S
M=]E/Q^%]OK@B=39(C;S*PK91EUBB*1>&[.]CQ8EF>/I!/;?+.?OJ'Q".%I1N
MHK-Y-M?/LS&\4>688\( &D'I[X0?@HV\<W]ELDYG;NUK+%38F<H.:3KQ%0O!
M;8&B%4'(GUH1*9I?9YH%!H(!9V'(Q1\ZWBLS0&5_(7_^M-D:>K;7T*@E=1R%
M;J-;85JOF2"'_7[=&0X"J H"=$U4 (F8]C-5O"K13LIV[G'Z[S<034#(.I$Z
M_IC+PA79GVM4>7M)T 8Z<.&FI;\Z=)*X"(_1$QI]PKLJ(KIY_3,J43K ,=2!
M4Z6A.=3C]N.ON^=M<]57+4X 81FHL!P5Q(3?<!L<[QCS+TV57D-S0Q& U73F
M/:C!?7*RBP-<#6)."_/1A6N>$1DQ3KZ,HGK3TG4V:OIVP@\+GUWM4K&XG% ?
MM/FJAFR=/CM>[.]6,,R>@I1]JA4OE50D?'%L!I>38TGFS T:R-*U<X\@J%X3
MJ>00M:1K^"8T!?$TJ;=43?$$)T,5;[H'*N6KXY5PBR;*55[IV.XC<$GGI#J4
MPE,<C4G(SJO_Z+LP;?3,Z%J>M,S:H:Z!#B>4J' ;VE*E'!%[(-52:^S<,X@8
M:"A&$Q;G&"\OK\1-DY!Q/*$<3B0[$WRNF\TJJF1KU<3NP;1/:F T1$HN'BOD
MBTYS[2CPTJI*D_F@1Y\AJ#N"0,B<9B_,V5G^%DU3MY<3:\^;J"]51^&K9IVP
MS)CNM*SM65Z348EGQ9)&4P^#FS"J"[3(=@='+$80#&GAY?BGOVGV_D!!_$ 2
MKE9=?;;-%(D<[+^#Z'R%]WU3]!Z^\'%,SX_NCVTEG9C4L@H1W4').B,Z#.MT
MT/IOQ5OIP'_[BC](C!K@./]-PRN]).GS,,3- >.BB)7&^DMA)E__KRU+!)&@
MQ-<)U)A,#!'P3#J[C@HD(%QS2:)<LNXF\K!GNE;81Z]$0VG,I5$J3;3X($Y]
MOP^S'Z9]A-T]7Z]2BV'227$JF8)I1AUR^8\"Y^,DD=,ZAHT%1;WQPC;*;?RQ
M[CRYWX9WRQJF$DY(ZK?D(5C>+:<_C<(A10,V7,[0C&+#;XE"1NGF[7$J,(HK
MMD@%YB=? +E=).1K=&QRI4S[<')+@FSY']0X]QC9A5),Z."HQ;9!@%]^%YFA
MI9*%!^?C%J'C=,.7C2QH>L-.:OUSMUN)3I@2S2UL.\'S 0A!2%L.*ON:?2$)
MLM/,291:HMZD)2,(Z55P8AN)TWG8](_53"L7[JA@0#R5;-Y2>-7^F6U)S<$\
M+XO>WCSO[7*B-D%0+R;[SQ)R]K=LN@F23PJ-J@ JG4EJR2]FIX'3N6DJU<TF
MMSSQ[7Q#A-SF4584:#V[1C_ST3->5=4+1/> N>"J!DCDL>F2S<C=$:!"89^#
M\&G3]ZI]I"HD-U?I*Q=#U;O<R#6TN(2E7&W)IN_9VEV\ Y"A^!)5MI_#1JUT
MXD1AF/SY.GE1M7'=09*S@4/9S2:(*=QQO\\-4&=_:E(AT[;339K)%T?EJ/[J
MV=>8+I4I6.Q_MFA+?]]"XE+<VDNHP<#T?="P.\'W!6 >GTWEE4.!T&4W:TT4
MD\"WZK8B3>*NSCG&;W8QRQ" >T66'+:Y7*YW2+\WER,;_KG!['3,-BR6UJ4J
MP?_KC]P-'CZSK^0UO<69K69<3RG$8@@D$ F=Y\N[%EH;M]<[ .>%S*1.^?\?
MX8+H1B>OX'X&^>A!Y%>!$,#F,[W9,V9+#']7YQ-C_'E6+^,R!@KP)B)?: 3W
M/1P:^*B=7B;KM:*#X0\'Y.D*#Z1IVG.1Q#W]@8Y!=:=@+KBN^HR*N\N^=]J\
M;JP6GX$9+3'N[D6M%D#/(A^)&2YO[] 0*]L89!-$;U,9HE,4<+87JG;2D1SO
M$XLAF93*JF<'I]E2 -U=]YIH6"9IT/CP;OS9CC4T*<&QWUFW$C_X!;!)SE'P
M0SJ;:GW/9]T?;]%'=]*.FYFG_^;UG_C9]-OH8%Y1/V.6"O:=/.D;A8/>M9 E
MDY662+]/<.4;'80*CAN"1Q$&(S<?V*D+HP> %'/&K^_$/#HD#;UU,G8AU^[9
M0\2,QC(_&A=\WGCD=BY^E_YEQ@ G2C^@7!>_44FX?&<LH82A+]W07&,8[(G@
M/ZF*L-S3W!'J(U@A+KRL8&E&;C7XV'II2-Y#FZ""1/MMYT>FRK??(#S7:*M^
M+^6J73TAM[( ??CL4_Y]R-@Y:^P?L(]VE2&EZ X;>X^5 &?GD8UX[CMZX3&A
M'YUOI:G[FO"V+!;%PU*%P"-,S_LH[,*VXJ;,4^1[J3]&?F,S3*3.E;NEOYHZ
MZNN#9<,S'E/\VEU$AAM]VR"UZ[TU0A;LFRUM+\0BM)BJ+SN7C3;=6ZL@,._7
MC$?H] N@1V R!N_+D)V3^[.K>U\FS?/X@OJRSHS/"8WBWD;)AI<3**HC5K$5
M9IE!&YS@S.\S.,2R0^+E*$9*UKS0S@Y[]' QJ/5RS0<R@45CW5_Y)4V\NU.]
MDYA',_[8Z '!AY<:XE>;3RM-ZT!Z$HLU2%E=FS]=H_O@V"F11PU)[3=BJ8<)
M)^FQA! ;*3CTC%J'"\(=*@$LGZ3FSKC)T:WQX^2G1CQ,7P7_S$)JYC[_TDXX
MR5+)!/5DS7 :2SPPN(VZ:JIMH^H1\(R&@MQ#B$E_;+5I].)KN^F]JEF4W!\.
MP P4'SR;#Q#2%R,CGG-9KSE\B-0_LECD9+<W8EQHQ2M0@EJ;KFU=GLAXX]G?
MJ,A?@K(P/02-9C*5[/K*61,%MV2P?H@&E*\'_[")![HCG<O7AVKS/ .'EEMB
M_+YE8\AT8-=]/8+[22]9UX;FR3;%]5:N@A8F4K6_,BR'$%]#M=1&W"=J:X]N
M3(SP'/?>M-5*R 5OQP^SY7RL_3OUPV3286!8&F[U_OX5X"K[K3$&MS@^^-J0
MI?N@<$8S-CG] OYQVL->)JW/B'O>I+')$030V-VYY28/)H3>11>ORIC>U-\B
M0C 7^WD>M6Y[9)=$">["FY,^:+^Z$II$TE\<VYB(>,=3C]/PTVZ5*H'#>8"F
M3NBS\'J$D+W]9FTC^\\R4RN$#FZ,Z!25.UT(3FY*E'):^ .1D!:K$/OVLC_F
M6ZLTE01VG.K81KD_&V+Q)'5.-UFKP^)RL/B1A0J#D'I_[\BH>%."O"=%"D/V
M'F^O \O'&5AA[;#X:_M$<:9_?"K]N.L7:+J5NDR(\W.36V-LG#6"F;598P6[
MD?A63VS4@\[1J($?4EMD]A ?]_8SH[0H06T3WAO5J=T.!#&RXA*LW]]=D-%V
M$XT^;(B^\>^6*P79>W)RY[L+*HK%)\:@>1L57P)3*;">B[8:6;].U=I6)(3
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MML9?'-' 52B\WM*K%40L45GO+6'L;ZV:US3,6PU<#$VU-8'Y)J.T5HYAR2R
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MG_*9FA0YP13C=*CRHJC&'^ HLM/&-1G3(;U,PN+9H-1WX:_-%2&9GQ'>QM;
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MUC=TM%&+1Y:-1%X4D(P-Q/(0ENM)EM? G0U1N/U]5:NB>VH/ZJ1'G'N6.G8
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MCN.5&<,7^;#; BYS_ XX"V$'V@>"1T>8]12TCZ@BY[O#'C-OG(.WL7&@]B*
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MP%88]AD_4Y(6'>I_E42RA_Q*%3X#"*YIQX/8 9N0%U=%#/H!_,!M#^;E(=A
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MV:(@-F9DOZVU2>&L^6Z+K8]>[+;<L_V6)JD4MRKA2N@$M=4:^M"<O9(DE.S
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ML 582L,D\7^;\WRBC/NPE%O,6,@K/$]I]*U#E! ;<T0LKG-.M4(T- 6W$-V
M:&M')#NI%<NB/+RYJ] 8;WVPADN:=?>$\MM;P8L/BX<#4J"3#D%Z@;0:2H"I
MB<3P,QIM*;K^\8DO0"=RIJFVMCA@\J/07'2=$B2-K7 '^<!G\XL"H&KPG'3S
M(^+U\I@Q9]Y50L7#U-K!*I/TF?(S]KPE!Z[?M4,=/Z>S/\&69XD$=QZH,ZU8
M/]5!1EW/K(A+C@>H#BEJ$A,]2WV,GK.CS66K\^QXBCE]?OW'^.R5$N+)<ZM8
MZ">Z5*X%%Y,5W[CL5RUN:1CAY/:Z;_;*O?O1@+9251O/$_S)B6PUVO!I!D/$
ME>7C1@32DT@MY3K2(IA_2?*>X:]?^+<RN19K[GT^-#)*3#43('2)TTJE_>G(
MNN)M23<WF=,I'++TZ:MNB*42W9#4>$M/!P<4WN6S>WRO_A[-5$M$&#B_6?<1
M5F+-INQ[(F(NVZ"@DAY@5,[!2R& HH]( FS\*>W=)O?_Z7[=YT'2BE(6K!G*
MUZW\^5T>8O9VM>V]I;\4A]5_#9Q!,!'%SY*1B;(ZWSDS6>3?4]+AIR:>_DP^
MWQWSS%I%N7-)=)"IY_90= 7O96=E-)G5"!Y.>U,6LLWLXPK8WU-8*GO8:3^L
M#.7!72N-D!!6-F7]&K+-57T#J)C#X5OGW9*8*:IU+4PN?.FG7%(?1\3IQQ#$
MZ<<.R#E[CV-7$+?:.&*'0^*$=]OM+;(:.,DY?1LJ!U,)68^F"BV'A1N:CT=)
M[T;,:W]%-82B;6^0R8T3BZ#3"^UZFJ43YRN$&XP5,IGV-([;AY\,W!*";-2I
M:"MVD$7N?C0?G(VZSMM N5=0FO_I6M%6 @]H6]EZ.EHW%EE4A!GQV4@W< F#
MPIW63*/DX2K7^@91L3C2]09 \=Q3UMXP%1\KPWGMY#5CG,4^^D+VF-%!>*:4
MKN+!G]U^2A1^<=$3_Q$Y'/R?D<.X_TWD< 1L%!3]@IU/1-/!;%J.B*&EF)PG
M_D,)!P_HE.UI,C)*^P90"^[$X;V83/T6!%;NZL^F[]&,\BSZ(Q#X+X'P%QEM
M=UU5&0<OHSWO9.5".]P@ZY_*,>UTZ?3,I1<?$DE7<JKHP9YOW;L^(AL-'8=5
MCKPG">E4\>X6=\,D E828U8U2(=8E5/R3511GM8EG^^/_>FH0JR#3/7RW>G+
M\>AM^=.^QB.>C5OU2JX[<=UC;#@SJ1#LLZP+L7@DFU*+3RQ_9VOMXR-0>,4M
MUT-J.5XQRK_##76D].RL*^8=CF:B]]0%CZ;S6.E7DFG<'^3RC)5AKW57!YP/
MG#5?@Z>/D\_16]UCU^OER%P1D$;!1/?/L3< *J3@?/%[4GS\U)VUT9@JXWV_
M1-D#N2+J<9%;L/N?06]?XB(4T'!#!'^KCPGN1!;)+)M<>6??8K,!'>N_*=08
MLB]*AO^8YYF[,NN#0?^!UKY0PS'E>#GG?,_E%[890-'A/V:+WC XHKD.=8J;
M>O!8LBW,OGM'ONWGCV TY225-!HNUNYZ2DS44D@9W+O1=@HF(2::>Q)B$K1U
M]=[([ ;PN!.J._TP26F_=2)P:B!]J#R?WZ13E[MBDLUB =8Y]4;,H8WL(G(B
M9P?J>0,(\&*8,V-PY>0.K=!@#JDF.BTV5]$(ZQY7?'^OPS4LZ3&RRZN#E/<C
MF2TL>([%L"E0/[FEECMQN8%U6PV*6DXW,XZH(2;>=LWG2<;^ ,*=36FJD]E<
M/<+B:K-D"?\XGAQ$X@F;,R-9*_AL7%+-7GLOVKMZ2UGW2@+V&[YS+D4]UT/0
M\I2<E"*F75_,G2X(16;^=/LY3[+^@J:C96J DIG'XS@4(5+?<7B4;XAHJ8;J
M163SGK*+LTAC!=*S0/OVT;%0\L.HB\J2/R_;EP3;>3D"?H%!L$_?>4)=W9/"
MK "_-"79"S\M#J@74EL7MYZ3L.E63Y:>A!,&B#4%'' ^'%,['-(W-9[3BN-G
M]WQDXB(N_V3*#&(XR;E,OLL\V]>)YKI:Z$"!65LQSC5;.7IL6KB[JECZ.=B,
MCN](:-?$16E_*[I#P '&$[]AT4?QQEV5[;X+:+4#:CEVD7C='$@S2R3U0UZ^
M4'Z9,T)L)>L3I.$-F>-ZK?RWDE_#K!^\<]B_H"]+[3[NA,OH("$KV ?^LNU1
ML^@O^;J8;=!SBS6(>:F>>N[T6> OKC+_[FQFXAD*JU?/P['W6T+%4O,UB=1
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M %WM@@?A&[KS&;=.#<0] P]V[8:;,+.>92N[C^9[G[YBP5,4_H_<BI(,9H\
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MZ$*A=-^(M]#2:IV73^8)XM?;KST#]LE,=EV1,#]J0%Q/D2M,R?DS/">M(/0
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M!!-VSD@WM><[C;V.FUBPZ;!Z$/, @6^D!X_WW^4L84%5V;-3@-XZ+')QLM\
MVO,W'74(VV:^>1Q4\VVDSG"H\GU\BBQK\YTEEK0]D%J5 <O(8R+M2-6, W0X
MZ+Y/TS'2(T3?(O3\FF?K+/C%WG#Q2:PD@LXZS9;W@'O,?IVOYYU-\*TE!-A@
M'A_BXK\M3O5$E;W2I\=7;C]=($'0!=P RO9IHX:4A6S9^WZ1.6X-Z+?9YR&9
M.IR 'L "]8FRK[XT=51;/9S?1_;<PYPA.$P]C6]TA+.WH=AK+==CSEIA[AX5
MVXBH5HX(56\Z_+5%?%6:23Y@6)YP?8L$<?>LB'X?_$H3GJ&&0*_S_B7<=5Q
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M/C_7N_P]J;A<B*;S?#[=]>$/FM]/U$5<,CN7%1E+H\9@<02QO)M49%^5QC0
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MKTX;Q7SEF2M<-)3KD<IX!;?RQ!9)YK*I'-ZS?)I]G2<DN511-#/0P"^;\NA
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MW+0%?C';>=J2"M=*M&BO4WN1$+Z_KL! MO1J(5._K=29'?GXLQH3":VR@?N
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MVD$\S\589K(O\E3U!=7ME\=H+1(5^ VV,TA$N@)H.UM1S82.I+JB^8%%^>F
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MSXMM\#8VIB][?R$T<3Z*2=[\F,B;DNCW[%JN9!= VSEG5<"1W&L%V"OUK:?
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MOYU/>_-_P W8<BB0V%LLK_;_F,:F^,FV@H?F$$( B"KULTG^NW J)?=RJRF
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MDZ:%CV$39N44?]/W1[5>'"OXG:9P_/= _^)I.7R2I]-7V<)*<"\?;\3#4;R
M 61)13MQKHQF-_FQ.F8M6![GNJ01X=<45^[P3GIZ[ALJA;[N/'T/3^4T"@EB
M:1J1F.U1NC_K)S'M&B^$]44Y"W"7:K2G&QP=)$0>N('.N3;Q3++LYZKI,4'<
MOT84:GK$/_(NQC4,4<9,]@FW[\<P28Q\.NMB60[E)I6;"PC "./T=XX@[Z[4
MW!,/F^43;>Y>8. H>QN@17+UYRN]D/&/MC#1PTPN_4%^['37A/5 D8^$/RA,
MDZ]U\2/I8O/[4:<?=VH\=%.7#Q"<Z(F:;W#662?+VX=[-@O)1AFG'E#U\6.B
M8?3T7H1DRD^1P$4 RI^(#'5N;=1&PVMWFR6(XJJ>T!1')I126/U+-K7Z=0B>
M<GRW= 7=GU>=*K)PY^H.F76C)RJH6;X&W;:]*V%J?$]'VI]F75W "LK0=G=:
M3;AM^G&N^_6SL?*6I])*SR9^PRD[&;&!GA[UO&6);W1>T]<)7=6U="!=GZ/4
M,?!<4IWP^'W;SL.,M\L/7(%[B/7,GL9>GV]KXQ!^'S]?M/A)QM)L4?),]!"&
M?(;;WM"(LCJX81FH\2V;0>@R:TTO_/MKC4&>.!G.#9WIE:#;F^^47>,MY_],
M*%X_U.T)(ZDWG-K'WP-;66T:$WL5D%5DS%^J9Z('NB/!ZJ%H<,11IH).3=VO
MT<501T&+O8^AL^!GYOOOJ\3$8J^,<+A8)VIQ_"D.U26I%P7.DI81D?EU&%-'
M \'2SPYEFL?[CW]B#-LV5*6K939'U5 ?Z:5J5N35G!#=O*(02=X;1^6I5= Q
MVSCJH[)3W5]8>\G0Y;&\$:_UVFBZGE]N?UO\[()51U&ND3K)RR?1728:%6O6
MC-PQZP"3&B3O\KO&BLHW H"L(%+F"T_46FD>-+6S:\$0K9/J2F?RIO[N1;AZ
M@UTA?@1^P#M$),8I(IF* IMX9IS:L&L#(Z30B:U\KM>;3S/9@[F&=25+M#RB
M38-EI;KZI@@JX>'.;OJY,(H2EWC)CJ^#F9Z=+K/CDC,63G.S&<#8\27.RD&0
MX]#]'8U*0:H.GS.M$HU0==(1[TS0<>GC:96< ]G70N8A81.5>#F'BBT8PQ&D
M((SU5^2#Q2LSP(\ <LSC3&=4^+"+BV X=-571I"<0WALB)(9@VB=X.,=6ZX=
MS66\=XW_]Y-@>C_7$ *P$F<%0^;"-FXV7"PW1[V5LW@LIJ)TO\F8/,V7/]./
MX=]G!*OJHL ?<C#@F->5=8-3XYPSO)BPZ&,"$$T KGBI&%+JP_)-.IW=04:J
M55W[I;X:1(EAG,%Z=J$'?:^;V<=^6H0QMK#NPM@#K/(D0^VJHO>4\K\6:L>&
MN>^':?+4M(C[;9;*B5&;5QI)[K6JB7UHJH<O:70JRFZG+?2D>#*50<WMO[];
M &0A213%_@*LT2\NIXZ7:HT_82F79ME],+7AM&&WG//)>(8HFRUPPNBQ<\I)
MP5%4'$S2-:OPT)X7TH[G@2#Y6+'1T]*/=IUO]-909\G\+@UD\%DNO8+4PH\K
M_/SEZ]]&25[O9R]W&!%<F=9@@+F_);^!OP^V6WXW3S7K0&IU0LPU87X0WZA[
MB'CQDZB<O#8$X!41)9 _S0Z(,]X=(AC&8,K'9@QGUR<T3ACP1/$11O&'[^+T
MER9W$=3R*).TP >L&PM<JK2YCD'<9I?* V)V[U^=06)GD6)H2KRN!I84)GHL
M&0<_$# /XA\(EE*GHG6V:JTQM=BQ7IH#KT5K)6];OBAUK#;"/8_[H^(P,?F'
M\C-EWWRCPHDO ?CDDHM?Q'NO!PF]INP\<@S29@K5=X^K!.T%"0^)5RZ$(QUS
MIF[\[H6D7"VCM:4YNVBI'PC[MA77=&-4NRTIE$^M@^L\:+E362(-M;%>#Q\(
MN4:A!1S>D=JUA%;#Z%1ALK%O5J?Z>^T3I3B%\60.)+^P*JC]6&\JU\JY^YME
M#27$B7[K9,@*1WE!@Y'2D@F?KW<S[B-.,V:1?RS5T%T9BX$O.65YW^R]<?W"
M.G-P.&3=%(%]76BUE453#C>Z/?*E>V#.#"$+FD+^;>9K7G&L)@!!3>F(-+QZ
MKG"4N.V;Z[2V/$:4M5!2_/T^C5-8-B*]>:U\!H9$X>T:MUNRQ(>MT3<:1JSN
MA\JI)'^AV)V1.US]L.,7T9EA%NEA QD-BVM(!XZ:XU^>_G)DD^3JF5AVN1L3
M[&Z^'J*JOR@W@C28./K2WT??Y/Y1$0>9Q+U>(@ T&]5W)K$IM_+B'K0"FA:^
M?%6=?6@"@%J/+J''9Q9HO^:F"Y8O#KH_1)'ZOHD'^U+-\P)R'WGCD'HP,:86
M..E\<9G=O&(9@<9[KW!YCR^\5PVH5J8_&KU;(\:WVCV0%ZS7Z;?07>.#[JQ0
M_F!-H7D^1#X8LG @9$  S/NA.9L?2P(>F5&^TT[WH)5\THN 8'D)@,#]A>._
MR(0-V('Q;O/V"@$P!4Y<.7 *Z,OF]K[NJI\?)% ULQ7D[6S+A0BU2[A$UDQG
M_8>\1(74E5>2;]<:![M@!]>V8,?;>-9%#=+FE:!& D T:W;9- 2 I4JO01_#
MQJN4]YJFY_K,C-*V9=\;HH$KQVJ_<E:GJ#^ (3^?U=B403J#A"9[40M1/^<?
MEU@[WI\I[Y*QO'1<=F;%\=1'S%SGKQ7NFU>PIXRQEP4=W@C/\D)$P5_;W7Y5
M2V-\N@*>DH(5&9YJ![C:%]Y$8%2W&$.9_#\M,L8M-?5\O'P*JQ<AY>Y<C?BP
M7[VNH@(>6" /A4<^2^G:5X@A  V0S9GMYPV_4N:Z7HQ%G_&=>;N&6ZI#$IAY
M$\]RE:87$S7[@< 0;5_QB.Y]&O6L6+]3QCGGLX3K0O;;YL)1ZHI;/M,KL$E0
MY\\6*FE:_N^ /[A#S?V(GVK.0N?!NZ?1NM;:4-TV?NKV90N/]><3'+-4LQ'@
M=7=!56019&(:\3&(-4WR&N/L%]QNM)XP2</HHD_4#DZE:';3+^&.:O]O":D8
M.L]T8$==/$!QV+E!ZF;A#U-M1UFR5SJUE.D?%R6C]KRYQ?I%#W027H%L!M7\
M)IJ[)#D=C; ZSNJT7];KOH86<U/P?Y$;#!H\9^TL83___J?273\\7I#S.)LN
M/C:(RIG[B2&C8W!7F0<*.A,R40NA',??P.9T#:R]%"'1T8$:4<A8$,O+HU?J
MI(_JO]67K9ADKW(X7:OO<-P<;BE469_&I5KT0%-54?"?I_00U"[33/NY*AO;
M<)&HR%REM^+*1*D-U-ZJ"L,6Y1KH?,WYCT*PG[P2:X4F'_?%/:*U%EW8:A[(
MP<HL6K _0\_,;\DGS*D&OWI8-Y,P_?V2*)<KK*['5NL6["V#9TR"Y^( E#^^
MLD#6*@I<[QUY\$TOF462@Y)U#PRCJZ1EB/!PJ8C=B[F..VB6-Y1;AK,0#_]I
M193</["'YS;$C00FP_,3JQ41TA8\Q> -1)Q+Z;*UH!V5;@&=TVFW(>/\/#1'
MC6+^I9E;].2 ](.UBB!:6._=6F+S K^0*M;@J824JG0E;&$Z+"=S@$G\-:5L
M!D,TN&WA2BL*8N-KP_KWE)'2/L'C><)T Z0SW3- %1M+ZIC4X-Y[$W>KBUTP
M^A1!!EW0'@L0A@C/"$1EO[_]49!<B?2K[:$E/8;RV<<N&&/I\BCKJO$*(U.1
M(>:* VD#MG5I,Q\M\?6GBH[KLHD>7TAD[N)"^RX7 6@/>S96*E /">:\_S&S
MRFR9\L.>LRIU7@^IQJ2UL3$HJ\3 .8 )8Y=& *A^;8[.=M-5_V$YBV'7R 1\
M:[JLJ$V@$*MP?5;&=A5WKACR[N_>Z>'-[CFX*]5Q4]-*$H\B>?WBD@=P[AC>
MN(HE6G]_)3*XO6M:Q#VXW]1$9=HQ0\B$9]OW#Q4/=H!S(TI!](4E6B>)I0*;
M-0'Y7<BQ^D@%6>9Y7++/"CFGPCQ2SO_ 9 9-HB]/LJ-_9T6QV\!>:-)K@YB<
MUO.+>7P1$D>]:"^G$>7=3#T)_:7&?1?],B$H_L,AQ\^S9M*18)5]9B>#(AQ?
MZ.Z ;2)@M1V-(@#V,"P!J#^'7U(T4G95;[JB?PI,=3L$E+V*5S%:SD:H7V82
M@&7\]A;LB LX%XU>;KB'46D/XAA+-1S[46L6K@BZ?EM#>4OV BLG)K*W&R7U
M0#HOA@NHL+J)\R.*[S=W F Y#!.T,@'W_B,8!>8P9*55SQ#E:!,G$4%F#PD
M@N@[CQB-H-WX^W,V^$:KL^?X_^4N(\H!C8I3W&>BZ;'\!1,]+VIZ<0EO7LEC
M.#]..@.//P?Q$ #,ON1%Q!FX-Y7_P#CBTAM1LDX XGUALQI_FAX1T9?8H;%=
M"@3:0 @ GQL,*8=_(7?OW[8!3S[5GS_' I1N*R?C4M[-ID![R!OK$#0_QP-
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MYQ+;8XPD'EF03<?=3.,X'1^1,[R?:Q9I8Y3]<T\%F685-,CEW3F<./,R95K
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M-ME3V9X96U9%U?#+=U#^?;LN+#<&C4"A,0QAWX;LQ_*><0"#/YDFU9-GB/[
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M_]^_$/S_2JQ[(WBQ]NTU!.#U>!54W.5=^,'LU\4CN6'PG^9*!MSG, )@64X
M1(%SV..QG6.(=GUYIGU(O?*1'$45PC&+M_S"I=27M[1IL<GFJ'?7DA(MTVUE
M4Z=,O]-<_VDOIAPO. 1VO= B +W*_,?'O(#?E;"E0.Z.(7WY6!CKK-M/$RX-
ME/#7EW;Y&.XV4_5O<N'?2F>TO*D[$LJ5GEEZ7LC#>GZ7$@#D"&Q#;M6*U5J!
MGTW.00OH];C*/*/( CJ*QXG'D\*&.AW/X.C26.'.Z2OUK5[]#[D38;60EJ7+
MKU5UK_1TJMY$&+7X.L^"!9<8:+"IJ,XCF<J#M_0'^IS7J7$;I#NF*Q)!(E")
MD35]W^.+Y^DW1;?T>@0+"H(XH;78FK:?<P\U,ZEC(RYJ.1$IQ^+2!O9+<O,9
M+!]Y4A7VN2JN@&X[D&ZY8LWX*(3YT0FF0?8X,7\]S,V$,HE=^7.Q$'PK CYS
MXH9DI:5WZODD$\+M:>Z\&Q&ESHD-)96M$'GYY^NGN+JC?B P7ML33X=APL*)
M/C25S[: <^R=W) 1J6V"]=V]NP6<0A,2\<N\I):-68/Z8ZBZVK!+Z^M*ENZX
M[21LWY)--O2NL4!@TESA@Q[5E9?"+>)46MG]I0_>&WK]C3$,D'<@G;28D)78
M8=7LO5F700 BFYA';TA90EX.U2Z&WVSXN"S98=8]UHSB&[&][J8@S:>GI@/Y
M,A1$@\WHJ"[V=G\G?B_VC\L]*<'#;(:<RD%>J+W)IYOP8BT5YF"6](WBE6:F
M %&,1FAITQSK<.W]:RDUL[67D-$@&MQ]N$7\!?N3SVI_;4YUZXRD/;<U^9)+
MH8/M\[Q9BM[.C[E-A"Z*5@Y-_8)R'8NF;JS&;,O]OD1:AC?Y7&83@)77HS#^
M=<MV=#/^/J_&A@/I/1-,=SA.S?O$&?PB=.*MO4U2^NB(=ZR&^2_V=.<_YF:)
MFEZ;">;"G0ND^5$XE1OC#2:-U4\W*SW6?ZAM]^%IL ,&#.:!)/B[UQ-PM6-9
M\5FP9"#PEJ<G?69E*OL5P7"YV1T_D/D<O,.5VHF]V!Y2.J/OU@UB^;I6RQ_'
MIX@?&$'JEJ<%#2OVA2!?%\%(&\A/' PCY:B: Y89*7F?GV8S/&C&)J/H)? 0
M[CF/:>XO9F__ ?&FZ;1PE!>,L>W0D7W8HBN";O@$\2GH!LD"T_$JK\$4Z0'K
M!@SP?OD365;IJ,>@XD)CF)W-\*V*]^&HWJ_$@W/OT'F-1D$OUCY8&Q*MOMN,
M_C1MK[@%:ZMKCCOOGFP0>$OZNJP+V'.#K':%/Q!^GDQ3K=6:S5"_[YVI\7A4
MH[)L+U%,+=10KMY9=:VN&6NF3D$ OD6/'FJ@3#2N-J_$$X"94-B&F)4:L=^:
MVX];3Q'3GW2.@=2F/?^*?PXZ6H&QJC*+O8_O8"OI#@9IH"RTDR_+<EV$*]/>
M1!Z]0:15P8)-]V)_] 7(J3CBOM]^*?O*3106,G]S[&V#Z;1<QR^]MQM_7T0)
MW>'QSF8(F&B H!88S+M=B[8^3?<+SX&%;U:52.YZJRCN[:R99']ZP^O'==:^
M3 !PL?6N%\15_PU<C5,@  D,CPA F1>HKABB'!1A>YJ>/&(VD]VG<L0*OH>Q
MC%HRE+G@-XK>[^-TE?Q9=F_9'A?)WKP'YKQ0NIS3Q=<Q7-($JXWLG<QW4:2O
MO8B36ZD 2TIV,I"W*R3?;';Z9<\AA(S$O<&HYQ9#ZV0A>BMQY+0?=*ZE;/@]
MNQT$@IS'?4U=?UYS=[M!,)<MFR%/MM'38.+;H==V[1[S.+T#N#O=8*(1?=&%
M-NV3S66*G#+.+*D#/LE864S.B>_&*(C>^26!TF03R8D&Q#(G&GQ0< 8K;G$P
M.'1B4<15O'> X>%<798*Q"?])4VDM!XB3M70/7 YGLNRCT2F7BKF2@.)9C9#
MF9?AU4U+P4H%4X,='R.*:0MENTK;!('8/,\J%MND2?" %0BG=3.M=,Y!0=B)
M[A/#Z:'572?X 4T]\:89X I(2?%LAN_5%T[X=_M<*_>F5E?6U9/'BBF,6E:X
ML*X=,FK-'UUOQJ!& O\$=HEM$ILL2SDK%JB3HK";J_AG(?@N7R5H=)M/'KT6
MXE$]_:.8O/*O&VMO;ZG0>(GM**R2"47_0V;MI#, A9G!ZURXGFXC;VNL),'/
ME_$L(%^\&/0Z;T+#/0?.QU2]B_CGPIVN9"H?K*Y.LZE1&&+!?5D\Z-C!F  #
MS_P9\V[2L_RU3TQ*-IL6J]T[VPBS^[8&IB,ZO*R";X<HA]/?(5X7:ZT;F^=A
M"("OXWEXKN/W:;GQG6TZVO&9;$1BI;B5%=9[F:JT;#69&6K"=O=A\J 0"61#
M@\]*MQ"GX#\99Y.NMGW4FDVK@:X.H"< ]UCSUV!M\?^^(JRDH-PM[%G*=8FT
M^CW.?^W)>O+68T[*3O&<O\T)0/9<_.6%$W!R*=P]SXYT91M]-"&^9^]"<IW8
M(ANZLY;0RPXPR7+:J15W$WTNYQCN^I*(MUCFXPGHT$J>0PM\H X>;RG98.'L
M)>:;%_4:M&##^*E].E@M:'T)%G9[[<X@PC0OK"@1 M'#L"65_;B4/Q%+[O((
M;W(=:2*#G,]G\&5/?V8\*^*X7= 9J8I44.7:;S=D,^MT=Q>1^AE <=TD*"V;
MX9=(R2[I$^6F$)L"OAI&:H9E4UG@B38+"%Z\G>X2YN!2I5)9'>SMLVEB:DC4
MS3*+CQ8*QC6U7X_N"\LM-U>R1^)FBIV9..\,R]L:^84J(N2'@^86K3@=:Q1>
M=;#D=:N^>="3S5 IQF"."0]!U;&I63T+'YZTI:9>>9F2 :TY=VZ<_G1_N!BS
M)[:^/RV,OSL!/^XQHASB<LFW+Y[2]7VM/.AZ[4_]D4 IDA$-)S*Z"KY._-W1
M?UR<'=(O<]I,L]'B'*Q$ &CM6Q:.I/ZEI93+^;C(5/Z(0P0=6K+M@@#PWI--
M23TY:;M&S52H1(3WIG'0+:CHTA,>T\MBI47 P%L>:62I66'6(Q1;?P>1JGH/
MK6"!GD^2S[_,)6]K^Y[V6H>,9B,(A,W";=68RHTA;E-EI+KWTAD69C-D2TJ6
M5F+I3I_=?A)7,OY7#Z/;^L1@5;W9B5^QRP!JU3G(O*6\'@/6J\IZL/1L]8..
MH#C<*1#1PG#5TG'3SUO%V]ZB35YG3I/_P6;Z1&;)O77'4SW5H"+'\Q_%;W*-
M&_>^N56?])[FN80VZ0T=\WJB]N-RJ[),/!(C33CC)LB"'U,C"H^+152U4+ZH
M!!]=(>W@4Y)@"4?EB<RRJ=+Y-*]4^=WAT6_%QX?YK8.,AM^P9<OMJ6_O]E\W
M'F^.2#^7+,@FB1;)IN&JKLC?>&>W_[1>'PKJ.MU,'QQ6)=(NHSF';.93VD)-
MH2+F]-4FHJV*) #'8^!^/GK,C<$/.&UGF,N%SF(<@T%>#/XSZ&2[OBMFQZU(
MVC"[S&-FB?(#0D[JQ\RV_($E<\A58:7BZO3&ZCI4RIBX,<>/&CN>]7)$:L-U
M G CB/]\:PQTW*+$R4LO_FJ+[PYZ[Z/ S)9I8U5)JVZOX*NC(ACZ5P/G/\LO
M_O($UO;/7YV2"<"'Y,7!<XX2V'X%GG5DQKS=QYFWL^&CD+3$BO=&^T0P;<:7
MM[OS_E%D[M=N__4#Q)AU,,WA."V?$PNQ%Z%;;C+EU/V^KMV2?)=QDPYLDA=3
MZHZ\AH]X&,TC6AC.>)H7Z?]!R>:;!S;2#UJ?>^B56>XO687MV$F9;U</]URA
M280D8WLA2X&/VVC%*>91RZ\"1ADL&SS3UU5OH.6[C=#G<] $%Z216]"S6T_S
MYX/5X'K(RGX/?A6#AK@EC?WK1<H+L0$JJ)D0UV*G3Z9_-*^;?UU$]J=[SZVW
M(Z(2C#O?[3LEDO08?P)G*2'\D7@>K'^W@6NA4_DLI^4-P;[/!5TB)(;_SD*&
M$4OPT#+A!]88\N('.ZS/F7OE6J$(%'MP@$SVK!.SKA]-X21][VJCV-\@+NBM
M!O!2<FU-[/+H[LH\9YQ[G#O<%#B?-> ,&Z!3;7"9VS7O1'8@**?,,_QCWTTK
M:;4^?>QI;M6UP**/6KAR[[MQCTV*&Y72NH.BW!\L/XHB<\F0\F9-89]J*CLC
MIX# 4RED*>!_ B\R<:I>6NI"W21J?K'W(7M[H.<3=&J'X0[GNEU5PDFMQV/*
MM_;? Q5+..]=>6]K1#*LS?(/[_S_.OY/W=&_?CS-AJWD\9\?QY\948"C J0\
M463#WGV\;;>NQ5DL[&9!:C'['U]CP*WZON^#9W7=F?[(X%YLC$*M&5@"1$=W
MA33?L#T<YH&QS8NM9IJJ7#+N5=[JN^TH;^+/I#)$V1#4#S^0V(8='\'/Z7UA
M'<UGM],C+H/R#UFW^"OL<1_K%RX#A?%AEA88J5"<]9A))&!Y7>ADQ8@2*6^%
M678E .:I9V!X *0ZVA5D^6"#]O[[;X+?RGZ,=@;QFW& )MZ&,);I?E43ZU67
MP=T;E?3RS-T<I4XW+XG)%^0W!0RG)M9TXDYFX7-%+J2S5;[?(W I4 *P(PH[
M$K3L1%/>3>EK'W&2_J:3E@8(_I1;?EFAZXJ)>I,V+FA@E&*G"+C(@DX,H-V[
MM,[,4$N5T+!^$\9[-I^H$0:N[%#?YS4G_0DMN]+(4!P$,Q<?J5HJ: "3 W%_
M\: EG0Y6@04K2!N@]'(]#SJ>2ZY:_K9T1]O<3])#&S3\*@37&:WPY33R!:N_
MO<SV9H=;5):+'[1-D6Z)S:CS3Y7&AY7D& %BO^/=Q%K555HVE[4_QR?_6<2S
M'@F'&2M\>/OPD^[G1O708'7C7QK3&ARHN/7U9X725P,5N"YH.!*IGHIT,5(
MK <:L;<E5-DQ(E9G!A_@NS23BXEZB.R&6Q@53:379);99.D:C6JK#/GZ=+!R
MJ<N\6"G3P:T7)J;L6\I$3[X?7DZOLD0 IA9=4^YL4:G]%)ML\,> M4>\(!_]
M]3_7U2;3D#+24>BH@),#K@Z['+MR9UH;!7P9#ZLIO&8=+*OAP'_&L F//T18
M8ZT(@, 5^-$_2LW/=VTTL *W/=K$#4W2KD*KQ2APE>8]%5$"?R81(1VFHJ-Z
M_<F?ZRQCF3+,'CT8*8BA^)+Q^AW96W[O^B0K30+09H+:/Z>;)  +JV4RRRQ#
M%E@:O=<)-^+I7GQ>\<IF8$+KQ!?@M#$!3 MLB2* Q.Y0@9K8-C>WHM>%8JDS
M\NT3B7&^<12\HCY>8+5\4!79.$39U:1L1 #8O675N)\ >.MZW^$ 5LS#0:-'
M)3YTFD?K)'4(;D_,QR>D^%!]W,3OA=ASLU;G'*<'WTU%#F9]YCH!A:7.=9Q0
MD\)H)72E-W*E0#U7;AW.*#XRVN5*Y\1R^PD=:->"H1WDN02/JCZ/7>BOB6)
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MLR/*'4!"1J$QSN6N?_$MV+#[WM?A-^5OIV3(Y=Y-0<PS:&2P/\^=/C<!&#.
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M'_6L''VV;T4L=YODU"2IDNB<2M34G"]DGW3_-$CBNAVCD$CQ9NO9%7?>=^F
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M?BDM?L0,'AH+P/>>M,6<Q+P5:%'VSU/L=K,Z_COPW/\ N#^BM$1[OB0LN B
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M@9ME>^M Q?KPHZ=\14_UR7X&C2$V]LF\CEGWIMP!CK&4="9J*5 1RR'4*T4
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MC;[6+$UDS]>XWC<@]5<D6TPN-$SN$TY=7C1W3#71W%'S)J/I)L6F\-/"2DR
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M231)N[D<E'&<&VTW"%?>#>2EFYS*B^_9\ F[F\_^$58G<V\SE=7\UGLU1XI
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MY))_#BD1.RQ#YZZ $#Z8Q25F3?G%^1)*/P"4Z6WQ!#[V)-7=W/#]:S2RM A
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M^63Q?HU6]=F#WO/U:LB?/;C%4Y.Y#KL;'5A@!EO^HAQ K_I_[6S!GP_-&T7
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M..-$??$.I#57F9JRD,,70CIU4$GA@+(GWNSS=,"/9A_XL,5(DB:)F?V-$ZR
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ML6AG;.B-ROW V]X[YDGBPEL>6-%RM'4&MR^],XGSI<Q@K/">ZYE>[-'B8RH
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M FSVZ&:<RDI$GT6NST\(X,^;#+$]W(L=3 N) I5HRU$(1S,-*%2HJ7$8/)B
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M)<:K@TKQ\<;4W<5D]9/ZVM#E7JV%DX(21NJA@4D^/F8=D_)J!999<IKV0?=
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M?8 ]XCDH8NO=6&QTIGDRS417G3AD-$%^-@4-N6- 'O8M%GQ?]]V+1G:D\Q7
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M!XPX7<X4!"X,003,QEKYCUI6;UJ'WY_,M6%W]Q.AZ"7:9+%<>/@KT73:JW^
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MPCSS %-"V:/")GXY5$1,12P6!T]#?TP3LXJRL3,R[\R0#JA4Q%*NE.>%;7;
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M_ YBGYZ,\1>3>/OWMSGUBJ>L9G);?XE=#?%<%* "((>M%O*QW/-?;,K";T]
MR9H^L%,O<F@]M@8J  ?=)TSGUC=DN;HRMIP,MVCKK0S[]H,BJ)S3ETM4:GVX
MYF5FN=06Z=9PY0'TD0D"1O5<)W8ZJ:TZ0WD5<C=&XU\RT$Z>K>TCVDDS4]%F
M8$R5;LFDZP<I>*:65,2\GM7R)FUZ0J+(W@6:)A(=/J;G;[UT^)LOPDS^(I*J
MC2!H;_)!_$+[?ULD<5I-8V*RE!U4,[C*P2O"^UBKJ1C: 64J1PO-3LPX*ID^
MJ"_7%CL?%\30IW*!9CF#BWB8O2ITL61P>6 [-WY"HW"U*[A+W6:4K8TMYAV\
M2B]!?^BU345%6H1Z"]/-O;DQ) 5@7L*ACQD<88>#%"#$R;Z15ET\QR)G4+0J
M][YF=3,X%W"#E5& X)4?E=4$^BEMI71$M1>KOM?I7=]$'69V\UL_6B+C,EN^
MQ0(%_P?[I_Z_&;2!A/P6/Q'L\919+E7QR>GP1DN*N0;H_=78*!F4_U/N)SQV
M/V1\OBI:F^K0A"H\(X&K7_[GHPCYPJE@W,#.E[''Y>K$:FN0Q&\/Z0 AKL9J
MV7:ID4SQO[>K:'>YUO<>@#ZM(L^0)+(M<UN/QG)9;TT]CR9SK<5A/[258+,>
M D\>_F'T^*_=P/3_0M"@BQT/CKEC/ HL;[*;8RWK"59&^(2V!C%"<L2^AOZN
M<4KY5[T8J>H_#$M&1EKW3[,41LOPTY4)_%N^^3-_U!,OTIG,-FU==:  ;%)_
M%>GCMZ*J,'2!5';#HOB)::UDR<@QO=$;4I=D%G-LK-5]33/8(M#G.SO'*H39
MWF93!_<T$[GH&4:N :]9E>'ZPC-H*_#[T3RJHQD)HM<%G[%J=0P&J,MVSZ_$
MEJ\EF:<;+^.T>KNP- =K,!V$"J'.2AE_.*DHZ25S/@&K)C3[JZYL 1R#X"^&
M>[S>2Y'ZNZW>;IO$A1WH];M. 39QMFY"*=\ME25H?P6ZD2R$[@*>%( #(C8.
MY^O4#K0;M@77AFEH]%7IXZ5N+X!B%?2BDVK?'WPSFJJZ2+M[M@">MXSD1QC%
MTXIP9ZR:7_%]OD5.W!</J;N83;33#YT9Q(I]N+0K4&R@J)+)]GG/*"9#>N"O
MB&KTMI^0OVTUKZBO-=<>+*C.(9\XILTS:O<ZJJV$\Q=?"S%ECD6B3>CBSVH#
MY>S&JNBN"]]NP@6A? 1D8&T[-F%A>W/9>K$WMCB]BA6TG\F6A7!:T( V^\C-
M3/]P,&*_PW;#:47*:<$HVB/ES]H8QU,LVYD_-@NS*M^A@A[>%49@"F GPATY
MSF4MM$D#+?(-:\70K$'X\-/9187O+/LXND5_UXB+*)/D-(48LDGVA*2X=S%(
M#ZE-[Z.D.6L1?+O?Y3DT[SA\2 OUL.((K&83GO%X%(;RYU_+D!U,%0V5\)W3
MBIV[<>[@^ DR=)8%%3!?W9NY6T><"O[+[..ZK2GT8F%6")Y_CYA[FF9;9-%J
MVW!YL8#?>V.B(;BJ5K<\_$UQ+N,7+F]!5*4>)@DB?M,H^O7OMUDXT=&.-@H0
MF?]H"(<_B%URCI?GO)>_?1Y$NY_)0$(2PLR'2;?D9QFF>UPNN"Q];S[,?;UP
M-/:-!!U2?V*7I8><=W9<7E]^VBW)8<U.Z'A3T8I@P"NFB8611*LX[GJ\_6VL
ML+&T$&RUY$$!A-R0U<A$ -&=3;I->$U% S;]QD_W ^0;F:,[T<ZST>Y[&&WB
MRKRS4ZN/"?H&ZJOAJQTUD#VAS\B,( 4BZU.=Q(\HY.JO?>2$&EFS%G:R=7J5
MMBMAWJOM(L\[>/!#V_TG=,CK,.(S&#MT5:V  LS2DB2&R:S$H195<,#ETE$/
M S7?9E<)WB5C<SK"Q,]MXC,T&_7*/.J5(-)56LZYO,9BIPF6WQ/3BX>RWS\4
MW6RFA>HO-8B27M<-57CON;!]"PVIU(.^;0VB][V?\M6A=C3I37G*?.J$YA.;
M\.><,!%XY#6$%.'&7V?]MGM1[H/ABP*J29WR-*JDA\2 !.^>PMF/(#5]4N.O
M>CN<%U:O3JO@2DS1-['6X*7?T/!COI\Y""O\C1(;R>VB^/:+GJ7WLL&Y2K>(
M!CBF(E>/4Q[SZK@[#8YWV2V#/\^Y?GX ^O$/IYBFD>S&*HS8B'=OE*>-.XO+
M/J^#]RIC=#%73C.AB]HH<BVUIP%F1+%Y0?,V*^[4%=.&I!W;](_JGSH%?$RS
M9W_>S9O6C7XRR&,K4@*,!2,X")A0DAK.H:C"SVJF]U7Z)]&4+@$?QCU?*D+\
M0<GW:V/4]5[UXFN_\M>(@AV!'5081(-POXA@/':O<;38KM3K@_P-[:$04<_B
MJ(7DJ#HMW,_)"P/[>INC6KOG"'U"\W4+.,D(::P! WNPA'H.^^R2PJC_0./.
M^2%_]&" AEP3WVCV-\1-\F#]SWC?OK*?WCW1BS>T,&D4 .<$WR"'FL_V(%L:
M@HC6%$#4BSQM0U47$LNH<ZL;&'BDH,:Q;KS2Z<Y["J /'+?BO,+S"-*!K]_\
MS9.;%@Y?CJLM"^R"IKNB!4BNWX@>[B=2/ _B>Y<^U85*VA0KGSK)'7B,G@LS
M'A!3NP=K ([C07O%+M@A-FZ28U+'=NXW/5#5KT+[,_E4BQL^<W-$W37O&<SI
MT&W2X#(;/WLH+V1D7\>1V(A#D3[ZB9!KT:=T8W]2B]8=)@Q[IJ*Y7H97&E&9
ME6F!IZW(ZQ[!Z^!-\+<>!P&&B#MWWAVI;.T5H8+ Y_<-D0_JAA1Z;ID7!+F$
M+(F(?[@I8^4VYZ=J% Z^8/NSUG) /49R[OB\YJGK0_H$7%_[W#?&9F>/D#T;
M=:09<+S38$]00I%,[0B>)_I5HW^S2V)/NI_2\-^:<QUL2*A*N2&UD*K(')L9
MI#;6)21-=2-K!<@_.L>,P/&R[#U=(^,OZ?>B3O61M=?V -->*(__E8U*B(RS
MFM9(7GGD.*+&A /RJM>M<T]A^W@T2RCQR_2LOJ:NM2252?R%[+<6&B,>65IA
M/H7WJ#?MO3A$M@1H\,^A4!XP]JZO#F:]N5(]H^J=N1^B YN:2$X)!'24NN\<
MC(_?*=USQU?J9)[#^G7$D:E&7K=X*SHJXW%,);]O>JR1]B,*L('Q)'Z?^T.R
MPX'+)Z\J):TMMVB>S,P6 1[DBV-%=7JX$\/[XZV2G0RT)1@1X@!!E@+H#$OM
MP=AFZ^M_(8:ZV2^"3AH[QSCQ'?,&\"MCCX<J.'IX;_5G48",S\Q(U3#<6-@-
M?V'XL:7I0Q:QPG='967NR .DY ,0!BYG3#@;A5_?:+.Z-B)>DY@MIR- /)W8
MZZ E8,ZES3?&3*SK&+%;2=[M!40 NWS] VE4ZL2:%6?%0%&X2;6R+7BWCPXI
M8^5GC=_M(TJX%7M[5^]"AF-B/0%3<#K@QS[7XXW0PQFPW%.T>DI&?ETX-JDX
MW51U?C^6?(.#]_'/DDT)*M3L4!PN08>:&5KU;&D<&5G:-. 4S%/":+KK=R+_
MTZ$M+;DI<]E+0N4TNX>1#2KPJ,?UJ2SG*SXRMC^<7^K<_RO!V#??AY(_:AOC
MRYUN89M+?YN_]\V?CB"&#E(W$#VN3#ZHL,BB0_QRFQ07_#XE1JAJ;11RD'5(
M'KK]:BAO9/<"R-A/!FM/ZX0+:PNO\\CO3/C2^E6K-7.U==@T<^PSD1;G'X$3
M--SW$W]2\Y.CS7IBR7/N@UO3 4;[WUZW8(5U9,A6X4W#;(9M'XKF;$9"MV5Z
MH8F(Z6^(EX2&HG>#SV!&]BDXJ5!-TC^;JS+=TW[.,FEYN?#K?M!5;ZH/4Q_+
M(-T@)F<2[W?^6??1=;A84Z/) +5(!7*S2$X$_QCW,./J^&-)4O?;FZY;@PV?
M\!WA1>J/,B?7DYP_+0F@;D_Y>RQ/U#>VHB.CF!T*.IS@^<&LM M#<9';""X<
M$_2L?>/XJ-(CBUOF;QU<T4,;FF"H/9(= 7,C0,8,TZQJ?16'24GOXX+2.CN,
M]/=F8X7$1A$JV6:&V>N<SSJW0ZEM";*/\Q?\Y_]H.PKP(I@"9+/X4( MJLV^
MQ"1]O I-![PY$/>)P<)_C<X[2FH\T2)_W/X?>I/_>3BU-XD'O2P?5:#VIBP1
MCO@"\8N0D54PO@PBA.SW,J0Z)S;B@[/@9D&DQ=B>P5I%=W=4BO'=<T/,YU4.
M,)<(+FUHOF?P8O+@4!M/7%N";(Y#[%DC08EU*9['@_OI*M+EWKB,P5NWNLXW
MB;YU6DP[2?.%1C.Y>6X(UIE]\!:LO1ZVF JXD"0QX>@]P6$*L!U(YBK*(CD2
M_%'>[,/%-@WAX'1QJIIR7Z[?)G/;M?8=LZXU'C93 $8\++I!!+\=7M%MVL\%
M_F4LEBK3EH*%7@>.3?HLHY[A(T8*T6<,WLVA<,YUJ*:Q;IY93I)[;='P36+D
MB>/O]6_5R@#:\1 5RJUDAFP>"<6SBXCVRIV.=H%SX:8!'H9J.L0OAZE%;0_,
M)!/.>FL_YH!G,E( ?&G#92KE>U&)H0%$-#7$06.%A(<JGKX875+R[&VV<?#?
M05F-;$D1Y'!SQL@J^84.S3#T8,-;8O*W-2%A0F$"T1^X_/:K(EO#M"R4#SAA
M'%Q6FU1^DZ42:\.:/\P>9V':CN;JP1F=[7&SDXD]T'X<'ILM3H?*=2&J3C@9
MG7-XT$?^8:X3M[83*]'L#]V(*2#F]=T*K&)ZRPKR1+A23;8"C@)$6=T,LRIU
M.GVW/C^2]R1>Y5RSL;:OC^GH:!7[],1=-_;?[S(](-@&"R)J3@Q/ 8+VI/3/
MM91I0_I=.U\QH<84-M%GZW05*,"9R9QHR(#329[%SH6W;&N:?+/GZUQ @>6T
M",)16<TD,VP&.B<'4W&$\:J[?IM*<59@BKK3-U5Y$?Q581U<;I+@Y9VY5M4O
M(J\8KY06..0)%"M1ZYAJ'(CF]RS5'@WJ?+)(>!?)!J,65&^_OR*Q2J=&J^#W
MX<";H[8%EECB&DS?_G@8<A7?LJ[JG@L98)C0>3J%6F; *(WL48 PV 422OQ)
M[.@6@ZA6P(I&K+9$/^(BS@!V%N[MGJ:64OR"0SY(SQ6=)N Z&0GL;(?-0$:E
M()=FB=9MJ>^K+G5VT96Q-QLCTWT3$?6$C(%R<*3B<2%8]+5P@LA/V@28SBK?
MAY$])D'-\_X#C%U'D< @U:^>J<P2^0]JY==YA!G!+RR"UL+)2VZB0U&(1\3!
MXE1B??H164NI<;_YG_<]8.QYB6Y%\$A?M;O3,C?F?*^*DH,"(&/]^[[.OCJ5
MPT4"\H\R7\2.;UGQ$-*PY'_F S57,N@1%65@4AGS^V%<D)Z*QG7I@!EEQ607
M7-21(G;%HV%AX">JTT2Z8_OHVB@%V%_C(;^WIUUM9)PV\L59RJXO:R=Y.X^D
M3WX'F_W!"!'>5'RW1X+D?8OXUIU\49?/$D/O*V-XJ:HLA<!&#IY G>*A+0&0
MSJ]OBHT'!\TC[G/(2R(9B8?4:FN#'K,Y0@^;J-5V*!VLVHN91S'/H,]/]<!G
M'(QFHQ%UKOT/0#1%"!-"<I1'32%"1("@G7_XDME%9'@E,DR/^'W!!;1!^ ,O
MLOLDQR9S0Z9>:T%$P+1JQF&&#\^=YC?/9"E\U4PYX$,+Y)4%7@62U^!.N%$"
M;<>$<Y<ZC(;2,Y8 BS9711=W-<&/6[^;]67?^!H+^3W@G57_?<7H/ )&@$54
MK S522RW%"Z]..]W0")B/)%L\E:TJA>,_]I4["2>ZF+2R/R.E62 L#= #.5T
MB5LJJYZ7^[P<(#]'3"!P-O-]UINWK4ZT"++^V6'D7+%W/V&>7\.\]<&&ZTWN
MG=O+I_0("D#XWNX#C7[CWLURQJ,^3K0+'@:Z%&U:1#1M-4UJ9)@;*-9)=A]-
MTS]\M*8II#,O'2UTG7"E[M@E!/'G<8TN MTPB^:R H=3 /8Z]H([#5=X.'+"
M()8SJK[.A7UA9CE" #%8%A[*'0">3G9MLU/I<4$X$M[$+#!0[W?6O3[1AGH_
MP7/M@!]-EE/EQ';85H6OY^GO@2.T/AY]$6%)8*V8OR9O!#J*J""5QX,;+Q_T
M<:WR628>AOB?DW<+%IQ2]):8OH\\WE^:+5LJ-/57&;9-])(WF7FY4C)S%?A!
M3%N8I7=Z:TXLN?$J]AYW[ I_Y7&T*TQW+?4]7W&*"_)U<U8Z;0'7 KC<+QKY
M)]62/+(+&5BR:U!,L-1I.KV+:1":;&E#EZ*OVNV2RVG6'O_?L*OG/]WQ,W2B
M_7L'CM:_?6@\345I0XBO5VNU,=N9-7NT^]W4'=3$;0-O?OT10$WX-L-"= )Z
MS2H.'W_D0A9P>'>VF][VN4^T3"8;^W]?DWB<1Q295Z!*+N[=28OL.Z+GVW_Z
MRV0L<'D=!%* N GP\2(RUX\'=Y,M1+Y?&_FVL?,!J-.*94A>K8_CKO6\RDI%
M=%=Y(I:F3[O'+RK+0=4S*D?++K<M;N);T$]5@4,,ND&9!'&6/2%S:"@*5I9^
MOO\-LN )S2KNFT.BM&MRD"]F>VJ/__AOEBP-48"BIDPVCO(77TAFD4Y]<9='
MU,?$2[>O-'0%V50'J61?RHF\J+NGL#N&;0RM0D\8PQ/T KJ84+/8X(\BC:M.
M'_%]6!0GW*SG=8;RMG"T\Y.:SLFCEP&0-(+MGJI7B(=$RB=Z R_U0^4UF#1"
M5*>!F,\<=T-+5M\O5.O;S'5BXKR+X,>RM]:!?VB<7>(+?3TP+XCB^+](UHF&
MLF]WK.L_OY1_\>O:QA%!4\B(X&W6,9\['%_0M#.[?E-B'<DZU>Z%ZU&TMY#E
MMS\2^JG#M40!^,@"??,2-J-[G=TSYL6B,3JRTAA<Y Z,@?2$:I'FG&CXIC2C
M-4-7+EW>CGX &H%<&BM25\KN*;!*6&P?9LTKK;NV<,J&Y4^^AY;-[-;VB3Q*
M:$>SDW06=@4_EFR&?'*N#!9[]M,#XT54F'M6)XX[K&E .>^/,W?'/O'U#PU0
M5UK@*T,8UC^F*WG:1+MF>2,$?W_YL,E+M6([12ASU29(P*W\#-)* CQO![UH
M=.H>=FPZPF</'C<)%O"^UC%WE9::07"#?'*+U55G\ /GI&3II=J2DW@[VGV%
M?<%64&GBQZ5[-D&0Q%T>[/99-"LQT2/MW"^S:<%QV)S_"N%*O0%..E8G4OVR
M6.)PP.PX]F&HMT0T[1$C@"_ZUXL*$K_DP4<2V>06*:JFDQBA /;;1V?6D-M5
M>YELBGB7YFEK; ;8\.4O<B^OE7:TZ,\J6Z,?Q<'DBZUMR#WN(22!JE,*I>E)
M-B-U7+CA@<*]216<'I_F3M)T$@1;"R8Z@,\C^WG^479HTC_O3[!E&LQASHJ%
M9KMR\OOM=%VWL[>PR?!/C/B*#H-QWN!N=MG<EJZ,#U7??ACKFII+-3)BAVU?
M*Z(TM+$3$\I9C.KQ'6\1P9]3"6Q<]F8KK2B^^I$OW8P,!I._@X-R]DA?:0<\
M4.-8C>()R+?)VI!J ?^@NEG#VC$R'_ROA'9*TI,XXSN@)7=Q\(+E+?( 1)0[
M0VOH=?2GCE2#-\?[Q:9W2L8:1(CK$BE/%C_^PDB^?QO)ZDI:I=UD4HOSLF7I
MY.7(?*XA]V@,1 "U)\/8U,6=7:U=6+HOL\^_=(T%.2;@4#';ZFZXPV$7J>=5
M<;8VDPS*"QN:@NW>2ELT%$!8'KD_1I(8=>IJM&<[8L^F ,6-.$TAF3GT^^.J
M6/>JQI+Z\B#Y=R&OIC^C,HMC%PX\"5SUY66*W_.Y8I@^*!U<W"O>/H!3J4%V
M@=P /C8M=$3N,-11?X6- F2F D=J<YM2+@0WPY!PR9A+HLAJIY+3;.3BY;Q3
M:.Z[1D;D8MDX<DP/N<=I:;K%3P$NLRBMG5ZE;?@/BPO-#6P=RR3#P6P-_M^/
MB-FF=209JN)7HP!O2I&K7/.SM)K43A[CU&%-B@',RT9XFF"\'C:?CDP:;+X:
M?6V>/!X-:SYQ0-R>1Y]W>I3_N[+ODO7I0MRI8W['Z=5QXK0TNZM@VZ6$]7&5
MXL,YDX_._F!'I=YJ[]^!?F/VP@'4@?M-?7ZH00AYY[X6*<:WL</E/ 6P(8IO
MRC2(-KI(!W?24CGU\ASR2"()NK\S>\Q0A(F9&!]3]Z]];?1I2S?@*YGL0^T,
MICBC-BF>)F=OA=.8WX<\M,_M/?$UH)I""A!!EAM$V!4W?W/P3.8>%*9WO:&B
M(JYN6D]TPO&\?XE?"G(T$ZSOF0OW+FW8+//YS)>_@'K?0'4X[W4>^('O!DT<
M*Q_>(?SM?:=AE&=/:S2W$HYMG#-XXC6MD;EC(UX@\IE<,=?P[]8:9HCT\T:;
MC5R&V?=7NNLL2PK(Y'=&BQ*)Q C/ S#/_L_R!SU<:\_9;E.YMT28 ABC_T;Z
M(?H;RT,;OO*<\-R?L]Z&$D>FY0["QEPJU'R?R?MI&)LR/I5;]"^G&2,A" Q#
MZI=2W0U/NE?^+$!;HU=VN9:0C/XB]@VTH03,YIO\FO0?&-89GE@5R)<T0I2E
M"P="D_MA?)=3.&#U/@-9Y.L9@H]J[E_U=)VU-QGCN75Y67^IM&-XKA_4A^14
MA^406]MNKJ<^R6TO88BX\Z=;T8< TT9<(7 0$YJ20OZH'VPL&>YOD$J>@L]#
M.(FOH&?7.5=K);G'^CL:%%&>>GN+8Z 3*/S]&OER[8 X0N>=;!3ZR*&)?"O@
MIK^"/7>J4FS?.,]+2TSJ+]5KO<J83']>N']?*_E<J;GMT8J1K&F')/+TR3RR
M'$1"*<+V6RG *XP=WR 1B;ON>$_SYK._#]?=-,$0A#6!?92$=.55RRR%/+81
MR@X^=:HO)<[B#%R8=+(J45]Y3<#7 AB"C\=8\/FM)F0%PE11P>V#J*>[ZE]/
MP1EANY@L*.X1D9,<\AW:TX@-@%CCP1&<U+N=E_(X]R?W>U\$+?+MY_F&NN&*
M4VF=(<X'P]LB%15O9413.D04=NVPLW1/B:8FI;4#FZ,3OVR.$N5"7N^M_#'-
M6WWA?P7!=\($<3$&2R:0I'NA^D#&23.:C2Q^=.AC.2PEFU[:YW 8"*DI9K(Z
MS5!@TLUPYG_PK(7Y?<(V.H_^K2KDY[Q1*.12NG#,O/MK/>;@)621AQEZBV;>
M6;]]ZT5I1;FGA?>/)$FH*H!L-N)R-#.-'M/*<!"M3/^MK:C">(1%IOMIP6XB
MV/$9607$&H^-\&FIHLG?N^=.MC]3@!@?6#LRTBPY0$$#,HIM&5UZD^7 ^]O\
M4F@'KSS-^D<3\'N%FKJ[.%\I$WC\-3OC9YS* B>C2X!;@P@!%E+N=B"(-*ZH
MVNTGK[\FM38ZSGE @_PY"'=N&P^\F9A0\;=5)/Z91<M3@%@K4#6!.X[U^POV
MI/4N_8\/NVYWD6_5!;= N=5UYJ),?NC&+].[)$E$!_PO[+UG6%3!EBZ\$90L
M(#FC1"5)#@)M(DM0A):L A*:(#DU-(*@-D@4D" @.;=(SI*3Y"BYFPP"W<0&
MFNZ+<[\?Y\QSYILY]SDS<^:Y]\?ZMW?5KK#>];Y5JVJG9;P,$O.97,27+]8S
MCU^OUPY_J/2YAZIIM5%[$13NXCEW9;,5KY:@+6<8J;;Y--@7<0,#ZVBFQ4YT
M_;YVC[.RGCOY#C1ZX8L? ?@116Z^KL)5T]RD#C>=H(KYM@R09=#0H'=Q">R@
M,RKN<Q;(Y$6$:SX!C&&3]W!;W4H7X,8?-HAO(R4 :FR'!&!:''^7R?)P"*8(
M[(-(H9P32K9?2XML8+94CSKN]]4K<7@Q#L':Y'VB\,'3+G@0GC%D<2'"KSKX
M@'^D1'I& 64DVO3DU_):66DXGDV]G?O@\BAL-^^"DP!'B'<JS'5H[Q"G"DA/
M9K+=EZD&XVEO6?_)/A7>T>QQ/+^9_5!==J)<+O^K=7)'=\O[4&%L8K[/J?9X
M8UE5U9F">9.FLQM- 8(:=B*:0 ".&"S/6>_28+Q;%FBQVGIRH])R7EO'T[/<
MB5O)M>B0>^C<^N)LD_:]@,JKRV\P*SWGD,VB>@V7$O[*F@A-JD+#L4@RF3U0
M.S>%!50)$SMKG&#J%3=0'>W!L<;]3@LXK7\<=B?@RBI+-)^]<V^A(L ,Q\YH
MHL<'PZ$0U^QI'08#39%B+K/MQ72M4_]6+HF03DN:E7H2RL_;TPIQ2LM4MI@.
M'[U6Q(F(X/D) ?@"6/F,(B-K%S^/0(;B9LJZOI#=N7?<[VU)@I-#4ENLF\UJ
M[#N\_M+GHG*;;$?"XB*DV4TD'\6XYEFH(3BZP3''NO(R>[)9MH4X,0QZ>I U
M6&=='=.IZXJ% V=73C>DSV51&]^ND24-Y@+]4"O0>Z>=)AZ5ZOP/@M6FS=*W
MK/@?6!,E'XM?R"):I]U >E7_O-XF)_P8#]<7XJB)6O$W>& $JFKOG[^50#?W
M@^R9T:-%NM2##'*<"R:NC4L4G7TJ/X*(KJ*RJ4)J;,Q_#P2P46=2'6X;;DW7
M&W4E?2[?XSV9K.9^.T_2A0OW2D^!?80NH+8EFKAQ.C,.;"PODP0CQ*U%4VDN
M9&\:1A#>()B3, J]5V#2:FWQ(D4IY("Q93.=&'<3I0%^/%PZ/ZT0AL5%.#X/
M;)BP[4!0ZRR!R#>:A$8R[7.?/>A]+ZD5#4J46;.@QS:B0%>, X(><(Z1'UO5
M=O\ZZ  TEUS>3@^^<4PQ-*U([N>@QL2R:BJ]:O1?M T75[J'K'5$?,E)_HD1
M]KSE0XSN\&F."+R)#>GR"L_K)WEM6G[I10B?Q" G9+J)U$=KJVV>-7;OT$1A
M]RJTBI,Y'U0"N#970#6J_9YF[<HNP@#A<15&K3W<G9&^"*<(H5- N MF=Z?,
M&[7%*2;[,Q\^ YM?!'^W^R@>IL(\K95?(E,9[58R],T27PEX28.C<9+8VD*?
M)8M$O8;1$M&EA[-LUW[M;@843>9?RBT@ #PI"Z>+!."4'!$?R)#9@XD=Y[A4
M/'J)QO7;Y+A)'B[8!;85\B^)16#L!:_D3QL\/[F@-7>9 H6Q)C!B[+2RK1XU
M9TE[DZ.-G[ M?^ 7X;0+D@HWZ,#?&/6\K9YRI!'[_(Z\(.\AHD#)'_E,R13I
MGT(.[-]/^%#6_6)P"XX=6>T,D )#A+-O2DO^]E1^+TUT>*4,U1=%BA,8/F2'
M:/LG[M$ZIEYK;!3N!R&_>L).F2NBSE::.QOK'PQY---"0</;,A#YG1+\SW=6
M:YS*A2#L4SP) ?CJ,+CO@LF@820 8:$7/'O=8@2T>^');(>#H8%RM9C2<%=?
M;QN(G=6GW"DBX.#P='SW+U\LDN.B&JW8I;3<2..LU)$?>!LEE-Z(71L)DCU4
M!NE->FQ4;(U%HJ;U26+H6U@''4X6EO2"/78O]^4YG%+!7AKG2)RX<C&\29U@
M#H7:%.-D,1\GCWY*_63QE<J*BR8:Y*P;NW"/!D]0AZANF\Z(B."SQ_MLMT_"
MN<B7(C\1_58AQU3L0_F=G+$5Y;\Z*F</W;M )3Z381[^!""B2:8^SJ!1@D]S
M5>6'9+[N[0:_T\FJ#:[+"6U(Z30NJ_""C)]O83 <'.U"@DTX1EJ&._>?1X2:
M0Y/B.!8Y,'?9 E70G%VM7]3UQ@]23JQ#EV?8NZ\L_J#?B(S?;N+ K(_AV4#O
MUU3W2Y#GFPB=A64X>N%#.ET*ZN&$+)M31(\35<JP&;2CF[>ZTO^B;32>MN@P
MIVO0+F_OJVL6F[-_UBD_8MTUQU0DL?,;E<)M#*Z"G\^ 7@'7T*6QXP(<;)$5
MSVAI?]H4!Q.)D:Y_O$S\&OJGZJ3%0;IYG# F=-1RJMMPLB=)8D J[18!:!_\
M0(JZ\\O^U"EB>$95X!#,+>%&MOW;CGB2OD-TB28X.?2L,/R-4Y6AQ9OOP@,$
MP%;\A.,0=KI/ 'YU^.6U#5[IR8'*LIGO;2?O*(]\Q5]3UUNQ8,RV= "1-5U_
M-%D5*WT'WD1ZVC[@!F(##G:GE2?Q=**BDG(!Y?)'4Q"]109QYC?F2:_Y4MS.
M(L!Q.%7,$DYW[.",^D:KYP=3B@B55\X!5Q7!PX$D0R D&]KK2V[UZ53F.?)0
M:8A4_=^][>D?:Z37,>)M(/0G[*V]'GK/5AI).OP4*?= #?>O,Y,9J_QU9E+Z
MF;X]\6\#,).CZ;8R-.S=0;^%CDG?HS#*#2(:2?JXM$;,73J(Q67TX/O2C@E$
M5HNW/,O5E?*H'Q,KE16R7L,S,YV\<(G*IQZ7<C*#;FTJ.J656/''G]?I.0FU
M=9Z3%2L+(W??'FBO-(Y*:_M#XEF,::O4M\QE&("(PJW*3[>5[[&60O2QODA1
M(RO1HU"(5%RLKOJ>S.CCNRQLX&"HS->: #GUJNH70_F")\D+ %&0A"H#0$O6
MPLHXZ)!V&=U9>3U 7:WJRX<>$3*\6AV;$''Z")0&^>6JGI3.<$G)K+>^WK[,
MD$<F'%C=Q1$CS0V>XD<;AYU6&[M5W)D&.>],JK*)/"ZVD\T,8O CTLT,DO(L
M(=;","9.'?H+[6P?7_DEX!HSFF.[CB=!=[W;25[3&EZL3/I48"W:K:PN4'=+
MB#CQ'7+RK=,A:)NE0MBZ86'5-Z/*VU9A:\M$<2U,VO):!X?)0#HC2LTM_+I2
MH%KE>L95*3RC7- %[IA4X!9P=A=*3F<1=,I4 I*[P*#?ZQE4.J2MBJ1A;*^&
M/;H=(Q;)J:QQ4QMC$Z'X1*O"^R^;*B-]!FT9G>' $@% &F*Y^_=A2(Z*A=0U
MT<G]TG#=X8-M ?%;K0/"'IS1AIM"Q,'8$M%,K+6J>R;GTUXMM50DRR)Q"R=&
M#ZN#3,))+.8[[:#V=E[%Y-KL?"W;PS/.2O)&*!;1N"9[ HPI)79LX/<EEW-+
M;#AG@67>-5:<L!8<Z!M6NI/MXS9>4N'/LGW]E<@3R==Z*(B6QL2S:3GS[L4B
MXEDV3P:B_HUY %T:4YB;]R)SIL7O;7R2MK5MR'PQ)(T&?:$ +>0F/&I<V$!U
MUH)1W1,K#$0/](:EY\2U\?UE%1HB1_%[8/D6EAO?*Z( '_"])M,Y<=7JREJ+
MV.N.43\G-56!EUM-=$-*CZP4!Y*HD5$[ODE+>S+NNL,5VX(ZYHJMXSP5AM,W
MS)88_># RG8@IX]:WV/S^S,/JB*W-6T^,74+8K)3D%UOQ60$QFR&2M(PZ3_M
M-1T3#K?,=1B (."V(H6Z:JRL.E%\&)ERA^)%$<5X#A^0WAAO<\5026;=QVJ^
M0E.>T\/L,15VGSN&8P+-34-.>75?JGN$F?JX+2K'']_EL,7=<B&Z4/*5]B?-
MV%$4%KSHPV_\$KU=6)=:=&DVL'+JXIEJG##L@NU>3  [V/.9@&)9 B"=,!#@
M-ZD/ ,!MTDL)<,"Z+'M8VDW(^D48:4VI0QMR\*UTOYKR_;[[U6$[ O.Q!8XA
M6Q-U\(L9/]% @T30SN7,EV3?\U:D+MPQY0F\4FKAXZXQ)ATZXOS;*J%%C83D
M2T:@9\%%Y]E9_!F#, OUX8H:QVE=CJXTF)2IQ^.[K"9K814NUV9RFLI?,"YK
MS,1;#Y*BI9.9PSPLJ5I$%&73.5/=JM:>];0HWTF>R R2]'2ALDO>C!\[F!*[
MM]4 "[4VA=Y&&Z:V0F T)MDA-:)XF8GAN[0S)BVV%!TN%*IL!X8L"#YLOW7R
M^%QDC MRW[_0[*$197GJ?:F!VP$!15/V.72?)51%%*\I,!#%(P,$SVC:O!2]
M@3864JY&'<BP*G =B* E4_[HGIP>!!4N[EO=9..OV/'MZ;[P>RTAXI31!B*D
MSHU[_&$?G"A#HN]>P,7Z^/U\0X!HB,)$B#@A!-D5LEVI.O9UJ"06P[^?\-ST
M^G[JX6&)LGN;HMR'ZQJ>'U6$NX=6C.[[X#Y"_O4@#A, BI0?L -1DT 7O,RO
MX;LLR<QO/6BHDG0_YCYX9=-) $324_9E]/",:V\CB^N^#FWC9[_[9CI6/?B#
M!>;*#("1436RA+T]6H2M,YUQV<&M2, '5V0$!UJ'<>S(79HN)3^C1.I"70FA
M^U,OL,DANFB:T(HO!F=:;:K5P?M\)[VF2H>;D.S,((JV2>C%"]?Z.)('XB\O
M==[^*. &XC7]I$_*1P"HH,S\Q5Z(#%.6&WR93-!+?L<E_>SW1W#*+T4J4N2W
M14.8]D;E>[8F*NPR+GV3:2;Q@;1[WU\#C_#4?Z8B=7._P/1S!B(]O9'?'O4D
M9=^K-)ST7[QDY:'I+*L4?S=//[ZZ[W)PQSA];!G&:R[*0#2PD4:,KHI$'IPS
M35\AY0GZ@[12?!)2'+=X>@X @X+8]KA6C$9]5HS6]].0E@R:9-YO+N\7. 2C
M+SF)\K=ISI!I6@XR'LC6/:]"GP_'_IS]$<,Y)(X14WQJ(OCV0/RJIG2R6@IC
M5C^^+#K6=%^@BHSD>43(&!N 083@66PF#FFNE7Z2[F,/I;1W&;A+LM^C_![Q
M*MOPJ7[^UZ<>P,N$('8^B(@.>^GR:\,W.]3N=2Y!2L+9#D4%&Z>B#<SYFL:?
MJM1\E'4\/ND3F77FH/=;31K/+"W7O4;G%/HT9MX(HF5&+V;O]'2+E3UC2<5+
M^1OZ^2&945K)_U\>*[LQ.BT$=3$_Z,W%*!''+=R]6<,X5F0_T?&&GTYCN=^?
M:#5W,5J=$TJ"&=@@*\.1Q;JN/X]5V65<]==$BX=)WVR8DU*KJHX[ZR7'6T\^
M4&4@^ECL8W /<VE[W*-;+ B/Y3TQ=!+\D<8\E+M?T<\T/:];_XD>UU,*AP/"
MPL_0$Q\1G?2&HU_K'I^C83D.%U.233U822:C;W7#3[FQ(GU>7_-<QV7XOW9[
MYO_9_U![ZC[(6$$CO5/6'B+2/T3A<_W3;042:S; Y.^^<34_KS9LXO9^=UG!
M\XRR33U GZ3BO[MQ_X3FEGYM"M$6X%' $^Y,IH*J$P7A[U4U'W: HDO=42ZX
M."=_?&/4/N/P!@'8HZXD *4W<:& \=^;<5_JTCFMO%J=.6-J3,L?>3KOU=/5
M&WO%90BL:=85>1C>2/^@LO9[0*QFONG=KO/$:.)3-F!C_6\FU3>,+JG#/5TH
M?9PGEC3J9/>U;SY9)/[150+XF3.N+9 J:19@LUJN$ "C&JG9\,0H7\ :4%:I
M!%^\).-"B76>6+MX:53SIM%KHB7BB2!E,?C^0AB>;^RP.6QDLRZT)1G#=)^/
MAPKII@@.>P;5Q<8C' 1FM)IKTVP5GEW_\"QJ)$BE,K/)/ X%;A\DGVO'W]!.
M%YVY=.=SJ^UD!B(#QXGRAS'[N"T8OO'R#5G3VZEVO<M^F%2,#5=''SSN*]J\
M;:S.ZZ26](WEU.@+=!03]R2]W?*:2(6PFX4\JWXGJ#$N_:*"J.^-56..7QO*
MDP2KDKS5;W"$<67FE9H:C3L&<OOP/%HZEGT=^I'42"6]Q >,$XGZT"2<#&FF
M:7&K&N9.<LJZRN ?*T2\L2G<&L@.?3Z&\#P84M("P7@=-5."V8?@H]B9)5%8
M&TV>V ?H4:?5OI.^M^<A ]%O#_!/?4@Z>VF&YF*X8:P@*]C4IH4[WF^MK8\
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MR5WN^,BC_Z49--/3[&R;<>?@O_LXVS_L6%P/3N<"#YP0L,DR_,LZY?\< F:
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M:+B1*%MM^PH,+WJB]3&KC[&H^OYDR\EAH[I)34UM?5W:.&^G33Q\3;G<HJ/
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MTP_JS6WKOV63(K_WLY =]&BU7$D4J4U#<:%T7U60E+OM<15#DL8"694)0,1
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MK583#P;/A8DT/_MN%.O!PHN_$\T_)..*>F6.KPT;=X\1\BK3+$O&TKPBHL>
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M59G=]D T2Q@=4X V'8BZC:G9PU)JNITQ D>"H8:ZO_S%)UO&# I(Y[2</\U
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MB/-S_L9_;XD_<*L--.C! 7])9OY?SAOP_*9_#%PJ,!G1SPH=5?#\NUPA!CH
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M I/U>BV$LKOKFP+BDELDZ+P28+I/O#=8VFK/5H:&QX9?.C2-Q+6N>E(;W45
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M?#7DWS+J?^P_]A_[?VO @R__ E!+ P04    " !3@F%2R8DQ-Z74  !I# $
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M2VM;7__ (&)H>.3[Y-3TS.S<_.\%Y#IJ8W-K>V=W#W-\<GIV?H&]O/H/+P(
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MJQ#H=.Z!-4P=1YBBB9T 7]9^NU0]RS/9*,[XT]^-!/9U(>A\.]FVF+<1BBR
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M[T(DVF=?6NC NTA)\@N$I\7=7G8DE/P2J5AR4_F:E?=I-Q?B6-\0+T5@NR<
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M[G91H)$3,N^:N A?> Q5 ]#M(7;%=?:'/]?L*R450.7FD7UXHIFS3C+R]N#
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MC<$,;XXR)$F3P)D;]3A9#%]<R!34SW3]X>"WH>YM"&.7C$O3F#,]C5:UX$.
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MZR"TOVFV+D9RZK62G;Y7NG4M)B 2I]C)\P5('IX@R8313GSJGG[=UC*J3/7
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MM,)<V&0'(W<S^*DI[P1))!2L&;/.T-??(Q7FNHM)P#.<>/0KA1[HL5@O(>0
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MB;FMFK2RB!U=L$#DMG":"P;HO*DH$9X- [P 5S]4N.6+(GY;)6J,T2?JZN]
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MA=0.Z4&UB+^_Y;X?H\L6P;I6MUK%NPEU=WF_JGP4"EKU$[B]SE!RN"ECR<;
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MA$4<W?,G/;V TSJR4KIA:6ID/3E[C\6*WX45(]16! _N\>*L'^'R4+^=6$5
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M=V*+YR#02E&];OJP"N=_\V(_"O\03.?F+TSQ!@MJU4.K',)J%:%[,*[;LPK
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MJJ!.'SU$#]]::(3EN/G@I*7Z*;T;*G<R>)GC?G6\UJWERJUO<:<+M-0,\.)
M]Y@?&35R06K OF/[9=%IV5@&:*K<[K_]LVDZWNI@.(#^,5EVZ C#L0EAS_QB
M9/JW4GX(O[2N"$M:<.?X0WV^FB-<"AK/O-5*.-.6<]+2#Y6 M*E^J A'Z:["
MBT014*'FU2S'PTR:'ZJKF/)6S5*J5X.UUX",=]> 'T5BU6S7@+5%L?/O&=PD
MM%OZV86^5C<QX4"'[\\QFFGB:\#!'LWED=2@HVCG-'/"<6#+Q87,-< '?)EE
M?PT0>W -^*;N]&C9)Z1:@V,;V_?T).+J+.=<XMO5:]IKP,>"U6<]YR16189_
M,)+Y"P=GRHA*UQCJ(^4_R M]J]F\^C)^CC$,.BIDLRW-Q5#2)!?[6NGX#JA?
MK%\-(JX!Z9]/1Q1QNGS>/U[&OW3J@DQ-*DG[H&M"9XQFKH9H:+;52<CA)=#5
MZHW :X!U3/)=U10O8OIZ!6</AE?O,#R*QFLK#"*XYUS,1 (]:"(N[$6^4$#O
M[68N5#CI_0RX,/>"SY:0$%2&P,V^2Z]Y<Q)1>I3X$ /L&QQ4RWC&*YW3/'O/
MIO3IQ6775DOQ$#.63YQI=IEGIJ6[B625V,?9+>(++S_^WI1?Y=IT(T5E;A[U
MM<E&A>2<7V5V[R_BN_VJH4_TF;US:_@W^2F??X_X79#9ZR#ZR<8_45=(UC]0
MB3[FWZK2/N WE33@RMSR//>F^54A,_._\V8/B#IF5]50KIWY[2&.F=+?*DL;
M/-59U\DS,@JR0Z!\_ /-&UOY(97*.,$;6<<M\BFIKEN96I$*J\D',,R/15DN
M*@@5)M\QDM\;1R20]= FYT:EQA8>LN+&JN+&5OO]9QX0T^-:*[>.S[+A.G5_
MXD>Z6?^2HD6^>[A$ZF/MJ_.?J$\U^S(3M2U7NXD"<[ KRV9/^^1-;P(MJ]M-
M=DR0VV-B=MP>\.S$,@$RXVU%X[JCC>%47!Z]O,)%Y0_?!W6EY;YLVZ@ZLG.M
M/GW3RBCF/@)^8;KJ,S9P$M!18;5[&AXX%0XPJ"^A$NOVZQ>=N%.4NU=G\F%U
M=&@80AT0ZGVZ,1VZ;'8DPHP-]7<CZ&FBO3_J&=<[-?GYE;8)/5(W/DC.6O<S
ME@B$M(A=VVPB-8):D;=\19(%N&RD>?R^_'.AM%DZTP-QQC72 M71B2G^\'SK
M)4;4J&-*.V,]C/RE(:+/L+MFD;CWE*1L3GP[7*>'8\V8ET+Y5./:U"WB^J-:
M45SO1UA+P)15\.!/N3' 7NIF0;%E(W6^1"]3'*<>4A4)%KSU>N9Z6CE=X2VY
M*%NMZUB:$#.DS.=ONM25?BP(#])>LMOB9*8<Y@MDDG]*_<:/\S/I828[Y0Z(
M.HXH]:.SJ-V\1I!FL?59KHYY4K*X,J5)<>*7N /M.F10%[<(4TGH#B5_)U5Q
M?T2'@,P!>LDV\989UN:6MY2M5UY*QCS5,SY<"P10B'R-M%?488)PV6=I5<^D
M:>=']VNICA![6Q;F=/G0"4FX^WL^*-7>"IW&%[3Q0!4JXFQG)_[.^\712LPO
M7@E9U/OP=!A:C>D,ZX7>/] 7%.KALY;F#@82@C!=V("T>5+ HKH8$@1:*1MJ
M)CDQ#)CW_[JQ#C/>VP*E2< AO5&PG*YRV&EATVN[Y?O#UU*>W5TJRL%K]V)B
M2_#NOF3[T5X\RA*O:Z_L($X9!%^T/Y$5%H!#AK@@!*^TO1Q>7C%4\U.S(FHU
ML%94K@',RL'D]VNIF3DY32J-*Z#VBW&%- ]L.R1S(2.[F7A&>[AESLK![QU)
M,;4)K^(6O^$=;3^ALE?Y.-H>'ZW8*WZF>0WH5'1=ACQ]'75W(,6ZGL:OU!#K
MXO%(V2$I!T=>,D,\9_?-6%#F)_RS@WPE^>3$^BG$/%S.W\2'QV!HT58.80]@
M0Q8RTF+NEU%T9V"S'B*?L""Y7YJ;T;^W_GJB6U#V88%_R Z4R+)WHH*!]TF2
M9'H55\LW_:OG$=\/IR^$_*MRKEMHJ1-??IXI->_^-(@^GB90\Q*\KP0"%6M=
M T@N9$I?^EK25S]+M>U-]XT#>%VEE4'<)M2>03_T&=1U>F_LV9J)X>>'"Y]F
M3=A/,!)]\Z;;[<\BZNS**6@J,D/Q8Y4M8UDLUINYD$@_!FHL:6K>B9"P0G7G
M_4:M0.BES[]-NCE"-.TM5KGW0J?)MJ#J]/%'ZQ7?!;>OW5!*\$M=8BGLGS+V
M;35-3'MNX'%$HQ>7I5U6_ST5S,-,C)/]]DXG:Z<4:;!]W=EA.6-5S7A"AY.,
MC<QTEP#YV?'BF+US+0[!:31'ON>!XL.%H\Z,4';[E>!E;U->%(YVJ.&#]M>E
MQ=RQ,]/-.MRRH*,"5?1W:)36=TGGU3\WTG!V D3_[,Z+J ;580%Y@ 6$$](*
M5HSA*Y2_B((RGN>?:B'?"&U<Z')/$^.:"_8[C'],3::/YBX=#-7BP'Q34GI$
M4P,\#;'; -,.MBT^5K3V2!JY,-%^Y#SMJ7H-L'1OHF%MV#LJAQ"_8A!5<=A6
M8VMB&XBO/]/T+HT3]M:K%I8\%^ALF3,<C]CZ=O,&]O#5^8E7U7D-$)[8S]FJ
M]!W@NRCT8A K^]@=? VP.*D]_W(V=)FR^.T'QZ;!PK%VRUKRE;I//,?I:DL<
M]>?@"4/3]FO !V_=RY5+JRODGOW/A*/R5^>LA@=(7V;1+R07!X:]$6;MF^65
M"]> J8]L5_M7U;Z_<IVH^XT-C7G(E4?YBDR5\='$Y.XUX'=88K^RA<[^SN=W
ME%.<9YM;[K[']B&^'UM*&8_=0F[>82VE7A%3)C?. /04?&SU"TPO!AK#E75W
MM]\):*;F.*[.KA [8A:_UCBU^ N]VC&K,M>^,*BZA23NLTOWDH9]]0]"MI2D
M1-*]?AZ#?2._M$:2_:*?Q)QB.U,D.-M@9@+^K*3<8U$-ERAV.KPZ3C'^[Y)!
MCXR.EH@V185VL3^G% ,',!VZB0;<)5LGM'Z&\'4\9\2HB*?6$IGV:")BS%*3
MJ-K#[A!ME54^_J#+J+@7[NXR\ZW4"ST\"9+?6I$+C<3<'5L)(A*<;#K7['U;
MXGWIW9WL5KFPIK3WZHKOTHK<-R1BKWS38-'61&S_1LS/(/C7@/B;9JB_!/=5
M_RI!$E^?6P$*ZUX>W0CP(Y)8;*Q\1>Y7]6F\_IS4Y)4@V=[R:_FO>ILX*G?X
M:[TE_'L4TG0KYE_TC-CY7;&_JV4KT<?E6%CLK\S/Y^_-K^#XA6C#.37-C=7]
M^%&^*7/#MN56O<%_J%?[=_7J^T3@7O7ON=V@A]^TXO:SW/Z<]>4U0+,E3FAK
M:.E2YTH#-_9].A^B<J%E:H[]5OUWQD69=>5>A#;*C#?/S\C\4G51].0G8?N'
M3_Q\T+%2PYA,==;=\V\,&\%?RZU//'>WW%'%6.KK<*7SC[O3+PWD'.OO=XNP
M>+NT+F.-<T9]#ND$-6.C9<)SJ9B@:JG_F3Z,+@!D@&#CJB>ELD*E32M!CGEJ
MLB>]/MB<X*QH!7<3-4SN#U2L5CF?;N>.K84+>\! B[]NW).4@[G0 _@C8\*9
MNB)W05E1MO(_'=^53GWH(5I]JD(> ;.;ULM@?U'J29U%&=1E/'M8+K*;-/"N
M?.CCKOUN2:XK>#"@(UIDX/W'OMFN:%3,)4UOJ"FA#JM:&W^%^56<8><F?5#S
M<5L+K2RW+WE$!SFR!F%+A*A."==ZI EU*IWJI/H15/;B[+EX^CMTGHZ]A"%V
M5>$=)K VHB8L5X:M(Q @KBA3;ATC^IY^/(.\-XO;33/"-/Y+XL$EYW=/\X)7
M(16XCHC1::C%>7N?2=M'7/=N:V3U7E"&4R8OR1O!G8LJ_D J2#K1B!T';R&=
M.7.*=J@/,_&:&<BV4,"_A&V'K<Q X^OY^&<Q-0U>V^/7G/N15]LKPECV02Z(
MP84&1$N'C;F):!(?8^"-(UO-=\IA2A]EWL,'GJ6+5DROK,#H/>+]K+W=V@7E
M%\-_2=&-X'Y]I,2E]5)C=B7\&B _=T:M!ZGKWSHP).CZ<-(K.!M#W2_].HXQ
ME(V  FA6J])HN@D^:=9I[Y!S;_]I+([4'#^:Y*O+K*ZQ[5>[@[5<D#8@_9:-
MW2XXT]UX6A]KI@\DQ)P?RI:\*3_Y%H^#;GG$^7Q3'T^F6K<0JU(I+FD)6F_O
M#&0ON6?U]:.)"(MY96 "0O"+C^<T&]TD[POSN=>V39K-I245[MQ[62!7GU;+
M]".)X9^RY!A=YN>:2Q=/$!= .Z4DD;YWY/3> $_3Y%ZYM!&'E4'D($*7!4H1
MVQ#6U/X=(?"6/;1A>TKOG>X.[(VMS/-DW1@GCK@GU$1: 5H79";#WWEFN^IK
M:8%S"'ZS+PFQ%K4\&W,L!Z8+9'&^.D=":JNZ'7,%>!L&AHO?YC;!73EK!$QB
M:9XNV315DM< O8E3S4I!%IV.0/$X:P>5#D=9D2+/,<J05[F$X!>5HV IU/_7
M+7L\/UC9[)>LRK:'I402U=@.O2@47(-('] ZO,E\)66P_[E_*4/>D'7ISB40
MC7M"8L3F_[#WU7%U+DFB!PCN&AR"!'=W2(+K08,37(*[6Y <W!/<74)P=W=W
M=W>W1W+O[+T[;V;NS,K;V=WW1_/CZU-?5755]==6U;7!(F2$(4]8F!$E73]L
MUW?GS3>0*<VXO<]5)!S2]/D[E5MAJ#,K6!B'__E<S5KDYB"56ZD?+3?<6-7[
M6!8X8M0<,%$A!0PN;%ZY4NI$[ZDB@$K\*,X:4Q]<O5%(3A;P^W"AW5T46U&Y
ME;XG3)%-3FDFI:R"(,Y5O$%R&J5Z@MB&ALU[)<IZHC11CB_QYM4ZKG26?ET2
MQO*PFUZO_&'HXO2!U Q2<'U-QY=)KE:&R;U4DO;S-);&1V**R0$@P%: SSWW
M FN!Y=UFBM$*'U;KNJRE ;A8CD^!>A_AR)$8"?ZF%V[^2_QC%SAG."19EQ=N
M9X/<\C$]FUZD=N0>RFS4QU1U,DZ\"MM_T^$'ICL5:C,VG(X*H[UB7@\AV AC
MV-4PY=OM**OJ3@>Q]3M7)!,Y@G9"2#%@Y3*A"18S- 7K1W()FN<)JS?P"0">
M\S'#@-Y0:7KI&O-YY>O0RP[L;_L:\KL?\?OI.Y\ S;G/50J5P.^AAB_U/)<5
M/9OSYBAG1%G@2YN.J1D%&F1F1'JY,O$..2#NQG4\7>(,Z'NYOMSHBD"=1,PF
M>;7ED,3UD1XF*L18RWZ-C/D*7$6G(0N$NQLC+@=-,JV_R]A1(< I]?5>C"?5
MF2?DHU8W.&OP1S#O8Q@0QUE(FG=1'""4YNC=+$D0FJ750#X"AEWFM4#2MRCT
M=W_'";O\A34X=KGUULMIRWNXL&M,'@,\RLT/#AR/D*+W<$G?0Z)M&>OPGAN4
M\0CYD],OFG_01*;'"7J^G3FJ.6&ESJ]8 K.9Q#HI$G'&V=@]\GPFFI][SG&\
MFC_D.8LTX^30J@MF]%DR5CJ=9WSUF;(1&HW]CSMRE/I0M9DS!@O=Z)X+5LB"
MYUE.@R[U3=W=8G697S)8MQ*6'-]N#=0VJKQWY[$UH+>QYF7\+X<B8%3!S$RR
M'6S1$2T=3 6HC(A^I"3UJ[N#FA3MCW9B#D,,G"52,TI;8T6'!%IB;<R)OG(C
MILHL1ZQ[FC+3.&ORLKF%>[+0,^I#FY3*EQUV VBTKH*Y_KI!Q/J;64*+:Y=A
M^L!QNR\5\)9E3# P'?P$U)SF6/-><@BH>PKSFF^Q\9*4NM=>?VKP]@EC$[^=
MX '?G&^K.?9/H>TC:<&U3013N[RUPSJ&(0$#[%-O.@+>RE,NO-Y7),^5R(P8
MW-5"+6^H03]0(M:SX)Y,\D\PRF[;: \L7+"B$2TX/#]0BE>W3T 3J_N\]KKD
MC7,62U28>,HC&HX1:J3?6?S^!'CD@OHS.]U($L&^\XHS8#7W.S,@FVTCK9W*
MVXHZ^"^*^!<D985NK_1,[,KR"S!Y$52$:(_;!9QV,Q9CJ73##=DAW85IZ+-L
MQ=\-C)^KNPL#L?WFAG4CZ9@Y"QM;3Z _BX"1E.LSI=+V0[G@BI&)@P&IFPCR
MMF59I#946AR@UEQB.CT.:=(KQ\P/]+!.VM.9N0!*/J2!%LV$%YH5>/8*7Z,9
M#^*3X&/$>XP_S#OQR+BVL9 @=G%VJ8U*8M.:EZ+12O@&.Q9AVB62HG85B9-T
M$</TU)A&"TU$*ALE"IG>EH08&,DN^+WPJ-@>20M.OX2#%$7Z:F[)%4_96H,]
MH 9C&VE")K5AI02(M\?.P'Q'G!X,_'%$\X\[5_]W*?_.HQBD$1RR\0DLKOF%
M7+#O$1LX3-TXF)\S39%MBS7>-7ME5!>ESU6A7PD;[(RUO*ZPBEBSPC\1Q(O^
M,RQL+:0;^8>=&.;WRX8YT=7:447 ^@2#Q# *;*BH&)#/^!F=*W"<C0BMS<R$
M4LZ&*UO;9/'UMT^+=/-O.$4V"8;V5%$6%XE0V1;RH5!K\,-<INH:IRHB+M_"
MP6AO/,\;8,63@W7CV<N)\(7)@ST_+HZ"]6!^YS77'RI%[5K14-^9E?$UP=7D
M39<)@&!#,\4E?.@^/3L09Z=X0Y>TF+9JIXFF/F>CF-;%ULSZ^*J!6;MP;^-5
M]UJ%L:FL"8/?)E;_AB124\C'[1/_XWG0FX-I9N--1_KX$(I2LU;NA\YT?U@B
M!NS-V@*?'@@>QALAMBTM: -IFT=&V2S'65#8_DX<Q2?+#36JLA1T[#M+>T*3
M/#/N[)I"/!XJJU3"C-'B:T>UIF_C8S*-X1Q?%O)S?'%9BKE#M6WM;T=WNR.N
M>X=+6WIV@%1)]AIXZV)-JRDHB^*ND"&?$E3G+-G>]"E,\O+D4>^R0(MC4\XI
MK0G'M8-.T4_%8XJ0\3[&[%\^G# *%$DFE**WB;ZSTZ*>)*\<GG1U!F=!838+
M*B^;9$.Q@-PG<,$B6E._'4QD,X>B)->M#PW _)SO9"H-+V96QT7&(RC $B\A
M]64L&+B#*Z&1%6QBLQ*HH:\<B[<QVXSLLLE+D"^99])BV FT[K#K)+=)13^-
MWPD.A=N3']X1)LC-9_FO-O[_!AT,[_7FH(M#'C4%656O,5AALBYS2K0R>X)Q
M^)X*I$84:#9\$PO^JO0][AN9VH.>*,XNEU^V<7_O7J"W!8'IN]J9Q&ITQVQI
M8PW:1I;P?R?^4M^+\9Q5;4VF?YD7/KW<80K9$6;^U&@3<T;T QR[,CF1GV;H
M(F5TH>E+_NC'1,534E'5#'ISPLF-*FDX@7%%Z94'@8K,MX\0ZCA9&#8DRB0J
M7.Z>@J%K[V(785K1G&9I?)9*=L+%#1 3Q/%.JN,O18)9]!^6)(K-4QTWB4U<
M68QUY:]#&5IO^3J3#/C..MUNT,EEBXQ-U&(>LU@GI[#NT#_<%.08C]-W:- Q
MJHO"6WX&4(RFO&(I&:"9/JU;$% XOJPT^E;![(.\IURN2?T$ $Z]:FS\E*8P
M/)4M_D*>?BL8_4@2'Q7R1HXJSVZ '!2D;NI<]?F<I\[\#=X<9Q^&^9SH6]63
MV=W:S32,N-A.3!5$;ZTR5EABL#@'*K11@GH1,$S^?FWUCZOU*ND+C<F1:BS^
M\D@3_#$#TO9%N[$I,V.J,<'!6$-9+F.O5TKC2+YBQGSC.E7$S9+BJRL-6S$G
MVXG%YIIO2YR\UR^S81(/Q@?SEL_M,,[0@^W[.N^. 13Z)[CFZ3^]0$<[_:V+
M7P21CH0)MO_ZI;AI1JB)E'L["HJN@KSVJ5 </>CBH=;Q':,EN.X6*V+$8(M5
MJMXBT%5JG6.&E>:FJYPM9X!?[]+\5\YBHQD0=%'R8ZH0"+@ $[X.RJUX+,8,
M\"20(U0QASD!U75V#%309V$2=O)JJ'"?@BZU<!$(P^A45@VR*-(WJE:RK-0Q
M=YTIWYZK+,H1;U LR!_R)"IM$"4WX.12$8#6JK::"#@09&,8E8_UBG.0D+;"
MG9'5H].;H<@DB2C/($B4U=,+K:'E=5 FTYED_^6W>/\_*LZB?Q02!/C;D9M4
MP8P<"CL!)7R48)_<0AXG]$TN82T+AZP*)3G7E4NAS1YC?#.SND\01Z(<8\+B
M^"@ALOX)'"3_6<N_VW$S7,3&]D!>D2[IK@X.($[6+AT*@Z],&&'/6[O0*H9G
MC&]8J:^S9K7=8,8BTUA5/4GAS_9JW/;_=L_]3RL*L)"56_%(!VT8@%L:[L=#
M/$ZU76<',KW79?N\ZIFFLM_A.XSX_ !VK(KDGS7@.NI/L)(,7"I9%CY%^#OO
M"1) 8L:X%NW<VL&R=72_HPF7M5:F8Z-Q?P,9.RI$$I$( M0)BR"AT[7D4C2
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M_1H:U;XQ1,\C>!XNXC2-#_G618D)Q$:A.7*;BX,O?$=.:REIY29$35$J(R4
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M%)</8?>7F,LITXU_PBB+>:OI\>97N*N'IA\GV7YO;5?QA+V#;7P6_)Q4+BE
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MTB78X@?H9$CXB*BDF4SW0L;6A$UJ!,JAT3P&.]BWZ',8Y1WF;:RW@R^KWTL
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M/4PQL)ZOW@M-&&/7+Z]JY'*[.YJB.>;EIKM(E,OMK7HG_?RH<TI!MF7B82(
M38,(]WM3W3AG(Y\"J^0'$.O'N79V-47OI%VN:%B#I*JBU%X'I <UR6:.349;
M4Y0B-).C0_3]UU]X>OF#<VQ"NY4G]E@"T"C3$8D1,KX- "NON'DY3/87HR<W
M0XGSQTV LWN_UZ][O#<H0ESX+=V114C5-UI NW=F1TR'@M&;C^BQN**:6%-R
M9IV"D1F.$+E-[F,]H*DYW+D'(BJM"UYEQY<[T:KN1P]-^I4>&IP+3W7^.0F$
M9NHK\^J\ C6]P7BO<YHKF-@P\, "XD'?8V=O;KKGA;6C4R7ZZ)?TK+\U;)DA
M<@ -A!9$IH.MTH#78*7#4O\?*JZYM!Q&#7[U5.;).BGS3Y0'@J@AKX[\\6"9
MP*#*'T/RQM*>.8<5^ T%CAGT=.>Q=SS2_% [2"Z7Q)XG X.E?V3E!Q+)1.&2
M2G"R[MH/K_I'^/?JPX-)<,>;?#TB[*&E%,D5B#:^LIBE1G[%VV@F:.K:F"MS
M%%VZ3.$#%&)Z<#22XOZ&!,F=KC5_LFF$[FD@03[O\*; SB?RIL03/FT\OH5P
MJ*H>%+/,7!MNT)@CMFEV%!DU9R8(M-'KY<43^KCL^,28"J+%8O_)WMD0[&BL
MZ8@Z0_3%!'VH*'66MJ38N#$'-[T*FXDZ0Z@&37HTE2N]I!@\CZY+>/COVLQ0
MB(<;G7GM6'QQ"I>^NVBQ*DX'E.7ATXJ#>[)%GDN"]0_][JW_O;>E2[9K/8+
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MUZ9MZYM'[_JW19/:^&<H9Q,I30FU"QC$K+UJ#]]DZ+UR',ERF=:YAA^25N;
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M6^1('/[M2_/A"YJ;-AP[/A=+/#,'J_+&D40:MX+CU#DF&=88C+]-*L"]TF2
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M3'K>V\%3/Y<W'=+-DC20^@1T1*DD;3#@%M^-J<<'S:*0+EN7LCR:4&A.5T[
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MG=#T@$21I51?HF!:?51A>-IE-L,&FEJ4W*6>KXXI\@OS(2[9'*;UH\&5C7K
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M/G59(DL;GEBQU[+5JEYHPOU#-;H%(];7@XRP&AI +LLA9/*,4ZWW\1 AW_G
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M.K3QHEY>3$3XT5I?R"OF%:RFDQDX]<-QE6OPFK=S3SP"3*W/'=-1'>#,Q-4
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MKSK(G(0RB:OZX"(8_A.BR&91[I!F1?>"_OIRI>\9;=%$,D:F6MCA/I0Y%[^
M2EI#"HSXS -NC3<XD-Q^Y[G5HD&=!G5?42^*J?S\FL6+XT9QEKY,EG%-M4'M
MAG>P_,_7W_RP(ZY>O[DP6+,G7+HIG?\]+'0-<5@XN[D'K[3)(A)[66XGZ/6\
M\FP/R9V\DKH*:S**<.!_WB^BK'JB>.R_95&L8/-C/=6HK\)OP6:/S"TE<BF
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MF'WU)9/ JV"T*Q9?_XELT%MY]'%2J+^N;5'G* ZT[TK-L-P#@]N$T=R?'D$
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MM"]^G6S;F[Q+F)F0.V_F5,7>Q(V":\[BN0W[-G56K!]K"N-C3E[B_<TFXEM
MK.EI>6165*9@_6\#-:%[A\ :_RFJ_3#<]<TVMLM;0+Q9(T(B=9I?D9-:.>WC
M%!?)8VV0\^^EMNYKT'?)OC]$%;OA? O;=02QHIL/8@T:($]GQ$SAG'Y$U7NI
M+<-#HD&>'V;U8XU[C&$-7];8G@1=+6RE)%@SO03YFUW+OX7Q_7FR&[<G8MXY
M:L\B+<1P_L"-/\^0Z5IBT,5DAO'Y<#%K._%QV#:JQ]O5Q\XZ*(:(7(3871$U
MM1/<D.>0&\$^RO&W$5Q][!C,2YT+Z2-QMH%>6Y#N=W-.AM$!(NG9!Q@ R%_?
MZ(N+HF:6!I*YJCPU)L^3]?6K00ZK3:!\]J45UK ]VGM=M*5.@O$"!%R*\A?\
MPV'&$03CH*9/\NK[TJR9ZP%YHYA!QE\7P_1+T2!']]$I TA)W\9J9IZEN]C^
MLZJQ@>&\E#,5/KL"'8Z/U^H8MOG?4'C&3KL(6^-,"?>QEH!X^GL3I(\!QO54
MJIK'WHPR1-EB-$=VZ1_5*,GH3$\H@;3U](2[B;OK9#Q%I3B4E\/$\-T@&O8D
MN\1[OZRK#9D%K=[,<?<W,4F^%*-K*7O<O4S4.O6'$+)6X6; I.[RF"F;B'35
M9;&(B6DF0$B2Q$<(,1K([:)DS(VR_&;41Z' ]<6T?IW]^"\-[!5#4!Z:<Z:R
M6=:V_&*RVQ+D+;?R@+B2B6 V+N#.:9?\>Y+^CX)"^^!_/(3^\>'HOU84XA_]
MQT/H_X4!2#EE8%VW,"L[J.COBASZ'B93217=D7&T_=JPU\:"]7SYTP\B\DT/
M;N[MZ\D3Z7YT92*#-RY(&1CV2<GR9SS]\\JHI+QLR8G5Z1L1SXTWWE?UQ*7<
M\/3UAYZOU734*.:6 @-$4^%'EN#(L*01!3%5=U_FN>0MHT3G_G9@.WCE:4W%
MJ_Z'$6F# 3CX60[TSBL("/A>BE9ZA9(!1OZA365EI&F#=?*B)X0QV]"=IQVX
M)OE$3+/$(Z5;O6!X?AC\((1S/6#KE;A\B00TKO0B$H0D&+TRF(K'_LS!YA T
M=L]P#;&PQDS%VU4.+DY8^4;'2O22J %EOVGTH>1CORDJ75$M;?SYE>1P3)*P
M.'$2HFBML@"/%@1*!2OJM+.;%8'?8TO?M&\7J:-OH,2FLF\_%N?AE;X"%*D:
M ;]; !VG,W2SW$T;GWS4O?MO])^'_ T9F+_-0,F],_ZH;\_.L;!/RTC5E2J"
M)[Q_D%SXS5U&+[^^C!BM'[-[)N?B&J=A&4/@<JJ%[)Z*U?L^2*1L0$A84%>;
MO&?$!5Q<\H+)2X2 ^4*F:CSWR OT:JH"^W'"/<6U4?S3'&:>ODLC5FO/A_]\
M-I%?VP^]!>@P6U^EUM&'?:+??^%VA:\U#!SDT 1-[6I[@7/DQ!E[);Z%2I0K
ME%GCJ_J713^]F;Z?)6NR_=)N6(.Q5DJ65"/QW^8->+7C/5*%R9T$575^[9!!
MACXCLRIE;<9!> EAG;^3A ;A\L+<846&)DGTLPB;J$;S#<F[D%%ZS%Z5V\@4
M55PWU:NM+5XCY!IO1?3[*&PV3B7U"+XF/<@N1'N/?[;_@5KLLEPT"CAJX_4V
M[KU97=3W6/-# ]*J5^E0+4OQ#V)KM+3C:0^[:R=P&9W*)74/*@I>Z\D_VQL@
M<*IM-!@>ROGP.3SKQW=3X(P,21?>VX;Y/"S^9-Z/;K5;];+/O0\L]A.4'C;;
MDD9E"1"R9X*;4O8=7]X"OJ0>;(8*3W$4TV"E4YG,ZT&6 GGN8C60M(HX^//T
MG*O5>Z=&2PJ?OOV&UN;)Y!GWZY^__2+ M7AEYQI$V05E'K")%V#LI72GW92*
MB7DI%$5)RMM6^TLS[.D05Q>-YL]7S+J=,F7"Q:>/6]I3HAV<IV90PS\;JJTH
MCD&4YR4[Y9:&SM:MH3_S*%ZDJ$>E=N[AXO%QHK 8IG;S#)L-/T41G2ET5/Z*
MF%NWM"6.Z)2^3O]0F_*$?EEZ_TA6@OJZ7G)Z9)6P>\,/.A<7%Z1I,6G+<HW@
M\M4PJ3!9YV0A,016?!JR\I$107*\6Y]R $O3NDTHT]18WN1\5%J;3?MN;GYF
MG#J:)M,<F:1ZQ_G-)C>[-!:DC(@)4")6E<^^6[P$8D+S*^UE:Y)<:2=Z!ZL4
M-D *^DDEQ>_[%_<*!(66RAX"(U^T,C;&"X0YL7]ZXEGV<5] #95@?&H<08L7
M;MBIF;U4::7ZX:E<?_V[ E]GS=XB"[-9%OUM(!ZO-^-B;IUYXTM!KM=QL?I3
M)$:Z/>?;;WQ?*\BVA,[K);,6KV:*?@^.$]@4WV._7)X?WHJ6X3WCF])+X?[H
MI.!,9O6;5LDI'@SZY?*-Y3JW5'RXNV\[66[T<^I>#)Z!S@#2<2>F57'0RG]&
M.?) MZ2_<HYER<(9,P 3I2WH7ME;<[O"JZ,+\[H%>&IB7\M!]DY-D>^R[+6,
M\!7C/6(QGGH8CNDX=W?.C>7/]2.O #OLAI*$_J,ZMX"'I->Q1"S)$J//"$7^
M[-BLJ1-A'\4)@5+/8[P:9Z$XJY.'!0U.CP->1PS5(="%4MN-P;32*'Y3[<DC
M.WQ#Z2!2<$#V"<9+K4+$U2S/<2+DO:-351FP^W6E29R^-U5R?:A"1?Z&V&=)
M+) MJJG>@3(X<F?)7V3$0["9=I@I4D]!>Z^XO,S7:UX?5RJ\Y1)80#,^T)3G
M:GP 3G;9)@JG)2ZA].'PE7(W!Q?K05LV:P2?U&EOOAGPQU(?5TM3WJD>%I-"
M*';I5NZZG'#]$-[PE/?QO ,BMP 90T5X5G K(Z*G!E9@TESUU<XSVT[#*TD,
M-@6E[6D&:4TLC'Q92\(3H8O*_Q1Q_E-,/KJ+KX#+ZLP+(_KC?929CXSZ@L'2
M?!.U8GB.)87ITR1F+T?#.HC/PZG)CV[CW,^2A_O9JFMA4CO>]!5N1D1^)'H>
M)G)MT_/4"]M*973MXSW[L))SR*]N1[K[I.+YYD.W@!3(:-5(\<B9A.NKE>5W
MN#%P=_'?%OPYMFM$)(;^?:UAQ8I91PM5F*0SCH\]>(<1S%%>C%]4('@^IN(E
MXXK;=[N7RM? U;+_; 4/;>T:G<K<GW6Y-Y U---2U_Z'0BE60%31_WS[CF!+
M#?N^EG52B:R:N# %'OMOJ75U7UXMG/G-4--;SW"8W@(J;0[1[17>]G-'4Y\6
M+P*U4,0+]ZZ2(3:%S>$4@S]5C\#Q/@H_5*P7QKF/V6<[Z QL$=2=R$^CKL5#
M_ONYQ7?QW;_BLYX/+4*I5=#:7IAV,^,6D .<'BZ?ZVI/\#R52AU)ZU;V"'W2
M>N"LW=SUNJQ%Q_>,43WO*;?&A>MJS_CVEQHK!I!![KLO)Z1G;"I>)TR((*7^
MWB+G*,1[PJ1=F"",W..IPC?"-P=L+6YK//5#8KIG$*.L+<?ITOR;)6+H:@O1
M>P0F(%E7[><;9_9W3D?+A8ULG8B]UKDT;.-V--BMF4.C@&TB,6-!=&<P%?<N
M5.IOY?P%S?Y?N0OKT_]'_B) ;&'5"/WU[JM9.?^;Y!;>9J8UHRA[/A4\%4OL
M8-2PDL32ZYO< :#591\ELQ/[1 TWY?*^2+F;NH>\P:3J='A#<X@6?_L(+G;;
M>\#>AFN$0-PL&RM']RD =.=_<0^KJGS5Q-E5$^2EG8O9N%-J:,@>-WD:.4 G
MEQ8*EA+/)FCD.3Y'R7^28^\T@?$3$5J/KBZ]=[4G&'P)#=)_^USU]0#=W&'F
MU+VCLW-B@P5Y1ZRP"$W"*)$G7E3)I=;),S->!A70'X_F69-,&+;9L!]5_">]
M!\-G^3IH4+QH[UCE </$,&IT;F:5Z\"S(G/I=>K9E:RF['P$J=>]", Q_4\?
MVUM =F;L+< '<J&Q3%.'/) D/JV&7QX6UEUS]GV;6?TD0"[<!_4:?J;)4:Y!
M9A@<(PO@_!L@ Q#B<BW^'NOA8;D@,?U:$A;13,,MX$+6%)HJE;UWKNM3$CAF
M?Y)+N9MH]V:]"C@%2]K+I$5R1S1;ER_N&C+X4O4^BIGKEN%DS]V6Z-K.)JRQ
MR62:^$Z@KAQXM,+ /YV>YA:K);=[8=%([5WF78\>M%[_(6(7'40TT1S6X]XX
M1(?3,(8";S8VUDX=<FXT1-F>Y,8UOD+UZ>ZY$E5?J/=B:,.4PQGJIA7GAQ^8
MVL27->C1M11C-?V3]3<UIZ"/;5F4Z]N:$V7M[4(V3&?Q'",35/5^2EA=M!2O
M[/GQMPKB:TV,J%3K]64* :JP]CPEWP\@((&H"@LK".>@3GLYI9T" W+)>ZL:
M#8+C-FO"P2U*"2;#SXYSL8X@QB@4Q!HAE^99X*$U,X\:5!P,ECP>HI.^!63I
MWH@2&WJZ&2FGJZG]TKJT\4QZ7F9^R"U/Y>*9>KQWYGQ>T)!8MX';GC_M:OTY
ML<^RR&!ER1__HYS*EC?(N=#Z53[/,-N?N%"'I8=@ * =<&\6U#7Z*K9F*WX+
M36 <ZC3S^7)='='6G44NK/.9:F3J-"2?.,I[N\(!PX20:UGSCB/+,;O6]OG5
M*_@,+>O[Y4,\ZY;!K][*UJ@&X*YQ?2F4++Z(3GE0I4_=OJQWGO[E!78'55:X
MF(R-;$W5;!>K9Y%Y.X!FU;(!4I8DS5B\\^BA@%!>N(!<1.1.WOTL0PO[-(VA
MTI<*.IQQ!2(V.'><]5CI/T]-_@^S;U&!XM96V?CLL41V%E:%&^EK(9;#^88R
MHTGU7A#^F7$#GIZIF*OTXRZIPYPN8F9/+?R&/2+2@7T4I[A]=OLS,T.-&9QQ
M[@]I;H#7,#&0K=@'YLI383;C;7+S$OFAI*D7YY]$\%.31:E+6C<(_?'V.#B8
MJNMP0RSWAF-03C\S>4?&Y<8[#0P_C(X?;M?6\(PT*1_$>&OVY^JL>:0=U7>4
ML%8**PWH]^F;Y-&IBXB3#$@4CV*098[S"SWGSZ3N0EU)<:XF"^<LJYPH0VX$
M&]Z_%)<HF54'FLQDC8_8!=:E:U->\)K8V_U'G!Y_A],3F;C#:2IZP]T)W]]C
MO-N$,R6/4N<NN*F).IN\8O0\+/45J>JF0!H\L=9EZ<>=G/ #Y^2KPR%MDGML
MUPBPR:!F*.J,U3R!L@-HN/[FR[&Q,^6I6(1?4F%+Y/N))]H(G-,"S;%$O9@U
M):VH^.3> M(Y&EGJ=RNN4B\:=GRD>*M.3$'Z9ZL1G1F44TK=RZZFCQ)C8B*V
M"Y&/4VZ&WG!?&]A8H=]F@OZ82'PZ* K20DS;>C^I(OT#3G,A ?0+5=K8/]&7
M)&;,1NV!)?0&?XS^>>%V-JSOX.R]\[;*0<_&-7Z/[&>ZV&#6&V>M>P_NBU"M
M&U<UIF..R"0V3!H7-.-L377D:+@(9+UX"I,R!O.TU.WV>BT:G)UM-R_5@'(/
M: A1 ;K6"_'']"--PH<Y#9HZWUYA,U!IKT80?UW7O,)KU/X^&5)1 F1][]1R
M*JSM$MG?<%P;JP6O,4;L[//-G:GJU6@,DJL>YJAVJ>OMJ<4J_(IV>$80%U75
M7]KW!LIKM[CF?.ZL.Z7U'BH[-3X1M"./S]/Q).8Y7M[/$M;<:KNKZK?E_P/:
M4_<K"VR?;Z6X@DE#A5^$Q^G[XS)10D2JH2TJ846=5+&AE95<$V1U6L1;V&)P
MI1ML_2M8T?@;2@G*B:UQ'Y["W3J2RVJ]-U5-VR7 BG^HZJ]#GN[144YP<7T:
MMX/8=LN[G!TU?/WFR0[#FFF<C]CIYGSQNMA*FF0U*K!^*T"LZ,,%M*0PR0*R
MVN+D_H3!.C#JG5ML&G)?U^\IDOMKL\*Z)Q>]3.LDGS&X5K8)\U+J\OV5HTX6
MHAJMT+C$EW5_4<&8AV>N26*%1\/QRRFP9/460.I1IX\L&&XMRZG]80K\><(4
M=RQSAQSH5=_0Q?X-:2BLMU_->,+4&2C9,]^@>APP+ @)B'^I0O&%<W<*%1\,
M\#A1M8&9*<^TJN?S1>2[J>?QXB"95"%7/5<V,B.4<Y%:[ V1S7JE!/?BSB]J
M_R<7\AHU&1Z6P9YQ=?5"NV](1A%Q6Y.'%;%?(931 TN&S0&"\\SJ2?:?-;\W
M\\,Y9>"<H06091WQY!_4U,^#US:=.TQ:?K*%M/6R1UM(V:_]P=E+2:C#FXCE
MXK]*]]<]$!/.MU$=?@&!*-$TYN_7R)-?-;E@X+< ]>4 $9%_*SGP#XJ_P!G8
M/[1G9#_._#>2O^#,?VS0^/>(Q%,PVCX?"?D:%EJ^P23_T^$JN-0C66KBE6\3
MS'1=R<U7H(.#;X*PS#<Q"/.#&_G.-^RDQ[E1((XPP9@VHYYC;K!A,]]Y.K:!
M_]!\:AKGQL*(?.[&_'AW&R*3\%1K,(E"E[MSF 5#<MHB;UZKR95\[42FO(*@
M:ROP\FW]@J\6EC04X*+_23.:787LHYWC]38]S^E9!=YV[Q8_\NEY@3<[\'W@
MIC+X8VX$^["(]/_JL/*_N3U2I!JFEEMGZWJ@Q;D5&"@8OY3&8&F\S=\D:ZU<
M7M+F&B?BF#I-0ZMB:?U\ \YZ<:1P:,#9&VTM%G*6R%(Y.5.N.R=ED6;RP;)$
M7,EMD)+.R-TY1DC!V7N!<NS""[AE33F:O:H5+$#VT[\L1 K%Q&\1 4^R'G1S
M[4UD^D68J"IK8?7/E-PKKLS5BU3(<0Z)%Y#VO4=1 OZ&W.R+^'P*3HLE6IA;
MDGMFS$P22F**_?R=$)H5BZM+'NG2:'9E#I_-M5ZC5V@.;W!J<W<XX.DH709&
M]HK4=0N[9GCU$@@LSX\M>!(K- TS;_#< O9GW)+*T:!8^:IW8L(%->SV%'*>
MWWD,\AY<PZ'HEZ;KD:-4K75P(8X#V^2ICC-O2\XMFHVGI]E$<O_V;O][K+#9
M\3</(WNL'&41*&W?3Q+)Y%%X+8,H"GU4>$8M.S4Q1*SY]3<6L]MY-I'LN[RO
M)GP:=!$\*A#:&1\]I+2H$ :V9L6WH)7Y/'6/.N"0*@6P3NB?Y W\]UU"_RU3
MX_]K BF!QT?LCX7MBH1B^/O[U _$AU7T*YL\N.VT'@H'/LTZ3X,A*HK5SA*J
M9T<J9)4%+6@4.*?15P5W[O]]_2JW51Z]*S8*Q3^UDVH':/KA*;G7@7&5?S>)
MF9,XIV^0&6TXK2P&/,(&@"Q>$Y\QW7#U"="E)9S%DT6P0O@._Y:A9?_7_K;A
M;1J"\9<"Z@/.P=%I,<UXJ3]>RWW[??R-2?-Y_V[,Z;T-#"-2H'JM[;Z><FIS
M2N-(C98HZP K\:.-)X"]>S29*.@:[6L]1&^9<=&>U^%(L>MC]V2S>N%C9GWZ
M1%3'B"1>#S1EC;/HJ^E,@EZ=]U<%*S7%,"LX2V/)JE9=,"H+?]_H"?]+EQ8M
M^!6*$W8>*VPUA[O!%M=+5 #P^CL8^T-/LBJX_Q,K^J>NHKY$'1-&-0CF!(KM
M]A_R>+< ]TVFN"E8]NR^2!(L DK+Y4OB[?W8:CIGBO)70D)4 ,^"1$O9-R1V
M-R=8 9DQ$E=T0>BKYI%#6/=*_U.-/.S<$DN\^@TEU6@W/0TTW5'?@\J7%]<R
MG+G)&MU!E4(IA(7B/]!<3QWMSJ+HMZ1YZG'_Y$.H-3Q&L2'_1(N?B_?]]W;T
M_NS./V<\AH:S"FVSG((V6PSJN?,R4SVCE>U)A]K%J*&C[GC1X8M<2RV?;TZT
MGI#R;\UN.P/#[<Z[VG%YH\ZTS3Z#S]K/4"RS(&'NKW9\:7,F,X=O!8:Z%Y8Z
M'S,1#BQU^8OLBY&..HI/3W?:IK[5>LOR?6P;:W\15B4FVCGAK*@RBJ$NZ2)G
MFWQO"0+;)=?NXON2NJ(DH/RDH- %NX/3^%]_-=Y]^U]>^OD_R?[KTF>(V!!_
M@N;G\"P\E>)]$95Y.\P2GY_EO+E*HBD67KN[^%_3TD(-GR!&RNB*\JWI+9JC
M=;14:H8N'GQ"C,BKV !V[;/C]WJ]/0J.#=^R,F.).B\W5_=(/O8!YG@8'EU8
MPYX:/IA[VN\M8)840QXP.Z+L!:J T<.E;JK6"8C>TO.]XIGBDO_,@D.$QAE[
M-!IR&C+FPU-D'9EUZ@'4$W>.\=?]U].YV1[/KJ?VPE\:#4;#S=U9J*5H4I.6
M3.7<A#0I6>;K%4<CEK'J:^JA]L2=H>_F>3^H^310[-8&O#YPN04$G6D]T:-L
M?BX<?O^'1?)2QN\C!7$E$*(%%FR+85,P7@,K<5F9_[(VA \P,V)C/Y2!6-!6
M:[O1(_(X.1CJDI5$MK3'V(>0BC^H::JN8)J(OT3../N^\A,P=6H)?/-TY,BR
M"N4M=%ST::<C:L@FDO\[@ .$%RD?XVJ.#$XE"O(1)RPHZWARK30TJQFN\DQA
M??985A])WQ-)3W 1;TMH2Z354!^.%5H7K6/P;D]X1-0/^-NZC:2\!@*T:2RG
M(X-%Z7Z7_Z'4>*1#:AKC18PNQOHYCE:"RS9&*B-'0U>A$;N!LJY8X9^XY_3-
M#L_Z(6\@SYLN(EFB_$9SK%MIIBNV&C-?32Y) YD^MB=\4Q$#5?S3)IA4^O?H
MTLY46)->?:[J*5X@&:?$'EA%R9WQCZGJJI6QJ:O'[*A%Q%>+9>0C7:+/Y!"1
M/\(7MOCV-[9A$DE+'GHR]1,<9MZ7>6D?&VQ/FDWQ6B-:V[500-C7OH$:85(-
MD)Z144LUFPL3MLL=9G*@_E^^/_]/L_\>J46V?"_S=-W\^7CIAQOCY4Z*]?$:
M+A0CV&M:._] @["*.RH5).@OG%5^3>D2D/7"X6N;Z>(]O]YUS+H\B/EQ^,?
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M6A10I(E2E181 14102'TJ"!5I$DO41%!!"(@(%U%I 02Z9TH'120&J7W%EJ
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MRY_]J*T3)NO65P_8NOHOY"#2)5P[ V30^UZ2[Q4I9 T9NJMA]#Y*87K>[\F
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MJFHY"DF'5M23WY)O>RL1ASX\$\DG(6.-9ATK#GL*N4Y'Y&$:P&O'VH0&,3A
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M%I;1OB14(9^]T/K8N'?/G&5\)K&R+K%X_-M<_T:2E]N'V">L;[V.N'DSR\]
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M9*BPA6<4PVT#8TF-BJ-:+W_6IB0FG4,!CJ/O,4(F0YJA6/E5Q7HXZ43%,C4
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MSD3",^I'<TW/C1$\CF?K$>9,XT+$>[\"4P!TUJH O[.F@^YC&WPS*<'+<!P
M.;-:-3W_1-0'5IP;S*;(R5\C0])_J<I,P9CIH+YYV%*>;YZ6%VT+$C_ILS:(
MNP\G[=*$SC_YG9?[!\ B4HLA#P&?-8GS-T'!F^' _:*S(>O"%C,?Z2#2;@<8
MH06>XN([0PD!,(@<P^ /PXS?>?X$X!_F\20LSB>-\BQC%J/Q*?7S/[+M-GQ:
MG?0>?")#F(>\X5Z%-^B1Q'@QU/O@9FC?7UZZA&Q-TD%UY'0V[5K1.@Z2P%&
M-.A1D$..M36'X,US'%0W^)0ESH*B0=NHYIGWZ1[\?]5/B(SZR=RU[S'JO8*:
M&W$-B'"Q:*HO8L:<)Q@^Z= -QU5@_? S-&T)V/?:GS0+8U_Q]]H?NK< 0^*J
MHT@35,@83K7(?^QY9-Y/.7[GCYY'B3_3ZAP\#& )*O>=R4 0:JUF: # ^-,F
M/^/\V58J?R35YS[I$5>#:.7H5?3+?^3>I4_A4R,=ZRJM3THB&,R #N+%2<1T
M8@#>,&%QQ_^@+#%TL=8?"(K0HSW>,XO HA^1XJ/5P!@.MUVO!F.Z.0+<QCE3
M1:H_!I#).](" HO)"#9@I 6"Z#5;;N=PLO,_4.KF;H _\SDRQ#*)!=L%8727
MUDCO+ZJQE8)$"'APZ5ONQP7_F50_M(3CTVB7&D:H'@@2]O4+.@@#V-(!2G-:
M;4>\XY](]4P.F>?#R.HQ>SBAB9Q(90)8Y= $CBS[.;5)]__1!1;H%S$D8*SZ
M$N !M9Z'+.6 V90&J#T:2C/$]P8\F] C'2 @R 3X%$P .LLO0&&I0:Z>/<V7
M/J &2/OF+$#)#2$K4#QC>I0PP/8M^BMSUF0AFZVIF6RERGZ_MV_U&(W@%P%?
MS$#'Q,WD"SSZ@UB_S5J"3/3#-CE6WRB'$]$ ^7R>,?.;_[WU!V_UQW<ZMA&D
M22R6<*P7'?0EPE<;<)[J[("#&),V !&EXZ<1)_T$LW\2Z^8?]8! UPCB_G><
M$W?F ;^O^\)"XAN'4%Y8>-%J$*O<A#;_"#R8=ODDX/XP;1(+>0E@&;[9-' O
M/Q$1S MFP4S>@Q ^X@8<ZVNXX<V#<%P0M@1KNP]>XQ\UT^&>L;))\6FA41W[
MM']D[X$EI!CYWH<\>11V(E?W/(-0 F,,@ZWJ$M+($U1-3^Z_,.N3OS#KX]@J
MBB(P[R>QU&F:QVCO,@3039,Z )_UP:0$(NIA2TCLNBT ;S6_Y-I_)=9K5<[?
ME%P"M($U_. 9_".O>FQ+'5CFD@C:%N V*UO.Q*T0*H'FL00&!*.?W<@R9A7-
MP:CUE,%'8#.P;)<9RK.C:Y1O=683MMUQ&#P ">ZP*=.*WWK 6O_.KK'U4**U
MNP&QLX_1Y"A8]K,EN^F[%74SK"B3YK$AY>\!6)& /(),AL_ K#Z.-"%G,;)I
M^PN4]!ZGK9X:@F,Y<):?+.578FA:?&CR&-7QF^/=+2J!+-R1.J/_HVVL8/UW
MO@QMQ-)$$ :([PG3J%??(\@?Q#CPO0H@AX2T *YNF6=Q2&\S+!"YQE5BVQ2[
MB &6U0 "F&L]<B 06-:W /Q#YP;5:3-KC-@Q_8\9ZW;72F'_O_:8J2 F-BEA
M9&>J?QIU5XT/^G4-!-Z,9@!<"R/%-I-(U0@&5M ,#"4E&])DY_)$:><V8(2/
MD/7]9KR_]X;EKZ>1F+[!L3L8";*[]K!5SB#J/'%0>X"4_)R(S?X*#&XT]<//
M.?T3*>ZKN4P$XOLQ,.#'*.#ST+X5^-;@#WA_!OZ%%Z/W$DT ?$Z$8_= 8OTB
M//',6R,M@9DIJNV(']38>/AG5OH?1.)K('9A #?'YJ:1]R )&N; TGZ/92:0
M=4Y3 YI(P+74IH;8/S%C0?0M(B"[CB@ODY<@L8'(5#JH7*<W$#!AA.8?>SYX
M+#)"*-[JM%$@D&%8%/Z#3JW_Q"G9)[)F9$)%3NV4651FXF?;:/-Q#I/T-QM#
M1BB;E. UAQ;;&B9=+[VK0!RK$SQ_8A;TBL/H3=0E<58V?C>Q7TY7UZOE124X
MC_6&.6Y=G.115(Z:OJ:]/#F_!U50E=H]ZAGBBX56?+*07VSKZ3X5YI;S^NWM
M5U8#7-N^S*YY^XXT#A^IT(E04O H'3@2M2O0J'UO8*SGVK7W5?B:!W&EGFO-
M^>9Q^R_FGNNO=C7OH)R [2(T;-)V%)NNT$&U><JU:K(%O>LVR;5'XL3Z['6L
MCC@)0R) OO+_$\>0N]-.K62@P^4T,@<OKRA=+/BH O<58SXO\2K'-"6\/S@S
M:F^ZQ^U++7$#-JNJ:G?N!O)_88XAC@^8]Q$$F#]>=W@/&U*9<[W?MS%LV?Q\
MQC_!9C+M"C3_S>Y._<#Y<):6+Q39=T3_*QNNE8/M7GH>R@G'7I +!>%[8_//
M\=L@1R7R]&Z45>OQ>B>VV034#O<O2+ING1CX@-)K4F,J[ZKB1,(@X54ZON\_
M7"JMJ&3G2G[XA,^'&T?X[YZW^Y=4MOR?,]V- %P*BUNB5VT\ G?YTS#> 8YS
M;<HT=<\T0@/@N;#3?]\\\LU5NDYOABSHI&'V8U<K[OF/+2-$?N?&ZKV?13]T
M)/\S7QZA^ +.5-M-J]9>0S$QJEQR]AC"D.-Z+IJF>8H.8J5><:!<(:O]9W*1
M#-/-U0.87 I DK ,HC3PYY<CK!1O0*P:?"6.5R/'M"EA77"LNZ7$+Z2Z1Y8.
MVE2<!P*JP-0/]EP6QLB4]4EO[@0"ZC>^FYN,3:L^,]XM\)X6VAPZC*!'8AT&
M?N%[< [(_L?VI]+1D;#23X2S^0(<6D0(K108B(=CKV-K#1!T\WHP0Z8$T_!E
MZ@9<NGEMIORO/4Y$,H9/U8'1X_2F4))8"*#/<UHZ$+4-X+-:E1U!P)OW]6!P
MT720TBBA@\0!Z'>"*.VQ8Q41 MP"NPZM7'H-W;<&(?'H= :&Q*LFX#SZ[#"K
M;(AYQQA4(:/?V1I^'98T 7EBR3DAQQ#J'!<D *(<EK9J( \GST*>HW/_^GJ,
M8Q. ^1""UB'$8[TGX%4E1H8IC02MP ;[ ZL6U04F3S*8:5\E,82ZZ/M;2L+;
MBZ8*! A_N'A_+HS!>8M&EA%39H9X[[3QPJ[?:OTW[_I/_3-M1FW^<SH;AOS1
M,>=# !27P']"<4'#:%_@^(ET.!9@>(N&XQB #7C/CA 88LN/86C"XC!(2T(?
M\?"8)QV$7^/9FB!AN^/2\%/,##X .SWP@SO"KIK"FUZ "6WPV #G W30)TS:
MK$\LNQ,?[;PK3;X/*IH.;[X*::QH)4K:XO<//"9N9[2H9^$[_L:;ES%_RV$3
M! %4C[)6A4VWBX\<7A]. \+)  R0L\U&-5&_M1I&90+SHX %!.TJ-_JW/B!_
M2V%[_W93.*\2@_8)8UG^TMI3O;T*T (02LPS#!D'7D-KB-%!@>D #8L":-C)
MO_3N=!BN2S_$3%[N CZ+(,B3F??3095- !-+4(U,'*&IW68LI](B+O1G%K_2
ME[+)5Z'TWN\4X)2/%TXQTH9"E@PJ@J8@)W*V>!K35H_AP 2&<*E10G\YHTSD
M#H!.NMU6U"[Q_[4E1[HVC<0-IE46>QE.V\"78U6O'K['<,GO)#HK[_?<-4Q4
MJN.V\DYM@/ ( C=9!H^]I#\(;RK"+(&G+G@=QEL"JN"H3L?O;GB1"-DLEGZ#
M39J'K7)5_:@[K2, '_(S($L%%B;!FVM@TFV"YANJ!C\V&$>A*AG"Q1IRF3+!
MMR)\1;3Q4P]#;;[B_G.*.O'/_'H03"-<IT!RSN+!+')J?U#HI[]FKU'M  WP
M)S%8GL[8,G$MADK&_K%I EA*8N[Z+)P=B%;&B=\Y 3!.+LQD$@X"B)NP!0D$
M$1B?R(C)]]6"VEC0-G4H.FO'X:QJNF@?(B!WA"S06VT4W$?D<" ?8"KQCK0U
MN!(5'(H9@J)G.P"8\X?C>.8ERO3*,)?')N@@8XR^16U  QDZXSU2<'_T+YTL
M*CJ,%C6$$Q]UDV8X!BS&)L<6CH(;A #B=*,3,P+(9[ 3@-,N=% -IAUC,-9!
M.J@Q0RI\4MK8D2D%GP!@ ="=Q?=_ZT&)!22@X'-@(N1IADB&H+\*>8T.1:\T
M3V?@TQF;+.K_V&3QE_SS@BD1!QB2DB.8L$X'M=<T!6$0T,Y 6S5AZ_MI>R"3
MMRJ &0'W5<=5.8Z)4L(5880Z,K:@[]OF%FZ=41U(/P>LJ!>%K2_CSBQX%<"B
MAXD]Z @TY9)@!GCLU<^C17(Y^.'-4;EP+-*(>M-[@G8APHI6;5IQ*FV9B\I(
MR'0@)/Z@T4^A)13&TEYD%%W0W65!U Z&,A-H\]H';ZJ"+W%,F:O^_!.6/.&I
M153]=@Q0NSZ#/^K./N _)YHU_/^:BB:',)J(2]30:V>0%-MNT[_W?%C-05:9
M"X#A[V%T+G_]_]A[\WBHO_]M?(K2AE22O2(JH4AEG38D2;),UJF0$))MK!.*
M["%$,<J^#B&[R4[*OF0W]MV,=3 S?J]1MM+O?M_?^_WYWO?O_OEC'H]&S)S7
M.<_S/-=YGNNZ3BVPFZ=8;,!F>*5/"1[#(N5)QBGYHL]7.]8GCQ->+MD(S#K4
M-.U,@HT?5IAX4PR8S^K WR,3 )P^E_DKU;\\+'887M:/F"F0[=/H^8WJ,=9-
M/8?R(<@*60=OJI7 PKRZ4^HV,+HV FG(L%,F2;8*+&T:G^"#'*D1^!L+'T2]
MW+A^V.T''IIJD9CMU:<AJE&(<29>MNB<:8.?)D!$ET#/ F+Q0"BSN*V Z42>
M%24$L*S9'3)PQ 4^!#8OER8VO?@"#=^#IS=.Q-VU+L-#D$-NLT.^9<F9NUF/
M#!P1F=+P^P#CZ!%OT,SS+<X[5J](Z]R,-'0L:CY2SBAY.\W^]U*UI5=1YQZ1
MP[ZXTIOU2(,9 Q'+LDCSQS^,_?; Z&>1DKF?%[7?-':85EM&0[[;SV8MQHSJ
M4S45G/;'MNH)54;%J9;D^W,U7=W-?)%6D7L)M)WC^87SV2Z&T^^$79J>U!9X
MC@S>(&_( GWY,K2.JY"/TY>J3U.7EVODF1F37A1-;.<^X_.,5O%VK=2PW7U8
MXF1.H5HRSB6,>]P/K2_,^%UH4A)FJ/6&W?]=Y;W]-\BU?'91)( >PIP,)+L#
MO/HQ)>^B971#=1T)%V!4(J735?";(S;\H;)=1OM;!Y/T+"!9,M,\6$G3UB#Z
M@^1="_OU!NQMCHKL1DND[VK*<@__;HKUSM*EOG_/?MY;;@B,\='3$+*]!JEA
M*)1Q^%&J0_1F<C8&GS-(R&=CYK_,G/"?O&3H7W;AS+&>=2"%*S"]2=O<:OT?
M^J6HQ[SS=-/ IMZ(L#/7W9$HH9 +[?TVC-\W3_A#,*#Y9TWZ4S?4"5$U+=+B
M]'E5.G!LM1:-N=3I8<7\5M8>(?@7D(S"S0 Y\674<MV1@K3=?KQ<>!Q2AN)=
M'Q#I%MXVX *G;5>KBLEQ*^P0S"4O-/]IUB))26"[Z6GU4[H40D)NPI"?A:_T
MC6_SZ'"8&>C;B&1LL36DP&N>%FAF8G^.TAJ.AD;K )M4HP9@[13^NH*8C6E;
M6^&E\=#Q/<#:^>G"BO09^Q<"R%WH#!\\2[\[5YYX=0[U\YP9:I2/HC4*&#9Y
M*,3B@8$3#".(PTVQ&U0"])V+HT0HJ2R5\(L+$LL QCL>CYO!SMA=L*HGD@,3
MY9$R]A&07XX1)(EYX22H;H&@ '[Y6 R\Z031+'\$,<E:#Q\9EB7L:K+$P(E7
M&0((SZ #T(1^^"1/P$<"-8\U?^,*][^)4_V1&ZG:1HQ$72R![\O9XGML\3VV
M^![_'^![]!!/P<LO-L*!W0SM#P@K5IHHE9="&JSHQ&_9A/$ 7$#_+>)AFW<:
M4YA.XO5LZ-R[^29'R/K:] *8!IZ%A-:$J,T*X=8)D0O7".'(2BQ*:RA_AAD8
MQ&TM*PLU+(!T@L+2<G%Q A]7" S&..M<TWQ3AAVP%QT+@^<!&Z(<L5:B&'H)
M9 L/MHLH1$R><:Z:TJ$T\D#<5@%VG$!J /:9>H.HR8->@_JGFXBBI ,L?7P<
MY)=H&4H#17M_E^Z15 :^^)45>J7F V4&XDA21I.8AYAO^I&&;0+BR!2(HR$@
MG&V]*. LR(_X2AN)LB&Q _"R0C.@.\ )UMRPI@+9^2.&J!'G&:1V0LK$7-,@
MB78GL4K5J*@&]P+9B$P@!LH(Q?F(W@0O,PLD[)=7$Y9+0)>QD0K@2@D+:PP.
MTP?@CE,+R&]WFQ$L&P#S :0!:62/ ^&2. :-,J981)#V8<)!X\ 6R0NV!&IC
M_9IAM>X-2K!DU -C_>DFZ50S8^4$>Q+LU3G)-82:F81/,\SWYSGA","'D@Z)
MH9RD<ZL0_1DJ$J_RB2VTWQB"JXI,W:0&75H+[Z76!OKA((G-N6(QU&/,:M3_
M[%J/1A1I=CI8K];4?F-,CZALI'.HYB^!)DQ^Y?P]9VS. %__'3SR O$UMR1'
M> .?H[6(=0)^8B'$=$X(3*J0Q*,F&K]KPE:Y'-U8UF*=J)\9_Z<!T>F-H!G9
M0&E"% ?6N%PMX(%D=*5QWC-7K5D/0Y+P0+"\9IXC6+!^S;%:3^E82+0F]O$J
MS@,!+7KX3PDQL,#A3[928/F*@:V*<<>_=</#1]?B!A'NR!$ZA%ZV/IJC&I6!
M"J+]L@329J(N/01JO]"M+ ))+)@2%C_0:OGXGM^M.!VRSX]KQSE\BQ:F>;E2
MY010_B]==K^=?"JLU<0?B>.4]"U6Z3VS$%+FWVDH(/S<4JGR-AY1DH;GBE0=
M8CF&I8V(>5_$TNX<+/RU^=P2R+(<G  R,_T/WH*Q)6']/U7"6B)-C)2=D[&!
MQ,++-.:(V2CB"_TQJ4V+N:B=>,4\:,SW5X-6%X%)/),5L!BG$:>AN I#ZW7@
M$RGS=J0%*%V25"12M%LUTREMP#6/R./V \ P4*<XZ.\D!XJ_4B/LT@.!_L[2
M<)L&%M4JU=5JK5KPBAP5WTF/Y\,@Z $$#WEK=0S*B5< HLZ;5/&^@G]I^^#W
M'^CL@N?)XL&Q9XMLCF^LU.9PH9WQGJ1R#">0B=(ZB\ 3^C7+IV1NP*9A[.)B
MS[Q2PT/<6@T7Z58$0-L0/^KE@@F9Y@"O%WA2$%BH2!Y/^3 (42*!Y/%D@6*!
M]SY+^\F?<< @\1XJ)/X,015 HMZWP,!N1KXJ#LL_./RG&+3+F+7@T3HQ: YD
MN?S$S$C,0DTB]7[#HJWH3F *S!-O5:9_J=J[.<R<]UPM6BX\JR.*A/Y<0$=@
M 41U_!+HVK=H_<>=P/**3?R4*;I2Q,W7!)K0QOF%9)[#+.D)K->3VP' VT=B
M*F'8%T=FD+:DAO3N"(,W59!F<Y?47-,(-!I3A7<[-KP$NF"L!*PST\"P[FP!
M>N<0\6K:M!=) A#O\0<D[<8R2O<_J\/5D%QST"P9$ 0>R* ^QD \JFL2S0;_
MA*/TLHLSK%C>;R[X,_/F>2\Q%_$N*E"",3$RS^HW-%I]R8O0(;;,235M7*UK
M&ZF)KR'1@8SVF@;'9F!"JG$^>+F!^/ C;R,OPLX^O_-+W#"*S9<F2S1E'?<!
M;;>.%8'D!S"X3<SPTPJ33465@B11Y6EA+]QL *$0'WMS'19ERZARW93WD-.Y
M&4=BYGTK47QRWHY$]QSV6U%">JP T8$CG?8,JYI($-([#\#BY>)-\)%!(.5!
MU9K*.FF ?OTX@IJ9AK]&)I+J7K$(-$&NZA5.[@,FCBC1 _0B2^[G'&DT!.]1
M2LP0M38P!U#*0#F+S9P0=*5FJP6S)HH ,\HN;>3/Q?JW>NT#-7@Q[SS'0A4P
M7!^S^2;FLJ#=T$!^G/*DP3HNL0;E>C ZB!<G#N?")8!<-[*^7DO-NE"\X#I^
M<)RW%B5<0O"-HJ@W T:1XO&OX_-MW=#-. \:Z,T9$@L!5/"R3ZS@[^\%\B[8
M"FY2J8V/@^*FG4GLH@1U.F"F$"AMQ.%.D@*\'LS:0%8_-K)"PMBQ@?OPL.DW
M:H0(,]XJSVU*$,O(%KZ!*=P#75_(_5R%ZH1^%)D?-V.@P#NBNAZE<?&N%G%M
M#.#=-V9.+H%(E?)?MMAK]=KT$;)2UDEV?=:9X8::%TL@6-0PZIST(QM+C59@
M7,792&&;<W.-0FP77,0Z#C\/]/"X?H8C413HYJ?PT^B1M7_C!Q@_7<P?+R<=
MEE5VK9@ E1%_HT L,&[D2-1?@A+%DV?@@<70'K&@33$F*^D,532 \%260*Y4
MXD=:C<$=2(\B6U1@.;6'53#);6#WZ&J-Z_=JK7XOTJ5S4FX&M3!!V&%K!.PW
M<JM^9ON3R1NJM9B)EXA)P2C"4]]Y2$:3T7YX+CY@F?&&7ZO8KAI? ID>3AL2
M_#/1'UP^9XUE&,"[+7@1K(!'#0U";>011_!V2S;L'K517E^JQ0[/LKX 3Y(!
M^YS$GGG(<.;$XIM<2#_0RYLJ[CH9,6%/_@W%W>]UO,QPK(*0>0J/+U**.;RR
M+X'#R%^P+@F __L'Q4W3$/&#5CJOSL\E-SSISDHW0AM7+SC^J"9/BG!0J[+8
M*][?MF.*&2K\V9V*D**\X)D<"K,>$_)H;\^AOM!Y=J+BAL)]D/![X^*G :S;
M4QU/+>[,C&N^*KL0_OZUJ//-=DQG 7P?SGS,R"8&.1'@%X+%%T3],#VTK?;Q
MQ?06/_O<G/1%OF_%H2^=F#7'LMMF2O4:_H4;QOYZ9]*68&Y+,+=>,.<F\!?N
M0"+U_POC@& $K._>IKET@Y8FS2'IJV713*$5LNY\'C].&RW&?Q7 <&>GK^;)
MXF*60"?8(,!#.,[O62CX_0>5^P' \$OM<'UC210&V<#:1;V"=S1]7#YQHEOC
MYA:O%4NA="Y$+M'3/P4/.TLKH9LBT0D[$6!%Z]/_24W9@8;.,Z0N4[D_KU"Y
MHQ"DC4S#/]C(P)#+-1ZABP0S>)]&@P;7\NKJZ0%$'G0>DEZ( N;!%#XPV,@^
MA&ZUZ&<K",P#ECMPTNHZQ;P"QJ;[HO"65Y:%.Y!&+"\^>Y[H''BG<86=^\SJ
M5Y44Z5 "?'^&['-@5O<*>3%M D4U%DG-*-L+ &5D &D^?_&=0#:BY-"(^</7
M&HA/NA.P")FA/^U#E!G@>$<#.+!;/*:R(+F\12SNOA#PK2\*&Y8(!$V!Z%,D
M&%<%I)'N"6)6*7ZDFJN*",1#^:5LX'.2@?"8YD/,#8,!4',0 #5CMGN[C.8/
MI*(6>@@R-C/0JSA&XO4$7F(&L 6 AAJS+N;8 KC&]\??+$*JC+/#XBA2@.F8
M<;MP[T8>0;+-1IX!@<P190]IL)/D8#.UUEFC$FRP_=!XI$.<EZ]'^P\8K2)2
M5V!6 @CGJ4+:Y+.V6;8D!0M6[!COHO.\@A]S*=Y:FH@F*D@:(V@W9Q!8YFW*
M-Q@13,>[]4WB:_JJ-!NX$FO!O?34M9D,(ZE>\SNO32,KSZ&VGR^P>9*[O(G;
M!F6S ?:2/F[ #KNIAG@U+_-WL*I.*B@I@@L7PA TF+!K:W@4%E" G&?T(CRU
MFFT9[::>J_(! )-IWFI!M&R%M0N,(]BUZO9ZQ?W&8FC!1NJN=N>$*:H(Q:>#
M2>EMF4,X ;%R MC+Y'16YC#D#J!1>!=SU,3%*60-SHW08$5T!W)=T^8&&786
M'HN<MZFCAX%1I*I>@4Y%J$T9!+F%F_(-9GB82,08,?B[2_HV3Q:>_5D)55;Z
MG;R+<UT"[?/4@S(L&UY<6S6\V+.12%#\.]$ )HR;L:7K-^F^("FUGIU;DK>^
M5FJ @.>AKEM.M6TJ:6O9DK3]_UO21H-)7"R9)1X*/D_)*)W]:=&T]%MFUKF\
M<;ZS%+?]AE1HET">40V:7FHUY^-4MR?DJ>I_MJ!@ND\S<IE9H*_>_(*)N@R"
MY\29'R,:EK'X:UB.%RZQ>B$'SP[>ZCI?(384)E\3: T)_Q07HW3GJY4#'Y</
MMHT[80B.<5>EK!MF/Q-%M+Q*I>P5%1I*%=G2+9Q]+_&!0<U-^^H%![[3*DZ5
M+<)<)[D?'O$\TBBPL,TU:%W1,=IH?[GV4WM\;DU2)R*[5 54EHV-<GIBR- Q
MHO;)5>N2EJ[$E>@S.6:A>D$SG[TB.XLMC<\;'3O[^>J.4FBB?I4-(]K+V7LP
MY/;G\W'!2H+JAH]"GMYRYMQ'947C.GC>@^M+%MSK? FF*]5S/F%@G_\3^IOW
MG[5AQRZS>/P;%H=_>VW)TK9D:5NRM"U9VI8L;4N6MB5+VY*E;<G2_CMD:7$Q
MHJ-6IA-1UYB:[&7?^(@U<+=RUN9,%MN=_.&"6&0LK&W[9L(^8;[H%3I4;06)
MK+E\:#H\3X:GW8Q3,O?'OF\("PL;:\6OZZJX0<-(1K;GBO;D+-W!BA,^4N<7
MW[@1-*_GGQMQ= 5ARVRX,;XW,W,<%5!)(;UMV?A:UG8'NPDF8PC^F$[7KCQV
M8/KM"O?>^VJTE[LW6<O[]C8*T5W$-+_(H0Z*K)H>:P,&+@]Y22Z.!/+&WK(O
MV&."BVV37-#\(-1+=EPP=]2+,V-!E?JL?+H?G!^[Y _R"7OF36\;4=AB$VRQ
M";;8!%ML@BTVP1:;8(M-L,4FV&(3_-_/)@@\'T=^X-; ;@9_S5'!J'J+_0G%
MJ4G@=N\]K!^.A%*1Y8><KL=+=<N(Z]0<JYL>2K 9.14(MWSZ87;<T,KZOJ+7
M'KT66X2[@.R^BHCF>\,UT8COJ5X/VTK@;LQ79N@%/"QC80$%*D6W\FAR&HZG
M)RTR'6B^I/V:8H?4D:^8L[#H/&:<9E% G@ *6^IJ4.SWO>@1E_6MR6A;VYVB
MEJ'4RG]2;O^]U_\U%UB"-[N7$E@A-JVN$KC68 ;#7^^K_*U(]O.^RA+624Z2
M!HA4&?L\LN%M.O!Q+"RDO;#8I?754]>F-!L@"WFKR"Z,Z\_L6P(1OB^$5824
M6J[<HYUX?*6H"GVO:2[Q0[29FR0G[>#;3$:EMQE0Q5WL3I@DW'XB>:UFG17!
M)'*-3! &S&!;1,4D*5=F_1157?N%3?/$D"55*H@OI,)*A=B9)G OF+0;K4<L
MT"1. 2L>_H4 [T(OJC)#].^VNC,Y543QVFGHA[ZJ1U;M?URRTM2/JT('O,!]
M)QTN%=;LF0=W1^'?>$")6=2]7"._O;UTC3 )!]98)S;TP0WH$PU=I[-*)!Y;
M EEKN,V(#(V;:JQ34]&M 5,;#4Y<_'3T3^$U(ZN@C24P#%^;EO5W>PM0DP++
M\KO<S>NKP\V_U'<AME 7A.0J_F18TU=!R5X1#_)]P%\W-943APW$TFZT(%#<
M2"/H!&(,"/^JR4=F>3MAZIL1!+YMZE.@6H2:G!A88-&^IKJJI"H?_(5(\_;2
MXZ^;H\6 Z<SU>EC$9+/+1ZPG-JFN$B2=X+W*U)#Y%-?T$MN+?SH0;'83"93N
M50N4WQ]1XID%H.]=,P4;30@N_\8C^ KO!$+)Q4Y+%JU3D;;!@V"J83V-P,Z^
M"#Z.G2'0]\MJ1JXS(>CF7N,0H$1+QCWC5^X6X66 EP60)-T 0L$-YQ5CH_ N
M5J4D*@_2,VZ:BHJX ZHXS_36HV8,L0?>JP!?&&]HA^S%1!'%)4G*%/4&RT#$
M8I^LO)-J,# -K<6)73%ZJW<TEE>8_/#,7W4@N+O*'I!C+K&!Q,#+[D[]G'FU
M8M2$,>G!M/Z% /Q+7O#/TXY<-F#6=-3GN4'C^SLG>0,J2-4O+X55_X%>_5_4
M =2E$ORNNMW83S/+EP_M^*UFVI\G@0,R[PDZ8!E'A@'[- O2TJU 4J!XVD@6
M>%"_A$Y>9%WHFAE+ZX:N55137H$[Q6Y,#636XE91)]N*K&J3D]8->'.#LJHY
M )Y;2RJ$ER,*JGSUUWL/8/0VT =0DMV\<XHC"_Q 7H.N@<X,V#IEU7S'Q='@
M2V)AT1]=NX2O_EIYJ0_\S1)WCGHS!]WZ#!.B^.MYXA-T C9EJ.)WM*G]I\"J
MFPO/)QAC\WB$=)TXM=HJ<:X'"430$!!!=<"7+1[.$P(BR#.HE& +GD(F=TWT
M-$Q# ZM>-3-SKI-/_6:"^]F6N$"@&:@RB5Z54"E;K0#1'GW2-1<Q&ZZY6(.<
MJ/7"JD1WSL5BL.*\JRI_S]?93F!83[$"\=JMN%91G28IIDSF2>N&B7H1*W:"
M==%Q'D*]]L^!2^W>>?_[+Z38 #7U?U=4P<"$\5^I7=QK/=9TWJ"FRH8Y$B9Z
M4?*5(0.2*W SWFA52+6)G\8=8-6"UL-'&@$8T;"PH:*:< I^0"Q:5K/[ZP:H
MZ;5!2H52K(*W10RC2/'[L4GW 9"U]\,SN-S6:JG]N,Z7C/>)'/> /%LIO.RU
M',B[ &1-T[HAGR50+'Q.!F29_@4UOQ_X69+[$FB1VTK;$O';#T! B\V)O-6)
M.5<(+W<L2$6/ZDSZ2:&MIMSM4K=E;C!X(@\1P[U$?S<<*4Q^?/@N==JW1@^;
M6S*GS[L7ZM/=:;>&Y#6H$H0J%%/U51=O&(8:)G^S=QZYS**X!-IM42*[0),Z
ML0ALWEKUH)0C'8+U1/:AUS"DN+-TNK1R"ZTSN_ #$]_,S-E$M[M)8GM3]=LO
M%LDU*W-R5"B^+J>H80H>FD^:C81Q=5-Y]\1].IX<R!M?^%">YO$7D0,^FA_F
M\L7>;&O_-^YU_^M][R>PUXA2D;E+((W.Q;.)GS-Y75DG900F%F:70,TO06H8
M3OPK%3J"I21IA;NF-K?!/.M/BNQ&?;_3GPX 9>!>;>D&XJU*Y)<JQ!\G^?T"
M?Q9.%WE.X'1)M:'OT?HKA_K/&'X53*%D'KBF#\TO</13B,W9JT"&W_0>=3]@
M;U<6R8J&QWB0,$?C/\ <RV5EEQ[J^8-I<%)11M5L_1LTW(N:E%=8F2#K0&BQ
M_AK%=<$)3NPGR/55:>:L45EI5J ILO)<-ML3EE%_TNG,!/VFIEAIP!9,GG,Q
M,H^K =S+:[VB*)[%,V*5YNVB+K!]&.Q<.]&WA*S53.6"ET!Y57WSI%I)^T^3
MK ]AI*/WTR@H*Z1')T&VB[1,:2,.ZV\NZU=C^;L5P$*'#H# AZQXJR<'4D0-
ML[[3 5] D'FVZIHU9:.#J5B]^>^E#0(K3[PI@03:3S%)._/[^_?'B/-@##&Z
MD ;C@BDD2MZ CP#)\O2<"@:YP3@+OA]8HY'BR]I/WG7N6&Y (IM]1\#BX_3R
M> _BE:P4?AYE4GJ]S]N<N-J!WQ2NSCQ9L523%2,QG^/^ ?-YXX%^[,:2J9$S
M' C_@7E^H4XR$9Y-2Z']PIN<^B=T0^<MI@C4?!\25NRQ>J>-YG>7XIJ4H3O<
MB<>%GR* Z4Q;9L8BN!EQ-7=N,ZQJ%U8(GCSC'(=O+E;M$7NWR6'^I_-_%DV1
M;D4&O($5LCV2ZL "^,(*O>%$/_3W@JDV>*(>7H3BX\2D]+6L/]"?'UY?+$5=
M[@;/P1:([E.<R77K3O2-#Z\52J$A/1:22M2/@'GX--B);J.T_R%NO?!_@8("
MOAT9B_>\)3$X6[6F[7^Y7O2?\ZV*,!D54\A=V;%*8:7]!5#U>_LR1R7OKY[H
MQZS62*,]>\2X-A7T3]EN)OYO-#&:IZOH6\83L9#?+YX#MJ%VY+HO<,U6RV3O
M[;_C4)/?J:W9P$!VQ,*=9R3%V- 2SFOL52SO&D9M+F*=0+!;3K4-V:S>#^>]
MXI:U234I$=P=@/>UU2$1B^747VZTS*I =0S!@8U%%5JG/&W#<3Y,8,,%#EBZ
MQ5A@7P'D-^3:G0UJ(FMV6?@)QMG;[UGEZH$!9/ZP0K5TV5S.;^V\J?A_6$V0
M9%%ALP2Z\+01USS=]^=E#9\2?O?-PM(2Z9GJ\\Z;O=EP<3;M1EV_VT;5/\8"
M.[S ^VV@Z(FG[SI+K"8/&W8@63B-$#/@*K,JK6) :^U> 7N ^L<KOECQN2OW
MEV.!CG)AJP];]G#2>KS\I?8]7O,'!+P69O0ZU]RR(!('"=T(DBHB$-NW1E[%
MGE[#J L6^^&9RX3HS,1N:MR<%R$?'^>\]L^I]X9EG139[,N'; XKH)_M#S7_
MH-$&O3_J#AH^?[BT@:A#"W=?T-^L_AEON\F9?]Y%FEFB#KN8P,_KR#F35GMU
M$E(T,7]RH9-@073(2_O-+BN'E3CW*[E_+"VHFF<"EGXI?%R;?F'>.J<L]9PK
MQ+G)92N7L)4[SQHOKIAD;4)064]:U2.LQZB-;U NK J<R5AM:^H"UOEMG? F
M8WQ<:=QZBRQH[ !J_.X,-!#HW!K]5>)J\1H\G;(Q*O!(@A\\0Z(),R_[1/S2
M\NM._]3V/Q?A14.+H%0PG0+?H87W<Z>,9X?"B\Q];IPU]E2@:<GENHKS1:-H
MAI.'L@R*Z]IOQ']E3_4Y]YS/4GM[DMCOVG^D4/WE)=#+J8_OS6JCB ]S#^=$
MR3>9]N'Z(BIU"$6'^5K+>>K2M!Z>#>]) %FE'2+S]NY8?Q6:R!6LKT*]0';"
MWL(+C9]ER!/VI2^XQ\9&2)';OS<'!@*2WGC!#VW+>?,S3#/%0<)'E\.2W46:
M7_BPX*6Y4O1E%ND(G&K!Q0#]&%QKR>S"V!ST5*)#0<@7*]MS&F[AN+A"3=4D
MS(!S2(F"SREV[=3[AX^&:MJ/! TN@3Y-3\QC@)A'<1%I[^ L;C.T1R90YMQI
M4V7W=F1Z8,&EZ>@5 =+_3X'9+4"[!6BW .T6H-T"M%N =@O0;@':+4#[OP9H
M6[N@^%? CWY(P G^N7PY51O?_\F1_.]X;= ?T38V;<![H7M#?A,@Z8=L1'Q_
MNI[^<7:>U+3Q=)V> N\>8X4J#VP 4-G"'[)[FY(_3/^UBU"48,2@91JEP2_]
M?>*U5:O_+F,4P[3P6029F,E?W$CAFS,^D;4K>I-S),+>PO^8L$<*I&018,B/
MFR-_ZGP--[ZUX<6B260<S1[7=7Q.6,(ZQU+4G:HE4%MGK$CFJ(7?BC=I]QK-
M<[[DHI:!8[M/#4D_V?,7/!>^J52IT]'N="=O?7^1J2CCF@ ?>7K-[U^/'S77
MC$>1R/.JO]"=POEE==)(SS#^R4P,?A< T[^E='__^X&YXU^/V5&JWX ^5^<5
M7V!1F]5)6!4C)=Y>07QV1NY$>IBL>_4R:VT_TI=X&EY^@Z3G"@66KJ3?WJ>\
M '=R$ED;CCP4HQ%;)T32H-V ^B:Z6>?2!I?/7,37D%VRS9I$"5+<#5^]WML^
M>2I@<S_2[,Y-&9]V":M;@0&2G:W9/["S_4UWG[;1\!\(-/<8&Y(;A6J7SLO-
MO/QM2C<5Y\_D2"^!>$B>% H"J;_PG5K(FD:I*QE1)&EXL N8V9E48:7@/RU)
M\XA_TCWK83I$\=<S\'>7XFQTZJQ^E]PW2FSB^X^%>41,">KB'X]$?W3%>*G]
MH;O_P_5_7Q1AP0L7T'^=>-@F>Z/T7A2RT?1_D$F2.,$*K0G1FA727Y7?)QY?
MY_<_U68X.)P_6N!Z,O%@4L&&(_11Z(8#=M3EKHDNQ1FH=_FK=I;F=<?H3U%K
MQ^N!@<#V1V'FDG8F:4HN>Y-^7.5WVKQ/%WTU2KNBOE<\L<[LGZ9-I]AJLQ-T
M#:--#ML7*@V ;#%O@R*Q\69N_I+?)TJL./U/N1M]\3B+8.1=]O)]#OF-Q*G_
MFV7I4_AB@RRP5@X4V9RL7N]*JG%B'<,S^Y(C8:J7Y+_!NR))^B2R"OLV<47?
M*$=*V@C^ BT6VWFQO-\"\6?F+ZQ7WN_<X/<_;7<<R#BD^V<S_W[_;'"/77G=
M_U'WSVXX2M??>-#.0D44A8K/O\=Y>-=N@'A8Y#JMDJI.YP2RAK2-]E@!>0$K
M.J6\"R@LN]4;^#(N\5C^QO62)-69->@W6 #/D2?Y7:>(B:SW)=4XL8[EB;K=
M33T')OG=6@BT ?F&!>CH#+#?TYEU;^Q,/)H9N^:TWI"NC'FZPI[MA6\\3K>E
MW'C</LP$; ./_UA ?>M&8A$RNILY^GMMIM&'E'2+=7[K=2[)O0WT*I)\=I6H
M^(<N*6T##DPG[5L&?F;[0_<V")-@%NMQ8/HK< =1>ID\9;<J3BI9 8&;^$HH
M;C DA6ZD>M8&8-F&7\R*G=D@2X+-K,>",VISA*\:<5,D7V'N%5?2C*P5EJ>=
MD0=.[C-UM[8KL,/OR2'%\*E?Y^IBOP[:JRG>V0# PWL/?'$7L/Q_:HJ$!.(W
M_N _)SC?]$5;;B.=53^:L]?6.&)W3N\/K;,$[&%T#C*OK9I"5=SRNM&'CN_H
M$23H$R%1N2%Q'SF6&CN_!"($" YI(+><[;><[;><[;><[;><[;><[;><[;><
M[;><[?\W.]NGV%R)371&CQ#D2L3C*3G$'%VG<L&2 7=Q6ATG0W3!Z.-!.W.E
MOY>:7M=Z 17_4B)TAR).[I[8WB8OEYQCD<.CV\N-=_%M:\YBZ/@3FOTG7IE&
MKU1FJIQS. 7:0^7.^)2"O .X]IOON>?UI$G^3GN+*K1%6M^"W*3U:X26IWA;
MO.BN4&K.QASN)=">$?DZO!3:.E!)V.U5PL1HX!QWXY1'%]R:4\3N"%(CGHN:
M8E#%H(B_M>6&!O7,=NO 1_?@;9"'!S';TQ^3N3?8'<+QJS3P"'!?D[(T'&>U
M2>3I5R\=9-J&V].;8X:)R\_BM)\QD+Y=&\*8#;LHSMG2;Q!UU%3GZ,PXUX_?
MS$KO4)Q"\[YLX?F 9N:85!W3U@IJ8/87GE,D]RQ,2D#@%(2H">1FG?@CY:HA
MY,"<?T%]==X9;RG920@:M(B:"Y@*I=I+I*4"=CQ7F"V60#OYY(!G<P;V;*&>
M0%0[TG/E=B ZH)4>0X0^_" 9 (U?7@.00;4DL$[FN[^!%WRHA@^R 9NHKI*;
M$\N?%V8%MX0+@;I0Z#N#X&F:)CA&\P0K)MJ4=6'7" IWSB>[??FCEC_U^27>
M=0V4Q)]FIB Z"$T0]VDESBU_S,7-6JBHVNF@05]/<[=[3N5IU%$!K!%A%\.T
M[=K'OM?J'G\^B<+ID Z8JTJ ^6H/X*&BAFD<%[KH,LJHL8R)>GJ6Z)!+M_8E
M<7[*%>8\"I;#> ;,\-D'\(1>>/V56.BZYJF/3Q,GB:9&LA.\ W=:[_MYG<_!
MT:%5YZ_[MH]0?;E_. =8/S^0W>'\0KVK9'C()"[N5-GQP>U@;,L,]UK3$I2B
M_7RKSWB)L.[ "WJ1%I8J BI-4(P*9L7OAVK::2M 03LH7+=8,5^3"\Y!!4OR
M/]!Z"EW7?5Y_:=$-G1T;!^[DQJ'RZY@@_9K$\E]LR]\P<%HH"AO1\S*,PPQH
MI2-'AZG@P58[US[Y:C4UT'M.MA@+/%ZO$W< A9=1^8QC1+LIG*(=3XVU;$G/
MEAS<8:6T]A<J60WL\3_BO42 )IQ#5\T3&Y= &-'8!QCGRV1D=YJ %2/:K<EZ
M^?D828_::/!Y-_O_S%->9F-M80#"1..3ZBP<8WU.TSA.ZSUB&EA3BIIBUI[3
M[&G,21N>?,UO"7GD.)4:%Z<IY5LS>RW3P:_CH)A($<$E$+BEDTB19L6R]@W7
M8DX)?^91>+H7 [\LWB) ^73;$DB.+NJO@6[_GFY=V(9M"%3(NF>LIO!' 9$A
MG))6$B_-Y&,HN00Z>+?59A<F(>SP<KM:+=+!/DV1ZUH?ER 7=X&+K0J,O@4S
M(<+34'AJ/6\Q:IPMG=XP0Q=+BYOKQ-Q:0[Y_SF?W_,=3>6C?A@GZJ,UF!\:O
M?NQ\NDJVL!FW10916PHIN_;KPV&"5SK.4/,Z=G&^&.L[(&X1S^8Y8KJ-<!CH
MD(*WF '\$D@?CF-I&+1>"UU!A??!K72G10AB5#B[LU>!)E=%AG8C_MZFX9W_
M* 8NL^A:8G@+TFM=.+,;F9]_X;;,GKFO1XXC0Q]I5^<Q,],6)%<'21*%-2+6
M19AKVO7XM_&;33N^FYTCCF)!CJ[3S&O3-"PPZ=,_RDWA_+^E1+^[<UW.3@*@
MC]U3RD]S+VKX _]CC[RQKN=+;O,,4I]A39ESS"_+:$!AV.%8 4N[O3!C!=[6
MF12O!;@1!BF^KE?ZE)ZUN_FQV"!VY@AY9!K-),%'CS9P_J4]T0;)$9K_.$M?
MMBR>R.?=-[PKSM@ZX9*\=QXNG?B"\N[R;(?_G.U@7-",S%K'I'KH%BN?4V8Q
M1>S(N?2*;FRAN51V>A884ZN5O.D 'C[:,*BZ%@?2O@^^_O/ ');8$ 0?LG"\
MZ.RR??Q0_2<O>IU0CUB]RY#7UO5F9%T6&;#!12-L (P*9D@GDB.!F05Y@#N!
MCCY.$S&;2FNUS>8RZVNDY/HN57E6DZS, A/;!WO*Y$8P CI=[]U?IV[]A1_L
MWALS)GC=W+'(7GO68R%PWOQ.:IF#$G,+OW+I-64XIBH/0'D(#]4ET';($L@%
MJ;"N+>B[3W'WXBT3TK],[%.)+$.:16AD*TU'$T QP%.M3?QIT;5!\'W_+AOH
MTUTVQZI!I;-.V:6$ZQI_FRUW?P_0-ZPOA+8=(58W6?Z>AH$4=7$4>+S9AR4]
M2N6"X"%@&^L2,Y:W Z92[4O9_REP^/"4(?PH5]W%M0AJ:(QN>$?K/8!8GT]O
MHBBFR=7#[C2=!0\?G^DT6DMI[PP<I)C^6<*LI=_8Y=\00.Y)Y+0,SVQH;NOU
M-=T-=E%KBE[WV7?>ATX</BQ20/T\[]!GWV].$_<DAORRR>:YU38L0W'5ZY+F
MLU_9?C?&NA#KSO,A<=M8=,:_D>S_ZXNQ:T]7D[-AZ&-M5&/SD?M.]?3.O<^X
MJM/7&J&;N@)NX.NP33;<@87^LU>%YZ+*+J&3N4>IR_9,!Z^%3*)BU(E'Q5J6
M _A37E3PJMETX._&Y-=]<?'(^DG(^.3 C7^$X%Y7_D?0XY1UIP/+D?KM;F[?
MM6>G.ZV F7-U9RQU\V)^5Z^:7AN\KFP)U*U?OVXD:P6B:+6 !VS!'\9T1[,:
M-5:"APBH@I#U67-F/;*2Y?]?2$M_79O^87#_$2!</-#G&C1!2M[C9L^^/9/*
MHICAT@A;^_V&@F?.!:.'14HZN\ ON;4Z*?N3W&'"AK,#DRK 2.[1+$1,$8!0
MZ+*&?%@763?#P\=_9,I]X<R?H"[)4+^F1M8J9WS[[Z%H1O9?PN/_4V->G@>L
MN3 53E33GJ1\BCLF"PS3E&OA]&*4PF\)5"B&$R;:"1CA=T.)' FJ-E28XM@G
MKG,JBB-I1C>]JO=,)ZS]19J?GH_2$R7)$/AZ''(6=RUTF]<8):E]O.L'2/GS
M/\_E_Y')/G 118[GAS-$%(^G#J]L7H!M_;[%KHEY'  '3L!_7W&5BU7.*$D&
M<^9#*4OLQ8F?+W?!H\X2KX:@@-"./P(=L62=V:\WO6Z3$5&>U"?YSQMEQO8?
M'W:_=\:8@P40_IS:MN'1\6=2V>2(HD3]NG7S-[KRCH4;V;>CN+UH85V;,L.9
M%X:!JDG4@VDFQ$.ESN"!12 %?)G=L/1_70WO3NJ2LUE.&2049_$W8$3_ST8=
M]%^8YY&H_"40=1;?A0^)^PO)F<6_6RRN^T!+*)Y_PA$UT*,$/ $0W=UZWTDN
M6BW;C^4V*LJR<_?7+&S3"%B'51/3I+A^Q_UO;(Y6'P()4)J0$3_RJL_^]P;T
MJ4\VQZNO/X&G"E0"NZ&W;DWPY5_F@\B>(FHO1N6"8#H%7DYYA["\+[3S&J:;
M,C)5FQ].B36<M@D[@KY'-3-D15<(W@W35_22KS7][# IH*U,68]\+D&]K\AT
M-I[Z=W_$+]C/@3PI71XZMY\_4AY3OV/U'L(5-HP1Q["K"^^8-!UP$A=5+('H
MSGVWDGD =DS=S1LTEMK'4VN9P/J6* ^>^V;Y0[63/G0?@&)5%%HN%GYGJ>V[
M>>LHU;#DU;;NK);_AJ+2A@(3M>M-1K1_#K5L"LEC>^$WC^T*F#3:R'F&>M?0
M15_I&)=':9+W Q+C?(2I&E)(8U (G6HEA<T\N"3]=U_#7\.T[E> :!5C6 *%
MM*03*<J) ATURV'*2@FO,@!F#UGO$H@!B V</M$:0/:LG+@F:_'E<+<16 *)
MIAGAJ7WQCTGS%HV<'XN#=]D@>M3'#BW#$TP3?A;(36*R6"!LJ)U0 Y])P&,2
M[F&1>F>K&5O-V&K&5C.VFK'5C*UF;#5CJQE;S=AJQO]T,YX@=N6<9WO(T9!!
M0822?C"QYH@4]>7%/2+K+;=J/7XJ>)? 4$,_?/L2J/<J@EC OP0:31MZ\Q\3
M79,8NA"Y>@/38#'KQ69_QL?[<SQ+G^\P"=)Y97.E>Z\VJG;:#7:&O9\NS\^[
M#SJQX\Y3ZMQGG2SC.LX%0J8W;J0CY#QXSM7I<"**]DR/:'N8XI2J>?V/R]%%
MGBM%7SZBPNK".S&S^)U5KC;HJ_5C)77B?:TW!]UCIA/]<WIN8)5R8VPD4-4<
M=>?+M#\]IS=B\_[QMKSGL1@Q#5*8T"UJ5*1QNF;<1MJ$X5[;Z2OGY:*U>T2%
M'CX7E7#M2AV[/5=L=[+1-#J-RTU:E"DA6S3OL%1$Z;>B+NS8'9P)I,$0?PV)
MXX+DO6UK/BUM!*<Z(.&223\6@@@&63'3]MD=:A"P->IJGPTSB]>@O-HY=CO@
MQA?P>(4!A;NFO4(:8C_,%?P\"^YBD!;X$.6Y*TCG1T0D[_%(DU9ZS@B0->7=
M!F2==*TA,GPQ20(Z; W9W6.=8%U 9$G'BD<BSX\98AFSI4"3$1+';N_DVU6E
MUB0>?SOK6PL'XHB8>D]"6^@2J(I]6^;"YQI<]<[^]X;O9#[KMZ/T'K_Y=NC^
M3K;7IQLLFUR0:2.R+GFL=6-F3IZE=Y2E"XX?40^UF&B,U[7RC(BRN9N!F6YY
M,>?/]\/M+1Y_V".E<A?S2;+<#4ZEJOXM9O5"#0VC0>%3JM\^W*UY\^259]=,
M?Q+Q?^T:J*W7O__Z']ZJIK/Q_9]:N'_Q12]V C/FY6K*Y<%YYVKU+2'/6,FK
MHOGQE'OJBHD,=3VU'8SJ#UO:S:\\U9G4:A':2;[?6#WAT+9"F%%!2P+"/<WK
MT#!81PKYX9Y/+0>G88>$:D<<#BR.Y0CL8;:6JT\=>3QF)O4B]F'6/LTOI6Q,
M3:% LCR**4&B)QCU&,9?,EU4"@JEM- ]$Z*L3('E,AVH31,116<F"! @12H!
M 82(Z-%K3#I<AQZ?C:4V&=:/^OA<I%,<@WAE*KM[1.R($Y=D^KLQ5NULODFE
MRT_W]#CZ-D7<AR$E&U*IFVOGI!KROO>W).0\OL_>9U?#JC:W $EI$NB![O)B
M %:!9GF]@ OFAM=NO3[NR[%+NYS-G:;E^;DT]8-%+#S5">>Y)?;JJ^Y\'#3>
M+VAQ_NN+"[3&D[WVC5GZS#SWS!8KYA4/']MGWN@:):S)E%['R3I7%A>D^*;%
M/'!'^)R/AHAT>I7WU91M=9>Z$^]0(& (<2SW7!$WM7)2W9A6<AV94^<SVO!.
M]RY-=WD)CVYS7&S><2&#V*'.1XNG6/5V8 FCFM/(:Q^?\QM$-+0J9WGV-S:?
M;Y";M?2YJF72^73L'N)?I<AOO?[]UW_-!?$?WI=2!NLI"0C9^]D),_AQME+J
M+NLYP\]\V:8[S$-$I]1M+9&E!R!?[NR/>%6?4$DA7QY**2I?VB3&)"V,V#_X
MJ$XVTTPVK;5]MS]?^T7*6''SY*P*AC)W^B/;PRUH>\1XZI%Y1RL,NAC5Q61X
MKB:WJ7V/YG,Z9[\$.E/@3]G4F#UQ:"2N"[[K&OLYEZAVVN!8072X(9U%.CGQ
MT+8&.0W+[EQH4<>N&C3V4);/L+_<#0=BS5BM:'019<VGYQ*[F<Z)ZJ+V\^8H
M1@V]AOD6!J5Z1(1*\8P=:.$TWIW/2Z_->:G7$5%W:-M@*N08VKI=ODC%/0NO
MDHV@^E[L]\'AK-HVA[[D#,KF+Y6P@=I/-E<280[%,R[C,S!3L^=+H*)/S6R>
MC[*W/5,.V/>CBDD3^)BT4EA%L5644QKE<6%K1ET#WD2E]CZ?:YE2TW)$@: E
MT/Y$R<+OU!!IF&="/%\^N8ZP2,$-]L5]!UV+<"\U$YK;86J=>MU$NOJPCH3M
M$G) PFBA8"GE['@N:N6*YDWST)'%I40,]LA;FE8L*NOH6SB=Z_.[!#I[Y\>"
MKX1OO/XIK+Q\-4\:1W:2ZW>>XQ G 2WNUM-A;".7F=NOB=8?SH,@3D>].^K!
MC[]EM6V>8>H=+]VP2G%'C#Y5.J5GIM%Y[^*PM@)7^BOS-\Z0\=-47BFQ?O@!
MYZQOR^F)ITY1RDX_V%;V\5(!K8L?Q;=M=W?WSE2E@:S\:,OUYX3Z7C:^,\QZ
M8VYULV@,'B_;MYMLVV2T$N,5S4&4GQ8,7&3EY=*#O>TM%CZZ8!K'Q.!^9U>X
MJ1G[@0AC;\^, <%0JH6.X;UIY@Z*WG+?GD!2J,(P,<H.,8^.@OBDQC3T,4H=
MHSB.O9EITH$]/LK.S;T*+8R6%8:M&;[CUHVEQ>I*!FSHQAC1[$/^U_?'4<7E
MC%6-7#X,1W/6"^S=2[@FGNQ@S:7]X%#*5_DJ[<7BI]1?SS7EWL. 7QF*R*.%
M933Z=W7YVS9[BG3=[\EET XW9Z4V&/MX)X8EZ!)+GH;LB(8%VCK8Y!;N9%8>
M(H8[13GLZ^M7BHV7&5_WV8/]3Y(U1R?NU<!&? ]X82H*-4Y)1VG16>C2!<XJ
M<@7_R&>&]3*D4\7%P!^,"+W,2S"*_5%\O[:Y_>I!DQNT+I3I[ABA;9</#V!=
MJ^*KPA^;'] +,&]3^U3&YG20T/B,^OOHMNA^K&T'(DXWRSSN@ZP1QP>P[R'L
MK1,OF Y6W-\/&_+41^!H#\ +,CVGIXPMS,ZG) ^K6C(109"/ZLKY,.]XK#--
MV:=(^,LWO327F=2((@T?L 4P>2)-AL>H?__P*:H/+Q[GLPE.3E)_A15KU.)-
MF$M=$85"B0B.P#A+NR<G:W>S!8LJ/F=Q=C=/E"RR^*2[!$IE"32F]?@^PN,
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M=(:QJ@SEL(/UI6D]2%%4]JZS5)+/))H#UD-__(B[Q_R>3$4@%GN9S98=1QE
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M;2D];SXGU2^1\O_0]I9A<2U;M&CC$"RX0W""NUL$#S02)'@@:-.X-&[!+4"
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M@F ?ZK1WBKI8!0SREXSE&KRJ![8Z?U9%H@\7-M6!R;Q6\ROF1K$7U,6I67T
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MIYOP2I>\IWJ1<;0YEI[#<8JBLQ 8^]/BI/P;<7I9CM5Z%#,+YE<1,ZV^9SR
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M<P.,@\4%')E3IBU08>;]S_R$%T[]/WF.HMFM/P"(]@RQ1C>FP6?-H'UAQ;#
M)=)T)6XU_\H 7CF/D<D6WV*(VYNJJ?/#)Z1G)66I1^SE/WJQ[X38Z. C-A.2
M@@^  <9IJ67H V ,/FT16AN#?[70J6L7 CZKK:I.$<;NV;A$7Z$+HK<N8HY#
MTU=%*WPA[B8('\$,"7^+$RG*&_O)6K$D?XXI.6]>Y[62'/C)R]QSVK<(MR61
MT^+*I;ZV _EO3$?97X&C[V%\M*EW79>$=\ U::JZGLVZ+ T'!TJ]4,WEC@\9
M4Q).\V[!SJD.%Z>GUD*>"B1)N-O"ERJ##P $Q,KEM9;>!T!8050(\]%N#DW(
M$0L2M!F44!M;NAZNY"?Y.N5E*+ 9('\;Y6"("6^K@[7JJ=6EOJJM"51I$+S$
M]ZY+A_K?LFU&7NS)Z(^9<Q5WXV3#BCQNDZ;IA&-HNI?5UW^6>ZX)W0;?VH@]
M<IS4:19.08_'/31;X8/S'=/X-69)Z*%_W$GW]R-YY*B/X,MA[Q+FWGNA&2^2
M]^_=F8),W8@FQQ;PJ&X0X[F9*?N^WQ9DCFKU13X )G=R[K]>K/R8>0X?N9<Q
M(+GO<GT 7&-]1MAILDGYF/B^3LS3TS/./7K9E-7_'J[YJ'<M^JC9I\5I3*YS
M/03JCI(IZ/IA![DE\3&-E8$S5>6]C154+':XW:4(&IXVZ!(/ (]:A*)<D%;3
M?1AJ45Y__"MQSYR!/LF0<FZ(0,C7_66&*1<)Q>_>S, :8N7-Y$1XWN+&A_=>
M=>LS#-K\\/9O*X3)Z]@/ /2,$JYC0N?JM,L+#0.+8(,/,UZO=SH3RE4#<)%M
MLC ]B-OO"B2F,]W0ZZ?8^PDZFY\%CDU>:KQK_^.76]_@5%V[ON0M?.QH2*KU
M<?/V4J%(GX#C4)__;O&1HGN9H?ZD/I8ISPWL)LX3,')A&9& U'B -EV:;K+D
MC%#*[0(5A'DW_*J4E;Z^*+4+DSI5/G\T[4^/R9-3]@RB\81)WE3A:O3^FT=1
M]LN'G?09P=!J)I&,K3RU3:+U[VY4J*.,#:A-U(#\FDU87*K,.I[_Y3O43%N&
MTYI1(7K43)C150HD1&8,C>=7\,6J;Q7-$DT$S7B36)AQ=7U#<Y*U'#D9HY>K
MVN0]HA^W%]LZ(?S-S&@4A<;$AVJS=_CWC+*#6*L H VUMXR")^Q&C(;8:IDJ
M<?SR4&BSF\]=./1 ^? G=8N'1;S:%?6\YBA.CF.S;9U(QH6J1]0VJQ1*QRT;
M32_-J88/C>\,Z/@.3YIJJ*=;L/Y47U\Q]A5YHIN37Y8+PS13%.Q+W8V?\YWH
MKP,<UY4FY##XW5(W'ZX]CWY%CU#CI O7DRM=$DS4,H\AIX9/%932/*^B^Z3R
MC$*Z/>I#UD%VV-9%5@)UAZ5QLT P7H15I%EL$C/4WIL%R4T'KAD=[TF<09]Q
MJ?[95DGL]0JMD<:<7.,SK=;<<7U=.?[Z<3TQK"\?6-])1(_+;8#ZQ8F7Z5._
MI4"C;!BKX^XOW,TMC^C,+:)PD-]7"ZXB16-[V 75[=P"UZ*DWH7SD2_UM+^7
M<MX(D.*V1*Q/AMU(:'3/-&&Y)E4NZ;YF<A+7(_K\K];$LE(=2P_/%6LA3&2,
M7J"Z)T T_H#MT^\+=J'[-!?H@0^ 5P+)97F7H6W<G?ER[,]1X\TYU<Q?[FY)
MR2[$QOU6#K.0*-L#3A?,=-&?P.I@/N9TU^+42:PX$L80ZBQ-TA8'&_5QV/:;
M]MJ)8P:=LF,FF=F#%;=G/&8CX XME508AHLK7"I8_&TE_>[)EF<H;Q$#3@%V
M8'H!X'J&IL#06M0FA3H9%B/I^Z3UFV"J9R6J.=JEDI XSD<?LBQ<NZ_^D0[C
M_[K/FZ3[_@]PQ@LP.A@CF4=SFL4M VNSP=G^]6E E#055<*XD8[>4B^9.F1:
M!GL2D6_(Q #R;4Q >_SL1JE5_93K?, RJU3J6.QIUHV%P"N-*?/1>_SZ/+O[
MIA4EV5<[K@B9TXUL%%%V:Y==@]BV?&8NYJ[ 0KE-:,K""->61?S(&U6T;&M#
MQO ^]9 W ;U[-VIQ7,(+>H??F1P2S6GE),]-7\^4N<S:8F&P:^@IOF\(,.OJ
M7D^C7D+?<-"7BL2_NP466"_CI;J%2O8UZ<G1-"<N%"[M.'64V04W!27FY:[H
M?U6F+KY\XR*\;5!>L_K!M'J=]"(+9_Y1X#Y)R<AJ,OL(M4/IWB<=B%[F/?+Q
MTS3"!EVTL8QRN*2R;"IY?NHA5D7"XC&T!^89_;YN7.0!L)_JRPKS(?IN?*64
MKXCZQN%-AS>#DS3%=7OX@7/)U=E&-.Q2_9.MWB- F59^ Y0NO1"2R,$[W[_X
MSL"[_KR^R\1?5WU)?O60]'R8;<B+\I[>"'7/AZ\J\;O>_D!N8YQ8:'*&_.2)
M_R-*<80%2F 4FW"[8"^!\EV"UOQ6/O<F9V,+)]-MK<<"(G (X'H-#%V=/#[B
MW^6P9:_#=,%EK.LP6 #*HBBH2P;7@X9O$8H%<V#8VC>N2X<M&N2L0 *L9Z'>
M$S3%-S-?51$T*XY1@CXG,6%LSTI-=9*YV641F8<#^D[:0P_%WZWM>UOWBN1
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M6'\.R. [CO9F<VS@"M:G(?6='7"[C?,3K7@*FC8D'^-T ;_XOK!0#B,YYCD
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M#]T!C]:-YLOY^H2$]5%S>6?6',8&M*DI=L%&:SJ6C/'3#<+M?B(<>ANSC/@
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MA8JD4E3RI(P^ #ZNPTCN""X? .UG"+MGVE]\OSG ,>_#;AX *]=2:\)700^
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MI,B0.4 J,Y^MJ2T!H0+JKK?_<8H_!:B?A&3X3]P_6%#N3W'P:@K_0ED0<O8
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MR%P19??O'HI2XUG_DHY)02!S!B &%BB/=CZ=6S/=GUM\(<LNI]F2$:*7ESF
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MRIQXED RGKN9!CEVL;OR\UUSL&/W=P_^AG!5B@BME3-I+;/3??,WZ?L'$"(
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MNIW0]-%0A6S/'<J[D\4K0\'"EKJ]>UN75[XV/D,?RQ;#8DP.U!)4'W1$N84
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MHC]%)\+ (&)_0?:"_3]\P-L [">("RBIB B4P"-L!$1L!'@7  ( A,<(_W(
M?S@0'B$B/49&>8**]O2A0?4SX!$"(N(C),3'CY&0'LYZ/IP'D+ ?X[QX)8:,
MJZR/0FF+Q_XY^L<3*O'R=OQW8R?4' 9VOJAH!(1$Q"0TM'3T+QDXN;AY>/GX
M)5Y+2DG+R+YY_T%%54U=0]/0R-C$U,S<PM[!T<G9Q=7-[XM_0&!0<$A,[->X
M^(1OB4D9F5G9.;EY^045E575-;5U]0T=G5W=/;U]_0/C$Y-3TS._9N=6U]8W
M-K>V=W;W(*=GYQ>75]#KF]_\0@ 0$?[U^*M^83_X]0@)"1$)Y3>_$!XY_]8
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MW5VGGX/,DW;TM[GH*HI,*")Q'UU&>MS\M* &GLAXWQ6G6&*OEJRGO6Z%FH<
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ML(RY!P?(J_-L6"RMF5DX=U;>'65KE"$HN9GNZ@Y'2Y-8RDR]ORU@8\#.50]
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MP4\KHB>?Y>(+^G^Q5);@13&CRR^EK8)&KM]>UA-X ;C,34.(=8UM"[G)QI*
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M+**=82B/+ ++Y\CC,(G+[\GV]S!D>3%_@0-%-;:P77SW#Z,3[Q.-S1.)U<P
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M)%2CLF125V>/VX_ZYKZR1#AGU)C&G?B2&$Q%8,.J<S9+$_J,U-[:UKP^*-C
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MNO3(PP6$%[/,.,&-@SAX^K%K*-.S(=$LDZMB,ASYH=NV+^;7^AS5L=],Z::
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M]E?=T]O/ZGO#$28Y@6)?I"FTVY4+O7=WI1T7;Q#HJ?ONQ;&O83X".U 16S,
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M]#G.7KP5N4]>IPR?DYIVR>O(?#!_H\"E6Z]8+)>CEQ^XT4%66E&H ?5!  -
MRY\RXJPKN<[30=9O0K'X-Y6KXX:+MU?"#FK$:,/&U3ANB?RT3D3107&)R,4:
M,M;(%+*9&D YLT3-.>,3^ZUU=;)MF-QK8&Q:M.+)?> ZK+>)MJ@4! A(9=SO
MDJ2_"_5F:AZSM;J<-H$?D0]2JHWB#"0^SS[H9&6Q@%V7&6[3.)VLGR.%.E$1
M9X7\&=_O$I%UBK "FX?'BM42NJA7Y%O/F_2DW$_)"5-<M]6/]U-[ (0;O5?_
M((/0"&_@2'" &Y2.ME:XE@=/:I"IDM1>FDMS"(U)9827#HJ(AJ"FVDZCTV4@
M)% ?$EN*/ Z7P';'"5&>/(0L#D->Y=PHFXA8Y[>DB,/0ZY(=:IP+J+T_*:/)
M38#EVF&ICL@IVY;?D^=YBC7)'+Z!IN'1UXG W3V>K46K +CQ9;1L+!7H*.6(
MSDIF9"-"'Z"ZP)?:,ZNKZ2#>4PLE6Y1@<;)DBV"+&@>TW%?G=UG)U?IPTD$;
MY$8=)L'CT0*XVU<&V:BE10?E2% 6FP/T8%R2Q$X(='R5Q-6YCHQ7_=0%F3IB
M!9S1$3KH$J=]A@V*<# /^/1!.NA]4!%LRA4"SL1C;@*A^M6_&ZH?&4.?%*CP
M@@/75P\-#9JUN4C4U'Z]MFMHZFG^^EA8] CVY17\G@G!#!<!^1KR@6(OK9()
M><+Z,:6[S#A-;HY=<Y(3+%Z70RHK4C54OO@L-A]MW-.=_!BL>QGOZC=QNS4J
M_=*C,<MDEC5T-S1LOI(OMNXH< N!RPA:'2L^1;M$./U4]6FIT%<LFNA411/$
MU0IO\^D\VPW=;\#S0'#YSS<L^"OM$82]7-1G@K3.IP4N>5@+9;\F^MW'@N\"
M93$^=BPF6?F!@K==>BD_>W;CV!0T%T *!4<<%!HY<!7.MW#C>\H^IRKR&BQP
M+/CT^NH>ZQBHYC=E+L>&$T4W+U9ED^_K-RAKG9$Z$U'<5,K_3"44I/JG6RO]
MQ2W4_N]I$7T9TB"=_8^4L.(CYRJ@8#KH0.6G1XZOCL:]U=9P\KQ@&XUN+%S3
M6K."JCG&5*K&;)AEERND7S_<=-ZL_-P"&*G6\[''(OICU]F'UP^!4$+R79SG
M,P\J"5_OXUV_Y<*9/8/YW@WPK2NO?H2MC(:;7QCV$X: [JL-I5C3.G(!&=F,
MW"9C)J_/8:Q4Z^+$Q7*.H51O='P+*^/F]S60D#*VZ=_1QO[7LW"EPDNN^IP5
M;-F/TVHJ3S#J4D2E<9#92*R)-K)X]'K@)2VG)/^3SLZA!2M1E(Y9FD !_F3)
M1]E)]TCKEV\G!TXPK+Q[4,8B6$^N'^[<UO/JY_DB\)J9[7H#T0=XA(!\P0Z-
MDCE=#!*XSQJ<37M@]3*V*%U-) EU-78BNCI(++OMS&^8%$<0L89IW-;K>3/&
M")KVO@901S=_Y"(PF %]#TT@HFO)MP4E.XI,[;?Y_:;%2KCOU:L@,$4E_@O'
M1=BS7JH_3I,-53BE($*F!:2%)NMS>[*_-C9%TT'7[^?KJ3WT>/JKC( #RGG*
MI!NY.(R)5AO7)7'*M)&WC&-KD02)!<C&RFA3$BZ-$A1G1?7*MJ2#)'TUW"A?
MZ:!!0.;G_9,4KZ885)3DXK[K&[>)G+4"?9%C!=>H8ATWT?FDMME9M[>)3HNP
M?CR2IJ:)7!R#^F-#PQP&4*FX+&$JRLO%JJ,25!RW6%4HK0N^)KPGQB+2(R>N
M1#= B" ,]/TKE,5,M&$X;G+.F]4\LMY BX3:*>M8._Z,2=YU$PXDG@U),M%A
M%JZ#_0X["0P4U$[ ]:>YS#Z ,.M^&5N=[%F'ORW!86@:\? M(1*T779M"XC$
M)$$[Y!!R&GZQ9PSR@JIC?Y8.\@TG0F> !Y,S.?WLIX+^#5(6"Z;@O!#L/'*E
M:"W'U IGM(+#4D+2*73020]MGVL S6_<7T.KZ"(QDNPK4]J!>[SG'AT$FZ?X
M/;8<Y0A_/RDYKK^!_. ;)(:^3?SI2?JO% L-?X239'PR[;(QG.KH, LS50S"
MY2+K(\@8-F1C86PRI7]#_2UP-O$0\AB*?"#3Y=8-  NU4=1'NM2]!J5;PKDD
M,W@H&1A*-Y[\I)!_M&Q*NGW015.\L=ECO04"IY.[[CE)O'@J4'PI/Y*-?Q:7
MD^[+M[#K*1WD]W0B^7G[L"0==.2BP(;';)U7BXEFA]V&A+QA<4%=]WD9O2=[
M]C]B4_'"?L F> . %W%2B$P'%=%!'<^>J+#L)+CZQ#^)!BZ!F[+LQXA/,\UT
M+287J8J7P!I<*$LI=&/:KL\:(AL3%7>>J!]H5%'SH(-J=??90#WWM:*M=M]9
MZ#T].SA\L8SOT2R#P*7W3#0Y_+Z&%Q0%"SLKL-:G$6V!A/(\@0;'KV=]''OS
M-N*WZ:#=\+E8Z04HM%<>RV3C7B19AB@:=J&M*DQ^!!^=V%6&TL9Q97JF>F?.
MA;;E7;@I3>R-K;\J'Z?^-*UF3=<ILVKZ*7:/ L3?>D_GT\;&I'C>UX$<&XS[
M%/^F8@DOB)AQ,\9>.]7.IAGMRTKI[7V#ZG=BU_A.J5*]-M#0'+>:2N9.;Z7-
MP+L%?JMGK2(][(WV;YZIRT5=>G>3(7'8C*)!?'K8?_1J7OMZ_X4UA]O*Q9L,
MKY#BB^4'QY10#-6^'>A16^::-PFY[*B;!8/_P42EQVSX*;S:5N ZDG5.\4WG
MO;*@:Y85A"U^-"[<VZD;^@&+\M;L4#;*A,\%U'B&]Q]^<,+J7.8!'2F1UH."
M[QPO\D"%6"@NHN4O545'<BV%]P^%;-^'< X23W9ZL>V9*XR%+X[GAXJ0GI*>
MS$;T%INL,GG?]*^WBIT037I_*[(WF'LVO"),M6 8^/Q"0Q6O1.K"E^$K-KS7
M^3[=57C/LO"G>\+_+A,-^T/JZ?_U?1;_GYLX./[-P^64XN)H<W_9H96&)V*\
MVF7";W!"%(\%Y 80N-=ROA2'!PPDO)Y/-U%SX?N.U;]Q2/#ZD:J<D2_ONSYF
MN<U$O'9TTC>D@_P9?S#YE&.'+LVYR^3?9%"F[<<-EBG9.')91#[VI+FTN-^J
M]A1=6ZB>J1(A./!>(.@V54;/]7PCGJ(^* $(^*HI(8W5?:XTL8[97G0\ V,C
MH>!9.3,2^\&F5.R5S68ZP]NMPJ@6ZPXU^\CKC80T?1?1%GFWF1\;&62.F@WV
M]6L[N8C7,2-B7)49<V$J^*"%"0'#:K'9"&$OUZ&@VOVSQ5F(GLV;CU7X,_=L
M+-VVAF&IK&7C+=24@3.]N:;J:ZFU7Z1.3YVV>&Z6X)UMY>&$$ _V"C1GKE'B
M#Z$9;' &GM(M%)EZ\SK2]UEN%78S8KJP(:W6 ]X#]C( IQ<13@%TXC/I\T\1
M8S6Q2_@K^2V#4!FMH LJC6>@7;6[12M!&K>B<=-SK@ FKCIC:C'2LU+7%$2B
M8(,X]ZCQYO)(9*<2%5R+&/1E!8)W$2#"X$*=Y>_8\.'MQ6DTM<X-^-LY@*9Z
M:<P<_S5#(#\I85NCC:-.N1UY0O@0:N!Q+*)>X]Y-HK!I%]I;UHH9RBCBM_=&
MCFOD2/\B3!>OC"+JG/5'/H5$F[O?11&OK8\@I\>1"1Z1==^@!>7AI<DUW1F6
M0:8KJZ,4.=4$X,*Z5#E^YX5;!8"&('X%.+O=Y7(5S0#04()> 53E*YH%?52
M8K$^P@F$U\<;5AU"K) I]2Y:  D+-4VK"2<=!MCG!YI+#S93@^BX#H%\QXR*
MTT&!M'L[I.#G?GW0WZ/P^O*O( USM<#5;I]EI:G U4CQ*"8 (ST*Z"!'.BC:
M9P]<V?N"T6"]:_5PCTA?WQDI16BA47/F</*7H<&<AM/??:/=&;;1;\.YKL3S
M)M":*/U%:H;Y6OF&VZ:YC4Z$)5/S+*PC(=2H#[C*'_J-\S>T1INA3Q [:!@
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MY6UK7UQ8\T2L[KF+51P*S;N^;:3M%"ON_8,MP\^[Q]/4?;1HE7PD;%?!VM%
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M)"["J&%[B0:/5#GQ&XW_ -SU\ O((:&FCSE=DZ)EP*&>_FU6V6]F#"SBET*
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M,R3W:G ,R ^0'>).;._19W39J5J6G0JB,R7(((5Z+]OZ"B08.W"I%8K_]NJ
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M"0EC^3H%33EAKZX]V<*A=J\.(/['G]ST5R\"TM<$U%BHUMNQ^/$K)%JWY5;
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M1A(AAZKK-I-2+>@*K<UKB>G+)O1H)KHU2B<4BEYXU2-P&(_+MM7;^ I98]V
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M!N5M&">D@-N19AFXPB9YW[ D[HK6""&S0WD<:?&%(??'500S_(/3;64L9O(
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M\1N.[Q9@BB.)SV#.K8X[>^V$YK7,%TI+&<4%.@W#SCTX4;-E?U$82+(Y:P[
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MEE,]^(L%(LER^&R;[> %UO=HLUNGQ+..]RSJVOI@I\Y)P^; 2R!UF>OX6(U
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MG&G<IZ*H:H!)O7?I0U7%^>HNZ+,JNGMT3ED2<2<W4V/3US)N9NP:T6]X&,8
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M>BOXVOJQ\H-^^SD '35 @HUF*=+"Z!5N$C0:95Y_86[(UXD[DW]MB([N>3V
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M:ADO?[K >@G?=6Z)&.*M43=QVF![>MX@>,^Y%FJ;A]'6CNAX^,!I"N0N'+O
M'.FW1A#C<VGT>\1IO@%0 <9X'Q+_%ZE[";_671EY;"/.,.:&*V(@(,17&+%5
M77T0&[9/MVS\"/K7E^ZVJ*S\K-T%8=$W@.Q>=KDUON_G3 GH1/-Z;(T)%/4M
M@'R8TYE)'LBI^2!G\F&61*.=,IP$%8AC2K8V\_SW(>XDQB,D>I,WTI(N/=Y'
MG/_X7LPPTLDN)U' AS()&5DY2('C8RUM>UFDYOXTG$<CF/?]JFU!K7.<#0R0
M736PR\VMC:R:@X%Z'/ZQ("5,[)X^-_ZFO&C2I3V#?ZO\[-]+ WTSHD6XW*:I
M+MHI;SA?&N^K,_=G?=Z#V !&#%2 B]X]&Y\NTH_OO]7GJLNT>:'_BNYAC%QK
M=$&9[%^'/R]<<HKG;(X+I!<W-%PA2X* '=!5XY"\DY0(?">?Y2-/43J\WU:Z
M,FHN),754F:J/(A/')WKHX+(J[6:T?-_'W%4$DG@EH[\O!S=,;7TIW*[#;4K
MT ,_EBY:8)XZ(D_6F7FD\RTU>V*\AN/[GQ*=]O=8!(B)-Y0_AGA ]9(B:WR=
M!PV><YV6\\E2?;_*.2'BL,1^'^6DT_[7P8MWCY>W? &J*OG^B5%0TJE'8Y0O
M,\M**]GOZ/"1'Z(/T7A?=$S)R[1]_H\9(W/\ 4*::/&;IP^*P?Z$0+N2[0IK
M$?_WBN?5D6/]U4?=0K?O L0>V=& HHE!.]5R08O3"W%D0<[4T9S^>!SO_N<Y
M_3/]7KC$PQ7%F>5=.\'$A56/$^,]0P8:ZMQ7/>I5O,9F6D0]/<K!3;<)3D1Z
M@9^=7YI^H^7622?7B))">X!9IOW;[TZ2MA, /?)GYPT7(+C9]?6AN0G?K]D+
M!B1B,O#ZE(Z^1Q9;Z[553!\O+,V5%O< Q/6@C4(#ZZ&<GHSCE<$!9R2CID<U
M39]8NQ%#,1VT8EFX#:^]3>M\1;6DTZ$2U$NS<XL@"%9.?4.D>2CT^D5%OT1L
M8?N?,,K+UBE'C=.IX*TD\5M7@&N^]A?_O\0S+U\GD>!@H+0+ F\$JJJ0APW2
MH?AIXA[OS?B,*3T)<*4E^%=ICY%I/7VA[26VWOJY$'>RHDJ6<1-3KA=RFC>[
M+7 N0B3R)GI>%O 1-2+">";5P$<*L9Z:,Z--\\ LB PF3S9R\18G_M<C\V"H
M ]6..\G%M!\JV*Z,\8DT77J0^@M<@)WT\K ]SZ.!%9YZ7?$H1&U#@YF#F(E$
M=SVE,TJ'\$49'+8HJJ!CEX4F^XC3"FL+T%'._W=P];?)+6#7(@IG:V-4@<LS
M3X@/\3?!^-C''0B"^FWW>P_M$\8@P<J-4S6BX=BZ<:3?T"QMCQI_-7GTVGSZ
M$YAKJR/C5WT9E=-5VXZ>!DT_7+H'\T=B5JCC/*XV-H?XP]GB6C %?\;U'5*R
M,GVD JAU=+]%HG!19R#OY=B&U53+-C$FG7'$TV5G7--7JTNT(V@NTLND5FNJ
M.UU^&1%A_G]2'<J:F&'9&61$M1NT?X-8^BK!/J)P+L'>IA_UOMQ?IB_K$S9Z
ML,6WKFO8&P:7-X$;E>U_'1-1_R=@0IMD:QVF0BH>/HM5=^<Q](>?O6.>JR#0
M**"7P HK#=C<8@,L;OZ!)D89AM=)) CN'\FG@-[V!Y?5:[WEGD DTJ'\BM7V
M_U.Z&8[7T(9HC8- "S8B%#J< </G($^T,M'EM!>^2EZX?XVQ&/ECAB9_*N<_
M33=*=1;2 ZHE+C;E=M7HVELW&<>V%L82[_..GUYN<#D^S<8;"GL-.P^Y-'/.
M<=*7IY@G&1G&=#13.QA\=,L/_3U9<HNO[V$T,'>XT-H07> \9O^$"8S4KU"[
MC&%#':_MK]5U]<P<7:_[\"O)5EW_@9K8$4?4A"M^2.*B=,GE]*=$0V/>VM:6
M#Y;DOT)8(_LFIR1^FQ/9_QOI:+:T7I](U(:WT!=Q/NS4]N1HHSUK]W+J/%,@
ME;FMT.D\2(?\0F86@!+[@8/PKV^3E=0M$I4*]QZVD4R;\J]YC-WL7=JI$!65
M*[4YJ7F(#X$@/=XTR>4H1+[<T>7.3^B=BK,X<!IUI972)\G_@UZ!J@K^RZ:/
M5$1 O7K^K8R.Q<@_TPEEVJ.CC=:5&UF])/44E41<Y6.%U7/GJVSWCKE^0 1>
M[<^9OX4>1GN8^ZJ[T(CBS)>_D5QV$-/N-/IQ'^V2G?KC[7*'HOXJN1C>@XBB
M?8"9\32T OG->N*+O>M$7@.-CJL3IV&KD,-XP^_#?%NK$GK+-V:GM:EZ]/P#
M:>P[+?!E-14*,AEP:N./N^T$+C1WLGPX;_(]PIY!>WXS;I:QL.2I#TI^.O7L
M;HS.=J4NZ&<+EWW=(%9,!7T'*I5IN5[W_QALQ+C]1?>.?;_1IX"/H9\"N:)X
MHYR2UWSP5X8]NNM%^LX_PWPJK 6KEBSFV]8\^H;^$<7 OTG\F7 '(K'U-?5%
M<&^OEKA"CBUSJ,H[D><7_<5.2 =9 Q%8KYT(;(/2#>IO%6C&"(SOWU%A:5E5
M_4,O<RL('0)QWGD/]+0 1B[6Q(C\-/\D^='/H@/V2EI\7<K[+/-SBV%,SSH2
ME\G6M :<>C&H^_AG_WYNB?\6G/Y&3F'DSU"N.N#9M-&WC,TII:B$48L<BXZ=
M?[A*G9'@N1=4TQ5_AUNIZF)>!@+X>XU[)FTX>6HBU3+=R #&V+,>YKPD)Y9L
MDOPB/BX/(@NA.*J]:#$YUC@EQS_+OD)P.N$UN*23<YH&G5>6: 2U:F1L<B5X
M19+ZK2'Q5(V!BD92]X5[*+A0(H5)F[X:YY-QE;%+^JNP^:/%]PXKI4^H!1;"
M YD77PI[F"8Z0&=P_V;JMD__GIC_/H)O:ZT.+<8WPY6O)& &[N4P+$S>SA\H
M_)M_K<.H>=[SX1IUBY.$RTRR5'^>>T"?N.0AS'3=\7[^O)!Q_%JZ0'?(I,P
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M.Z0ZDT?J@JP[+VH"=RFZ\N[%Z6H+@EG$B1/UO7:4Y'2M!";J8ASM^] 'IK'
MGAC.)RN"!UQ P*(7Q;*]:?S%'*_NU^ R5Q[9L![- -T.&R1H<YE6-D,-N,$
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M/*4NKTJSO)ADLO;[)-B3OC7?>Y$>7H& H&\/Y\MS*X3=Z2)2E)IVV0MLZJN
M)"]'F3I;6T/&[Z>RHQ86$'[!RBI^]RT3CO4Q)C\'W<^<3\)4!B)<PV_.L;\(
MRZ?@DY>%!&%-4Y#Z\K,0I:=3(^19K?LD7&PPLPUR7(MGVYXJPGH:3;27N6=K
M"'8>8EV=O!IM0$U0N:Q:Q#9MME"<N63,D6U0L]GVH1R;/1T]0PVWC([$N00*
MJ.S9;8<VTW<.8J[WM*3,T^_A<I#YYPY#[6ZO:M,6M].K'&)Z4PI>9+P0820[
M:SP<!"/' Q=49S9/ 2H<Z3AR^^NZP(10%T%M=E?/_2:$6OY\HY;+Y.B3\IPT
MW=(O\9:_\3?^QB_(X(6R516A!FV:;I(.7OCV6#(Y3$=DNIQX!@\$NU7[[T'&
M5M_S>:8KW9D0NY@>SO?X?"U[_ 8(V,^"U'FQ+^=C8;/T_M8AB5YE0HF2;=FZ
M& 6:2_<5#LOTRMQA&=@>"_0)K8LQ]:%-_7$B37MP>9)WS:)((^!0!!.;KJ9"
MUHG,M)F[&G_YM#ZG7HIRC9'59=H3)_IHBU!$&H,G'VC7].(!VQ<DU=Q @9R0
M(C68ESWKVDJ[#<D]YH[BW<>8@R<MYZX5\9^![22<_RTLFD*O_PLC-Q7[5OI0
MN(=4(:X+6SM'+F-O*RI/(P:?E5TC L])!;OYF,5X1)PSJ"YV5:R1BU:ZLMOQ
MO^'V\V_\_R*/$UM[-H8N>Z::&9XXE:9]C@>S9Z)QL']<CR/3*=28A'0G;]]]
M70QET4*FRK:DX 'R/57LI8N ZU2P@ #VM=XL5';X,#M]+$74/(\MA0$E*UE]
M'4>:NE55)>Z<Y'*_!K/_]N#(>Q673"1S5'#O<,AQ>I.*U\^#-=VDF6*K[FP#
MTX9]&VM[?%W!"<GTC1-FS]SQFT]Y<]MJR+;D^JFL%$]> W+;RMJE/;L0!JBA
MA@YN&QJC#B91'0IKZ7K0MDU?OVX,_UQ"%YID"E/O_"SG:O;9'W#B^B*Y-^"R
M6G?)9:C^Z;+=5[THFW!&[^,04=#,KO)YC\?D+*'9+CXC#B\.631PIG%D6[Y!
M08% 2>:*:%KJ-G5]O9=C$!XPZFO8*.&H*)V70) /+9E-I+\LCN5EAKOX7.W@
M?8P9^S:A.0IY]65U>(M*^6OTW)3?05GC9%P.U@BK80[RT!=N8R)[TGU%7?Q.
M G84\67S1"\3,7Y5&C[:.70A!UMC9&&/!X82*$%XH-%ZABI@4J!:R3D".9+$
MO_Y5YN/)^IH$9$"<=P9)-0)OSM08&],:U\*=YE7DP^];.5,]KB2Q$Y5_Y7'?
MPS'/S*TS3(\S"GW-3T-N<"&8[-Z!ZVSZ%HOOG!29EM9R.!RAM005,5<9BJ\L
MD77SG+Q/8!4WQ[_FE/R-O_$W_L9_"%CQ(_\%4$L#!!0    ( %."85*/!0_H
M/)8  .+F   6    9V%P:S!J=3!O>F5X,# P,# X+FIP9^Q\!U!47;KM021)
MEAQ;!<E!<@91FR@B.8-(IB7GV (2)2A)!23G*$B0+#E)3I*S-)DF-M#A\4^]
M=\.$>_^9N6_FOGKW4*N*ZC[5=;Y]]OZ^M=:WS\'\Q"P#9"H*R@H %A86\.+Z
M#\#, 8\!?%Q</%P<?#P\/ ("_%M$E,1$A(1$=+<I2"F9Z$',3/2,C'=8^=CO
MW.-A863D$./D>2 @+"P,8I>0$1>4YA,2%OSM1[ (" B("(EHB8EI!>\RWA7\
MJP_,=X <_P82EP$;ZQYP@QP+FQP+TPF    +!^L/!_"_#ZP;V#=Q</'P"6X1
M7I]00P;<P,+&OG$3&P?GYLWK;P.NOP=NDN/<OBL@CTNA88YWSX52,.A]%C[+
MH\HV*LW10U:AEZ[!!+>H:6CIZ.^SL7-P<@F+B(J)2T@^?@)64%125M'2UM'5
MTS<PM+"TLK:QM;-W<_?P]/+V\0UY$QH6'A$9%9^0F)3\X>.GE.R<W+S\@L*B
MXJJOU36U==_J&]H[.KNZ>WK[^L?&)R:GIG_.S*ZLKJUO_-J$;6W#CXY/3L_.
M$1>7O\6%!6!C_9_CS\9%?AW7C9LWL6_B_187U@VOWTX@OXES5P#WMKP&GKD+
MQ3W!('S*1^^S*ML(6(0T#ZE>NH[>HF857KD/_RVT/T3V^P(+_ILB^Y? _C6N
M68 (&^OZYF&3 W+ ^25']NM;_X/_M\#-H ]72,KJK31]]G1?\$MGWCK+M.VO
M_%&D?/Y.9:.^,9[M$+,HK;OL6F$6Y(N,F# LNVFG.X."9=0F07ULDKW1E&DN
M27V@*'<A>GLRE.-8+?TMV']-K%..<E @X4KWR3!8QYATK*1GM5G%YZN7CQ %
MTKP7K>->S\ZM_//8_E=E5-.]F9,:JK44TE@1)E%+FMNIJ5J31H7,W<V.W6?$
M"D-2)5X+E"%WIFH.C[-/?VZUK6V]G*[/,2&DU "_\ REU'B(\S_XQX'E@0Z/
M']'8N(E7]\"V@/+B[ UQTO"(E,FIBE6&I-N#(N-@.O//$<WAFT_A'/2DG3*D
MFC4WA)MYG5R+'X"^R>4I'U83,O#J*;U;79TZ'>#<"1E!)PXS0#M[>ICIQN\R
MY"H;^@@@N7 ED-MGB1+^+3OVI'M(#+#,I!?EH3,F+0+U:=R,Y0-VXA^"AEJL
MDO52])(5>/:[/J:O3U<@'R'<^ H*S1 IO&H=/-SHR U+IDS2YHR>/.\]"YEA
M&F'7S:BM%]E17.H\"V,;@D8.,MJKS9"5I-UX@P6#^O[NMH0Y&4BO>^@]/"<M
MT^;#_KZQL7UX-[7"K73$CNG$PJ%RK\%+"&C_ JT(!5/J)0=X:X I@?_!/Q18
M@]OI9+''VI+Y&0&BJ8$#-1MO+,4Q@)VKD"8LG:INS,EZ@NU;\KG&1P>_3PUK
M(R3M=; LNR\R7O2P*H7>-:[OP:0NIN1K<>'G#>"3NF2RZC-! :=WECWI/RM\
M<N^0!PL2LY6;1W1T-SFPK'?'3)Y5/7!Z)%%2VR"#&B=.3MC=7S3H\I(CSPP#
M1<M2AW'$B^<]^$2N#5Q\#'F_V%S)HO2.U;8P)U/C-:<"I]2 UA"ZWQ.! ; W
M0U;4?-M'%CMLA(PX!V[(Y?G:A$B[91L;=.1_N<+I?,$1^RPZ( XQ[?WP3K @
MZ7-(,-RFXZV:MLQB>@GQ\"*'.%% ,W?6P*Q?T8PG3/N!6WO@45SSXM5GV(OO
M5'="1J(,X;SLG>GW#Q-_C5GZ?2,[)NK9U-A5\S4+1]KE(H)N=(DEN,J>4/B7
MDIZ6YM'@V3$E"B3N\ H'Q$9%<>1Z_-/3R?^G8.:$<Z-5Q=ZT[H6C8T7V/%8S
M;K>N?_561?^$PM9,I_]P#AW]9OBKFEX!P5>? M=+.C@K!*?\1=WG0M743.^0
M[GLPF(>9J?W$ *?35=IZU",+[2/S3ZH4.G#T=;^4%/!,3I]6]D2T=>=LAL4C
M4="2=#NK52<R;U/:H3S067GBDNL^Z:=$O[6"-9-?;U>9A,QJ#7;YXI^>/G(>
M.&6"?&P>$2$E^7%NJ'BI]M:--RW$BWDR/@7WTRH>Y(#$I"6AA)T?7YKB)-O=
MT'C$2T&X9.)-<]KY[N6E;$N<UH1MA60-O+9D969LH*OV:?&SR:9H*_7IJ<9&
M8H5QK5JC5,XQV]2<NX,O/P_!=*)/C,YXKY?UX(THCLS_P=^)E*&2F!^XSW#5
M#3U<97D3Y<L1OLJQO*%3M.E!E3VG.<7RHU_+LZ,XL"*YE/19PKB<G7WI UP6
M21/55T$4RN2#K;,3G'OOZ4-,8I@H]H/V1_ZS5/Q'<];TWT]I]W\Y5T^@'*$B
M-2.[4*#D((*S+NG,L&,B0^6<EGE P55MKBO]59$<4L%:ZNY$.<NE$OA\OY5E
MDOO@QI*=T&?%=K%!; _1<M>X79F2ZDEW"*_USPXO,J?].@_9R;[2V=;@7_KY
MQ#ZY-K?6#A2X]?!UIR1EE]:=!U5BDVKBE#U,6S?/PQ+@^(^=&Z"1#F;J32"^
M,Q!+AIG]_LL4B36#>Q[NYN_Z78DM!AVR$*UJS)8NQIT=P8H_PB_IUZT/AR.0
M=[F-O1VWRG>_)E=]/&%>S*]/<?&TT;81+T%J[-=A@&!?-:I>6UFY\1IEG+SM
MFE"$N*WU,L4NI/SF@_YW\C"P\+X30;<]_.4HF)+RFJL"_X._#50?5HE)ECHE
MG]32W"QT^L3HH<"$7Z;2!E=+;_6PH?#V/6,P*EQR\REYMS:>E=M=)X$W(7L/
M82X[@/I TGR#D76'K7MNSM-OPD(/$;>J(QJ9_3B[$P-PSTLW1C#!ET1<_&U6
MRXAVX:1A&\GWQ:_ D:3O=ZH9T4FC6[+B(R+^K&);E NKWW!%\<:)H\K.)XP<
MLIPZ?(F8&4?7*D/?UJJJWMW>]V&=:K[WQ8HHE\R7S,[6H:XP_LOUO _[<[%H
M3M0$R"F]'H1Z4>++-?G(A1OFK2Q1_/3.GO6+$>]]&:7.\Y5/#&2OB@$(M_1F
M$^R]DMM75RQFLS4-:)BCO(=7C(?;\PBM2HM? ZW^@*2K;6Q9P=RI/.]M2"ML
M6#Z[R-C^TBJMF^&SPAC!PSYE&QUS!(4&M/UQ-G3$0AT#?$_$ /3 D5.DV9%!
MTWT,\$KNQ*4"4D&""/*S"X#'M;L:&G<X1[W R7XGCC<D;:GW;00+3/G\7Z 6
M+YPL&@LFBGX@STCO08G5M<U,VSBZSZ!YN)M*:L#;&AI>8P>3Y:J=;!W=U'+P
M3Y-6[U:O<1<)JO VG-:_83L\<T"1F")+$K"3I1T#'M Z$+=ZY&XF"W*LW#K:
MQ0!8_O(KQ"R=[\E]'&_^O+"6#P/%N(*E#98MKJIF6^*;(R]&H!DJ4Y7P^V?A
M[@U>$2Q20A'[WR^4SLO[)2S2[[(ZED>+<[D26VDFA*!4"K@\#CC\JHS.+SX:
MXD6[9Y I1K =E>,M!9LE)4[+&V=$2&/G[0@&%,\S,*ST#^,-#'^C"F[  )%-
MM#M.Y4:B.04A-8Y9="]D,,#EZ>>]^H*:)+E57JF<L<+209#9N,B<BTCHF K^
MAEL8*-QP/-\QQ1[&D1V%^X];$\]-GYZ=B5$HI*['BGJH'Y )X@#J8.\0I 7<
MWW8(3<)5+/CCY4= QE=;MY7!7]T_^BR=.G:%<KF:F^5U@'@FCU\>U0""HM/W
M0^2)A).'VH.MX]Q? N2Z=,^QA@>'W2[T_OGTZ.\&BV!V\LL;L;DIANM()W/S
M$K;/!4N+)D9Y7=]UKB3:W$+:9!,A(Y:S/7'^8CD;?"*T>1\*DK".:3.>\D$2
MFU*@=+@F8FWOLYEQ%HXNV+>!V<FI+?3MP^FPLME5;@ZM%P/#8C\"<U-@=^(Y
M,V/U#0S9G_?J9>'E<U1M<[>$BRW'$9MY0]22"7?.&GQ ON6KN@*HT707$S"E
MEN.J2AN84I/VCTMI2/D6_5"."\-6P\FLN_TWRUA6AY[I7UH&9H?1WA7H<-56
M)%XX!H@H'XJB#JD'%&,'+./I&-GH>K==IKXYA4+A6V70Z2L,(&3"UKC2NM?'
MXE:\3>V'Q>!@\O#5Y8::^58KT9[P)T)#2$H[;L(/CV,MH@"T"@M<%"5'R5ZE
M>CF:U*1W^$$%[MC*5^%5:-HA'%6LR=NH,!J[6@E=>6@K=T(]T7H$P@ 4IM6X
MN)RVV)O$9FVU@02(@I540NY/F[%VF1^K?_;*.@I\9TXZ"? NZ*RXX%F\C0%J
M09?BTS4C#ZXY!]D?1ZR+ =1K)LI2%O>IXD692.W7TH?U#E\-BGSR6^!)JU9,
M5MG?PB?"?X$O(U]F-^DRNMW(>/IEM/ B.=Y(!&4?O0<RKIK:>S-5%0R-$@RT
MNHQJ9;43=F",*(]^H!,F7ZZG?Y@6Z>K!>TO+P9ODJ<5^LW(VHH8]XTI*1[W*
MGO HR1$;9%^DJ6D\<6K2D"/^\CZ!G^3V< X, _1=T%T.=_2FK"\A C=.YD:'
MR)#1 5W:U?"AO,QGM<P\E=[PH[>]$TE.;K%R7"<J%3X6$"BVO-<--08B*I>4
MS3H+/87AE-2OR)M5K343#LFK0]Z_(L.)HHD-*J1;#OERLA<8, #!8C7O9!FK
MA,(9<Y*%"B+LO7&,5&?R8/YBK-BW=K%6&8Y69YUZDV+N0$4OL""G18I(/#M)
MM"#=,_F"<;%_E"4HY _& />&RC" J1L4AMLTMXR'C$K)0$&ANV]-$U;Y+Z@]
MG"Z/4S' 0Y%?2X#<NO8$!MBYGH"6AKB^"]?K+_B?387_7GP[8#29T3>U]?(-
M;3>:Z_!FRG5[+2[R<Y))2V%<I)":^%DWX;?$?0)!7.!RM&Q<?GU(JA-*YL_I
MM;(#NS.UQZP7=ROK@EU$-!).VNYY2?5&<"<YDM437L(9*']+D%L/377^1@YF
M/-YZ\#WGW_R?9>>\:[=%?_:AXN'QEM=[DR<Q-2E"[TCS;">)^<'CPDJF3(+=
MA$H+=8+M0?*R-8&I=0^O[]6[OU=F_EE8[I@R5TVM=/;5FI_?-Z53@VCHT(DW
M9K/C3\3Q)(VVSVW/%KS9-%(S-USM3%-T;=;VF[:#>.'L-0P[W>MC( HFYNVJ
M%G,6%NJN4EC#T?<HY]MY,H'D%S*%/1TW3+>LL4"60%WK$EOQT(J@ ^?6Q?#5
MUL% =C>#V=K0 HAG-^&599+ZXUC%D<D TLYDPPE]A:-]FH-V)!G$^DNBL4EN
M[+=G5.;>VY]^52&\.EM($^>] [<J2O%X;?AY\.K*'&&RLN,>=K)]GO3M2.>1
M'RX)NW[31OKT&"#D)(XLWS&3T!EO0-)Y #'E6=L=V/]\*O5";N>Q-YF"?&]>
MA; 30K6)9)ZBU(Y[^]F)X8X[B&9+]DXTH=W9,[Q!H@QN[&<;CZJ<DF"#VQS9
MG[[\WS6[7%O$X6],J<;E'[(VIT9HC<]?/5^(3%O#KU>UA'C'/S$CVL[Z)"_J
M&I2 ;JN00. <>1MIZ:[$[#M#YPV/U?1,)DZ+?M2=NSY5[L7Y!I)_OG7Y>3_)
MF;WR6SP!GKOXH*+$+^DQZ:F-D<ORJ&4TR!N&B&>K:IFM&R4*EE22":Q9U&%W
M&RO0%+F7QW2]F//U_QMX?W^7;]B/:.S&ZXB#V-F9WT?GN*LGW/ E63^C&H2V
M0^ 4Z#?"U^PX"RW2O*I<ZAY'O678M=$I4)%\MLOJC'\SY!OV2<^:D=EA(@QT
M0O?E^LS0:QZM"HDY>%GWYM3!3;<RQ<1-D=ZR_TI3@ TU$%LSH@/A51C0B,FM
M:@C[C78]H\5&Z*3DJ_RV6MO_@ZQ#2HE(P@#W4]O-SCHP@"+]60-<_=]S]?\T
M<9'8&!\FZB4$M#Z#7E>Z7H]E@?,NG;$F/9&RD7$/1$SS=W&#RJ-F3ZK'.J.[
MIZE:.//RK0T+TS"(]Z2:Z\1D(,=:45BBU1Z'E&Q)#KKQ0U+2A."UDI7/*R>V
MGD32<,0&G,]JB)-(V.Y4CM=(J>E..O+>-R"+75"<T)[(72VO,1G(B8Q1'+AO
MQQ=W.4E]&4V_[H$!PB^M*_AG]Y2_M.)Q2X/X91%HCVD- \-?QV^LRUA]2DWO
MP?E#\HR<R QK3B/$C7I][OAA@-.=^C&/!3&C.H-2OOCG"BHAQZ2%)6-@QM&/
M&V!WQUM?>N5"G2];.ZII%#4.3\>WIC/W9Z,?29Q3UBA(UW B98^0S_:CC@?D
MF.PEF?I_>E=UK4I\;XQQC3GM\O+TFFH(;1BVDW936*!C$&9W4]*)/INOO.9F
MPO_:#QM ZF, RIY(QYYP'9*DHPL),@S@;G/@-BW2V;'&'^7%S);046G</9MK
ML$2:1$I+)[W&1%H&!!"#?5J#4U<-X+?B*(N)Q?I?+3\^1_0L_&J^][<78RXZ
M)]Y,NI15VN_HJR #+UG>$0<LP>WD>:A+!Y2+P#5J(55;CT:LBY2$FZHN&9(,
MZF!4&_[%%8E(\G"]XI$6*:R7(7J_#.I.&DWH'#NX3 \%^QQ.^P?X(VI''/9&
M3KS>60;>'$7%P7%17V7K( YT<BX6=* (2F.99C1MW=$UHQRA2\(U"([3A&P.
M1\Z&+"+Z/1;IQ;7O :YXC--9T/:ZE@:':33[!&UZ">,;TOZFM1XT+09XXV2D
M';,>OV@Y'W>7-6&)+5^OLBLN25ES2E1OWU5; RR_FII.TI*@#G=,E7:H.^^O
MV,\]XMY*DDHDG[=NL3Y,#N&/:)+'271B5?T\S.7Q4 H%F<(+;E(OX!-NI6C$
M&C'>P !9)3'#9OR):VI7=8I9&J;^UHB8_(I!XOQ<K/7@(C3E^!K*L2-&O?W\
MX;GHMKZ.\8EL)16<K44Q:]186HZRFB7(]X.N&FHF6P*%XSCKW=%QGDGKH1H(
M;9F3^TP#5JB1<&!U&-4 >SB)_Q#JNB,W[PQ-4GTZ<2WR@+\)N:R LCAVD<@U
M82)@OB;R\I^E,,"-!*0M]K.H']?#%?<8 V0.?<8 0<IH$<<Q]!"*;G=_^9N.
MN'78PV70XRB@\M_J\'\4=/A/59D$+"!S'S-OBW8*/J"337+\>JI&\6PJGFJ"
M-]DCM#."0?K!P4/:1;YQ)%/@64\7R'(^\T+6_Y>LU-I-Z_HXA&(+N:^='()Q
M"6GB)3D<6JU.]C&VK #L^?(FVU&@,8K8$@.T5QZ:H0C/6E.A,:RB ^D458>#
M,=%]*W%? S[V?9*.C [QE%&6*<DJ76#HN-0+WULD9NN7TO]<)YCO(]LTE:3E
M99F9'<5)]&='O=P3 W1ZC2RHX<2%'_ 3*>(,[X_&5=[YE3/29 ,IM7>STYH=
M-B]ZTI@RZ]+'G'E.R>N)E[^I=ATY7I2_"@:('USAOS+' #DQ?B9_HFE^SP!B
M6\;<C\Z-HM-_$2PNTKTM2]LTYIBJ=7@2BK^QIWQAM&621Y4G&1\RTEV#KVMZ
MMF,SR7@6NEKBH(U*\;@2.7(^;&6\LFZ@;YOVY[<KB9.0<_%N=;5<WERLXO%7
M#,B<Y\M896VGB"A_O1+>;+O5G=TLUXB,]3!U!_$&M*86#->M>U9KW4N66#5X
MZ0SKN!NT/+Z3MC]?YF=N5SA73>,)'_R#8ED^D"8L@NFQ7;5[#9/AN7Q]7_7&
MEV@Z>U2YY--0HDW+)G&N_Y/P/=4"[^"9ZKG%3\Z/Q%K45?;6WM^/L8R9' U[
MS-DK\KD$1N]8[VC>6J.L:-U-&T#L(N@-[423)!6,.!JBOS,-VEVSLLS3'&V;
M0<V,K@/^SI,4[O@1:6C>SNVWJM$S9B%AP1:Q 5@')@["^PZ_^:7FUT/W7"_2
M%@,<N:;$755@@.SDYMHF544,D) X 5V HBBKL?:J_U.31*=<A%!*/O7MQ^R>
M\Y^W@*]@-R]FF</!+Q*3>^L]MO,BEJIPLX?'THW:#=_>I>'H]PYRY[";QB\J
M[</* <2Y4:-# _3-@3YS[$7/4>'@0:??)FHHPP)")^W$^@!E6R^G'S>CAOP$
M<Y_R ,_O4OHFF/K["ZR]/2*>CDQ>4->.E8[;U"0-XW9MJV%R>_ZI<3?!Z21[
M5Z9,L5KVBLEA.$+83PZ!F-ACD8T1#+FPKN27946\_.$_C3;?97FTU)^*UV%&
MW!4G.KFO=" 4#[&>[I"\GU(\MU4+HRD8R-A4R+HZGPF46W<]\M>H223=W;N'
M/F</8;2$JKR A[]U&I>$AA'YP!Q#^$^I%N\WD6. DC 1#.#QL,CV*ZF-QH%<
M/;._.2*FD'.!-_US0MNCBKC-I\RX<-[M]T6(8DU:U[LF!1=ZV1K@D&TXE,+I
ME_/U,B)TWY!HFJ@A;$K7-? N@ZB'HVF_.HQNN7Q=8_C\$?VIRWU"PU+;5C-V
M%$PK[" XAU(+K?*+"+-?S<YL+]38%7B6_2E;^=7U;<&^U047"]M%JN75Y(VM
M] CT2F:5%7-09N>6#G\^'0Z7W(^V2NBCH>XE]*G,6&%<CYU,76F]91_(.7]I
MS](>5[G!\Z" #JW0$@&G0;Z5K$/Y#%[G3?ICI]>@(RY[Z"D* U3QJM^3/D_6
M;-[?]6PA.?2H".51*3IV7/]EH(3"J[F^3)W*)7P%\HW8-J6'+#<M_<9&Y<'*
M)\VRL$!T_^+3<]LVD;<^RR"B)3>V#_1UY^\_0EE,>"GU([6B6^Z[O?Z&,+#6
MKXDM*YR%OX[D[Y<K4_!G6>/&'?J\&@"39"TDD(ND@KEK5@E=ULBF^ H-HQ?@
M%,^<%NVF]"IC2T$)"&Q%)(^:PIA:RH?0@P0F4V$IR @G'54WW>, ,+7Y;GX+
M7>N/U3(T)\+5X*:;JDA3>AR%"V*UKLQ?*\OTQ>/B66H9ROY,M$&)%[ULJKN
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MFGM0DV>^T]_1#-5WL\<<SK'./[E"K!D(55TBRK+E=[-+-9YU5[ZQJ"+C8 )
M\JK_2?N<BG@= UA5??M&T-H?D^'HNVQ#)4*)M9(2UWWU%B6X/XPFC]3:(VLR
M:CKRW-<4.I?9245 X;?7OE^J3<:=,=:E^Z.O"<Z#?-GG C$%8RW)LS)X&PJC
M,#DN7#=97#@$,? D0<,/MXI3XNV S4(:X)9&:K@%^\Z$0XG_E^0>9VG$D@\E
M"BP9!0PVC BG+H.',IPX9+SNFR_XBQQ.]M[E95Z260ZHF=90Z8W4?-/"ZHRW
MDFH8@DHH7S1D7'>\EH:%A4.1:R@)Z,AI(;\S=&.=O,N7B=* #F4*LMX93?>^
M)G/,=D7HU,PNOY!@ATBJ.XBTY&_TY9%^MIW+KZ^G1:C7R138@ZL?7T:>TB"\
MJK"%#G695E;1"26:+^3U=3B>]9B%N$X;CQT\%)T^5"%5JWANZFWV>$*B86S/
MTNE V$(DU.>PL4//@-.)E7BNWY^T/^;Q^1]HQ6Y'2< 4'LP.\AH:KC?5M!7(
MUE*+G>T6-RS<,]YRSVX31:-5W1@-'7ZA"AJ[)A1?S2A! UHCA1523I2(.?57
M)@C+9R&E[_N"D,7>: Z#'O8/T#Q[ZGW)59X@Q*^WF9>#L@V^.<W9]6_-(F3I
M&UYDS')29*R\(X,X$ANIU].%G>%=BF?#QD3N\GYRC0);F2>]4*S,^U=G4D=-
M"RTOEG':A@%.*'1WDN'\T>XR?%._QOPFQ4@I.&(D[KP#W^QWB6KZ',MP=ITW
MW[%]Q0!FG-<,<KI2+Q3),.V^1&Q@3YV2-]9Q_P=L-/TG-M4^V3!5IRJ/(,_[
M+[U6$KA)^QS:;T[?UM^GU'CZ)3N* _B[4:^(2%K^N6X9$#@A&(_?X0SE4D<8
MM!!B@*S@Z2.GPTR2JJB!47_%'$241.X8_VJCDI(!D<^%\M:$;M[O;A>[I@O
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M[IS<*]Q.D4FN?&7>&/%@MZ,XP\(X?J#4F\_AJV/3F-!YY;&BX5%W^9?1,PS
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M%CA'#HK]C )=_-R%E0LO>(^K]WR"./F&E. "Z(=C%;%606?V]"+KXMO;;\I
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MN8$)XS(YO_BZB<LCA8'JZPCW405?\"M_+LD Z*,,JB-,0IV1J=\2C6_Q,I$
M X_=7ENH%^^J'I,O*]Q:;<=2+:7Q]=\9LOO_4)[_D-,1_ZK0#U/$ CB$%O<8
M+SG*U2?0UDLM-&<E-3QO9F;6 #QT'U:O"W#UW.N<X42=STQ/O,)\GU*<<3Z
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MO ('_IW-BN&W2=>L:H@%Q,6-R\Y'8P'RPEYVO^^NA#<H_Q4%]W%5V!,J^S:
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M"T:H?,$QEA+L<J2*I;[[3)J:EKEXT5I/(EY!LNGM*FX#'0;\7>W'SKR$MDQ
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M,R+N+&SM50.JPKG Y&4N+'(#N+OX\9V3 ']/"ZNVY# >%M"N<4)]M050O-F
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MYY#(Z*-=P^-AE(8BS,6+.AM6D[FKG'[*FF$RF$//];DH<97I[UX@_+_B?V=
M3U[3%R7CJ8<%?:P(+EK,W5]3<J*9=BA\+1VCA<"?U54DJ^S#;)U8"\II;^E1
MWV @DOB3-W63?*-1,=1;OVQ'HK3ET_C=A6X'3CQFN\%OTFYFT%P;ZU:^!M,[
M90%E+WVB#N3G;X1-1SGDMQ 8>@2,812-_Z;C8(GR7S;4(%F<>[S&%G7+_/64
MGT'&M0G[8]-;4PNFZN-&2@T>M-2R"02&9SBC''-;;__B)]>;W@,!(Y,Z-8BM
M3^ :]+DC$ FF6XR %2$VUR3'686+7T=*'_N'Y19MNY[+)$M?C@>&L<WY;$L3
M[QU@ :I1VR?7;L2B!^YL%\_*'#$)_==GEZGJ(B/G,T-91VV%'H#Q<@(M+)7;
M 7C2(3()PM$A-;.I4UGUB)*34<G7>:(/VW#+1$9JIAA2TZ7)$\K=_0<Z8"#I
MZ3=CCY2RY1)CHE]QT4O9P^!WV*MRC*V_SHDIY7W<T])X[$ZK1F#LMPFNUE,,
M$98LY5*]\"DA<*1[)C2P.+"G.&(^>4';"R;@M-^=$M(JL&!^S_U'^U'_@O@G
ME37)KG6X'QI&*T#'S:MJ4G8,N+U#F.D:L8 [,O-<HIA[^]2041DH%@#-O(RT
M=H?JCC6++T=RZ$,;HD0X$0GV3<1XKX^8?,$@#$5P@.RFN,/YKSLWORZL1P?6
MI&L#*U/L])^EJB0PVG1QF7_M,?&O*Q:41Q(G+-.Z9:HTJ7[*L2OIFX*E:\_%
M7^T:]__:<]+B;X_E]+Q&U+56D[U7GR$6?*$6YBW8]3]/V8#%RP40KG$6*USI
MVMI(,@(/,/W LX\:A]PJ$J^T5VHU\-&:7\==C'K,? B$3@I\G[%0O9($YR46
MRD#7WB4F72UA289T>3*MW]5"<"WHK5];S#7&77RI3>A&$63Q2?.B)NHI15:A
ML0F]O;GHW>JF&X#=.>6>A=.B141N%A;P^6@112R+*M+WB=+7)_5Y@.%<;V5!
MM6_HPMC&2_/,*^HDW^7OUQ66D7"(#\O4..B.KXW5J*925[52/M0HST(7I9L/
M7V]15L]QFMMK97#OWE>"W?]:_ZDE8K>ZF+'>1]YK.)T2?:QQL:G??VX1T9B1
MZV!![/9]20%7Y1B"TAK! D8\'="XC&A=(T-I.G*;N<0(C]A#:<6AD#2\>YAS
MLO-#+MF 4:"IX5RDD^6!N8'()\ 0L>-I\;A-C;2$5B%?E,C9W"$?8''& -3*
M*2I*VBDSG9FV\C7?Q"@_HI5I\V#K_I>JL4]]PB.,#S@8.64#]1#LH7DV)NQ(
MUM/:1QK<;NZ*,0(ZKUS*7X3=+LV>)K0)P<7/N9[F\B)N,VG5YC36V!#]G5Y5
M >:P9V$!SQBZ0IIBI7N$,J49D(>]",N:(M$080>2[:0GR)]?1^>N^??[^&P'
M)0DM\"$I*H7IM99A8^V0AY)*%@>GQ!X.)@G:;8RO:U#IY8; P4_?GUJN]]F2
MIC$</75I*@YST% ('P'),$^T,H%H>'(G-(%M-(]BX.Q2?FF$!QX%?/MHY259
M\JEI>J5MO9E$38J5 -I+GX<00BR@SQ I>ND8?<;#%RV[ZHK(O/2F>6?:<?A5
M;3;]A'H9N0PAVN(P#3>R3KE. ]+Z%)HT95F.@G>>SCCX\1Q'BB=P)*Q<=+#@
MBA>V/H#T24W*[J0[MTI<\2/%? B4Y+@06.Q1WEE?[BL3L>4RODQED60$<UA6
M):]CL\TQH<RZ4>LA&^SY?0S>*<,SG@JDF4AQ<;H+2T1$B9PL[F1(<^7"["Q:
M$,:3U>*'K+7M*UM&D/="\X*ZB-P2I\6%'N?K9]I/3V*;;J_D:D_6S&+P\"X*
M3^^@@@UA:)(BGXRUTII2=JW*9BF\ZVD9TA/Z5I]W8K9E[M5,IA\0TJYR3'IB
M/H^[:!!NT4@8E[ZWO-"\/+,6I1#;-P'S3':'YX$R2+6>C1O?WL4M<?IQ5R8P
M]>#+WE[BWJ+O,+J_<O1( R'B8MBBK8N0@19MBVKUT7]+^HFL6+I#2.A;/8^_
MM]SQ(Z:Q)B$[@\O2'+R=UVCW5"-:%05QMKC3WF$Y$.WM;#04#&+;:*.H"W13
M.BDA\YP8&LB8OWNIDE\<X&-X25S>1EDG$>Q_U-34D (*M9O,4-CNH0>1M$ET
M9Q6 3#C#]O:4<VH:S?V,$ $9-XU18"_;19*CX46F@U=X3!PWE>C6*S!T68D7
M76Y;@\VGY6M02T"&/$@;%5MG=99]'RWM53X1WBZ1%-JLT_C%H:"TIJ5E-09/
MUVGU^F.<#)GFT;QM7\Y*I-UBX!=HU&X*/S>E,]_W\$46J:.3PE\4H">C"0MX
M_0"2G*MQQM.#:;Y*_E2O46,X9M;)\-3\0A;6(9R:#FF7V$MPYOUZ"A.M"K$,
MTNW^OI* WJF8+#F67,*?LN&RH,"+#SGE/VKK[?%<\^7$ HI&H#N7D$\YG>>E
MNSWAU>5$73YL@:6="LJ6$;N6W3(OO,!?:O0.08CG^3G0I.U1DY47,#3'"M'#
M?CN#8RXB^>3;J?O=G@B;NNC <6]E1..T %N;P77!"+^V#?+,Y28B/@5D?M S
M2J?>9>=UJ;%]EB@!D';W> ]NYS[^,(M=J.ZIZ.N/BL?Y1$8^IJO:XZEHMO)[
MAJCBCD0.HQK8#$(NJ+XFYE%$PX:#E.-QV:S2Q#W=,3N'E8NJ;D;R8?1C& \W
MFM:[U:8YB?_3FV?BW(/?>C: )B05<6J(J&1K3F:E)5J_W0Q(*>=/="D6@'O$
MMM<*R0I>L9:9+T-!GN[0=[4EOMXNCI(%;@GOA')+R7I(-\RROH@-'@E;JT&\
M0>4N;1FAH\E"H*:)C:9D6$!O:2$$?JL@SK<+:GKP@&^!;=/)A%*&'>D0:%=N
M#W8V6^?H'^$UCBZ4'2M%,1I-K$X(V]T#UAN&1XI7<N#0CE?(H"?+@V0/-*K+
MSU>Y.-H;KJ L8;F9TZSB$8DO14UB IV^U3DUAZ?U64X.A,%=3YQ&%&X[.?'Q
M&_3)PZ'TY4$<O2:*1M]B.T?Q&R$KMFGXZY:0NQX'M@B]^)WZI<CI&Q''6( ^
MD 8'9*6CZ;,43G#;-6V8J,T5=YP6]S"77M63NA;N6KM(46/ RWN7B3M;LWDE
MK<7MZS!YNT.0?,P5VI6D/VV789PL2]G& I2JZ^M?![#&^$^=PTE\\J.OHW84
M:80B*3(+)16E\WQ?N+==C_>4#S#L@P!I:,J$^<)G[-*@0GIZ@P)96_4_K(Z%
M1]RWAR07;VTK,^&:L\O+!'K@'I5!.B%(5E3"%Y!69*T;?ZJU^<_2":N#4@C#
M-@*(4MGC7#7@:#1EIYI8;; 70V];0,QC%TU;L0!$ER(JTVT-"R &(L#P$ZB_
MT);5&7K6)SH#U8M)B$'LK671M(;]U)CBG=:6_OA><5O- :6M;L?1/@..BY!Z
M$=DQDJ%Q6&;6AF^.A(;S4LH8U.LPOL!%P<H6QO1^8@%"%K07PA"^O@R_*^5!
M\4?KM']VN"?680$<''F0)D9,F,VO.28.&'6-YUB J^PEV>1N]>\<RO[2<Z'<
MT:S(6D1O2;DI%93X,Z=,5D5B2L*HJ>!MBE[)BVT)<.FT1M-&)Z/#N+ BY@Z4
MX(HA0/,@/QY" D'S<SU6UCS?OU.(Q5?=V^0:+!4NIT>5?Y\X$JVN&->=>A+W
MF4>,SI/.,DGS2)I$8ZSZDIT]7+VRKCHR:OVEV6V\X^4R?>DE>E\[-XUXDR=,
MT)J/'8Y4FU1NC)H!*/A3G;U?=PC^5>,XOEKQ5DB7J6:U'NX-Z@G2\_'EB9^\
MK*0=/G8L&6&QA;(?A1-$_;W%I8:Y&^6K>C><^>5BK4\62$=^L@E.;8W(B6E1
M/'MQ.W?$1_U1FV,1JO)@I<WA1$1AUL,%W<'B>7//!ZDOQ?EFO%E;.J^)6H8Y
M68#WTQJ[Z8DTKKI842ONY&XSR\WUP+(X:RDW(F8UYH^QA7NT^3;@.2@B":TP
MQEO]Q;5RK$,(;HA??"\Z_AZL2$2-K08JIVH"2O+61EHI(C*:>.,\+'RX1XLJ
MWB:XIG>P%.-W7>T6%TN+Y[>V(:?]$*3NEKX$>X*7>,;^\\J,-X_,$^<-HI?E
MGV(!MV$!6,!C-5$LX!H+%H#_V%VD:H66D0:M@Q@\_D!YIX=PY,F &"!N?:-"
MIN;(SMTJ^B?W$18087(OJG^,X.W4MZ[7$4P<0U(_]!O^B^%?:W=?65HU88O;
MA3EQ4[:]FPT>X( O-$^@^9&/FPY\V_$AP\8K#H?#6Z9/1K66DWOT<51*&C(V
M;OZ(#G9T=Y+S\=Z2/I$QAKK*YK>X56NJ<=$+;76G>;RIOOK?DBU-$I9V914:
MFNLK(V&J#5)]X>+BLN.Y-K]$?EWK[9'R&H4)BUIP/>0XZ $^+A;@3@R--(KN
M $I)?*!$ONRB[\1;Z][\_-J'"QA&D8H#=^8=[SCW2:QS*VZC#1^H(>"B9+W#
M'R7IDJ.%P&06;5/HPQV;-,QGE^[W BZBC@OE:0U[&>H..4$TTAE-N8/YICG2
MU1W$15W*:'G="6^^W.U&5J#\A#K,D?QA]A,2>O'2%$Z"R"CA*.%(Q?Z<ZPWS
M3[\U4N2XPQT<6"F)G0X,5=[P',_"&E4X=]X!N<B$6AB&%?VRJQ1>]'!_[TJ.
M;I"V:5D,<BF>]YP%9BR"CRMW(T_?X8Y#@?#LJ#KB1*;FZK#S(9!!&[]*+AU.
M1, +:PGYC/ \^7P#%I[JI_@E7='K-L=DUP:-W"F?9"RMWU$E^>2F3'=/Z.W&
MO.*MVI_5.VH2?;8_?RC93;QB)L2OD:?GIK>WV&QE&$?+TK=;(QMY.O.L1<5M
M*W9@?DN74N[!%^\4L #[@^;2BR&1P]E\SXFK;T% G=(=\+HL_+4/;7W=1U4&
M.%<0HTJP(:(U;OG&!QN*M91[GU85'NX<O>Z]>A,X-YMILZ1#JF.[6"/$XIS1
M0R]=V*+%B^$T[.E@B4'I(J4MTD WPO?Y-6\U']/-U_FY$!C+.>B-?DD@-KO;
M (Z^''%G#'2)UU3\2!<=S<T.XI)^ Q-D&TIZE/;PV )S_QQ_0:$*>2ODMH,
M;%O&-<V<IK6?6N7K#8;;PB8]&K7CKQX!G[&$.]J]1^ ='>7D/)?("ZF.9!]_
M.GY__*=F[ )I#?FG"IQM&UH^DJUSWW*/(L/N'; [(#D\EIA_MDYE(CM\Q]$
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MR?V6RLEG4!^-NC^JVH%M+CCJXKU[;22Q (K;Y1Q58T=;QY*ID.-BO/:L(YZ
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MJYL< %L:T+]?O>78_I2=((W^#U!+ P04    " !3@F%28Y \WL]A  "_P@
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MKI6:7*5U-Y:#C+V6@$^;EU&!]_Y4H+Z+"C#3P*C A:\=E)TLE,.%E844+,7
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M5[7WM,'8YPW=7UU/W LY5E+Y["9GOD[9M*LQ#9;9JF&8JX"WZG.<O-&E6;%
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MV.:K KN8IX\3WP@GH-^(Y^>QJ;62S#"QRN.F:NV4#?84O%DY*5@JB)Q+4?<
M(0#-+_E=H0\EQ%"T92Z"CMX)/BUEV6?Y<^"@93B2[+_+EXPW)<Q N8[+"1V<
M-/.Q?96,3X2&8SIENQ\W'<_2*4TZ2VML9-,Q@BNQ G_&T42F")&TA'[8NT_S
M59T**&*64UH1%"_45],MNXT3Q"+)I@XJ\,,7C7J5CZ8MOG2SE=7H[&!LY&Y[
M=7>GS>(6IDO9 +[2#C^F"$*QJ7B*057.5D"=G@6+#&%?3O7.4J;=$$>_%/*C
MO)Z&>$;"LSH,KZGY<>:CYI?:2IGV>?MQ%+(?J7U _S8M9][5''7CSIW5+9C>
M4/C)X]8/&N^=C$_!.@@448&]PW9V)P+SV*X_R;M X<A5W;]1PGY_R&3"D<3"
MF3(F<%8M;CJW(:#Q1IEJHP =38-Q%4ZBORI5*0Z=H^%Z 2NSW\L^=R#_HY9[
M[]4O0XX9$A)W@V7@HW/WC>O<RRW('][IW*&)7+@G8B30P&L9AA47?QPW!S7+
M-J$"CVJ";RRZ(+K+[8^.F 46YC=#/24]BT+6'%EF'=(MS.%Y:EKX2_<OXUP(
M_<4QZ?;K,P?[Y%0K/+1>JW/6TV-XQ-9RXX^ZOE6R^"B->;_!*U<9K-)GVC]K
M)ZAA>G$XTB0FNGJ@B;X(BIMZU*-:7MHKF9>XI5_V/FZL\?0J[=N\Z%!)>HG[
M8V?&^R;[7"54YKGT$2/";PBIRFF>9TCV6N*UN70H<G[6<!'E-=<MAQ+[BY !
MRY$0N>ZN"YV"2>;:44+K8O46>ET4$S=9KGU((X!.*$ENR,@R/ZDFYWZ\FGL0
M=O"\B+[8L!Z+\+2Z4 2CAKF"20=&\>1A%%:+S] L+<1UZK9MZZUJIQ%%UVQ+
M\4YD?2)?17>TFW\ZL(?'@R: 1:>VV&#?:[9H>JBIJ8*)7>%F^=/YX_M[- L+
M8FZ]V1VGU. ]:B4'&7A-!1)/4H&1'6G)+ST\1,7%V8LD+@]=*MA2?>_$\(0E
MKJS!>1"!F+\[GU;2F834K7["?C%4^D+)EGJ1>^J.$VJVN[.[SA$9XE I1\_:
M1T)K* (5."KPT*J'U*O9OVN@N=E8^<L<XU4<)$Q.0J_M:BE>%(&\K1'&Z8!H
MFD*I)6=6M#W7A/'$7U2(C4L<-ZD.FKW74-F<?#+#W+5&;+AL9&<3.2E[+O%
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M>@]&:BF3YQ='15.N2^?.UY7F>5#V+^VSW428XR:6=U&!9V%T^\7]Z+GSL*'
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MK-/L,$33#A\X&2E:X!@TK]P?4858S8LN17#8'<WU;%,M[)4>O!ZIP72MMN6
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M\9];F5/U_R=?1\.JX[(KB[XT_O355W11M>$4.>B6%0A57L<BR50 BD<I$,
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M)E$PK@WH9->-'7]B(2MXQR:^W<F_*2R;&5EWA["6T^057_<A-]IDR#@$@!A
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M&E 4?V X0E#FS_RE;,F'5AK)07QKK]E<[TH' B\$>)X#XNMC:)4,9@/&T ^
MQJ<A8\ 88KXIS4(2B5$;3F""$UXLZAZCK5&:7K4X[1$RC.@!!F8P$X%-R@&
MK0@8)*<U_7W5+,L% YZ!!!@!><YO/01F;TI]Y>#L>N>N3.=IT(4!/=0%[-:O
M'02F?*65'"3YK6_>_/MIAHR #B;AA7K_T<',M4F_.U8E]@_]A0&W4 _G9<1O
MH$26Z_=AX'^JF:]&5?# #O*NIN0VDW:>8FO[[3Q<AY/-=<8D9&*:)Y)HIA?V
M_-RPD#_1U"L;%<,Z,-.;//3%NV,,@UYFR49/D1!X.M09W!@Q9$6=Y+FVG>ON
MG9Y&OR,\W#6;-"'C-TJ L@1FWHQ*H:AU:=$+F-._F_D/;28K"*==F2&E/<AI
MJ1*M&?799?3(-9V  Y4QPY;A,0L[/%#O^I>AI084D $[P/CR::%_6\6_F]FZ
MF?HY\#L&U7V5Q>$9\</S^6DE'[E_ ;%;-9R*7XI?KSLX2@%]3Y(UTA <<)-@
MSG<9M:(I/,\_L<%H?@*7N'VY""\Q:*02K5.+7H#UE$:0B^6(B64O?E?4F?]O
MH?O?S?RWFH%*>S0.S* "??@\LY6R51T[5H789?=SY!H6+:$4"+ T@<>XQ6[7
M!T7ED4AZOK#@V:'^V;&Y+.@!]/"CR?[%NK7= J\2] #9:UU+[O*O)?-H3Z_\
MBPOY#CD3G)6*.IYU6+1B?14/;W??SED7.K0<W[:I)N=:"V:[H B2180]+D*6
M;W<_ANM@B7C U8+H<35XC%$G!31LU :?"J" 3@S['9KHT$8SG30KS@^ZYHB]
M?8?)S^Q,!UF+Z$"6Q1?&?:Z4TA8ZF?O^E>+G0VIRF7P-,IQ95SV2JN+M'N]+
M[?E8+DMW(E3I(]V$P<ZG0^+3PW'&+:[LU8$A[^<4_(4ZOYC!@ZS<6ALU7I<8
MA">&U+9(*:=/Z<K;N ',+"7=IWYHI_#I6Y*F+W.(O@[>/T_Q\VH6Y37L:%$4
MA2;S\LZGY 2D-92'?&@GRID]T\$XNWV4:F$]%J/L;M8%UJUOE;*U]<U4>OZY
MZ_-$I_#7W9^/<5DVW5+"=@1FY;H4/74=5&& [^VVBEI&VY8H>N"*]!DM>646
MG%?5ZE955B5GA$BO[2D@7KAHORY6"O#D>>Y5HA>^")+K]-#6S0BLZ6.CZ:\D
MU*(=!633+53(*>T<POW"T)THP%MBD$/HFK1" AA0XZ66@!2-=)QG2 NNWYVA
MYSCF3W=T[@H_T==TY:.N^4S,R.WH)[)+]-OJ\-SP' :#('SOU+'L,.<J-UV6
ML[PL*DY"5:(XY-C]5?"D37K8$(.J%G'BJVYOEY%=7\'2>1J32?KW\ 0&@YL3
M1<V_6=4K.8C>,6$H'-(AK=&[(]_-@QC+4%OC?-^7[]DS?^;+/YT(]S>^V+Q%
MXK;=U6?&N$M<7 +I4,4&N)GZRI#R%R=%1BY$TY.FGC@WFA Z!"L '<"%]NTZ
MZJEC="ZM=_B)\0VK\,+Y7=9F99YF$:1K=Y*^B!Z_>/:^.:>.5V:]J8T,2TN^
M;:V 0XM>V "8?YB'KME+FV=/'"ZX*DQ2K64T=E52(_!>]^N'EP]SR<ZT /,D
M_=@ ?'ZKB@"&:L-]K3XFZ1B3S+@JH0\\1CP5"6^9>Z&7=#O<7G9U]73+E]3=
M@MT5XWAR[&WCR*7F'RN/XM+>&L>OBL^;<B$\SJ<(#&=*!#KOUSESO[3[>EXG
M8";Q 4U+$*-P*O/D<=M&(N.2KD,(K!','H>\GD/OP:9]4@.*K45B=-KM\ 8"
MWJL/JYP$9#EU%FE[FZ:CC)&?[Y6;.GPJ<[^94#2:8'AIH*;-@I#@Z_P"OJ)0
M'?6!FP)*/*]<T9EUJ>#N$F3!MG!9_]>]YG]SU+7Z2*2,+\6*>;DE[2FKKOW8
M<EC"S[EQT/;B5C5XD;%>PL.AH=<T:-D&M]OEB-CX,M"H;V>^+\?UK,B2X)VL
M>NC WGJGX[5?TV+BWBULG^?C?GL@]F'YX4X?,>FV0JT5[\Q;RDR#$'])YYEX
MUF+:9OWI?%\+S-E78MJM]$-T(->3OJ!96TFE.9'BLH$P%X,S?9^#M 8]*C))
MM@_%"DX75MGVY&A-'IQVN<)<%2W.,%IPPW/2SZBC) >NU[*@?X]AU?O6Z3N]
M+/#=K)V[K*:-?C3?&8+\_%^F1_.*[YH7QNU69G<QEY;+'$]F+&.OC(<'/S1O
M$2'8L9HRWOK%[[KE(6*]S59E":&3(5>[3H2G/MFM.Y\4HEO6D)G>/Q'O\MCN
M>LI707.Z6Y]3*"!HSL\U,8U7>D5GWV/T._F<AK(N><*0L<^-;")H[6)RS'9H
M+!UJU.U\&9:.:Q,Z4BE=T.2["U+C(UU>@.M+<'UFRU2@?5__W,B8Y-D/.O??
M1= %7&Y/[33A]3C.:1$PF "OVFDU0WR/-!:/[S/OGEB %!IZ8J<\71WNZD;<
ML3/UP#?;%TQQ"S2?VJ9\V)TCW+9I?/Q1<1[0^2.;RZLA,'[A.NW<*(Q&H<J]
MJT+EO...-^"::KFM,R(E![.SC<_Q/ST8+C*>(D'.M_CWJS=_/1HV&H6O<!#A
MM)W>V\7H"&:;@KK#)L,5[_?>0'QJG#),>Z$G/1KC:L>L>?2EL,!0S3DDM*(;
M'E8J_50^E=XE2>"PVT>!0Q&\<'=CL@N?=[]@&R=^F7R;#"XG8SI1I<>E]F;U
M)"=*#-$)9S;R1WD.(N4&ZV;L]6XWB:0EMK!:=4]:;TMA[J0M4T\F*.2M3GV^
MI%DJ%A\S.1U9,7-9\\F)T-7XVB8B_Z 1TRY\F<SLQXF+YQJBRGVZYCW9G0*6
MFQ::%XD([,VK!D@**)@H$8/K>#\9#PW)%E"/'>M799^&NW/30?@?IJ"(XJTI
MK]M%\&7-)G:9GO:.S9GP*CZ'2L.];3Z"SEFD6 WEY-*?K:JRWC\(5U[,@*E"
M:[A^RH]5:3-2S<]]</-H;HGDJQ7C#,R8:MF5$L&W7I+]MJ\%#=M2T81([.CK
M0 &L:(X4_2Q$)[(SR4Q7YFA+J>K@+I=% YGN3S,"K.:QC=M#F2-7M()>#]R9
MS1&I:15035A\^-3.HB?27RB_[$ZF"P5$4-7%7B1:6^^.C#-ULS#I'SDAM-RJ
MU2P0L5 DL%@RB58Y>'I6J0:\)Z!SNL62 N+,@G[5;21Y(,XWMTO!?#V'2+SZ
M84]7^5/5HG::<D2'&IOU=*110+?=ELBL8HOD<3_,HA$O>SBI_X(+T<9L$3'S
MI8UK?MDO6(8[7#T\VP 2,I&,5'1TARG/&>\H;#I*RP03?VL_%* [@<T:(3PB
M'^$'=X4]\M^#\9N.;CV(D<DK/XUK7[K+CZ]Z:76YNR]U'J!&'TX],>;R?,[Y
M=)@"6AR,K194;WKWIK@<<>_&259;E\5%E>'LJ!VT$K6'5MIG+BG.<;T<-(!>
MM&6WU30[+C#UBX6Y^'L2GWJ5#.1-6=N,:\[/,W8PO6M=ASJ/_T0!N;ZP$R2S
M+!6ISRBTF@:J?S1VNS$TIQFB.3%"-O7UH8 ^8)3_S7*[[=]7B.OS5J@O'P#8
MX?0103PRH(JNJL\T/=CA>1W#$1;VS#AZF:Y+^H4!>5 V@LTIZZ-L*MUU-UK/
M3]U8];=_PRY!G*AT'R.;1C4C#)C(9'+_A9</YR?E.(0$1DUMHW#5@1VO4?6#
M]6>X68H]M7[)'3$CSRU))=5D$9Z?G;//&J2WR(]035(I7$XI3'13;9Q\>V1"
MU\LE46SUVG%?\Q2,%3V329&%L730.^*$TIN1_'#D'UWO])*H@))/GNAS#N"I
M"KZV%]47V2B[P_;)P%".)WH1&AY\9ZP]K;!Y-DG2[G:AVG:^:5$N5?[/005%
M38139]ZT7)]UR/^)Z3F"-\%120'^F:L2IJ!'WB>X;PP9EE8;83T*_4@;4:6%
M#/71%)G'H/2LFWM$KM':24KNPY\0K[%Y[ /#O98L:@T:,ZT/FE35OES=G,*G
M9@X_M'"XC/4=W:1M4Q9&Y,M.JX@Y/<U6W5;1E[K9=QX7<\0O$$Q4/+B#A&Z'
MG<E8W"]X"]ZII=X3N]#, K"AD']_D7:JQ>4STX[)U^)!HSX*WH/O+:SPJL+=
M.O10=)31(R^L\U4T&/&J/9\GQ#I)Q[K0B"&PY_!U1B=2KQFDO(^_28O[2-M
M]TZO)V0#VQA<;%PV855K;D\IF#5^+ENH!-DO'OY\OY*WY_:"$P2X<NZ;.4S(
M4!N_6;QKD;;<L??=S@W@_>4RK3FE\$PKKX9H%EW]QVU!"K?M6+@Y]LH.E;FP
M=09^013&&C79FP5H?!JIVY^RY"QX/;*)O#.K&IM@IM^>O0#>5W>=I;ZPTMI&
MY6?R1YV;Q$S,]+(>C@(2*AL9=;-24<Q6W 5JS7AV_X^LCV,$0Z;"4KMXRC+Z
M,_K$HNV@OAAT$V-219'Z@0EF*^AN5#*O;U6*SWPBZLBD^CR1+[>#>#R%$*)S
MK6WF;#W]D5W2?/Z$L %?6F6<^>>1A*188>;\0K;8ETX=Y_ JDI&66 _DN?<A
M/7XRMP#_GF%\D2R1Z[#7(PA6O"I_NN>M&NO^6D.A!J<I/?(!7$U,NE7=HIYO
MDLWM79X-L_"5A6AS+)J%<%G%%CLQC719NE\L[U;-*"%Q>"^3DDQ[:D[#K#GX
MIHY]L+<3]@M'+5;T0;T9/[J;7\5W/.@<'WZP9'+$!;J[5\_6>6JENJ5W,OIP
MZ'7]H\JD=N+4B[1FHQMY)07O-KU8^/_CL6W'JWR5@A(]*ZV1FHY'BK21X^JZ
MB7^PN=3#S+>$]_#OITETX>2H'^,\455'^FK_&"UU94%!87<(1$EV)RCMO[FE
M0M!H1]\\[8XV9O5]KLH:PDEOV]HTMIUX<?BLQHN=(%K0EG[.W\=??B HG_X+
M4$L#!!0    ( %."85*N@T Y'HH  'G;   6    9V%P:S!J=3!O>F5X,# P
M,#$P+FIP9^R\=UC3W9HU_$-$$)4.TKOT7J2#BG01Z=)5:HB ]%Z5W@0$5'H'
MZ27THO0BT@F]A-X3:H"0?/A,>6?F.V>N>>;]YCWS?G-^7.NO)#O7O;/W?:^U
M]KW!3&&6 ")5115%  L+"WAU_0=@9@%Y ._6+=Q;.'BXN+BW;^/AWR6[=_?.
MG;M4)*2$9'34#/1TU+2TC*Q\[(S,/"RTM!QBG#P"@B(B(@SL$C+B0M)\PB)"
MOP?!NGW[]MT[=RGOW:,48J)E$OK3#^8[0(QW X&#P,9B!FX08V$38V$Z 08
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MS^ M@\$?:A65+-QL?-H$/?8"#1F(2M^T((.7I3P#!9O$7U%&(?:>(^C*6DK
MC>QA=C6A%*>D_CU-J<H_*A-BYKD.(H\O9\O#3,D;0T9!C,&I \Q,7%]PB_9T
M:;PC!V,PP'VD_T_K+G6V]L7O54,XN8)J;Q$U&M0X7.X$'_1.,[*VXI&*HO&_
MJ.YU%8),%>[^4CUA/;0MZ-R1NBZKV*9&,T8#TC_[PF!/?OHY3NF=II&%+Q>_
M3*.R,-+5RG4B6/A<Z-^17+XI6XENHF4/S+-&ZA<J=B:&KT=CR9!A=:G#.SIF
M#.")246BWP;=L+A9VQX.G3F/P?/@>BF^8/B.=FU]=3KG BBB&_&QDT@PT,B,
M@&>?IYG0TL']YD?5S) 8!:X.N*@#+.'0K"@>J75DS;O<8MN^T>EUFE=DJ.[Z
MKH[WYLLZT$V;W"@"/#H<C9R.TU@Z6^+IK3HB$'5TD4'B,D<@(FHIYL1V8587
M+A8F*K$TEC\NDG+^;'%SQ;ES(^$P1GD5JI\#/@23..:9SG3?<I_K-D<)*-IJ
MJ?.K^5$G<N=?^6M_1;HZ79C4EF;.UX[E/^\2Q@#2L3\)MT&+A&\'9VT76+]H
MI!3^>F)= QX[_UJP4LJM4S>9=*0(2=(N^OZV[*[J\Y\;!'Y?KKB;1DM(GXWL
M[68;\V@&][1Y@6H;TD_KSM$!H\\'6J[S01IZY3W\_D4&I3]T%@.P%9OAMJVJ
M,)P<\:,_@-!88WR9_B1Y\S7#O%TK9$),)OWN3L+CN@X$$ P0R-(T6E93W)2B
M+:5B)UIB]2R$=2F 0'(TLJK.HWQ84O1JXR+R>C_W@:%R.Z-RJUPAD?DSVPQ4
MTD^AFK>?JM!PB7&GNM/=<_#04!I_@) MAMDI3LU EH@[[C!\9OS>=P;[AG37
M: Z%E8?MKT&^\.;%"-*6?.!><I.Y)[X)RW@ZD*"N4LX__ LQF6Q]/U::;[B]
M(J7(D#-*CLGUW$.\5"/<4#$#-V#?(N077OI4<6<?I5:!3*52]%M^OF;K98F]
M/:LD#CZ#/)<G3PB3X[WU,CJ-C"(7L;<I3BM4I'\6UXJ/5],KO=;& 'S0\FT&
MAS6T!6(!%+FT)WMD)%##O"#F("%_8U;)?!R:X?-XTF502;&R?LQE.LNC#"9H
MG&).(>LXQD@]A9 -_V;BH=VA;62H(G?J&:$6^<SGYXVE**_W,['W^:I7^._A
MN<Q3&UD&CKZIXZ[\7(1K^SY6M0BE?NJ_5O2)OS?9]8JIC?B-48,T'6V'4Y];
MX/E.&F0<&=DAJ7L67%9Z+['9MI(D*B[@1> X\4M9UI&3:*_%]M%9PW,QBGC/
M*IXTHC(!0BCYP[IR<&-2!E_TZ\SY+E^A<SN1]V>:[^?$Y,]'XYMI]<XLNW8H
M+OD'DUNI;$EM3;''UNJM0,0^53\]Q0]T_![TFUW>ZA!72WN,'?M":/&GOOIR
M-+&TU/*L#*^18S!@A3YR%QU$/:MSM,[=5A6O:HU>G%:9O;)='RO,^(KJ#?*)
MYMW% "SEXY_XHEUR,@,#,$"K^KM%_!IO[&5_2)]]_,^COJ1/]M^''J=G!+N+
MA>Y1BZPS&OT,C C\Y=2L+P8?_;7>T\YY;[ZY0I7-N4J'RS%#7I,APC3RB 9I
M;H\!LB*7IQ+4D76ETP;970X/&OO?: ;/)\S4[3M(V]<)W?$54[&1IPM>\XF;
M%?V2OW46B7#7:?8V2)K8(]=[\X%)0AI[M*;,CV%+7U_H^1EU@"=EY1UW1BK9
MZ2P?P>,KI=.\G0OF[B^NL"W^%1/5#O6(\0UO>18*6K=!)=B>WAH%'>DS.81@
MVSD6PV&?7/A0_BW'XX(MO]MC+BG( \;TD]Q8<1+C)GX6NMM=UF8>+-HIG>Z2
M7<GA?*4/4G'P*[MG=0C>.Z6^V-W]/)EL)1=>TRMB(O]#TK<-/WE1K/BA/BNT
M@" 1MB T#!EP(/&PXLX@-9X;$%V8RK/)N45Z>"B0(Q<#'N9WL/=A6+HL+M76
M2GB1)ERE0J[[.3TR&-!VF&O:;U\X5*O;_CG_>"@<Y7OK<ZAK2,+E^16U:41;
M$:JXJ4Q^>2%!)C148>] [.*];[X;2VH=HQ]565MF7U:9;C\&R%<_3X,>Q\K!
MU:Y2>NBYQZ!7+].L )>;V>LM-^H9;BC:H]1AOL;.M- GK XOOF6B&\HN8JL9
M%,[OH;1._N?Z"KHFBO"IEVI.%7W"C##Q;C5JF@I>-9WY3;EP?TF8?V6S-DQN
MT=8K!_2PM'_&T F) 4#(#7@A*U(^TUCY04/3Q(//_E2-<LN*+?+RK3?I0T4@
M'80W%K<>R0;#U*;H/(F-,T1IIJ(BYH9%9;26\ZHF>7PBZQTOIWZ9?_)Z?\6Y
M3T-3HZG ^)=\, D,0.??&USN#XUJN[A=IKUDADI8OT[]T_[Q4/V_+H&!X\9_
M&B3&@[DA..NK:/Q#2LO7'VU5.;"#VY":R[.SL0\%'1T2XN/$[UQ$3 _[W,]&
MNC8/<#N-F=._+7#6EU?@9N$8SJ-RYB@.)M-\-LZ1'0'\&7"E%Q7(%X.2*82C
M>H3(91="CXH_:=EN=SS_M7X_.$$3,O8\H^CITZ3HM1XQT O?L?-K2=.D0*Z^
MJ*>J]WL5ME\K^+N^9AUNDI,Y^0OS(NTFLF8/B:( ]IAFY]'<R9H[A$1&73@7
MPCVDX>2/>U@F(1R9-W7QLW0 7 "_'T&6O).K1I&"E;3M,%^T^V6I\H( ;!A!
MW;I4(RPME].5M3G\LF> XV?TU08[*]JJ9C,[Q=V=Y)^_]\;_.'"U'!KWF0L9
M]%;.?6(6>_VQ=$=^BOA-Q)'#KEE$QK'(UB(2OPVESC#51BZW"1IK@Y/[([\"
MFZY49:2P6W$DO3#<NL]5V(>5E-O<A66DC^ '4:2=21>Q82>14E-V*ZX*$40?
M*'HRZ1/GQV8XO=!OZ<N6%<BT@.P(#H 5*Z%+2"+GBYH"L^3[(-W ]08Y$INO
M"^4/?NV]+CGNC$J,F'NCQ.ANG^E[S]J'CL>'2$Q*RC?[635MPA$U2VGW1.*O
MA$Y9CBKXX=,$GH3YYVX==G@#O;[%M!X7:IS9U.O!OOE&_3^T8"91[V6;7L(*
MD;54->7T6_2L2;?9QF#1F9^RDP1)/])@UXEXG.E5(W!#":)SA6SO)^=R\<B)
MQU[EL^RO+ 17>>]<^7\V,)WU3 ^(J6)N).KO8(PY(5TT5!((W\\T('P* N02
MG25/\\0^^&"M[]]SO<M-0CK?"_NVY7=CK&!8\X3I07>>D$/\5J[==L]E@;0?
MF<Q\[1,C[A,I+^XHI/\W$W6"G!PSU=$Y4,+GIU&>+GTS&LL1NUMMC%"K_ZSV
M"_C'[?_M:-'02%QE/S,\K-> %=\1.:;2\F%&=;=261F;=8E@_9L_&-1V3%1S
M+=T&T*)='F>=RXPQ'1H->D>W+.+9<;''F&OR%'59LV/>*O*EX=OGN%=.F'@4
M/*U.[L_0##=V S)6N=:2"BP+\R^E/J\S[*;[<YUC@**^XJ_V>:YYI@\&2X*I
MGBL/W=L%#R>9T)NY;GOH')T?7<*-6XW2,8"")>@"G>%9\.,=M':D)NRV7N)C
MW*VOU5>E^1A@^,D8&@/P(Z&?EUGWS#<G;.U,1(S+"#N]%AJE?0ML)$V.]2KF
M'HU*B>!OL.R8C$HJ1R"J&@7ZJU*#N >E57SM"E"O1ZR;TIC"#,7Y-K"S<EM9
M,S)6!QSF[?P-<S1>(G##?)B'YVV+'7SSJC\DV81 8]FIN*/,$87-YL7S2C!^
M/-^(?9O2_?TVC\J&&PKG'BQMAN4KZJ\\JCK0Q(/X5/:6#:XD0VL5,:)#[(Z4
MTEXZ] *02X*V)2/CC?Z&VQGY,TPE.7YK4@:SU3+B+MF5HM$4)EH*_-_F9F:Y
MEGINWTG8-BK?,?9+<'=>/@A[9R.P7;6X=?8B^09(NCLZ1"XR0<5V5VW$^+B1
M.WH<PMWBT#6T/,!=  E9(.8='PFLW\A^/UM8[.47S/ !UC+.H-O:&/R&;V2N
MWYA/@M4J\7C=F]SN;9VD5UYQ+\+F+%ZQR^3-&TI:(D=CMH2">8\V=?3LN.M
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M>&84@\.!/AJFE>D T8%KY17A.@[?*XZSM']:=\BY$_/4\VQ%MCOA^>FVJ-V
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MELY]* 5ML$[3_&V3PL4LM?9L[PQ2Y*@W16=PE*:8@P"!3"-4]"H148X.4L$
M_J\P /X)_QVDFQP!R,R*A*J,U9SUB/@]2[H*:M!N!/R ? 1G?W;?@Z(E'V4<
M^^BZ"K3ICTWBBG&O/W&FE[5_+R/#7?4O^ !D KF#?LKKC6ZVO"ZMZDX9-S#
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MU%?2Y&KI,4WUXC(4EH$OS5;,KK!)T5?R_]R1W&C>PY,-'@B_"Q6*A3DY^1.
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M@OO7[1_?F6B<Q *L&[QK:I/.-A42ONC)I0N9FT8I*<2$WS;B4_4JUC8O[\L
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M0FZ)<,8N'CY>-*9HPKS*.X41.4\_39[:B#TARCU5M18WY\^2D&TWT#;^L4?
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M5F?>J:+?I\/^GI8I-E$,LD;2^+G<<H)7JVTEV\8VN,J'4CS/"]Y*WU0]_>F
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M$!-V?8U^0^,02FH9Z?9L;*?0).Q!A:8SA[^6YG<#C^57176W,FB@:@U(NSP
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M7 Y2D^W,DP0T(4B)L'T\2R!^)Q]?1E;#_P*7%2U87^4]%1#,1]'FKM2.=U2
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M*C)$Q9III@OMU06U#!-Y[C9^Q7L$DK^<JE&\+F,% IK:8)#N<'PHT/!F1C2
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M_+=$R8Z'W6@#(_&BZMU2K7/N\BNC"X%.K_CO[^H?Q5"9F,Z)6^S5;\'I\TW
MD8>J=?[CB?;T?'6OE@#80%%(FY>[\5G=Z5\<HWK*H&C)-M>D;@!Q'31F3<;_
M*]Z1,:E_6UOO^=]Z.,[O.2ZCHQ>ME^GX2W'C_XLFVI?^@D[YU@!ZUK@&T0RR
M*):P_&5,+*>T-3LNI;;HO1:7+KIC_(&3![?JT(CFANS3!_V%[I+W3/]Q/]H
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M&Z"C#D.10=>%YI?@I"I%[]=^BS-B/3\S):JK[BDX?5R=Q[9<G7/BD"CK6!*
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M2/8<GW02)2V^=S]ZK2W:#:V0OH8@6] Y,4+<)[_5L>S9ADJ^I;T,GY["6@G
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M2!-X3=(MNNKELZMP0)+% "FJU<^LPNH2&]@>&J$LXOP-JMM/J.UDQ RVE?*
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MFM,R=DT>EYU-5PBPVFI=;?[::[L!.@9T!Q])7GM%BMD,.B=5+(1=9S/NEM\
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M#LAPK!S&0T\HI%:F9K]96\AE+WS\!8D-P0-<F9A]I-A!O;]F_(<*RJ G^;"
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MJ?.<FM+92TU(O$C8+K:T6?/HNP6)_@X*R0#]\JOF$1_&$$;%J0<'ZI39)_*
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M<4# C5LM>-Y<P8Z-3.;59+#Y^%RS.\$E(<G;[&GN _$1G*>5/=!WR-@6AP=
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M"_"<,,ZUGO+0IE'AJ"E+11D<Z;3E,4RF"L96UO1PG =W2"\2+"-$YMR&,!S
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M>!0SHZ-O?I5I_7'<TIB0B$-.OI8C3<+FIZ(][WU)6<K'1_PB ;64Q-Z-0UJ
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M_A=W;QT7Y;?N#=_# *-(B70+*""HQ- UJ+2TA'3+T%T",XB@(BE(B3 (0XB
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MLSRI6DCZ8*+--5"><6]3"4?2!O FH/.T@8.];.!G(V/L';MHRR,7(D"*9E'
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MZ[^41&I5)$(+.IWVDV1"8&#*1U-Q!WL1#H6';!9+Q+Z_XVXTT#-EC@;LESC
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M;I"AC63=' H<>M(S7UYNT,$SGKFB*VK8C)Y&4 JD/:YY] V7@*M7G.&SS+T
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M17G)&T6H>AUUWNI+QD.BBG9&$+UE*A*K)&4W;3L0&#F,<>R=NX)X>0'<V8G
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MJU;5#+\YJVK.JK+20B+H!H.+%(K,>O?U!7PJY+<'RT#M\W'Y14GA4X<VU;/
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M03Z,O[G0V,U(RYT-RIXT4JOUY6SJ$K)QY?.B^J%(4WD%('3PLOPT,HGL)Z^
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M.WX!C[DP&*$6Z7:7#]^V@PQQETNY1M2KT(:[@/1/U\\YK<YMC PLNKL4>06
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M@QH>@=W$:L?;J:;,O T"*$RM-%KQ:O?>-:)HJ(B\<7(^CJMTHX?#^]-PY0A
M3KY90>/+"9$J$XJM5.Y*6C<"&&[I@?;C$V%?C6CH0O+/D'I>8M\7\G"%0O-M
MT)?:>@<V'!9]'U$6IJ<9:BACD@;7;87!XYJUM.<+0:OMH'QOVO.T+2N[5P,*
MB&!"[HF<3_UNX?6 H.$%*RTR%2YTZXW!>;3Z7.ZNH($E+_9T+?7S]NJ6 T%5
M%R]Y9'O:?^KT-9^'_^2\H:&6UE1OB'8+G/I&RS,N"MOMUD#75+[UD7>9E9.I
M)ZUIO @B!HXOA8!QP YYTP"K70)D2R:!W1<DO*9NBQ(AW&R.^P([LYL.Q\44
M^OQ@OB9+'?!<:_WKC<N(;\"/"KQ*$8":AZ<@F;T7\4Q_$][7J,3S.2!&2G9_
M)KSQHPY"<Z]ND1.76)(8O3(O(K]+LD^R\K2SENWH:Q#_*0C$8-*1;>R/[-EW
M@]$^$:Y<N@7=H;A$UO)YMCB?TAB+P]BJ;!*PU;,N"GVH^GA$FY^EYT7++!/4
M?D$ 9/9N;V@U'1(D(X-%"/IX^?#1H<M<WS*7@*I :J+,^/1TP;LN2*[;,E^_
M:J@:<[_.0^F%1I=Q*5X*V?S[F:5=F0L2G8H68(@)V19YP73=](ADX?_:X/VW
M\&#7(2A(RA:HEO[)ZQ];=ZJI_]N7_EPENJP!).^].93<I\\\<'?EN0IFHEH
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M%0IT>S(:+_A?/B\-_C7]+U!+ P04    " !3@F%2NJ8K7X@_ 0!AO0$ %@
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M)Y3GK][J<?'G_-EXK>9BJ)SYW:6F\DJ/:AZS&UT5R:<@Q7HGI9^1 _K]9 J
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MXDM^1PQNN<)#X6*ZA,6M$W7ZYVA>XN^Y=[M(/J/ I,RRR8+[L][UR:YTRQ2
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M+-8T'4VBN9(7NT'A1,$]+X,IH1=K1GCIUL*O\/?'%G-74?V+I@<=?ID5B:1
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M<G9%O<V6V+72+_L23:YTBS8M.LHI5$NU-U. Y1_'?ICY-O+OQ#]002+(H(X
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M4#L(;\1]-)RJG\4@%#3K]3H@:U/N0"7*6KQ&WCO26H&2B<U%"!BC&WFIYPO
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M8&9WHV&BMS.?C49]Q-B]IDF=&E7EG$K-L_H-Y?>(>@1WH&7= PUDU97EA!%
M$S#PYUES)U%*;9%&9/_K6%NFV<MORW:U4FPHWQYW%CTX"K.^>;_V_2_6OLNH
M#MZZ6X&7:% _+?VLOES'&?WK4Z"B*DP".Q]>D1_3(8^+T?-ZM5?PMFX899[-
MB;,HL]S4W[26G#0_W2/[Z1K,1@Y7LZY5!]QR:!5EO=$V5P<+UE>D4Z.W]VD
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M[E0,]5>=)HBE231\R644#CJ_UFC^;Z_?\#?^:_$W7?_W@#A,#P'O4"HX+WO
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MN+L$=RNTL.+4]W7?[KU'][VC^W3O_9T^=_^88S#&N^I]%_7.]<SG67/.55H
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M/$-^.=/">RZANRN54W?7<^Q==Z#.I.N%KOSH$L\K,XPOVCRX3TWVG!\\[\&
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M2__P>Y.-$D>A%BY,0\0X[ 0.9[^A^$'E%P]N[V^]!Z3C(35;\W7*D36*YYC
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M9)Z27&UBX]FCY@B5?Z%]ZT+F$Q_G]\B6M^!ELOYSSW1OZVEU1]S4PA*K(Y_
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MSI+6-DZAT()10C2S$9R1?_S LWO[*NZ4?08RP,%1<B:2Q5A\W+N9L7E:X++
M<J);3V H-ZAXF4+#.GXCLCRG0J.C'V]1MUL;27RMF[' QO>NRHI2F[6%(>5H
MRG_1+M$@>C;UE5_5UODYPJ"M3#KL4Q8 [<V(L:O!:/XA0W4J\YB.E"RQCES
MWY2H2(@3N3I1Y;(F!=FSA@'L).D<-7FOQ"&U)]O)>9QAE<B3#R:W8_J]58*'
MC*Q93F'K.8@OHI?J$C<X!<JK5!4=CG)8!<4Y$=_K/R?15-%9&!=CC4^E]<'!
M<JJQ7^X +A,"$_;KUQ=O!,8G>?K_J);>E,\!C3_B&9.36)8N5(9-RUSD D-
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M.KJ.HHVCS.=KQV:40:JH8D%FSU<_5C $"5$UBWD*E-*>:^-_S$4K==H)U.Z
MY2!#V,*)$<;?L?IWNJ>L"Z:ZR"1O1@(-\)?GWMW$*2+'\987&RRO+*.LPJ/4
M*X/S(JA]=XWN77RA*^*+/!6LYVRCH"7P?<L'ZSO _;<_]\OV[YD^':!&=M B
M*M,XRAD/'DO@I(IJYW)1Q ><3D,2H7BV+(*?:H:U\#)M;1W/A=2&-<Z^*2U*
M^#LK[(^9C'U;5KD,2W(U?$%!5+II[#%K<8QN,"L5I:&N^.#':K]TW7:R>(NV
MC\83-QO(;$#+.'G![:P#JW/[[![W]-?[[-]LQ;?3$1X]Q<9-%"2O62<Z>"$R
MTZB;ERO-*P3<2QY*Z?+]7G.C6$SE2Z1>J_[KW;5"SUM!4!;^1WMS"O=7M"&@
ML7V$MCBQ]EJ7"KSOX@Z@HXTU!DKG+_45=Q^<OW($4XOC144)6U[,&3Q%FJA]
M+O1,/\01+PU+[[@#/*U,^GF8I@:/:2&T0<R 7_OIF0N=:1K'D"::X5\U6$]M
ML8SF:P21DSCVI<]&.]%ZX@>?O:Q_!3ACOQ]*V/T.8,BEEC'@]D4'T?K&<$>7
M7JC6!VCK[UE.=LLJ#<2W&:;.%KW^-IE#TNAPFE4IW_OIS>@B=U P]WUZ1L*L
MW@0 2BG+VL8:/K[WU__O]HO_I/A'/1:(9ZY+;O%8K,LV8C$DS[CD1544"CU#
M)XAX/'E:A:FNV_A/ ?&KFAU;/#MYT]Z/VJ0SO;RWPLMJO53S7ABR%'O=ZQ55
M,#Y.X]%!P5NU5-L;J(/5I38=^T+9]8E\Y Q]\P<&!LR*DE,:CE.@>"\34QWU
MU&O'I<%PBX\H'4^2O+ SD==H],)7PI@HUU*L\'U+$7N7]7=G%H(H[;$_J3EX
MAALZ%CZLD@PNW@BV?&:WYW/BS!/*1148PA4BE8[FWNR1-9,W7>KH?I"9_B +
MO@-\=)IU68+DO[K<JJ- N;:!D1"="J:!\D1K%'NC]J/-VHJXB_<CM:<EGFM(
MV^164GIEN'RFRDJ$''>=!MA7!F<H1;7!_^9(8IE7;]*/9]*..R4O7MY*5%?&
M"L'R&LW[7;;[C!&)TXMF4AO*TZ489=[NQ5<WG6I/"CS1+IGL.S9J]F\T5YKD
M:;T8S>\ 0P;-R3HA^>&SC>:T:6"'(;92-4L[TO2V?G(?[7SY]O+:.X!;I2DB
M9IN]!8ZG+!!HNODKJ659.UW@(Z<9A;P<;2#,ZIV%A$1'J2>5 [)4S<<SO$?M
MFG$R7+CJ"W)&^#X^&1'/DF;A&_YY5E@K^X.>*F-$XL[+6[=*<<$07C&.*Q25
MX<L7)\3+CH%ID* ?$SF!.F2JW9!J(ZLJRR1S\VFC^-/L?3V=SM[L. ,]55TQ
MC?>FUA,WXX#PX[:,1,V*D$/5EH !S\PT'7#.=,!LI@V!^ D:&#A+Z"5WGQ@^
M@1)MCS#815<$M,Y-UMIYZXR#:I@9N0S/94&2BX9KG,DYH:T4L#Y.?)/%+D:"
MK^/'N)%5CIUFI&41S28;5DS[?$+:(U^H&U-:<*;'S%&]FN?:ZMU%/&M3RF2!
M5G> A JFFS\#[*YI(..@WY=-3:YBV$N)'@99>:W(MV#C*Y,F$3]J;7MAN-JE
M#0.T-;3DG/.QS<@J]V'W19!1E,(8_#ZV!^X\M#BC'$5FV_0.\3\U4H!.*"P=
M$>E\'SG,N?X![ X[_1(FB((_O-+<55@?N7X#I&N570'+HJY8HBZ"P)]_EM=<
M]?FW!$/*OU='HH<M:1PS)'_^>=Z'*I=>R@%_;A=^9W3Y6JU!IY.DV&'\3Q<4
M%F-3[;#Z#KL[?T#O:4>+&Q]0EOB*59NX6@8 V+KW0QG_R&X(RMZOC/D209Z+
M+1X<9R]F 0I(H\>Z6:[DA9Q9-B6=R8/TW07T=65\%CJB96XOE#:3-L*G<J"F
MV]"3=?QU^7/:Q#N N#I*N_TV5;.>*2:IF;A%@#3B_7RES^9L/4NIG2G$4F^N
M-2:!7$3>H,PXGESIJ49< _N?>^7_Z,+)?TV/^_<\L.N_WP.'G0FS>L +NPO"
M?YRN#Q\5#3W926"\G"SMOI"#QK\A,C:("4EF\XXQD:*5P[,";PF##WRNF;^E
MK3F#N;NA/-P)1)?Z:]7&/)-L/PB7>2+[><$TB1UU9+BND(:)@$[(WTT<R^JO
MG).;?4 JIPP)C?S"?1+46U,>NE^RTCH]8%0P>=7K!XF/AA6#>JB)C&7N4TB#
M_G3^7G 6LAJAE5&;T"L3,"2-9V'XD$*JGF,O)S39+5FX -@?GQX0E_:RZB,H
M] Y0^Z5EC@CJR+IY!RAS]$U<E+#'>/L63G;<\UAJ7X\T06 V:+@F #S_S560
MQ!04^CB?479:82&RMM3HZ#8HHCF=I#-;TK.7O(PZ'>:E1ZE]Q!U;1%+2MAYA
ME37=<[3T 78Z7$/FK^P8B;95-04@_@, V'MI79BJJ+(H;TY'SOKL>Q@+SC^G
ME^F_#_Y9EYMAEK.&\P33KH)2\ZTIW;)PY4'ECR/ST=-'*[=RL\?JB10///(^
MW0@Y9H)C/DSN^>F2A"1?+,BHU8S#:&=7,+*>W$;!' V@[56!.CSS/>4&!;U,
MSF>EJ@D\'.*HK>6"8)_%@RZ3CZ+/+H[9SW;B U2UU1"Z^5V?B6T_96K+ 6CR
M(T%AH%< EG# RXEV@\K"WKV]'$7-O^RAOPCX)^]\_><'R9L+K;*QQI9JL#S6
M5[?<DX@N?_:1_^]M.K2_L;R2OSX%_4\/.[_Q;X>I1TW'#Z2F9+IF,B]3PI-Q
M8(<OZU#6T5)XHZ,9I-@8XG:>HM=G;W_^QYS4NI,W(NRPT6JE"J$;?."R<$TS
MOF<V#/)LCH$?DGA@8H[=R&;.&VW?^P9O=**8:?-AK"RDFXJ?&(OYU$?+'8:@
M> "Z5&0M#6O@40EL-8IL*+^2EJZJ(FQQ956+WW8>\YDS4M=[98C$QH]G)&@Q
M2=!N]T1.;8#BU-X++BJQHD;CH0JY ^PM[7EFUB:MTSJ+KR0PU4SZB]AAJ2#8
M4_O$*TJDH 3D6I'C<E)7D_(1/J:>.3ND7K2? 2E:#8(/8CZ%&$5[(=215MU3
M[N+/$MN;Z<M(O9)/J)Z)&P7>?CN9K$-^5D.<J_%(OM+9KC*\'1OUYZNJ$_5=
M216X-K:SG=/X@-'L;5ZI]TMJ"K/!Y/'N.>KY\/+X?A>I*@6TOCT_!R$<<M3U
MO9CG,5Z,D4#KN<31)]6D2YV#=_AJWX:Q<HR,Y"'VC,?5TZO@?M^'GM6)I<B:
M;@%=74KV<6&YE <1A(IL])HOWTA=Z:HA<'1#6NLKNCKU#&L8MO5;L!D(D.A3
M#_4J(SNB-"4I9DT^5S7A=NZN#!$KTXS4"54U1'*3,^1RB>V E3N3)VO@OT3%
M5A(BYPWS;0Y398*&[/+F=<@Z#Q>0I>W.3'WT_;6FXSY=B<LEVU5X7G!]C-XQ
M+L:SE0& M6W]'>"S*&Z^@1&DYL@VV6B/P2T2C2 B=/?0.,G.(5&GS$C.*3;#
M5;S#LA88O@5;IN@#.,P 8TH2?[X;6L'C*F.\3<5""3-C>/TE6K#&IW<GOR,C
ME!X>-.!G<<"R!13\=7&@<?8.8%0S):J1H_P^LHCJH4AWDY?*/WTE_,:_'5:V
M5PN1(8_?+/6,=#-\?$P<C=^247AQ-1CZ(HE7Q=N"38ZG\W'8S.IHZ0ZE:UJ1
MU?.<LWHCPQXN1.URV'$ZO@_?*%6W0<6BAR.1RJOPV5"BM85!A5MF=,X@+E!S
M 1S/D<'#)?%+I>)Z3$Q #\D.:=KSD5+V1F05E8-_M$P/<;CK<G(+7C'I>9_=
M8Z7H_-E\+( N2*!=[>'\ZQ/EE3ZRF.D*;IE8-<U)?\&0H<_BW(:+-H5=4ZHJ
MY2I1\9_>'7F/(N,-V^X 9'MGEQ-!0:./DB5YB(.ZQ;\EGX%Y%7^,%$^.J59%
MSBY@D@IV 7+&*QMHWO[:.Z.R/K!+/Y1_UL.'UN^QVBGLFA[$\5& VTC-(5C0
M+"BP[*W@LH[51^.AE4-_^G1#9_0^5J6.EXSV0AAG)<'MK;1$HX>$!]U2%1]6
MGNB\THR&&&J-G.[;#L_NZ,2 )55]ZC!E 1:0F$YX"\8"+AE'8L+^.C?Y("0&
MJ5@R9^#A9T>D'L_^?B_7H8][)J8!$'ZV;9QH8V-O!J&!%2L3$^#E?QZ1-;-=
M?'0TV.!E#U(AG=Q9]L]5)&/"R $X&--Q(^?@JJDV?SR>G+59$LWP:0@81-OR
M .FVQG(&BGH76U_%/,V9\XQ6NGGYBSW\=-L8EFWM91SXSJZRB!E&Q_2<GIPB
MOZH4S[J97F%,=RRC4>\7\W.*N63 BCCS3L+51&I>"-\,Z<[.L50Z\P%.$S:C
M2ZGT2'%+Q2E$1)K+-.CIK21Z@?4BP;U."-FPJ4Q],3LH1VX9ZJ!B-_P7[:%.
MQ2K'F**G**88KG6JCH4/UWL;TEG/%<883FW.$I">W!#V^T'2_\KX)_9D_\9_
M,'[G#/]]\!^U]?<;_WS\?C_\OPU^A^O_@M 2T.6:F5-T%/D8!F+K]\9)+O/1
MSU4N]K ][\4(992I]A>],$18UJU"%/\XJHYP!'WC#3COK"6X#*0)V&B0P/((
M6]6I@;#N"T.H^EYIN\346%6[NP^R#C4#/<Z'VG0<D(8=#HIY"S+'Q>5X^>WC
M<<9-N3M>?C#(.4QXA^HK-D/_IS5"L2WT];_Q*CK>N\D&(@PFK12JCSB'A[%
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M(J7X)"XW!6YO^:!MV)EW@"&AEL/MDH0PP$;+RH/A.\#FMZ6+TY$[P*,7(7<
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ME:,K/$LS@HB>J&&::;/K\MP. UC]7VBKO^G^W71]1]*7E)-%MN&+KXWH$WJ
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M./STX(_P";#2!BX-#QSN5/386IEH& <P>-0=]DY4.\^WY%>=9NC3,YEM7="
M+%\JX<&53% P3U?CTC(L>\ERXHPFA[VD!/N36RNCHPZ*PU9SP,9TI8@>KZN
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M6W95^UYNWD5U;]VB!JBEQ<B(T5J6HTB[5]7P7\!(BN98%7ZM5Y@?.8+I!"E
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M!$1MTIP^=%NH+7?Q1Q'@L]X?\&1YB'0%&6KVL;U5J,:(W7%Z2'9%BJCQRV;
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M-R[D5,2K-1J">8^L@EW(:.9E 2\LS#>LT"1'8(#/=@#[3RI</ 3W. 1CL]-
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MJ9RKS*@,9B6HBHC$7PYE>J2)3NC/_8XY!#]U,W9RYWW;>G(E?1-SCH/,\:?
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M>Z\O&S)RV(*UN;TS\U:<7]8'E).JT.!Y*L>T3_F3/)DU^V\ZUCNH\I-2_06
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MVS%UO.(P%=^!K0>.JU!270WM[ ZB.C3%!@<J/>-<?8?BSO>,L6!GCH:/*0\
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M$FG=^'',>FM3Q,GJ1DO\A^@A6B,7Q7?V:QCPKB\>S:(2;W34.FF$& *QIX!
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M@<C0!X#-+V7G[M._HTGII33^FX4W0.T&U9]$3-*+?XR\<_$DKE'1:<R7AP^
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MYX"CIU@_ DD.2/=)'&08YQC?M3=]_28[UN(B*&0N$'^9)7/8[UOX%S4^.V)
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M_=_V;_NW_=_9P^)_ U!+ 0(4 Q0    ( %."85)<H]8;>\L%  [,8@ 5
M          "  0    !F9V5N+3$P:U\R,#(P,3(S,2YH=&U02P$"% ,4
M" !3@F%2KS?4."HE  !EQ0$ $0              @ &NRP4 9F=E;BTR,#(P
M,3(S,2YX<V102P$"% ,4    " !3@F%2UADE$E\9  #EGP$ %0
M    @ $'\04 9F=E;BTR,#(P,3(S,5]C86PN>&UL4$L! A0#%     @ 4X)A
M4OYT)3K*5   2,\& !4              ( !F0H& &9G96XM,C R,#$R,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( %."85(D[JG5]=4  $[4#  5
M  "  99?!@!F9V5N+3(P,C Q,C,Q7VQA8BYX;6Q02P$"% ,4    " !3@F%2
M<3V0\$J*   V@PL %0              @ &^-0< 9F=E;BTR,#(P,3(S,5]P
M<F4N>&UL4$L! A0#%     @ 4X)A4E2YDQ(\P@  )(<) !,
M ( !.\ ' &9G96XM97@Q,#,U7S8P-"YH=&U02P$"% ,4    " !3@F%2T^K>
MH# 9   L@ $ $P              @ &H@@@ 9F=E;BUE>#$P,S9?-C U+FAT
M;5!+ 0(4 Q0    ( %."85)K0UXY:AD  '+]   3              "  0F<
M" !F9V5N+65X,3 T-%\R,#0N:'1M4$L! A0#%     @ 4X)A4M4PMV(G P
MR14  !(              ( !I+4( &9G96XM97@R,3%?,C0Q+FAT;5!+ 0(4
M Q0    ( %."85+OHAMNGP(  )8'   1              "  ?NX" !F9V5N
M+65X,C,Q7S$P+FAT;5!+ 0(4 Q0    ( %."85)S&V@12 <  $XD   1
M          "  <F[" !F9V5N+65X,S$Q7S$T+FAT;5!+ 0(4 Q0    ( %."
M85+-@S[J8@<  .PD   0              "  4##" !F9V5N+65X,S$R7SDN
M:'1M4$L! A0#%     @ 4X)A4K9.7CW3!0  P1H  !$              ( !
MT,H( &9G96XM97@S,C%?,3,N:'1M4$L! A0#%     @ 4X)A4@[]!%:K8P$
M>>(! !8              ( !TM ( &=A<&LP:G4P;WIE># P,# P,2YJ<&=0
M2P$"% ,4    " !3@F%2WYG2+\%T 0#!K0$ %@              @ &Q- H
M9V%P:S!J=3!O>F5X,# P,# R+FIP9U!+ 0(4 Q0    ( %."85+8X<X>B]D
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M+FIP9U!+ 0(4 Q0    ( %."85*ZIBM?B#\! &&] 0 6              "
M 1FG$P!G87!K,&IU,&]Z97@P,# P,3(N:G!G4$L%!@     : !H O 8  -7F
$%     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
